<SEC-DOCUMENT>0001628280-21-021760.txt : 20211104
<SEC-HEADER>0001628280-21-021760.hdr.sgml : 20211104
<ACCEPTANCE-DATETIME>20211104160913
ACCESSION NUMBER:		0001628280-21-021760
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		87
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211104
DATE AS OF CHANGE:		20211104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Akebia Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001517022
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				208756903
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36352
		FILM NUMBER:		211379986

	BUSINESS ADDRESS:	
		STREET 1:		245 FIRST STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-871-2098

	MAIL ADDRESS:	
		STREET 1:		245 FIRST STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>akba-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:8995f2ec-9597-4fb5-818e-5018ad7b3654,g:f42f20af-e08c-4deb-ba3d-2a8688a2b01d,d:32bac828c69741158be14bdef01bfe8b--><html xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:akba="http://akebia.com/20210930" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>akba-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80L2ZyYWc6YWZmNmM1YWE4MzYxNDc0NDhmMjY3ZDc4M2Q3ZTI4NDYvdGFibGU6ZTc4ZWZkNDViOTA1NDk1ZjkzZTMyYjBiOTJlMmNhMTIvdGFibGVyYW5nZTplNzhlZmQ0NWI5MDU0OTVmOTNlMzJiMGI5MmUyY2ExMl8zLTEtMS0xLTIyMzU3_43f5b333-eac1-4615-9b44-d1bee2ef85a9">false</ix:nonNumeric><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80L2ZyYWc6YWZmNmM1YWE4MzYxNDc0NDhmMjY3ZDc4M2Q3ZTI4NDYvdGFibGU6ZTc4ZWZkNDViOTA1NDk1ZjkzZTMyYjBiOTJlMmNhMTIvdGFibGVyYW5nZTplNzhlZmQ0NWI5MDU0OTVmOTNlMzJiMGI5MmUyY2ExMl80LTEtMS0xLTIyMzU3_ae4e388e-1a7f-4346-a612-d72036ecbf7a">2021</ix:nonNumeric><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80L2ZyYWc6YWZmNmM1YWE4MzYxNDc0NDhmMjY3ZDc4M2Q3ZTI4NDYvdGFibGU6ZTc4ZWZkNDViOTA1NDk1ZjkzZTMyYjBiOTJlMmNhMTIvdGFibGVyYW5nZTplNzhlZmQ0NWI5MDU0OTVmOTNlMzJiMGI5MmUyY2ExMl81LTEtMS0xLTIyMzU3_0b5d21a6-1757-43e5-9abc-fa6e922489d8">Q3</ix:nonNumeric><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80L2ZyYWc6YWZmNmM1YWE4MzYxNDc0NDhmMjY3ZDc4M2Q3ZTI4NDYvdGFibGU6ZTc4ZWZkNDViOTA1NDk1ZjkzZTMyYjBiOTJlMmNhMTIvdGFibGVyYW5nZTplNzhlZmQ0NWI5MDU0OTVmOTNlMzJiMGI5MmUyY2ExMl82LTEtMS0xLTIyMzU3_4fa98e07-6ed6-4dd3-afe4-40675f069790">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80L2ZyYWc6YWZmNmM1YWE4MzYxNDc0NDhmMjY3ZDc4M2Q3ZTI4NDYvdGFibGU6ZTc4ZWZkNDViOTA1NDk1ZjkzZTMyYjBiOTJlMmNhMTIvdGFibGVyYW5nZTplNzhlZmQ0NWI5MDU0OTVmOTNlMzJiMGI5MmUyY2ExMl83LTEtMS0xLTIyMzU3_cbe1ae1e-526c-4221-9117-6ae6428f91d2">0001517022</ix:nonNumeric><ix:nonNumeric contextRef="i3e2950be526b427487e169a221babd7d_I20201231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNy0wLTEtMS0yMjM1Nw_8a62ce00-dd9c-44ee-980f-eb68f6cf0efd">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i44af4abac88448b5893045bc0002855c_I20210930" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNy0wLTEtMS0yMjM1Nw_a0731d02-abdf-4cad-9588-f670833c69ba">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ic6020a0180d34b6a86d7589b54358a92_D20191111-20191111" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83MC9mcmFnOjJmNDgxYzA3ZjViOTRjMTliZjhiMTE3ZjM5ZGYyY2I0L3RhYmxlOjY2NWRmZmJiMjI4MDQ5YjlhMTE3NDM4MTBhODZmMWExL3RhYmxlcmFuZ2U6NjY1ZGZmYmIyMjgwNDliOWExMTc0MzgxMGE4NmYxYTFfMy0xLTEtMS0yMjM1Nw_bc747731-c308-4c8f-ace4-99c7df61d167">5</ix:nonNumeric><ix:nonNumeric contextRef="ia2f38973bd944cfd9a74bfad2e344e99_D20210101-20210930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83OS9mcmFnOmQ4YjFmNjVkOWNlMjRjOGE5ODM4NjM4MjkwMDQ5MTlhL3RhYmxlOmUxNGVhODk0OTRlZjQxYTBhNzEzZjdhN2U4ZTQ3YjkxL3RhYmxlcmFuZ2U6ZTE0ZWE4OTQ5NGVmNDFhMGE3MTNmN2E3ZThlNDdiOTFfMi0xLTEtMS0yMjM1Nw_c757861e-59a7-4bf9-a91f-e80e4cbb2170">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i3082be42de6d46968f452cdc31f89952_D20210101-20210930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83OS9mcmFnOmQ4YjFmNjVkOWNlMjRjOGE5ODM4NjM4MjkwMDQ5MTlhL3RhYmxlOmUxNGVhODk0OTRlZjQxYTBhNzEzZjdhN2U4ZTQ3YjkxL3RhYmxlcmFuZ2U6ZTE0ZWE4OTQ5NGVmNDFhMGE3MTNmN2E3ZThlNDdiOTFfMy0xLTEtMS0yMjM1Nw_d31484cc-3124-4102-be7f-d00d3f0aa743">P3Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i82b10f09670f4bceac19cdca7e3acc7f_D20210101-20210930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83OS9mcmFnOmQ4YjFmNjVkOWNlMjRjOGE5ODM4NjM4MjkwMDQ5MTlhL3RhYmxlOmUxNGVhODk0OTRlZjQxYTBhNzEzZjdhN2U4ZTQ3YjkxL3RhYmxlcmFuZ2U6ZTE0ZWE4OTQ5NGVmNDFhMGE3MTNmN2E3ZThlNDdiOTFfNC0xLTEtMS0yMjM1Nw_00db3825-3b88-40ff-8a20-881875209668">0.3333</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ia03fed5c8b21488386bbe6f120dd55c1_D20210101-20210930" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83OS9mcmFnOmQ4YjFmNjVkOWNlMjRjOGE5ODM4NjM4MjkwMDQ5MTlhL3RhYmxlOmUxNGVhODk0OTRlZjQxYTBhNzEzZjdhN2U4ZTQ3YjkxL3RhYmxlcmFuZ2U6ZTE0ZWE4OTQ5NGVmNDFhMGE3MTNmN2E3ZThlNDdiOTFfNC0xLTEtMS0yMjM1Nw_d3a13164-941b-4c42-9e50-c5809f1fea55">0.3333</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i7864c0c76ead4a41b2717cf096dfc1df_D20210101-20210930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83OS9mcmFnOmQ4YjFmNjVkOWNlMjRjOGE5ODM4NjM4MjkwMDQ5MTlhL3RhYmxlOmUxNGVhODk0OTRlZjQxYTBhNzEzZjdhN2U4ZTQ3YjkxL3RhYmxlcmFuZ2U6ZTE0ZWE4OTQ5NGVmNDFhMGE3MTNmN2E3ZThlNDdiOTFfNC0xLTEtMS0yMjM1Nw_de58b467-dd9d-444d-bde2-db6eb3da5d4d">0.3333</ix:nonFraction><ix:nonNumeric contextRef="ia03fed5c8b21488386bbe6f120dd55c1_D20210101-20210930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83OS9mcmFnOmQ4YjFmNjVkOWNlMjRjOGE5ODM4NjM4MjkwMDQ5MTlhL3RhYmxlOmUxNGVhODk0OTRlZjQxYTBhNzEzZjdhN2U4ZTQ3YjkxL3RhYmxlcmFuZ2U6ZTE0ZWE4OTQ5NGVmNDFhMGE3MTNmN2E3ZThlNDdiOTFfNS0xLTEtMS0yMjM1Nw_4419b77a-0f12-4345-8c3a-5f0347d2d1e2">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i7864c0c76ead4a41b2717cf096dfc1df_D20210101-20210930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83OS9mcmFnOmQ4YjFmNjVkOWNlMjRjOGE5ODM4NjM4MjkwMDQ5MTlhL3RhYmxlOmUxNGVhODk0OTRlZjQxYTBhNzEzZjdhN2U4ZTQ3YjkxL3RhYmxlcmFuZ2U6ZTE0ZWE4OTQ5NGVmNDFhMGE3MTNmN2E3ZThlNDdiOTFfNi0xLTEtMS0yMjM1Nw_b52cdafd-6e15-49a5-bea2-0756f2fc0f82">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="i82b10f09670f4bceac19cdca7e3acc7f_D20210101-20210930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83OS9mcmFnOmQ4YjFmNjVkOWNlMjRjOGE5ODM4NjM4MjkwMDQ5MTlhL3RhYmxlOmUxNGVhODk0OTRlZjQxYTBhNzEzZjdhN2U4ZTQ3YjkxL3RhYmxlcmFuZ2U6ZTE0ZWE4OTQ5NGVmNDFhMGE3MTNmN2E3ZThlNDdiOTFfNy0xLTEtMS0yMjM1Nw_f1d988ac-3107-4d6d-9ef8-0d8db062d672">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i700b68cc599f4438ba55fcd9dc69cd7a_D20210101-20210930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83OS9mcmFnOmQ4YjFmNjVkOWNlMjRjOGE5ODM4NjM4MjkwMDQ5MTlhL3RhYmxlOmUxNGVhODk0OTRlZjQxYTBhNzEzZjdhN2U4ZTQ3YjkxL3RhYmxlcmFuZ2U6ZTE0ZWE4OTQ5NGVmNDFhMGE3MTNmN2E3ZThlNDdiOTFfOC0xLTEtMS0yMjM1Nw_2c6f6187-1ac1-4169-943c-bbc4e67846f8">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i44af4abac88448b5893045bc0002855c_I20210930" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOmY2NDc1MWJlODBmNTRjOTY4ZDg5NTUxMjc1NTZjNDVjL3RhYmxlcmFuZ2U6ZjY0NzUxYmU4MGY1NGM5NjhkODk1NTEyNzU1NmM0NWNfNC0wLTEtMS0yMjM1Nw_6f24d764-2b2d-4991-9474-8d0770053a51">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="akba-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="if87a4fc02b5c41baadaddd8ae45a20ef_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i44af4abac88448b5893045bc0002855c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e2950be526b427487e169a221babd7d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i0c63b2719b7a493f89992c1c8a6feb94_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1897c1e5242647279d4844ddf93043fa_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i679a26fb513c4e229079d19e687e23ea_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6c63a1921cf449cbb7d42a58f2ca535_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if41d416d81e34b9cb6976b49960bf999_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia875941982fa4b738ad20ad8c02ee280_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d2476903d214660b7d10dfda90d5e62_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic49c106b11074ca28afbe6423ad1783c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9abd651243dc4b3888719db25453a613_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieac2241d842b494ab83cde4c6efacf46_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cc88afc4d2144b0820d54de176e706b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7aec38034ce44b18a632886540cf60f7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i068e2607df3e46ad958c3aac8d56c8bb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i789136767052440b86082df6969545de_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35244d2350f3498ebd27593263ce18df_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife5f777362b84a18b96a34f6b3515a94_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f2d1adb364d4ff18d2ad533959fe847_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2d99e2664f844a2acf2c4573bf8df03_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id85007bc927a4536b6b47497569aa944_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31f726c664944828986c9bc152d3cdbf_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2342b55b98df4c4f97a6deb300c2a324_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86dc89425ef046d69fcf7b7442f7b3af_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief1a730691f34e3697272cf628a7de24_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16965583159a4fb1943935fe0821c8b0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f18d61adce243dbaa08d8980a32a679_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6909ec0393ec4db2b3cc2706b5126477_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45ee7fe7e4ea40449ec5093c5cfe4dab_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97143382c5d94af882a7a099bb719c08_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i847e92f55f2743cc8282356cea6026ae_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib807b33284ab430ca5e62866cfe3994b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i889ed5ea677d43a19e0b2f90cc53dd3f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18bc18c0ef5546c5baeae2af38f6fac6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i264a47d635da444c86cb87a405c909c4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82c195ab2c01450cb6639257d18f6117_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82c5946e60d04544ab9e41f12a391895_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62615678941c40648470b93e883c6c27_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c14e7a0bd4c4f3b838b097690f0db73_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5eb0e7b9743b4b5bb8dcad4532a676f4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icff6bb56ef7f4b71b0ee5439d93c832d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2821e9d04730493782461dc080013c07_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04f6e21078d54815b0fbcd7ccc3af0dc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa53bc3c09164606aeaedf64079be5bc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7f690b3768a4f10ad9965db748015b2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i575073ad687946c3958e67e8c915001f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i264fd5873c584be39232727f484cadd7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i751bbd3aed3c44479e98241e0fabf680_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0c080b6e3284262a5a2ac05fc8be6d8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied2865777ae543ccb7e6733cedf24ead_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibedefb3b11734e53bd359a1087a22569_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i717676096b5a4c5eab55661e5e686861_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cbbd7587d264a93a0fac886a04d7c90_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i319c95fd8a8d4153a2394567a88f22ab_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd7f6d1ca07a4a7c81755f54e71d3a96_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a772f431b4b4e039d186148c8287a6a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f40f8942af14045ad47dc41f0a655f5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id832960589e2403f88473dd831c88c68_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc035820389e4d8a96227a92fb46d718_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00f6c8320acf4b159907d88edddf5125_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02a8ba6ff0054b678403f9ad5ed7efc4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba37ce69556348a28b16ed216da9256d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbc0260c7ae64edbabae5c84ce6356df_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib48d1a5470e1451ea0d90314033b3dfe_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2fc62f68c514632b6ff5532a6c05123_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic634149430a042a0af7eced0d7b1f3bc_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba476346b25f4a3b8f5eacda5b591d48_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i952bff9821b4497aa3ea95191dd2fe53_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i362dc8956d2b485d99df3ac257386849_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9932b64331a4dd3b00728c94fbb38e0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9bbe8c544974328bc9207e0b78b0928_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a813010cea049e3b9d06fd62cbe9afe_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0d58cac5ebc4dde9442518ff67901b4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c64672624aa423384622e444a575831_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i688f4e0d7a5c4c7e9ee5af402822f7f3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>akba:segment</xbrli:measure></xbrli:unit><xbrli:context id="id1bafbc3960143019bb39d791680d09e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:ChargebacksAndDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3e27925f7eb4396b50788b1c147f040_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:RebatesFeesAndOtherDeductionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88110b1102464bb8b4bcc45b892e9014_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:ReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic65dcd125e83450aa6300973fab408bb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:ChargebacksAndDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic138834fb069491a89247c930e50e034_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:RebatesFeesAndOtherDeductionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73f8120fb3ba417a90e8a529c456c779_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:ReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85f7bb9f4e384e1aa0a5e37af52be036_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:ChargebacksAndDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ef44b64c28a444cac3e40fe925ba315_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:RebatesFeesAndOtherDeductionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34bd677f66094393bebcca2b049effef_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:ReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6297767fc6bf43fe877f509f140dada7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:ChargebacksAndDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3450ded174e45858afc144e1af9ffac_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:RebatesFeesAndOtherDeductionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97d48e8612f24efe8996ef27cb3c6569_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:ReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i634b8d926257462d9d9e328283bb4259_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:ChargebacksAndDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i745cf671aea747ba929766351832a180_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:RebatesFeesAndOtherDeductionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a65cd87641e499c9df380248f663449_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:ReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88b205f60522473db4b1791f35bad380_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:ChargebacksAndDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbe29fe4d71b45a2807b94520a5f1004_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:RebatesFeesAndOtherDeductionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e838c8dba8c42b0b61db36cee11b10c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:ReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba72f4028b53419a9e3df0bc0bb323b5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68832275b6f74879ad43622f402f836b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefbe221ac071402e9aa1ff3c33efbea9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1709d1103fa3444fb8a09367a5e7e52e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31651748afca476c98590cfaeef98a69_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aabb65b896b4d4693a54ed68c0aa03a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefd530a7f1a248edbdc9b05c847c8a7e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib09d90891a274c3c818a2cef521eace2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73b11af5f04a42d9a1071752d045891e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6fc2047fffc4e2d8558725e0f1d34a0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i945ff9fde11644a58dafd0226b9d6c0f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i738510817c5048b98d2eea09c5a05cf1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f482f3f6423440ea0d9f6c8bef66818_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a84c225ba714f219479e22fc09d67e9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0acbf4b49164475f8a36f3979f8e5aff_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib52d8a3a1f814ede864dcab830d03ad3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae7692c90eb746178a141c1b78cb6a28_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2af3aa2c9e5f4db7bac920c367ee4124_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95f34cfdea4546b9916e24a997553533_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d24e1b865b1425f8c6a7c9541a10db2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1b71df432394860be208c54b443aacb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06aa1c9bc80b4b6497171fe4199a0347_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f865ba0db994d3fbe5976932bc384f2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifce4f17d7a3d4682a27f359eb185448b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0455e41ef2d6462b91d81400d4c2e0dd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6939d08f8a54431bf1d08db5ff563d4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e10b28a9e47483eab1daecf6b5559db_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70c28a2a28bc4932a1c94051311c07d4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4a2508fbe7b4b60998f2800a6721219_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4010db64fe4c4fd08b2112d996676126_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:ViforPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9022775c979849d481205605464f30c6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d809bfac669408289ffd42f4682ebdf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac0b3b12cdd94293a710efe9b099ccbf_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if43c4eaad1e5445d9f05ae88eab7739b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97125a084ecb413d80709a70f9e28986_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79eda260de9049ddb3c4152a914c8bc8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd7a9c2a482c488c9e39c164f7f25286_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3404eb43c0644986a1e29bf11447aefa_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i196a4d9a61ec429197ab955e5ff2ae4b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7a97c0c8d344bda97e123e206e6b3c8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c709aa7d7814c7bab26eccc3b81e798_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia93c22c9b15f4c919a2252df1363cdd4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id60c0fe0efd942ad8b113bef4877c974_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:AccruedExpensesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76b75bcd1b964770ae1b56eaf8e7a892_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:AccruedExpensesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i253a75db63844161bc3f8de0b86f9a31_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:AccruedExpensesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6b0e1ca966948bf9b3b29017f33c08b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie67e37ea23d74352995b356f2d5e00a5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i062a629a2436472793e654eaff2d5751_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8991531a317948b9b93df5b26ec241f8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9224c9eaaef4b0fbb6b3ecd626f0fb5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0467c81517d465385733a7970a7a414_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcc593671c2e4622975ac665de36e6c1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i595577133c66457b807c06fb447cc0ff_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd56d876b06146709b43ea24c7d1c59b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib43b28b4e0ab493fa74148aeaab24813_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee7892ead75d4547be97c8704445856f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe962a59b6ea455b88176426838ddf81_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i381ae62687174e09adb9da00b0c38527_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:AccruedExpensesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13ca6bac21b04356ab2ca6e641f44077_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:AccruedExpensesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id42d54e97e794a2e966b66e8d2cb3aa4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:AccruedExpensesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="performance_obligation"><xbrli:measure>akba:performance_obligation</xbrli:measure></xbrli:unit><xbrli:context id="i5ffb0dde1c014cb9abf1b7695c63c0d2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf4981c415ac4d3faa22e3d1e690bfbf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeResearchAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59b89b0dc1714bceaf61d6592940372e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">akba:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bea31568bfb475da7ac289ff0a194bb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeResearchAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">akba:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i049242e1c959495ba03db706d555ef59_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">akba:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8270fb936c044bacb333691798285cad_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8873d2f4f3ab410f8ea8fdc1148178ff_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2b65de4f50a4ba0aba4c2a04561a742_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77a8fd0e1e314ec995a1ea4cb3e26298_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75a8e981279d4597a75912a5c2d89696_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeResearchAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ab7efb86c7e4332bb5d1393a1103c7a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84bfabdde428494b8286364e0b2e04f8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec08195269f1492b95a796511ae43b19_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic04e3a3ad82e497eab9e0ccc53e84bb7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddee3a51bc8e41009393c7fffc1d6be2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5008d093e2c14f8e9b0c70b8ad2d6cdf_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30255726ea164f57b4faf87425b440bf_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c9c4fa43e814dbbaf59df410140075b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e8a7ecf26094b9985196caeaf40209b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0713ae0f1c084dc1a951ad2de75526f0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93d500fdcbc947168636b67aefe164f2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64af70fdf31a4cfcbd5d1dd0c6e667f3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c2d9393a8d94a97b1a20c634e92642c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:ContractWithCustomerLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d43ffd6494e45cea49745bc245eb588_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2182ac591eaa4895935be370490ebd61_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i729bdb2febbe40f7a0d7e8b9d41b5707_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05703e7e166b4e6aa26567e3dd53b0d4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">akba:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib36601c7c6054547b257cbee1cadedd2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">akba:GlobalDevelopmentPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="icf1d9f1217594ee99787532eb6416a3e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5df4e367c4894f3baca804f2eba217c6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i044f764231f14772829db57c3b4d1639_D20161201-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">akba:UpFrontNonRefundableAndNonCreditableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbdd2b99003a4b868da41de914cb59b4_D20161201-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i500c6fdc5af04a21900cf4f2d9069a5b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:HIFProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if916aba0a4c34bab87b14d995442b804_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicensedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4eff79078bbb43e1882ae7742d0279b6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0094621113146aebebb1a65434da333_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6acee9f4bf9402baacb58cb5f057459_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51de58b6c7be4fb9899538b241b86615_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5c623ee9ed146eb8cee4622f170592a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70b7ea01a52041328c8e4e5bcda17a4c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21debe3a35d84013a5c0a46700b925d1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fdc68385d154fbd8c01df1bd39dde5d_D20170425-20170425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">akba:UpFrontNonRefundableAndNonCreditableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-04-25</xbrli:startDate><xbrli:endDate>2017-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i871f553557614df48044678d328520cb_D20170101-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id317514fef48482db39eba1dc979e0ad_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicensedHIFProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i587afcb2ee994fd1823e352650f8c16f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicensedHIFProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f62756447d54a2ea8980a3e5189c028_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicensedHIFProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie73bc5c571f84ec38080d5e084633f19_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicensedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9874741da84a44769dea47ee0e59d980_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02e592c97e6f450ca8dbb9dfbdb2b298_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0ad25ebad234cb5a72142b53cc43ba6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac660281115d42f3adbe6635fbbac7b5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieeebde433f7a49538c99f8eedfadce25_D20170209-20170209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JanssenPharmaceuticaNVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeResearchAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-09</xbrli:startDate><xbrli:endDate>2017-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcf133937bdc4353b3c3ba86e059f5cb_I20170209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JanssenPharmaceuticaNVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeResearchAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc1340b1d3414996b23a8b1c78d66a9b_I20170209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JohnsonAndJohnsonInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeResearchAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b7b728d6820482185b5f4c1ce9f6131_I20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JohnsonAndJohnsonInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeResearchAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc1441455f5f427d888f9be3a658edc4_D20210604-20210604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">akba:CyclerionTherapeuticsLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-04</xbrli:startDate><xbrli:endDate>2021-06-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f7c79b242f844ddad0fc74aecc7c6ca_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">akba:CyclerionTherapeuticsLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ae72c8b1a6046dc8ea43e24fa8b97b6_I20170512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:ViforInternationalLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22c6d8b4a8754f2cabfbd65f0be236dd_D20170512-20170512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:ViforInternationalLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-12</xbrli:startDate><xbrli:endDate>2017-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a3012cc53274e7386ae899217cc4ae0_D20200214-20200214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:PriorityReviewVoucherLetterAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:ViforInternationalLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-14</xbrli:startDate><xbrli:endDate>2020-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e2acaca8c4648fc8c17812d445090de_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:ViforInternationalLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41e46089042845efb8effbe91d3866a0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">akba:PanionAndBFBiotechIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i042537cbb7204196925307a6b7f16840_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">akba:PanionAndBFBiotechIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3aadde62784b4aefa36a71ef6d3bb27b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">akba:PanionAndBFBiotechIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib037a9facfea4d249380bdea73ce519b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">akba:PanionAndBFBiotechIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cc1c74d758f401f8afecb62a3e1d9dd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:SublicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iead0fd037fa94b5eac362dee913b3b35_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:SublicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3917cbc6ebab4fcba1653703ddcaeb89_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:SublicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bce44b505714f94a8b535b4ea2e5717_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:SublicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i016c3424f40c49faa098233e6b0ce0ef_I20210225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b1ce5c7f57f4300b066a27bf7644888_D20210225-20210225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-25</xbrli:startDate><xbrli:endDate>2021-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56d517c10b584fe0aaec8d914de26be7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie80f8a6467b14c7cafd2f2e4ce22adf5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>akba:security</xbrli:measure></xbrli:unit><xbrli:context id="i4eaaeb5ff6074e36abf2df5bbdcad9c3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e52064c653743f2a16fd27d8c9a323a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6cdf790d03c4fed810871ebfea1a32f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i582013b1f37743bc8285c94f50c08ca4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia131987e763f4587a941882e026ee367_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5b97b6dc8c6458eb7afd794c342c79a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81fe9de9bf004275abc9aead5654fef0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9965cd10ee2c479390becf868ab08d6b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib35a112c936c43008fd53a2e71e369fe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5926c8f9dfa40cb830ffa5f3015b27d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51612bc1340040cb897112531943a394_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9db8d25d5e404f14935648663eb92df6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i469e62d61f624f13a913c992818f42a8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c2c9bd113fe46629d3834ae5a39ba17_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b81649bc6244591a493ea134990b511_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a8144587d5e488cabffbbd0bae0e7a5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">akba:OtherThanDerivativeLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i616cde0a70c94c6eb173090f144c4c43_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9033a88870c408dba279ef74720efd3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">akba:OtherThanDerivativeLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e237cd7f54f4646aa36f63692c06c40_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e72ecf91b664cca962bacefd5439368_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cd36c7e7311497ba175179857b7257c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fdb433b2bca4b748b2b7fa719b097c9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia76ea517ec23406588672981c217b653_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">akba:DevelopedProductRightsForAuryxiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30e4e068c6214ffabd5a128e3d85c999_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">akba:DevelopedProductRightsForAuryxiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dcd869a04c44f3ea928848929217e86_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OffMarketFavorableLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34034b5b7fbe48fe92390732c9576345_D20181212-20181212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">akba:DevelopedProductRightsForAuryxiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-12</xbrli:startDate><xbrli:endDate>2018-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c756e20d9664648aeb18aebeb242523_I20191111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="tranche"><xbrli:measure>akba:tranche</xbrli:measure></xbrli:unit><xbrli:context id="i3c0d403601654c72b47819a9afbd0792_I20191111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">akba:TrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia190616222f745278c0dc5a7620042c1_I20191111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">akba:TrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia00bb356464246a7b22e1821a884688d_D20191111-20191111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">akba:ThreeMonthLondonInterbankOfferedRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-11</xbrli:startDate><xbrli:endDate>2019-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8147f4e6a02545de933ea73e8af97025_D20191111-20191111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-11</xbrli:startDate><xbrli:endDate>2019-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c34013e3d5d42798cb44d8508b1ac83_D20191111-20191111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="akba:DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis">akba:DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-11</xbrli:startDate><xbrli:endDate>2019-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06ee360513f94ae993a4c6898c417de2_D20191111-20191111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="akba:DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis">akba:DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-11</xbrli:startDate><xbrli:endDate>2019-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6020a0180d34b6a86d7589b54358a92_D20191111-20191111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-11</xbrli:startDate><xbrli:endDate>2019-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cd1fb13915744c284881cee3c9a4457_I20191125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">akba:TrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefce2ff8ab894b54be64daf36220401a_D20201210-20201210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">akba:TrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BPCRLimitedPartnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-10</xbrli:startDate><xbrli:endDate>2020-12-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied529b6124d840a6ad7b272239c35283_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43a607fdad03489084b28ba60875d452_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8d3eda1fa3b436883677e9840266d97_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida5e89d4588d4e3dbdc420f58130b868_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i541f7e6319644772b0d0e20228d16057_I20170228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:JanssenAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e4cb62597ae4760a7f0d14dd934eeeb_I20200604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia500545ec09246ce9dedea5a7cd9b0d4_D20191112-20191112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-12</xbrli:startDate><xbrli:endDate>2019-11-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81c8895c1f2d4c56b6435144097a2e33_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66deeb6acb77474a959a2ca2688e2657_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a4aafef7ebc4f4dbc4da7e3e7952d94_D20200312-20200312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-12</xbrli:startDate><xbrli:endDate>2020-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6fcc0f0e17240bd92fefbacdd946b14_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48ac3ceb90a14e55a606e7ed5d3716d1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i678d4d68b8d44706b86e94178a818447_D20210225-20210225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">akba:AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-25</xbrli:startDate><xbrli:endDate>2021-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c3f11e1bf924040bbe2698d14b92960_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">akba:AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45bac3731ae447399855606573e4e297_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">akba:AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic405d5f9a6194033b54c67f003fb5108_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:InducementAwardProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8e692bb054345cb9980a00457fd17f1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:InducementAwardProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a334797d16148a8bc4de0e3cd01d3a6_I20140228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:TwoThousandAndFourteenPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24f27ec785a94f77bff6f9932edbe262_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:TwoThousandAndFourteenPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i928990fc0f0544d7bdc2c92d83eb4503_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">akba:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:TwoThousandAndFourteenPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c0679f11ab54281a697554a5d1b0a16_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:TwoThousandAndFourteenPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if883a99477df492ebd6e2365f0c4bb6a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic68dc20e53ac4d9f9315ecf7c3ede580_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67dd5c6046f64d0e9109b42763967f24_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">akba:ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f98c7914a2d4498b3182d130d0cb47a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>akba:installment</xbrli:measure></xbrli:unit><xbrli:context id="ib0f30762d9654703a976783f7172781a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i010b303706c744e2922ea62d41c6df9a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dd32faea92444fe9357160c0a7b15cc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:TwoThousandAndFourteenPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a366e7c1d9547a89b545b4c5b2edc75_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">akba:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:TwoThousandAndFourteenPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8c33b8456b445388314a4b181f4ad55_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:TwoThousandAndFourteenPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id334eb22f65f47a2b8f9ed60a00a7faf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">akba:ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i700b68cc599f4438ba55fcd9dc69cd7a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73aee313a7a7411d983faf613acc515c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fe3737b757e4dcb9d9bd2fd3a908513_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:TwoThousandAndFourteenPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02cb18bdb22b463a8143eb77464ade75_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie796bd13e7ae4237ba6a1435f0aa706a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2f38973bd944cfd9a74bfad2e344e99_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">akba:ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3082be42de6d46968f452cdc31f89952_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">akba:ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82b10f09670f4bceac19cdca7e3acc7f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">akba:ShareBasedPaymentArrangementTrancheThreeThirdAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia03fed5c8b21488386bbe6f120dd55c1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">akba:ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7864c0c76ead4a41b2717cf096dfc1df_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">akba:ShareBasedPaymentArrangementTrancheTwoSecondAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i8c4a114c87d04f9a86f0cd36147b5c17_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:CambridgeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f8032b3bd82471cbcff6a003f19e33b_D20160701-20160731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:CambridgeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-01</xbrli:startDate><xbrli:endDate>2016-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ee517b85db6461e9394aeeb76fb30a0_D20170101-20170101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:CambridgeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe11b29f86744551b0e34d4c7a45321d_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:CambridgeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">akba:OfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2085d352fbe244bfae6189887c1b70b1_I20160731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:CambridgeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc753862bba346a4b87baf73046febb4_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:CambridgeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">akba:OfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i319033b22a7e40f680e6a60fdad1e84d_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:CambridgeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">akba:OfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f13ec3e12bf451caafb2291ffc4a2a8_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:CambridgeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">akba:OfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i395d6be571b646d2a729d3d38b72c91b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">akba:OfficeSpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:BostonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36039c1763334766b650c9db8ccac9a8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">akba:OfficeSpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:BostonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="extensionoption"><xbrli:measure>akba:extensionOption</xbrli:measure></xbrli:unit><xbrli:context id="iae8a04efe54e4e2cba598fe2b46d3589_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:CambridgeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">akba:OfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f8574ce39ac48ada29733a02df6fe06_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">akba:OfficeSpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:BostonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbf6fa923bcf4b2b92e43786d4da64a2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">akba:OfficeSpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:BostonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b38f2f3c3db48cdacc6e3dab5c4477a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">akba:OfficeSpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:BostonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8e6a7b6910d48e294bcb23008415abd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">akba:OfficeSpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:BostonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99da615448e74f1b956e0da8fde046d6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">akba:OfficeSpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:BostonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2521a8d2d711470090bd6f68bb353f22_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:CambridgeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dca46c47d4447088630d11a10807fbe_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:BostonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0784525677704a0f9da4e0961490be27_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if648f232fd8d44f2853c2848e528087c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1dd7b6af62e48d89630458d90d092cb_D20200904-20200904"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:BioVectraIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-04</xbrli:startDate><xbrli:endDate>2020-09-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03f1a8e55f924ca6b788d5e2067ae377_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:BioVectraIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2c7ce4bacf943a6ae4661730894183c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:SiegfriedEvionnazSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93ce46eca8a74081a9a0a15945f34ee2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:SiegfriedEvionnazSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ce765a46da74d3ebd33dec7f304c9a8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85c91980832440e88454196ba38dbd5f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0bd0fdce45f4f2eb878365dff48b0ae_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49ee8d5e6ee44e0aa71f48df84288db0_D20190409-20190409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:EsteveQuimicaSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-09</xbrli:startDate><xbrli:endDate>2019-04-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia777a099e6224fe895fa66b20db9e666_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:EsteveQuimicaSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc3ad8cedbf646a3badc26d2e706ac87_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">akba:SupplyAgreementPatheonIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa82e47edba04966993a43c23b18a792_D20200402-20200402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:STAPharmaceuticalHongKongLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-02</xbrli:startDate><xbrli:endDate>2020-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6768bc85e77b42ec85b465655fe66cb8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:STAPharmaceuticalHongKongLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1413873e0fc3463794f8307e9bce1a4a_D20210210-20210210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:WuXiSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-10</xbrli:startDate><xbrli:endDate>2021-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7117791645b42058a5acb1a3ca00398_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16a3e0fb50c54a4081eec1b8b2e9d068_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i395ce7f5b8ae45baad50acde1847e4cd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b7e133601904c7a84c219de00bcfe1b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85f449f89e6c4ad9b140a31a285c766d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56668d4d1ae84d8c98f3182984b4d052_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001517022</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i32bac828c69741158be14bdef01bfe8b_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.625%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGV4dHJlZ2lvbjpmYTc3MzBkOTA4ZmU0ODY0YWNhOTVkNGMwYTBjYjI3N18yMjE4_2411eb51-21b0-41b8-a749-e9f7c5f2f709">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.625%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark&#160;One)</span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGV4dHJlZ2lvbjpmYTc3MzBkOTA4ZmU0ODY0YWNhOTVkNGMwYTBjYjI3N18yMjEy_8eabecd0-bf02-4f87-9d53-41e5f12bf653">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGV4dHJlZ2lvbjpmYTc3MzBkOTA4ZmU0ODY0YWNhOTVkNGMwYTBjYjI3N18xNjQ5MjY3NDQxODkwOQ_968e40fa-a265-4511-a933-ab5927bb7126">September&#160;30, 2021</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGV4dHJlZ2lvbjpmYTc3MzBkOTA4ZmU0ODY0YWNhOTVkNGMwYTBjYjI3N18yMjEw_c7f8f339-e2ea-4c04-b8e8-249b0ac7501e">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the transition period from __________to__________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGV4dHJlZ2lvbjpmYTc3MzBkOTA4ZmU0ODY0YWNhOTVkNGMwYTBjYjI3N18yMjEz_81cc97eb-1486-49f9-b351-f0d3d35a813e">001-36352</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.625%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGV4dHJlZ2lvbjpmYTc3MzBkOTA4ZmU0ODY0YWNhOTVkNGMwYTBjYjI3N18yMjE0_035dc588-1fb4-402b-b8df-7b2f34fc37ea">AKEBIA THERAPEUTICS, INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.625%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:21.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.971%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6NGRlNWVjN2MyM2I2NDZlOTg4N2RlODhmMmVmZTIwMWQvdGFibGVyYW5nZTo0ZGU1ZWM3YzIzYjY0NmU5ODg3ZGU4OGYyZWZlMjAxZF8wLTAtMS0xLTIyMzU3_9732e761-08d9-4a5b-84de-732032de737f">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6NGRlNWVjN2MyM2I2NDZlOTg4N2RlODhmMmVmZTIwMWQvdGFibGVyYW5nZTo0ZGU1ZWM3YzIzYjY0NmU5ODg3ZGU4OGYyZWZlMjAxZF8wLTQtMS0xLTIyMzU3_9297334a-638f-457a-ace4-20d20c04d3de">20-8756903</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;<ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6NGRlNWVjN2MyM2I2NDZlOTg4N2RlODhmMmVmZTIwMWQvdGFibGVyYW5nZTo0ZGU1ZWM3YzIzYjY0NmU5ODg3ZGU4OGYyZWZlMjAxZF8zLTAtMS0xLTIyMzU3L3RleHRyZWdpb246Njk1ZGNhOGQ4OWVhNGRlNjgxYzRhZWNlODI3NDgzNzJfMjc0ODc3OTA2OTUwNA_b6ea468f-b3a0-4211-a5d1-e79d93f57020">245 First Street</ix:nonNumeric>, <ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6NGRlNWVjN2MyM2I2NDZlOTg4N2RlODhmMmVmZTIwMWQvdGFibGVyYW5nZTo0ZGU1ZWM3YzIzYjY0NmU5ODg3ZGU4OGYyZWZlMjAxZF8zLTAtMS0xLTIyMzU3L3RleHRyZWdpb246Njk1ZGNhOGQ4OWVhNGRlNjgxYzRhZWNlODI3NDgzNzJfOA_abb9a84e-ce0a-4125-b00f-dffd21fa3b22">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6NGRlNWVjN2MyM2I2NDZlOTg4N2RlODhmMmVmZTIwMWQvdGFibGVyYW5nZTo0ZGU1ZWM3YzIzYjY0NmU5ODg3ZGU4OGYyZWZlMjAxZF8zLTAtMS0xLTIyMzU3L3RleHRyZWdpb246Njk1ZGNhOGQ4OWVhNGRlNjgxYzRhZWNlODI3NDgzNzJfMTI_9d3d2bab-6668-4f3e-bf0c-1a23d042275f">MA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6NGRlNWVjN2MyM2I2NDZlOTg4N2RlODhmMmVmZTIwMWQvdGFibGVyYW5nZTo0ZGU1ZWM3YzIzYjY0NmU5ODg3ZGU4OGYyZWZlMjAxZF8zLTQtMS0xLTIyMzU3_2ed02a5a-3655-4566-8cf7-4fb74ce5905f">02142</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGV4dHJlZ2lvbjpmYTc3MzBkOTA4ZmU0ODY0YWNhOTVkNGMwYTBjYjI3N181NTI_a34abf85-5356-4409-90ca-b03f1579de8a">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGV4dHJlZ2lvbjpmYTc3MzBkOTA4ZmU0ODY0YWNhOTVkNGMwYTBjYjI3N18yMjE1_25f1dfb9-9052-4d01-8e53-8b05e1b29dc8">871-2098</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n/a</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name, former address and formal fiscal year, if changed since last report)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.625%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Trading symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6NjQ4Yjc0YTkyOTE1NDlhYjkwZWUxOGYzZTFmYmJhYmQvdGFibGVyYW5nZTo2NDhiNzRhOTI5MTU0OWFiOTBlZTE4ZjNlMWZiYmFiZF8yLTAtMS0xLTIyMzU3_32b7113d-cfde-4ee7-9f42-b10d7a5f8cca">Common Stock, par value $0.00001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6NjQ4Yjc0YTkyOTE1NDlhYjkwZWUxOGYzZTFmYmJhYmQvdGFibGVyYW5nZTo2NDhiNzRhOTI5MTU0OWFiOTBlZTE4ZjNlMWZiYmFiZF8yLTEtMS0xLTIyMzU3_bfc94008-1103-44f2-99b3-5562e12f4e45">AKBA</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6NjQ4Yjc0YTkyOTE1NDlhYjkwZWUxOGYzZTFmYmJhYmQvdGFibGVyYW5nZTo2NDhiNzRhOTI5MTU0OWFiOTBlZTE4ZjNlMWZiYmFiZF8yLTItMS0xLTIyMzU3_e797ff86-3757-4c2b-bc3a-49cb95ca84e8">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGV4dHJlZ2lvbjpmYTc3MzBkOTA4ZmU0ODY0YWNhOTVkNGMwYTBjYjI3N18yMjE2_04511a67-f98b-4bbd-b88f-5523c898e924">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGV4dHJlZ2lvbjpmYTc3MzBkOTA4ZmU0ODY0YWNhOTVkNGMwYTBjYjI3N18yMjEx_c3045fa0-6a3d-454d-a0b2-80ab0bb2acdc">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6N2U5MGQxY2E2ZGMwNDJjMmFiZWUyNDhkMjNiMmQzMDUvdGFibGVyYW5nZTo3ZTkwZDFjYTZkYzA0MmMyYWJlZTI0OGQyM2IyZDMwNV8wLTAtMS0xLTIyMzU3_b6989c42-fa8f-4cf6-b591-ad9181bb8360">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#253;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#168;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6N2U5MGQxY2E2ZGMwNDJjMmFiZWUyNDhkMjNiMmQzMDUvdGFibGVyYW5nZTo3ZTkwZDFjYTZkYzA0MmMyYWJlZTI0OGQyM2IyZDMwNV8yLTMtMS0xLTIyMzU3_cb488505-9133-48e0-beb9-7028a5cdf0a4">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6N2U5MGQxY2E2ZGMwNDJjMmFiZWUyNDhkMjNiMmQzMDUvdGFibGVyYW5nZTo3ZTkwZDFjYTZkYzA0MmMyYWJlZTI0OGQyM2IyZDMwNV80LTMtMS0xLTIyMzU3_3ba730a4-1526-4768-8329-7c7d33b4314d">&#9744;</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" format="ixt:fixed-false" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGV4dHJlZ2lvbjpmYTc3MzBkOTA4ZmU0ODY0YWNhOTVkNGMwYTBjYjI3N18yMjE3_4da466fb-d3ad-41a1-b567-0709d91c592a">&#253;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Outstanding&#160;at&#160;October&#160;31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if87a4fc02b5c41baadaddd8ae45a20ef_I20211031" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6Y2FlNzA1NjVmMTAyNGYyMWFkMTU2OTA2MDYzODAyOTMvdGFibGVyYW5nZTpjYWU3MDU2NWYxMDI0ZjIxYWQxNTY5MDYwNjM4MDI5M18xLTEtMS0xLTIyMzU3L3RleHRyZWdpb246MDkzMjExYTgyMGNkNDlmODgyZmU5OTA1Y2FlNjAxN2VfNA_b3c9b191-d984-4c13-afe2-a20d7c1398fd">174,960,413</ix:nonFraction></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i32bac828c69741158be14bdef01bfe8b_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements that are being made pursuant to the provisions of the U.S. Private Securities Litigation Reform Act of 1995 with the intention of obtaining the benefits of the &#8220;safe harbor&#8221; provisions of that Act. All statements contained in this Quarterly Report on Form&#160;10&#8209;Q other than statements of historical fact are forward-looking statements. These forward-looking statements may be accompanied by words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;build,&#8221; &#8220;can,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;designed,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;future,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;likely,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;strategy,&#8221; &#8220;seek,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and other words and terms of similar meaning, but the absence of these words does not necessarily mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements about:</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">the potential therapeutic benefits, safety profile, and effectiveness of vadadustat;&#160;</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:49.8pt">establishing vadadustat as a new oral standard of care for treatment of adult patients with anemia due to chronic kidney disease;</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">the timing, investment and associated activities involved in the continued commercialization of Auryxia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ferric citrate), its growth opportunities and Akebia's ability to execute thereon;</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">the potential indications, demand and market opportunity, potential and acceptance of Auryxia and vadadustat, if approved, including the size of eligible patient populations;&#160;</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">the&#160;timing of or likelihood of regulatory filings and approvals, including labeling or other restrictions, such as the anticipated timing of a response by the U.S. Food and Drug Administration, or FDA, to our New Drug Application for vadadustat and our planned filing of a E.U. Marketing Authorization Application for vadadustat with the European Medicines Agency, the likelihood of approval of vadadustat and our outlook related thereto, and potential indications for vadadustat;&#160;</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">the potential therapeutic applications of the hypoxia inducible factor pathway;&#160;</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">our pipeline and portfolio, including its potential, and our related research and development activities;&#160;</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">our competitive position, including estimates, developments and projections relating to our competitors and their products and product candidates, and our industry;&#160;</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">our expectations with respect to (i) the ongoing anticipated financial impact and potential benefits to us related to our merger with Keryx Biopharmaceuticals, Inc., or Keryx, that was completed on December 12, 2018, (ii) integration of the businesses subsequent to the merger, and (iii) other matters related to the merger;</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">our expectations, projections and estimates regarding our capital requirements, need for additional capital, financing our future cash needs, costs, expenses, revenues, capital resources, cash flows, financial performance, profitability, tax obligations, liquidity, growth, contractual obligations, the period of time our cash resources and collaboration funding will fund our current operating plan, our internal control over financial reporting and disclosure controls and procedures, and remediation of the material weakness we have identified in our internal control over financial reporting relating to our inventory process or any future deficiencies or material weaknesses in our internal controls and procedures; </span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">the direct or indirect impacts of the coronavirus 2 (SARS-CoV-2) pandemic on our business, operations and the markets and communities in which we and our partners, collaborators, vendors, and customers operate;</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">our manufacturing, supply and quality matters and any recalls, write-downs, impairments or other related consequences or potential consequences;&#160;</span></div><div style="padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">estimates, beliefs and judgments related to the valuation of intangible assets, goodwill, contingent consideration, debt and other assets and liabilities, including our impairment analysis and our methodology and assumptions regarding fair value measurements;</span></div><div style="padding-left:54pt;text-indent:-36pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">the&#160;timing of the availability and disclosure of clinical trial data and results;</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">our and our collaborators&#8217; strategy, plans and expectations with respect to the development, manufacturing, supply, commercialization, launch, marketing and sale of Auryxia and vadadustat, if approved, and the associated timing thereof;&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">the designs of our studies, and the type of information and data expected from our studies and the expected benefits thereof;&#160;</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">our ability to maintain any marketing authorizations we currently hold or will obtain, including our marketing authorizations for Auryxia and our ability to complete post-marketing requirements with respect thereto;</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">our ability to negotiate, secure and maintain adequate pricing, coverage and reimbursement terms and processes on a timely basis, or at all, with third-party payors for Auryxia and vadadustat, if approved;</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">the targeted timing of enrollment of our clinical trials;&#160;</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">the&#160;timing of initiation of our clinical trials&#160;and plans to conduct preclinical and clinical studies in the future;&#160;</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">the timing and amounts of payments from or to our collaborators and licensees, and the anticipated arrangements and benefits under our collaboration and license agreements, including with respect to milestones and royalties;&#160;</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">our intellectual property position, including obtaining and maintaining patents, and the timing, outcome and impact of administrative, regulatory, legal and other proceedings relating to our patents and other proprietary and intellectual property rights, as well as Abbreviated New Drug Applications filed by generic drug manufacturers and potential FDA approval thereof, and associated patent infringement suits that we have filed or may file, or other actions that we may take against such companies, and the timing and resolution thereof;</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">expected ongoing reliance on third parties, including with respect to the development, manufacturing, supply and commercialization of Auryxia and vadadustat, if approved;</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">accounting standards and estimates, their impact, and their expected timing of completion;</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">estimated periods of performance of key contracts;</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">our facilities, lease commitments, and future availability of facilities;</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">cybersecurity;</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">insurance coverage;</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">management of our key personnel, including our management team, and our employees, including employee compensation, employee relations, and our ability to attract, train and retain high quality employees;</span></div><div style="margin-bottom:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">the implementation of our business model, current operating plan, and strategic plans for our business, product candidates and technology, and business development opportunities including potential collaborations, alliances, mergers, acquisitions or licensing of assets; and</span></div><div style="padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:50.5pt">the timing, outcome and impact of current and any future legal proceedings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any or all of these forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be inaccurate. These forward-looking statements involve risks and uncertainties, including those that are discussed below under the heading "Risk Factor Summary", and the risk factors identified further in Part II, Item&#160;1A. "Risk Factors" included in this Quarterly Report on Form 10-Q and elsewhere in this Quarterly Report on Form 10-Q, that could cause our actual results, financial condition, performance or achievements to be materially different from those indicated in these forward-looking statements. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Except as required by law, we assume no obligation to publicly update or revise these forward-looking statements for any reason. Unless otherwise stated, our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q also contains estimates and other information concerning our industry and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Unless otherwise expressly stated, we obtained this industry, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Quarterly Report on Form 10-Q, unless otherwise stated or the context otherwise requires, references to &#8220;Akebia,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company,&#8221; and similar references refer to Akebia Therapeutics, Inc. and, where appropriate, its subsidiaries, including Keryx.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AURYXIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, AKEBIA Therapeutics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Vafseo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and their associated logos are trademarks of Akebia and/or its affiliates. All other trademarks, trade names and service marks appearing in this Quarterly Report on Form 10-Q are the property of their respective owners. All website addresses given in this Quarterly Report on Form 10-Q are for information only and are not intended to be an active link or to incorporate any website information into this document.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i32bac828c69741158be14bdef01bfe8b_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">RISK FACTORS SUMMARY</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in our common stock involves numerous risks, including the risks summarized below and described in further detail in &#8220;Part II, Item 1A. Risk Factors&#8221; of this Quarterly Report on Form 10-Q, any one of which could materially adversely affect our business, financial condition, results of operations, and prospects. These risks include, but are not limited to, the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses since our inception, and anticipate that we will continue to incur significant losses and cannot guarantee when, if ever, we will become profitable or attain positive cash flows;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will require substantial additional financing to achieve our goals. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Our obligations in connection with the Loan Agreement with </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">BioPharma Credit PLC, BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> could adversely affect our financial condition and restrict our operations;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Royalty Interest Acquisition Agreement with HealthCare Royalty Partners IV, L.P. contains various covenants and other provisions, which, if violated, could materially adversely affect our financial condition;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Royalties from commercial sales of vadadustat under our Collaboration Agreement with Mitsubishi Tanabe Pharma Corporation will likely fluctuate and could impact our rights to receive future payments from our Royalty Interest Acquisition Agreement with HealthCare Royalty Partners IV, L.P.;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product and product candidates on unfavorable terms to us;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may engage in strategic transactions to acquire assets, businesses, or rights to products, product candidates or technologies or form collaborations or make investments in other companies or technologies that could harm our operating results, dilute our stockholders&#8217; ownership, increase our debt, or cause us to incur significant expense;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We may fail to realize the anticipated benefits of our merger with Keryx, those benefits may take longer to realize than expected, and we may encounter significant integration difficulties and liabilities, which may have a material adverse effect on our business and financial position;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business has been and may continue to be, directly or indirectly, adversely affected by the COVID-19 pandemic;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to successfully commercialize any approved product, including our ability to achieve their widespread market acceptance, is critical to the success of our business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to maintain sales and marketing capabilities or to enter into additional agreements with third parties, we may not be successful in commercializing Auryxia, vadadustat, if approved, and any other product candidate that may be approved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain or maintain contracts with key distribution partners, or adequate or favorable reimbursement for our products, our business could be materially harmed;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face substantial competition, which may result in others discovering, developing or commercializing products before, or more successfully than, we do;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The commercialization of Riona and Vafseo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan and our current and potential future efforts with respect to the development and commercialization of our products and product candidates outside of the United States subject us to a variety of risks associated with international operations, which could materially adversely affect our business;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">In addition to Auryxia, we will continue to depend heavily on the success of our product candidate, vadadustat, for which we submitted an NDA to the FDA, which was accepted for filing in May 2021. Clinical drug development involves a lengthy and expensive process with an uncertain outcome. We will incur additional costs in connection with, and may experience delays in completing, or ultimately be unable to complete, the development and commercialization of vadadustat and any other product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may find it difficult to enroll patients in our clinical studies, which could delay or prevent clinical studies of Auryxia, vadadustat or any other product or product candidate, including those that may be in-licensed or acquired;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Conducting clinical trials outside of the United States makes us subject to additional risks and complexities and we may not complete such trials successfully, in a timely manner, or at all, which could affect our ability to obtain regulatory approvals;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Auryxia, vadadustat or any other product and product candidate, including those that may be in-licensed or acquired, may cause undesirable side effects or have other properties that delay or limit their commercial potential, or in the case of vadadustat, prevent its marketing approval;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be successful in our efforts to identify, acquire, discover, develop and commercialize additional products or product candidates, which could impair our ability to grow our business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to obtain marketing approval for, or successfully commercialize, vadadustat, or we may experience significant delays in doing so, any of which would materially harm our business;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Products approved for marketing are subject to extensive post-marketing regulatory requirements and could be subject to post-marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, or product candidates, when and if any of them is approved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to a complex regulatory scheme that requires significant resources to ensure compliance. Failure to comply with applicable laws could subject us to government scrutiny or government enforcement, potentially resulting in costly investigations and/or fines or sanctions, or impacting our relationships with key regulatory agencies such as the U.S. Food and Drug Administration, the U.S. Securities and Exchange Commission or the European Medicines Agency;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our relationships with healthcare providers, physicians and third party payors are subject to applicable anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security, and other healthcare laws and regulations, which, in the event of a violation, could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the licensor of certain intellectual property relating to Auryxia terminates, modifies or threatens to terminate existing contracts or relationships with us, our business may be materially harmed;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to conduct our clinical studies and certain of our preclinical studies for our product and product candidates. If they do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to optimize the commercialization of Auryxia or obtain marketing approval for or commercialize vadadustat or any other product candidates, and our business could be substantially harmed;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to conduct all aspects of our product manufacturing. The loss of these manufacturers, their failure to supply us on a timely basis, or their failure to successfully carry out their contractual duties or comply with regulatory requirements or guidance could cause delays in or disruptions to our supply chain and substantially harm our business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may seek to establish additional collaborations and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to adequately protect our intellectual property, third parties may be able to use our intellectual property or develop similar intellectual property, which could adversely affect our ability to compete in the market;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to protect our intellectual property rights throughout the world;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to attract, keep and motivate senior management and key personnel, we may be unable to successfully develop and commercialize any product candidates and approved product(s);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our employees, independent contractors, principal investigators, contract research organizations, contract manufacturing organizations, consultants and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading laws and regulations;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may encounter difficulties in managing our growth and expanding our operations successfully;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our stock price has been and may continue to be volatile, which could result in substantial losses for purchasers of our common stock and lawsuits against us and our officers and directors;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have identified a material weakness in our internal control over financial reporting relating to our inventory process. If we are not able to remediate this material weakness, or if we experience additional material weaknesses or other deficiencies in the future or otherwise fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting which would harm our business and the trading price of our common stock; and</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance initiatives and corporate governance practices.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i32bac828c69741158be14bdef01bfe8b_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Akebia Therapeutics, Inc.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:92.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.196%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_16">Part I. Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_19">Item&#160;1&#160;&#8211;&#160;Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_22">Condensed Consolidated Balance Sheets as of </a><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_22">September </a><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_22">30, 2021 and December&#160;31, 20</a>20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i32bac828c69741158be14bdef01bfe8b_22">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_25">Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three</a><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_25"> and </a><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_25">Nine</a><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_25"> Months Ended </a><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_25">September</a><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_25"> 30</a><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_25">, 202</a><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_25">1</a><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_25"> and 20</a>20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i32bac828c69741158be14bdef01bfe8b_25">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_28">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three</a><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_28"> and </a><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_28">Nine</a><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_28"> Months Ended </a><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_28">September</a><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_28"> 30</a><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_28">, 202</a><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_28">1</a><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_28"> and 20</a>20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i32bac828c69741158be14bdef01bfe8b_28">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_31">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_31">Nine</a><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_31"> Months Ended </a><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_31">September</a><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_31"> 30</a><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_31">, 202</a><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_31">1</a><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_31"> and 20</a>20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i32bac828c69741158be14bdef01bfe8b_31">11</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_34">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i32bac828c69741158be14bdef01bfe8b_34">12</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_88">Item&#160;2&#160;&#8211;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i32bac828c69741158be14bdef01bfe8b_88">35</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_109">Item&#160;3&#160;&#8211;&#160;Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i32bac828c69741158be14bdef01bfe8b_109">49</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_112">Item&#160;4&#160;&#8211;&#160;Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i32bac828c69741158be14bdef01bfe8b_112">49</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_115">Part II. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i32bac828c69741158be14bdef01bfe8b_115">51</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_118">Item&#160;1&#160;&#8211;&#160;Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i32bac828c69741158be14bdef01bfe8b_118">51</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_121">Item&#160;1A&#160;&#8211;&#160;Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i32bac828c69741158be14bdef01bfe8b_121">57</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_124">Item&#160;2&#160;&#8211;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i32bac828c69741158be14bdef01bfe8b_124">110</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_127">Item&#160;3&#160;&#8211;&#160;Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i32bac828c69741158be14bdef01bfe8b_127">110</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_130">Item&#160;4&#160;&#8211;&#160;Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i32bac828c69741158be14bdef01bfe8b_130">110</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_133">Item&#160;5&#160;&#8211;&#160;Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i32bac828c69741158be14bdef01bfe8b_133">110</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_136">Item&#160;6&#160;&#8211;&#160;Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i32bac828c69741158be14bdef01bfe8b_136">111</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#007bff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i32bac828c69741158be14bdef01bfe8b_139">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i32bac828c69741158be14bdef01bfe8b_139">112</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i32bac828c69741158be14bdef01bfe8b_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="i32bac828c69741158be14bdef01bfe8b_19"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;Financial Statements.</span></div><div><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_22"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AKEBIA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMy0xLTEtMS0yMjM1Nw_05b1594c-562d-4d2c-a21c-089ab5be5341">207,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMy0zLTEtMS0yMjM1Nw_04999223-4008-49a6-9f12-515bcfd7051e">228,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfNC0xLTEtMS0yMjM1Nw_5d11599b-6180-424c-8269-8021aa741035">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfNC0zLTEtMS0yMjM1Nw_313050e6-094b-40e7-a76a-bf6694fe3c1f">39,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfNS0xLTEtMS0yMjM1Nw_9afb3dc9-7a9a-439b-bed2-74b8dd77452c">33,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfNS0zLTEtMS0yMjM1Nw_54c40916-ba02-42c7-8242-510057c59669">61,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfNi0xLTEtMS0yMjM1Nw_521ee917-b41c-4e56-a642-2b6b8919cd55">49,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfNi0zLTEtMS0yMjM1Nw_a66fd837-f7d2-4bf2-af7e-97aee2c652de">26,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfNy0xLTEtMS0yMjM1Nw_b7e8d7c8-e56e-482d-a9a5-2afeee881027">39,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfNy0zLTEtMS0yMjM1Nw_601a3843-3011-4704-8945-46cd8a0dc62a">14,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfOC0xLTEtMS0yMjM1Nw_4f8f38fb-d5ab-485b-a927-4b8c586465f0">330,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfOC0zLTEtMS0yMjM1Nw_a79b3fa1-920f-4317-aa2d-5c0e0a0b29c8">371,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfOS0xLTEtMS0yMjM1Nw_61bdc14f-1d60-4390-bf9b-d02f2b7b12a8">7,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfOS0zLTEtMS0yMjM1Nw_a706cfad-64ad-4ade-bbec-47c1f6ab82e7">8,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTAtMS0xLTEtMjIzNTc_7402cf7d-ab72-4901-a3e1-7a0f1483b6ec">23,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTAtMy0xLTEtMjIzNTc_f6b460cd-4e0b-4038-9037-2897374063f4">26,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTEtMS0xLTEtMjIzNTc_262b4849-381d-460c-ad2d-c3e5081b21a7">55,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTEtMy0xLTEtMjIzNTc_fd280cab-4fcf-4b95-9e8a-c4ff6f97f285">55,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTItMS0xLTEtMjIzNTc_84a45ebc-4935-4b2a-a2df-8be6acfb1009">117,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTItMy0xLTEtMjIzNTc_92b5f11d-70c4-44b0-aa0d-a6fc1a092654">144,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTMtMS0xLTEtMjIzNTc_8859be7b-7724-44d3-88bc-2135f8625409">69,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTMtMy0xLTEtMjIzNTc_61715161-56b8-4715-bae6-ddf34d922772">37,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTQtMS0xLTEtMjIzNTc_a6803592-2ab0-4ecb-a248-ef7cfa6a9462">602,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTQtMy0xLTEtMjIzNTc_30973626-fdc5-472e-96cd-69e2ecd13c96">644,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTctMS0xLTEtMjIzNTc_52c7c274-fa21-4820-a455-77840ee6b987">28,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTctMy0xLTEtMjIzNTc_5ec19c83-64d8-4228-8845-5edc19d608b1">41,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTgtMS0xLTEtMjIzNTc_7986a137-ca68-4a23-974c-5405d48f033b">144,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTgtMy0xLTEtMjIzNTc_373f0cea-62f6-4482-988e-f0787b29e59b">130,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTktMS0xLTEtMjIzNTc_94ba85d2-443e-4bbe-b46f-cb85ed25244b">15,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTktMy0xLTEtMjIzNTc_960d6d68-7d1a-4eb9-b8f4-07eae27dec9c">15,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjAtMS0xLTEtMjIzNTc_dfd93a96-e828-4ae0-b6e8-d6532a9e26cf">189,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjAtMy0xLTEtMjIzNTc_d50a939b-7a1b-4e06-91fd-f8532407f77f">187,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjEtMS0xLTEtMjIzNTc_0e6560a5-897d-4973-945d-ed9c0981a687">27,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjEtMy0xLTEtMjIzNTc_ab11753d-b30d-45e8-ab05-1214498c0301">25,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjItMS0xLTEtMjIzNTc_ae21ccc9-cda6-4505-8648-4fc48b8fd369">20,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjItMy0xLTEtMjIzNTc_5bfbb088-1598-423d-96d1-95fea377bf67">24,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjMtMS0xLTEtMjIzNTc_dd0ed045-43a7-4cc5-b988-50169c54f253">1,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjMtMy0xLTEtMjIzNTc_c63a1682-50ee-456d-9d10-9245e56e098b">2,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjQtMS0xLTEtMjIzNTc_be7fb2f1-607f-4ab6-9d35-c9bce6fff2bd">97,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjQtMy0xLTEtMjIzNTc_b5c0ca84-9750-4248-ac1a-3b6c1f81a3a4">96,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liability related to sale of future royalties, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjUtMS0xLTEtMjIzNTc_bf708764-e008-4739-b4f7-cc1c93878ede">51,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:fixed-zero" name="akba:ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjUtMy0xLTEtMjIzNTc_c2670a9a-71ce-4f7d-8157-ee7c3b20debf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjYtMS0xLTEtMjIzNTc_bfbc88ba-5f61-4aa7-be6c-2472a340037b">77,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjYtMy0xLTEtMjIzNTc_f58fc42a-acc2-46ba-9ea2-04efcc8b2429">60,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjctMS0xLTEtMjIzNTc_c5f8eb73-8ec0-46b6-b215-ab491a9f4ed6">465,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjctMy0xLTEtMjIzNTc_24d2f497-4711-4dd8-a06a-92c4d33e209d">396,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 14)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjgtMS0xLTEtMjIzNTc_82df45b9-0417-4d8d-b489-55e25829df17"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjgtMy0xLTEtMjIzNTc_66a32945-758e-4fa7-9d82-9c197189e17d"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock $<ix:nonFraction unitRef="usdPerShare" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzAtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjoyYzQwMTMyMjkyMmE0YTJlYTIzM2IwYjY4ZjUyN2ExZl8yMA_505dd588-d5e5-4dac-9298-74b97fa817d9"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzAtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjoyYzQwMTMyMjkyMmE0YTJlYTIzM2IwYjY4ZjUyN2ExZl8yMA_be67952d-c919-40c9-b653-f3d4e20c0186">0.00001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzAtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjoyYzQwMTMyMjkyMmE0YTJlYTIzM2IwYjY4ZjUyN2ExZl8zNA_21a75bd6-f645-4ae1-adb9-06f2f18bcd7e"><ix:nonFraction unitRef="shares" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzAtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjoyYzQwMTMyMjkyMmE0YTJlYTIzM2IwYjY4ZjUyN2ExZl8zNA_d9da8a9c-33c5-49eb-ba03-a77e75610862">25,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzAtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjoyYzQwMTMyMjkyMmE0YTJlYTIzM2IwYjY4ZjUyN2ExZl81Ng_4740ef7b-3357-45bd-ab30-61ea67f23022"><ix:nonFraction unitRef="shares" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzAtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjoyYzQwMTMyMjkyMmE0YTJlYTIzM2IwYjY4ZjUyN2ExZl81Ng_5d60582a-8b1a-4183-8333-5191996f1db3"><ix:nonFraction unitRef="shares" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzAtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjoyYzQwMTMyMjkyMmE0YTJlYTIzM2IwYjY4ZjUyN2ExZl81Ng_7dad568c-c638-4fb4-80ed-59b2839ad442"><ix:nonFraction unitRef="shares" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzAtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjoyYzQwMTMyMjkyMmE0YTJlYTIzM2IwYjY4ZjUyN2ExZl81Ng_c3003e90-2969-4c4e-9743-49d3e4b35eb9">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160; outstanding at September&#160;30, 2021 and December 31, 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzAtMS0xLTEtMjIzNTc_30ef0f10-29c7-4fcb-957a-6f4150f83e0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzAtMy0xLTEtMjIzNTc_0b3e1f88-ebd8-4cec-9813-564bad483e0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock $<ix:nonFraction unitRef="usdPerShare" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzEtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjo4YTlmMDAyYjgxOTE0MjUyOGI3ODlmZGZjNjVmMTEyMV8xOA_73b60055-7193-4ebe-ad9a-12e71e5d96b4"><ix:nonFraction unitRef="usdPerShare" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzEtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjo4YTlmMDAyYjgxOTE0MjUyOGI3ODlmZGZjNjVmMTEyMV8xOA_e769b4d4-d315-4d8e-9664-41f87ae3393a">0.00001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzEtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjo4YTlmMDAyYjgxOTE0MjUyOGI3ODlmZGZjNjVmMTEyMV8zMg_0d30c230-f621-450a-a005-bce4ea5cedbb"><ix:nonFraction unitRef="shares" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzEtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjo4YTlmMDAyYjgxOTE0MjUyOGI3ODlmZGZjNjVmMTEyMV8zMg_ca414d86-2206-4e5d-98b1-ba81409c49af">350,000,000</ix:nonFraction></ix:nonFraction> shares authorized at September&#160;30, 2021 and December 31, 2020; <ix:nonFraction unitRef="shares" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzEtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjo4YTlmMDAyYjgxOTE0MjUyOGI3ODlmZGZjNjVmMTEyMV84Mg_0d1b7068-9c3f-49fe-8eaf-97fdc73845c1"><ix:nonFraction unitRef="shares" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzEtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjo4YTlmMDAyYjgxOTE0MjUyOGI3ODlmZGZjNjVmMTEyMV84Mg_c69b48e8-65df-4261-a54c-ce309078edb2">174,551,989</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzEtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjo4YTlmMDAyYjgxOTE0MjUyOGI3ODlmZGZjNjVmMTEyMV84OQ_08a8c5cb-774b-40ed-a581-f2f05fdba6f6"><ix:nonFraction unitRef="shares" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzEtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjo4YTlmMDAyYjgxOTE0MjUyOGI3ODlmZGZjNjVmMTEyMV84OQ_9c94e722-22dc-4f6f-84fe-f08382a7aa97">148,074,085</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September&#160;30, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzEtMS0xLTEtMjIzNTc_8faa3d81-8a1c-446f-8098-9e16a732ec24">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzEtMy0xLTEtMjIzNTc_302c84ad-81d7-46a8-b5d8-71f34d4bce01">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzItMS0xLTEtMjIzNTc_62ee4741-2de9-44f7-9757-703fcd37b584">1,526,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzItMy0xLTEtMjIzNTc_ac064d46-8013-482f-aa9a-544c5e0060a7">1,425,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzMtMS0xLTEtMjIzNTc_410998c5-88a0-4771-b896-d2c3d5cc793d">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzMtMy0xLTEtMjIzNTc_6288c8bf-7ef6-4da0-b02e-66018fe654c4">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzQtMS0xLTEtMjIzNTc_9a80b854-18b8-471a-9d39-2a9796b60067">1,389,673</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzQtMy0xLTEtMjIzNTc_343e86ca-820f-48e8-bf09-2eddc819b14a">1,177,511</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzUtMS0xLTEtMjIzNTc_8df30f57-5952-4e40-809b-2706b6c3763f">137,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzUtMy0xLTEtMjIzNTc_62354a70-755a-4fb1-bf59-3a66af547b7a">247,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzYtMS0xLTEtMjIzNTc_7e2cdcc0-541e-4709-b617-a7a4787604a3">602,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzYtMy0xLTEtMjIzNTc_a0649dae-f290-437b-b9aa-5a6654e6a0c9">644,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i32bac828c69741158be14bdef01bfe8b_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AKEBIA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c63b2719b7a493f89992c1c8a6feb94_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMy0xLTEtMS0yMjM1Nw_44c25078-0cf0-454b-857a-26fc499cf727">36,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1897c1e5242647279d4844ddf93043fa_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMy0zLTEtMS0yMjM1Nw_34a03147-5918-448e-94a4-2435ba4f2626">34,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i679a26fb513c4e229079d19e687e23ea_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMy01LTEtMS0yMjM1Nw_a776fc18-352d-4c65-96f1-144a3bc7f567">100,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6c63a1921cf449cbb7d42a58f2ca535_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMy03LTEtMS0yMjM1Nw_e4f90322-799c-4293-b487-bf9b35381777">94,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License, collaboration and other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if41d416d81e34b9cb6976b49960bf999_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfNC0xLTEtMS0yMjM1Nw_25abf111-100a-4dbe-9b78-60d239a8b59a">12,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia875941982fa4b738ad20ad8c02ee280_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfNC0zLTEtMS0yMjM1Nw_f2608666-9f2a-4178-b825-3264deea440e">25,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d2476903d214660b7d10dfda90d5e62_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfNC01LTEtMS0yMjM1Nw_61c4ba7d-2e2b-496b-ba31-f99041edac43">53,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic49c106b11074ca28afbe6423ad1783c_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfNC03LTEtMS0yMjM1Nw_fecdc811-383d-4137-8a25-dc196d462dc6">144,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfNS0xLTEtMS0yMjM1Nw_e79e9791-c02c-4cc1-b398-e60e08476e0d">48,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfNS0zLTEtMS0yMjM1Nw_772bae21-177b-4bb7-9994-31c1a5e84cce">59,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfNS01LTEtMS0yMjM1Nw_e1fefd4d-1b70-4303-8c9d-cdb94bed9434">153,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfNS03LTEtMS0yMjM1Nw_90e87db9-3f8a-45de-b63c-43644aaf9831">238,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfNy0xLTEtMS0yMjM1Nw_4bf2be1b-d924-4efa-b63f-8335a9ad446f">6,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfNy0zLTEtMS0yMjM1Nw_dfe07700-27e1-4bcd-b835-d8d539c0b81e">24,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfNy01LTEtMS0yMjM1Nw_74baea4a-41ae-48af-aea7-c5202f8a9902">76,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfNy03LTEtMS0yMjM1Nw_3ee72d4d-cabd-46ca-bc4a-a3bd967999d7">92,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfOC0xLTEtMS0yMjM1Nw_a01ea53e-1fb9-43d4-99de-260de1488385">9,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfOC0zLTEtMS0yMjM1Nw_1e3a46dc-4dc9-4ca2-a699-3dbd57acdd88">6,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfOC01LTEtMS0yMjM1Nw_a7bccc0d-c3a9-4279-a96e-a966183e19d9">27,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfOC03LTEtMS0yMjM1Nw_bb0f8c6f-12e9-4f95-b8e3-adeee4d14206">24,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of intangible asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="akba:ProductionRelatedImpairmentsOrChargesIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfOS0xLTEtMS0yMjM1Nw_01e0a69d-79ae-410a-850d-47a84fcc3a13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="akba:ProductionRelatedImpairmentsOrChargesIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfOS0zLTEtMS0yMjM1Nw_ea8477e2-571f-436d-9415-1e581ba6c2fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="akba:ProductionRelatedImpairmentsOrChargesIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfOS01LTEtMS0yMjM1Nw_a81cad87-e087-4419-a2bf-03cd1697a02e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ProductionRelatedImpairmentsOrChargesIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfOS03LTEtMS0yMjM1Nw_f88e51a6-25e3-4236-a124-03d7d1ea2673">115,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTAtMS0xLTEtMjIzNTc_30e63280-45d1-4f69-8c7c-c060bed74f06">15,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTAtMy0xLTEtMjIzNTc_d80941ef-acac-4159-9eec-a065911fb2cc">30,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTAtNS0xLTEtMjIzNTc_7aff8aa6-f3c0-47c5-8a9c-bf20e4b36e1c">103,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTAtNy0xLTEtMjIzNTc_14caee38-6e89-481d-b3cb-025c5a3698f9">232,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTItMS0xLTEtMjIzNTc_946c5c60-23d9-4072-86d6-52278a054fc5">40,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTItMy0xLTEtMjIzNTc_ee4b7d3f-68d3-4065-a928-704e469bb146">46,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTItNS0xLTEtMjIzNTc_42b13497-3d77-4261-885b-59b4d6d8c01d">118,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTItNy0xLTEtMjIzNTc_1ff3e81b-afc0-4981-9b17-da547b1e99e7">180,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTMtMS0xLTEtMjIzNTc_d1d3d60f-61c1-4512-9a05-f12e075e2012">46,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTMtMy0xLTEtMjIzNTc_c3623ec1-5b29-4def-9f00-75e08ade43c1">40,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTMtNS0xLTEtMjIzNTc_b863b1ad-2d48-4c54-babc-5fe869c9ae43">129,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTMtNy0xLTEtMjIzNTc_fc96e6e3-9977-4810-bdcd-51e38b04c717">113,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-3" name="akba:LicenseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTQtMS0xLTEtMjIzNTc_0cb3dbe5-6272-4f8f-b03f-7972b8377734">870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-3" name="akba:LicenseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTQtMy0xLTEtMjIzNTc_b82752a5-6fd5-4e61-9813-f1195d49ed3c">710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:LicenseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTQtNS0xLTEtMjIzNTc_d6ecce70-8e31-4f93-8b00-e3001f9c6e7b">2,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="akba:LicenseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTQtNy0xLTEtMjIzNTc_de77343e-ad19-4957-a92b-2dde3ff94035">2,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTUtMS0xLTEtMjIzNTc_1e80d041-2d42-4eb8-8cde-0b99a9e38351">87,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTUtMy0xLTEtMjIzNTc_dbe65565-4222-40e5-b081-8d0bfff0defa">87,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTUtNS0xLTEtMjIzNTc_36934ca4-b504-494a-b438-0a3c3d4dd88a">250,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTUtNy0xLTEtMjIzNTc_58139d1f-6bfb-4c18-bbe6-f043da0f4f9a">296,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTYtMS0xLTEtMjIzNTc_9070ac93-b429-4ef9-9f2d-d38f4efcc529">54,886</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTYtMy0xLTEtMjIzNTc_db05c486-f6b0-4160-afcc-3ae83e718cc2">58,095</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTYtNS0xLTEtMjIzNTc_632d072e-21e4-4134-8f83-63f28d426d1f">199,163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTYtNy0xLTEtMjIzNTc_0549ecdd-53b9-4619-95b3-b3324cd6c810">291,039</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTgtMS0xLTEtMjIzNTc_c7be4cf5-758e-495a-8fc0-fa599bcea941">5,085</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTgtMy0xLTEtMjIzNTc_c3053759-8e2f-42ee-864b-cce14540ac77">2,274</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTgtNS0xLTEtMjIzNTc_98e1daea-3836-48fb-9165-50b563fca060">14,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTgtNy0xLTEtMjIzNTc_1d301af0-ec20-4765-b566-8079f12098c4">6,554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTktMS0xLTEtMjIzNTc_b4590276-98a1-4799-81d4-a8395e2103c3">427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTktMy0xLTEtMjIzNTc_681257ac-f005-4e22-b6ea-6109d0d74109">410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTktNS0xLTEtMjIzNTc_04fcfecb-0e80-4e31-981b-eb35a26e20d1">1,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTktNy0xLTEtMjIzNTc_576a6006-b9fe-4c9d-87c6-45e83d70c95d">1,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjAtMS0xLTEtMjIzNTc_a0213a69-67ea-4e44-a1d2-1ae287e0e842">59,544</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjAtMy0xLTEtMjIzNTc_e3c3c714-1e32-40b1-8058-34a8318f6ac7">59,959</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjAtNS0xLTEtMjIzNTc_34624dc4-55a1-4c32-b57a-32f4a2dd445f">212,162</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjAtNy0xLTEtMjIzNTc_1205d296-b3d0-447a-807f-ca38d23ee8b6">296,457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjEtMS0xLTEtMjIzNTc_65a82cb2-69d7-492b-9f3b-ba26d8a47a4b"><ix:nonFraction unitRef="usdPerShare" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjEtMS0xLTEtMjIzNTc_da6c7e6a-8976-4ae7-909c-1879a7dac6cf">0.34</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjEtMy0xLTEtMjIzNTc_881482a8-3532-481b-be74-5bba91005c90"><ix:nonFraction unitRef="usdPerShare" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjEtMy0xLTEtMjIzNTc_c747173c-3146-4456-9b5f-468e5ed32acb">0.42</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjEtNS0xLTEtMjIzNTc_8fd89876-41dd-41d3-ad29-bbff517decbc"><ix:nonFraction unitRef="usdPerShare" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjEtNS0xLTEtMjIzNTc_b75c4cc5-d3f5-468c-9192-2b1561743429">1.30</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjEtNy0xLTEtMjIzNTc_e87a2e76-a121-49db-a3d3-aed965f6956c"><ix:nonFraction unitRef="usdPerShare" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjEtNy0xLTEtMjIzNTc_e918d623-2889-4552-b232-21f7a01ee60c">2.18</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares - basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjItMS0xLTEtMjIzNTc_8ee19cc6-d233-4994-9c1e-6bd6303da7f4"><ix:nonFraction unitRef="shares" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjItMS0xLTEtMjIzNTc_ce1da341-e2ad-440a-a7d5-139ced613673">173,782,151</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjItMy0xLTEtMjIzNTc_500540fc-8280-4a2d-8eb3-e55c4a3afef2"><ix:nonFraction unitRef="shares" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjItMy0xLTEtMjIzNTc_9b4951cf-4919-4ec7-8963-ab4c6b70bb6d">143,314,729</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjItNS0xLTEtMjIzNTc_40fe2027-f749-4d4a-bd61-a6e908aedbf8"><ix:nonFraction unitRef="shares" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjItNS0xLTEtMjIzNTc_f3d550ab-56c2-4fa1-8992-98fa0ddeaf28">163,050,769</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjItNy0xLTEtMjIzNTc_bc0f2731-2d75-4b94-9bb6-8bd94cd2d998"><ix:nonFraction unitRef="shares" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjItNy0xLTEtMjIzNTc_ea51b116-b017-4962-98cf-6da18cbaf782">136,230,889</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjQtMS0xLTEtMjIzNTc_db9c9a54-7b23-4586-97d0-f7fb79d5818b">59,544</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjQtMy0xLTEtMjIzNTc_788d914f-ebec-4b44-bfde-fc6c1cad9096">59,959</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjQtNS0xLTEtMjIzNTc_9f57be9d-132c-447f-a813-4906f564d38d">212,162</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjQtNy0xLTEtMjIzNTc_2e8153ed-99e4-4d41-a7cf-e5b1ac1e215a">296,457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive gain (loss) - unrealized gain (loss) on debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjUtMS0xLTEtMjIzNTc_8120024a-6d1c-4675-9c94-4ad2fa93854c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjUtMy0xLTEtMjIzNTc_3bbf9129-4865-4ca7-9f5f-b922b8a5d3da">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjUtNS0xLTEtMjIzNTc_5cf6d5ef-bc0b-476e-9499-91706cc51b40">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjUtNy0xLTEtMjIzNTc_aa50f34c-1f44-49fc-8f40-9a0efef2800c">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjYtMS0xLTEtMjIzNTc_26874859-49f7-40f4-a16b-905028fbcff7">59,544</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjYtMy0xLTEtMjIzNTc_b36fa1f0-2c02-47bd-8a73-753e128928f2">59,944</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjYtNS0xLTEtMjIzNTc_bdb9016c-db23-4d39-a1db-9f3b14ce81d3">212,169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjYtNy0xLTEtMjIzNTc_7978abee-ec0b-480c-a28f-2b5cba80a619">296,451</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i32bac828c69741158be14bdef01bfe8b_28"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AKEBIA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMS0zLTEtMS0yMjM1Ny90ZXh0cmVnaW9uOmU2YmIyZTFkZGVmZTQ0YTE5ZTY3YzIwZDViMGFiN2IyXzQ_2313b99e-5bae-4ca9-bdcb-b4e24fdedfc8">0.00001</ix:nonFraction></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Par Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Unrealized<br/>Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders'<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieac2241d842b494ab83cde4c6efacf46_I20191231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMi0xLTEtMS0yMjM1Nw_ce59793d-710f-4d45-a483-98c331fad351">121,674,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac2241d842b494ab83cde4c6efacf46_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMi0zLTEtMS0yMjM1Nw_8e42ba3a-935f-49a0-b2f3-9e4b71ed609a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cc88afc4d2144b0820d54de176e706b_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMi01LTEtMS0yMjM1Nw_129923f6-60bf-429d-b58b-220562998680">1,188,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aec38034ce44b18a632886540cf60f7_I20191231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMi03LTEtMS0yMjM1Nw_7a9758e6-31f9-4523-b329-a652050db885">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i068e2607df3e46ad958c3aac8d56c8bb_I20191231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMi05LTEtMS0yMjM1Nw_c5ccb6d5-422f-4113-a738-2b3209642b26">794,054</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i789136767052440b86082df6969545de_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMi0xMS0xLTEtMjIzNTc_d6340d93-2f93-4d51-a88c-d9c21e99f4f2">394,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net of<br/>&#160;&#160; issuance costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i35244d2350f3498ebd27593263ce18df_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMy0xLTEtMS0yMjM1Nw_f015ba4c-58fe-4a7e-bbd7-eab4662b38bc">7,973,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5f777362b84a18b96a34f6b3515a94_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMy01LTEtMS0yMjM1Nw_1685ec7e-5983-4241-a065-b6b57f415103">56,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f2d1adb364d4ff18d2ad533959fe847_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMy0xMS0xLTEtMjIzNTc_269b6a24-3fcc-4e36-8400-576fee18efa8">56,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of stock under<br/>&#160;&#160; employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i35244d2350f3498ebd27593263ce18df_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNC0xLTEtMS0yMjM1Nw_f6ba4805-ecc6-4a6b-85b5-7500829a5cd0">115,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5f777362b84a18b96a34f6b3515a94_D20200101-20200331" decimals="-3" name="akba:StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNC01LTEtMS0yMjM1Nw_28baad10-30c0-43c3-9b42-401b2b6d58a7">451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f2d1adb364d4ff18d2ad533959fe847_D20200101-20200331" decimals="-3" name="akba:StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNC0xMS0xLTEtMjIzNTc_41c62f2e-dd2d-4d3d-8475-7ad825eb29b5">451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5f777362b84a18b96a34f6b3515a94_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNS01LTEtMS0yMjM1Nw_d49fd727-1640-41c2-90a3-2895c7aad5b4">4,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f2d1adb364d4ff18d2ad533959fe847_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNS0xMS0xLTEtMjIzNTc_4777d9f4-ce83-4d03-9299-da90215897d2">4,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i35244d2350f3498ebd27593263ce18df_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNi0xLTEtMS0yMjM1Nw_8a121e67-a5fb-46d3-91b1-ce2107d128e8">64,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5f777362b84a18b96a34f6b3515a94_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNi01LTEtMS0yMjM1Nw_2dfc8c4d-5c4c-4bc3-877a-64a0f08e24d8">412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f2d1adb364d4ff18d2ad533959fe847_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNi0xMS0xLTEtMjIzNTc_0765cfb6-a5bc-431f-a453-4c7b4428e00e">412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock unit vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i35244d2350f3498ebd27593263ce18df_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNy0xLTEtMS0yMjM1Nw_446bd146-54e8-426d-a819-d3e94c10112f">423,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2d99e2664f844a2acf2c4573bf8df03_D20200101-20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfOC05LTEtMS0yMjM1Nw_50e7fe32-7ff5-4e68-a55d-7d06c3159bfd">60,747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f2d1adb364d4ff18d2ad533959fe847_D20200101-20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfOC0xMS0xLTEtMjIzNTc_28ecea8d-4ac6-445d-af93-5fcd1f3eeba0">60,747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id85007bc927a4536b6b47497569aa944_I20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfOS0xLTEtMS0yMjM1Nw_0f2f36b0-dcd8-4ece-95f4-fd32ce783143">130,251,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id85007bc927a4536b6b47497569aa944_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfOS0zLTEtMS0yMjM1Nw_0651cb5b-0bb6-4255-8a9a-447a4fc7523f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31f726c664944828986c9bc152d3cdbf_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfOS01LTEtMS0yMjM1Nw_e95a7d8d-8fa8-4256-ad1a-98a30ec41bf0">1,251,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2342b55b98df4c4f97a6deb300c2a324_I20200331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfOS03LTEtMS0yMjM1Nw_b7152991-0a5f-4cd8-a066-b3bfc4a005cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86dc89425ef046d69fcf7b7442f7b3af_I20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfOS05LTEtMS0yMjM1Nw_a1eccc25-a763-40fc-a4ff-12fe615eaa19">854,801</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1a730691f34e3697272cf628a7de24_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfOS0xMS0xLTEtMjIzNTc_ae1c2db6-2b4c-4e0e-9c00-f4e575f070fc">396,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net of<br/>&#160;&#160; issuance costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16965583159a4fb1943935fe0821c8b0_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTAtMS0xLTEtMjIzNTc_2b016a21-d99e-4d28-84f0-5c55628455a5">12,650,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f18d61adce243dbaa08d8980a32a679_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTAtNS0xLTEtMjIzNTc_55c0d82f-d570-4ddc-bd51-01d6342f0ad1">142,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6909ec0393ec4db2b3cc2706b5126477_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTAtMTEtMS0xLTIyMzU3_a359d242-17f3-4a7b-a5a8-bf1df7dcfb0a">142,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f18d61adce243dbaa08d8980a32a679_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTEtNS0xLTEtMjIzNTc_94d3c5b5-c867-446c-afb5-2dcdbd725ba0">6,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6909ec0393ec4db2b3cc2706b5126477_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTEtMTEtMS0xLTIyMzU3_3a2110ad-5bec-445a-a0ce-0afe1f876e59">6,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16965583159a4fb1943935fe0821c8b0_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTItMS0xLTEtMjIzNTc_2ba26d26-024f-406e-acca-fde6be4c3514">48,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f18d61adce243dbaa08d8980a32a679_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTItNS0xLTEtMjIzNTc_c138f28e-794c-41a5-a9da-6aa6179e9750">409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6909ec0393ec4db2b3cc2706b5126477_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTItMTEtMS0xLTIyMzU3_63c8aab3-0ec0-47ef-a062-e637ce047eb5">409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock unit vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16965583159a4fb1943935fe0821c8b0_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTMtMS0xLTEtMjIzNTc_42371c12-73bf-400c-a301-f0d8db6b1a9f">179,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45ee7fe7e4ea40449ec5093c5cfe4dab_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTQtNy0xLTEtMjIzNTc_33b41c3e-d465-4358-9719-d6417bb11728">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6909ec0393ec4db2b3cc2706b5126477_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTQtMTEtMS0xLTIyMzU3_c7139429-a4aa-45f3-8227-2ceeb3fe52ed">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97143382c5d94af882a7a099bb719c08_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTUtOS0xLTEtMjIzNTc_c494c9ad-74ad-4f7d-8206-a86a0e89c754">175,751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6909ec0393ec4db2b3cc2706b5126477_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTUtMTEtMS0xLTIyMzU3_f6fb059a-f6a3-4403-8f52-5da6e8ea9676">175,751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i847e92f55f2743cc8282356cea6026ae_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTYtMS0xLTEtMjIzNTc_899f991e-e5aa-4a2a-b497-0fd375cfb1f9">143,129,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i847e92f55f2743cc8282356cea6026ae_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTYtMy0xLTEtMjIzNTc_df61e776-5dd4-40a4-9f8a-e04bb1216791">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib807b33284ab430ca5e62866cfe3994b_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTYtNS0xLTEtMjIzNTc_357b7e3d-fd42-407c-9707-fb469ea0387d">1,400,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i889ed5ea677d43a19e0b2f90cc53dd3f_I20200630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTYtNy0xLTEtMjIzNTc_ccafed8d-89af-40dc-80ca-6db75cdf02dc">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bc18c0ef5546c5baeae2af38f6fac6_I20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTYtOS0xLTEtMjIzNTc_b2085594-761f-422f-8151-796511523633">1,030,552</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i264a47d635da444c86cb87a405c909c4_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTYtMTEtMS0xLTIyMzU3_ed15f7a0-07b1-49ca-a2d1-b5bcdb94cd6f">370,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of stock under</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">employee stock purchase plan</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82c195ab2c01450cb6639257d18f6117_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTctMS0xLTEtMjI4NTE_fa1f2aeb-86a9-4f9c-81f5-88f035e71ddf">120,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c5946e60d04544ab9e41f12a391895_D20200701-20200930" decimals="-3" name="akba:StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTctNS0xLTEtMjI5NTU_27c78912-1330-4736-bdf1-ec20deeed34c">649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-3" name="akba:StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTctMTEtMS0xLTIzMTAy_a3c764fc-cced-4584-b689-35d5033c60c4">649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c5946e60d04544ab9e41f12a391895_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTgtNS0xLTEtMjI5NjI_23258fce-2d36-4d88-adc4-7cec1bf4741c">6,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTgtMTEtMS0xLTIzMTA5_540c8a07-c904-496a-8e1d-bf9232be8146">6,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82c195ab2c01450cb6639257d18f6117_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTktMS0xLTEtMjI4NjY_8a31c160-722b-4965-9b02-808a35ee893d">54,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c5946e60d04544ab9e41f12a391895_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTktNS0xLTEtMjI5Njk_4133bb5a-bd97-45c3-ae2a-acb6ce6cfab2">405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTktMTEtMS0xLTIzMTE2_8a49c4a6-d64b-4373-8f0f-f724f3c3f290">405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock unit vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82c195ab2c01450cb6639257d18f6117_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjAtMS0xLTEtMjI4NzM_88b963c9-763e-4223-a257-ec04bc65e893">24,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62615678941c40648470b93e883c6c27_D20200701-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjEtNy0xLTEtMjMwMzI_036f57b7-b6fa-4340-a926-d779a21f1c5c">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjEtMTEtMS0xLTIzMTMw_75222538-12d3-463b-acf6-82a65fa16555">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c14e7a0bd4c4f3b838b097690f0db73_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjItOS0xLTEtMjMwODg_48a1e74b-f117-4a59-9d9b-965af866f0eb">59,959</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjItMTEtMS0xLTIzMTM3_a2f0ac71-55a3-48d6-a3b4-74d139f4bda8">59,959</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5eb0e7b9743b4b5bb8dcad4532a676f4_I20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjMtMS0xLTEtMjI4OTQ_f20b1991-6ac1-41f5-9b7a-da28c170bd64">143,328,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eb0e7b9743b4b5bb8dcad4532a676f4_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjMtMy0xLTEtMjI5NDg_f51f844e-11e9-47aa-9ac7-01027be1b769">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icff6bb56ef7f4b71b0ee5439d93c832d_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjMtNS0xLTEtMjI5OTc_d5f36c65-03b3-47e2-bfee-9eab703ff999">1,408,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2821e9d04730493782461dc080013c07_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjMtNy0xLTEtMjMwNDY_b87ba005-4469-464a-ac30-3c77edddcc15">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04f6e21078d54815b0fbcd7ccc3af0dc_I20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjMtOS0xLTEtMjMwOTU_357c6448-634f-40ff-9437-40cb0cb2b677">1,090,511</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa53bc3c09164606aeaedf64079be5bc_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjMtMTEtMS0xLTIzMTQ0_7685d109-63c0-4706-a9d4-54ea56bc4675">317,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7f690b3768a4f10ad9965db748015b2_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTgtMS0xLTEtMjIzNTc_2189f5df-f9a0-4caf-a67e-c64c86aa6f53">148,074,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f690b3768a4f10ad9965db748015b2_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTgtMy0xLTEtMjIzNTc_093d9adb-9d58-4ddb-aeb0-61ed8cbcc6e1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i575073ad687946c3958e67e8c915001f_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTgtNS0xLTEtMjIzNTc_4a5f5f12-8b91-4e0a-832d-3e3dedb9b1e0">1,425,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i264fd5873c584be39232727f484cadd7_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTgtNy0xLTEtMjIzNTc_08775dd2-2291-43ba-9abd-b00c8154410c">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i751bbd3aed3c44479e98241e0fabf680_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTgtOS0xLTEtMjIzNTc_1cdb71a5-01a9-43f6-96d9-be23de07400f">1,177,511</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTgtMTEtMS0xLTIyMzU3_85d09e3d-dce9-44a6-8e36-48611fdf3b1e">247,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net of<br/>&#160;&#160; issuance costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0c080b6e3284262a5a2ac05fc8be6d8_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTktMS0xLTEtMjIzNTc_3da3015e-f6a4-4095-9c67-d68742e8dec4">9,228,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0c080b6e3284262a5a2ac05fc8be6d8_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTktMy0xLTEtMjIzNTc_246483f9-35c8-4791-a9bb-31703350e7ec">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied2865777ae543ccb7e6733cedf24ead_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTktNS0xLTEtMjIzNTc_b2953ef6-d7e1-4ff7-8a69-6de43dccd560">29,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibedefb3b11734e53bd359a1087a22569_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTktMTEtMS0xLTIyMzU3_21bc7ab5-61d5-44cf-b582-5acc808f0267">29,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of stock under<br/>&#160;&#160; employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0c080b6e3284262a5a2ac05fc8be6d8_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjAtMS0xLTEtMjIzNTc_0bc20de6-31d3-430a-931a-9c3968c8fc0d">154,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied2865777ae543ccb7e6733cedf24ead_D20210101-20210331" decimals="-3" name="akba:StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjAtNS0xLTEtMjIzNTc_c716f90f-1b31-4b20-a653-03f69a2580a1">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibedefb3b11734e53bd359a1087a22569_D20210101-20210331" decimals="-3" name="akba:StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjAtMTEtMS0xLTIyMzU3_def14ce3-7c8e-420d-83be-0e778d8d5a5f">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied2865777ae543ccb7e6733cedf24ead_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjEtNS0xLTEtMjIzNTc_a16b3232-35ba-4195-9683-8a9f8838f6fa">5,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibedefb3b11734e53bd359a1087a22569_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjEtMTEtMS0xLTIyMzU3_1ce0e808-8c38-4604-8cff-c772abc5f4db">5,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock unit vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0c080b6e3284262a5a2ac05fc8be6d8_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjItMS0xLTEtMjIzNTc_19dbb31d-31ee-4652-bea4-b6fdcce23b9f">1,063,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i717676096b5a4c5eab55661e5e686861_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjMtNy0xLTEtMjIzNTc_14d90125-7405-4bb9-b2f1-8c096b3390eb">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibedefb3b11734e53bd359a1087a22569_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjMtMTEtMS0xLTIyMzU3_19b8ea85-1c4b-4aa0-b580-b15e80239597">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cbbd7587d264a93a0fac886a04d7c90_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjQtOS0xLTEtMjIzNTc_9ec9b30c-4785-44f9-8918-838d27938a17">69,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibedefb3b11734e53bd359a1087a22569_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjQtMTEtMS0xLTIyMzU3_6faa81c5-f9a1-4ef3-922b-1db0b6e87eaa">69,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i319c95fd8a8d4153a2394567a88f22ab_I20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjUtMS0xLTEtMjIzNTc_b3a981e5-dabc-4ec5-9880-6f07e0636e89">158,520,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i319c95fd8a8d4153a2394567a88f22ab_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjUtMy0xLTEtMjIzNTc_f74b5739-44cb-472a-b202-723d7e029ede">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd7f6d1ca07a4a7c81755f54e71d3a96_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjUtNS0xLTEtMjIzNTc_5bbac3dd-ce09-4341-bbcc-62639faf4355">1,460,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a772f431b4b4e039d186148c8287a6a_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjUtNy0xLTEtMjIzNTc_b02a2e65-c9ae-4c79-9f05-fc9577982e43">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f40f8942af14045ad47dc41f0a655f5_I20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjUtOS0xLTEtMjIzNTc_6b2be9c2-619e-4568-8b8d-7f42830b55e9">1,247,091</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id832960589e2403f88473dd831c88c68_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjUtMTEtMS0xLTIyMzU3_dcfed127-e746-4f7e-bae9-61ded945874e">213,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net of<br/>&#160;&#160; issuance costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc035820389e4d8a96227a92fb46d718_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjYtMS0xLTEtMjIzNTc_a17045ff-0cd3-4cdb-82cd-5e3f712822c6">10,446,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6c8320acf4b159907d88edddf5125_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjYtNS0xLTEtMjIzNTc_315818d6-4ea2-4f56-b42f-19214e57c536">37,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a8ba6ff0054b678403f9ad5ed7efc4_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjYtMTEtMS0xLTIyMzU3_b722d334-9022-4098-99f6-8b0609373bed">37,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00f6c8320acf4b159907d88edddf5125_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjctNS0xLTEtMjIzNTc_77d9d4e9-3227-4913-8438-52eeab3890a7">6,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a8ba6ff0054b678403f9ad5ed7efc4_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjctMTEtMS0xLTIyMzU3_a74947fc-116a-4330-b79f-379c604e6801">6,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock unit vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc035820389e4d8a96227a92fb46d718_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjktMS0xLTEtMjIzNTc_06d9861a-c730-449b-8b32-38b5eaaa9587">685,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba37ce69556348a28b16ed216da9256d_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMzAtNy0xLTEtMjIzNTc_120d565b-87d4-4dd3-968f-8eb48d4e3352">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02a8ba6ff0054b678403f9ad5ed7efc4_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMzAtMTEtMS0xLTIyMzU3_8d9cdc21-b29c-42b2-8c22-ef843179c013">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbc0260c7ae64edbabae5c84ce6356df_D20210401-20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMzEtOS0xLTEtMjIzNTc_5d05455b-59c4-4c05-b9bc-baf9811dcab3">83,038</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02a8ba6ff0054b678403f9ad5ed7efc4_D20210401-20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMzEtMTEtMS0xLTIyMzU3_8a2b3632-121d-4988-b878-5e705419f712">83,038</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib48d1a5470e1451ea0d90314033b3dfe_I20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMzItMS0xLTEtMjIzNTc_057fce88-b275-4d59-8c19-0f9e7bef2801">169,651,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48d1a5470e1451ea0d90314033b3dfe_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMzItMy0xLTEtMjIzNTc_1c44b164-5cda-44f5-bd9f-e3a5b345272e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2fc62f68c514632b6ff5532a6c05123_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMzItNS0xLTEtMjIzNTc_28d2ff7b-485c-4ffa-85da-15ffccf78e81">1,504,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic634149430a042a0af7eced0d7b1f3bc_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMzItNy0xLTEtMjIzNTc_54e1be2b-d4c3-4dc4-b59b-725cf85c3eb6">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba476346b25f4a3b8f5eacda5b591d48_I20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMzItOS0xLTEtMjIzNTc_59895b46-d040-4912-99ff-255b6391ff18">1,330,129</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i952bff9821b4497aa3ea95191dd2fe53_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMzItMTEtMS0xLTIyMzU3_daa03561-a148-42a7-bc32-04101c3bb896">174,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net of<br/>&#160;&#160; issuance costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i362dc8956d2b485d99df3ac257386849_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDAtMS0xLTEtMjMyMDU_8c9182b5-8e13-482f-b706-b9c4ccc2101f">4,730,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9932b64331a4dd3b00728c94fbb38e0_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDAtNS0xLTEtMjMyOTY_ba001e31-0237-43fd-8a78-ddfed6e30da5">16,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDAtMTEtMS0xLTIzNDQ1_413e714e-e60f-4d97-a6b1-dddd9f5cf2ff">16,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of stock under<br/>&#160;&#160; employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i362dc8956d2b485d99df3ac257386849_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDEtMS0xLTEtMjQ5ODg_bf2e4f1d-0882-40bc-b775-7f64d248d360">152,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9932b64331a4dd3b00728c94fbb38e0_D20210701-20210930" decimals="-3" name="akba:StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDEtNS0xLTEtMjUwMDU_1b16f53a-317a-48ee-9f30-e18f05c4311d">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-3" name="akba:StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDEtMTEtMS0xLTI1MDY2_08eae059-0a23-4e56-a4e6-d38482f64a43">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9932b64331a4dd3b00728c94fbb38e0_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDEtNS0xLTEtMjMzMDM_06fa3df8-30d1-49c4-99f0-3095299c6398">5,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDEtMTEtMS0xLTIzNDUy_ff7b37ca-1494-4180-a991-f59f722b5ded">5,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock unit vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i362dc8956d2b485d99df3ac257386849_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDMtMS0xLTEtMjMyMTU_905bed48-8098-44d7-bb00-7010fa0802aa">17,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9bbe8c544974328bc9207e0b78b0928_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDUtOS0xLTEtMjM0MzE_debbd729-ba1d-49e3-8865-d1a19e25aa9c">59,544</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDUtMTEtMS0xLTIzNDgw_fc77ac4c-5c2a-4d12-9851-c0d774066884">59,544</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a813010cea049e3b9d06fd62cbe9afe_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDYtMS0xLTEtMjMyMzY_8ab98d37-b23f-486c-80f2-04af02633ca6">174,551,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a813010cea049e3b9d06fd62cbe9afe_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDYtMy0xLTEtMjMyODk_9954fb61-e2f6-4fd4-96bd-bcb83ae8e4a0">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0d58cac5ebc4dde9442518ff67901b4_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDYtNS0xLTEtMjMzNDA_d0c5296b-617b-4712-a022-b29fd9749443">1,526,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c64672624aa423384622e444a575831_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDYtNy0xLTEtMjMzODk_740ba228-52db-4ca8-975f-7b997809f597">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i688f4e0d7a5c4c7e9ee5af402822f7f3_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDYtOS0xLTEtMjM0Mzg_85527458-853b-4c2b-bbe8-fd763c4d931d">1,389,673</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDYtMTEtMS0xLTIzNDg3_838d9650-1286-486b-a0d2-b68db68e64bc">137,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i32bac828c69741158be14bdef01bfe8b_31"></div><hr style="page-break-after:always"/><div style="min-height:22.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AKEBIA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMy0xLTEtMS0yMjM1Nw_f1db319e-1e6f-401f-94e3-5a0b2cabd40c">212,162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMy0zLTEtMS0yMjM1Nw_75fa879c-2647-4614-b06b-48fa638716cd">296,457</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfNS0xLTEtMS0yMjM1Nw_32e1306d-2cc0-4e8b-a4fc-e85e326f2880">1,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfNS0zLTEtMS0yMjM1Nw_c7f4c8d8-3747-447b-96cc-b296386c9499">1,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfNi0xLTEtMS0yMjM1Nw_beed3701-7c94-4b9b-8db9-06efffc8b696">27,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfNi0zLTEtMS0yMjM1Nw_1e2cd45a-38ff-4a5c-a830-a502d3accafe">24,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Intangible asset impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfNy0xLTEtMS0yMjM1Nw_509e455d-46ba-450c-a4f0-11cb6254e4c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfNy0zLTEtMS0yMjM1Nw_ed91cc37-d600-41b6-beae-facde2fbff5b">115,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premium/discount on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfOC0xLTEtMS0yMjM1Nw_1adda107-219a-4d48-beb2-c0b5c7ef9da1">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfOC0zLTEtMS0yMjM1Nw_5cf78a4d-b361-4cd9-b2e0-3212c211f225">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense related to sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfOS0xLTEtMS0yMjM1Nw_4d39b833-9dfd-4358-8afa-30318dd55924">6,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="akba:ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfOS0zLTEtMS0yMjM1Nw_89aec5c9-b843-4d4c-ba27-d7709270132f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue related to sale of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" name="akba:ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTAtMS0xLTEtMjIzNTc_754603f1-a212-4da1-a716-9ced398a5205">425</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="akba:ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTAtMy0xLTEtMjIzNTc_7aa8e466-c8a5-4783-a8fe-630b6bd325e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" name="akba:NoncashInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTEtMS0xLTEtMjIzNTc_33cb41e0-ab75-4ed4-85f4-702d8abbd1cf">852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="akba:NoncashInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTEtMy0xLTEtMjIzNTc_5604fff2-99c3-429f-8872-db6f5dae80ef">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StraightLineRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTItMS0xLTEtMjIzNTc_4e695068-e267-4262-8ab5-3da517f4f8eb">1,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StraightLineRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTItMy0xLTEtMjIzNTc_d083bac6-df87-49dc-93f6-8640ba032927">1,660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value step-up of inventory sold or written off</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:FairValueAdjustmentToInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTMtMS0xLTEtMjIzNTc_a1148cb2-98b6-4df4-9bee-65485b712df3">21,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="akba:FairValueAdjustmentToInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTMtMy0xLTEtMjIzNTc_3e6c61b4-4da1-4547-bf10-e045e09fc373">39,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-down of inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTQtMS0xLTEtMjIzNTc_f25dfd5f-e76b-40cf-8cda-a3ae3d1b9214">7,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTQtMy0xLTEtMjIzNTc_fa0a0f38-0c62-4e14-9c51-07490d4d977b">18,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in excess inventory purchase commitments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ExcessInventoryPurchaseCommitmentsExpenseReversal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTUtMS0xLTEtMjIzNTc_4995f24e-45fb-4171-95ac-4c6b22ef75a6">15,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ExcessInventoryPurchaseCommitmentsExpenseReversal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTUtMy0xLTEtMjIzNTc_92e5c8a5-1204-4142-8818-2f6ce426e9e1">10,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTYtMS0xLTEtMjIzNTc_dafbdd8c-7014-4a86-b8e4-ede51b91531a">18,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTYtMy0xLTEtMjIzNTc_ef4cdb95-2cc8-433c-a095-7025482c77e1">18,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTctMS0xLTEtMjIzNTc_b7be2470-f916-4362-b2af-8220f6125b88">490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTctMy0xLTEtMjIzNTc_07605618-e318-4a18-ae79-84770fe87440">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTktMS0xLTEtMjIzNTc_32b4b216-03c6-4405-bcbb-a3564ac6a817">22,837</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTktMy0xLTEtMjIzNTc_2aea5724-d337-4e7c-8d96-922603edad4a">14,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjAtMS0xLTEtMjIzNTc_0f981a66-ea47-4d8e-8d1b-a66971417432">35,282</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjAtMy0xLTEtMjIzNTc_d22df0d6-7556-4496-a171-f452a5ca19e1">6,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjEtMS0xLTEtMjIzNTc_bf44f4eb-8b79-498b-bf2b-7c13f4fe840d">25,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjEtMy0xLTEtMjIzNTc_9c96cd96-5e07-4352-906f-d9f1723a7b12">2,279</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjItMS0xLTEtMjIzNTc_255e64a0-cdd4-4f2b-b2e5-cc37e150addf">4,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjItMy0xLTEtMjIzNTc_aad48ef2-c891-42a5-bfbf-5ec10f17922e">6,518</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjMtMS0xLTEtMjIzNTc_b38744c4-8138-4b2e-861f-dd3ee1d4f5d3">14,933</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjMtMy0xLTEtMjIzNTc_275444ac-7a0f-4f6e-a70f-b8480752c922">3,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjQtMS0xLTEtMjIzNTc_69aa829b-de08-443d-94c7-111d186316c7">15,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjQtMy0xLTEtMjIzNTc_2fb3b03a-0025-4df2-a372-aa21cd087ea9">6,072</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjUtMS0xLTEtMjIzNTc_a751a693-2117-4f0c-99d4-230349a5ca48">1,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjUtMy0xLTEtMjIzNTc_4272c994-39b1-458c-ab7c-a7c23750c25a">1,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjYtMS0xLTEtMjIzNTc_e93cabbb-021a-4129-9653-78cbe0e5b223">3,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjYtMy0xLTEtMjIzNTc_f36cb99c-3f67-4c5d-9e22-77bbd1e1dcf7">21,256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjctMS0xLTEtMjIzNTc_024bebbb-c95b-4364-9f67-69b4da56238e">190,157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjctMy0xLTEtMjIzNTc_cbbfbba9-e12b-494f-a8ed-e2c361b559bf">79,606</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjktMS0xLTEtMjIzNTc_d1d69438-ba16-4505-8309-599ee03671e4">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjktMy0xLTEtMjIzNTc_d3498494-bc5b-43f6-a595-bed507f5536f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of available for sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzAtMS0xLTEtMjIzNTc_730a71c5-1b4f-4fd7-9925-0b6732218a57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzAtMy0xLTEtMjIzNTc_4df5fc38-29e6-4e26-a14c-8487bcfb2c05">99,932</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the maturities of available for sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzEtMS0xLTEtMjIzNTc_be743b1c-2c8f-41b9-bad3-56fafbabbacb">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzEtMy0xLTEtMjIzNTc_37cf64f1-7e23-49aa-9add-4f24a377dce1">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzItMS0xLTEtMjIzNTc_191fa284-e9f1-45d5-a3fb-2b8a9f45815f">39,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzItMy0xLTEtMjIzNTc_a14e96a2-ef71-4287-ae04-faf5a3dc5676">99,687</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of future royalties, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzQtMS0xLTEtMjIzNTc_efd552e9-d3cb-45f5-87bf-47b9e2ad9ce6">44,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="akba:ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzQtMy0xLTEtMjIzNTc_eccfd2ac-9390-4cd9-95f8-47f0ffb21d09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the issuance of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzUtMS0xLTEtMjIzNTc_56801f67-0c80-485a-abc6-a8a3982c91ae">82,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzUtMy0xLTEtMjIzNTc_16dcdb05-d83b-4ed8-8240-742ea6cea61f">198,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the sale of stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzYtMS0xLTEtMjIzNTc_2a673c3d-c10a-437f-b10e-a18a8c158af3">746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzYtMy0xLTEtMjIzNTc_8d5e1bab-770e-44a4-8aaf-26d73342975b">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzctMS0xLTEtMjIzNTc_189bc58e-af1c-4b96-83e5-5559b485868d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzctMy0xLTEtMjIzNTc_39a225d4-4794-4daf-9888-8aaa2a306eba">1,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzgtMS0xLTEtMjIzNTc_01a730e1-6675-4ccc-881e-7d35e798719f">128,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzgtMy0xLTEtMjIzNTc_cedd5033-0113-4a67-b1a3-c853b3ac57b4">201,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzktMS0xLTEtMjIzNTc_2df72b0a-798c-438f-abde-e29d887d5c67">21,888</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzktMy0xLTEtMjIzNTc_5b45e969-6b38-4a4d-85f9-48d27544230d">21,916</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfNDAtMS0xLTEtMjIzNTc_51fc8bb0-8df6-4734-bb73-45f535db53f3">231,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i789136767052440b86082df6969545de_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfNDAtMy0xLTEtMjIzNTc_b3bed82f-a5e5-4619-9625-d3ae5f2afa31">149,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of the period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfNDEtMS0xLTEtMjIzNTc_9b434d4f-76cd-43a8-9993-37ff8a351031">209,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa53bc3c09164606aeaedf64079be5bc_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfNDEtMy0xLTEtMjIzNTc_0d6fcf93-0e38-4c1a-946a-c4501e0b9ac0">171,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid offering costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" name="akba:DeferredUnpaidOfferingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfNDMtMS0xLTEtMjIzNTc_4a6f8209-d473-4c15-827b-93d7d5256da5">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" name="akba:DeferredUnpaidOfferingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfNDMtMy0xLTEtMjIzNTc_a9a4422b-c859-41c5-abd8-e9f5c721d7e2">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i32bac828c69741158be14bdef01bfe8b_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Akebia Therapeutics, Inc.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_37"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zNy9mcmFnOjExOTI1ZjA5NDA2ZjQ4M2Y5YWNiMjJmZDQyZTJlYzUyL3RleHRyZWdpb246MTE5MjVmMDk0MDZmNDgzZjlhY2IyMmZkNDJlMmVjNTJfNTUzOQ_7cb06414-86d0-4a99-81e7-7b19fabac0f2" continuedAt="ia9d55151d08d4061b10c343782523070" escape="true">Nature of Organization and Operations</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ia9d55151d08d4061b10c343782523070" continuedAt="i4ccaff225d6e4c9084df8019f7ea9fb7"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Akebia Therapeutics, Inc., referred to as Akebia or the Company, was incorporated in the State of Delaware in 2007. Akebia is a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease. Akebia&#8217;s lead investigational product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease, or CKD. Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, or HIF-PHI, designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, or HIF, which stimulates erythropoietin, or EPO, production, and can lead to red blood cell, or RBC, production and improved oxygen delivery to tissues. Vadadustat is approved and marketed in Japan as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients under the trade name Vafseo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The Company submitted a New Drug Application, or NDA, to the U.S. Food and Drug Administration, or FDA, for vadadustat in March of 2021 for the treatment of anemia due to CKD in adult patients with CKD on dialysis, or DD-CKD, and adult patients with CKD not on dialysis, or NDD-CKD. The Company's NDA submission was accepted for filing by the FDA in May 2021 and </span><span style="background-color:#ffffff;color:#373737;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">at the time of filing the NDA, the FDA indicated that they were not currently planning to hold an Advisory Committee meeting to discuss the application</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for vadadustat. The FDA also assigned the application standard review and a Prescription Drug User Fee Act (PDUFA) target action date of March 29, 2022. The Company&#8217;s collaboration partner, Otsuka Pharmaceutical Co. Ltd., submitted a Marketing Authorization Application, or MAA, for vadadustat for the treatment of anemia due to CKD in adult patients to the European Medicines Agency, or EMA, in October 2021</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In addition, the Company has a commercial product, Auryxia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (ferric citrate), which is currently approved by the FDA and marketed for two indications in the United States: the control of serum phosphorus levels in DD-CKD adult patients and the treatment of iron deficiency anemia, or IDA, in NDD-CKD adult patients. Ferric citrate is also approved and marketed in Japan as an oral treatment for IDA in adult patients for the improvement of hyperphosphatemia in adult patients with DD-CKD and NDD-CKD under the trade name Riona (ferric citrate hydrate).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has devoted most of its resources to research and development, including its preclinical and clinical development activities, and providing general and administrative support for these operations. The Company began recording revenue from the U.S. sales of Auryxia and revenue from sublicensing rights to Auryxia in Japan from the Company&#8217;s Japanese partners, Japan Tobacco, Inc. and its subsidiary Torii Pharmaceutical Co., Ltd., collectively JT and Torii, on December 12, 2018 following the consummation of a merger with Keryx Biopharmaceuticals, Inc., or Keryx, or the Merger. Additionally, following regulatory approval of vadadustat in Japan, the Company began recognizing royalty revenues from Mitsubishi Tanabe Pharma Corporation, or MTPC, from the sale of Vafseo in August 2020. In February 2021, the Company entered into a royalty interest acquisition agreement with HealthCare Royalty Partners IV, L.P., or the Royalty Agreement, whereby the Company sold its right to receive royalties and sales milestones under its Collaboration Agreement with MTPC, or the MTPC Agreement, subject to certain caps and other terms and conditions (see Note 5 for additional information). The Company has not generated a profit to date and may never generate profits from product sales. Vadadustat and the Company&#8217;s other potential product candidates are subject to long development cycles, and the Company may be unsuccessful in its efforts to develop, obtain marketing approval for or market vadadustat and its other potential product candidates. If the Company does not successfully commercialize Auryxia, vadadustat or any other potential product candidate, if approved, it may be unable to achieve profitability.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s management completed its going concern assessment in accordance with Accounting Standards Codification, or ASC, 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, or ASC 205-40. The Company believes that its cash resources will be sufficient to allow the Company to fund its current operating plan through at least the next <ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" format="ixt-sec:durwordsen" name="akba:OperatingPlanSufficientlyFundedByCashResourcesPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zNy9mcmFnOjExOTI1ZjA5NDA2ZjQ4M2Y5YWNiMjJmZDQyZTJlYzUyL3RleHRyZWdpb246MTE5MjVmMDk0MDZmNDgzZjlhY2IyMmZkNDJlMmVjNTJfNDI5Mw_6a408bfb-5730-4228-a978-b101062123ed">twelve months</ix:nonNumeric> from the filing of this Quarterly Report on Form 10-Q. If the Company receives regulatory approval of vadadustat in the U.S., the Company expects to incur significant incremental costs to its current operating plan to commercialize vadadustat, including costs of marketing, manufacturing and distribution. The potential timely regulatory approval of vadadustat and the receipt of associated regulatory milestones is an important source of funding of the Company's cash runway. However, the Company will require additional funding to fund its operating plan beyond the next twelve months. There are numerous risks and uncertainties associated with research, development and commercialization activities, and actual results could vary materially as a result of a number of factors, many of which are outside of the Company's control. There can be no assurance, however, that the current operating plan will be achieved in the time frame anticipated by the Company, or that its cash resources will fund the Company&#8217;s operating plan for the period anticipated by the Company or that additional funding will be available on terms acceptable to the Company, or at all. The Company will require additional capital to pursue development and commercial activities related to Auryxia and vadadustat or any additional products and product candidates, including those that may be in-licensed or acquired. The Company expects to finance future cash needs through product </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i4ccaff225d6e4c9084df8019f7ea9fb7">revenue, public or private equity or debt transactions, payments from its collaborators, strategic transactions, or a combination of these approaches. However, additional financing may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise capital in sufficient amounts when needed or on attractive terms, it may not be able to pursue development and commercial activities related to Auryxia and vadadustat or any additional products and product candidates, including those that may be in-licensed or acquired.</ix:continuation></span></div><div><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_40"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80MC9mcmFnOjM0MjMzYjg1NTNmZjRjMTViZDRjYTBlZWRhZTEyMGJiL3RleHRyZWdpb246MzQyMzNiODU1M2ZmNGMxNWJkNGNhMGVlZGFlMTIwYmJfNjMwNg_7635cd15-61d5-47d3-9a83-05868e173547" continuedAt="i0b0946f7ce6847e59a2520bc77e2d2f0" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i0b0946f7ce6847e59a2520bc77e2d2f0" continuedAt="i76298d3ab08e45f18d21a7c67fb87292"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80MC9mcmFnOjM0MjMzYjg1NTNmZjRjMTViZDRjYTBlZWRhZTEyMGJiL3RleHRyZWdpb246MzQyMzNiODU1M2ZmNGMxNWJkNGNhMGVlZGFlMTIwYmJfNjMwNw_36182b39-fb58-43e7-b1ad-752d00143c98" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S., or GAAP, for interim financial reporting and as required by Regulation&#160;S-X, Rule&#160;10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the ASC and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board, or FASB.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80MC9mcmFnOjM0MjMzYjg1NTNmZjRjMTViZDRjYTBlZWRhZTEyMGJiL3RleHRyZWdpb246MzQyMzNiODU1M2ZmNGMxNWJkNGNhMGVlZGFlMTIwYmJfNjMxMA_b5b5d5de-0e8b-4a74-81da-2f4e13b9e9c2" continuedAt="i5485d2a649dc470cab4f71366f3681ba" escape="true">In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the unaudited condensed consolidated financial statements have been included. Interim results for the three and nine months ended September&#160;30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending December&#160;31, 2021 or any other future period.</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5485d2a649dc470cab4f71366f3681ba">The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</ix:continuation> Management has determined that the Company operates in&#160;<ix:nonFraction unitRef="segment" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80MC9mcmFnOjM0MjMzYjg1NTNmZjRjMTViZDRjYTBlZWRhZTEyMGJiL3RleHRyZWdpb246MzQyMzNiODU1M2ZmNGMxNWJkNGNhMGVlZGFlMTIwYmJfMTM5Ng_0ec5b73b-a0a5-4cc0-8a91-d0affcf08ca4">one</ix:nonFraction>&#160;segment, which is the business of developing and commercializing novel therapeutics for people with kidney disease. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company&#8217;s consolidated financial statements and the accompanying notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020 filed with the U.S. Securities and Exchange Commission on February 25, 2021, or the 2020 Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies used in preparation of these unaudited condensed consolidated financial statements for the three and nine months ended September&#160;30, 2021 are consistent with those discussed in Note 2 to the consolidated financial statements in the Company&#8217;s 2020 Annual Report on Form 10-K and are updated below as necessary.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80MC9mcmFnOjM0MjMzYjg1NTNmZjRjMTViZDRjYTBlZWRhZTEyMGJiL3RleHRyZWdpb246MzQyMzNiODU1M2ZmNGMxNWJkNGNhMGVlZGFlMTIwYmJfNjMxMQ_824ed544-b9db-4e6d-8bf8-f3ee062a33c9" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Pronouncements &#8211; Recently Adopted</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard became effective for the Company on January 1, 2021. ASU 2019-12 requires certain amendments to be applied using a modified retrospective approach, which requires a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption, while other amendments should be applied on a prospective basis. The adoption of this standard did not have a material impact on the Company&#8217;s unaudited condensed consolidated financial statements and related disclosures.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80MC9mcmFnOjM0MjMzYjg1NTNmZjRjMTViZDRjYTBlZWRhZTEyMGJiL3RleHRyZWdpb246MzQyMzNiODU1M2ZmNGMxNWJkNGNhMGVlZGFlMTIwYmJfNjMxMg_224ac1d4-4457-4fac-9c25-6fa446e80926" continuedAt="i04e7a9e86bbe499b83fad82bf09a26bf" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: prepaid and accrued research and development expense, operating lease assets and liabilities, derivative liabilities, other non-current liabilities, including the excess purchase commitment liability, stock-based compensation expense, product and collaboration revenues including various rebates and reserves related to product sales, non-cash interest expense on the liability related to sale of future royalties, inventories, income taxes, intangible assets and goodwill. The Company has made estimates of the impact of COVID-19 within the unaudited condensed consolidated financial statements and there may be changes to those estimates in future periods including changes to sales, payor mix, reserves and allowances, intangible assets and goodwill. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i76298d3ab08e45f18d21a7c67fb87292"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i04e7a9e86bbe499b83fad82bf09a26bf">Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</ix:continuation></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="akba:ContractualArrangementRoyaltiesAgreementLiabilityPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80MC9mcmFnOjM0MjMzYjg1NTNmZjRjMTViZDRjYTBlZWRhZTEyMGJiL3RleHRyZWdpb246MzQyMzNiODU1M2ZmNGMxNWJkNGNhMGVlZGFlMTIwYmJfNjMxMw_6a73dbb8-274c-48c2-ba52-d3180984b673" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liability Related to Sale of Future Royalties</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company treats the liability related to sale of future royalties, see Note 5, as a debt financing, amortized under the effective interest rate method over the estimated life of the related expected royalty stream. The liability related to sale of future royalties and the debt amortization are based on the Company&#8217;s current estimates of future royalties expected to be paid over the life of the arrangement. The Company will periodically assess the expected royalty payments. To the extent the Company&#8217;s estimates of future royalty payments are greater or less than previous estimates or the estimated timing of such payments is materially different than previous estimates, the Company will adjust the effective interest rate and recognize related non-cash interest expense on a prospective basis. Non-cash royalty revenue is reflected as royalty revenue within license, collaboration and other revenue, and non-cash amortization of debt is reflected as interest expense in the unaudited condensed consolidated statements of operations and comprehensive loss.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt"><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_43"></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RleHRyZWdpb246N2M1YjYwNGM1ZGNkNGM2NmI3NWY2MjhmY2Q5MDQ3NDlfMTE0MA_931e5232-4da1-4df3-ac3b-e89eb2d91446" continuedAt="i9ad2d48ce6b94412bf3091d0ae43023d" escape="true">Product Revenue and Reserves for Variable Consideration</ix:nonNumeric></span></div><ix:continuation id="i9ad2d48ce6b94412bf3091d0ae43023d"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company&#8217;s only source of product revenue has been from the U.S. sales of Auryxia. Total net product revenue was $<ix:nonFraction unitRef="usd" contextRef="i0c63b2719b7a493f89992c1c8a6feb94_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RleHRyZWdpb246N2M1YjYwNGM1ZGNkNGM2NmI3NWY2MjhmY2Q5MDQ3NDlfMTg3_16bea064-4eec-49af-8915-9159d65d02d9">36.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1897c1e5242647279d4844ddf93043fa_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RleHRyZWdpb246N2M1YjYwNGM1ZGNkNGM2NmI3NWY2MjhmY2Q5MDQ3NDlfMTk0_d1c81325-9d23-426e-8700-1bf595d54157">34.4</ix:nonFraction> million for the three months ended September&#160;30, 2021 and 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i679a26fb513c4e229079d19e687e23ea_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RleHRyZWdpb246N2M1YjYwNGM1ZGNkNGM2NmI3NWY2MjhmY2Q5MDQ3NDlfMjUz_9743feb0-fa3b-412d-a922-02bf67ceb9a9">100.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic6c63a1921cf449cbb7d42a58f2ca535_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RleHRyZWdpb246N2M1YjYwNGM1ZGNkNGM2NmI3NWY2MjhmY2Q5MDQ3NDlfMjYw_a84d9042-9445-4be8-8776-46460163552f">94.3</ix:nonFraction> million for the nine months ended September&#160;30, 2021 and 2020, respectively. <ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="akba:ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RleHRyZWdpb246N2M1YjYwNGM1ZGNkNGM2NmI3NWY2MjhmY2Q5MDQ3NDlfMTE0MQ_74173fd4-bfd1-4783-a66e-6faf6c383038" continuedAt="ifaff7f397c6c41cca3ce805360cea529" escape="true">The following table summarizes activity in each of the product revenue allowance and reserve categories for the nine months ended September&#160;30, 2021 and 2020 (in thousands):</ix:nonNumeric></span></div><ix:continuation id="ifaff7f397c6c41cca3ce805360cea529"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:52.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks<br/>and Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates, Fees<br/>and other<br/>Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1bafbc3960143019bb39d791680d09e_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMS0xLTEtMS0yMjM1Nw_bc04d067-dc1d-41ab-8701-c94bcb11597c">802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3e27925f7eb4396b50788b1c147f040_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMS0zLTEtMS0yMjM1Nw_c9218a95-2246-4434-9b8f-6f5954b8e065">39,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88110b1102464bb8b4bcc45b892e9014_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMS01LTEtMS0yMjM1Nw_72d91eef-a83b-4fcc-90a8-0d7904327c27">649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMS03LTEtMS0yMjM1Nw_5b934a5c-2414-4a9b-9ee2-527d31d21253">41,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provisions related to sales in current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic65dcd125e83450aa6300973fab408bb_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMi0xLTEtMS0yMjM1Nw_354667cc-f146-46f0-a5af-73e8f7c4f262">8,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic138834fb069491a89247c930e50e034_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMi0zLTEtMS0yMjM1Nw_c76689ec-4a91-49bb-8fdb-53ba88fea34b">105,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f8120fb3ba417a90e8a529c456c779_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMi01LTEtMS0yMjM1Nw_ae3759dd-24b8-494e-a800-3fc041948d19">4,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMi03LTEtMS0yMjM1Nw_2c236c93-ec57-4aeb-a3e3-4fe13e51d651">119,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments related to prior year sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic65dcd125e83450aa6300973fab408bb_D20210101-20210930" decimals="-3" sign="-" name="akba:ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMy0xLTEtMS0yMjM1Nw_cbd08ffd-eeec-440a-bb44-c797e6518cda">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic138834fb069491a89247c930e50e034_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="akba:ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMy0zLTEtMS0yMjM1Nw_1d2eee87-7c44-41e5-a11b-3c18d996d277">1,590</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f8120fb3ba417a90e8a529c456c779_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="akba:ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMy01LTEtMS0yMjM1Nw_904d561d-66d3-4365-8ac9-56b787d1b263">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="akba:ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMy03LTEtMS0yMjM1Nw_d0b5b3b6-3670-448f-9eb6-cc7a7ed58c53">1,591</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments made</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic65dcd125e83450aa6300973fab408bb_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfNC0xLTEtMS0yMjM1Nw_0a44d332-d550-4fc3-8094-a164f9fd3e2c">8,593</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic138834fb069491a89247c930e50e034_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfNC0zLTEtMS0yMjM1Nw_1fed2e9b-5885-47d9-ad0a-fde388f6e939">99,518</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f8120fb3ba417a90e8a529c456c779_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfNC01LTEtMS0yMjM1Nw_8a160a73-de98-4f4b-8f16-210b88e11960">4,979</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfNC03LTEtMS0yMjM1Nw_55d09429-f20b-4ba9-ad31-50d02ce35511">113,090</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85f7bb9f4e384e1aa0a5e37af52be036_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfNS0xLTEtMS0yMjM1Nw_96ab608e-2ce1-4fe2-8b97-a46451b253ab">1,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ef44b64c28a444cac3e40fe925ba315_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfNS0zLTEtMS0yMjM1Nw_7b1719b0-03c7-4a6e-aaf8-7659a609d5f1">44,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bd677f66094393bebcca2b049effef_I20210930" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfNS01LTEtMS0yMjM1Nw_43d97dc8-6d4c-4ee9-a36c-7db18be18cdd">536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfNS03LTEtMS0yMjM1Nw_36d4e515-3ed6-45a7-b5c7-a74470cc52dd">45,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6297767fc6bf43fe877f509f140dada7_I20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfNy0xLTEtMS0yMjM1Nw_1b5ceee6-6993-4421-9737-e902c32a1a88">738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3450ded174e45858afc144e1af9ffac_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfNy0zLTEtMS0yMjM1Nw_81d18acf-fc61-4a49-9611-95c417cd1ec0">30,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97d48e8612f24efe8996ef27cb3c6569_I20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfNy01LTEtMS0yMjM1Nw_67e55253-39c6-4eab-b554-5fbcda32a01e">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i789136767052440b86082df6969545de_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfNy03LTEtMS0yMjM1Nw_c18e3bf9-22b6-4ef8-8fa6-48b2c32d552e">31,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provisions related to sales in current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i634b8d926257462d9d9e328283bb4259_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfOC0xLTEtMS0yMjM1Nw_b188b900-6542-4e29-a6c6-7fa2d44df5f4">7,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i745cf671aea747ba929766351832a180_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfOC0zLTEtMS0yMjM1Nw_abafbced-6c7b-494c-9d56-14517be8a570">107,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a65cd87641e499c9df380248f663449_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfOC01LTEtMS0yMjM1Nw_ea9a97bc-c57d-4493-9df1-d3b41677dc11">4,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfOC03LTEtMS0yMjM1Nw_07f47ea9-7b92-4b1f-b304-b76ff59e6ca3">119,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments related to prior year sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i634b8d926257462d9d9e328283bb4259_D20200101-20200930" decimals="-3" sign="-" name="akba:ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfOS0xLTEtMS0yMjM1Nw_4adc4ee5-5a64-4f5b-9e8b-a633d2eb63af">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i745cf671aea747ba929766351832a180_D20200101-20200930" decimals="-3" name="akba:ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfOS0zLTEtMS0yMjM1Nw_1de04737-a9e7-47d6-89d2-f43e73150364">703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a65cd87641e499c9df380248f663449_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfOS01LTEtMS0yMjM1Nw_ab3872ef-3700-480a-85da-8b7a49173162">2,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfOS03LTEtMS0yMjM1Nw_1a2eba44-9b52-4593-bf3c-9af1f8335568">2,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments made</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i634b8d926257462d9d9e328283bb4259_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMTAtMS0xLTEtMjIzNTc_b8546fbf-b3e0-4f76-951f-f4beb16ac78f">7,701</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i745cf671aea747ba929766351832a180_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMTAtMy0xLTEtMjIzNTc_3394540e-6c0e-4466-b33f-6f83bc958ae8">96,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a65cd87641e499c9df380248f663449_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMTAtNS0xLTEtMjIzNTc_1b89b2c2-0453-423e-adea-a25eea609afb">5,991</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMTAtNy0xLTEtMjIzNTc_f4037ad8-730b-4bc8-a6ee-1c7ff8af39d3">110,499</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b205f60522473db4b1791f35bad380_I20200930" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMTEtMS0xLTEtMjIzNTc_5b47a9c9-dfce-46ff-94b3-8ab1c94e7c68">785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbe29fe4d71b45a2807b94520a5f1004_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMTEtMy0xLTEtMjIzNTc_5241c527-464c-4bef-8a28-700f09cb68f4">41,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e838c8dba8c42b0b61db36cee11b10c_I20200930" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMTEtNS0xLTEtMjIzNTc_066d056e-d4fb-4a92-860b-90d66a7f6db4">774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa53bc3c09164606aeaedf64079be5bc_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMTEtNy0xLTEtMjIzNTc_40cb8fa5-fd37-4609-85f4-af55ab88c0ad">43,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks, discounts and returns are recorded as a direct reduction of revenue on the unaudited condensed consolidated statement of operations with a corresponding reduction to accounts receivable on the unaudited condensed consolidated balance sheets. Rebates, distribution-related fees, and other sales-related deductions are recorded as a reduction in revenue on the unaudited condensed consolidated statement of operations with a corresponding increase to accrued liabilities or accounts payable on the unaudited condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net related to product sales was approximately $<ix:nonFraction unitRef="usd" contextRef="iba72f4028b53419a9e3df0bc0bb323b5_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RleHRyZWdpb246N2M1YjYwNGM1ZGNkNGM2NmI3NWY2MjhmY2Q5MDQ3NDlfMTEwMA_ae89c95e-0ba2-406f-9e46-402153d4494a">22.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i68832275b6f74879ad43622f402f836b_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RleHRyZWdpb246N2M1YjYwNGM1ZGNkNGM2NmI3NWY2MjhmY2Q5MDQ3NDlfMTEwNw_b11803db-2470-48d7-9496-2f03ed48b1c0">21.9</ix:nonFraction> million as of September&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div></ix:continuation><div><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_46"></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDU5MzM_7f463d5e-2ebb-4af1-904d-56fde984eb3e" continuedAt="i0b83e947411d455eb73571163cb023bb" escape="true">License, Collaboration and Other Significant Agreements</ix:nonNumeric></span></div><ix:continuation id="i0b83e947411d455eb73571163cb023bb" continuedAt="ic4f10c8306154ed68cd7e69d40078ed2"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="akba:CollaborativeArrangementRevenueRecognitionTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDU5Mzc_641d2846-0863-4f58-9c16-ff895ea89eac" continuedAt="i82d633d6031a4cf68fa71ead95cd2a47" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="akba:DeferredRevenueRecognitionTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDU5MzY_762e413f-2b83-404c-90a4-ef2f0bee1f5d" continuedAt="i75e1f593e1784aa4b92d7e03be6895d6" escape="true">During the three and nine months ended September&#160;30, 2021 and 2020, the Company recognized the following revenues from its license, collaboration and other significant agreements and had the following deferred revenue balances as of September&#160;30, 2021:</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic4f10c8306154ed68cd7e69d40078ed2" continuedAt="idf395c0e55824e66affec3acb8ba0d69"><div style="margin-top:5pt"><ix:continuation id="i82d633d6031a4cf68fa71ead95cd2a47"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">License, Collaboration and Other Revenue:</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MTPC Agreement</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefbe221ac071402e9aa1ff3c33efbea9_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfMy0xLTEtMS0yMjM1Nw_deab0fc3-e74e-4832-966f-8d355c02c80f">2,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1709d1103fa3444fb8a09367a5e7e52e_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfMy0zLTEtMS0yMjM1Nw_5622727b-631c-4523-9c65-d7755439645b">373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31651748afca476c98590cfaeef98a69_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfMy01LTEtMS0yMjM1Nw_8ed1d7dd-9515-40c2-87b2-97c8eeb7f046">7,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aabb65b896b4d4693a54ed68c0aa03a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfMy03LTEtMS0yMjM1Nw_e717cf79-3f40-439c-a08a-bc3d0a7eb4c2">15,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otsuka U.S. Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefd530a7f1a248edbdc9b05c847c8a7e_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNC0xLTEtMS0yMjM1Nw_adaa7f34-2a59-4d1d-a9df-b9e613543586">6,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib09d90891a274c3c818a2cef521eace2_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNC0zLTEtMS0yMjM1Nw_2c002284-16ff-4e01-9f09-d636224e054d">16,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73b11af5f04a42d9a1071752d045891e_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNC01LTEtMS0yMjM1Nw_22b16297-55f7-48f2-a718-01c712eab274">28,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fc2047fffc4e2d8558725e0f1d34a0_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNC03LTEtMS0yMjM1Nw_884dc9af-9d3d-400f-bdca-17bf405d42f1">80,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otsuka International Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i945ff9fde11644a58dafd0226b9d6c0f_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNS0xLTEtMS0yMjM1Nw_133dc8f0-8048-4227-92fa-d1a5bf1c155c">1,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i738510817c5048b98d2eea09c5a05cf1_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNS0zLTEtMS0yMjM1Nw_5c9a9979-df3e-4cc0-b883-f364fb0e753d">7,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f482f3f6423440ea0d9f6c8bef66818_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNS01LTEtMS0yMjM1Nw_1528b88f-857f-4aa8-8aae-64a0757205d8">13,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a84c225ba714f219479e22fc09d67e9_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNS03LTEtMS0yMjM1Nw_b535a7a9-6a0a-4872-b7b3-b6a466c8ddc2">39,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Proportional Performance Revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0acbf4b49164475f8a36f3979f8e5aff_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNi0xLTEtMS0yMjM1Nw_2de9b062-271a-4a73-999a-30dffeadbd97">10,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52d8a3a1f814ede864dcab830d03ad3_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNi0zLTEtMS0yMjM1Nw_c3f7b7dd-dfb1-449c-b371-0574fc77df06">23,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae7692c90eb746178a141c1b78cb6a28_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNi01LTEtMS0yMjM1Nw_854db31c-90e4-4c62-a0d9-a94ea459eb20">49,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af3aa2c9e5f4db7bac920c367ee4124_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNi03LTEtMS0yMjM1Nw_7406ca17-180f-4742-8241-e8d0bca5168d">135,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JT and Torii</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95f34cfdea4546b9916e24a997553533_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNy0xLTEtMS0yMjM1Nw_df553ac8-565a-47ae-8633-d8944fbbb5d1">1,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d24e1b865b1425f8c6a7c9541a10db2_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNy0zLTEtMS0yMjM1Nw_43420c38-c52c-4411-8501-8957eea1cc3d">1,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1b71df432394860be208c54b443aacb_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNy01LTEtMS0yMjM1Nw_c04447c5-9ba2-4e72-b1cf-a84d2583076a">4,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06aa1c9bc80b4b6497171fe4199a0347_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNy03LTEtMS0yMjM1Nw_1ff300e9-d109-445e-8e0c-c33165bcd924">4,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MTPC Other Revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f865ba0db994d3fbe5976932bc384f2_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfOC0xLTEtMS0yMjM1Nw_e88cdeea-68d9-43c2-9ca0-8fce16dd85d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifce4f17d7a3d4682a27f359eb185448b_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfOC0zLTEtMS0yMjM1Nw_1651a5ae-a17b-48b5-8e70-cb91ebfa61ac">541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0455e41ef2d6462b91d81400d4c2e0dd_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfOC01LTEtMS0yMjM1Nw_a793ecab-6a7c-4a39-b884-8c29b908f4ee">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6939d08f8a54431bf1d08db5ff563d4_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfOC03LTEtMS0yMjM1Nw_628291d8-7a7b-4485-ab06-49b7717a9747">4,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total License, Collaboration and Other Revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if41d416d81e34b9cb6976b49960bf999_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfOS0xLTEtMS0yMjM1Nw_e4014c29-548d-481b-90a1-b0cb0fe4ad20">12,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia875941982fa4b738ad20ad8c02ee280_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfOS0zLTEtMS0yMjM1Nw_248e7458-1a69-4ec9-b03c-b337ebc403b8">25,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d2476903d214660b7d10dfda90d5e62_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfOS01LTEtMS0yMjM1Nw_cce9626d-11da-4a12-9b36-168215218cdc">53,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic49c106b11074ca28afbe6423ad1783c_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfOS03LTEtMS0yMjM1Nw_bcd8a34c-58e0-4ac7-b827-a73324bcdff9">144,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><ix:continuation id="i75e1f593e1784aa4b92d7e03be6895d6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-Term</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-Term</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred Revenue:</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MTPC Agreement</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e10b28a9e47483eab1daecf6b5559db_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfMy0xLTEtMS0yMjM1Nw_4dcdaec6-fcee-485b-8eab-1c8cb7d58a03">4,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e10b28a9e47483eab1daecf6b5559db_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfMy0zLTEtMS0yMjM1Nw_ec7d6f45-084c-405e-8ca6-dc2bb6832259">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e10b28a9e47483eab1daecf6b5559db_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfMy01LTEtMS0yMjM1Nw_aa1ea9a3-2d5e-4be5-baff-b54199e4346c">4,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otsuka U.S. Agreement</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70c28a2a28bc4932a1c94051311c07d4_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfNC0xLTEtMS0yMjM1Nw_8f22e554-7ae6-4fa9-b9cc-5ed17c59f7d7">6,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70c28a2a28bc4932a1c94051311c07d4_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfNC0zLTEtMS0yMjM1Nw_d2b87f51-f81a-49f4-9c9e-036bbea57cf4">16,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70c28a2a28bc4932a1c94051311c07d4_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfNC01LTEtMS0yMjM1Nw_3748a76f-3471-47e9-9313-488ae11050cf">22,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otsuka International Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4a2508fbe7b4b60998f2800a6721219_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfNS0xLTEtMS0yMjM1Nw_5c646180-cc40-4b60-bedc-922ce1dd4c4d">4,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4a2508fbe7b4b60998f2800a6721219_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfNS0zLTEtMS0yMjM1Nw_5603621d-7e18-41df-a7ac-d1362bc686df">6,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4a2508fbe7b4b60998f2800a6721219_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfNS01LTEtMS0yMjM1Nw_8034047d-f26a-4485-885a-87e821fcbe02">11,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vifor Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4010db64fe4c4fd08b2112d996676126_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfNi0xLTEtMS0yMjM1Nw_01275c0e-37c1-4da3-a466-35de96a04481">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4010db64fe4c4fd08b2112d996676126_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfNi0zLTEtMS0yMjM1Nw_7ce03fc4-13ac-49bf-a24d-6c71565af69a">4,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4010db64fe4c4fd08b2112d996676126_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfNi01LTEtMS0yMjM1Nw_12d2bbce-49d7-4fab-96c4-402761e15f99">4,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfNy0xLTEtMS0yMjM1Nw_559781be-2741-489c-b240-1e4557d90af7">15,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfNy0zLTEtMS0yMjM1Nw_6f8f266f-d24f-4869-b160-eb882c62559f">27,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfNy01LTEtMS0yMjM1Nw_c63a7579-41af-4f42-8978-ff77d33e7b9b">43,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDU5MzE_8ac98eba-5b70-4fbf-b126-f7bb92f0f922" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the Company&#8217;s contract assets and liabilities during the nine months ended September&#160;30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:52.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>Beginning of<br/>Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at End<br/>of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable(1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9022775c979849d481205605464f30c6_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMi0xLTEtMS0yMjM1Nw_5903214a-16fd-4ae4-a62c-8b96eae10add">3,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d809bfac669408289ffd42f4682ebdf_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ContractWithCustomerAssetAdditions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMi0zLTEtMS0yMjM1Nw_2db38d32-5888-42c6-8f15-3239c901aecb">38,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d809bfac669408289ffd42f4682ebdf_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ContractWithCustomerAssetDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMi01LTEtMS0yMjM1Nw_c739f25a-2dc2-45c2-962a-0483b0e8b4d3">20,427</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac0b3b12cdd94293a710efe9b099ccbf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMi03LTEtMS0yMjM1Nw_2eb30c14-5009-46ee-942d-ba05b3f089f9">21,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43c4eaad1e5445d9f05ae88eab7739b_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMy0xLTEtMS0yMjM1Nw_ded3ccb0-ece7-4375-b842-7d439a9df5d8">1,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97125a084ecb413d80709a70f9e28986_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ContractWithCustomerAssetAdditions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMy0zLTEtMS0yMjM1Nw_3da18160-ca2e-452e-b4c2-ee83b7731aa9">1,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97125a084ecb413d80709a70f9e28986_D20210101-20210930" decimals="-3" name="akba:ContractWithCustomerAssetDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMy01LTEtMS0yMjM1Nw_3bcea715-543f-4826-82a7-eaf5b8178e79">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79eda260de9049ddb3c4152a914c8bc8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMy03LTEtMS0yMjM1Nw_8e4230df-8e93-493d-b42c-5efc8c18d3f1">3,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd7a9c2a482c488c9e39c164f7f25286_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfNS0xLTEtMS0yMjM1Nw_fa68218e-93eb-433b-85cc-61b5a08b171d">40,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3404eb43c0644986a1e29bf11447aefa_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ContractWithCustomerLiabilityAdditions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfNS0zLTEtMS0yMjM1Nw_70192772-ab33-4c18-af77-4c6cededd977">65,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3404eb43c0644986a1e29bf11447aefa_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ContractWithCustomerLiabilityDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfNS01LTEtMS0yMjM1Nw_7658a572-5266-4ada-b1bc-5f980a20e71c">62,792</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i196a4d9a61ec429197ab955e5ff2ae4b_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfNS03LTEtMS0yMjM1Nw_90764af3-3ab8-4098-a0ac-165db8b90b7a">43,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a97c0c8d344bda97e123e206e6b3c8_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfNi0xLTEtMS0yMjM1Nw_975dbf49-b1dd-47d2-ba2f-afc485e99b95">7,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c709aa7d7814c7bab26eccc3b81e798_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="akba:ContractWithCustomerLiabilityAdditions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfNi0zLTEtMS0yMjM1Nw_a4a5804f-6b64-4804-977d-1a6e7fd19ae9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c709aa7d7814c7bab26eccc3b81e798_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ContractWithCustomerLiabilityDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfNi01LTEtMS0yMjM1Nw_f78811cd-4f84-4831-911a-d4f718e16910">7,227</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia93c22c9b15f4c919a2252df1363cdd4_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfNi03LTEtMS0yMjM1Nw_63c03918-12c5-4240-8be6-5c6a81709583">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id60c0fe0efd942ad8b113bef4877c974_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfNy0xLTEtMS0yMjM1Nw_7d6b0897-d0e4-4919-8f3a-5463b21d28ef">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76b75bcd1b964770ae1b56eaf8e7a892_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="akba:ContractWithCustomerLiabilityAdditions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfNy0zLTEtMS0yMjM1Nw_4eb92ff9-1f6f-4292-b238-e8a2b2316911">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76b75bcd1b964770ae1b56eaf8e7a892_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="akba:ContractWithCustomerLiabilityDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfNy01LTEtMS0yMjM1Nw_6483ac3d-53ad-4b4c-95f5-84db91725f21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i253a75db63844161bc3f8de0b86f9a31_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfNy03LTEtMS0yMjM1Nw_c3524073-a842-4715-8773-09a15935e5c0">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable(1)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b0e1ca966948bf9b3b29017f33c08b_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTEtMS0xLTEtMjIzNTc_5019ad1f-101f-455b-8baa-60130288932e">15,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie67e37ea23d74352995b356f2d5e00a5_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ContractWithCustomerAssetAdditions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTEtMy0xLTEtMjIzNTc_0d33cd1d-75be-471d-aa8f-10704e280f85">143,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie67e37ea23d74352995b356f2d5e00a5_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ContractWithCustomerAssetDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTEtNS0xLTEtMjIzNTc_19b46174-f64e-4111-9e1e-3f2ad9ce52ac">156,209</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i062a629a2436472793e654eaff2d5751_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTEtNy0xLTEtMjIzNTc_1adb1e67-f5b9-446b-89f3-55eb43c14459">2,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8991531a317948b9b93df5b26ec241f8_I20191231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTItMS0xLTEtMjIzNTc_b5ece30c-e2bd-407b-9fc9-81a73b46bbe5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9224c9eaaef4b0fbb6b3ecd626f0fb5_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ContractWithCustomerAssetAdditions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTItMy0xLTEtMjIzNTc_aefd5d7d-c691-40bd-8a93-b22a704cd25c">1,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9224c9eaaef4b0fbb6b3ecd626f0fb5_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="akba:ContractWithCustomerAssetDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTItNS0xLTEtMjIzNTc_8b19da1d-adde-4ae6-9e34-1afbd977f381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0467c81517d465385733a7970a7a414_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTItNy0xLTEtMjIzNTc_a82b6d92-396c-47c4-bd2d-8eee471a3170">1,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcc593671c2e4622975ac665de36e6c1_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTQtMS0xLTEtMjIzNTc_96a1880c-1be3-4b8c-af6a-cca2a10bee72">72,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i595577133c66457b807c06fb447cc0ff_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ContractWithCustomerLiabilityAdditions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTQtMy0xLTEtMjIzNTc_e26b4015-bfd1-4f9c-9a58-a21d9a8ee898">110,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i595577133c66457b807c06fb447cc0ff_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ContractWithCustomerLiabilityDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTQtNS0xLTEtMjIzNTc_d09b776a-43fe-4e13-97f4-3a9e62d14b77">131,551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd56d876b06146709b43ea24c7d1c59b_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTQtNy0xLTEtMjIzNTc_ca72fe86-2a01-4f68-8dd0-32ea11348b5d">51,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib43b28b4e0ab493fa74148aeaab24813_I20191231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTUtMS0xLTEtMjIzNTc_8aea9ad9-33c6-437b-ae7d-b381dfe76d68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee7892ead75d4547be97c8704445856f_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ContractWithCustomerLiabilityAdditions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTUtMy0xLTEtMjIzNTc_b8603285-b90c-4c19-aa8a-88b8dc77009c">10,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee7892ead75d4547be97c8704445856f_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ContractWithCustomerLiabilityDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTUtNS0xLTEtMjIzNTc_6d6f7390-428f-45ba-9945-32e274bfe213">5,651</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe962a59b6ea455b88176426838ddf81_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTUtNy0xLTEtMjIzNTc_c3c35a5d-9e7e-412c-9251-dbdde099805a">4,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i381ae62687174e09adb9da00b0c38527_I20191231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTYtMS0xLTEtMjIzNTc_c1745b8a-1deb-4317-b8df-8b4cb64ae5cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13ca6bac21b04356ab2ca6e641f44077_D20200101-20200930" decimals="-3" name="akba:ContractWithCustomerLiabilityAdditions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTYtMy0xLTEtMjIzNTc_c5dbd1c6-9b96-492a-b836-b5329c0e6e61">615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13ca6bac21b04356ab2ca6e641f44077_D20200101-20200930" decimals="-3" name="akba:ContractWithCustomerLiabilityDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTYtNS0xLTEtMjIzNTc_6866efc8-061f-4334-862c-4fbf37e36cbe">615</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id42d54e97e794a2e966b66e8d2cb3aa4_I20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTYtNy0xLTEtMjIzNTc_01cadeb0-59ca-4cf7-937f-59652535a6e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Excludes accounts receivable from other services related to clinical and regulatory activities performed by the Company on behalf of MTPC that are not included in the performance obligations identified under the MTPC Agreement as of September&#160;30, 2021 and 2020 and December&#160;31, 2020 and 2019. Also excludes accounts receivable related to amounts due to the Company from product sales which are included in the accompanying unaudited condensed consolidated balance sheet as of September&#160;30, 2021 and December&#160;31, 2020.</span></div></ix:nonNumeric><div style="margin-top:2pt"><span><br/></span></div><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="akba:ScheduleOfRevenueRecognizedResultingFromChangesInContractAssetAndContractLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDU5MzI_7c3ff6a3-1363-47b9-b633-8e93f556d032" continuedAt="i59e428080b5444ea8e3a9b34a8fb70aa" escape="true"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021 and 2020, the Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the respective periods (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="idf395c0e55824e66affec3acb8ba0d69" continuedAt="i80c77286ac664e6099474931c1d6aab5"><div style="margin-top:5pt"><ix:continuation id="i59e428080b5444ea8e3a9b34a8fb70aa"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue Recognized in the Period from:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts included in deferred revenue at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjY4NzE5ZmUwNGM3MTRiOGFhYTcyMmU3YmEwMzIxNWJiL3RhYmxlcmFuZ2U6Njg3MTlmZTA0YzcxNGI4YWFhNzIyZTdiYTAzMjE1YmJfMi0xLTEtMS0yMjM1Nw_4b642edc-a018-4eb2-9c19-7c3d7e38f9b8">9,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjY4NzE5ZmUwNGM3MTRiOGFhYTcyMmU3YmEwMzIxNWJiL3RhYmxlcmFuZ2U6Njg3MTlmZTA0YzcxNGI4YWFhNzIyZTdiYTAzMjE1YmJfMi0zLTEtMS0yMjM1Nw_b2dd033e-6b8e-49fd-b622-0b224c887ea3">6,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjY4NzE5ZmUwNGM3MTRiOGFhYTcyMmU3YmEwMzIxNWJiL3RhYmxlcmFuZ2U6Njg3MTlmZTA0YzcxNGI4YWFhNzIyZTdiYTAzMjE1YmJfMi01LTEtMS0yMjM1Nw_d5d4e197-4d27-4a02-8ee8-0d366d354f9f">20,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjY4NzE5ZmUwNGM3MTRiOGFhYTcyMmU3YmEwMzIxNWJiL3RhYmxlcmFuZ2U6Njg3MTlmZTA0YzcxNGI4YWFhNzIyZTdiYTAzMjE1YmJfMi03LTEtMS0yMjM1Nw_d0e7a952-bb1d-4b18-91f4-5f197e0bdfda">29,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance obligations satisfied in previous periods</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjY4NzE5ZmUwNGM3MTRiOGFhYTcyMmU3YmEwMzIxNWJiL3RhYmxlcmFuZ2U6Njg3MTlmZTA0YzcxNGI4YWFhNzIyZTdiYTAzMjE1YmJfMy0xLTEtMS0yMjM1Nw_109248e6-ef5b-4bd5-bc4e-a69aff76112b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjY4NzE5ZmUwNGM3MTRiOGFhYTcyMmU3YmEwMzIxNWJiL3RhYmxlcmFuZ2U6Njg3MTlmZTA0YzcxNGI4YWFhNzIyZTdiYTAzMjE1YmJfMy0zLTEtMS0yMjM1Nw_5d5202eb-97e9-485e-a4d3-5acc9b3778b5">20,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjY4NzE5ZmUwNGM3MTRiOGFhYTcyMmU3YmEwMzIxNWJiL3RhYmxlcmFuZ2U6Njg3MTlmZTA0YzcxNGI4YWFhNzIyZTdiYTAzMjE1YmJfMy01LTEtMS0yMjM1Nw_cf186fa4-d048-4737-bbbc-3f8fc33831ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjY4NzE5ZmUwNGM3MTRiOGFhYTcyMmU3YmEwMzIxNWJiL3RhYmxlcmFuZ2U6Njg3MTlmZTA0YzcxNGI4YWFhNzIyZTdiYTAzMjE1YmJfMy03LTEtMS0yMjM1Nw_b8a758a7-97fe-4e2a-a9a5-7ec4e31f22a3">21,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mitsubishi Tanabe Pharma Corporation Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On December 11, 2015, the Company and MTPC entered into a collaboration agreement, or the MTPC Agreement, providing MTPC with exclusive development and commercialization rights to vadadustat in Japan and certain other Asian countries, collectively, the MTPC Territory. In addition, the Company will supply vadadustat for both clinical and commercial use in the MTPC Territory, subject to MTPC&#8217;s option to manufacture commercial drug product in the MTPC Territory. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">A more detailed description of this collaboration agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In February 2021, the Company entered into a royalty interest acquisition agreement with HealthCare Royalty Partners IV, L.P., or the Royalty Agreement, whereby the Company sold its right to receive royalties and sales milestones under the MTPC Agreement, subject to certain caps and other terms and conditions (see Note 5 for additional information). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the elements of the MTPC Agreement in accordance with the provisions of ASC 606 and concluded that the contract counterparty, MTPC, is a customer. The Company&#8217;s arrangement with MTPC contains the following material promises under the contract at inception: (i) license under certain of the Company&#8217;s intellectual property to develop and commercialize vadadustat in the MTPC Territory, (ii) clinical supply of vadadustat, (iii) knowledge transfer, (iv) Phase 2 dosing study research services, and (v) rights to future know-how.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified <ix:nonFraction unitRef="performance_obligation" contextRef="i5ffb0dde1c014cb9abf1b7695c63c0d2_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="akba:NumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjkwMw_8ab6c49b-f99b-486c-ac5a-7582e8b50934">two</ix:nonFraction> performance obligations in connection with its material promises under the MTPC Agreement as follows: (i) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Research and Clinical Supply Performance Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and (ii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rights to Future Know-How Performance Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Factors considered in making the assessment of which material promises will be accounted for as separate performance obligations included, among other things, the capabilities of the collaboration partner, whether any other vendor sells the item separately, whether the good or service is highly interdependent or highly interrelated to the other elements in the arrangement, and whether there are other vendors that can provide the items. Additionally, the MTPC Agreement does not include a general right of return.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price to each performance obligation based on the Company&#8217;s best estimate of the relative standalone selling price. The Company developed a best estimate of the standalone selling price for the Rights to Future Know-How Performance Obligation primarily based on the likelihood that additional intellectual property covered by the license conveyed will be developed during the term of the arrangement and determined it is immaterial. As such, the Company did not develop a best estimate of standalone selling price for the License, Research and Clinical Supply Performance Obligation and allocated the entire transaction price to this performance obligation. The deliverables associated with the License, Research and Clinical Supply Performance Obligation were satisfied as of June 30, 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price at inception was comprised of: (i) the up-front payment, (ii) the estimated cost for the Phase 2 studies, (iii) a non-substantive milestone associated with the first patient enrolled in the NDD-CKD Phase 3 study, and (iv) the cost of all clinical supply provided to MTPC for the Phase 3 studies. No other development and no regulatory milestones were included in the transaction price at inception, as all other milestone amounts were fully constrained. Subsequent to inception, the transaction price also included certain development and regulatory milestones, as described below. As part of its evaluation of the constraint, the Company considers numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee&#8217;s efforts.&#160;Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to MTPC and therefore have also been excluded from the transaction price.&#160;The Company re-evaluates the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. The Company determined that the remaining consideration that may be payable to the Company subsequent to MTPC's commercial launch of Vafseo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the third quarter of 2020 is quarterly royalties on net sales, sales milestones, and certain regulatory milestones.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i80c77286ac664e6099474931c1d6aab5" continuedAt="i359c58a117ba4d9a9a1a92bca2f12cb8"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the transaction price was comprised of: (i) the up-front payment of $<ix:nonFraction unitRef="usd" contextRef="ibf4981c415ac4d3faa22e3d1e690bfbf_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="akba:UpfrontCashPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNjA4NQ_350275b8-1905-4f64-a623-a9156b9d64bc">20.0</ix:nonFraction> million, (ii) the cost for the Phase 2 studies of $<ix:nonFraction unitRef="usd" contextRef="ibf4981c415ac4d3faa22e3d1e690bfbf_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="akba:CostOfResearchServices" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNjEzMA_0ffb9d35-c579-42ad-a1f8-d5f3cae9324f">20.5</ix:nonFraction> million, (iii) the cost of all clinical supply provided to MTPC for the Phase 3 studies, (iv) $<ix:nonFraction unitRef="usd" contextRef="ibf4981c415ac4d3faa22e3d1e690bfbf_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="akba:MilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNjIxOQ_e51ced0b-dcad-49ba-922a-546b1e95e687">10.0</ix:nonFraction>&#160;million in development milestones received, (v) $<ix:nonFraction unitRef="usd" contextRef="i59b89b0dc1714bceaf61d6592940372e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="akba:MilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNjI2Mg_c2b8fd4b-6178-4d8d-a01d-cc6bc9e828bf">25.0</ix:nonFraction>&#160;million in regulatory milestones received, comprised of $<ix:nonFraction unitRef="usd" contextRef="i8bea31568bfb475da7ac289ff0a194bb_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="akba:MilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNjMxMw_c6325a8f-797b-4b47-9f73-1b99da17505b">10.0</ix:nonFraction> million relating to the NDA filing in Japan and $<ix:nonFraction unitRef="usd" contextRef="i049242e1c959495ba03db706d555ef59_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="akba:MilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNjM0OA_2d26665b-d56a-4602-928f-016d1676eded">15.0</ix:nonFraction> million relating to regulatory approval of vadadustat in Japan, and (vi) $<ix:nonFraction unitRef="usd" contextRef="i8270fb936c044bacb333691798285cad_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNjQxNg_09d95025-1c9a-4c7f-bb21-f55d3d284532">0.9</ix:nonFraction> million in royalties from net sales of Vafseo. As of September&#160;30, 2021, all development milestones and $<ix:nonFraction unitRef="usd" contextRef="i59b89b0dc1714bceaf61d6592940372e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="akba:MilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNjQ5OQ_08233a63-0ab8-4145-ab27-836eab63a0f6">25.0</ix:nonFraction>&#160;million in regulatory milestones have been achieved. No other regulatory milestones have been assessed as probable of being achieved and as a result have been fully constrained. Revenue for the License, Research and Clinical Supply Performance Obligation for the MTPC Agreement is being recognized using a proportional performance method, for which all deliverables have been completed. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i8873d2f4f3ab410f8ea8fdc1148178ff_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNjkwNA_ac89215c-40e3-4040-a726-e44d06968349">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia2b65de4f50a4ba0aba4c2a04561a742_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ5MTA2NA_a43a8f34-655e-4abd-a64c-88285c94d217">0.4</ix:nonFraction> million of revenue from MTPC royalties for the three and nine months ended September&#160;30, 2021, respectively. The Company recognized a $<ix:nonFraction unitRef="usd" contextRef="i049242e1c959495ba03db706d555ef59_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="akba:MilestonePaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNzAxMA_2d26665b-d56a-4602-928f-016d1676eded">15.0</ix:nonFraction> million regulatory milestone relating to regulatory approval of vadadustat in Japan as revenue during the nine months ended September&#160;30, 2020. As noted above, in February 2021, the Company entered into the Royalty Agreement, whereby the Company sold its right to receive these royalties and sales milestones under the MTPC Agreement, subject to certain caps and other terms and conditions (see Note 5 for additional information). The revenue is classified as collaboration revenue in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss. As of September&#160;30, 2021, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i77a8fd0e1e314ec995a1ea4cb3e26298_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTA5OTUxMTY4MDYyMQ_51fcfed6-8480-4bed-8cab-8bb44e988f75">0.2</ix:nonFraction>&#160;million in accounts receivable, <ix:nonFraction unitRef="usd" contextRef="i75a8e981279d4597a75912a5c2d89696_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNzY0Nw_398a0ff2-666e-4930-833e-e44c5b302ee1">no</ix:nonFraction> deferred revenue, and <ix:nonFraction unitRef="usd" contextRef="i75a8e981279d4597a75912a5c2d89696_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNzY3Mg_e5b18d70-87ce-4c5a-be58-40ec994451c9">no</ix:nonFraction> contract assets. There were no asset or liability balances classified as long-term in the unaudited condensed consolidated balance sheet as of September&#160;30, 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supply of Drug Product to MTPC</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, in connection with the MTPC Agreement, the Company and MTPC entered into a letter agreement, pursuant to which the Company agreed to supply MTPC with certain vadadustat process validation drug product for commercial use and MTPC agreed to reimburse the Company for certain manufacturing-related expenses. In connection with this arrangement, the Company invoiced the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i5ab7efb86c7e4332bb5d1393a1103c7a_D20200401-20200630" decimals="-5" format="ixt:num-dot-decimal" name="akba:UpfrontCashPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfODIxOA_089382e1-da96-42fb-8edb-dc0b32233187">10.4</ix:nonFraction> million, which it received during the three months ended June 30, 2020. The Company does not recognize revenue under this arrangement until delivery has occurred and risk of loss passes to MTPC. <ix:nonFraction unitRef="usd" contextRef="i84bfabdde428494b8286364e0b2e04f8_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ5NjAwMA_6834e442-f662-4a01-a76f-d19557c0ec6a"><ix:nonFraction unitRef="usd" contextRef="iec08195269f1492b95a796511ae43b19_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ5NjAwMA_e344e9ba-e6d5-4997-9770-7e0fcff84362">No</ix:nonFraction></ix:nonFraction> revenues were recognized during the three and nine months ended September&#160;30, 2021 and approximately $<ix:nonFraction unitRef="usd" contextRef="ic04e3a3ad82e497eab9e0ccc53e84bb7_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTA5OTUxMTY4MDI5OA_b0492925-e858-4961-b099-470020ae6131">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iddee3a51bc8e41009393c7fffc1d6be2_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTA5OTUxMTY4MDMyNw_0ec0b227-d4e6-44d5-bb30-82f41ec87192">4.5</ix:nonFraction> million of revenue was recognized during the three and nine months ended September&#160;30, 2020, respectively, for drug product that was delivered during the applicable period. As of September&#160;30, 2021, the Company recorded <ix:nonFraction unitRef="usd" contextRef="i5008d093e2c14f8e9b0c70b8ad2d6cdf_I20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ5NjAzMg_b0c67fb2-0946-409d-ba9c-a4c0bfc1794d">no</ix:nonFraction> accounts receivable, <ix:nonFraction unitRef="usd" contextRef="i5008d093e2c14f8e9b0c70b8ad2d6cdf_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfODYwNw_b0cf8eb1-cfad-40db-9254-f86a8643bec1">no</ix:nonFraction> deferred revenue, $<ix:nonFraction unitRef="usd" contextRef="i30255726ea164f57b4faf87425b440bf_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfODYzMg_d58113fc-1357-4d28-baec-7d399c28fe60">3.0</ix:nonFraction> million in other current liabilities and $<ix:nonFraction unitRef="usd" contextRef="i2c9c4fa43e814dbbaf59df410140075b_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfODY2OA_cd1c5928-e608-47fb-aa17-4f5a0af6cd6f">0.4</ix:nonFraction>&#160;million in other non-current liabilities for drug product that was subject to return by MTPC.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2020, the Company and its collaboration partner MTPC entered into a supply agreement, or the MTPC Supply Agreement. The MTPC Supply Agreement includes the terms and conditions under which the Company will supply vadadustat drug product to MTPC for commercial use in Japan and certain other Asian countries, as contemplated by the MTPC Agreement. A more detailed description of this supply agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i8e8a7ecf26094b9985196caeaf40209b_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ5MTQyOQ_f92332fb-a0fb-4411-8b0f-d1a300cb00cb">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0713ae0f1c084dc1a951ad2de75526f0_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfOTM1MQ_98f1485b-7f0c-4d4c-a698-dff04ee663ac">6.7</ix:nonFraction> million of revenue under the MTPC Supply Agreement during the three and nine months ended September&#160;30, 2021, respectively. During the nine months ended September&#160;30, 2021, the Company invoiced MTPC for $<ix:nonFraction unitRef="usd" contextRef="i93d500fdcbc947168636b67aefe164f2_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BilledContractReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfOTUwMQ_78f93a08-40d5-4080-a9f8-edb5942b86f9">13.4</ix:nonFraction> million in payments for vadadustat drug product ordered by MTPC. As of September&#160;30, 2021, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i64af70fdf31a4cfcbd5d1dd0c6e667f3_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BilledContractReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfOTU5Mg_8e27bc66-e5bb-41c1-9cb6-a1d497004a31">4.5</ix:nonFraction> million in accounts receivable, $<ix:nonFraction unitRef="usd" contextRef="i5c2d9393a8d94a97b1a20c634e92642c_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BilledContractReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfOTYxOQ_6eaeb336-04c5-4c07-8c9c-75fd7e4911f9">4.9</ix:nonFraction> million in deferred revenue, $<ix:nonFraction unitRef="usd" contextRef="i2d43ffd6494e45cea49745bc245eb588_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BilledContractReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfOTY0Mw_a47259ef-a729-402e-aa77-eea82a2a8857">16.3</ix:nonFraction> million in other current liabilities and $<ix:nonFraction unitRef="usd" contextRef="i2182ac591eaa4895935be370490ebd61_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BilledContractReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfOTY3OQ_9983a1d5-37da-4649-ad9f-4fbb25db3042">5.8</ix:nonFraction> million in other non-current liabilities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Collaboration and License Agreement with Otsuka Pharmaceutical Co. Ltd.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 18, 2016, the Company entered into a collaboration and license agreement with Otsuka, or the Otsuka U.S. Agreement. The collaboration is focused on the development and commercialization of vadadustat in the United States. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Otsuka U.S. Agreement, the Company granted to Otsuka a co-exclusive, non-sublicensable license under certain intellectual property controlled by the Company solely to perform medical affairs activities and to conduct non-promotional and commercialization activities related to vadadustat in the United States in accordance with the associated plans. The co-exclusive license relates to activities that will be jointly conducted by the Company and Otsuka pursuant to the terms of the Otsuka U.S. Agreement. Additionally, the parties agreed not to promote, market or sell any competing product in the territory covered by the Otsuka U.S. Agreement. A more detailed description of this collaboration agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K.</span></div></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i359c58a117ba4d9a9a1a92bca2f12cb8" continuedAt="i704d5bfca3724d618b89612b15fc9454"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the elements of the Otsuka U.S. Agreement in accordance with the provisions of ASC 606 and concluded that the contract counterparty, Otsuka, is a customer. The Company&#8217;s arrangement with Otsuka contains the following material promises under the contract at inception: (i) license under certain of the Company&#8217;s intellectual property to develop, perform medical affairs activities with respect to and conduct non-promotional and commercialization activities related to vadadustat and products containing or comprising vadadustat, (ii) development services to be performed pursuant to the current global development plan, (iii) rights to future intellectual property, and (iv) joint committee services.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company has identified <ix:nonFraction unitRef="performance_obligation" contextRef="i729bdb2febbe40f7a0d7e8b9d41b5707_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="akba:NumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTE4MDk_61c6ceb7-55ca-44f8-9654-f15c713f4c68">three</ix:nonFraction> performance obligations in connection with its obligations under the Otsuka U.S. Agreement as follows: i) License and Development Services Combined (License Performance Obligation); (ii) Rights to Future Intellectual Property (Future IP Performance Obligation) and (iii) Joint Committee Services (Committee Performance Obligation). Factors considered in making the assessment of which material promises will be accounted for as separate performance obligations included, among other things, the capabilities of the collaboration partner, whether any other vendor sells the item separately, whether the good or service is highly interdependent or highly interrelated to the other elements in the arrangement, and whether there are other vendors that can provide the items. Additionally, the Otsuka U.S. Agreement does not include a general right of return. A more detailed description of the performance obligations under this agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price to each performance obligation based on the Company&#8217;s best estimate of the relative standalone selling price. The Company developed a best estimate of standalone selling price for the Committee Performance Obligation after considering the nature of the services to be performed and estimates of the associated effort and rates applicable to such services that would be expected to be realized under similar contracts. The Company developed a best estimate of standalone selling price for the Future IP Performance Obligation primarily based on the likelihood that additional intellectual property covered by the license conveyed will be developed during the term of the arrangement. The Company did not develop a best estimate of standalone selling price for the License Performance Obligation due to the following: (i) the best estimates of standalone selling price associated with the Future IP Performance Obligation was determined to be immaterial and (ii) the period of performance and pattern of recognition for the License Performance Obligation and the Committee Performance Obligation was determined to be similar. The Company has concluded that a change in the key assumptions used to determine the best estimate of standalone selling price for each performance obligation would not have a significant impact on the allocation of arrangement consideration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price at inception was comprised of: (i) the up-front payment, (ii) the cost share payment with respect to amounts incurred by the Company through December 31, 2016, and (iii) an estimate of the cost share payments to be received with respect to amounts incurred by the Company subsequent to December 31, 2016. <ix:nonFraction unitRef="usd" contextRef="i05703e7e166b4e6aa26567e3dd53b0d4_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="akba:MilestonePaymentReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTQ2NDU_80df0d1e-8d12-492e-a157-419c88a7bdf0">No</ix:nonFraction> development or regulatory milestones were included in the transaction price at inception, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee&#8217;s efforts. Any consideration related to sales-based milestones will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Otsuka and therefore have also been excluded from the transaction price.&#160;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company re-evaluates the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. The Company determined that under ASC 606, the contract was modified in the second quarter of 2019 when the Otsuka Funding Option became effective and the Company became eligible to receive the Additional Funding (defined below) amount. In connection with the modification, the Company adjusted the transaction price to include the Additional Funding amount as additional variable consideration. The Company constrains the variable consideration to an amount for which a significant revenue reversal is not probable. In the event that there is consideration received by Otsuka in the form of activities performed by Otsuka under the global development plan, such consideration is reflected as a reduction to the transaction price as contra revenue rather than as an expense because the associated services are not distinct from the License Performance Obligation. The Company estimates the additional funding as a result of exercising the Otsuka Funding Option, or the Additional Funding, to total approximately $<ix:nonFraction unitRef="usd" contextRef="ib36601c7c6054547b257cbee1cadedd2_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="akba:CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0Mzk_7ad5e4bc-1c87-40f2-b06d-19ee11a905f2">139.8</ix:nonFraction> million or more, depending on the actual costs incurred toward the current global development plan. The Additional Funding is fully creditable against future payments due to the Company under the arrangement, provided that future payments due to the Company may not be reduced by more than <ix:nonFraction unitRef="number" contextRef="icf1d9f1217594ee99787532eb6416a3e_D20210101-20210930" decimals="2" name="akba:ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY3MjQ_4e8e18ec-ea95-4fcc-9936-abebf4e9ad44">50</ix:nonFraction>% in any calendar year and any remaining creditable amount above <ix:nonFraction unitRef="number" contextRef="i5df4e367c4894f3baca804f2eba217c6_D20210101-20210930" decimals="2" name="akba:PercentageOfRemainingCreditableAmountAppliedToFuturePayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY3OTA_cbf36339-998c-4cfb-bd85-182caca9755e">50</ix:nonFraction>% in any calendar year will be applied to subsequent future payments until fully credited. As of September&#160;30, 2021, the Additional Funding was $<ix:nonFraction unitRef="usd" contextRef="i729bdb2febbe40f7a0d7e8b9d41b5707_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="akba:CollaborativeArrangementsAdditionalCostSharingPaymentsAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY5MTk_81d5dcb9-fc4a-4a15-9811-df9e303fae4d">106.7</ix:nonFraction> million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No amounts were allocated to the Future IP Performance Obligation because the associated best estimate of standalone selling price was determined to be immaterial. Due to the similar performance period and recognition pattern between the License Performance Obligation and the Committee Performance Obligation, the transaction price has been allocated to the License Performance Obligation and the Committee Performance Obligation on a combined basis. Accordingly, the Company will </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i704d5bfca3724d618b89612b15fc9454" continuedAt="i80cf3387145244aeb6210dfc2853c43e"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognize revenue related to the allocable arrangement consideration on a proportional performance basis as the underlying development services are performed pursuant to the current global development plan which is commensurate with the period and consistent with the pattern over which the Company&#8217;s obligations are satisfied for both the License Performance Obligation and the Committee Performance Obligation. Effectively, the Company has treated the arrangement as if the License Performance Obligation and the Committee Performance Obligation are a single performance obligation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the transaction price totaling $<ix:nonFraction unitRef="usd" contextRef="i729bdb2febbe40f7a0d7e8b9d41b5707_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="akba:CollaborativeAndLicenseArrangementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTgwMzE_a36352ef-2757-4742-b7bd-bbefb6e7a82a">504.2</ix:nonFraction> million was comprised of: (i) the up-front payment of $<ix:nonFraction unitRef="usd" contextRef="i044f764231f14772829db57c3b4d1639_D20161201-20161231" decimals="-5" format="ixt:num-dot-decimal" name="akba:UpfrontCashPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTgwODA_18af043e-fd11-4ddd-93a4-d0031b639718">125.0</ix:nonFraction> million, (ii) the cost share payment with respect to amounts incurred by the Company through December 31, 2016 of $<ix:nonFraction unitRef="usd" contextRef="icbdd2b99003a4b868da41de914cb59b4_D20161201-20161231" decimals="-5" format="ixt:num-dot-decimal" name="akba:PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTgxODk_94c2b287-6885-40f4-8b79-923cfa959282">33.8</ix:nonFraction> million, and (iii) the estimate of the net cost share consideration to be received of approximately $<ix:nonFraction unitRef="usd" contextRef="icbdd2b99003a4b868da41de914cb59b4_D20161201-20161231" decimals="-5" format="ixt:num-dot-decimal" name="akba:CollaborativeArrangementsCostSharingPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTgyODQ_ca00ed0c-9ff8-42be-b206-539e0b43efe6">345.4</ix:nonFraction> million with respect to amounts incurred by the Company subsequent to December 31, 2016. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i500c6fdc5af04a21900cf4f2d9069a5b_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="akba:RevenueRemainingPerformanceObligationVariableConsiderationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ4ODE5MQ_d6905de7-a59b-4e5c-ba19-65bac581b7a2">65.0</ix:nonFraction> million in regulatory milestone payments for the first HIF product to achieve the associated event and up to $<ix:nonFraction unitRef="usd" contextRef="if916aba0a4c34bab87b14d995442b804_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="akba:RevenueRemainingPerformanceObligationVariableConsiderationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ4ODI5OA_fc89c038-b628-4ec6-9f79-ceee5c5fc673">575</ix:nonFraction> million in commercial milestone payments associated with aggregate sales of licensed products. These future milestones are subject to reduction as a result of the Company's exercise of the Otsuka Funding Option, as described above. As of September&#160;30, 2021, <ix:nonFraction unitRef="usd" contextRef="i05703e7e166b4e6aa26567e3dd53b0d4_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="akba:MilestonePaymentReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTgzNzg_0060f9f3-e3f9-4c03-9391-ba36556effa7">no</ix:nonFraction> development or regulatory milestones have been assessed as probable of being reached and thus have been fully constrained.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021 and 2020, the Company recognized revenue totaling approximately $<ix:nonFraction unitRef="usd" contextRef="iefd530a7f1a248edbdc9b05c847c8a7e_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTg1OTg_3c673c77-c380-45d3-b465-42107c07a1dc">6.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib09d90891a274c3c818a2cef521eace2_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTg2MDU_eaacef14-3dae-472f-bb20-cfa00a8b99a5">16.3</ix:nonFraction> million, respectively, and approximately $<ix:nonFraction unitRef="usd" contextRef="i73b11af5f04a42d9a1071752d045891e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTg2NDE_104f92a4-8b74-4ee9-8f10-ee9b09c2d465">29.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib6fc2047fffc4e2d8558725e0f1d34a0_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTg2NDg_dd40ecb0-5c48-4bc2-af86-302678223ad1">80.7</ix:nonFraction> million, during the nine months ended September&#160;30, 2021 and 2020, respectively, with respect to the Otsuka U.S. Agreement. The revenue is classified as collaboration revenue in the accompanying unaudited condensed consolidated statements of operations. As of September&#160;30, 2021, there was approximately $<ix:nonFraction unitRef="usd" contextRef="i70c28a2a28bc4932a1c94051311c07d4_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTg5MTI_2c81ef54-1b92-4f60-b7ab-14fa644252c9">23.0</ix:nonFraction> million of deferred revenue related to the Otsuka U.S. Agreement of which $<ix:nonFraction unitRef="usd" contextRef="i70c28a2a28bc4932a1c94051311c07d4_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTg5ODE_4e34a4b5-edb2-4e54-a35f-1f5437cd5e11">6.3</ix:nonFraction> million is classified as current and $<ix:nonFraction unitRef="usd" contextRef="i70c28a2a28bc4932a1c94051311c07d4_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTkwMTM_3eb4c57f-0aa4-4a7d-8fd0-b6599697434e">16.7</ix:nonFraction> million is classified as long-term in the accompanying unaudited condensed consolidated balance sheet based on the performance period of the underlying obligations. Additionally, as of September&#160;30, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i4eff79078bbb43e1882ae7742d0279b6_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTA5OTUxMTY4MDY0MQ_de785720-0a7a-426a-9ff6-cf1760d71572">2.4</ix:nonFraction> million in accounts receivable and $<ix:nonFraction unitRef="usd" contextRef="ib0094621113146aebebb1a65434da333_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTkyNTU_49efc963-e772-490a-91d5-e0fa2f3e0bd1">2.4</ix:nonFraction> million in prepaid expenses and other current assets in the accompanying unaudited condensed consolidated balance sheet. As of December&#160;31, 2020, there was approximately $<ix:nonFraction unitRef="usd" contextRef="ic6acee9f4bf9402baacb58cb5f057459_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTk0MDU_12954688-9f7e-4f49-a742-1a847c03ad14">5.0</ix:nonFraction> million in contract liabilities (included in accounts payable) and $<ix:nonFraction unitRef="usd" contextRef="i51de58b6c7be4fb9899538b241b86615_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTk0Njc_b8b5fbb0-da3c-4d4c-a43c-d0157e4d8cba">1.2</ix:nonFraction> million in prepaid expenses and other current assets in the consolidated balance sheet.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the medical affairs, commercialization and non-promotional activities elements of the Otsuka U.S. Agreement represent joint operating activities in which both parties are active participants and of which both parties are exposed to significant risks and rewards that are dependent on the success of the activities. Accordingly, the Company is accounting for the joint medical affairs, commercialization and non-promotional activities in accordance with ASC No. 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Additionally, the Company has determined that in the context of the medical affairs, commercialization and non-promotional activities, Otsuka does not represent a customer as contemplated by ASC 606-10-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers &#8211; Scope and Scope Exceptions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As a result, the activities conducted pursuant to the medical affairs, commercialization and non-promotional activities plans will be accounted for as a component of the related expense in the period incurred. During the three months ended September&#160;30, 2021 and 2020, the Company incurred approximately $<ix:nonFraction unitRef="usd" contextRef="ic5c623ee9ed146eb8cee4622f170592a_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="akba:CostShareCostsIncurredForLicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjA2NDI_426c2347-7863-4131-b399-5bc212c4a1a3">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i70b7ea01a52041328c8e4e5bcda17a4c_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="akba:CostShareCostsIncurredForLicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjA2NDk_fd3eb0d4-373b-47d4-a3ad-5c1337f03987">1.2</ix:nonFraction> million, respectively, of costs related to the cost-sharing provisions of the Otsuka U.S. Agreement, of which approximately $<ix:nonFraction unitRef="usd" contextRef="ic5c623ee9ed146eb8cee4622f170592a_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="akba:PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjA3Njg_1e9d70d2-e058-4e0a-8ec4-4e9fdd986dfe">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i70b7ea01a52041328c8e4e5bcda17a4c_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="akba:PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjA3NzU_b9461e5d-4f48-4a25-b7f1-fc8d8ba4f9f0">0.5</ix:nonFraction> million are reimbursable by Otsuka and recorded as a reduction to research and development expense during the three months ended September&#160;30, 2021 and 2020, respectively. During the three months ended September&#160;30, 2021, Otsuka incurred <ix:nonFraction unitRef="usd" contextRef="ic5c623ee9ed146eb8cee4622f170592a_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="akba:CostShareCostsIncurredByPartnerForLicenseAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjA5OTU_ece954f8-4c61-4c82-a8ed-575e06682fab">no</ix:nonFraction> costs related to the cost-sharing provisions of the Otsuka U.S. Agreement. During the three months ended September&#160;30, 2020, Otsuka incurred $<ix:nonFraction unitRef="usd" contextRef="i70b7ea01a52041328c8e4e5bcda17a4c_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="akba:CostShareCostsIncurredByPartnerForLicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjEwMDI_fdd3066a-414e-4e4f-9e1b-dd77b7d825b4">0.5</ix:nonFraction> million of costs related to the cost-sharing provisions of the Otsuka U.S. Agreement, of which approximately $<ix:nonFraction unitRef="usd" contextRef="i70b7ea01a52041328c8e4e5bcda17a4c_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="akba:PaymentForLicenseAgreementReimbursementOfCostsIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjExMjg_aad51662-92ae-44db-abaf-be28f9005138">0.3</ix:nonFraction> million were reimbursable by the Company and recorded as an increase to research and development expense during the three months ended September&#160;30, 2020.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Collaboration and License Agreement with Otsuka Pharmaceutical Co. Ltd.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2017, the Company entered into a collaboration and license agreement with Otsuka, or the Otsuka International Agreement. The collaboration is focused on the development and commercialization of vadadustat in Europe, Russia, China, Canada, Australia, the Middle East and certain other territories, collectively, the Otsuka International Territory. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Otsuka International Agreement, the Company granted to Otsuka an exclusive, sublicensable license under certain intellectual property controlled by the Company to develop and commercialize vadadustat and products containing or comprising vadadustat in the Otsuka International Territory. Additionally, under the terms of this agreement, the Company is responsible for leading the development of vadadustat. Otsuka has the sole responsibility, at its own cost, for the commercialization of vadadustat in the Otsuka International Territory, subject to the approval by the relevant regulatory authorities. A more detailed description of this collaboration agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i80cf3387145244aeb6210dfc2853c43e" continuedAt="i90d82e8452774d9e925f0abec0059b15"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounted for the Otsuka International Agreement separately from the collaboration arrangement with Otsuka with respect to the U.S. due to the lack of interrelationship and interdependence of the elements and payment terms within each of the contracts as they relate to the respective territories. Accordingly, the Company has applied the guidance in ASC 606 solely in reference to the terms and conditions of the Otsuka International Agreement, while the Otsuka U.S. Agreement has continued to be accounted for as a discrete agreement in its own right. The Company evaluated the Otsuka International Agreement in accordance with the provisions of ASC 606 and concluded that the contract counterparty, Otsuka, is a customer. The Company&#8217;s arrangement with Otsuka related to the Otsuka International Territory contains the following material promises under the contract at inception: (i) license under certain of the Company&#8217;s intellectual property to develop and commercialize (including the associated packaging) vadadustat and products containing or comprising vadadustat and development services to be performed pursuant to the current global development plan, (ii) rights to future intellectual property and (iii) joint committee services.</span></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company has identified <ix:nonFraction unitRef="performance_obligation" contextRef="i21debe3a35d84013a5c0a46700b925d1_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="akba:NumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjQwNjI_61cf3965-ffe8-4bde-b126-c91c7b1d9f2c">three</ix:nonFraction> performance obligations in connection with its obligations under the Otsuka International Agreement as follows: i) License and Development Services Combined (License Performance Obligation); (ii) Rights to Future Intellectual Property (Future IP Performance Obligation) and (iii) Joint Committee Services (Committee Performance Obligation). Factors considered in making this assessment of which material promises will be accounted for as a separate performance obligation included, among other things, the capabilities of the collaboration partner, whether any other vendor sells the item separately, whether the good or service is highly interdependent or highly interrelated to the other elements in the arrangement, and whether there are other vendors that can provide the items.&#160;Additionally, the Otsuka International Agreement does not include a general right of return. A more detailed description of the performance obligations under this agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price to each performance obligation based on the Company&#8217;s best estimate of the relative standalone selling price. The Company developed a best estimate of standalone selling price for the Committee Performance Obligation after considering the nature of the services to be performed and estimates of the associated effort and rates applicable to such services that would be expected to be realized under similar contracts. The Company developed a best estimate of standalone selling price for the Future IP Performance Obligation primarily based on the likelihood that additional intellectual property covered by the license conveyed will be developed during the term of the arrangement. The Company did not develop a best estimate of standalone selling price for the License Performance Obligation due to the following: (i) the best estimates of standalone selling price associated with the Future IP Performance Obligation was determined to be immaterial and (ii) the period of performance and pattern of recognition for the License Performance Obligation and the Committee Performance Obligation was determined to be similar. The Company has concluded that a change in the key assumptions used to determine the best estimate of standalone selling price for each performance obligation would not have a significant impact on the allocation of arrangement consideration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price at inception was comprised of: (i) the up-front payment, (ii) the cost share payment with respect to amounts incurred by the Company during the quarter ended March 31, 2017, and (iii) an estimate of the cost share payments to be received with respect to amounts incurred by the Company subsequent to March 31, 2017. No development or regulatory milestones were included in the transaction price at inception, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including whether the receipt of the milestone payment is outside the control of the Company and contingent upon success in future clinical trials and the licensee&#8217;s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Otsuka and therefore have also been excluded from the transaction price.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company re-evaluates the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. In the event that there is consideration received by a customer in the form of activities performed by such customer under the global development plan, such consideration is reflected as a reduction to the transaction price as contra revenue rather than as an expense because the associated services are not distinct from the License Performance Obligation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the transaction price totaling $<ix:nonFraction unitRef="usd" contextRef="i21debe3a35d84013a5c0a46700b925d1_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="akba:CollaborativeAndLicenseArrangementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjgxNTE_a833f467-6aa8-41b1-9754-350b03724dee">310.4</ix:nonFraction> million was comprised of: (i) the up-front payment of $<ix:nonFraction unitRef="usd" contextRef="i0fdc68385d154fbd8c01df1bd39dde5d_D20170425-20170425" decimals="-5" format="ixt:num-dot-decimal" name="akba:UpfrontCashPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjgyMDA_cb085b14-6401-45f8-bb61-66d8a0ed7003">73.0</ix:nonFraction> million, (ii) the cost share payment with respect to amounts incurred by the Company during the quarter ended March 31, 2017 of $<ix:nonFraction unitRef="usd" contextRef="i871f553557614df48044678d328520cb_D20170101-20170331" decimals="-5" format="ixt:num-dot-decimal" name="akba:PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjgzMjM_f60cbd97-91f8-474b-ae1d-92c5ecb77b38">0.2</ix:nonFraction> million, and (iii) an estimate of the net cost share consideration to be received with respect to amounts incurred by the Company subsequent to March 31, 2017 of $<ix:nonFraction unitRef="usd" contextRef="i871f553557614df48044678d328520cb_D20170101-20170331" decimals="-5" format="ixt:num-dot-decimal" name="akba:EstimateSubsequentCostFundingUnderPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjg0ODA_359c39b4-8ff6-4129-914c-d54339ded8b1">237.3</ix:nonFraction> million. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, the Company is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="id317514fef48482db39eba1dc979e0ad_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="akba:RevenueRemainingPerformanceObligationVariableConsiderationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ5MDAxNA_da1de08d-8884-458e-833b-92d39b7120b5">17.0</ix:nonFraction> million in regulatory milestone payments for the licensed HIF product if the Company achieves the associated event within <ix:nonNumeric contextRef="i587afcb2ee994fd1823e352650f8c16f_D20210101-20210930" format="ixt-sec:durmonth" name="akba:RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ5NjAzOQ_71919e09-6a48-4c8b-ac7e-b498bcb87173">12</ix:nonNumeric> to <ix:nonNumeric contextRef="i4f62756447d54a2ea8980a3e5189c028_D20210101-20210930" format="ixt-sec:durmonth" name="akba:RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ5NjA0OA_237e6155-301a-46e0-91d3-e7fbb0aa8910">24</ix:nonNumeric> months of the first HIF product approval. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i90d82e8452774d9e925f0abec0059b15" continuedAt="ie26e2cde08ae4a4bb1b37da3053dce51"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company is eligible for up to $<ix:nonFraction unitRef="usd" contextRef="ie73bc5c571f84ec38080d5e084633f19_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="akba:RevenueRemainingPerformanceObligationVariableConsiderationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ5MDAwNA_0b2c91c1-244e-44aa-bec2-753239a78f5a">525.0</ix:nonFraction> million in commercial milestone payments associated with the aggregate sales of all licensed products. As of September&#160;30, 2021, no development or regulatory milestones have been assessed as probable of being reached and thus have been fully constrained.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021 and 2020, the Company recognized revenue totaling approximately $<ix:nonFraction unitRef="usd" contextRef="i945ff9fde11644a58dafd0226b9d6c0f_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjg3MTU_41c8b3bf-ec18-41a6-b342-34a7c22b4cac">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i738510817c5048b98d2eea09c5a05cf1_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjg3MjI_eb5e25fa-a960-46ac-aa87-c90e45c03657">7.2</ix:nonFraction> million, respectively, and approximately $<ix:nonFraction unitRef="usd" contextRef="i7f482f3f6423440ea0d9f6c8bef66818_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjg3NTg_f4e8c1cf-18e5-44e5-af7e-97d7eaab1c1a">13.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8a84c225ba714f219479e22fc09d67e9_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjg3NjU_44221040-d6cc-45f4-a66a-ec234cb3293b">39.4</ix:nonFraction>&#160;million, respectively, during the nine months ended September&#160;30, 2021 and 2020, with respect to the Otsuka International Agreement. The revenue is classified as collaboration revenue in the accompanying unaudited condensed consolidated statements of operations. As of September&#160;30, 2021, there was approximately $<ix:nonFraction unitRef="usd" contextRef="ia4a2508fbe7b4b60998f2800a6721219_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjkwMzg_2fe76e44-573f-4059-aea5-0b5bf4a4ed4a">11.1</ix:nonFraction> million of deferred revenue related to the Otsuka International Agreement of which $<ix:nonFraction unitRef="usd" contextRef="ia4a2508fbe7b4b60998f2800a6721219_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjkxMTY_8ed179e9-224c-43c9-9e8c-602e3a1741bb">4.5</ix:nonFraction> million is classified as current and $<ix:nonFraction unitRef="usd" contextRef="ia4a2508fbe7b4b60998f2800a6721219_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjkxNDg_008896b2-ff79-4829-b0aa-47f86b223c68">6.6</ix:nonFraction> million is classified as long-term in the accompanying unaudited condensed consolidated balance sheet based on the performance period of the underlying obligations. Additionally, as of September&#160;30, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i9874741da84a44769dea47ee0e59d980_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTA5OTUxMTY4MDY5MA_379a5b87-9582-4beb-8373-11c68e2a3d1e">1.1</ix:nonFraction> million in accounts receivable and $<ix:nonFraction unitRef="usd" contextRef="i02e592c97e6f450ca8dbb9dfbdb2b298_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjkzOTA_16c6ce1a-06ac-4c35-88e9-30be71995989">1.1</ix:nonFraction> million in prepaid expenses and other current assets in the accompanying unaudited condensed consolidated balance sheet. As of December&#160;31, 2020, there was approximately $<ix:nonFraction unitRef="usd" contextRef="ib0ad25ebad234cb5a72142b53cc43ba6_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjk1NDA_4dc4d6de-f756-4abb-83a0-0238836ffce1">2.3</ix:nonFraction> million in contract liabilities (included in accounts payable) and $<ix:nonFraction unitRef="usd" contextRef="iac660281115d42f3adbe6635fbbac7b5_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjk2MDI_f43d60e0-73c9-4bb9-ba98-c99bd175937e">0.5</ix:nonFraction> million in prepaid expenses and other current assets in the consolidated balance sheet.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Pharmaceutica NV Research and License Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2017, the Company entered into a Research and License Agreement, or the Janssen Agreement, with Janssen Pharmaceutica NV, or Janssen, a subsidiary of Johnson &amp; Johnson, pursuant to which Janssen granted the Company an exclusive license under certain intellectual property rights to develop and commercialize worldwide certain HIF prolyl hydroxylase targeted compounds.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Janssen Agreement, Janssen granted to the Company a license for a <ix:nonNumeric contextRef="ieeebde433f7a49538c99f8eedfadce25_D20170209-20170209" format="ixt-sec:durwordsen" name="akba:CollaborativeArrangementTerm" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDU5Mzg_6b872c39-58d2-4ff8-a42d-03f148705de5">three-year</ix:nonNumeric> research term to conduct research on the HIF compound portfolio, which research term is now expired. During the research term, the Company could designate one or more compounds as candidates for development and commercialization. Once a compound was designated for development and commercialization, the Company was to be solely responsible for the development and commercialization of the compound worldwide at its own cost and expense.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Under the terms of the Janssen Agreement, the Company made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ifcf133937bdc4353b3c3ba86e059f5cb_I20170209" decimals="-5" format="ixt:num-dot-decimal" name="akba:UpfrontPaymentPaidInCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzA3NTk_780a1b1b-598c-4836-b9d8-a91ed3f81a7b">1.0</ix:nonFraction> million in cash to Janssen and issued a warrant, or the Warrant, to purchase <ix:nonFraction unitRef="shares" contextRef="ifc1340b1d3414996b23a8b1c78d66a9b_I20170209" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzA4MzM_ca647c25-8c93-4cef-9354-b5ebf97756f2">509,611</ix:nonFraction> shares of the Company&#8217;s common stock with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifc1340b1d3414996b23a8b1c78d66a9b_I20170209" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzA4OTk_6868358b-68e6-4a54-b9fc-0053b77a2496">9.81</ix:nonFraction> per share to Johnson &amp; Johnson Innovation &#8211; JJDC, Inc., or JJDC, an affiliate of Janssen. The Warrant is exercisable by JJDC, in whole or in part, at any time prior to February 9, 2022. The Warrant and the shares issuable upon exercise of the Warrant will be sold and issued without registration under the Securities Act of 1933, as amended, or the Securities Act. The Company recorded the fair value of the Warrant in the amount of $<ix:nonFraction unitRef="usd" contextRef="i8b7b728d6820482185b5f4c1ce9f6131_I20170331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzEzMzU_7c4174bb-76ef-46b8-b9ab-56109965145f">3.4</ix:nonFraction> million to additional paid-in capital and research and development expense in March 2017.&#160;In addition, Janssen is eligible to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ieeebde433f7a49538c99f8eedfadce25_D20170209-20170209" decimals="-5" format="ixt:num-dot-decimal" name="akba:PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzE0OTI_13e6c490-04b5-4534-bd9c-27aa0c07bc1b">16.5</ix:nonFraction> million from the Company in specified development milestone payments on a product-by-product basis. Janssen is also eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ieeebde433f7a49538c99f8eedfadce25_D20170209-20170209" decimals="-5" format="ixt:num-dot-decimal" name="akba:PotentialPaymentForAchievementOfSpecifiedCommercialMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzE2MzQ_4faafd06-95e9-4fd8-9493-1f25e308483a">215.0</ix:nonFraction> million from the Company in specified commercial milestones as well as tiered, escalating royalties ranging from a low- to mid-single digit percentage of net sales, on a product-by-product basis, and subject to reduction upon expiration of patent rights or the launch of a generic product in the territory. A more detailed description of this collaboration agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cyclerion Therapeutics License Agreement</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Summary of Agreement</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 4, 2021, the Company entered into a License Agreement, the Cyclerion Agreement, with Cyclerion Therapeutics Inc., or Cyclerion, pursuant to which Cyclerion granted the Company an exclusive global license under certain intellectual property rights to research, develop and commercialize praliciguat, an investigational oral sGC stimulator.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the Cyclerion Agreement, the Company made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ifc1441455f5f427d888f9be3a658edc4_D20210604-20210604" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzI2NTA_8c539fd5-77a5-46a2-bdbb-3c3951c8ee2d">3.0</ix:nonFraction> million in cash to Cyclerion, which was paid during the second quarter of 2021. Substantially all of the fair value of the assets acquired in conjunction with the Cyclerion Agreement was concentrated in the acquired license. As a result, the Company accounted for this transaction as an asset acquisition under ASU No. 2017-01, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Business Combinations (Topic 805): Clarifying the Definition of a Business</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The upfront payment was charged to expense at acquisition, as it relates to a development stage compound with no alternative future use. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, Cyclerion is eligible to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ifc1441455f5f427d888f9be3a658edc4_D20210604-20210604" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzMyNzg_7eaadf63-c616-447d-bc9c-85d5ea7e96a7">222.0</ix:nonFraction> million from the Company in specified development and regulatory milestone payments on a product-by-product basis. Cyclerion will also be eligible to receive specified </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie26e2cde08ae4a4bb1b37da3053dce51" continuedAt="ib34fd24b8a1d4842894cf1b029c17f63"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">commercial milestones as well as tiered royalties ranging from a low-single-digit- to mid-double-digit percentage of net sales, on a product-by-product basis, and subject to reduction upon expiration of patent rights or the launch of a generic product in the territory. The Company recorded the upfront payment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">in the amount of $<ix:nonFraction unitRef="usd" contextRef="i0f7c79b242f844ddad0fc74aecc7c6ca_D20210601-20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzM3Njk_99dc6719-6915-4a47-8f0c-3931bdde8686">3.0</ix:nonFraction> million to research and development expense in June 2021.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Unless earlier terminated, the Cyclerion Agreement will expire on a product-by-product and country-by-country basis upon the expiration of the last royalty term, which ends upon the longer of the expiration of the patents licensed under the Cyclerion Agreement, the expiration of regulatory exclusivity for such product, or <ix:nonNumeric contextRef="ifc1441455f5f427d888f9be3a658edc4_D20210604-20210604" format="ixt-sec:duryear" name="akba:AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzQxNDc_e99a0a8e-6c7d-4afb-912d-0bd96042bb10">10</ix:nonNumeric> years from first commercial sale of such product. The Company may terminate the Cyclerion Agreement in its entirety or only with respect to a particular licensed compound or product upon <ix:nonNumeric contextRef="ifc1441455f5f427d888f9be3a658edc4_D20210604-20210604" format="ixt-sec:durday" name="akba:AssetAcquisitionAgreementTerminationNoticePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzQzMzE_86d03782-8c42-463a-8dc3-4b5fef3a6d96">180</ix:nonNumeric> days&#8217; prior written notice to Cyclerion. The parties also have customary termination rights, subject to a cure period, in the event of the other party&#8217;s material breach of the Cyclerion Agreement or in the event of certain additional circumstances. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vifor Pharma License Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2017, the Company entered into a License Agreement, or the Vifor Agreement, with Vifor (International) Ltd., or Vifor Pharma, pursuant to which the Company granted Vifor Pharma an exclusive license to sell vadadustat solely to Fresenius Kidney Care Group LLC, or FKC, an affiliate of Fresenius Medical Care North America, or FMCNA, in the United States. On April 8, 2019, the Company and Vifor Pharma entered into an Amended and Restated License Agreement, or the Vifor Amended Agreement, which amended and restated in full the Vifor Agreement. Pursuant to the Vifor Amended Agreement, the Company granted Vifor Pharma an exclusive license to sell vadadustat to FKC and to certain third party dialysis organizations approved by the Company, or Third Party Dialysis Organizations, in the United States. A more detailed description of this collaboration agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the Vifor Agreement, in May 2017, the Company and Vifor Pharma entered into an investment agreement, or the Investment Agreement, pursuant to which the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="i9ae72c8b1a6046dc8ea43e24fa8b97b6_I20170512" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzU4ODU_7a10b57d-428b-43c1-8ba7-49e7cc4116fd">3,571,429</ix:nonFraction> shares of the Company&#8217;s common stock, or the Shares, to Vifor Pharma at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9ae72c8b1a6046dc8ea43e24fa8b97b6_I20170512" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzU5ODE_3f7901a6-8a35-45a9-b75c-d1a48402713b">14.00</ix:nonFraction> for a total of $<ix:nonFraction unitRef="usd" contextRef="i22c6d8b4a8754f2cabfbd65f0be236dd_D20170512-20170512" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzU5OTk_45684a82-ae94-4321-bd8e-bdfbccd8d6dd">50.0</ix:nonFraction> million. The amount representing the premium over the closing stock price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9ae72c8b1a6046dc8ea43e24fa8b97b6_I20170512" decimals="2" name="akba:ClosingStockPriceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzYwNzE_00ba6cfe-c4c4-45d1-9feb-a064950ccced">12.69</ix:nonFraction> on the date of the transaction, totaling $<ix:nonFraction unitRef="usd" contextRef="i9ae72c8b1a6046dc8ea43e24fa8b97b6_I20170512" decimals="-5" format="ixt:num-dot-decimal" name="akba:CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzYxMTU_dd61c79f-a6ca-4521-96ea-537b793c0fbd">4.7</ix:nonFraction> million, was determined by the Company to represent consideration related to the Vifor Agreement.&#160;As the parties&#8217; rights under the Vifor Agreement are conditioned upon (a) the approval of vadadustat for DD-CKD adult patients by the FDA; (b) the earlier of a determination by the Centers for Medicare &amp; Medicaid Services, or CMS, that vadadustat will be reimbursed using Medicare&#8217;s bundled reimbursement model or that vadadustat will be reimbursed using the Transitional Drug Add-On Payment Adjustment; and (c) payment by Vifor Pharma of a $<ix:nonFraction unitRef="usd" contextRef="i22c6d8b4a8754f2cabfbd65f0be236dd_D20170512-20170512" decimals="-5" format="ixt:num-dot-decimal" name="akba:PotentialPaymentForAchievementOfSpecifiedMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzY1OTk_99def8e4-3b6c-40b3-b5ec-610619258aff">25.0</ix:nonFraction>&#160;million milestone upon the occurrence of (a) and (b), in accordance with ASC 606, the Company has determined that the full transaction price is fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including clinical and regulatory risks that must be overcome in order for the parties&#8217; rights to become effective and the probability of the $<ix:nonFraction unitRef="usd" contextRef="i22c6d8b4a8754f2cabfbd65f0be236dd_D20170512-20170512" decimals="-5" format="ixt:num-dot-decimal" name="akba:PotentialPaymentForAchievementOfSpecifiedMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzY5ODU_6f586ef1-2fe6-496a-9deb-fa107df2a9ff">25.0</ix:nonFraction> million milestone being achieved. Accordingly, the $<ix:nonFraction unitRef="usd" contextRef="i9ae72c8b1a6046dc8ea43e24fa8b97b6_I20170512" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzcwMzE_cb3f92d6-0bf0-4383-bbf9-c6e2f06095a1">4.7</ix:nonFraction> million continues to be recorded as deferred revenue in the accompanying unaudited condensed consolidated balance sheets. Upon the satisfaction of the aforementioned conditions, revenue will be recognized as the Company supplies vadadustat to Vifor Pharma using a proportional performance method.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vifor Pharma agreed to a&#160;lock-up&#160;restriction such that it agreed not to sell the Shares for a period of time following the effective date of the Investment Agreement as well as a customary standstill agreement. In addition, the Investment Agreement contains voting agreements made by Vifor Pharma with respect to the Shares. The Shares have not been registered pursuant to the Securities Act, and were issued and sold in reliance upon the exemption from registration contained in Section 4(a)(2) of the Securities Act and Rule 506 promulgated thereunder.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Priority Review Voucher Letter Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 14, 2020, the Company entered into a letter agreement, or the Letter Agreement, with Vifor Pharma relating to Vifor Pharma&#8217;s agreement with a third party to purchase a Priority Review Voucher, or the PRV, issued by the FDA, subject to satisfaction of customary closing conditions, or the PRV Purchase. A PRV entitles the holder to priority review of a New Drug Application, or NDA, or a Biologics License Application for a new drug, which reduces the target FDA review time to six months after official acceptance of the submission, and could lead to expedited approval. Pursuant to the Letter Agreement, Akebia paid Vifor Pharma $<ix:nonFraction unitRef="usd" contextRef="i8a3012cc53274e7386ae899217cc4ae0_D20200214-20200214" decimals="-5" format="ixt:num-dot-decimal" name="akba:AggregateCollaborationAgreementPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzg1NjE_82973862-69d5-4c22-8573-8bdae7119a4a">10.0</ix:nonFraction> million in connection with the closing of the PRV Purchase. Vifor Pharma is obligated to retain all rights to, and maintain the validity of, the PRV until Akebia and Vifor Pharma (a) enter into a definitive agreement setting forth the financial and other terms by which Vifor Pharma will assign the PRV to Akebia for use with Akebia&#8217;s NDA for </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib34fd24b8a1d4842894cf1b029c17f63" continuedAt="iadfa81dffabc417390cab96c7b76d791"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vadadustat for the treatment of anemia due to CKD in both dialysis-dependent and non-dialysis dependent patients, or (b) make a mutual decision to sell the PRV and share the proceeds based on certain terms. In March of 2021, the Company submitted an NDA for the treatment of anemia due to CKD in both DD-CKD and NDD-CKD adult patients. The Company's NDA submission did not include a PRV. In August 2021, the Company and Vifor Pharma entered into an amendment to the Letter Agreement whereby the parties agreed that Vifor Pharma would sell the PRV to a third party, and the Company and Vifor Pharma will share the proceeds from the sale based on certain terms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended March 31, 2020, the $<ix:nonFraction unitRef="usd" contextRef="i7e2acaca8c4648fc8c17812d445090de_D20200101-20200331" decimals="-5" name="akba:AggregateCollaborationAgreementPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzkzMzI_189a7a60-1901-4eab-9d52-b934770f0fe3">10.0</ix:nonFraction> million payment to Vifor Pharma was recorded to research and development expense in the unaudited condensed consolidated statement of operations and as an operating cash outflow in the unaudited condensed consolidated statement of cash flows.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Panion&#160;&amp; BF Biotech, Inc.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger, Keryx entered into a license agreement, or the Panion License Agreement, which was amended from time to time, with Panion&#160;&amp; BF Biotech, Inc., or Panion, under which Keryx in-licensed the exclusive worldwide rights, excluding certain Asian-Pacific countries, or the Licensor Territory, for the development and commercialization of ferric citrate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On April&#160;17, 2019,&#160;the Company and Panion&#160;entered into a second amended and restated license agreement, or the Panion Amended License Agreement, which amends and restates in full the Panion License Agreement, effective as of April 17, 2019. The Panion Amended License Agreement provides Keryx with an exclusive license under Panion-owned&#160;know-how&#160;and patents with the right to sublicense, develop, make, use, sell, offer for sale, import and export ferric citrate worldwide, excluding the Licensor Territory. The Panion Amended License Agreement also provides Panion with an exclusive license under the Keryx-owned patents, with the right to sublicense (with the Company&#8217;s written consent), develop, make, use, sell, offer for sale, import and export ferric citrate in certain countries in the Licensor Territory. Under the Panion Amended License Agreement, Panion is eligible to receive from the Company or any sublicensee royalty payments based on a&#160;mid-single&#160;digit percentage of sales of ferric citrate in the Company&#8217;s licensed territories. The Company is eligible to receive from Panion or any sublicensee royalty payments based on a&#160;mid-single&#160;digit percentage of net sales of ferric citrate in Panion&#8217;s licensed territories. A more detailed description of this license agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized royalty payments due to Panion of approximately $<ix:nonFraction unitRef="usd" contextRef="i41e46089042845efb8effbe91d3866a0_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="akba:RoyaltyPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDE2NTA_7d51bfc7-c67a-40d6-935b-68f6805ef4bb">3.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i042537cbb7204196925307a6b7f16840_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="akba:RoyaltyPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ4Nzg4MQ_2b8385b3-7777-49dd-a462-2a72427fae5f">2.9</ix:nonFraction> million during the three months ended September&#160;30, 2021 and 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i3aadde62784b4aefa36a71ef6d3bb27b_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="akba:RoyaltyPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDE3MDU_bf02985e-6fa9-4d38-9eb7-20cc57caea60">8.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib037a9facfea4d249380bdea73ce519b_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="akba:RoyaltyPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ4NzkyOA_458efc1c-b239-4f4d-85a8-b6ec4dcb1b89">8.2</ix:nonFraction> million during the nine months ended September&#160;30, 2021 and 2020, respectively, relating to the Company&#8217;s sales of Auryxia in the United States and JT and Torii&#8217;s sales of Riona in Japan, as the Company is required to pay a mid-single digit percentage of net sales of ferric citrate in the Company&#8217;s licensed territories to Panion under the terms of the Panion Amended License Agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sublicense Agreement with Japan Tobacco, Inc. and its subsidiary, Torii Pharmaceutical Co., Ltd.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Merger, the Company has an Amended and Restated Sublicense Agreement, which was amended in June 2013, with JT and Torii, or the JT and Torii Sublicense Agreement, under which Keryx, the Company&#8217;s wholly owned subsidiary, remains the contracting party. Under the JT and Torii Sublicense Agreement, JT and Torii obtained the exclusive sublicense rights for the development and commercialization of ferric citrate hydrate in Japan. JT and Torii are responsible for the future development and commercialization costs in Japan. A more detailed description of this sublicense agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the elements of the JT and Torii Sublicense Agreement in accordance with the provisions of ASC 606 and concluded that the contract counterparty, JT and Torii, is a customer. The Company&#8217;s arrangement with JT and Torii contains the following material promises under the contract at inception: (i) exclusive license to develop and commercialize ferric citrate hydrate in Japan, (ii) supply of ferric citrate hydrate until JT and Torii could secure their own source, (iii) knowledge transfer, and (iv) rights to future know-how. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified <ix:nonFraction unitRef="performance_obligation" contextRef="i0cc1c74d758f401f8afecb62a3e1d9dd_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="akba:NumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDM1ODU_92b852e5-2168-464d-bb7f-2cf144b232ea">two</ix:nonFraction> performance obligations in connection with its obligations under the JT and Torii Sublicense Agreement: (i) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Supply Performance Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and (ii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rights to Future Know-How Performance Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company allocated the transaction price to each performance obligation based on the Company&#8217;s best estimate of the relative standalone selling price. The Company developed a best estimate of the standalone selling price for the Rights to Future Know-How Performance Obligation primarily based on the likelihood that additional intellectual property covered by the license </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iadfa81dffabc417390cab96c7b76d791"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conveyed will be developed during the term of the arrangement and determined it immaterial. As such, the Company did not develop a best estimate of standalone selling price for the License and Supply Performance Obligation and allocated the entire transaction price to this performance obligation. Additionally, as of the consummation of the Merger, the services associated with the License and Supply Performance Obligation were completed and JT and Torii had secured their own source to manufacture ferric citrate hydrate. As such, any initial license fees as well as any development-based milestones and manufacturing fee revenue were received and recognized prior to the Merger. The Company determined that the remaining consideration that may be payable to the Company under the terms of the sublicense agreement are either quarterly royalties on net sales or payments due upon the achievement of sales-based milestones. In accordance with ASC 606, the Company recognizes sales-based royalties, including milestone payments based on the level of sales, when the related sales occur as these amounts have been determined to relate predominantly to the license granted to JT and Torii and therefore are recognized at the later of when the performance obligation is satisfied, or the related sales occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized license revenue of $<ix:nonFraction unitRef="usd" contextRef="iead0fd037fa94b5eac362dee913b3b35_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDU1MjI_527c617a-1949-423a-95e5-836f6f835fe0">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3917cbc6ebab4fcba1653703ddcaeb89_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDU1Mjk_a129b9e5-8bf3-4384-89b1-0ea133a2d64e">1.2</ix:nonFraction> million during the three months ended September&#160;30, 2021 and 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i0cc1c74d758f401f8afecb62a3e1d9dd_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDU1OTE_1c3c8d41-9fd9-42d9-aa07-a068e859c853">4.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1bce44b505714f94a8b535b4ea2e5717_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDU1OTg_ac168fa8-fd34-4a2f-99f3-a007e438e3ab">4.0</ix:nonFraction> million, respectively, during the nine months ended September&#160;30, 2021 and 2020, respectively, related to royalties earned on net sales of Riona in Japan. The Company records the associated mid-single digit percentage of net sales royalty expense due to Panion, the licensor of Riona, in the same period as the royalty revenue from JT and Torii is recorded.</span></div></ix:continuation><div><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_49"></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RleHRyZWdpb246MTdiYTE0MmM3OTkyNGNiNTkxODk5NGZjMWYzMTgxNjJfNDIxMw_c64a31ac-77fe-4924-8282-7290514dc0c5" continuedAt="ie784ff8eaa6446f0980f05c94715166a" escape="true">Liability Related to Sale of Future Royalties</ix:nonNumeric></span></div><ix:continuation id="ie784ff8eaa6446f0980f05c94715166a" continuedAt="i2a95406ed885472b9792774eb3398bbd"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2021, the Company entered into the Royalty Agreement with HealthCare Royalty Partners IV, L.P., or HCR, pursuant to which the Company sold to HCR its right to receive royalties and sales milestones for vadadustat in Japan and certain other Asian countries, such countries, collectively, the MTPC Territory, and such payments collectively the Royalty Interest Payments, in each case, payable to the Company under the MTPC Agreement, subject to an annual maximum &#8220;cap&#8221; of $<ix:nonFraction unitRef="usd" contextRef="i016c3424f40c49faa098233e6b0ce0ef_I20210225" decimals="-5" format="ixt:num-dot-decimal" name="akba:ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RleHRyZWdpb246MTdiYTE0MmM3OTkyNGNiNTkxODk5NGZjMWYzMTgxNjJfNTM3_2442b8f9-bdb9-4b59-8df8-c69dd9883060">13.0</ix:nonFraction>&#160;million, or the Annual Cap, and an aggregate maximum &#8220;cap&#8221; of $<ix:nonFraction unitRef="usd" contextRef="i016c3424f40c49faa098233e6b0ce0ef_I20210225" decimals="-5" format="ixt:num-dot-decimal" name="akba:ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RleHRyZWdpb246MTdiYTE0MmM3OTkyNGNiNTkxODk5NGZjMWYzMTgxNjJfNTk0_68f4f666-c52b-4a35-94ba-92ef2316b79a">150.0</ix:nonFraction>&#160;million, or the Aggregate Cap. After HCR receives Royalty Interest Payments equal to the Annual Cap in a given calendar year, the Company will receive <ix:nonFraction unitRef="number" contextRef="i8b1ce5c7f57f4300b066a27bf7644888_D20210225-20210225" decimals="2" name="akba:ContractualArrangementRoyaltiesAgreementPercentageOfRoyaltyPaymentsToBeReceivedContingentOnReachingMaximumAnnualRoyaltyPayoutCapacity" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RleHRyZWdpb246MTdiYTE0MmM3OTkyNGNiNTkxODk5NGZjMWYzMTgxNjJfNzQw_718ea4cf-00e9-4728-b9fd-3271d17aba8d">85</ix:nonFraction>% of the Royalty Interest Payments for the remainder of that year. After HCR receives Royalty Interest Payments equal to the Aggregate Cap, or the Company pays the Aggregate Cap to HCR (net of the Royalty Interest Payments already received by HCR), the Royalty Interest Payments will revert back to the Company, and HCR would have no further right to any Royalty Interest Payments. The Company received $<ix:nonFraction unitRef="usd" contextRef="i8b1ce5c7f57f4300b066a27bf7644888_D20210225-20210225" decimals="-5" format="ixt:num-dot-decimal" name="akba:ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RleHRyZWdpb246MTdiYTE0MmM3OTkyNGNiNTkxODk5NGZjMWYzMTgxNjJfMTE0NA_7595dab7-3ea4-4c0e-9a69-272adedff605">44.8</ix:nonFraction>&#160;million from HCR (net of certain transaction expenses) under the Royalty Agreement, and the Company is eligible to receive an additional $<ix:nonFraction unitRef="usd" contextRef="i8b1ce5c7f57f4300b066a27bf7644888_D20210225-20210225" decimals="-5" format="ixt:num-dot-decimal" name="akba:ContractualArrangementRoyaltiesAgreementProceedsContingentOnAnnualSalesMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RleHRyZWdpb246MTdiYTE0MmM3OTkyNGNiNTkxODk5NGZjMWYzMTgxNjJfMTI3Ng_c8445579-4b78-494b-a5f7-550e5c445dd1">5.0</ix:nonFraction>&#160;million in each year from 2021 through 2023 under the Royalty Agreement if specified annual sales milestones are achieved for vadadustat in the MTPC Territory, subject to the satisfaction of certain customary conditions. The Company retains the right to receive all potential future regulatory milestones for vadadustat under the MTPC Agreement. The Royalty Agreement will terminate on the earlier of the date on which HCR has received (i) the last Royalty Interest Payment or (ii) payment by the Company of an amount equal to the Aggregate Cap minus the aggregate amount of all Royalty Interest Payments actually received by HCR.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company sold its right to receive royalties and sales milestones for vadadustat in the MTPC Territory as described above, as a result of its ongoing involvement in the cash flows related to these royalties, the Company will continue to account for these royalties as revenue. The Company recognized the proceeds received from HCR as a liability that is being amortized using the effective interest method over the life of the arrangement. At the transaction date, the Company recorded the net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i016c3424f40c49faa098233e6b0ce0ef_I20210225" decimals="-5" format="ixt:num-dot-decimal" name="akba:ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RleHRyZWdpb246MTdiYTE0MmM3OTkyNGNiNTkxODk5NGZjMWYzMTgxNjJfMjQyMQ_3fb24d60-e91f-4161-b55d-c28f41853890">44.8</ix:nonFraction>&#160;million as a liability. In order to determine the amortization of the liability, the Company is required to estimate the total amount of future net royalty payments to be made to HCR over the term of the Royalty Agreement. The total threshold of net royalties to be paid, less the net proceeds received, will be recorded as interest expense over the life of the liability. The Company imputes interest on the unamortized portion of the liability using the effective interest method. The annual effective interest rate as of September&#160;30, 2021 was <ix:nonFraction unitRef="number" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="3" name="akba:ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RleHRyZWdpb246MTdiYTE0MmM3OTkyNGNiNTkxODk5NGZjMWYzMTgxNjJfMjk0Nw_c1480bb6-615a-4b2c-b6a3-a10e30aac14c">19.2</ix:nonFraction>% which is reflected as interest expense in the unaudited condensed consolidated statements of operations and comprehensive loss. Over the course of the Royalty Agreement, the actual interest rate will be affected by the amount and timing of royalty revenue recognized and changes in forecasted royalty revenue. There are a number of factors that could materially affect the amount and timing of royalty payments from MTPC, none of which are within the Company's control. On a quarterly basis, the Company reassesses the effective interest rate and adjusts the rate prospectively as needed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RleHRyZWdpb246MTdiYTE0MmM3OTkyNGNiNTkxODk5NGZjMWYzMTgxNjJfNDIxMg_2178d2ae-bf75-4ceb-84d1-77b4166da6a9" continuedAt="ia30fdd6fa0d64c10a19d00e95c584451" escape="true">The following table shows the activity within the liability account for the nine months ended September&#160;30, 2021:</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2a95406ed885472b9792774eb3398bbd"><div><ix:continuation id="ia30fdd6fa0d64c10a19d00e95c584451"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to sale of future royalties, net &#8212; beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:fixed-zero" name="akba:ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RhYmxlOmIwZTJkYTVhOGRlNTQ0NzM4ODFiMzg2ZTdmYTAyNWNkL3RhYmxlcmFuZ2U6YjBlMmRhNWE4ZGU1NDQ3Mzg4MWIzODZlN2ZhMDI1Y2RfMi0xLTEtMS0yMjM1Nw_f3d8aca3-a17c-41f2-a1b7-ab77e3dd01cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of future royalties, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RhYmxlOmIwZTJkYTVhOGRlNTQ0NzM4ODFiMzg2ZTdmYTAyNWNkL3RhYmxlcmFuZ2U6YjBlMmRhNWE4ZGU1NDQ3Mzg4MWIzODZlN2ZhMDI1Y2RfMy0xLTEtMS0yMjM1Nw_9f1e0c64-a375-456f-8a14-6a76675b8654">44,783</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MTPC royalties payable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" name="akba:ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RhYmxlOmIwZTJkYTVhOGRlNTQ0NzM4ODFiMzg2ZTdmYTAyNWNkL3RhYmxlcmFuZ2U6YjBlMmRhNWE4ZGU1NDQ3Mzg4MWIzODZlN2ZhMDI1Y2RfNC0xLTEtMS0yMjM1Nw_c5f4b2d8-c9d7-4a50-84a6-53eece412d12">425</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RhYmxlOmIwZTJkYTVhOGRlNTQ0NzM4ODFiMzg2ZTdmYTAyNWNkL3RhYmxlcmFuZ2U6YjBlMmRhNWE4ZGU1NDQ3Mzg4MWIzODZlN2ZhMDI1Y2RfNS0xLTEtMS0yMjM1Nw_bfc18b56-d2b5-4a08-a84f-5effe5ad03d7">6,779</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to sale of future royalties, net &#8212; ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RhYmxlOmIwZTJkYTVhOGRlNTQ0NzM4ODFiMzg2ZTdmYTAyNWNkL3RhYmxlcmFuZ2U6YjBlMmRhNWE4ZGU1NDQ3Mzg4MWIzODZlN2ZhMDI1Y2RfNi0xLTEtMS0yMjM1Nw_5dd828ba-73bb-4a50-928a-e56ae061a893">51,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Royalty Agreement requires the Company to take certain actions, including actions with respect to the Royalty Interest Payments, the MTPC Agreement, the MTPC Supply Agreement, and the Company's intellectual property. The Royalty Agreement also contains certain representations and warranties, covenants, indemnification obligations, events of default and other provisions that are customary for a royalty monetization transaction of this nature. In addition, the Company granted HCR a precautionary security interest in connection with the Royalty Interest Payments.</span></div></ix:continuation><div><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_52"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RleHRyZWdpb246NzVhMzkxYzVlYjE1NDIyZGE4MDVhNjgzMmFhYzcwYzlfNDk2_119b26d9-ea3e-4116-beb8-1107aae7868a" continuedAt="i91e0789d68b8421eb477f1a3610505e3" escape="true">Available For Sale Securities</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i91e0789d68b8421eb477f1a3610505e3"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RleHRyZWdpb246NzVhMzkxYzVlYjE1NDIyZGE4MDVhNjgzMmFhYzcwYzlfNDk3_2d087986-330c-4798-95f1-64a5434dcd54" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and available for sale securities at September&#160;30, 2021 and December&#160;31, 2020 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfMy0xLTEtMS0yMjM1Nw_a7fb527e-535c-4552-abe4-c712c972b4ab">207,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfMy03LTEtMS0yMjM1Nw_d0fe45bd-77b9-4c47-a241-0afad83818d3">207,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56d517c10b584fe0aaec8d914de26be7_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfNS0xLTEtMS0yMjM1Nw_39b50ac9-dd37-4ad0-a9ed-98596dea1cbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56d517c10b584fe0aaec8d914de26be7_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfNS0zLTEtMS0yMjM1Nw_494dd71d-0033-47f5-afd4-2fadd90a1e95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56d517c10b584fe0aaec8d914de26be7_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfNS01LTEtMS0yMjM1Nw_90a30147-688d-4066-9542-ac5f2009cee6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56d517c10b584fe0aaec8d914de26be7_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfNS03LTEtMS0yMjM1Nw_0a3c60b8-abc6-4b0a-a37d-860b55978c72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfNi0xLTEtMS0yMjM1Nw_d436b1b0-52a0-4b15-b18d-66f0257c98af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfNi0zLTEtMS0yMjM1Nw_964dcb55-368e-4fd3-b433-cb3d5205086f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfNi01LTEtMS0yMjM1Nw_bee893b9-02c5-4c91-bf33-d877061207df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfNi03LTEtMS0yMjM1Nw_2fd410f2-d6ef-4428-ada2-92edefe83ccb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and available for sale securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:CashCashEquivalentsAndShortTermInvestmentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfNy0xLTEtMS0yMjM1Nw_55326865-8bdc-4d7b-9e5c-d81609142a46">207,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfNy0zLTEtMS0yMjM1Nw_9d3eeed5-984a-4794-827a-689965e16a89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfNy01LTEtMS0yMjM1Nw_ef393ae6-b4f6-4cc3-a45c-52ec295239d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfNy03LTEtMS0yMjM1Nw_438baaf4-1366-4930-b44d-3497a2f7d13d">207,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfMy0xLTEtMS0yMjM1Nw_321cbfe6-3984-4386-947a-0915cb17ac4d">228,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfMy03LTEtMS0yMjM1Nw_8384e63a-ad7a-4971-9763-32dec234ceb4">228,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie80f8a6467b14c7cafd2f2e4ce22adf5_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfNS0xLTEtMS0yMjM1Nw_e647610b-12ed-49c4-af3d-1a00a58be0c3">39,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie80f8a6467b14c7cafd2f2e4ce22adf5_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfNS0zLTEtMS0yMjM1Nw_259ac122-2ce7-49fb-adf2-b7fba357b799">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie80f8a6467b14c7cafd2f2e4ce22adf5_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfNS01LTEtMS0yMjM1Nw_a6de48a1-f192-41c9-be9e-09eafd976396">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie80f8a6467b14c7cafd2f2e4ce22adf5_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfNS03LTEtMS0yMjM1Nw_8fc305f6-2db4-492f-afcc-4a7642711e87">39,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfNi0xLTEtMS0yMjM1Nw_665e2b58-1de3-478c-95c4-ac5dfb8bdf7d">39,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfNi0zLTEtMS0yMjM1Nw_26bc2977-a77a-49f9-8802-08f0522e3578">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfNi01LTEtMS0yMjM1Nw_e766f0e6-0c75-412f-803f-1a62bef53a51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfNi03LTEtMS0yMjM1Nw_da8e6cb3-8d04-4c0c-8f57-a637ee156cd1">39,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and available for sale securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="akba:CashCashEquivalentsAndShortTermInvestmentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfNy0xLTEtMS0yMjM1Nw_4fa0682b-9b1e-4aec-b18b-ddad388fa3b1">268,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfNy0zLTEtMS0yMjM1Nw_f3a5a242-dd2b-4b8d-b4d0-adbcd1259e10">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfNy01LTEtMS0yMjM1Nw_c73e745e-4b4b-46bb-bece-b25248e1e51d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfNy03LTEtMS0yMjM1Nw_9b4757bf-25dc-4a79-b55f-77c8d6a6efe3">268,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RleHRyZWdpb246NzVhMzkxYzVlYjE1NDIyZGE4MDVhNjgzMmFhYzcwYzlfMTU3_38398184-f68f-44c9-b40e-9fcda898b728"><ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RleHRyZWdpb246NzVhMzkxYzVlYjE1NDIyZGE4MDVhNjgzMmFhYzcwYzlfMTU3_79dd0387-8cc0-4e6c-b0ce-66cc1b6b68aa"><ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RleHRyZWdpb246NzVhMzkxYzVlYjE1NDIyZGE4MDVhNjgzMmFhYzcwYzlfMTU3_bfeb1f9a-50ad-4ffd-831a-63aaf212b17b"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RleHRyZWdpb246NzVhMzkxYzVlYjE1NDIyZGE4MDVhNjgzMmFhYzcwYzlfMTU3_c2b446dc-e8bf-4ee8-826b-2c07be2c8aae">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> realized gains or losses on available for sale securities for the three and nine months ended September&#160;30, 2021 and 2020 and the Company did <ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RleHRyZWdpb246NzVhMzkxYzVlYjE1NDIyZGE4MDVhNjgzMmFhYzcwYzlfMjgz_10b25e30-762a-4728-91cb-cf020731f0e3"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RleHRyZWdpb246NzVhMzkxYzVlYjE1NDIyZGE4MDVhNjgzMmFhYzcwYzlfMjgz_bcbed93d-72b6-486c-8859-aae545071546"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RleHRyZWdpb246NzVhMzkxYzVlYjE1NDIyZGE4MDVhNjgzMmFhYzcwYzlfMjgz_c0a0b671-b6f8-4959-b7e4-17c3478933ef"><ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RleHRyZWdpb246NzVhMzkxYzVlYjE1NDIyZGE4MDVhNjgzMmFhYzcwYzlfMjgz_ea497839-875f-466f-85d5-f96c0db231ea">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t recognize any credit losses during the three and nine months ended September&#160;30, 2021 and 2020. Additionally, the Company did <ix:nonFraction unitRef="security" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RleHRyZWdpb246NzVhMzkxYzVlYjE1NDIyZGE4MDVhNjgzMmFhYzcwYzlfMzk0_2f940232-09e6-4364-a7b8-93906cc06dfb"><ix:nonFraction unitRef="security" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RleHRyZWdpb246NzVhMzkxYzVlYjE1NDIyZGE4MDVhNjgzMmFhYzcwYzlfMzk0_a1965191-2239-4c52-b1fc-7556abe80f70">no</ix:nonFraction></ix:nonFraction>t have any available for sale securities that were in an unrealized loss position as of September&#160;30, 2021 and December&#160;31, 2020.</span></div></ix:continuation><div><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_55"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RleHRyZWdpb246YzJjODU5ZmMyNTIwNDk1MWFkMzkwMWQ2MWZmODQyZjRfMzgyMg_5d58620a-f834-4362-aa1d-2bc1ee325aaa" continuedAt="i1970348e56024be7b73a3bb1385fe1df" escape="true">Fair Value of Financial Instruments</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1970348e56024be7b73a3bb1385fe1df" continuedAt="i2bcc26556bf744b689d5561d185acc3c">The Company utilizes a portfolio management company for the valuation of the majority of its investments. This company is an independent, third-party vendor recognized to be an industry leader with access to market information that obtains or computes fair market values from quoted market prices, pricing for similar securities, recently executed transactions, cash flow models with yield curves and other pricing models. For valuations obtained from the pricing service, the Company performs due </ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2bcc26556bf744b689d5561d185acc3c" continuedAt="iec214d024e5146d68f43777ca84a2359"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">diligence to understand how the valuation was calculated or derived, focusing on the valuation technique used and the nature of the inputs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the fair value hierarchy, the Company classifies its cash equivalents and available for sale securities within Level&#160;1 or Level&#160;2. This is because the Company values its cash equivalents and available for sale securities using quoted market prices or alternative pricing sources and models utilizing market observable inputs.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RleHRyZWdpb246YzJjODU5ZmMyNTIwNDk1MWFkMzkwMWQ2MWZmODQyZjRfMzgyMw_d0492cf9-9f93-48c4-bf79-cf15ff307de2" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets measured or disclosed at fair value on a recurring basis as of September&#160;30, 2021 and December&#160;31, 2020 are summarized below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:52.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eaaeb5ff6074e36abf2df5bbdcad9c3_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfNS0xLTEtMS0yMjM1Nw_8331e825-d98d-416e-a341-0a7d9c40ec30">207,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e52064c653743f2a16fd27d8c9a323a_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfNS0zLTEtMS0yMjM1Nw_dc11b480-b785-41e2-854e-90625ff45659">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6cdf790d03c4fed810871ebfea1a32f_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfNS01LTEtMS0yMjM1Nw_cceb39a8-3ee1-4459-b6b8-aa090054c18c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i582013b1f37743bc8285c94f50c08ca4_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfNS03LTEtMS0yMjM1Nw_6c23bbee-6199-41e5-b3fc-a0d8e63e5344">207,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eaaeb5ff6074e36abf2df5bbdcad9c3_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfNy0xLTEtMS0yMjM1Nw_98b503f5-37a2-47db-a792-9fb39b7e8b19">207,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e52064c653743f2a16fd27d8c9a323a_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfNy0zLTEtMS0yMjM1Nw_78fbd334-6cfa-4885-a7d7-ef1a3afe81a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6cdf790d03c4fed810871ebfea1a32f_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfNy01LTEtMS0yMjM1Nw_5db44e0e-74c6-4b00-8f8b-593639e5340b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i582013b1f37743bc8285c94f50c08ca4_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfNy03LTEtMS0yMjM1Nw_c43ec7a4-1904-490a-9783-d3d3e1765680">207,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eaaeb5ff6074e36abf2df5bbdcad9c3_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfOS0xLTEtMS0yMjM1Nw_9b33dd35-8d13-40d3-be5c-9e129e82da85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e52064c653743f2a16fd27d8c9a323a_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfOS0zLTEtMS0yMjM1Nw_d1871dfc-53be-4101-b03a-1ac1e7d8ed5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6cdf790d03c4fed810871ebfea1a32f_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfOS01LTEtMS0yMjM1Nw_c5f07bbe-7cd8-464b-b18f-87dd8e4f58c4">1,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i582013b1f37743bc8285c94f50c08ca4_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfOS03LTEtMS0yMjM1Nw_094154c0-f961-44d4-b8be-74512ca5b259">1,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eaaeb5ff6074e36abf2df5bbdcad9c3_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfMTAtMS0xLTEtMjIzNTc_7bf38ac9-9f8d-4b21-9773-bdd63ceed6da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e52064c653743f2a16fd27d8c9a323a_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfMTAtMy0xLTEtMjIzNTc_d9a4feaa-b814-466b-977d-1f3029b70b20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6cdf790d03c4fed810871ebfea1a32f_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfMTAtNS0xLTEtMjIzNTc_32e38e58-05c7-422d-a256-0be3e67dceec">1,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i582013b1f37743bc8285c94f50c08ca4_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfMTAtNy0xLTEtMjIzNTc_e498e973-7959-492f-94cf-a697558326aa">1,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:52.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia131987e763f4587a941882e026ee367_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfNS0xLTEtMS0yMjM1Nw_be4eea8e-de83-4102-927b-7ce262a2cf22">228,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5b97b6dc8c6458eb7afd794c342c79a_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfNS0zLTEtMS0yMjM1Nw_ae0b0662-dd28-478e-9e0e-fac8aa7e97c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81fe9de9bf004275abc9aead5654fef0_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfNS01LTEtMS0yMjM1Nw_7c5d7b84-2aad-492c-8136-b7ec8231f406">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9965cd10ee2c479390becf868ab08d6b_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfNS03LTEtMS0yMjM1Nw_eb7f9316-6535-406e-aa69-4903b71b8879">228,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib35a112c936c43008fd53a2e71e369fe_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfNi0xLTEtMS0yMjM1Nw_8206514d-aa03-4f8b-8622-e4257b01fae2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5926c8f9dfa40cb830ffa5f3015b27d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfNi0zLTEtMS0yMjM1Nw_2f872d71-fd8e-43b8-927e-66cdd097f68e">39,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51612bc1340040cb897112531943a394_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfNi01LTEtMS0yMjM1Nw_4c57de27-b68c-47b2-8217-99b9e6129299">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9db8d25d5e404f14935648663eb92df6_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfNi03LTEtMS0yMjM1Nw_1aed2c82-ff23-4b20-ba68-ef5df03e8de5">39,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia131987e763f4587a941882e026ee367_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfNy0xLTEtMS0yMjM1Nw_a657f201-8d7a-4529-83ef-21684d85b8fd">228,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5b97b6dc8c6458eb7afd794c342c79a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfNy0zLTEtMS0yMjM1Nw_760e7dd6-288d-4645-a1f4-3853f25728be">39,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81fe9de9bf004275abc9aead5654fef0_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfNy01LTEtMS0yMjM1Nw_67965131-9340-4f15-b362-a19f6cc2b80f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9965cd10ee2c479390becf868ab08d6b_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfNy03LTEtMS0yMjM1Nw_f71e6325-118d-485d-94da-ca91a3d4dc72">268,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia131987e763f4587a941882e026ee367_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfOS0xLTEtMS0yMjM1Nw_129f9085-5563-4813-aec3-4d68da27b90c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5b97b6dc8c6458eb7afd794c342c79a_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfOS0zLTEtMS0yMjM1Nw_6af962cf-4f1c-48e9-b400-e51159c40fd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81fe9de9bf004275abc9aead5654fef0_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfOS01LTEtMS0yMjM1Nw_143891e8-7e60-404f-beda-9e7ff79d6370">2,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9965cd10ee2c479390becf868ab08d6b_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfOS03LTEtMS0yMjM1Nw_14569a9e-b252-4d7a-b4fa-cc2c2681b2e9">2,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia131987e763f4587a941882e026ee367_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfMTAtMS0xLTEtMjIzNTc_8a51005c-3913-404f-a2f5-0b89d81453ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5b97b6dc8c6458eb7afd794c342c79a_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfMTAtMy0xLTEtMjIzNTc_7e6b1334-0e52-4426-a0da-bd85d69624aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81fe9de9bf004275abc9aead5654fef0_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfMTAtNS0xLTEtMjIzNTc_628bd7b1-261b-4902-b72f-76eaa26edbf8">2,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9965cd10ee2c479390becf868ab08d6b_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfMTAtNy0xLTEtMjIzNTc_163bffed-c256-4ed9-855a-1f7646579990">2,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Loan Agreement with Pharmakon (see Note 11) contains certain provisions that change the underlying cash flows of the debt instrument, including a potential extension to the interest-only period dependent on both (a) no event of default having occurred and continuing and (b) the Company achieving certain regulatory and revenue conditions. The Company also assessed the acceleration of the obligations under the Loan Agreement under an event of default. In addition, under certain circumstances, a default interest rate will apply on all outstanding obligations during the occurrence and continuance of an event of default. In accordance with ASC 815, the Company concluded that these features are not clearly and closely related to the host instrument, and represent a single compound derivative that is required to be re-measured at fair value on a quarterly basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The events of default include maintaining, on an annual basis, a minimum liquidity threshold which started in 2021, and on a quarterly basis, a minimum net sales threshold for Auryxia which started in the fourth quarter of 2020. The Company recorded a derivative liability related to the Company&#8217;s Loan Agreement with Pharmakon of $<ix:nonFraction unitRef="usd" contextRef="i469e62d61f624f13a913c992818f42a8_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RleHRyZWdpb246YzJjODU5ZmMyNTIwNDk1MWFkMzkwMWQ2MWZmODQyZjRfMjMzNw_8cf5de2d-f6ad-4003-a19b-6c4341342836">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3c2c9bd113fe46629d3834ae5a39ba17_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RleHRyZWdpb246YzJjODU5ZmMyNTIwNDk1MWFkMzkwMWQ2MWZmODQyZjRfMjM0NA_29fdce09-ef58-475f-a0e6-c9c2919b6307">2.4</ix:nonFraction> million as of September&#160;30, 2021 and December&#160;31, 2020, respectively. The Company classified the derivative liability as a non-current liability on the unaudited condensed consolidated balance sheet as of September&#160;30, 2021 and December&#160;31, 2020. The estimated fair value of the derivative liability on both September&#160;30, 2021 and December&#160;31, 2020 was determined using a scenario-based approach and discounted cash flow model that includes principal and interest payments under various scenarios involving clinical development success for vadadustat and various cash flow assumptions. Probabilities surrounding clinical development success were derived using industry benchmarks. Should the Company&#8217;s assessment of the probabilities around these scenarios change, including for changes in market conditions, there could be a change to the fair value of the derivative liability.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iec214d024e5146d68f43777ca84a2359"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RleHRyZWdpb246YzJjODU5ZmMyNTIwNDk1MWFkMzkwMWQ2MWZmODQyZjRfMzgyNA_422a9dc0-d9cc-4aa2-b79d-5b1dbd461fbc" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll-forward of the fair value of the derivative liability (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:81.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjJiNGViNzNlNmM2YjQ3NWFiZmFiMmQ0ZTBmNGE4YzA1L3RhYmxlcmFuZ2U6MmI0ZWI3M2U2YzZiNDc1YWJmYWIyZDRlMGY0YThjMDVfMC0xLTEtMS0yMjM1Nw_08576cd2-1a23-46cc-a95d-b43c846e4ff3">2,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability, recorded as other expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibedefb3b11734e53bd359a1087a22569_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjJiNGViNzNlNmM2YjQ3NWFiZmFiMmQ0ZTBmNGE4YzA1L3RhYmxlcmFuZ2U6MmI0ZWI3M2U2YzZiNDc1YWJmYWIyZDRlMGY0YThjMDVfMS0xLTEtMS0yMjM1Nw_3cf2884c-b91b-4604-82ff-493efa8ea84a">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id832960589e2403f88473dd831c88c68_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjJiNGViNzNlNmM2YjQ3NWFiZmFiMmQ0ZTBmNGE4YzA1L3RhYmxlcmFuZ2U6MmI0ZWI3M2U2YzZiNDc1YWJmYWIyZDRlMGY0YThjMDVfMi0xLTEtMS0yMjM1Nw_d0d078a7-bd34-4026-b148-06b0c26f2223">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability, recorded as other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02a8ba6ff0054b678403f9ad5ed7efc4_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjJiNGViNzNlNmM2YjQ3NWFiZmFiMmQ0ZTBmNGE4YzA1L3RhYmxlcmFuZ2U6MmI0ZWI3M2U2YzZiNDc1YWJmYWIyZDRlMGY0YThjMDVfMy0xLTEtMS0yMjM1Nw_ee90bd73-57ef-400a-a72f-9a8971505848">570</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i952bff9821b4497aa3ea95191dd2fe53_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjJiNGViNzNlNmM2YjQ3NWFiZmFiMmQ0ZTBmNGE4YzA1L3RhYmxlcmFuZ2U6MmI0ZWI3M2U2YzZiNDc1YWJmYWIyZDRlMGY0YThjMDVfNC0xLTEtMS0yMjM1Nw_ba3c2570-54d5-46f1-8792-cee0b416eee5">1,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability, recorded as other income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjJiNGViNzNlNmM2YjQ3NWFiZmFiMmQ0ZTBmNGE4YzA1L3RhYmxlcmFuZ2U6MmI0ZWI3M2U2YzZiNDc1YWJmYWIyZDRlMGY0YThjMDVfNS0xLTEtMS0yMjYyMw_719369e0-a6e3-4a22-af7d-656af84c3a6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjJiNGViNzNlNmM2YjQ3NWFiZmFiMmQ0ZTBmNGE4YzA1L3RhYmxlcmFuZ2U6MmI0ZWI3M2U2YzZiNDc1YWJmYWIyZDRlMGY0YThjMDVfNi0xLTEtMS0yMjYzMA_f02bcea2-0f19-4dd1-85ca-d0e83c42a449">1,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="usd" contextRef="i9b81649bc6244591a493ea134990b511_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RleHRyZWdpb246YzJjODU5ZmMyNTIwNDk1MWFkMzkwMWQ2MWZmODQyZjRfMzI1Ng_1e1e950d-e38c-4523-80a5-f0cfc4d71957"><ix:nonFraction unitRef="usd" contextRef="i0a8144587d5e488cabffbbd0bae0e7a5_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RleHRyZWdpb246YzJjODU5ZmMyNTIwNDk1MWFkMzkwMWQ2MWZmODQyZjRfMzI1Ng_4f9c3c37-8534-4b9d-be6e-d7a1ca1cc13d"><ix:nonFraction unitRef="usd" contextRef="i616cde0a70c94c6eb173090f144c4c43_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RleHRyZWdpb246YzJjODU5ZmMyNTIwNDk1MWFkMzkwMWQ2MWZmODQyZjRfMzI1Ng_79277f01-ac94-4242-8819-0f20bec7bd27"><ix:nonFraction unitRef="usd" contextRef="ia9033a88870c408dba279ef74720efd3_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RleHRyZWdpb246YzJjODU5ZmMyNTIwNDk1MWFkMzkwMWQ2MWZmODQyZjRfMzI1Ng_a203a0d1-77dc-4658-a338-341718859adc">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> other assets or liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level&#160;3) at September&#160;30, 2021 and December&#160;31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities are exposed to various risks such as interest rate, market and credit risks. When the Company holds investment securities, due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the value of investment securities, the Company considers if changes in risks in the near term would result in material changes in the fair value of investments.</span></div></ix:continuation><div><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_58"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RleHRyZWdpb246Yjg1YmFhMWU0YzdlNGNhZGJiOWE0ZGUzMmM1MzkyMDFfMTE5NA_2f1bff46-2322-4619-b539-217bfc4915ef" continuedAt="i24fe28912eb04ce89aa2fc67210a50e2" escape="true">Inventory</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i24fe28912eb04ce89aa2fc67210a50e2"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RleHRyZWdpb246Yjg1YmFhMWU0YzdlNGNhZGJiOWE0ZGUzMmM1MzkyMDFfMTE5NQ_d761d21b-ef68-453d-a1b1-ea4e0e98bfcb" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjRiNWFiMjQwZTdlYjQzMjFhODFhZmZmYTc5NzhkYjAzL3RhYmxlcmFuZ2U6NGI1YWIyNDBlN2ViNDMyMWE4MWFmZmZhNzk3OGRiMDNfMi0xLTEtMS0yMjM1Nw_227e4e4f-a0e1-4b9f-be40-d7e41d34009d">2,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjRiNWFiMjQwZTdlYjQzMjFhODFhZmZmYTc5NzhkYjAzL3RhYmxlcmFuZ2U6NGI1YWIyNDBlN2ViNDMyMWE4MWFmZmZhNzk3OGRiMDNfMi0zLTEtMS0yMjM1Nw_469d0702-a561-4a31-9fdf-ee115810e03c">2,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjRiNWFiMjQwZTdlYjQzMjFhODFhZmZmYTc5NzhkYjAzL3RhYmxlcmFuZ2U6NGI1YWIyNDBlN2ViNDMyMWE4MWFmZmZhNzk3OGRiMDNfMy0xLTEtMS0yMjM1Nw_5e354252-ffd4-4a5d-84c7-390036b0d360">76,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjRiNWFiMjQwZTdlYjQzMjFhODFhZmZmYTc5NzhkYjAzL3RhYmxlcmFuZ2U6NGI1YWIyNDBlN2ViNDMyMWE4MWFmZmZhNzk3OGRiMDNfMy0zLTEtMS0yMjM1Nw_19f4992b-6047-4228-9c85-c1378cb2eb12">64,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjRiNWFiMjQwZTdlYjQzMjFhODFhZmZmYTc5NzhkYjAzL3RhYmxlcmFuZ2U6NGI1YWIyNDBlN2ViNDMyMWE4MWFmZmZhNzk3OGRiMDNfNC0xLTEtMS0yMjM1Nw_2621c0f9-9cd6-4453-8fb6-72fce7745af4">16,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjRiNWFiMjQwZTdlYjQzMjFhODFhZmZmYTc5NzhkYjAzL3RhYmxlcmFuZ2U6NGI1YWIyNDBlN2ViNDMyMWE4MWFmZmZhNzk3OGRiMDNfNC0zLTEtMS0yMjM1Nw_2739e9fd-c22f-4cc9-9d6e-8502658b2e27">19,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:InventoryNetCurrentAndNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjRiNWFiMjQwZTdlYjQzMjFhODFhZmZmYTc5NzhkYjAzL3RhYmxlcmFuZ2U6NGI1YWIyNDBlN2ViNDMyMWE4MWFmZmZhNzk3OGRiMDNfNS0xLTEtMS0yMjM1Nw_ad5a3c81-1e97-49ad-8e32-58d5cc4bb989">95,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="akba:InventoryNetCurrentAndNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjRiNWFiMjQwZTdlYjQzMjFhODFhZmZmYTc5NzhkYjAzL3RhYmxlcmFuZ2U6NGI1YWIyNDBlN2ViNDMyMWE4MWFmZmZhNzk3OGRiMDNfNS0zLTEtMS0yMjM1Nw_934cefe0-e2b1-4791-a5bc-6104735f6f2a">86,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term inventory, which primarily consists of raw materials and work in process, is included in other assets in the Company&#8217;s unaudited condensed consolidated balance sheets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjNjMmI3YmU0Y2QwNzRlNjQ4NDQ2OWExNTJlOTEyMzA5L3RhYmxlcmFuZ2U6M2MyYjdiZTRjZDA3NGU2NDg0NDY5YTE1MmU5MTIzMDlfMy0xLTEtMS0yMjM1Nw_b5595d3a-a8de-492d-875e-6dae7d10c572">33,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjNjMmI3YmU0Y2QwNzRlNjQ4NDQ2OWExNTJlOTEyMzA5L3RhYmxlcmFuZ2U6M2MyYjdiZTRjZDA3NGU2NDg0NDY5YTE1MmU5MTIzMDlfMy0zLTEtMS0yMjM1Nw_136ae577-06f7-41c0-82c9-584af1a51b60">61,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjNjMmI3YmU0Y2QwNzRlNjQ4NDQ2OWExNTJlOTEyMzA5L3RhYmxlcmFuZ2U6M2MyYjdiZTRjZDA3NGU2NDg0NDY5YTE1MmU5MTIzMDlfNC0xLTEtMS0yMjM1Nw_048553f3-40e1-48cc-a55b-38a3ffd8ce3b">61,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjNjMmI3YmU0Y2QwNzRlNjQ4NDQ2OWExNTJlOTEyMzA5L3RhYmxlcmFuZ2U6M2MyYjdiZTRjZDA3NGU2NDg0NDY5YTE1MmU5MTIzMDlfNC0zLTEtMS0yMjM1Nw_ff762e4a-3181-48d9-aba7-d190c2ef2496">25,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:InventoryNetCurrentAndNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjNjMmI3YmU0Y2QwNzRlNjQ4NDQ2OWExNTJlOTEyMzA5L3RhYmxlcmFuZ2U6M2MyYjdiZTRjZDA3NGU2NDg0NDY5YTE1MmU5MTIzMDlfNS0xLTEtMS0yMjM1Nw_a45904c5-dccb-4d1f-af28-6ee03fecfed9">95,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="akba:InventoryNetCurrentAndNonCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjNjMmI3YmU0Y2QwNzRlNjQ4NDQ2OWExNTJlOTEyMzA5L3RhYmxlcmFuZ2U6M2MyYjdiZTRjZDA3NGU2NDg0NDY5YTE1MmU5MTIzMDlfNS0zLTEtMS0yMjM1Nw_f85b5996-2a1d-46a1-890c-b102cce557f9">86,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory amounts written down as a result of excess, obsolescence, scrap or other reasons and charged to cost of goods sold totaled $<ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RleHRyZWdpb246Yjg1YmFhMWU0YzdlNGNhZGJiOWE0ZGUzMmM1MzkyMDFfMzk0_38766fa0-aaae-4f91-812c-be6b5b1a7104">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RleHRyZWdpb246Yjg1YmFhMWU0YzdlNGNhZGJiOWE0ZGUzMmM1MzkyMDFfNDAx_ca82695a-6095-4862-a2b4-339566b03f86">7.1</ix:nonFraction> million during the three and nine months ended September&#160;30, 2021, respectively, and totaled $<ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RleHRyZWdpb246Yjg1YmFhMWU0YzdlNGNhZGJiOWE0ZGUzMmM1MzkyMDFfNjU5NzA2OTc2ODI4Nw_7858e659-e383-411f-af48-88ddcc12ae02">8.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RleHRyZWdpb246Yjg1YmFhMWU0YzdlNGNhZGJiOWE0ZGUzMmM1MzkyMDFfNjU5NzA2OTc2ODI5NQ_8de23bb6-36d6-40c1-8fe6-435e284b0086">18.6</ix:nonFraction> million during the three and nine months ended September&#160;30, 2020, respectively. The decrease in inventory amounts written down for the three and nine months ended September&#160;30, 2021 as compared to the three and nine months ended September&#160;30, 2020 was primarily due to lower write-downs to inventory reserves related to a previously disclosed manufacturing quality issue related to Auryxia during 2020. In addition, there were <ix:nonFraction unitRef="usd" contextRef="i3e237cd7f54f4646aa36f63692c06c40_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RleHRyZWdpb246Yjg1YmFhMWU0YzdlNGNhZGJiOWE0ZGUzMmM1MzkyMDFfMTY0OTI2NzQ0NDIzOQ_b008e216-f47f-4dba-8eee-bca83ccbe1ea">no</ix:nonFraction> related step-up charges during the three months ended September&#160;30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="i4e72ecf91b664cca962bacefd5439368_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RleHRyZWdpb246Yjg1YmFhMWU0YzdlNGNhZGJiOWE0ZGUzMmM1MzkyMDFfMTY0OTI2NzQ0NDI4Mw_6fa60f5e-c8f7-4e69-b684-98b1815820b3">1.4</ix:nonFraction> million related step-up charges during the three months ended September&#160;30, 2020. Related step-up charges were $<ix:nonFraction unitRef="usd" contextRef="i1cd36c7e7311497ba175179857b7257c_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RleHRyZWdpb246Yjg1YmFhMWU0YzdlNGNhZGJiOWE0ZGUzMmM1MzkyMDFfNDg4_9a7a029f-8611-4ef3-b9e4-a4912a4f4959">8.7</ix:nonFraction> million during the nine months ended September&#160;30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="i9fdb433b2bca4b748b2b7fa719b097c9_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RleHRyZWdpb246Yjg1YmFhMWU0YzdlNGNhZGJiOWE0ZGUzMmM1MzkyMDFfNjU5NzA2OTc2ODQyNQ_577daf22-1c69-4707-b523-272501b25e09">7.4</ix:nonFraction> million during the nine months ended September&#160;30, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If future sales of Auryxia are lower than expected, the Company may be required to write-down the value of such inventories. Inventory write-downs and losses on purchase commitments are recorded as a component of cost of sales in the unaudited condensed consolidated statement of operations.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_61"></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfMTIzMg_5bccc1fa-2660-40f0-a6ea-2abde0b1988e" continuedAt="i1c28ea6acafd41af9d2b198e62dc7933" escape="true">Intangible Assets and Goodwill</ix:nonNumeric></span></div><ix:continuation id="i1c28ea6acafd41af9d2b198e62dc7933"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfMTIzMw_a4e9645d-e7ab-4a26-93a0-26c1a8863ab5" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s intangible assets at September&#160;30, 2021 and December&#160;31, 2020 (in thousands): </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.964%"><tr><td style="width:1.0%"></td><td style="width:50.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.376%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.376%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed product rights for Auryxia</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia76ea517ec23406588672981c217b653_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOjUzNDMzMGNhNThjYjQ3NjM5MGFmYjdhNjJjZDA3ZDA2L3RhYmxlcmFuZ2U6NTM0MzMwY2E1OGNiNDc2MzkwYWZiN2E2MmNkMDdkMDZfMy0xLTEtMS0yMjM1Nw_73e442fb-c551-4e1f-a64f-2b0e742fc877">213,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia76ea517ec23406588672981c217b653_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOjUzNDMzMGNhNThjYjQ3NjM5MGFmYjdhNjJjZDA3ZDA2L3RhYmxlcmFuZ2U6NTM0MzMwY2E1OGNiNDc2MzkwYWZiN2E2MmNkMDdkMDZfMy0zLTEtMS0yMjM1Nw_23c9ec93-e7c0-422c-8418-53ca9d31a144">96,465</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia76ea517ec23406588672981c217b653_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOjUzNDMzMGNhNThjYjQ3NjM5MGFmYjdhNjJjZDA3ZDA2L3RhYmxlcmFuZ2U6NTM0MzMwY2E1OGNiNDc2MzkwYWZiN2E2MmNkMDdkMDZfMy01LTEtMS0yMjM1Nw_79f49e09-3d9d-4bc3-9f7a-63b92ed219fb">117,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"></td><td style="width:45.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ASC 842<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed product rights for Auryxia</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30e4e068c6214ffabd5a128e3d85c999_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOmRmNWY4ZDUzNmU2NDQwMDA4MWI4YWM4NDYzNTIyN2M2L3RhYmxlcmFuZ2U6ZGY1ZjhkNTM2ZTY0NDAwMDgxYjhhYzg0NjM1MjI3YzZfMy0xLTEtMS0yMjM1Nw_098f81ca-a230-4a58-9350-970af7cf8de1">213,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30e4e068c6214ffabd5a128e3d85c999_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOmRmNWY4ZDUzNmU2NDQwMDA4MWI4YWM4NDYzNTIyN2M2L3RhYmxlcmFuZ2U6ZGY1ZjhkNTM2ZTY0NDAwMDgxYjhhYzg0NjM1MjI3YzZfMy0zLTEtMS0yMjM1Nw_b975024d-d3fd-44af-be6b-776a567ded60">69,433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30e4e068c6214ffabd5a128e3d85c999_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOmRmNWY4ZDUzNmU2NDQwMDA4MWI4YWM4NDYzNTIyN2M2L3RhYmxlcmFuZ2U6ZGY1ZjhkNTM2ZTY0NDAwMDgxYjhhYzg0NjM1MjI3YzZfMy03LTEtMS0yMjM1Nw_ccf317c6-d5a3-4ce1-9df5-2e655045975b">144,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Favorable lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dcd869a04c44f3ea928848929217e86_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOmRmNWY4ZDUzNmU2NDQwMDA4MWI4YWM4NDYzNTIyN2M2L3RhYmxlcmFuZ2U6ZGY1ZjhkNTM2ZTY0NDAwMDgxYjhhYzg0NjM1MjI3YzZfNC0xLTEtMS0yMjM1Nw_845f8538-c67a-40cb-85ae-adbf05107ba3">545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6dcd869a04c44f3ea928848929217e86_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOmRmNWY4ZDUzNmU2NDQwMDA4MWI4YWM4NDYzNTIyN2M2L3RhYmxlcmFuZ2U6ZGY1ZjhkNTM2ZTY0NDAwMDgxYjhhYzg0NjM1MjI3YzZfNC0zLTEtMS0yMjM1Nw_87b5fe40-102d-4dc1-9b8e-23950431bfc2">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6dcd869a04c44f3ea928848929217e86_I20201231" decimals="-3" sign="-" name="akba:FiniteLivedIntangibleAssetsAdoptionAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOmRmNWY4ZDUzNmU2NDQwMDA4MWI4YWM4NDYzNTIyN2M2L3RhYmxlcmFuZ2U6ZGY1ZjhkNTM2ZTY0NDAwMDgxYjhhYzg0NjM1MjI3YzZfNC01LTEtMS0yMjM1Nw_b0565d07-3fdf-452c-9844-3ac4cfa24e2a">540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dcd869a04c44f3ea928848929217e86_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOmRmNWY4ZDUzNmU2NDQwMDA4MWI4YWM4NDYzNTIyN2M2L3RhYmxlcmFuZ2U6ZGY1ZjhkNTM2ZTY0NDAwMDgxYjhhYzg0NjM1MjI3YzZfNC03LTEtMS0yMjM1Nw_a66ed007-ca6c-4cae-81f2-28c76b83e729">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOmRmNWY4ZDUzNmU2NDQwMDA4MWI4YWM4NDYzNTIyN2M2L3RhYmxlcmFuZ2U6ZGY1ZjhkNTM2ZTY0NDAwMDgxYjhhYzg0NjM1MjI3YzZfNS0xLTEtMS0yMjM1Nw_1e1cae3b-3ad2-4604-961e-e28085dacdf3">214,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOmRmNWY4ZDUzNmU2NDQwMDA4MWI4YWM4NDYzNTIyN2M2L3RhYmxlcmFuZ2U6ZGY1ZjhkNTM2ZTY0NDAwMDgxYjhhYzg0NjM1MjI3YzZfNS0zLTEtMS0yMjM1Nw_f5b4dd86-736b-4253-b876-c70c57e1b6aa">69,438</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" sign="-" name="akba:FiniteLivedIntangibleAssetsAdoptionAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOmRmNWY4ZDUzNmU2NDQwMDA4MWI4YWM4NDYzNTIyN2M2L3RhYmxlcmFuZ2U6ZGY1ZjhkNTM2ZTY0NDAwMDgxYjhhYzg0NjM1MjI3YzZfNS01LTEtMS0yMjM1Nw_bc84b626-7d27-4484-8f31-d13581568935">540</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOmRmNWY4ZDUzNmU2NDQwMDA4MWI4YWM4NDYzNTIyN2M2L3RhYmxlcmFuZ2U6ZGY1ZjhkNTM2ZTY0NDAwMDgxYjhhYzg0NjM1MjI3YzZfNS03LTEtMS0yMjM1Nw_8ee1d88c-dc47-46e4-bb8f-644fc9083e7c">144,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 12, 2018, the Company completed the Merger, whereby it acquired certain definite-lived intangible assets, including the developed product rights for Auryxia and a favorable lease. The Company amortizes its definite-lived intangible assets acquired as part of the Merger using the straight-line method, which is considered the best estimate of economic benefit, over its estimated useful life of <ix:nonNumeric contextRef="i34034b5b7fbe48fe92390732c9576345_D20181212-20181212" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfMjc0ODc3OTA3MDcxMA_9dd1eebd-685b-443a-95ec-3a667077c444">six years</ix:nonNumeric>. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfNTc5_f0c88edd-421c-4aba-8895-55b69b112d4c">9.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfNTg2_f2b06c11-abf2-4870-873e-a943853a523f">6.1</ix:nonFraction> million in amortization expense related to the developed product rights for Auryxia during the three months ended September&#160;30, 2021 and 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfNzI0_16972fcc-8595-40d2-9f9c-00c794262825">27.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfNzMx_42eb26d1-cb02-48b2-b2a1-3ab54a285c99">24.3</ix:nonFraction> million during the nine months ended September&#160;30, 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill was $<ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfODEw_c2372a12-8c21-40a6-b699-afd02afd8fcb"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfODEw_f2c951c5-bb53-4627-8b0d-2fcc6cb727d9">55.1</ix:nonFraction></ix:nonFraction> million as of September&#160;30, 2021 and December&#160;31, 2020. The Company operates in <ix:nonFraction unitRef="segment" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfODU0_0ec5b73b-a0a5-4cc0-8a91-d0affcf08ca4">one</ix:nonFraction> operating segment which the Company considers to be the only reporting unit. Goodwill is evaluated for impairment at the reporting unit level on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstances suggest that an impairment may exist. There were <ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfMTE1OA_2699deee-c5a5-41b8-a5ee-b2fa713a0ed8"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfMTE1OA_9d184092-fc85-4088-b316-44f9c4ac8753"><ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfMTE1OA_d391e83e-4d8d-4f63-9834-8edeeccb6fc5"><ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfMTE1OA_f2393f3c-634b-4aea-b36f-ca0b22d2fbea">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairments of goodwill during the three and nine months ended September&#160;30, 2021 or 2020.</span></div></ix:continuation><div><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_64"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RleHRyZWdpb246YzMwZjgxYTkzZWM3NDZkMmIyMTA0MTY5YWMwZDEwOTRfNzY_9096f7d7-8dd2-4686-b145-d738af311ef3" continuedAt="ia898d0cb2dee43c28951d4110b6890f4" escape="true">Accrued Expenses</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ia898d0cb2dee43c28951d4110b6890f4"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RleHRyZWdpb246YzMwZjgxYTkzZWM3NDZkMmIyMTA0MTY5YWMwZDEwOTRfNzc_1400faba-4b9c-442d-99f9-1000cef4ece8" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses as of September&#160;30, 2021 and December&#160;31, 2020 are as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:59.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue allowances</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:AccruedProductRevenueAllowancesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfMi0xLTEtMS0yMjM1Nw_f016259a-ce3d-4098-ac5e-b1f91af9f5a3">44,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="akba:AccruedProductRevenueAllowancesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfMi0zLTEtMS0yMjM1Nw_70989a53-b412-4eb2-b65c-17d3f69ae190">38,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:AccruedClinicalExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfMy0xLTEtMS0yMjM1Nw_875495d0-6609-4201-9575-320eed72ba57">19,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="akba:AccruedClinicalExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfMy0zLTEtMS0yMjM1Nw_99ad66ea-9fb7-44d7-bb15-5b1f783db3f8">28,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts due to collaboration partners</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:CollaborativeArrangementAccruedLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNC0xLTEtMS0yMjM1Nw_6a970d1b-9b46-4c6d-a344-d595a7cd1659">27,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="akba:CollaborativeArrangementAccruedLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNC0zLTEtMS0yMjM1Nw_c100e9cb-9322-43e5-9d16-8b2a0cba4db9">17,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otsuka PRV contribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNS0xLTEtMS0yMjM1Nw_95882df2-0dcd-466e-a61a-7e95a621cb09">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="akba:CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNS0zLTEtMS0yMjM1Nw_cac1a703-e155-4b01-abff-ad080d5dadb6">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNi0xLTEtMS0yMjM1Nw_62545827-86f1-473c-869c-a1100eceb4e0">12,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNi0zLTEtMS0yMjM1Nw_b1ad97f4-2cac-40e2-9e39-acf249cab3a4">14,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNy0wLTEtMS0yMjM1Nw_8a62ce00-dd9c-44ee-980f-eb68f6cf0efd"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNy0wLTEtMS0yMjM1Nw_a0731d02-abdf-4cad-9588-f670833c69ba">Lease liability</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNy0xLTEtMS0yMjM1Nw_5db3ca47-2d26-4873-b903-9320ba5fc8d7">5,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNy0zLTEtMS0yMjM1Nw_d0cb8872-b2ae-4d51-8b98-c096fcabd977">5,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfOS0xLTEtMS0yMjM1Nw_c920389b-ce52-4cf2-8a2f-975f520c318d">3,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfOS0zLTEtMS0yMjM1Nw_ab7d26c0-8c2a-4247-94d9-aea2c31e27d0">2,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfMTAtMS0xLTEtMjIzNTc_435ab9cd-6c4f-4679-bad4-2c40ccd21316">9,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfMTAtMy0xLTEtMjIzNTc_a3727fa7-3800-4367-a22e-8b5b9d9e2d55">3,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commercial manufacturing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:AccruedCommercialManufacturingCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfMTEtMS0xLTEtMjIzNTc_e90ca1c9-3a3a-4508-862f-a6f616f4b829">1,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" name="akba:AccruedCommercialManufacturingCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfMTEtMy0xLTEtMjIzNTc_c871965c-b292-49be-adab-e75223773676">514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfMTMtMS0xLTEtMjIzNTc_322ff401-4ce7-467d-9a74-761b4804e139">11,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfMTMtMy0xLTEtMjIzNTc_9b9b4d64-2d48-43f0-a6e2-4f4865f1ef7d">8,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfMTQtMS0xLTEtMjIzNTc_a6d4772d-57f0-411d-ba34-7a3819b78162">144,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfMTQtMy0xLTEtMjIzNTc_26a4e871-0a21-4214-8acb-660444ff6ae1">130,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_67"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfNTk2MQ_64079cdd-a861-417f-b368-53716a7ffa3b" continuedAt="i7b1047db106043439866fb140aa41e93" escape="true">Debt</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i7b1047db106043439866fb140aa41e93" continuedAt="i26a0c14ede634e368271d20a8b89770f"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term Loans</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 11, 2019, the Company, with Keryx as guarantor, entered into a loan agreement, or the Loan Agreement, with BioPharma Credit PLC as collateral agent and a lender, or the Collateral Agent, and BioPharma Credit Investments V (Master) LP as a lender, pursuant to which term loans in an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i4c756e20d9664648aeb18aebeb242523_I20191111" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMzQ3_dd48da69-55d9-4df1-9803-31c4cf9ab4c6">100.0</ix:nonFraction> million were made available to the Company in <ix:nonFraction unitRef="tranche" contextRef="i4c756e20d9664648aeb18aebeb242523_I20191111" decimals="INF" format="ixt-sec:numwordsen" name="akba:LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMzg4_2e2ebf31-1d62-4d5c-9b85-e53447fd3929">two</ix:nonFraction> tranches, subject to certain terms and conditions, or the Term Loans. BioPharma Credit PLC subsequently transferred its interest in the Term Loans, solely in its capacity as a lender, to its affiliate, BPCR Limited Partnership. The Collateral Agent and the lenders are collectively referred to as Pharmakon. The first tranche of $<ix:nonFraction unitRef="usd" contextRef="i3c0d403601654c72b47819a9afbd0792_I20191111" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfNzIw_7126f276-3345-46b6-acec-426f815d7164">80.0</ix:nonFraction> million, or Tranche A, was drawn on November&#160;25, 2019, or the Tranche A Funding Date, and the second&#160;tranche of $<ix:nonFraction unitRef="usd" contextRef="ia190616222f745278c0dc5a7620042c1_I20191111" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfODEy_b35894b8-8261-400c-906a-98f7a0dc7dbb">20.0</ix:nonFraction> million, or Tranche B, was drawn on December 10, 2020, or the Tranche B Funding Date. Each of the Tranche A Funding Date and the Tranche B Funding Date, a Funding Date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from the Term Loans may be used for general corporate purposes. The Company and Keryx entered into a Guaranty and Security Agreement with the Collateral Agent, or the Guaranty and Security Agreement, on the Tranche A Funding Date. Pursuant to the Guaranty and Security Agreement, the Company&#8217;s obligations under the Term Loans are unconditionally guaranteed by Keryx, or the Guarantee. Additionally, the obligations of the Company and Keryx under the Term Loans and the Guarantee are secured by a first priority lien on certain assets of the Company and Keryx, including Auryxia and certain related assets, cash, and certain equity interests held by the Company and Keryx, collectively the Collateral.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loans bear interest at a floating rate per annum equal to the three-month LIBOR rate plus <ix:nonFraction unitRef="number" contextRef="ia00bb356464246a7b22e1821a884688d_D20191111-20191111" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMTc4OA_87c133f6-0592-4bbe-9684-5dd5b7c8caef">7.50</ix:nonFraction>%, subject to a <ix:nonFraction unitRef="number" contextRef="i8147f4e6a02545de933ea73e8af97025_D20191111-20191111" decimals="INF" name="akba:DebtInstrumentFloorRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMTgwNQ_e5b9f0db-7a08-4487-b82b-5f639b277f2f">2.00</ix:nonFraction>% LIBOR floor and a <ix:nonFraction unitRef="number" contextRef="i8147f4e6a02545de933ea73e8af97025_D20191111-20191111" decimals="INF" name="akba:DebtInstrumentCapRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMTgyNg_607a0dae-7d02-425f-9887-160510796e0d">3.35</ix:nonFraction>% LIBOR cap, payable quarterly in arrears. The Term Loans will mature on the fifth anniversary of the Tranche A Funding Date, or the Maturity Date. The Company will repay the principal under the Term Loans in equal quarterly payments starting on the <ix:nonNumeric contextRef="i2c34013e3d5d42798cb44d8508b1ac83_D20191111-20191111" format="ixt-sec:durmonth" name="akba:LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMTk3NQ_78374598-6fb8-4d84-8509-b4a0ee364b78">33</ix:nonNumeric>rd-month anniversary of the applicable Funding Date or, if certain conditions are met, it will have the option to repay the principal in equal quarterly payments starting on the <ix:nonNumeric contextRef="i06ee360513f94ae993a4c6898c417de2_D20191111-20191111" format="ixt-sec:durmonth" name="akba:LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMjE1NQ_05c0761f-0f2b-44f1-b8eb-98f07699aea2">48</ix:nonNumeric>th-month anniversary of the applicable Funding Date, or collectively the Amortization Schedule. Under certain circumstances, unless certain liquidity conditions are met, the Maturity Date may decrease by up to <ix:nonNumeric contextRef="ic6020a0180d34b6a86d7589b54358a92_D20191111-20191111" format="ixt-sec:durwordsen" name="akba:DebtInstrumentCovenantTermsPotentialMaturityTermReduction" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMjM2Nw_18923edb-8afd-4ae3-ac34-f9a0726fb984">one year</ix:nonNumeric>, and the Amortization Schedule may correspondingly commence up to <ix:nonNumeric contextRef="ic6020a0180d34b6a86d7589b54358a92_D20191111-20191111" format="ixt-sec:durwordsen" name="akba:DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMjQzNg_23c354af-f04c-4b9a-873b-536e6e0650f3">one year</ix:nonNumeric> earlier.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the Tranche A Funding Date,&#160;the Company paid to Pharmakon a facility fee equal to <ix:nonFraction unitRef="number" contextRef="ic6020a0180d34b6a86d7589b54358a92_D20191111-20191111" decimals="INF" name="akba:FacilityFeePercentagePaidOnPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMjUzNg_49e74135-18cc-4c88-b04e-2cde5e9855cf">2.00</ix:nonFraction>% of the aggregate principal amount of the Term Loans, or $<ix:nonFraction unitRef="usd" contextRef="ic6020a0180d34b6a86d7589b54358a92_D20191111-20191111" decimals="-5" format="ixt:num-dot-decimal" name="akba:DebtInstrumentFacilityFeePaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMjU5NQ_180051f3-f829-4e97-aebb-ef6d5bb3ed1f">2.0</ix:nonFraction> million, in addition to other expenses incurred by Pharmakon and reimbursed by the Company, or Lender Expenses. The Tranche A draw was $<ix:nonFraction unitRef="usd" contextRef="i8cd1fb13915744c284881cee3c9a4457_I20191125" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMjcyNQ_28e4a08c-5877-40c7-ad76-d2485e2a383d">77.3</ix:nonFraction> million, net of facility fee, Lender Expenses and issuance costs. The Tranche B draw was $<ix:nonFraction unitRef="usd" contextRef="iefce2ff8ab894b54be64daf36220401a_D20201210-20201210" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMjgwOQ_1cec80b4-6a3a-4e1e-9133-7a6fa1ed6773">20.0</ix:nonFraction>&#160;million, net of immaterial Lender Expenses and issuance costs. The Loan Agreement permits voluntary prepayment at any time in whole or in part, subject to a prepayment premium. The prepayment premium would be <ix:nonFraction unitRef="number" contextRef="ic6020a0180d34b6a86d7589b54358a92_D20191111-20191111" decimals="INF" name="akba:PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMzAxMw_d3562936-e9bb-49ac-b38a-3c6f31c52ad0">2.00</ix:nonFraction>% of the principal amount being prepaid prior to the third anniversary of the applicable Funding Date, <ix:nonFraction unitRef="number" contextRef="ic6020a0180d34b6a86d7589b54358a92_D20191111-20191111" decimals="INF" name="akba:PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMzExNw_97ebad9e-a560-4d77-a886-baa56ff44418">1.00</ix:nonFraction>% on or after the third anniversary, but prior to the fourth anniversary, of the applicable Funding Date, and <ix:nonFraction unitRef="number" contextRef="ic6020a0180d34b6a86d7589b54358a92_D20191111-20191111" decimals="INF" name="akba:PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMzIyOA_23f01c23-7aeb-4dc6-a73e-81d81776a8c3">0.50</ix:nonFraction>% on or after the fourth anniversary of the applicable Funding Date but prior to the Maturity Date, and a make-whole premium on or prior to the second anniversary of the applicable Funding Date in an amount equal to foregone interest through the second anniversary of the applicable Funding Date. A change of control triggers a mandatory prepayment of the Term Loans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement contains customary representations, warranties, events of default and covenants of the Company and its subsidiaries, including maintaining, on an annual basis, a minimum liquidity threshold which started in 2021, and on a quarterly basis, a minimum net sales threshold for Auryxia which started in the fourth quarter of 2020.&#160;If an event of default occurs and is continuing under the Loan Agreement, the Collateral Agent is entitled to take enforcement action, including acceleration of amounts due under the Loan Agreement. Under certain circumstances, a default interest rate will apply on all outstanding obligations during the occurrence and continuance of an event of default. As of September&#160;30, 2021 and December&#160;31, 2020, the Company determined that no events of default had occurred.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the terms and features of the Loan Agreement in order to identify any potential embedded features that would require bifurcation or any beneficial conversion feature. As part of this analysis, the Company assessed the economic characteristics and risks of the Loan Agreement, including put and call features. The terms and features assessed include a potential extension to the interest-only period dependent on both no event of default having occurred and continuing and the Company achieving certain regulatory and revenue conditions. The Company also assessed the acceleration of the obligations under the Loan Agreement under an event of default. In addition, under certain circumstances, a default interest rate will apply on all outstanding obligations during the occurrence and continuance of an event of default. In accordance with ASC 815, the Company concluded that these features are not clearly and closely related to the host instrument, and represent a single compound derivative that is required to be re-measured at fair value on a quarterly basis.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i26a0c14ede634e368271d20a8b89770f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the derivative liability related to the Company&#8217;s Loan Agreement with Pharmakon was $<ix:nonFraction unitRef="usd" contextRef="i469e62d61f624f13a913c992818f42a8_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfNTU3Mg_5468e543-d2dc-4c33-a655-5085fdc21c36">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3c2c9bd113fe46629d3834ae5a39ba17_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfNTU3OQ_feb5606e-e963-4d42-963b-1fcdd72ed1d2">2.4</ix:nonFraction> million as of September&#160;30, 2021 and December&#160;31, 2020, respectively. The Company classified the derivative liability as a non-current liability on the unaudited condensed consolidated balance sheet as of September&#160;30, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized interest expense related to the Loan Agreement of $<ix:nonFraction unitRef="usd" contextRef="ied529b6124d840a6ad7b272239c35283_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfNTgyNg_9cf4e5a0-9668-457f-a757-c6e44074a063">2.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i43a607fdad03489084b28ba60875d452_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfNTgzMw_4c38da69-6fb9-4753-abe5-9dbe5077f9e4">2.2</ix:nonFraction> million, respectively, during the three months ended September&#160;30, 2021 and 2020, and $<ix:nonFraction unitRef="usd" contextRef="ia8d3eda1fa3b436883677e9840266d97_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfNTg5Ng_d56b41b9-9c0a-4bad-89ed-4128c8790d25">8.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ida5e89d4588d4e3dbdc420f58130b868_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfNTkwMw_3b05415c-1c77-412b-9c4f-507ec2b4d2b5">6.6</ix:nonFraction> million for the first nine months ended September&#160;30, 2021 and 2020, respectively.</span></div></ix:continuation><div><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_73"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="akba:WarrantDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83My9mcmFnOjc3ZjZiNzE2M2NjODRlM2FhZGRlMzdlZTgxYThkNDY1L3RleHRyZWdpb246NzdmNmI3MTYzY2M4NGUzYWFkZGUzN2VlODFhOGQ0NjVfNzc5_826727a0-4807-44cb-9c14-94eee1167914" continuedAt="id96f6d01ba8d45e2aa359b8aec2be2a9" escape="true">Warrant</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id96f6d01ba8d45e2aa359b8aec2be2a9">In connection with the Janssen Agreement, in February 2017, the Company issued a warrant to purchase <ix:nonFraction unitRef="shares" contextRef="i541f7e6319644772b0d0e20228d16057_I20170228" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83My9mcmFnOjc3ZjZiNzE2M2NjODRlM2FhZGRlMzdlZTgxYThkNDY1L3RleHRyZWdpb246NzdmNmI3MTYzY2M4NGUzYWFkZGUzN2VlODFhOGQ0NjVfMTE2_b8910977-b006-4b4c-9bb2-44f55eafc529">509,611</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i541f7e6319644772b0d0e20228d16057_I20170228" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83My9mcmFnOjc3ZjZiNzE2M2NjODRlM2FhZGRlMzdlZTgxYThkNDY1L3RleHRyZWdpb246NzdmNmI3MTYzY2M4NGUzYWFkZGUzN2VlODFhOGQ0NjVfMTgw_ca2980f2-3793-4c6e-af15-8bd12423524b">9.81</ix:nonFraction> per share. The warrant was fully vested upon issuance and exercisable in whole or in part, at any time prior to February 9, 2022. The warrant satisfied the equity classification criteria of ASC 815, and is therefore classified as an equity instrument. The fair value at issuance of $<ix:nonFraction unitRef="usd" contextRef="i541f7e6319644772b0d0e20228d16057_I20170228" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83My9mcmFnOjc3ZjZiNzE2M2NjODRlM2FhZGRlMzdlZTgxYThkNDY1L3RleHRyZWdpb246NzdmNmI3MTYzY2M4NGUzYWFkZGUzN2VlODFhOGQ0NjVfNDY1_61e5677e-da43-4aa6-a861-451d75253029">3.4</ix:nonFraction> million was calculated using the Black Scholes option pricing model and was charged to research and development expense as it represented consideration for a license for which the underlying intellectual property was deemed to have no alternative future use. As of September&#160;30, 2021, the warrant remains outstanding and expires on February&#160;9, 2022.</ix:continuation></span></div><div><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_76"></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfOTU0MA_181e1abb-c3d5-4d52-8490-c72b3ae16576" continuedAt="i0acf2eb659b5464cb7f81a58c4a92b2b" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i0acf2eb659b5464cb7f81a58c4a92b2b" continuedAt="ie32bb40c9b1242c9adab30a7b7463110"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Authorized and Outstanding Capital Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 5, 2020, the Company filed a Certificate of Amendment to its Ninth Amended and Restated Certificate of Incorporation, or its Charter, to increase the number of authorized shares of common stock from <ix:nonFraction unitRef="shares" contextRef="i8e4cb62597ae4760a7f0d14dd934eeeb_I20200604" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMjc1_a600d785-7311-4351-9a03-c0f1293cb090">175,000,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMjgx_25251880-276a-48fa-a78e-6e6ca6bf3b68">350,000,000</ix:nonFraction>. As of September&#160;30, 2021, the authorized capital stock of the Company included <ix:nonFraction unitRef="shares" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMzQ4_25251880-276a-48fa-a78e-6e6ca6bf3b68">350,000,000</ix:nonFraction> shares of common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMzg1_1c936585-a0fb-4207-9100-43dc77a0fd20">0.00001</ix:nonFraction> per share, of which <ix:nonFraction unitRef="shares" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNDA4_0d88bbfb-4491-4419-ae54-f2afff7d5bc6"><ix:nonFraction unitRef="shares" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNDA4_77871782-3dfd-42d4-8219-c925368e042d">174,551,989</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNDE1_bb4e2c9f-808f-4d20-b592-c6e276d742c3"><ix:nonFraction unitRef="shares" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNDE1_f9bbb3f1-593f-4630-8f12-644388d0a5a9">148,074,085</ix:nonFraction></ix:nonFraction> shares were issued and outstanding as of September&#160;30, 2021 and December&#160;31, 2020, respectively; and <ix:nonFraction unitRef="shares" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNDg4_e4a53937-0291-40b8-8098-b160777ce7ee">25,000,000</ix:nonFraction> shares of undesignated preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNTQx_6069ddff-5b1f-41a8-b4bc-365421c3e50e">0.00001</ix:nonFraction> per share, of which <ix:nonFraction unitRef="shares" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNTY0_2969ba1c-db2f-4be0-9922-be22002860e7"><ix:nonFraction unitRef="shares" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNTY0_6ec3b9f6-d173-49c0-a71c-3a3d9e9c6d06"><ix:nonFraction unitRef="shares" contextRef="i3e2950be526b427487e169a221babd7d_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNTY0_7bc63cda-cd53-4b18-aed9-1581e161d59d"><ix:nonFraction unitRef="shares" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNTY0_a0d73625-1e85-49d1-99e0-53c2a0c7902b">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares were issued and outstanding as of September&#160;30, 2021 and December&#160;31, 2020.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market Facility</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 12, 2019, the Company entered into an Amended and Restated Controlled Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement with Cantor Fitzgerald &amp; Co. for the offer and sale of common stock at the then current market prices in amounts to be determined from time to time. Also, on November 12, 2019, the Company filed a prospectus supplement pursuant to which it was able to offer and sell under the sales agreement up to $<ix:nonFraction unitRef="usd" contextRef="ia500545ec09246ce9dedea5a7cd9b0d4_D20191112-20191112" decimals="-5" format="ixt:num-dot-decimal" name="akba:CommonStockSalesAgreementAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMTA1Nw_01060b93-4a65-4dd0-b3bd-0c5c2c6cea0f">75.0</ix:nonFraction> million of its common stock at the then current market prices from time to time. Through December 31, 2019, the Company sold <ix:nonFraction unitRef="shares" contextRef="i81c8895c1f2d4c56b6435144097a2e33_D20190101-20191231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMTE3Nw_28549177-c7de-4865-86ac-2db1a0de4cfb">2,684,392</ix:nonFraction> shares of common stock under this program with net proceeds (after deducting commissions and other offering expenses) of $<ix:nonFraction unitRef="usd" contextRef="i81c8895c1f2d4c56b6435144097a2e33_D20190101-20191231" decimals="-5" format="ixt:num-dot-decimal" name="akba:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMTMwMQ_d13e65cd-130f-4427-89d4-59da65b14593">16.8</ix:nonFraction> million. During the three months ended March 31, 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="i66deeb6acb77474a959a2ca2688e2657_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMTM2OA_0b7f30a6-b1d6-4b7c-bd18-dba450b268d1">7,973,967</ix:nonFraction> shares of common stock under this program with net proceeds (after deducting commissions and other offering expenses) of $<ix:nonFraction unitRef="usd" contextRef="i66deeb6acb77474a959a2ca2688e2657_D20200101-20200331" decimals="-5" format="ixt:num-dot-decimal" name="akba:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMTQ5Mg_493b034d-e11e-4492-a306-dd5a72b7ab47">56.7</ix:nonFraction> million. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2020, the Company filed a prospectus supplement relating to the sales agreement, pursuant to which it was able to offer and sell up to $<ix:nonFraction unitRef="usd" contextRef="i7a4aafef7ebc4f4dbc4da7e3e7952d94_D20200312-20200312" decimals="-5" format="ixt:num-dot-decimal" name="akba:CommonStockSalesAgreementAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMTY0NA_d601a59a-263f-4b38-8d0e-0ca3b3b9fb79">65.0</ix:nonFraction> million of its common stock at current market prices from time to time. Through December&#160;31, 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="ia6fcc0f0e17240bd92fefbacdd946b14_D20200101-20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMTc0MA_1746ab7e-4a71-453f-bbfc-bedd4082a529">3,509,381</ix:nonFraction> shares of common stock under this program with net proceeds (after deducting commissions and other offering expenses) of $<ix:nonFraction unitRef="usd" contextRef="ia6fcc0f0e17240bd92fefbacdd946b14_D20200101-20201231" decimals="-5" format="ixt:num-dot-decimal" name="akba:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMTg2NA_96a11b56-ad64-49f8-a2de-0046c2a79f0f">10.6</ix:nonFraction>&#160;million. During the three months ended March 31, 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i48ac3ceb90a14e55a606e7ed5d3716d1_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMTkzMQ_ff408765-5398-4369-9eea-381f89fa4c74">5,224,278</ix:nonFraction> shares of common stock under this program with net proceeds (after deducting commissions and other offering expenses) of $<ix:nonFraction unitRef="usd" contextRef="i48ac3ceb90a14e55a606e7ed5d3716d1_D20210101-20210331" decimals="-5" format="ixt:num-dot-decimal" name="akba:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMjA1NQ_95a43a63-3ebf-4fe2-8346-ab5bff67f29b">15.9</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2021, the Company filed a prospectus relating to the sales agreement with its new shelf registration statement (which replaced the prior shelf registration statement and the sales agreement prospectus supplement), pursuant to which it is able to offer and sell up to $<ix:nonFraction unitRef="usd" contextRef="i678d4d68b8d44706b86e94178a818447_D20210225-20210225" decimals="-5" format="ixt:num-dot-decimal" name="akba:CommonStockSalesAgreementAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMjM0Mw_e01c4dbc-763c-42f8-a905-f15f42f4900e">100.0</ix:nonFraction>&#160;million of its common stock at current market prices from time to time. During the three and nine months ended September&#160;30, 2021 and through the date of this Quarterly Report on Form 10-Q, the Company sold <ix:nonFraction unitRef="shares" contextRef="i7c3f11e1bf924040bbe2698d14b92960_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMjUyOA_ead8076d-77f2-4449-9f89-b983a0ffb052">4,730,466</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i45bac3731ae447399855606573e4e297_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMjUzNQ_d9764576-2822-42db-a607-f90025d6671d">19,180,365</ix:nonFraction> shares of common stock under this program with net proceeds (after deducting commissions and other offering expenses) of $<ix:nonFraction unitRef="usd" contextRef="i7c3f11e1bf924040bbe2698d14b92960_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="akba:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMjY1OQ_7ac4729e-1095-46a8-90dc-b08baac6a2c3">16.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i45bac3731ae447399855606573e4e297_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="akba:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMjY2Ng_c78505a5-2c75-4874-8f6f-99698e69e837">67.2</ix:nonFraction> million, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Plans</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains one stock incentive plan, the 2014 Incentive Plan, or the 2014 Plan, as well as the 2014 Employee Stock Purchase Plan, or the 2014 ESPP. The 2014 Plan replaced the Company&#8217;s Amended and Restated 2008 Equity Incentive Plan, or the 2008 Plan, however, options or other awards granted under the 2008 Plan prior to the adoption of the 2014 Plan that have not been settled or forfeited remain outstanding and effective. On June 6, 2019, the Company&#8217;s shareholders approved the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie32bb40c9b1242c9adab30a7b7463110" continuedAt="i42b205072ad44b60a00b4921c79d9238"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amended and Restated 2014 Employee Stock Purchase Plan, or the ESPP. The Company also maintains an inducement award program that is separate from the Company's equity plans under which inducement awards may be granted consistent with Nasdaq Listing Rule 5635(c)(4). During the nine months ended September&#160;30, 2021, the Company granted <ix:nonFraction unitRef="shares" contextRef="ic405d5f9a6194033b54c67f003fb5108_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMzUwNw_199a2eb1-ad51-4a32-8ddd-26ce3f28f3d1">1,228,200</ix:nonFraction> options to purchase shares of the Company&#8217;s common stock to new hires as inducements material to such employees' entering into employment with the Company, of which <ix:nonFraction unitRef="shares" contextRef="id8e692bb054345cb9980a00457fd17f1_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMzY3NQ_6402089c-a073-4871-a518-1f94bc9299fa">1,154,200</ix:nonFraction> options remained outstanding as of September&#160;30, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2014 Plan allows for the granting of stock options, stock appreciation rights, or SARs, restricted stock, unrestricted stock, RSUs, performance awards and other awards convertible into or otherwise based on shares of the Company&#8217;s common stock. Dividend equivalents may also be provided in connection with an award under the 2014 Plan. The Company&#8217;s employees, officers, directors and consultants and advisors are eligible to receive awards under the 2014 Plan. The Company initially reserved <ix:nonFraction unitRef="shares" contextRef="i1a334797d16148a8bc4de0e3cd01d3a6_I20140228" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNDI0MA_024dc522-d538-49dd-b810-5faa329427d9">1,785,000</ix:nonFraction> shares of its common stock for the issuance of awards under the 2014 Plan. The 2014 Plan provides that the number of shares reserved and available for issuance under the 2014 Plan will automatically increase annually on January&#160;1 of each calendar year, by an amount equal to three percent (<ix:nonFraction unitRef="number" contextRef="i24f27ec785a94f77bff6f9932edbe262_D20210101-20210930" decimals="INF" name="akba:AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNDUzMw_2d512bbc-4182-4551-9c9b-85e495c8f766">3</ix:nonFraction>%)&#160;of the number of Akebia Shares (as defined in Note 1 of the 2020 Annual Report on Form 10-K) outstanding on a fully diluted basis as of the close of business on the immediately preceding December&#160;31, or the 2014 Plan Evergreen Provision. The Company&#8217;s Board of Directors may act prior to January&#160;1 of any year to provide that there will be no automatic increase in the number of Akebia Shares available for grant under the 2014 Plan for that year (or that the increase will be less than the amount that would otherwise have automatically been made). On December 12, 2018, in connection with the consummation of the Merger, the Company assumed outstanding and unexercised options to purchase Keryx Shares (as defined in Note 1 of the 2020 Annual Report on Form 10-K), as adjusted by the Exchange Multiplier pursuant to the terms of the Merger Agreement, under the following Keryx equity plans, or the Keryx Equity Plans: the Keryx 1999 Share Option Plan, the Keryx 2004 Long-Term Incentive Plan, the Keryx 2007 Incentive Plan, the Keryx Amended and Restated 2013 Incentive Plan, and the Keryx 2018 Equity Incentive Plan, or the Keryx 2018 Plan. In addition, the number of Keryx Shares available for issuance under the Keryx 2018 Plan, as adjusted by the Exchange Multiplier pursuant to the terms of the Merger Agreement, may be used for awards granted by the Company under its 2014 Plan, or the Assumed Shares, provided that the Company uses the Assumed Shares for individuals who were not employees or directors of the Company prior to the consummation of the Merger.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants annual service-based stock options to employees under the 2014 Plan. During the nine months ended September&#160;30, 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="i928990fc0f0544d7bdc2c92d83eb4503_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNjExMw_4397c920-4caf-4e6f-9f00-7fcbf5f11906">1,997,200</ix:nonFraction> options to employees. In addition, the Company issues stock options </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to directors, new hires and occasionally to other employees not in connection with the annual grant process. During the nine months ended September&#160;30, 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="i8c0679f11ab54281a697554a5d1b0a16_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNjM1MA_4f48ba63-52e4-4d02-a932-47ff7263babe">200,800</ix:nonFraction> options to directors under the 2014 Plan. Options granted by the Company vest over periods of between <ix:nonNumeric contextRef="if883a99477df492ebd6e2365f0c4bb6a_D20210101-20210930" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNjQ1NQ_60603d25-115e-412f-9d12-1e5d9f7c7f2b">12</ix:nonNumeric> and <ix:nonNumeric contextRef="ic68dc20e53ac4d9f9315ecf7c3ede580_D20210101-20210930" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNjQ2Mg_b15e168e-f31b-420a-9ea2-6cf8bf0c90e4">48</ix:nonNumeric> months, subject, in each case, to the individual&#8217;s continued service through the applicable vesting date. Options vest either <ix:nonFraction unitRef="number" contextRef="i67dd5c6046f64d0e9109b42763967f24_D20210101-20210930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNjU4NA_d2c2ee25-764c-4448-a5c8-816620a5621c">100</ix:nonFraction>% on the first anniversary of the grant date or in installments of (i) <ix:nonFraction unitRef="number" contextRef="i8f98c7914a2d4498b3182d130d0cb47a_D20210101-20210930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNjY1Ng_16e3fa01-3b00-4e1b-b840-11d9ffb28caf">25</ix:nonFraction>% at the <ix:nonNumeric contextRef="i8f98c7914a2d4498b3182d130d0cb47a_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNjY2Ng_73e67ff8-a235-4b72-83a5-91a4baf6c36c">one year</ix:nonNumeric> anniversary and (ii) <ix:nonFraction unitRef="installment" contextRef="ib0f30762d9654703a976783f7172781a_D20210101-20210930" decimals="INF" name="akba:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNjY5MA_37240d88-bb79-4fec-a852-d3eb3ab003f0">12</ix:nonFraction> equal quarterly installments beginning after the <ix:nonNumeric contextRef="ib0f30762d9654703a976783f7172781a_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNjc0Mg_15b7e905-942e-471c-bbb3-47cfb54f1e5f">one year</ix:nonNumeric> anniversary of the grant date, subject to the individual&#8217;s continuous service with the Company. Options generally expire <ix:nonNumeric contextRef="i010b303706c744e2922ea62d41c6df9a_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNjg2Ng_84174d76-d64f-4a5f-97fb-dfaa12c3e897">10</ix:nonNumeric> years after the date of grant.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also grants performance-based stock options to employees under the 2014 Plan.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The performance-based stock options granted by the Company vest in connection with the achievement of specified commercial and regulatory milestones. The performance-based stock options also feature a time-based vesting component. The expense recognized for these awards is based on the grant date fair value of the Company&#8217;s common stock multiplied by the number of options granted and recognized over time based on the probability of meeting such commercial and regulatory milestones.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company issued <ix:nonFraction unitRef="shares" contextRef="i2dd32faea92444fe9357160c0a7b15cc_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMTY0OTI2NzQ1NTI1MQ_c7f6650b-af54-4ea2-ad1c-b55d84539c38">99,558</ix:nonFraction> performance-based stock options during the nine months ended September&#160;30, 2021.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company also grants annual service-based restricted stock units, or RSUs to employees under the 2014 Plan. During the nine months ended September&#160;30, 2021, the Com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">pany issued <ix:nonFraction unitRef="shares" contextRef="i8a366e7c1d9547a89b545b4c5b2edc75_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNzA2Mg_0b52dfdd-0dfd-4691-b542-7b390d51652d">3,396,012</ix:nonFraction> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">RSUs to employees. In addition, the Company issued <ix:nonFraction unitRef="shares" contextRef="id8c33b8456b445388314a4b181f4ad55_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNzExNg_096be165-6ec9-473e-a5ba-5a665637c10b">82,200</ix:nonFraction> RSUs to directors under the 2014 Plan during the nine months ended September&#160;30, 2021. The Company also occasionally issues RSUs not in connection with the annual grant process to employees. Generally, RSUs granted by the Company vest in one of the following ways: (i) <ix:nonFraction unitRef="number" contextRef="id334eb22f65f47a2b8f9ed60a00a7faf_D20210101-20210930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNzM3MQ_5dba28b7-ed7f-42c8-b7be-0325bceb9ab7">100</ix:nonFraction>% of each RSU grant vests on either the first anniversary of the grant date, (ii) one third of each RSU grant vests on the first, second and third anniversaries of the grant date, or (iii) <ix:nonFraction unitRef="number" contextRef="i700b68cc599f4438ba55fcd9dc69cd7a_D20210101-20210930" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNzY3Mg_b17a0e17-d3ab-48a1-adb7-6830b48df9da">50</ix:nonFraction>% of each RSU grant vests on the first anniversary and <ix:nonFraction unitRef="number" contextRef="i73aee313a7a7411d983faf613acc515c_D20210101-20210930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNzcyOA_98b8b8f7-2d4a-4696-869a-c84237cf662d">25</ix:nonFraction>% of each RSU grant vests every <ix:nonNumeric contextRef="i73aee313a7a7411d983faf613acc515c_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNzc2MQ_0c42b08f-0192-4cb2-ac60-ac5a8d9cc2cd">six months</ix:nonNumeric> after the <ix:nonNumeric contextRef="i73aee313a7a7411d983faf613acc515c_D20210101-20210930" format="ixt-sec:durwordsen" name="akba:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNzc3NA_a81dcbe8-050d-42ec-b153-98d293b616f8">one year</ix:nonNumeric> anniversary of the grant date, subject, in each case, to the individual&#8217;s continued service through the applicable vesting date. The expense recognized for these awards is based on the grant date fair value of the Company&#8217;s common stock multiplied by the number of units granted and recognized on a straight-line basis over the vesting period. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company also grants performance-based restricted stock units, or PSUs to employees under the 2014 Plan. The PSUs granted by the Company vest in connection with the achievement of specified commercial and regulatory milestones. The PSUs also feature a time-based vesting component. The expense recognized for these awards is based on the grant date fair value of the Company&#8217;s common stock multiplied by the number of units granted and recognized over time based on the probability of meeting such commercial and regulatory milestones.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> The Company issued <ix:nonFraction unitRef="shares" contextRef="i6fe3737b757e4dcb9d9bd2fd3a908513_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMTY0OTI2NzQ1NTI0NA_44524b26-904f-471d-a4d1-6af2e7d26e0b">37,150</ix:nonFraction> PSUs during the nine months ended September&#160;30, 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i42b205072ad44b60a00b4921c79d9238">The ESPP provides for the issuance of options to purchase shares of the Company&#8217;s common stock to participating employees at a discount to their fair market value. As noted above, the Company&#8217;s stockholders approved the ESPP, which amended and restated the Company&#8217;s 2014 ESPP, on June 6, 2019. As of September&#160;30, 2021, the maximum aggregate number of shares of the Company&#8217;s common stock available for future issuance under the ESPP is <ix:nonFraction unitRef="shares" contextRef="i02cb18bdb22b463a8143eb77464ade75_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfOTA2MA_92575872-6a9f-40a0-8c65-7b7821a89c7d">5,173,141</ix:nonFraction>. Under the ESPP, each offering period is <ix:nonNumeric contextRef="ie796bd13e7ae4237ba6a1435f0aa706a_D20210101-20210930" format="ixt-sec:durwordsen" name="akba:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfOTEwNA_b206c1b2-3aba-4110-835e-4a1a7e57ad69">six months</ix:nonNumeric>, at the end of which employees who elect to purchase shares of the Company&#8217;s common stock through payroll deductions made over the term of the offering. The per-share purchase price at the end of each offering period is equal to the lesser of eighty-five percent (<ix:nonFraction unitRef="number" contextRef="ie796bd13e7ae4237ba6a1435f0aa706a_D20210101-20210930" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfOTM2Mg_ba43533c-0e21-4b8b-964e-e1d1f0648431">85</ix:nonFraction>%) of the closing price of the Company&#8217;s common stock at the beginning or end of the offering period. The Company issued <ix:nonFraction unitRef="shares" contextRef="ie796bd13e7ae4237ba6a1435f0aa706a_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfOTQ4NA_7b595627-1614-4c68-9376-e806b6b4c77c">307,193</ix:nonFraction> shares under the ESPP during the nine months ended September&#160;30, 2021.</ix:continuation></span></div><div><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_82"></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTcwNTA_ca1dc4e6-f0c6-48f3-a8ef-8559f0711dbc" continuedAt="i9b2013cf40374f41ad04afd84859fb98" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i9b2013cf40374f41ad04afd84859fb98" continuedAt="iaa90c0de66134253b1454d9c0b846169"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="i8c4a114c87d04f9a86f0cd36147b5c17_I20201130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNzY_a84e7900-61d4-41a0-bb48-42aba064759b">65,167</ix:nonFraction> square feet of office and lab space in Cambridge, Massachusetts under a lease which was most recently amended in November 2020, collectively the Cambridge Lease. Under the Third Amendment to the Cambridge Lease, or the Third Amendment, executed in July 2016, total monthly lease payments under the initial base rent were approximately $<ix:nonFraction unitRef="usd" contextRef="i2f8032b3bd82471cbcff6a003f19e33b_D20160701-20160731" decimals="-3" format="ixt:num-dot-decimal" name="akba:OperatingLeaseAnnualRentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNDE0_38bc9b5d-96fd-4abe-bb8b-59da9834b431">242,000</ix:nonFraction> and are subject to annual rent escalations.&#160;In addition to such annual rent escalations, base rent payments for a portion of said premises commenced on January 1, 2017 in the monthly amount of approximately $<ix:nonFraction unitRef="usd" contextRef="i1ee517b85db6461e9394aeeb76fb30a0_D20170101-20170101" decimals="-3" format="ixt:num-dot-decimal" name="akba:OperatingLeaseMonthlyRentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNjEx_52f532f9-cb7e-474e-84c0-babf7ae71796">22,000</ix:nonFraction>. The Fourth Amendment to the Cambridge Lease, executed in May 2017, provided additional storage space to the Company and did not impact rent payments. In April 2018, the Company entered into a Fifth Amendment to the Cambridge Lease, or the Fifth Amendment, for an additional <ix:nonFraction unitRef="sqft" contextRef="ibe11b29f86744551b0e34d4c7a45321d_I20180430" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfODg5_5ce5a26c-3893-45d4-a1ea-2d2593889d5d">19,805</ix:nonFraction> square feet of office space on the 12t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">h</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> floor. Monthly lease payments for the existing <ix:nonFraction unitRef="sqft" contextRef="i2085d352fbe244bfae6189887c1b70b1_I20160731" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfOTc5_71ee5dc0-6985-42a0-8ead-9fa76e7eecfa">45,362</ix:nonFraction> square feet of office and lab space, under the Third Amendment, remain unchanged. The new space leased by the Company was delivered in September 2018 and additional monthly lease payments of approximately $<ix:nonFraction unitRef="usd" contextRef="ifc753862bba346a4b87baf73046febb4_D20190201-20190228" decimals="-3" format="ixt:num-dot-decimal" name="akba:OperatingLeaseMonthlyRentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTE4Nw_d04d4012-61fd-4760-9149-989e776abaa5">135,000</ix:nonFraction> commenced in February 2019 and are subject to annual rent escalations, which commenced in September 2019. In November 2020, the Company entered into a Sixth Amendment to the Cambridge Lease, or the Sixth Amendment, to extend the term of the Cambridge Lease with respect to the lab space from November 30, 2021 to January 31, 2025. The Sixth Amendment includes <ix:nonNumeric contextRef="i319033b22a7e40f680e6a60fdad1e84d_D20201201-20201231" format="ixt-sec:durwordsen" name="akba:OperatingLeaseFreeMonthlyRentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTU1MA_afbd8895-57f4-4b48-a268-971eed9bbb79">two months</ix:nonNumeric> of free rent starting in December 2020 and additional monthly lease payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i7f13ec3e12bf451caafb2291ffc4a2a8_D20211201-20211231" decimals="0" format="ixt:num-dot-decimal" name="akba:OperatingLeaseMonthlyRentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTY0Nw_77e706b8-45fb-4e96-9f48-321c9950a999">48,000</ix:nonFraction> commencing in December 2021, and is subject to annual rent escalations, which commence in December 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, as a result of the Merger, the Company has a lease for <ix:nonFraction unitRef="sqft" contextRef="i395d6be571b646d2a729d3d38b72c91b_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTgyNQ_6d532524-5ca4-4fa4-bc73-1fa0a9ecb893">27,300</ix:nonFraction> square feet of office space in Boston, Massachusetts, or the Boston Lease, which expires in February 2023. The total monthly lease payments under the base rent are approximately $<ix:nonFraction unitRef="usd" contextRef="i36039c1763334766b650c9db8ccac9a8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:OperatingLeaseMonthlyRentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTk5NQ_dd748911-ff2b-4a1a-adc5-a04da10c128a">136,000</ix:nonFraction> and are subject to annual rent escalations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Cambridge Lease with respect to the office space expires on September&#160;11, 2026, with <ix:nonFraction unitRef="extensionoption" contextRef="iae8a04efe54e4e2cba598fe2b46d3589_I20210930" decimals="INF" format="ixt-sec:numwordsen" name="akba:LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMjEyOA_3336642f-3421-4149-b5d5-4bad1f17361c">one</ix:nonFraction> <ix:nonNumeric contextRef="iae8a04efe54e4e2cba598fe2b46d3589_I20210930" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTcwNTE_ce44fa73-4c3c-43ee-96eb-f82476d50bcf">five-year</ix:nonNumeric> extension option available. The term of the Boston Lease office space expires on February&#160;28, 2023, with an extension option for <ix:nonFraction unitRef="extensionoption" contextRef="i3f8574ce39ac48ada29733a02df6fe06_I20210930" decimals="INF" format="ixt-sec:numwordsen" name="akba:LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMjI1Mw_188899e0-97eb-4869-8e50-77e4617366b2">one</ix:nonFraction> additional <ix:nonNumeric contextRef="i3f8574ce39ac48ada29733a02df6fe06_I20210930" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTcwNTI_acc19e1b-cc0d-4743-b939-6bf75e0037e9">five-year</ix:nonNumeric> term available. The renewal options in these real estate leases were not included in the calculation of the operating lease assets and operating lease liabilities as the renewal is not reasonably certain. The term of the Cambridge Lease with respect to the lab space expires on January&#160;31, 2025, with an extension option for one additional period through September&#160;11, 2026. The renewal option in this real estate lease was included in the calculation of the operating lease assets and operating lease liabilities as the renewal is reasonably certain. The lease agreements do not contain residual value guarantees. Operating lease costs were $<ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMjgyNw_20e83c03-edfe-492a-85d2-f9daddbf4df2"><ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMjgyNw_cf3bbcbb-437b-4360-833f-181f90a2bb9c">1.7</ix:nonFraction></ix:nonFraction> million for each of the three months ended September&#160;30, 2021 and 2020 and $<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMjg3OQ_0cd96eee-d1c6-488c-b5cc-8bd175a118bd"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMjg3OQ_6d974785-8259-4030-bc90-41919012257c">5.0</ix:nonFraction></ix:nonFraction> million for each of the nine months ended September&#160;30, 2021 and 2020. Cash paid for amounts included in the measurement of operating lease liabilities was $<ix:nonFraction unitRef="usd" contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMzAxMQ_2241e56d-5f2f-41d7-a289-84f918a6f890"><ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMzAxMQ_4d93dea0-18af-4f0b-bea0-333ce8907e60">1.8</ix:nonFraction></ix:nonFraction> million for each of the three months ended September&#160;30, 2021 and 2020 and $<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMzA2Mw_9b7ba49a-1421-4e09-a297-1c96ab6a01d7"><ix:nonFraction unitRef="usd" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMzA2Mw_a9a182f0-fb8b-4c2b-93a2-46255ffbdd6a">5.3</ix:nonFraction></ix:nonFraction> million for each of the nine months ended September&#160;30, 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, Keryx entered into an agreement to sublease the Boston office space to Foundation Medicine, Inc., or Foundation. The sublease is subject and subordinate to the Boston Lease between Keryx and the landlord. The term of the sublease commenced on October&#160;16, 2019, upon receipt of the required consent from the landlord for the sublease agreement, and expires on February&#160;27, 2023. Foundation is obligated to pay Keryx rent that approximates the rent due from Keryx to its landlord with respect to the Boston Lease. Sublease rental income is recorded to other income. Keryx continues to be obligated for all payment terms pursuant to the Boston Lease, and the Company will guaranty Keryx&#8217;s obligations under the sublease. Keryx recorded $<ix:nonFraction unitRef="usd" contextRef="ibbf6fa923bcf4b2b92e43786d4da64a2_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMzg0OA_13c4e309-5959-4450-8483-c40e2bf0c922"><ix:nonFraction unitRef="usd" contextRef="i9b38f2f3c3db48cdacc6e3dab5c4477a_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMzg0OA_c909ebec-eeb5-44a5-8183-a856407d0998">0.4</ix:nonFraction></ix:nonFraction> million in sublease rental income from Foundation during each of the three months ended September&#160;30, 2021 and 2020 and $<ix:nonFraction unitRef="usd" contextRef="ib8e6a7b6910d48e294bcb23008415abd_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMzk0NQ_16183bd0-849c-449a-a396-d340bb889abc"><ix:nonFraction unitRef="usd" contextRef="i99da615448e74f1b956e0da8fde046d6_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMzk0NQ_4b540079-2f1c-4630-9919-e808069a8e17">1.3</ix:nonFraction></ix:nonFraction> million during each of the nine months ended September&#160;30, 2021 and 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not entered into any material short-term leases or financing leases as of September&#160;30, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total security deposit in connection with the Cambridge Lease is $<ix:nonFraction unitRef="usd" contextRef="i2521a8d2d711470090bd6f68bb353f22_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNDE2MA_7a0c9751-9aa8-414d-9547-6a0e082b0989">1.6</ix:nonFraction> million as of September&#160;30, 2021. Additionally, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i0dca46c47d4447088630d11a10807fbe_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNDIwOA_31f297e4-ddd7-4e0d-8bfb-2d4b843e2d5c">0.4</ix:nonFraction> million for the security deposit under the Boston Lease. Both the Cambridge Lease and the Boston Lease have their security deposits in the form of a letter of credit, all of which are included as restricted cash in other assets in the Company&#8217;s unaudited condensed consolidated balance sheets as of September&#160;30, 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="iaa90c0de66134253b1454d9c0b846169" continuedAt="i4335f5797c2d48c4a8113f5b831d07c8"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTcwNTM_8563c7ef-c6d7-4916-80e3-5eab19ff7b0b" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, undiscounted minimum rental commitments under non-cancelable leases, for each of the next five years and total thereafter are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Payments<br/>to be Received<br/>from Sublease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Operating<br/>Lease Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfMi0xLTEtMS0yMjM1Nw_a7b204ce-82aa-437f-8683-7b9082dc6cbd">1,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfMi0zLTEtMS0yMjM1Nw_73131cc0-e14a-4fb3-b02f-99b40e3f6067">454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfMi01LTEtMS0yMjM1Nw_6d2b2ffa-ac75-4795-add5-5f6883a18965">1,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfMy0xLTEtMS0yMjM1Nw_9bfdd798-0cca-4e65-9071-757c89cf336c">7,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfMy0zLTEtMS0yMjM1Nw_610558f5-3bfa-4068-b50a-c2e14fa5a3ff">1,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfMy01LTEtMS0yMjM1Nw_6375fe97-d454-4697-b11c-156b1523857d">5,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfNC0xLTEtMS0yMjM1Nw_2a4fb828-dc08-40b0-abe3-b4bad71326b2">5,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfNC0zLTEtMS0yMjM1Nw_394760e1-5734-469f-a160-ec4d6ac2ca4f">307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfNC01LTEtMS0yMjM1Nw_c3d404d9-f736-418e-b823-994ddeb69406">5,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfNS0xLTEtMS0yMjM1Nw_b2fdff4e-adbc-43e9-8c2e-95ccde3a6d47">5,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfNS0zLTEtMS0yMjM1Nw_3902a79a-5a79-418d-97a9-46259224563a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfNS01LTEtMS0yMjM1Nw_9f790c75-fa4f-4e79-bf0a-450eeab43f8b">5,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfNi0xLTEtMS0yMjM1Nw_1931e0b9-d4f5-4dea-b049-66eea36af948">5,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfNi0zLTEtMS0yMjM1Nw_33a41dd1-1a0e-430b-992d-bf1932caa54e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfNi01LTEtMS0yMjM1Nw_df89903c-0a45-4201-9355-27e7d973f476">5,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfNy0xLTEtMS0yMjM1Nw_ea696d7a-fe4f-4713-b0c1-3a98092a497f">4,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:fixed-zero" name="akba:LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfNy0zLTEtMS0yMjM1Nw_748f8052-4954-4818-873a-0ed1fffdae93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfNy01LTEtMS0yMjM1Nw_6c7984bf-41a2-415a-940c-05a3bbdb717a">4,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfOC0xLTEtMS0yMjM1Nw_918770c7-08a4-422f-b5b4-835582f96e65">30,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfOC0zLTEtMS0yMjM1Nw_6a8648ec-101b-4fc3-90b5-533faa5af737">2,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="akba:LesseeOperatingLeaseLiabilityPaymentsDueNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfOC01LTEtMS0yMjM1Nw_2f62de59-9da6-4ec0-97ce-fcc21a0be26d">28,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arriving at the operating lease liabilities, the Company applied incremental borrowing rates ranging from <ix:nonFraction unitRef="number" contextRef="i0784525677704a0f9da4e0961490be27_I20210930" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNDc2OA_5e220e61-6e24-4b22-9e5f-064b8097443f">6.22</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="if648f232fd8d44f2853c2848e528087c_I20210930" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNDc3NA_0a7b7ce7-4a02-4dfc-a4a0-a4f385e1ec4e">6.94</ix:nonFraction>%, which were based on the remaining lease term at either the date of adoption of ASC 842 or the effective date of any subsequent lease term extensions. As of September&#160;30, 2021, the remaining lease terms ranged from <ix:nonNumeric contextRef="i0784525677704a0f9da4e0961490be27_I20210930" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNDk3Ng_a58e4464-fd92-4d6f-9cd2-d9bc1c4f9c5d">1.41</ix:nonNumeric> years to <ix:nonNumeric contextRef="if648f232fd8d44f2853c2848e528087c_I20210930" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNDk4Mg_3896d8b0-4f18-4865-a7d5-9f2b2f4ba8e3">4.95</ix:nonNumeric> years. <ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="akba:ScheduleOfDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesAndOperatingLeaseLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTcwNTQ_3dfe1b7d-7d5d-4cfe-9e15-4735b41f840d" continuedAt="i1c67b5fc81af47cd8fbe8613962363d5" escape="true">As of September&#160;30, 2021, the following represents the difference between the remaining undiscounted minimum rental commitments under non-cancelable leases and the operating lease liabilities:</ix:nonNumeric></span></div><ix:continuation id="i1c67b5fc81af47cd8fbe8613962363d5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:81.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating <br/>Leases</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undiscounted minimum rental commitments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOmY2NDc1MWJlODBmNTRjOTY4ZDg5NTUxMjc1NTZjNDVjL3RhYmxlcmFuZ2U6ZjY0NzUxYmU4MGY1NGM5NjhkODk1NTEyNzU1NmM0NWNfMi0xLTEtMS0yMjM1Nw_3a060581-9892-449a-95b4-f65681945d9c">30,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value adjustment using incremental borrowing rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOmY2NDc1MWJlODBmNTRjOTY4ZDg5NTUxMjc1NTZjNDVjL3RhYmxlcmFuZ2U6ZjY0NzUxYmU4MGY1NGM5NjhkODk1NTEyNzU1NmM0NWNfMy0xLTEtMS0yMjM1Nw_2e6e8334-5fc3-4b3c-995c-60ef7e0ece87">4,380</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOmY2NDc1MWJlODBmNTRjOTY4ZDg5NTUxMjc1NTZjNDVjL3RhYmxlcmFuZ2U6ZjY0NzUxYmU4MGY1NGM5NjhkODk1NTEyNzU1NmM0NWNfNC0wLTEtMS0yMjM1Nw_6f24d764-2b2d-4991-9474-8d0770053a51">Operating lease liabilities</span></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOmY2NDc1MWJlODBmNTRjOTY4ZDg5NTUxMjc1NTZjNDVjL3RhYmxlcmFuZ2U6ZjY0NzUxYmU4MGY1NGM5NjhkODk1NTEyNzU1NmM0NWNfNC0xLTEtMS0yMjM1Nw_1d00f0e0-5005-4460-9f84-b4395c50cffe">26,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing Agreements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Merger, the Company's contractual obligations include Keryx&#8217;s commercial supply agreements with BioVectra Inc., or BioVectra, and Siegfried Evionnaz SA, or Siegfried, to supply commercial drug substance for Auryxia.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the Manufacture and Supply Agreement with BioVectra and the Product Manufacture and Supply and Facility Construction Agreement with BioVectra, collectively the BioVectra Agreement, the Company agreed to purchase minimum quantities of Auryxia drug substance annually at predetermined prices. On September 4, 2020, the Company and BioVectra entered into an Amended and Restated Product Manufacture and Supply and Facility Construction Agreement, which provided for reduced minimum quantity commitments and revised the predetermined prices. The price per kilogram decreases with an increase in quantity above the predetermined purchase quantity tiers. In addition, the Manufacture and Supply Agreement with BioVectra and the Amended and Restated Product Manufacture and Supply and Facility Construction Agreement with BioVectra, collectively the Amended BioVectra Agreement, requires the Company to reimburse BioVectra for certain costs in connection with construction of a new facility for the manufacture and supply of Auryxia drug substance. These construction costs are recorded in other assets and amortized into drug substance as inventory is released to the Company from BioVectra. The term of the Manufacture and Supply Agreement with BioVectra expires on December 31, 2022. The term of the Amended and Restated Product Manufacture and Supply and Facility Construction Agreement expires on December 31, 2026, after which it automatically renews for successive <ix:nonNumeric contextRef="if1dd7b6af62e48d89630458d90d092cb_D20200904-20200904" format="ixt-sec:durwordsen" name="akba:LongTermPurchaseCommitmentRenewalPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTcwNDk_7d0e1426-167d-4dd3-a531-489bf15c9702">one-year</ix:nonNumeric> terms unless either party gives notice of its intention to terminate within a specified time prior to the end of the then-current term. In addition, the Company and BioVectra each have the ability to terminate these agreements upon the occurrence of certain conditions. As of September&#160;30, 2021, the Company is required to reimburse BioVectra for certain costs in connection with the construction of the new facility and to purchase minimum quantities of Auryxia drug substance annually for a total cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i03f1a8e55f924ca6b788d5e2067ae377_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="akba:CostOfPurchasedMinimumQuantityProduct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNzQxNw_1272ece4-7f26-40d8-8616-511101d14224">82.9</ix:nonFraction> million through the end of the contract term.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the Siegfried Master Manufacturing Services and Supply Agreement, as amended (the most recent amendment having been executed on February 11, 2021), or the Siegfried Agreement, the Company has agreed to purchase a minimum quantity of drug substance of Auryxia at predetermined prices. The term of the Siegfried Agreement expires on December&#160;31, 2022, subject to our option to extend the term through December 31, 2023 by providing <ix:nonNumeric contextRef="ib2c7ce4bacf943a6ae4661730894183c_D20210101-20210930" format="ixt-sec:durmonth" name="akba:LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNzg4Ng_734e4487-ddd7-4806-8aee-4d2178cab6d4">12</ix:nonNumeric> months&#8217; prior written notice to Siegfried. The Siegfried Agreement provides the Company and Siegfried with certain early termination rights. As of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4335f5797c2d48c4a8113f5b831d07c8" continuedAt="i26b3d97edd4247b4aba3b3e7a147666f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September&#160;30, 2021, the Company is required to purchase a minimum quantity of drug substance for Auryxia annually at a total cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i93ce46eca8a74081a9a0a15945f34ee2_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="akba:CostOfPurchasedMinimumQuantityProduct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfODE2MA_29f22caf-1130-41aa-9f24-10e74f9e8fc6">27.7</ix:nonFraction> million through the year ending December 31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of purchase accounting, the Company identified executory contracts in the commercial supply agreements between Keryx and its contract manufacturers for Auryxia, which include future firm purchase commitments. These executory contracts were deemed to have an off-market element related to the amount of purchase commitments that exceed the current forecast. The Company regularly reviews its estimate of the excess purchase commitment liability including a review of assumptions of expected future demand, estimates of anticipated expiry of inventory under firm purchase commitments that are estimated to expire before they could be sold as well as any modifications to supply agreements during each reporting period. The excess purchase commitment liability relating to these executory contracts was $<ix:nonFraction unitRef="usd" contextRef="i3ce765a46da74d3ebd33dec7f304c9a8_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="akba:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNzY5NjU4MTQxMjkzNQ_8c2daca8-dedc-4535-ba11-2e9fa85632d7">71.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i85c91980832440e88454196ba38dbd5f_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="akba:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNzY5NjU4MTQxMjk0Mw_21642b99-8b9a-486f-841d-e619fa413864">55.8</ix:nonFraction> million as of September&#160;30, 2021 and December&#160;31, 2020, respectively. During the quarter ended September 30, 2021, the Company reviewed the detailed assumptions above and recorded a $<ix:nonFraction unitRef="usd" contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930" decimals="-6" sign="-" name="akba:ExcessInventoryPurchaseCommitmentsExpenseReversal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTY0OTI2NzQ2MDgwMA_2eddafa1-19c4-4885-aefa-801e96463691">6.0</ix:nonFraction> million reduction to the excess purchase commitments liability within cost of goods sold. The reduction to the excess purchase commitments liability was primarily due to the settlement of all patent litigation proceedings related to Abbreviated New Drug Applications filed with respect to Auryxia, which allows for generic versions of Auryxia beginning in March 2025. The Company recognized this non-cash gain in accordance with ASC 270 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interim Reporting, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">specifically ASC 270-10-45-6(c) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other Presentation Matters, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">which allows for recovery of losses on the same inventory in later interim periods of the same fiscal year as long as the as long as the recovery of losses does not exceed the previously recognized loss. During the quarter ended June 30, 2021, the Company completed a routine update of its long-range plan and related estimates of expiry. This routine update included the impact of recent activity with regards to our long-term payor contract strategy which continues to focus on contract economics and net revenue growth and resulted in a $<ix:nonFraction unitRef="usd" contextRef="i02a8ba6ff0054b678403f9ad5ed7efc4_D20210401-20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostDirectMaterial" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTY0OTI2NzQ2MzExNQ_44fe6b3c-3be0-4805-8daa-37a09d7d2ed2">30.3</ix:nonFraction> million charge to cost of goods sold during the quarter ended June&#160;30, 2021. In addition, as of June&#160;30, 2021, the Company also considered whether this increase was a potential indicator of impairment of the Auryxia asset group as of June&#160;30, 2021. As part of its assessment, the Company reviewed the Auryxia net sales and estimated future cash flows included in its long-range plan and concluded that the increase in excess purchase commitment liability was not an indicator of impairment of the Auryxia asset group as of June&#160;30, 2021. In addition, during the first quarter ended March 31, 2021, the Company recorded a non-cash gain to cost of goods sold of $<ix:nonFraction unitRef="usd" contextRef="ib0bd0fdce45f4f2eb878365dff48b0ae_D20210101-20210331" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="akba:ExcessInventoryPurchaseCommitmentsExpenseReversal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTAxMTM_128d4e8e-97a0-41f4-9a2b-2404a95a663b">9.0</ix:nonFraction> million driven largely by a reduction in purchase commitments due to the amendment to the Siegfried Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 9, 2019, the Company entered into a Supply Agreement with Esteve Qu&#237;mica, S.A., or Esteve, or the Esteve Agreement. The Esteve Agreement includes the terms and conditions under which Esteve will manufacture vadadustat drug substance for commercial use. Pursuant to the Esteve Agreement, the Company provides rolling forecasts to Esteve on a quarterly basis, or the Esteve Forecast. The Esteve Forecast reflects the Company&#8217;s needs for vadadustat drug substance produced by Esteve over a certain number of months, represented as a quantity of vadadustat drug substance per calendar quarter. The parties have agreed to a volume-based pricing structure under the Esteve Agreement. The Esteve Agreement has an initial term of <ix:nonNumeric contextRef="i49ee8d5e6ee44e0aa71f48df84288db0_D20190409-20190409" format="ixt-sec:durwordsen" name="akba:InitialTermOfSupplyAgreement" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTA5ODQ_bea0b8ac-9452-4a07-9236-2965bcc54912">four years</ix:nonNumeric>, beginning April 9, 2019 and ending April 9, 2023. Pursuant to the Esteve Agreement, the Company has agreed to purchase a certain percentage of the global demand for vadadustat drug substance from Esteve. As of September&#160;30, 2021, the Company has committed to purchase $<ix:nonFraction unitRef="usd" contextRef="ia777a099e6224fe895fa66b20db9e666_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermPurchaseCommitmentAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTEyNDA_7de03ebf-ffaf-46cf-8282-4492d6055361">34.4</ix:nonFraction> million of vadadustat drug substance from Esteve through the fourth quarter of 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On March 11, 2020, the Company entered into a Supply Agreement with Patheon Inc., or Patheon, or the Patheon Agreement. The Patheon Agreement includes the terms and conditions under which Patheon will manufacture vadadustat drug product for commercial use. Pursuant to the Patheon Agreement, the Company provides Patheon a long-term forecast on an annual basis, as well as short-term forecasts on a quarterly basis, or the Patheon Forecast. The Patheon Forecast reflects the Company&#8217;s needs for commercial supply of vadadustat drug product produced by Patheon, represented as a quantity of drug product per calendar quarter. The parties have agreed to a volume-based pricing structure under the Patheon Agreement. The Patheon Agreement has an initial term beginning March 11, 2020 and ending June 30, 2023. Pursuant to the Patheon Agreement, the Company has agreed to purchase a certain percentage of the global demand for vadadustat drug product from Patheon. As of September&#160;30, 2021, the Company had a minimum commitment with Patheon for $<ix:nonFraction unitRef="usd" contextRef="ifc3ad8cedbf646a3badc26d2e706ac87_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTIzNDY_5cd4181e-9d8f-4dcd-b3e4-c9216b39eeb6">4.2</ix:nonFraction> million through the third quarter of 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On April 2, 2020, the Company entered into a Supply Agreement with STA Pharmaceutical Hong Kong Limited, a subsidiary of WuXi AppTec, or WuXi STA, as amended on April 15, 2021, or the WuXi STA DS Agreement. The WuXi STA DS Agreement includes the terms and conditions under which WuXi STA will manufacture vadadustat drug substance for commercial use. Pursuant to the WuXi STA DS Agreement, the Company provides rolling forecasts to WuXi STA on a quarterly basis, or the WuXi STA DS Forecast. The WuXi STA DS Forecast reflects the Company&#8217;s needs for vadadustat drug substance produced by WuXi STA over a certain number of quarters. The parties have agreed to a volume-based pricing structure under the WuXi STA DS Agreement. The WuXi STA DS Agreement has an initial term of <ix:nonNumeric contextRef="ifa82e47edba04966993a43c23b18a792_D20200402-20200402" format="ixt-sec:durwordsen" name="us-gaap:LongtermPurchaseCommitmentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTMxMjk_04140c53-8c49-490b-ace2-dc670d4f2093">four years</ix:nonNumeric>, beginning April 2, 2020 and ending April 2, 2024.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Pursuant to the WuXi STA DS Agreement, the Company has agreed to purchase a certain percentage of the global demand for vadadustat drug substance from WuXi STA. As of September&#160;30, 2021, the Company has committed to purchase $<ix:nonFraction unitRef="usd" contextRef="i6768bc85e77b42ec85b465655fe66cb8_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LongTermPurchaseCommitmentAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTMzOTI_3e1bea0d-a9ad-4845-a297-5993a61e5b64">44.8</ix:nonFraction> million of vadadustat drug substance from WuXi STA through the end of 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On February 10, 2021, the Company entered into a Supply Agreement with WuXi STA, or the WuXi STA DP Agreement. The WuXi STA DP Agreement includes the terms and conditions under which WuXi STA will manufacture and supply vadadustat </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i26b3d97edd4247b4aba3b3e7a147666f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">drug product for commercial purposes. Pursuant to the WuXi STA DP Agreement, the Company will provide rolling forecasts to WuXi STA on a quarterly basis, or the WuXi STA DP Forecast. Each WuXi STA DP Forecast will reflect the quantities of vadadustat drug product that the Company expects to order from WuXi STA over a certain number of months, represented as a quantity of vadadustat drug product per calendar quarter. Pursuant to the WuXi STA DP Agreement, the Company has agreed to purchase a certain percentage of global demand for vadadustat drug product from WuXi STA. The parties have agreed to a volume-based pricing structure under the WuXi STA DP Agreement. The vadadustat drug product price will remain fixed for the first <ix:nonNumeric contextRef="i1413873e0fc3463794f8307e9bce1a4a_D20210210-20210210" format="ixt-sec:durmonth" name="akba:LongTermPurchaseCommitmentFixedPricePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTQ0Mzk_d4ac4f1c-1456-4d57-bc65-afb601597f1d">12</ix:nonNumeric> months and thereafter shall be annually reviewed by the Company and WuXi STA. The Company will also reimburse WuXi STA for certain reasonable expenses. The WuXi STA DP Agreement has an initial term of <ix:nonNumeric contextRef="i1413873e0fc3463794f8307e9bce1a4a_D20210210-20210210" format="ixt-sec:durwordsen" name="us-gaap:LongtermPurchaseCommitmentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTQ2MzY_7956a8df-8e8c-4372-9c6b-51fa28a257f0">four years</ix:nonNumeric>, beginning February 10, 2021 and ending February 10, 2025. The WuXi STA DP Agreement may be renewed or extended by mutual agreement of the Company and WuXi STA with at least <ix:nonNumeric contextRef="i1413873e0fc3463794f8307e9bce1a4a_D20210210-20210210" format="ixt-sec:durmonth" name="akba:LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTQ4MTM_81122226-f267-48ef-ba22-0fbec57000c2">18</ix:nonNumeric> months&#8217; prior written notice. The WuXi STA DP Agreement allows the Company to terminate the agreement on <ix:nonNumeric contextRef="i1413873e0fc3463794f8307e9bce1a4a_D20210210-20210210" format="ixt-sec:durday" name="akba:LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTQ5MTQ_c6192017-cfe1-41fa-a791-9013f7c1e5e4">180</ix:nonNumeric> calendar days&#8217; prior written notice to WuXi STA for any reason. In addition, each party has the ability to terminate the WuXi STA DP Agreement upon the occurrence of certain conditions.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Third Party Contracts</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s agreement with IQVIA to provide contract research organization services for the PRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TECT and INNO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VATE programs, the total remaining contract costs as of September&#160;30, 2021 were approximately $<ix:nonFraction unitRef="usd" contextRef="i44af4abac88448b5893045bc0002855c_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="akba:PurchaseCommittedProgramRemainingContractCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTUzMjg_646b33a6-2e15-4b0b-9e57-367702d28fde">7.6</ix:nonFraction> million, of which Otsuka reimburses a significant portion back to the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantive performance for the committed work with IQVIA was completed in 2020 and close out activities will be performed throughout 2021. The Company also contracts with various other organizations to conduct research and development activities with remaining contract costs to the Company of approximately $<ix:nonFraction unitRef="usd" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTU3MDk_d8c91153-8ad6-46bb-917e-3d344af15e62">244.4</ix:nonFraction> million at September&#160;30, 2021. The scope of the services under these research and development contracts can be modified and the contracts cancelled by the Company upon written notice. In some instances, the contracts may be cancelled by the third party upon written notice.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation and Related Matters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become subject to legal proceedings and claims which arise in the ordinary course of its business. Consistent with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company&#8217;s policy is to record a liability if a loss in a significant legal dispute is considered probable and an amount can be reasonably estimated. The Company provides disclosure when a loss in excess of any reserve is reasonably possible, and if estimable, the Company discloses the potential loss or range of possible loss. Significant judgment is required to assess the likelihood of various potential outcomes and the quantification of loss in those scenarios. The Company&#8217;s estimates change as litigation progresses and new information comes to light. Changes in Company estimates could have a material impact on the Company&#8217;s results and financial position. As of September&#160;30, 2021, the Company does not have any significant legal disputes that require a loss liability to be recorded. The Company continually monitors the need for a loss liability for litigation and related matters.</span></div></ix:continuation><div><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_85"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84NS9mcmFnOmFkNzhiNmM2ZmE1YzQ3NzRiYzJlMDdhZjkzNzUwNWIyL3RleHRyZWdpb246YWQ3OGI2YzZmYTVjNDc3NGJjMmUwN2FmOTM3NTA1YjJfNjky_36531871-0585-4f65-a9a2-aeb916ffbb77" continuedAt="ia260ab4b5f3349f4b0ab8f23d17df63f" escape="true">Net Loss per Share</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ia260ab4b5f3349f4b0ab8f23d17df63f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the diluted net loss per share calculation, preferred stock, stock options, warrants, restricted stock and RSUs are considered to be common stock equivalents and have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for periods presented. Therefore, basic and diluted net loss per share were the same for all periods presented in the unaudited Condensed Consolidated Statement of Operations and Comprehensive Loss. <ix:nonNumeric contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84NS9mcmFnOmFkNzhiNmM2ZmE1YzQ3NzRiYzJlMDdhZjkzNzUwNWIyL3RleHRyZWdpb246YWQ3OGI2YzZmYTVjNDc3NGJjMmUwN2FmOTM3NTA1YjJfNjkz_fc9e9af9-9052-46f8-92d6-91929d29f09b" continuedAt="iea553e459f24412ca6d638a2323317d0" escape="true">The shares in the table below were excluded from the calculation of diluted net loss per share, prior to the use of the treasury stock method, due to their anti-dilutive effect:</ix:nonNumeric></span></div><div><ix:continuation id="iea553e459f24412ca6d638a2323317d0"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7117791645b42058a5acb1a3ca00398_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84NS9mcmFnOmFkNzhiNmM2ZmE1YzQ3NzRiYzJlMDdhZjkzNzUwNWIyL3RhYmxlOmMzM2U4NDhiYjVhZTQwMDliMjZlZGU0N2JiZjIwNDU1L3RhYmxlcmFuZ2U6YzMzZTg0OGJiNWFlNDAwOWIyNmVkZTQ3YmJmMjA0NTVfMi0xLTEtMS0yMjM1Nw_6373da03-596f-4c08-a79a-299aa7463a71">509,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16a3e0fb50c54a4081eec1b8b2e9d068_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84NS9mcmFnOmFkNzhiNmM2ZmE1YzQ3NzRiYzJlMDdhZjkzNzUwNWIyL3RhYmxlOmMzM2U4NDhiYjVhZTQwMDliMjZlZGU0N2JiZjIwNDU1L3RhYmxlcmFuZ2U6YzMzZTg0OGJiNWFlNDAwOWIyNmVkZTQ3YmJmMjA0NTVfMi0zLTEtMS0yMjM1Nw_fc7746a1-a16c-4946-93d0-60a331773c1f">509,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i395ce7f5b8ae45baad50acde1847e4cd_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84NS9mcmFnOmFkNzhiNmM2ZmE1YzQ3NzRiYzJlMDdhZjkzNzUwNWIyL3RhYmxlOmMzM2U4NDhiYjVhZTQwMDliMjZlZGU0N2JiZjIwNDU1L3RhYmxlcmFuZ2U6YzMzZTg0OGJiNWFlNDAwOWIyNmVkZTQ3YmJmMjA0NTVfMy0xLTEtMS0yMjM1Nw_fa940169-c907-43a7-882b-d0e702cf91b8">11,593,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b7e133601904c7a84c219de00bcfe1b_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84NS9mcmFnOmFkNzhiNmM2ZmE1YzQ3NzRiYzJlMDdhZjkzNzUwNWIyL3RhYmxlOmMzM2U4NDhiYjVhZTQwMDliMjZlZGU0N2JiZjIwNDU1L3RhYmxlcmFuZ2U6YzMzZTg0OGJiNWFlNDAwOWIyNmVkZTQ3YmJmMjA0NTVfMy0zLTEtMS0yMjM1Nw_33b807ef-58d9-46c4-a629-46f4eda57247">10,681,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i85f449f89e6c4ad9b140a31a285c766d_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84NS9mcmFnOmFkNzhiNmM2ZmE1YzQ3NzRiYzJlMDdhZjkzNzUwNWIyL3RhYmxlOmMzM2U4NDhiYjVhZTQwMDliMjZlZGU0N2JiZjIwNDU1L3RhYmxlcmFuZ2U6YzMzZTg0OGJiNWFlNDAwOWIyNmVkZTQ3YmJmMjA0NTVfNC0xLTEtMS0yMjM1Nw_f8cfb01c-2300-4093-9993-a56efe2fcc82">5,378,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56668d4d1ae84d8c98f3182984b4d052_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84NS9mcmFnOmFkNzhiNmM2ZmE1YzQ3NzRiYzJlMDdhZjkzNzUwNWIyL3RhYmxlOmMzM2U4NDhiYjVhZTQwMDliMjZlZGU0N2JiZjIwNDU1L3RhYmxlcmFuZ2U6YzMzZTg0OGJiNWFlNDAwOWIyNmVkZTQ3YmJmMjA0NTVfNC0zLTEtMS0yMjM1Nw_61b1e61b-26b2-4ce3-bd6e-22efa41c6f25">4,971,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84NS9mcmFnOmFkNzhiNmM2ZmE1YzQ3NzRiYzJlMDdhZjkzNzUwNWIyL3RhYmxlOmMzM2U4NDhiYjVhZTQwMDliMjZlZGU0N2JiZjIwNDU1L3RhYmxlcmFuZ2U6YzMzZTg0OGJiNWFlNDAwOWIyNmVkZTQ3YmJmMjA0NTVfNS0xLTEtMS0yMjM1Nw_3fc79471-7d77-4ff7-9bb1-86ccc7c5bd3a">17,482,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84NS9mcmFnOmFkNzhiNmM2ZmE1YzQ3NzRiYzJlMDdhZjkzNzUwNWIyL3RhYmxlOmMzM2U4NDhiYjVhZTQwMDliMjZlZGU0N2JiZjIwNDU1L3RhYmxlcmFuZ2U6YzMzZTg0OGJiNWFlNDAwOWIyNmVkZTQ3YmJmMjA0NTVfNS0zLTEtMS0yMjM1Nw_fa986263-1f50-4a12-a45d-d46b9e8b0656">16,163,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_88"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following information should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the U.S. Securities and Exchange Commission, or the SEC, on February 25, 2021, or the 2020 Annual Report on Form 10-K, including the audited consolidated financial statements and related notes therein. This discussion and analysis contains forward-looking statements that involve significant risks and uncertainties. As a result of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">many factors, such as those set forth under &#8220;Risk Factors&#8221; in Part II, Item 1A. of this Quarterly Report on Form 10-Q, our actual results may differ materially from those anticipated in these forward-looking statements.</span></div><div><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_91"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company with the purpose of bettering the life of each person impacted by kidney disease. Since our initial public offering in 2014, we have built a business focused on developing and commercializing innovative renal therapeutics that we believe serves as a foundation for future growth. As a leader in the kidney community, we remain committed to helping patients and others where we believe our current and future products have the ability to deliver value. Our portfolio includes a late-stage product candidate and a commercial product:</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:30.53pt">Vadadustat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, or HIF-PHI, designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, or HIF, which stimulates erythropoietin, or EPO, production and can lead to red blood cell, or RBC, production and improved oxygen delivery to tissues. The significance of the HIF pathway was recognized by the 2019 Nobel Prize and the 2016 Albert Lasker Basic Medical Research Award, which honored the three physician-scientists who discovered the HIF pathway and elucidated this primary oxygen sensing mechanism that is essential for survival. We believe that, based on the HIF-PHI mechanism of action and clinical data to date, vadadustat has the potential to set a new oral standard of care for the treatment of anemia due to chronic kidney disease, or CKD.</span></div><div style="padding-left:72pt"><span><br/></span></div><div style="padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed the global Phase 3 clinical development program for vadadustat in 2020, which included two separate programs, INNO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VATE and PRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TECT. INNO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VATE evaluated vadadustat for the treatment of anemia due to CKD in adult patients on dialysis, or DD-CKD, and PRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TECT evaluated vadadustat for the treatment of anemia due to CKD in adult patients not on dialysis, or NDD-CKD.</span></div><div style="padding-left:72pt"><span><br/></span></div><div style="padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May of 2020, we announced positive top-line results from our Phase 3 INNO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VATE program that showed vadadustat was non-inferior to darbepoetin alfa, an injectable erythropoiesis-stimulating agent, or ESA, with respect to hematological efficacy (change in hemoglobin concentration) and cardiovascular safety (assessed in a time to the first occurrence of a major adverse cardiovascular event (MACE) analysis, which is the composite of all-cause mortality, nonfatal myocardial infarction, or a nonfatal stroke) in treating anemia due to CKD in DD-CKD adult patients. In addition to meeting the primary endpoints of the INNO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VATE program, vadadustat met the key secondary hematological efficacy endpoint in each of the two studies in the program and also met the program's key secondary safety endpoints. The results of the INNO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VATE program were presented at American Society of Nephrology, or ASN, in October of 2020 and published in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New England Journal of Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in April of 2021. </span></div><div style="padding-left:72pt"><span><br/></span></div><div style="padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September of 2020, we announced top-line results from our Phase 3 PRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TECT program that showed vadadustat was non-inferior to darbepoetin alfa with respect to hematological efficacy in treating anemia due to CKD in NDD-CKD adult patients. While the PRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TECT data showed that vadadustat achieved both the primary and key secondary hematological efficacy endpoints, it did not meet the program's primary cardiovascular safety (MACE) endpoint. These cardiovascular outcomes contrast with those reported within the INNO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">VATE program, which evaluated vadadustat for the treatment of anemia due to CKD in DD-CKD adult patients. The results of the PRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TECT program were presented at ASN in October of 2020 and published in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">New England Journal of Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in April of 2021. Simultaneous with the PRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TECT ASN presentation, we presented additional analyses, conducted by Akebia, of data from the PRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TECT program that revealed that the greater number of MACE events observed among vadadustat patients as compared to the active comparator was primarily related to an excess of non-cardiovascular death and death-of-unknown-causes in regions outside of the United States where significant differences in treatment patterns for NDD-CKD patients were observed.</span></div><div style="padding-left:72pt"><span><br/></span></div><div style="padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We submitted a New Drug Application, or NDA, to the U.S. Food and Drug Administration, or FDA, for vadadustat in March of 2021 for the treatment of anemia due to CKD in both DD-CKD and NDD-CKD adult patients. Our NDA submission was accepted for filing by the FDA in May 2021 and </span><span style="background-color:#ffffff;color:#373737;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at the time of filing the NDA, the FDA indicated that they were not currently planning to hold an Advisory Committee meeting to discuss the NDA </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for vadadustat. The FDA also assigned the application standard review and a Prescription Drug User Fee Act (PDUFA) target action date of March 29, 2022. We expect to have frequent communications with the FDA with respect to the NDA, including attending meetings, responding to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information requests, and engaging in labeling negotiations, among other things. We plan to provide updates, if and as appropriate, on these communications through our Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K filed with the SEC.</span></div><div style="padding-left:72pt"><span><br/></span></div><div style="padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our collaboration partner, Otsuka Pharmaceutical Co. Ltd., submitted a Marketing Authorization Application, or MAA, for vadadustat for the treatment of anemia due to CKD in adult patients to the European Medicines Agency, or EMA, in October 2021.</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As vadadustat did not meet the PRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TECT program's primary safety endpoint, we are remaining cautious in our outlook for potential approval of vadadustat in NDD-CKD adult patients in the United States and Europe.</span></div><div style="padding-left:72pt"><span><br/></span></div><div style="padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June of 2020, we announced the first regulatory approval of vadadustat for the treatment of anemia due to CKD in DD-CKD and NDD-CKD adult patients in Japan. Our collaboration partner in Japan, Mitsubishi Tanabe Pharma Corporation, or MTPC, commenced commercial sales of vadadustat in Japan under the trade name, Vafseo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in August 2020.</span></div><div style="padding-left:72pt"><span><br/></span></div><div style="padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to anemia due to CKD, we believe that vadadustat has the potential to treat other serious or life-threatening conditions, including preventing and lessening the severity of acute respiratory distress syndrome, or ARDS, a complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or COVID-19, infection. More specifically, in July of 2020, we announced an investigator-sponsored clinical study by The University of Texas Health Science Center at Houston, or UTHealth, in Houston, Texas, evaluating the use of vadadustat as a potential therapy to prevent and lessen the severity of ARDS in up to 400 adult patients who have been hospitalized due to COVID-19. Within this randomized, double-blind, placebo-controlled study, patients will be dosed with vadadustat or a placebo starting within 24 hours of hospital admission and continuing for up to 14 days. This study is being conducted under an FDA Investigational New Drug application, or IND, with UTHealth as the study sponsor and is currently enrolling patients. In January of 2021, UTHealth announced that it had been awarded $5.1 million in funding from the U.S. Department of Defense, or DOD, to expand this clinical trial at its facilities. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Auryxia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(ferric citrate)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is approved and marketed in the United States for two indications: (1) the control of serum phosphorus levels in adult patients with DD-CKD, or the Hyperphosphatemia Indication, and (2) the treatment of iron deficiency anemia, or IDA, in adult patients with NDD-CKD, or the IDA Indication. Ferric citrate is also approved and marketed in Japan as an oral treatment for IDA in adult patients and the improvement of hyperphosphatemia in adult patients with CKD, including DD-CKD and NDD-CKD, under the trade name Riona (ferric citrate hydrate). Auryxia is our only product approved for sale in the United States and it generated approximately $36.8 million and $34.4 million in revenue from U.S. product sales during the three months ended September&#160;30, 2021 and 2020, respectively. </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to commercialize vadadustat, subject to FDA approval, in the United States with our well-established, nephrology-focused commercial organization, while leveraging our collaboration with Otsuka and its U.S. nephrology commercial organization. We granted Otsuka exclusive rights to commercialize vadadustat in Europe, China and certain other markets, subject to marketing approvals. We granted MTPC exclusive rights to commercialize vadadustat in Japan, where MTPC commenced commercial sales of vadadustat under the trade name, Vafseo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in August 2020, and in certain other countries in Asia, subject to marketing approvals. In addition, we granted Vifor (International) Ltd., or Vifor Pharma, an exclusive license to sell vadadustat to Fresenius Kidney Care Group LLC, or FKC, an affiliate of Fresenius Medical Care North America, or FMCNA, and to certain third party dialysis organizations approved by us, or Third Party Dialysis Organizations, which combined manage up to approximately 60% of the dialysis patients in the United States, which would be effective upon FDA approval of vadadustat, the earlier of vadadustat&#8217;s reimbursement under a bundled reimbursement model or using the Transitional Drug Add-On Payment Adjustment, or the TDAPA, and a milestone payment by Vifor Pharma. During the term of the license agreement, Vifor Pharma is not permitted to sell any HIF product that competes with vadadustat in the United States to FKC or its affiliates or to any Third Party Dialysis Organization, and we may not directly supply vadadustat to FKC or any other affiliate of FMCNA or any Third Party Dialysis Organization.</span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never been profitable and have incurred net losses in each year since inception. Our net losses were $59.5 million and $60.0 million for the three months ended September&#160;30, 2021 and 2020, respectively, and $212.2 million and $296.5 million for the nine months ended September&#160;30, 2021 and 2020, respectively. Substantially all of our net losses resulted from costs incurred in connection with the continued commercialization of Auryxia and development efforts relating to vadadustat, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including preparing for and conducting clinical studies of vadadustat, providing general and administrative support for these operations and protecting our intellectual property.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and operating losses for the foreseeable future. The amount of our future net losses will depend, in part, on the rate of our future expenditures, and our financial position will depend, in part, on product revenue, collaboration revenue, and our ability to obtain additional funding. We expect to continue to incur significant expenses if and as we:</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">conduct and enroll patients in any clinical trials, including any post-marketing approval studies, any Phase 4 studies or any other clinical trials for Auryxia, vadadustat or any other product or product candidate, including those that may be in-licensed or acquired;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continue our commercialization activities for Auryxia and plan for the commercialization of vadadustat, if approved, and any other product or product candidate, including those that may be in-licensed or acquired;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">adapt to any regulatory changes, including changes relating to reimbursement;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">adapt to any changes in reimbursement practices by third party payors;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">seek marketing approvals for vadadustat and any other product candidate, including those that may be in-licensed or acquired;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">maintain marketing approvals for Auryxia, vadadustat, if approved, and any other product, including those that may be in-licensed or acquired;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">have Auryxia, vadadustat and any other product or product candidate, including those that may be in-licensed or acquired, manufactured for clinical trials and for commercial sale;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">seek to discover and develop additional product candidates or platforms that may lead to the discovery of additional product candidates;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">engage in transactions, including strategic, merger, collaboration, acquisition and licensing transactions, pursuant to which we would market and develop commercial products, or develop and commercialize other product candidates and technologies;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">make royalty, milestone or other payments under our license agreements and any future license agreements;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">maintain, protect and expand our intellectual property portfolio;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">attract, hire and retain qualified personnel;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continue to create additional infrastructure and expend additional resources to support our operations as a fully integrated, publicly traded biopharmaceutical company; and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">experience any delays or encounter issues with any of the above.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated, and may not generate, enough product revenue to realize net profits from product sales. We have no manufacturing facilities, and all of our manufacturing activities are contracted out to third parties. Additionally, we currently utilize contract research organizations, or CROs, to carry out our clinical development activities. If we obtain marketing approval for vadadustat, and as we continue to commercialize Auryxia, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. We expect to finance future cash needs through product revenue, public or private equity or debt transactions, payments from our collaborators, royalty transactions, strategic transactions, or a combination of these approaches. If we are unable to raise additional capital in sufficient amounts when needed or on attractive terms, we may not be able to pursue development and commercial activities related to Auryxia and vadadustat, if approved, or any additional products and product candidates, including those that may be in-licensed or acquired. Any of these events could significantly harm our business, financial condition and prospects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through September&#160;30, 2021, we raised approximately $787.5 million of net proceeds from the sale of equity, including $519.8 million from various underwritten public offerings, $217.7 million from at-the-market offerings, or ATM offerings, pursuant to sales agreements with Cantor Fitzgerald &amp; Co., and $50.0 million from the sale of 3,571,429 shares of common stock to Vifor Pharma. During the quarter ended September 30, 2021 and through the date of this Quarterly Report on Form 10-Q, we raised $16.1 million of net proceeds from ATM offerings. At inception of our collaboration agreements with Otsuka and MTPC, our collaborators committed to an aggregate of approximately $573.0 million or more in cost-share funding, which we generally continue to receive on a quarterly prepaid basis, and license payments. Of these commitments, we received approximately $272.0 million at the onset of the collaboration agreements. On November 11, 2019, we entered into a loan agreement, or the Loan Agreement, with funds managed by Pharmakon Advisors LP, or Pharmakon, pursuant to which term </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loans in an aggregate principal amount of $100.0 million were made available to us in two tranches, subject to certain terms and conditions, or the Term Loans. As of March 31, 2021, we had drawn down the full amount $100.0 million made available to us under the Loan Agreement. In addition, on February 25, 2021, we received an upfront payment of $44.8 million (net of certain transaction expenses) in connection with our sale to HealthCare Royalty Partners IV, L.P., or HCR, of the right to receive all royalties and sales milestones payable to us under our collaboration agreement with MTPC, or the MTPC Agreement, subject to certain caps and other terms and conditions described elsewhere in this Quarterly Report on Form 10-Q.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impacts of COVID-19 Pandemic</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or COVID-19, pandemic has presented a substantial public health and economic challenge around the world and continues to affect our employees, patients, healthcare providers with whom we interact, customers, collaboration partners, CROs, contract manufacturing organizations, or CMOs, vendors, communities and business operations. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition continues to depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning the COVID-19 pandemic, any resurgences or mutations of COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets where the healthcare providers with whom we interact, our partners, our CROs, our CMOs, and our other vendors operate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe our revenue growth was negatively impacted in the first three quarters of 2021 primarily as the kidney patient populations that we serve continue to experience both high hospitalization and mortality rates due to COVID-19. While we are unable to quantify the impact of the COVID-19 pandemic on future revenues and revenue growth, COVID-19 continues to adversely and disproportionately impact our patient population; therefore, we expect COVID-19 to continue to have a negative impact on our revenue growth for the foreseeable future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The majority of our office-based employees began working from home in March 2020, and continue to primarily work from home. In October 2021, we announced a requirement that all of our employees be fully vaccinated by January 1, 2022, subject to limited medical and religious exemptions. At this time, it is not possible to predict with certainty the exact impact that our vaccine requirement will have on us or on our workforce, and the requirement may result in employee distraction, absences, resignations, attrition and difficulty securing future labor needs which could have an adverse effect on our business, results of operations and cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In addition, several healthcare facilities have previously restricted access for non-patients, including the members of our sales force. For example, DaVita, Inc., or DaVita, and Fresenius Medical Care, or Fresenius, which account for a vast majority of the dialysis population in the United States, have restricted access to their clinics. As a result, we continue to engage with some healthcare providers and other customers virtually, where possible. The restrictions on our customer-facing employees' in-person interactions with healthcare providers could negatively impact our access to healthcare providers and, ultimately, our sales. Recently, such precautionary measures have been relaxed at certain healthcare facilities and, as a result, members of our sales force have resumed in person interactions with certain customers. Nevertheless, some restrictions remain, and more restrictions may be put in place again due to a resurgence in COVID-19 cases, including those involving new variants of COVID-19 which may be more contagious and more severe than prior strains of the virus. Given this uncertain environment and the disproportionate impact of the COVID-19 pandemic on CKD patients, we are actively monitoring the demand for Auryxia, including the potential for further declines or changes in prescription trends and customer orders. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the direct and indirect impacts of the pandemic or the response efforts to the pandemic, including among others, competition for labor and resources and increases in labor, sourcing, manufacturing and shipping costs, may cause disruptions to, closures of, or other impacts on our CMOs and other vendors in our supply chain on which we rely for the supply of our products and product candidates.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At this time, our third party contract manufacturers continue to operate at or near normal levels. However, it is possible that the COVID-19 pandemic and response efforts may have an impact in the future on our contract manufacturers' ability to manufacture and deliver Auryxia and vadadustat (which is currently marketed under the trade name Vafseo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> by MTPC in Japan), which may result in delays in, increased costs or disruptions to manufacturing and supply of our products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COVID-19 pandemic precautions have caused moderate delays in enrolling new clinical trials and may cause delays in enrolling other new clinical trials. We are using remote monitoring and central monitoring, where possible.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This uncertain COVID-19 pandemic environment has presented new risks to our business. While we are working aggressively to mitigate the impacts on our business, we are mindful that many of these risks and the impact to the larger healthcare market are outside of our control.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the various risks posed by the COVID-19 pandemic, please refer to Part II, Item 1A. Risk Factors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_94"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, our revenues have been derived from collaboration revenues, which include license and milestone payments, royalty and cost-sharing revenue generated through collaboration and license agreements with partners for the development and commercialization of vadadustat and, following the Merger, commercial sales of Auryxia and royalty revenue from sales of Riona in Japan. Cost-sharing revenue represents amounts reimbursed by our collaboration partners for expenses incurred by us for research and development activities and, potentially, co-promotion activities, under our collaboration agreements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our revenue to continue to be generated primarily from our collaborations with Otsuka and MTPC and any other collaborations into which we may enter, as well as commercial sales of Auryxia and, if approved, vadadustat, in the United States, and royalty revenue from Japan Tobacco, Inc., or JT, and its subsidiary, Torii Pharmaceutical Co., Ltd., or Torii, based on net sales of Riona in Japan.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold includes direct costs to manufacture commercial drug substance and drug product for Auryxia, as well as indirect costs including costs for packaging, shipping, insurance and quality assurance, idle capacity charges, write-offs for inventory that fails to meet specifications or is otherwise no longer suitable for commercial sale, changes in our excess purchase commitment liability, and royalties due to the licensor of Auryxia related to the U.S. product sales recognized during the period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Merger and the application of purchase accounting, costs of goods sold also includes both amortization expense and, if applicable, impairment charges associated with the fair value of the developed product rights for Auryxia as well as expense associated with the fair value inventory step-up. The fair value of the developed product rights for Auryxia is being amortized over its estimated useful life, which as of September&#160;30, 2021 is estimated to be six years. The fair value inventory step-up as a result of the Merger was fully amortized as of the first quarter of 2021.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for the development of vadadustat, which include:</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">personnel-related expenses, including salaries, benefits, recruiting fees, travel and stock-based compensation expense of our research and development personnel;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expenses incurred under agreements with CROs and investigative sites that conduct our clinical studies;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of acquiring, developing and manufacturing clinical study materials through CMOs;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies; and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">costs associated with preclinical, clinical and regulatory activities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and our clinical sites.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot determine with certainty the duration and completion costs of current or future clinical studies of Auryxia and vadadustat or if, when, or to what extent we will generate revenue from the commercialization and sale of vadadustat, if approved. We may never succeed in achieving marketing approval for vadadustat.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The duration, costs and timing of clinical studies and development of Auryxia and vadadustat will depend on a variety of factors including, but not limited to, those described in Part II, Item 1A. Risk Factors. A change in the outcome of any of these variables with respect to the development of Auryxia and vadadustat could mean a significant change in the costs and timing associated with that development. For example, if the FDA, the EMA, or other regulatory authorities were to require us to conduct clinical studies in addition to or different from those that we currently anticipate, or if we experience delays in any of our clinical studies, we could be required to expend significant additional financial resources and time on the completion of clinical development.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through September&#160;30, 2021, we have incurred $1.4&#160;billion in research and development expenses. We expect to have significant research and development expenditures for the foreseeable future as we continue the development of Auryxia, vadadustat and any other product or product candidate, including those that may be in-licensed or acquired.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our direct research and development expenses consist principally of external costs, such as fees paid to clinical trial sites, consultants, central laboratories and CROs in connection with our clinical studies, and drug substance and drug product manufacturing for clinical studies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we completed our global Phase 3 clinical program for vadadustat to which the majority of our research and development costs have been attributable. A significant portion of our research and development costs have been external costs, which we track on a program-by-program basis. These external costs include fees paid to investigators, consultants, central laboratories and CROs in connection with our clinical trials, and costs related to acquiring and manufacturing clinical trial materials. Our internal research and development costs are primarily personnel-related costs, depreciation and other indirect costs. We do not track our internal research and development expenses on a program-by-program basis as they are deployed across multiple projects under development.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our external research and development expenses by program, as well as expenses not allocated to programs, for the three and nine months ended September&#160;30, 2021 and 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.648%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vadadustat external costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External costs for other programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,999&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Headcount, consulting, facilities and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,471&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,857&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,296&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,907&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of salaries and related costs for personnel, including stock-based compensation and travel expenses for our commercial personnel, including our field sales force and other commercial support personnel, as well as personnel in executive and other administrative or non-research and development functions. Other selling, general and administrative expenses include facility-related costs, fees for directors, accounting and legal services fees, recruiting fees and expenses associated with obtaining and maintaining patents.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="i32bac828c69741158be14bdef01bfe8b_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended September&#160;30, 2021 and 2020</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.982%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in&#160;thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License, collaboration and other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,593)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,756&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,988&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,232)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of goods sold</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,944&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,345&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,401)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,386)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,886)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,095)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,209&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,658)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,864)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,794)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,544)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,959)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Net product revenue is derived from sales of our only commercial product in the United States, Auryxia. We distribute our product principally through a limited number of wholesale distributors as well as certain specialty pharmacy providers. Net product revenue was $36.8 million for the three months ended September&#160;30, 2021, compared to net product revenue of $34.4 million for the three months ended September&#160;30, 2020. The increase was due to lower volume rebates related to the negative impact to sales volume as a result of COVID-19 and improved payer mix. We believe our revenue growth continues to be negatively impacted primarily as the kidney patient populations that we serve continue to experience high hospitalization and mortality rates due to COVID-19.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an oral drug, Auryxia is covered by Medicare only under Part D. However, in September 2018, CMS decided that Auryxia would no longer be covered by Medicare for the IDA Indication. While this decision does not impact CMS coverage of the Hyperphosphatemia Indication, it requires Part D plan sponsors to impose prior authorization or other steps to ensure that Auryxia is used only for the Hyperphosphatemia Indication. However, due to the COVID-19 pandemic, CMS has issued a guidance that expressly encouraged Part D plans to waive all prior authorization requirements. This guidance was issued in March of 2020 and updated in May of 2020. In both versions of the guidance, CMS clarified that due to COVID-19, Part D plan sponsors are encouraged to waive prior authorization requirements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, on October 15, 2019, we filed a complaint in the United States District Court for the District of Massachusetts against CMS and the U.S. Department of Health and Human Services challenging CMS&#8217;s decision that Auryxia would no longer be covered by Medicare for the IDA Indication and imposing a prior authorization requirement for Auryxia in the Hyperphosphatemia Indication, or the CMS Decision. On October 22, 2021, the parties agreed to dismiss the litigation. See Part II, Item 1. Legal Proceedings for further information. While we believe that the vast majority of the Medicare prescriptions written for Auryxia today are for the Hyperphosphatemia Indication and therefore will continue to be covered by Medicare with prior authorization,&#160;the CMS Decision has had and will continue to have an adverse impact on the sales and future growth of Auryxia for the Hyperphosphatemia Indication and the IDA Indication.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Other Revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue was $12.0 million for the three months ended September&#160;30, 2021 compared to $25.6 million for the three months ended September&#160;30, 2020. We recognized $10.6 million in collaboration revenue for the three months ended September&#160;30, 2021 from our cost sharing arrangement under the Otsuka collaboration agreement for the United States, or the Otsuka U.S. Agreement, and the Otsuka collaboration agreement for certain territories outside the United States, or the Otsuka International Agreement, and royalty revenue under our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration agreement with MTPC, or the MTPC Agreement. We recognized $23.9 million in collaboration revenue for the three months ended September&#160;30, 2020 from our cost sharing arrangement under the Otsuka U.S. Agreement and the Otsuka International Agreement, as well as royalty revenue under our collaboration agreement with MTPC. The $13.3 million decline in collaboration revenue was driven by lower development costs incurred subject to cost sharing arrangements under both the Otsuka U.S. Agreement and Otsuka International Agreement as we completed our global Phase 3 clinical development program for vadadustat in 2020 and are currently engaged in close-out activities with respect to the program. We expect our Otsuka collaboration revenue to continue to decrease in the near term for that reason. The decrease in Otsuka collaboration revenue was partially offset by an increase in royalty revenue under the MTPC Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Goods Sold - Product</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Cost of goods sold of $6.9 million for the three months ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consisted of costs associated with the manufacturing of Auryxia partially offset by a $6.0 million reduction to the liability for excess purchase commitments, primarily due to the settlement of all patent litigation proceedings related to Abbreviated New Drug Applications filed with respect to Auryxia, which allows for generic versions of Auryxia beginning in March 2025. Refer to Note 14 to our condensed consolidated financial statements for further details on the excess purchase commitments liability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold of $24.2 million for the three months ended September&#160;30, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consisted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of costs associated with the manufacturing of Auryxia, $8.4 million in non-cash charges related to the fair-value inventory step-up from the application of purchase accounting, and $8.5 million primarily related to the write-down of inventory associated with specific lots of Auryxia as it was determined that these lots were not manufactured in conformance with the FDA's GMP guidance relating to validation. These charges were partially offset by a $0.7 million non-cash gain related to a reduction to the liability for excess purchase commitments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Goods Sold - Amortization of Intangibles. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangibles relates to the acquired developed product rights for Auryxia. During the three months ended September&#160;30, 2021, this intangible asset was being amortized using a straight-line method over its estimated useful life of approximately six years. Amortization of intangibles during the three months ended September&#160;30, 2021 and 2020 was $9.0 million and $6.1 million, respectively. The increase in amortization charges is due to the prospective adjustment of the estimated useful life of the developed product rights for Auryxia that occurred in the fourth quarter of 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development expenses were $40.5 million for the three months ended September&#160;30, 2021, compared to $46.9 million for the three months ended September&#160;30, 2020, a decrease of $6.4 million. The decrease was primarily due to the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:81.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in&#160;millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vadadustat development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Headcount, consulting and facilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net decrease</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in the costs related to the development of vadadustat is primarily attributable to a decrease in external costs related to our global Phase 3 program for vadadustat (INNO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:1.26pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VATE and PRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:1.26pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TECT), for which we reported top-line data in the second and third quarters of 2020, respectively. Although we expect our research and development expenses to continue to decrease in the near term compared to the full year 2020 as we completed our global Phase 3 clinical development program for vadadustat in 2020, we will continue to incur significant research and development expenses in future periods in support of ongoing or planned studies with respect to Auryxia and vadadustat and development of other potential product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Selling, general and administrative expenses were $46.4 million for the three months ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021, compared to $40.2 million for the three months ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2020. The increase of $6.2 million was primarily due to increases in headcount related costs and one-time legal costs. For the remainder of 2021, we expect our selling, general and administrative expenses for our ongoing commercialization of Auryxia to continue to increase modestly from 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License expense related to royalties due to Panion relating to sales of Riona in Japan were $0.9 million and $0.7 million for the three months ended September&#160;30, 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Expense, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Other expense, net, was $4.7 million for the three months ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to $1.9 million for the three months ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2020. Other expense, net, for the three months ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021 was primarily due to interest expense associated with our Term Loans and non-cash interest expense on the liability related to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the sale of our right to receive royalties and sales milestones from MTPC as further described in Note 5 to our condensed consolidated financial statements in Part I, Item 1. Financial Statements (unaudited). Other expense, net, for the three months ended September&#160;30, 2020 was primarily due to interest expense associated with our Term Loans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Nine Months Ended September&#160;30, 2021 and 2020</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in&#160;thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License, collaboration and other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,458)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,973&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,608&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,635)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,828)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of intangible asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115,527)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,674&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129,630)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,092&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,973&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,881)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199,163)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291,039)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,876&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,999)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,581)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212,162)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(296,457)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,295&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Net product revenue is derived from sales of our only commercial product in the United States, Auryxia. We distribute our product principally through a limited number of wholesale distributors as well as certain specialty pharmacy providers. Net product revenue was $100.1 million for the nine months ended September&#160;30, 2021, compared to net product revenue of $94.3 million for the nine months ended September&#160;30, 2020. The increase was primarily due to an increase in units sold and improved payer mix. partially offset by the negative impact from COVID-19. We believe our revenue growth continues to be negatively impacted primarily as the kidney patient populations that we serve continue to experience high hospitalization and mortality rates due to COVID-19.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Collaboration and Other Revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License, collaboration and other revenue was $53.9 million for the nine months ended September&#160;30, 2021 compared to $144.3 million for the nine months ended September&#160;30, 2020. We recognized $49.7 million in collaboration revenue for the nine months ended September&#160;30, 2021 from our cost sharing arrangement under the Otsuka U.S. Agreement and the Otsuka International Agreement, and royalty revenue under the MTPC Agreement. We recognized $135.5 million in collaboration revenue for the nine months ended September&#160;30, 2020 from our cost sharing arrangement under the Otsuka U.S. Agreement and the Otsuka International Agreement and recognition of a milestone and royalty revenue earned under the MTPC Agreement. The $85.7 million decline in collaboration revenue was driven by lower payments recognized under both the Otsuka U.S. Agreement and Otsuka International Agreement as we completed our global Phase 3 clinical development program for vadadustat in 2020 and are currently engaged in close-out activities with respect to the program. We expect our Otsuka collaboration revenue to continue to decrease in the remainder of 2021 for that reason.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Cost of Goods Sold - Product</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Cost of goods sold of $76.0 million for the nine months ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">September&#160;30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">consisted of costs associated with the manufacturing of Auryxia, $15.4 million in non-cash charges related to an increase to the liability for excess purchase commitments, $21.6 million in non-cash charges related to the fair-value inventory step-up from the application of purchase accounting, and $7.1 million related to inventory reserves associated with a previously disclosed manufacturing quality issue related to Auryxia. Refer to Note 14 to our condensed consolidated financial statements for further details of the increase to the liability for excess purchase commitments.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold of $92.8 million for the nine months ended September&#160;30, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consisted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of costs associated with the manufacturing of Auryxia and $39.5 million in non-cash charges related to the fair-value inventory step-up from the application of purchase accounting, $18.6 million primarily related to the write-down of inventory associated with specific lots of Auryxia because it was determined that these lots were not manufactured in conformance with the FDA's GMP guidance relating to validation, and $10.3 million in non-cash charges related to an increase to the liability for excess purchase commitments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Goods Sold - Amortization of Intangibles. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangibles relates to the acquired developed product rights for Auryxia. During the nine months ended September&#160;30, 2021, this intangible asset was being amortized using a straight-line method over its estimated useful life of approximately six years. Amortization of intangibles during the nine months ended September&#160;30, 2021 and 2020 was $27.0 million and $24.3 million, respectively. The increase in amortization charges is due to the prospective adjustment of the estimated useful life of the developed product rights for Auryxia that occurred in the fourth quarter of 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Goods Sold - Impairment of Intangible Asset.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the second quarter of 2020, in connection with a routine business review, we reduced our short-term and long-term Auryxia revenue forecast. This reduction was primarily driven by the compounding impact of the CMS Decision that rescinded Medicare Part D coverage of Auryxia for the IDA Indication, and imposed a prior authorization requirement for Auryxia for the Hyperphosphatemia Indication. As a result, we recorded an impairment charge of $115.5 million to the Auryxia intangible asset during the nine months ended September&#160;30, 2020. There were no such impairment charges during the nine months ended September&#160;30, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development expenses were $118.3 million for the nine months ended September&#160;30, 2021, compared to $180.9 million for the nine months ended September&#160;30, 2020, a decrease of $62.6 million. The decrease was primarily due to the following:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in&#160;millions)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vadadustat development expenses</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Headcount, consulting and facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net decrease</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in the costs related to the development of vadadustat is primarily attributable to a decrease in external costs related to our global Phase 3 program for vadadustat (INNO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:1.26pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VATE and PRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:1.26pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TECT), for which we reported top-line data in the second and third quarters of 2020, respectively. Although we expect our research and development expenses to continue to decrease in the near term compared to the full year 2020 as we completed our global Phase 3 clinical development program for vadadustat in 2020, we will continue to incur significant research and development expenses in future periods in support of ongoing or planned studies with respect to Auryxia and vadadustat and development of other potential product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Selling, general and administrative expenses were $129.3 million for the nine months ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021, compared to $113.6 million for the nine months ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2020. The increase of $15.7 million was primarily due to higher marketing expenses, increased headcount related costs, and one-time legal costs. For the remainder of 2021, we expect our selling, general and administrative expenses for our ongoing commercialization of Auryxia to continue to increase modestly from 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License expense related to royalties due to Panion relating to sales of Riona in Japan were $2.5 million and $2.4 million for the nine months ended September&#160;30, 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Expense, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Other expense, net, was $13.0 million for the nine months ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to $5.4 million for the nine months ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2020. Other expense, net, for the nine months ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021 was primarily due to interest expense associated with our Term Loans and non-cash interest expense on the liability related to the sale of our right to receive royalties and sales milestones from MTPC as further described in Note 5 to our condensed consolidated financial statements in Part I, Item 1. Financial Statements (unaudited). Other expense, net, for the nine months ended September&#160;30, 2020 was primarily due to interest expense associated with our Term Loans.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="i32bac828c69741158be14bdef01bfe8b_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have funded our operations principally through sales of our common stock, payments received from our collaboration partners, and following the Merger, product sales, debt and a royalty transaction. As of September&#160;30, 2021, we had cash and cash equivalents and available for sale securities of approximately $207.2 million. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Accordingly, available for sale securities, consisting principally of corporate and government debt securities stated at fair value, are also available as a source of liquidity. At inception of our collaboration agreements with Otsuka and MTPC, our collaborators committed to an aggregate of approximately $573.0 million or more in cost-share funding, of which we received approximately $272.0 million at the onset of the collaborations, and the remainder of which we generally continue to receive on a quarterly prepaid basis, and through license payments.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the primary sources and uses of cash for each of the periods set forth below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in&#160;thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,606)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,687)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,888)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,916&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities of $190.2 million for the nine months ended September&#160;30, 2021 was largely driven by payroll-related expenses, rebate payments and payments for inventory. These payments were partially offset by adjustments for non-cash items, including amortization of intangibles of $27.0 million, fair value step-up of inventory sold or written off of $21.6 million, stock-based compensation expense of $18.1 million, an increase to the liability for excess purchase commitments of $15.4&#160;million, write-downs of inventory of $7.1 million, and non-cash interest expense related to sale of future royalties of $6.8&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities of $79.6 million for the nine months ended September&#160;30, 2020 was largely driven by payments for the Phase 3 development program for vadadustat, rebate payments and payments for inventory. These payments were partially offset by adjustments for non-cash items, including the intangible asset impairment charge of $115.5 million, fair value step-up of inventory sold or written off of $39.5 million, amortization of intangibles of $24.3 million, stock-based compensation expense of $18.4 million, an increase to the liability for excess purchase commitments of $10.3 million and write-downs of inventory of $18.6 million primarily associated with specific lots of Auryxia because it was determined that these lots were not manufactured in conformance with the FDA's GMP guidance relating to validation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Net cash provided by investing activities for the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September&#160;30, 2021 was $39.9 million and was comprised of proceeds from the maturities of available for sale securities of $40.0&#160;million, partially offset by immaterial purchases of equipment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the nine months ended September&#160;30, 2020 was $99.7 million and was comprised primarily of purchase of available for sale securities of $99.9 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September&#160;30, 2021 was $128.3 million and consisted of net proceeds from the sale of future royalties of $44.8&#160;million, net proceeds from the public issuance of common stock in connection with our ATM sales agreement of $82.8 million, and proceeds from the sale of stock under our employee stock purchase plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the nine months ended September&#160;30, 2020 was $201.2 million and consisted primarily of proceeds from the public issuance of common stock of $198.9 million, proceeds from the exercise of stock options and proceeds from the sale of stock under our employee stock purchase plan.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Capital Requirements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We have one product, Auryxia, approved for commercial sale in the United States, but have not generated, and may not generate, enough product revenue from the sale of Auryxia to realize net profits from product sales. We have incurred losses and cumulative negative cash flows from operations since our inception in February 2007, and as of September&#160;30, 2021, we had an accumulated deficit of $1.4&#160;billion. We anticipate that we will continue to incur losses for the foreseeable future, and we expect to continue to incur additional research and development and selling, general and administrative expenses for our ongoing research and development and potential commercialization of vadadustat and our ongoing development and commercialization of Auryxia. We expect our cash resources to fund our current operating plan for at least twelve months from the date of this filing. If we receive regulatory approval of vadadustat in the U.S., we expect to incur significant incremental costs to our current operating plan to commercialize vadadustat, including costs of marketing, manufacturing and distribution. The potential timely regulatory approval of vadadustat and the receipt of associated regulatory milestones is an important source of funding of our cash runway. However, we will require additional funding to fund our operating plan beyond the next twelve months. There are numerous risks and uncertainties associated with research, development and commercialization activities, and actual results could vary materially as a result of a number of factors, many of which are outside of our control. We have based these estimates on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Furthermore, our regulatory milestones may not be achieved, we may not receive the anticipated funding from our collaboration partners, and we may not secure other sources of financing. If we are unable to obtain sufficient funding, we could be required to delay our development efforts, limit activities and reduce costs, which could adversely affect our business prospects. The period over which our cash runway extends is also dependent on the execution of our commercial plan, which is dependent on the overall market, the competitive environment, and the execution of reimbursement strategies. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to finance future cash needs through product revenue, public or private equity or debt transactions, payments from our collaborators (including associated regulatory approval milestones), royalty transactions, strategic transactions, or a combination of these approaches.&#160;Additionally, we will require additional capital to pursue development and commercial activities related to Auryxia and vadadustat, if approved, or any additional products and product candidates, including those that may be in-licensed or acquired. Additional funds may not be available to us on acceptable terms or at all. If we are unable to raise additional capital in sufficient amounts when needed or on attractive terms, we may not be able to pursue development and commercial activities related to Auryxia and vadadustat, if approved, or any additional products or product candidates, including those that may be in-licensed or acquired. If we raise additional funds through the issuance of additional debt or equity securities, it could result in dilution to our existing stockholders or increased fixed payment obligations, and any such securities may have rights senior to those of our common stock. Any of these events could significantly harm our business, financial condition and prospects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may be substantially different than actual results, and we could utilize our available capital resources sooner than we currently expect. Our future funding requirements, both near- and long-term, will depend on many factors including, but not limited to, those described under Part II, Item 1A. Risk Factors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition and results of operations could be materially adversely affected.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of September&#160;30, 2021, other than as disclosed in Note 14 to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, there have been no material changes to our contractual obligations and commitments from those described under &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our 2020 Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term Loans</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On November 11, 2019, Akebia, with Keryx as guarantor, entered into a loan agreement, or the Loan Agreement, with BioPharma Credit PLC as collateral agent and a lender, or the Collateral Agent, and BioPharma Credit Investments V (Master) LP as a lender, pursuant to which term loans in an aggregate principal amount of $100.0 million were made available to us in two tranches, subject to certain terms and conditions, or the Term Loans. BioPharma Credit PLC subsequently transferred its interest in the Term Loans, solely in its capacity as a lender, to its affiliate, BPCR Limited Partnership. The Collateral Agent and the lenders are collectively referred to as Pharmakon. The first tranche of $80.0 million, or Tranche A, was drawn on November 25, 2019, or the Tranche A Funding Date, and the second&#160;tranche of $20.0 million, or Tranche B, was drawn on December 10, 2020, or the Tranche B Funding Date. A more detailed description of the term loans can be found in Note 11 to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liability Related to Sale of Future Royalties</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On February 25, 2021, we entered into the Royalty Agreement with HealthCare Royalty Partners IV, L.P., or HCR, pursuant to which we sold to HCR our right to receive royalties and sales milestones for vadadustat in the MTPC Territory, such payments collectively the Royalty Interest Payments, in each case, payable to us under the MTPC Agreement, subject to an annual maximum &#8220;cap&#8221; of $13.0&#160;million, or the Annual Cap, and an aggregate maximum &#8220;cap&#8221; of $150.0&#160;million, or the Aggregate Cap. After HCR receives Royalty Interest Payments equal to the Annual Cap in a given calendar year, we will receive 85% of the Royalty Interest Payments for the remainder of that year. After HCR receives Royalty Interest Payments equal to the Aggregate Cap, or we pay the Aggregate Cap to HCR (net of the Royalty Interest Payments already received by HCR), the Royalty Interest Payments will revert back to us, and HCR would have no further right to any Royalty Interest Payments. We received $44.8&#160;million from HCR (net of certain transaction expenses) under the Royalty Agreement, and we are eligible to receive an additional $5.0&#160;million in each year from 2021 through 2023 under the Royalty Agreement if specified annual sales milestones are achieved for vadadustat in the MTPC Territory, subject to the satisfaction of certain customary conditions. We retain the right to receive all potential future regulatory milestones for vadadustat under the MTPC Agreement. A more detailed description of the liability related to the sale of future royalties can be found in Note 5 to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.</span></div><div><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_103"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, we did not have any off-balance sheet arrangements as defined in the rules and regulations of the SEC.</span></div><div><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_106"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our unaudited condensed consolidated financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue, prepaid and accrued research and development expenses and stock-based compensation. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. In making estimates and judgments, management employs critical accounting policies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021, we had the following material change to our critical accounting policies as reported in our 2020 Annual Report on Form 10-K:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability Related to Sale of Future Royalties</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We treat the liability related to sale of future royalties (see Note 5 to our condensed consolidated financial statements in Part I, Item 1. Financial Statements (unaudited) included in this Quarterly Report on Form 10-Q) as a debt financing, amortized under the effective interest rate method over the estimated life of the related expected royalty stream. The liability related to sale of future royalties and the debt amortization are based on our current estimates of future royalties expected to be paid over the life of the arrangement. We will periodically assess the expected royalty payments. To the extent our estimates of future royalty payments are greater or less than previous estimates or the estimated timing of such payments is materially different than previous estimates, we will adjust the effective interest rate and recognize related non-cash interest expense on a prospective basis. Non-cash royalty revenue is reflected as royalty revenue within license, collaboration and other revenue, and non-cash amortization of debt is reflected as interest expense in the unaudited condensed consolidated statements of operations and comprehensive loss in Part I, Item 1. Financial Statements (unaudited) included in this Quarterly Report on Form 10-Q.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other material changes to our critical accounting policies as reported in our 2020 Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion of recent accounting pronouncements, please refer to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Accounting Pronouncements &#8211; Recently Adopted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included within Note 2 to our condensed consolidated financial statements in Part I, Item 1. Financial Statements (unaudited) included in this Quarterly Report on Form 10-Q.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i32bac828c69741158be14bdef01bfe8b_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk related to changes in interest rates. As of September&#160;30, 2021 and December&#160;31, 2020, we had cash and cash equivalents and available for sale securities of $207.2 million and $268.7 million, respectively, consisting primarily of money market mutual funds consisting of U.S. government debt securities, certificates of deposit and corporate debt securities. Interest rate sensitivity is affected by changes in the general level of U.S. interest rates, particularly because our investments are in short-term securities. Our investments are subject to interest rate risk and will fall in value if market interest rates increase. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our portfolio.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we are exposed to market risk related to exchange rates. A substantial portion of our revenues for the nine months ended September&#160;30, 2021 was received in U.S. dollars, including revenues we receive from royalty payments converted to U.S. dollars based on the net sales of Riona and Vafseo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in Japanese yen. Our exchange rate risk arises from such foreign currency net sales. As a result, we are exposed to movements in the exchange rates of the Japanese yen against the U.S. dollar.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the royalty payments we received based on net sales of Riona and Vafseo in Japan for the nine months ended September&#160;30, 2021 a 5.0% appreciation or depreciation of the Japanese yen against the U.S. dollar would have increased or decreased, respectively, our revenues in the nine months ended September&#160;30, 2021 by approximately $0.2 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have generally accepted the exposure to exchange rate movements without using derivative financial instruments to manage this foreign currency risk.</span></div><div><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_112"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is (1)&#160;recorded, processed, summarized, and reported within the time periods specified in the U.S. Securities and Exchange Commission&#8217;s rules and forms and (2)&#160;accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on our evaluation, our management concluded that, as of September&#160;30, 2021, our disclosure controls and procedures were not effective because our internal control over financial reporting was not adequate due to the material weakness described below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As reported in our Annual Report on Form 10-K for the year ended December 31, 2020, or the 2020 Annual Report on Form 10-K, our internal control over financial reporting as of December 31, 2020 was not effective due to the following material weakness: the Company did not design and maintain effective controls over the completeness, accuracy and presentation and disclosure of inventory. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company&#8217;s annual or interim consolidated financial statements will not be prevented or detected on a timely basis. Specifically, we did not maintain effective controls related to (i) the review of inventory reconciliations, (ii) the validation of the inventory costing and (iii) the periodic assessment of excess and obsolete inventory related reserves. Management has taken actions to remediate the deficiencies in its internal control over financial reporting and implemented additional processes and controls designed to address the underlying causes associated with the material weakness. Management is committed to finalizing the remediation of the material weakness during 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As management continues to evaluate and work to improve its internal control over financial reporting, management may determine it is necessary to take additional measures to address the material weakness. Until the controls have been operating for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively, the material weakness described above will continue to exist. As such, management has concluded that the material weakness cannot be considered remediated as of September&#160;30, 2021.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the nine months ended September&#160;30, 2021, we implemented certain internal controls in connection with our remediation efforts described above. There have been no other changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="i32bac828c69741158be14bdef01bfe8b_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="i32bac828c69741158be14bdef01bfe8b_118"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Legal Proceedings.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings Relating to Vadadustat</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opposition Proceedings Against Akebia</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July&#160;2011, a third party filed an opposition to our issued European Patent No.&#160;2044005, or the &#8217;005 EP Patent, in the European Patent Office, or the EPO. During the oral proceedings, which took place on April&#160;10, 2013, the Opposition Division of the EPO maintained the &#8217;005 EP Patent. This decision resulted in the maintenance of a claim directed to a compound chosen from a group of eight compounds, including vadadustat, as well as claims to compositions and methods for treating various diseases, including, but not limited to, anemia. Both parties appealed the decision of the Opposition Division of the EPO. On February 27, 2018, we withdrew the &#8217;005 EP Patent from appeal and filed a divisional patent application to pursue a focused claim set that includes claims for vadadustat, as well as pharmaceutical compositions and methods of treating anemia.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September&#160;2018, Dr. Reddy&#8217;s Laboratories Limited filed an opposition to our issued Indian Patent No.&#160;287720 in the Indian Patent Office.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Filed by Akebia Against FibroGen, Inc.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Europe</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We filed an opposition in the EPO against FibroGen, Inc.&#8217;s, or FibroGen&#8217;s, European Patent No. 1463823, or the &#8217;823 EP Patent on December 5, 2013, and an oral proceeding took place March 8 and 9, 2016. Following the oral proceeding, the Opposition Division of EPO ruled that the patent as granted did not meet the requirements for patentability under the European Patent Convention and, therefore, revoked the patent in its entirety. FibroGen has appealed that decision. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 13, 2015, May 20, 2015 and July 6, 2015, we filed oppositions to FibroGen&#8217;s European Patent Nos. 2322155, or the &#8217;155 EP Patent, 1633333, or the &#8217;333 EP Patent, and 2322153, or the &#8217;153 EP Patent in the EPO, respectively, requesting the patents be revoked in their entirety. These method of use patents do not prevent persons from using the compound for other uses, including any previously known use of the compound. In particular, these patents do not claim methods of using any of our product candidates for purposes of inhibiting HIF-PH for the treatment of anemia due to chronic kidney disease, or CKD. While we do not believe these patents will prevent us from commercializing vadadustat for the treatment of anemia due to CKD, we filed these oppositions to provide us and our collaborators with maximum flexibility for developing vadadustat and our pipeline of investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, or HIF-PHI, compounds.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oppositions to the &#8217;155 EP Patent and the &#8217;153 EP Patent were also filed in the EPO by Glaxo Group Limited, or Glaxo, and by Bayer Intellectual Property GmbH, Bayer Pharma Aktiengesellschaft, and Bayer Animal Health GmbH, or, collectively, Bayer. Glaxo withdrew its oppositions on March 2, 2020 and Bayer withdrew its oppositions on June 30, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to the opposition that we filed in Europe against the &#8217;333 EP Patent, an oral proceeding took place on December 8 and 9, 2016. Following the oral proceeding, the Opposition Division of the EPO ruled that the patent as granted did not meet the requirements for patentability under the European Patent Convention and, therefore, revoked the patent in its entirety. On December 9, 2016, FibroGen filed a notice to appeal the decision to revoke the &#8217;333 EP Patent. An oral proceeding for the appeal is scheduled for February 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In oral proceedings held on&#160;May 29, 2017, regarding the &#8217;155 EP Patent, the European Opposition Division ruled that the &#8217;155 EP Patent as granted did not meet the requirements for patentability under the&#160;European Patent Convention&#160;and, therefore, revoked the patent in its entirety. FibroGen filed a notice to appeal the decision to revoke the &#8217;155 EP Patent on May&#160;29,&#160;2017. An oral proceeding for the appeal is scheduled for February 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subsequently, in related oral proceedings held on&#160;May 31, 2017&#160;and&#160;June 1, 2017&#160;for the &#8217;153 EP Patent, the Opposition Division of the EPO maintained the patent after FibroGen significantly narrowed the claims to an indication for which vadadustat is not intended to be developed. We and Glaxo separately filed notices to appeal the decision to maintain the &#8217;153 EP Patent on November 9, 2017. Bayer filed a notice to appeal the decision on November 14, 2017. Glaxo withdrew its appeal on March 2, 2020 and Bayer withdrew its appeal on June 30, 2021. An oral proceeding for the appeal is scheduled for February 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 3, 2019, we filed oppositions to FibroGen&#8217;s European Patent Nos. 2289531, or the &#8217;531 EP Patent, and 2298301, or the &#8217;301 EP Patent in the EPO, respectively, requesting the patents be revoked in their entirety. Oral proceedings for oppositions to the two patents were held on September 7-8 and 10, 2021. Following oral proceedings, the Opposition Division </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of the EPO maintained certain claims in amended form in the two patents. We do not expect the Opposition Division&#8217;s decision on the two patents to have any effect on our commercialization of vadadustat in Europe.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 10, 2020, we filed an opposition to FibroGen&#8217;s European Patent No. 2324834, or the &#8217;834 EP Patent, in the EPO requesting the patent to be revoked in its entirety. On October 19, 2021, FibroGen submitted a request to the Opposition Division to terminate these opposition proceedings and revoke the '834 patent.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canada</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On May 21, 2018, we filed a Statement of Claim in Canadian Federal Court to challenge the validity of three of FibroGen&#8217;s HIF-related patents in Canada: CA 2467689, CA 2468083, and CA 2526496. On June 25, 2020, the parties agreed to dismiss the CA 2467689 patent from the lawsuit. On February 16, 2021, the parties agreed to dismiss the lawsuit in its entirety.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Japan</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2014, we filed an invalidity proceeding before the Japan Patent Office, or JPO, against certain claims of FibroGen&#8217;s Japanese Patent No. 4804131, or the &#8217;131 JP Patent, which is the Japanese counterpart to the &#8217;823 EP Patent, and the JPO issued a preliminary decision finding all of the challenged claims to be invalid. FibroGen subsequently amended the claims and the JPO accepted the amendments. The resulting &#8217;131 JP Patent does not cover vadadustat or any pyridine carboxamide compounds. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2018, we and our collaboration partner in Japan, Mitsubishi Tanabe Pharma Corporation, or MTPC, jointly filed a Request for Trial before the JPO to challenge the validity of one of FibroGen&#8217;s HIF-related patents in Japan, JP4845728. On July 20, 2018 and August 13, 2018, we and MTPC jointly filed a Request for Trial before the JPO to challenge the validity of two additional FibroGen HIF-related patents in Japan, JP5474872 and JP5474741, respectively. On September 26, 2019, the JPO conducted an invalidation trial for JP5474872 and JP4845728. On November 11, 2019, the JPO conducted an invalidation trial for JP5474741. On February 10, 2020, the JPO issued a pre-notice of a trial decision for JP4845728, which invalidated all claims except two claims in amended form. On March 11, 2020, the JPO issued a pre-notice of a trial decision for JP5474872, which invalidated all claims except one claim in amended form. On April 2, 2020, the JPO issued a pre-notice of a trial decision for JP5474741, which invalidated all claims except two claims in amended form. We expect the JPO to issue a final decision this year. We do not believe these decisions will prevent our collaboration partner MTPC from commercializing vadadustat for the treatment of anemia due to CKD in Japan.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United Kingdom</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 13, 2018, we and our collaboration partner, Otsuka Pharmaceutical Co. Ltd., or Otsuka, filed Particulars of Claim in the Patents Court of the United Kingdom, to challenge the validity of FibroGen&#8217;s six HIF-related patents in the UK: the &#8217;823 EP Patent (UK), the &#8217;333 EP Patent (UK), the &#8217;153 EP Patent (UK), the &#8217;155 EP Patent (UK), European Patent (UK) No. 2,289,531, or the &#8217;531 EP Patent (UK), and European Patent (UK) No. 2,298,301, or the &#8217;301 EP Patent (UK).&#160;In May 2019, Astellas Pharma Inc., or Astellas, the exclusive licensee of FibroGen&#8217;s HIF-related patents, sued Akebia and Otsuka for patent infringement in the Patents Court of the UK. In September 2019, we and Otsuka filed an Amended Particulars of Claim to include FibroGen&#8217;s European Patent No. 1487472, or the &#8217;472 EP Patent (UK). On February 28, 2020, the parties agreed to dismiss the &#8217;472 EP Patent (UK) from the trial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A trial was conducted in March 2020. On April 20, 2020, the Patents Court of the UK issued a judgment in favor of Akebia, which invalidated all the claims at issue in each of the &#8217;823 EP Patent (UK), the &#8217;333 EP Patent (UK), the &#8217;153 EP Patent (UK), the &#8217;155 EP Patent (UK) and the &#8217;301 EP Patent (UK). The &#8217;531 EP Patent (UK) was amended to a single claim to recite one specific compound; this claim was held to be valid but not infringed by vadadustat. On June 11, 2020, FibroGen and Astellas appealed the Patents Court&#8217;s judgment on the invalidity of the &#8217;823 EP Patent (UK), the &#8217;301 EP Patent (UK), the &#8217;333 EP Patent (UK), the &#8217;153 EP Patent (UK), and the &#8217;155 EP Patent (UK) in the Court of Appeal (Civil Division).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 8, 2021 - June 10, 2021, the United Kingdom Court of Appeal held a three-day hearing for the appeal.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 24, 2021, the Court of Appeal issued a judgment, which reversed the Patents Court&#8217;s judgment on the invalidity of the &#8217;823 EP Patent (UK) and maintained certain claims of the &#8217;823 EP Patent (UK) and the &#8217;301 EP Patent (UK) in amended form, and which affirmed the Patents Court&#8217;s judgment on the invalidity of the &#8217;333 EP Patent (UK), the &#8217;155 EP Patent (UK), and the &#8217;153 EP Patent (UK). We do not expect the UK Court of Appeal&#8217;s judgment to have any effect on our commercialization of vadadustat in the UK.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">On March 29, 2021, we and our collaboration partner Otsuka America Pharmaceutical, Inc. filed a lawsuit against FibroGen and AstraZeneca AB in the United States District Court for the District of Delaware to seek a declaratory judgment of non-infringement and invalidity of FibroGen&#8217;s twelve HIF-related patents in the United States:  U.S. Patent Nos. 8,318,703, 8,466,172, 8,614,204, 9,920,011, 8,629,131, 8,604,012, 8,609,646, 8,604,013, 10,626,090, 10,894,774, 10,882,827, and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">10,927,081. The defendants filed a motion to dismiss the lawsuit on June 4, 2021. We and Otsuka filed an opposition to the defendants&#8217; motion on July 2, 2021, and the defendants filed a reply brief on July 16, 2021. We and Otsuka requested oral argument on the motion on July 23, 2021. The Court has discretion whether to hear oral argument on the motion. </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings Relating to Auryxia</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ANDA Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October&#160;31, 2018, November&#160;6, 2018, December 24, 2018 and February 4, 2019, Keryx </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Biopharmaceuticals, Inc., or Keryx,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> received Paragraph IV certification notice letters regarding Abbreviated New Drug Applications, or ANDAs, submitted to the U.S. Food and Drug Administration, or FDA, by Lupin Atlantis Holdings SA, or Lupin, Teva Pharmaceuticals USA, Inc., or Teva, Chemo Research S.L., or Chemo, and Mylan Pharmaceuticals Inc., or Mylan, respectively, requesting approval for generic versions of Auryxia tablets (210 mg ferric iron per tablet). On December&#160;13, 2018, Keryx and its licensors, Panion&#160;&amp; BF Biotech, Inc., or Panion, and Chen Hsing Hsu, M.D., filed a complaint for patent infringement against Lupin and Lupin Ltd., or the Lupin Defendants, in the United States District Court for the District of Delaware, or the Delaware District Court, arising from Lupin&#8217;s ANDA filing with the FDA. On December&#160;19, 2018, Keryx and Panion filed a complaint for patent infringement against Teva and Teva Pharmaceutical Industries Limited, or the Teva Defendants, in the Delaware District Court arising from Teva&#8217;s ANDA filing with the FDA. On February 1, 2019, Keryx, Panion and Dr. Hsu filed a complaint for patent infringement against Chemo and Insud Pharma S.A., or the Chemo Defendants, in the Delaware District Court arising from Chemo&#8217;s ANDA filing with the FDA. On March 15, 2019, Keryx, Panion and Dr. Hsu filed a complaint for patent infringement against Mylan in the United States District Court for the Northern District of West Virginia arising from Mylan&#8217;s ANDA filing with the FDA. On April 18, 2019, Keryx, Panion and Dr. Hsu filed a motion with the Judicial Panel on Multidistrict Litigation seeking to consolidate these four cases in the Delaware District Court for pretrial proceedings. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March&#160;29, 2019, April 2, 2019, and April 12, 2019, Keryx received Paragraph IV certification notice letters regarding ANDAs submitted to the FDA by Lupin Ltd., Watson Laboratories, Inc., or Watson, a wholly-owned, indirect subsidiary of Teva, and Par Pharmaceutical, Inc., or Par, an Endo International company, or Endo, respectively, requesting approval for generic versions of Auryxia tablets (210 mg ferric iron per tablet). On May 10, 2019, Keryx, Panion and Dr. Hsu filed a complaint for patent infringement against Lupin Ltd. in the Delaware District Court arising from Lupin Ltd.&#8217;s ANDA filing with the FDA. On May 10, 2019, Keryx and Panion filed a complaint for patent infringement against Watson and the Teva Defendants, or the Watson Defendants, in the Delaware District Court arising from Watson&#8217;s ANDA filing with the FDA. On May 15, 2019, Keryx and Panion filed a complaint for patent infringement against the Watson Defendants in the United States District Court for the District of Nevada, or the Nevada District Court, from Watson&#8217;s ANDA filing with the FDA. On May 23, 2019, Keryx and Panion filed a complaint for patent infringement against Par in the Delaware District Court arising from Par&#8217;s ANDA filing with the FDA. On May 24, 2019, Keryx and Panion filed a complaint for patent infringement against Par, in the United States District Court for the Southern District of New York, or the Southern New York District Court, arising from Par&#8217;s ANDA filing with the FDA. On June 4, 2019, Keryx and Panion filed a notice of voluntary dismissal to dismiss the suit in the Nevada District Court in view of the Watson Defendants&#8217; consent to venue of the Delaware District Court. On June 26, 2019, Keryx, Panion and Dr. Hsu notified the Judicial Panel on Multidistrict Litigation of additional actions in the Delaware District Court against the Lupin Defendants and the Watson Defendants. On July 31, 2019, the Judicial Panel on Multidistrict Litigation issued an order to consolidate all of our ANDA cases in Delaware District Court for pretrial proceedings. On August 26, 2019, Keryx filed an amended complaint against the Lupin Defendants in the Delaware District Court arising from the Lupin Defendants&#8217; ANDA filings with the FDA. On September 19, 2019, the Delaware District Court set a trial date for February 8, 2021. The trial was rescheduled for June 28, 2021. On January 13, 2021, the Delaware District Court vacated the deadlines for the case involving Mylan pending resolution of a discovery dispute.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On July 22, 2019, Keryx received from Teva a supplemental Paragraph IV certification notice letter regarding its ANDA. On July 22, 2019, Keryx received from Watson a supplemental Paragraph IV certification notice letter regarding its ANDA. On July 31, 2019, Keryx received from Lupin a supplemental Paragraph IV certification notice letter regarding its ANDA. On July 31, 2019, Keryx received from Lupin Ltd. a supplemental Paragraph IV certification notice letter regarding its ANDA. On September 17, 2019, Keryx received from Par a supplemental Paragraph IV certification notice letter regarding its ANDA. On October 16, 2019, Keryx received from Mylan a supplemental Paragraph IV certification notice letter regarding its ANDA.&#160;On May 14, 2020, Keryx received from Chemo a supplemental Paragraph IV certification notice letter regarding its ANDA.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 27, 2020, the Delaware District Court conducted a Markman hearing concerning certain claim construction issues with respect to four Orange Book-listed patents, and issued an order in favor of Keryx.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2019, Keryx and Panion entered into a settlement and license agreement with Par. This settlement resolved patent litigation brought by Keryx and Panion in response to Par&#8217;s ANDA seeking approval to market a generic version of Auryxia tablets prior to the expiration of the applicable patents. Pursuant to the terms of the settlement, Keryx and Panion granted Par a license to market a generic version of Auryxia in the United States beginning on March 20, 2025 (subject to FDA approval), or earlier under certain circumstances customary for settlement agreements of this nature. Additionally, in accordance with the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement, the parties terminated all ongoing litigation between Keryx and Panion and Par regarding Auryxia patents pending in the Delaware District Court and the Southern New York District Court. The settlement and license agreement is confidential and subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice. On August 5, 2019, the parties filed a request to stay the litigation pending a review of the settlement and license agreement by these regulatory authorities. On September 6, 2019 and September 9, 2019, the Southern New York District Court and the Delaware District Court, respectively, entered a stipulation and order of dismissal filed by the parties to terminate the actions against Par.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 30, 2020, Keryx and Panion entered into a settlement and license agreement with Teva and Watson. This settlement resolved patent litigation brought by Keryx and Panion in response to Teva and Watson&#8217;s ANDAs seeking approval to market a generic version of Auryxia tablets prior to the expiration of the applicable patents. Pursuant to the terms of the settlement, Keryx and Panion granted Teva and Watson a license to market a generic version of Auryxia in the United States beginning on March 20, 2025 (subject to FDA approval), or earlier under certain circumstances customary for settlement agreements of this nature. Additionally, in accordance with the agreement, the parties terminated all ongoing litigation between Keryx and Panion and Watson and Teva regarding Auryxia patents pending in the Delaware District Court. The settlement and license agreement is confidential and subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice. On May 4, 2020, the Delaware District Court entered a stipulation and order of dismissal filed by the parties to terminate the action against Teva and Watson.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 24, 2020, Keryx, Panion and Dr. Hsu entered into a settlement and license agreement with the Lupin Defendants. This settlement resolved patent litigation brought by Keryx and Panion in response to Lupin and Lupin Ltd.&#8217;s ANDAs seeking approval to market a generic version of Auryxia tablets prior to the expiration of the applicable patents. Pursuant to the terms of the settlement, Keryx and Panion granted Lupin and Lupin Ltd. a license to market a generic version of Auryxia in the United States beginning on March 20, 2025 (subject to FDA approval), or earlier under certain circumstances customary for settlement agreements of this nature. Additionally, in accordance with the agreement, the parties terminated all ongoing litigation among Keryx, Panion, the Lupin Defendants and Dr. Hsu regarding Auryxia patents pending in the Delaware District Court. The settlement and license agreement is confidential and subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice. On October 5, 2020, the Delaware District Court entered a stipulation and order of dismissal filed by the parties to terminate the action against the Lupin Defendants.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2021, Keryx and Panion entered into a settlement and license agreement with the Chemo Defendants. This settlement resolved patent litigation brought by Keryx and Panion in response to Chemo&#8217;s ANDA seeking approval to market a generic version of Auryxia tablets prior to the expiration of the applicable patents. Pursuant to the terms of the settlement, Keryx and Panion granted Chemo a license to market a generic version of Auryxia in the United States beginning on March 20, 2025 (subject to FDA approval), or earlier under certain circumstances customary for settlement agreements of this nature. Additionally, in accordance with the agreement, the parties terminated all ongoing litigation among Keryx, Panion, and the Chemo Defendants regarding Auryxia patents pending in the Delaware District Court. The settlement and license agreement is confidential and subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice. On March 26, 2021, the Delaware District Court entered a stipulation and order of dismissal filed by the parties to terminate the action against the Chemo Defendants.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2021, Keryx, Panion and Dr. Hsu entered into a settlement and license agreement with Mylan. This settlement resolved patent litigation brought by Keryx, Panion, and Dr. Hsu in response to Mylan&#8217;s ANDA seeking approval to market a generic version of Auryxia tablets prior to the expiration of the applicable patents. Pursuant to the terms of the settlement, Keryx, Panion, and Dr. Hsu granted Mylan a license to market a generic version of Auryxia in the United States beginning on March 20, 2025 (subject to FDA approval), or earlier under certain circumstances customary for settlement agreements of this nature. Additionally, in accordance with the agreement, the parties terminated all ongoing litigation among Keryx, Panion, Dr. Hsu, and Mylan regarding Auryxia patents pending in the Delaware District Court and the North District Court of West Virginia. The settlement and license agreement is confidential and subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice. On September 28, 2021, the Delaware District Court entered a stipulation and order of dismissal filed by the parties to terminate the action against Mylan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Keryx, Panion and, as applicable, Dr. Hsu have now entered into settlement and license agreements resolving all patent litigation proceedings brought by Keryx, Panion and, as applicable, Dr. Hsu, in response to ANDAs filed by third parties seeking approval to market generic versions of Auryxia&#174; (ferric citrate) tablets prior to the expiration of the applicable patents.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CMS Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 15, 2019, we filed a complaint in the United States District Court for the District of Massachusetts, or the Massachusetts District Court, against Centers for Medicare &amp; Medicaid Services, or CMS, the U.S. Department of Health and Human Services, Alex M. Azar II in his official capacity as Secretary of Health and Human Services, and Seema Verma in her </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">official capacity as administrator for CMS challenging CMS&#8217;s decision that Auryxia would no longer be covered by Medicare for the treatment of iron deficiency anemia, or IDA, in adult patients with CKD not on dialysis, or the IDA Indication, and imposing a prior authorization requirement for Auryxia in the treatment of adult patients with CKD on dialysis, or the Hyperphosphatemia Indication. On October 29, 2019, we filed a motion for a preliminary injunction asking the court to provide relief while the lawsuit is pending, specifically, to restore coverage of Auryxia for the IDA Indication, and to remove the prior authorization requirement for Auryxia for the Hyperphosphatemia Indication. In the alternative, we filed a motion for summary judgment with the court asking it to decide the case on the merits. On February 4, 2020, the court denied our request for a preliminary injunction. We filed an expedited appeal with the Court of Appeals for the First Circuit challenging the District Court&#8217;s denial of our motion for a preliminary injunction. The First Circuit Court of Appeals held oral argument on August 14, 2020, and affirmed the District Court&#8217;s denial of our request for a preliminary injunction on September 30, 2020. We then attempted to reach a settlement with CMS, but we were unsuccessful in these efforts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 22, 2021, the parties agreed to dismiss the litigation. As a result, Auryxia remains not covered by Medicare for the IDA Indication and the prior authorization requirement for Auryxia for the Hyperphosphatemia Indication also remains in place.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Litigation Relating to Auryxia Supply</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Four&#160;putative class action lawsuits were filed against Keryx, and certain of its former officers (Gregory P. Madison, Scott A. Holmes, Ron Bentsur, and James Oliviero) and consolidated in the Massachusetts District Court, captioned Karth v. Keryx Biopharmaceuticals, Inc., et al. (filed October 26, 2016, with an amended complaint filed on February 27, 2017). Plaintiff sought to represent all stockholders who purchased shares of Keryx common stock between May 8, 2013 and August 1, 2016. The complaint alleges that Keryx and the named individual defendants violated Sections 10(b) and/or 20(a) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and Rule 10b-5 promulgated thereunder by making allegedly false and/or misleading statements concerning Keryx, its supplier relationships, and future prospects, and that the allegedly misleading statements were not made known to the market until Keryx&#8217;s August 1, 2016 announcement of an interruption in its supply of Auryxia.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 23, 2019, the Massachusetts District Court issued a Memorandum and Order denying plaintiff&#8217;s motion for class certification, granting defendants&#8217; motion for judgment on the pleadings, and denying plaintiff&#8217;s motion for leave to further amend his Complaint.&#160;That same day, the Massachusetts District Court entered a final judgment in favor of defendants on all claims.&#160;On September 24, 2019, plaintiff filed a notice of appeal. On June 21, 2021, the First Circuit affirmed the District Court&#8217;s judgment in its entirety. The time for plaintiff to seek a rehearing before the First Circuit has now lapsed. Plaintiff has until November 18, 2021 to file a petition for certiorari to the United States Supreme Court to the extent Plaintiff wishes to seek any further appellate review.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Two&#160;stockholder derivative complaints also were filed on December 16, 2016 against Keryx and certain of its former officers (Gregory P. Madison, Scott A. Holmes, Ron Bentsur and James Oliviero) certain of its former directors (Kevin J. Cameron, Daniel P. Regan, Steven C. Gilman, Michael Rogers Michael P. Tarnok, Joseph Feczko, Jack Kaye Wyche Fowler, Jr. and John P. Butler), some of whom are current directors and officers of ours, in the Superior Court of Massachusetts, one captioned Venkat Vara Prasad Malledi v. Keryx Biopharmaceuticals, Inc., et al., and one captioned James Anderson v. Keryx Biopharmaceuticals, Inc., et al.&#160;Each of these two complaints generally alleged breach of fiduciary duty, unjust enrichment, abuse of control, mismanagement and corporate waste. On June 27, 2017, the Superior Court of Massachusetts granted the parties&#8217; motion to consolidate and stay the derivative litigations pending the outcome of the federal securities litigation. On July 15, 2021, the plaintiffs in these actions filed a Notice of Dismissal, without prejudice, of all claims. </span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Litigation Relating to the Merger</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 28, 2018, we entered into an Agreement and Plan of Merger with Keryx and Alpha Therapeutics Merger Sub, Inc., or the Merger Sub, pursuant to which the Merger Sub would merge with and into Keryx, with Keryx becoming a wholly owned subsidiary of ours, or the Merger. On December 12, 2018, we completed the Merger. In October and November 2018, four purported shareholders of Keryx filed four separate putative class actions, or the Merger Securities Actions, against Keryx, a former officer and director of Keryx (Jodie P. Morrison), former directors of Keryx (Kevin J. Cameron, Mark J. Enyedy, Steven C. Gilman, Michael T. Heffernan, Daniel P. Regan and Michael Rogers, some of whom are current members of our Board of Directors), and, with respect to the Rosenblatt action discussed below, the Merger Sub and Akebia, challenging the disclosures made in connection with the Merger.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three of the Merger Securities Actions were filed in the Delaware District Court: Corwin v. Keryx Biopharmaceuticals, Inc., et al. (filed October 16, 2018); Van Hulst v. Keryx Biopharmaceuticals, Inc., et al. (filed October 24, 2018); and Andreula v. Keryx Biopharmaceuticals, Inc., et al. (filed November 1, 2018). The fourth Merger Securities Action was filed in the Massachusetts District Court: Rosenblatt v. Keryx Biopharmaceuticals, Inc., et al. (filed October 23, 2018). On February 19, 2019, the plaintiff in the Rosenblatt action filed a notice of voluntary dismissal of the action without prejudice. On March 27, 2019, the plaintiff in the Van Hulst action filed a notice of voluntary dismissal of the action without prejudice.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 2, 2019, the Delaware District Court granted Abraham Kiswani, a member of the putative class in both the Andreula and Corwin actions, and plaintiff John Andreula&#8217;s motion to consolidate the remaining two Merger Securities Actions pending in the Delaware District Court and consolidated the Corwin and Andreula cases under the caption In re Keryx Biopharmaceuticals, Inc., or the Consolidated Federal Action. The Delaware District Court also appointed Kiswani and plaintiff Andreula as lead plaintiffs for the Consolidated Federal Action. On June 3, 2019, the lead plaintiffs filed a consolidated amended complaint in the Consolidated Federal Action, or the Consolidated Complaint. The Consolidated Complaint generally alleged that the registration statement filed in connection with the Merger contained allegedly false and misleading statements or failed to disclose certain allegedly material information in violation of Section 14(a) and 20(a) of the Exchange Act, and Rule 14a-9 promulgated thereunder. The alleged misstatements or omissions related to (i) certain financial projections for Keryx and Akebia and certain financial analyses performed by our advisors and (ii) any alleged negotiations that may have taken place regarding the conversion of certain convertible notes of Keryx in connection with the Merger. The Consolidated Complaint sought compensatory and/or rescissory damages, a declaration that the defendants violated Sections 14(a) and 20(a) of the Exchange Act and Rule 14a-9 thereunder, and an award of lead plaintiffs&#8217; costs, including reasonable allowance for attorneys&#8217; fees and experts&#8217; fees. The defendants in the Consolidated Federal Action moved to dismiss the Consolidated Complaint in its entirety and with prejudice on August 2, 2019. On April 15, 2020, the Delaware District Court granted the defendants&#8217; motion and dismissed the Consolidated Complaint in its entirety. On July 2, 2020, lead plaintiffs filed a second consolidated amended complaint, or the Second Consolidated Complaint. The Second Consolidated Complaint (i) asserts the same claims under the Exchange Act as the Consolidated Complaint, (ii) names the same defendants as the Consolidated Complaint, (iii) seeks the same relief as the Consolidated Complaint and (iv) as with the Consolidated Complaint, challenges as false or misleading alleged misstatements or omissions related to certain financial projections for Keryx and Akebia and certain financial analyses performed by our advisors. The defendants in the Consolidated Federal Action moved to dismiss the Second Consolidated Amended Complaint in its entirety with prejudice on August 10, 2020. On April 1, 2021, the Delaware District Court granted the defendants&#8217; motion and dismissed the Second Consolidated Complaint in its entirety. On April 29, 2021, lead plaintiffs filed a notice of appeal in the United States Court of Appeals for the Third Circuit.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Briefing on the appeal was completed on October 7, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 15, 2021, a purported former Keryx stockholder filed a putative class action in the Supreme Court of the State of New York against Akebia, a current officer of Akebia (John P. Butler), a former officer of Akebia (Jason A. Amello), former directors of Akebia (Muneer A. Satter, Scott A. Canute, Michael D. Clayman, Maxine Gowen, Duane Nash, Ronald C. Renaud, Jr., and Michael S. Wyzga), a current director of Akebia (Cynthia Smith), a former director and officer of Keryx (Jodie P. Morrison), a former officer of Keryx (Scott A. Holmes) and former directors of Keryx (Michael Rogers, Kevin J. Cameron, Steven C. Gilman, Daniel P. Regan, Mark J. Enyedy, and Michael T. Heffernan, some of whom are current members of our Board of Directors). The action is captioned Loper v. Akebia Therapeutics Inc., et al., or the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Loper </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Action. The complaint in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Loper </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Action alleges that the registration statement filed in connection with the Merger contained allegedly false and misleading statements or failed to disclose certain allegedly material information in violation of Section 11, 12(a)(2), and 15 of the Securities Act of 1933, as amended. The alleged misstatements or omissions relate to the safety, approvability, and commercial viability of vadadustat. The complaint in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Loper </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Action seeks damages including interest thereon, an award of plaintiffs&#8217; and the class&#8217;s costs and expenses, including counsel fees and expert fees, and rescission, disgorgement, or such other equitable or injunctive relief that the Court deems appropriate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 16, 2021, another purported former Keryx stockholder filed a putative class action making substantially similar allegations and asserting the same claims as the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Loper</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Action, also in the Supreme Court of the State of New York against the same defendants named in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Loper</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Action (except for Kevin J. Cameron, Scott A. Holmes, and Daniel P. Regan). The action is captioned Panicho v. Akebia Therapeutics, Inc., et al., or the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Panicho</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Action.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 15, 2021, the Supreme Court of the State of New York entered a joint stipulation and order consolidating the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Loper</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Action and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Panicho</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Action under the caption In re Akebia Therapeutics, Inc. Securities Litigation, or the Consolidated State Action, providing for the filing of a consolidated complaint in the Consolidated State Action by October 27, 2021, and providing for briefing to be completed on any motion to dismiss such consolidated complaint by March 28, 2022. The consolidated complaint was filed on October 27, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We deny any allegations of wrongdoing and intend to continue vigorously defending against the shareholder lawsuits described in this Legal Proceedings section. There is no assurance, however, that we will be successful in the defense of these lawsuits, or any associated appeals, or that insurance will be available or adequate to fund any settlement or judgment or the litigation costs of these actions. Moreover, we are unable to predict the outcome or reasonably estimate a range of possible losses at this time. A resolution of these lawsuits in a manner adverse to us, however, could have a material effect on our financial position and results of operations in the period in which a particular lawsuit is resolved.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i32bac828c69741158be14bdef01bfe8b_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We face a variety of risks and uncertainties in our business. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also become important factors that affect our business. If any of the following risks occurs, our business, financial statements and future growth prospects could be materially and adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Financial Position and Need for Additional Capital</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since our inception, and anticipate that we will continue to incur significant losses and cannot guarantee when, if ever, we will become profitable or attain positive cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in pharmaceutical product development and commercialization is highly speculative because it requires upfront capital expenditures and significant risk that a product candidate will fail to gain marketing approval or that an approved product will not be commercially viable. Since our inception, we have devoted most of our resources to research and development, including our preclinical and clinical development activities and, following the merger, or the Merger, whereby Keryx Biopharmaceuticals, Inc., or Keryx, became a wholly owned subsidiary of ours, commercialization. We have financed our operations primarily through sales of equity securities, our strategic collaborations and, following the Merger, product revenues, a royalty monetization transaction and debt. Prior to the Merger, we had no products approved for commercial sale and had not generated any revenue from the sale of products. We are not currently profitable and have incurred net losses each year since our inception, including net losses of $212.2 million for the nine months ended September&#160;30, 2021. As of September&#160;30, 2021, we had an accumulated deficit of $1.4 billion. We cannot guarantee when, if ever, we will become profitable. Our ability to generate product revenue and achieve profitability depends significantly on our success in many areas, including the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developing, commercializing and marketing Auryxia, vadadustat, if approved, and any other product or product candidate, including those that may be in-licensed or acquired;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining marketing approvals for vadadustat and any other product candidate, including those that may be in-licensed or acquired, and the timing and scope of such approvals, and maintaining marketing approvals for Auryxia, vadadustat, if approved, and any other product, including those that may be in-licensed or acquired;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developing sustainable and scalable manufacturing processes for Auryxia, vadadustat and any other product or product candidate, including those that may be in-licensed or acquired;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate products that are compliant with good manufacturing practices, or GMPs, to support the clinical development and the market demand for Auryxia, vadadustat, if approved, and any other product and product candidate, including those that may be in-licensed or acquired;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining adequate or favorable pricing and reimbursement from private and governmental payors for Auryxia, vadadustat and any other product or product candidate, including those that may be in-licensed or acquired;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining and maintaining market acceptance of Auryxia, vadadustat and any other product candidate, including those that may be in-licensed or acquired;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the size of any market in which Auryxia, vadadustat and any other product or product candidate, including those that may be in-licensed or acquired, receives approval and obtaining adequate market share in those markets;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">competing effectively with any competitive products and any products that may disrupt the biotechnology industry;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">identifying, assessing, acquiring, in-licensing and/or developing new product candidates;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">negotiating favorable terms in any transaction into which we may enter, including collaboration, merger, acquisition and licensing arrangements;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">attracting, hiring and retaining qualified personnel.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and operating losses for the foreseeable future. The amount of our future net losses will depend, in part, on the rate of our future expenditures, and our financial position will depend, in part, on product revenue, collaboration revenue, and our ability to obtain additional funding. We expect to continue to incur significant expenses if and as we:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">conduct and enroll patients in any clinical trials, including post-marketing approval studies, any Phase 4 studies or any other clinical trials for Auryxia, vadadustat or any other product or product candidate, including those that may be in-licensed or acquired;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continue our commercialization activities for Auryxia and plan for the commercialization of vadadustat, if approved, and any other product or product candidate, including those that may be in-licensed or acquired;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">adapt to any regulatory changes, including changes relating to reimbursement;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">adapt to any changes in reimbursement practices by third party payors;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">seek marketing approvals for vadadustat and any other product candidate, including those that may be in-licensed or acquired;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">maintain marketing approvals for Auryxia, vadadustat, if approved, and any other product, including those that may be in-licensed or acquired;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">have Auryxia, vadadustat and any other product or product candidate, including those that may be in-licensed or acquired, manufactured for clinical trials and for commercial sale;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">seek to discover and develop additional product candidates or platforms that may lead to the discovery of additional product candidates;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">engage in transactions, including strategic, merger, collaboration, acquisition and licensing transactions, pursuant to which we would market and develop commercial products, or develop and commercialize other product candidates and technologies;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">make royalty, milestone or other payments under our license agreements and any future license agreements;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">maintain, protect and expand our intellectual property portfolio;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">attract, hire and retain qualified personnel;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continue to create additional infrastructure and expend additional resources to support our operations as a fully integrated, publicly traded biopharmaceutical company; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">experience any delays or encounter issues with any of the above.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have and will continue to expend significant resources in our legal proceedings, as described under Part II, Item 1. Legal Proceedings, or any other such legal proceedings brought by or against us in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with pharmaceutical product development and commercialization, we are unable to accurately predict the timing or amount of increased expenses. The net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. In any particular quarter, the progress of our clinical development and our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we succeed in receiving marketing approval for and are able to commercialize vadadustat in the United States and other regions, we will continue to incur substantial expenditures relating to continued commercialization and post-marketing requirements for Auryxia, vadadustat and any other products, including those that may be in-licensed or acquired, as well as costs relating to the research and development of any other product candidate, including those that may be in-licensed or acquired. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expenses could increase beyond expectations if we are required by the U.S. Food and Drug Administration, or FDA, the European Medicines Agency, or the EMA, or other regulatory authorities, or if we otherwise believe it is necessary, to change our manufacturing processes or assays, to amend or replace our study protocols, to repeat any of our clinical trials, to perform studies in addition to, different from or larger than those currently expected, if there are any delays in completing our clinical trials or if there are delays in or issues with obtaining marketing approval for vadadustat in the United States, the EU or other jurisdictions. Even if vadadustat and any other product candidate, including those that may be in-licensed or acquired, are approved for commercial sale, we anticipate incurring significant costs associated with commercialization. In addition, our ability to generate revenue would be negatively affected if the size of our addressable patient population is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, or the patient population for treatment is narrowed by competition, physician choice, coverage or reimbursement, or payor or treatment guidelines. Even though we generate product revenue from Auryxia and royalties from Riona and Vafseo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan and may generate revenue and royalties from the sale of any products that may be approved in the future, including those that may be in-licensed or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquired, we may never generate revenue and royalties that are significant enough for us to become and remain profitable, and we will need to obtain additional funding to continue operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional financing to achieve our goals. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, our cash and cash equivalents and available for sale securities were $207.2 million. We expect to continue to expend substantial amounts of cash for the foreseeable future as we continue to commercialize Auryxia and develop and commercialize vadadustat, if approved, and any other product or product candidate, including those that may be in-licensed or acquired. These expenditures will include costs associated with research and development, manufacturing, potentially obtaining marketing approvals and marketing products approved for sale, if any. In addition, other unanticipated costs may arise. Because the outcome of our current and anticipated clinical trials is highly uncertain, we cannot reasonably estimate the actual amount of funding necessary to successfully complete the clinical development, including post-marketing studies, and to successfully commercialize Auryxia and vadadustat, if approved. Our future capital requirements depend on many factors, including:</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the scope, progress, results and costs of conducting clinical studies or any post-marketing approval requirements, Phase 4 studies or any other clinical trials for Auryxia, vadadustat and any other product or product candidate, including those that may be in-licensed or acquired;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">the cost and timing of commercialization activities, including product manufacturing, marketing, sales and distribution costs, for Auryxia, vadadustat, if approved, and any other product or product candidate, including those that may be in-licensed or acquired;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the results of our meetings with the FDA, the EMA and other regulatory authorities and any consequential effects, including on timing of and ability to obtain and maintain marketing approval, study design, study size and resulting operating costs;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">difficulties or delays in enrolling patients in our clinical trials;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing of, and the costs involved in obtaining, and, if approved, maintaining, marketing approvals for vadadustat and any other product candidate, including those that may be in-licensed or acquired, including to fund the preparation, filing and prosecution of regulatory submissions, and the costs of maintaining marketing approvals for Auryxia or any other product, including those that may be in-licensed or acquired;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the outcome of our efforts to obtain marketing approval for vadadustat in the United States, Europe and in other jurisdictions and any other product candidates, including those that may be in-licensed or acquired;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of securing and validating commercial manufacturing of vadadustat and any other product candidate, including those that may be in-licensed or acquired, and maintaining our manufacturing arrangements for Auryxia or any other product, including those that may be in-licensed or acquired, or securing and validating additional arrangements;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs involved in preparing, filing and prosecuting patent applications and maintaining, defending and enforcing our intellectual property rights, including litigation costs, and the outcome of such litigation;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs involved in any legal proceedings to which we are a party;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to attract, hire and retain qualified personnel; </span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:32.5pt">any ongoing costs related to the creation of additional infrastructure and expansion of additional resources to support our operations as a fully integrated, publicly traded biopharmaceutical company; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the extent to which we engage in transactions, including strategic, merger, collaboration, acquisition and licensing transactions, pursuant to which we would develop and market commercial products, or develop other product candidates and technologies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we expect to continue to incur costs associated with operating as a fully integrated, publicly traded biopharmaceutical company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that our cash resources will be sufficient to allow us to fund our current operating plan through at least the next twelve months from the filing of this Quarterly Report on Form 10-Q. We have based these estimates on assumptions that may prove to be wrong due to a variety of factors, including due to the effects of the ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or COVID-19, pandemic, and we could use our available capital resources sooner than we currently expect. In addition, there can be no assurance that the current operating plan will be achieved in the time frame anticipated by us, or that our cash resources will fund our operating plan for the period anticipated by us or that additional </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">funding will be available on terms acceptable to us, or at all. Furthermore, our regulatory milestones may not be achieved, we may not receive the anticipated funding from our collaboration partners, and we may not secure other sources of financing. We expect to finance future cash needs through product revenue, public or private equity or debt transactions, payments from our collaborators, royalty transactions, strategic transactions, or a combination of these approaches. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic objectives.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, if we receive regulatory approval of vadadustat in the U.S., we expect to incur significant incremental costs to our current operating plan to commercialize vadadustat, including costs of marketing, manufacturing and distribution. The potential timely regulatory approval of vadadustat and the receipt of associated regulatory milestones is an important source of funding of our cash runway. However, we will require additional funding to fund our operating plan beyond the next twelve months. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any additional fundraising efforts may divert our management&#8217;s attention away from their day-to-day activities, which may adversely affect our ability to develop and commercialize Auryxia, vadadustat and any other products or product candidates, including those that may be in-licensed or acquired. Also, additional funds may not be available to us in sufficient amounts or on acceptable terms or at all.&#160;If we are unable to raise additional capital in sufficient amounts when needed or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development and/or commercialization of Auryxia, vadadustat, if approved, and any other products or product candidates, including those that may be in-licensed or acquired. Any of these events could significantly harm our business, financial condition and prospects.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our obligations in connection with the Loan Agreement with Pharmakon could adversely affect our financial condition and restrict our operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we entered into a loan agreement, or the Loan Agreement, with funds managed by Pharmakon Advisors LP, or Pharmakon, pursuant to which senior secured term loans in an aggregate principal amount of $100.0 million, or the Term Loans, were made available to us in two tranches.&#160;The first tranche of $80.0 million closed on November 25, 2019, and the second tranche of $20.0 million closed on December 10, 2020. See Note 11 to our unaudited condensed consolidated financial statements in Part I, Item 1. Financial Statements (unaudited) included in this Quarterly Report on Form 10-Q for additional information regarding our obligations under the Loan Agreement. Our Loan Agreement with Pharmakon contains affirmative and negative covenants applicable to us and our subsidiaries, including maintaining, on an annual basis, a minimum liquidity threshold starting in 2021, and on a quarterly basis, a minimum net sales threshold for Auryxia, which started in the fourth quarter of 2020. Failure to maintain compliance with these or other covenants could result in an event of default under the Loan Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event there is an acceleration of our and certain of our subsidiaries&#8217; liabilities under the Loan Agreement as a result of an event of default, we may not have sufficient funds or may be unable to arrange for additional financing to repay the liabilities or to make any accelerated payments, and Pharmakon could seek to enforce security interests in the collateral securing the Loan Agreement and Keryx&#8217;s guarantee of the Term Loans, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement permits voluntary prepayment at any time in whole or in part, subject to prepayment premiums and make-whole premiums prior to certain dates. Upon a change of control, mandatory prepayment provisions require us to prepay the principal amount outstanding, the applicable prepayment premium and make-whole premium and accrued and unpaid interest. In addition, our obligations in connection with the Loan Agreement could have additional significant adverse consequences, including, among other things:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restricting our activities, including limitations on transferring certain of our assets, engaging in certain transactions, incurring certain additional indebtedness, creating certain liens, paying dividends or making certain other distributions and investments;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limiting our flexibility in planning for, or reacting to, changes in our business and our industry;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">placing us at a competitive disadvantage compared to our competitors who have a smaller amount of debt or competitors with comparable debt at more favorable interest rates; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limiting our ability to borrow additional amounts for working capital, capital expenditures, research and development efforts, acquisitions, debt service requirements, execution of our business strategy and other purposes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Royalty Interest Acquisition Agreement with HealthCare Royalty Partners IV, L.P. contains various covenants and other provisions, which, if violated, could materially adversely affect our financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2021, we entered into a royalty interest acquisition agreement, or the Royalty Agreement, with HealthCare Royalty Partners IV, L.P., or HCR, pursuant to which we sold to HCR our right to the to receive royalties and sales milestones for vadadustat, collectively the Royalty Interest Payments, in each case, payable to us under our Collaboration Agreement dated December 11, 2015, or the MTPC Agreement, with Mitsubishi Tanabe Pharma Corporation, or MTPC, subject to an annual maximum &#8220;cap&#8221; of $13.0 million, or the Annual Cap, and an aggregate maximum &#8220;cap&#8221; of $150.0 million, or the Aggregate Cap. Under the Royalty Agreement, we are required to comply with various covenants, including obligations to take certain actions, such as actions with respect to the Royalty Interest Payments, the MTPC Agreement, our agreement with MTPC for the commercial supply of vadadustat drug product, and our intellectual property. In addition, the Royalty Agreement includes customary events of default upon the occurrence of enumerated events, including failure to perform certain covenants and the occurrence of insolvency events. In the event we violate certain covenants and other provisions, we may not receive sales milestones from HCR even if the applicable sales thresholds are met. Upon the occurrence of an event of default, HCR would have the ability to exercise all available remedies in law and equity, which could have a material adverse effect on our financial condition. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties from commercial sales of vadadustat under our Collaboration Agreement with MTPC will likely fluctuate and will impact our rights to receive future payments from our Royalty Agreement with HCR.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Royalty Agreement with HCR, we sold to HCR our right to receive the Royalty Interest Payments payable to us under our the MTPC Agreement, subject to the Annual Cap and the Aggregate Cap. After HCR receives Royalty Interest Payments equal to the Annual Cap in a given calendar year, we will receive 85% of the Royalty Interest Payments for the remainder of that year. After HCR receives Royalty Interest Payments equal to the Aggregate Cap, or we pay the Aggregate Cap to HCR (net of the Royalty Interest Payments already received by HCR), the Royalty Interest Payments will revert back to us, and HCR would have no further right to any Royalty Interest Payments. We received $44.8 million from HCR (net of certain transaction expenses) under the Royalty Agreement, and we are eligible to receive up to an additional $15.0 million under the Royalty Agreement if specified sales milestones are achieved for vadadustat in the territory covered by the MTPC Agreement, subject to the satisfaction of certain customary conditions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The royalty revenues under the MTPC Agreement may fluctuate considerably because they depend upon, among other things, the rate of growth of sales of vadadustat in the territory covered under the MTPC Agreement. Negative fluctuations in these royalty revenues could delay, diminish or eliminate our right to receive up to the additional $15.0 million under the Royalty Agreement upon achievement of the specified sales milestones, our ability to receive 85% of the Royalty Interest Payments after the Annual Cap is achieved in a given calendar year, or our ability to receive 100% of the Royalty Interest Payments after the Aggregate Cap is achieved. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product and product candidates on unfavorable terms to us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to finance our cash needs through product revenues, public or private equity or debt transactions, payments from our collaborators, royalty transactions, strategic transactions, or a combination of these approaches. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common stockholders will be diluted, our fixed payment obligations may increase, any such securities may have rights senior to those of our common stock, and the terms may include liquidation or other preferences and anti-dilution protections that adversely affect the rights of our common stockholders. Additional debt financing, if available, may involve agreements that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, make capital expenditures, declare dividends, acquire, sell or license intellectual property rights, and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through royalty transactions, we may have to relinquish valuable rights to our portfolio and future revenue streams, and enter into agreements that would restrict our operations and strategic flexibility. If we raise additional funds through strategic transactions with third parties, we may have to do so at an earlier stage than otherwise would be desirable. In connection with any such strategic transactions, we may be required to relinquish valuable rights to our product and product candidate, future revenue streams or research programs or grant licenses on terms that are not favorable to us. If we are unable to raise additional funds when needed, we may not be able to pursue planned development and commercialization activities and we may need to grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may engage in strategic transactions to acquire assets, businesses, or rights to products, product candidates or technologies or form collaborations or make investments in other companies or technologies that could harm our operating results, dilute our stockholders&#8217; ownership, increase our debt, or cause us to incur significant expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business strategy, we may engage in additional strategic transactions to expand and diversify our portfolio, including through the acquisition of assets, businesses, or rights to products, product candidates or technologies or through strategic alliances or collaborations, similar to the Merger and our existing collaboration and license arrangements. We may not identify suitable strategic transactions, or complete such transactions in a timely manner, on favorable terms, on a cost-effective basis, or at all. Moreover, we may devote resources to potential opportunities that are never completed or we may incorrectly judge the value or worth of such opportunities. Even if we successfully execute a strategic transaction, we may not be able to realize the anticipated benefits of such transaction and may experience losses related to our investments in such transactions. Integration of an acquired company or assets into our existing business may not be successful and may disrupt ongoing operations, require the hiring of additional personnel and the implementation and integration of additional internal systems and infrastructure, and require management resources that would otherwise focus on developing our existing business. Even if we are able to achieve the long-term benefits of a strategic transaction, our expenses and short-term costs may increase materially and adversely affect our liquidity. Any of the foregoing could have a detrimental effect on our business, results of operations and financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, future transactions may entail numerous operational, financial and legal risks, including:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">incurring substantial debt, dilutive issuances of securities or depletion of cash to pay for acquisitions;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">exposure to known and unknown liabilities, including contingent liabilities, possible intellectual property infringement claims, violations of laws, tax liabilities and commercial disputes;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">higher than expected acquisition and integration costs;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">difficulty in integrating operations, processes, systems and personnel of any acquired business;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:32.5pt">increased amortization expenses or, in the case of a write-down of the value of acquired assets, impairment losses, such as the Auryxia intangible asset impairment in the second quarter of 2020 and corresponding adjustments to the estimated useful life of the developed product rights for Auryxia;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">impairment of relationships with key suppliers or customers of any acquired business due to changes in management and ownership;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">inability to retain personnel, customers, distributors, vendors and other business partners integral to an in-licensed or acquired product, product candidate or technology;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">potential failure of the due diligence processes to identify significant problems, liabilities or other shortcomings or challenges;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">entry into indications or markets in which we have no or limited direct prior development or commercial experience and where competitors in such markets have stronger market positions; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">other challenges associated with managing an increasingly diversified business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully manage any transaction in which we may engage, our ability to develop new products and continue to expand and diversify our portfolio may be limited.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Merger</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may fail to realize the anticipated benefits of our merger with Keryx, those benefits may take longer to realize than expected, and we may encounter significant integration difficulties and liabilities, which may have a material adverse effect on our business and financial position.</span></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On December 12, 2018, we completed the Merger. There can be no assurance that we will realize the full benefit of the anticipated synergies and cost savings relating to the Merger or that these benefits will be realized within the expected time frames or at all. Our ability to realize the anticipated benefits of the Merger will depend, to a large extent, on our ability to continue to integrate our business and Keryx&#8217;s business and realize anticipated growth opportunities and synergies. If we are unable to successfully integrate the businesses, or integrate them in a timely fashion, we have faced, and may continue to face, adverse effects, some of which may be material, including, but not limited to (i) diversion of the attention of management and key personnel and potential disruption of our ongoing business, (ii) the loss of employees, (iii) challenges of managing a larger company, including challenges of conforming standards, controls, procedures and accounting and other policies and compensation structures, (iv) difficulties in achieving anticipated cost savings, (v) declines in our results of operations, financial condition or cash flows, and (vi) potential liabilities, adverse consequences, increased expenses or other problems associated with our company following completion of the Merger. Many of these factors are outside of our control, and any one of them </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">could result in increased costs, decreased expected revenues and further diversion of management time and energy, which could materially impact our business, financial statements and prospects</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and cause a decline in the market price of our common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, following the Merger, we have become responsible for Keryx&#8217;s liabilities and obligations, including with respect to legal, financial, regulatory and compliance matters, including certain post-approval regulatory requirements with respect to Auryxia and obligations under collaboration, license, supply and manufacturing agreements. These obligations have, and will continue to, result in additional cost and investment by us and, if we have underestimated the amount of these costs and investments or if we fail to satisfy any such obligations, we may not realize the anticipated benefits of the transaction. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, it is possible that there may be unknown, contingent or other liabilities or problems that may arise in the future, the existence and/or magnitude of which we were previously unaware. Any such liabilities or problems could have an adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lawsuits have been filed challenging the Merger and additional lawsuits may be filed in the future. Any monetary damages, or other adverse judgment could have a material adverse effect on us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is an ongoing appeal of a putative class action lawsuit filed in federal court, and an ongoing putative class action lawsuit in state court, each filed by purported Keryx shareholders challenging the disclosures made in connection with the Merger. See Part II, Item 1. Legal Proceedings for further information relating to the lawsuits. Additional lawsuits arising out of the Merger may be filed in the future. We have, and may continue to be required to, expend significant resources in the defense of these lawsuits, including but not limited to, costs associated with the indemnification of Keryx and Akebia directors and officers, and the lawsuits, regardless of outcome, could have a negative effect on our reputation, stock price and results of operations. In addition, monetary damages or other adverse judgment would have a material adverse effect on our business and financial position.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our financial statements include goodwill and an intangible asset as a result of the Merger. The intangible asset has become impaired and could become further impaired in the future under certain conditions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In addition, goodwill could become impaired in the future under certain conditions. Any potential future impairment of goodwill or intangible assets may significantly impact our results of operations and financial condition.</span></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of September&#160;30, 2021, we had approximately $172.2 million of goodwill and a definite lived intangible asset from the Merger. In accordance with generally accepted accounting principles, or GAAP, we are required annually, or more frequently upon certain indicators of impairment, to review our estimates and assumptions underlying the fair value of our goodwill and our definite lived intangible assets when indicators of impairment are present. Events giving rise to impairment of goodwill or intangible assets are an inherent risk in the pharmaceutical industry and often cannot be predicted. Conditions that could indicate impairment and necessitate such a review include, but are not limited to, Auryxia&#8217;s commercial performance, our inability to execute on our strategic initiatives, the deterioration of our market capitalization such that it is significantly below our net book value, a significant adverse change in legal factors, unexpected adverse business conditions, and an adverse action or assessment by a regulator. To the extent we conclude that goodwill and/or definite lived intangible assets have become impaired, we may be required to incur material write-offs relating to such impairment and any such write-offs could have a material impact on our future operating results and financial position. For example, in the second quarter of 2020, in connection with a routine business review, we reduced our short-term and long-term Auryxia revenue forecast. This reduction was primarily driven by the impact of the September 2018 Centers for Medicare &amp; Medicaid Services, or CMS, decision that Auryxia would no longer by covered by Medicare for the treatment of iron deficiency anemia, or IDA, in adult patients with CKD not on dialysis, or the IDA Indication. While this decision does not impact CMS coverage for the use of Auryxia for the control of serum phosphorus levels in adult patients with CKD on dialysis, or the Hyperphosphatemia Indication, it requires all Auryxia prescriptions for Medicare patients to undergo a prior authorization to ensure their use of Auryxia for the Hyperphosphatemia Indication. As a result, we recorded an impairment charge of $115.5 million during the three months ended June 30, 2020, which was entirely allocated to our only intangible asset, the developed product rights for Auryxia, and made a corresponding adjustment to the estimated useful life of the developed product rights for Auryxia, which we again adjusted during the three months ended December 31, 2020. The estimates, judgments and assumptions used in our impairment testing, and the results of our testing, are discussed in Note 9 to the consolidated financial statements in the Company&#8217;s 2020 Annual Report on Form 10-K. If these estimates, judgments and assumptions change in the future, including if the Auryxia asset group does not meet its current forecasted projections, additional impairment charges could be recorded in the future and additional corresponding adjustments may need to be made to the estimated useful life of the developed product rights for Auryxia, which could materially impact our financial position, certain of our material agreements, and our future operating results.</span></div><div style="margin-top:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the COVID-19 Pandemic</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business has been and may continue to be, directly or indirectly, adversely affected by the COVID-19 pandemic.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing COVID-19 pandemic has presented a substantial public health and economic challenge around the world and continues to affect our employees, patients, healthcare providers with whom we interact, customers, collaboration partners, contract research organizations, or CROs, our contract manufacturing organizations, or CMOs, vendors, communities and business operations. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition continues to depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, any resurgences or mutations of COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets where the healthcare providers with whom we interact, our partners, our CROs, our CMOs, and our other vendors operate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our revenue growth was negatively impacted in the first three quarters of 2021 primarily as the kidney patient populations that we serve continue to experience both high hospitalization and mortality rates due to COVID-19. While we are unable to quantify the impact of the COVID-19 pandemic on future revenues and revenue growth, COVID-19 continues to adversely and disproportionately impact our patient population; therefore, we expect COVID-19 to continue to have a negative impact on our revenue growth for the foreseeable future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The majority of our office-based employees began working from home on March 13, 2020 and continue to primarily work from home. In addition, several healthcare facilities have previously restricted access for non-patients, including the members of our sales force. For example, DaVita, Inc., or DaVita, and Fresenius Medical Care, or Fresenius, which account for a vast majority of the dialysis population in the United States, have restricted access to their clinics. As a result, we continue to engage with some healthcare providers and other customers virtually, where possible. The restrictions on our customer-facing employees' in-person interactions with healthcare providers could negatively impact our access to healthcare providers and, ultimately, our sales. Recently, such precautionary measures have been relaxed at certain healthcare facilities and, as a result, members of our sales force have resumed in person interactions with certain customers. Nevertheless, some restrictions remain, and more restrictions may be put in place again due to a resurgence in COVID-19 cases, including those involving new variants of COVID-19, which may be more contagious and more severe than prior strains of the virus. Given this uncertain environment and the disproportionate impact of the COVID-19 pandemic on CKD patients, we are actively monitoring the demand for Auryxia, including the potential for further declines or changes in prescription trends and customer orders, which could have a material adverse effect on our business, results of operations, and financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While most of our office-based operations can be performed remotely, there is no guarantee that we will continue to be as effective while working remotely because our team is dispersed, many employees may have additional personal needs to attend to (such as looking after children as a result of school closures or family members who may become sick), and employees may become sick themselves and be unable to work. Further, our increased reliance on remote access to our information systems increases our exposure to potential cybersecurity breaches.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Moreover, our future success and profitability substantially depends on the management skills of our executives and certain other key employees. The unanticipated loss or unavailability of key employees due to the pandemic could harm our ability to operate our business or execute our business strategy and we may not be successful in finding and integrating suitable successors in the event of key employee loss or unavailability.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For example, in October 2021, we announced a requirement that all of our employees be fully vaccinated by January 1, 2022, subject to limited medical and religions exemptions. At this time, it is not possible to predict with certainty the exact impact that our vaccine requirement will have on us or on our workforce, and the requirement may result in employee distraction, absences, resignations, attrition and difficulty securing future labor needs which could have an adverse effect on our business, results of operations and cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the direct and indirect impacts of the pandemic or the response efforts to the pandemic, including, among others, competition for labor and resources and increases in labor, sourcing, manufacturing and shipping costs, may cause disruptions to, closures of or other impacts on our CMOs and other vendors in our supply chain on which we rely for the supply of our products and product candidates. At this time, our third party contract manufacturers continue to operate at or near normal levels. However, it is possible that the COVID-19 pandemic and response efforts may have an impact in the future on our contract manufacturers' ability to manufacture and deliver Auryxia and vadadustat (if approved in the U.S. and which is currently marketed under the trade name Vafseo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> by MTPC in Japan), which may result in delays in or disruptions to manufacturing and supply of our products. These impacts could lead to delays, increased costs or disruptions in supply of our products and product candidates and have a negative effect on our inventory reserves, which could result in an increase in inventory write-offs due to expiry.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The pandemic has resulted in closures of and may continue to impact clinical trial sites on which we rely and will rely for the completion of certain clinical trials and COVID-19 pandemic precautions have caused moderate delays in enrolling new clinical trials and may cause delays in enrolling other new clinical trials. We are using remote monitoring and central monitoring, where possible. Further, the pandemic has impacted and is likely to continue to impact the business of the FDA, the EMA and other government authorities, which potentially could result in delays in meetings, reviews, inspections and approvals relating to our product and product candidates. Any decision by the FDA, EMA or other governmental authorities to delay meeting with us or our collaboration partners or scheduling inspections in light of COVID-19 could have a material adverse effect on clinical trials of our product candidates or on our efforts to obtain marketing approvals for our product candidate, which could increase our operating expenses and have a material adverse effect on our financial results, including the timing and amount of future regulatory milestones we could receive from our partners.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any of the third parties with whom we engage, including our collaboration partners, were to experience shutdowns, delays or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted, which could have a material adverse effect on our business and our financial results. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pandemic has already caused significant disruptions in the financial markets, and may continue to cause such disruptions, that could impact our ability to raise additional funds and has also impacted, and may continue to impact, the volatility of our stock price and trading in our stock. Moreover, it is possible the pandemic will significantly impact economies worldwide, which could result in adverse effects on our business and operations. Even after the COVID-19 pandemic has been contained or mitigated, we may continue to experience adverse impacts to our business as a result of any economic recession or depression that has occurred or may occur in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global impact of COVID-19 continues to rapidly evolve, and we will continue to monitor the situation closely. In particular, areas we are monitoring include possible COVID-related changes in our commercial revenue payor mix, overall product sales, and reserves and allowances, as well as negative trends that could potentially have a further significant impact on product demand and, ultimately, product revenue, or could cause goodwill, intangible assets, and other assets to be impaired. This uncertain pandemic environment has presented new risks to our business. While we are working to mitigate the impacts on our business, we are mindful that many of these risks and the impact to the larger healthcare market are outside of our control. The extent to which COVID-19 impacts our business will depend on future developments, which are highly uncertain and the magnitude of which cannot be predicted, including new information that may emerge concerning the severity of COVID-19 and the actions to contain COVID-19, effectiveness of vaccines against virus variants, or treat its impact, among others.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to successfully commercialize any approved product, including our ability to achieve widespread market acceptance, is critical to the success of our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our ability to generate significant product revenue will depend almost entirely on our ability to execute on our commercialization plans, the level of market adoption for, the availability of and continued use of any approved product by physicians, hospitals, dialysis clinics, wholesalers and patients, and the terms of arrangements with healthcare payors, including government payors, consumers, managed care organizations, pharmacy benefit managers, or PBMs, and pharmacies. If we are not successful in commercializing any approved product, including achieving and maintaining an adequate level of market adoption, our profitability and our future business prospects will be adversely impacted. Market acceptance of any approved product depends on a number of other factors, including:</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">the availability of adequate coverage and reimbursement by and the availability of discounts, rebates and price concessions from third party payors, PBMs, and governmental authorities;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the safety and efficacy of the product, as demonstrated in clinical trials and in the post-marketing setting;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the prevalence and complications of the disease treated by the product;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the clinical indications for which the product is approved and the product label approved by regulatory authorities, including any warnings or limitations that may be required on the label as a consequence of potential safety risks associated with the product;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the countries in which marketing approvals are obtained;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the claims we and our collaborators are able to make regarding the safety and efficacy of the product;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the success of our physician and patient communications and education programs;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">acceptance by physicians and patients of the product as a safe and effective treatment and the willingness of the target patient population to try new therapies and of physicians to prescribe new therapies;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost, safety and efficacy of the product in relation to alternative treatments;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing of receipt of marketing approvals and product launch relative to competing products and potential generic entrants;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">relative convenience and ease of administration;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the prevalence and severity of adverse side effects;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">adverse publicity about our products or favorable or adverse publicity about competing products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the effectiveness of our and our collaborators&#8217; sales, marketing and distribution efforts; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the restrictions on the use of the product together with other medications, if any.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market acceptance is critical to our ability to generate significant product revenue. Any product may achieve only limited market acceptance or none at all. If any of our approved products is not accepted by the market to the extent that we expect or market acceptance decreases, we may not be able to generate significant product revenue and our business would suffer.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Generic competitors are seeking approval of generic versions of Auryxia and the market entry of one or more generic competitors would limit Auryxia sales and have an adverse impact on our business and results of operation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although composition and use of Auryxia are currently claimed by 15 issued patents that are listed in the FDA&#8217;s Orange Book, we cannot assure that we will be successful in defending against third parties attempting to invalidate or design around our patents or assert that our patents are invalid or otherwise unenforceable or not infringed, or in competing against third parties introducing generic equivalents of Auryxia or any of our future products.</span></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Hatch-Waxman Act allows applicants seeking to market a generic equivalent of a drug that relies, in whole or in part, on the FDA&#8217;s prior approval of a patented brand name drug, to provide notice to the holder of the New Drug Application, or NDA, for the brand name drug of its application, called a Paragraph IV certification notice, if the applicant is seeking to market its product prior to the expiration of the patents with claims directed to the brand name drug. After the introduction of a generic competitor, a significant percentage of the prescriptions written for a product may be filled with the generic version, resulting in a loss in sales of the branded product. We received Paragraph IV certification notice letters regarding Abbreviated New Drug Applications, or ANDAs, submitted to the FDA requesting approval for generic versions of Auryxia tablets (210 mg ferric iron per tablet). We have filed complaints for patent infringement relating to such ANDAs, and have entered into settlement and license agreements with such ANDA filers. See Part II, Item 1. Legal Proceedings for further information relating to the ANDAs, lawsuits and settlements. It is possible that we may receive Paragraph IV certification notice letters from additional ANDA filers, and may not ultimately be successful in an ANDA litigation. Generic competition for Auryxia or any of our future products could have a material adverse effect on our sales, results of operations and financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, litigation to enforce or defend intellectual property rights is complex, costly and involves significant management time. If our Orange Book-listed patents are successfully challenged by a third party and a generic version of Auryxia is approved and launched, revenue from Auryxia could decline significantly, which would have a material adverse effect on our sales, results of operations and financial condition.</span></div><div style="margin-top:12pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain sales and marketing capabilities or to enter into additional agreements with third parties, we may not be successful in commercializing Auryxia, vadadustat, if approved, and any other product candidate that may be approved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any approved product, we intend to continue to invest in sales and marketing, which will require substantial effort and significant management and financial resources. We devote significant effort, in particular, to recruiting individuals with experience in the sales and marketing of pharmaceutical products. Competition for personnel with these skills is significant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are risks involved with maintaining our own sales and marketing capabilities, including the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">potential inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">potential inability of sales personnel to obtain access to physicians, including restrictions due to COVID-19;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">potential lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">costs and expenses associated with maintaining our own sales and marketing organization.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are unable to maintain our own sales and marketing capabilities and our arrangements with third parties with respect to sales and marketing, or we are unsuccessful in entering into additional arrangements with third parties to sell and market or are </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">unable to do so on terms that are favorable to us, we will not be successful in commercializing Auryxia, vadadustat, if approved, and any other product candidate that may be approved.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and reimbursement may be limited or unavailable in certain market segments for any approved product, which could make it difficult for us or our collaboration partners to sell any approved products profitably.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market acceptance and sales of any approved products depends significantly on the availability of adequate coverage and reimbursement from third party payors and may be affected by existing and future healthcare reform measures. Governmental authorities, third party payors, and PBMs, decide which drugs they will cover, as well as establish formularies or implement other mechanisms to manage utilization of products and determine reimbursement levels. Coverage and reimbursement by a governmental authority, third-party payor or PBM may depend upon a number of factors, including the determination that use of a product is:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a covered benefit under the health plan;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">safe, effective and medically necessary;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">appropriate for the specific patient; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">cost effective.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining coverage and reimbursement approval for a product from a governmental authority, PBM or a third-party payor is a time consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products to the payor. In the United States, there are multiple governmental authorities, PBMs and third-party payors with varying coverage and reimbursement levels for pharmaceutical products, and the timing of commencement of reimbursement by a governmental payor is dependent on the assignment of codes via the Healthcare Common Procedural Coding System, which codes are assigned on a quarterly basis. Within Medicare, for oral drugs dispensed by pharmacies and also administered in facilities, coverage and reimbursement may vary depending on the setting. CMS, local Medicare administrative contractors, Medicare Part D plans and/or PBMs operating on behalf of Medicare Part D plans, may have some responsibility for determining the medical necessity of such drugs, and therefore coverage, for different patients. Different reimbursement methodologies may apply, and CMS may have some discretion in interpreting their application in certain settings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As an oral drug, Auryxia is covered by Medicare only under Part D. However, in September 2018, CMS decided that Auryxia would no longer be covered by Medicare for the IDA Indication. While this decision does not impact CMS coverage of the Hyperphosphatemia Indication, it requires Part D plan sponsors to impose prior authorization or other steps to ensure that Auryxia is used only for the Hyperphosphatemia Indication. While we believe that the vast majority of the Medicare prescriptions written for Auryxia today are for the Hyperphosphatemia Indication and therefore will continue to be covered by Medicare with prior authorization, the CMS Decision has had and will continue to have an adverse impact on the sales and future growth of Auryxia for the Hyperphosphatemia Indication and the IDA Indication. For example, in the second quarter of 2020, we reduced our short-term and long-term Auryxia revenue forecast, primarily driven by the compounding impact of the CMS Decision. As a result, we recorded an impairment charge of $115.5 million to the Auryxia intangible asset associated with the developed product rights for Auryxia during the three months ended June 30, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid reimbursement of drugs varies by state. Private third-party payor reimbursement policies also vary and may or may not be consistent with Medicare reimbursement methodologies. Manufacturers of outpatient prescription drugs may be required to provide discounts or rebates under government healthcare programs or to certain third-party payors in order to obtain coverage of such products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we may be required to enter into contracts with third party payors and/or PBMs offering rebates or discounts on our products in order to obtain favorable formulary status. We may not be able to agree upon commercially reasonable terms with such third party payors or PBMs, or provide data sufficient to obtain favorable coverage and reimbursement for many reasons, including that we may be at a competitive disadvantage relative to companies with more extensive product lines. In addition, third party payors, PBMs and other entities that purchase our products may impose restrictions on our ability to raise prices for our products over time without incurring additional costs. We cannot be sure that coverage or adequate reimbursement will be available for our product or any of our potential future products. Even if we obtain coverage for any approved product, third party payors may not establish adequate reimbursement amounts, which may reduce the demand for our product and prompt us to have to reduce pricing for the product. If reimbursement is not available or is limited, we may not be able to commercialize certain of our products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, vadadustat was approved in Japan for the treatment of adult patients with anemia due to CKD and is being marketed by MTPC in Japan under the trade name Vafseo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Pricing and reimbursement strategy is a key component of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MTPC's commercialization plans for Vafseo in Japan. If coverage and reimbursement terms change, MTPC may not be able to, or may decide not to, continue commercialization of Vafseo in Japan.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain or maintain contracts with key distribution partners, or adequate or favorable reimbursement for our products, our business could be materially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have four distributors, Fresenius Medical Care Rx, McKesson Corporation, Cardinal Health, Inc. and Amerisource Bergen Drug Corporation, that, in the aggregate, accounted for a significant percentage of our gross accounts receivable as of September&#160;30, 2021. If we are not able to maintain our contracts with these key distributors on favorable terms, on a timely basis or at all, or if there is any adverse change in one or more of these distributors&#8217; business practices or financial condition, or such distributors&#8217; end users&#8217; prescribing practices or clinical protocols, it would adversely impact the market opportunity for Auryxia, our product revenues and operating results.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if vadadustat is approved in the United States and included in the fixed reimbursement model for a bundle of dialysis services, or the bundle, we would be required to enter into contracts to supply vadadustat to specific dialysis providers, instead of through distributors, which we believe could be challenging. The dialysis market is unique and is dominated by two providers: DaVita and Fresenius, which account for a vast majority of the dialysis population in the United States. In May 2017, we entered into a license agreement, which was amended and restated in April 2019, pursuant to which we granted Vifor (International) Ltd., or Vifor Pharma, an exclusive license to sell vadadustat to Fresenius Kidney Care Group LLC, or FKC, and certain third party dialysis organizations, or the Third Party Dialysis Organizations, approved by us, in the United States. The license would be effective upon the following:  FDA approval of vadadustat for anemia due to CKD in adult patients with dialysis-dependent CKD, the earlier of CMS&#8217;s determination that vadadustat will be reimbursed using the Transitional Drug Add-On Payment Adjustment, or the TDAPA, and inclusion in the bundle, and a milestone payment by Vifor Pharma. Under this amended license agreement with Vifor Pharma, or the Vifor Agreement, FKC and the Third Party Dialysis Organizations are not obligated to utilize vadadustat in their U.S. clinics. In addition, even if FKC and the Third Party Dialysis Organizations choose to utilize vadadustat in their clinics in the United States, they are not restricted from utilizing other therapies for anemia due to CKD. The Vifor Agreement restricts us from directly supplying vadadustat to FKC or any other affiliate of Fresenius Medical Care North America and the Third Party Dialysis Organizations. The Vifor Agreement does not restrict us from entering into supply agreements with other dialysis clinics, such as DaVita; however, these dialysis clinics may choose not to contract with us for vadadustat or they may choose to contract with us for a limited supply of vadadustat. If vadadustat is approved and we are not able to maintain the Vifor Agreement or enter into a supply agreement with DaVita, our business may be materially harmed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we currently believe it is likely that vadadustat, if approved, will be reimbursed using the TDAPA followed by reimbursement via the bundled reimbursement model, if vadadustat is neither reimbursed under the TDAPA nor the bundled reimbursement model, then the Vifor Agreement will not become effective, and patients would access vadadustat through contracts we negotiate with third party payors for reimbursement of vadadustat, which would be subject to the risks and uncertainties described above. Additionally, applying for and obtaining reimbursement under the TDAPA is expected to take several months following approval, which would affect adoption, uptake and product revenue for vadadustat during that time, and if there are updates to the TDAPA rule that decrease the basis for reimbursement or eligibility criteria during the transition period or if the TDAPA is eliminated, then our profitability may be adversely affected</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For example, the Medicare Payment Advisory Commission, or MedPAC, an independent legislative branch advisory body to Congress on issues related to the Medicare program, has recommended that TDAPA not be provided to newly approved drug products considered to fall within &#8220;functional categories&#8221; for which costs are already accounted for in the bundled reimbursement model, such as for anemia management drugs. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be unable to sell Auryxia or vadadustat, if approved, to dialysis providers on a profitable basis if CMS significantly reduces the level of reimbursement for dialysis services and providers choose to use alternative therapies or look to negotiate their contracts with us. Our profitability may also be affected if our costs of production increase faster than increases in reimbursement levels. Adequate coverage and reimbursement of our products by government and private insurance plans are central to patient and provider acceptance of any products for which we receive marketing approval.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The successful commercialization of any approved product will depend in part on the extent to which third party payors, PBMs and governmental authorities establish adequate reimbursement levels and pricing policies.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third party payors are increasingly attempting to contain healthcare costs by limiting both coverage and reimbursement levels for new drugs. As a result, significant uncertainty exists as to whether and how much reimbursement third party payors will </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provide for newly approved drugs which, in turn, will put downward pressure on the pricing of drugs. Cost control initiatives may decrease coverage and payment levels for any drug and, in turn, the price that we will be able to charge and/or the volume of our sales. Certain third party payors require prior authorization for, or even refuse to provide, reimbursement for Auryxia, and others may do so in the future with respect to Auryxia, vadadustat and any of our other products or product candidates, if approved. In addition, certain third party payors require some form of prior authorization for the administration of ESAs for the treatment of anemia due to CKD within the non-dialysis patient population, and a similar prior authorization may be applicable to the HIF-PHI class for the treatment of anemia due to CKD within the non-dialysis patient population if vadadustat is approved for non-dialysis patients. Our business would be materially adversely affected if we are not able to receive approval for reimbursement from third party payors on a broad, timely or satisfactory basis; if reimbursement is subject to overly broad or restrictive prior authorization requirements; or if reimbursement is not maintained at satisfactory levels. We are unable to predict all changes to the coverage or reimbursement methodologies that will be applied by private or government payors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in some countries, including member states of the European Union, or EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take a significant amount of time after receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices, and in certain instances render commercialization in certain markets infeasible or disadvantageous from a financial perspective. In some countries, we or our collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product and/or our product candidates to other available products in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third party payors or government authorities may lead to further pressure on the prices or reimbursement levels. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, the commercial launch of our product and/or product candidates could be delayed, possibly for lengthy periods of time, we or our collaborators may not launch at all in a particular country, we may not be able to recoup our investment in one or more product candidates, and there could be a material adverse effect on our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently, there has been considerable public and government scrutiny in the United States of pharmaceutical pricing and proposals to address the perceived high cost of pharmaceuticals. There have also been several recent state legislative efforts to address drug costs, which generally have focused on increasing transparency around drug costs or limiting drug prices or price increases. Adoption of new legislation at the federal or state level could affect demand for, or pricing of, our products or product candidates, if approved, and could diminish our ability to establish what we believe is a fair price for our products, ultimately diminishing our revenue for our products if they are approved.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before, or more successfully than, we do.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new drugs is highly competitive and subject to rapid and significant technological change. Our future success depends on our ability to demonstrate and maintain a competitive advantage with respect to the development and commercialization of Auryxia, vadadustat and any other product or product candidate, including those that may be in-licensed or acquired. Our objective is to continue to commercialize Auryxia and develop and commercialize new products with superior efficacy, convenience, tolerability and/or safety. In many cases, any approved products that we commercialize will compete with existing, market-leading products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Auryxia is competing in the hyperphosphatemia market in the United States with other FDA-approved phosphate binders such as Renagel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (sevelamer hydrochloride) and Renvela</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (sevelamer carbonate), both marketed by Sanofi, PhosLo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and Phoslyra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (calcium acetate), marketed by Fresenius Medical Care North America, Fosrenol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (lanthanum carbonate), marketed by Shire Pharmaceuticals Group plc, and Velphoro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (sucroferric oxyhydroxide), marketed by Fresenius Medical Care North America, as well as over-the-counter calcium carbonate products such as TUMS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and metal-based options such as aluminum, lanthanum and magnesium. Most of the phosphate binders listed above are now also available in generic forms. In addition, other agents are in development, including OPKO Health Inc.&#8217;s Alpharen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Tablets (fermagate tablets), that may impact the market for Auryxia.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auryxia is competing in the IDA market in the United States with over-the-counter oral iron, ferrous sulfate, other prescription oral iron formulations, including ferrous gluconate, ferrous fumerate, and polysaccharide iron complex, and intravenous iron formulations, including Feraheme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ferumoxytol injection), Venofer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (iron sucrose injection), Ferrlicit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sodium ferric gluconate complex in sucrose injection), Injectafer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ferric carboxymaltose injection), and Triferic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ferric pyrophosphate citrate).&#160;In addition, other new therapies for the treatment of IDA may impact the market for Auryxia, such as Shield </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therapeutics plc's Feraccru</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ferric maltol), which is available in Europe for the treatment of IDA and Accrufer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ferric maltol), which was launched in the United States for the treatment of IDA on July 1, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, Auryxia&#8217;s commercial opportunities may be reduced or eliminated if our competitors develop and market products that are less expensive, more effective, safer or offer greater patient convenience than Auryxia. Other companies have product candidates in various stages of pre-clinical or clinical development to treat diseases and complications of the diseases for which we are marketing Auryxia.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drugs that may compete with vadadustat include Epogen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (epoetin alfa) and Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(darbepoetin alfa), both commercialized by Amgen, Procrit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (epoetin alfa) and Eprex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (epoetin alfa), commercialized by Johnson&#160;&amp; Johnson in the United States and Europe, respectively, and Mircera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (methoxy PEG-epoetin beta), commercialized by Vifor Pharma in the United States and Roche Holding Ltd. outside the United States. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We and our partners may also face competition from potential new anemia therapies. There are several other HIF-PHI product candidates in various stages of development for anemia indications that may be in direct competition with vadadustat if and when they are approved and launched commercially. These candidates are being developed by companies such as FibroGen Inc., together with its collaboration partners, Astellas Pharma Inc. and AstraZeneca PLC, Japan Tobacco International, or JT, GlaxoSmithKline plc, or GSK, and Bayer HealthCare AG, or Bayer. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the United States, FibroGen Inc., or FibroGen, filed an NDA for its product candidate, roxadustat, with the FDA, but the FDA issued a complete response letter indicating the FDA will not approve the NDA in its present form and requested that an additional clinical trial of roxadustat be conducted prior to resubmission of the NDA or additional response to the FDA's complete response letter. In Europe however, roxadustat is approved for the treatment of anemia in patients with CKD.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In Japan, roxadustat is approved for the treatment of anemia due to CKD in patients on dialysis, or DD-CKD, and patients not on dialysis, or NDD-CKD. In addition, daprodustat, GSK&#8217;s product candidate, and enarodustat, JT&#8217;s product candidate, are approved in Japan for the treatment of anemia due to CKD. In addition. Bayer HealthCare AG has submitted an NDA for its product candidate for the treatment of renal anemia in Japan. In China, roxadustat has launched for the treatment of anemia of DD-CKD and for the treatment of anemia due to CKD in NDD-CKD patients. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Recently, GSK announced that its Phase 3 ASCEND program, evaluating the efficacy and safety profile of daprodustat for patients with anemia due to CKD, met its primary endpoints and across the ASCEND program, daprodustat was generally well tolerated in both non-dialysis and dialysis patients. Furthermore, certain companies are developing potential new therapies for renal-related diseases that could potentially reduce injectable ESA utilization and thus limit the market potential for vadadustat if they are approved and launched commercially. Other new therapies are in development for the treatment of conditions inclusive of renal anemia that may impact the market for anemia-targeted treatment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A biosimilar is a biologic product that is approved based on demonstrating that it is highly similar to an existing, FDA-approved branded biologic product. The patents for the existing, branded biologic product must expire in a given market before biosimilars may enter that market without risk of being sued for patent infringement. In addition, an application for a biosimilar product cannot be approved by the FDA until 12 years after the existing, branded product was approved under a Biologics License Application, or BLA. The patents for epoetin alfa, an injectable ESA, expired in 2004 in the EU, and the remaining patents expired between 2012 and 2016 in the United States. Because injectable ESAs are biologic products, the introduction of biosimilars into the injectable ESA market in the United States will constitute additional competition for vadadustat if we are able to obtain approval for and commercially launch our product. Several biosimilar versions of injectable ESAs are available for sale in the EU. In the United States, Pfizer&#8217;s biosimilar version of injectable ESAs, Retacrit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(epoetin alfa-epbx), was approved by the FDA in May 2018 and launched in November 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our potential competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining marketing approvals, recruiting patients and manufacturing pharmaceutical products. Large and established companies such as Amgen and Roche, among others, compete in the market for drug products to treat kidney disease. In particular, these companies have greater experience and expertise in conducting preclinical testing and clinical trials, obtaining marketing approvals, manufacturing such products on a broad scale and marketing approved products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and have collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we are developing obsolete. Smaller and other early stage companies may also prove to be significant competitors. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or marketing approval, or discovering, developing and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercializing competitive products, before, or more effectively than, we do. If we are not able to compete effectively against potential competitors, our business will not grow and our financial condition and operations will suffer.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercialization of Riona and Vafseo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> in Japan and our current and potential future efforts with respect to the development and commercialization of our products and product candidates outside of the United States subject us to a variety of risks associated with international operations, which could materially adversely affect our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Japanese sublicensee, Japan Tobacco, Inc., or JT, and its subsidiary, Torii Pharmaceutical Co., Ltd., or Torii, commercialize Riona, the trade name for ferric citrate hydrate in Japan, as an oral treatment for the improvement of hyperphosphatemia in patients with CKD, including DD-CKD and NDD-CKD, and for the treatment of adult patients with iron deficiency anemia, or IDA, in Japan. We also granted Otsuka Pharmaceutical Co. Ltd., or Otsuka, exclusive rights to commercialize vadadustat in Europe, China and certain other markets, subject to marketing approvals. In Japan and certain other countries in Asia, we granted Mitsubishi Tanabe Pharma Corporation, or MTPC, exclusive rights to commercialize vadadustat, which has been approved and is being marketed by MTPC in Japan under the trade name Vafseo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. In addition, we have conducted and in the future plan to conduct clinical trials outside of the United States for Auryxia, vadadustat and any other product or product candidate that may be in-licensed or acquired. As a result of these and other activities, we are or may become subject to additional risks in developing and commercializing Auryxia and vadadustat outside the United States, including:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">political, regulatory, compliance and economic developments that could restrict our ability to manufacture, market and sell our products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in international medical reimbursement policies and programs;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in healthcare policies of foreign jurisdictions;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">trade protection measures, including import or export licensing requirements and tariffs;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to develop relationships with qualified local distributors and trading companies;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">political and economic instability in particular foreign economies and markets;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">diminished protection of intellectual property in some countries outside of the United States;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">differing labor regulations and business practices;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory and compliance risks that relate to maintaining accurate information and control over sales and distributors&#8217; and service providers&#8217; activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, or FCPA, the UK Bribery Act or similar local regulation;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">compliance with the EU General Data Protection Regulation, or GDPR;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">potentially negative consequences from changes in or interpretations of tax laws;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">business interruptions resulting from geopolitical actions, including war and terrorism or natural disasters including earthquakes, typhoons, floods and fires.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we receive revenues from royalty payments converted to U.S. dollars based on net sales of Riona and Vafseo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in Japanese yen. The exchange rates between the Japanese yen on the one hand, and the U.S. dollar, on the other hand, have changed substantially in recent years and may fluctuate substantially in the future. Our results of operations could be adversely affected over time by certain movements in exchange rates, particularly if the Japanese yen depreciates against the U.S. dollar. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any of these factors may, individually or as a group, have a material adverse effect on our business and results of operations. As and if we continue to expand our commercialization efforts, we may encounter new risks.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Clinical Development</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In addition to Auryxia, we will continue to depend heavily on the success of our product candidate, vadadustat, for which we submitted an NDA to the FDA, which was accepted for filing in May 2021. Clinical drug development involves a lengthy and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">expensive process with an uncertain outcome. We will incur additional costs in connection with, and may experience delays in completing, or ultimately be unable to complete, the development and commercialization of vadadustat and any other product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk of failure in drug development is high. We depend heavily on the successful commercialization of Auryxia and the successful clinical development, marketing approval and commercialization of vadadustat in the United States and other jurisdictions, which may never occur. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development and conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical trials are expensive, difficult to design and implement, can take several years to complete, and their outcomes are inherently uncertain. Failure can occur at any time during the clinical trial process. Further, the results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials, interim results of a clinical trial do not necessarily predict final results, and results of Phase 3 clinical trials for one indication may not be predictive of results of Phase 3 clinical trials for another indication. For example, while we announced positive top-line results from INNO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VATE and vadadustat achieved the primary and key secondary efficacy endpoint in each of the two PRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TECT studies, the PRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TECT program did not meet the primary MACE safety endpoint. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans or will receive marketing approval.</span></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay, prevent or make more challenging our ability to receive or maintain marketing approval or commercialize our product candidates. Our clinical trials may take longer to complete than currently anticipated, or may be delayed, suspended, required to be repeated, prematurely terminated or may not successfully demonstrate safety and/or efficacy needed for regulatory approval for a variety of other reasons, such as:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs are greater than we anticipate;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of patients required for clinical trials may be larger than we anticipate;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">enrollment in our clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our third party contractors, such as our CROs, may fail to comply with regulatory requirements, perform effectively, or meet their contractual obligations to us in a timely manner, or at all, or we may fail to communicate effectively or provide the appropriate level of oversight of such third party contractors;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the supply or quality of our starting materials, drug substance and drug product necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulators, independent data monitoring committees, or IDMCs, institutional review boards, or IRBs, safety committees, or ethics committees, may require that we suspend or terminate our clinical trials for various reasons, including noncompliance with regulatory requirements, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using our product candidate, or a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials, repeat a clinical trial or abandon product development programs;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">lack of adequate funding to continue a clinical trial, including unforeseen costs due to enrollment delays, requirements to conduct additional clinical trials or repeat a clinical trial and increased expenses associated with the services of our CROs and other third parties;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">failure to initiate, delay of or failure to complete a clinical trial as a result of an Investigational New Drug application, or IND, being placed on clinical hold by the FDA, the EMA, the Japanese Pharmaceuticals and Medical Devices Agency, or PMDA, or other regulatory authorities, or for other reasons, such as failure to recruit or enroll suitable patients or patients' failure to return for post-treatment follow up;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may determine to change or expand a clinical trial, including after it has begun;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical trial sites and investigators deviating from the clinical protocol, failing to conduct the trial in accordance with regulatory requirements, or dropping out of a trial, or failure by us or our CROs to communicate effectively or provide the appropriate level of oversight of such clinical sites and investigators;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">inability, delay, or failure in identifying and maintaining a sufficient number of clinical trial sites, many of which may already be engaged in other clinical programs;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delay or failure in reaching agreement with the FDA, the EMA, the PMDA or other regulatory authorities on a clinical trial design upon which we are able to execute;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delay or failure in obtaining authorization to commence a clinical trial or inability to comply with conditions imposed by a regulatory authority regarding the scope or design of a clinical trial;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in reaching, or failure to reach, agreement on acceptable terms with prospective clinical trial sites and prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA, the EMA, the PMDA or other regulatory authorities may require us to submit additional data or impose further requirements before permitting us to initiate a clinical trial or during an ongoing clinical trial;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA, the EMA, the PMDA or other regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials, or may change the requirements for approval even after it has reviewed and commented on the design for our clinical trials;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">failure to comply with good practice quality guidelines and regulations, or GXP, including good laboratory practice, good clinical practice, or GCP, and current good manufacturing practice, or cGMP; or</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in governmental regulations or administrative actions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has resulted in closures of and may continue to impact clinical trial sites on which we rely and will rely for the completion of certain clinical trials and may delay enrollment of certain planned and ongoing clinical trials.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to successfully complete clinical trials of Auryxia and vadadustat, if the results of those trials and studies are not positive or are only modestly positive, or if there are concerns with the profile due to efficacy or safety. For example, the PRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TECT program did not meet the primary MACE safety endpoint, and we are remaining cautious in our outlook for potential approval of vadadustat for the treatment of anemia due to CKD in adult non-dialysis dependent patients. If any of the foregoing occurs, the following may occur:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulators may require that we conduct additional clinical trials, repeat clinical trials or conduct other studies beyond those that we currently contemplate;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be delayed in obtaining marketing approval for vadadustat;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may not obtain marketing approval for vadadustat at all;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may obtain approval with labeling that includes significant use or distribution restrictions or safety warnings that would reduce the potential market for any approved product or inhibit our ability to successfully commercialize any approved product;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a Risk Evaluation and Mitigation Strategies, or REMS, or FDA-imposed risk management plans that use risk minimization strategies to ensure that the benefits of certain prescription drugs outweigh their risks, may be required;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be subject to additional post-marketing restrictions and/or requirements; or</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the product may be removed from the market after obtaining marketing approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development costs may also increase if we experience development delays or delays in receiving the requisite marketing approvals. Our preclinical studies or clinical trials may need to be restructured or may not be completed on schedule, or at all. Significant preclinical or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize vadadustat or any other product candidate, including those that may be in-licensed or acquired, or allow our competitors to bring products to market before we do. This could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may find it difficult to enroll patients in our clinical studies, which could delay or prevent clinical studies of Auryxia, vadadustat or any other product or product candidate, including those that may be in-licensed or acquired.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Identifying and qualifying patients to participate in clinical studies is critical to our success. The timing of our clinical studies depends, in part, on the speed at which we can recruit patients to participate in our clinical trials. Patients may be unwilling to participate in our clinical studies because of concerns about adverse events observed with the current standard of care, competitor products and/or other investigational agents, in each case for the same indications and/or similar patient populations. In addition, in the case of clinical studies of any product candidate, patients currently receiving treatment with the current standard of care or a competitor product may be reluctant to participate in a clinical trial with an investigational drug. Furthermore, COVID-19 resulted in closures of, and may continue to impact, clinical trial sites on which we rely for the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">conduct of certain clinical trials and COVID-19 pandemic precautions have caused moderate delays in enrolling new clinical trials and may cause delays in enrolling other new clinical trials. We are using remote monitoring and central monitoring, where possible. Finally, competition for clinical study sites may limit our access to patients appropriate for our clinical trials. As a result, the timeline for recruiting patients and conducting studies may be delayed. These delays could result in increased costs, delays in advancing our development of any product or product candidate, or termination of the clinical studies altogether.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics, to complete our clinical studies in a timely manner. Patient enrollment is affected by many factors, including:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">severity of the disease under investigation;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">design of the study protocol;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">size and nature of the patient population;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">eligibility criteria for, and design of, the study in question;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">perceived risks and benefits of the product or product candidate under study, including as a result of adverse effects observed in similar or competing therapies;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">proximity and availability of clinical study sites for prospective patients;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">availability of competing therapies and clinical studies and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product or product candidate being studied in relation to available therapies or other product candidates in development;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">efforts to facilitate timely enrollment in clinical studies;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical trial sites and investigators failing to perform effectively; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">patient referral practices of physicians.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may not be able to initiate or complete clinical studies in a timely manner, or at all, if we cannot enroll a sufficient number of eligible patients to participate in the clinical studies required by regulatory agencies. If we have difficulty enrolling a sufficient number of patients to conduct our clinical studies as planned, we may need to delay, limit or terminate ongoing or planned clinical studies, any of which may delay approval, or result in failure to obtain approval, of our product candidates, which would have a material adverse effect on our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Conducting clinical trials outside of the United States makes us subject to additional risks and complexities and we may not complete such trials successfully, in a timely manner, or at all, which could affect our ability to obtain regulatory approvals. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to successfully initiate, enroll and complete a clinical study in any country outside of the United States is subject to numerous additional risks unique to conducting business in jurisdictions outside the United States, including:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">difficulty in establishing or managing relationships with qualified CROs, physicians and clinical trial sites;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">difficulty in complying with different local standards for the conduct of clinical studies;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">difficulty in complying with various and complex import laws and regulations when shipping drug to certain countries; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential burden of complying with a variety of laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data obtained from studies conducted in the United States may not be accepted by the EMA, the PMDA and other regulatory authorities outside of the United States. Also, certain jurisdictions require data from studies conducted in their country in order to obtain approval in that country. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our collaboration partners have difficulty conducting our clinical studies in jurisdictions outside the United States as planned, we may need to delay, limit or terminate ongoing or planned clinical studies, any of which could have an adverse effect on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Positive results from preclinical and clinical studies are not necessarily predictive of the results of any future clinical studies.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. Success in preclinical studies may not be predictive of similar results in humans during clinical trials, successful results from early or small clinical trials may not be replicated in later and larger clinical trials, and successful interim results from ongoing clinical studies may not be indicative of results obtained when those studies are completed. For example, while we announced positive top-line results from INNO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">VATE and vadadustat achieved the primary and key secondary efficacy endpoint in each of the two PRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TECT studies, the PRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TECT program did not meet the primary </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MACE safety endpoint. Many companies in the biopharmaceutical industry have suffered significant setbacks in late-stage clinical studies after achieving positive results in early stage development, and we may face similar setbacks. If the results of our ongoing or future clinical studies for a product candidate are inconclusive with respect to efficacy, if we do not meet our clinical endpoints with statistical significance, or if there are safety concerns or adverse events, we may be prevented from or delayed in obtaining marketing approvals of a product candidate. For example, the PRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TECT program did not meet the primary MACE safety endpoint, and we are remaining cautious in our outlook for potential approval of vadadustat for the treatment of anemia due to CKD in adult non-dialysis dependent patients. If the results from any of our studies are not positive, our business could be materially adversely affected. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to identify, acquire, discover, develop and commercialize additional products or product candidates, which could impair our ability to grow.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we continue to focus a substantial amount of our efforts on the commercialization of Auryxia and the development and potential commercialization of vadadustat, a key element of our long-term growth strategy is to acquire, develop and/or market additional products and product candidates. Research programs to identify product candidates require substantial technical, financial and human resources, regardless of whether product candidates are ultimately identified. Our research and development programs may initially show promise, yet fail to yield product candidates for clinical development or commercialization for many reasons, including the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the research methodology used may not be successful in identifying potential indications and/or product candidates;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may not be able or willing to assemble sufficient resources to acquire or discover additional product candidates;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a product candidate may be shown to have harmful side effects, a lack of efficacy or otherwise not meet applicable regulatory criteria;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">product candidates we develop may nevertheless be covered by third party patents or other exclusive rights;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the market for a product candidate may change during our program so that the continued development of that product candidate is no longer reasonable;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; or</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a product candidate may not be accepted as safe and effective by patients, the medical community, or third party payors, if applicable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, we may be forced to abandon our research and development efforts for one or more of our programs, or we may not be able to identify, discover, develop or commercialize additional product candidates, which would have a material adverse effect on our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on research programs and product candidates for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our internal research capabilities are limited, we may be dependent upon other pharmaceutical and biotechnology companies, academic scientists, and other researchers to sell or license products or technology to us. The success of this strategy depends partly upon our ability to identify, select, and acquire promising product candidates and products. The process of identifying, selecting, negotiating and implementing a license or acquisition of a product candidate or an approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing and sales resources, may compete with us for the license or acquisition of a product candidate or an approved product. We have limited resources to identify and execute the acquisition or in-licensing of third party products, businesses, and technologies and integrate them into our current infrastructure.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts, including, for example, with respect to the Merger. Any product candidate that we acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval by the FDA, the EMA, the PMDA or other regulatory authorities, or post-approval testing or other requirements if approved. All product candidates are prone to risks of failure typical of pharmaceutical product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we cannot provide assurance that any products that we develop or approved products that we acquire will be manufactured profitably, achieve market acceptance or not require substantial post-marketing clinical trials.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, there can be no assurance that we will ever be able to identify additional therapeutic opportunities for Auryxia or vadadustat or to acquire or develop suitable additional products or product candidates, which could materially adversely affect our future growth and prospects. We may focus our efforts and resources on potential products, product candidates or other programs that ultimately prove to be unsuccessful.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Auryxia, vadadustat or any other product and product candidate, including those that may be in-licensed or acquired, may cause undesirable side effects or have other properties that delay or limit their commercial potential, or in the case of vadadustat, prevent its marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable effects caused by, or other undesirable properties of, Auryxia, vadadustat or any other product or product candidate, including those that may be in-licensed or acquired, or competing commercial products or product candidates in development that utilize a common mechanism of action could cause us or regulatory authorities to interrupt, delay or halt clinical trials, could result in a more restrictive label or the delay, denial or withdrawal of marketing approval by the FDA or other regulatory authorities, and could lead to potential product liability claims. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of undesirable effects or unexpected characteristics.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or others identify undesirable effects caused by or other undesirable properties of Auryxia, vadadustat, or any other product or product candidate, including those that may be in-licensed or acquired, either before or after receipt of marketing approval, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our clinical trials may be put on hold;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">patient recruitment could be slowed, and enrolled patients may not want to complete the clinical trial;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be unable to obtain marketing approval or regulatory authorities may withdraw marketing approval;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory authorities may require warnings on the label, such as the warning on Auryxia&#8217;s label regarding iron overload;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">REMS or FDA-imposed risk management plans that use restrictive risk minimization strategies, may be required;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we could be sued and held liable for harm caused to patients; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reputation may suffer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining marketing approval and, ultimately, market acceptance or penetration of Auryxia, vadadustat or any other product or product candidate, including those that may be in-licensed or acquired, could substantially increase our costs, and could significantly impact our ability to successfully commercialize Auryxia, vadadustat or any other product and product candidate, including those that may be in-licensed or acquired, and generate product revenue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patient populations treated with Auryxia and potential patient populations for vadadustat, if approved, have CKD, a serious disease that increases the risk of cardiovascular disease including heart attacks and stroke and, in its most severe form, results in, kidney failure and the need for dialysis or kidney transplant. Many patients with CKD are elderly with comorbidities making them susceptible to significant health risks. Therefore, the likelihood of these patients having adverse events, including serious adverse events is high.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the global INNO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VATE Phase 3 program, the incidence of treatment emergent adverse events during the incident dialysis patient study (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Correction and Conversion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in vadadustat treated patients was 83.8% and 85.5% in darbepoetin alfa treated patients. During the study, the most common treatment emergent adverse events reported in vadadustat/darbepoetin alfa treated patients were hypertension (16.2%/ 12.9%) and diarrhea (10.1%/ 9.7%). Serious treatment emergent adverse events were lower in vadadustat treated patients at 49.7% compared to 56.5% for darbepoetin alfa treated patients. The incidence of treatment emergent adverse events during the prevalent dialysis patient study (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conversion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in the vadadustat treated patients was 88.3%, and 89.3% in darbepoetin alfa treated patients. During the study, the most common treatment emergent adverse events reported in vadadustat/darbepoetin alfa treated patients were diarrhea (13.0%/ 10.1%), pneumonia (11.0%/ 9.7%), hypertension (10.6%/ 13.8%), and hyperkalemia (9.0%/ 10.8%). Serious treatment emergent adverse events were slightly lower for vadadustat treated patients at 55.0% and 58.3% for darbepoetin alfa-treated patients.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the global PRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TECT Phase 3 program, the incidence of treatment emergent adverse events during the erythropoiesis stimulating agent, or ESA,-untreated patients study (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Correction</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in the vadadustat-treated patients was 90.9%, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 91.6% in darbepoetin alfa-treated patients. During the study, the most common treatment emergent adverse events reported in vadadustat/darbepoetin alfa-treated patients were end-stage renal disease (34.7%/ 35.2%), hypertension (17.7%/ 22.1.%), hyperkalemia (12.3.%/ 15.6%), urinary tract infection (12.9%/ 12.0%), diarrhea (13.9%/ 10.0%), peripheral oedema (12.5%/ 10.5%), fall (9.6%/ 10%) and nausea (10%/ 8.2%). Serious treatment emergent adverse events were 65.3% for vadadustat-treated patients and 64.5% for darbepoetin alfa-treated patients. The incidence of treatment emergent adverse events during the ESA-treated patients study (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conversion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in vadadustat treated patients was 89.1% and 87.7% in darbepoetin alfa-treated patients. During the study, the most common treatment emergent adverse events reported in vadadustat/darbepoetin alfa-treated patients were end-stage renal disease (27.5%/ 28.4%), hypertension (14.4%/ 14.8%), urinary tract infection (12.2%/ 14.5%), diarrhea (13.8.%/ 8.8.%), peripheral oedema (9.9%/ 10.1%) and pneumonia (10.0%/ 9.7%). Serious treatment emergent adverse events were 58.5% for vadadustat-treated patients and 56.6% for darbepoetin alfa-treated patients.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Serious adverse events considered related to vadadustat and any other product candidates could have material adverse consequences on the development of such product candidates and our business as a whole. Our understanding of adverse events in prior clinical trials of our product candidates may change as we gather more information, and additional unexpected adverse events may be observed in future clinical trials or in the market. For example, we previously reported that in our Phase 2b study of vadadustat in non-dialysis patients with anemia due to CKD, one subject had a serious adverse event of an abnormal liver function test, considered a case of drug induced liver injury, or DILI, meeting the biochemical criteria of Hy&#8217;s Law. Following the completion of our global Phase 3 clinical program for vadadustat, there was a review of hepatic safety across the vadadustat clinical program. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The review of hepatic safety included a blinded assessment of all hepatic events in the studies by a panel of hepatic experts and analysis by an independent hepatic expert and our team.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> Based on this review, we concluded that the data across the clinical program showed that the overall hepatic safety profiles of vadadustat and darbepoetin alfa appear to be similar. In addition, we concluded that </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">there were no events across the clinical program that met the biochemical criteria for Hy&#8217;s Law. More specifically, we concluded that the DILI from our Phase 2b study of vadadustat in non-dialysis patients with anemia due to CKD that we previously reported as Hy&#8217;s Law did not, in fact, meet the biochemical criteria of Hy&#8217;s Law. Our conclusion on this case was reflected in our NDA for vadadustat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most commonly reported adverse reactions in the clinical trials that supported the approval of Auryxia for the Hyperphosphatemia Indication in the United States included diarrhea (21%), discolored feces (19%), nausea (11%), constipation (8%), vomiting (7%), and cough (6%). Gastrointestinal adverse reactions were the most common reason for discontinuing Auryxia (14%) in clinical trials for the Hyperphosphatemia Indication. The most commonly reported adverse reactions in the clinical trials that supported the approval of Auryxia in the United States for the IDA Indication included discolored feces (22%), diarrhea (21%), constipation (18%), nausea (10%), abdominal pain (5%) and hyperkalemia (5%). Diarrhea was the most common reason for discontinuing Auryxia (2.6%) in clinical trials for the IDA Indication.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or others identify previously unknown undesirable effects, if known undesirable effects are more frequent or severe than in the past, if we or others detect and confirm unexpected safety signals for Auryxia, vadadustat, or any other product or product candidate perceived to be similar to Auryxia or vadadustat, or if any of the foregoing are perceived to have occurred, either before or after receipt of marketing approval, a number of potentially significant negative consequences could result, including:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">sales may be impaired;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulatory approvals may be restricted or withdrawn;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may decide to, or be required to, send drug warnings or safety alerts to physicians, pharmacists and hospitals (or the FDA or other regulatory authorities may choose to issue such alerts), or we may decide to conduct a product recall or be requested to do so by the FDA or other regulatory authority;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">reformulation of the product, additional nonclinical or clinical studies, restrictive changes in labeling or changes to or re-approvals of manufacturing facilities may be required;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may be precluded from pursuing additional development opportunities to enhance the clinical profile of a product within its indicated populations, or studying the product or product candidate in additional indications and populations or in new formulations; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">government investigations or lawsuits, including class action suits, may be brought against us.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the above occurrences could delay or prevent us from achieving or maintaining marketing approval, harm or prevent sales of Auryxia or, if approved, vadadustat or any other product or product candidate, including those that may be in-licensed or acquired, increase our expenses and impair or prevent our ability to successfully commercialize Auryxia, vadadustat or any other products or product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, any post-marketing clinical trials conducted, if successful, may expand the patient populations treated with Auryxia, vadadustat or any other product we acquire or for which we receive marketing approval, within or outside of their </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">current indications or patient populations, which could result in the identification of previously unknown undesirable effects, increased frequency or severity of known undesirable effects, or result in the identification of unexpected safety signals.&#160;In addition, as Auryxia, vadadustat, if approved, and any other products are commercialized, they will be used in significantly larger patient populations, in less rigorously controlled environments and, in some cases, by less experienced and less expert treating practitioners, than in clinical studies, which could result in increased or more serious adverse effects being reported.&#160;As a result, regulatory authorities, healthcare practitioners, third party payors or patients may perceive or conclude that the use of Auryxia or any other products are associated with serious adverse effects, undermining our commercialization efforts.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Approval</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain marketing approval for, or successfully commercialize, vadadustat, or we may experience significant delays in doing so, any of which would materially harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials, manufacturing and marketing of any product or product candidate are subject to extensive and rigorous review and regulation by numerous governmental authorities in the United States and other jurisdictions. Before obtaining marketing approval for the commercial sale of any product candidate, we must demonstrate through extensive preclinical testing and clinical trials that the product candidate is safe and effective for use in each target indication. This process can take many years and marketing approval may never be achieved. Of the large number of drugs in development in the United States and in other jurisdictions, only a small percentage successfully complete the FDA&#8217;s and other jurisdictions&#8217; marketing approval processes and are commercialized. Accordingly, even if we are able to obtain the requisite capital to continue to fund our development and commercialization efforts, we may be unable to continue commercialization of Auryxia or successfully develop, obtain regulatory approval for, or commercialize vadadustat or any other product or product candidate, including those that may be in-licensed or acquired.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We and Otsuka, our collaboration partner, are not permitted to market vadadustat in the United States until we receive approval from the FDA, in the EU until we receive approval from the EMA, or in any other jurisdiction until the requisite approval from regulatory authorities in such jurisdiction is received. As a condition to receiving marketing approval for vadadustat, we may be required to conduct additional preclinical or clinical studies required by the FDA, the EMA or other regulatory authorities. We submitted an NDA to the FDA for vadadustat for the treatment of anemia due to CKD in adult dialysis-dependent and non-dialysis dependent patients in March 2021. Our NDA submission was accepted for filing by the FDA in May 2021. </span><span style="color:#373737;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA assigned the application standard review and a Prescription Drug User Fee Act (PDUFA) target</span><span style="background-color:#ffffff;color:#373737;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> action date of </span><span style="color:#373737;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">March 29, 2022</span><span style="background-color:#ffffff;color:#373737;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. At the time of filing, the FDA also indicated that they were not currently planning to hold an Advisory Committee meeting to discuss the application for vadadustat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Vadadustat may not receive marketing approval. While we remain cautious in our outlook for potential approval of vadadustat for the treatment of anemia due to CKD in adult non-dialysis dependent patients as vadadustat did not meet the primary safety endpoint of the PRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TECT program, we look forward to working with the FDA in their review of all of the data. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, vadadustat may not receive marketing approval in the United States or the EU even if it is approved in other countries. For example, although vadadustat is approved in Japan for the treatment of adult patients with anemia due to CKD, such approval does not guarantee approval in the United States by the FDA or in the EU by the EMA. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining marketing approval in the United States and other jurisdictions depends upon numerous factors, many of which are subject to the substantial discretion of the regulatory authorities, including that regulatory agencies may not complete their review processes in a timely manner and, following completion of the review process, may not grant marketing approval or such marketing approval may be limited. Furthermore, approval of a drug does not ensure successful commercialization. For example, on September 23, 2015, the European Commission, or EC, approved Fexeric for the control of hyperphosphatemia in adult patients with CKD. Pursuant to the sunset clause under EU law, the EC&#8217;s approval of Fexeric in the EU was contingent on, among other things, our commencing marketing of Fexeric within three years; although we successfully negotiated an extension to December 23, 2019, we did not commence marketing Fexeric by such date and therefore the Fexeric approval in the EU has ceased to be valid.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the safety concerns associated with the current standard of care for the indications for which we are seeking marketing approval for vadadustat and any other product candidate, including those that may be in-licensed or acquired, may affect the FDA&#8217;s, the EMA&#8217;s or other regulatory authorities&#8217; review of the safety results of our compounds in development. Further, the policies or regulations, or the type and amount of clinical data necessary to gain approval, may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. It is possible that vadadustat and any other product candidate, including those that may be in-licensed or acquired, will never obtain marketing approval in certain jurisdictions. The FDA may delay, limit or deny approval of vadadustat or any other product candidate, including those that may be in-licensed or acquired, for many reasons including, among others:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may not be able to demonstrate that vadadustat is safe and effective in treating adult patients with anemia due to CKD or that any other product candidate is safe and effective for its proposed indications to the satisfaction of the FDA;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the results of our clinical trials may only be modestly positive, or there may be concerns with the profile due to efficacy or safety;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the results of our clinical trials may not meet the level of statistical or clinical significance required by the FDA for review and/or marketing approval;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA may disagree with the number, design, size, conduct or implementation of our clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA may not approve the formulation, labeling or specifications we request for vadadustat or any other product candidate;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA may approve vadadustat or any other product candidate for use only in a small patient population or for fewer or more limited indications than we request;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA may require that we conduct additional clinical trials or repeat one or more clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA may grant approval contingent on the performance of costly post-marketing clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA's onsite inspections may be delayed due to the COVID-19 pandemic;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we, or our CROs or other vendors, may fail to comply with GXP or fail to pass any regulatory inspections or audits;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we or our third party manufacturers may fail to perform in accordance with the FDA&#8217;s cGMP requirements and guidance;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA may disagree with inclusion of data obtained from certain regions outside the United States to support the NDA for potential reasons such as differences in clinical practice from United States standards;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA may disagree with our interpretation of data from our preclinical studies and clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA could deem that our financial relationships with certain principal investigators constitute a conflict of interest, such that the data from those principal investigators may not be used to support our applications;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#373737;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">although at the time of filing the NDA for vadadustat, the FDA indicated that they were not currently planning to hold an Advisory Committee meeting to discuss the NDA,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> the FDA may ask an Advisory Committee to review portions of the NDA, the FDA may have difficulty scheduling an Advisory Committee meeting in a timely manner or, if convened, an FDA Advisory Committee could recommend non-approval, conditions of approval or restrictions on approval, and the FDA may ultimately agree with the recommendations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA may require development of a REMS as a condition of approval or post-approval;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA&#8217;s review process and decision-making regarding vadadustat and any other product candidate may be impacted by the results of our and our competitors&#8217; clinical trials and safety concerns of marketed products used to treat the same indications as the indications for which vadadustat and any other product candidate are being developed;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA may not approve the manufacturing processes or facilities of third party manufacturers with whom we contract; or</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the policies or regulations of the FDA may significantly change in a manner that renders our clinical data insufficient for approval, or requires us to amend or submit new clinical protocols.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, similar reasons may cause the EMA or other regulatory authorities to delay, limit or deny approval of vadadustat or any other product candidate outside the United States.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in obtaining approval, or if we fail to obtain approval of vadadustat or any other product candidate, including those that may be in-licensed or acquired, the commercial prospects for vadadustat or any other such product candidate may be harmed and our ability to generate revenues will be materially impaired, which could have a material adverse effect on our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be delayed in obtaining, or be unable to obtain, marketing approval or reimbursement for vadadustat or any other product candidate in certain countries outside of the United States.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities outside of the United States will require compliance with numerous and varying requirements. The approval procedures vary among jurisdictions and may involve requirements for additional testing, and the time required to obtain approval may differ from that required to obtain FDA approval. In addition, in many countries outside the United States, a drug must be approved for reimbursement before it can be marketed or sold in that country. In some cases, the prices that we intend to charge for our products are also subject to approval. Approval by the FDA does not ensure approval by regulatory or reimbursement authorities outside the United States, and approval by one regulatory or reimbursement authority outside the United States does not ensure approval by the FDA or any other regulatory or reimbursement authorities. However, the failure to obtain approval or reimbursement in one jurisdiction may negatively impact our ability to obtain approval or reimbursement in another jurisdiction. The marketing approval process in countries outside of the United States may include all of the risks associated with obtaining FDA approval and, in some cases, additional risks. We may not be able to file for or obtain such regulatory or reimbursement approvals on a timely basis, if at all. Also, favorable pricing in certain countries depends on a number of factors, some of which are outside of our control.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we could face heightened risks with respect to seeking marketing approval in the United Kingdom, or UK, as a result of the recent withdrawal of the UK from the EU, commonly referred to as Brexit. Pursuant to the formal withdrawal arrangements agreed between the UK and the EU, the United Kingdom withdrew from the EU, effective December 31, 2020. On December 24, 2020, the United Kingdom and European Union entered into a Trade and Cooperation Agreement. The agreement sets out certain procedures for approval and recognition of medical products in each jurisdiction. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of the Trade and Cooperation Agreement would prevent us from commercializing vadadustat or any other product candidate, including those that may be in-licensed or acquired, in the UK and/or the EU and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the UK and/or the EU for vadadustat or any other product candidate, which could significantly and materially harm our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Products approved for marketing are subject to extensive post-marketing regulatory requirements and could be subject to post-marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, or product candidates, when and if any of them is approved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing approvals may be subject to limitations on the approved indicated uses for which the product may be marketed or other conditions of approval, or contain requirements or commitments for potentially costly post-marketing studies and surveillance to monitor the safety and efficacy of the product, including REMS, or registries or observational studies. For example, in connection with the FDA approvals of Auryxia, we initially committed to the FDA to conduct certain post-approval pediatric studies of Auryxia under the Pediatric Research Equity Act of 2003, or PREA. With regard to the Hyperphosphatemia Indication, we committed to completing the post-approval pediatric study and submitting a final report to the FDA by December 31, 2019. With regard to our IDA Indication, we initially committed to completing the post-approval pediatric study and submitting a final report to the FDA by January 2023. We cannot guarantee that we will be able to complete these studies and submit the final reports in a timely manner. For example, with regard to the Hyperphosphatemia Indication, we did not complete and submit the post-marketing requirement pediatric clinical study report by December 31, 2019, and we received a notification of noncompliance with PREA. Our request to extend this deadline was denied, and the study is considered delayed. With regard to the IDA Indication, we did not meet a milestone relating to the post-approval pediatric study of Auryxia in a timely manner and received a notification from the FDA. Subsequently, the FDA agreed to extend the pediatric clinical study timelines for the IDA Indication. We subsequently communicated to the FDA that we would be delaying the start of the clinical trial to produce smaller size tablets. In response, the FDA issued a clinical hold until we manufacture the smaller tablets and provide the FDA with relevant information regarding the smaller sized product for review. If we are unable to complete these studies successfully, we will need to inform the FDA, have further discussions, and if the FDA finds that we failed to comply with pediatric study requirements, it could initiate proceedings to seize or enjoin the sale of Auryxia, which would have a material adverse impact on our ability to commercialize Auryxia and our ability to generate revenues from Auryxia. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for Auryxia, and any other product for which we receive regulatory approval, will be subject to extensive and ongoing regulatory requirements and guidance. These requirements and guidance include manufacturing processes and procedures (including record keeping), the implementation and operation of quality systems to control and assure the quality of the product, submissions of safety and other post-marketing information and reports, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. If we, our CMOs or other third parties we engage fail to adhere to such regulatory requirements and guidance, we could suffer significant consequences, including </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product seizures or recalls, loss of product approval, fines and sanctions, reputational damage, loss of customer confidence, shipment delays, inventory shortages, inventory write-offs and other product-related charges and increased manufacturing costs, and our development or commercialization efforts may be materially harmed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the FDA and other regulatory authorities closely regulate the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA and other regulatory authorities impose stringent restrictions on companies&#8217; communications regarding use of their products, and if we promote any approved product beyond its approved indications or inconsistent with the approved label, we may be subject to enforcement actions or prosecution arising from such activities. Violations of the U.S. Federal Food, Drug, and Cosmetic Act, or the FD&amp;C Act, relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and abuse and other laws, as well as state consumer protection laws, insurance fraud laws, third party payor actions, shareholder actions and other lawsuits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-approval discovery of previously unknown problems with an approved product, including adverse events of unanticipated severity or frequency or relating to manufacturing operations or processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions on the marketing, distribution, use or manufacturing of the product;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">withdrawal of the product from the market, or product recalls;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions on the labeling or marketing of a product;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">fines, restitution or disgorgement of profits or revenues;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">warning or untitled letters or clinical holds;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">refusal by the FDA or other regulatory authorities to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product approvals;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">product seizure or detention, or refusal to permit the import or export of products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">REMS; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For example, we recently had three limited, voluntary recalls of Auryxia. These and any other recalls or any supply, quality or manufacturing issues in the future could result in significant negative consequences, including reputational harm, loss of customer confidence, and a negative impact on our financials, any of which could have a material adverse effect on our business and results of operations, and may impact our ability to supply Auryxia, Vafseo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in Japan or vadadustat for commercial and clinical use.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-compliance with the FDA, the EMA, the PMDA and other regulatory authorities&#8217; requirements regarding safety monitoring or pharmacovigilance can also result in significant financial penalties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s policies and those of other regulatory authorities may change, and additional government regulations may be enacted. We cannot predict the likelihood, nature or extent of government regulations that may arise from future legislation or administrative action, either in the United States or in other jurisdictions. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would materially adversely affect our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Governmental Regulation and Compliance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to a complex regulatory scheme that requires significant resources to ensure compliance. Failure to comply with applicable laws could subject us to government scrutiny or government enforcement, potentially resulting in costly investigations and/or fines or sanctions, or impacting our relationships with key regulatory agencies such as the FDA, the U.S. Securities and Exchange Commission, or the SEC, or the EMA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A variety of laws apply to us or may otherwise restrict our activities, including the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">laws and regulations governing the conduct of preclinical and clinical studies in the United States and other countries in which we are conducting such studies;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">laws and regulations in the United States and in countries in which we are interacting with healthcare providers, patients, patient organizations and other constituencies that prohibit promoting a drug prior to approval and/or reimbursement;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">laws and regulations of countries outside the United States that prohibit pharmaceutical companies from promoting prescription drugs to the general public;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">laws, regulations and industry codes that vary from country to country and govern our relationships with healthcare providers, patients, patient organizations, and other constituencies, prohibit certain types of gifts and entertainment, establish codes of conduct and, in some instances, require disclosure to, or approval by, regulatory authorities for us to engage in arrangements with such constituencies;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">anti-corruption and anti-bribery laws, including the FCPA, the UK Bribery Act and various other anti-corruption laws in countries outside of the United States;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">data privacy laws existing in the United States, the EU and other countries in which we operate, including the U.S. Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, the GDPR, and state privacy and data protection laws, such as the California Consumer Privacy Act, or CCPA, as well as state consumer protection laws;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">federal and state laws requiring the submission of accurate product prices and notifications of price increases;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">federal and state securities laws; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">international trade laws, which are laws that regulate the sale, purchase, import, export, re-export, transfer and shipment of goods, products, materials, services and technology.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with these and other applicable laws and regulations requires us to expend significant resources. Failure to comply with these laws and regulations may subject us to government investigations, enforcement actions by regulatory authorities, penalties, damages, fines, the restructuring of our operations, or the imposition of a clinical hold, any of which could materially adversely affect our business and would result in increased costs and diversion of management attention and could negatively impact the development, regulatory approval and commercialization of Auryxia or vadadustat, any of which could have a material adverse effect on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will incur significant liability if it is determined that we are promoting any &#8220;off-label&#8221; use of Auryxia or any other product we may develop, acquire or in-license or if it is determined that any of our activities violates the federal Anti-Kickback Statute.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physicians are permitted to prescribe drug products for uses that differ from those approved by the FDA or other applicable regulatory agencies. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of treatments, the FDA and other regulatory agencies do restrict manufacturer communications regarding unapproved uses of an approved drug. Companies are not permitted to promote drugs for unapproved uses or in a manner that is inconsistent with the FDA-approved labeling. There are also restrictions about making comparative or superiority claims based on safety or efficacy that are not supported by substantial evidence. Accordingly, we may not promote Auryxia in the United States for use in any indications other than the Hyperphosphatemia Indication and the IDA Indication, and all promotional claims must be consistent with the FDA-approved labeling for Auryxia. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Promoting a drug off-label is a violation of the FD&amp;C Act and can give rise to liability under the federal False Claims Act, as well as under additional federal and state laws and insurance statutes. The FDA, the Department of Justice and other regulatory and enforcement authorities enforce laws and regulations prohibiting promotion of off-label uses and the promotion of products for which marketing approval has not been obtained, as well as the false advertising or misleading promotion of drugs. In addition, laws and regulations govern the distribution and tracing of prescription drugs and prescription drug samples, including the Prescription Drug Marketing Act of 1976 and the Drug Supply Chain Security Act, which regulate the distribution and tracing of prescription drugs and prescription drug samples at the federal level and set minimum standards for the regulation of drug distributors by the states. A company that is found to have improperly promoted off-label uses or to have otherwise engaged in false or misleading promotion or improper distribution of drugs will be subject to significant liability, potentially including civil and administrative remedies as well as criminal sanctions. It may also be subject to exclusion and debarment from federal healthcare reimbursement programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the regulatory restrictions on off-label promotion, the FDA and other regulatory authorities allow companies to engage in truthful, non-misleading, and non-promotional scientific communications concerning their products in certain circumstances. In addition, under some relatively recent guidance from the FDA, companies may also promote information that is consistent with the prescribing information and proactively speak to formulary committee members of payors regarding data for an unapproved drug or unapproved uses of an approved drug. We intend to engage in these discussions and communicate with healthcare providers, payors and other constituencies in compliance with all applicable laws, regulatory guidance and industry best practices. Although we believe we have put in place a robust compliance program and processes designed to ensure that all such activities are performed in a legal and compliant manner, Auryxia is our first commercial product in the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States, so our implementation of our compliance program in connection with commercialization activities is still relatively new.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if a company&#8217;s activities are determined to have violated the federal Anti-Kickback Statute, this can also give rise to liability under the federal False Claims Act and such violations can result in significant fines, criminal and civil remedies, and exclusion from Medicare and Medicaid.&#160;There is increased government focus on relationships between the pharmaceutical industry and physicians, pharmacies (especially specialty pharmacies), and other sources of referrals. Common industry activities, such as speaker programs, insurance assistance and support, relationships with foundations providing copayment assistance, and relationships with patient organizations and patients are receiving increased governmental attention.&#160;If any of our relationships or activities is determined to violate applicable federal and state anti-kickback laws, false claims laws, or other laws or regulations, the company and/or company executives, employees, and other representatives could be subject to significant fines and criminal sanctions, imprisonment, and potential exclusion from Medicare and Medicaid.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions in the FDA and other government agencies caused by funding shortages or global health concerns could prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the United States government has shut down. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In response to the COVID-19 pandemic, on March 10, 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July 10, 2020, the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. This risk-based assessment system identifies the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. In May 2021, the FDA issued a new report &#8220;Resiliency Roadmap for FDA Inspectional Oversight&#8221; which include its detailed plan to move towards a more consistent state of operations; best-case, base-case and worst-case scenarios are identified, as well as the drivers that determine these scenarios and the impact these will have on inspection activities.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Regulatory authorities outside the United States may also impose similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the EU, including personal health data, is subject to the GDPR, which took effect across all member states of the European Economic Area, or EEA, in May 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data when required, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, when required, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third party processors. The GDPR increases our obligations with respect to sponsors with clinical trial sites in the EEA by expanding the definition of personal data to include coded data and requiring changes to informed consent practices and more detailed notices for clinical trial patients and investigators. In addition, the GDPR also imposes strict rules </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the transfer of personal data to countries outside the EU, including the United States and, as a result, increases the scrutiny that clinical trial sites located in the EEA should apply to transfers of personal data from such sites to countries that are considered to lack an adequate level of data protection, such as the United States. The GDPR also permits data protection authorities to require destruction of improperly gathered or used personal information and/or impose substantial fines for violations of the GDPR, which can be up to four percent of global revenues or 20 million Euros, whichever is greater, and it also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR.&#160;In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the breadth and depth of changes in data protection obligations, complying with the GDPR&#8217;s requirements is rigorous and time intensive and requires significant resources and a review of our technologies, systems and practices, as well as those of any third party collaborators, service providers, contractors or consultants that process or transfer personal data collected in the EU. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from our clinical trials, could require us to change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing business, and could lead to government enforcement actions, private litigation and significant fines and penalties against us and could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar privacy and data security requirements are either in place or underway in the United States. There are a broad variety of data protection laws that may be applicable to our activities, and a range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns. The Federal Trade Commission and state Attorneys General all are aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered at both the state and federal levels. For example, the CCPA, which went into effect on January 1, 2020, is creating similar risks and obligations as those created by GDPR. Because of this, we may need to engage in additional activities (e.g., data mapping) to identify the personal information we are collecting and the purposes for which such information is collected. In addition, we will need to ensure that our policies recognize the rights granted to consumers (as that phrase is broadly defined in the CCPA and can include business contact information). Many other states are considering similar legislation. A broad range of legislative measures also have been introduced at the federal level. Accordingly, failure to comply with current and any future federal and state laws regarding privacy and security of personal information could expose us to fines and penalties. We also face a threat of potential consumer class actions related to these laws and the overall protection of personal data. Even if we are not determined to have violated these laws, investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with healthcare providers, physicians and third party payors are subject to applicable anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security, and other healthcare laws and regulations, which, in the event of a violation, could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third party payors play a primary role in the recommendation and prescription of Auryxia and any other product candidates for which we obtain marketing approval. Our arrangements with healthcare providers, physicians and third party payors expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute Auryxia and vadadustat, if approved, and any other products for which we may obtain marketing approval. In addition, we may be subject to transparency laws and patient privacy regulation by federal and state governments and by governments in foreign jurisdictions in which we conduct our business. Restrictions under applicable federal and state healthcare laws and regulations include the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FD&amp;C Act which among other things, strictly regulates drug product marketing and promotion and prohibits manufacturers from marketing such products for off-label use;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs, and laws requiring notification of price increases;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arranging of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal False Claims Act imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, false or fraudulent claims for payment by a federal healthcare program or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties, currently set at $11,181 to $22,363, per false claim </span><span style="background-color:#fefefe;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for penalties assessed between January 29, 2018 and June 19, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and $11,665 to $23,331, per false claim </span><span style="background-color:#fefefe;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for penalties assessed after June 19, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and violations of the FD&amp;C Act, the federal government pricing laws, and the federal Anti-Kickback Statute trigger liability under the federal False Claims Act;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">HIPAA imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">HIPAA, as amended by the HITECH, and their respective implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal Physician Payments Sunshine Act (renamed the Open Payments Act) requires applicable manufacturers of covered drugs to report payments and other transfers of value to physicians and teaching hospitals;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws and gift ban and transparency statutes, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by state Medicaid or other programs, or non-governmental third party payors, including private insurers, and which are not preempted by federal laws and often differ from state to state, thus complicating compliance efforts; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">U.S. state laws restricting interactions with healthcare providers and other members of the healthcare community or requiring pharmaceutical manufacturers to implement certain compliance standards, which vary from state to state.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these U.S. laws, and their non-U.S. equivalents, and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent healthcare reforms have strengthened these laws. For example, the Health Care Reform Act, among other things, amended the intent requirement of the federal Anti-Kickback Statute. A person or entity no longer needs to have actual knowledge of the statute or specific intent to violate the law. The Health Care Reform Act also amended the False Claims Act, such that violations of the Anti-Kickback Statute are now deemed violations of the False Claims Act.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines, such as the Pharmaceutical Research and Manufacturers of America Code on Interactions with Health Care Professionals, known as the PhRMA Code. Additionally, some state and local laws require the registration of pharmaceutical sales representatives in the jurisdiction. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations involve substantial costs. One of the potential areas for governmental scrutiny involves federal and state requirements for pharmaceutical manufacturers to submit accurate price reports to the government. Because our processes for calculating applicable government prices and the judgments involved in making these calculations involve subjective decisions and complex methodologies, these calculations are subject to risk of errors and differing interpretations. In addition, they are subject to review and challenge by the applicable governmental agencies, or potential qui tam complaints, and it is possible that such reviews could result in changes, recalculations, or defense costs that may have adverse legal or financial consequences. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government funded healthcare programs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain for any products that are approved in the United States or foreign jurisdictions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of vadadustat, or any other product candidate, restrict or regulate post-approval activities and affect our ability to profitably sell Auryxia and vadadustat, if approved. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by legislative initiatives. Current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any FDA approved product, such as Auryxia.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sales prices for physician-administered drugs. In addition, this legislation provided authority for limiting the number of drugs that will be covered in any therapeutic class. Cost reduction initiatives and other provisions of this legislation could decrease the coverage and price that we receive for Auryxia and any other approved products. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private payors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or, collectively, the ACA. Among the provisions of the ACA of potential importance to our business including, without limitation, our ability to commercialize and the prices we obtain for Auryxia and may obtain for any of our product candidates that are approved for sale, are the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">an annual, non-deductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expansion of healthcare fraud and abuse laws, including the civil False Claims Act and the federal anti-kickback statute, new government investigative powers and enhanced penalties for noncompliance;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a new Medicare Part&#160;D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">extension of manufacturers&#8217; Medicaid rebate liability;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expansion of eligibility criteria for Medicaid programs;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">new requirements to report certain financial arrangements with physicians and teaching hospitals;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes and regulatory have been proposed and adopted since the ACA was enacted. These changes include the Budget Control Act of 2011, which, among other things, led to aggregate reductions to Medicare payments to providers of 2% per fiscal year. The Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, suspended the 2% Medicare sequester from May 1, 2020 through December 31, 2020, and extended the sequester, through 2030. The American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. In addition, other legislative and regulatory changes have been proposed, but not yet adopted. For example, in July 2019, HHS proposed regulatory changes in kidney health policy and reimbursement. Any new legislative or regulatory changes may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for Auryxia or vadadustat, if approved, or the frequency with which Auryxia and vadadustat, if approved, is prescribed or used.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reimbursement physicians receive for administering any approved product. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the enactment of the Tax Cuts and Jobs Act of 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. According to the Congressional Budget Office, the repeal of the individual mandate will cause an estimated 13&#160;million fewer Americans to be insured in 2027 and premiums in insurance markets may rise. The prior administration also took executive actions to undermine or delay implementation of the ACA. In addition, CMS has proposed regulations that would give states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, on December 14, 2018, a United States District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA and, therefore, because the mandate was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. On November 10, 2020, the United States Supreme Court heard this case. On June 17, 2021, the Supreme Court dismissed this case after finding that the plaintiffs do not have standing to challenge the constitutionality of the ACA. Accordingly, all of the provisions in the ACA but the individual mandate to buy health insurance remain in effect. It is unclear how such litigation and other efforts to repeal and replace the ACA will impact the ACA and our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs and prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. To date, there have been several recent United States congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, there have been several recent United States congressional inquiries and proposed federal and proposed and enacted state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. At the federal level, Congress and the current administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs.&#160;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the former administration issued five executive orders intended to lower the costs of prescription drug products. Several of these orders are reflected in recently promulgated regulations, and one of these regulations is currently subject to a nationwide preliminary injunction. The current administration has frozen certain of the previous administration&#8217;s measures to reform drug prices, pending further review It remains to be seen how the current administration will address this issue but, under Medicare Part D, the new administration may seek to establish a ceiling for the launch prices of all branded, biologic, and certain generic drugs by referencing the average price of these drugs in other developed countries. At the same time, the administration may seek to limit Medicare Part D and public option drug prices through a tax penalty on manufacturers for increases in the cost of drugs and biologics above the general inflation rate. The American Rescue Plan Act of 2021, comprehensive COVID-19 relief legislation recently enacted under the current administration, includes a number of healthcare-related provisions, such as support to rural health care providers, increased tax subsidies for health insurance purchased through insurance exchange marketplaces, financial incentives to states to expand Medicaid programs and elimination of the Medicaid drug rebate cap effective in 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. These measures could reduce the ultimate demand for our products or put pressure on our product pricing.&#160;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is likely that federal and state legislatures within the United States and foreign governments will continue to consider changes to existing healthcare legislation. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for Auryxia and any product candidates for which we receive marketing approval or additional pricing pressures. We cannot predict the reform initiatives that may be adopted in the future or whether initiatives </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that have been adopted will be repealed or modified. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the demand for Auryxia and any products candidates for which we receive marketing approval;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to set a price that we believe is fair for our products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to obtain and maintain coverage and reimbursement approval for Auryxia or any other approved product;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to generate revenues and achieve or maintain profitability; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the level of taxes that we are required to pay.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the use and disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from the use of hazardous materials by our employees, contractors or consultants, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Reliance on Third Parties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the licensor of certain intellectual property relating to Auryxia terminates, modifies or threatens to terminate existing contracts or relationships with us, our business may be materially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own the rights to our product, Auryxia. We have licensed and sublicensed the rights, patent and otherwise, to Auryxia from a third party, Panion, who in turn licenses certain rights to Auryxia from one of the inventors of Auryxia. The license agreement with Panion, or the Panion License Agreement, requires us to meet development milestones and imposes development and commercialization due diligence requirements on us. In addition, under the Panion License Agreement, we must pay royalties based on a mid-single digit percentage of net sales of product resulting from the licensed technologies, including Auryxia, and pay the patent filing, prosecution and maintenance costs related to the license. If we do not meet our obligations in a timely manner, or if we otherwise breach the terms of the Panion License Agreement, Panion could terminate the agreement, and we would lose the rights to Auryxia. For example, following announcement of the Merger, Panion notified Keryx in writing that Panion would terminate the Panion License Agreement on November 21, 2018 if Keryx did not cure the breach alleged by Panion, specifically, that Keryx failed to use commercially reasonable best efforts to commercialize Auryxia outside the United States. Keryx disagreed with Panion&#8217;s claims, and the parties entered discussions to resolve this dispute. On October 24, 2018, prior to the consummation of the Merger, we, Keryx and&#160;Panion entered into a letter agreement, or the Panion Letter Agreement, pursuant to which Panion agreed to rescind any and all prior termination threats or notices relating to the Panion License Agreement and waived its rights to terminate the license agreement based on any breach by us of our obligation to use commercially reasonable efforts to commercialize Auryxia outside the United States until the parties executed an amendment to the Panion License Agreement in accordance with the terms of the Panion Letter Agreement, following consummation of the Merger. On April 17, 2019, we and Panion entered into an amendment and restatement of the Panion License Agreement, or the Panion Amended License Agreement, which reflects certain revisions consistent with the terms of the Panion Letter Agreement.&#160;See Note 4 to the Condensed Consolidated Financial Statements (unaudited) contained in this Quarterly Report on Form 10-Q for additional information regarding the Panion Amended License Agreement. Even though we entered into the Panion Amended License Agreement, there are no assurances that Panion will not allege other breaches of the Panion Amended License Agreement or otherwise attempt to terminate the Panion Amended License Agreement in the future. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if Panion breaches its agreement with the inventor from whom it licenses rights to Auryxia, Panion could lose its license, which could impair or delay our ability to develop and commercialize Auryxia.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may have disagreements with Panion, or Panion may have disagreements with the inventor from whom it licenses rights to Auryxia, regarding the terms of the agreements or ownership of proprietary rights, which could impact the commercialization of Auryxia, could require or result in litigation or arbitration, which would be time-consuming and expensive, could lead to the termination of the Panion Amended License Agreement, or force us to negotiate a revised or new license agreement on terms less favorable than the original. In addition, in the event that the owners and/or licensors of the rights we license were to enter into bankruptcy or similar proceedings, we could potentially lose our rights to Auryxia or our rights could otherwise be adversely affected, which could prevent us from continuing to commercialize Auryxia.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct our clinical studies and certain of our preclinical studies. If they do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to optimize the commercialization of Auryxia or obtain marketing approval for or commercialize vadadustat, and our business could be substantially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to independently conduct certain preclinical and clinical trials. We are currently relying, and expect to continue to rely, on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct our current and future preclinical studies and our clinical trials. The third parties on whom we rely may fail to perform effectively, or terminate their engagement with us, for a number of reasons, including the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if third parties experience staffing difficulties;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if we fail to communicate effectively or provide the appropriate level of oversight;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if third parties undergo changes in priorities or corporate structure or become financially distressed; or</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if they form relationships with other entities, some of which may be our competitors.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the third parties on whom we rely to conduct our trials fail to adhere to clinical trial protocols or to regulatory requirements, the quantity or accuracy of the data obtained by the third parties may be compromised.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could cause our preclinical and clinical trials, including post-approval clinical trials, to be extended, delayed, suspended, required to be repeated or terminated, or we may receive untitled warning letters or be the subject of an enforcement action, which could result in our failing to obtain and maintain marketing approval of vadadustat or any other product candidates on a timely basis, or at all, or fail to maintain marketing approval of Auryxia, or any other products, any of which would adversely affect our business operations. In addition, if the third parties on whom we rely fail to perform effectively or terminate their engagement with us, we may need to enter into alternative arrangements, which could delay, perhaps significantly, the continued optimization of the commercialization of Auryxia and the development and commercialization of vadadustat or any other product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even though we do not directly control the third parties on whom we rely to conduct our preclinical and clinical trials and therefore cannot guarantee the satisfactory and timely performance of their obligations to us, we are nevertheless responsible for ensuring that each of our clinical and preclinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements, including GXP requirements, and scientific standards, and our reliance on these third parties, including CROs, will not relieve us of our regulatory responsibilities. If we or any of our CROs, their subcontractors, or clinical or preclinical trial sites fail to comply with applicable GXP requirements, the clinical data generated in our trials may be deemed unreliable or insufficient, our clinical trials could be put on hold, and/or the FDA, the EMA or other regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In addition, our clinical and preclinical trials must be conducted with drug product that meets certain specifications and is manufactured under applicable cGMP regulations. These requirements include, among other things, quality control, quality assurance, and the satisfactory maintenance of records and documentation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development, marketing approval or commercialization, resulting in additional costs and depriving us of potential product revenue.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct all aspects of our product manufacturing. The loss of these manufacturers, their failure to supply us on a timely basis, or their failure to successfully carry out their contractual duties or comply with regulatory requirements or guidance could cause delays in or disruptions to our supply chain and substantially harm our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not have any manufacturing facilities and do not expect to independently manufacture any product or product candidates. We currently rely, and expect to continue to rely, on third party manufacturers to produce all of our commercial, clinical and preclinical supply, including the vadadustat drug product that we supply to our collaboration partner, MTPC, for the Japanese market. Our reliance on third party manufacturers increases the risk that we will not have sufficient quantities of Auryxia and vadadustat or the ability to obtain such quantities at an acceptable cost or quality, which could delay, prevent or impair our and our partners' development or commercialization efforts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have two suppliers of Auryxia drug substance, Siegfried Evionnaz SA (two approved sites) and BioVectra Inc. (one approved site), and one supplier of Auryxia drug product, Patheon Inc., or Patheon (three approved sites). We have entered into supply agreements with Esteve Qu&#237;mica, S.A. and STA Pharmaceutical Hong Kong Limited, a subsidiary of Wuxi AppTec, or STA, for the commercial manufacture of vadadustat drug substance and Patheon Inc. and STA for the commercial manufacture of vadadustat drug product. If any of the following occurs, we may not have sufficient quantities of Auryxia and/or vadadustat to support our clinical trials, commercialization, or obtaining and maintaining marketing approvals, which could materially and adversely impact our business and results of operations:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we are unsuccessful in implementing additional redundant supply arrangements for commercial quantities of vadadustat or in maintaining our redundant supply arrangements for commercial quantities of Auryxia and vadadustat;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercial supply arrangements for Auryxia or vadadustat are terminated;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of our third party manufacturers is unable to fulfill the terms of their agreements with us or is unable or unwilling to continue to manufacture on the manufacturing lines included in our regulatory filings; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of our third party manufacturers breaches our supply agreements, does not comply with quality or regulatory requirements and guidance, is subject to regulatory review or ceases its operations for any reason. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our third party manufacturers cannot or do not perform as agreed or expected, including as a result of COVID-19, a misappropriation of our proprietary information, if they terminate their engagements with us, if we terminate our engagements with them, or if there is a significant disagreement, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into agreements with other third party manufacturers, which we may not be able to do in a timely manner or on favorable or reasonable terms, if at all. In some cases, there may be a limited number of qualified replacement manufacturers, or the technical skills or equipment required to manufacture a product or product candidate may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third party, or a feasible alternative may not exist. These factors would increase our reliance on our current manufacturers or require us to file to obtain licenses in order to have another third party manufacture Auryxia or vadadustat. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the qualification of a new manufacturer and validation of manufacturing processes would negatively affect our ability to supply clinical trials, obtain and maintain marketing approval, or commercialize or satisfy patient demand for Auryxia and vadadustat, where approved, in a timely manner within budget or at all.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There are a limited number of manufacturers that are capable of manufacturing Auryxia and vadadustat for us and complying with cGMP regulations and guidance and other stringent regulatory requirements and guidance enforced by the FDA, EMA, PMDA and other regulatory authorities. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation, which occur in addition to our own quality assurance releases. The facilities and processes used by our third party manufacturers to manufacture Auryxia may be inspected by the FDA and other regulatory authorities at any time, and the facilities and processes used by our third party manufacturers to manufacture vadadustat will be inspected by the FDA, the EMA and other regulatory authorities prior to or after we submit our marketing applications. Although we have general visibility into the manufacturing processes of our third party manufacturers, we do not ultimately control such manufacturing processes of, and have little control over, our third party manufacturers, including, without limitation, their compliance with cGMP requirements and guidance for the manufacture of certain starting materials, drug substance and finished drug product. Similarly, although we review final production, we have little control over the ability of our third party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. Our third party manufacturers may experience problems with their manufacturing and distribution operations and processes, including, for example, quality issues, such as product specification and stability failures, procedural deviations, improper equipment installation or operation, utility failures, contamination, natural disasters and public health epidemics. We may also encounter difficulties relating to our own quality processes and procedures, including regulatory compliance, lot release, quality control and quality assurance, as well as shortages of qualified personnel. If our third party manufacturers cannot successfully manufacture material that conforms to our specifications and regulatory requirements and guidance, or if we or our third party manufacturers experience manufacturing, operations and/or quality issues, including an inability or unwillingness to continue manufacturing our products at all, in accordance with agreed-upon processes or on currently validated manufacturing lines, we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">may not be able to supply patient demand or maintain marketing approval for Auryxia or secure and maintain marketing approval for vadadustat.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA, the EMA or other regulatory authorities do not approve the facilities being used to manufacture vadadustat, or if they withdraw any approval of the facilities being used to manufacture Auryxia or Vafseo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan, we may need to find alternative manufacturing facilities, which would significantly impact our ability to continue commercializing Auryxia or develop, obtain marketing approval for or market our product candidates, if approved. Moreover, our failure or the failure of our third party manufacturers to comply with applicable regulations or guidance, or our failure to oversee or facilitate such compliance, could result in sanctions being imposed on us or our third party manufacturers, including, where applicable, clinical holds, fines, injunctions, civil penalties, delays in, suspension of or withdrawal of approvals, license revocation, seizures or recalls of Auryxia or vadadustat, operating restrictions, receipt of a Form 483 or warning letter, or criminal prosecutions, any of which could significantly and adversely affect the supply of Auryxia or vadadustat. For example, we recently had three limited, voluntary recalls of Auryxia. These and any other recalls or any supply, quality or manufacturing issues in the future and any related write-downs of inventory or other consequences could result in significant negative consequences, including reputational harm, loss of customer confidence, and a negative impact on our financials, any of which could have a material adverse effect on our business and results of operations, and may impact our ability to supply Auryxia, Vafseo in Japan or vadadustat for commercial and clinical use. Also, if our starting materials, drug substance or drug product are damaged or lost while in our or our third party manufacturers&#8217; control, it may adversely impact our ability to supply Auryxia or vadadustat, and we may incur significant financial harm. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, Auryxia and vadadustat may compete with other products and product candidates for access to third party manufacturing facilities. A third party manufacturer may also encounter delays or operational issues brought on by sudden internal resource constraints, labor disputes, shifting priorities or shifting regulatory protocols, including, in each case, relating to the COVID-19 pandemic. Certain of these third party manufacturing facilities may be contractually prohibited from manufacturing Auryxia or vadadustat due to exclusivity provisions in agreements with our competitors. Any of the foregoing could negatively impact our third party manufacturers' ability to meet our demand, which could adversely impact our ability to supply Auryxia or vadadustat, and we may incur significant financial harm. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and anticipated future dependence on third parties for the manufacture of Auryxia and vadadustat may adversely affect our and our partners' ability to commercialize Auryxia and vadadustat, where approved, on a timely and competitive basis and any future profit margins.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third party manufacturers may be unable to manufacture Auryxia and vadadustat in sufficient quality and quantity, which would delay or prevent us from commercializing and developing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the large quantity of materials required for the production of Auryxia and vadadustat and the large quantities of tablets that are required for our commercial success, the commercial viability of Auryxia and vadadustat, if and where approved, depends on adequate supply of starting materials that meet quality, quantity and cost standards and the ability of our contract manufacturers to continually produce drug substance and finished drug product that meets all manufacturing requirements on a commercial scale. Failure to achieve and maintain these levels of supply can jeopardize and prevent the successful continued commercialization of Auryxia and commercialization of vadadustat, if and where approved. Moreover, issues that may arise in any scale-up and technology transfer and continued commercial scale manufacture of our products may lead to significant delays in our development, marketing approval and commercial timelines and negatively impact our financial performance. For example, a production-related issue resulted in an interruption in the supply of Auryxia in the third and fourth quarters of 2016. This supply interruption negatively impacted Keryx&#8217;s revenues in 2016. Although this supply interruption was resolved and actions designed to prevent future interruptions in the supply of Auryxia are ongoing, any future supply interruptions, whether quality or quantity based, for Auryxia and vadadustat, if and where approved, would negatively and materially impact our reputation and financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in order to complete our development of and commercialize vadadustat, if approved in regions beyond Japan, we will need to work with third party manufacturers to manufacture vadadustat in large quantities, including to prepare for launch demand. Our current and future third party manufacturers may be unable to successfully achieve commercial scale production of vadadustat in a timely or cost-effective manner, if at all. COVID-19 may also impact our third party manufacturers and their ability to supply vadadustat in sufficient quantities, or at all. In addition, quality issues may arise during scale-up activities. Any changes in our manufacturing processes as a result of scaling up may result in the need to obtain additional marketing approvals. If our third party manufacturers are unable to achieve commercial scale production or there is a need for additional marketing approvals of vadadustat, the development, marketing approval and commercialization of vadadustat may be delayed or infeasible, or ongoing commercialization of Auryxia or Vafseo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan may be unsuccessful, any of which could significantly harm our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on collaborations with third parties for the development and commercialization of Auryxia, Riona and vadadustat. If our collaborations are not successful or if our collaborators terminate their agreements with us, we may not be able to capitalize on the market potential of Auryxia, Riona and vadadustat, and our business could be materially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sublicensed the rights to commercialize Riona to JT and Torii in Japan. We entered into collaboration agreements with Otsuka to develop and commercialize vadadustat in the United States, Europe, China and certain other territories. We also entered into a collaboration agreement with MTPC to develop and commercialize vadadustat in Japan and certain other Asian countries. In addition, we have a license agreement with Vifor Pharma pursuant to which we granted an exclusive license to sell vadadustat to FKC and the Third Party Dialysis Organizations, approved by us, in the United States, which license would become effective only upon the satisfaction of certain conditions. We may form or seek other strategic alliances, joint ventures, or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our and our partners' commercialization efforts with respect to Auryxia, Riona, Vafseo and our and our partners' development and commercialization efforts with respect to vadadustat and any other product candidates. Our likely collaborators for any collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to maintain our collaborations and our collaborations may not be successful due to a number of important factors, including the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborators may have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborations may be terminated in accordance with the terms of the collaborations and, if terminated, may make it difficult for us to attract new collaborators or adversely affect how we are perceived in scientific and financial communities, and may result in a need for additional capital and expansion of our internal capabilities to pursue further development or commercialization of the applicable products and product candidates;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if permitted by the terms of the collaborations, collaborators may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in their strategic focus, availability of funding or other external factors such as a business combination that diverts resources or creates competing priorities;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if permitted by the terms of the collaborations, collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a collaborator with marketing and distribution rights to our products may not commit sufficient resources to their marketing and distribution;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if permitted by the terms of the collaboration, we and our collaborator may have a difference of opinion regarding the development or commercialization strategy for a particular product or product candidate, and our collaborator may have ultimate decision making authority;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes may arise between a collaborator and us that cause the delay or termination of activities related to research, development or commercialization of Auryxia or vadadustat and any other product candidate, or that result in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborations may not lead to development or commercialization of products and product candidates, if approved, in the most efficient manner or at all;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a significant change in the senior management team, a change in the financial condition or a change in the business operations, including a change in control or internal corporate restructuring, of any of our collaborators, could result in delayed timelines, re-prioritization of our programs, decreasing resources or funding allocated to support our programs, or termination of the collaborations; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborators may not comply with all applicable regulatory requirements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occurs, the market potential of Auryxia and vadadustat, if and where approved, and any other products or product candidates, could be reduced, and our business could be materially harmed. We also cannot be certain that, following a collaboration, the benefits of the collaboration will outweigh the potential risks.</span></div><div style="margin-top:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek to establish additional collaborations and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will require substantial additional cash to fund the continued commercialization of Auryxia and the development and potential commercialization of vadadustat and any other product candidates. We may decide to enter into additional collaborations for the development and commercialization of vadadustat or Auryxia. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be successful in entering into additional collaborations as a result of many factors, including the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">competition in seeking appropriate collaborators;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a reduced number of potential collaborators due to recent business combinations in the pharmaceutical industry;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">inability to negotiate collaborations on acceptable terms;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">inability to negotiate collaborations on a timely basis;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:32.5pt">a potential collaborator&#8217;s evaluation of Auryxia, vadadustat and any other product or product candidate;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a potential collaborator&#8217;s resources and expertise; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions due to an existing collaboration agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to enter into additional collaborations, we may have to delay or curtail the commercialization of Auryxia or vadadustat, if and where approved, reduce or delay its development program or other of our other development programs, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop or commercialize Auryxia or vadadustat, in the case of commercialization, where approved.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we enter into additional collaboration agreements and strategic partnerships or license our intellectual property, we may not be able to maintain them or they may be unsuccessful, which could delay our timelines or otherwise adversely affect our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may incur losses as a result of unforeseen or catastrophic events, including the emergence of a pandemic, terrorist attacks, extreme weather events or other natural disasters.&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of unforeseen or catastrophic events, including the emergence of a pandemic, such as COVID-19 discussed above, or other widespread health emergency (or concerns over the possibility of such an emergency), terrorist attacks, extreme terrestrial or solar weather events or other natural disasters, could create economic and financial disruptions, and could lead to operational difficulties that could impair our ability to manage our businesses or result in reduced sales or delays in our clinical studies, which could have a material adverse effect on our financial results. If we or any of the third parties with whom we engage were to experience shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted, which could have a material adverse effect on our business and our financial results.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to adequately protect our intellectual property, third parties may be able to use our intellectual property, which could adversely affect our ability to compete in the market.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success will depend in part on our ability, and the ability of our licensors, to obtain and maintain patent protection on our drug product and technologies, and to successfully defend these patents against third party challenges. We seek to protect our proprietary products and technology by filing patent applications in the United States and certain foreign jurisdictions. The process for obtaining patent protection is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications in a cost effective or timely manner. In addition, we may fail to identify patentable subject matter early enough to obtain patent protection. Further, license agreements with third parties may not allow us to control the preparation, filing and prosecution of patent applications, or the maintenance or enforcement of patents. Such third parties may decide not to enforce such patents or enforce such patents without our involvement. Thus, these patent applications and patents may not under these circumstances, be prosecuted or enforced in a manner consistent with the best interests of the company.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pending patent applications may not issue as patents and may not issue in all countries in which we develop, manufacture or potentially sell our product or in countries where others develop, manufacture and potentially sell products using our technologies. Moreover, our pending patent applications, if issued as patents, may not provide additional protection for our product.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions. No consistent policy regarding the breadth of claims allowed in pharmaceutical and biotechnology patents has emerged to date. Changes in the patent laws or the interpretation of the patent laws in the United States and other jurisdictions may diminish the value of our patents or narrow the scope of our patent protection. Accordingly, the patents we own or license may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products. Furthermore, others may independently develop similar or alternative drug products or technologies or design around our patented drug product and technologies which may have an adverse effect on our business. If our competitors prepare and file patent applications in the United States that claim technology also claimed by us, we may have to participate in interference or derivation proceedings in front of the U.S. Patent and Trademark Office, or USPTO, to determine priority of invention, which could result in substantial cost, even if the eventual outcome is favorable to us. Because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that any related patent may expire prior to, or remain in existence for only a short period following, commercialization, thus reducing any advantage of the patent. The patents we own or license may be challenged or invalidated or may fail to provide us with any competitive advantage. Since we have licensed or sublicensed many patents from third parties, we may not be able to enforce such licensed patents against third party infringers without the cooperation of the patent owner and the licensor, which may not be forthcoming. In addition, we may not be successful or timely in obtaining any patents for which we submit applications.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the laws of foreign countries may not protect our intellectual property rights to the same extent as do the laws of the United States. For example, claims in a patent application directed to methods of treatment of the human body are not patentable or are restricted in many non-U.S. countries. Further, we may not pursue or obtain patent protection in all major markets. In addition, in jurisdictions outside the United States where we own or license patent rights, we may be unable to prevent unlicensed parties from selling or importing products or technologies derived elsewhere using our proprietary technology.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, the first to file a patent application is entitled to the patent if all other requirements of patentability are met. However, prior to March 16, 2013, in the United States, the first to invent was entitled to the patent. Since publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. Moreover, the laws enacted by the Leahy-Smith America Invents Act of 2011, or the Act, which reformed certain patent laws in the United States, introduce procedures that permit competitors to challenge our patents in the USPTO after grant, including&#160;inter partes&#160;review and post grant review. Similar laws exist outside of the United States. The laws of the European Patent Convention, for example, provide for post-grant opposition procedures that permit competitors to challenge, or oppose, our European patents administratively at the European Patent Office.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July&#160;2011, a third party filed an opposition to our issued European patents, European Patent No.&#160;2044005, or the &#8217;005 EP Patent, which covers vadadustat. During the oral proceedings, which took place on April&#160;10, 2013, the Opposition Division of the European Patent Office decided to maintain certain claims of the patent directed to a compound chosen from a group of eight compounds, including vadadustat, as well as claims to compositions and methods for treating various diseases including, but not limited to, anemia. Both parties appealed the decision of the Opposition Division. On February 27, 2018, we withdrew the &#8217;005 EP Patent from appeal and filed a divisional patent application to pursue a focused claim set that includes claims for vadadustat, as well as pharmaceutical compositions and methods of treating anemia. We cannot be assured that such claims in the divisional application will be granted by the European Patent Office. If such claims are not granted, or the scope of the claims is significantly narrowed, we may not be able to adequately protect our rights, provide sufficient exclusivity, or preserve our competitive advantage.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may become involved in addressing patentability objections based on third party submission of references, or we may become involved in defending our patent rights in oppositions, derivation proceedings, reexamination, inter partes review, post grant review, interference proceedings or other patent office proceedings or litigation, in the United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse result in any such proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged on such a basis in the courts or patent offices in the United States and abroad. As a result of such challenges, we may lose exclusivity or freedom-to-operate or patent claims may be narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to prevent third parties from using or commercializing similar or identical products, or limit the duration of the patent protection for our products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patents protecting our product candidate might expire before or shortly after such candidate is commercialized. Thus, our patent portfolio may not provide sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trade secrets and know-how to protect our intellectual property where we believe patent protection is not appropriate or obtainable. Trade secrets are difficult to protect. While we require our employees, licensees, collaborators and consultants to enter into confidentiality agreements, this may not be sufficient to adequately protect our trade secrets or other proprietary information. In addition, we share ownership and publication rights to data relating to our drug product and technologies with our research collaborators and scientific advisors. If we cannot maintain the confidentiality of this information, our ability to receive patent protection or protect our trade secrets or other proprietary information will be at risk.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The intellectual property and related non-patent exclusivity that we own or have licensed relating to our product, Auryxia, is limited, which could adversely affect our ability to compete in the market and adversely affect the value of Auryxia.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent rights and related non-patent exclusivity that we own or have licensed relating to Auryxia are limited in ways that may affect our ability to exclude third parties from competing against us. For example, a third party may design around our owned or licensed composition of matter patent claims or not market a product for methods of use covered by our owned or licensed patents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining proof of direct infringement by a competitor for a method of use patent requires us to demonstrate that the competitors make and market a product for the patented use(s). Alternatively, we can prove that our competitors induce or contribute to others in engaging in direct infringement. Proving that a competitor contributes to or induces infringement of a patented method by another has additional proof requirements. For example, proving inducement of infringement requires proof of intent by the competitor. If we are required to defend ourselves against claims or to protect our own proprietary rights against others, it could result in substantial costs to us and the distraction of our management. An adverse ruling in any litigation or administrative proceeding could prevent us from marketing and selling Auryxia, increase the risk that a generic or other similar version of Auryxia could enter the market to compete with Auryxia, limit our development and commercialization of Auryxia, or otherwise harm our competitive position and result in additional significant costs. In addition, any successful claim of infringement asserted against us could subject us to monetary damages or injunction, which could prevent us from making or selling Auryxia. We also may be required to obtain licenses to use the relevant technology. Such licenses may not be available on commercially reasonable terms, if at all.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, physicians may prescribe a competitive identical product for indications other than the one for which the product has been approved, or &#8220;off-label&#8221; indications, that are covered by the applicable patents. Although such off-label prescriptions may directly infringe or contribute to or induce infringement of method of use patents, such infringement is difficult to prevent.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any limitations of our patent protection described above may adversely affect the value of our drug product and may inhibit our ability to obtain a collaboration partner at terms acceptable to us, if at all.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA has the authority to grant additional regulatory exclusivity protection for approved drugs where the sponsor conducts specified testing in pediatric or adolescent populations. If granted, this pediatric exclusivity may provide an additional six months which are added to the term of any non-patent exclusivity that has been awarded as well as to the regulatory protection related to the term of a relevant patent, to the extent these protections have not already expired.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent protection, we may utilize, if granted by the FDA, pediatric exclusivity or other provisions of the FDCA such as new chemical entity, or NCE, exclusivity, or exclusivity for a new use or new formulation, to provide non-patent exclusivity for a drug product. The FDCA provides a five-year period of non-patent exclusivity within the United States to the first applicant to gain approval of a new drug application, or NDA, for an NCE. A drug is an NCE if the FDA has not previously approved any other new drug containing the same active moiety, which consists of the molecule(s) or ion(s) responsible for the action of the drug substance (but not including those portions of the molecule that cause it to be a salt or ester or which are not bound to the molecule by covalent or similar bonds). During the exclusivity period, the FDA may not accept for review an ANDA or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an ANDA or 505(b)(2) </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NDA that references an NDA product with NCE exclusivity may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application (for example, for new indications, dosages, or strengths of an existing drug). This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. The three-year exclusivity period, unlike five-year exclusivity, does not prevent the submission of a competing ANDA or 505(b)(2) NDA. Instead, it only prevents the FDA from granting final approval to such a product until expiration of the exclusivity period. Five-year and three-year exclusivity will not delay the submission (in the case of five-year exclusivity) or the approval (in the case of three-year exclusivity) of a full NDA submitted under section 505(b)(1) of the FDCA; however, an applicant submitting a full NDA would be required to conduct all of its own studies needed to independently support a finding of safety and effectiveness for the proposed product, or have a full right of reference to all studies not conducted by the applicant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 23, 2018, Keryx submitted a Citizen Petition requesting, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter alia,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that the FDA recognize that Auryxia is eligible for five years of new chemical entity, or NCE, exclusivity based on its novel active ingredient and for three years exclusivity for the IDA Indication.&#160;On January 19, 2019, the FDA responded that Auryxia is eligible for a three-year exclusivity period for the IDA Indication, which expired on November 6, 2020.&#160;The FDA, however, denied the NCE exclusivity based on its determination that Auryxia contains a previously-approved active moiety (ferric cation). FDA&#8217;s decision on the Citizen Petition is subject to further review both within the FDA and in the courts. On February 21, 2019, we filed a Petition for Reconsideration of the FDA&#8217;s decision on the NCE determination for Auryxia.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s determination as to whether to grant NCE exclusivity to Auryxia may also affect the timing of the 30-month stay barring the FDA from granting final approval to generic versions of Auryxia. When an ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months after the receipt of the Paragraph IV notice, expiration of the patent, or a decision in the infringement case that is favorable to the ANDA applicant. We have received Paragraph IV certification notice letters regarding ANDAs submitted to the FDA, from generic drug manufacturers requesting approval for generic versions of Auryxia tablets (210 mg ferric iron per tablet), have filed complaints for patent infringement relating to such ANDAs, and have entered into settlement and license agreements with such ANDA filers. See Part II, Item 1. Legal Proceedings for further information relating to the ANDAs, lawsuits and settlements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In cases where NCE exclusivity has been granted to a new drug product, the 30-month stay triggered by such litigation is extended by the amount of time such that seven years and six months will elapse from the date of approval of the NDA for that product. Without NCE exclusivity, the 30-month stay on FDA final approval of an ANDA runs from the date on which the sponsor of the reference listed drug receives notice of a Paragraph IV certification from the ANDA applicant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure that Auryxia or any drug candidates we may acquire or in-license will obtain such pediatric exclusivity, NCE exclusivity or any other market exclusivity in the United States, EU or any other territory, or that we will be the first to receive the respective regulatory approval for such drugs so as to be eligible for any non-patent exclusivity protection. We also cannot assure that Auryxia or any drug candidates we may acquire or in-license will obtain patent term extension.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we rely on third parties to assist with research, development and manufacture of our product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, services agreements, material transfer agreements, consulting agreements, research agreements or other similar agreements with our advisors, employees, third party contractors, collaborators and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such information becomes known by our competitors, is inadvertently incorporated into the technology of others, or is disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, these agreements typically restrict the ability of our advisors, employees, third party contractors, and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. For example, any academic institution with which we may collaborate will usually expect to be granted rights to publish data arising out of such collaboration. We often grant such rights, provided that we are notified in advance and given the opportunity to delay publication for a limited time period in order for us to secure patent protection of intellectual property rights arising from the collaboration and remove confidential or trade secret information from any such publication. In the future, we may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties or independent development or disclosure or publication of information by any of our employees, advisors, consultants, third party contractors or collaborators. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation or third party claims of intellectual property infringement may be costly and time consuming and may delay or harm our drug discovery, development and commercialization efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be forced to initiate litigation to enforce our contractual and intellectual property rights, or we may be sued by third parties asserting claims based on contract, tort or intellectual property infringement. In addition, third parties may have or may obtain patents in the future and claim that our product or any other technologies infringe their patents. If we are required to defend against suits brought by third parties, or if we sue third parties to protect our rights, we may be required to pay substantial litigation costs, and our management&#8217;s attention may be diverted from operating our business. In addition, any legal action against our licensor, licensees or us that seeks damages or an injunction of commercial activities relating to Auryxia, vadadustat or any other product candidates or other technologies, including those that may be in-licensed or acquired, could subject us to monetary liability, a temporary or permanent injunction preventing the development, marketing and sale of such products or such technologies, and/or require our licensor, licensees or us to obtain a license to continue to use such products or other technologies. We cannot predict whether our licensor, licensees or we would prevail in any of these types of actions or that any required license would be made available on commercially acceptable terms, if at all.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. The pharmaceutical and biotechnology industries are characterized by extensive litigation over patent and other intellectual property rights. We have in the past and may in the future become a party to, or be threatened with, future adversarial litigation or other proceedings regarding intellectual property rights with respect to our product and product candidates. As the pharmaceutical and biotechnology industries expand and more patents are issued, the risk increases that our drug candidates may give rise to claims of infringement of the patent rights of others.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our product candidate is in preclinical studies and clinical trials, we believe that the use of our product candidate in these preclinical studies and clinical trials in the United States falls within the scope of the exemptions provided by 35 U.S.C. Section&#160;271(e), which provides that it shall not be an act of infringement to make, use, offer to sell, or sell within the United States or import into the United States a patented invention solely for uses reasonably related to the development and submission of information to the FDA. As a result of the Merger, our portfolio includes a commercial product, Auryxia.&#160;Consequently, there is an increased possibility of a patent infringement claim against us. We attempt to ensure that our product and product candidate and the methods we employ to manufacture them, as well as the methods for their use which we intend to promote, do not infringe other parties&#8217; patents and other proprietary rights. There can be no assurance they do not, however, and competitors or other parties may assert that we infringe their proprietary rights in any event.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may hold or obtain patents or other intellectual property rights and allege in the future that the use of our product or product candidate infringes these patents or intellectual property rights, or that we are employing their proprietary technology without authorization. We do not believe that there are any currently issued United States patents that will prevent us from commercializing Auryxia or vadadustat; nor do we make any admission that any of such patents are valid, enforceable or infringed. Under United States law, a party may be able to patent a discovery of a new way to use a previously known compound, even if such compound itself is patented, provided the newly discovered use is novel and nonobvious. Such a method-of-use patent, however, if valid, only protects the use of a claimed compound for the specified methods claimed in the patent. This type of patent does not prevent persons from using the compound for any previously known use of the compound. Further, this type of patent does not prevent persons from making and marketing the compound for an indication that is outside the scope of the patented method. We are not aware of any valid United States patents issued to FibroGen, or any other person, that claim methods of using any of our product candidates for purposes of inhibiting hypoxia-inducible factor prolyl hydroxylases, or HIF-PHs, for the treatment of anemia due to CKD. For example, we are aware of certain patents that have been acquired by FibroGen directed to certain heterocyclic carboxamide compounds that are described as inhibitors of prolyl-4-hydroxylase. Those patents, however, are believed to have expired as of December&#160;2014.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FibroGen has also filed other patent applications in the United States and other countries directed to purportedly new methods of using such previously known heterocyclic carboxamide compounds for purposes of treating or affecting specified conditions, and some of these applications have since issued as patents. To the extent any such patents issue or have been issued, we may initiate opposition or other legal proceedings with respect to such patents. We discuss the status of the opposition and/or invalidation proceedings against certain FibroGen patents in Part II, Item 1. Legal Proceedings of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be other patents of FibroGen or patents of other third parties of which we are currently unaware with claims to compounds, materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Also, because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties, including FibroGen, may in the future claim that our product and product candidate and other technologies infringe upon their patents and may challenge our ability to commercialize Auryxia and vadadustat, if approved. Parties making claims against us or our licensees may seek and obtain injunctive or other equitable relief, which could effectively block our or their ability to continue to commercialize Auryxia or further develop and commercialize vadadustat or any other product candidates, including those that may be in-licensed or acquired. If any third party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our products or product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product or product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. Similarly, if any third party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or our intended methods of use, including patient selection methods, the holders of any such patent may be able to block or impair our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. We may also elect to enter into a license in order to settle litigation or in order to resolve disputes prior to litigation. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our products or product candidates. Should a license to a third party patent become necessary, we cannot predict whether we would be able to obtain a license or, if a license were available, whether it would be available on commercially reasonable terms. If such a license is necessary and a license under the applicable patent is unavailable on commercially reasonable terms, or at all, our ability to commercialize our product or product candidate may be impaired or delayed, which could in turn significantly harm our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, defense of infringement claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties or redesign our products, which may be impossible or require substantial time and monetary expenditure.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently involved in a patent infringement lawsuit, a declaratory judgment of non-infringement and invalidity lawsuit, opposition and invalidation proceedings, and may in the future be involved in additional lawsuits or administrative proceedings to challenge the patents of our competitors or to protect or enforce our patents, which could be expensive, time consuming, and unsuccessful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents or misappropriate our trade secrets or confidential information. To counter infringement or unauthorized use, we may be required to file infringement or misappropriation claims, which can be expensive and time-consuming. We may not be able to prevent infringement of our patents or misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and held not infringed and could put our patent applications at risk of not issuing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there may be a challenge or dispute regarding inventorship or ownership of patents or applications currently identified as being owned by or licensed to us. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. Interference proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various administrative proceedings are also available for challenging patents, including interference, reexamination, inter partes review, and post-grant review proceedings before the USPTO or oppositions and other comparable proceedings in foreign </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">jurisdictions. An unfavorable outcome in any current or future proceeding in which we are challenging third party patents could require us to cease using the patented technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all. Even if we are successful, participation in interference or other administrative proceedings before the USPTO or a foreign patent office may result in substantial costs and distract our management and other employees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in an action against our competitors in the federal district court to obtain a declaratory judgment of non-infringement and invalidity of certain patents of the competitors. In addition, we are currently involved in opposition and invalidation proceedings in the European Patent Office, the Japan Patent Office, and the Patents Court of the UK. These proceedings may be ongoing for a number of years and may involve substantial expense and diversion of employee resources from our business. In addition, we may become involved in additional opposition proceedings or other legal or administrative proceedings in the future. For more information, see the other risk factors under &#8220;Risks Related to our Intellectual Property&#8221; and Part II, Item 1. Legal Proceedings of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation and some administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure during discovery. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and governmental patent agencies in other jurisdictions also require compliance with a number of procedural, documentary, fee payment (such as annuities) and other similar provisions during the patent application process. While an inadvertent lapse in many cases can be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees, and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received confidential and proprietary information from potential collaborators, prospective licensees and other third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. We may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive. Consequently, the breadth of our intellectual property rights in some countries outside the United States may be less extensive than those in the United States. In addition, the laws of some countries do not protect intellectual property rights to the same extent as laws in the United States. As a result, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other countries. Competitors may use our technologies in countries where we have not obtained patent protection to develop their own products and, further, may infringe our patents in territories where we have </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patent protection, but enforcement is not as strong as in the United States. These products may compete with our product and product candidate and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in certain countries. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property, particularly those relating to pharmaceutical and biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in countries outside of the United States could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Business and Industry</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to attract, keep and motivate senior management and key personnel, we may be unable to successfully develop, obtain and/or maintain marketing approval of and commercialize Auryxia and vadadustat.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified personnel is critical to our success. We are also highly dependent on our executives, certain members of our senior management and certain members of our commercial organization. The loss of the services of our executives, senior managers or other key employees, including employees in our commercial, development, regulatory, manufacturing and quality organizations, could impede the achievement of our research, development, regulatory and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Losing such key personnel subjects us to a number of risks, including the failure to coordinate responsibilities and tasks, the necessity to create new management systems and processes, the impact on corporate culture, and the retention of historical knowledge. Furthermore, replacing executives, senior managers and other key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, obtain and/or maintain marketing approval of and commercialize Auryxia and vadadustat. Our future financial performance and our ability to develop, obtain and/or maintain market approval of and commercialize Auryxia and vadadustat and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to hire, train, integrate, and retain additional personnel with sufficient experience. We may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the intense competition among numerous biopharmaceutical companies for similar personnel, particularly in our geographic region.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also experience competition for the hiring of personnel from universities and research institutions. In addition, we rely on contractors, consultants and advisors, including scientific and clinical advisors, to assist us in formulating and executing our research and development and commercialization strategy. Our contractors, consultants and advisors may become employed by companies other than ours and may have commitments with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to grow and pursue our business strategy will be limited.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product, product candidate or indication and fail to capitalize on products, product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on products, research programs and product candidates for specific indications. As a result, we may forgo or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security breaches and unauthorized use of our information technology systems and information, or the information technology systems or information in the possession of our collaborators and other third-parties, could damage the integrity of our clinical studies, impact our regulatory filings, compromise our ability to protect our intellectual property, and subject us to regulatory actions that could result in significant fines or other penalties.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, our collaborators, contractors and other third parties rely significantly upon information technology, and any failure, inadequacy, interruption or security lapse of that technology, including any cyber security incidents, could harm our ability to operate our business effectively.&#160;In addition, we and our collaborators, contractors and other third parties rely on information technology networks and systems, including the Internet, to process, transmit and store clinical trial data, patient information, and other electronic information, and manage or support a variety of business processes, including operational and financial transactions and records, personal identifying information, payroll data and workforce scheduling information. We purchase some of our information technology from vendors, on whom our systems depend. We rely on commercially available systems, software, tools and monitoring to provide security for the processing, transmission and storage of company and customer information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we and our third party contractors maintain personal and other sensitive data on our and their respective networks, including our intellectual property and proprietary or confidential business information relating to our business and that of our clinical trial patients and business partners. In particular, we rely on CROs and other third parties to store and manage information from our clinical trials. We also rely on third parties to manage patient information for Auryxia. The secure maintenance of this sensitive information is critical to our business and reputation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies and other entities and individuals have been increasingly subject to a wide variety of security incidents, cyber-attacks and other attempts to gain unauthorized access to systems and information. These threats can come from a variety of sources, ranging in sophistication from individual hackers to state-sponsored attacks. Cyber threats may be broadly targeted, or they may be custom-crafted against our information systems or those of our vendors or third party service providers. A security breach, cyber-attack or unauthorized access of our clinical data or other data could damage the integrity of our clinical trials, impact our regulatory filings, cause significant risk to our business, compromise our ability to protect our intellectual property, and subject us to regulatory actions, including under the GDPR and CCPA discussed elsewhere in these risk factors and the privacy or security rules under federal, state, or other local laws outside of the United States protecting confidential or personal information, that could be expensive to defend and could result in significant fines or other penalties. Cyber-attacks can include malware, computer viruses, hacking or other unauthorized access or other significant compromise of our computer, communications and related systems. Although we take steps to manage and avoid these risks and to be prepared to respond to attacks, our preventive and any remedial actions may not be successful and no such measures can eliminate the possibility of the systems&#8217; improper functioning or the improper access or disclosure of confidential or personally identifiable information such as in the event of cyber-attacks. Security breaches, whether through physical or electronic break-ins, computer viruses, ransomware, impersonation of authorized users, attacks by hackers or other means, can create system disruptions or shutdowns or the unauthorized disclosure of confidential information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Likewise, although we believe our collaborators, vendors and service providers, such as our CROs, take steps to manage and avoid information security risks and respond to attacks, we may be vulnerable to attacks against our collaborators, vendors or service providers, and we may not have adequate contractual remedies against such collaborators, vendors and service providers in such event. Additionally, outside parties may attempt to fraudulently induce employees, collaborators, or other contractors to disclose sensitive information or take other actions, including making fraudulent payments or downloading malware, by using &#8220;spoofing&#8221; and &#8220;phishing&#8221; emails or other types of attacks.&#160;Our employees may be targeted by such fraudulent activities.&#160;Outside parties may also subject us to distributed denial of services attacks or introduce viruses or other malware through &#8220;trojan horse&#8221; programs to our users&#8217; computers in order to gain access to our systems and the data stored therein. In the recent past, cyber-attacks have become more prevalent and much harder to detect and defend against and, because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and continuously become more sophisticated, often are not recognized until launched against a target and may be difficult to detect for a long time, we may be unable to anticipate these techniques or to implement adequate preventive or detective measures, and we might not immediately detect such incidents and the damage caused by such incidents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such attacks, whether successful or unsuccessful, or other compromises with respect to our information security and the measures we implement to prevent, detect and respond to them, could result in our incurring significant costs related to, for example, rebuilding internal systems, defending against litigation, responding to regulatory inquiries or actions, paying damages or fines, or taking other remedial steps with respect to third parties, inadvertent diversion of cash, divert the attention of our management and key information technology resources, disrupt key business operations, harm our reputation and deter business partners from working with us. A compromise with respect to our information security could lead to public exposure of personal information of our clinical trial patients, Auryxia patients and others, and negative publicity. Publicity about vulnerabilities and attempted or successful incursions could damage the integrity of our studies or delay their completion. If a compromise to our information security were to occur and cause interruptions in our operations, it could result in a disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, any loss of clinical trial data could result in delays in our regulatory approval efforts for our product candidates and significantly increase our costs to recover or reproduce the data.&#160;In addition, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such attacks could compromise our ability to protect our trade secrets and proprietary information from unauthorized access or misappropriation and a loss of, or damage to, our data or marketing applications. Inappropriate public disclosure of confidential or proprietary information could subject us to liability and cause delays in our product research, development and commercialization efforts. We currently do not maintain cybersecurity insurance to protect against losses due to security breaches.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure to maintain proper functionality and security of our internal computer and information systems could result in a loss of, or damage to, our data or marketing applications or inappropriate disclosure of confidential or proprietary information, interrupt our operations, damage our reputation, subject us to liability claims or regulatory penalties, under a variety of federal, state or other applicable privacy laws, such as HIPAA, the GDPR, or state data protection laws including the CCPA, harm our competitive position and delay the further development and commercialization of our products and product candidates, or impact our relationships with Auryxia patients.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, CROs, CMOs, consultants and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, CMOs, consultants and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or unauthorized activities that violate applicable laws, including the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA and other healthcare authorities&#8217; regulations, including those laws that require the reporting of true, complete and accurate information to regulatory authorities, and those prohibiting the promotion of unapproved drugs or approved drugs for an unapproved use;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">quality standards, including GXP;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">federal and state healthcare fraud and abuse laws and regulations and their non-U.S. equivalents;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">anti-bribery and anti-corruption laws, such as the FCPA and the UK Bribery Act or country-specific anti-bribery or anti-corruption laws, as well as various import and export laws and regulations;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">laws that require the reporting of true and accurate financial information and data; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">United States state and federal securities laws and regulations and their non-U.S. equivalents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently closing out global clinical trials for vadadustat and plan to initiate pediatric trials in countries where corruption is prevalent, and violations of any of these laws by our personnel or by any of our vendors or agents, such as our CROs or CMOs, could have a material adverse impact on our clinical trials and our business and could result in criminal or civil fines and sanctions. We are subject to complex laws that govern our international business practices. These laws include the FCPA, which prohibits United States companies and their intermediaries, such as CROs or CMOs, from making improper payments to foreign government officials for the purposes of obtaining or keeping business or to obtain any kind of advantage for the company. The FCPA also requires companies to keep accurate books and records and maintain adequate accounting controls. A number of past and recent FCPA investigations by the Department of Justice and the U.S. Securities and Exchange Commission, or the SEC, have focused on the life sciences sector.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. Some of the countries in which we are conducting clinical trials have a history of corruption, which increases our risks of FCPA violations. In addition, the FCPA presents unique challenges in the pharmaceutical industry because in many countries&#8217; hospitals are operated by the government, and doctors and other hospital employees are considered foreign government officials. Certain payments made by pharmaceutical companies, or on their behalf by CROs, to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the UK Bribery Act applies to our global activities and prohibits bribery of private individuals as well as public officials. The UK Bribery Act prohibits both the offering and accepting a bribe and imposes strict liability on companies for failing to prevent bribery, unless the company can show that it had &#8220;adequate procedures&#8221; in place to prevent bribery.&#160;There are also local anti-bribery and anti-corruption laws in countries where we are conducting clinical trials, and many of these also carry the risk of significant financial or criminal penalties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to trade control regulations and trade sanctions laws that restrict the movement of certain goods, currency, products, materials, services and technology to, and certain operations in, various countries or with certain persons. Our ability </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to transfer people and products among certain countries is subject to maintaining required licenses and complying with these laws and regulations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. This could include violations of HIPAA, other United States federal and state law, and requirements of non-U.S. jurisdictions, including the European Union Data Protection Directive. We are also exposed to risks in connection with any insider trading violations by employees or others affiliated with us. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The internal controls, policies and procedures, and training and compliance programs we have implemented to deter prohibited practices may not be effective in preventing our employees, contractors, consultants, agents or other representatives from violating or circumventing such internal policies or violating applicable laws and regulations. The failure to comply with laws governing international business practices may impact our clinical trials, result in substantial civil or criminal penalties for us and any such individuals, including imprisonment, suspension or debarment from government contracting, withdrawal of our products, if approved, from the market, or being delisted from The Nasdaq Global Market. In addition, we may incur significant costs in implementing sufficient systems, controls and processes to ensure compliance with the aforementioned laws.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws and regulations referenced above may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. It is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, or if any such action is instituted against our employees, consultants, independent contractors, CROs, CMOs, vendors or principal investigators, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, curtailment of our operations, disclosure of our confidential information and imprisonment, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-top:12pt"><span style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:109%">If any of our service providers are later legally deemed to be employees, we could be subject to employment and tax withholding liabilities and other additional costs as well as other multiple damages and attorneys&#8217; fees.</span></div><div><span><br/></span></div><div><span style="color:#3a3a3a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We rely on independent third parties to provide certain services to us. We structure our relationships with these outside service providers in a manner that we believe results in an independent contractor relationship, not an employee relationship. An independent contractor is generally distinguished from an employee by his or her degree of autonomy and independence in providing services. A high degree of autonomy and independence is generally indicative of an independent contractor relationship, while a high degree of control is generally indicative of an employment relationship. Tax or other regulatory authorities may challenge our characterization of services providers as independent contractors both under existing laws and regulations and under laws and regulations adopted in the future. If such regulatory authorities or state, federal or foreign courts were to determine that our service providers are employees and not independent contractors, we would, among other things, may be required to withhold income taxes, to withhold and pay Social Security, Medicare and similar taxes, to pay unemployment and other related payroll taxes, and to provide certain employee benefits. We could also be liable for unpaid past taxes, interest and other costs and subject to penalties. Likewise, our service providers themselves may later successfully challenge their classification as independent contractors, which may result in additional damages, including back wages, penalties, interest and attorneys&#8217; fees. As a result, any legally binding determination that the service providers we characterize as independent contractors are actually our employees could have a material adverse effect on our business, financial condition and results of operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may encounter difficulties in managing our growth and expanding our operations successfully.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we commercialize Auryxia and advance vadadustat through development and, if approved, commercialization, we have expanded and may need to further expand our capabilities or contract with third parties to provide these capabilities for us. In addition, we may encounter difficulties in managing the expanded operations of a larger and more complex company following the Merger as well as challenges associated with managing an increasingly diversified business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have strategic collaborations for the commercialization of Riona and the development and commercialization of vadadustat, which is now being marketed under the trade name Vafseo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by our collaboration partner, MTPC, in Japan. As our operations expand, including as they relate to vadadustat in the United States, we expect that we will need to manage additional relationships with various strategic collaborators, consultants, vendors, suppliers and other third parties. Future growth will impose significant added responsibilities on members of management.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have experienced and may continue to experience significant growth in our employee base. This growth to date has imposed, and future growth or attrition will continue to impose, significant added responsibilities on members of management, including the need to recruit, hire, retain, motivate and integrate additional employees, including employees who joined us in connection with the Merger or since the COVID-19 pandemic. Also, our management may have to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth-related activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our future financial performance and our ability to commercialize Auryxia and vadadustat, if and where approved, and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To manage our recent and anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, procedures and processes, expand our facilities and continue to recruit, train, and retain additional qualified personnel. We may not be able to implement these improvements in an efficient or timely manner and may discover deficiencies in existing systems, procedures and processes. Moreover, the systems, procedures and processes currently in place or to be implemented may not be adequate for such growth. Due to our limited financial resources and the limited experience of our management team in managing a company with such growth, along with the competitive landscape for talent acquisition and retention in the biopharmaceutical industry, we may not be able to effectively manage the expansion of our operations or recruit, train, and retain additional qualified personnel. In addition, we may need to adjust the size of our workforce as a result of changes to our expectations for our business, which can result in diversion of management attention, disruptions to our business, and related expenses. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. We may not be able to accomplish these tasks, and our failure to accomplish any of them could prevent us from successfully growing our company or realizing the anticipated benefits of the Merger.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of Auryxia and vadadustat, if approved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the clinical and commercial use of Auryxia and vadadustat. For example, we may be sued if Auryxia or vadadustat allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product or product candidate, negligence, strict liability and breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of Auryxia or vadadustat, if approved. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, product liability claims may result in:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">decreased demand for Auryxia or vadadustat, if approved;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delay or termination of clinical trials;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our inability to continue to develop Auryxia or vadadustat;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">significant costs to defend the related litigation;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a diversion of management&#8217;s time and our resources;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">substantial monetary awards to study subjects or patients;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">product recalls or withdrawals, or labeling, marketing or promotional restrictions;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">decreased demand for Auryxia or vadadustat;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">loss of revenue;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the inability to commercialize any Auryxia or vadadustat, if approved; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a decline in our stock price.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop. We currently carry product liability insurance that we believe is appropriate for our company. Although we maintain product liability insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have insufficient or no coverage. If we have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, we may not have, or be able to obtain, sufficient capital to pay such amounts.&#160;In addition, insurance coverage is becoming </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increasingly expensive, and we may not be able to maintain insurance coverage at a reasonable cost. We also may not be able to obtain additional insurance coverage that will be adequate to cover product liability risks that may arise.&#160;Consequently, a product liability claim may result in losses that could be material to our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price has been and may continue to be volatile, which could result in substantial losses for purchasers of our common stock and lawsuits against us and our officers and directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been and will likely continue to be volatile. The stock market in general and the market for similarly situated biopharmaceutical companies have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. Since our initial public offering in March&#160;2014, the price of our common stock as reported on The Nasdaq Global Market has ranged from a low of $2.09 on October 30, 2020 to a high of $31.00 on June 20, 2014. The daily closing market price for our common stock has varied between a high price of $5.06 on February 8, 2021 and a low price of $2.22 on October 30, 2020 in the twelve-month period ending on September 30, 2021. During this time, the price of our common stock has ranged from an intra-day low of $2.09 per share to an intra-day high of $5.14 per share. The market price of shares of our common stock could be subject to wide fluctuations in response to many risk factors listed in this section, developments related to and results of our clinical studies, developments related to our regulatory submissions, developments related to our ability to commercialize Auryxia and vadadustat, if approved, and any other product candidates, announcements by us or our competitors of significant mergers, acquisitions, licenses, strategic collaborations, joint ventures, collaborations or capital commitments, negative publicity around Auryxia or vadadustat, the results of competitive clinical trials, products or technologies, regulatory or legal developments in the United States and other countries, developments or disputes concerning patent applications, issued patents or other proprietary rights, the recruitment or departure of key personnel, the level of expenses related to Auryxia and vadadustat or any other product or product candidate, actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts, variations in our financial results or those of companies that are perceived to be similar to us, changes in the structure of healthcare payment systems, market conditions in the biopharmaceutical sector, general economic, industry and market conditions and others beyond our control. As a result of this volatility, our shareholders may not be able to sell their common stock at or above the price at which they purchased it.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, companies that have experienced volatility in the market price of their stock have frequently been the subject of securities class action and shareholder derivative litigation.&#160;See Part II, Item 1. Legal Proceedings for information concerning securities class action and shareholder derivative lawsuits initiated against Keryx and certain current and former directors and officers of ours and Keryx&#8217;s. In addition, we could be the target of other such litigation in the future. Class action and shareholder derivative lawsuits, whether successful or not, could result in substantial costs, damage or settlement awards and a diversion of our management&#8217;s resources and attention from running our business, which could materially harm our reputation, financial condition and results of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The issuance of additional shares of our common stock or the sale of shares of our common stock by any of our directors, officers or significant shareholders will dilute our shareholders&#8217; ownership interest in Akebia and may cause the market price of our common stock to decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our outstanding common stock can be traded without restriction at any time. As such, sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell such shares, could reduce the market price of our common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of September&#160;30, 2021 and based on the amounts reported in the most recent filings made under Section 13(d) and 13(g) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, State Street Corporation, or State Street, beneficially owned approximately 8.0% of our outstanding shares of common stock and BlackRock, Inc., or BlackRock, beneficially owned approximately 6.5% of our outstanding shares of common stock. In addition, as of September&#160;30, 2021, our former director, Muneer Satter, beneficially owned approximately 1.8% of our outstanding common stock. In addition, pursuant to our Fourth Amended and Restated Investors&#8217; Rights Agreement, as amended, with Mr. Satter, he has the right, subject to certain conditions and with certain exceptions, to require us to file registration statements covering the shares common stock he owns or to include his shares in registration statements that we may file or in public offerings of our shares of common stock. Following their registration and sale under the applicable registration statement, those shares would become freely tradable. By selling a large number of shares of common stock, BlackRock, State Street, or Mr. Satter could cause the price of our common stock to decline. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a significant number of shares that are subject to outstanding options, restricted stock units and a warrant, and in the future we may issue additional options, restricted stock units, warrants or other derivative securities convertible into our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common stock. The exercise or vesting of any such options, restricted stock units, warrants or other derivative securities, and the subsequent sale of the underlying common stock, could cause a further decline in our stock price. These sales also might make it difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. Also, the Merger was financed by the issuance of shares of our common stock to shareholders of Keryx, comprising approximately 50.6% of our issued and outstanding shares of common stock, calculated based on our fully diluted market capitalization as of the date of signing the Agreement and Plan of Merger relating to the Merger. Keryx shareholders may decide not to hold the shares of our common stock they received in the Merger.&#160;Other Keryx shareholders, such as funds with limitations on the amount of stock they are permitted to hold in individual issuers, may be required to sell the shares of our common stock they received in the Merger.&#160;Such sales of our common stock could result in higher than average trading volume and may cause the market price for our common stock to decline.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we currently have on file with the SEC a shelf registration statement, which allows us to offer and sell certain registered securities, such as common stock, preferred stock, debt securities, warrants and units, from time to time pursuant to one or more offerings at prices and terms to be determined at the time of sale.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of substantial amounts of shares of our common stock or other securities by our employees or our other shareholders or by us under our shelf registration statement, pursuant to at-the-market offerings or otherwise, could dilute our stockholders, lower the market price of our common stock and impair our ability to raise capital through the sale of equity securities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insiders and significant stockholders could cause us to take actions that may not be, or refrain from taking actions that may be, in our best interest or in the best interest of all of our stockholders.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of September&#160;30, 2021, we believe that our directors and executive officers, together with their affiliates, owned, in the aggregate, approximately 1.6% of our outstanding common stock. In addition, we have certain significant stockholders, including State Street, which beneficially owned approximately 8.0% of our outstanding shares of common stock, and BlackRock, which beneficially owned approximately 6.5% of our outstanding shares of common stock based on the amounts reported in the most recent filings made by such significant stockholders under Section 13(d) and 13(g) of the Exchange Act. If they were to choose to act together, they would have significant influence on all matters submitted to our stockholders for approval, as well as our management and affairs, such as:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the composition of our Board of Directors;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the adoption of amendments to our Ninth Amended and Restated Certificate of Incorporation, as amended, or Charter, and our Amended and Restated By-Laws, or Bylaws;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the approval of mergers or sales of substantially all of our assets;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our capital structure and financing; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the approval of contracts between us and these shareholders or their affiliates, which could involve conflicts of interest.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This concentration of ownership could harm the market price of our common stock by:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delaying, deferring or preventing a change in control of our company and making some transactions more difficult or impossible without the support of these stockholders, even if such transactions are beneficial to other stockholders;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">impeding a merger, consolidation, takeover or other business combination involving our company; or</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">entrenching our management or our Board of Directors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the interests of these stockholders may conflict with the interests of other stockholders, and we may be required to engage in transactions that may not be agreeable to or in the best interest of us or other stockholders.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance initiatives and corporate governance practices.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, and particularly since December 31, 2019 when we ceased to be an &#8220;emerging growth company&#8221; and December 31, 2020 when we became a "large accelerated filer", we have and will continue to incur significant legal, accounting and other expenses. The Sarbanes-Oxley Act of 2002, or the SOX Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and certain corporate governance practices. Our management and other personnel will need to continue to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have and will continue to increase our legal and financial compliance costs and make some activities more time-consuming and costly.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict or estimate the amount of additional costs we may incur to continue to operate as a public company, nor can we predict the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies, which could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have identified a material weakness in our internal control over financial reporting relating to our inventory process. If we are not able to remediate this material weakness, or if we experience additional material weaknesses or other deficiencies in the future or otherwise fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting which would harm our business and the trading price of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, is designed to prevent fraud. Any failure to maintain or implement required new or improved controls, or difficulties encountered in implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us, as and when required, conducted in connection with Section 404 of the SOX Act, or Section 404, or any testing by our independent registered public accounting firm, which became required for us as of December 31, 2019, may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. For example, as of December 31, 2019, management and our independent registered public accounting firm concluded that our internal control over financial reporting relating to our inventory process was not effective because of a material weakness due to our failure to design and maintain effective controls over the completeness, accuracy and presentation and disclosure of inventory. Despite remediation efforts we undertook during fiscal 2020 and continue to make, our management and independent registered public accounting firm concluded that, as of December 31, 2020, our internal control over financial reporting relating to our inventory process was not effective because of a material weakness due to our failure to design and maintain effective controls over the completeness, accuracy and presentation and disclosure of inventory. For more information about this material weakness, see Part I, Item 4. Controls and Procedures of this Quarterly Report on Form 10-Q and Part II, Item 9A. Controls and Procedures of our Annual Report on Form 10-K for the year ended December 31, 2020. Additionally, as revised and enhanced controls need to be in operation for a sufficient period of time and be tested to ensure that the controls are operating as designed, management has concluded that the material weakness cannot be considered remediated as of September 30, 2021. Although we have initiated remediation measures to address the material weakness, we cannot provide assurance that we will be able to correct this material weakness in a timely manner or that our remediation efforts will be adequate to allow us to conclude that our internal controls will be effective in the future. Even if this material weakness is remediated in the future, our internal control over financial reporting could in the future have additional material weaknesses, deficiencies or conditions that could require correction or remediation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will need to continue to dedicate internal resources, engage outside consultants and maintain a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to remediate the material weakness relating to our inventory process described above and any future control deficiencies or material weaknesses, and improve control processes as appropriate, validate through testing that controls are functioning as documented and maintain a continuous reporting and improvement process for internal control over financial reporting. If we are not able to correct material weaknesses or deficiencies in internal controls in a timely manner or otherwise comply with the requirements of Section 404 in a timely manner, our ability to record, process, summarize and report financial information accurately and within applicable time periods may be adversely affected and we could be subject to sanctions or investigations by the SEC, the Nasdaq Stock Market or other regulatory authorities as well as shareholder litigation which would require additional financial and management resources and could adversely affect the market price of our common stock. Furthermore, if we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Charter and our Bylaws contain provisions that eliminate, to the maximum extent permitted by the General Corporation Law of the State of Delaware, or DGCL, the personal liability of our directors and executive officers for monetary damages for breach of their fiduciary duties as a director or officer. Our Charter and our Bylaws also provide that we will indemnify our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">directors and executive officers and may indemnify our employees and other agents to the fullest extent permitted by the DGCL.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as permitted by Section 145 of the DGCL our Bylaws and our indemnification agreements that we have entered into with our directors and executive officers provide that:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will indemnify our directors and officers, as defined in our Bylaws, for serving us in those capacities or for serving other related business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of Akebia and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The rights conferred in our Bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any claims for indemnification made by our directors or officers could impact our cash resources and our ability to fund the business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our organizational documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our Charter and our Bylaws contain provisions that may have the effect of discouraging, delaying or preventing a change in control of us or changes in our management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our Board of Directors is responsible for appointing certain members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our Board of Directors. Among other things, these provisions:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">authorize &#8220;blank check&#8221; preferred stock, which could be issued by our Board of Directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">create a classified Board of Directors whose members serve staggered three-year terms;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">specify that special meetings of our stockholders can be called only by our Board of Directors pursuant to a resolution adopted by a majority of the total number of directors;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">prohibit stockholder action by written consent;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our Board of Directors;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provide that our directors may be removed only for cause;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provide that vacancies on our Board of Directors may be filled only by a majority of directors then in office, even though less than a quorum;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">require a supermajority vote of 75% of the holders of our capital stock entitled to vote or the majority vote of our Board of Directors to amend our Bylaws; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">require a supermajority vote of 85% of the holders of our capital stock entitled to vote to amend the classification of our Board of Directors and to amend certain other provisions of our Charter.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions, alone or together, could delay or prevent hostile takeovers, changes in control or changes in our management.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Section 203 of the DGCL prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any provision of our Charter, our Bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating losses to offset future taxable income may be subject to certain limitations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section&#160;382 of the Internal Revenue Code, or Section 382, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change net operating losses, or NOLs, to offset future taxable income. On December 12, 2018, we completed the Merger, which we believe has resulted in an ownership change under Section 382. In addition, the Tax Cuts and Jobs Act, including amendments made by the CARES Act, includes changes to United States federal tax rates and the rules governing net operating loss carryforwards that may significantly impact our ability to utilize our net operating losses to fully offset taxable income in the future. Future changes in our stock ownership, many of which are outside of our control, could result in an additional ownership change under Section&#160;382. As a result, if we generate taxable income, our ability to use our pre-change NOL carryforwards to offset federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us.&#160;At the state level, state net operating losses generated in one state cannot be used to offset income generated in another state and there may be periods during which the use of NOL carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our ability to utilize our NOLs is conditioned upon our attaining profitability and generating United States taxable income. As described above under &#8220;&#8212;Risks Related to our Financial Position and Need for Additional Capital,&#8221; we have incurred significant net losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future; thus, we do not know whether or when we will generate the United States taxable income necessary to utilize our NOLs. A valuation allowance has been provided for the entire amount of our NOLs.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Charter designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Charter provides that, subject to limited exceptions, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (1)&#160;any derivative action or proceeding brought on our behalf, (2)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3)&#160;any action asserting a claim against us arising pursuant to any provision of the DGCL our Charter or our Bylaws, or (4)&#160;any other action asserting a claim against us, our directors, officers or other employees that is governed by the internal affairs doctrine. Under our Charter, this exclusive forum provision will not apply to claims that are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction. For instance, the provision would not apply to actions arising under federal securities laws, including suits brought to enforce any liability or duty created by the Exchange Act, or the rules and regulations thereunder. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our Charter described above. This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of our Charter inapplicable to, or unenforceable with respect to, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently subject to legal proceedings that could result in substantial costs and divert management's attention, and we could be subject to&#160;additional legal proceedings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently subject to legal proceedings as described in Part II, Item 1. Legal Proceedings and additional claims may arise in the future. In addition,&#160;securities class action&#160;and derivative lawsuits and other legal proceedings are often brought against companies for any of the risks described in this Quarterly Report on Form 10-Q following a decline in the market price of their securities. In connection with any litigation or other legal proceedings, we could incur substantial costs, and such costs and any related settlements or judgments may not be covered by insurance. In addition, if other resolution or actions taken as a result of legal proceedings were to restrain our ability to operate or market our products and services, our consolidated financial position, results of operations or cash flows could be materially adversely affected. We could also suffer an adverse impact on our reputation, negative publicity and a diversion of management&#8217;s attention and resources, which could have a material adverse effect on our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any cash dividends on our capital in the foreseeable future, capital appreciation, if any, will be our stockholders&#8217; sole source of gain.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. Any payment of cash dividends in the future would be at the discretion of our Board of Directors and would depend on, among other things, our earnings, financial condition, capital requirements, level of indebtedness, statutory and contractual restrictions applying to the payment of dividends and other considerations that the Board of Directors deems relevant. We currently intend to retain all of our future earnings, if any, to finance the development and growth of our business. In addition, the terms of the Loan Agreement preclude us from paying cash dividends and future debt agreements may preclude us from paying cash dividends. As a result, capital appreciation, if any, of our common stock will be our stockholders&#8217; sole source of gain for the foreseeable future.</span></div><div style="margin-bottom:6pt"><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_124"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales of Unregistered Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended September&#160;30, 2021, we did not have any sales of unregistered securities. </span></div><div><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_127"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Defaults Upon Senior Securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_130"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Mine Safety Disclosures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="i32bac828c69741158be14bdef01bfe8b_133"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5. Other Information.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><div id="i32bac828c69741158be14bdef01bfe8b_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits.</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.212%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibits</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1517022/000119312514121774/d700849dex31.htm">Ninth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, filed on March 28, 2014).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1517022/000119312520164639/d934672dex31.htm">Certificate of Amendment of Ninth Amended and Restated Certificate of Incorporation of Akebia Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K, filed on June 9, 2020).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1517022/000119312514121774/d700849dex32.htm">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K, filed on March 28, 2014).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101-formofperforman.htm">Form of Officer Performance-Based Stock Option Award, under the Company's 2014 Incentive Plan, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2*&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102-formofpsuagreem.htm">Form</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102-formofpsuagreem.htm"> of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102-formofpsuagreem.htm">Officer Performance-Based Restricted Stock Unit Award, under the Company's 2014 Incentive Plan, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3*&#8224;#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit103-akebiaxformofca.htm">Form of Officer Cash Bonus Letter Agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311-q320211.htm">Certification of Principal Executive Officer Required Under Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312-q320211.htm">Certification of Principal Financial Officer Required Under Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321-q320211.htm">Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. 1350.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Filed, or submitted electronically, herewith</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"># Indicates portions of the exhibit (indicated by asterisks) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224; Indicates management contract or compensatory plan.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><div id="i32bac828c69741158be14bdef01bfe8b_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:42.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AKEBIA THERAPEUTICS, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:&#160;&#160;November&#160;4, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John P. Butler</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John P. Butler</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer (Principal Executive Officer)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:  November&#160;4, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David A. Spellman</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David A. Spellman</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Senior Vice President, Chief Financial Officer and Treasurer (Principal Financial Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:  November&#160;4, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Violetta Cotreau</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Violetta Cotreau</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Senior Vice President, Chief Accounting Officer (Principal Accounting Officer)</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101-formofperforman.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i52a9610a77bc4c48b2bca99c4c8461d6_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Exhibit 10.1</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;&#9679;&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Number of Shares of Stock subject to Option&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;&#9679;&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exercise Price Per Share&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$&#91;&#9679;&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date of Grant&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;&#9679;&#93;</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:115%">Officer Performance-Based Stock Option Award </font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">granted under the</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:115%">AKEBIA THERAPEUTICS, INC.<br>2014 Incentive Plan</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Non-statutory Stock Option Agreement</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">This agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) evidences a performance-based stock option granted by Akebia Therapeutics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) to the undersigned (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Optionee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), pursuant to and subject to the terms of the Akebia Therapeutics, Inc. 2014 Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  </font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27pt;text-decoration:underline">Grant of Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The Company grants to the Optionee on the date set forth above (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Date of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) an option (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) to purchase, on the terms provided herein and in the Plan, the number of shares of Stock of the Company set forth above (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) with an exercise price per Share as set forth above, in each case subject to adjustment pursuant to Section 7 of the Plan in respect of transactions occurring after the date hereof.  </font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Stock Option evidenced by this Agreement is a non-statutory option (that is, an option that does not qualify as an incentive stock option under Section 422 of the Code) and is granted to the Optionee in connection with the Optionee&#8217;s employment by or service to the Company and its qualifying subsidiaries.  For purposes of the immediately preceding sentence, &#8220;qualifying subsidiary&#8221; means a subsidiary of the Company as to which the Company has a &#8220;controlling interest&#8221; as described in Treas. Regs. &#167;1.409A-1(b)(5)(iii)(E)(1).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27pt;text-decoration:underline">Meaning of Certain Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.  The following terms have the following meanings&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Beneficiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, in the event of the Optionee&#8217;s death, the beneficiary named in the written designation (in form acceptable to the Administrator) most recently filed with the Administrator by the Optionee prior to the Optionee&#8217;s death and not subsequently revoked, or, if there is no such designated beneficiary, the executor or administrator of the Optionee&#8217;s estate.  An effective beneficiary designation will be treated as having been revoked only upon receipt by the Administrator, prior to the Optionee&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">death, of an instrument of revocation in form acceptable to the Administrator.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means the occurrence of any of the following events other than in connection with the consummation of an initial public offering of the Company&#8217;s securities&#58; (i) any &#8220;person&#8221; (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) who is not a shareholder of the Company as of the date of this Agreement or an affiliate thereof is or becomes the &#8220;beneficial owner&#8221; (as defined in Rule 13d-3 under said Act), directly or indirectly, of securities of the Company representing 50% or more of the total voting power represented by the Company&#8217;s then outstanding voting securities&#59; (ii) a change in the composition of the Board occurring within a two-year period, as a result of which less than a majority of the directors are Incumbent Directors&#59; (iii) the date of the consummation of a merger, scheme of arrangement or consolidation of the Company with any other corporation that has been approved by the stockholders of the Company, other than a merger, scheme of arrangement or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity outstanding immediately after such merger or consolidation&#59; or (iv) the date of the consummation of the sale or disposition by the Company of all or substantially all the Company&#8217;s assets.  Notwithstanding the foregoing, a transaction will not constitute a Change in Control if&#58; (i) its sole purpose is to change the domicile of the Company&#8217;s incorporation&#59; or (ii) its sole purpose is to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#8217;s securities immediately before such transaction.  In all respects, the definition of Change in Control shall be interpreted to comply with Section 409A of the Code, and any successor statute, regulation and guidance thereto.    </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Incumbent Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means directors who either (A) are directors of the Company as of the date hereof, or (B) are elected, or nominated for election, to the Board with the affirmative votes of at least a majority of the remaining Incumbent Directors at the time of such election or nomination (but will not include an individual whose election or nomination is in connection with an actual or threatened proxy contest relating to the election of directors to the Company). </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Option Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means the Optionee or, if as of the relevant time the Stock Option has passed to a Beneficiary, the Beneficiary.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27pt;text-decoration:underline">Vesting&#59; Method of Exercise&#59; Treatment of the Stock Option Upon Cessation of Employment and a Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-2-</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt;text-decoration:underline">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  As used herein with respect to the Stock Option or any portion thereof, the term &#8220;vest&#8221; means to become exercisable and the term &#8220;vested&#8221; as applied to any outstanding Stock Option means that the Stock Option is then exercisable, subject in each case to the terms of the Plan.   Unless earlier terminated, forfeited, relinquished or expired, and subject to the immediately following sentence and the terms of any Executive Severance Agreement or other written agreement between the Optionee and the Company, the Stock Option will vest upon satisfaction of the performance and service vesting conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> attached hereto.  Notwithstanding the foregoing, the Stock Option, to the extent outstanding immediately prior to a Change in Control but not then vested in full, shall automatically and immediately become fully vested and exercisable upon such Change in Control to the extent set forth on Schedule A.    </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt;text-decoration:underline">Exercise of the Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  No portion of the Stock Option may be exercised until such portion vests.  Each election to exercise any vested portion of the Stock Option will be subject to the terms and conditions of the Plan and shall be in writing and signed by the Option Holder (or in such other form as is acceptable to the Administrator).  Each such written exercise election must be received by the Company at its principal office or by such other party as the Administrator may prescribe and be accompanied by payment in full as provided in the Plan.  The exercise price may be paid (i) by cash or check acceptable to the Administrator, (ii) at the election of the Optionee, by the Administrator&#8217;s holding back of Shares from this Stock Option having a fair market value equal to the exercise price in payment of the exercise price of this Stock Option, (iii) to the extent permitted by the Administrator, through a broker assisted cashless exercise program acceptable to the Administrator, (iv) by such other means, if any, as may be acceptable to the Administrator or (v) by any combination of the foregoing permissible forms of payment.  In the event that the Stock Option is exercised by a person other than the Optionee, the Company will be under no obligation to deliver Shares hereunder unless and until it is satisfied as to the authority of the Option Holder to exercise the Stock Option and compliance with applicable securities laws.  The latest date on which the Stock Option or any portion thereof may be exercised will be the 10th anniversary of the Date of Grant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Final Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  If the Stock Option is not exercised by the Final Exercise Date the Stock Option or any remaining portion thereof will thereupon immediately terminate.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt;text-decoration:underline">Treatment of the Stock Option Upon Cessation of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  If the Optionee&#8217;s Employment ceases, the Stock Option, to the extent not already vested will be immediately forfeited, and any vested portion of the Stock Option that is then outstanding will be treated as follows&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-3-</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.69pt">Subject to clauses (ii) and (iii) below and Section 4 of this Agreement, the Stock Option to the extent vested immediately prior to the cessation of the Optionee&#8217;s Employment will remain exercisable until the earlier of (A) the date that is three (3) months following the date of such cessation of Employment, or (B) the Final Exercise Date, and except to the extent previously exercised as permitted by this Section 3(c)(i) will thereupon immediately terminate.</font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21.36pt">Subject to clause (iii) below and Section 4 of this Agreement, the Stock Option, to the extent vested prior to the cessation of the Optionee&#8217;s Employment due to death, will remain exercisable until the earlier of (A) the first anniversary of the Optionee&#8217;s death or (B) the Final Exercise Date, and except to the extent previously exercised as permitted by this Section 3(c)(ii) will thereupon immediately terminate. </font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:18.03pt">If the Optionee&#8217;s Employment is terminated by the Company and its subsidiaries in connection with an act or failure to act constituting Cause (as the Administrator, in its sole discretion, may determine), or such termination occurs in circumstances that in the determination of the Administrator would have entitled the Company and its subsidiaries to terminate the Optionee&#8217;s Employment for Cause, this Stock Option (whether or not vested) will immediately terminate and be forfeited upon such termination.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Notwithstanding the foregoing, to the extent the Optionee is a party to an Executive Severance Agreement or other written agreement with the Company that provides for the Stock Option to remain outstanding and continue to vest during a specified period of time following the Optionee&#8217;s cessation of Employment (such period, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Severance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), the Stock Option shall remain outstanding and shall continue to vest in accordance with the terms of this Agreement during the Severance Period as if the Optionee had remained employed during such period, subject to any conditions on continued vesting as may be contained in such Executive Severance Agreement or other written agreement and to the extent set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Any portion of this Stock Option that vests during such Severance Period will remain exercisable until the earlier of (A) the date that is three (3) months following the date that is the last day of such Severance Period, or (B) the Final Exercise Date, and except to the extent previously exercised as permitted by this Section 3(c) will thereupon immediately terminate.  For the avoidance of doubt, any portion of the Stock Option that fails to vest during the Severance Period will immediately be forfeited on the last day of such period.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-4-</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Extension of Exercise Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Notwithstanding anything in Section 3(b) or 3(c) to the contrary, if, as of the Final Exercise Date or the last date during the period specified in Section 3(c)(i), as applicable, the Optionee is prohibited by applicable law or written Company policy applicable to similarly situated employees from engaging in any open-market sales of Stock, the Final Exercise Date or such period specified in Section 3(c)(i), as applicable, will be automatically extended to that date that is thirty (30) days following the date the Optionee is no longer prohibited from engaging in such open-market sales.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27pt;text-decoration:underline">Forfeiture&#59; Recovery of Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">The Administrator may cancel, rescind, withhold or otherwise limit or restrict the Stock Option at any time if the Optionee is not in compliance with all applicable provisions of this Agreement and the Plan, or if the Optionee breaches any agreement with the Company or its subsidiaries with respect to non-competition, non-solicitation, invention assignment or confidentiality, including, but not limited to, any employment agreement or offer letter with the Company or the Company&#8217;s standard Employee Agreement (Confidentiality, Non-Solicitation, Non-Competition and Developments Agreement).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">By accepting the Stock Option, the Optionee expressly acknowledges and agrees that his or her rights, and those of any permitted transferee of the Stock Option, under the Stock Option, including to any Stock acquired under the Stock Option or proceeds from the disposition thereof, are subject to Section 6(a)(5) of the Plan (including any successor provision). Nothing in the preceding sentence shall be construed as limiting the general application of Section 8 of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27pt;text-decoration:underline">Transfer of Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The Stock Option may not be transferred except as expressly permitted under Section 6(a)(3) of the Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27pt;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The exercise of the Stock Option will give rise to &#8220;wages&#8221; subject to withholding.  The Optionee expressly acknowledges and agrees that the Optionee&#8217;s rights hereunder, including the right to be issued Shares upon exercise, are subject to the Optionee promptly paying to the Company in cash (or by such other means as may be acceptable to the Administrator in its discretion) all taxes required to be withheld.  No Shares will be transferred pursuant to the exercise of this Stock Option unless and until the person exercising this Stock Option has remitted to the Company an amount sufficient to satisfy any federal, state, or local withholding tax requirements, or has made other arrangements satisfactory to the Company with respect to such taxes.  The Optionee authorizes the Company and its subsidiaries to withhold such amount from any amounts otherwise owed to the Optionee, but nothing in this sentence shall be construed as relieving the Optionee of any liability for satisfying his or her obligation under the preceding provisions of this Section.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-5-</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27pt;text-decoration:underline">Effect on Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Neither the grant of the Stock Option, nor the issuance of Shares upon exercise of the Stock Option, will give the Optionee any right to be retained in the employ or service of the Company or any of its Affiliates, affect the right of the Company or any of its Affiliates to discharge or discipline such Optionee at any time, or affect any right of such Optionee to terminate his or her Employment at any time.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27pt;text-decoration:underline">Provisions of the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  This Agreement is subject in its entirety to the provisions of the Plan, which are incorporated herein by reference.  A copy of the Plan as in effect on the Date of Grant has been furnished to the Optionee.  By exercising all or any part of the Stock Option, the Optionee agrees to be bound by the terms of the Plan and this Agreement.  In the event of any conflict between the terms of this Agreement and the Plan, the terms of the Plan shall control.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27pt;text-decoration:underline">Provisions of Executive Severance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.   To the extent the Optionee has entered into an Executive Severance Agreement with the Company, for so long as such Executive Severance Agreement remains in effect, the terms of such Executive Severance Agreement as they relate to the Stock Option shall control in the event of any conflict with the terms of this Agreement except to the extent set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21pt;text-decoration:underline">Acknowledgements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The Optionee acknowledges and agrees that (i) this Agreement may be executed in two or more counterparts, each of which shall be an original and all of which together shall constitute one and the same instrument, (ii) this agreement may be executed and exchanged using facsimile, portable document format (PDF) or electronic signature, which, in each case, shall constitute an original signature for all purposes hereunder and (iii) such signature by the Company will be binding against the Company and will create a legally binding agreement when this Agreement is countersigned by the Optionee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">&#91;Signature page follows.&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-6-</font></div><div><font><br></font></div></div></div><div id="i52a9610a77bc4c48b2bca99c4c8461d6_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer.  </font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:216.6pt;text-indent:-216.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">AKEBIA THERAPEUTICS, INC. </font></div><div style="padding-left:216.6pt;text-indent:-216.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:216.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">By&#58;&#160;&#160;&#160;&#160;______________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Name&#58; &#91;&#9679;&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; &#91;&#9679;&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Dated&#58;  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Acknowledged and Agreed&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">By_______________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">    &#91;Optionee&#8217;s Name&#93; </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> &#91;Signature Page to Non-Statutory Performance-Based Option Agreement - Officers&#93;</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i52a9610a77bc4c48b2bca99c4c8461d6_7"></div><hr style="page-break-after:always"><div style="min-height:85.96pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Schedule A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Performance Vesting Schedule</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:91.78pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit102-formofpsuagreem.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3753d8b3789f4c27986397b77c2303bc_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Exhibit 10.2</font></div><div style="margin-bottom:6pt;text-align:right"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:115%">Officer Performance-Based Restricted Stock Unit Award </font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">granted under the</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:115%">AKEBIA THERAPEUTICS, INC.<br>2014 Incentive Plan</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Performance-Based Restricted Stock Unit Award Agreement</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">This agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) evidences the grant of a performance-based restricted stock unit award by Akebia Therapeutics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) to the undersigned (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), pursuant to and subject to the terms of the Akebia Therapeutics, Inc. 2014 Incentive Plan (as amended from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  For purposes of this Agreement, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; will mean &#91;&#9679;&#93;.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27pt;text-decoration:underline">Performance-Based Restricted Stock Unit Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The Participant is hereby awarded, pursuant to the Plan and subject to its terms, a Performance-Based Restricted Stock Unit award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) giving the Participant the conditional right to receive, without payment but subject to the conditions and limitations set forth in this Agreement and in the Plan, &#91;&#9679;&#93; shares of Stock of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27pt;text-decoration:underline">Meaning of Certain Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.  For purposes of this Award, the following terms have the following meanings&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means the occurrence of any of the following events other than in connection with the consummation of an initial public offering of the Company&#8217;s securities&#58; (i) any &#8220;person&#8221; (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) who is not a shareholder of the Company as of the date of this Agreement or an affiliate thereof is or becomes the &#8220;beneficial owner&#8221; (as defined in Rule 13d-3 under said Act), directly or indirectly, of securities of the Company representing 50% or more of the total voting power represented by the Company&#8217;s then outstanding voting securities&#59; (ii) a change in the composition of the Board occurring within a two-year period, as a result of which less than a majority of the directors are Incumbent Directors&#59; (iii) the date of the consummation of a merger, scheme of arrangement or consolidation of the Company with any other corporation that has been approved by the stockholders of the Company, other than a merger, scheme of arrangement or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity outstanding immediately after such merger or consolidation&#59; or (iv) the date of the consummation of the sale or disposition by the Company of all or substantially all the Company&#8217;s assets.  Notwithstanding the foregoing, a transaction will not constitute a Change in Control if&#58; (i) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">its sole purpose is to change the domicile of the Company&#8217;s incorporation&#59; or (ii) its sole purpose is to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#8217;s securities immediately before such transaction.  In all respects, the definition of Change in Control will be interpreted to comply with Section 409A of the Code, and any successor statute, regulation and guidance thereto.    </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Incumbent Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means directors who either (A) are directors of the Company as of the date hereof, or (B) are elected, or nominated for election, to the Board with the affirmative votes of at least a majority of the remaining Incumbent Directors at the time of such election or nomination (but will not include an individual whose election or nomination is in connection with an actual or threatened proxy contest relating to the election of directors to the Company). </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27pt;text-decoration:underline">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Unless earlier terminated, forfeited, relinquished or expired, and subject to Section 6 of this Agreement and the terms of any Executive Severance Agreement or other written agreement between the Participant and the Company, the Award will become vested, subject to the Participant&#8217;s continuous Employment though the applicable vesting date, based on the achievement of the performance metrics and continued Employment requirements, set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.    </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The treatment of the Award in connection with a Change in Control is set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27pt;text-decoration:underline">Delivery of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Subject to Section 5 of this Agreement, the Company will, within thirty (30) days of the vesting date described in Section 3 with respect to any portion of the Award, effect delivery of the Shares with respect to such vested portion to the Participant (or, in the event of the Participant&#8217;s death, to the person to whom the Award has passed by will or the laws of descent and distribution).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> No Shares will be issued pursuant to this Award unless and until all legal requirements applicable to the issuance or transfer of such Shares have been complied with to the satisfaction of the Administrator.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27pt;text-decoration:underline">Dividends&#59; Other Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> The Award will not be interpreted to bestow upon the Participant any equity interest or ownership in the Company or any Affiliate prior to the date on which the Company delivers Shares to the Participant.  The Participant is not entitled to vote any Shares by reason of the granting of this Award or to receive or be credited with any dividends declared and payable on any Share prior to the payment date with respect to such Share.  The Participant will have the rights of a shareholder only as to those Shares, if any, that are actually delivered under this Award.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27pt;text-decoration:underline">Treatment of Award Upon Cessation of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  If the Participant&#8217;s Employment ceases, the Award, to the extent not already vested, will be immediately forfeited, except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27pt;text-decoration:underline">Certain Tax Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">The Participant expressly acknowledges that because this Award consists of an unfunded and unsecured promise by the Company to deliver Shares in the future, subject to the terms hereof, it is not possible to make a so-called &#8220;83(b) election&#8221; with respect to the Award.  In no event will the Company have any liability relating to the failure or alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of Section 409A.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Notwithstanding anything to the contrary in this Award, if at the time of the Participant&#8217;s termination of Employment, the Participant is a &#8220;specified employee,&#8221; as defined below, any and all amounts payable under this Award on account of such separation from service that constitute deferred compensation and would (but for this provision) be payable within six (6) months following the date of termination, will instead be paid on the next business day following the expiration of such six (6) month period or, if earlier, upon the Participant&#8217;s death&#59; except (A) to the extent of amounts that do not constitute a deferral of compensation within the meaning of Treasury Regulation Section 1.409A-1(b) or (B) other amounts or benefits that are not subject to the requirements of Section 409A.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">For purposes of this Award, all references to &#8220;termination of employment&#8221; and correlative phrases will be construed to require a &#8220;separation from service&#8221; (as defined in Section 1.409A-1(h) of the Treasury Regulations after giving effect to the presumptions contained therein), and the term &#8220;specified employee&#8221; means an individual determined by the Company to be a specified employee under Treasury Regulation Section 1.409A-1(i).  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The award, vesting or delivery of the Shares acquired hereunder may give rise to &#8220;wages&#8221; subject to withholding.  The Participant expressly acknowledges and agrees that his or her rights hereunder, including the right to be delivered Shares upon vesting, are subject to the Participant promptly paying the Company in cash (or by such other means as may be acceptable to the Administrator in its discretion) all taxes required to be withheld.  No Shares will be delivered pursuant to this Award unless and until the Participant will have remitted to the Company in cash or by check an amount sufficient to satisfy any federal, state or local withholding tax requirements or tax payments, or will have made other arrangements satisfactory to the Administrator with respect to such taxes.  The Administrator may, in its sole discretion, hold back Shares from an award or permit the Participant to tender previously owned shares of Stock in satisfaction of tax withholding or tax payment requirements (but not in excess of the applicable minimum statutory withholding rate).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27pt;text-decoration:underline">Forfeiture&#59; Recovery of Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">The Administrator may cancel, rescind, withhold or otherwise limit or restrict the Award at any time if the Participant is not in compliance with all applicable provisions of this Agreement and the Plan, or if the Participant breaches any agreement with the Company or its subsidiaries with respect to non-competition, non-solicitation, invention assignment or confidentiality, including, but not limited to, any employment agreement or offer letter with the Company or the Company&#8217;s standard Employee </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Agreement (Confidentiality, Non-Solicitation, Non-Competition and Developments Agreement).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">By accepting the Award, the Participant expressly acknowledges and agrees that his or her rights, and those of any permitted transferee of the Award, under the Award, including to any Stock delivered under the Award or proceeds from the disposition thereof, are subject to Section 6(a)(5) of the Plan (including any successor provision).  Nothing in the preceding sentence will be construed as limiting the general application of Section 11 of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27pt;text-decoration:underline">Transfer of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The Award may not be transferred except as expressly permitted under Section 6(a)(3) of the Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21pt;text-decoration:underline">Effect on Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Neither the grant of this Award, nor the delivery of Shares under this Award, will give the Participant any right to be retained in the employ or service of the Company or any of its Affiliates, affect the right of the Company or any of its Affiliates to discharge or discipline such Participant at any time, or affect any right of such Participant to terminate his or her Employment at any time.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21pt;text-decoration:underline">Provisions of the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  This Agreement is subject in its entirety to the provisions of the Plan, which are incorporated herein by reference.  A copy of the Plan as in effect on the Grant Date has been furnished to the Participant.  By accepting this Award, the Participant agrees to be bound by the terms of the Plan and this Agreement.  In the event of any conflict between the terms of this Agreement and the Plan, the terms of the Plan will control. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21pt;text-decoration:underline">Acknowledgements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The Participant acknowledges and agrees that (i) this Agreement may be executed in two or more counterparts, each of which will be an original and all of which together will constitute one and the same instrument, (ii) this agreement may be executed and exchanged using facsimile, portable document format (PDF) or electronic signature, which, in each case, will constitute an original signature for all purposes hereunder and (iii) such signature by the Company will be binding against the Company and will create a legally binding agreement when this Agreement is countersigned by the Participant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </font></div><div style="margin-bottom:12pt;padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">&#91;Signature page follows.&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-4-</font></div></div></div><div id="i3753d8b3789f4c27986397b77c2303bc_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer.  </font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:216.6pt;text-indent:-216.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">AKEBIA THERAPEUTICS, INC. </font></div><div style="padding-left:216.6pt;text-indent:-216.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:216.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">By&#58;______________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Name&#58; &#91;&#9679;&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; &#91;&#9679;&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Dated&#58;  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Acknowledged and Agreed&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">By_______________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">    &#91;Participant&#8217;s Name&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">CONFIDENTIAL</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">EXHIBIT A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">PERFORMANCE VESTING SCHEDULE</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>exhibit103-akebiaxformofca.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i4e17b2d178244a65bacc282c5b310172_1"></div><div style="min-height:72pt;width:100%"><div style="padding-right:-1.8pt"><font style="color:#767676;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-right:-1.8pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions.</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Exhibit 10.3</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">FORM</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;Date&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Personal and Confidential</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;First Name Last name&#93;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;Address&#93;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Re&#58;  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">ELT Special Bonus Program</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Dear &#91;First Name Last name&#93;&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">I am pleased to offer you the opportunity to earn additional bonus payments related to your important work on the vadadustat program (the &#8220;ELT Special Bonus Program&#8221;) in recognition of your significant value to Akebia Therapeutics, Inc. (&#8220;Akebia&#8221; or the &#8220;Company&#8221;) and in anticipation of the important contributions you will make in the next year and beyond.  The purpose of this letter agreement (the &#8220;Agreement&#8221;) is to outline the terms and conditions associated with the bonus payments (&#8220;Bonus Payments&#8221;) offered to you by Akebia.  These Bonus Payments are in addition to your annual bonus payment.  If you accept the terms of this Agreement, please return a signed Agreement to &#91;Name&#93; no later than &#91;Date&#93;.  </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Special Bonus Payment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Subject to the terms and conditions set forth below, and in recognition of your contributions to the vadadustat program to date, the Company will provide you with a lump sum payment of $&#91;&#9679;&#93;, less all required taxes, withholdings and deductions, payable within fifteen (15) days of the date hereof (the &#8220;Special Bonus Payment&#8221;).</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.  &#160;&#160;&#160;&#160;Retention Cash Incentive Award.  Subject to the terms and conditions set forth below and the terms of the Company&#8217;s Cash Incentive Plan, the Company will provide you with the following&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a) &#160;&#160;&#160;&#160;lump sum payment of $&#91;&#9679;&#93;, less all required taxes, withholdings and deductions (&#8220;Incentive Payment 1&#8221;) upon &#91;**&#93; (&#8220;Event 1&#8221;), payable within fifteen (15) days of Event 1.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;lump sum payment of $&#91;&#9679;&#93;, less all required taxes, withholdings and deductions (&#8220;Incentive Payment 2&#8221; and together with Incentive Payment 1, the &#8220;Incentive Payments&#8221;) upon &#91;**&#93; (&#8220;Event 2&#8221;), payable within fifteen (15) days of Event 2.</font></div><div style="height:63.93pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">In order to be eligible for any Incentive Payment, you must remain an employee of the Company in good standing (i.e., meeting the requirements of your position) through the date of the corresponding event.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Repayment of Special Bonus Payment Upon Termination</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  If you voluntarily terminate your employment with the Company within twelve (12) months after you receive the Special Bonus Payment, then you shall repay $&#91;&#9679;&#93; within thirty (30) days after the effective date of such termination.  Should you become obligated to repay to the Company the Special Bonus Payment as set forth herein, you hereby authorize the Company to deduct any owed amount from your final, accrued wages (including, without limitation, any accrued but unused paid time off).  You acknowledge and agree that any such deductions would constitute permissible, valid offsets under the Massachusetts Payment of Wages Act, M.G.L. c. 149 &#167; 148 et seq.  You further agree that should your final, accrued wages be insufficient to satisfy your entire repayment obligation, you will repay any outstanding amount by personal check.  You agree that you will be responsible for paying the Company&#8217;s costs of collection, if any (including attorneys&#8217; fees and other expenses), should the Company be required to resort to legal action to collect any such then-outstanding amount.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Prior Agreements</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Upon your acceptance of the terms and conditions of this Agreement, the Employee Agreement (Confidentiality, Non-Solicitation, Non-Competition and Developments Agreement) last executed by you in connection with your employment with Akebia and the Executive Severance Agreement between you and the Company will remain in full force and effect in accordance with their terms, and by your signature below are confirmed, ratified and incorporated herein.   </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">At-Will Employment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Nothing in this Agreement should be taken as a guarantee of continued employment, a specific term of employment and&#47;or a contract of employment, and at all times you will be expected to meet Company performance standards and abide by all Company policies and procedures.  Your employment remains at will and you and the Company agree that this Agreement does not in any way modify the at-will nature of your employment by the Company.  Accordingly, your employment, as well as the terms and conditions thereof (except for this Agreement), may be modified or terminated with or without Cause or notice.  For purposes of this Agreement, the definition of &#8220;Cause&#8221; shall be the same definition of &#8220;Cause&#8221; included in your Executive Severance Agreement. </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The terms and conditions of this Agreement, the existence of the ELT Special Bonus Program, and the Bonus Payments are strictly confidential except as required by applicable law.  To the extent permitted by applicable law, you shall not discuss or reveal any information concerning this Agreement to any past or present employee of the Company or any third person or entity other than the individual who presented you with this Agreement, an Akebia Human Resources representative, counsel and members of your immediate family.  </font></div><div><font><br></font></div><div style="height:63.93pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Complete Agreement&#59; Miscellaneous</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  This Agreement, together with the Cash Incentive Plan and the Executive Severance Agreement, sets forth the complete agreement between you and the Company with respect to your eligibility for, and the payment to you of, the Bonus Payments. The provisions of this Agreement will not supersede or modify the provisions of the Employee Agreement, and nothing herein shall preclude the continued validity of the Employee Agreement which shall remain in full force and effect.  You agree that each provision and the subparts of each provision in this Agreement shall be treated as separate and independent clauses, and the unenforceability of any one clause shall in no way impair the enforceability of any of the other clauses of this Agreement.  In the event of any dispute, this Agreement will be construed as a whole, will be interpreted in accordance with its fair meaning, and will not be construed strictly for or against either you or the Company.  This Agreement may not be changed, amended, modified, altered or rescinded except upon the express written consent of both you and an authorized Company officer, subject to the terms of the Cash Incentive Plan, as applicable.  Any waiver of any provision of this Agreement by the Company shall not constitute a waiver of any other provision of this Agreement unless the Company expressly so indicates otherwise. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without regard to conflicts of laws principles thereof.  Both parties agree that any dispute under this Agreement shall be heard by a court of competent jurisdiction within Massachusetts. The parties hereby acknowledge that they are subject to the personal jurisdiction of the Massachusetts courts in any county where the Company has operations or facilities and&#47;or you reside. </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Except as otherwise provided herein, this Agreement shall be binding upon, inure to the benefit of and be enforceable by the Company and you and their respective heirs, legal representatives, successors and assigns.  If the Company shall be merged into or consolidated with another entity, the provisions of this Agreement shall be binding upon and inure to the benefit of the entity surviving such merger or resulting from such consolidation.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">We are pleased to be able to offer you participation in the ELT Special Bonus Program, and we look forward to your continuing commitment and focus on fulfilling your responsibilities.  Please feel free to reach out to me should you have any questions.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Sincerely,</font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;First Name, Last name&#93;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;Title&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:63.93pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:115%">AGREED AND ACCEPTED&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:115%">I acknowledge and agree that I have read the foregoing Agreement and the Cash Incentive Plan, have had the opportunity to consult with counsel and that I have freely and voluntarily entered into this Agreement.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:115%">________________________________</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#91;First Name, Last name&#93;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Dated&#58; _______________, 2021</font></div><div style="height:63.93pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">4</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>exhibit311-q320211.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i15f1bb264a7d4d91ab03c97c91ac959d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John P. Butler, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">I have reviewed this Quarterly Report on Form 10-Q of Akebia Therapeutics, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the Audit Committee of the registrant&#8217;s Board of Directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.318%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.065%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 4, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John P. Butler</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John P. Butler</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>exhibit312-q320211.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i4e39222d07714cbb81c5fce15aa9685a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David A. Spellman, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">I have reviewed this Quarterly Report on Form 10-Q of Akebia Therapeutics, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the Audit Committee of the registrant&#8217;s Board of Directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.318%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.065%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 4, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David A. Spellman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David A. Spellman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Chief Financial Officer and Treasurer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>exhibit321-q320211.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ieeb1f4a5aa4c426d837b559ba7b79ec7_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. Section&#160;1350)</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the accompanying Quarterly Report of Akebia Therapeutics, Inc. (the&#160;&#8220;Company&#8221;) on Form 10-Q for the  quarter ended June 30, 2021 (the &#8220;Report&#8221;), I, John P. Butler, as Chief Executive Officer and President of the Company, and I, David A. Spellman, as Senior Vice President, Chief Financial Officer and Treasurer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge&#58;</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:57.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.196%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 4, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John P. Butler</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John P. Butler</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 4, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David A. Spellman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David A. Spellman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Chief Financial Officer and Treasurer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>akba-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:8995f2ec-9597-4fb5-818e-5018ad7b3654,g:f42f20af-e08c-4deb-ba3d-2a8688a2b01d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:akba="http://akebia.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://akebia.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="akba-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="akba-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="akba-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="akba-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://akebia.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://akebia.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://akebia.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofOrganizationandOperations" roleURI="http://akebia.com/role/NatureofOrganizationandOperations">
        <link:definition>2101101 - Disclosure - Nature of Organization and Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofOrganizationandOperationsAdditionalInformationDetails" roleURI="http://akebia.com/role/NatureofOrganizationandOperationsAdditionalInformationDetails">
        <link:definition>2402401 - Disclosure - Nature of Organization and Operations - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://akebia.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://akebia.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://akebia.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2405402 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueandReservesforVariableConsideration" roleURI="http://akebia.com/role/ProductRevenueandReservesforVariableConsideration">
        <link:definition>2106103 - Disclosure - Product Revenue and Reserves for Variable Consideration</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueandReservesforVariableConsiderationTables" roleURI="http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationTables">
        <link:definition>2307301 - Disclosure - Product Revenue and Reserves for Variable Consideration (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueandReservesforVariableConsiderationAdditionalInformationDetails" roleURI="http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationAdditionalInformationDetails">
        <link:definition>2408403 - Disclosure - Product Revenue and Reserves for Variable Consideration - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueandReservesforVariableConsiderationProductRevenueAllowanceandReserveCategoriesDetails" roleURI="http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationProductRevenueAllowanceandReserveCategoriesDetails">
        <link:definition>2409404 - Disclosure - Product Revenue and Reserves for Variable Consideration - Product Revenue Allowance and Reserve Categories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandOtherSignificantAgreements" roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreements">
        <link:definition>2110104 - Disclosure - License, Collaboration and Other Significant Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandOtherSignificantAgreementsTables" roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsTables">
        <link:definition>2311302 - Disclosure - License, Collaboration and Other Significant Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails" roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails">
        <link:definition>2412405 - Disclosure - License, Collaboration and Other Significant Agreements - Revenues Recognized From License, Collaboration and Other Significant Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails" roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails">
        <link:definition>2413406 - Disclosure - License, Collaboration and Other Significant Agreements - Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails" roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails">
        <link:definition>2414407 - Disclosure - License, Collaboration and Other Significant Agreements - Changes in Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandOtherSignificantAgreementsRevenueRecognizedResultingfromChangesinContractAssetsandLiabilitiesDetails" roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenueRecognizedResultingfromChangesinContractAssetsandLiabilitiesDetails">
        <link:definition>2415408 - Disclosure - License, Collaboration and Other Significant Agreements - Revenue Recognized Resulting from Changes in Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails" roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails">
        <link:definition>2416409 - Disclosure - License, Collaboration and Other Significant Agreements - Mitsubishi Tanabe Pharma Corporation Collaboration Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails" roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails">
        <link:definition>2417410 - Disclosure - License, Collaboration and Other Significant Agreements - U.S. Collaboration and License Agreement with Otsuka Pharmaceutical Co. Ltd. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails" roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails">
        <link:definition>2418411 - Disclosure - License, Collaboration and Other Significant Agreements - International Collaboration and License Agreement with Otsuka Pharmaceutical Co. Ltd. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails" roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails">
        <link:definition>2419412 - Disclosure - License, Collaboration and Other Significant Agreements - Janssen Pharmaceutica NV Research and License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandOtherSignificantAgreementsCyclerionTherapeuticsLicenseAgreementDetails" roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsCyclerionTherapeuticsLicenseAgreementDetails">
        <link:definition>2420413 - Disclosure - License, Collaboration and Other Significant Agreements - Cyclerion Therapeutics License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails" roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails">
        <link:definition>2421414 - Disclosure - License, Collaboration and Other Significant Agreements - Vifor Pharma License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandOtherSignificantAgreementsLicenseAgreementwithPanionBFBiotechIncDetails" roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsLicenseAgreementwithPanionBFBiotechIncDetails">
        <link:definition>2422415 - Disclosure - License, Collaboration and Other Significant Agreements - License Agreement with Panion&#160;&amp; BF Biotech, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseCollaborationandOtherSignificantAgreementsSublicenseAgreementwithJapanTobaccoIncanditssubsidiaryToriiPharmaceuticalCoLtdDetails" roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsSublicenseAgreementwithJapanTobaccoIncanditssubsidiaryToriiPharmaceuticalCoLtdDetails">
        <link:definition>2423416 - Disclosure - License, Collaboration and Other Significant Agreements - Sublicense Agreement with Japan Tobacco, Inc. and its subsidiary, Torii Pharmaceutical Co., Ltd. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtoSaleofFutureRoyalties" roleURI="http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyalties">
        <link:definition>2124105 - Disclosure - Liability Related to Sale of Future Royalties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtoSaleofFutureRoyaltiesTables" roleURI="http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables">
        <link:definition>2325303 - Disclosure - Liability Related to Sale of Future Royalties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetails" roleURI="http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetails">
        <link:definition>2426417 - Disclosure - Liability Related to Sale of Future Royalties - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtoSaleofFutureRoyaltiesRollforwardofLiabilityRelatedtoSaleofFutureRoyaltiesDetails" roleURI="http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesRollforwardofLiabilityRelatedtoSaleofFutureRoyaltiesDetails">
        <link:definition>2427418 - Disclosure - Liability Related to Sale of Future Royalties - Rollforward of Liability Related to Sale of Future Royalties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecurities" roleURI="http://akebia.com/role/AvailableforSaleSecurities">
        <link:definition>2128106 - Disclosure - Available for Sale Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableForSaleSecuritiesTables" roleURI="http://akebia.com/role/AvailableForSaleSecuritiesTables">
        <link:definition>2329304 - Disclosure - Available For Sale Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails" roleURI="http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails">
        <link:definition>2430419 - Disclosure - Available For Sale Securities - Cash Cash Equivalents and Available for Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails_1" roleURI="http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails_1">
        <link:definition>2430419 - Disclosure - Available For Sale Securities - Cash Cash Equivalents and Available for Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableForSaleSecuritiesAdditionalInformationDetails" roleURI="http://akebia.com/role/AvailableForSaleSecuritiesAdditionalInformationDetails">
        <link:definition>2431420 - Disclosure - Available For Sale Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstruments" roleURI="http://akebia.com/role/FairValueofFinancialInstruments">
        <link:definition>2132107 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsTables" roleURI="http://akebia.com/role/FairValueofFinancialInstrumentsTables">
        <link:definition>2333305 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails" roleURI="http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails">
        <link:definition>2434421 - Disclosure - Fair Value of Financial Instruments - Assets Measured or Disclosed at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsAdditionalInformationDetails" roleURI="http://akebia.com/role/FairValueofFinancialInstrumentsAdditionalInformationDetails">
        <link:definition>2435422 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsFairValueDerivativeLiabilityDetails" roleURI="http://akebia.com/role/FairValueofFinancialInstrumentsFairValueDerivativeLiabilityDetails">
        <link:definition>2436423 - Disclosure - Fair Value of Financial Instruments - Fair Value Derivative Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://akebia.com/role/Inventory">
        <link:definition>2137108 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://akebia.com/role/InventoryTables">
        <link:definition>2338306 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryComponentsofInventoryDetails" roleURI="http://akebia.com/role/InventoryComponentsofInventoryDetails">
        <link:definition>2439424 - Disclosure - Inventory - Components of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryComponentsofInventoryDetails_1" roleURI="http://akebia.com/role/InventoryComponentsofInventoryDetails_1">
        <link:definition>2439424 - Disclosure - Inventory - Components of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryAdditionalInformationDetails" roleURI="http://akebia.com/role/InventoryAdditionalInformationDetails">
        <link:definition>2440425 - Disclosure - Inventory - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwill" roleURI="http://akebia.com/role/IntangibleAssetsandGoodwill">
        <link:definition>2141109 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillTables" roleURI="http://akebia.com/role/IntangibleAssetsandGoodwillTables">
        <link:definition>2342307 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillIntangibleAssetsDetails" roleURI="http://akebia.com/role/IntangibleAssetsandGoodwillIntangibleAssetsDetails">
        <link:definition>2443426 - Disclosure - Intangible Assets and Goodwill - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillAdditionalInformationDetails" roleURI="http://akebia.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails">
        <link:definition>2444427 - Disclosure - Intangible Assets and Goodwill - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://akebia.com/role/AccruedExpenses">
        <link:definition>2145110 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://akebia.com/role/AccruedExpensesTables">
        <link:definition>2346308 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://akebia.com/role/AccruedExpensesDetails">
        <link:definition>2447428 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://akebia.com/role/Debt">
        <link:definition>2148111 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtDetails" roleURI="http://akebia.com/role/DebtDetails">
        <link:definition>2449429 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Warrant" roleURI="http://akebia.com/role/Warrant">
        <link:definition>2150112 - Disclosure - Warrant</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDetails" roleURI="http://akebia.com/role/WarrantDetails">
        <link:definition>2451430 - Disclosure - Warrant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://akebia.com/role/StockholdersEquity">
        <link:definition>2152113 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://akebia.com/role/StockholdersEquityDetails">
        <link:definition>2453431 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://akebia.com/role/CommitmentsandContingencies">
        <link:definition>2154114 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://akebia.com/role/CommitmentsandContingenciesTables">
        <link:definition>2355309 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>2456432 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails" roleURI="http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails">
        <link:definition>2457433 - Disclosure - Commitments and Contingencies - Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1" roleURI="http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1">
        <link:definition>2457433 - Disclosure - Commitments and Contingencies - Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesandOperatingLeasesLiabilitiesDetails" roleURI="http://akebia.com/role/CommitmentsandContingenciesDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesandOperatingLeasesLiabilitiesDetails">
        <link:definition>2458434 - Disclosure - Commitments and Contingencies - Difference Between Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases and Operating Leases Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShare" roleURI="http://akebia.com/role/NetLossperShare">
        <link:definition>2159115 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareTables" roleURI="http://akebia.com/role/NetLossperShareTables">
        <link:definition>2360310 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossperShareDetails" roleURI="http://akebia.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossperShareDetails">
        <link:definition>2461435 - Disclosure - Net Loss per Share - Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="akba_ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock" abstract="false" name="ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="akba_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="akba_LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="akba_ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember" abstract="true" name="ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodOneMember" abstract="true" name="DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable" abstract="false" name="ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_OperatingLeaseFreeMonthlyRentPeriod" abstract="false" name="OperatingLeaseFreeMonthlyRentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="akba_ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue" abstract="false" name="ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_CollaborativeAndLicenseArrangementTransactionPrice" abstract="false" name="CollaborativeAndLicenseArrangementTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_FairValueAdjustmentToInventory" abstract="false" name="FairValueAdjustmentToInventory" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction" abstract="false" name="DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="akba_AssetAcquisitionAgreementTerminationNoticePeriod" abstract="false" name="AssetAcquisitionAgreementTerminationNoticePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="akba_BPCRLimitedPartnershipMember" abstract="true" name="BPCRLimitedPartnershipMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis" abstract="true" name="DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="akba_AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member" abstract="true" name="AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember" abstract="true" name="MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_CollaborativeArrangementAccruedLiability" abstract="false" name="CollaborativeArrangementAccruedLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm" abstract="false" name="LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember" abstract="true" name="DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_LicenseAgreementMember" abstract="true" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_CostShareCostsIncurredByPartnerForLicenseAgreement" abstract="false" name="CostShareCostsIncurredByPartnerForLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_ViforInternationalLimitedMember" abstract="true" name="ViforInternationalLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_FacilityFeePercentagePaidOnPrincipalAmount" abstract="false" name="FacilityFeePercentagePaidOnPrincipalAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="akba_WuXiSTAMember" abstract="true" name="WuXiSTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember" abstract="true" name="DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding" abstract="false" name="PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="akba_CollaborativeArrangementsAdditionalCostSharingPaymentsAmount" abstract="false" name="CollaborativeArrangementsAdditionalCostSharingPaymentsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_ContractWithCustomerLiabilityAdditions" abstract="false" name="ContractWithCustomerLiabilityAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_ContractWithCustomerAssetAdditions" abstract="false" name="ContractWithCustomerAssetAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_SublicenseAgreementMember" abstract="true" name="SublicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_DeferredUnpaidOfferingCosts" abstract="false" name="DeferredUnpaidOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod" abstract="false" name="LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="akba_NoncashInterestExpense" abstract="false" name="NoncashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_TermLoanMember" abstract="true" name="TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_ExcessInventoryPurchaseCommitmentsExpenseReversal" abstract="false" name="ExcessInventoryPurchaseCommitmentsExpenseReversal" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_CambridgeMember" abstract="true" name="CambridgeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_PaymentForLicenseAgreementReimbursementOfCostsIncurred" abstract="false" name="PaymentForLicenseAgreementReimbursementOfCostsIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_DebtInstrumentFacilityFeePaid" abstract="false" name="DebtInstrumentFacilityFeePaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_PurchaseCommittedProgramRemainingContractCosts" abstract="false" name="PurchaseCommittedProgramRemainingContractCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember" abstract="true" name="DevelopmentAndCommercializeResearchAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_FiniteLivedIntangibleAssetsAdoptionAdjustment" abstract="false" name="FiniteLivedIntangibleAssetsAdoptionAdjustment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_ContractWithCustomerLiabilityRollForward" abstract="true" name="ContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="akba_DeferredRevenueRecognitionTableTextBlock" abstract="false" name="DeferredRevenueRecognitionTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="akba_LicenseCollaborationAndOtherRevenueMember" abstract="true" name="LicenseCollaborationAndOtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_UpfrontCashPaymentReceived" abstract="false" name="UpfrontCashPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_TrancheAMember" abstract="true" name="TrancheAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_CyclerionTherapeuticsLicenseAgreementMember" abstract="true" name="CyclerionTherapeuticsLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_ContractualArrangementRoyaltiesAgreementLiabilityPolicyPolicyTextBlock" abstract="false" name="ContractualArrangementRoyaltiesAgreementLiabilityPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="akba_ContractWithCustomerLiabilityMember" abstract="true" name="ContractWithCustomerLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain" abstract="true" name="DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_SiegfriedEvionnazSAMember" abstract="true" name="SiegfriedEvionnazSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_BostonMember" abstract="true" name="BostonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember" abstract="true" name="BiopharmaCreditInvestmentsVMasterLimitedPartnerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_ShareBasedPaymentArrangementTrancheThreeThirdAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember" abstract="true" name="ShareBasedPaymentArrangementTrancheThreeThirdAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_JohnsonAndJohnsonInnovationMember" abstract="true" name="JohnsonAndJohnsonInnovationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_ViforPharmaMember" abstract="true" name="ViforPharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_ContractualArrangementRoyaltiesAgreementProceedsContingentOnAnnualSalesMilestones" abstract="false" name="ContractualArrangementRoyaltiesAgreementProceedsContingentOnAnnualSalesMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember" abstract="true" name="JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_OtherThanDerivativeLiabilitiesMember" abstract="true" name="OtherThanDerivativeLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember" abstract="true" name="ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_JanssenPharmaceuticaNVMember" abstract="true" name="JanssenPharmaceuticaNVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_CostOfPurchasedMinimumQuantityProduct" abstract="false" name="CostOfPurchasedMinimumQuantityProduct" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher" abstract="false" name="CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" abstract="true" name="LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodTwoMember" abstract="true" name="DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_DevelopmentAndRegulatoryMilestonesMember" abstract="true" name="DevelopmentAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_HIFProductMember" abstract="true" name="HIFProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_OperatingLeaseMonthlyRentExpense" abstract="false" name="OperatingLeaseMonthlyRentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_ProductionRelatedImpairmentsOrChargesIntangibles" abstract="false" name="ProductionRelatedImpairmentsOrChargesIntangibles" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred" abstract="false" name="PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_InventoryNetCurrentAndNonCurrent" abstract="false" name="InventoryNetCurrentAndNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_JanssenAgreementMember" abstract="true" name="JanssenAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_AccruedExpensesAndOtherCurrentLiabilitiesMember" abstract="true" name="AccruedExpensesAndOtherCurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_ClosingStockPriceOfCommonStock" abstract="false" name="ClosingStockPriceOfCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="akba_ShareBasedPaymentArrangementTrancheTwoSecondAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember" abstract="true" name="ShareBasedPaymentArrangementTrancheTwoSecondAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount" abstract="false" name="CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward" abstract="true" name="ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="akba_DevelopedProductRightsForAuryxiaMember" abstract="true" name="DevelopedProductRightsForAuryxiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_CollaborativeArrangementRevenueRecognitionTableTextBlock" abstract="false" name="CollaborativeArrangementRevenueRecognitionTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="akba_TrancheBMember" abstract="true" name="TrancheBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="akba_ContractualArrangementRoyaltiesAgreementPercentageOfRoyaltyPaymentsToBeReceivedContingentOnReachingMaximumAnnualRoyaltyPayoutCapacity" abstract="false" name="ContractualArrangementRoyaltiesAgreementPercentageOfRoyaltyPaymentsToBeReceivedContingentOnReachingMaximumAnnualRoyaltyPayoutCapacity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="akba_ScheduleOfDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesAndOperatingLeaseLiabilitiesTableTextBlock" abstract="false" name="ScheduleOfDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesAndOperatingLeaseLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding" abstract="false" name="PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="akba_DebtInstrumentFloorRate" abstract="false" name="DebtInstrumentFloorRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="akba_RegulatoryMilestonePaymentsMember" abstract="true" name="RegulatoryMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_UpFrontNonRefundableAndNonCreditableMember" abstract="true" name="UpFrontNonRefundableAndNonCreditableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones" abstract="false" name="PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding" abstract="false" name="AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="akba_DebtInstrumentCapRate" abstract="false" name="DebtInstrumentCapRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="akba_UpfrontPaymentPaidInCash" abstract="false" name="UpfrontPaymentPaidInCash" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost" abstract="false" name="CashCashEquivalentsAndShortTermInvestmentsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding" abstract="false" name="PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="akba_ContractWithCustomerAssetDeductions" abstract="false" name="ContractWithCustomerAssetDeductions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_ScheduleOfRevenueRecognizedResultingFromChangesInContractAssetAndContractLiabilityTableTextBlock" abstract="false" name="ScheduleOfRevenueRecognizedResultingFromChangesInContractAssetAndContractLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="akba_LongTermPurchaseCommitmentRenewalPeriod" abstract="false" name="LongTermPurchaseCommitmentRenewalPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="akba_LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour" abstract="false" name="LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_TwoThousandAndFourteenPlansMember" abstract="true" name="TwoThousandAndFourteenPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_DebtInstrumentCovenantTermsPotentialMaturityTermReduction" abstract="false" name="DebtInstrumentCovenantTermsPotentialMaturityTermReduction" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="akba_AggregateCollaborationAgreementPayments" abstract="false" name="AggregateCollaborationAgreementPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_BioVectraIncMember" abstract="true" name="BioVectraIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod" abstract="false" name="AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="akba_ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable" abstract="false" name="ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="akba_KeryxMember" abstract="true" name="KeryxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_DevelopmentAndCommercializeCollaborationAgreementMember" abstract="true" name="DevelopmentAndCommercializeCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_CollateralAgentPharmakonMember" abstract="true" name="CollateralAgentPharmakonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_CommonStockSalesAgreementAmount" abstract="false" name="CommonStockSalesAgreementAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_CollaborativeArrangementTerm" abstract="false" name="CollaborativeArrangementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="akba_LicenseExpense" abstract="false" name="LicenseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_LongTermPurchaseCommitmentFixedPricePeriod" abstract="false" name="LongTermPurchaseCommitmentFixedPricePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="akba_ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage" abstract="false" name="ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="akba_EsteveQuimicaSAMember" abstract="true" name="EsteveQuimicaSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales" abstract="false" name="ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_CostOfResearchServices" abstract="false" name="CostOfResearchServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_InducementAwardProgramMember" abstract="true" name="InducementAwardProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_AccruedProductRevenueAllowancesCurrent" abstract="false" name="AccruedProductRevenueAllowancesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_CollaborativeArrangementsCostSharingPayments" abstract="false" name="CollaborativeArrangementsCostSharingPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_MitsubishiTanabePharmaCorporationSupplyAgreementMember" abstract="true" name="MitsubishiTanabePharmaCorporationSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_OperatingLeaseAnnualRentExpense" abstract="false" name="OperatingLeaseAnnualRentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions" abstract="false" name="LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="akba_PerformanceBasedRestrictedStockUnitsMember" abstract="true" name="PerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_NumberOfPerformanceObligations" abstract="false" name="NumberOfPerformanceObligations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="akba_ThreeMonthLondonInterbankOfferedRateMember" abstract="true" name="ThreeMonthLondonInterbankOfferedRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrentRollForward" abstract="true" name="ContractualArrangementRoyaltiesAgreementLiabilityNoncurrentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="akba_OfficeSpaceMember" abstract="true" name="OfficeSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_PanionAndBFBiotechIncorporationMember" abstract="true" name="PanionAndBFBiotechIncorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_WarrantDisclosureTextBlock" abstract="false" name="WarrantDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="akba_ServiceBasedRestrictedStockUnitsMember" abstract="true" name="ServiceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_CostShareCostsIncurredForLicenseAgreement" abstract="false" name="CostShareCostsIncurredForLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent" abstract="false" name="ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_LicenseCollaborationAndOtherRevenueAbstract" abstract="true" name="LicenseCollaborationAndOtherRevenueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="akba_OtsukaPharmaceuticalCompanyLimitedMember" abstract="true" name="OtsukaPharmaceuticalCompanyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_AccruedCommercialManufacturingCurrent" abstract="false" name="AccruedCommercialManufacturingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_KeryxBiopharmaceuticalsIncMember" abstract="true" name="KeryxBiopharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMember" abstract="true" name="ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_AtTheMarketEquityOfferingProgramMember" abstract="true" name="AtTheMarketEquityOfferingProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_LicensedHIFProductMember" abstract="true" name="LicensedHIFProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_OperatingPlanSufficientlyFundedByCashResourcesPeriod" abstract="false" name="OperatingPlanSufficientlyFundedByCashResourcesPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="akba_ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity" abstract="false" name="ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_LesseeOperatingLeaseLiabilityPaymentsDueNet" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueNet" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" abstract="false" name="ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_SupplyAgreementPatheonIncMember" abstract="true" name="SupplyAgreementPatheonIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_ChargebacksAndDiscountsMember" abstract="true" name="ChargebacksAndDiscountsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome" abstract="false" name="ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_MilestonePaymentReceived" abstract="false" name="MilestonePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_RoyaltyPaymentsDue" abstract="false" name="RoyaltyPaymentsDue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_PotentialPaymentForAchievementOfSpecifiedMilestones" abstract="false" name="PotentialPaymentForAchievementOfSpecifiedMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod" abstract="false" name="LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="akba_PercentageOfRemainingCreditableAmountAppliedToFuturePayments" abstract="false" name="PercentageOfRemainingCreditableAmountAppliedToFuturePayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="akba_ContractWithCustomerLiabilityDeductions" abstract="false" name="ContractWithCustomerLiabilityDeductions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity" abstract="false" name="ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_DeferredRevenueMember" abstract="true" name="DeferredRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_InitialTermOfSupplyAgreement" abstract="false" name="InitialTermOfSupplyAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="akba_LicensedProductsMember" abstract="true" name="LicensedProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_ReturnsMember" abstract="true" name="ReturnsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock" abstract="false" name="CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_GlobalDevelopmentPlanMember" abstract="true" name="GlobalDevelopmentPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_MitsubishiTanabePharmaCorporationMember" abstract="true" name="MitsubishiTanabePharmaCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_EmployeesMember" abstract="true" name="EmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties" abstract="false" name="ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan" abstract="false" name="StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_STAPharmaceuticalHongKongLimitedMember" abstract="true" name="STAPharmaceuticalHongKongLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_DerivativeLiabilityFairValueGrossLiabilityRollForward" abstract="true" name="DerivativeLiabilityFairValueGrossLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="akba_RebatesFeesAndOtherDeductionsMember" abstract="true" name="RebatesFeesAndOtherDeductionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandAndFourteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_EstimateSubsequentCostFundingUnderPlan" abstract="false" name="EstimateSubsequentCostFundingUnderPlan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" abstract="false" name="PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_AccruedClinicalExpensesCurrent" abstract="false" name="AccruedClinicalExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_PotentialPaymentForAchievementOfSpecifiedCommercialMilestones" abstract="false" name="PotentialPaymentForAchievementOfSpecifiedCommercialMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="akba_PriorityReviewVoucherLetterAgreementMember" abstract="true" name="PriorityReviewVoucherLetterAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="akba_LicenseCollaborationAndOtherRevenueRoyaltiesMember" abstract="true" name="LicenseCollaborationAndOtherRevenueRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>akba-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:8995f2ec-9597-4fb5-818e-5018ad7b3654,g:f42f20af-e08c-4deb-ba3d-2a8688a2b01d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://akebia.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="akba-20210930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://akebia.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_437530bc-edcd-49f1-8321-10be94e0ee53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_25142cf5-39f0-4a9a-aedb-50362b221d83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_437530bc-edcd-49f1-8321-10be94e0ee53" xlink:to="loc_us-gaap_DerivativeLiabilities_25142cf5-39f0-4a9a-aedb-50362b221d83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_22fa265c-655f-470c-a1e5-ca9516ff6f81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_437530bc-edcd-49f1-8321-10be94e0ee53" xlink:to="loc_us-gaap_LiabilitiesCurrent_22fa265c-655f-470c-a1e5-ca9516ff6f81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_ad05a3a3-7b83-4d20-aa6d-92ef13a8a855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_437530bc-edcd-49f1-8321-10be94e0ee53" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_ad05a3a3-7b83-4d20-aa6d-92ef13a8a855" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_46f49d44-dd69-46c7-943d-1bd7710fcb31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_437530bc-edcd-49f1-8321-10be94e0ee53" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_46f49d44-dd69-46c7-943d-1bd7710fcb31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_295b7d63-9c85-4fdc-b4e7-545dbe21a6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_437530bc-edcd-49f1-8321-10be94e0ee53" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_295b7d63-9c85-4fdc-b4e7-545dbe21a6c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9c36bf86-a176-46b4-ab60-5e91c6ff63ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_437530bc-edcd-49f1-8321-10be94e0ee53" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9c36bf86-a176-46b4-ab60-5e91c6ff63ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent_fd74b5eb-d647-48a0-acc8-bb0d60a37e4b" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_437530bc-edcd-49f1-8321-10be94e0ee53" xlink:to="loc_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent_fd74b5eb-d647-48a0-acc8-bb0d60a37e4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7b5f12e8-39bf-486d-944a-efb85f5c8a00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fbfcdeb4-e258-4704-b776-05eaba7ad6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b5f12e8-39bf-486d-944a-efb85f5c8a00" xlink:to="loc_us-gaap_AssetsCurrent_fbfcdeb4-e258-4704-b776-05eaba7ad6ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0843c6d8-66e7-44d2-9bef-88ae5e296e46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b5f12e8-39bf-486d-944a-efb85f5c8a00" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0843c6d8-66e7-44d2-9bef-88ae5e296e46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_fc5aa4ef-7bb3-4046-a56b-e5c7e74f0dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b5f12e8-39bf-486d-944a-efb85f5c8a00" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_fc5aa4ef-7bb3-4046-a56b-e5c7e74f0dd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b362aaea-cb67-4a78-9363-a2d7a25dc9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b5f12e8-39bf-486d-944a-efb85f5c8a00" xlink:to="loc_us-gaap_Goodwill_b362aaea-cb67-4a78-9363-a2d7a25dc9ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_d733b9d5-308c-42ed-b8d8-a0a842eabdee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b5f12e8-39bf-486d-944a-efb85f5c8a00" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_d733b9d5-308c-42ed-b8d8-a0a842eabdee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_eb822156-551e-4358-9dd1-8a46b1ec530c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7b5f12e8-39bf-486d-944a-efb85f5c8a00" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_eb822156-551e-4358-9dd1-8a46b1ec530c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_86cbc216-1278-4c87-8a13-eb9a092f85eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5193ad74-9647-4f00-b904-8ea1355a4a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_86cbc216-1278-4c87-8a13-eb9a092f85eb" xlink:to="loc_us-gaap_Liabilities_5193ad74-9647-4f00-b904-8ea1355a4a91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_48666207-7ad9-4967-8888-1a0ac96ed76f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_86cbc216-1278-4c87-8a13-eb9a092f85eb" xlink:to="loc_us-gaap_CommitmentsAndContingencies_48666207-7ad9-4967-8888-1a0ac96ed76f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5b575c92-deba-4a46-ae9c-7a234d966853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_86cbc216-1278-4c87-8a13-eb9a092f85eb" xlink:to="loc_us-gaap_StockholdersEquity_5b575c92-deba-4a46-ae9c-7a234d966853" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_637378b6-bbe9-42dd-9347-7770c7b7f1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_46d7e04a-2053-4d24-92b9-3aef1733c838" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_637378b6-bbe9-42dd-9347-7770c7b7f1eb" xlink:to="loc_us-gaap_PreferredStockValue_46d7e04a-2053-4d24-92b9-3aef1733c838" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f52586c3-34bb-44ae-bfa6-9349b15c6fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_637378b6-bbe9-42dd-9347-7770c7b7f1eb" xlink:to="loc_us-gaap_CommonStockValue_f52586c3-34bb-44ae-bfa6-9349b15c6fb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_656d5db6-0e7d-4910-a8ba-ac90594b3c78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_637378b6-bbe9-42dd-9347-7770c7b7f1eb" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_656d5db6-0e7d-4910-a8ba-ac90594b3c78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9755bfc4-433d-41a8-9d7e-e2a5106bc571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_637378b6-bbe9-42dd-9347-7770c7b7f1eb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9755bfc4-433d-41a8-9d7e-e2a5106bc571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e6a52574-84e5-48f3-9c44-541f41e14cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_637378b6-bbe9-42dd-9347-7770c7b7f1eb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e6a52574-84e5-48f3-9c44-541f41e14cf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_423e97cd-391d-4123-8f4d-184ef90d79ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_435e725e-4193-456f-bb04-95d9a33338d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_423e97cd-391d-4123-8f4d-184ef90d79ce" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_435e725e-4193-456f-bb04-95d9a33338d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b3a59785-b0b0-4030-bdcb-af9b2f6f001d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_423e97cd-391d-4123-8f4d-184ef90d79ce" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b3a59785-b0b0-4030-bdcb-af9b2f6f001d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_80340f92-6eb7-45ae-b610-49a1bd1581bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_423e97cd-391d-4123-8f4d-184ef90d79ce" xlink:to="loc_us-gaap_InventoryNet_80340f92-6eb7-45ae-b610-49a1bd1581bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9e0313ef-26af-4dde-b42e-744a76a581ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_423e97cd-391d-4123-8f4d-184ef90d79ce" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9e0313ef-26af-4dde-b42e-744a76a581ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0e894506-5a63-4192-8d9f-18434e67c867" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_423e97cd-391d-4123-8f4d-184ef90d79ce" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0e894506-5a63-4192-8d9f-18434e67c867" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_93dd4a4e-6750-4d2e-a9fb-cd7bf11c6fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0ce48588-7baf-4e30-92ac-9882d9ff77bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_93dd4a4e-6750-4d2e-a9fb-cd7bf11c6fb9" xlink:to="loc_us-gaap_AccountsPayableCurrent_0ce48588-7baf-4e30-92ac-9882d9ff77bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2471e9c4-cacc-4878-89ea-90a2ba308be8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_93dd4a4e-6750-4d2e-a9fb-cd7bf11c6fb9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2471e9c4-cacc-4878-89ea-90a2ba308be8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_44456f93-9736-44ae-bf5d-564eda52e2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_93dd4a4e-6750-4d2e-a9fb-cd7bf11c6fb9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_44456f93-9736-44ae-bf5d-564eda52e2fd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="akba-20210930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_2e5bfc80-188f-491d-849d-36c5db656733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_4a2832a1-9446-45d5-b697-83f1018461ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_2e5bfc80-188f-491d-849d-36c5db656733" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_4a2832a1-9446-45d5-b697-83f1018461ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_ea94e865-3c25-45ce-833a-669dbfadcf97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_2e5bfc80-188f-491d-849d-36c5db656733" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_ea94e865-3c25-45ce-833a-669dbfadcf97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ProductionRelatedImpairmentsOrChargesIntangibles_175320b3-4f5b-47c3-b9bd-37861f7abce9" xlink:href="akba-20210930.xsd#akba_ProductionRelatedImpairmentsOrChargesIntangibles"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_2e5bfc80-188f-491d-849d-36c5db656733" xlink:to="loc_akba_ProductionRelatedImpairmentsOrChargesIntangibles_175320b3-4f5b-47c3-b9bd-37861f7abce9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6489d2f3-9d33-42c2-bf0f-b12c50710848" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_28ed7f65-dc73-453a-a5b1-2abcc281c976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6489d2f3-9d33-42c2-bf0f-b12c50710848" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_28ed7f65-dc73-453a-a5b1-2abcc281c976" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_bb1e3b5f-093c-4a1e-90b1-3ae86578fc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6489d2f3-9d33-42c2-bf0f-b12c50710848" xlink:to="loc_us-gaap_CostOfRevenue_bb1e3b5f-093c-4a1e-90b1-3ae86578fc4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e3ce36d6-95f4-470f-bac5-8c0b7309152d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6489d2f3-9d33-42c2-bf0f-b12c50710848" xlink:to="loc_us-gaap_OperatingExpenses_e3ce36d6-95f4-470f-bac5-8c0b7309152d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c4051829-f4db-4770-9161-750d38248bea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6864ca78-89ec-4139-8a6b-c7971e2e98f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c4051829-f4db-4770-9161-750d38248bea" xlink:to="loc_us-gaap_NetIncomeLoss_6864ca78-89ec-4139-8a6b-c7971e2e98f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4ad6139c-8592-4a52-ad9f-2f2b010687dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c4051829-f4db-4770-9161-750d38248bea" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4ad6139c-8592-4a52-ad9f-2f2b010687dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c15420eb-d800-4178-a8f5-00fd097214a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e6837c29-ea21-4b69-9251-ab4f16db457a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c15420eb-d800-4178-a8f5-00fd097214a0" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e6837c29-ea21-4b69-9251-ab4f16db457a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c1da21a7-926f-4faf-8827-213dc2875705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c15420eb-d800-4178-a8f5-00fd097214a0" xlink:to="loc_us-gaap_OperatingIncomeLoss_c1da21a7-926f-4faf-8827-213dc2875705" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_86276a0d-bff9-4c25-bd16-bce52af2c9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c15420eb-d800-4178-a8f5-00fd097214a0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_86276a0d-bff9-4c25-bd16-bce52af2c9a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_185399a9-fa29-4501-afac-b73104c02fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1499085c-035b-4c54-800d-b7155ec6651e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_185399a9-fa29-4501-afac-b73104c02fb0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1499085c-035b-4c54-800d-b7155ec6651e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7d798ee2-6db8-4544-b408-0406070c8f74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_185399a9-fa29-4501-afac-b73104c02fb0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7d798ee2-6db8-4544-b408-0406070c8f74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseExpense_286216e7-7dc3-4cd3-bced-e8066c86e84d" xlink:href="akba-20210930.xsd#akba_LicenseExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_185399a9-fa29-4501-afac-b73104c02fb0" xlink:to="loc_akba_LicenseExpense_286216e7-7dc3-4cd3-bced-e8066c86e84d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="akba-20210930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86fb4e24-8aba-4708-9632-b8fb72759542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_859cf0a6-9ff2-4d43-9dcd-ceb654a8c4b3" xlink:href="akba-20210930.xsd#akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86fb4e24-8aba-4708-9632-b8fb72759542" xlink:to="loc_akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_859cf0a6-9ff2-4d43-9dcd-ceb654a8c4b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties_52d5bca1-346b-430d-8e8a-abc6384e0d4a" xlink:href="akba-20210930.xsd#akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86fb4e24-8aba-4708-9632-b8fb72759542" xlink:to="loc_akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties_52d5bca1-346b-430d-8e8a-abc6384e0d4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_7e09b1c1-509a-4a81-947c-c3753ae482b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86fb4e24-8aba-4708-9632-b8fb72759542" xlink:to="loc_us-gaap_ProceedsFromStockPlans_7e09b1c1-509a-4a81-947c-c3753ae482b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ab0591ce-17bd-4241-a4f3-c718baa3f629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86fb4e24-8aba-4708-9632-b8fb72759542" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ab0591ce-17bd-4241-a4f3-c718baa3f629" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95c81b97-87aa-410e-9c39-9fd5378258e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dff8dd4f-ff32-413f-b25e-be66bfbe07da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95c81b97-87aa-410e-9c39-9fd5378258e5" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dff8dd4f-ff32-413f-b25e-be66bfbe07da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_3719061f-a9aa-48aa-ba63-6403ea4d7a20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95c81b97-87aa-410e-9c39-9fd5378258e5" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_3719061f-a9aa-48aa-ba63-6403ea4d7a20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8ac1caa4-11d2-4687-a9bb-0d949aa66f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95c81b97-87aa-410e-9c39-9fd5378258e5" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8ac1caa4-11d2-4687-a9bb-0d949aa66f6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2fc80ef8-927f-4e89-8144-67aac830ad83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a164c20f-c8bf-476e-9e91-aa3783c3b16a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2fc80ef8-927f-4e89-8144-67aac830ad83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a164c20f-c8bf-476e-9e91-aa3783c3b16a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_607a9698-f7a7-4b85-804c-47377829114b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2fc80ef8-927f-4e89-8144-67aac830ad83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_607a9698-f7a7-4b85-804c-47377829114b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e9aed209-ebb9-4dcf-a924-4449902e4c75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2fc80ef8-927f-4e89-8144-67aac830ad83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e9aed209-ebb9-4dcf-a924-4449902e4c75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e17e74f-41e1-441f-8518-5f0a22268991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a3e50a41-bcc5-4fea-952b-c0e7eea89f67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e17e74f-41e1-441f-8518-5f0a22268991" xlink:to="loc_us-gaap_NetIncomeLoss_a3e50a41-bcc5-4fea-952b-c0e7eea89f67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_98fd2ff9-4b36-462b-8de9-bc197366b215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e17e74f-41e1-441f-8518-5f0a22268991" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_98fd2ff9-4b36-462b-8de9-bc197366b215" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_eadb6236-1c8a-4a55-ba26-7b37904b6b28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e17e74f-41e1-441f-8518-5f0a22268991" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_eadb6236-1c8a-4a55-ba26-7b37904b6b28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3d2f0341-7e36-4a42-b2e8-a8cac7b19786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e17e74f-41e1-441f-8518-5f0a22268991" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3d2f0341-7e36-4a42-b2e8-a8cac7b19786" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_NoncashInterestExpense_640afe8d-fa89-479d-808a-cbcfd526f8d6" xlink:href="akba-20210930.xsd#akba_NoncashInterestExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e17e74f-41e1-441f-8518-5f0a22268991" xlink:to="loc_akba_NoncashInterestExpense_640afe8d-fa89-479d-808a-cbcfd526f8d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StraightLineRent_7060934a-6aa2-463e-bf4a-113f13617fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StraightLineRent"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e17e74f-41e1-441f-8518-5f0a22268991" xlink:to="loc_us-gaap_StraightLineRent_7060934a-6aa2-463e-bf4a-113f13617fc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_FairValueAdjustmentToInventory_cb5006da-aa11-440e-9e8e-ef1ab98c0da0" xlink:href="akba-20210930.xsd#akba_FairValueAdjustmentToInventory"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e17e74f-41e1-441f-8518-5f0a22268991" xlink:to="loc_akba_FairValueAdjustmentToInventory_cb5006da-aa11-440e-9e8e-ef1ab98c0da0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_dabe4868-7d1c-476b-a2c0-46eeed12d2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e17e74f-41e1-441f-8518-5f0a22268991" xlink:to="loc_us-gaap_InventoryWriteDown_dabe4868-7d1c-476b-a2c0-46eeed12d2b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5f55388c-9d16-4ffc-bcfa-f19f687a1455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e17e74f-41e1-441f-8518-5f0a22268991" xlink:to="loc_us-gaap_ShareBasedCompensation_5f55388c-9d16-4ffc-bcfa-f19f687a1455" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_a3b53908-2c26-465c-a826-968fc97531e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e17e74f-41e1-441f-8518-5f0a22268991" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_a3b53908-2c26-465c-a826-968fc97531e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a32ab125-77bf-467d-b629-4b2fe45952a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e17e74f-41e1-441f-8518-5f0a22268991" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a32ab125-77bf-467d-b629-4b2fe45952a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c5591fdf-8d13-4b73-87d5-22c3f219c2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e17e74f-41e1-441f-8518-5f0a22268991" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c5591fdf-8d13-4b73-87d5-22c3f219c2e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bde01792-ee11-46d8-abb3-bde09ad01593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e17e74f-41e1-441f-8518-5f0a22268991" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bde01792-ee11-46d8-abb3-bde09ad01593" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_128d8dd3-9697-426d-b907-29472b7c3427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e17e74f-41e1-441f-8518-5f0a22268991" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_128d8dd3-9697-426d-b907-29472b7c3427" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_40c8cc39-fc00-4817-9533-15d7ee64c219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e17e74f-41e1-441f-8518-5f0a22268991" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_40c8cc39-fc00-4817-9533-15d7ee64c219" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1830ff44-4b03-4d81-ba3a-796ef739cfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e17e74f-41e1-441f-8518-5f0a22268991" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1830ff44-4b03-4d81-ba3a-796ef739cfd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c94614cb-2356-4941-b09d-5986d9bd7421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e17e74f-41e1-441f-8518-5f0a22268991" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c94614cb-2356-4941-b09d-5986d9bd7421" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a0a8f42f-f206-4712-b67d-b272be6b86f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e17e74f-41e1-441f-8518-5f0a22268991" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a0a8f42f-f206-4712-b67d-b272be6b86f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ExcessInventoryPurchaseCommitmentsExpenseReversal_3ed1d056-7788-4c3d-99ba-831f3385ef79" xlink:href="akba-20210930.xsd#akba_ExcessInventoryPurchaseCommitmentsExpenseReversal"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e17e74f-41e1-441f-8518-5f0a22268991" xlink:to="loc_akba_ExcessInventoryPurchaseCommitmentsExpenseReversal_3ed1d056-7788-4c3d-99ba-831f3385ef79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome_d5e3375c-13a6-4f93-8ace-6d9b9cac51f9" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e17e74f-41e1-441f-8518-5f0a22268991" xlink:to="loc_akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome_d5e3375c-13a6-4f93-8ace-6d9b9cac51f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue_1d82509f-e5f8-498b-b27f-8d589c8720ac" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue"/>
    <link:calculationArc order="21" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e17e74f-41e1-441f-8518-5f0a22268991" xlink:to="loc_akba_ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue_1d82509f-e5f8-498b-b27f-8d589c8720ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_0bff6763-0ae6-4ee0-aba8-4c93df5bddfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="22" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e17e74f-41e1-441f-8518-5f0a22268991" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_0bff6763-0ae6-4ee0-aba8-4c93df5bddfe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails"/>
  <link:calculationLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_53b93266-d403-4f09-98c4-07846daf119b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e0d819ad-0547-4177-a11b-431e445d53cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_53b93266-d403-4f09-98c4-07846daf119b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e0d819ad-0547-4177-a11b-431e445d53cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_874f9176-7df9-4feb-8ed6-b0e5a51ad2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_53b93266-d403-4f09-98c4-07846daf119b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_874f9176-7df9-4feb-8ed6-b0e5a51ad2bf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_44502558-f32d-455e-985b-5310adcf7778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_38c5d786-b1cb-4342-b447-dec43a9027c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_44502558-f32d-455e-985b-5310adcf7778" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_38c5d786-b1cb-4342-b447-dec43a9027c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f20ff8ba-0c57-4c1f-b2b1-cbfa61e3f26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_44502558-f32d-455e-985b-5310adcf7778" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f20ff8ba-0c57-4c1f-b2b1-cbfa61e3f26d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost_c65eab22-0db5-46ec-844e-a0b1e6b38b1e" xlink:href="akba-20210930.xsd#akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0716fe97-fccc-4dda-884b-023239bf0e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost_c65eab22-0db5-46ec-844e-a0b1e6b38b1e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0716fe97-fccc-4dda-884b-023239bf0e3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_577abd69-76dc-4c67-83a8-23763e751992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost_c65eab22-0db5-46ec-844e-a0b1e6b38b1e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_577abd69-76dc-4c67-83a8-23763e751992" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_50ea0156-612c-4a53-8a13-a257b3e95b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost_c65eab22-0db5-46ec-844e-a0b1e6b38b1e" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_50ea0156-612c-4a53-8a13-a257b3e95b6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b4dd5161-65fd-49bc-82c4-8303bbb96132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4bb4b2ef-7602-4687-a807-758c8086f4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b4dd5161-65fd-49bc-82c4-8303bbb96132" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4bb4b2ef-7602-4687-a807-758c8086f4c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_73b57f7b-ae38-4cba-ad66-977d16b90866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b4dd5161-65fd-49bc-82c4-8303bbb96132" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_73b57f7b-ae38-4cba-ad66-977d16b90866" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0ec91599-ed13-4f0d-81fa-fc59b7c13408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b4dd5161-65fd-49bc-82c4-8303bbb96132" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0ec91599-ed13-4f0d-81fa-fc59b7c13408" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails_1" xlink:type="simple" xlink:href="akba-20210930.xsd#AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails_1"/>
  <link:calculationLink xlink:role="http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost_0c518514-7917-4601-9120-1465820c7e0a" xlink:href="akba-20210930.xsd#akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_48369d0d-3390-4fdb-b911-06d9e6741b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost_0c518514-7917-4601-9120-1465820c7e0a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_48369d0d-3390-4fdb-b911-06d9e6741b8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7877896a-8b7d-4ddb-82cb-58939edf4c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost_0c518514-7917-4601-9120-1465820c7e0a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7877896a-8b7d-4ddb-82cb-58939edf4c6b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8176038b-e904-4d19-b9a9-a1e6f334eca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_24778c91-c2d2-4b4b-8eb2-b94f250e38c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8176038b-e904-4d19-b9a9-a1e6f334eca8" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_24778c91-c2d2-4b4b-8eb2-b94f250e38c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5cea8f6d-a60c-4103-a783-12c147b07b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8176038b-e904-4d19-b9a9-a1e6f334eca8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5cea8f6d-a60c-4103-a783-12c147b07b04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_918f2c17-7de5-465c-824f-76344e8494ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_3476258a-4e2c-4dfd-b700-ede128726a74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_918f2c17-7de5-465c-824f-76344e8494ab" xlink:to="loc_us-gaap_DerivativeLiabilities_3476258a-4e2c-4dfd-b700-ede128726a74" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://akebia.com/role/InventoryComponentsofInventoryDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#InventoryComponentsofInventoryDetails"/>
  <link:calculationLink xlink:role="http://akebia.com/role/InventoryComponentsofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_akba_InventoryNetCurrentAndNonCurrent_e014ca7b-2d82-42d2-a176-bc371889c642" xlink:href="akba-20210930.xsd#akba_InventoryNetCurrentAndNonCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_36f5b02d-679d-4388-afa8-32f11a0fee37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_InventoryNetCurrentAndNonCurrent_e014ca7b-2d82-42d2-a176-bc371889c642" xlink:to="loc_us-gaap_InventoryNoncurrent_36f5b02d-679d-4388-afa8-32f11a0fee37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5c6d0be5-80ca-4c70-9dc4-716a0939251b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_InventoryNetCurrentAndNonCurrent_e014ca7b-2d82-42d2-a176-bc371889c642" xlink:to="loc_us-gaap_InventoryNet_5c6d0be5-80ca-4c70-9dc4-716a0939251b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://akebia.com/role/InventoryComponentsofInventoryDetails_1" xlink:type="simple" xlink:href="akba-20210930.xsd#InventoryComponentsofInventoryDetails_1"/>
  <link:calculationLink xlink:role="http://akebia.com/role/InventoryComponentsofInventoryDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_akba_InventoryNetCurrentAndNonCurrent_da432ed9-8ce5-47f3-b093-b644aa93bdb7" xlink:href="akba-20210930.xsd#akba_InventoryNetCurrentAndNonCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_7b8c7d7f-d796-42a3-ab3a-6eb654ceb729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_InventoryNetCurrentAndNonCurrent_da432ed9-8ce5-47f3-b093-b644aa93bdb7" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_7b8c7d7f-d796-42a3-ab3a-6eb654ceb729" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_7f009295-2e0a-474c-9f47-928e816b51c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_InventoryNetCurrentAndNonCurrent_da432ed9-8ce5-47f3-b093-b644aa93bdb7" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_7f009295-2e0a-474c-9f47-928e816b51c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_3d6a2661-dfb9-4777-8bcb-e423416fe474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_InventoryNetCurrentAndNonCurrent_da432ed9-8ce5-47f3-b093-b644aa93bdb7" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_3d6a2661-dfb9-4777-8bcb-e423416fe474" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://akebia.com/role/IntangibleAssetsandGoodwillIntangibleAssetsDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#IntangibleAssetsandGoodwillIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://akebia.com/role/IntangibleAssetsandGoodwillIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d44b261b-bae0-49d2-ad44-6693fc06b420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d7714814-ee63-4530-8784-f567bb184f97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d44b261b-bae0-49d2-ad44-6693fc06b420" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d7714814-ee63-4530-8784-f567bb184f97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fbbb4cf7-cf17-4787-b34c-9273e198b8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d44b261b-bae0-49d2-ad44-6693fc06b420" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fbbb4cf7-cf17-4787-b34c-9273e198b8d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_FiniteLivedIntangibleAssetsAdoptionAdjustment_385a804b-7aee-4062-aab1-5a982a2cf66e" xlink:href="akba-20210930.xsd#akba_FiniteLivedIntangibleAssetsAdoptionAdjustment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d44b261b-bae0-49d2-ad44-6693fc06b420" xlink:to="loc_akba_FiniteLivedIntangibleAssetsAdoptionAdjustment_385a804b-7aee-4062-aab1-5a982a2cf66e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://akebia.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://akebia.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2933402e-e325-4122-a33b-9487d8112657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AccruedProductRevenueAllowancesCurrent_917c911c-4dce-43ad-8afc-09a1a66f6733" xlink:href="akba-20210930.xsd#akba_AccruedProductRevenueAllowancesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2933402e-e325-4122-a33b-9487d8112657" xlink:to="loc_akba_AccruedProductRevenueAllowancesCurrent_917c911c-4dce-43ad-8afc-09a1a66f6733" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AccruedClinicalExpensesCurrent_39925f53-4055-45eb-ba97-481eafca504a" xlink:href="akba-20210930.xsd#akba_AccruedClinicalExpensesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2933402e-e325-4122-a33b-9487d8112657" xlink:to="loc_akba_AccruedClinicalExpensesCurrent_39925f53-4055-45eb-ba97-481eafca504a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeArrangementAccruedLiability_d45264e2-c9bb-43ae-8eb7-3be62c47aac0" xlink:href="akba-20210930.xsd#akba_CollaborativeArrangementAccruedLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2933402e-e325-4122-a33b-9487d8112657" xlink:to="loc_akba_CollaborativeArrangementAccruedLiability_d45264e2-c9bb-43ae-8eb7-3be62c47aac0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_3ad832f7-1316-4a4f-a6fb-2a3133cd749d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2933402e-e325-4122-a33b-9487d8112657" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_3ad832f7-1316-4a4f-a6fb-2a3133cd749d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ff36b046-9c74-42da-81b4-22ba5795052b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2933402e-e325-4122-a33b-9487d8112657" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ff36b046-9c74-42da-81b4-22ba5795052b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f1564919-239f-494e-9220-ddeb3a6c11d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2933402e-e325-4122-a33b-9487d8112657" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f1564919-239f-494e-9220-ddeb3a6c11d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AccruedCommercialManufacturingCurrent_6860343a-5e40-43cb-85a6-368dc18224d7" xlink:href="akba-20210930.xsd#akba_AccruedCommercialManufacturingCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2933402e-e325-4122-a33b-9487d8112657" xlink:to="loc_akba_AccruedCommercialManufacturingCurrent_6860343a-5e40-43cb-85a6-368dc18224d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b7bee069-7ede-417a-b088-0bd6d54b00a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2933402e-e325-4122-a33b-9487d8112657" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b7bee069-7ede-417a-b088-0bd6d54b00a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_4a9ff5de-5f68-4e4e-9687-276c788ae73e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2933402e-e325-4122-a33b-9487d8112657" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_4a9ff5de-5f68-4e4e-9687-276c788ae73e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher_198a8bb5-8085-4989-9ae0-0832c02bd851" xlink:href="akba-20210930.xsd#akba_CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2933402e-e325-4122-a33b-9487d8112657" xlink:to="loc_akba_CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher_198a8bb5-8085-4989-9ae0-0832c02bd851" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"/>
  <link:calculationLink xlink:role="http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne_4d226498-2bd5-40de-aba4-817774e5e2bb" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f2c7da4e-00de-4226-9c3b-fbee60a6d36b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne_4d226498-2bd5-40de-aba4-817774e5e2bb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f2c7da4e-00de-4226-9c3b-fbee60a6d36b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_073c5240-e4e0-4eae-821c-c53080a2e89d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne_4d226498-2bd5-40de-aba4-817774e5e2bb" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_073c5240-e4e0-4eae-821c-c53080a2e89d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNet_37d5128f-5f76-44b6-80a4-7f7f78a2a6e9" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsDueNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_de828118-6ad2-4fb7-aca0-ca612f5ff1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNet_37d5128f-5f76-44b6-80a4-7f7f78a2a6e9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_de828118-6ad2-4fb7-aca0-ca612f5ff1d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_e6197ebd-8e4a-4799-a0d6-efd18f4e1230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNet_37d5128f-5f76-44b6-80a4-7f7f78a2a6e9" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_e6197ebd-8e4a-4799-a0d6-efd18f4e1230" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree_a59adc51-7437-4320-8701-2ef95b06a600" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d5ca1fda-24c3-432b-8ff2-7e78b381b824" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree_a59adc51-7437-4320-8701-2ef95b06a600" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d5ca1fda-24c3-432b-8ff2-7e78b381b824" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_c57c192b-bce2-401c-93e8-2a15fb890326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree_a59adc51-7437-4320-8701-2ef95b06a600" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_c57c192b-bce2-401c-93e8-2a15fb890326" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour_ca546efb-d3b5-467e-9f1e-3c24982fe867" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour_deb6b073-a02b-43b2-b4d6-e1d554ebff67" xlink:href="akba-20210930.xsd#akba_LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour_ca546efb-d3b5-467e-9f1e-3c24982fe867" xlink:to="loc_akba_LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour_deb6b073-a02b-43b2-b4d6-e1d554ebff67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_bbb137c2-9f98-491e-9026-8d2f9b74f4ab" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour_ca546efb-d3b5-467e-9f1e-3c24982fe867" xlink:to="loc_akba_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_bbb137c2-9f98-491e-9026-8d2f9b74f4ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_b36487a6-0852-4373-a30a-9cd22df627eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_96543f7f-9a31-49da-8031-af55b45b44bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_b36487a6-0852-4373-a30a-9cd22df627eb" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_96543f7f-9a31-49da-8031-af55b45b44bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_a1f314dd-1cfa-4c3d-8c87-d5cbf14345b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_b36487a6-0852-4373-a30a-9cd22df627eb" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_a1f314dd-1cfa-4c3d-8c87-d5cbf14345b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_f62a2337-4b04-4a96-bb1a-4c63dd0b2677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_b36487a6-0852-4373-a30a-9cd22df627eb" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_f62a2337-4b04-4a96-bb1a-4c63dd0b2677" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_92d78ccd-f782-4da8-a3c3-6bc23a5d9c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_b36487a6-0852-4373-a30a-9cd22df627eb" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_92d78ccd-f782-4da8-a3c3-6bc23a5d9c49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_f9fa10bf-9fee-4aa1-bc1e-61f8929a3ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_b36487a6-0852-4373-a30a-9cd22df627eb" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_f9fa10bf-9fee-4aa1-bc1e-61f8929a3ee5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour_58320789-6b78-4de8-a556-70a997204b88" xlink:href="akba-20210930.xsd#akba_LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_b36487a6-0852-4373-a30a-9cd22df627eb" xlink:to="loc_akba_LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour_58320789-6b78-4de8-a556-70a997204b88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo_57502245-44eb-4b91-8ecd-71b277930e2b" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_30890523-0601-4368-8c20-f021395a2043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo_57502245-44eb-4b91-8ecd-71b277930e2b" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_30890523-0601-4368-8c20-f021395a2043" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1a5fb498-ea72-4cd0-8401-e35805b4b8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo_57502245-44eb-4b91-8ecd-71b277930e2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1a5fb498-ea72-4cd0-8401-e35805b4b8d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear_3e99491d-02f6-41eb-8006-d3dd75e1d056" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_25a39d22-5642-414c-9dc8-ffaf36d1dd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear_3e99491d-02f6-41eb-8006-d3dd75e1d056" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_25a39d22-5642-414c-9dc8-ffaf36d1dd7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1c305b71-8d08-4b6d-8082-efece874eac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear_3e99491d-02f6-41eb-8006-d3dd75e1d056" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1c305b71-8d08-4b6d-8082-efece874eac8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_62bb1f54-1200-4b9e-b152-e27853a69dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dad23fbd-8290-41c8-993d-34a763e8ee56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_62bb1f54-1200-4b9e-b152-e27853a69dc8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dad23fbd-8290-41c8-993d-34a763e8ee56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fdabcf0e-9644-4657-9688-7e99dd50a4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_62bb1f54-1200-4b9e-b152-e27853a69dc8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fdabcf0e-9644-4657-9688-7e99dd50a4fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_75e36700-a89f-42fa-81b1-c9d7684c20a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_62bb1f54-1200-4b9e-b152-e27853a69dc8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_75e36700-a89f-42fa-81b1-c9d7684c20a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_3c35dd9c-d354-4ac4-a026-88171e6d925d" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_62bb1f54-1200-4b9e-b152-e27853a69dc8" xlink:to="loc_akba_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_3c35dd9c-d354-4ac4-a026-88171e6d925d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ff05c35d-3f6b-4ed7-838b-9c72c527005f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_62bb1f54-1200-4b9e-b152-e27853a69dc8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ff05c35d-3f6b-4ed7-838b-9c72c527005f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ebe43267-157d-4aff-86a7-2b202dbe10f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_62bb1f54-1200-4b9e-b152-e27853a69dc8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ebe43267-157d-4aff-86a7-2b202dbe10f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour_88bc67d0-8eba-4900-874d-527189561f8b" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cd5d6c7e-554d-45c3-a6cc-db2d8346922d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour_88bc67d0-8eba-4900-874d-527189561f8b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cd5d6c7e-554d-45c3-a6cc-db2d8346922d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_96c15888-5d48-424a-9807-276e7b6f38f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour_88bc67d0-8eba-4900-874d-527189561f8b" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_96c15888-5d48-424a-9807-276e7b6f38f9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1" xlink:type="simple" xlink:href="akba-20210930.xsd#CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNet_03d6b273-8940-4ec6-a79f-8979eb57e59a" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsDueNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour_ba6b4f2e-4d8c-4da5-a486-22ad1a15ebaa" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNet_03d6b273-8940-4ec6-a79f-8979eb57e59a" xlink:to="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour_ba6b4f2e-4d8c-4da5-a486-22ad1a15ebaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour_2ec668ed-7e86-40f9-bfa5-cb52dc407ac3" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNet_03d6b273-8940-4ec6-a79f-8979eb57e59a" xlink:to="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour_2ec668ed-7e86-40f9-bfa5-cb52dc407ac3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo_5d8173c1-dd04-430b-b00b-5b111cc7f21a" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNet_03d6b273-8940-4ec6-a79f-8979eb57e59a" xlink:to="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo_5d8173c1-dd04-430b-b00b-5b111cc7f21a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne_80e4d8ae-a965-4b1e-b935-5a4002235767" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNet_03d6b273-8940-4ec6-a79f-8979eb57e59a" xlink:to="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne_80e4d8ae-a965-4b1e-b935-5a4002235767" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear_5e21f553-6f85-4aba-9948-9773caac80e4" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNet_03d6b273-8940-4ec6-a79f-8979eb57e59a" xlink:to="loc_akba_LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear_5e21f553-6f85-4aba-9948-9773caac80e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree_10438766-362c-4e47-93c7-747258c14333" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNet_03d6b273-8940-4ec6-a79f-8979eb57e59a" xlink:to="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree_10438766-362c-4e47-93c7-747258c14333" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://akebia.com/role/CommitmentsandContingenciesDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesandOperatingLeasesLiabilitiesDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#CommitmentsandContingenciesDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesandOperatingLeasesLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://akebia.com/role/CommitmentsandContingenciesDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesandOperatingLeasesLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9cdd8ef9-efd1-495e-a044-e6136834267f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c951afe1-8b71-4641-8572-8b4ca36b2fda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9cdd8ef9-efd1-495e-a044-e6136834267f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c951afe1-8b71-4641-8572-8b4ca36b2fda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_fb9eea51-2b43-487d-a538-b7108f354731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9cdd8ef9-efd1-495e-a044-e6136834267f" xlink:to="loc_us-gaap_OperatingLeaseLiability_fb9eea51-2b43-487d-a538-b7108f354731" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>akba-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:8995f2ec-9597-4fb5-818e-5018ad7b3654,g:f42f20af-e08c-4deb-ba3d-2a8688a2b01d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="akba-20210930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="ie75b57bd046b4b4a820063976b291bac_CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_0d63d4d2-48b8-457f-aef4-5a3dbeee2e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:to="loc_us-gaap_RevenuesAbstract_0d63d4d2-48b8-457f-aef4-5a3dbeee2e7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fc4f1a00-950e-4897-a16c-6d803865861a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_0d63d4d2-48b8-457f-aef4-5a3dbeee2e7e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fc4f1a00-950e-4897-a16c-6d803865861a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_70157653-690b-41ab-ad51-0281eb8a8408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:to="loc_us-gaap_CostOfRevenueAbstract_70157653-690b-41ab-ad51-0281eb8a8408" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_a13927ab-912b-4d21-990e-355f8540a554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_70157653-690b-41ab-ad51-0281eb8a8408" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_a13927ab-912b-4d21-990e-355f8540a554" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_d68910d8-cf86-4c77-b2d8-74184496fa4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_70157653-690b-41ab-ad51-0281eb8a8408" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_d68910d8-cf86-4c77-b2d8-74184496fa4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ProductionRelatedImpairmentsOrChargesIntangibles_a64327e4-8f1b-43e5-a917-bf2df702fb8e" xlink:href="akba-20210930.xsd#akba_ProductionRelatedImpairmentsOrChargesIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_70157653-690b-41ab-ad51-0281eb8a8408" xlink:to="loc_akba_ProductionRelatedImpairmentsOrChargesIntangibles_a64327e4-8f1b-43e5-a917-bf2df702fb8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_4fd299f4-616b-49ad-af9a-d4dae58a7064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_70157653-690b-41ab-ad51-0281eb8a8408" xlink:to="loc_us-gaap_CostOfRevenue_4fd299f4-616b-49ad-af9a-d4dae58a7064" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_8487a518-c5f3-4e41-a725-dbf9488948ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:to="loc_us-gaap_OperatingExpensesAbstract_8487a518-c5f3-4e41-a725-dbf9488948ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f56eea9c-f0b3-42cb-9e62-f8038293bc7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8487a518-c5f3-4e41-a725-dbf9488948ce" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f56eea9c-f0b3-42cb-9e62-f8038293bc7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4c66a6e2-f2f8-4946-92da-2c45fde44b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8487a518-c5f3-4e41-a725-dbf9488948ce" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4c66a6e2-f2f8-4946-92da-2c45fde44b8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseExpense_d4c7c64d-3d5e-4e10-b83f-a1ad9a7636cc" xlink:href="akba-20210930.xsd#akba_LicenseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8487a518-c5f3-4e41-a725-dbf9488948ce" xlink:to="loc_akba_LicenseExpense_d4c7c64d-3d5e-4e10-b83f-a1ad9a7636cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_59ea986d-250f-4b4b-82c9-7175be2e3f04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8487a518-c5f3-4e41-a725-dbf9488948ce" xlink:to="loc_us-gaap_OperatingExpenses_59ea986d-250f-4b4b-82c9-7175be2e3f04" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0cf6c400-29cd-4583-b364-73a924d8944e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:to="loc_us-gaap_OperatingIncomeLoss_0cf6c400-29cd-4583-b364-73a924d8944e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_31d3099f-5104-4de2-a337-790e26e44e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_31d3099f-5104-4de2-a337-790e26e44e8a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_0f04e9f3-3ff3-438c-9115-3d65e00fb238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_31d3099f-5104-4de2-a337-790e26e44e8a" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_0f04e9f3-3ff3-438c-9115-3d65e00fb238" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e8cbc382-bb04-436e-8c24-ecf54f3e40a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_31d3099f-5104-4de2-a337-790e26e44e8a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e8cbc382-bb04-436e-8c24-ecf54f3e40a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_162d6fff-b472-4912-bb3e-9dc8ab9617b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:to="loc_us-gaap_NetIncomeLoss_162d6fff-b472-4912-bb3e-9dc8ab9617b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7fed8e49-afde-4991-99ac-13fa1b175fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:to="loc_us-gaap_EarningsPerShareBasic_7fed8e49-afde-4991-99ac-13fa1b175fd6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c7977bc9-8934-4bbf-9ea7-4f3d72f89828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c7977bc9-8934-4bbf-9ea7-4f3d72f89828" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8b236d2b-a735-45f3-9e93-675a9749eaef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8b236d2b-a735-45f3-9e93-675a9749eaef" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c326cce8-a7b0-4298-a116-0db8c9de0bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c326cce8-a7b0-4298-a116-0db8c9de0bc6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_7e2b7a93-f589-4736-9cd4-9b36ef508e19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_7e2b7a93-f589-4736-9cd4-9b36ef508e19" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3b92053c-14c0-4ff1-ae7f-42b9465220e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_25bbb25b-fba2-4434-9bf5-b3517b1996b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_7e2b7a93-f589-4736-9cd4-9b36ef508e19" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_25bbb25b-fba2-4434-9bf5-b3517b1996b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_740e36b4-c749-4259-9c1a-edeb7f4bc9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_7e2b7a93-f589-4736-9cd4-9b36ef508e19" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_740e36b4-c749-4259-9c1a-edeb7f4bc9e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a35f6cdf-0c07-4604-9a75-46986f977efa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:to="loc_us-gaap_StatementTable_a35f6cdf-0c07-4604-9a75-46986f977efa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fb4319a3-e6cf-42b7-ac95-1042c0f2e3cf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a35f6cdf-0c07-4604-9a75-46986f977efa" xlink:to="loc_srt_ProductOrServiceAxis_fb4319a3-e6cf-42b7-ac95-1042c0f2e3cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fb4319a3-e6cf-42b7-ac95-1042c0f2e3cf_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fb4319a3-e6cf-42b7-ac95-1042c0f2e3cf" xlink:to="loc_srt_ProductsAndServicesDomain_fb4319a3-e6cf-42b7-ac95-1042c0f2e3cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_815a2f73-88ce-4e05-9d5d-fdfe834d6e27" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fb4319a3-e6cf-42b7-ac95-1042c0f2e3cf" xlink:to="loc_srt_ProductsAndServicesDomain_815a2f73-88ce-4e05-9d5d-fdfe834d6e27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_a84d5da6-b612-47b0-92f6-9bbc154efedd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_815a2f73-88ce-4e05-9d5d-fdfe834d6e27" xlink:to="loc_us-gaap_ProductMember_a84d5da6-b612-47b0-92f6-9bbc154efedd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseCollaborationAndOtherRevenueMember_320f09c3-8a6e-4768-becc-a4dbb0e8fd36" xlink:href="akba-20210930.xsd#akba_LicenseCollaborationAndOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_815a2f73-88ce-4e05-9d5d-fdfe834d6e27" xlink:to="loc_akba_LicenseCollaborationAndOtherRevenueMember_320f09c3-8a6e-4768-becc-a4dbb0e8fd36" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="akba-20210930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i2018629dc43047de8a9375df748b47b5_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e0b9cf94-bd60-4215-b4d3-d8f2c49aba1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e0b9cf94-bd60-4215-b4d3-d8f2c49aba1f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cf7e9054-d183-4f5b-892a-7fa1f82f1cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_cf7e9054-d183-4f5b-892a-7fa1f82f1cd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eb64545d-25d5-4860-a109-22602b824f83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_us-gaap_StockholdersEquity_eb64545d-25d5-4860-a109-22602b824f83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14d74b31-4df5-465b-9508-4aabe9f341bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14d74b31-4df5-465b-9508-4aabe9f341bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_554dc8c6-9143-4dca-bd33-da737a1192f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_554dc8c6-9143-4dca-bd33-da737a1192f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_36bd458c-0b02-4a16-85c5-31e795fb741c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_36bd458c-0b02-4a16-85c5-31e795fb741c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan_cc079881-dd83-4c01-9d43-a2ba1f34069d" xlink:href="akba-20210930.xsd#akba_StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_akba_StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan_cc079881-dd83-4c01-9d43-a2ba1f34069d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_455b0377-42ca-49b6-85a7-28ef5110c3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_455b0377-42ca-49b6-85a7-28ef5110c3ed" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_63a0b426-5465-4d52-8ff7-ed20ab6cd101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_63a0b426-5465-4d52-8ff7-ed20ab6cd101" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ff04f329-3d8b-46bd-9934-74fbd82b0422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ff04f329-3d8b-46bd-9934-74fbd82b0422" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_a00b28cc-fa16-45c3-a905-15de06bb2461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_a00b28cc-fa16-45c3-a905-15de06bb2461" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_509a0719-0e01-4dfc-87ab-ea7ec04dcdc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_509a0719-0e01-4dfc-87ab-ea7ec04dcdc6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7a78d4fb-6eb1-459e-bbeb-cbeaadd9dce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_us-gaap_NetIncomeLoss_7a78d4fb-6eb1-459e-bbeb-cbeaadd9dce3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f77b3346-a0ea-4c7b-9fc6-ddcc3877db16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_66391be3-4b67-4613-baf9-6987313dc3df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ffe6b9d9-f18b-4dd2-9675-c9c2e8eed1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e0b9cf94-bd60-4215-b4d3-d8f2c49aba1f" xlink:to="loc_us-gaap_StatementTable_ffe6b9d9-f18b-4dd2-9675-c9c2e8eed1ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c196e0b4-d03c-4b11-8a51-bdca2ff80fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ffe6b9d9-f18b-4dd2-9675-c9c2e8eed1ab" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c196e0b4-d03c-4b11-8a51-bdca2ff80fe1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c196e0b4-d03c-4b11-8a51-bdca2ff80fe1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c196e0b4-d03c-4b11-8a51-bdca2ff80fe1" xlink:to="loc_us-gaap_EquityComponentDomain_c196e0b4-d03c-4b11-8a51-bdca2ff80fe1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ad05dce5-07a8-4e0a-8601-7256b96ae414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c196e0b4-d03c-4b11-8a51-bdca2ff80fe1" xlink:to="loc_us-gaap_EquityComponentDomain_ad05dce5-07a8-4e0a-8601-7256b96ae414" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_810beb7b-5bd8-47df-b2f3-0ac37865af6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ad05dce5-07a8-4e0a-8601-7256b96ae414" xlink:to="loc_us-gaap_CommonStockMember_810beb7b-5bd8-47df-b2f3-0ac37865af6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ee54a7f4-dd23-4b81-a61f-3e48081ef6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ad05dce5-07a8-4e0a-8601-7256b96ae414" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ee54a7f4-dd23-4b81-a61f-3e48081ef6a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_145466d7-2d15-43a2-a0d4-6640bfe8e3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ad05dce5-07a8-4e0a-8601-7256b96ae414" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_145466d7-2d15-43a2-a0d4-6640bfe8e3a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_119daab8-a429-4938-9e80-18a689daf8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ad05dce5-07a8-4e0a-8601-7256b96ae414" xlink:to="loc_us-gaap_RetainedEarningsMember_119daab8-a429-4938-9e80-18a689daf8ce" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationAdditionalInformationDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#ProductRevenueandReservesforVariableConsiderationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationAdditionalInformationDetails" xlink:type="extended" id="icbf6b56edabf43cf9701a574cb4b6420_ProductRevenueandReservesforVariableConsiderationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8946a90b-c257-4f9c-821b-5e30046a6a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6781d89f-1c19-4164-a7a3-9e1682990235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8946a90b-c257-4f9c-821b-5e30046a6a5b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6781d89f-1c19-4164-a7a3-9e1682990235" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_b2d7b0b0-644c-4ab5-8566-77d1a0235f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8946a90b-c257-4f9c-821b-5e30046a6a5b" xlink:to="loc_us-gaap_AccountsReceivableNet_b2d7b0b0-644c-4ab5-8566-77d1a0235f1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_c63c3559-b7df-43e2-b0c7-2b0843c6de3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8946a90b-c257-4f9c-821b-5e30046a6a5b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_c63c3559-b7df-43e2-b0c7-2b0843c6de3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3958201b-077a-4b9d-986f-a9462a20bd58" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c63c3559-b7df-43e2-b0c7-2b0843c6de3c" xlink:to="loc_srt_ProductOrServiceAxis_3958201b-077a-4b9d-986f-a9462a20bd58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3958201b-077a-4b9d-986f-a9462a20bd58_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3958201b-077a-4b9d-986f-a9462a20bd58" xlink:to="loc_srt_ProductsAndServicesDomain_3958201b-077a-4b9d-986f-a9462a20bd58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e903a5ae-01b0-4a7c-b568-37a616ef9bce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3958201b-077a-4b9d-986f-a9462a20bd58" xlink:to="loc_srt_ProductsAndServicesDomain_e903a5ae-01b0-4a7c-b568-37a616ef9bce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5f835f92-d81d-4239-aa5e-5f564f62f84d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e903a5ae-01b0-4a7c-b568-37a616ef9bce" xlink:to="loc_us-gaap_ProductMember_5f835f92-d81d-4239-aa5e-5f564f62f84d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationProductRevenueAllowanceandReserveCategoriesDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#ProductRevenueandReservesforVariableConsiderationProductRevenueAllowanceandReserveCategoriesDetails"/>
  <link:definitionLink xlink:role="http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationProductRevenueAllowanceandReserveCategoriesDetails" xlink:type="extended" id="i1583e71f7b674150ab2279c520cf9ae7_ProductRevenueandReservesforVariableConsiderationProductRevenueAllowanceandReserveCategoriesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_f17554c0-ec4f-4cb0-b6ad-7408e7856300" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ed31189f-a963-4f26-9eab-aa7f8c531bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_f17554c0-ec4f-4cb0-b6ad-7408e7856300" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ed31189f-a963-4f26-9eab-aa7f8c531bc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_1d90a6d8-3205-4cb9-9c92-f2c2cc1f6661" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ed31189f-a963-4f26-9eab-aa7f8c531bc4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_1d90a6d8-3205-4cb9-9c92-f2c2cc1f6661" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_163c8cb8-6f38-4e53-879a-9756ea66da9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ed31189f-a963-4f26-9eab-aa7f8c531bc4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_163c8cb8-6f38-4e53-879a-9756ea66da9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales_d7913954-d73a-42a4-9737-c2c036db24e5" xlink:href="akba-20210930.xsd#akba_ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ed31189f-a963-4f26-9eab-aa7f8c531bc4" xlink:to="loc_akba_ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales_d7913954-d73a-42a4-9737-c2c036db24e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_a7a6b7c2-88de-42c9-89ca-afb70a5ac26b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ed31189f-a963-4f26-9eab-aa7f8c531bc4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_a7a6b7c2-88de-42c9-89ca-afb70a5ac26b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_c13a731c-22e6-4310-9555-f3e9546e4695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5d129709-d1af-4080-81d5-ec53ccf99831" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_f17554c0-ec4f-4cb0-b6ad-7408e7856300" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5d129709-d1af-4080-81d5-ec53ccf99831" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5f34195b-d344-4aa8-88a7-97ce28b861b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5d129709-d1af-4080-81d5-ec53ccf99831" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5f34195b-d344-4aa8-88a7-97ce28b861b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_5f34195b-d344-4aa8-88a7-97ce28b861b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5f34195b-d344-4aa8-88a7-97ce28b861b7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_5f34195b-d344-4aa8-88a7-97ce28b861b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8ec3af55-94f0-4cf2-ade0-0d5de7570516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5f34195b-d344-4aa8-88a7-97ce28b861b7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_8ec3af55-94f0-4cf2-ade0-0d5de7570516" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ChargebacksAndDiscountsMember_031ca2bb-5688-47d1-b03c-80d9274362bf" xlink:href="akba-20210930.xsd#akba_ChargebacksAndDiscountsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8ec3af55-94f0-4cf2-ade0-0d5de7570516" xlink:to="loc_akba_ChargebacksAndDiscountsMember_031ca2bb-5688-47d1-b03c-80d9274362bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_RebatesFeesAndOtherDeductionsMember_27416548-d989-472c-87f4-5c5a8c944f07" xlink:href="akba-20210930.xsd#akba_RebatesFeesAndOtherDeductionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8ec3af55-94f0-4cf2-ade0-0d5de7570516" xlink:to="loc_akba_RebatesFeesAndOtherDeductionsMember_27416548-d989-472c-87f4-5c5a8c944f07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ReturnsMember_0cadf150-af1a-43a8-aae5-0bf733a6b392" xlink:href="akba-20210930.xsd#akba_ReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8ec3af55-94f0-4cf2-ade0-0d5de7570516" xlink:to="loc_akba_ReturnsMember_0cadf150-af1a-43a8-aae5-0bf733a6b392" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails"/>
  <link:definitionLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails" xlink:type="extended" id="i29c3e92230144afa993438ddc150fd2d_LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ff6d87b7-7c47-44b6-8f79-aa87d948b578" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseCollaborationAndOtherRevenueAbstract_b83e8649-2ce1-4e4b-80af-e0c8e1440304" xlink:href="akba-20210930.xsd#akba_LicenseCollaborationAndOtherRevenueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ff6d87b7-7c47-44b6-8f79-aa87d948b578" xlink:to="loc_akba_LicenseCollaborationAndOtherRevenueAbstract_b83e8649-2ce1-4e4b-80af-e0c8e1440304" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e17b71a4-aa25-4ef1-bc66-b6b9b2433e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_LicenseCollaborationAndOtherRevenueAbstract_b83e8649-2ce1-4e4b-80af-e0c8e1440304" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e17b71a4-aa25-4ef1-bc66-b6b9b2433e41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37523ac8-c9ce-4e1c-b3c3-0bc9f4399a66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ff6d87b7-7c47-44b6-8f79-aa87d948b578" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37523ac8-c9ce-4e1c-b3c3-0bc9f4399a66" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bfc4912f-268c-4fc3-a876-28a7d29f392e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37523ac8-c9ce-4e1c-b3c3-0bc9f4399a66" xlink:to="loc_srt_ProductOrServiceAxis_bfc4912f-268c-4fc3-a876-28a7d29f392e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bfc4912f-268c-4fc3-a876-28a7d29f392e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_bfc4912f-268c-4fc3-a876-28a7d29f392e" xlink:to="loc_srt_ProductsAndServicesDomain_bfc4912f-268c-4fc3-a876-28a7d29f392e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ffdec67c-cfba-4f16-b47f-7e3513ffcb94" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_bfc4912f-268c-4fc3-a876-28a7d29f392e" xlink:to="loc_srt_ProductsAndServicesDomain_ffdec67c-cfba-4f16-b47f-7e3513ffcb94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseCollaborationAndOtherRevenueMember_667d10c1-8a3d-4846-a053-81c4d212021e" xlink:href="akba-20210930.xsd#akba_LicenseCollaborationAndOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ffdec67c-cfba-4f16-b47f-7e3513ffcb94" xlink:to="loc_akba_LicenseCollaborationAndOtherRevenueMember_667d10c1-8a3d-4846-a053-81c4d212021e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_46f9ece0-9fef-4f61-99a5-8c2202050904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37523ac8-c9ce-4e1c-b3c3-0bc9f4399a66" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_46f9ece0-9fef-4f61-99a5-8c2202050904" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_46f9ece0-9fef-4f61-99a5-8c2202050904_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_46f9ece0-9fef-4f61-99a5-8c2202050904" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_46f9ece0-9fef-4f61-99a5-8c2202050904_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_156fbc22-d0b8-4d28-8c5b-7c46f6ac2683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_46f9ece0-9fef-4f61-99a5-8c2202050904" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_156fbc22-d0b8-4d28-8c5b-7c46f6ac2683" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeMember_7a5f26c6-b999-492e-8681-cca178f38820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_156fbc22-d0b8-4d28-8c5b-7c46f6ac2683" xlink:to="loc_us-gaap_OtherIncomeMember_7a5f26c6-b999-492e-8681-cca178f38820" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bc3c04f3-e173-4128-8272-ccce74c81b9b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37523ac8-c9ce-4e1c-b3c3-0bc9f4399a66" xlink:to="loc_srt_CounterpartyNameAxis_bc3c04f3-e173-4128-8272-ccce74c81b9b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc3c04f3-e173-4128-8272-ccce74c81b9b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_bc3c04f3-e173-4128-8272-ccce74c81b9b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc3c04f3-e173-4128-8272-ccce74c81b9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf112496-ea1f-4d48-aa51-725087ef3deb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_bc3c04f3-e173-4128-8272-ccce74c81b9b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf112496-ea1f-4d48-aa51-725087ef3deb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_MitsubishiTanabePharmaCorporationMember_b69f95f1-65f0-4ac0-b5c6-eaded4ddbfb7" xlink:href="akba-20210930.xsd#akba_MitsubishiTanabePharmaCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf112496-ea1f-4d48-aa51-725087ef3deb" xlink:to="loc_akba_MitsubishiTanabePharmaCorporationMember_b69f95f1-65f0-4ac0-b5c6-eaded4ddbfb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OtsukaPharmaceuticalCompanyLimitedMember_4f1b498a-9914-41d4-bd89-35864a78e6e1" xlink:href="akba-20210930.xsd#akba_OtsukaPharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf112496-ea1f-4d48-aa51-725087ef3deb" xlink:to="loc_akba_OtsukaPharmaceuticalCompanyLimitedMember_4f1b498a-9914-41d4-bd89-35864a78e6e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember_d1c2c0d0-fae8-4a84-833c-8462627916a0" xlink:href="akba-20210930.xsd#akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf112496-ea1f-4d48-aa51-725087ef3deb" xlink:to="loc_akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember_d1c2c0d0-fae8-4a84-833c-8462627916a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember_92058cdf-a669-4c93-ae0c-6f7db8c82f56" xlink:href="akba-20210930.xsd#akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf112496-ea1f-4d48-aa51-725087ef3deb" xlink:to="loc_akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember_92058cdf-a669-4c93-ae0c-6f7db8c82f56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a3fddaf9-0979-462a-a877-8fad626a7e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37523ac8-c9ce-4e1c-b3c3-0bc9f4399a66" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a3fddaf9-0979-462a-a877-8fad626a7e32" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a3fddaf9-0979-462a-a877-8fad626a7e32_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a3fddaf9-0979-462a-a877-8fad626a7e32" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a3fddaf9-0979-462a-a877-8fad626a7e32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_95b3d038-16dc-4d93-84a5-b77bb55aade9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a3fddaf9-0979-462a-a877-8fad626a7e32" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_95b3d038-16dc-4d93-84a5-b77bb55aade9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember_c21034d9-855b-4d33-89ab-92991aa59707" xlink:href="akba-20210930.xsd#akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_95b3d038-16dc-4d93-84a5-b77bb55aade9" xlink:to="loc_akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember_c21034d9-855b-4d33-89ab-92991aa59707" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember_b262b6c5-b522-4bae-a6aa-2f8eec32b449" xlink:href="akba-20210930.xsd#akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_95b3d038-16dc-4d93-84a5-b77bb55aade9" xlink:to="loc_akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember_b262b6c5-b522-4bae-a6aa-2f8eec32b449" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails"/>
  <link:definitionLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails" xlink:type="extended" id="i55634a6ee05142559ca55c137a7ee394_LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_597a5330-3287-4fbc-9faf-febc81fb61bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract_b044cc03-2f0f-4e01-9bd5-815435f253c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_597a5330-3287-4fbc-9faf-febc81fb61bb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityAbstract_b044cc03-2f0f-4e01-9bd5-815435f253c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_95ddbab2-d5ce-4568-a84d-46f45ce8993e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_b044cc03-2f0f-4e01-9bd5-815435f253c7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_95ddbab2-d5ce-4568-a84d-46f45ce8993e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e1ff7df2-7be5-4748-9645-818f3cca1f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_b044cc03-2f0f-4e01-9bd5-815435f253c7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e1ff7df2-7be5-4748-9645-818f3cca1f24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8e43fdfc-1338-4fae-b069-cd425282ed5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_b044cc03-2f0f-4e01-9bd5-815435f253c7" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8e43fdfc-1338-4fae-b069-cd425282ed5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c69de8c1-1f10-4b82-a7f3-606af71f37ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_597a5330-3287-4fbc-9faf-febc81fb61bb" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c69de8c1-1f10-4b82-a7f3-606af71f37ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_63f5e698-4da3-4a49-89b2-735bbb787c95" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c69de8c1-1f10-4b82-a7f3-606af71f37ad" xlink:to="loc_srt_CounterpartyNameAxis_63f5e698-4da3-4a49-89b2-735bbb787c95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_63f5e698-4da3-4a49-89b2-735bbb787c95_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_63f5e698-4da3-4a49-89b2-735bbb787c95" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_63f5e698-4da3-4a49-89b2-735bbb787c95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d551d26f-4759-487a-8d04-95913c2782f0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_63f5e698-4da3-4a49-89b2-735bbb787c95" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d551d26f-4759-487a-8d04-95913c2782f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_MitsubishiTanabePharmaCorporationMember_698b700a-d38a-45eb-a481-c57da200b963" xlink:href="akba-20210930.xsd#akba_MitsubishiTanabePharmaCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d551d26f-4759-487a-8d04-95913c2782f0" xlink:to="loc_akba_MitsubishiTanabePharmaCorporationMember_698b700a-d38a-45eb-a481-c57da200b963" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OtsukaPharmaceuticalCompanyLimitedMember_0c725171-599e-4fa9-8c6d-6ba1e9fe80d8" xlink:href="akba-20210930.xsd#akba_OtsukaPharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d551d26f-4759-487a-8d04-95913c2782f0" xlink:to="loc_akba_OtsukaPharmaceuticalCompanyLimitedMember_0c725171-599e-4fa9-8c6d-6ba1e9fe80d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ViforPharmaMember_71b671f2-c67a-4297-ba8d-29272363f532" xlink:href="akba-20210930.xsd#akba_ViforPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d551d26f-4759-487a-8d04-95913c2782f0" xlink:to="loc_akba_ViforPharmaMember_71b671f2-c67a-4297-ba8d-29272363f532" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a6f9a987-f0bc-4da0-a897-7abf2baeaa95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c69de8c1-1f10-4b82-a7f3-606af71f37ad" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a6f9a987-f0bc-4da0-a897-7abf2baeaa95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a6f9a987-f0bc-4da0-a897-7abf2baeaa95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a6f9a987-f0bc-4da0-a897-7abf2baeaa95" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a6f9a987-f0bc-4da0-a897-7abf2baeaa95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4ce6c923-5f2d-48c6-bf88-2ecd99391cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a6f9a987-f0bc-4da0-a897-7abf2baeaa95" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4ce6c923-5f2d-48c6-bf88-2ecd99391cb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndCommercializeCollaborationAgreementMember_c825aa21-9e9b-41b3-9a7a-4d4fb04c9fa1" xlink:href="akba-20210930.xsd#akba_DevelopmentAndCommercializeCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4ce6c923-5f2d-48c6-bf88-2ecd99391cb2" xlink:to="loc_akba_DevelopmentAndCommercializeCollaborationAgreementMember_c825aa21-9e9b-41b3-9a7a-4d4fb04c9fa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember_a39b3d98-b73a-4e0f-92f0-72406bcc093e" xlink:href="akba-20210930.xsd#akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4ce6c923-5f2d-48c6-bf88-2ecd99391cb2" xlink:to="loc_akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember_a39b3d98-b73a-4e0f-92f0-72406bcc093e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember_f87f6bed-7ffd-48ea-87a6-e127239915a8" xlink:href="akba-20210930.xsd#akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4ce6c923-5f2d-48c6-bf88-2ecd99391cb2" xlink:to="loc_akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember_f87f6bed-7ffd-48ea-87a6-e127239915a8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails" xlink:type="extended" id="i870f91815f3445bd8fef2db05901455c_LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e52ffe0e-4037-4ff8-bea1-f771417b8476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward_31e4324e-db45-4a33-ac6b-7452eb583aa7" xlink:href="akba-20210930.xsd#akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e52ffe0e-4037-4ff8-bea1-f771417b8476" xlink:to="loc_akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward_31e4324e-db45-4a33-ac6b-7452eb583aa7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_20dede1e-b29e-46fa-88d6-4b9f207c10a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward_31e4324e-db45-4a33-ac6b-7452eb583aa7" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_20dede1e-b29e-46fa-88d6-4b9f207c10a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractWithCustomerAssetAdditions_90620541-0948-470e-9a28-72531c94ad04" xlink:href="akba-20210930.xsd#akba_ContractWithCustomerAssetAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward_31e4324e-db45-4a33-ac6b-7452eb583aa7" xlink:to="loc_akba_ContractWithCustomerAssetAdditions_90620541-0948-470e-9a28-72531c94ad04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractWithCustomerAssetDeductions_9cfcbb0f-fe2e-4868-91f1-93ba30792a0c" xlink:href="akba-20210930.xsd#akba_ContractWithCustomerAssetDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward_31e4324e-db45-4a33-ac6b-7452eb583aa7" xlink:to="loc_akba_ContractWithCustomerAssetDeductions_9cfcbb0f-fe2e-4868-91f1-93ba30792a0c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_0a367f95-8618-4207-b039-5efcd1b8dc22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractWithCustomerLiabilityRollForward_c7ee6123-0ea0-4755-b53a-813e309f24a5" xlink:href="akba-20210930.xsd#akba_ContractWithCustomerLiabilityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e52ffe0e-4037-4ff8-bea1-f771417b8476" xlink:to="loc_akba_ContractWithCustomerLiabilityRollForward_c7ee6123-0ea0-4755-b53a-813e309f24a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_cddffc4b-5c57-458c-ab6d-2b6dbca0fbde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_ContractWithCustomerLiabilityRollForward_c7ee6123-0ea0-4755-b53a-813e309f24a5" xlink:to="loc_us-gaap_ContractWithCustomerLiability_cddffc4b-5c57-458c-ab6d-2b6dbca0fbde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractWithCustomerLiabilityAdditions_eca9f22d-1d59-447f-b140-e8103bfac127" xlink:href="akba-20210930.xsd#akba_ContractWithCustomerLiabilityAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_ContractWithCustomerLiabilityRollForward_c7ee6123-0ea0-4755-b53a-813e309f24a5" xlink:to="loc_akba_ContractWithCustomerLiabilityAdditions_eca9f22d-1d59-447f-b140-e8103bfac127" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractWithCustomerLiabilityDeductions_fba21e48-04d2-451a-80c4-ba81081809d4" xlink:href="akba-20210930.xsd#akba_ContractWithCustomerLiabilityDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_ContractWithCustomerLiabilityRollForward_c7ee6123-0ea0-4755-b53a-813e309f24a5" xlink:to="loc_akba_ContractWithCustomerLiabilityDeductions_fba21e48-04d2-451a-80c4-ba81081809d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_78288fd1-c10f-4e60-9c4d-740899f135ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_eed1492a-7905-4ffa-87e6-fcc4975bfeea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e52ffe0e-4037-4ff8-bea1-f771417b8476" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_eed1492a-7905-4ffa-87e6-fcc4975bfeea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_212c8e44-1ca4-4466-803f-6e8a46b6ef05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_eed1492a-7905-4ffa-87e6-fcc4975bfeea" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_212c8e44-1ca4-4466-803f-6e8a46b6ef05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_212c8e44-1ca4-4466-803f-6e8a46b6ef05_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_212c8e44-1ca4-4466-803f-6e8a46b6ef05" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_212c8e44-1ca4-4466-803f-6e8a46b6ef05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6d80f880-5ef3-4dbb-8918-6edb8ea4924d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_212c8e44-1ca4-4466-803f-6e8a46b6ef05" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6d80f880-5ef3-4dbb-8918-6edb8ea4924d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_bb208495-2456-4b47-8886-b4dbd3a21837" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6d80f880-5ef3-4dbb-8918-6edb8ea4924d" xlink:to="loc_us-gaap_AccountsReceivableMember_bb208495-2456-4b47-8886-b4dbd3a21837" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_11f04305-35e9-4b61-990c-4e0f075bcd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6d80f880-5ef3-4dbb-8918-6edb8ea4924d" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_11f04305-35e9-4b61-990c-4e0f075bcd3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DeferredRevenueMember_9725153d-439c-4bb0-9d98-31484574c990" xlink:href="akba-20210930.xsd#akba_DeferredRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6d80f880-5ef3-4dbb-8918-6edb8ea4924d" xlink:to="loc_akba_DeferredRevenueMember_9725153d-439c-4bb0-9d98-31484574c990" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableMember_d142032a-bdf4-460f-b4ce-e6c268245b39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6d80f880-5ef3-4dbb-8918-6edb8ea4924d" xlink:to="loc_us-gaap_AccountsPayableMember_d142032a-bdf4-460f-b4ce-e6c268245b39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AccruedExpensesAndOtherCurrentLiabilitiesMember_7dcad049-ee23-4a76-bd24-95003d26b4e8" xlink:href="akba-20210930.xsd#akba_AccruedExpensesAndOtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6d80f880-5ef3-4dbb-8918-6edb8ea4924d" xlink:to="loc_akba_AccruedExpensesAndOtherCurrentLiabilitiesMember_7dcad049-ee23-4a76-bd24-95003d26b4e8" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails"/>
  <link:definitionLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails" xlink:type="extended" id="ifd78fb5ae33e4daaa2bbbb3e1281738b_LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_NumberOfPerformanceObligations_481f48ef-f63e-42f4-bb44-9da882f1061d" xlink:href="akba-20210930.xsd#akba_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:to="loc_akba_NumberOfPerformanceObligations_481f48ef-f63e-42f4-bb44-9da882f1061d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_UpfrontCashPaymentReceived_1427a609-7af9-4fa2-8567-596ba3c80493" xlink:href="akba-20210930.xsd#akba_UpfrontCashPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:to="loc_akba_UpfrontCashPaymentReceived_1427a609-7af9-4fa2-8567-596ba3c80493" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CostOfResearchServices_d48a26ba-581a-4b80-9471-74d4e3cbe0ab" xlink:href="akba-20210930.xsd#akba_CostOfResearchServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:to="loc_akba_CostOfResearchServices_d48a26ba-581a-4b80-9471-74d4e3cbe0ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_MilestonePaymentReceived_83472824-5a29-4119-a18c-c29f9a9b9df4" xlink:href="akba-20210930.xsd#akba_MilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:to="loc_akba_MilestonePaymentReceived_83472824-5a29-4119-a18c-c29f9a9b9df4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_84175e09-4710-4a4a-b890-bff555335698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_84175e09-4710-4a4a-b890-bff555335698" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_1f5c07ab-21c4-4f61-ac5c-1eca3108a9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:to="loc_us-gaap_ContractWithCustomerLiability_1f5c07ab-21c4-4f61-ac5c-1eca3108a9fa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5839ab87-5558-435c-828e-ebf761103760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5839ab87-5558-435c-828e-ebf761103760" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e747dd19-ac30-4f17-aaa1-37c58f8eab92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e747dd19-ac30-4f17-aaa1-37c58f8eab92" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_445a6b26-1e90-4d29-bfde-a51262406ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_445a6b26-1e90-4d29-bfde-a51262406ca3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b05cdd23-f0ab-4b3f-9735-b0681d0eebaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b05cdd23-f0ab-4b3f-9735-b0681d0eebaa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables_8df29572-6eb2-4a09-8f60-91b6aff7b5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BilledContractReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:to="loc_us-gaap_BilledContractReceivables_8df29572-6eb2-4a09-8f60-91b6aff7b5ed" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_769bf9bc-9b4c-492d-be9f-39ffdbbd6dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_769bf9bc-9b4c-492d-be9f-39ffdbbd6dd8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_32b649be-6727-47a6-871f-3925c083a4bc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_769bf9bc-9b4c-492d-be9f-39ffdbbd6dd8" xlink:to="loc_srt_CounterpartyNameAxis_32b649be-6727-47a6-871f-3925c083a4bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32b649be-6727-47a6-871f-3925c083a4bc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_32b649be-6727-47a6-871f-3925c083a4bc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32b649be-6727-47a6-871f-3925c083a4bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5843784-0e6c-4cbb-9686-d5b5626eb491" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_32b649be-6727-47a6-871f-3925c083a4bc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5843784-0e6c-4cbb-9686-d5b5626eb491" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_MitsubishiTanabePharmaCorporationMember_39d7c079-4cb1-4211-ae4a-603f9a2c8d5c" xlink:href="akba-20210930.xsd#akba_MitsubishiTanabePharmaCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5843784-0e6c-4cbb-9686-d5b5626eb491" xlink:to="loc_akba_MitsubishiTanabePharmaCorporationMember_39d7c079-4cb1-4211-ae4a-603f9a2c8d5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_22495fc4-c8b1-49c0-b904-115f64d8d46e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_769bf9bc-9b4c-492d-be9f-39ffdbbd6dd8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_22495fc4-c8b1-49c0-b904-115f64d8d46e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22495fc4-c8b1-49c0-b904-115f64d8d46e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_22495fc4-c8b1-49c0-b904-115f64d8d46e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22495fc4-c8b1-49c0-b904-115f64d8d46e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0ef77f29-ad49-4870-b222-84196c7945d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_22495fc4-c8b1-49c0-b904-115f64d8d46e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0ef77f29-ad49-4870-b222-84196c7945d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndCommercializeCollaborationAgreementMember_14d94e23-d130-4903-a12b-442f81f88fdf" xlink:href="akba-20210930.xsd#akba_DevelopmentAndCommercializeCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0ef77f29-ad49-4870-b222-84196c7945d1" xlink:to="loc_akba_DevelopmentAndCommercializeCollaborationAgreementMember_14d94e23-d130-4903-a12b-442f81f88fdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember_51db736c-ed30-4632-b263-f4448cbea158" xlink:href="akba-20210930.xsd#akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0ef77f29-ad49-4870-b222-84196c7945d1" xlink:to="loc_akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember_51db736c-ed30-4632-b263-f4448cbea158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember_ea18b7fb-1ad0-4773-a761-fb66c35cc97d" xlink:href="akba-20210930.xsd#akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0ef77f29-ad49-4870-b222-84196c7945d1" xlink:to="loc_akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember_ea18b7fb-1ad0-4773-a761-fb66c35cc97d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_MitsubishiTanabePharmaCorporationSupplyAgreementMember_8d015bc6-42be-44ea-888d-67cc109d4f44" xlink:href="akba-20210930.xsd#akba_MitsubishiTanabePharmaCorporationSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0ef77f29-ad49-4870-b222-84196c7945d1" xlink:to="loc_akba_MitsubishiTanabePharmaCorporationSupplyAgreementMember_8d015bc6-42be-44ea-888d-67cc109d4f44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_361c734b-1efa-4501-9aeb-0c177795c119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_769bf9bc-9b4c-492d-be9f-39ffdbbd6dd8" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_361c734b-1efa-4501-9aeb-0c177795c119" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_361c734b-1efa-4501-9aeb-0c177795c119_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_361c734b-1efa-4501-9aeb-0c177795c119" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_361c734b-1efa-4501-9aeb-0c177795c119_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_9e0aee38-a9cb-4b8c-b6ac-1da17d45d3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_361c734b-1efa-4501-9aeb-0c177795c119" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_9e0aee38-a9cb-4b8c-b6ac-1da17d45d3ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_RegulatoryMilestonePaymentsMember_2b00de2b-90fd-4fea-a0ff-57d7d191128b" xlink:href="akba-20210930.xsd#akba_RegulatoryMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_9e0aee38-a9cb-4b8c-b6ac-1da17d45d3ae" xlink:to="loc_akba_RegulatoryMilestonePaymentsMember_2b00de2b-90fd-4fea-a0ff-57d7d191128b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b23203b6-5003-4c46-929d-7d6118952874" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_769bf9bc-9b4c-492d-be9f-39ffdbbd6dd8" xlink:to="loc_srt_ProductOrServiceAxis_b23203b6-5003-4c46-929d-7d6118952874" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b23203b6-5003-4c46-929d-7d6118952874_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b23203b6-5003-4c46-929d-7d6118952874" xlink:to="loc_srt_ProductsAndServicesDomain_b23203b6-5003-4c46-929d-7d6118952874_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dad31844-9895-4570-8c78-a4067b256aad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b23203b6-5003-4c46-929d-7d6118952874" xlink:to="loc_srt_ProductsAndServicesDomain_dad31844-9895-4570-8c78-a4067b256aad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseCollaborationAndOtherRevenueMember_4351cf99-8942-40e9-8141-ae8dbf314e93" xlink:href="akba-20210930.xsd#akba_LicenseCollaborationAndOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dad31844-9895-4570-8c78-a4067b256aad" xlink:to="loc_akba_LicenseCollaborationAndOtherRevenueMember_4351cf99-8942-40e9-8141-ae8dbf314e93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseCollaborationAndOtherRevenueRoyaltiesMember_1d4dbd5b-2372-4865-b93c-4a530fded5da" xlink:href="akba-20210930.xsd#akba_LicenseCollaborationAndOtherRevenueRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_LicenseCollaborationAndOtherRevenueMember_4351cf99-8942-40e9-8141-ae8dbf314e93" xlink:to="loc_akba_LicenseCollaborationAndOtherRevenueRoyaltiesMember_1d4dbd5b-2372-4865-b93c-4a530fded5da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4167619a-a1f8-4db6-9185-a09e8b43982f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_769bf9bc-9b4c-492d-be9f-39ffdbbd6dd8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4167619a-a1f8-4db6-9185-a09e8b43982f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4167619a-a1f8-4db6-9185-a09e8b43982f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4167619a-a1f8-4db6-9185-a09e8b43982f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4167619a-a1f8-4db6-9185-a09e8b43982f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9286aed7-fc6c-426b-9017-b8c7177284c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4167619a-a1f8-4db6-9185-a09e8b43982f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9286aed7-fc6c-426b-9017-b8c7177284c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_2599bc6e-621c-45dd-8af4-0e25d57acee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9286aed7-fc6c-426b-9017-b8c7177284c4" xlink:to="loc_us-gaap_AccountsReceivableMember_2599bc6e-621c-45dd-8af4-0e25d57acee6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_92673123-26ec-4d3e-88d5-c465d2cd334c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9286aed7-fc6c-426b-9017-b8c7177284c4" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_92673123-26ec-4d3e-88d5-c465d2cd334c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_13ddd951-2b7d-4dac-8250-e3951096660e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9286aed7-fc6c-426b-9017-b8c7177284c4" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_13ddd951-2b7d-4dac-8250-e3951096660e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractWithCustomerLiabilityMember_b292c2b4-2a71-4c63-bf61-f2c8722ac13b" xlink:href="akba-20210930.xsd#akba_ContractWithCustomerLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9286aed7-fc6c-426b-9017-b8c7177284c4" xlink:to="loc_akba_ContractWithCustomerLiabilityMember_b292c2b4-2a71-4c63-bf61-f2c8722ac13b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"/>
  <link:definitionLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails" xlink:type="extended" id="i24ac6e1255c340c6b00fbf5c544b2a70_LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_NumberOfPerformanceObligations_6290a7ff-4480-435b-a654-7445a99c96a1" xlink:href="akba-20210930.xsd#akba_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_NumberOfPerformanceObligations_6290a7ff-4480-435b-a654-7445a99c96a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_MilestonePaymentReceived_5911fe41-2b45-4d96-ab7f-5fb4b2d34aa4" xlink:href="akba-20210930.xsd#akba_MilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_MilestonePaymentReceived_5911fe41-2b45-4d96-ab7f-5fb4b2d34aa4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount_cf0e2188-68a2-4883-85dd-56741bfa51dc" xlink:href="akba-20210930.xsd#akba_CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount_cf0e2188-68a2-4883-85dd-56741bfa51dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable_306a5e48-af1c-4f67-abbd-142c4136b112" xlink:href="akba-20210930.xsd#akba_ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable_306a5e48-af1c-4f67-abbd-142c4136b112" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PercentageOfRemainingCreditableAmountAppliedToFuturePayments_67e206d4-d810-4564-8efd-8b560c19ee23" xlink:href="akba-20210930.xsd#akba_PercentageOfRemainingCreditableAmountAppliedToFuturePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_PercentageOfRemainingCreditableAmountAppliedToFuturePayments_67e206d4-d810-4564-8efd-8b560c19ee23" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsAmount_ff91bcb6-5b01-4f10-ae61-ae1bc8bf4185" xlink:href="akba-20210930.xsd#akba_CollaborativeArrangementsAdditionalCostSharingPaymentsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsAmount_ff91bcb6-5b01-4f10-ae61-ae1bc8bf4185" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeAndLicenseArrangementTransactionPrice_8ecdea8c-cb97-4af6-8a7f-0d756e1e023f" xlink:href="akba-20210930.xsd#akba_CollaborativeAndLicenseArrangementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_CollaborativeAndLicenseArrangementTransactionPrice_8ecdea8c-cb97-4af6-8a7f-0d756e1e023f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_UpfrontCashPaymentReceived_0bff8124-b4d6-4a91-9c38-1b72915b663d" xlink:href="akba-20210930.xsd#akba_UpfrontCashPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_UpfrontCashPaymentReceived_0bff8124-b4d6-4a91-9c38-1b72915b663d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred_c079e195-5181-4374-99b0-1aebc0e441bf" xlink:href="akba-20210930.xsd#akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred_c079e195-5181-4374-99b0-1aebc0e441bf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeArrangementsCostSharingPayments_d050fa54-751a-43c8-be23-439dbe24ff2c" xlink:href="akba-20210930.xsd#akba_CollaborativeArrangementsCostSharingPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_CollaborativeArrangementsCostSharingPayments_d050fa54-751a-43c8-be23-439dbe24ff2c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount_69374189-5960-402e-b7a2-17e7a4818054" xlink:href="akba-20210930.xsd#akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount_69374189-5960-402e-b7a2-17e7a4818054" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_319277f9-5406-4a17-9a39-9163766fe6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_319277f9-5406-4a17-9a39-9163766fe6e0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_13f893ba-cbf7-44b3-a118-0f129236f3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_13f893ba-cbf7-44b3-a118-0f129236f3c5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fc0e418f-dadc-4235-b2ab-283754a0cefe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fc0e418f-dadc-4235-b2ab-283754a0cefe" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3b037d8d-a01b-4018-978e-9fb48520aadf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3b037d8d-a01b-4018-978e-9fb48520aadf" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_65dac2bf-5bef-4703-8617-4156f2cc0ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_65dac2bf-5bef-4703-8617-4156f2cc0ac6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CostShareCostsIncurredForLicenseAgreement_7b142246-a424-480a-af2a-5322ba3662f3" xlink:href="akba-20210930.xsd#akba_CostShareCostsIncurredForLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_CostShareCostsIncurredForLicenseAgreement_7b142246-a424-480a-af2a-5322ba3662f3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred_de0a7ce7-4715-4672-b6e9-4228fb3df204" xlink:href="akba-20210930.xsd#akba_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred_de0a7ce7-4715-4672-b6e9-4228fb3df204" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CostShareCostsIncurredByPartnerForLicenseAgreement_28bc96bf-1ff5-4bef-bcc8-3d987303799a" xlink:href="akba-20210930.xsd#akba_CostShareCostsIncurredByPartnerForLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_CostShareCostsIncurredByPartnerForLicenseAgreement_28bc96bf-1ff5-4bef-bcc8-3d987303799a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PaymentForLicenseAgreementReimbursementOfCostsIncurred_7731e768-34e0-45b1-aa95-657c375f4d5a" xlink:href="akba-20210930.xsd#akba_PaymentForLicenseAgreementReimbursementOfCostsIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_PaymentForLicenseAgreementReimbursementOfCostsIncurred_7731e768-34e0-45b1-aa95-657c375f4d5a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_19de97e9-643c-4e3b-9e17-6b897dfd276b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_19de97e9-643c-4e3b-9e17-6b897dfd276b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_044c8cd9-4b1e-4577-89a3-db58f3c5234e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_19de97e9-643c-4e3b-9e17-6b897dfd276b" xlink:to="loc_srt_CounterpartyNameAxis_044c8cd9-4b1e-4577-89a3-db58f3c5234e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_044c8cd9-4b1e-4577-89a3-db58f3c5234e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_044c8cd9-4b1e-4577-89a3-db58f3c5234e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_044c8cd9-4b1e-4577-89a3-db58f3c5234e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7c02d90-486e-4582-8030-787c81101813" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_044c8cd9-4b1e-4577-89a3-db58f3c5234e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7c02d90-486e-4582-8030-787c81101813" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OtsukaPharmaceuticalCompanyLimitedMember_d4dfba7c-c45f-42bd-bdd7-8ab35bf2328a" xlink:href="akba-20210930.xsd#akba_OtsukaPharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7c02d90-486e-4582-8030-787c81101813" xlink:to="loc_akba_OtsukaPharmaceuticalCompanyLimitedMember_d4dfba7c-c45f-42bd-bdd7-8ab35bf2328a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1d66f6e3-c871-4aad-8d9a-a06b91e62f30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_19de97e9-643c-4e3b-9e17-6b897dfd276b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1d66f6e3-c871-4aad-8d9a-a06b91e62f30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d66f6e3-c871-4aad-8d9a-a06b91e62f30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1d66f6e3-c871-4aad-8d9a-a06b91e62f30" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d66f6e3-c871-4aad-8d9a-a06b91e62f30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1ba0048-4f26-47af-af9c-3da5eb5c3c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1d66f6e3-c871-4aad-8d9a-a06b91e62f30" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1ba0048-4f26-47af-af9c-3da5eb5c3c6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember_3fd7454d-471a-4692-bdb2-7b228fb9fb45" xlink:href="akba-20210930.xsd#akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1ba0048-4f26-47af-af9c-3da5eb5c3c6b" xlink:to="loc_akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember_3fd7454d-471a-4692-bdb2-7b228fb9fb45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_cb6131c4-075f-40cd-976f-39bb471e69d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_19de97e9-643c-4e3b-9e17-6b897dfd276b" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_cb6131c4-075f-40cd-976f-39bb471e69d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_cb6131c4-075f-40cd-976f-39bb471e69d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_cb6131c4-075f-40cd-976f-39bb471e69d9" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_cb6131c4-075f-40cd-976f-39bb471e69d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_6e5b4d51-e28c-459b-a2e9-e3ac9b0843bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_cb6131c4-075f-40cd-976f-39bb471e69d9" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_6e5b4d51-e28c-459b-a2e9-e3ac9b0843bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_UpFrontNonRefundableAndNonCreditableMember_30a6e9cf-9615-45ff-a2bc-1ca7a2d0d2e1" xlink:href="akba-20210930.xsd#akba_UpFrontNonRefundableAndNonCreditableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_6e5b4d51-e28c-459b-a2e9-e3ac9b0843bd" xlink:to="loc_akba_UpFrontNonRefundableAndNonCreditableMember_30a6e9cf-9615-45ff-a2bc-1ca7a2d0d2e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_RegulatoryMilestonePaymentsMember_563e7aa6-4ca3-44f4-b7f4-79c306077155" xlink:href="akba-20210930.xsd#akba_RegulatoryMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_6e5b4d51-e28c-459b-a2e9-e3ac9b0843bd" xlink:to="loc_akba_RegulatoryMilestonePaymentsMember_563e7aa6-4ca3-44f4-b7f4-79c306077155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndRegulatoryMilestonesMember_235c4b26-dbb3-4354-bf32-26eba5366c8d" xlink:href="akba-20210930.xsd#akba_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_6e5b4d51-e28c-459b-a2e9-e3ac9b0843bd" xlink:to="loc_akba_DevelopmentAndRegulatoryMilestonesMember_235c4b26-dbb3-4354-bf32-26eba5366c8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_12116b9f-8d94-4b18-931c-60a62527b412" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_19de97e9-643c-4e3b-9e17-6b897dfd276b" xlink:to="loc_srt_ProductOrServiceAxis_12116b9f-8d94-4b18-931c-60a62527b412" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_12116b9f-8d94-4b18-931c-60a62527b412_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_12116b9f-8d94-4b18-931c-60a62527b412" xlink:to="loc_srt_ProductsAndServicesDomain_12116b9f-8d94-4b18-931c-60a62527b412_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d6523aa4-f190-4836-8074-3ec541e631ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_12116b9f-8d94-4b18-931c-60a62527b412" xlink:to="loc_srt_ProductsAndServicesDomain_d6523aa4-f190-4836-8074-3ec541e631ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseCollaborationAndOtherRevenueMember_aa4f6075-f643-4a00-a91a-8df45f0deb76" xlink:href="akba-20210930.xsd#akba_LicenseCollaborationAndOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d6523aa4-f190-4836-8074-3ec541e631ed" xlink:to="loc_akba_LicenseCollaborationAndOtherRevenueMember_aa4f6075-f643-4a00-a91a-8df45f0deb76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_HIFProductMember_e230d38a-2a27-4b0b-be0a-30c51b48246b" xlink:href="akba-20210930.xsd#akba_HIFProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d6523aa4-f190-4836-8074-3ec541e631ed" xlink:to="loc_akba_HIFProductMember_e230d38a-2a27-4b0b-be0a-30c51b48246b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicensedProductsMember_9c889e1b-f41d-402f-9a0c-ca51f8a79927" xlink:href="akba-20210930.xsd#akba_LicensedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d6523aa4-f190-4836-8074-3ec541e631ed" xlink:to="loc_akba_LicensedProductsMember_9c889e1b-f41d-402f-9a0c-ca51f8a79927" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f5460be7-1332-45d8-89ee-8d3ced174fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_19de97e9-643c-4e3b-9e17-6b897dfd276b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f5460be7-1332-45d8-89ee-8d3ced174fcc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f5460be7-1332-45d8-89ee-8d3ced174fcc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f5460be7-1332-45d8-89ee-8d3ced174fcc" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f5460be7-1332-45d8-89ee-8d3ced174fcc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3465d853-d786-488a-bbc8-d0653e89fe95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f5460be7-1332-45d8-89ee-8d3ced174fcc" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3465d853-d786-488a-bbc8-d0653e89fe95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_990f13fd-33ab-40f0-acc6-6a96f3b7eb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3465d853-d786-488a-bbc8-d0653e89fe95" xlink:to="loc_us-gaap_AccountsReceivableMember_990f13fd-33ab-40f0-acc6-6a96f3b7eb4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_13c98772-016c-4d37-8a6d-a383a6303430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3465d853-d786-488a-bbc8-d0653e89fe95" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_13c98772-016c-4d37-8a6d-a383a6303430" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableMember_bb4888a8-0432-429e-a696-782d9bf6ed77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3465d853-d786-488a-bbc8-d0653e89fe95" xlink:to="loc_us-gaap_AccountsPayableMember_bb4888a8-0432-429e-a696-782d9bf6ed77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ab21e24f-f1d9-4d5a-be38-e2ddb71c5d8e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_19de97e9-643c-4e3b-9e17-6b897dfd276b" xlink:to="loc_srt_RangeAxis_ab21e24f-f1d9-4d5a-be38-e2ddb71c5d8e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ab21e24f-f1d9-4d5a-be38-e2ddb71c5d8e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ab21e24f-f1d9-4d5a-be38-e2ddb71c5d8e" xlink:to="loc_srt_RangeMember_ab21e24f-f1d9-4d5a-be38-e2ddb71c5d8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a1e3c79e-5651-4362-bd05-623e7d454837" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ab21e24f-f1d9-4d5a-be38-e2ddb71c5d8e" xlink:to="loc_srt_RangeMember_a1e3c79e-5651-4362-bd05-623e7d454837" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c7f34ffb-4f11-4058-9b73-04dd66789f67" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a1e3c79e-5651-4362-bd05-623e7d454837" xlink:to="loc_srt_MinimumMember_c7f34ffb-4f11-4058-9b73-04dd66789f67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1897a150-7dfb-4e19-ac24-636067f5a1b1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a1e3c79e-5651-4362-bd05-623e7d454837" xlink:to="loc_srt_MaximumMember_1897a150-7dfb-4e19-ac24-636067f5a1b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a6c869c5-abf4-4ad9-9a16-e34ddc49c5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_19de97e9-643c-4e3b-9e17-6b897dfd276b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a6c869c5-abf4-4ad9-9a16-e34ddc49c5dc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a6c869c5-abf4-4ad9-9a16-e34ddc49c5dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a6c869c5-abf4-4ad9-9a16-e34ddc49c5dc" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a6c869c5-abf4-4ad9-9a16-e34ddc49c5dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1655105c-ad5c-449d-aef1-1931ec159b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a6c869c5-abf4-4ad9-9a16-e34ddc49c5dc" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1655105c-ad5c-449d-aef1-1931ec159b62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_GlobalDevelopmentPlanMember_32169fda-a4e9-4c9f-bfb6-1d87c6b7a83b" xlink:href="akba-20210930.xsd#akba_GlobalDevelopmentPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1655105c-ad5c-449d-aef1-1931ec159b62" xlink:to="loc_akba_GlobalDevelopmentPlanMember_32169fda-a4e9-4c9f-bfb6-1d87c6b7a83b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"/>
  <link:definitionLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails" xlink:type="extended" id="i11a4b23203ca45c389a38306c4139ae4_LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_NumberOfPerformanceObligations_2b58d00f-d1f2-497f-ba23-0cf64b9c412d" xlink:href="akba-20210930.xsd#akba_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:to="loc_akba_NumberOfPerformanceObligations_2b58d00f-d1f2-497f-ba23-0cf64b9c412d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeAndLicenseArrangementTransactionPrice_e9e27b7e-151f-4830-a707-999909e42f70" xlink:href="akba-20210930.xsd#akba_CollaborativeAndLicenseArrangementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:to="loc_akba_CollaborativeAndLicenseArrangementTransactionPrice_e9e27b7e-151f-4830-a707-999909e42f70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_UpfrontCashPaymentReceived_18fdb5a1-ac18-4bf6-b449-4ed2afafa6ad" xlink:href="akba-20210930.xsd#akba_UpfrontCashPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:to="loc_akba_UpfrontCashPaymentReceived_18fdb5a1-ac18-4bf6-b449-4ed2afafa6ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred_fa7302b9-0ff8-4bde-beea-cc664028b465" xlink:href="akba-20210930.xsd#akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:to="loc_akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred_fa7302b9-0ff8-4bde-beea-cc664028b465" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_EstimateSubsequentCostFundingUnderPlan_144dacf3-d726-47d5-9e48-a724027ffc64" xlink:href="akba-20210930.xsd#akba_EstimateSubsequentCostFundingUnderPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:to="loc_akba_EstimateSubsequentCostFundingUnderPlan_144dacf3-d726-47d5-9e48-a724027ffc64" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount_308c9593-b7c0-41c1-ae7a-51d76e860111" xlink:href="akba-20210930.xsd#akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:to="loc_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount_308c9593-b7c0-41c1-ae7a-51d76e860111" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod_662aa5e8-80b3-4708-a0df-9af4fe73aca6" xlink:href="akba-20210930.xsd#akba_RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:to="loc_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod_662aa5e8-80b3-4708-a0df-9af4fe73aca6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0aa36882-c8f8-4627-8b61-7e1dd01137d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0aa36882-c8f8-4627-8b61-7e1dd01137d8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_0b3c5565-c747-4517-882d-9bc2b27738c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:to="loc_us-gaap_ContractWithCustomerLiability_0b3c5565-c747-4517-882d-9bc2b27738c6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_81ae279a-0c2c-409c-ade0-9745c3160f68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_81ae279a-0c2c-409c-ade0-9745c3160f68" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bf7c051b-67db-4efc-89fb-ca6aaa2c4f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bf7c051b-67db-4efc-89fb-ca6aaa2c4f3b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_0c417812-2d20-44c7-9e62-28d371f2c611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_0c417812-2d20-44c7-9e62-28d371f2c611" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c7f68bd8-94d3-49ff-80c9-983bb91557c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c7f68bd8-94d3-49ff-80c9-983bb91557c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fe739ff1-8a1e-4158-8d86-b8592ce3a014" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c7f68bd8-94d3-49ff-80c9-983bb91557c9" xlink:to="loc_srt_CounterpartyNameAxis_fe739ff1-8a1e-4158-8d86-b8592ce3a014" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe739ff1-8a1e-4158-8d86-b8592ce3a014_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_fe739ff1-8a1e-4158-8d86-b8592ce3a014" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe739ff1-8a1e-4158-8d86-b8592ce3a014_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5ff0fa9d-dd74-4a49-99dd-0e9787697186" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_fe739ff1-8a1e-4158-8d86-b8592ce3a014" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5ff0fa9d-dd74-4a49-99dd-0e9787697186" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OtsukaPharmaceuticalCompanyLimitedMember_9165206a-acd8-40b3-97a9-ccec0a039110" xlink:href="akba-20210930.xsd#akba_OtsukaPharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5ff0fa9d-dd74-4a49-99dd-0e9787697186" xlink:to="loc_akba_OtsukaPharmaceuticalCompanyLimitedMember_9165206a-acd8-40b3-97a9-ccec0a039110" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_c84d4e7e-368d-4e50-a014-fba110b8bbee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c7f68bd8-94d3-49ff-80c9-983bb91557c9" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_c84d4e7e-368d-4e50-a014-fba110b8bbee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_c84d4e7e-368d-4e50-a014-fba110b8bbee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_c84d4e7e-368d-4e50-a014-fba110b8bbee" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_c84d4e7e-368d-4e50-a014-fba110b8bbee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_fe19d39a-6337-420a-ab41-794e20887902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_c84d4e7e-368d-4e50-a014-fba110b8bbee" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_fe19d39a-6337-420a-ab41-794e20887902" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_UpFrontNonRefundableAndNonCreditableMember_c62acaf9-c81c-4318-96e1-fb2c9155feaf" xlink:href="akba-20210930.xsd#akba_UpFrontNonRefundableAndNonCreditableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_fe19d39a-6337-420a-ab41-794e20887902" xlink:to="loc_akba_UpFrontNonRefundableAndNonCreditableMember_c62acaf9-c81c-4318-96e1-fb2c9155feaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4f18fdc0-25da-474b-9906-9a92f886ef50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c7f68bd8-94d3-49ff-80c9-983bb91557c9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4f18fdc0-25da-474b-9906-9a92f886ef50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f18fdc0-25da-474b-9906-9a92f886ef50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4f18fdc0-25da-474b-9906-9a92f886ef50" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f18fdc0-25da-474b-9906-9a92f886ef50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2912b6ae-834b-4370-9e2c-6e09bd3e4687" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4f18fdc0-25da-474b-9906-9a92f886ef50" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2912b6ae-834b-4370-9e2c-6e09bd3e4687" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember_9802f9dc-e2ff-435b-ba96-69c2a6ee5c71" xlink:href="akba-20210930.xsd#akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2912b6ae-834b-4370-9e2c-6e09bd3e4687" xlink:to="loc_akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember_9802f9dc-e2ff-435b-ba96-69c2a6ee5c71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1e0e91cd-592c-4249-b68e-be10d6ee116f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c7f68bd8-94d3-49ff-80c9-983bb91557c9" xlink:to="loc_srt_ProductOrServiceAxis_1e0e91cd-592c-4249-b68e-be10d6ee116f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1e0e91cd-592c-4249-b68e-be10d6ee116f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1e0e91cd-592c-4249-b68e-be10d6ee116f" xlink:to="loc_srt_ProductsAndServicesDomain_1e0e91cd-592c-4249-b68e-be10d6ee116f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_def7c20f-27a1-46f3-a5b0-1f4bfe1ce734" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1e0e91cd-592c-4249-b68e-be10d6ee116f" xlink:to="loc_srt_ProductsAndServicesDomain_def7c20f-27a1-46f3-a5b0-1f4bfe1ce734" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseCollaborationAndOtherRevenueMember_2dfd01dc-a98a-442f-ac5e-ea0a36b1aef9" xlink:href="akba-20210930.xsd#akba_LicenseCollaborationAndOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_def7c20f-27a1-46f3-a5b0-1f4bfe1ce734" xlink:to="loc_akba_LicenseCollaborationAndOtherRevenueMember_2dfd01dc-a98a-442f-ac5e-ea0a36b1aef9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicensedHIFProductMember_6045065b-af3e-4f67-afb8-c84a3c6a04a2" xlink:href="akba-20210930.xsd#akba_LicensedHIFProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_def7c20f-27a1-46f3-a5b0-1f4bfe1ce734" xlink:to="loc_akba_LicensedHIFProductMember_6045065b-af3e-4f67-afb8-c84a3c6a04a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicensedProductsMember_61d130c1-99e4-4be2-86f3-3ea9633b41e3" xlink:href="akba-20210930.xsd#akba_LicensedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_def7c20f-27a1-46f3-a5b0-1f4bfe1ce734" xlink:to="loc_akba_LicensedProductsMember_61d130c1-99e4-4be2-86f3-3ea9633b41e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_399c65bb-08e1-423e-8991-bc8e7727778f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c7f68bd8-94d3-49ff-80c9-983bb91557c9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_399c65bb-08e1-423e-8991-bc8e7727778f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_399c65bb-08e1-423e-8991-bc8e7727778f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_399c65bb-08e1-423e-8991-bc8e7727778f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_399c65bb-08e1-423e-8991-bc8e7727778f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_645360bd-83d4-4ce2-a7c7-ed9c4e8954a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_399c65bb-08e1-423e-8991-bc8e7727778f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_645360bd-83d4-4ce2-a7c7-ed9c4e8954a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_a0b8377a-fde6-448f-99d8-9ecc55ab2ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_645360bd-83d4-4ce2-a7c7-ed9c4e8954a6" xlink:to="loc_us-gaap_AccountsReceivableMember_a0b8377a-fde6-448f-99d8-9ecc55ab2ce5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_c013d129-ed8b-4192-9505-5c63c7434993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_645360bd-83d4-4ce2-a7c7-ed9c4e8954a6" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_c013d129-ed8b-4192-9505-5c63c7434993" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableMember_f89aec8d-b4d4-4d33-8650-a67b815c8356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_645360bd-83d4-4ce2-a7c7-ed9c4e8954a6" xlink:to="loc_us-gaap_AccountsPayableMember_f89aec8d-b4d4-4d33-8650-a67b815c8356" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e5a2eccf-0687-4166-87e0-39e3928f6c35" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c7f68bd8-94d3-49ff-80c9-983bb91557c9" xlink:to="loc_srt_RangeAxis_e5a2eccf-0687-4166-87e0-39e3928f6c35" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e5a2eccf-0687-4166-87e0-39e3928f6c35_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e5a2eccf-0687-4166-87e0-39e3928f6c35" xlink:to="loc_srt_RangeMember_e5a2eccf-0687-4166-87e0-39e3928f6c35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_54ee0793-e911-48a4-a889-13b070c2ffc8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e5a2eccf-0687-4166-87e0-39e3928f6c35" xlink:to="loc_srt_RangeMember_54ee0793-e911-48a4-a889-13b070c2ffc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_19f7b702-e4f5-4302-82f6-9b47e589add7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_54ee0793-e911-48a4-a889-13b070c2ffc8" xlink:to="loc_srt_MinimumMember_19f7b702-e4f5-4302-82f6-9b47e589add7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_21d8d953-8512-4ade-b41b-d30b921914e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_54ee0793-e911-48a4-a889-13b070c2ffc8" xlink:to="loc_srt_MaximumMember_21d8d953-8512-4ade-b41b-d30b921914e2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails"/>
  <link:definitionLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails" xlink:type="extended" id="i03db04e1b8d0422c92c67883221df3d8_LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3129c963-7916-46d8-9cde-b8d46704a874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeArrangementTerm_15b5b211-60fe-42d9-b161-b5fa3d1e00e9" xlink:href="akba-20210930.xsd#akba_CollaborativeArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3129c963-7916-46d8-9cde-b8d46704a874" xlink:to="loc_akba_CollaborativeArrangementTerm_15b5b211-60fe-42d9-b161-b5fa3d1e00e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_UpfrontPaymentPaidInCash_30fc8d30-1396-4628-8b0d-bae1d89d3d5d" xlink:href="akba-20210930.xsd#akba_UpfrontPaymentPaidInCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3129c963-7916-46d8-9cde-b8d46704a874" xlink:to="loc_akba_UpfrontPaymentPaidInCash_30fc8d30-1396-4628-8b0d-bae1d89d3d5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_685756fd-0869-443f-977b-e16586e991b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3129c963-7916-46d8-9cde-b8d46704a874" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_685756fd-0869-443f-977b-e16586e991b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7bfb5c9a-851b-4137-989c-574f2e2dba20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3129c963-7916-46d8-9cde-b8d46704a874" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7bfb5c9a-851b-4137-989c-574f2e2dba20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_c7c2e612-4c32-4e2c-9d30-6c52781d2025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3129c963-7916-46d8-9cde-b8d46704a874" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_c7c2e612-4c32-4e2c-9d30-6c52781d2025" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones_d93a1dc9-e283-4bda-b2d4-c02412411129" xlink:href="akba-20210930.xsd#akba_PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3129c963-7916-46d8-9cde-b8d46704a874" xlink:to="loc_akba_PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones_d93a1dc9-e283-4bda-b2d4-c02412411129" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PotentialPaymentForAchievementOfSpecifiedCommercialMilestones_26f23ef8-2a99-4240-98f1-54d41cbbb143" xlink:href="akba-20210930.xsd#akba_PotentialPaymentForAchievementOfSpecifiedCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3129c963-7916-46d8-9cde-b8d46704a874" xlink:to="loc_akba_PotentialPaymentForAchievementOfSpecifiedCommercialMilestones_26f23ef8-2a99-4240-98f1-54d41cbbb143" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3eb1164-f5c4-43a9-9144-b54b54ddac86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3129c963-7916-46d8-9cde-b8d46704a874" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3eb1164-f5c4-43a9-9144-b54b54ddac86" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_186691e1-85b0-47bd-b64a-c6bb0a7dc7cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3eb1164-f5c4-43a9-9144-b54b54ddac86" xlink:to="loc_srt_CounterpartyNameAxis_186691e1-85b0-47bd-b64a-c6bb0a7dc7cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_186691e1-85b0-47bd-b64a-c6bb0a7dc7cd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_186691e1-85b0-47bd-b64a-c6bb0a7dc7cd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_186691e1-85b0-47bd-b64a-c6bb0a7dc7cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_debb79f3-5422-4e18-adaf-4500c67cd750" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_186691e1-85b0-47bd-b64a-c6bb0a7dc7cd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_debb79f3-5422-4e18-adaf-4500c67cd750" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_JanssenPharmaceuticaNVMember_8e236cf5-f92a-4988-bcc4-2d9c048bb40e" xlink:href="akba-20210930.xsd#akba_JanssenPharmaceuticaNVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_debb79f3-5422-4e18-adaf-4500c67cd750" xlink:to="loc_akba_JanssenPharmaceuticaNVMember_8e236cf5-f92a-4988-bcc4-2d9c048bb40e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_JohnsonAndJohnsonInnovationMember_66273b7e-ffff-401e-a858-6e3ada82babd" xlink:href="akba-20210930.xsd#akba_JohnsonAndJohnsonInnovationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_debb79f3-5422-4e18-adaf-4500c67cd750" xlink:to="loc_akba_JohnsonAndJohnsonInnovationMember_66273b7e-ffff-401e-a858-6e3ada82babd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2a85d721-79c3-4c77-8018-3f75530f37bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3eb1164-f5c4-43a9-9144-b54b54ddac86" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2a85d721-79c3-4c77-8018-3f75530f37bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2a85d721-79c3-4c77-8018-3f75530f37bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2a85d721-79c3-4c77-8018-3f75530f37bb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2a85d721-79c3-4c77-8018-3f75530f37bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_de6a5378-6a34-437b-a79d-294b73fabc43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2a85d721-79c3-4c77-8018-3f75530f37bb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_de6a5378-6a34-437b-a79d-294b73fabc43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember_b0a3dd93-aa7b-4529-88b7-7843030023fd" xlink:href="akba-20210930.xsd#akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_de6a5378-6a34-437b-a79d-294b73fabc43" xlink:to="loc_akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember_b0a3dd93-aa7b-4529-88b7-7843030023fd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsCyclerionTherapeuticsLicenseAgreementDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreementsCyclerionTherapeuticsLicenseAgreementDetails"/>
  <link:definitionLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsCyclerionTherapeuticsLicenseAgreementDetails" xlink:type="extended" id="icbaea8c1b1df4aa8a9881c8fac6258be_LicenseCollaborationandOtherSignificantAgreementsCyclerionTherapeuticsLicenseAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_6bef640b-df29-47b4-954b-94e90bf1065c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_6101cfbe-a381-4e55-a737-da30a8def45b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_6bef640b-df29-47b4-954b-94e90bf1065c" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_6101cfbe-a381-4e55-a737-da30a8def45b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_04b983b3-b0ad-4faf-8b5e-c8cd1a397bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_6bef640b-df29-47b4-954b-94e90bf1065c" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_04b983b3-b0ad-4faf-8b5e-c8cd1a397bb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_69b5afaa-628f-4851-bc98-a4e6c8a88286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_6bef640b-df29-47b4-954b-94e90bf1065c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_69b5afaa-628f-4851-bc98-a4e6c8a88286" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod_7c3549a7-610a-4dee-9183-754c9d128107" xlink:href="akba-20210930.xsd#akba_AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_6bef640b-df29-47b4-954b-94e90bf1065c" xlink:to="loc_akba_AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod_7c3549a7-610a-4dee-9183-754c9d128107" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AssetAcquisitionAgreementTerminationNoticePeriod_596febe3-673a-49b6-ae95-eb3540cd531e" xlink:href="akba-20210930.xsd#akba_AssetAcquisitionAgreementTerminationNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_6bef640b-df29-47b4-954b-94e90bf1065c" xlink:to="loc_akba_AssetAcquisitionAgreementTerminationNoticePeriod_596febe3-673a-49b6-ae95-eb3540cd531e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_95343ec0-22d1-4290-827b-cc978b38707a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_6bef640b-df29-47b4-954b-94e90bf1065c" xlink:to="loc_us-gaap_AssetAcquisitionTable_95343ec0-22d1-4290-827b-cc978b38707a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_8cb7af8d-c9c8-4c83-a1f3-32df3045512d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_95343ec0-22d1-4290-827b-cc978b38707a" xlink:to="loc_us-gaap_AssetAcquisitionAxis_8cb7af8d-c9c8-4c83-a1f3-32df3045512d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_8cb7af8d-c9c8-4c83-a1f3-32df3045512d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_8cb7af8d-c9c8-4c83-a1f3-32df3045512d" xlink:to="loc_us-gaap_AssetAcquisitionDomain_8cb7af8d-c9c8-4c83-a1f3-32df3045512d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_cdc632a9-e130-40d9-8d88-88245b40d67f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_8cb7af8d-c9c8-4c83-a1f3-32df3045512d" xlink:to="loc_us-gaap_AssetAcquisitionDomain_cdc632a9-e130-40d9-8d88-88245b40d67f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CyclerionTherapeuticsLicenseAgreementMember_b12eb8f6-eb27-4c0f-b4c0-7590e6c05c37" xlink:href="akba-20210930.xsd#akba_CyclerionTherapeuticsLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_cdc632a9-e130-40d9-8d88-88245b40d67f" xlink:to="loc_akba_CyclerionTherapeuticsLicenseAgreementMember_b12eb8f6-eb27-4c0f-b4c0-7590e6c05c37" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails"/>
  <link:definitionLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails" xlink:type="extended" id="i796da1901e1948059bc50fa5a1e99baf_LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e302148e-c8ae-43a6-8eda-291b45732006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_6db87af5-066d-48de-b0db-13e7db9aa5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e302148e-c8ae-43a6-8eda-291b45732006" xlink:to="loc_us-gaap_CommonStockSharesIssued_6db87af5-066d-48de-b0db-13e7db9aa5eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_8c95a353-a800-48e8-ade2-e37b374b375c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e302148e-c8ae-43a6-8eda-291b45732006" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_8c95a353-a800-48e8-ade2-e37b374b375c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ce9e2a48-2545-45b2-a91d-7cfdbdffb421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e302148e-c8ae-43a6-8eda-291b45732006" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ce9e2a48-2545-45b2-a91d-7cfdbdffb421" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ClosingStockPriceOfCommonStock_91582d8e-0fd5-4129-b398-4ad28f1929bd" xlink:href="akba-20210930.xsd#akba_ClosingStockPriceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e302148e-c8ae-43a6-8eda-291b45732006" xlink:to="loc_akba_ClosingStockPriceOfCommonStock_91582d8e-0fd5-4129-b398-4ad28f1929bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock_8b43c8b3-cbb5-4b06-b340-62886e73564c" xlink:href="akba-20210930.xsd#akba_CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e302148e-c8ae-43a6-8eda-291b45732006" xlink:to="loc_akba_CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock_8b43c8b3-cbb5-4b06-b340-62886e73564c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PotentialPaymentForAchievementOfSpecifiedMilestones_8fb4c0b5-e552-47a7-9b15-7afdd9abc15f" xlink:href="akba-20210930.xsd#akba_PotentialPaymentForAchievementOfSpecifiedMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e302148e-c8ae-43a6-8eda-291b45732006" xlink:to="loc_akba_PotentialPaymentForAchievementOfSpecifiedMilestones_8fb4c0b5-e552-47a7-9b15-7afdd9abc15f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f9a228e5-2ea4-4098-ba4e-989b63ed07bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e302148e-c8ae-43a6-8eda-291b45732006" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f9a228e5-2ea4-4098-ba4e-989b63ed07bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AggregateCollaborationAgreementPayments_ad9b2fd3-9f0b-4eb1-9d59-7b61ef73e2dc" xlink:href="akba-20210930.xsd#akba_AggregateCollaborationAgreementPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e302148e-c8ae-43a6-8eda-291b45732006" xlink:to="loc_akba_AggregateCollaborationAgreementPayments_ad9b2fd3-9f0b-4eb1-9d59-7b61ef73e2dc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_887a636e-d3f6-46bd-a381-684f19d36783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e302148e-c8ae-43a6-8eda-291b45732006" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_887a636e-d3f6-46bd-a381-684f19d36783" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_507658ba-d900-45bb-8c94-22e5f2695f0f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_887a636e-d3f6-46bd-a381-684f19d36783" xlink:to="loc_srt_CounterpartyNameAxis_507658ba-d900-45bb-8c94-22e5f2695f0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_507658ba-d900-45bb-8c94-22e5f2695f0f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_507658ba-d900-45bb-8c94-22e5f2695f0f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_507658ba-d900-45bb-8c94-22e5f2695f0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1b32548f-2801-4bec-81a2-67ddef8abc29" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_507658ba-d900-45bb-8c94-22e5f2695f0f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1b32548f-2801-4bec-81a2-67ddef8abc29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ViforInternationalLimitedMember_da52b5d6-9323-48e4-845b-4200c90816da" xlink:href="akba-20210930.xsd#akba_ViforInternationalLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1b32548f-2801-4bec-81a2-67ddef8abc29" xlink:to="loc_akba_ViforInternationalLimitedMember_da52b5d6-9323-48e4-845b-4200c90816da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8d85e8be-0831-4f11-9bef-16f40e8beff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_887a636e-d3f6-46bd-a381-684f19d36783" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8d85e8be-0831-4f11-9bef-16f40e8beff9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d85e8be-0831-4f11-9bef-16f40e8beff9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8d85e8be-0831-4f11-9bef-16f40e8beff9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d85e8be-0831-4f11-9bef-16f40e8beff9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d3c8bfc-22c3-4e8b-b97b-5396c56653ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8d85e8be-0831-4f11-9bef-16f40e8beff9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d3c8bfc-22c3-4e8b-b97b-5396c56653ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseAgreementMember_dfb11aba-2c75-4b93-a3dd-c74e64dfdcea" xlink:href="akba-20210930.xsd#akba_LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d3c8bfc-22c3-4e8b-b97b-5396c56653ad" xlink:to="loc_akba_LicenseAgreementMember_dfb11aba-2c75-4b93-a3dd-c74e64dfdcea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PriorityReviewVoucherLetterAgreementMember_4e714177-4856-479f-9dd9-35ac90747256" xlink:href="akba-20210930.xsd#akba_PriorityReviewVoucherLetterAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d3c8bfc-22c3-4e8b-b97b-5396c56653ad" xlink:to="loc_akba_PriorityReviewVoucherLetterAgreementMember_4e714177-4856-479f-9dd9-35ac90747256" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_97c59ad7-eacd-4a4f-9dc0-7715d96577d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_887a636e-d3f6-46bd-a381-684f19d36783" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_97c59ad7-eacd-4a4f-9dc0-7715d96577d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_97c59ad7-eacd-4a4f-9dc0-7715d96577d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_97c59ad7-eacd-4a4f-9dc0-7715d96577d5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_97c59ad7-eacd-4a4f-9dc0-7715d96577d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_da0fc4bc-718b-4b01-a728-302d51eede06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_97c59ad7-eacd-4a4f-9dc0-7715d96577d5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_da0fc4bc-718b-4b01-a728-302d51eede06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0043682f-1204-40c1-ad36-331afe0ad2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_da0fc4bc-718b-4b01-a728-302d51eede06" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0043682f-1204-40c1-ad36-331afe0ad2a5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsLicenseAgreementwithPanionBFBiotechIncDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreementsLicenseAgreementwithPanionBFBiotechIncDetails"/>
  <link:definitionLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsLicenseAgreementwithPanionBFBiotechIncDetails" xlink:type="extended" id="i7fdcb7f39800434a95623719c947d1ec_LicenseCollaborationandOtherSignificantAgreementsLicenseAgreementwithPanionBFBiotechIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d1770946-f722-4573-9a12-834edd8237af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_RoyaltyPaymentsDue_7a943b64-4361-435f-8fa9-d0af63ee07f1" xlink:href="akba-20210930.xsd#akba_RoyaltyPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d1770946-f722-4573-9a12-834edd8237af" xlink:to="loc_akba_RoyaltyPaymentsDue_7a943b64-4361-435f-8fa9-d0af63ee07f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1df47ce8-3c44-466b-a2fe-13735cc111a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d1770946-f722-4573-9a12-834edd8237af" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1df47ce8-3c44-466b-a2fe-13735cc111a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e275be04-8dad-4a9b-9e20-05b3bb14421c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1df47ce8-3c44-466b-a2fe-13735cc111a4" xlink:to="loc_srt_CounterpartyNameAxis_e275be04-8dad-4a9b-9e20-05b3bb14421c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e275be04-8dad-4a9b-9e20-05b3bb14421c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e275be04-8dad-4a9b-9e20-05b3bb14421c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e275be04-8dad-4a9b-9e20-05b3bb14421c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e2c2d50-f574-43c2-b1e2-32acf3f91416" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e275be04-8dad-4a9b-9e20-05b3bb14421c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e2c2d50-f574-43c2-b1e2-32acf3f91416" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember_d81a21a9-d8fe-4c98-aeb7-463cb5f63a77" xlink:href="akba-20210930.xsd#akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e2c2d50-f574-43c2-b1e2-32acf3f91416" xlink:to="loc_akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember_d81a21a9-d8fe-4c98-aeb7-463cb5f63a77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1bbb646d-a738-4cf9-9c47-921bc5487346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1df47ce8-3c44-466b-a2fe-13735cc111a4" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1bbb646d-a738-4cf9-9c47-921bc5487346" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1bbb646d-a738-4cf9-9c47-921bc5487346_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1bbb646d-a738-4cf9-9c47-921bc5487346" xlink:to="loc_us-gaap_RelatedPartyDomain_1bbb646d-a738-4cf9-9c47-921bc5487346_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_42b4b7d4-5a18-4ff1-8aee-27b49d50b736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1bbb646d-a738-4cf9-9c47-921bc5487346" xlink:to="loc_us-gaap_RelatedPartyDomain_42b4b7d4-5a18-4ff1-8aee-27b49d50b736" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PanionAndBFBiotechIncorporationMember_f833801d-4121-49ab-9afa-503f155646d0" xlink:href="akba-20210930.xsd#akba_PanionAndBFBiotechIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_42b4b7d4-5a18-4ff1-8aee-27b49d50b736" xlink:to="loc_akba_PanionAndBFBiotechIncorporationMember_f833801d-4121-49ab-9afa-503f155646d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a1e61f5d-98b0-4073-9fee-b9799b91afaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1df47ce8-3c44-466b-a2fe-13735cc111a4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a1e61f5d-98b0-4073-9fee-b9799b91afaa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a1e61f5d-98b0-4073-9fee-b9799b91afaa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a1e61f5d-98b0-4073-9fee-b9799b91afaa" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a1e61f5d-98b0-4073-9fee-b9799b91afaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0042c90b-72ac-4cb5-bdee-d32b96e81910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a1e61f5d-98b0-4073-9fee-b9799b91afaa" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0042c90b-72ac-4cb5-bdee-d32b96e81910" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseAgreementMember_aa0471fb-8ea6-48f9-ae77-5602bc64f694" xlink:href="akba-20210930.xsd#akba_LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0042c90b-72ac-4cb5-bdee-d32b96e81910" xlink:to="loc_akba_LicenseAgreementMember_aa0471fb-8ea6-48f9-ae77-5602bc64f694" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsSublicenseAgreementwithJapanTobaccoIncanditssubsidiaryToriiPharmaceuticalCoLtdDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreementsSublicenseAgreementwithJapanTobaccoIncanditssubsidiaryToriiPharmaceuticalCoLtdDetails"/>
  <link:definitionLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsSublicenseAgreementwithJapanTobaccoIncanditssubsidiaryToriiPharmaceuticalCoLtdDetails" xlink:type="extended" id="i345ef5b8fe354eb4aaddbc439d356886_LicenseCollaborationandOtherSignificantAgreementsSublicenseAgreementwithJapanTobaccoIncanditssubsidiaryToriiPharmaceuticalCoLtdDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_18fbadb8-be59-4443-bfe5-410ccd3c50a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_NumberOfPerformanceObligations_6c434fbf-93b4-4513-a1a1-a67623e28c36" xlink:href="akba-20210930.xsd#akba_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_18fbadb8-be59-4443-bfe5-410ccd3c50a6" xlink:to="loc_akba_NumberOfPerformanceObligations_6c434fbf-93b4-4513-a1a1-a67623e28c36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aec59665-0bc5-41f2-bc03-2320d484d1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_18fbadb8-be59-4443-bfe5-410ccd3c50a6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aec59665-0bc5-41f2-bc03-2320d484d1ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_363ba9df-9526-4af0-afef-869998b3fc12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_18fbadb8-be59-4443-bfe5-410ccd3c50a6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_363ba9df-9526-4af0-afef-869998b3fc12" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_54f8f5bd-59bd-4d30-89fb-426e540d3bc0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_363ba9df-9526-4af0-afef-869998b3fc12" xlink:to="loc_srt_CounterpartyNameAxis_54f8f5bd-59bd-4d30-89fb-426e540d3bc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_54f8f5bd-59bd-4d30-89fb-426e540d3bc0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_54f8f5bd-59bd-4d30-89fb-426e540d3bc0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_54f8f5bd-59bd-4d30-89fb-426e540d3bc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87a7452a-fed8-489d-ae5d-3da9be4e78ff" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_54f8f5bd-59bd-4d30-89fb-426e540d3bc0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87a7452a-fed8-489d-ae5d-3da9be4e78ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember_4823065d-8ca0-41a3-a50a-2c0ccc8c5bda" xlink:href="akba-20210930.xsd#akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87a7452a-fed8-489d-ae5d-3da9be4e78ff" xlink:to="loc_akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember_4823065d-8ca0-41a3-a50a-2c0ccc8c5bda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b20c772c-b635-4cd6-aece-d010bfdd96ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_363ba9df-9526-4af0-afef-869998b3fc12" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b20c772c-b635-4cd6-aece-d010bfdd96ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b20c772c-b635-4cd6-aece-d010bfdd96ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b20c772c-b635-4cd6-aece-d010bfdd96ae" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b20c772c-b635-4cd6-aece-d010bfdd96ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_51c2e8d4-7128-492e-a91e-f1fdb417aa71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b20c772c-b635-4cd6-aece-d010bfdd96ae" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_51c2e8d4-7128-492e-a91e-f1fdb417aa71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_SublicenseAgreementMember_9733c1fb-f88b-418e-8d26-fa0c2d86c2fc" xlink:href="akba-20210930.xsd#akba_SublicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_51c2e8d4-7128-492e-a91e-f1fdb417aa71" xlink:to="loc_akba_SublicenseAgreementMember_9733c1fb-f88b-418e-8d26-fa0c2d86c2fc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails" xlink:type="extended" id="i36be53f38dd84dd38a3d7b7931ea74db_AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a48883cd-3cdf-4090-93ae-ae7fb98921cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4ff7079e-3b83-498f-ba1a-52bb6e3d8735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a48883cd-3cdf-4090-93ae-ae7fb98921cc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4ff7079e-3b83-498f-ba1a-52bb6e3d8735" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_555483a0-5fa6-4952-9289-ab59c854d6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a48883cd-3cdf-4090-93ae-ae7fb98921cc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_555483a0-5fa6-4952-9289-ab59c854d6a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_e56b05d9-93f7-4175-9798-66b099095b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a48883cd-3cdf-4090-93ae-ae7fb98921cc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_e56b05d9-93f7-4175-9798-66b099095b9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8b5a311a-78ba-49e0-acad-a042285be9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_e56b05d9-93f7-4175-9798-66b099095b9b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8b5a311a-78ba-49e0-acad-a042285be9d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_19807444-6f38-41af-a3c5-53556302b9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_e56b05d9-93f7-4175-9798-66b099095b9b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_19807444-6f38-41af-a3c5-53556302b9e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1d7e05bc-3c0f-4aee-973d-c974aa033717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_e56b05d9-93f7-4175-9798-66b099095b9b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1d7e05bc-3c0f-4aee-973d-c974aa033717" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0fa04612-7a33-445e-8acf-248d3e2f4a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_e56b05d9-93f7-4175-9798-66b099095b9b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0fa04612-7a33-445e-8acf-248d3e2f4a6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost_4238768e-79e8-4692-ac15-42556910011d" xlink:href="akba-20210930.xsd#akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a48883cd-3cdf-4090-93ae-ae7fb98921cc" xlink:to="loc_akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost_4238768e-79e8-4692-ac15-42556910011d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_01e749d3-9ac0-487f-b7e1-d3b38a6bba7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a48883cd-3cdf-4090-93ae-ae7fb98921cc" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_01e749d3-9ac0-487f-b7e1-d3b38a6bba7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d0ceaeba-89ac-44c9-972d-badf311da210" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a48883cd-3cdf-4090-93ae-ae7fb98921cc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d0ceaeba-89ac-44c9-972d-badf311da210" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3f354bac-cec4-4d78-bc43-ee8fa5d573a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d0ceaeba-89ac-44c9-972d-badf311da210" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3f354bac-cec4-4d78-bc43-ee8fa5d573a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3f354bac-cec4-4d78-bc43-ee8fa5d573a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3f354bac-cec4-4d78-bc43-ee8fa5d573a0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3f354bac-cec4-4d78-bc43-ee8fa5d573a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d158d016-c079-4747-ad04-2b4b9ecc9447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3f354bac-cec4-4d78-bc43-ee8fa5d573a0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d158d016-c079-4747-ad04-2b4b9ecc9447" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_83ca418e-cbe9-46f8-a2d0-33e3564cbe44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d158d016-c079-4747-ad04-2b4b9ecc9447" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_83ca418e-cbe9-46f8-a2d0-33e3564cbe44" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails" xlink:type="extended" id="i5932a10c41bf4d3db8bb7adf7aa96f19_FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5db006fc-e823-4b7f-a655-aa4022609d57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_4fb78468-cba2-405b-86e4-79da146009da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5db006fc-e823-4b7f-a655-aa4022609d57" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_4fb78468-cba2-405b-86e4-79da146009da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2606e847-ab47-453b-94b8-209ea4a7230d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_4fb78468-cba2-405b-86e4-79da146009da" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2606e847-ab47-453b-94b8-209ea4a7230d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5052f5e5-b8d1-415e-a547-867e6e46466c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_4fb78468-cba2-405b-86e4-79da146009da" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5052f5e5-b8d1-415e-a547-867e6e46466c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_fbbfe6f1-782a-46a9-8efb-1507926237d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_4fb78468-cba2-405b-86e4-79da146009da" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_fbbfe6f1-782a-46a9-8efb-1507926237d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_b4d09b44-7c40-4e7a-a052-9185b77edf62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5db006fc-e823-4b7f-a655-aa4022609d57" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_b4d09b44-7c40-4e7a-a052-9185b77edf62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_3e985962-20c8-4479-ab7c-e78e1901cdad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_b4d09b44-7c40-4e7a-a052-9185b77edf62" xlink:to="loc_us-gaap_DerivativeLiabilities_3e985962-20c8-4479-ab7c-e78e1901cdad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_11504fdb-6c24-4721-bfde-337315a71110" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_b4d09b44-7c40-4e7a-a052-9185b77edf62" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_11504fdb-6c24-4721-bfde-337315a71110" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fde1e103-d867-4ad9-bea5-e1fef0c9006f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5db006fc-e823-4b7f-a655-aa4022609d57" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fde1e103-d867-4ad9-bea5-e1fef0c9006f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eed663b6-23ce-4a7f-ace4-0902e4d908bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fde1e103-d867-4ad9-bea5-e1fef0c9006f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eed663b6-23ce-4a7f-ace4-0902e4d908bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_eed663b6-23ce-4a7f-ace4-0902e4d908bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eed663b6-23ce-4a7f-ace4-0902e4d908bd" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_eed663b6-23ce-4a7f-ace4-0902e4d908bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f3046dbc-93b9-4f82-b32c-cae237910047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eed663b6-23ce-4a7f-ace4-0902e4d908bd" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f3046dbc-93b9-4f82-b32c-cae237910047" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_036f0742-b1af-4efb-97c0-0eeabe5de70c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f3046dbc-93b9-4f82-b32c-cae237910047" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_036f0742-b1af-4efb-97c0-0eeabe5de70c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de77e96b-88ce-4de9-af9f-52a553d8e0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fde1e103-d867-4ad9-bea5-e1fef0c9006f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de77e96b-88ce-4de9-af9f-52a553d8e0ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_de77e96b-88ce-4de9-af9f-52a553d8e0ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de77e96b-88ce-4de9-af9f-52a553d8e0ef" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_de77e96b-88ce-4de9-af9f-52a553d8e0ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53a31137-8e95-4f62-adf2-cca694bfa452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de77e96b-88ce-4de9-af9f-52a553d8e0ef" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53a31137-8e95-4f62-adf2-cca694bfa452" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_859c82ca-512c-412d-a43b-c745c990bc88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53a31137-8e95-4f62-adf2-cca694bfa452" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_859c82ca-512c-412d-a43b-c745c990bc88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ba714965-ff92-4bf7-b6d3-0c6e54648e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53a31137-8e95-4f62-adf2-cca694bfa452" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ba714965-ff92-4bf7-b6d3-0c6e54648e3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2ca87d6c-be59-4464-8b31-778577bf5ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53a31137-8e95-4f62-adf2-cca694bfa452" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2ca87d6c-be59-4464-8b31-778577bf5ce0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_00672efb-b1d0-4631-b08b-ca6e9397b5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fde1e103-d867-4ad9-bea5-e1fef0c9006f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_00672efb-b1d0-4631-b08b-ca6e9397b5b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_00672efb-b1d0-4631-b08b-ca6e9397b5b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_00672efb-b1d0-4631-b08b-ca6e9397b5b5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_00672efb-b1d0-4631-b08b-ca6e9397b5b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d9b39800-2291-423b-9dcd-22df66a86f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_00672efb-b1d0-4631-b08b-ca6e9397b5b5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d9b39800-2291-423b-9dcd-22df66a86f8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4f1972a1-7b43-4f6d-97a4-6b8e134c7a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d9b39800-2291-423b-9dcd-22df66a86f8f" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4f1972a1-7b43-4f6d-97a4-6b8e134c7a1d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://akebia.com/role/FairValueofFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#FairValueofFinancialInstrumentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://akebia.com/role/FairValueofFinancialInstrumentsAdditionalInformationDetails" xlink:type="extended" id="i4e42920db0754cbf8cf312e53df1bfef_FairValueofFinancialInstrumentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2d865857-8038-4ffc-99e9-3cf32a4c7301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_1fc271a8-464e-470d-afdc-7e7069b1bd96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2d865857-8038-4ffc-99e9-3cf32a4c7301" xlink:to="loc_us-gaap_DerivativeLiabilities_1fc271a8-464e-470d-afdc-7e7069b1bd96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_96dcbd72-81b2-461a-87e4-b8855c1f24ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2d865857-8038-4ffc-99e9-3cf32a4c7301" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_96dcbd72-81b2-461a-87e4-b8855c1f24ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_76e43b48-8aa0-4cea-b69f-d1ad8bf192d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2d865857-8038-4ffc-99e9-3cf32a4c7301" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_76e43b48-8aa0-4cea-b69f-d1ad8bf192d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1221e614-86bb-40c1-931c-fbf74f9d5684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2d865857-8038-4ffc-99e9-3cf32a4c7301" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1221e614-86bb-40c1-931c-fbf74f9d5684" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ee8df490-25ab-45e9-bdd6-0990f2a6ea1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1221e614-86bb-40c1-931c-fbf74f9d5684" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ee8df490-25ab-45e9-bdd6-0990f2a6ea1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ee8df490-25ab-45e9-bdd6-0990f2a6ea1a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ee8df490-25ab-45e9-bdd6-0990f2a6ea1a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ee8df490-25ab-45e9-bdd6-0990f2a6ea1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9154c36a-86f4-4ca5-838a-52ede7909810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ee8df490-25ab-45e9-bdd6-0990f2a6ea1a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9154c36a-86f4-4ca5-838a-52ede7909810" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollateralAgentPharmakonMember_4ac06bca-eb31-410f-afca-262a9e7e2dfd" xlink:href="akba-20210930.xsd#akba_CollateralAgentPharmakonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9154c36a-86f4-4ca5-838a-52ede7909810" xlink:to="loc_akba_CollateralAgentPharmakonMember_4ac06bca-eb31-410f-afca-262a9e7e2dfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7e9c145b-5672-4873-8865-d3b58f0967f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1221e614-86bb-40c1-931c-fbf74f9d5684" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7e9c145b-5672-4873-8865-d3b58f0967f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e9c145b-5672-4873-8865-d3b58f0967f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7e9c145b-5672-4873-8865-d3b58f0967f5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e9c145b-5672-4873-8865-d3b58f0967f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0977d406-1704-4979-b741-d31a2139e5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7e9c145b-5672-4873-8865-d3b58f0967f5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0977d406-1704-4979-b741-d31a2139e5d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0851a3b4-cc63-43f3-87e3-c654715d2c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0977d406-1704-4979-b741-d31a2139e5d5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0851a3b4-cc63-43f3-87e3-c654715d2c6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8199b871-9a91-4719-a27f-b33a1f0567eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1221e614-86bb-40c1-931c-fbf74f9d5684" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8199b871-9a91-4719-a27f-b33a1f0567eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8199b871-9a91-4719-a27f-b33a1f0567eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8199b871-9a91-4719-a27f-b33a1f0567eb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8199b871-9a91-4719-a27f-b33a1f0567eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d48d2ec-3a78-44a7-bc8a-6103ad570def" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8199b871-9a91-4719-a27f-b33a1f0567eb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d48d2ec-3a78-44a7-bc8a-6103ad570def" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OtherThanDerivativeLiabilitiesMember_c7360cc5-566e-4428-8ea1-c796f56524ac" xlink:href="akba-20210930.xsd#akba_OtherThanDerivativeLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d48d2ec-3a78-44a7-bc8a-6103ad570def" xlink:to="loc_akba_OtherThanDerivativeLiabilitiesMember_c7360cc5-566e-4428-8ea1-c796f56524ac" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://akebia.com/role/InventoryAdditionalInformationDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#InventoryAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://akebia.com/role/InventoryAdditionalInformationDetails" xlink:type="extended" id="ib991e6ada1674b3093997205589ea4b0_InventoryAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5c27fbc9-7581-4945-bac8-9ef9c9196920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_8615ef84-360d-45d6-90c6-e5ee2d44cdf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5c27fbc9-7581-4945-bac8-9ef9c9196920" xlink:to="loc_us-gaap_InventoryWriteDown_8615ef84-360d-45d6-90c6-e5ee2d44cdf6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_a6bec215-0df8-412c-bbfb-cd2de51add84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5c27fbc9-7581-4945-bac8-9ef9c9196920" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_a6bec215-0df8-412c-bbfb-cd2de51add84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8d968cc8-e010-4eaa-a880-7107fc5f4648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5c27fbc9-7581-4945-bac8-9ef9c9196920" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8d968cc8-e010-4eaa-a880-7107fc5f4648" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_71afd362-7774-4316-b109-089b1632473f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8d968cc8-e010-4eaa-a880-7107fc5f4648" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_71afd362-7774-4316-b109-089b1632473f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_71afd362-7774-4316-b109-089b1632473f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_71afd362-7774-4316-b109-089b1632473f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_71afd362-7774-4316-b109-089b1632473f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_395cd714-a7b7-4da1-9d72-3cb27d44a686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_71afd362-7774-4316-b109-089b1632473f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_395cd714-a7b7-4da1-9d72-3cb27d44a686" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_KeryxBiopharmaceuticalsIncMember_aaca6163-1f49-4c93-be5c-c832ef717738" xlink:href="akba-20210930.xsd#akba_KeryxBiopharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_395cd714-a7b7-4da1-9d72-3cb27d44a686" xlink:to="loc_akba_KeryxBiopharmaceuticalsIncMember_aaca6163-1f49-4c93-be5c-c832ef717738" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://akebia.com/role/IntangibleAssetsandGoodwillIntangibleAssetsDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#IntangibleAssetsandGoodwillIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://akebia.com/role/IntangibleAssetsandGoodwillIntangibleAssetsDetails" xlink:type="extended" id="i9ccd7468539144de844f3fbc366bb9da_IntangibleAssetsandGoodwillIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f7cd59b7-5cac-4563-9329-213480ad242b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d50a9749-b5ed-4fc9-8d57-91378b8deb65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f7cd59b7-5cac-4563-9329-213480ad242b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d50a9749-b5ed-4fc9-8d57-91378b8deb65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8e308d51-8482-4ccc-a954-e6aa068f2b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f7cd59b7-5cac-4563-9329-213480ad242b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8e308d51-8482-4ccc-a954-e6aa068f2b6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_FiniteLivedIntangibleAssetsAdoptionAdjustment_42a01913-562a-4944-a4a9-d89dc050485a" xlink:href="akba-20210930.xsd#akba_FiniteLivedIntangibleAssetsAdoptionAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f7cd59b7-5cac-4563-9329-213480ad242b" xlink:to="loc_akba_FiniteLivedIntangibleAssetsAdoptionAdjustment_42a01913-562a-4944-a4a9-d89dc050485a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cd1b31b7-9097-466e-9397-b591fe04750c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f7cd59b7-5cac-4563-9329-213480ad242b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cd1b31b7-9097-466e-9397-b591fe04750c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_fabc0e76-e159-4e38-8899-6c471de08f71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f7cd59b7-5cac-4563-9329-213480ad242b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_fabc0e76-e159-4e38-8899-6c471de08f71" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_566307e2-660a-4e62-b2e3-b4bd9111eeb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f7cd59b7-5cac-4563-9329-213480ad242b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_566307e2-660a-4e62-b2e3-b4bd9111eeb4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b9eca029-ad93-457d-b6f4-ff8782beac3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_566307e2-660a-4e62-b2e3-b4bd9111eeb4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b9eca029-ad93-457d-b6f4-ff8782beac3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b9eca029-ad93-457d-b6f4-ff8782beac3b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b9eca029-ad93-457d-b6f4-ff8782beac3b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b9eca029-ad93-457d-b6f4-ff8782beac3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_386d4df5-3228-4ec8-9e4c-d75fdcd0aaa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b9eca029-ad93-457d-b6f4-ff8782beac3b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_386d4df5-3228-4ec8-9e4c-d75fdcd0aaa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopedProductRightsForAuryxiaMember_059ec177-0099-4148-bf1b-2d67f504f881" xlink:href="akba-20210930.xsd#akba_DevelopedProductRightsForAuryxiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_386d4df5-3228-4ec8-9e4c-d75fdcd0aaa1" xlink:to="loc_akba_DevelopedProductRightsForAuryxiaMember_059ec177-0099-4148-bf1b-2d67f504f881" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketFavorableLeaseMember_527493f2-2d29-4b04-8dfa-47e5ecf152f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffMarketFavorableLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_386d4df5-3228-4ec8-9e4c-d75fdcd0aaa1" xlink:to="loc_us-gaap_OffMarketFavorableLeaseMember_527493f2-2d29-4b04-8dfa-47e5ecf152f1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://akebia.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#IntangibleAssetsandGoodwillAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://akebia.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails" xlink:type="extended" id="i465f5dac797743a28ed65e31b04464f4_IntangibleAssetsandGoodwillAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4acb5b2e-a74b-43c3-8de9-903a4a4c32b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_fad65e35-c53f-4574-aba7-2439bbaefac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4acb5b2e-a74b-43c3-8de9-903a4a4c32b5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_fad65e35-c53f-4574-aba7-2439bbaefac0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d561bc82-53cb-4f3a-99d9-c980198f0240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4acb5b2e-a74b-43c3-8de9-903a4a4c32b5" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d561bc82-53cb-4f3a-99d9-c980198f0240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_dbeade6c-f28f-4aaf-bb0c-5912c5aa2521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4acb5b2e-a74b-43c3-8de9-903a4a4c32b5" xlink:to="loc_us-gaap_Goodwill_dbeade6c-f28f-4aaf-bb0c-5912c5aa2521" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_83dd35a2-a535-4c67-b6d1-c057e6d58396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4acb5b2e-a74b-43c3-8de9-903a4a4c32b5" xlink:to="loc_us-gaap_NumberOfOperatingSegments_83dd35a2-a535-4c67-b6d1-c057e6d58396" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_4e2050b0-4232-4292-87a7-fdd79b4f24ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4acb5b2e-a74b-43c3-8de9-903a4a4c32b5" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_4e2050b0-4232-4292-87a7-fdd79b4f24ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1c397be0-59de-4b29-96f8-b6de8e555563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4acb5b2e-a74b-43c3-8de9-903a4a4c32b5" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1c397be0-59de-4b29-96f8-b6de8e555563" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e4abbaa9-d8e8-4d79-b312-3ea8f1e4fa73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1c397be0-59de-4b29-96f8-b6de8e555563" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e4abbaa9-d8e8-4d79-b312-3ea8f1e4fa73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e4abbaa9-d8e8-4d79-b312-3ea8f1e4fa73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e4abbaa9-d8e8-4d79-b312-3ea8f1e4fa73" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e4abbaa9-d8e8-4d79-b312-3ea8f1e4fa73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b20eace3-70ff-4d57-a148-26bede1d9f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e4abbaa9-d8e8-4d79-b312-3ea8f1e4fa73" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b20eace3-70ff-4d57-a148-26bede1d9f8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopedProductRightsForAuryxiaMember_619154c9-2904-4115-bdcf-b6e323fbac96" xlink:href="akba-20210930.xsd#akba_DevelopedProductRightsForAuryxiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b20eace3-70ff-4d57-a148-26bede1d9f8f" xlink:to="loc_akba_DevelopedProductRightsForAuryxiaMember_619154c9-2904-4115-bdcf-b6e323fbac96" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://akebia.com/role/DebtDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#DebtDetails"/>
  <link:definitionLink xlink:role="http://akebia.com/role/DebtDetails" xlink:type="extended" id="i88c7708137dc4ed7be8cb08487988b81_DebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1732856d-8a94-4922-8772-b0eae2887478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1732856d-8a94-4922-8772-b0eae2887478" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches_77c2313f-35ed-44ee-a8b8-c4a5cc3bb8b0" xlink:href="akba-20210930.xsd#akba_LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_akba_LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches_77c2313f-35ed-44ee-a8b8-c4a5cc3bb8b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f0e3046d-47fc-47dd-9950-5b67f1deff41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f0e3046d-47fc-47dd-9950-5b67f1deff41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentFloorRate_0e64ec37-7096-46c6-a8eb-d80169874fe4" xlink:href="akba-20210930.xsd#akba_DebtInstrumentFloorRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_akba_DebtInstrumentFloorRate_0e64ec37-7096-46c6-a8eb-d80169874fe4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentCapRate_e17a02c8-d9ff-4931-8810-faa608646586" xlink:href="akba-20210930.xsd#akba_DebtInstrumentCapRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_akba_DebtInstrumentCapRate_e17a02c8-d9ff-4931-8810-faa608646586" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_aa151d5b-d8fb-4245-ae26-d2f0f39f7939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_us-gaap_DebtInstrumentTerm_aa151d5b-d8fb-4245-ae26-d2f0f39f7939" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm_40207454-d8b0-4f78-bd4b-71068ddf2d34" xlink:href="akba-20210930.xsd#akba_LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_akba_LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm_40207454-d8b0-4f78-bd4b-71068ddf2d34" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentCovenantTermsPotentialMaturityTermReduction_f557ec1d-30ad-4fe0-8699-7ff4cd31aaf9" xlink:href="akba-20210930.xsd#akba_DebtInstrumentCovenantTermsPotentialMaturityTermReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_akba_DebtInstrumentCovenantTermsPotentialMaturityTermReduction_f557ec1d-30ad-4fe0-8699-7ff4cd31aaf9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction_ae485e45-7dd4-4b31-8767-6c6056594369" xlink:href="akba-20210930.xsd#akba_DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_akba_DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction_ae485e45-7dd4-4b31-8767-6c6056594369" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_FacilityFeePercentagePaidOnPrincipalAmount_c4a9f31d-7bfe-40a9-a108-da4a7d5dda82" xlink:href="akba-20210930.xsd#akba_FacilityFeePercentagePaidOnPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_akba_FacilityFeePercentagePaidOnPrincipalAmount_c4a9f31d-7bfe-40a9-a108-da4a7d5dda82" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentFacilityFeePaid_27169481-85d7-4c2a-a357-138fcde48641" xlink:href="akba-20210930.xsd#akba_DebtInstrumentFacilityFeePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_akba_DebtInstrumentFacilityFeePaid_27169481-85d7-4c2a-a357-138fcde48641" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_275bb9f2-e656-46e3-b73a-0f32f68a1571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_us-gaap_LongTermDebt_275bb9f2-e656-46e3-b73a-0f32f68a1571" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_d1ad20e2-0dff-4767-a73a-a6c9e67eae9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_d1ad20e2-0dff-4767-a73a-a6c9e67eae9b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding_96fbb545-eae3-4600-a18c-78b980138d42" xlink:href="akba-20210930.xsd#akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding_96fbb545-eae3-4600-a18c-78b980138d42" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding_6e191486-adf4-4e40-9c88-29b0479674b4" xlink:href="akba-20210930.xsd#akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding_6e191486-adf4-4e40-9c88-29b0479674b4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding_7820c4c4-39b2-472f-b3e7-db0b69fb38bb" xlink:href="akba-20210930.xsd#akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding_7820c4c4-39b2-472f-b3e7-db0b69fb38bb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_6eb16b4b-e205-4e10-8b6a-a9a8261fb640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_us-gaap_DerivativeLiabilities_6eb16b4b-e205-4e10-8b6a-a9a8261fb640" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_2439c2a3-10be-4080-93ba-c8baa4be57ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_us-gaap_InterestExpenseDebt_2439c2a3-10be-4080-93ba-c8baa4be57ac" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_581c3e52-199d-4950-af61-e511f566f8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_581c3e52-199d-4950-af61-e511f566f8f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_d9164b34-651e-4300-bc1a-dff88eac9221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_581c3e52-199d-4950-af61-e511f566f8f0" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_d9164b34-651e-4300-bc1a-dff88eac9221" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_d9164b34-651e-4300-bc1a-dff88eac9221_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_d9164b34-651e-4300-bc1a-dff88eac9221" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_d9164b34-651e-4300-bc1a-dff88eac9221_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_058bf54a-bd1b-4a35-81cd-b776caa7a339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_d9164b34-651e-4300-bc1a-dff88eac9221" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_058bf54a-bd1b-4a35-81cd-b776caa7a339" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember_f314f227-cec4-457f-82c2-51d8b43c334e" xlink:href="akba-20210930.xsd#akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_058bf54a-bd1b-4a35-81cd-b776caa7a339" xlink:to="loc_akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember_f314f227-cec4-457f-82c2-51d8b43c334e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_BPCRLimitedPartnershipMember_545d22cf-6abe-4558-99b0-ec766c8a99be" xlink:href="akba-20210930.xsd#akba_BPCRLimitedPartnershipMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_058bf54a-bd1b-4a35-81cd-b776caa7a339" xlink:to="loc_akba_BPCRLimitedPartnershipMember_545d22cf-6abe-4558-99b0-ec766c8a99be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_3854876e-0503-4e63-ae04-3ad95dfbff5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsByNatureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_581c3e52-199d-4950-af61-e511f566f8f0" xlink:to="loc_us-gaap_GuaranteeObligationsByNatureAxis_3854876e-0503-4e63-ae04-3ad95dfbff5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_3854876e-0503-4e63-ae04-3ad95dfbff5b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_3854876e-0503-4e63-ae04-3ad95dfbff5b" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_3854876e-0503-4e63-ae04-3ad95dfbff5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_ac6ef5d5-bd18-48fe-8afc-0b0b4297da88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_3854876e-0503-4e63-ae04-3ad95dfbff5b" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_ac6ef5d5-bd18-48fe-8afc-0b0b4297da88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_KeryxMember_30aa19b2-99e3-49ea-b3ac-d0cb19fd10bf" xlink:href="akba-20210930.xsd#akba_KeryxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_ac6ef5d5-bd18-48fe-8afc-0b0b4297da88" xlink:to="loc_akba_KeryxMember_30aa19b2-99e3-49ea-b3ac-d0cb19fd10bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_27983b99-6e8c-4dee-8254-b7e37345f518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_581c3e52-199d-4950-af61-e511f566f8f0" xlink:to="loc_us-gaap_CreditFacilityAxis_27983b99-6e8c-4dee-8254-b7e37345f518" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_27983b99-6e8c-4dee-8254-b7e37345f518_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_27983b99-6e8c-4dee-8254-b7e37345f518" xlink:to="loc_us-gaap_CreditFacilityDomain_27983b99-6e8c-4dee-8254-b7e37345f518_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7f5ab425-9271-418d-844d-dba0250faeef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_27983b99-6e8c-4dee-8254-b7e37345f518" xlink:to="loc_us-gaap_CreditFacilityDomain_7f5ab425-9271-418d-844d-dba0250faeef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_TermLoanMember_90754df0-2917-49f6-a7a2-5532a7d4a556" xlink:href="akba-20210930.xsd#akba_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_7f5ab425-9271-418d-844d-dba0250faeef" xlink:to="loc_akba_TermLoanMember_90754df0-2917-49f6-a7a2-5532a7d4a556" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_988a0004-7363-4e41-8326-7bd7ab936f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_581c3e52-199d-4950-af61-e511f566f8f0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_988a0004-7363-4e41-8326-7bd7ab936f5e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_988a0004-7363-4e41-8326-7bd7ab936f5e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_988a0004-7363-4e41-8326-7bd7ab936f5e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_988a0004-7363-4e41-8326-7bd7ab936f5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5cc7390c-a554-4490-aad6-05718cddafd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_988a0004-7363-4e41-8326-7bd7ab936f5e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5cc7390c-a554-4490-aad6-05718cddafd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollateralAgentPharmakonMember_9bca521d-fb60-4ea4-ac41-07850c3fd195" xlink:href="akba-20210930.xsd#akba_CollateralAgentPharmakonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5cc7390c-a554-4490-aad6-05718cddafd3" xlink:to="loc_akba_CollateralAgentPharmakonMember_9bca521d-fb60-4ea4-ac41-07850c3fd195" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3f337262-17eb-418c-95b8-4cdd9d228796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_581c3e52-199d-4950-af61-e511f566f8f0" xlink:to="loc_us-gaap_DebtInstrumentAxis_3f337262-17eb-418c-95b8-4cdd9d228796" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3f337262-17eb-418c-95b8-4cdd9d228796_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3f337262-17eb-418c-95b8-4cdd9d228796" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3f337262-17eb-418c-95b8-4cdd9d228796_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4b5e15d8-1645-443c-85c2-4b7b2497792f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3f337262-17eb-418c-95b8-4cdd9d228796" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4b5e15d8-1645-443c-85c2-4b7b2497792f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_TrancheAMember_78af4c06-da50-4407-b092-0c3d48d4e44d" xlink:href="akba-20210930.xsd#akba_TrancheAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4b5e15d8-1645-443c-85c2-4b7b2497792f" xlink:to="loc_akba_TrancheAMember_78af4c06-da50-4407-b092-0c3d48d4e44d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_TrancheBMember_713c87c5-6b4c-4413-80bb-a602a5789c85" xlink:href="akba-20210930.xsd#akba_TrancheBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4b5e15d8-1645-443c-85c2-4b7b2497792f" xlink:to="loc_akba_TrancheBMember_713c87c5-6b4c-4413-80bb-a602a5789c85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_52211f79-4f7e-4f78-80ad-7b7f912389a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_581c3e52-199d-4950-af61-e511f566f8f0" xlink:to="loc_us-gaap_VariableRateAxis_52211f79-4f7e-4f78-80ad-7b7f912389a0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_52211f79-4f7e-4f78-80ad-7b7f912389a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_52211f79-4f7e-4f78-80ad-7b7f912389a0" xlink:to="loc_us-gaap_VariableRateDomain_52211f79-4f7e-4f78-80ad-7b7f912389a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_00012e84-8414-4c3f-b2fe-7c52f239940f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_52211f79-4f7e-4f78-80ad-7b7f912389a0" xlink:to="loc_us-gaap_VariableRateDomain_00012e84-8414-4c3f-b2fe-7c52f239940f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ThreeMonthLondonInterbankOfferedRateMember_5f747a41-4d32-4865-be40-11b59a6fda9c" xlink:href="akba-20210930.xsd#akba_ThreeMonthLondonInterbankOfferedRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_00012e84-8414-4c3f-b2fe-7c52f239940f" xlink:to="loc_akba_ThreeMonthLondonInterbankOfferedRateMember_5f747a41-4d32-4865-be40-11b59a6fda9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_15bffa48-a346-4379-8f51-73e883c9ea0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_00012e84-8414-4c3f-b2fe-7c52f239940f" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_15bffa48-a346-4379-8f51-73e883c9ea0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis_2bb5e0b2-c911-4aac-acd9-7cd119dd9627" xlink:href="akba-20210930.xsd#akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_581c3e52-199d-4950-af61-e511f566f8f0" xlink:to="loc_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis_2bb5e0b2-c911-4aac-acd9-7cd119dd9627" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain_2bb5e0b2-c911-4aac-acd9-7cd119dd9627_default" xlink:href="akba-20210930.xsd#akba_DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis_2bb5e0b2-c911-4aac-acd9-7cd119dd9627" xlink:to="loc_akba_DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain_2bb5e0b2-c911-4aac-acd9-7cd119dd9627_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain_19559ec4-0c99-46da-99ca-453dd3701ebc" xlink:href="akba-20210930.xsd#akba_DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis_2bb5e0b2-c911-4aac-acd9-7cd119dd9627" xlink:to="loc_akba_DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain_19559ec4-0c99-46da-99ca-453dd3701ebc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodOneMember_e7258256-2ef6-4031-ab41-397c12444d23" xlink:href="akba-20210930.xsd#akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain_19559ec4-0c99-46da-99ca-453dd3701ebc" xlink:to="loc_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodOneMember_e7258256-2ef6-4031-ab41-397c12444d23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodTwoMember_24cd0a55-9f5a-4c9d-a96e-cabbdb653c25" xlink:href="akba-20210930.xsd#akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain_19559ec4-0c99-46da-99ca-453dd3701ebc" xlink:to="loc_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodTwoMember_24cd0a55-9f5a-4c9d-a96e-cabbdb653c25" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://akebia.com/role/WarrantDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#WarrantDetails"/>
  <link:definitionLink xlink:role="http://akebia.com/role/WarrantDetails" xlink:type="extended" id="i8ecbd5100dd240c1aedd62a505d93493_WarrantDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_7ad1a9d0-df5a-4dbc-8b73-2c08f3ab865b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_54de4581-490e-47c0-8b12-4e4a4db3a4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_7ad1a9d0-df5a-4dbc-8b73-2c08f3ab865b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_54de4581-490e-47c0-8b12-4e4a4db3a4c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f6c506df-d182-4e5c-942d-f9690d02510b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_7ad1a9d0-df5a-4dbc-8b73-2c08f3ab865b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f6c506df-d182-4e5c-942d-f9690d02510b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_ede672cd-e52e-42b8-8b34-dfa2277df838" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_7ad1a9d0-df5a-4dbc-8b73-2c08f3ab865b" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_ede672cd-e52e-42b8-8b34-dfa2277df838" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_f32d6fa2-63b5-4180-ac70-717f09334b10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_7ad1a9d0-df5a-4dbc-8b73-2c08f3ab865b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_f32d6fa2-63b5-4180-ac70-717f09334b10" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9f2b5888-bde8-487a-a74f-65b246782913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f32d6fa2-63b5-4180-ac70-717f09334b10" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9f2b5888-bde8-487a-a74f-65b246782913" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9f2b5888-bde8-487a-a74f-65b246782913_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9f2b5888-bde8-487a-a74f-65b246782913" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9f2b5888-bde8-487a-a74f-65b246782913_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5379ccae-fb2e-40f8-b879-fcd4b9156642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9f2b5888-bde8-487a-a74f-65b246782913" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5379ccae-fb2e-40f8-b879-fcd4b9156642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_JanssenAgreementMember_df772d3d-ea9f-4138-9071-4f991eb8739a" xlink:href="akba-20210930.xsd#akba_JanssenAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5379ccae-fb2e-40f8-b879-fcd4b9156642" xlink:to="loc_akba_JanssenAgreementMember_df772d3d-ea9f-4138-9071-4f991eb8739a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://akebia.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://akebia.com/role/StockholdersEquityDetails" xlink:type="extended" id="i8d196762fddc4d62b8ca5cdb429c4af4_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f7d5deea-ba4e-4fab-bb3f-3d9aab12e317" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f7d5deea-ba4e-4fab-bb3f-3d9aab12e317" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5607ce88-e4d0-410e-8cf5-f9bae99e6f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5607ce88-e4d0-410e-8cf5-f9bae99e6f57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_734752ad-f97b-4c01-9d44-c0b14f855e42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_CommonStockSharesIssued_734752ad-f97b-4c01-9d44-c0b14f855e42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2be3a260-9a6c-444d-bd83-2c3b68ebbad4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2be3a260-9a6c-444d-bd83-2c3b68ebbad4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9a84d183-ad73-4d27-8cd5-b6311d59e540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9a84d183-ad73-4d27-8cd5-b6311d59e540" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c0fa019a-be37-48ad-9cb3-4613a7f17223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c0fa019a-be37-48ad-9cb3-4613a7f17223" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_ecf7e8ff-438e-4942-9221-5fac94e82587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_PreferredStockSharesIssued_ecf7e8ff-438e-4942-9221-5fac94e82587" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f7711fc4-8fda-4f1a-94e9-0f555568bf32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f7711fc4-8fda-4f1a-94e9-0f555568bf32" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CommonStockSalesAgreementAmount_fc18fa37-2a6a-4e2a-be23-fb7fb4cfdf3d" xlink:href="akba-20210930.xsd#akba_CommonStockSalesAgreementAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_akba_CommonStockSalesAgreementAmount_fc18fa37-2a6a-4e2a-be23-fb7fb4cfdf3d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8f2e0218-14a9-4886-978c-57bee0ea144f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8f2e0218-14a9-4886-978c-57bee0ea144f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_86f29b29-674a-43b6-8427-ba5d680351ec" xlink:href="akba-20210930.xsd#akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_86f29b29-674a-43b6-8427-ba5d680351ec" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9e4579ed-da8b-4777-9cc1-8df19162586b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9e4579ed-da8b-4777-9cc1-8df19162586b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9620d562-d30c-4d17-bd0f-b764a08956af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9620d562-d30c-4d17-bd0f-b764a08956af" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a03660ee-3f81-489f-a76f-e4fa13344ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a03660ee-3f81-489f-a76f-e4fa13344ac5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding_ed3b2543-85ef-4cee-97c3-a3ff2cfaa0a6" xlink:href="akba-20210930.xsd#akba_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_akba_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding_ed3b2543-85ef-4cee-97c3-a3ff2cfaa0a6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5d3241a6-e963-482e-b8d9-18d1bf2a9332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5d3241a6-e963-482e-b8d9-18d1bf2a9332" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d3f19b77-4d2e-4d60-a292-fc08fa635a77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d3f19b77-4d2e-4d60-a292-fc08fa635a77" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments_a4d8bb54-f1f4-476f-8ef3-dc090bb729bb" xlink:href="akba-20210930.xsd#akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments_a4d8bb54-f1f4-476f-8ef3-dc090bb729bb" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f423f007-2ec6-4757-9fd8-bb63af695bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f423f007-2ec6-4757-9fd8-bb63af695bd4" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6c1daf8d-af54-453b-ac26-c10a6ee3a7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6c1daf8d-af54-453b-ac26-c10a6ee3a7c9" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod_f45f44e1-cf54-4fa6-ba59-b908370e86c2" xlink:href="akba-20210930.xsd#akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod_f45f44e1-cf54-4fa6-ba59-b908370e86c2" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_966a2391-639c-4ab7-b92b-40e5d4d68223" xlink:href="akba-20210930.xsd#akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_966a2391-639c-4ab7-b92b-40e5d4d68223" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_8b8f3e9f-a033-4a32-b915-bb561da45feb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_8b8f3e9f-a033-4a32-b915-bb561da45feb" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_272a56be-cf37-4782-a4ce-ef36daa1980d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_272a56be-cf37-4782-a4ce-ef36daa1980d" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_8ae6b429-71cb-4a94-9399-8cb4f5ee8876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_8ae6b429-71cb-4a94-9399-8cb4f5ee8876" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_34ca0a79-e4cc-4f1d-ae55-c454fb5e1501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8ae6b429-71cb-4a94-9399-8cb4f5ee8876" xlink:to="loc_us-gaap_PlanNameAxis_34ca0a79-e4cc-4f1d-ae55-c454fb5e1501" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_34ca0a79-e4cc-4f1d-ae55-c454fb5e1501_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_34ca0a79-e4cc-4f1d-ae55-c454fb5e1501" xlink:to="loc_us-gaap_PlanNameDomain_34ca0a79-e4cc-4f1d-ae55-c454fb5e1501_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_aafcb1e5-c06f-4598-855d-5ed014773055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_34ca0a79-e4cc-4f1d-ae55-c454fb5e1501" xlink:to="loc_us-gaap_PlanNameDomain_aafcb1e5-c06f-4598-855d-5ed014773055" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AtTheMarketEquityOfferingProgramMember_d1a226fb-a324-40e3-b249-c6d1769428d4" xlink:href="akba-20210930.xsd#akba_AtTheMarketEquityOfferingProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_aafcb1e5-c06f-4598-855d-5ed014773055" xlink:to="loc_akba_AtTheMarketEquityOfferingProgramMember_d1a226fb-a324-40e3-b249-c6d1769428d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_TwoThousandAndFourteenPlansMember_dd80e4e3-687d-4326-a6e6-df61b7cd922f" xlink:href="akba-20210930.xsd#akba_TwoThousandAndFourteenPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_aafcb1e5-c06f-4598-855d-5ed014773055" xlink:to="loc_akba_TwoThousandAndFourteenPlansMember_dd80e4e3-687d-4326-a6e6-df61b7cd922f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_793f46dd-cc44-4277-bc06-cdc8e1242d88" xlink:href="akba-20210930.xsd#akba_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_aafcb1e5-c06f-4598-855d-5ed014773055" xlink:to="loc_akba_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_793f46dd-cc44-4277-bc06-cdc8e1242d88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5ea6a566-e2b5-4476-a302-7fbd08fe0dcb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8ae6b429-71cb-4a94-9399-8cb4f5ee8876" xlink:to="loc_srt_RangeAxis_5ea6a566-e2b5-4476-a302-7fbd08fe0dcb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5ea6a566-e2b5-4476-a302-7fbd08fe0dcb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5ea6a566-e2b5-4476-a302-7fbd08fe0dcb" xlink:to="loc_srt_RangeMember_5ea6a566-e2b5-4476-a302-7fbd08fe0dcb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3b3262f3-6fb8-4473-91fa-12e9ca2b5116" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5ea6a566-e2b5-4476-a302-7fbd08fe0dcb" xlink:to="loc_srt_RangeMember_3b3262f3-6fb8-4473-91fa-12e9ca2b5116" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9cf91ef2-a405-45fe-8c95-01a8b5e15e74" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3b3262f3-6fb8-4473-91fa-12e9ca2b5116" xlink:to="loc_srt_MinimumMember_9cf91ef2-a405-45fe-8c95-01a8b5e15e74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_42e1629f-a520-42e4-b56e-7513e2505d9e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3b3262f3-6fb8-4473-91fa-12e9ca2b5116" xlink:to="loc_srt_MaximumMember_42e1629f-a520-42e4-b56e-7513e2505d9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_17fe126a-56b8-4490-af00-891d73aa15cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8ae6b429-71cb-4a94-9399-8cb4f5ee8876" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_17fe126a-56b8-4490-af00-891d73aa15cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_17fe126a-56b8-4490-af00-891d73aa15cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_17fe126a-56b8-4490-af00-891d73aa15cd" xlink:to="loc_us-gaap_EquityComponentDomain_17fe126a-56b8-4490-af00-891d73aa15cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b8eda34d-f8c9-4c42-95a3-8c87ad3f46da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_17fe126a-56b8-4490-af00-891d73aa15cd" xlink:to="loc_us-gaap_EquityComponentDomain_b8eda34d-f8c9-4c42-95a3-8c87ad3f46da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c027e1d4-a722-491a-9aa0-518aabe926ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8eda34d-f8c9-4c42-95a3-8c87ad3f46da" xlink:to="loc_us-gaap_CommonStockMember_c027e1d4-a722-491a-9aa0-518aabe926ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1787264d-7453-4a7e-9800-381e978c53b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8ae6b429-71cb-4a94-9399-8cb4f5ee8876" xlink:to="loc_us-gaap_AwardTypeAxis_1787264d-7453-4a7e-9800-381e978c53b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1787264d-7453-4a7e-9800-381e978c53b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1787264d-7453-4a7e-9800-381e978c53b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1787264d-7453-4a7e-9800-381e978c53b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d675b3ce-a1ce-425c-9ed2-d448ac2f338d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1787264d-7453-4a7e-9800-381e978c53b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d675b3ce-a1ce-425c-9ed2-d448ac2f338d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_InducementAwardProgramMember_40cf7c52-4da1-45d2-a0cd-c34f30ac6ccf" xlink:href="akba-20210930.xsd#akba_InducementAwardProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d675b3ce-a1ce-425c-9ed2-d448ac2f338d" xlink:to="loc_akba_InducementAwardProgramMember_40cf7c52-4da1-45d2-a0cd-c34f30ac6ccf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ab27a0e6-b095-4a53-96f4-5acc75bdd132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d675b3ce-a1ce-425c-9ed2-d448ac2f338d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ab27a0e6-b095-4a53-96f4-5acc75bdd132" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_68e6d51d-fe75-407c-84de-ad552a7daf34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d675b3ce-a1ce-425c-9ed2-d448ac2f338d" xlink:to="loc_us-gaap_PerformanceSharesMember_68e6d51d-fe75-407c-84de-ad552a7daf34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ServiceBasedRestrictedStockUnitsMember_39169fe0-08d5-41d8-b8dd-824c0e99ca4a" xlink:href="akba-20210930.xsd#akba_ServiceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d675b3ce-a1ce-425c-9ed2-d448ac2f338d" xlink:to="loc_akba_ServiceBasedRestrictedStockUnitsMember_39169fe0-08d5-41d8-b8dd-824c0e99ca4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PerformanceBasedRestrictedStockUnitsMember_f8f87132-ad7d-4ed4-ac65-662dc4cc0cdd" xlink:href="akba-20210930.xsd#akba_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d675b3ce-a1ce-425c-9ed2-d448ac2f338d" xlink:to="loc_akba_PerformanceBasedRestrictedStockUnitsMember_f8f87132-ad7d-4ed4-ac65-662dc4cc0cdd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_01e36c5d-b09a-455e-a50b-69e3d4781c3c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8ae6b429-71cb-4a94-9399-8cb4f5ee8876" xlink:to="loc_srt_TitleOfIndividualAxis_01e36c5d-b09a-455e-a50b-69e3d4781c3c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_01e36c5d-b09a-455e-a50b-69e3d4781c3c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_01e36c5d-b09a-455e-a50b-69e3d4781c3c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_01e36c5d-b09a-455e-a50b-69e3d4781c3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cf77b429-5384-4664-888d-8b64da4212a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_01e36c5d-b09a-455e-a50b-69e3d4781c3c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cf77b429-5384-4664-888d-8b64da4212a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_EmployeesMember_b52be249-da83-4f15-8c32-683d5224b04e" xlink:href="akba-20210930.xsd#akba_EmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cf77b429-5384-4664-888d-8b64da4212a9" xlink:to="loc_akba_EmployeesMember_b52be249-da83-4f15-8c32-683d5224b04e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_74eb1763-7317-4755-a7ba-0d47cee685da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cf77b429-5384-4664-888d-8b64da4212a9" xlink:to="loc_srt_DirectorMember_74eb1763-7317-4755-a7ba-0d47cee685da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_5b375371-1d4e-495a-a855-e9fd8d8c4fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8ae6b429-71cb-4a94-9399-8cb4f5ee8876" xlink:to="loc_us-gaap_VestingAxis_5b375371-1d4e-495a-a855-e9fd8d8c4fb3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_5b375371-1d4e-495a-a855-e9fd8d8c4fb3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_5b375371-1d4e-495a-a855-e9fd8d8c4fb3" xlink:to="loc_us-gaap_VestingDomain_5b375371-1d4e-495a-a855-e9fd8d8c4fb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_8c9268d0-8cb8-4cf1-90d5-8157de831e97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_5b375371-1d4e-495a-a855-e9fd8d8c4fb3" xlink:to="loc_us-gaap_VestingDomain_8c9268d0-8cb8-4cf1-90d5-8157de831e97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMember_d54c203b-9db1-4ebd-9a1a-d26fede9cf93" xlink:href="akba-20210930.xsd#akba_ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_8c9268d0-8cb8-4cf1-90d5-8157de831e97" xlink:to="loc_akba_ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMember_d54c203b-9db1-4ebd-9a1a-d26fede9cf93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_ca6eb036-587d-4736-8939-84a9a20f109a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_8c9268d0-8cb8-4cf1-90d5-8157de831e97" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_ca6eb036-587d-4736-8939-84a9a20f109a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_7a82ca01-93eb-42c0-9591-b93e002aaea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_8c9268d0-8cb8-4cf1-90d5-8157de831e97" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_7a82ca01-93eb-42c0-9591-b93e002aaea9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember_e45f0c9e-9fe2-46e0-85e3-0376a80bf1c7" xlink:href="akba-20210930.xsd#akba_ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_8c9268d0-8cb8-4cf1-90d5-8157de831e97" xlink:to="loc_akba_ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember_e45f0c9e-9fe2-46e0-85e3-0376a80bf1c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember_b834fe56-2ad6-43d6-9ca6-c9eb583ceffb" xlink:href="akba-20210930.xsd#akba_ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_8c9268d0-8cb8-4cf1-90d5-8157de831e97" xlink:to="loc_akba_ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember_b834fe56-2ad6-43d6-9ca6-c9eb583ceffb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ShareBasedPaymentArrangementTrancheTwoSecondAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember_98e9d71f-f9ee-4821-8fb4-a37fdd2b1e6c" xlink:href="akba-20210930.xsd#akba_ShareBasedPaymentArrangementTrancheTwoSecondAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_8c9268d0-8cb8-4cf1-90d5-8157de831e97" xlink:to="loc_akba_ShareBasedPaymentArrangementTrancheTwoSecondAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember_98e9d71f-f9ee-4821-8fb4-a37fdd2b1e6c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ShareBasedPaymentArrangementTrancheThreeThirdAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember_2cb6a9dd-b4a0-4bfc-ab70-43014af316b7" xlink:href="akba-20210930.xsd#akba_ShareBasedPaymentArrangementTrancheThreeThirdAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_8c9268d0-8cb8-4cf1-90d5-8157de831e97" xlink:to="loc_akba_ShareBasedPaymentArrangementTrancheThreeThirdAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember_2cb6a9dd-b4a0-4bfc-ab70-43014af316b7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8655467e-f4b5-4991-a6a3-dccdb40ceb89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8ae6b429-71cb-4a94-9399-8cb4f5ee8876" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8655467e-f4b5-4991-a6a3-dccdb40ceb89" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8655467e-f4b5-4991-a6a3-dccdb40ceb89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8655467e-f4b5-4991-a6a3-dccdb40ceb89" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8655467e-f4b5-4991-a6a3-dccdb40ceb89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a70c63b1-e48f-4ff9-89e9-a422ecf0d591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8655467e-f4b5-4991-a6a3-dccdb40ceb89" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a70c63b1-e48f-4ff9-89e9-a422ecf0d591" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member_aa506806-bdf3-492e-88e3-a0e9c3607afb" xlink:href="akba-20210930.xsd#akba_AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a70c63b1-e48f-4ff9-89e9-a422ecf0d591" xlink:to="loc_akba_AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member_aa506806-bdf3-492e-88e3-a0e9c3607afb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="icf428000b53c4da6b78f51c21f1008f5_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:href="akba-20210930.xsd#akba_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_9b84ccc5-4f18-4607-b803-ad06ba46306d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_9b84ccc5-4f18-4607-b803-ad06ba46306d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OperatingLeaseAnnualRentExpense_ea926272-2d4d-4805-a90c-045f847cb94b" xlink:href="akba-20210930.xsd#akba_OperatingLeaseAnnualRentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_OperatingLeaseAnnualRentExpense_ea926272-2d4d-4805-a90c-045f847cb94b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OperatingLeaseMonthlyRentExpense_a63632eb-09ec-4f66-9702-42bcb2034399" xlink:href="akba-20210930.xsd#akba_OperatingLeaseMonthlyRentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_OperatingLeaseMonthlyRentExpense_a63632eb-09ec-4f66-9702-42bcb2034399" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OperatingLeaseFreeMonthlyRentPeriod_2d52bee4-7c93-4e9b-a514-1c74a9a18cd6" xlink:href="akba-20210930.xsd#akba_OperatingLeaseFreeMonthlyRentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_OperatingLeaseFreeMonthlyRentPeriod_2d52bee4-7c93-4e9b-a514-1c74a9a18cd6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions_f1b72f2a-588b-499a-8e0e-9f5ffba0a90f" xlink:href="akba-20210930.xsd#akba_LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions_f1b72f2a-588b-499a-8e0e-9f5ffba0a90f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_1453a60b-e144-4c93-903f-10621a739c68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_1453a60b-e144-4c93-903f-10621a739c68" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_7515dbbf-f36c-43f2-9faf-c5d8f68a3c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_OperatingLeaseCost_7515dbbf-f36c-43f2-9faf-c5d8f68a3c19" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_0eaedaef-8d0f-4d9d-be78-e0080679e899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_OperatingLeasePayments_0eaedaef-8d0f-4d9d-be78-e0080679e899" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_cf3028c7-6bdc-4720-ad4b-c48499c2c73c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_SubleaseIncome_cf3028c7-6bdc-4720-ad4b-c48499c2c73c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_fa62ecc0-9743-41b9-aa5c-a219aaed253d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_SecurityDeposit_fa62ecc0-9743-41b9-aa5c-a219aaed253d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ba549b85-effe-418c-9a27-0f087b72df84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ba549b85-effe-418c-9a27-0f087b72df84" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_70276153-19d6-404f-b43f-9496f1659042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_70276153-19d6-404f-b43f-9496f1659042" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LongTermPurchaseCommitmentRenewalPeriod_dc767b21-f72a-4401-be9f-3efd95d902bc" xlink:href="akba-20210930.xsd#akba_LongTermPurchaseCommitmentRenewalPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_LongTermPurchaseCommitmentRenewalPeriod_dc767b21-f72a-4401-be9f-3efd95d902bc" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CostOfPurchasedMinimumQuantityProduct_d444fd92-ce93-4f1e-a3dc-f39a8e75ea37" xlink:href="akba-20210930.xsd#akba_CostOfPurchasedMinimumQuantityProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_CostOfPurchasedMinimumQuantityProduct_d444fd92-ce93-4f1e-a3dc-f39a8e75ea37" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod_d658eebc-d6b4-422c-86cc-65c50a1c3108" xlink:href="akba-20210930.xsd#akba_LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod_d658eebc-d6b4-422c-86cc-65c50a1c3108" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement_665e8ac3-a94a-4f75-95ef-9667859ecd36" xlink:href="akba-20210930.xsd#akba_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement_665e8ac3-a94a-4f75-95ef-9667859ecd36" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ExcessInventoryPurchaseCommitmentsExpenseReversal_52586dcb-6a9f-43a2-af98-612c16e805ea" xlink:href="akba-20210930.xsd#akba_ExcessInventoryPurchaseCommitmentsExpenseReversal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_ExcessInventoryPurchaseCommitmentsExpenseReversal_52586dcb-6a9f-43a2-af98-612c16e805ea" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial_e4b115c3-8c5c-490e-91dd-93e2c3cbc2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostDirectMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_CostDirectMaterial_e4b115c3-8c5c-490e-91dd-93e2c3cbc2b4" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_InitialTermOfSupplyAgreement_3f8546fd-6c3b-49a3-9942-7f300bee7d58" xlink:href="akba-20210930.xsd#akba_InitialTermOfSupplyAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_InitialTermOfSupplyAgreement_3f8546fd-6c3b-49a3-9942-7f300bee7d58" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_bc3e92bd-62f6-453c-9974-cd5265d1c1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_bc3e92bd-62f6-453c-9974-cd5265d1c1b0" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_b1356957-31e4-42b9-8166-b21055e1f23f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_b1356957-31e4-42b9-8166-b21055e1f23f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_8e77eeec-fbb5-45da-b1f8-90a1fa90a66e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_8e77eeec-fbb5-45da-b1f8-90a1fa90a66e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LongTermPurchaseCommitmentFixedPricePeriod_4ee41784-e649-4a26-a581-5798607e4d7e" xlink:href="akba-20210930.xsd#akba_LongTermPurchaseCommitmentFixedPricePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_LongTermPurchaseCommitmentFixedPricePeriod_4ee41784-e649-4a26-a581-5798607e4d7e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod_95a7543e-a071-440c-af38-1e0c1e1c80ef" xlink:href="akba-20210930.xsd#akba_LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod_95a7543e-a071-440c-af38-1e0c1e1c80ef" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PurchaseCommittedProgramRemainingContractCosts_c2aa444e-e30d-4176-b195-312ae09fd66c" xlink:href="akba-20210930.xsd#akba_PurchaseCommittedProgramRemainingContractCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_PurchaseCommittedProgramRemainingContractCosts_c2aa444e-e30d-4176-b195-312ae09fd66c" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_2beb0290-5d8f-4e34-b756-0cb6191e9ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_2beb0290-5d8f-4e34-b756-0cb6191e9ace" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CommitmentsAndContingenciesTable_9b89688e-26e9-4d76-92d7-1a770d087bbb" xlink:href="akba-20210930.xsd#akba_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_CommitmentsAndContingenciesTable_9b89688e-26e9-4d76-92d7-1a770d087bbb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_831f8bb2-46ce-47aa-825a-e2a823d2c75e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_akba_CommitmentsAndContingenciesTable_9b89688e-26e9-4d76-92d7-1a770d087bbb" xlink:to="loc_srt_StatementGeographicalAxis_831f8bb2-46ce-47aa-825a-e2a823d2c75e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_831f8bb2-46ce-47aa-825a-e2a823d2c75e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_831f8bb2-46ce-47aa-825a-e2a823d2c75e" xlink:to="loc_srt_SegmentGeographicalDomain_831f8bb2-46ce-47aa-825a-e2a823d2c75e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4fcf4bd2-f9f5-46ed-988f-a41c106a8967" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_831f8bb2-46ce-47aa-825a-e2a823d2c75e" xlink:to="loc_srt_SegmentGeographicalDomain_4fcf4bd2-f9f5-46ed-988f-a41c106a8967" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CambridgeMember_a91f0d01-783b-47b9-ad69-b0c2ea2edc0b" xlink:href="akba-20210930.xsd#akba_CambridgeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4fcf4bd2-f9f5-46ed-988f-a41c106a8967" xlink:to="loc_akba_CambridgeMember_a91f0d01-783b-47b9-ad69-b0c2ea2edc0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_BostonMember_1e45a5a6-cb20-4908-8df9-742afd0803fb" xlink:href="akba-20210930.xsd#akba_BostonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4fcf4bd2-f9f5-46ed-988f-a41c106a8967" xlink:to="loc_akba_BostonMember_1e45a5a6-cb20-4908-8df9-742afd0803fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ee7a6e53-afce-4476-887c-5d96600563c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_akba_CommitmentsAndContingenciesTable_9b89688e-26e9-4d76-92d7-1a770d087bbb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ee7a6e53-afce-4476-887c-5d96600563c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee7a6e53-afce-4476-887c-5d96600563c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ee7a6e53-afce-4476-887c-5d96600563c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee7a6e53-afce-4476-887c-5d96600563c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2f0d9e53-c87a-45b3-bcd4-7cb2c36dc75b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ee7a6e53-afce-4476-887c-5d96600563c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2f0d9e53-c87a-45b3-bcd4-7cb2c36dc75b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OfficeSpaceMember_a66a82df-e15a-497c-b73b-a185dd9b5893" xlink:href="akba-20210930.xsd#akba_OfficeSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2f0d9e53-c87a-45b3-bcd4-7cb2c36dc75b" xlink:to="loc_akba_OfficeSpaceMember_a66a82df-e15a-497c-b73b-a185dd9b5893" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_11c02d0c-ab46-471b-a1a0-0bc5061e0a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_akba_CommitmentsAndContingenciesTable_9b89688e-26e9-4d76-92d7-1a770d087bbb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_11c02d0c-ab46-471b-a1a0-0bc5061e0a6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_11c02d0c-ab46-471b-a1a0-0bc5061e0a6b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_11c02d0c-ab46-471b-a1a0-0bc5061e0a6b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_11c02d0c-ab46-471b-a1a0-0bc5061e0a6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a313229d-bd8e-45b4-8179-467d85c0fd24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_11c02d0c-ab46-471b-a1a0-0bc5061e0a6b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a313229d-bd8e-45b4-8179-467d85c0fd24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_KeryxBiopharmaceuticalsIncMember_4a66e4e4-f634-4e34-9305-f2d308ca2f6b" xlink:href="akba-20210930.xsd#akba_KeryxBiopharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a313229d-bd8e-45b4-8179-467d85c0fd24" xlink:to="loc_akba_KeryxBiopharmaceuticalsIncMember_4a66e4e4-f634-4e34-9305-f2d308ca2f6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_c8f1b944-1e46-41c4-b7f4-8c98a8af2e34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_akba_CommitmentsAndContingenciesTable_9b89688e-26e9-4d76-92d7-1a770d087bbb" xlink:to="loc_us-gaap_CreditFacilityAxis_c8f1b944-1e46-41c4-b7f4-8c98a8af2e34" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c8f1b944-1e46-41c4-b7f4-8c98a8af2e34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_c8f1b944-1e46-41c4-b7f4-8c98a8af2e34" xlink:to="loc_us-gaap_CreditFacilityDomain_c8f1b944-1e46-41c4-b7f4-8c98a8af2e34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b12c5eec-7c33-4ba4-83f7-9f4170963915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_c8f1b944-1e46-41c4-b7f4-8c98a8af2e34" xlink:to="loc_us-gaap_CreditFacilityDomain_b12c5eec-7c33-4ba4-83f7-9f4170963915" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_35209b13-2012-4529-bdca-ec3ea3684719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_b12c5eec-7c33-4ba4-83f7-9f4170963915" xlink:to="loc_us-gaap_LetterOfCreditMember_35209b13-2012-4529-bdca-ec3ea3684719" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_09aeb0c9-ea41-495c-9501-4faee8c96518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_akba_CommitmentsAndContingenciesTable_9b89688e-26e9-4d76-92d7-1a770d087bbb" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_09aeb0c9-ea41-495c-9501-4faee8c96518" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_09aeb0c9-ea41-495c-9501-4faee8c96518_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_09aeb0c9-ea41-495c-9501-4faee8c96518" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_09aeb0c9-ea41-495c-9501-4faee8c96518_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1ff1c5e7-321b-4932-a261-001638717481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_09aeb0c9-ea41-495c-9501-4faee8c96518" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1ff1c5e7-321b-4932-a261-001638717481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_db14bec4-01f9-41a8-a5b0-be1dc3492521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1ff1c5e7-321b-4932-a261-001638717481" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_db14bec4-01f9-41a8-a5b0-be1dc3492521" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a48cd2e6-18e4-42d5-ba47-bec7b69c4e53" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_akba_CommitmentsAndContingenciesTable_9b89688e-26e9-4d76-92d7-1a770d087bbb" xlink:to="loc_srt_RangeAxis_a48cd2e6-18e4-42d5-ba47-bec7b69c4e53" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a48cd2e6-18e4-42d5-ba47-bec7b69c4e53_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a48cd2e6-18e4-42d5-ba47-bec7b69c4e53" xlink:to="loc_srt_RangeMember_a48cd2e6-18e4-42d5-ba47-bec7b69c4e53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b3f12e5d-9266-4177-8872-006cbd1589b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a48cd2e6-18e4-42d5-ba47-bec7b69c4e53" xlink:to="loc_srt_RangeMember_b3f12e5d-9266-4177-8872-006cbd1589b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a89b55fd-f825-4654-a41e-4f2eababc25d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b3f12e5d-9266-4177-8872-006cbd1589b6" xlink:to="loc_srt_MinimumMember_a89b55fd-f825-4654-a41e-4f2eababc25d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5a0f6756-7729-4ae8-9e66-61f017f4337b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b3f12e5d-9266-4177-8872-006cbd1589b6" xlink:to="loc_srt_MaximumMember_5a0f6756-7729-4ae8-9e66-61f017f4337b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_795854dc-c1db-4470-a4a3-4ad984ee8559" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_akba_CommitmentsAndContingenciesTable_9b89688e-26e9-4d76-92d7-1a770d087bbb" xlink:to="loc_srt_CounterpartyNameAxis_795854dc-c1db-4470-a4a3-4ad984ee8559" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_795854dc-c1db-4470-a4a3-4ad984ee8559_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_795854dc-c1db-4470-a4a3-4ad984ee8559" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_795854dc-c1db-4470-a4a3-4ad984ee8559_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d13e2032-af6d-4bad-b0cf-6f783bd29b46" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_795854dc-c1db-4470-a4a3-4ad984ee8559" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d13e2032-af6d-4bad-b0cf-6f783bd29b46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_BioVectraIncMember_686a9d66-41ff-41f5-99db-3b619cf12518" xlink:href="akba-20210930.xsd#akba_BioVectraIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d13e2032-af6d-4bad-b0cf-6f783bd29b46" xlink:to="loc_akba_BioVectraIncMember_686a9d66-41ff-41f5-99db-3b619cf12518" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_SiegfriedEvionnazSAMember_fd8476eb-3770-409e-a13a-296fd4379a67" xlink:href="akba-20210930.xsd#akba_SiegfriedEvionnazSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d13e2032-af6d-4bad-b0cf-6f783bd29b46" xlink:to="loc_akba_SiegfriedEvionnazSAMember_fd8476eb-3770-409e-a13a-296fd4379a67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_EsteveQuimicaSAMember_4dd23374-e1dd-4df8-84dc-85f695e1e7db" xlink:href="akba-20210930.xsd#akba_EsteveQuimicaSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d13e2032-af6d-4bad-b0cf-6f783bd29b46" xlink:to="loc_akba_EsteveQuimicaSAMember_4dd23374-e1dd-4df8-84dc-85f695e1e7db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_STAPharmaceuticalHongKongLimitedMember_b6c1c51b-ad95-45cc-a8b6-c206ef8c51b7" xlink:href="akba-20210930.xsd#akba_STAPharmaceuticalHongKongLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d13e2032-af6d-4bad-b0cf-6f783bd29b46" xlink:to="loc_akba_STAPharmaceuticalHongKongLimitedMember_b6c1c51b-ad95-45cc-a8b6-c206ef8c51b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_WuXiSTAMember_7d89eeea-64bd-4a34-a7c1-847d55939ce5" xlink:href="akba-20210930.xsd#akba_WuXiSTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d13e2032-af6d-4bad-b0cf-6f783bd29b46" xlink:to="loc_akba_WuXiSTAMember_7d89eeea-64bd-4a34-a7c1-847d55939ce5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_9b95788f-684f-4513-9c0b-0fa9ca3fe38f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_akba_CommitmentsAndContingenciesTable_9b89688e-26e9-4d76-92d7-1a770d087bbb" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_9b95788f-684f-4513-9c0b-0fa9ca3fe38f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_9b95788f-684f-4513-9c0b-0fa9ca3fe38f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_9b95788f-684f-4513-9c0b-0fa9ca3fe38f" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_9b95788f-684f-4513-9c0b-0fa9ca3fe38f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_31d11ad4-d5b1-4480-8630-90dd4ffa49b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_9b95788f-684f-4513-9c0b-0fa9ca3fe38f" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_31d11ad4-d5b1-4480-8630-90dd4ffa49b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_SupplyAgreementPatheonIncMember_bf0f7fe4-ed9b-443b-b16f-2d960eb1936d" xlink:href="akba-20210930.xsd#akba_SupplyAgreementPatheonIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_31d11ad4-d5b1-4480-8630-90dd4ffa49b5" xlink:to="loc_akba_SupplyAgreementPatheonIncMember_bf0f7fe4-ed9b-443b-b16f-2d960eb1936d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_130b8c26-b85d-49f9-bdca-261f2d18d6be" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_akba_CommitmentsAndContingenciesTable_9b89688e-26e9-4d76-92d7-1a770d087bbb" xlink:to="loc_srt_StatementScenarioAxis_130b8c26-b85d-49f9-bdca-261f2d18d6be" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_130b8c26-b85d-49f9-bdca-261f2d18d6be_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_130b8c26-b85d-49f9-bdca-261f2d18d6be" xlink:to="loc_srt_ScenarioUnspecifiedDomain_130b8c26-b85d-49f9-bdca-261f2d18d6be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_c72a691c-6d4a-477b-95fe-0f4136ba4aaf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_130b8c26-b85d-49f9-bdca-261f2d18d6be" xlink:to="loc_srt_ScenarioUnspecifiedDomain_c72a691c-6d4a-477b-95fe-0f4136ba4aaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_c8b706cf-8950-4986-887f-9af6cf5f3351" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_c72a691c-6d4a-477b-95fe-0f4136ba4aaf" xlink:to="loc_srt_ScenarioForecastMember_c8b706cf-8950-4986-887f-9af6cf5f3351" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://akebia.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#NetLossperShareAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossperShareDetails"/>
  <link:definitionLink xlink:role="http://akebia.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossperShareDetails" xlink:type="extended" id="i82ca88a28ee44205a57356f4aba7fb37_NetLossperShareAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9bef5288-7a02-405c-8a7e-4ee57f90010d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d559b527-d84d-43fc-a4b1-1755dcf2e13f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9bef5288-7a02-405c-8a7e-4ee57f90010d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d559b527-d84d-43fc-a4b1-1755dcf2e13f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2d1c07a7-f1ad-4686-a5ef-3f22299e7911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9bef5288-7a02-405c-8a7e-4ee57f90010d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2d1c07a7-f1ad-4686-a5ef-3f22299e7911" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e7c25aec-f1f5-4249-aad7-a77fad480904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2d1c07a7-f1ad-4686-a5ef-3f22299e7911" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e7c25aec-f1f5-4249-aad7-a77fad480904" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e7c25aec-f1f5-4249-aad7-a77fad480904_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e7c25aec-f1f5-4249-aad7-a77fad480904" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e7c25aec-f1f5-4249-aad7-a77fad480904_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_619c48d7-a1e7-4d0c-8337-1503dca66a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e7c25aec-f1f5-4249-aad7-a77fad480904" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_619c48d7-a1e7-4d0c-8337-1503dca66a3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_389943f2-83eb-4fc8-b77a-de90cb81601a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_619c48d7-a1e7-4d0c-8337-1503dca66a3d" xlink:to="loc_us-gaap_WarrantMember_389943f2-83eb-4fc8-b77a-de90cb81601a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9034fe3d-bc21-475b-993e-5423a1eb7630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_619c48d7-a1e7-4d0c-8337-1503dca66a3d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9034fe3d-bc21-475b-993e-5423a1eb7630" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f3c1570e-24b7-4b70-8b8c-74a15c86acf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_619c48d7-a1e7-4d0c-8337-1503dca66a3d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f3c1570e-24b7-4b70-8b8c-74a15c86acf3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>akba-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:8995f2ec-9597-4fb5-818e-5018ad7b3654,g:f42f20af-e08c-4deb-ba3d-2a8688a2b01d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod_57caf561-e66b-4456-b244-9e433fc3d96f_terseLabel_en-US" xlink:label="lab_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting grace period</link:label>
    <link:label id="lab_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod_label_en-US" xlink:label="lab_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Grace Period</link:label>
    <link:label id="lab_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod_documentation_en-US" xlink:label="lab_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Grace Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod" xlink:href="akba-20210930.xsd#akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod" xlink:to="lab_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1fda8703-0f38-4056-91d9-514b282d460c_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_fb38da79-cfab-4f82-90a2-837ea82d6f39_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_f3b60f42-0b7d-4950-a898-bc5793c37db6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain/(Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_cf107fac-cfb2-4bca-8824-e18c3ecf46a0_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches_609461de-5472-4ec2-8f02-426366d630cc_terseLabel_en-US" xlink:label="lab_akba_LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, maximum borrowing capacity, number of available tranches</link:label>
    <link:label id="lab_akba_LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches_label_en-US" xlink:label="lab_akba_LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Maximum Borrowing Capacity, Number Of Available Tranches</link:label>
    <link:label id="lab_akba_LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches_documentation_en-US" xlink:label="lab_akba_LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Maximum Borrowing Capacity, Number Of Available Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches" xlink:href="akba-20210930.xsd#akba_LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches" xlink:to="lab_akba_LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1714cbe4-24c8-4f4f-a929-851591c150e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_ff28b164-a47e-4bfa-9075-06519766b9cd_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_0332a72b-c334-40ad-a043-513725cade58_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_79884f92-8e56-453b-8457-77705e8aa6eb_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding_7c0c686b-6799-424b-a699-9d03954e3d15_terseLabel_en-US" xlink:label="lab_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment premium percentage on principal if prepaid prior to fourth anniversary and after third anniversary of funding</link:label>
    <link:label id="lab_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding_label_en-US" xlink:label="lab_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Premium Percentage On Principal If Prepaid Prior To Fourth Anniversary And After Third Anniversary Of Funding</link:label>
    <link:label id="lab_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding_documentation_en-US" xlink:label="lab_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment premium percentage on principal if prepaid prior to fourth anniversary and after third anniversary of funding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding" xlink:href="akba-20210930.xsd#akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding" xlink:to="lab_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable_a7e39ca2-ffa4-478b-95df-01caacf30862_negatedTerseLabel_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTPC royalties payable</link:label>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable_label_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Arrangement, Royalties Agreement, Royalties, Earned And Payable</link:label>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable_documentation_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Arrangement, Royalties Agreement, Royalties, Earned And Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable" xlink:to="lab_akba_ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_10a17791-5504-4299-a592-9e04f445949b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_LicensedProductsMember_55266cc0-8ebb-43fb-9af5-d1588234d2fd_terseLabel_en-US" xlink:label="lab_akba_LicensedProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensed Products</link:label>
    <link:label id="lab_akba_LicensedProductsMember_label_en-US" xlink:label="lab_akba_LicensedProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensed Products [Member]</link:label>
    <link:label id="lab_akba_LicensedProductsMember_documentation_en-US" xlink:label="lab_akba_LicensedProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensed Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicensedProductsMember" xlink:href="akba-20210930.xsd#akba_LicensedProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_LicensedProductsMember" xlink:to="lab_akba_LicensedProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_b83e19ec-ba92-44f3-afdb-f2230ff2b250_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_5cac3cf8-ff18-4831-b0e8-01bbb8496675_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and related</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_a2230b28-69f8-4a22-aa4f-796a07a911ac_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d4e15e6b-fe93-44f1-a999-fe5daff20202_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_632a36f9-a3d1-4c69-abd1-33b839932802_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_6c5f2d4f-32cb-4e94-bd24-a04e84d98b72_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_6b311c15-b382-41b9-8141-5c545ddda53f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_6cd8c0f7-178a-4eb8-afcb-47c5a324f02a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_9ea91361-9beb-4abe-9e2c-58b54ee878f7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Contract Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_ee789456-1516-4406-b37b-0993ba30d8df_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_77a87cde-df00-403a-b177-1fcf31ac13e8_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c4ea0e88-576f-4996-93be-c6ca95c3e65a_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset impairment charge</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ShareBasedPaymentArrangementTrancheThreeThirdAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember_d6239126-f4f8-4ea0-b55f-306ea0800e8c_terseLabel_en-US" xlink:label="lab_akba_ShareBasedPaymentArrangementTrancheThreeThirdAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three, Third Anniversary After Grant Date, Subjected To Individual Continued Service</link:label>
    <link:label id="lab_akba_ShareBasedPaymentArrangementTrancheThreeThirdAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember_label_en-US" xlink:label="lab_akba_ShareBasedPaymentArrangementTrancheThreeThirdAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three, Third Anniversary After Grant Date, Subjected To Individual Continued Service [Member]</link:label>
    <link:label id="lab_akba_ShareBasedPaymentArrangementTrancheThreeThirdAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember_documentation_en-US" xlink:label="lab_akba_ShareBasedPaymentArrangementTrancheThreeThirdAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three, Third Anniversary After Grant Date, Subjected To Individual Continued Service</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ShareBasedPaymentArrangementTrancheThreeThirdAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember" xlink:href="akba-20210930.xsd#akba_ShareBasedPaymentArrangementTrancheThreeThirdAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ShareBasedPaymentArrangementTrancheThreeThirdAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember" xlink:to="lab_akba_ShareBasedPaymentArrangementTrancheThreeThirdAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_36457249-ea91-4c3a-b758-ad45e44ad331_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ContractWithCustomerLiabilityAdditions_d671afb3-4bb6-487d-b3aa-97fd4dbb3e6f_terseLabel_en-US" xlink:label="lab_akba_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_akba_ContractWithCustomerLiabilityAdditions_label_en-US" xlink:label="lab_akba_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Liability Additions</link:label>
    <link:label id="lab_akba_ContractWithCustomerLiabilityAdditions_documentation_en-US" xlink:label="lab_akba_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer liability additions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractWithCustomerLiabilityAdditions" xlink:href="akba-20210930.xsd#akba_ContractWithCustomerLiabilityAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ContractWithCustomerLiabilityAdditions" xlink:to="lab_akba_ContractWithCustomerLiabilityAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_48191605-32a3-47cc-94dd-16615e70d422_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_FairValueAdjustmentToInventory_15da013e-a1f3-4980-9809-f6ee8c3063ce_terseLabel_en-US" xlink:label="lab_akba_FairValueAdjustmentToInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value step-up of inventory sold or written off</link:label>
    <link:label id="lab_akba_FairValueAdjustmentToInventory_label_en-US" xlink:label="lab_akba_FairValueAdjustmentToInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment To Inventory</link:label>
    <link:label id="lab_akba_FairValueAdjustmentToInventory_documentation_en-US" xlink:label="lab_akba_FairValueAdjustmentToInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment To Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_FairValueAdjustmentToInventory" xlink:href="akba-20210930.xsd#akba_FairValueAdjustmentToInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_FairValueAdjustmentToInventory" xlink:to="lab_akba_FairValueAdjustmentToInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_74ea0771-b629-45fb-a097-42ccfe644351_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_e6346d5b-2cd3-4c5f-8846-a327d960c1d4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Available for Sale Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a2f46710-4d9e-4455-9536-ecd1a3bc2cf5_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_02ac9655-aa37-43b3-9af9-9cac83012ad3_verboseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_8b77d6fc-d45c-46eb-9a34-995af422cceb_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provisions related to sales in current year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_LongTermPurchaseCommitmentRenewalPeriod_ca6e9b43-fc80-4792-81ac-8a1df58b2338_terseLabel_en-US" xlink:label="lab_akba_LongTermPurchaseCommitmentRenewalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term minimum purchase commitment renewal term</link:label>
    <link:label id="lab_akba_LongTermPurchaseCommitmentRenewalPeriod_label_en-US" xlink:label="lab_akba_LongTermPurchaseCommitmentRenewalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Renewal Period</link:label>
    <link:label id="lab_akba_LongTermPurchaseCommitmentRenewalPeriod_documentation_en-US" xlink:label="lab_akba_LongTermPurchaseCommitmentRenewalPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Renewal Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LongTermPurchaseCommitmentRenewalPeriod" xlink:href="akba-20210930.xsd#akba_LongTermPurchaseCommitmentRenewalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_LongTermPurchaseCommitmentRenewalPeriod" xlink:to="lab_akba_LongTermPurchaseCommitmentRenewalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9915b854-bc4f-4743-8c4d-fb9060c9fc20_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_ea501414-9f6c-4fee-94b7-fb2348b75302_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangibles</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_af538a13-51ce-43c2-aab1-4d4d25465079_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_BostonMember_25218220-af4a-419d-9c80-eb2c037c0bdf_terseLabel_en-US" xlink:label="lab_akba_BostonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boston</link:label>
    <link:label id="lab_akba_BostonMember_label_en-US" xlink:label="lab_akba_BostonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boston [Member]</link:label>
    <link:label id="lab_akba_BostonMember_documentation_en-US" xlink:label="lab_akba_BostonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boston.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_BostonMember" xlink:href="akba-20210930.xsd#akba_BostonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_BostonMember" xlink:to="lab_akba_BostonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_8b70f72f-42b4-460d-9517-a390e4ba6d38_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_TwoThousandAndFourteenPlansMember_16256c17-1ffa-4e04-817d-b3e89d66c825_terseLabel_en-US" xlink:label="lab_akba_TwoThousandAndFourteenPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Plans</link:label>
    <link:label id="lab_akba_TwoThousandAndFourteenPlansMember_label_en-US" xlink:label="lab_akba_TwoThousandAndFourteenPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Fourteen Plans [Member]</link:label>
    <link:label id="lab_akba_TwoThousandAndFourteenPlansMember_documentation_en-US" xlink:label="lab_akba_TwoThousandAndFourteenPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand and fourteen plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_TwoThousandAndFourteenPlansMember" xlink:href="akba-20210930.xsd#akba_TwoThousandAndFourteenPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_TwoThousandAndFourteenPlansMember" xlink:to="lab_akba_TwoThousandAndFourteenPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodTwoMember_839a2398-6a88-469a-aa5d-ce3cd9304476_terseLabel_en-US" xlink:label="lab_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Quarterly Periodic Payment, Period Two</link:label>
    <link:label id="lab_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodTwoMember_label_en-US" xlink:label="lab_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, First Quarterly Periodic Payment, Period Two [Member]</link:label>
    <link:label id="lab_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodTwoMember_documentation_en-US" xlink:label="lab_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, First Quarterly Periodic Payment, Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodTwoMember" xlink:href="akba-20210930.xsd#akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodTwoMember" xlink:to="lab_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ad6781a6-ac0b-4786-a5c8-919522ae9d21_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities excluded from calculation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f52f2e42-6394-4ad4-afac-ab7bbce8bc7d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, incremental borrowing rates based on remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_768496d4-e215-4174-a942-c35ce917f0a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Components</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_213d0972-72fc-4452-960a-f6742b88f5b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Derivative Liability</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_bc0b6347-78d7-4207-a717-dccb5da9e5cc_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts included in deferred revenue at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ebce9137-158a-48a1-a2bb-f0ef51de0028_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_c5891e82-97cd-434d-be0a-8fb9a78cd601_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_9e296ed8-5deb-408d-8bad-df54d11f4c55_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_TermLoanMember_41dd2269-4f89-4ebe-be0c-4f22e75371fb_terseLabel_en-US" xlink:label="lab_akba_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_akba_TermLoanMember_label_en-US" xlink:label="lab_akba_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_akba_TermLoanMember_documentation_en-US" xlink:label="lab_akba_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_TermLoanMember" xlink:href="akba-20210930.xsd#akba_TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_TermLoanMember" xlink:to="lab_akba_TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_RoyaltyPaymentsDue_41d0d9e1-1f8b-4ecc-9b04-04e7dd037a95_terseLabel_en-US" xlink:label="lab_akba_RoyaltyPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payments</link:label>
    <link:label id="lab_akba_RoyaltyPaymentsDue_label_en-US" xlink:label="lab_akba_RoyaltyPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Payments Due</link:label>
    <link:label id="lab_akba_RoyaltyPaymentsDue_documentation_en-US" xlink:label="lab_akba_RoyaltyPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payments due.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_RoyaltyPaymentsDue" xlink:href="akba-20210930.xsd#akba_RoyaltyPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_RoyaltyPaymentsDue" xlink:to="lab_akba_RoyaltyPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_84a83827-5ca5-425f-bf9c-9d9b8e37c6a8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease_383b1bf5-1149-4d37-9b68-64d3433385b9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, recognized credit losses during period</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_b8062166-b3b9-4916-9e1b-298945dc590c_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_595b3ecd-55f1-4e0e-99e0-7eca37ea09c8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the maturities of available for sale securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d2ce6ea-566d-47b2-b798-546fd30d4ca6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_29b1cfa8-7f15-4761-bbe1-098723aca92c_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_08c3bb44-7d85-4919-aa58-0f1d0167c134_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_MitsubishiTanabePharmaCorporationMember_a9f2a243-c919-4dca-8e09-ac50e3da77e5_terseLabel_en-US" xlink:label="lab_akba_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation</link:label>
    <link:label id="lab_akba_MitsubishiTanabePharmaCorporationMember_label_en-US" xlink:label="lab_akba_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation [Member]</link:label>
    <link:label id="lab_akba_MitsubishiTanabePharmaCorporationMember_documentation_en-US" xlink:label="lab_akba_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_MitsubishiTanabePharmaCorporationMember" xlink:href="akba-20210930.xsd#akba_MitsubishiTanabePharmaCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_MitsubishiTanabePharmaCorporationMember" xlink:to="lab_akba_MitsubishiTanabePharmaCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c0fbfc42-d6e9-4072-b65b-65e02addd0a4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_CostShareCostsIncurredByPartnerForLicenseAgreement_7e26cada-04f2-42d8-96dc-70f137a15eb0_terseLabel_en-US" xlink:label="lab_akba_CostShareCostsIncurredByPartnerForLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost share costs by partner for license agreement</link:label>
    <link:label id="lab_akba_CostShareCostsIncurredByPartnerForLicenseAgreement_label_en-US" xlink:label="lab_akba_CostShareCostsIncurredByPartnerForLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Share Costs Incurred By Partner For License Agreement</link:label>
    <link:label id="lab_akba_CostShareCostsIncurredByPartnerForLicenseAgreement_documentation_en-US" xlink:label="lab_akba_CostShareCostsIncurredByPartnerForLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost share costs incurred by partner for license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CostShareCostsIncurredByPartnerForLicenseAgreement" xlink:href="akba-20210930.xsd#akba_CostShareCostsIncurredByPartnerForLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_CostShareCostsIncurredByPartnerForLicenseAgreement" xlink:to="lab_akba_CostShareCostsIncurredByPartnerForLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_d21caace-298a-48b6-a72d-11d167036de7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_3f05d353-deef-49c8-9e9d-f651dc73c604_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock $0.00001 par value, 25,000,000 shares authorized; 0 shares issued and &#160;&#160; outstanding at September&#160;30, 2021 and December 31, 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember_3bb2d20f-d844-49a4-9a31-4f094c5639f9_terseLabel_en-US" xlink:label="lab_akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otsuka U.S. Agreement</link:label>
    <link:label id="lab_akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Commercialize United States Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and commercialize united states collaboration and license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember" xlink:href="akba-20210930.xsd#akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember" xlink:to="lab_akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d5d97191-776a-4023-83de-d916b25fafa2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8423e56e-2ed8-4c5f-bbf7-1ee5835570cd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_AccruedExpensesAndOtherCurrentLiabilitiesMember_8c3d6cf6-74b5-4771-ba95-76aaab0d04da_terseLabel_en-US" xlink:label="lab_akba_AccruedExpensesAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_akba_AccruedExpensesAndOtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_akba_AccruedExpensesAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Current Liabilities [Member]</link:label>
    <link:label id="lab_akba_AccruedExpensesAndOtherCurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_akba_AccruedExpensesAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AccruedExpensesAndOtherCurrentLiabilitiesMember" xlink:href="akba-20210930.xsd#akba_AccruedExpensesAndOtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_AccruedExpensesAndOtherCurrentLiabilitiesMember" xlink:to="lab_akba_AccruedExpensesAndOtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_0aefea79-661a-4363-b364-27577adf30f4_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_b7e55151-340d-49c8-97d2-d2cedf308fd2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c344d080-1b1a-40cb-977e-3bd89182386d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_9e61ac74-d062-4100-a769-c1c572a045f6_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of property leased (in square feet)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9ea73370-1ab6-4039-8188-81990742c805_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_DevelopmentAndRegulatoryMilestonesMember_4b470587-503b-47b8-9a15-bbaccf1f181d_terseLabel_en-US" xlink:label="lab_akba_DevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestones</link:label>
    <link:label id="lab_akba_DevelopmentAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_akba_DevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_akba_DevelopmentAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_akba_DevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndRegulatoryMilestonesMember" xlink:href="akba-20210930.xsd#akba_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_DevelopmentAndRegulatoryMilestonesMember" xlink:to="lab_akba_DevelopmentAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9e9390f9-8899-4508-a17b-cce9e9f0c22b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f63f09d4-5ed4-48b5-b060-e0da2697f9f9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_19aa60ee-c583-4f6d-9760-e877ea3f1f03_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_EmployeesMember_9fec6c99-0dbf-40c5-a35f-97760ef98cc6_terseLabel_en-US" xlink:label="lab_akba_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees</link:label>
    <link:label id="lab_akba_EmployeesMember_label_en-US" xlink:label="lab_akba_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees [Member]</link:label>
    <link:label id="lab_akba_EmployeesMember_documentation_en-US" xlink:label="lab_akba_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_EmployeesMember" xlink:href="akba-20210930.xsd#akba_EmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_EmployeesMember" xlink:to="lab_akba_EmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions_c5bc5b75-1f1d-4b40-a213-8f3438296e63_terseLabel_en-US" xlink:label="lab_akba_LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease period, number of extension options</link:label>
    <link:label id="lab_akba_LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions_label_en-US" xlink:label="lab_akba_LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Leasing Arrangements Operating Leases Number Of Lease Period Extension Options</link:label>
    <link:label id="lab_akba_LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions_documentation_en-US" xlink:label="lab_akba_LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee leasing arrangements, operating leases, number of lease period extension options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions" xlink:href="akba-20210930.xsd#akba_LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions" xlink:to="lab_akba_LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0ee95826-b55a-49aa-b0df-a992b6558a77_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_82871272-82cd-4695-aef2-2987213f9b7e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_DeferredRevenueRecognitionTableTextBlock_2a3ec557-4eb2-4561-b0bf-573ccb336092_terseLabel_en-US" xlink:label="lab_akba_DeferredRevenueRecognitionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenues</link:label>
    <link:label id="lab_akba_DeferredRevenueRecognitionTableTextBlock_label_en-US" xlink:label="lab_akba_DeferredRevenueRecognitionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Recognition [Table Text Block]</link:label>
    <link:label id="lab_akba_DeferredRevenueRecognitionTableTextBlock_documentation_en-US" xlink:label="lab_akba_DeferredRevenueRecognitionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue recognition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DeferredRevenueRecognitionTableTextBlock" xlink:href="akba-20210930.xsd#akba_DeferredRevenueRecognitionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_DeferredRevenueRecognitionTableTextBlock" xlink:to="lab_akba_DeferredRevenueRecognitionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_DeferredUnpaidOfferingCosts_2ef93c91-256f-46ac-a308-0ff75a57859b_terseLabel_en-US" xlink:label="lab_akba_DeferredUnpaidOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid offering costs</link:label>
    <link:label id="lab_akba_DeferredUnpaidOfferingCosts_label_en-US" xlink:label="lab_akba_DeferredUnpaidOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Unpaid Offering Costs</link:label>
    <link:label id="lab_akba_DeferredUnpaidOfferingCosts_documentation_en-US" xlink:label="lab_akba_DeferredUnpaidOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred unpaid offering costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DeferredUnpaidOfferingCosts" xlink:href="akba-20210930.xsd#akba_DeferredUnpaidOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_DeferredUnpaidOfferingCosts" xlink:to="lab_akba_DeferredUnpaidOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred_d4c14385-9a59-41e0-ba5b-01a17caec6b4_terseLabel_en-US" xlink:label="lab_akba_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursable costs</link:label>
    <link:label id="lab_akba_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred_label_en-US" xlink:label="lab_akba_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Received For License Agreement Reimbursement Of Costs Incurred</link:label>
    <link:label id="lab_akba_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred_documentation_en-US" xlink:label="lab_akba_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment received for license agreement reimbursement of costs incurred.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" xlink:href="akba-20210930.xsd#akba_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" xlink:to="lab_akba_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_5ee3443f-e3b5-4139-a0f9-447ceebf96f5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity within Liability Related to Sale of Future Royalties, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_ba38edd2-7dea-4fb3-9743-9d98f3a3bca8_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis_e925d62d-1285-42a3-9f22-f42687caa464_terseLabel_en-US" xlink:label="lab_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Quarterly Periodic Payment, Period</link:label>
    <link:label id="lab_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis_label_en-US" xlink:label="lab_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, First Quarterly Periodic Payment, Period [Axis]</link:label>
    <link:label id="lab_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis_documentation_en-US" xlink:label="lab_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, First Quarterly Periodic Payment, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis" xlink:href="akba-20210930.xsd#akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis" xlink:to="lab_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_c0440dde-838d-4845-966a-db35b2cf498f_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_67fb28d1-bb34-407a-b86e-0a913333568b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_cafb7654-f612-4688-a00b-95305da98d18_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_a6f548ff-ef1f-4931-b480-697c391b3b05_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenue and Reserves for Variable Consideration</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_b3526675-5214-4637-b197-c8f446568e1d_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease rental income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_AccruedCommercialManufacturingCurrent_2493c32b-c1f5-42c2-b532-6793504fa03f_terseLabel_en-US" xlink:label="lab_akba_AccruedCommercialManufacturingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued commercial manufacturing</link:label>
    <link:label id="lab_akba_AccruedCommercialManufacturingCurrent_label_en-US" xlink:label="lab_akba_AccruedCommercialManufacturingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Commercial Manufacturing Current</link:label>
    <link:label id="lab_akba_AccruedCommercialManufacturingCurrent_documentation_en-US" xlink:label="lab_akba_AccruedCommercialManufacturingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Commercial Manufacturing Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AccruedCommercialManufacturingCurrent" xlink:href="akba-20210930.xsd#akba_AccruedCommercialManufacturingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_AccruedCommercialManufacturingCurrent" xlink:to="lab_akba_AccruedCommercialManufacturingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue_3b26cb16-7ce7-43e8-b4d4-9d085db5f39b_negatedTerseLabel_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties</link:label>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue_label_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Arrangement, Royalties Agreement, Noncash Royalty Revenue</link:label>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue_documentation_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Arrangement, Royalties Agreement, Noncash Royalty Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue" xlink:to="lab_akba_ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_2990ddfd-c367-4dcb-9a8d-ac900b0e0cf7_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_66823325-cb16-49d8-b8b0-e39ed592e1b4_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_CommitmentsAndContingenciesTable_e5f9b35a-d65f-4eae-94c6-ce20537fe8dc_terseLabel_en-US" xlink:label="lab_akba_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_akba_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_akba_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_akba_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_akba_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CommitmentsAndContingenciesTable" xlink:href="akba-20210930.xsd#akba_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_CommitmentsAndContingenciesTable" xlink:to="lab_akba_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_678d7af6-d360-4c42-8b70-2b96bfdb5961_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments_296253e5-b998-4c0c-8176-733171b7856f_terseLabel_en-US" xlink:label="lab_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of equal quarterly installments</link:label>
    <link:label id="lab_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments_label_en-US" xlink:label="lab_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Periodic Vesting Number Of Installments</link:label>
    <link:label id="lab_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments_documentation_en-US" xlink:label="lab_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, periodic vesting, number of installments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments" xlink:href="akba-20210930.xsd#akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments" xlink:to="lab_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_40fad2c5-1d1f-43f0-b7eb-ab98ae6ca412_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration from developmental and regulatory milestones</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_d8dc65fb-0076-45e6-bed1-7e01c75d6c2d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory step-up charges</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent_eb47ca93-cecc-4b8c-9a4c-1bb8c7a340e3_terseLabel_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of future royalties, net</link:label>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent_a0d3f34e-7f50-4478-9c7b-2f0d0f4949a1_periodStartLabel_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of future royalties, net &#8212; beginning balance</link:label>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent_07836aea-9065-4a75-8738-fba6bdc4d561_periodEndLabel_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of future royalties, net &#8212; ending balance</link:label>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent_label_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Arrangement, Royalties Agreement, Liability, Noncurrent</link:label>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent_documentation_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Arrangement, Royalties Agreement, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent" xlink:to="lab_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f4607687-d3d7-458a-953b-250adc19d82e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_a728d6d9-5bfd-4935-9975-bc89a75f755c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ViforPharmaMember_94f67e50-4da3-4782-87b4-70ede61a385f_terseLabel_en-US" xlink:label="lab_akba_ViforPharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vifor Pharma</link:label>
    <link:label id="lab_akba_ViforPharmaMember_label_en-US" xlink:label="lab_akba_ViforPharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vifor Pharma [Member]</link:label>
    <link:label id="lab_akba_ViforPharmaMember_documentation_en-US" xlink:label="lab_akba_ViforPharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vifor Pharma.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ViforPharmaMember" xlink:href="akba-20210930.xsd#akba_ViforPharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ViforPharmaMember" xlink:to="lab_akba_ViforPharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding_5929da74-68c5-4f70-84e0-1faa2e314f30_terseLabel_en-US" xlink:label="lab_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment premium percentage on principal if prepaid after fourth anniversary of funding</link:label>
    <link:label id="lab_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding_label_en-US" xlink:label="lab_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Premium Percentage On Principal If Prepaid On Or After Fourth Anniversary Of Funding</link:label>
    <link:label id="lab_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding_documentation_en-US" xlink:label="lab_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment premium percentage on principal if prepaid on or after fourth anniversary of funding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding" xlink:href="akba-20210930.xsd#akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding" xlink:to="lab_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_NoncashInterestExpense_f9446bdb-d4fb-4124-814a-ebeb1f0a5265_terseLabel_en-US" xlink:label="lab_akba_NoncashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_akba_NoncashInterestExpense_label_en-US" xlink:label="lab_akba_NoncashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Interest Expense</link:label>
    <link:label id="lab_akba_NoncashInterestExpense_documentation_en-US" xlink:label="lab_akba_NoncashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash interest expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_NoncashInterestExpense" xlink:href="akba-20210930.xsd#akba_NoncashInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_NoncashInterestExpense" xlink:to="lab_akba_NoncashInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward_43a0ffe6-ba74-437a-8b78-313816b9baa8_terseLabel_en-US" xlink:label="lab_akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets:</link:label>
    <link:label id="lab_akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward_label_en-US" xlink:label="lab_akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, After Allowance For Credit Loss, Current [Roll Forward]</link:label>
    <link:label id="lab_akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward_documentation_en-US" xlink:label="lab_akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, After Allowance For Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward" xlink:href="akba-20210930.xsd#akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward" xlink:to="lab_akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_48d7e73e-7ffe-4122-b63f-abfcc746d9a8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDepreciationAndAmortization" xlink:to="lab_us-gaap_OtherDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_CollaborativeArrangementTerm_e363a047-72a6-4d46-9530-32c96a827622_terseLabel_en-US" xlink:label="lab_akba_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, term</link:label>
    <link:label id="lab_akba_CollaborativeArrangementTerm_label_en-US" xlink:label="lab_akba_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_akba_CollaborativeArrangementTerm_documentation_en-US" xlink:label="lab_akba_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeArrangementTerm" xlink:href="akba-20210930.xsd#akba_CollaborativeArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_CollaborativeArrangementTerm" xlink:to="lab_akba_CollaborativeArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_ede21e74-18a0-4789-9ae8-4d657c9a16e1_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_PotentialPaymentForAchievementOfSpecifiedMilestones_03d2137d-d075-433a-a317-36354d77380d_terseLabel_en-US" xlink:label="lab_akba_PotentialPaymentForAchievementOfSpecifiedMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone revenue</link:label>
    <link:label id="lab_akba_PotentialPaymentForAchievementOfSpecifiedMilestones_label_en-US" xlink:label="lab_akba_PotentialPaymentForAchievementOfSpecifiedMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Payment For Achievement Of Specified Milestones</link:label>
    <link:label id="lab_akba_PotentialPaymentForAchievementOfSpecifiedMilestones_documentation_en-US" xlink:label="lab_akba_PotentialPaymentForAchievementOfSpecifiedMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential payment for achievement of specified milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PotentialPaymentForAchievementOfSpecifiedMilestones" xlink:href="akba-20210930.xsd#akba_PotentialPaymentForAchievementOfSpecifiedMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_PotentialPaymentForAchievementOfSpecifiedMilestones" xlink:to="lab_akba_PotentialPaymentForAchievementOfSpecifiedMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_fb104e64-1836-44a0-98e6-d4dc398c0150_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, net of facility fees, lender expenses and issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_ebd0fd40-5c94-4635-aa60-a7aaa2c86ec0_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets fair value disclosure</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_b54fd0a1-d20b-4f5a-ae18-5037ae026bf2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets measured at fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_3468d538-44f4-4f6d-9224-55467c8d60a6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c674fc8e-8173-485f-a4a9-1ac906c97e0a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_0ff612e6-39d0-48e0-87b7-5c0236ad9681_terseLabel_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Lease Payments</link:label>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_label_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Sublease Income, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_documentation_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Sublease Income, Fiscal Year Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" xlink:to="lab_akba_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_b2434c5f-1d5f-4d5d-8160-8d9b713f616f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_eb386279-e54c-436f-8acf-c762f407bc4b_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNet_9a9a5cab-a06b-45fc-abb1-2d350ae16292_totalLabel_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNet_label_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Payments Due Net</link:label>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNet_documentation_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee operating lease liability payments due net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNet" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsDueNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNet" xlink:to="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_11168b89-628d-44af-b3b4-ba744dac624f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_3705ad99-c31a-49c8-b43f-9048b6f9a957_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_8e78bc18-de04-4854-8fbc-7b3206f0e01c_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2b1884ea-fea3-4a64-bdfb-8a83b1211b34_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8c763689-d7c6-4f80-abcc-52da30876523_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8f35de5e-22d7-4a0c-a349-91e6b1dbefa4_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_87f93656-663c-44b4-8842-ec82bc5846ed_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_0fdbcbcd-e8f4-45b5-bb0f-51ed1907ca4e_totalLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0aac5feb-4c9e-49fa-b5a3-b015c0a46679_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Award Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_a150d7df-2ec8-42ec-9b51-e6cd7688bac3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_fe0d5673-631f-4547-8672-18f68d03de9d_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_2c75615e-1608-4782-8092-ccf2af711c57_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_LicenseExpense_6617eb3b-b53d-4511-903c-a2292639191d_terseLabel_en-US" xlink:label="lab_akba_LicenseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License expense</link:label>
    <link:label id="lab_akba_LicenseExpense_label_en-US" xlink:label="lab_akba_LicenseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Expense</link:label>
    <link:label id="lab_akba_LicenseExpense_documentation_en-US" xlink:label="lab_akba_LicenseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseExpense" xlink:href="akba-20210930.xsd#akba_LicenseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_LicenseExpense" xlink:to="lab_akba_LicenseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_deaf40dc-5c86-45da-bfe7-693a7783e191_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government debt securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f2aad794-ee74-4547-afe3-7e4a6553a8f7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_b5d8ec68-f4e4-499f-9960-96a0662b367e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_KeryxMember_39581426-3be4-4c0c-b5cd-f2759643cda8_terseLabel_en-US" xlink:label="lab_akba_KeryxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Keryx</link:label>
    <link:label id="lab_akba_KeryxMember_label_en-US" xlink:label="lab_akba_KeryxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Keryx [Member]</link:label>
    <link:label id="lab_akba_KeryxMember_documentation_en-US" xlink:label="lab_akba_KeryxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Keryx.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_KeryxMember" xlink:href="akba-20210930.xsd#akba_KeryxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_KeryxMember" xlink:to="lab_akba_KeryxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_2e04be69-14e5-42e9-a078-97a69f928e9f_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_a6dd0269-48f7-4282-80e7-47df540485e7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_b3a3ba74-2d65-449d-b8b0-648e1a8b7c5f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_2cf7f0d2-dee7-4ecd-9308-e045be21fdcc_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale securities:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_98b74cc4-f8d7-41d6-b990-13310d97016c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_d796dd8b-f947-4fad-8089-223cd9f60d23_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ContractWithCustomerAssetAdditions_8e9da556-31f7-4179-b151-5968543af024_terseLabel_en-US" xlink:label="lab_akba_ContractWithCustomerAssetAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_akba_ContractWithCustomerAssetAdditions_label_en-US" xlink:label="lab_akba_ContractWithCustomerAssetAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Asset Additions</link:label>
    <link:label id="lab_akba_ContractWithCustomerAssetAdditions_documentation_en-US" xlink:label="lab_akba_ContractWithCustomerAssetAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer asset additions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractWithCustomerAssetAdditions" xlink:href="akba-20210930.xsd#akba_ContractWithCustomerAssetAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ContractWithCustomerAssetAdditions" xlink:to="lab_akba_ContractWithCustomerAssetAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ff26ed8d-9c13-4bcd-af1c-9993754a19b5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ExcessInventoryPurchaseCommitmentsExpenseReversal_9f32ec6e-bc69-4c2a-aedc-14cc590a67a6_terseLabel_en-US" xlink:label="lab_akba_ExcessInventoryPurchaseCommitmentsExpenseReversal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in excess inventory purchase commitments</link:label>
    <link:label id="lab_akba_ExcessInventoryPurchaseCommitmentsExpenseReversal_2c7d88eb-b795-4aca-beda-1b35d67f7d89_verboseLabel_en-US" xlink:label="lab_akba_ExcessInventoryPurchaseCommitmentsExpenseReversal" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in purchase commitments</link:label>
    <link:label id="lab_akba_ExcessInventoryPurchaseCommitmentsExpenseReversal_label_en-US" xlink:label="lab_akba_ExcessInventoryPurchaseCommitmentsExpenseReversal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Inventory Purchase Commitments Expense (Reversal)</link:label>
    <link:label id="lab_akba_ExcessInventoryPurchaseCommitmentsExpenseReversal_documentation_en-US" xlink:label="lab_akba_ExcessInventoryPurchaseCommitmentsExpenseReversal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Inventory Purchase Commitments Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ExcessInventoryPurchaseCommitmentsExpenseReversal" xlink:href="akba-20210930.xsd#akba_ExcessInventoryPurchaseCommitmentsExpenseReversal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ExcessInventoryPurchaseCommitmentsExpenseReversal" xlink:to="lab_akba_ExcessInventoryPurchaseCommitmentsExpenseReversal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_29785890-a873-4582-869c-32092caf7c10_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_52dd32e3-ebc6-4e57-82e5-a3f2a50f21dd_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities fair value disclosure</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_82a3da0e-8170-469a-a882-8836e46038de_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities measured at fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_fd6bdd8b-de69-42c4-a55b-68f70ffabcb8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_3da8ecc6-906c-4194-8686-119a18c9b49b_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementProceedsContingentOnAnnualSalesMilestones_1cec1eff-9c9a-4f94-a072-a80821fbdea9_terseLabel_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementProceedsContingentOnAnnualSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible proceeds to be received, contingent on annual sales milestones</link:label>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementProceedsContingentOnAnnualSalesMilestones_label_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementProceedsContingentOnAnnualSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Arrangement, Royalties Agreement, Proceeds, Contingent On Annual Sales Milestones</link:label>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementProceedsContingentOnAnnualSalesMilestones_documentation_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementProceedsContingentOnAnnualSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Arrangement, Royalties Agreement, Proceeds, Contingent On Annual Sales Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementProceedsContingentOnAnnualSalesMilestones" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementProceedsContingentOnAnnualSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ContractualArrangementRoyaltiesAgreementProceedsContingentOnAnnualSalesMilestones" xlink:to="lab_akba_ContractualArrangementRoyaltiesAgreementProceedsContingentOnAnnualSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_a9c7538a-8f54-4ee3-ae39-2236633b39ec_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_a36fac49-5cd5-4f18-ac08-6b935ad30ec6_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3bb5815f-25f6-4606-9521-5538ed8259ec_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember_5a6d6b37-e0fb-45e4-9ad1-c38c31a382cd_terseLabel_en-US" xlink:label="lab_akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JT and Torii</link:label>
    <link:label id="lab_akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember_label_en-US" xlink:label="lab_akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan Tobacco Incorporation And Torii Pharmaceutical Company Limited [Member]</link:label>
    <link:label id="lab_akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember_documentation_en-US" xlink:label="lab_akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan tobacco incorporation and torii pharmaceutical company limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember" xlink:href="akba-20210930.xsd#akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember" xlink:to="lab_akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour_8c5f429a-021d-478f-b891-6b9ca77a3750_totalLabel_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour_label_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Payments Due Net After Year Four</link:label>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour_documentation_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Payments Due Net After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour" xlink:to="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_DevelopmentAndCommercializeCollaborationAgreementMember_aab60002-b09c-4d6d-9faf-bc1751eaf1a6_terseLabel_en-US" xlink:label="lab_akba_DevelopmentAndCommercializeCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTPC Agreement</link:label>
    <link:label id="lab_akba_DevelopmentAndCommercializeCollaborationAgreementMember_label_en-US" xlink:label="lab_akba_DevelopmentAndCommercializeCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Commercialize Collaboration Agreement [Member]</link:label>
    <link:label id="lab_akba_DevelopmentAndCommercializeCollaborationAgreementMember_documentation_en-US" xlink:label="lab_akba_DevelopmentAndCommercializeCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and commercialize collaboration agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndCommercializeCollaborationAgreementMember" xlink:href="akba-20210930.xsd#akba_DevelopmentAndCommercializeCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_DevelopmentAndCommercializeCollaborationAgreementMember" xlink:to="lab_akba_DevelopmentAndCommercializeCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_bff65e9e-badf-479e-a190-85714e439e2e_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_4f48a2f2-3530-4b38-ae8b-83060923072e_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_9342e7ce-0e68-4369-8855-ad579a9c570a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_PriorityReviewVoucherLetterAgreementMember_e477f289-37a0-4231-8859-4a7c4ae43cf4_terseLabel_en-US" xlink:label="lab_akba_PriorityReviewVoucherLetterAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Priority Review Voucher Letter Agreement</link:label>
    <link:label id="lab_akba_PriorityReviewVoucherLetterAgreementMember_label_en-US" xlink:label="lab_akba_PriorityReviewVoucherLetterAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Priority Review Voucher Letter Agreement [Member]</link:label>
    <link:label id="lab_akba_PriorityReviewVoucherLetterAgreementMember_documentation_en-US" xlink:label="lab_akba_PriorityReviewVoucherLetterAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Priority review voucher letter agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PriorityReviewVoucherLetterAgreementMember" xlink:href="akba-20210930.xsd#akba_PriorityReviewVoucherLetterAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_PriorityReviewVoucherLetterAgreementMember" xlink:to="lab_akba_PriorityReviewVoucherLetterAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_2f925fc3-4b7b-4430-8d31-1a3b5e8b9017_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_b4e7810a-0868-481f-9f4a-d543ff653888_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of &#160;&#160; issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_5943c55d-c5a4-437d-b10a-b4b09e9449a1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_4ad1d840-68ee-407b-b652-af0282b215db_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ProductionRelatedImpairmentsOrChargesIntangibles_ddd5942e-c5ba-4860-b6e5-8c2e1304fd7b_terseLabel_en-US" xlink:label="lab_akba_ProductionRelatedImpairmentsOrChargesIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible asset</link:label>
    <link:label id="lab_akba_ProductionRelatedImpairmentsOrChargesIntangibles_label_en-US" xlink:label="lab_akba_ProductionRelatedImpairmentsOrChargesIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Production Related Impairments Or Charges, Intangibles</link:label>
    <link:label id="lab_akba_ProductionRelatedImpairmentsOrChargesIntangibles_documentation_en-US" xlink:label="lab_akba_ProductionRelatedImpairmentsOrChargesIntangibles" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Production Related Impairments Or Charges, Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ProductionRelatedImpairmentsOrChargesIntangibles" xlink:href="akba-20210930.xsd#akba_ProductionRelatedImpairmentsOrChargesIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ProductionRelatedImpairmentsOrChargesIntangibles" xlink:to="lab_akba_ProductionRelatedImpairmentsOrChargesIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity_0db8f751-b232-49ee-8a9b-a79ef29062cc_terseLabel_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual royalty payout capacity</link:label>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity_label_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Arrangement, Royalties Agreement, Maximum Annual Royalty Payout Capacity</link:label>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity_documentation_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Arrangement, Royalties Agreement, Maximum Annual Royalty Payout Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity" xlink:to="lab_akba_ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_fe16c7f2-870b-4a50-83de-27883dbdca64_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_ef78dfd6-a10f-47b6-a632-eb08f0d52cef_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_1dd54d34-3e7a-42f4-a236-4df9cc25963f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b749f25a-a2df-4b73-8f41-7a8b01049b13_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d85df5e0-8d2e-4dda-a10f-ca66cad64145_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_b741cc6c-bd54-46fb-89fa-3200a7cf4821_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_88c1e2e7-298a-44ac-9eae-0a6305f88691_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_LicenseCollaborationAndOtherRevenueRoyaltiesMember_caf30ebb-a6eb-452f-b68a-2c52a8cdb9dd_terseLabel_en-US" xlink:label="lab_akba_LicenseCollaborationAndOtherRevenueRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Collaboration And Other Revenue, Royalties</link:label>
    <link:label id="lab_akba_LicenseCollaborationAndOtherRevenueRoyaltiesMember_label_en-US" xlink:label="lab_akba_LicenseCollaborationAndOtherRevenueRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Collaboration And Other Revenue, Royalties [Member]</link:label>
    <link:label id="lab_akba_LicenseCollaborationAndOtherRevenueRoyaltiesMember_documentation_en-US" xlink:label="lab_akba_LicenseCollaborationAndOtherRevenueRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Collaboration And Other Revenue, Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseCollaborationAndOtherRevenueRoyaltiesMember" xlink:href="akba-20210930.xsd#akba_LicenseCollaborationAndOtherRevenueRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_LicenseCollaborationAndOtherRevenueRoyaltiesMember" xlink:to="lab_akba_LicenseCollaborationAndOtherRevenueRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_085d3c4f-fdc9-4237-b5a0-b209599e3d57_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold:</link:label>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenueAbstract" xlink:to="lab_us-gaap_CostOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_ca7fb264-189c-4b21-ad3f-3ced980b4583_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_0fb62775-c7a2-41ee-82fe-bbb0b01ab8f5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock $0.00001 par value; 350,000,000 shares authorized at September&#160;30, 2021 and December 31, 2020; 174,551,989 and 148,074,085 shares issued and outstanding at September&#160;30, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_ac532b43-52af-42cc-ab78-cae907988379_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_d5eeb29b-6015-4938-89de-6630b57609c0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term minimum purchase commitment</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain_12d2c9e4-718d-434f-94b3-675314f30354_terseLabel_en-US" xlink:label="lab_akba_DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Quarterly Periodic Payment, Period</link:label>
    <link:label id="lab_akba_DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain_label_en-US" xlink:label="lab_akba_DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Quarterly Periodic Payment, Period [Domain]</link:label>
    <link:label id="lab_akba_DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain_documentation_en-US" xlink:label="lab_akba_DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Quarterly Periodic Payment, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain" xlink:href="akba-20210930.xsd#akba_DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain" xlink:to="lab_akba_DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetAbstract_cda2e8cd-5264-48c6-809a-1a7a0c24e75e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Classification:</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract" xlink:to="lab_us-gaap_InventoryNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerBasisOfPricingAxis_c10de984-32cc-42a3-be10-cd45f179142d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Basis of Pricing</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerBasisOfPricingAxis_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Basis of Pricing [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:to="lab_us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0eb831f3-fe3e-45a8-990b-86627e386b53_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_ce448e8a-a7f9-457d-a648-5634bbff05e9_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_SublicenseAgreementMember_f8592936-0fdc-4f70-8cad-7631ea9b3406_terseLabel_en-US" xlink:label="lab_akba_SublicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublicense Agreement</link:label>
    <link:label id="lab_akba_SublicenseAgreementMember_label_en-US" xlink:label="lab_akba_SublicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublicense Agreement [Member]</link:label>
    <link:label id="lab_akba_SublicenseAgreementMember_documentation_en-US" xlink:label="lab_akba_SublicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublicense agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_SublicenseAgreementMember" xlink:href="akba-20210930.xsd#akba_SublicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_SublicenseAgreementMember" xlink:to="lab_akba_SublicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_9b7c4acb-b147-496d-a8f2-b17a3b38c858_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 14)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d8b34599-a7be-4e5b-8050-0b1d8963ef2c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_ed705ba7-ab17-43e0-8e26-8d10c7b1ddad_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-down of inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_a6169c35-c3e5-4083-9d61-14221e9eb377_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory amounts written down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_fbc9c0aa-c20d-4cdd-9857-391f70a1b6dd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining 2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding_9ee5d5f1-136f-42d0-8ad4-d616c4a0c482_terseLabel_en-US" xlink:label="lab_akba_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental rate at which the shares reserved for issuance increase</link:label>
    <link:label id="lab_akba_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding_label_en-US" xlink:label="lab_akba_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Increase In Aggregate Number Of Shares Reserved For Future Issuance As Percentage Shares Outstanding</link:label>
    <link:label id="lab_akba_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding_documentation_en-US" xlink:label="lab_akba_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in aggregate number of shares reserved for future issuance as percentage shares outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding" xlink:href="akba-20210930.xsd#akba_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding" xlink:to="lab_akba_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0f5bd9dd-cbf7-48b6-8e3a-bb901a04bd1d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4b58a0e1-1bbc-4e79-8993-c83f38f822ed_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_d11f3eec-6614-4d6b-ad3a-2989c1c830ef_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for Sale Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_60b038e1-ebb4-422c-9632-f208d44c9e7a_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree_c142a9d0-d338-40b3-9b1c-5ec4157100b1_totalLabel_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree_label_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Payments Due Net Year Three</link:label>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree_documentation_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee operating lease liability payments due net year three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree" xlink:to="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_MilestonePaymentReceived_8d2b57fb-abb3-43c0-a623-7165e4095825_terseLabel_en-US" xlink:label="lab_akba_MilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone revenue</link:label>
    <link:label id="lab_akba_MilestonePaymentReceived_label_en-US" xlink:label="lab_akba_MilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Received</link:label>
    <link:label id="lab_akba_MilestonePaymentReceived_documentation_en-US" xlink:label="lab_akba_MilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_MilestonePaymentReceived" xlink:href="akba-20210930.xsd#akba_MilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_MilestonePaymentReceived" xlink:to="lab_akba_MilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_34c2d23f-7ebc-44af-88bf-e1bb6767a931_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b233fb2e-30a3-437b-b8f6-8c333b08a67e_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value adjustment using incremental borrowing rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_PanionAndBFBiotechIncorporationMember_6f8ebf18-7b4b-45dc-a32c-5909a768b767_terseLabel_en-US" xlink:label="lab_akba_PanionAndBFBiotechIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Panion &amp; BF Biotech, Incorporation</link:label>
    <link:label id="lab_akba_PanionAndBFBiotechIncorporationMember_label_en-US" xlink:label="lab_akba_PanionAndBFBiotechIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Panion And B F Biotech Incorporation [Member]</link:label>
    <link:label id="lab_akba_PanionAndBFBiotechIncorporationMember_documentation_en-US" xlink:label="lab_akba_PanionAndBFBiotechIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Panion and BF Biotech, Incorporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PanionAndBFBiotechIncorporationMember" xlink:href="akba-20210930.xsd#akba_PanionAndBFBiotechIncorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_PanionAndBFBiotechIncorporationMember" xlink:to="lab_akba_PanionAndBFBiotechIncorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StraightLineRent_b8d69648-7153-4f39-b7c1-d3db44a079fa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StraightLineRent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating lease expense</link:label>
    <link:label id="lab_us-gaap_StraightLineRent_label_en-US" xlink:label="lab_us-gaap_StraightLineRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Straight Line Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StraightLineRent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StraightLineRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StraightLineRent" xlink:to="lab_us-gaap_StraightLineRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_679bf077-d0da-48d0-a2c2-615a596259d1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsAmount_e8c5bb14-2466-4c99-aa69-1dd0a5126849_terseLabel_en-US" xlink:label="lab_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangements additional cost sharing payments amount</link:label>
    <link:label id="lab_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsAmount_label_en-US" xlink:label="lab_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements Additional Cost Sharing Payments Amount</link:label>
    <link:label id="lab_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsAmount_documentation_en-US" xlink:label="lab_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangements additional cost sharing payments amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsAmount" xlink:href="akba-20210930.xsd#akba_CollaborativeArrangementsAdditionalCostSharingPaymentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsAmount" xlink:to="lab_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_2b6dd27b-bfe6-4787-b303-ad4782266052_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment for asset acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_TrancheAMember_8275926a-df5e-4ec3-8e8d-258c29c27b9d_terseLabel_en-US" xlink:label="lab_akba_TrancheAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche A</link:label>
    <link:label id="lab_akba_TrancheAMember_label_en-US" xlink:label="lab_akba_TrancheAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche A [Member]</link:label>
    <link:label id="lab_akba_TrancheAMember_documentation_en-US" xlink:label="lab_akba_TrancheAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_TrancheAMember" xlink:href="akba-20210930.xsd#akba_TrancheAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_TrancheAMember" xlink:to="lab_akba_TrancheAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_168ae36f-d7d5-45bb-aadc-3be58330b1b0_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_ac41b24f-a05a-4ded-b4a3-8e1f98cb28c1_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_19c4ad07-bb86-4718-b09b-bed8c70bb2fe_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan_3e0ab77d-7f4a-44d1-94f1-44da94714f03_terseLabel_en-US" xlink:label="lab_akba_StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of stock under &#160;&#160; employee stock purchase plan</link:label>
    <link:label id="lab_akba_StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_akba_StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Including Offering Costs Employee Stock Purchase Plan</link:label>
    <link:label id="lab_akba_StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan_documentation_en-US" xlink:label="lab_akba_StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period value including offering costs employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan" xlink:href="akba-20210930.xsd#akba_StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan" xlink:to="lab_akba_StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_12a8aaf6-2026-4091-ba36-bb3865f34c11_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_9db3e637-c0a1-4eab-bfb8-a9ba933d7dba_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4032ec0c-ccab-4b5e-8a7d-0576cb585a56_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7b7360f3-8973-4756-925c-5afbd9a30ecf_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_c8a92d24-85bf-4114-b26f-3895bdf7a40f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost incurred in research and development activities</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember_0e879b1c-c99c-4d8e-96d1-80577570c348_terseLabel_en-US" xlink:label="lab_akba_ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Tranche, First Or Third Anniversary of Grant Date</link:label>
    <link:label id="lab_akba_ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember_label_en-US" xlink:label="lab_akba_ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Award Tranche First Or Third Anniversary Of Grant Date [Member]</link:label>
    <link:label id="lab_akba_ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember_documentation_en-US" xlink:label="lab_akba_ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation award tranche first or third anniversary of grant date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember" xlink:href="akba-20210930.xsd#akba_ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember" xlink:to="lab_akba_ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_3562f507-0b70-4897-bb0d-72df8c4cb768_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_f478c726-68b1-421b-9ab5-3b2a29da849f_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Payments to be Received from Sublease</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_436f1428-04d1-4b88-9044-9d7ed64e290f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_2f970c63-2642-46b2-bff0-6205c9dbe06b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_52359e57-b1a9-409c-ac66-5f7516e6b3fc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementPercentageOfRoyaltyPaymentsToBeReceivedContingentOnReachingMaximumAnnualRoyaltyPayoutCapacity_77a36c90-db8a-43d1-8149-9dae3e5405a1_terseLabel_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementPercentageOfRoyaltyPaymentsToBeReceivedContingentOnReachingMaximumAnnualRoyaltyPayoutCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalty payment to be received once maximum annual royalty payout has been paid</link:label>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementPercentageOfRoyaltyPaymentsToBeReceivedContingentOnReachingMaximumAnnualRoyaltyPayoutCapacity_label_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementPercentageOfRoyaltyPaymentsToBeReceivedContingentOnReachingMaximumAnnualRoyaltyPayoutCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Arrangement, Royalties Agreement, Percentage Of Royalty Payments To Be Received, Contingent On Reaching Maximum Annual Royalty Payout Capacity</link:label>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementPercentageOfRoyaltyPaymentsToBeReceivedContingentOnReachingMaximumAnnualRoyaltyPayoutCapacity_documentation_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementPercentageOfRoyaltyPaymentsToBeReceivedContingentOnReachingMaximumAnnualRoyaltyPayoutCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Arrangement, Royalties Agreement, Percentage Of Royalty Payments To Be Received, Contingent On Reaching Maximum Annual Royalty Payout Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementPercentageOfRoyaltyPaymentsToBeReceivedContingentOnReachingMaximumAnnualRoyaltyPayoutCapacity" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementPercentageOfRoyaltyPaymentsToBeReceivedContingentOnReachingMaximumAnnualRoyaltyPayoutCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ContractualArrangementRoyaltiesAgreementPercentageOfRoyaltyPaymentsToBeReceivedContingentOnReachingMaximumAnnualRoyaltyPayoutCapacity" xlink:to="lab_akba_ContractualArrangementRoyaltiesAgreementPercentageOfRoyaltyPaymentsToBeReceivedContingentOnReachingMaximumAnnualRoyaltyPayoutCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ContractWithCustomerLiabilityRollForward_12f42c42-5d15-4553-88b3-4df5d3b80959_terseLabel_en-US" xlink:label="lab_akba_ContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities:</link:label>
    <link:label id="lab_akba_ContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_akba_ContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_akba_ContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_akba_ContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractWithCustomerLiabilityRollForward" xlink:href="akba-20210930.xsd#akba_ContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ContractWithCustomerLiabilityRollForward" xlink:to="lab_akba_ContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_LongTermPurchaseCommitmentFixedPricePeriod_d94f8015-dfb1-41ba-942e-41535de50b01_terseLabel_en-US" xlink:label="lab_akba_LongTermPurchaseCommitmentFixedPricePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term purchase commitment, fixed price, period</link:label>
    <link:label id="lab_akba_LongTermPurchaseCommitmentFixedPricePeriod_label_en-US" xlink:label="lab_akba_LongTermPurchaseCommitmentFixedPricePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Fixed Price, Period</link:label>
    <link:label id="lab_akba_LongTermPurchaseCommitmentFixedPricePeriod_documentation_en-US" xlink:label="lab_akba_LongTermPurchaseCommitmentFixedPricePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Fixed Price, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LongTermPurchaseCommitmentFixedPricePeriod" xlink:href="akba-20210930.xsd#akba_LongTermPurchaseCommitmentFixedPricePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_LongTermPurchaseCommitmentFixedPricePeriod" xlink:to="lab_akba_LongTermPurchaseCommitmentFixedPricePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c4f0f00d-da8b-4947-b444-d913e240d732_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_b41d0192-dd15-49b2-aaf1-0007fdab2948_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsNet_57cdf63d-63ee-48a8-8a1a-5229636b3eae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets, net</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsNet" xlink:to="lab_us-gaap_OtherIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_96573920-a552-45c2-9ec0-29aae0ec7b44_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_EstimateSubsequentCostFundingUnderPlan_aa2a2fa7-1e43-45e9-9ff6-dd498cc246cb_terseLabel_en-US" xlink:label="lab_akba_EstimateSubsequentCostFundingUnderPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated current global development costs subsequent to March 31, 2017</link:label>
    <link:label id="lab_akba_EstimateSubsequentCostFundingUnderPlan_label_en-US" xlink:label="lab_akba_EstimateSubsequentCostFundingUnderPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate Subsequent Cost Funding Under Plan</link:label>
    <link:label id="lab_akba_EstimateSubsequentCostFundingUnderPlan_documentation_en-US" xlink:label="lab_akba_EstimateSubsequentCostFundingUnderPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate subsequent cost funding under plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_EstimateSubsequentCostFundingUnderPlan" xlink:href="akba-20210930.xsd#akba_EstimateSubsequentCostFundingUnderPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_EstimateSubsequentCostFundingUnderPlan" xlink:to="lab_akba_EstimateSubsequentCostFundingUnderPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_a729c482-ac59-489a-a898-90d5aec1eae5_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrant at issuance</link:label>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Not Settleable in Cash, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_98236ede-1e0b-4c8b-a95d-113965058e98_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2364534c-c586-42f8-ba41-edd5b5b662e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ddaf1a3c-6dd2-4f43-9929-bf85028db2df_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale securities, gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2d756862-303f-48d4-a7a1-03ec7ea77b8c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Collaboration and Other Significant Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_d59aed75-9b58-4ae4-abdf-5909162b8577_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gains (losses) on available for sale securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_189f4bfa-6d5d-40b9-a76e-74492d2529ef_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_645c2d99-d353-4dec-b3dd-e96f8e57a7c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_947a2870-11f3-4091-a60b-40ad0398a130_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_836cbd8b-df56-4db7-9ab0-8da96f22cf47_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_51fec543-8108-4197-9c36-1f129a6a90a0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_932566a3-d880-498b-bf30-a93c75845116_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, amortized cost</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_LicensedHIFProductMember_b68ceab6-36a5-4218-a3e7-634f9ab3747c_terseLabel_en-US" xlink:label="lab_akba_LicensedHIFProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensed HIF Product</link:label>
    <link:label id="lab_akba_LicensedHIFProductMember_label_en-US" xlink:label="lab_akba_LicensedHIFProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensed HIF Product [Member]</link:label>
    <link:label id="lab_akba_LicensedHIFProductMember_documentation_en-US" xlink:label="lab_akba_LicensedHIFProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensed HIF Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicensedHIFProductMember" xlink:href="akba-20210930.xsd#akba_LicensedHIFProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_LicensedHIFProductMember" xlink:to="lab_akba_LicensedHIFProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_DebtInstrumentFloorRate_188173f0-5e14-4f71-a1e5-57d390ae077c_terseLabel_en-US" xlink:label="lab_akba_DebtInstrumentFloorRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, floor rate</link:label>
    <link:label id="lab_akba_DebtInstrumentFloorRate_label_en-US" xlink:label="lab_akba_DebtInstrumentFloorRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Floor Rate</link:label>
    <link:label id="lab_akba_DebtInstrumentFloorRate_documentation_en-US" xlink:label="lab_akba_DebtInstrumentFloorRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument floor rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentFloorRate" xlink:href="akba-20210930.xsd#akba_DebtInstrumentFloorRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_DebtInstrumentFloorRate" xlink:to="lab_akba_DebtInstrumentFloorRate" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock_388441c6-728f-49d9-bce6-f19063c5ece2_terseLabel_en-US" xlink:label="lab_akba_CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium amount over the closing stock price of common stock</link:label>
    <link:label id="lab_akba_CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock_label_en-US" xlink:label="lab_akba_CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Of Premium Amount Over Closing Stock Price Of Common Stock</link:label>
    <link:label id="lab_akba_CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock_documentation_en-US" xlink:label="lab_akba_CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement of premium amount over closing stock price of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock" xlink:href="akba-20210930.xsd#akba_CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock" xlink:to="lab_akba_CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember_86e5e198-28d6-48b4-a5c4-b7de728710f2_terseLabel_en-US" xlink:label="lab_akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Commercialize Research And License Agreement</link:label>
    <link:label id="lab_akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember_label_en-US" xlink:label="lab_akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Commercialize Research And License Agreement [Member]</link:label>
    <link:label id="lab_akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and commercialize research and license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember" xlink:href="akba-20210930.xsd#akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember" xlink:to="lab_akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_STAPharmaceuticalHongKongLimitedMember_bce26d63-af3e-4a1b-bde2-5214861969bc_terseLabel_en-US" xlink:label="lab_akba_STAPharmaceuticalHongKongLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STA Pharmaceutical Hong Kong Limited</link:label>
    <link:label id="lab_akba_STAPharmaceuticalHongKongLimitedMember_label_en-US" xlink:label="lab_akba_STAPharmaceuticalHongKongLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STA Pharmaceutical Hong Kong Limited [Member]</link:label>
    <link:label id="lab_akba_STAPharmaceuticalHongKongLimitedMember_documentation_en-US" xlink:label="lab_akba_STAPharmaceuticalHongKongLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STA Pharmaceutical Hong Kong Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_STAPharmaceuticalHongKongLimitedMember" xlink:href="akba-20210930.xsd#akba_STAPharmaceuticalHongKongLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_STAPharmaceuticalHongKongLimitedMember" xlink:to="lab_akba_STAPharmaceuticalHongKongLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_JanssenAgreementMember_b5ebc1f7-4ad0-4ed0-b3b4-10fee6d626b1_terseLabel_en-US" xlink:label="lab_akba_JanssenAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Agreement</link:label>
    <link:label id="lab_akba_JanssenAgreementMember_label_en-US" xlink:label="lab_akba_JanssenAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Agreement [Member]</link:label>
    <link:label id="lab_akba_JanssenAgreementMember_documentation_en-US" xlink:label="lab_akba_JanssenAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_JanssenAgreementMember" xlink:href="akba-20210930.xsd#akba_JanssenAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_JanssenAgreementMember" xlink:to="lab_akba_JanssenAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_5f5f2e7f-5f06-4ade-bb80-860eeaef8337_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expense</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_20e1c9bf-149a-4224-bf3d-e0f0db29089d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of available for sale securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_911f50df-1ac1-470e-9040-203f8f672e94_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_e3420669-f05c-497d-bf10-c9fd6d34ab52_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_65c794c8-23a6-4fb7-8a91-18a17efeaae9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant to purchase common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ContractWithCustomerLiabilityMember_73477bcf-1909-41fc-bbb2-2513c1f5a5e7_terseLabel_en-US" xlink:label="lab_akba_ContractWithCustomerLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability</link:label>
    <link:label id="lab_akba_ContractWithCustomerLiabilityMember_label_en-US" xlink:label="lab_akba_ContractWithCustomerLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability [Member]</link:label>
    <link:label id="lab_akba_ContractWithCustomerLiabilityMember_documentation_en-US" xlink:label="lab_akba_ContractWithCustomerLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractWithCustomerLiabilityMember" xlink:href="akba-20210930.xsd#akba_ContractWithCustomerLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ContractWithCustomerLiabilityMember" xlink:to="lab_akba_ContractWithCustomerLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction_807d6bbe-5000-4ef9-8c27-edea9dadc472_terseLabel_en-US" xlink:label="lab_akba_DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, amortization period, potential reduction (up to)</link:label>
    <link:label id="lab_akba_DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction_label_en-US" xlink:label="lab_akba_DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Potential Amortization Period Reduction</link:label>
    <link:label id="lab_akba_DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction_documentation_en-US" xlink:label="lab_akba_DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Potential Amortization Period Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction" xlink:href="akba-20210930.xsd#akba_DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction" xlink:to="lab_akba_DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_39f7825c-c7d8-48bf-a8a2-e99298a2f5d0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_RegulatoryMilestonePaymentsMember_52ec8204-6674-46d1-96dc-a1a714d490dd_terseLabel_en-US" xlink:label="lab_akba_RegulatoryMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestone Payments</link:label>
    <link:label id="lab_akba_RegulatoryMilestonePaymentsMember_label_en-US" xlink:label="lab_akba_RegulatoryMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestone Payments [Member]</link:label>
    <link:label id="lab_akba_RegulatoryMilestonePaymentsMember_documentation_en-US" xlink:label="lab_akba_RegulatoryMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_RegulatoryMilestonePaymentsMember" xlink:href="akba-20210930.xsd#akba_RegulatoryMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_RegulatoryMilestonePaymentsMember" xlink:to="lab_akba_RegulatoryMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_RebatesFeesAndOtherDeductionsMember_e0be1a4d-12fd-4640-a1bd-223ba21973e5_terseLabel_en-US" xlink:label="lab_akba_RebatesFeesAndOtherDeductionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates, Fees and other Deductions</link:label>
    <link:label id="lab_akba_RebatesFeesAndOtherDeductionsMember_label_en-US" xlink:label="lab_akba_RebatesFeesAndOtherDeductionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates Fees And Other Deductions [Member]</link:label>
    <link:label id="lab_akba_RebatesFeesAndOtherDeductionsMember_documentation_en-US" xlink:label="lab_akba_RebatesFeesAndOtherDeductionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates, Fees and other Deductions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_RebatesFeesAndOtherDeductionsMember" xlink:href="akba-20210930.xsd#akba_RebatesFeesAndOtherDeductionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_RebatesFeesAndOtherDeductionsMember" xlink:to="lab_akba_RebatesFeesAndOtherDeductionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_a0dce6eb-411f-4bbb-be61-246ba14c16ab_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_OperatingLeaseMonthlyRentExpense_6eafa0bf-5bc0-4042-a025-0f82410e3c35_terseLabel_en-US" xlink:label="lab_akba_OperatingLeaseMonthlyRentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly lease expense</link:label>
    <link:label id="lab_akba_OperatingLeaseMonthlyRentExpense_label_en-US" xlink:label="lab_akba_OperatingLeaseMonthlyRentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Rent Expense</link:label>
    <link:label id="lab_akba_OperatingLeaseMonthlyRentExpense_documentation_en-US" xlink:label="lab_akba_OperatingLeaseMonthlyRentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OperatingLeaseMonthlyRentExpense" xlink:href="akba-20210930.xsd#akba_OperatingLeaseMonthlyRentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_OperatingLeaseMonthlyRentExpense" xlink:to="lab_akba_OperatingLeaseMonthlyRentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ae050a3b-c089-4258-b08a-be7465581ebd_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_80eb2bbb-521a-443e-bd9d-bc37e00eec5a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to Sale of Future Royalties</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_9f038ef0-5fb0-4658-90e9-be550a5f54a8_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales_1c24cfe8-c2a5-40d3-8e16-780635d1d261_terseLabel_en-US" xlink:label="lab_akba_ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments related to prior year sales</link:label>
    <link:label id="lab_akba_ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales_label_en-US" xlink:label="lab_akba_ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves Adjustments Related To Prior Period Sales</link:label>
    <link:label id="lab_akba_ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales_documentation_en-US" xlink:label="lab_akba_ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowances and reserves adjustments related to prior period sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales" xlink:href="akba-20210930.xsd#akba_ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales" xlink:to="lab_akba_ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsByNatureAxis_ccd91810-0e4b-4e3b-b052-5e27b8dc0898_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations, Nature</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsByNatureAxis_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations, Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsByNatureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="lab_us-gaap_GuaranteeObligationsByNatureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ViforInternationalLimitedMember_200eae4c-0078-41ac-8e17-f329906b3b49_terseLabel_en-US" xlink:label="lab_akba_ViforInternationalLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vifor (International) Ltd.</link:label>
    <link:label id="lab_akba_ViforInternationalLimitedMember_label_en-US" xlink:label="lab_akba_ViforInternationalLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vifor International Limited [Member]</link:label>
    <link:label id="lab_akba_ViforInternationalLimitedMember_documentation_en-US" xlink:label="lab_akba_ViforInternationalLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vifor International Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ViforInternationalLimitedMember" xlink:href="akba-20210930.xsd#akba_ViforInternationalLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ViforInternationalLimitedMember" xlink:to="lab_akba_ViforInternationalLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_21e53bf7-0f97-432e-85f2-a9fff8f848ec_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_e69dcae3-3762-4ae8-93ff-b8a5543b4101_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher_5fafc941-2af9-4350-9ec8-dfdb36edfb12_terseLabel_en-US" xlink:label="lab_akba_CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otsuka PRV contribution</link:label>
    <link:label id="lab_akba_CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher_label_en-US" xlink:label="lab_akba_CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Accrued Liability, Priority Review Voucher</link:label>
    <link:label id="lab_akba_CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher_documentation_en-US" xlink:label="lab_akba_CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Accrued Liability, Priority Review Voucher</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher" xlink:href="akba-20210930.xsd#akba_CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher" xlink:to="lab_akba_CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_900d924a-f04f-4db8-9c4f-79a3de6f6b4e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_f84f48e4-040d-4b18-a143-67ef6f0f242f_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_TrancheBMember_c73a9431-6d91-470b-abea-29ab4b971d6e_terseLabel_en-US" xlink:label="lab_akba_TrancheBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche B</link:label>
    <link:label id="lab_akba_TrancheBMember_label_en-US" xlink:label="lab_akba_TrancheBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche B [Member]</link:label>
    <link:label id="lab_akba_TrancheBMember_documentation_en-US" xlink:label="lab_akba_TrancheBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche B.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_TrancheBMember" xlink:href="akba-20210930.xsd#akba_TrancheBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_TrancheBMember" xlink:to="lab_akba_TrancheBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a8b440a8-3178-4bac-b306-066d928d3aaf_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8e82ce97-244b-430f-b0e4-c9bbefd33184_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_e63d7446-bb90-4611-9413-f00f34ccc9cc_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_72e865f0-0c07-403c-b19b-106ea4e1f7e4_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_3bd36c46-bfd9-4c3e-a2f9-7f6525a94616_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones_39c8bafb-20ad-4275-8552-e6074cc662aa_terseLabel_en-US" xlink:label="lab_akba_PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone revenue from developmental milestones (up to)</link:label>
    <link:label id="lab_akba_PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones_label_en-US" xlink:label="lab_akba_PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Payment For Achievement Of Specified Development Milestones</link:label>
    <link:label id="lab_akba_PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones_documentation_en-US" xlink:label="lab_akba_PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential payment for achievement of specified development milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones" xlink:href="akba-20210930.xsd#akba_PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones" xlink:to="lab_akba_PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_CommitmentsAndContingenciesLineItems_acc393b6-ad4d-4e47-9c9d-bd84f9df3e01_terseLabel_en-US" xlink:label="lab_akba_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_akba_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_akba_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_akba_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_akba_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CommitmentsAndContingenciesLineItems" xlink:href="akba-20210930.xsd#akba_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems" xlink:to="lab_akba_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_36e34d5f-ab34-4a0f-ba61-0b0ba86d5a8d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost_8ed2d5fd-8221-48a5-9857-29dd6669709f_totalLabel_en-US" xlink:label="lab_akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and available for sale securities, amortized cost</link:label>
    <link:label id="lab_akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost_label_en-US" xlink:label="lab_akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Short Term Investments Amortized Cost</link:label>
    <link:label id="lab_akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost_documentation_en-US" xlink:label="lab_akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash cash equivalents and short term investments amortized cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost" xlink:href="akba-20210930.xsd#akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost" xlink:to="lab_akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_e6feb1ec-e548-4423-b320-bc05c7e8d05e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_00dd83f4-1659-443c-8006-247372761ebf_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_30dfb947-3343-4a07-b589-a2bbefb1cefa_terseLabel_en-US" xlink:label="lab_akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_label_en-US" xlink:label="lab_akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock Net Of Issuance Costs</link:label>
    <link:label id="lab_akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock net of issuance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:href="akba-20210930.xsd#akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:to="lab_akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_60f47070-20a2-42c7-9c39-48ac7fa39be0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum purchase commitment, initial term</link:label>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_label_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4fdbca86-7c36-453e-898c-c24871362313_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_CollaborativeArrangementAccruedLiability_97e84f7e-69ae-4060-8767-160315f2e493_terseLabel_en-US" xlink:label="lab_akba_CollaborativeArrangementAccruedLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement accrued liability</link:label>
    <link:label id="lab_akba_CollaborativeArrangementAccruedLiability_label_en-US" xlink:label="lab_akba_CollaborativeArrangementAccruedLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Accrued Liability</link:label>
    <link:label id="lab_akba_CollaborativeArrangementAccruedLiability_documentation_en-US" xlink:label="lab_akba_CollaborativeArrangementAccruedLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Accrued Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeArrangementAccruedLiability" xlink:href="akba-20210930.xsd#akba_CollaborativeArrangementAccruedLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_CollaborativeArrangementAccruedLiability" xlink:to="lab_akba_CollaborativeArrangementAccruedLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2cd1e9fe-a1ca-4764-a2cd-9507a6140e78_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ClosingStockPriceOfCommonStock_e7383d82-a86b-4a72-a11d-9f13577ffdac_terseLabel_en-US" xlink:label="lab_akba_ClosingStockPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium over the closing stock price of common stock (in dollars per share)</link:label>
    <link:label id="lab_akba_ClosingStockPriceOfCommonStock_label_en-US" xlink:label="lab_akba_ClosingStockPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing Stock Price Of Common Stock</link:label>
    <link:label id="lab_akba_ClosingStockPriceOfCommonStock_documentation_en-US" xlink:label="lab_akba_ClosingStockPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing stock price of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ClosingStockPriceOfCommonStock" xlink:href="akba-20210930.xsd#akba_ClosingStockPriceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ClosingStockPriceOfCommonStock" xlink:to="lab_akba_ClosingStockPriceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodOneMember_51f42004-df52-4a2b-980f-36e109c8edc4_terseLabel_en-US" xlink:label="lab_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Quarterly Periodic Payment, Period One</link:label>
    <link:label id="lab_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodOneMember_label_en-US" xlink:label="lab_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, First Quarterly Periodic Payment, Period One [Member]</link:label>
    <link:label id="lab_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodOneMember_documentation_en-US" xlink:label="lab_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, First Quarterly Periodic Payment, Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodOneMember" xlink:href="akba-20210930.xsd#akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodOneMember" xlink:to="lab_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable_05df6687-0faf-4dbc-a1ae-2f2a23ac5944_terseLabel_en-US" xlink:label="lab_akba_ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in percentage of future payments due upon current global development costs creditable</link:label>
    <link:label id="lab_akba_ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable_label_en-US" xlink:label="lab_akba_ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction In Percentage Of Future Payments Due Upon Current Global Development Costs Creditable</link:label>
    <link:label id="lab_akba_ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable_documentation_en-US" xlink:label="lab_akba_ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in percentage of future payments due upon current global development costs creditable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable" xlink:href="akba-20210930.xsd#akba_ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable" xlink:to="lab_akba_ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_f34e9068-a467-4efd-8625-907277aa8eb5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0dbcab0c-558b-4726-b282-2d8069d140d9_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash financing activities</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_d6d6d92f-e518-4588-976d-491cf5fe4cf0_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligations satisfied in previous periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ContractWithCustomerLiabilityDeductions_3cd0a808-455f-4658-802a-5198d0883efa_negatedLabel_en-US" xlink:label="lab_akba_ContractWithCustomerLiabilityDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_akba_ContractWithCustomerLiabilityDeductions_label_en-US" xlink:label="lab_akba_ContractWithCustomerLiabilityDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Liability Deductions</link:label>
    <link:label id="lab_akba_ContractWithCustomerLiabilityDeductions_documentation_en-US" xlink:label="lab_akba_ContractWithCustomerLiabilityDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer liability deductions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractWithCustomerLiabilityDeductions" xlink:href="akba-20210930.xsd#akba_ContractWithCustomerLiabilityDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ContractWithCustomerLiabilityDeductions" xlink:to="lab_akba_ContractWithCustomerLiabilityDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_a446c9ae-757d-48ca-929d-6f039a603626_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_InducementAwardProgramMember_657ea264-8145-4f1a-b3de-3d54372ff065_terseLabel_en-US" xlink:label="lab_akba_InducementAwardProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Award Program</link:label>
    <link:label id="lab_akba_InducementAwardProgramMember_label_en-US" xlink:label="lab_akba_InducementAwardProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Award Program [Member]</link:label>
    <link:label id="lab_akba_InducementAwardProgramMember_documentation_en-US" xlink:label="lab_akba_InducementAwardProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement award program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_InducementAwardProgramMember" xlink:href="akba-20210930.xsd#akba_InducementAwardProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_InducementAwardProgramMember" xlink:to="lab_akba_InducementAwardProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_PercentageOfRemainingCreditableAmountAppliedToFuturePayments_2f9af824-7012-4de5-84b7-62a45155493e_terseLabel_en-US" xlink:label="lab_akba_PercentageOfRemainingCreditableAmountAppliedToFuturePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of remaining creditable amount applied to future payments</link:label>
    <link:label id="lab_akba_PercentageOfRemainingCreditableAmountAppliedToFuturePayments_label_en-US" xlink:label="lab_akba_PercentageOfRemainingCreditableAmountAppliedToFuturePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Remaining Creditable Amount Applied To Future Payments</link:label>
    <link:label id="lab_akba_PercentageOfRemainingCreditableAmountAppliedToFuturePayments_documentation_en-US" xlink:label="lab_akba_PercentageOfRemainingCreditableAmountAppliedToFuturePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of remaining creditable amount applied to future payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PercentageOfRemainingCreditableAmountAppliedToFuturePayments" xlink:href="akba-20210930.xsd#akba_PercentageOfRemainingCreditableAmountAppliedToFuturePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_PercentageOfRemainingCreditableAmountAppliedToFuturePayments" xlink:to="lab_akba_PercentageOfRemainingCreditableAmountAppliedToFuturePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_56a64ecb-05b7-4fb6-bc24-74dd1085d4b5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_41997aeb-8582-428f-b588-c4ca059ebc6c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_DebtInstrumentCovenantTermsPotentialMaturityTermReduction_489d560b-f8e5-4b89-b525-d84b8be81307_terseLabel_en-US" xlink:label="lab_akba_DebtInstrumentCovenantTermsPotentialMaturityTermReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, maturity term, potential reduction (up to)</link:label>
    <link:label id="lab_akba_DebtInstrumentCovenantTermsPotentialMaturityTermReduction_label_en-US" xlink:label="lab_akba_DebtInstrumentCovenantTermsPotentialMaturityTermReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Potential Maturity Term Reduction</link:label>
    <link:label id="lab_akba_DebtInstrumentCovenantTermsPotentialMaturityTermReduction_documentation_en-US" xlink:label="lab_akba_DebtInstrumentCovenantTermsPotentialMaturityTermReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Potential Maturity Term Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentCovenantTermsPotentialMaturityTermReduction" xlink:href="akba-20210930.xsd#akba_DebtInstrumentCovenantTermsPotentialMaturityTermReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_DebtInstrumentCovenantTermsPotentialMaturityTermReduction" xlink:to="lab_akba_DebtInstrumentCovenantTermsPotentialMaturityTermReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ebd83340-af5a-4fb7-ae8e-819d2e961e11_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3c4dd499-fdc5-4973-ad9b-f7db7da2015b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d8f48c4a-a722-4e4d-a99f-23858c1b4415_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_5fecc346-7a6d-4f1b-b198-20a826d5948c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_f4bfe314-ea3f-4755-9191-65885934862b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_NumberOfPerformanceObligations_478c2750-c06e-4102-a605-8fa0608de202_terseLabel_en-US" xlink:label="lab_akba_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_akba_NumberOfPerformanceObligations_label_en-US" xlink:label="lab_akba_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Performance Obligations</link:label>
    <link:label id="lab_akba_NumberOfPerformanceObligations_documentation_en-US" xlink:label="lab_akba_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of performance obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_NumberOfPerformanceObligations" xlink:href="akba-20210930.xsd#akba_NumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_NumberOfPerformanceObligations" xlink:to="lab_akba_NumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2dd7e4b0-7d6c-46ee-9c2e-9d01cbaf771b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of stock under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BilledContractReceivables_766684a7-8f07-43a3-adbf-9baa039a2fb1_terseLabel_en-US" xlink:label="lab_us-gaap_BilledContractReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front payments invoiced</link:label>
    <link:label id="lab_us-gaap_BilledContractReceivables_label_en-US" xlink:label="lab_us-gaap_BilledContractReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Billed Contracts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BilledContractReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BilledContractReceivables" xlink:to="lab_us-gaap_BilledContractReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_66c4729a-c64a-49f7-a7b8-83f82a6dda96_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_124aa703-266a-4c38-85b9-efc81abd55bb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_949f79fd-3b04-455b-b604-626550d2b20c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Award Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_4a244aec-d033-466e-b21d-745c3fa3a37f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_424e7773-9e71-4e48-ade2-e9998fefe675_verboseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_6f44c700-b006-4534-a362-c25867a5bdb2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ShareBasedPaymentArrangementTrancheTwoSecondAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember_b46f17d5-b16d-4578-be1e-fd0014037940_terseLabel_en-US" xlink:label="lab_akba_ShareBasedPaymentArrangementTrancheTwoSecondAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two, Second Anniversary After Grant Date, Subjected To Individual Continued Service</link:label>
    <link:label id="lab_akba_ShareBasedPaymentArrangementTrancheTwoSecondAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember_label_en-US" xlink:label="lab_akba_ShareBasedPaymentArrangementTrancheTwoSecondAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two, Second Anniversary After Grant Date, Subjected To Individual Continued Service [Member]</link:label>
    <link:label id="lab_akba_ShareBasedPaymentArrangementTrancheTwoSecondAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember_documentation_en-US" xlink:label="lab_akba_ShareBasedPaymentArrangementTrancheTwoSecondAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two, Second Anniversary After Grant Date, Subjected To Individual Continued Service</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ShareBasedPaymentArrangementTrancheTwoSecondAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember" xlink:href="akba-20210930.xsd#akba_ShareBasedPaymentArrangementTrancheTwoSecondAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ShareBasedPaymentArrangementTrancheTwoSecondAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember" xlink:to="lab_akba_ShareBasedPaymentArrangementTrancheTwoSecondAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_61e1e29b-cfcb-48ff-b022-f7fb1f645513_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits/payments made</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_efa7a875-a702-4b08-9551-754588416321_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fff4b89d-4215-43b4-8537-87f28d8b38a3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_043ed5b4-5465-4e77-a651-6136b1f17716_terseLabel_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_label_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee&#8203;, Operating &#8203;Lease&#8203;, Liability, &#8203;To Be Paid, &#8203;Due &#8203;After&#8203; Year&#8203; Four</link:label>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_documentation_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee&#8203;, Operating &#8203;Lease&#8203;, Liability, &#8203;To Be Paid, &#8203;Due &#8203;After&#8203; Year&#8203; Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:to="lab_akba_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock_710846a9-9aa2-4517-a113-c0c0d01a11a1_terseLabel_en-US" xlink:label="lab_akba_ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenue Allowance and Reserve Categories</link:label>
    <link:label id="lab_akba_ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock_label_en-US" xlink:label="lab_akba_ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Product Revenue Allowance And Reserve Categories [Table Text Block]</link:label>
    <link:label id="lab_akba_ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock_documentation_en-US" xlink:label="lab_akba_ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Product Revenue Allowance And Reserve Categories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock" xlink:href="akba-20210930.xsd#akba_ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock" xlink:to="lab_akba_ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_168b0036-e03c-4d6d-b316-b32d3c727d4a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_c4151dc9-04da-43b7-85e3-5226b4536ac1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_87847610-e7c6-4d36-81f7-e10ae159cfce_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_4c18a7e4-b44d-4789-9770-45c213226ab0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_96c41532-68d5-48ed-9b8b-f231e4d5276f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_713c6025-8bbe-4a91-92a5-6f8de41e2300_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f4ec69c1-ab49-4888-93fc-45d140c0b457_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_e6afabc9-9cdd-4533-9acc-37a180df2a97_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_cd77d5da-6f98-4c86-aad1-ad64677eb867_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_69472f83-855f-4387-bcd2-94c0aa15008b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_97f836b5-1af2-4209-916d-0f117e965a28_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTable" xlink:to="lab_us-gaap_AssetAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_920219c3-f24f-4ec0-b7ff-4b1ee56c3e0f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_ffa0cb31-3584-40f6-9126-f9fa8744802a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_bbb88b14-acbe-4f65-9e6b-d102dfd46fa0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member_7eff1b56-2843-49ad-903d-7b6fa0aa1fad_terseLabel_en-US" xlink:label="lab_akba_AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Equity Offering Program Authorized February 2021</link:label>
    <link:label id="lab_akba_AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member_label_en-US" xlink:label="lab_akba_AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Equity Offering Program Authorized February 2021 [Member]</link:label>
    <link:label id="lab_akba_AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member_documentation_en-US" xlink:label="lab_akba_AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Equity Offering Program Authorized February 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member" xlink:href="akba-20210930.xsd#akba_AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member" xlink:to="lab_akba_AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_86cbbdc3-c9e0-4b78-87a5-f1873ff5cb17_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c1ea9bd9-6866-41f8-8609-33c5c6bef0ae_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_BioVectraIncMember_1158e416-ad60-42c7-8ed9-1a14f3fb524b_terseLabel_en-US" xlink:label="lab_akba_BioVectraIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioVectra Inc</link:label>
    <link:label id="lab_akba_BioVectraIncMember_label_en-US" xlink:label="lab_akba_BioVectraIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bio Vectra Inc [Member]</link:label>
    <link:label id="lab_akba_BioVectraIncMember_documentation_en-US" xlink:label="lab_akba_BioVectraIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioVectra Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_BioVectraIncMember" xlink:href="akba-20210930.xsd#akba_BioVectraIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_BioVectraIncMember" xlink:to="lab_akba_BioVectraIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity_6e54c461-ffa1-4ba9-98aa-33a61ed459dd_terseLabel_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate royalty payout capacity</link:label>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity_label_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Arrangement, Royalties Agreement, Maximum Aggregate Royalty Payout Capacity</link:label>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity_documentation_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Arrangement, Royalties Agreement, Maximum Aggregate Royalty Payout Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity" xlink:to="lab_akba_ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecurityDeposit_8185d723-2e8b-42c4-ad03-aacdc8b1d176_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total security deposit in connection with lease</link:label>
    <link:label id="lab_us-gaap_SecurityDeposit_label_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_CollaborativeArrangementsCostSharingPayments_6ccc10d1-52b2-49c4-ac3a-64209484dd3f_terseLabel_en-US" xlink:label="lab_akba_CollaborativeArrangementsCostSharingPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangements cost sharing payments</link:label>
    <link:label id="lab_akba_CollaborativeArrangementsCostSharingPayments_label_en-US" xlink:label="lab_akba_CollaborativeArrangementsCostSharingPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements Cost Sharing Payments</link:label>
    <link:label id="lab_akba_CollaborativeArrangementsCostSharingPayments_documentation_en-US" xlink:label="lab_akba_CollaborativeArrangementsCostSharingPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangements cost sharing payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeArrangementsCostSharingPayments" xlink:href="akba-20210930.xsd#akba_CollaborativeArrangementsCostSharingPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_CollaborativeArrangementsCostSharingPayments" xlink:to="lab_akba_CollaborativeArrangementsCostSharingPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_9ea5e7b8-587d-4a85-99bc-00eaced3f160_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_201f0928-23f4-4f82-9314-e8a06c54f1d6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a8d90fdc-9a79-4b5d-9cde-ea30219af1d1_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_a92c866f-3520-459b-b0d2-c197dea1d413_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_OperatingLeaseFreeMonthlyRentPeriod_b8d8282e-e621-4ecd-9216-76f9c6c97aea_terseLabel_en-US" xlink:label="lab_akba_OperatingLeaseFreeMonthlyRentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, free monthly rent, period</link:label>
    <link:label id="lab_akba_OperatingLeaseFreeMonthlyRentPeriod_label_en-US" xlink:label="lab_akba_OperatingLeaseFreeMonthlyRentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Free Monthly Rent, Period</link:label>
    <link:label id="lab_akba_OperatingLeaseFreeMonthlyRentPeriod_documentation_en-US" xlink:label="lab_akba_OperatingLeaseFreeMonthlyRentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Free Monthly Rent, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OperatingLeaseFreeMonthlyRentPeriod" xlink:href="akba-20210930.xsd#akba_OperatingLeaseFreeMonthlyRentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_OperatingLeaseFreeMonthlyRentPeriod" xlink:to="lab_akba_OperatingLeaseFreeMonthlyRentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffMarketFavorableLeaseMember_55f9aeb1-1899-4fd3-b5b9-7ad4d27677cb_terseLabel_en-US" xlink:label="lab_us-gaap_OffMarketFavorableLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable lease</link:label>
    <link:label id="lab_us-gaap_OffMarketFavorableLeaseMember_label_en-US" xlink:label="lab_us-gaap_OffMarketFavorableLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off-Market Favorable Lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketFavorableLeaseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffMarketFavorableLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffMarketFavorableLeaseMember" xlink:to="lab_us-gaap_OffMarketFavorableLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_e87a7b7c-2daa-40c6-bed3-77fb21a2605e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_InventoryNetCurrentAndNonCurrent_cdaf2a39-59a2-4631-9509-9d3d936aa4e9_totalLabel_en-US" xlink:label="lab_akba_InventoryNetCurrentAndNonCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_akba_InventoryNetCurrentAndNonCurrent_label_en-US" xlink:label="lab_akba_InventoryNetCurrentAndNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Net Current And Non Current</link:label>
    <link:label id="lab_akba_InventoryNetCurrentAndNonCurrent_documentation_en-US" xlink:label="lab_akba_InventoryNetCurrentAndNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory net current and non current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_InventoryNetCurrentAndNonCurrent" xlink:href="akba-20210930.xsd#akba_InventoryNetCurrentAndNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_InventoryNetCurrentAndNonCurrent" xlink:to="lab_akba_InventoryNetCurrentAndNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_9e35a56a-07c3-46a0-970a-571836b3df82_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_DeferredRevenueMember_8b007b20-f2ef-46bd-9803-1d28bd64382a_terseLabel_en-US" xlink:label="lab_akba_DeferredRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_akba_DeferredRevenueMember_label_en-US" xlink:label="lab_akba_DeferredRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue [Member]</link:label>
    <link:label id="lab_akba_DeferredRevenueMember_documentation_en-US" xlink:label="lab_akba_DeferredRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DeferredRevenueMember" xlink:href="akba-20210930.xsd#akba_DeferredRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_DeferredRevenueMember" xlink:to="lab_akba_DeferredRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ServiceBasedRestrictedStockUnitsMember_6be3611c-b6c4-474b-9bf6-87f1281c76f3_terseLabel_en-US" xlink:label="lab_akba_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-Based Restricted Stock Units</link:label>
    <link:label id="lab_akba_ServiceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_akba_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_akba_ServiceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_akba_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ServiceBasedRestrictedStockUnitsMember" xlink:href="akba-20210930.xsd#akba_ServiceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ServiceBasedRestrictedStockUnitsMember" xlink:to="lab_akba_ServiceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsNatureDomain_7e80c560-54e3-450e-a3ba-6cf4eea4e0eb_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations, Nature</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsNatureDomain_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain" xlink:to="lab_us-gaap_GuaranteeObligationsNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1d24313e-e531-4572-8afe-147bcaa5b43d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4cb827d6-775a-46b6-bf68-a93b4ab4f2b2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_337e3a10-4bb7-4c2f-a997-70c8812b5086_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_491db40f-4ef3-421b-b229-fc3c07b203c2_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining 2021</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_77a0768c-a083-42ed-9f0d-81e197c785e1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_932a2eb8-98ed-4693-8b5d-fa15b3920409_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ScheduleOfRevenueRecognizedResultingFromChangesInContractAssetAndContractLiabilityTableTextBlock_d99fae96-8618-4d76-9935-35c7cb328644_terseLabel_en-US" xlink:label="lab_akba_ScheduleOfRevenueRecognizedResultingFromChangesInContractAssetAndContractLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognized Resulting from Changes in Contract Assets and Contract Liabilities</link:label>
    <link:label id="lab_akba_ScheduleOfRevenueRecognizedResultingFromChangesInContractAssetAndContractLiabilityTableTextBlock_label_en-US" xlink:label="lab_akba_ScheduleOfRevenueRecognizedResultingFromChangesInContractAssetAndContractLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Revenue Recognized Resulting From Changes In Contract Asset And Contract Liability [Table Text Block]</link:label>
    <link:label id="lab_akba_ScheduleOfRevenueRecognizedResultingFromChangesInContractAssetAndContractLiabilityTableTextBlock_documentation_en-US" xlink:label="lab_akba_ScheduleOfRevenueRecognizedResultingFromChangesInContractAssetAndContractLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenue recognized resulting from changes in contract asset and contract liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ScheduleOfRevenueRecognizedResultingFromChangesInContractAssetAndContractLiabilityTableTextBlock" xlink:href="akba-20210930.xsd#akba_ScheduleOfRevenueRecognizedResultingFromChangesInContractAssetAndContractLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ScheduleOfRevenueRecognizedResultingFromChangesInContractAssetAndContractLiabilityTableTextBlock" xlink:to="lab_akba_ScheduleOfRevenueRecognizedResultingFromChangesInContractAssetAndContractLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f2ef5c14-251d-4d82-9019-e3da0867d0dd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrentRollForward_524106ea-7299-4663-9c9c-a68c7bdf17c7_terseLabel_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Arrangement, Royalties Agreement, Liability, Noncurrent [Roll Forward]</link:label>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrentRollForward_label_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Arrangement, Royalties Agreement, Liability, Noncurrent [Roll Forward]</link:label>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrentRollForward_documentation_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Arrangement, Royalties Agreement, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrentRollForward" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrentRollForward" xlink:to="lab_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_3fa9be12-10f3-46cb-9ef1-e5bc1cf5e3b4_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Axis]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_673a3c04-43a7-4c07-b6b1-c39bbd991811_terseLabel_en-US" xlink:label="lab_akba_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_akba_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_akba_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Fourteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_akba_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_akba_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand and fourteen employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:href="akba-20210930.xsd#akba_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:to="lab_akba_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm_84c2ce90-a1e6-4f5f-adbf-3926bd1b294c_terseLabel_en-US" xlink:label="lab_akba_LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, first quarterly principal payment due in</link:label>
    <link:label id="lab_akba_LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm_label_en-US" xlink:label="lab_akba_LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, First Quarter Periodic Payment, Principal, Term</link:label>
    <link:label id="lab_akba_LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm_documentation_en-US" xlink:label="lab_akba_LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, First Quarter Periodic Payment, Principal, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm" xlink:href="akba-20210930.xsd#akba_LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm" xlink:to="lab_akba_LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember_ae1ec313-c7a0-45d2-8582-e91046713043_terseLabel_en-US" xlink:label="lab_akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biopharma Credit Investments V (Master) LP</link:label>
    <link:label id="lab_akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember_label_en-US" xlink:label="lab_akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biopharma Credit Investments V Master Limited Partner [Member]</link:label>
    <link:label id="lab_akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember_documentation_en-US" xlink:label="lab_akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biopharma Credit Investments V (Master) Limited Partner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember" xlink:href="akba-20210930.xsd#akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember" xlink:to="lab_akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_AccruedClinicalExpensesCurrent_54113637-997f-4f16-9bc7-deb1e352421c_terseLabel_en-US" xlink:label="lab_akba_AccruedClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical</link:label>
    <link:label id="lab_akba_AccruedClinicalExpensesCurrent_label_en-US" xlink:label="lab_akba_AccruedClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Expenses Current</link:label>
    <link:label id="lab_akba_AccruedClinicalExpensesCurrent_documentation_en-US" xlink:label="lab_akba_AccruedClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical expenses current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AccruedClinicalExpensesCurrent" xlink:href="akba-20210930.xsd#akba_AccruedClinicalExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_AccruedClinicalExpensesCurrent" xlink:to="lab_akba_AccruedClinicalExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9ee9c3ad-12ee-4af3-a956-50a69380be21_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1f189c5d-2e5e-4049-981a-1f3b13bc2163_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale securities, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ScheduleOfDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesAndOperatingLeaseLiabilitiesTableTextBlock_ac34e2ca-e7fb-4651-a900-fd154cbcce7f_terseLabel_en-US" xlink:label="lab_akba_ScheduleOfDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesAndOperatingLeaseLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Difference Between Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases and Operating Leases Liabilities</link:label>
    <link:label id="lab_akba_ScheduleOfDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesAndOperatingLeaseLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_akba_ScheduleOfDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesAndOperatingLeaseLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Difference Between Undiscounted Minimum Rental Commitments Under Non Cancelable Leases And Operating Lease Liabilities [Table Text Block]</link:label>
    <link:label id="lab_akba_ScheduleOfDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesAndOperatingLeaseLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_akba_ScheduleOfDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesAndOperatingLeaseLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of difference between undiscounted minimum rental commitments under non-cancelable leases and the operating lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ScheduleOfDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesAndOperatingLeaseLiabilitiesTableTextBlock" xlink:href="akba-20210930.xsd#akba_ScheduleOfDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesAndOperatingLeaseLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ScheduleOfDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesAndOperatingLeaseLiabilitiesTableTextBlock" xlink:to="lab_akba_ScheduleOfDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesAndOperatingLeaseLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_WarrantDisclosureTextBlock_95fbb6aa-3876-4f96-9c94-1273c029cf97_terseLabel_en-US" xlink:label="lab_akba_WarrantDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_akba_WarrantDisclosureTextBlock_label_en-US" xlink:label="lab_akba_WarrantDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Disclosure [Text Block]</link:label>
    <link:label id="lab_akba_WarrantDisclosureTextBlock_documentation_en-US" xlink:label="lab_akba_WarrantDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_WarrantDisclosureTextBlock" xlink:href="akba-20210930.xsd#akba_WarrantDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_WarrantDisclosureTextBlock" xlink:to="lab_akba_WarrantDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_1947073c-d033-48de-b9cf-9d8990c8b72f_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_844bf19d-65a0-441b-81ea-062902009a7a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_e86864f3-c86c-45ec-a485-b057bd0c70c4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_DerivativeLiabilityFairValueGrossLiabilityRollForward_93c13e97-d5fe-484b-941c-45cccf76e7bb_terseLabel_en-US" xlink:label="lab_akba_DerivativeLiabilityFairValueGrossLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability [Roll Forward]</link:label>
    <link:label id="lab_akba_DerivativeLiabilityFairValueGrossLiabilityRollForward_label_en-US" xlink:label="lab_akba_DerivativeLiabilityFairValueGrossLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability [Roll Forward]</link:label>
    <link:label id="lab_akba_DerivativeLiabilityFairValueGrossLiabilityRollForward_documentation_en-US" xlink:label="lab_akba_DerivativeLiabilityFairValueGrossLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DerivativeLiabilityFairValueGrossLiabilityRollForward" xlink:href="akba-20210930.xsd#akba_DerivativeLiabilityFairValueGrossLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_DerivativeLiabilityFairValueGrossLiabilityRollForward" xlink:to="lab_akba_DerivativeLiabilityFairValueGrossLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_904f9e66-dca9-47ac-8b9e-bd53832b8b85_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_d11ced3f-ae3a-4fff-86fe-55ee4dc8268e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price at the end of offering period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_3ff762e9-3f57-4632-b05b-9a1f9b52db3d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7be037cd-3c3e-4778-8c7e-944cd779d6ca_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_33d748a4-91d0-4b10-89c9-8ffe05dcedf1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_08539219-1177-4e6c-8b93-4ff3ccd4d46a_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod_4e178bf5-55e8-4325-a9bb-90c90257aff1_terseLabel_en-US" xlink:label="lab_akba_LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitment, option to extend, prior notice period</link:label>
    <link:label id="lab_akba_LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod_label_en-US" xlink:label="lab_akba_LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Option To Extend, Prior Notice Period</link:label>
    <link:label id="lab_akba_LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod_documentation_en-US" xlink:label="lab_akba_LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Option To Extend, Prior Notice Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod" xlink:href="akba-20210930.xsd#akba_LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod" xlink:to="lab_akba_LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember_e9285887-2072-434e-b076-6b8acadd1c63_terseLabel_en-US" xlink:label="lab_akba_ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One, First Anniversary After Grant Date, Subjected To Individual Continued Service</link:label>
    <link:label id="lab_akba_ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember_label_en-US" xlink:label="lab_akba_ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One, First Anniversary After Grant Date, Subjected To Individual Continued Service [Member]</link:label>
    <link:label id="lab_akba_ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember_documentation_en-US" xlink:label="lab_akba_ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One, First Anniversary After Grant Date, Subjected To Individual Continued Service</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember" xlink:href="akba-20210930.xsd#akba_ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember" xlink:to="lab_akba_ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_CollateralAgentPharmakonMember_685e7284-86ab-4464-b5ab-172e097746ce_terseLabel_en-US" xlink:label="lab_akba_CollateralAgentPharmakonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Agent, Pharmakon</link:label>
    <link:label id="lab_akba_CollateralAgentPharmakonMember_label_en-US" xlink:label="lab_akba_CollateralAgentPharmakonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Agent Pharmakon [Member]</link:label>
    <link:label id="lab_akba_CollateralAgentPharmakonMember_documentation_en-US" xlink:label="lab_akba_CollateralAgentPharmakonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Agent, Pharmakon.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollateralAgentPharmakonMember" xlink:href="akba-20210930.xsd#akba_CollateralAgentPharmakonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_CollateralAgentPharmakonMember" xlink:to="lab_akba_CollateralAgentPharmakonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f6d902e1-e1a2-4e32-ac41-956cd4e0e2ea_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_56c4ef48-ed2b-4a9c-97bf-73a93bca194d_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_abf52a30-6887-4d78-be37-f7e08d8d15c1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, estimated useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_bb65f701-3a0f-49b3-a727-a631ff979900_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f4bcf193-2a3c-472b-a7a3-56f337ba54a9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_UpfrontPaymentPaidInCash_ea3d1ef1-f119-4e65-bf45-42c840c064ea_terseLabel_en-US" xlink:label="lab_akba_UpfrontPaymentPaidInCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment made in cash</link:label>
    <link:label id="lab_akba_UpfrontPaymentPaidInCash_label_en-US" xlink:label="lab_akba_UpfrontPaymentPaidInCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment Paid In Cash</link:label>
    <link:label id="lab_akba_UpfrontPaymentPaidInCash_documentation_en-US" xlink:label="lab_akba_UpfrontPaymentPaidInCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment paid in cash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_UpfrontPaymentPaidInCash" xlink:href="akba-20210930.xsd#akba_UpfrontPaymentPaidInCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_UpfrontPaymentPaidInCash" xlink:to="lab_akba_UpfrontPaymentPaidInCash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_928530d3-e70f-47f6-93bb-f7094c11ed84_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a1b26a19-cb48-456e-a441-fb76528e58b7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome_309ffa3c-fade-4306-9949-f19abcb679e4_terseLabel_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense related to sale of future royalties</link:label>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome_e33682c6-948d-4855-aa49-ffbd20378d90_verboseLabel_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense recognized</link:label>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome_label_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Arrangement, Royalties Agreement, Noncash Interest Expense (Income)</link:label>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome_documentation_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Arrangement, Royalties Agreement, Noncash Interest Expense (Income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome" xlink:to="lab_akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b7612aee-43c1-4f08-8c8b-6ca977a03f71_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_71330e27-a64f-48f9-bd52-f9c4033cbca9_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_f10baddc-b391-4bd8-9bf0-e9617998ca23_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_AggregateCollaborationAgreementPayments_1365b0fe-09fd-4a9d-9a40-6e8426c1a18a_terseLabel_en-US" xlink:label="lab_akba_AggregateCollaborationAgreementPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for closing Priority Review Voucher purchase</link:label>
    <link:label id="lab_akba_AggregateCollaborationAgreementPayments_label_en-US" xlink:label="lab_akba_AggregateCollaborationAgreementPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Collaboration Agreement Payments</link:label>
    <link:label id="lab_akba_AggregateCollaborationAgreementPayments_documentation_en-US" xlink:label="lab_akba_AggregateCollaborationAgreementPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate collaboration agreement payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AggregateCollaborationAgreementPayments" xlink:href="akba-20210930.xsd#akba_AggregateCollaborationAgreementPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_AggregateCollaborationAgreementPayments" xlink:to="lab_akba_AggregateCollaborationAgreementPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_AccruedProductRevenueAllowancesCurrent_30a702bb-b8d4-4e0e-81f9-b77769b00377_terseLabel_en-US" xlink:label="lab_akba_AccruedProductRevenueAllowancesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue allowances</link:label>
    <link:label id="lab_akba_AccruedProductRevenueAllowancesCurrent_label_en-US" xlink:label="lab_akba_AccruedProductRevenueAllowancesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Product Revenue Allowances Current</link:label>
    <link:label id="lab_akba_AccruedProductRevenueAllowancesCurrent_documentation_en-US" xlink:label="lab_akba_AccruedProductRevenueAllowancesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued product revenue allowances current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AccruedProductRevenueAllowancesCurrent" xlink:href="akba-20210930.xsd#akba_AccruedProductRevenueAllowancesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_AccruedProductRevenueAllowancesCurrent" xlink:to="lab_akba_AccruedProductRevenueAllowancesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_7f7af6fd-c44b-4e12-a3bf-1d137091f9f5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from common stock sold</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_60a12735-582e-4ec4-9b2d-27bc774e9678_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_29cf664a-a9d4-4061-a756-60bc78ee6dfa_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_630f37a5-f35f-447c-845a-af72b773459e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_7dbff57f-14d3-45ec-a01a-f54860e66ac1_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_816f72f9-8e4e-44b9-92c4-e84a9b4e2559_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_481cbf67-c9a8-486a-b03c-ca36115701e6_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_8f2045c5-6f02-42a9-bc1b-89d7cbba9431_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_a4891516-3dd4-43ea-a213-2158de4ed0ca_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_b5edddba-afb4-45dd-8089-f4cea27cff62_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_PaymentForLicenseAgreementReimbursementOfCostsIncurred_a0967413-0ce0-4360-a1a1-f527115db984_terseLabel_en-US" xlink:label="lab_akba_PaymentForLicenseAgreementReimbursementOfCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs reimbursed</link:label>
    <link:label id="lab_akba_PaymentForLicenseAgreementReimbursementOfCostsIncurred_label_en-US" xlink:label="lab_akba_PaymentForLicenseAgreementReimbursementOfCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For License Agreement Reimbursement Of Costs Incurred</link:label>
    <link:label id="lab_akba_PaymentForLicenseAgreementReimbursementOfCostsIncurred_documentation_en-US" xlink:label="lab_akba_PaymentForLicenseAgreementReimbursementOfCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for license agreement reimbursement of costs incurred.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PaymentForLicenseAgreementReimbursementOfCostsIncurred" xlink:href="akba-20210930.xsd#akba_PaymentForLicenseAgreementReimbursementOfCostsIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_PaymentForLicenseAgreementReimbursementOfCostsIncurred" xlink:to="lab_akba_PaymentForLicenseAgreementReimbursementOfCostsIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_dd274a62-3fcb-43dc-9e94-edc2fc9fbbbc_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ChargebacksAndDiscountsMember_d81c91d2-a4f0-4f57-978a-b9ce6bd9ac40_terseLabel_en-US" xlink:label="lab_akba_ChargebacksAndDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks and Discounts</link:label>
    <link:label id="lab_akba_ChargebacksAndDiscountsMember_label_en-US" xlink:label="lab_akba_ChargebacksAndDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks And Discounts [Member]</link:label>
    <link:label id="lab_akba_ChargebacksAndDiscountsMember_documentation_en-US" xlink:label="lab_akba_ChargebacksAndDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks and Discounts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ChargebacksAndDiscountsMember" xlink:href="akba-20210930.xsd#akba_ChargebacksAndDiscountsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ChargebacksAndDiscountsMember" xlink:to="lab_akba_ChargebacksAndDiscountsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred_49a53ab8-581d-4e94-837c-226e1bebf1e9_terseLabel_en-US" xlink:label="lab_akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of costs</link:label>
    <link:label id="lab_akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred_label_en-US" xlink:label="lab_akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Receivable For License Agreement Reimbursement Of Previously Costs Incurred</link:label>
    <link:label id="lab_akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred_documentation_en-US" xlink:label="lab_akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment receivable for license agreement reimbursement of previously costs incurred.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred" xlink:href="akba-20210930.xsd#akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred" xlink:to="lab_akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_4712b7d1-8770-4e1e-808c-b8621b76ee29_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease extension period</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_OtherThanDerivativeLiabilitiesMember_54ea2711-7a03-4bfb-908a-66d97fc5b8bc_terseLabel_en-US" xlink:label="lab_akba_OtherThanDerivativeLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Derivative Liabilities</link:label>
    <link:label id="lab_akba_OtherThanDerivativeLiabilitiesMember_label_en-US" xlink:label="lab_akba_OtherThanDerivativeLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Than Derivative Liabilities [Member]</link:label>
    <link:label id="lab_akba_OtherThanDerivativeLiabilitiesMember_documentation_en-US" xlink:label="lab_akba_OtherThanDerivativeLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than derivative liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OtherThanDerivativeLiabilitiesMember" xlink:href="akba-20210930.xsd#akba_OtherThanDerivativeLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_OtherThanDerivativeLiabilitiesMember" xlink:to="lab_akba_OtherThanDerivativeLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerBasisOfPricingDomain_00864fee-5107-4bd6-9989-db56d01673db_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Basis of Pricing</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerBasisOfPricingDomain_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Basis of Pricing [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:to="lab_us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMember_cacdbf97-8e03-416d-817c-4b5306cc4be4_terseLabel_en-US" xlink:label="lab_akba_ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Tranche, First Anniversary of Grant Date</link:label>
    <link:label id="lab_akba_ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMember_label_en-US" xlink:label="lab_akba_ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Award Tranche First Anniversary Of Grant Date [Member]</link:label>
    <link:label id="lab_akba_ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMember_documentation_en-US" xlink:label="lab_akba_ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation award, tranche, first anniversary of grant date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMember" xlink:href="akba-20210930.xsd#akba_ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMember" xlink:to="lab_akba_ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_b4413d2c-9c5c-43f1-8e05-99b1b28f6c01_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_97bc5823-8e31-44a4-b046-7ab7fa4976b9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_eba4e7e6-63e2-4b34-a724-e0801be1f51d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod_a4f76d5f-f7c7-42b0-8e4c-c2c7b5e1eab5_terseLabel_en-US" xlink:label="lab_akba_LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term purchase commitment, option to terminate, prior notice period (at least)</link:label>
    <link:label id="lab_akba_LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod_label_en-US" xlink:label="lab_akba_LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Option To Terminate, Prior Notice Period</link:label>
    <link:label id="lab_akba_LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod_documentation_en-US" xlink:label="lab_akba_LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Option To Terminate, Prior Notice Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod" xlink:href="akba-20210930.xsd#akba_LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod" xlink:to="lab_akba_LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_DebtInstrumentFacilityFeePaid_8b9cb22d-bdee-460f-8f2f-c99478f128d2_terseLabel_en-US" xlink:label="lab_akba_DebtInstrumentFacilityFeePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility fee paid, amount</link:label>
    <link:label id="lab_akba_DebtInstrumentFacilityFeePaid_label_en-US" xlink:label="lab_akba_DebtInstrumentFacilityFeePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Facility Fee Paid</link:label>
    <link:label id="lab_akba_DebtInstrumentFacilityFeePaid_documentation_en-US" xlink:label="lab_akba_DebtInstrumentFacilityFeePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument facility fee paid.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentFacilityFeePaid" xlink:href="akba-20210930.xsd#akba_DebtInstrumentFacilityFeePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_DebtInstrumentFacilityFeePaid" xlink:to="lab_akba_DebtInstrumentFacilityFeePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1085eaa7-c2ac-4d5d-9f5b-43fd28d93a58_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_11e5ddac-2945-45e8-8436-accdc56e5b21_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_CollaborativeAndLicenseArrangementTransactionPrice_b0c3cffd-0a2f-46e3-b69f-cbf6203adb56_terseLabel_en-US" xlink:label="lab_akba_CollaborativeAndLicenseArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price</link:label>
    <link:label id="lab_akba_CollaborativeAndLicenseArrangementTransactionPrice_label_en-US" xlink:label="lab_akba_CollaborativeAndLicenseArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative And License Arrangement Transaction Price</link:label>
    <link:label id="lab_akba_CollaborativeAndLicenseArrangementTransactionPrice_documentation_en-US" xlink:label="lab_akba_CollaborativeAndLicenseArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and license arrangement, transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeAndLicenseArrangementTransactionPrice" xlink:href="akba-20210930.xsd#akba_CollaborativeAndLicenseArrangementTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_CollaborativeAndLicenseArrangementTransactionPrice" xlink:to="lab_akba_CollaborativeAndLicenseArrangementTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_UpfrontCashPaymentReceived_2de1c651-b7c8-4c98-93a7-780655d84841_terseLabel_en-US" xlink:label="lab_akba_UpfrontCashPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront cash payment received</link:label>
    <link:label id="lab_akba_UpfrontCashPaymentReceived_label_en-US" xlink:label="lab_akba_UpfrontCashPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Cash Payment Received</link:label>
    <link:label id="lab_akba_UpfrontCashPaymentReceived_documentation_en-US" xlink:label="lab_akba_UpfrontCashPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront cash payment received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_UpfrontCashPaymentReceived" xlink:href="akba-20210930.xsd#akba_UpfrontCashPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_UpfrontCashPaymentReceived" xlink:to="lab_akba_UpfrontCashPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_07ae3a87-34ed-4b2e-9606-6679e265bff8_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding_ab927c6c-6216-457b-9d21-5169e454b46e_terseLabel_en-US" xlink:label="lab_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment premium percentage on principal if prepaid prior to third anniversary of funding</link:label>
    <link:label id="lab_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding_label_en-US" xlink:label="lab_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Premium Percentage On Principal If Prepaid Prior To Third Anniversary Of Funding</link:label>
    <link:label id="lab_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding_documentation_en-US" xlink:label="lab_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment premium percentage on principal if prepaid prior to third anniversary of funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding" xlink:href="akba-20210930.xsd#akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding" xlink:to="lab_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ThreeMonthLondonInterbankOfferedRateMember_6474e694-cbe0-403e-9cfe-bbd55ffa159e_terseLabel_en-US" xlink:label="lab_akba_ThreeMonthLondonInterbankOfferedRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three-month LIBOR</link:label>
    <link:label id="lab_akba_ThreeMonthLondonInterbankOfferedRateMember_label_en-US" xlink:label="lab_akba_ThreeMonthLondonInterbankOfferedRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Month London Interbank Offered Rate [Member]</link:label>
    <link:label id="lab_akba_ThreeMonthLondonInterbankOfferedRateMember_documentation_en-US" xlink:label="lab_akba_ThreeMonthLondonInterbankOfferedRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three-month London interbank offered rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ThreeMonthLondonInterbankOfferedRateMember" xlink:href="akba-20210930.xsd#akba_ThreeMonthLondonInterbankOfferedRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ThreeMonthLondonInterbankOfferedRateMember" xlink:to="lab_akba_ThreeMonthLondonInterbankOfferedRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ae1aea10-b61a-4f29-9123-a1ea7b064275_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_cbc17b14-6f51-4181-a521-278d08496d39_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_AssetAcquisitionAgreementTerminationNoticePeriod_a62708dd-064d-4838-bdee-30c4a3d44cb0_terseLabel_en-US" xlink:label="lab_akba_AssetAcquisitionAgreementTerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement termination notice period</link:label>
    <link:label id="lab_akba_AssetAcquisitionAgreementTerminationNoticePeriod_label_en-US" xlink:label="lab_akba_AssetAcquisitionAgreementTerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Agreement Termination Notice Period</link:label>
    <link:label id="lab_akba_AssetAcquisitionAgreementTerminationNoticePeriod_documentation_en-US" xlink:label="lab_akba_AssetAcquisitionAgreementTerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Agreement Termination Notice Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AssetAcquisitionAgreementTerminationNoticePeriod" xlink:href="akba-20210930.xsd#akba_AssetAcquisitionAgreementTerminationNoticePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_AssetAcquisitionAgreementTerminationNoticePeriod" xlink:to="lab_akba_AssetAcquisitionAgreementTerminationNoticePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementLiabilityPolicyPolicyTextBlock_3d733884-65a2-41f9-9d9d-587f4aa3f95b_terseLabel_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementLiabilityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to Sale of Future Royalties</link:label>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementLiabilityPolicyPolicyTextBlock_label_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementLiabilityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Arrangement, Royalties Agreement, Liability, Policy [Policy Text Block]</link:label>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementLiabilityPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementLiabilityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Arrangement, Royalties Agreement, Liability, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementLiabilityPolicyPolicyTextBlock" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementLiabilityPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ContractualArrangementRoyaltiesAgreementLiabilityPolicyPolicyTextBlock" xlink:to="lab_akba_ContractualArrangementRoyaltiesAgreementLiabilityPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_d59cb938-609e-495c-95a7-0d289a6eab64_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear_be710dc3-9dfe-436a-9950-fb05bb599a54_totalLabel_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining 2021</link:label>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear_label_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Payments Net Reminder Of Fiscal Year</link:label>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear_documentation_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee operating lease liability payments net reminder of fiscal year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear" xlink:to="lab_akba_LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_PurchaseCommittedProgramRemainingContractCosts_10dc6bb2-1a3a-4d4d-963a-0bfea7dfb93a_terseLabel_en-US" xlink:label="lab_akba_PurchaseCommittedProgramRemainingContractCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total remaining contract costs</link:label>
    <link:label id="lab_akba_PurchaseCommittedProgramRemainingContractCosts_label_en-US" xlink:label="lab_akba_PurchaseCommittedProgramRemainingContractCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Committed Program Remaining Contract Costs</link:label>
    <link:label id="lab_akba_PurchaseCommittedProgramRemainingContractCosts_documentation_en-US" xlink:label="lab_akba_PurchaseCommittedProgramRemainingContractCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase committed program remaining contract costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PurchaseCommittedProgramRemainingContractCosts" xlink:href="akba-20210930.xsd#akba_PurchaseCommittedProgramRemainingContractCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_PurchaseCommittedProgramRemainingContractCosts" xlink:to="lab_akba_PurchaseCommittedProgramRemainingContractCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_d03510c9-19ad-4945-93b9-b70ca0b672d0_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_c032ffc8-01b8-4f9e-bca2-02f224b95e48_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_OperatingLeaseAnnualRentExpense_00129eda-dda9-412b-8aea-4e0299b83a4c_terseLabel_en-US" xlink:label="lab_akba_OperatingLeaseAnnualRentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual lease expense</link:label>
    <link:label id="lab_akba_OperatingLeaseAnnualRentExpense_label_en-US" xlink:label="lab_akba_OperatingLeaseAnnualRentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Annual Rent Expense</link:label>
    <link:label id="lab_akba_OperatingLeaseAnnualRentExpense_documentation_en-US" xlink:label="lab_akba_OperatingLeaseAnnualRentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Annual Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OperatingLeaseAnnualRentExpense" xlink:href="akba-20210930.xsd#akba_OperatingLeaseAnnualRentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_OperatingLeaseAnnualRentExpense" xlink:to="lab_akba_OperatingLeaseAnnualRentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_FiniteLivedIntangibleAssetsAdoptionAdjustment_779350bc-a7a7-4c81-b663-a02665aa863e_terseLabel_en-US" xlink:label="lab_akba_FiniteLivedIntangibleAssetsAdoptionAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC 842 Adjustment</link:label>
    <link:label id="lab_akba_FiniteLivedIntangibleAssetsAdoptionAdjustment_label_en-US" xlink:label="lab_akba_FiniteLivedIntangibleAssetsAdoptionAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets Adoption Adjustment</link:label>
    <link:label id="lab_akba_FiniteLivedIntangibleAssetsAdoptionAdjustment_documentation_en-US" xlink:label="lab_akba_FiniteLivedIntangibleAssetsAdoptionAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite lived intangible assets adoption adjustment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_FiniteLivedIntangibleAssetsAdoptionAdjustment" xlink:href="akba-20210930.xsd#akba_FiniteLivedIntangibleAssetsAdoptionAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_FiniteLivedIntangibleAssetsAdoptionAdjustment" xlink:to="lab_akba_FiniteLivedIntangibleAssetsAdoptionAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember_80ff4d98-104f-4c86-9f6d-fd65d18304c7_terseLabel_en-US" xlink:label="lab_akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Proportional Performance Revenue</link:label>
    <link:label id="lab_akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember_76903800-a2c8-4388-a721-d656c15a0aaf_verboseLabel_en-US" xlink:label="lab_akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited</link:label>
    <link:label id="lab_akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember_label_en-US" xlink:label="lab_akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited [Member]</link:label>
    <link:label id="lab_akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember_documentation_en-US" xlink:label="lab_akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation and Otsuka Pharmaceutical Company Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember" xlink:href="akba-20210930.xsd#akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember" xlink:to="lab_akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5c26ed94-cc90-4bb8-8beb-7a63cb7a91df_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_edaf8935-ab26-4e6f-81ad-768588567595_totalLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_d47f3bed-ce6c-49f6-a8a1-321d8bae9785_totalLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_227ebb32-9cf9-42e7-9a5c-65ffe3cddca6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at Beginning of Period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_b1221812-c477-40f1-a525-14b8d0458acc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at End of Period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_0831372e-f28c-470e-ae15-651a726e70bf_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1638a42a-2e10-415d-8319-40d1cf380cd2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_AtTheMarketEquityOfferingProgramMember_a33b380e-17d2-4b81-8f53-3356bbd1ba01_terseLabel_en-US" xlink:label="lab_akba_AtTheMarketEquityOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Equity Offering Program</link:label>
    <link:label id="lab_akba_AtTheMarketEquityOfferingProgramMember_label_en-US" xlink:label="lab_akba_AtTheMarketEquityOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Equity Offering Program [Member]</link:label>
    <link:label id="lab_akba_AtTheMarketEquityOfferingProgramMember_documentation_en-US" xlink:label="lab_akba_AtTheMarketEquityOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At the market equity offering program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AtTheMarketEquityOfferingProgramMember" xlink:href="akba-20210930.xsd#akba_AtTheMarketEquityOfferingProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_AtTheMarketEquityOfferingProgramMember" xlink:to="lab_akba_AtTheMarketEquityOfferingProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8619da85-a2fd-461e-b046-5778944e27e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod_9ea2042a-a184-4f3f-b0a7-25b7ad0a67ca_terseLabel_en-US" xlink:label="lab_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible milestone payments, period</link:label>
    <link:label id="lab_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod_label_en-US" xlink:label="lab_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount, Period</link:label>
    <link:label id="lab_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod_documentation_en-US" xlink:label="lab_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod" xlink:href="akba-20210930.xsd#akba_RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod" xlink:to="lab_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_b5155abd-dd40-490b-93fb-a554b5a5743f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_fa50775e-4a07-41ac-bfbf-7b57cb1f2fdd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ReturnsMember_df5182d3-d514-44f7-b352-42c56fe6a8d7_terseLabel_en-US" xlink:label="lab_akba_ReturnsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_akba_ReturnsMember_label_en-US" xlink:label="lab_akba_ReturnsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns [Member]</link:label>
    <link:label id="lab_akba_ReturnsMember_documentation_en-US" xlink:label="lab_akba_ReturnsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ReturnsMember" xlink:href="akba-20210930.xsd#akba_ReturnsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ReturnsMember" xlink:to="lab_akba_ReturnsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_2c09b116-d2d9-4beb-b8a6-82371e00fa33_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2870c62f-af75-4372-b8ef-b93bf5c521cc_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_CyclerionTherapeuticsLicenseAgreementMember_05274d2b-41e2-41fe-a33a-1677ef12e76b_terseLabel_en-US" xlink:label="lab_akba_CyclerionTherapeuticsLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cyclerion Therapeutics License Agreement</link:label>
    <link:label id="lab_akba_CyclerionTherapeuticsLicenseAgreementMember_label_en-US" xlink:label="lab_akba_CyclerionTherapeuticsLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cyclerion Therapeutics License Agreement [Member]</link:label>
    <link:label id="lab_akba_CyclerionTherapeuticsLicenseAgreementMember_documentation_en-US" xlink:label="lab_akba_CyclerionTherapeuticsLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cyclerion Therapeutics License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CyclerionTherapeuticsLicenseAgreementMember" xlink:href="akba-20210930.xsd#akba_CyclerionTherapeuticsLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_CyclerionTherapeuticsLicenseAgreementMember" xlink:to="lab_akba_CyclerionTherapeuticsLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_78eae796-6a6f-4f0c-928c-c8d4702f3104_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Measured or Disclosed at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_f720b88d-b97c-4cdd-82de-bffc16e46466_terseLabel_en-US" xlink:label="lab_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering period</link:label>
    <link:label id="lab_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_label_en-US" xlink:label="lab_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Offering Period</link:label>
    <link:label id="lab_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_documentation_en-US" xlink:label="lab_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, offering period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:href="akba-20210930.xsd#akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="lab_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_66cab4f8-409e-40d0-b296-6a7ed268dd64_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_1a15b70d-bfb2-4583-8c29-3e2d7089392c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ff31e193-360b-4f32-80a2-387ad00bdef9_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7bd8e4e2-c535-4a12-b7df-0b81d3501d7d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_332ae7c9-35e8-4377-9fbb-48f7d273deea_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c5ed39ab-61a3-4518-8ff5-278d0cce0665_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_CostOfPurchasedMinimumQuantityProduct_9dae3187-2cf4-4740-89ef-2fee21330666_terseLabel_en-US" xlink:label="lab_akba_CostOfPurchasedMinimumQuantityProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of purchased minimum quantity product</link:label>
    <link:label id="lab_akba_CostOfPurchasedMinimumQuantityProduct_label_en-US" xlink:label="lab_akba_CostOfPurchasedMinimumQuantityProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Purchased Minimum Quantity Product</link:label>
    <link:label id="lab_akba_CostOfPurchasedMinimumQuantityProduct_documentation_en-US" xlink:label="lab_akba_CostOfPurchasedMinimumQuantityProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of purchased minimum quantity product.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CostOfPurchasedMinimumQuantityProduct" xlink:href="akba-20210930.xsd#akba_CostOfPurchasedMinimumQuantityProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_CostOfPurchasedMinimumQuantityProduct" xlink:to="lab_akba_CostOfPurchasedMinimumQuantityProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_0a13997d-e9d5-4db3-8822-19847e22f220_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo_5910eefe-b233-4e37-85c3-411fd1e129aa_totalLabel_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo_label_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Payments Due Net Year Two</link:label>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo_documentation_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee operating lease liability payments due net year two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo" xlink:to="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod_01c74ca9-23a7-423f-861a-3849a594e0ab_terseLabel_en-US" xlink:label="lab_akba_AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement expiration, after first commercial sale, period</link:label>
    <link:label id="lab_akba_AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod_label_en-US" xlink:label="lab_akba_AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Agreement Expiration, After First Commercial Sale, Period</link:label>
    <link:label id="lab_akba_AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod_documentation_en-US" xlink:label="lab_akba_AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Agreement Expiration, After First Commercial Sale, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod" xlink:href="akba-20210930.xsd#akba_AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod" xlink:to="lab_akba_AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember_b24ae621-5f3d-4f4d-b6f3-94d383c355b6_terseLabel_en-US" xlink:label="lab_akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otsuka International Agreement</link:label>
    <link:label id="lab_akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Commercialize International Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and commercialize international collaboration and license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember" xlink:href="akba-20210930.xsd#akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember" xlink:to="lab_akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_048f6b42-457f-44cb-83e3-72407680f280_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock unit vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_6b340173-aee5-4494-947a-4839ef0ca9d2_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Domain]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_dd61dfa0-f11d-4d1a-8d87-e715a37e13b6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour_53e72a82-e50b-484a-8332-6425abafbf98_terseLabel_en-US" xlink:label="lab_akba_LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_akba_LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour_label_en-US" xlink:label="lab_akba_LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Due After Year Four</link:label>
    <link:label id="lab_akba_LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour_documentation_en-US" xlink:label="lab_akba_LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Due After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour" xlink:href="akba-20210930.xsd#akba_LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour" xlink:to="lab_akba_LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_a3b2a522-d60c-4a9f-bebb-7868eb403f60_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_c81a99d3-8dd3-4001-8107-837fe8ee61e9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive gain (loss) - unrealized gain (loss) on debt securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_aa07843d-3736-418a-b45d-7d52822ed81a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_CostShareCostsIncurredForLicenseAgreement_97a59086-9a7d-414c-99c0-37f55617547d_terseLabel_en-US" xlink:label="lab_akba_CostShareCostsIncurredForLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost share costs incurred</link:label>
    <link:label id="lab_akba_CostShareCostsIncurredForLicenseAgreement_label_en-US" xlink:label="lab_akba_CostShareCostsIncurredForLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Share Costs Incurred For License Agreement</link:label>
    <link:label id="lab_akba_CostShareCostsIncurredForLicenseAgreement_documentation_en-US" xlink:label="lab_akba_CostShareCostsIncurredForLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost share costs incurred for license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CostShareCostsIncurredForLicenseAgreement" xlink:href="akba-20210930.xsd#akba_CostShareCostsIncurredForLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_CostShareCostsIncurredForLicenseAgreement" xlink:to="lab_akba_CostShareCostsIncurredForLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_ca4780cf-bf4f-4817-b0ac-290766c5b96d_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognized in the Period from:</link:label>
    <link:label id="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInContractWithCustomerLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:to="lab_us-gaap_ChangeInContractWithCustomerLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_ceaf87c7-ce3c-46a6-9b82-b663a936b6cb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, maturity term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_5f5d22c6-9430-40d0-b741-e980eca56e06_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_7bf18437-ff52-42e6-b1e2-9edf987fe8b1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a9f666cc-9e74-4cfc-97a3-f94c0a93ff2a_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_227890d0-b96b-4fd6-9f40-f0d6f1455041_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_BPCRLimitedPartnershipMember_5d44ba80-9c4e-4d38-9776-53d9d1cccada_terseLabel_en-US" xlink:label="lab_akba_BPCRLimitedPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BPCR Limited Partnership</link:label>
    <link:label id="lab_akba_BPCRLimitedPartnershipMember_label_en-US" xlink:label="lab_akba_BPCRLimitedPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BPCR Limited Partnership [Member]</link:label>
    <link:label id="lab_akba_BPCRLimitedPartnershipMember_documentation_en-US" xlink:label="lab_akba_BPCRLimitedPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BPCR Limited Partnership</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_BPCRLimitedPartnershipMember" xlink:href="akba-20210930.xsd#akba_BPCRLimitedPartnershipMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_BPCRLimitedPartnershipMember" xlink:to="lab_akba_BPCRLimitedPartnershipMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_4dc563c9-7e75-459c-b4fb-7a5049e240dc_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_ddec42d1-64b8-41fb-a706-694cf85bdc63_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeMember_ec6d0adb-69f2-4795-bb3a-14873bfc6887_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTPC Other Revenue</link:label>
    <link:label id="lab_us-gaap_OtherIncomeMember_label_en-US" xlink:label="lab_us-gaap_OtherIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeMember" xlink:to="lab_us-gaap_OtherIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostDirectMaterial_a94f8ca2-660a-4990-992f-cb608025d102_terseLabel_en-US" xlink:label="lab_us-gaap_CostDirectMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge to cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostDirectMaterial_label_en-US" xlink:label="lab_us-gaap_CostDirectMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Direct Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostDirectMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostDirectMaterial" xlink:to="lab_us-gaap_CostDirectMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_77745fb0-432b-4266-95fa-4cc9e5f8db5b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_dbe84580-4739-43c7-ae6d-9e2bc6a090f0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableMember_edbe1513-e8a3-463a-8034-7e2bc3b3f649_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableMember_label_en-US" xlink:label="lab_us-gaap_AccountsPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableMember" xlink:to="lab_us-gaap_AccountsPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_LicenseCollaborationAndOtherRevenueMember_6d0b0d12-fd76-4172-b21f-ebd05bb5c2e3_terseLabel_en-US" xlink:label="lab_akba_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, collaboration and other revenue</link:label>
    <link:label id="lab_akba_LicenseCollaborationAndOtherRevenueMember_label_en-US" xlink:label="lab_akba_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Collaboration And Other Revenue [Member]</link:label>
    <link:label id="lab_akba_LicenseCollaborationAndOtherRevenueMember_documentation_en-US" xlink:label="lab_akba_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, collaboration and other revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseCollaborationAndOtherRevenueMember" xlink:href="akba-20210930.xsd#akba_LicenseCollaborationAndOtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_LicenseCollaborationAndOtherRevenueMember" xlink:to="lab_akba_LicenseCollaborationAndOtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_EsteveQuimicaSAMember_a478998e-fc7f-4510-958e-5a8561e6c3e6_terseLabel_en-US" xlink:label="lab_akba_EsteveQuimicaSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Esteve Qu&#237;mica, S.A</link:label>
    <link:label id="lab_akba_EsteveQuimicaSAMember_label_en-US" xlink:label="lab_akba_EsteveQuimicaSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Esteve Quimica S A [Member]</link:label>
    <link:label id="lab_akba_EsteveQuimicaSAMember_documentation_en-US" xlink:label="lab_akba_EsteveQuimicaSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Esteve Quimica, S.A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_EsteveQuimicaSAMember" xlink:href="akba-20210930.xsd#akba_EsteveQuimicaSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_EsteveQuimicaSAMember" xlink:to="lab_akba_EsteveQuimicaSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_612a3dad-119a-409f-8e68-36965ac9f16b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_CollaborativeArrangementRevenueRecognitionTableTextBlock_51c83303-b560-4371-9411-a3221f3a2bde_terseLabel_en-US" xlink:label="lab_akba_CollaborativeArrangementRevenueRecognitionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues Recognized from License, Collaboration and Other Significant Agreements</link:label>
    <link:label id="lab_akba_CollaborativeArrangementRevenueRecognitionTableTextBlock_label_en-US" xlink:label="lab_akba_CollaborativeArrangementRevenueRecognitionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Revenue Recognition [Table Text Block]</link:label>
    <link:label id="lab_akba_CollaborativeArrangementRevenueRecognitionTableTextBlock_documentation_en-US" xlink:label="lab_akba_CollaborativeArrangementRevenueRecognitionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement revenue recognition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeArrangementRevenueRecognitionTableTextBlock" xlink:href="akba-20210930.xsd#akba_CollaborativeArrangementRevenueRecognitionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_CollaborativeArrangementRevenueRecognitionTableTextBlock" xlink:to="lab_akba_CollaborativeArrangementRevenueRecognitionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_69f982d3-8542-4e9b-a20a-90e626e26508_verboseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_46a8eef2-bdc8-40b1-aaf0-0397f9991b23_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_ee7e3582-dc8f-440c-87a0-651f40f4c790_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_aa1174df-32e6-41b1-888d-359638b6a4c9_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_WuXiSTAMember_9d620591-9dec-45dc-86e8-15a375e6541e_terseLabel_en-US" xlink:label="lab_akba_WuXiSTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WuXi STA</link:label>
    <link:label id="lab_akba_WuXiSTAMember_label_en-US" xlink:label="lab_akba_WuXiSTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WuXi STA [Member]</link:label>
    <link:label id="lab_akba_WuXiSTAMember_documentation_en-US" xlink:label="lab_akba_WuXiSTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WuXi STA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_WuXiSTAMember" xlink:href="akba-20210930.xsd#akba_WuXiSTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_WuXiSTAMember" xlink:to="lab_akba_WuXiSTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_d0d0a950-0018-4e00-9df9-cea99cdebd5b_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_4ab2c462-5925-4160-b46c-e2d76cd1634d_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_SupplyAgreementPatheonIncMember_3961abfa-9441-4fe6-a65c-a87f7b1b0201_terseLabel_en-US" xlink:label="lab_akba_SupplyAgreementPatheonIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Agreement, Patheon Inc.</link:label>
    <link:label id="lab_akba_SupplyAgreementPatheonIncMember_label_en-US" xlink:label="lab_akba_SupplyAgreementPatheonIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Agreement, Patheon Inc. [Member]</link:label>
    <link:label id="lab_akba_SupplyAgreementPatheonIncMember_documentation_en-US" xlink:label="lab_akba_SupplyAgreementPatheonIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Agreement, Patheon Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_SupplyAgreementPatheonIncMember" xlink:href="akba-20210930.xsd#akba_SupplyAgreementPatheonIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_SupplyAgreementPatheonIncMember" xlink:to="lab_akba_SupplyAgreementPatheonIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_KeryxBiopharmaceuticalsIncMember_2cdd1fc2-d709-4f2d-9ed9-b41d2731c4ae_terseLabel_en-US" xlink:label="lab_akba_KeryxBiopharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Keryx Biopharmaceuticals, Inc.</link:label>
    <link:label id="lab_akba_KeryxBiopharmaceuticalsIncMember_label_en-US" xlink:label="lab_akba_KeryxBiopharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Keryx Biopharmaceuticals Inc [Member]</link:label>
    <link:label id="lab_akba_KeryxBiopharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_akba_KeryxBiopharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Keryx Biopharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_KeryxBiopharmaceuticalsIncMember" xlink:href="akba-20210930.xsd#akba_KeryxBiopharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_KeryxBiopharmaceuticalsIncMember" xlink:to="lab_akba_KeryxBiopharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_a1c65196-7245-4821-ac38-c59c9b954bd2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of available-for-sale securities in a unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_369a0635-7bee-4ca8-a50c-e7d9724a1748_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount_a22c19d7-f85c-4aff-aef6-9787b7683669_terseLabel_en-US" xlink:label="lab_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible milestone payments (up to)</link:label>
    <link:label id="lab_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount_label_en-US" xlink:label="lab_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:label id="lab_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount_documentation_en-US" xlink:label="lab_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:href="akba-20210930.xsd#akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:to="lab_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_1136bf8d-b1eb-4554-8b34-a762b61ffbbb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5010c9e0-003a-409d-bb88-fa2fa513de91_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_1184670f-d288-41ae-af89-5a60c4b82230_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionLineItems" xlink:to="lab_us-gaap_AssetAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_8dedb7e4-319b-4839-8ba0-bd4df36722c3_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangibles</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_DevelopedProductRightsForAuryxiaMember_9b044d19-c232-492c-bd2b-d9ecea6539d6_terseLabel_en-US" xlink:label="lab_akba_DevelopedProductRightsForAuryxiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed product rights for Auryxia</link:label>
    <link:label id="lab_akba_DevelopedProductRightsForAuryxiaMember_label_en-US" xlink:label="lab_akba_DevelopedProductRightsForAuryxiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Product Rights For Auryxia [Member]</link:label>
    <link:label id="lab_akba_DevelopedProductRightsForAuryxiaMember_documentation_en-US" xlink:label="lab_akba_DevelopedProductRightsForAuryxiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed product rights for Auryxia.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopedProductRightsForAuryxiaMember" xlink:href="akba-20210930.xsd#akba_DevelopedProductRightsForAuryxiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_DevelopedProductRightsForAuryxiaMember" xlink:to="lab_akba_DevelopedProductRightsForAuryxiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_8cd8f7d2-8ec8-4788-8634-3e5c8628b3ad_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premium/discount on investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_MitsubishiTanabePharmaCorporationSupplyAgreementMember_90612f9e-b842-4cbc-8157-2dbdef590bc5_terseLabel_en-US" xlink:label="lab_akba_MitsubishiTanabePharmaCorporationSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation Supply Agreement</link:label>
    <link:label id="lab_akba_MitsubishiTanabePharmaCorporationSupplyAgreementMember_label_en-US" xlink:label="lab_akba_MitsubishiTanabePharmaCorporationSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation Supply Agreement [Member]</link:label>
    <link:label id="lab_akba_MitsubishiTanabePharmaCorporationSupplyAgreementMember_documentation_en-US" xlink:label="lab_akba_MitsubishiTanabePharmaCorporationSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_MitsubishiTanabePharmaCorporationSupplyAgreementMember" xlink:href="akba-20210930.xsd#akba_MitsubishiTanabePharmaCorporationSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_MitsubishiTanabePharmaCorporationSupplyAgreementMember" xlink:to="lab_akba_MitsubishiTanabePharmaCorporationSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_d4fef741-2785-4672-a0f1-95a2b59b3a13_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_3c691130-3ed3-42d2-a80d-503a1c129d0c_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_b5b5d3b6-8d4a-4896-b301-c1b1e9e9c2ba_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at Beginning of Period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_8f3d7924-5f0f-46fe-9034-baf1953b02fe_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at End of Period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_794299bf-1fe3-4892-b1e6-f281e8bcb468_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aaffe5c9-70d9-4d86-af20-632befa736de_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ed6f2cd6-3bd6-4ca4-bc51-0483640678a5_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_OfficeSpaceMember_e24d2bc2-99a8-4a16-a48f-6389ab36c785_terseLabel_en-US" xlink:label="lab_akba_OfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space</link:label>
    <link:label id="lab_akba_OfficeSpaceMember_label_en-US" xlink:label="lab_akba_OfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space [Member]</link:label>
    <link:label id="lab_akba_OfficeSpaceMember_documentation_en-US" xlink:label="lab_akba_OfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OfficeSpaceMember" xlink:href="akba-20210930.xsd#akba_OfficeSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_OfficeSpaceMember" xlink:to="lab_akba_OfficeSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1f2332d1-7ca7-4f19-aa79-da2bfeba6af4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_a65983db-7070-4378-9a65-43e1758c75a7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_9a159509-9fcb-4938-9d5b-7cdabaeb7eec_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a90c83ef-2032-4c07-8cb6-9193496f43bd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_5ef13b3c-89a7-4c93-b9db-7140ea222b3b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_0ab47d30-996e-4a24-a791-d0ea07285bef_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_0ad5780f-af3f-44de-9d50-1dcc80e0f335_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_e0b01c0c-efc4-48b4-8a14-a83345b321d3_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_4c197a98-5c40-4c4c-ad08-fcef542c0718_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d32dae0a-9b73-453a-b688-3fb87511ad39_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8531ca69-62b1-4f61-a47d-dfb3d6fb98d3_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_446d8cf2-7120-4676-a7f3-875804442644_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1cac1263-0be4-4acb-80ec-c5f295805e03_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_PerformanceBasedRestrictedStockUnitsMember_badd0f61-075c-4ebc-910c-5f38628883ed_terseLabel_en-US" xlink:label="lab_akba_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units</link:label>
    <link:label id="lab_akba_PerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_akba_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_akba_PerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_akba_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PerformanceBasedRestrictedStockUnitsMember" xlink:href="akba-20210930.xsd#akba_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_PerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_akba_PerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_129e9d7c-2de0-4939-a39b-218d8f068a05_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_31b5e3fe-3daa-464b-90a9-b48c5f1e585d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ContractWithCustomerAssetDeductions_ddcced02-f982-4b8b-a51f-ca71467fd986_negatedLabel_en-US" xlink:label="lab_akba_ContractWithCustomerAssetDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_akba_ContractWithCustomerAssetDeductions_label_en-US" xlink:label="lab_akba_ContractWithCustomerAssetDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Asset Deductions</link:label>
    <link:label id="lab_akba_ContractWithCustomerAssetDeductions_documentation_en-US" xlink:label="lab_akba_ContractWithCustomerAssetDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer asset deductions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractWithCustomerAssetDeductions" xlink:href="akba-20210930.xsd#akba_ContractWithCustomerAssetDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ContractWithCustomerAssetDeductions" xlink:to="lab_akba_ContractWithCustomerAssetDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_c5a09801-d040-466a-bcb3-361c5e34bd01_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_02b6ffbc-0a87-44a9-83f5-a98d62a78f82_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liability, recorded as other expense (income)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_629fb0a8-ac22-4642-b554-0e0df4adbf1d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and available for sale securities, fair value</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_54f2777d-7f42-4f0f-86f2-ce02280a5eec_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_fbb0c511-403a-4c1c-ba6a-b692066c3028_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement_eb9d5ad4-82d0-422d-b2a0-d9f4a147d7cf_terseLabel_en-US" xlink:label="lab_akba_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preliminary fair value of the off-market element</link:label>
    <link:label id="lab_akba_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement_label_en-US" xlink:label="lab_akba_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Fair Value Of Off Market Element</link:label>
    <link:label id="lab_akba_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement_documentation_en-US" xlink:label="lab_akba_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination recognized identifiable assets acquired and liabilities assumed noncurrent liabilities fair value of off-market element.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement" xlink:href="akba-20210930.xsd#akba_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement" xlink:to="lab_akba_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c13e5d64-333e-42fe-b1e8-2b1e696b2a55_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on floating interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7cfead67-8d12-4067-80df-27d52bce27e8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_e2591a7b-c13e-453c-a3d3-80e774d61dff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_6f09d9c4-aeef-48f8-80d5-9346124d4470_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_bd4f73d6-67b9-484e-9449-1878d9dce100_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_91da18f4-5372-486e-a357-6b9d854c101d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_006e637f-347d-4581-bc55-2c03d31d05a4_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bfafa079-34a9-4938-a3b8-5a84956f0cf9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_715ecb45-4a1c-40b6-b400-8011683e74e6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_InitialTermOfSupplyAgreement_5883aa84-a560-4f9e-98c5-033f05f14940_terseLabel_en-US" xlink:label="lab_akba_InitialTermOfSupplyAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial term of supply agreement</link:label>
    <link:label id="lab_akba_InitialTermOfSupplyAgreement_label_en-US" xlink:label="lab_akba_InitialTermOfSupplyAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Term Of Supply Agreement</link:label>
    <link:label id="lab_akba_InitialTermOfSupplyAgreement_documentation_en-US" xlink:label="lab_akba_InitialTermOfSupplyAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial term of supply agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_InitialTermOfSupplyAgreement" xlink:href="akba-20210930.xsd#akba_InitialTermOfSupplyAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_InitialTermOfSupplyAgreement" xlink:to="lab_akba_InitialTermOfSupplyAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_178f29d1-bd79-4404-b20e-35c1c3d9e0fb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_HIFProductMember_89e950dc-bf32-4a5e-9678-d0a8d7656e45_terseLabel_en-US" xlink:label="lab_akba_HIFProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIF Product</link:label>
    <link:label id="lab_akba_HIFProductMember_label_en-US" xlink:label="lab_akba_HIFProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIF Product [Member]</link:label>
    <link:label id="lab_akba_HIFProductMember_documentation_en-US" xlink:label="lab_akba_HIFProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIF Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_HIFProductMember" xlink:href="akba-20210930.xsd#akba_HIFProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_HIFProductMember" xlink:to="lab_akba_HIFProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c6c3f9bf-fe95-4bb3-bcf5-67fb1779050c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_9c7ec385-9e82-4f15-8619-4dce85f3fa6e_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_4f39542e-f894-46c0-932a-9c37343515ea_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum purchase commitment</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_5546c7ba-64a6-4c83-bccd-73a078fa108f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_SiegfriedEvionnazSAMember_8ad96d06-64e4-4e20-b807-1a398c8a1c8d_terseLabel_en-US" xlink:label="lab_akba_SiegfriedEvionnazSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Siegfried Evionnaz SA</link:label>
    <link:label id="lab_akba_SiegfriedEvionnazSAMember_label_en-US" xlink:label="lab_akba_SiegfriedEvionnazSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Siegfried Evionnaz S A [Member]</link:label>
    <link:label id="lab_akba_SiegfriedEvionnazSAMember_documentation_en-US" xlink:label="lab_akba_SiegfriedEvionnazSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Siegfried Evionnaz SA.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_SiegfriedEvionnazSAMember" xlink:href="akba-20210930.xsd#akba_SiegfriedEvionnazSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_SiegfriedEvionnazSAMember" xlink:to="lab_akba_SiegfriedEvionnazSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_FacilityFeePercentagePaidOnPrincipalAmount_368a79c1-87f5-4c16-86a7-10477c2759dd_terseLabel_en-US" xlink:label="lab_akba_FacilityFeePercentagePaidOnPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility fee percentage on principal amount</link:label>
    <link:label id="lab_akba_FacilityFeePercentagePaidOnPrincipalAmount_label_en-US" xlink:label="lab_akba_FacilityFeePercentagePaidOnPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Fee Percentage Paid On Principal Amount</link:label>
    <link:label id="lab_akba_FacilityFeePercentagePaidOnPrincipalAmount_documentation_en-US" xlink:label="lab_akba_FacilityFeePercentagePaidOnPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility fee percentage paid on principal amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_FacilityFeePercentagePaidOnPrincipalAmount" xlink:href="akba-20210930.xsd#akba_FacilityFeePercentagePaidOnPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_FacilityFeePercentagePaidOnPrincipalAmount" xlink:to="lab_akba_FacilityFeePercentagePaidOnPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d0a468d4-6071-44cd-890f-0d5e9968ce43_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_2739e117-5710-4bec-9932-30e1c6816e20_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_CostOfResearchServices_ee0f3633-fa19-47c8-9720-061153d805c8_terseLabel_en-US" xlink:label="lab_akba_CostOfResearchServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of research services</link:label>
    <link:label id="lab_akba_CostOfResearchServices_label_en-US" xlink:label="lab_akba_CostOfResearchServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Research Services</link:label>
    <link:label id="lab_akba_CostOfResearchServices_documentation_en-US" xlink:label="lab_akba_CostOfResearchServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of research services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CostOfResearchServices" xlink:href="akba-20210930.xsd#akba_CostOfResearchServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_CostOfResearchServices" xlink:to="lab_akba_CostOfResearchServices" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_LicenseCollaborationAndOtherRevenueAbstract_3e3404b6-bc0e-40a5-9c95-25ed91f9ac3a_terseLabel_en-US" xlink:label="lab_akba_LicenseCollaborationAndOtherRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Collaboration and Other Revenue:</link:label>
    <link:label id="lab_akba_LicenseCollaborationAndOtherRevenueAbstract_label_en-US" xlink:label="lab_akba_LicenseCollaborationAndOtherRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Collaboration And Other Revenue [Abstract]</link:label>
    <link:label id="lab_akba_LicenseCollaborationAndOtherRevenueAbstract_documentation_en-US" xlink:label="lab_akba_LicenseCollaborationAndOtherRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, collaboration and other revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseCollaborationAndOtherRevenueAbstract" xlink:href="akba-20210930.xsd#akba_LicenseCollaborationAndOtherRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_LicenseCollaborationAndOtherRevenueAbstract" xlink:to="lab_akba_LicenseCollaborationAndOtherRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_58527f37-c3c7-4877-adf0-7aa173a59fe6_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_86deb94d-20a8-4d96-b1b8-9aa500dabe3c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1297e819-d3f3-4b17-9e9f-7f493375c90e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_ccf81b72-0504-4ae4-9897-32df9ddccccf_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_6ac3d2b0-0a01-4a33-b739-2590331ad852_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9d6e4159-c460-4ae0-ace8-25d811744c55_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_15f68cc9-eea5-4725-92bf-fefedd457ef3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements - Recently Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_OtsukaPharmaceuticalCompanyLimitedMember_f38eb6b5-7cb4-4398-953f-0bdc366db1e8_terseLabel_en-US" xlink:label="lab_akba_OtsukaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otsuka Pharmaceutical Company. Ltd.</link:label>
    <link:label id="lab_akba_OtsukaPharmaceuticalCompanyLimitedMember_label_en-US" xlink:label="lab_akba_OtsukaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otsuka Pharmaceutical Company Limited [Member]</link:label>
    <link:label id="lab_akba_OtsukaPharmaceuticalCompanyLimitedMember_documentation_en-US" xlink:label="lab_akba_OtsukaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otsuka Pharmaceutical Company Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OtsukaPharmaceuticalCompanyLimitedMember" xlink:href="akba-20210930.xsd#akba_OtsukaPharmaceuticalCompanyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_OtsukaPharmaceuticalCompanyLimitedMember" xlink:to="lab_akba_OtsukaPharmaceuticalCompanyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f2f30879-3751-424a-8ee6-c2906a25925d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_cdba5e3a-8968-4156-94ee-fcf00475c18d_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_d0d209dd-e9b7-4e19-b26f-e55d8a3b3988_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour_b0897722-221e-498a-80a5-6eec3431208e_totalLabel_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour_label_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Payments Due Net Year Four</link:label>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour_documentation_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee operating lease liability payments due net year four.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour" xlink:to="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_LicenseAgreementMember_667df5ef-e11b-424c-b64e-aafc6c96252a_terseLabel_en-US" xlink:label="lab_akba_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement</link:label>
    <link:label id="lab_akba_LicenseAgreementMember_label_en-US" xlink:label="lab_akba_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Member]</link:label>
    <link:label id="lab_akba_LicenseAgreementMember_documentation_en-US" xlink:label="lab_akba_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseAgreementMember" xlink:href="akba-20210930.xsd#akba_LicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_LicenseAgreementMember" xlink:to="lab_akba_LicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_CommonStockSalesAgreementAmount_88abf0c2-d751-4aaf-a6d5-e0b17184ad0f_terseLabel_en-US" xlink:label="lab_akba_CommonStockSalesAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock sales agreement amount</link:label>
    <link:label id="lab_akba_CommonStockSalesAgreementAmount_label_en-US" xlink:label="lab_akba_CommonStockSalesAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Sales Agreement Amount</link:label>
    <link:label id="lab_akba_CommonStockSalesAgreementAmount_documentation_en-US" xlink:label="lab_akba_CommonStockSalesAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock sales agreement amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CommonStockSalesAgreementAmount" xlink:href="akba-20210930.xsd#akba_CommonStockSalesAgreementAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_CommonStockSalesAgreementAmount" xlink:to="lab_akba_CommonStockSalesAgreementAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_d4de0824-ddc2-454e-b46f-3324d6f68c39_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_33e8ed6f-f30c-43e2-96d6-f0b2321607cf_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue:</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_5c294931-ae7f-415e-b095-609e2f8d7a56_periodStartLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_f4a1ea3a-3028-430e-bccb-29b17978fa03_periodEndLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_CambridgeMember_d2b23f79-047e-4165-b68b-8bd8405d0aa0_terseLabel_en-US" xlink:label="lab_akba_CambridgeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge</link:label>
    <link:label id="lab_akba_CambridgeMember_label_en-US" xlink:label="lab_akba_CambridgeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge [Member]</link:label>
    <link:label id="lab_akba_CambridgeMember_documentation_en-US" xlink:label="lab_akba_CambridgeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CambridgeMember" xlink:href="akba-20210930.xsd#akba_CambridgeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_CambridgeMember" xlink:to="lab_akba_CambridgeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_807d1467-739d-4408-814d-b51097b7d692_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_PotentialPaymentForAchievementOfSpecifiedCommercialMilestones_86f160aa-3635-4aa4-94ba-c573512f8675_terseLabel_en-US" xlink:label="lab_akba_PotentialPaymentForAchievementOfSpecifiedCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone revenue from commercial milestones (up to)</link:label>
    <link:label id="lab_akba_PotentialPaymentForAchievementOfSpecifiedCommercialMilestones_label_en-US" xlink:label="lab_akba_PotentialPaymentForAchievementOfSpecifiedCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Payment For Achievement Of Specified Commercial Milestones</link:label>
    <link:label id="lab_akba_PotentialPaymentForAchievementOfSpecifiedCommercialMilestones_documentation_en-US" xlink:label="lab_akba_PotentialPaymentForAchievementOfSpecifiedCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential payment for achievement of specified commercial milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PotentialPaymentForAchievementOfSpecifiedCommercialMilestones" xlink:href="akba-20210930.xsd#akba_PotentialPaymentForAchievementOfSpecifiedCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_PotentialPaymentForAchievementOfSpecifiedCommercialMilestones" xlink:to="lab_akba_PotentialPaymentForAchievementOfSpecifiedCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_UpFrontNonRefundableAndNonCreditableMember_88ccdaa3-7e0d-47b0-9b9e-00cfa66a537b_terseLabel_en-US" xlink:label="lab_akba_UpFrontNonRefundableAndNonCreditableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up Front Non Refundable And Non Creditable</link:label>
    <link:label id="lab_akba_UpFrontNonRefundableAndNonCreditableMember_label_en-US" xlink:label="lab_akba_UpFrontNonRefundableAndNonCreditableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up Front Non Refundable And Non Creditable [Member]</link:label>
    <link:label id="lab_akba_UpFrontNonRefundableAndNonCreditableMember_documentation_en-US" xlink:label="lab_akba_UpFrontNonRefundableAndNonCreditableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up front, non refundable and non creditable,</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_UpFrontNonRefundableAndNonCreditableMember" xlink:href="akba-20210930.xsd#akba_UpFrontNonRefundableAndNonCreditableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_UpFrontNonRefundableAndNonCreditableMember" xlink:to="lab_akba_UpFrontNonRefundableAndNonCreditableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_f956bbfe-8d1f-463f-94ac-3dba6604d094_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_dbb6184f-e720-490a-8762-ec81e2e52e3d_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage_2a647fe8-3915-4f53-8d17-0f617cc4ed14_terseLabel_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual effective interest rate</link:label>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage_label_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Arrangement, Royalties Agreement, Interest Rate, Effective Percentage</link:label>
    <link:label id="lab_akba_ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage_documentation_en-US" xlink:label="lab_akba_ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Arrangement, Royalties Agreement, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage" xlink:to="lab_akba_ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_453cb0a4-0022-4e7d-83b0-41653b27a69c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_83e154fa-1af6-4da5-b95d-31d0b07c7fa7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties_1de8bdc3-d3a9-4229-85c7-d9df990557ca_terseLabel_en-US" xlink:label="lab_akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of future royalties, net</link:label>
    <link:label id="lab_akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties_label_en-US" xlink:label="lab_akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Contractual Arrangement, Royalties Agreement, Sale Of Future Royalties</link:label>
    <link:label id="lab_akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Contractual Arrangement, Royalties Agreement, Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties" xlink:href="akba-20210930.xsd#akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties" xlink:to="lab_akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_6124a370-976b-4f82-86d9-0f23bb3dd277_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_DebtInstrumentCapRate_9a4b97b9-6263-490c-84d3-71e1564e5268_terseLabel_en-US" xlink:label="lab_akba_DebtInstrumentCapRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, cap rate</link:label>
    <link:label id="lab_akba_DebtInstrumentCapRate_label_en-US" xlink:label="lab_akba_DebtInstrumentCapRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Cap Rate</link:label>
    <link:label id="lab_akba_DebtInstrumentCapRate_documentation_en-US" xlink:label="lab_akba_DebtInstrumentCapRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument cap rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentCapRate" xlink:href="akba-20210930.xsd#akba_DebtInstrumentCapRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_DebtInstrumentCapRate" xlink:to="lab_akba_DebtInstrumentCapRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_7097709f-b998-4b57-9c6a-842c060cf449_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_7603061c-f6db-445b-b4d4-ba5221cdef5b_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Organization and Operations</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_40dff289-1d2c-437e-be4c-3e0f5e33e847_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_JohnsonAndJohnsonInnovationMember_18222d87-1791-4bf1-a517-193765ff06df_terseLabel_en-US" xlink:label="lab_akba_JohnsonAndJohnsonInnovationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Johnson &amp; Johnson Innovation</link:label>
    <link:label id="lab_akba_JohnsonAndJohnsonInnovationMember_label_en-US" xlink:label="lab_akba_JohnsonAndJohnsonInnovationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Johnson And Johnson Innovation [Member]</link:label>
    <link:label id="lab_akba_JohnsonAndJohnsonInnovationMember_documentation_en-US" xlink:label="lab_akba_JohnsonAndJohnsonInnovationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Johnson and Johnson Innovation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_JohnsonAndJohnsonInnovationMember" xlink:href="akba-20210930.xsd#akba_JohnsonAndJohnsonInnovationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_JohnsonAndJohnsonInnovationMember" xlink:to="lab_akba_JohnsonAndJohnsonInnovationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_OperatingPlanSufficientlyFundedByCashResourcesPeriod_067fa3f7-211e-4b07-9e6b-da22fe9de174_terseLabel_en-US" xlink:label="lab_akba_OperatingPlanSufficientlyFundedByCashResourcesPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period where operating plan is sufficiently funded by cash resources</link:label>
    <link:label id="lab_akba_OperatingPlanSufficientlyFundedByCashResourcesPeriod_label_en-US" xlink:label="lab_akba_OperatingPlanSufficientlyFundedByCashResourcesPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Plan Sufficiently Funded By Cash Resources Period</link:label>
    <link:label id="lab_akba_OperatingPlanSufficientlyFundedByCashResourcesPeriod_documentation_en-US" xlink:label="lab_akba_OperatingPlanSufficientlyFundedByCashResourcesPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating plan sufficiently funded by cash resources, period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OperatingPlanSufficientlyFundedByCashResourcesPeriod" xlink:href="akba-20210930.xsd#akba_OperatingPlanSufficientlyFundedByCashResourcesPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_OperatingPlanSufficientlyFundedByCashResourcesPeriod" xlink:to="lab_akba_OperatingPlanSufficientlyFundedByCashResourcesPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne_4669f0bb-723a-4da2-9fea-af7927a495eb_totalLabel_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne_label_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Payments Due Net Year One</link:label>
    <link:label id="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne_documentation_en-US" xlink:label="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Payments Due Net Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne" xlink:to="lab_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_2d2ca694-2b50-4dfa-ae2c-8187d15a00f6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount_40a0753b-cbdb-491d-bdec-6759b00340b6_terseLabel_en-US" xlink:label="lab_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangements additional cost sharing payments expected amount</link:label>
    <link:label id="lab_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount_label_en-US" xlink:label="lab_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements Additional Cost Sharing Payments Expected Amount</link:label>
    <link:label id="lab_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount_documentation_en-US" xlink:label="lab_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangements additional cost sharing payments expected amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount" xlink:href="akba-20210930.xsd#akba_CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount" xlink:to="lab_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_JanssenPharmaceuticaNVMember_0cbd3441-7c0e-496c-a661-4e28f3b75102_terseLabel_en-US" xlink:label="lab_akba_JanssenPharmaceuticaNVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceutica NV</link:label>
    <link:label id="lab_akba_JanssenPharmaceuticaNVMember_label_en-US" xlink:label="lab_akba_JanssenPharmaceuticaNVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceutica N V [Member]</link:label>
    <link:label id="lab_akba_JanssenPharmaceuticaNVMember_documentation_en-US" xlink:label="lab_akba_JanssenPharmaceuticaNVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceutica NV.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_JanssenPharmaceuticaNVMember" xlink:href="akba-20210930.xsd#akba_JanssenPharmaceuticaNVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_JanssenPharmaceuticaNVMember" xlink:to="lab_akba_JanssenPharmaceuticaNVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_akba_GlobalDevelopmentPlanMember_8d1bdad3-af30-4a2b-98f7-e6c2e168f1ba_terseLabel_en-US" xlink:label="lab_akba_GlobalDevelopmentPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Development Plan</link:label>
    <link:label id="lab_akba_GlobalDevelopmentPlanMember_label_en-US" xlink:label="lab_akba_GlobalDevelopmentPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Development Plan [Member]</link:label>
    <link:label id="lab_akba_GlobalDevelopmentPlanMember_documentation_en-US" xlink:label="lab_akba_GlobalDevelopmentPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global development plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_akba_GlobalDevelopmentPlanMember" xlink:href="akba-20210930.xsd#akba_GlobalDevelopmentPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_akba_GlobalDevelopmentPlanMember" xlink:to="lab_akba_GlobalDevelopmentPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_185051d2-d291-49a2-a3ef-a0ece3ad9945_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66adb9b7-fcf0-4673-8694-b88d6acad40d_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be5990b6-6f8e-48d0-a595-1dad0f8e0243_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Collaboration and Other Revenue:</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>akba-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:8995f2ec-9597-4fb5-818e-5018ad7b3654,g:f42f20af-e08c-4deb-ba3d-2a8688a2b01d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://akebia.com/role/CoverPage" xlink:type="simple" xlink:href="akba-20210930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://akebia.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_0b3479cb-7814-4955-b5c4-9eff7665db20" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_DocumentType_0b3479cb-7814-4955-b5c4-9eff7665db20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_b571f866-7834-453d-92a2-e16ddb4bcb1c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_DocumentQuarterlyReport_b571f866-7834-453d-92a2-e16ddb4bcb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_7f9719c2-1b20-4bfa-9a05-cb50ea679704" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_DocumentPeriodEndDate_7f9719c2-1b20-4bfa-9a05-cb50ea679704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_57a2732a-f3b9-40a5-9a73-b67d79405a09" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_DocumentTransitionReport_57a2732a-f3b9-40a5-9a73-b67d79405a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_544f1c11-773e-4c58-8156-e9a70c4d0751" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_EntityFileNumber_544f1c11-773e-4c58-8156-e9a70c4d0751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9d478193-069a-4117-b623-dc433e063227" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_EntityRegistrantName_9d478193-069a-4117-b623-dc433e063227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_61d051f8-4b7d-440a-be25-a04266ed8075" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_EntityIncorporationStateCountryCode_61d051f8-4b7d-440a-be25-a04266ed8075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_8e949975-b0eb-4f46-bc79-05c9e921abd4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_EntityTaxIdentificationNumber_8e949975-b0eb-4f46-bc79-05c9e921abd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d38d69d2-e8a2-47de-b97d-f1e0a7fc7770" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_EntityAddressAddressLine1_d38d69d2-e8a2-47de-b97d-f1e0a7fc7770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_87528350-6347-4030-8964-0b23af627630" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_EntityAddressCityOrTown_87528350-6347-4030-8964-0b23af627630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_63f35298-8a47-4db9-9129-0504c03148d3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_EntityAddressStateOrProvince_63f35298-8a47-4db9-9129-0504c03148d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5f110b59-1a3a-40d3-b998-b92155922766" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_EntityAddressPostalZipCode_5f110b59-1a3a-40d3-b998-b92155922766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_6e0949d8-8376-4848-bd3f-df7a852501dc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_CityAreaCode_6e0949d8-8376-4848-bd3f-df7a852501dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_06b473ea-c6bf-49ec-b81b-9c5289199108" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_LocalPhoneNumber_06b473ea-c6bf-49ec-b81b-9c5289199108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a68589d1-49a1-4727-a41e-aeaf03c502d0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_Security12bTitle_a68589d1-49a1-4727-a41e-aeaf03c502d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_934aed4b-4b9b-44f3-bc4f-15bbb01d1ae1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_TradingSymbol_934aed4b-4b9b-44f3-bc4f-15bbb01d1ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c01e4ef8-71d2-4451-9122-56464487a301" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_SecurityExchangeName_c01e4ef8-71d2-4451-9122-56464487a301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_0b238af9-cdd0-4ca5-b2fa-9b5d07032232" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_EntityCurrentReportingStatus_0b238af9-cdd0-4ca5-b2fa-9b5d07032232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_9ce21568-6863-4d29-bf8d-13daa436641f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_EntityInteractiveDataCurrent_9ce21568-6863-4d29-bf8d-13daa436641f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_bae74dcd-cd75-49d8-b48e-f53b5ed70575" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_EntityFilerCategory_bae74dcd-cd75-49d8-b48e-f53b5ed70575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_d2cc7a42-f5d7-49e7-b4fd-c3ed52a92c8a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_EntitySmallBusiness_d2cc7a42-f5d7-49e7-b4fd-c3ed52a92c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_354c51b5-bc1f-4bbb-8028-aa1fdeddc001" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_EntityEmergingGrowthCompany_354c51b5-bc1f-4bbb-8028-aa1fdeddc001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b511c81f-79b5-4357-ae91-ff2ca17f2b97" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_EntityShellCompany_b511c81f-79b5-4357-ae91-ff2ca17f2b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_a416853a-6737-49df-83d2-50a2031f7a41" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_a416853a-6737-49df-83d2-50a2031f7a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ff719010-410e-4abd-a804-a80ee220cb73" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_AmendmentFlag_ff719010-410e-4abd-a804-a80ee220cb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_020bd157-8ac6-461d-ba9b-60d1eef3f0fc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_DocumentFiscalYearFocus_020bd157-8ac6-461d-ba9b-60d1eef3f0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_19336f8f-36ba-4d64-9fcb-84a461394df2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_DocumentFiscalPeriodFocus_19336f8f-36ba-4d64-9fcb-84a461394df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_4b2f0317-cad3-4cb2-a4a2-eb8a4fc52243" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_CurrentFiscalYearEndDate_4b2f0317-cad3-4cb2-a4a2-eb8a4fc52243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_9a2f2630-6ea1-4d71-b410-4e7be00fe103" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5dac9d54-4a12-4e77-a6cc-71939bfbdd90" xlink:to="loc_dei_EntityCentralIndexKey_9a2f2630-6ea1-4d71-b410-4e7be00fe103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="akba-20210930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://akebia.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7418c5e7-2a79-411e-8fec-f360eedb62d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5ca7984b-61d3-4d3f-9523-d66fad25b579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7418c5e7-2a79-411e-8fec-f360eedb62d8" xlink:to="loc_us-gaap_AssetsAbstract_5ca7984b-61d3-4d3f-9523-d66fad25b579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_85f52809-de94-4623-9f22-ea2d42ead23d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5ca7984b-61d3-4d3f-9523-d66fad25b579" xlink:to="loc_us-gaap_AssetsCurrentAbstract_85f52809-de94-4623-9f22-ea2d42ead23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0a307ae1-69d7-49a8-8d13-0a036c513c68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_85f52809-de94-4623-9f22-ea2d42ead23d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0a307ae1-69d7-49a8-8d13-0a036c513c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ba900f40-e16c-4b7a-8905-fc6309f00ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_85f52809-de94-4623-9f22-ea2d42ead23d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ba900f40-e16c-4b7a-8905-fc6309f00ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_102ec4e3-ab79-47dc-a005-b7ed1fd63169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_85f52809-de94-4623-9f22-ea2d42ead23d" xlink:to="loc_us-gaap_InventoryNet_102ec4e3-ab79-47dc-a005-b7ed1fd63169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7e051c36-305b-48b6-bb01-82b305b38596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_85f52809-de94-4623-9f22-ea2d42ead23d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7e051c36-305b-48b6-bb01-82b305b38596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cf494781-1da2-41c9-beeb-4b0c0084460d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_85f52809-de94-4623-9f22-ea2d42ead23d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cf494781-1da2-41c9-beeb-4b0c0084460d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f39b1cba-b958-4bb8-8940-09dde634ca94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_85f52809-de94-4623-9f22-ea2d42ead23d" xlink:to="loc_us-gaap_AssetsCurrent_f39b1cba-b958-4bb8-8940-09dde634ca94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2e3f0a1e-d8ce-4e35-90bc-449db3e73569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5ca7984b-61d3-4d3f-9523-d66fad25b579" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2e3f0a1e-d8ce-4e35-90bc-449db3e73569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_316ea403-6d38-4c1e-a7fd-2de4c478930d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5ca7984b-61d3-4d3f-9523-d66fad25b579" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_316ea403-6d38-4c1e-a7fd-2de4c478930d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b31e90b7-6145-4291-a632-66bc1e464f12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5ca7984b-61d3-4d3f-9523-d66fad25b579" xlink:to="loc_us-gaap_Goodwill_b31e90b7-6145-4291-a632-66bc1e464f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_b8de119d-dd0a-414e-98ff-86c89127fb33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5ca7984b-61d3-4d3f-9523-d66fad25b579" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_b8de119d-dd0a-414e-98ff-86c89127fb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bce97ae5-9a9d-4dff-b9bd-640a928bb0af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5ca7984b-61d3-4d3f-9523-d66fad25b579" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bce97ae5-9a9d-4dff-b9bd-640a928bb0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_65956acd-6870-49a7-9392-5ae0ce009e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5ca7984b-61d3-4d3f-9523-d66fad25b579" xlink:to="loc_us-gaap_Assets_65956acd-6870-49a7-9392-5ae0ce009e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4655bfb2-457d-4db2-aca5-9050c70ad46b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7418c5e7-2a79-411e-8fec-f360eedb62d8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4655bfb2-457d-4db2-aca5-9050c70ad46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_aa162be2-c7d0-4e56-b64c-382cc0b2f10e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4655bfb2-457d-4db2-aca5-9050c70ad46b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_aa162be2-c7d0-4e56-b64c-382cc0b2f10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d2080c64-bdd7-44ce-b229-5ff5457d1c80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_aa162be2-c7d0-4e56-b64c-382cc0b2f10e" xlink:to="loc_us-gaap_AccountsPayableCurrent_d2080c64-bdd7-44ce-b229-5ff5457d1c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3cee5596-1660-4de3-bcce-51175efdac32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_aa162be2-c7d0-4e56-b64c-382cc0b2f10e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3cee5596-1660-4de3-bcce-51175efdac32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5a308830-72ae-4178-b912-c93a67614262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_aa162be2-c7d0-4e56-b64c-382cc0b2f10e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5a308830-72ae-4178-b912-c93a67614262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_67a36daa-4876-4df1-b81c-c14bc8d888fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_aa162be2-c7d0-4e56-b64c-382cc0b2f10e" xlink:to="loc_us-gaap_LiabilitiesCurrent_67a36daa-4876-4df1-b81c-c14bc8d888fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_eca22fb0-6583-489c-9e4e-1d13c52b5998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4655bfb2-457d-4db2-aca5-9050c70ad46b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_eca22fb0-6583-489c-9e4e-1d13c52b5998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5a382050-6ec2-4147-9e62-1f5b6bf8e6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4655bfb2-457d-4db2-aca5-9050c70ad46b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5a382050-6ec2-4147-9e62-1f5b6bf8e6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_0094dd8f-c37d-418c-94f6-22eed759659e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4655bfb2-457d-4db2-aca5-9050c70ad46b" xlink:to="loc_us-gaap_DerivativeLiabilities_0094dd8f-c37d-418c-94f6-22eed759659e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_77d0e5a7-6aae-492f-b15d-6ad1e99fcdd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4655bfb2-457d-4db2-aca5-9050c70ad46b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_77d0e5a7-6aae-492f-b15d-6ad1e99fcdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent_401be200-dd3a-4188-bc6c-c074e5d1a89f" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4655bfb2-457d-4db2-aca5-9050c70ad46b" xlink:to="loc_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent_401be200-dd3a-4188-bc6c-c074e5d1a89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5d7acb56-a150-4e4b-8295-67ea4361434e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4655bfb2-457d-4db2-aca5-9050c70ad46b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5d7acb56-a150-4e4b-8295-67ea4361434e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_efd84a07-8eaf-4f74-a057-43e5f1f81bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4655bfb2-457d-4db2-aca5-9050c70ad46b" xlink:to="loc_us-gaap_Liabilities_efd84a07-8eaf-4f74-a057-43e5f1f81bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_13746cde-9871-45fb-9795-3e13ee4cbb03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4655bfb2-457d-4db2-aca5-9050c70ad46b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_13746cde-9871-45fb-9795-3e13ee4cbb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2e5c874e-7def-4c14-9f0c-3ff3dcee1540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4655bfb2-457d-4db2-aca5-9050c70ad46b" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2e5c874e-7def-4c14-9f0c-3ff3dcee1540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_1a2463ab-1665-4d46-b704-f831b809036c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2e5c874e-7def-4c14-9f0c-3ff3dcee1540" xlink:to="loc_us-gaap_PreferredStockValue_1a2463ab-1665-4d46-b704-f831b809036c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_220606d5-c974-4d99-85b4-23e86d84301d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2e5c874e-7def-4c14-9f0c-3ff3dcee1540" xlink:to="loc_us-gaap_CommonStockValue_220606d5-c974-4d99-85b4-23e86d84301d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_4b61b594-397f-471a-9c7a-3b3cf6715541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2e5c874e-7def-4c14-9f0c-3ff3dcee1540" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_4b61b594-397f-471a-9c7a-3b3cf6715541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2d1647f1-bc30-4f98-a23d-86f96ff166ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2e5c874e-7def-4c14-9f0c-3ff3dcee1540" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2d1647f1-bc30-4f98-a23d-86f96ff166ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ddc2e998-8686-4d9c-8c49-dab6907abfc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2e5c874e-7def-4c14-9f0c-3ff3dcee1540" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ddc2e998-8686-4d9c-8c49-dab6907abfc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fa8f6db0-5178-449c-8392-8c083a228c28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2e5c874e-7def-4c14-9f0c-3ff3dcee1540" xlink:to="loc_us-gaap_StockholdersEquity_fa8f6db0-5178-449c-8392-8c083a228c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_dd870fb5-1d18-4e03-988c-5bfcc090ef4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4655bfb2-457d-4db2-aca5-9050c70ad46b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_dd870fb5-1d18-4e03-988c-5bfcc090ef4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="akba-20210930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://akebia.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b142de5f-2bf5-4b57-bdf5-eb1f13831358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a4c2b1c7-dd28-4e14-ab8b-377e2fe50157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b142de5f-2bf5-4b57-bdf5-eb1f13831358" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a4c2b1c7-dd28-4e14-ab8b-377e2fe50157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8d7f92ac-32e8-41ba-8b54-20e335031a13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b142de5f-2bf5-4b57-bdf5-eb1f13831358" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8d7f92ac-32e8-41ba-8b54-20e335031a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_d515808d-54d0-4666-82d6-a41ce15c4abb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b142de5f-2bf5-4b57-bdf5-eb1f13831358" xlink:to="loc_us-gaap_PreferredStockSharesIssued_d515808d-54d0-4666-82d6-a41ce15c4abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_dcb557ca-23c5-4921-9810-ba74b4846ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b142de5f-2bf5-4b57-bdf5-eb1f13831358" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_dcb557ca-23c5-4921-9810-ba74b4846ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b57b2ee3-ad21-4e98-b232-145a644af252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b142de5f-2bf5-4b57-bdf5-eb1f13831358" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b57b2ee3-ad21-4e98-b232-145a644af252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_251091c3-463a-49ec-b454-aec961696ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b142de5f-2bf5-4b57-bdf5-eb1f13831358" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_251091c3-463a-49ec-b454-aec961696ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c6c34659-59d5-4aa4-9b4a-ad256dea89ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b142de5f-2bf5-4b57-bdf5-eb1f13831358" xlink:to="loc_us-gaap_CommonStockSharesIssued_c6c34659-59d5-4aa4-9b4a-ad256dea89ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_fa80a3c3-22e0-4e4a-98f7-114cb921606f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b142de5f-2bf5-4b57-bdf5-eb1f13831358" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_fa80a3c3-22e0-4e4a-98f7-114cb921606f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="akba-20210930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_ef2083da-a86a-4588-a9e6-02310ac389ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a35f6cdf-0c07-4604-9a75-46986f977efa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ef2083da-a86a-4588-a9e6-02310ac389ea" xlink:to="loc_us-gaap_StatementTable_a35f6cdf-0c07-4604-9a75-46986f977efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fb4319a3-e6cf-42b7-ac95-1042c0f2e3cf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a35f6cdf-0c07-4604-9a75-46986f977efa" xlink:to="loc_srt_ProductOrServiceAxis_fb4319a3-e6cf-42b7-ac95-1042c0f2e3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_815a2f73-88ce-4e05-9d5d-fdfe834d6e27" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fb4319a3-e6cf-42b7-ac95-1042c0f2e3cf" xlink:to="loc_srt_ProductsAndServicesDomain_815a2f73-88ce-4e05-9d5d-fdfe834d6e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_a84d5da6-b612-47b0-92f6-9bbc154efedd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_815a2f73-88ce-4e05-9d5d-fdfe834d6e27" xlink:to="loc_us-gaap_ProductMember_a84d5da6-b612-47b0-92f6-9bbc154efedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseCollaborationAndOtherRevenueMember_320f09c3-8a6e-4768-becc-a4dbb0e8fd36" xlink:href="akba-20210930.xsd#akba_LicenseCollaborationAndOtherRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_815a2f73-88ce-4e05-9d5d-fdfe834d6e27" xlink:to="loc_akba_LicenseCollaborationAndOtherRevenueMember_320f09c3-8a6e-4768-becc-a4dbb0e8fd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a35f6cdf-0c07-4604-9a75-46986f977efa" xlink:to="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_0d63d4d2-48b8-457f-aef4-5a3dbeee2e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:to="loc_us-gaap_RevenuesAbstract_0d63d4d2-48b8-457f-aef4-5a3dbeee2e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fc4f1a00-950e-4897-a16c-6d803865861a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0d63d4d2-48b8-457f-aef4-5a3dbeee2e7e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fc4f1a00-950e-4897-a16c-6d803865861a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_70157653-690b-41ab-ad51-0281eb8a8408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:to="loc_us-gaap_CostOfRevenueAbstract_70157653-690b-41ab-ad51-0281eb8a8408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_a13927ab-912b-4d21-990e-355f8540a554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_70157653-690b-41ab-ad51-0281eb8a8408" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_a13927ab-912b-4d21-990e-355f8540a554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_d68910d8-cf86-4c77-b2d8-74184496fa4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_70157653-690b-41ab-ad51-0281eb8a8408" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_d68910d8-cf86-4c77-b2d8-74184496fa4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ProductionRelatedImpairmentsOrChargesIntangibles_a64327e4-8f1b-43e5-a917-bf2df702fb8e" xlink:href="akba-20210930.xsd#akba_ProductionRelatedImpairmentsOrChargesIntangibles"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_70157653-690b-41ab-ad51-0281eb8a8408" xlink:to="loc_akba_ProductionRelatedImpairmentsOrChargesIntangibles_a64327e4-8f1b-43e5-a917-bf2df702fb8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_4fd299f4-616b-49ad-af9a-d4dae58a7064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_70157653-690b-41ab-ad51-0281eb8a8408" xlink:to="loc_us-gaap_CostOfRevenue_4fd299f4-616b-49ad-af9a-d4dae58a7064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_8487a518-c5f3-4e41-a725-dbf9488948ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:to="loc_us-gaap_OperatingExpensesAbstract_8487a518-c5f3-4e41-a725-dbf9488948ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f56eea9c-f0b3-42cb-9e62-f8038293bc7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8487a518-c5f3-4e41-a725-dbf9488948ce" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f56eea9c-f0b3-42cb-9e62-f8038293bc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4c66a6e2-f2f8-4946-92da-2c45fde44b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8487a518-c5f3-4e41-a725-dbf9488948ce" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4c66a6e2-f2f8-4946-92da-2c45fde44b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseExpense_d4c7c64d-3d5e-4e10-b83f-a1ad9a7636cc" xlink:href="akba-20210930.xsd#akba_LicenseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8487a518-c5f3-4e41-a725-dbf9488948ce" xlink:to="loc_akba_LicenseExpense_d4c7c64d-3d5e-4e10-b83f-a1ad9a7636cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_59ea986d-250f-4b4b-82c9-7175be2e3f04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8487a518-c5f3-4e41-a725-dbf9488948ce" xlink:to="loc_us-gaap_OperatingExpenses_59ea986d-250f-4b4b-82c9-7175be2e3f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0cf6c400-29cd-4583-b364-73a924d8944e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:to="loc_us-gaap_OperatingIncomeLoss_0cf6c400-29cd-4583-b364-73a924d8944e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_31d3099f-5104-4de2-a337-790e26e44e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_31d3099f-5104-4de2-a337-790e26e44e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_0f04e9f3-3ff3-438c-9115-3d65e00fb238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_31d3099f-5104-4de2-a337-790e26e44e8a" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_0f04e9f3-3ff3-438c-9115-3d65e00fb238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e8cbc382-bb04-436e-8c24-ecf54f3e40a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_31d3099f-5104-4de2-a337-790e26e44e8a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e8cbc382-bb04-436e-8c24-ecf54f3e40a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_162d6fff-b472-4912-bb3e-9dc8ab9617b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:to="loc_us-gaap_NetIncomeLoss_162d6fff-b472-4912-bb3e-9dc8ab9617b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7fed8e49-afde-4991-99ac-13fa1b175fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:to="loc_us-gaap_EarningsPerShareBasic_7fed8e49-afde-4991-99ac-13fa1b175fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c7977bc9-8934-4bbf-9ea7-4f3d72f89828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c7977bc9-8934-4bbf-9ea7-4f3d72f89828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8b236d2b-a735-45f3-9e93-675a9749eaef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8b236d2b-a735-45f3-9e93-675a9749eaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c326cce8-a7b0-4298-a116-0db8c9de0bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c326cce8-a7b0-4298-a116-0db8c9de0bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_7e2b7a93-f589-4736-9cd4-9b36ef508e19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1e0396a7-3f24-4ba1-a196-bfe8cde735fe" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_7e2b7a93-f589-4736-9cd4-9b36ef508e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3b92053c-14c0-4ff1-ae7f-42b9465220e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_7e2b7a93-f589-4736-9cd4-9b36ef508e19" xlink:to="loc_us-gaap_NetIncomeLoss_3b92053c-14c0-4ff1-ae7f-42b9465220e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_25bbb25b-fba2-4434-9bf5-b3517b1996b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_7e2b7a93-f589-4736-9cd4-9b36ef508e19" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_25bbb25b-fba2-4434-9bf5-b3517b1996b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_740e36b4-c749-4259-9c1a-edeb7f4bc9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_7e2b7a93-f589-4736-9cd4-9b36ef508e19" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_740e36b4-c749-4259-9c1a-edeb7f4bc9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="akba-20210930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7df4cecd-941e-4459-bb77-773e7b464a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ffe6b9d9-f18b-4dd2-9675-c9c2e8eed1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7df4cecd-941e-4459-bb77-773e7b464a7a" xlink:to="loc_us-gaap_StatementTable_ffe6b9d9-f18b-4dd2-9675-c9c2e8eed1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c196e0b4-d03c-4b11-8a51-bdca2ff80fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ffe6b9d9-f18b-4dd2-9675-c9c2e8eed1ab" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c196e0b4-d03c-4b11-8a51-bdca2ff80fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ad05dce5-07a8-4e0a-8601-7256b96ae414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c196e0b4-d03c-4b11-8a51-bdca2ff80fe1" xlink:to="loc_us-gaap_EquityComponentDomain_ad05dce5-07a8-4e0a-8601-7256b96ae414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_810beb7b-5bd8-47df-b2f3-0ac37865af6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ad05dce5-07a8-4e0a-8601-7256b96ae414" xlink:to="loc_us-gaap_CommonStockMember_810beb7b-5bd8-47df-b2f3-0ac37865af6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ee54a7f4-dd23-4b81-a61f-3e48081ef6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ad05dce5-07a8-4e0a-8601-7256b96ae414" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ee54a7f4-dd23-4b81-a61f-3e48081ef6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_145466d7-2d15-43a2-a0d4-6640bfe8e3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ad05dce5-07a8-4e0a-8601-7256b96ae414" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_145466d7-2d15-43a2-a0d4-6640bfe8e3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_119daab8-a429-4938-9e80-18a689daf8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ad05dce5-07a8-4e0a-8601-7256b96ae414" xlink:to="loc_us-gaap_RetainedEarningsMember_119daab8-a429-4938-9e80-18a689daf8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e0b9cf94-bd60-4215-b4d3-d8f2c49aba1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ffe6b9d9-f18b-4dd2-9675-c9c2e8eed1ab" xlink:to="loc_us-gaap_StatementLineItems_e0b9cf94-bd60-4215-b4d3-d8f2c49aba1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e0b9cf94-bd60-4215-b4d3-d8f2c49aba1f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cf7e9054-d183-4f5b-892a-7fa1f82f1cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_cf7e9054-d183-4f5b-892a-7fa1f82f1cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eb64545d-25d5-4860-a109-22602b824f83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_us-gaap_StockholdersEquity_eb64545d-25d5-4860-a109-22602b824f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14d74b31-4df5-465b-9508-4aabe9f341bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14d74b31-4df5-465b-9508-4aabe9f341bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_554dc8c6-9143-4dca-bd33-da737a1192f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_554dc8c6-9143-4dca-bd33-da737a1192f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_36bd458c-0b02-4a16-85c5-31e795fb741c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_36bd458c-0b02-4a16-85c5-31e795fb741c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan_cc079881-dd83-4c01-9d43-a2ba1f34069d" xlink:href="akba-20210930.xsd#akba_StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_akba_StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan_cc079881-dd83-4c01-9d43-a2ba1f34069d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_455b0377-42ca-49b6-85a7-28ef5110c3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_455b0377-42ca-49b6-85a7-28ef5110c3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_63a0b426-5465-4d52-8ff7-ed20ab6cd101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_63a0b426-5465-4d52-8ff7-ed20ab6cd101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ff04f329-3d8b-46bd-9934-74fbd82b0422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ff04f329-3d8b-46bd-9934-74fbd82b0422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_a00b28cc-fa16-45c3-a905-15de06bb2461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_a00b28cc-fa16-45c3-a905-15de06bb2461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_509a0719-0e01-4dfc-87ab-ea7ec04dcdc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_509a0719-0e01-4dfc-87ab-ea7ec04dcdc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7a78d4fb-6eb1-459e-bbeb-cbeaadd9dce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_us-gaap_NetIncomeLoss_7a78d4fb-6eb1-459e-bbeb-cbeaadd9dce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f77b3346-a0ea-4c7b-9fc6-ddcc3877db16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f77b3346-a0ea-4c7b-9fc6-ddcc3877db16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_66391be3-4b67-4613-baf9-6987313dc3df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ec77be9b-07ae-49d9-8850-42c72e6590f7" xlink:to="loc_us-gaap_StockholdersEquity_66391be3-4b67-4613-baf9-6987313dc3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="akba-20210930.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a9c307e3-09f0-415a-8762-3e5806cb0aef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_86f95edf-69de-44e5-85d6-4f6dd2d4f8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a9c307e3-09f0-415a-8762-3e5806cb0aef" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_86f95edf-69de-44e5-85d6-4f6dd2d4f8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="akba-20210930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_3a42694f-510f-445b-8f44-153d593fa086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ce310414-e356-4b47-8877-2b09b9dc7106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3a42694f-510f-445b-8f44-153d593fa086" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ce310414-e356-4b47-8877-2b09b9dc7106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7da6aa5b-36f6-47bc-ab44-5e3fc268372e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ce310414-e356-4b47-8877-2b09b9dc7106" xlink:to="loc_us-gaap_NetIncomeLoss_7da6aa5b-36f6-47bc-ab44-5e3fc268372e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d065656f-1365-494e-a53d-0a9b55df2a05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ce310414-e356-4b47-8877-2b09b9dc7106" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d065656f-1365-494e-a53d-0a9b55df2a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_47bc7ea6-a7f0-4100-aa93-08f57c3faa8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d065656f-1365-494e-a53d-0a9b55df2a05" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_47bc7ea6-a7f0-4100-aa93-08f57c3faa8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1535dc7e-fd49-42cd-ba55-af9a81902212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d065656f-1365-494e-a53d-0a9b55df2a05" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1535dc7e-fd49-42cd-ba55-af9a81902212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3338a482-dc7b-448f-a019-804ae238b031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d065656f-1365-494e-a53d-0a9b55df2a05" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3338a482-dc7b-448f-a019-804ae238b031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_f837e1a9-1392-48fa-a926-6dc8ddd3aeec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d065656f-1365-494e-a53d-0a9b55df2a05" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_f837e1a9-1392-48fa-a926-6dc8ddd3aeec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome_aa6cad52-a1fc-4daf-ac32-580bb9a4f5af" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d065656f-1365-494e-a53d-0a9b55df2a05" xlink:to="loc_akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome_aa6cad52-a1fc-4daf-ac32-580bb9a4f5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue_d47c5c46-3329-445d-86da-eb224d20d6e9" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d065656f-1365-494e-a53d-0a9b55df2a05" xlink:to="loc_akba_ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue_d47c5c46-3329-445d-86da-eb224d20d6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_NoncashInterestExpense_1cd9f011-ba43-4784-9449-3da8e36fea4f" xlink:href="akba-20210930.xsd#akba_NoncashInterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d065656f-1365-494e-a53d-0a9b55df2a05" xlink:to="loc_akba_NoncashInterestExpense_1cd9f011-ba43-4784-9449-3da8e36fea4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StraightLineRent_5268a19b-6c6d-488a-bca3-55ae7022ed1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StraightLineRent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d065656f-1365-494e-a53d-0a9b55df2a05" xlink:to="loc_us-gaap_StraightLineRent_5268a19b-6c6d-488a-bca3-55ae7022ed1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_FairValueAdjustmentToInventory_4927abf2-434e-40e2-acfe-83628d110a1c" xlink:href="akba-20210930.xsd#akba_FairValueAdjustmentToInventory"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d065656f-1365-494e-a53d-0a9b55df2a05" xlink:to="loc_akba_FairValueAdjustmentToInventory_4927abf2-434e-40e2-acfe-83628d110a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_0edc15da-8898-437e-90bf-d330d0b0348a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d065656f-1365-494e-a53d-0a9b55df2a05" xlink:to="loc_us-gaap_InventoryWriteDown_0edc15da-8898-437e-90bf-d330d0b0348a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ExcessInventoryPurchaseCommitmentsExpenseReversal_c2efe97b-e3b1-46cf-8d95-37f13e2567a5" xlink:href="akba-20210930.xsd#akba_ExcessInventoryPurchaseCommitmentsExpenseReversal"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d065656f-1365-494e-a53d-0a9b55df2a05" xlink:to="loc_akba_ExcessInventoryPurchaseCommitmentsExpenseReversal_c2efe97b-e3b1-46cf-8d95-37f13e2567a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7cd5cb8b-1914-41ef-b7c0-dc53463441f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d065656f-1365-494e-a53d-0a9b55df2a05" xlink:to="loc_us-gaap_ShareBasedCompensation_7cd5cb8b-1914-41ef-b7c0-dc53463441f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_2b58ea06-db3c-43a9-886f-536ca0c174c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d065656f-1365-494e-a53d-0a9b55df2a05" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_2b58ea06-db3c-43a9-886f-536ca0c174c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9e2709c0-b670-4889-a504-09a861b7676e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d065656f-1365-494e-a53d-0a9b55df2a05" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9e2709c0-b670-4889-a504-09a861b7676e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_62bf100d-1b13-4807-a98d-3adb895abad0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9e2709c0-b670-4889-a504-09a861b7676e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_62bf100d-1b13-4807-a98d-3adb895abad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_dbfdfdbd-3e3d-4399-8449-932af1a1d20f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9e2709c0-b670-4889-a504-09a861b7676e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_dbfdfdbd-3e3d-4399-8449-932af1a1d20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c34cd485-6d16-4e58-8790-71eb8ba2ecf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9e2709c0-b670-4889-a504-09a861b7676e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c34cd485-6d16-4e58-8790-71eb8ba2ecf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e1c6241c-3d96-4504-a7d2-74beecd934cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9e2709c0-b670-4889-a504-09a861b7676e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e1c6241c-3d96-4504-a7d2-74beecd934cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_49968127-d29c-4cb6-9640-ac8e112af447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9e2709c0-b670-4889-a504-09a861b7676e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_49968127-d29c-4cb6-9640-ac8e112af447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1a39003b-4c94-4baf-bbe5-189e670cd7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9e2709c0-b670-4889-a504-09a861b7676e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1a39003b-4c94-4baf-bbe5-189e670cd7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8f82dd2b-62a0-4f16-9dc3-e26c2e655060" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9e2709c0-b670-4889-a504-09a861b7676e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8f82dd2b-62a0-4f16-9dc3-e26c2e655060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f1025022-3f72-4d1c-b434-613e83e963f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9e2709c0-b670-4889-a504-09a861b7676e" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f1025022-3f72-4d1c-b434-613e83e963f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54f85c87-a7d6-464b-bd37-31efc92ad78f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ce310414-e356-4b47-8877-2b09b9dc7106" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_54f85c87-a7d6-464b-bd37-31efc92ad78f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8b12dc7a-fe37-4f7f-b528-b5dd5407330a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3a42694f-510f-445b-8f44-153d593fa086" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8b12dc7a-fe37-4f7f-b528-b5dd5407330a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_df44ef6c-16dc-4183-9c55-16454cf274b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8b12dc7a-fe37-4f7f-b528-b5dd5407330a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_df44ef6c-16dc-4183-9c55-16454cf274b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_ac187238-a875-4c27-a90b-9cb2ae7595d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8b12dc7a-fe37-4f7f-b528-b5dd5407330a" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_ac187238-a875-4c27-a90b-9cb2ae7595d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_6d3bb70e-bec2-4dc0-94fb-30ceca292269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8b12dc7a-fe37-4f7f-b528-b5dd5407330a" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_6d3bb70e-bec2-4dc0-94fb-30ceca292269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7a084f7b-8397-4835-8a92-6654764bcd3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8b12dc7a-fe37-4f7f-b528-b5dd5407330a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7a084f7b-8397-4835-8a92-6654764bcd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fc0c61c2-34fa-4795-a544-988643b026fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3a42694f-510f-445b-8f44-153d593fa086" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fc0c61c2-34fa-4795-a544-988643b026fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties_3e08bc24-8b36-4766-881f-564b497b2a4d" xlink:href="akba-20210930.xsd#akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fc0c61c2-34fa-4795-a544-988643b026fc" xlink:to="loc_akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties_3e08bc24-8b36-4766-881f-564b497b2a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_5ecf6674-2c2f-4305-a90e-e7b32c039df5" xlink:href="akba-20210930.xsd#akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fc0c61c2-34fa-4795-a544-988643b026fc" xlink:to="loc_akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_5ecf6674-2c2f-4305-a90e-e7b32c039df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_ec21b7ed-8530-4375-b40e-497d7c77a149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fc0c61c2-34fa-4795-a544-988643b026fc" xlink:to="loc_us-gaap_ProceedsFromStockPlans_ec21b7ed-8530-4375-b40e-497d7c77a149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f0685b66-79b5-4e99-8fbf-fb782ecf4885" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fc0c61c2-34fa-4795-a544-988643b026fc" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f0685b66-79b5-4e99-8fbf-fb782ecf4885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0207dd28-01c8-4be1-8f6d-f1641ec16948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fc0c61c2-34fa-4795-a544-988643b026fc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0207dd28-01c8-4be1-8f6d-f1641ec16948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b3be78a2-0fa7-4ec6-a08a-159221f7cd38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3a42694f-510f-445b-8f44-153d593fa086" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b3be78a2-0fa7-4ec6-a08a-159221f7cd38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ac010792-fc62-4638-88b1-abaee20c2bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3a42694f-510f-445b-8f44-153d593fa086" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ac010792-fc62-4638-88b1-abaee20c2bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c921e0aa-5f35-4b21-9c4d-a80d61467710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3a42694f-510f-445b-8f44-153d593fa086" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c921e0aa-5f35-4b21-9c4d-a80d61467710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_e4cbd38f-ff1b-456a-b095-91c10dd3b24f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3a42694f-510f-445b-8f44-153d593fa086" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_e4cbd38f-ff1b-456a-b095-91c10dd3b24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DeferredUnpaidOfferingCosts_20faa26f-4cc0-4739-853c-20d768a397d4" xlink:href="akba-20210930.xsd#akba_DeferredUnpaidOfferingCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_e4cbd38f-ff1b-456a-b095-91c10dd3b24f" xlink:to="loc_akba_DeferredUnpaidOfferingCosts_20faa26f-4cc0-4739-853c-20d768a397d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/NatureofOrganizationandOperations" xlink:type="simple" xlink:href="akba-20210930.xsd#NatureofOrganizationandOperations"/>
  <link:presentationLink xlink:role="http://akebia.com/role/NatureofOrganizationandOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2273050a-b411-44d4-b0a2-bc3ffab913f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_c5b569d9-3c6d-43b2-8eb1-91d86afcf713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2273050a-b411-44d4-b0a2-bc3ffab913f8" xlink:to="loc_us-gaap_NatureOfOperations_c5b569d9-3c6d-43b2-8eb1-91d86afcf713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/NatureofOrganizationandOperationsAdditionalInformationDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#NatureofOrganizationandOperationsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/NatureofOrganizationandOperationsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7915b8a8-4ef1-4df6-9aa4-b4bd48302bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OperatingPlanSufficientlyFundedByCashResourcesPeriod_b673323a-dd94-47c9-a1d0-e0abd767abe1" xlink:href="akba-20210930.xsd#akba_OperatingPlanSufficientlyFundedByCashResourcesPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7915b8a8-4ef1-4df6-9aa4-b4bd48302bd1" xlink:to="loc_akba_OperatingPlanSufficientlyFundedByCashResourcesPeriod_b673323a-dd94-47c9-a1d0-e0abd767abe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="akba-20210930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://akebia.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fcd6ca52-5222-42cf-9d3f-49e89292eef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4d9e3a22-39fa-4a02-8629-3c785012d826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fcd6ca52-5222-42cf-9d3f-49e89292eef1" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4d9e3a22-39fa-4a02-8629-3c785012d826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="akba-20210930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://akebia.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9a21f18f-f2a1-475b-acbe-3d1797037c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_51f63af7-e365-4cf6-873d-ee59d15ad911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9a21f18f-f2a1-475b-acbe-3d1797037c4a" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_51f63af7-e365-4cf6-873d-ee59d15ad911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_e893cfbd-44ce-45d3-94bc-99e47c5de8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9a21f18f-f2a1-475b-acbe-3d1797037c4a" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_e893cfbd-44ce-45d3-94bc-99e47c5de8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7e9cd8f9-0047-4b6f-9edc-39ff6f04b8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9a21f18f-f2a1-475b-acbe-3d1797037c4a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7e9cd8f9-0047-4b6f-9edc-39ff6f04b8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_7c569581-9eb9-45f2-8c8e-58167d9f6886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9a21f18f-f2a1-475b-acbe-3d1797037c4a" xlink:to="loc_us-gaap_UseOfEstimates_7c569581-9eb9-45f2-8c8e-58167d9f6886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementLiabilityPolicyPolicyTextBlock_26206773-dae1-42f6-9626-960e8ccf02b7" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementLiabilityPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9a21f18f-f2a1-475b-acbe-3d1797037c4a" xlink:to="loc_akba_ContractualArrangementRoyaltiesAgreementLiabilityPolicyPolicyTextBlock_26206773-dae1-42f6-9626-960e8ccf02b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2f945a2c-7b42-449a-89eb-471a2018b00c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_8fe67edb-9ca5-4315-ab45-2e0cfe8688af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f945a2c-7b42-449a-89eb-471a2018b00c" xlink:to="loc_us-gaap_NumberOfOperatingSegments_8fe67edb-9ca5-4315-ab45-2e0cfe8688af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/ProductRevenueandReservesforVariableConsideration" xlink:type="simple" xlink:href="akba-20210930.xsd#ProductRevenueandReservesforVariableConsideration"/>
  <link:presentationLink xlink:role="http://akebia.com/role/ProductRevenueandReservesforVariableConsideration" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ff161476-1964-4eaa-bbf3-cd7c341694c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_ae19c21b-f2cb-4bdf-8305-89c5ea6cbe1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ff161476-1964-4eaa-bbf3-cd7c341694c3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_ae19c21b-f2cb-4bdf-8305-89c5ea6cbe1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationTables" xlink:type="simple" xlink:href="akba-20210930.xsd#ProductRevenueandReservesforVariableConsiderationTables"/>
  <link:presentationLink xlink:role="http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_53764968-1d72-486b-b1bf-ca8fd2f697d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock_0a0db3ba-8ec5-4158-be29-3e82c3567f5b" xlink:href="akba-20210930.xsd#akba_ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_53764968-1d72-486b-b1bf-ca8fd2f697d3" xlink:to="loc_akba_ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock_0a0db3ba-8ec5-4158-be29-3e82c3567f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationAdditionalInformationDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#ProductRevenueandReservesforVariableConsiderationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b8b43a33-d6aa-4294-a691-b6a8d4b61b34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_c63c3559-b7df-43e2-b0c7-2b0843c6de3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b8b43a33-d6aa-4294-a691-b6a8d4b61b34" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_c63c3559-b7df-43e2-b0c7-2b0843c6de3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3958201b-077a-4b9d-986f-a9462a20bd58" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c63c3559-b7df-43e2-b0c7-2b0843c6de3c" xlink:to="loc_srt_ProductOrServiceAxis_3958201b-077a-4b9d-986f-a9462a20bd58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e903a5ae-01b0-4a7c-b568-37a616ef9bce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3958201b-077a-4b9d-986f-a9462a20bd58" xlink:to="loc_srt_ProductsAndServicesDomain_e903a5ae-01b0-4a7c-b568-37a616ef9bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5f835f92-d81d-4239-aa5e-5f564f62f84d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e903a5ae-01b0-4a7c-b568-37a616ef9bce" xlink:to="loc_us-gaap_ProductMember_5f835f92-d81d-4239-aa5e-5f564f62f84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8946a90b-c257-4f9c-821b-5e30046a6a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c63c3559-b7df-43e2-b0c7-2b0843c6de3c" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_8946a90b-c257-4f9c-821b-5e30046a6a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6781d89f-1c19-4164-a7a3-9e1682990235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8946a90b-c257-4f9c-821b-5e30046a6a5b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6781d89f-1c19-4164-a7a3-9e1682990235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_b2d7b0b0-644c-4ab5-8566-77d1a0235f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8946a90b-c257-4f9c-821b-5e30046a6a5b" xlink:to="loc_us-gaap_AccountsReceivableNet_b2d7b0b0-644c-4ab5-8566-77d1a0235f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationProductRevenueAllowanceandReserveCategoriesDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#ProductRevenueandReservesforVariableConsiderationProductRevenueAllowanceandReserveCategoriesDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationProductRevenueAllowanceandReserveCategoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_eccc82e5-b609-4129-ac8c-cbb02a003295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5d129709-d1af-4080-81d5-ec53ccf99831" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_eccc82e5-b609-4129-ac8c-cbb02a003295" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5d129709-d1af-4080-81d5-ec53ccf99831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5f34195b-d344-4aa8-88a7-97ce28b861b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5d129709-d1af-4080-81d5-ec53ccf99831" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5f34195b-d344-4aa8-88a7-97ce28b861b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8ec3af55-94f0-4cf2-ade0-0d5de7570516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5f34195b-d344-4aa8-88a7-97ce28b861b7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_8ec3af55-94f0-4cf2-ade0-0d5de7570516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ChargebacksAndDiscountsMember_031ca2bb-5688-47d1-b03c-80d9274362bf" xlink:href="akba-20210930.xsd#akba_ChargebacksAndDiscountsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8ec3af55-94f0-4cf2-ade0-0d5de7570516" xlink:to="loc_akba_ChargebacksAndDiscountsMember_031ca2bb-5688-47d1-b03c-80d9274362bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_RebatesFeesAndOtherDeductionsMember_27416548-d989-472c-87f4-5c5a8c944f07" xlink:href="akba-20210930.xsd#akba_RebatesFeesAndOtherDeductionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8ec3af55-94f0-4cf2-ade0-0d5de7570516" xlink:to="loc_akba_RebatesFeesAndOtherDeductionsMember_27416548-d989-472c-87f4-5c5a8c944f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ReturnsMember_0cadf150-af1a-43a8-aae5-0bf733a6b392" xlink:href="akba-20210930.xsd#akba_ReturnsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8ec3af55-94f0-4cf2-ade0-0d5de7570516" xlink:to="loc_akba_ReturnsMember_0cadf150-af1a-43a8-aae5-0bf733a6b392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_f17554c0-ec4f-4cb0-b6ad-7408e7856300" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5d129709-d1af-4080-81d5-ec53ccf99831" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_f17554c0-ec4f-4cb0-b6ad-7408e7856300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ed31189f-a963-4f26-9eab-aa7f8c531bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_f17554c0-ec4f-4cb0-b6ad-7408e7856300" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ed31189f-a963-4f26-9eab-aa7f8c531bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_1d90a6d8-3205-4cb9-9c92-f2c2cc1f6661" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ed31189f-a963-4f26-9eab-aa7f8c531bc4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_1d90a6d8-3205-4cb9-9c92-f2c2cc1f6661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_163c8cb8-6f38-4e53-879a-9756ea66da9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ed31189f-a963-4f26-9eab-aa7f8c531bc4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_163c8cb8-6f38-4e53-879a-9756ea66da9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales_d7913954-d73a-42a4-9737-c2c036db24e5" xlink:href="akba-20210930.xsd#akba_ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ed31189f-a963-4f26-9eab-aa7f8c531bc4" xlink:to="loc_akba_ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales_d7913954-d73a-42a4-9737-c2c036db24e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_a7a6b7c2-88de-42c9-89ca-afb70a5ac26b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ed31189f-a963-4f26-9eab-aa7f8c531bc4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_a7a6b7c2-88de-42c9-89ca-afb70a5ac26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_c13a731c-22e6-4310-9555-f3e9546e4695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ed31189f-a963-4f26-9eab-aa7f8c531bc4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_c13a731c-22e6-4310-9555-f3e9546e4695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreements" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreements"/>
  <link:presentationLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_19190801-eb2f-44c7-93b3-2b15f0eac17d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_a2361448-4cbb-4e06-ab88-0034c8e265b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_19190801-eb2f-44c7-93b3-2b15f0eac17d" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_a2361448-4cbb-4e06-ab88-0034c8e265b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsTables" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreementsTables"/>
  <link:presentationLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0e565ea9-b140-488f-9f5b-31e919650e33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeArrangementRevenueRecognitionTableTextBlock_8cb3878c-868b-4691-8693-2ab2c9bd9a90" xlink:href="akba-20210930.xsd#akba_CollaborativeArrangementRevenueRecognitionTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0e565ea9-b140-488f-9f5b-31e919650e33" xlink:to="loc_akba_CollaborativeArrangementRevenueRecognitionTableTextBlock_8cb3878c-868b-4691-8693-2ab2c9bd9a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DeferredRevenueRecognitionTableTextBlock_96545913-dcc3-4da1-b5af-cdb4ad7e8284" xlink:href="akba-20210930.xsd#akba_DeferredRevenueRecognitionTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0e565ea9-b140-488f-9f5b-31e919650e33" xlink:to="loc_akba_DeferredRevenueRecognitionTableTextBlock_96545913-dcc3-4da1-b5af-cdb4ad7e8284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_05abee27-623b-4f7a-bd68-68b3d4f3da43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0e565ea9-b140-488f-9f5b-31e919650e33" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_05abee27-623b-4f7a-bd68-68b3d4f3da43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ScheduleOfRevenueRecognizedResultingFromChangesInContractAssetAndContractLiabilityTableTextBlock_f143ad9f-41a0-4798-9415-e6e98235972b" xlink:href="akba-20210930.xsd#akba_ScheduleOfRevenueRecognizedResultingFromChangesInContractAssetAndContractLiabilityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0e565ea9-b140-488f-9f5b-31e919650e33" xlink:to="loc_akba_ScheduleOfRevenueRecognizedResultingFromChangesInContractAssetAndContractLiabilityTableTextBlock_f143ad9f-41a0-4798-9415-e6e98235972b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c27eb0a3-b1c7-477f-8fff-5effffe129d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37523ac8-c9ce-4e1c-b3c3-0bc9f4399a66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c27eb0a3-b1c7-477f-8fff-5effffe129d1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37523ac8-c9ce-4e1c-b3c3-0bc9f4399a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bfc4912f-268c-4fc3-a876-28a7d29f392e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37523ac8-c9ce-4e1c-b3c3-0bc9f4399a66" xlink:to="loc_srt_ProductOrServiceAxis_bfc4912f-268c-4fc3-a876-28a7d29f392e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ffdec67c-cfba-4f16-b47f-7e3513ffcb94" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_bfc4912f-268c-4fc3-a876-28a7d29f392e" xlink:to="loc_srt_ProductsAndServicesDomain_ffdec67c-cfba-4f16-b47f-7e3513ffcb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseCollaborationAndOtherRevenueMember_667d10c1-8a3d-4846-a053-81c4d212021e" xlink:href="akba-20210930.xsd#akba_LicenseCollaborationAndOtherRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ffdec67c-cfba-4f16-b47f-7e3513ffcb94" xlink:to="loc_akba_LicenseCollaborationAndOtherRevenueMember_667d10c1-8a3d-4846-a053-81c4d212021e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_46f9ece0-9fef-4f61-99a5-8c2202050904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37523ac8-c9ce-4e1c-b3c3-0bc9f4399a66" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_46f9ece0-9fef-4f61-99a5-8c2202050904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_156fbc22-d0b8-4d28-8c5b-7c46f6ac2683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_46f9ece0-9fef-4f61-99a5-8c2202050904" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_156fbc22-d0b8-4d28-8c5b-7c46f6ac2683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeMember_7a5f26c6-b999-492e-8681-cca178f38820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_156fbc22-d0b8-4d28-8c5b-7c46f6ac2683" xlink:to="loc_us-gaap_OtherIncomeMember_7a5f26c6-b999-492e-8681-cca178f38820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bc3c04f3-e173-4128-8272-ccce74c81b9b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37523ac8-c9ce-4e1c-b3c3-0bc9f4399a66" xlink:to="loc_srt_CounterpartyNameAxis_bc3c04f3-e173-4128-8272-ccce74c81b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf112496-ea1f-4d48-aa51-725087ef3deb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_bc3c04f3-e173-4128-8272-ccce74c81b9b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf112496-ea1f-4d48-aa51-725087ef3deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_MitsubishiTanabePharmaCorporationMember_b69f95f1-65f0-4ac0-b5c6-eaded4ddbfb7" xlink:href="akba-20210930.xsd#akba_MitsubishiTanabePharmaCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf112496-ea1f-4d48-aa51-725087ef3deb" xlink:to="loc_akba_MitsubishiTanabePharmaCorporationMember_b69f95f1-65f0-4ac0-b5c6-eaded4ddbfb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OtsukaPharmaceuticalCompanyLimitedMember_4f1b498a-9914-41d4-bd89-35864a78e6e1" xlink:href="akba-20210930.xsd#akba_OtsukaPharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf112496-ea1f-4d48-aa51-725087ef3deb" xlink:to="loc_akba_OtsukaPharmaceuticalCompanyLimitedMember_4f1b498a-9914-41d4-bd89-35864a78e6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember_d1c2c0d0-fae8-4a84-833c-8462627916a0" xlink:href="akba-20210930.xsd#akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf112496-ea1f-4d48-aa51-725087ef3deb" xlink:to="loc_akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember_d1c2c0d0-fae8-4a84-833c-8462627916a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember_92058cdf-a669-4c93-ae0c-6f7db8c82f56" xlink:href="akba-20210930.xsd#akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf112496-ea1f-4d48-aa51-725087ef3deb" xlink:to="loc_akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember_92058cdf-a669-4c93-ae0c-6f7db8c82f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a3fddaf9-0979-462a-a877-8fad626a7e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37523ac8-c9ce-4e1c-b3c3-0bc9f4399a66" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a3fddaf9-0979-462a-a877-8fad626a7e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_95b3d038-16dc-4d93-84a5-b77bb55aade9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a3fddaf9-0979-462a-a877-8fad626a7e32" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_95b3d038-16dc-4d93-84a5-b77bb55aade9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember_c21034d9-855b-4d33-89ab-92991aa59707" xlink:href="akba-20210930.xsd#akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_95b3d038-16dc-4d93-84a5-b77bb55aade9" xlink:to="loc_akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember_c21034d9-855b-4d33-89ab-92991aa59707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember_b262b6c5-b522-4bae-a6aa-2f8eec32b449" xlink:href="akba-20210930.xsd#akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_95b3d038-16dc-4d93-84a5-b77bb55aade9" xlink:to="loc_akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember_b262b6c5-b522-4bae-a6aa-2f8eec32b449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ff6d87b7-7c47-44b6-8f79-aa87d948b578" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37523ac8-c9ce-4e1c-b3c3-0bc9f4399a66" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ff6d87b7-7c47-44b6-8f79-aa87d948b578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseCollaborationAndOtherRevenueAbstract_b83e8649-2ce1-4e4b-80af-e0c8e1440304" xlink:href="akba-20210930.xsd#akba_LicenseCollaborationAndOtherRevenueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ff6d87b7-7c47-44b6-8f79-aa87d948b578" xlink:to="loc_akba_LicenseCollaborationAndOtherRevenueAbstract_b83e8649-2ce1-4e4b-80af-e0c8e1440304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e17b71a4-aa25-4ef1-bc66-b6b9b2433e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_LicenseCollaborationAndOtherRevenueAbstract_b83e8649-2ce1-4e4b-80af-e0c8e1440304" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e17b71a4-aa25-4ef1-bc66-b6b9b2433e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1081cab0-4821-4636-b42d-0e1c99c44848" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c69de8c1-1f10-4b82-a7f3-606af71f37ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1081cab0-4821-4636-b42d-0e1c99c44848" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c69de8c1-1f10-4b82-a7f3-606af71f37ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_63f5e698-4da3-4a49-89b2-735bbb787c95" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c69de8c1-1f10-4b82-a7f3-606af71f37ad" xlink:to="loc_srt_CounterpartyNameAxis_63f5e698-4da3-4a49-89b2-735bbb787c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d551d26f-4759-487a-8d04-95913c2782f0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_63f5e698-4da3-4a49-89b2-735bbb787c95" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d551d26f-4759-487a-8d04-95913c2782f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_MitsubishiTanabePharmaCorporationMember_698b700a-d38a-45eb-a481-c57da200b963" xlink:href="akba-20210930.xsd#akba_MitsubishiTanabePharmaCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d551d26f-4759-487a-8d04-95913c2782f0" xlink:to="loc_akba_MitsubishiTanabePharmaCorporationMember_698b700a-d38a-45eb-a481-c57da200b963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OtsukaPharmaceuticalCompanyLimitedMember_0c725171-599e-4fa9-8c6d-6ba1e9fe80d8" xlink:href="akba-20210930.xsd#akba_OtsukaPharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d551d26f-4759-487a-8d04-95913c2782f0" xlink:to="loc_akba_OtsukaPharmaceuticalCompanyLimitedMember_0c725171-599e-4fa9-8c6d-6ba1e9fe80d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ViforPharmaMember_71b671f2-c67a-4297-ba8d-29272363f532" xlink:href="akba-20210930.xsd#akba_ViforPharmaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d551d26f-4759-487a-8d04-95913c2782f0" xlink:to="loc_akba_ViforPharmaMember_71b671f2-c67a-4297-ba8d-29272363f532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a6f9a987-f0bc-4da0-a897-7abf2baeaa95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c69de8c1-1f10-4b82-a7f3-606af71f37ad" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a6f9a987-f0bc-4da0-a897-7abf2baeaa95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4ce6c923-5f2d-48c6-bf88-2ecd99391cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a6f9a987-f0bc-4da0-a897-7abf2baeaa95" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4ce6c923-5f2d-48c6-bf88-2ecd99391cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndCommercializeCollaborationAgreementMember_c825aa21-9e9b-41b3-9a7a-4d4fb04c9fa1" xlink:href="akba-20210930.xsd#akba_DevelopmentAndCommercializeCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4ce6c923-5f2d-48c6-bf88-2ecd99391cb2" xlink:to="loc_akba_DevelopmentAndCommercializeCollaborationAgreementMember_c825aa21-9e9b-41b3-9a7a-4d4fb04c9fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember_a39b3d98-b73a-4e0f-92f0-72406bcc093e" xlink:href="akba-20210930.xsd#akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4ce6c923-5f2d-48c6-bf88-2ecd99391cb2" xlink:to="loc_akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember_a39b3d98-b73a-4e0f-92f0-72406bcc093e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember_f87f6bed-7ffd-48ea-87a6-e127239915a8" xlink:href="akba-20210930.xsd#akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4ce6c923-5f2d-48c6-bf88-2ecd99391cb2" xlink:to="loc_akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember_f87f6bed-7ffd-48ea-87a6-e127239915a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_597a5330-3287-4fbc-9faf-febc81fb61bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c69de8c1-1f10-4b82-a7f3-606af71f37ad" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_597a5330-3287-4fbc-9faf-febc81fb61bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract_b044cc03-2f0f-4e01-9bd5-815435f253c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_597a5330-3287-4fbc-9faf-febc81fb61bb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityAbstract_b044cc03-2f0f-4e01-9bd5-815435f253c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_95ddbab2-d5ce-4568-a84d-46f45ce8993e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_b044cc03-2f0f-4e01-9bd5-815435f253c7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_95ddbab2-d5ce-4568-a84d-46f45ce8993e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e1ff7df2-7be5-4748-9645-818f3cca1f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_b044cc03-2f0f-4e01-9bd5-815435f253c7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e1ff7df2-7be5-4748-9645-818f3cca1f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8e43fdfc-1338-4fae-b069-cd425282ed5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_b044cc03-2f0f-4e01-9bd5-815435f253c7" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8e43fdfc-1338-4fae-b069-cd425282ed5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_70bea8c3-7926-4f82-af84-0eb1f7e8c044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_eed1492a-7905-4ffa-87e6-fcc4975bfeea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_70bea8c3-7926-4f82-af84-0eb1f7e8c044" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_eed1492a-7905-4ffa-87e6-fcc4975bfeea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_212c8e44-1ca4-4466-803f-6e8a46b6ef05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_eed1492a-7905-4ffa-87e6-fcc4975bfeea" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_212c8e44-1ca4-4466-803f-6e8a46b6ef05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6d80f880-5ef3-4dbb-8918-6edb8ea4924d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_212c8e44-1ca4-4466-803f-6e8a46b6ef05" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6d80f880-5ef3-4dbb-8918-6edb8ea4924d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_bb208495-2456-4b47-8886-b4dbd3a21837" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6d80f880-5ef3-4dbb-8918-6edb8ea4924d" xlink:to="loc_us-gaap_AccountsReceivableMember_bb208495-2456-4b47-8886-b4dbd3a21837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_11f04305-35e9-4b61-990c-4e0f075bcd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6d80f880-5ef3-4dbb-8918-6edb8ea4924d" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_11f04305-35e9-4b61-990c-4e0f075bcd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DeferredRevenueMember_9725153d-439c-4bb0-9d98-31484574c990" xlink:href="akba-20210930.xsd#akba_DeferredRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6d80f880-5ef3-4dbb-8918-6edb8ea4924d" xlink:to="loc_akba_DeferredRevenueMember_9725153d-439c-4bb0-9d98-31484574c990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableMember_d142032a-bdf4-460f-b4ce-e6c268245b39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6d80f880-5ef3-4dbb-8918-6edb8ea4924d" xlink:to="loc_us-gaap_AccountsPayableMember_d142032a-bdf4-460f-b4ce-e6c268245b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AccruedExpensesAndOtherCurrentLiabilitiesMember_7dcad049-ee23-4a76-bd24-95003d26b4e8" xlink:href="akba-20210930.xsd#akba_AccruedExpensesAndOtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6d80f880-5ef3-4dbb-8918-6edb8ea4924d" xlink:to="loc_akba_AccruedExpensesAndOtherCurrentLiabilitiesMember_7dcad049-ee23-4a76-bd24-95003d26b4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e52ffe0e-4037-4ff8-bea1-f771417b8476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_eed1492a-7905-4ffa-87e6-fcc4975bfeea" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e52ffe0e-4037-4ff8-bea1-f771417b8476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward_31e4324e-db45-4a33-ac6b-7452eb583aa7" xlink:href="akba-20210930.xsd#akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e52ffe0e-4037-4ff8-bea1-f771417b8476" xlink:to="loc_akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward_31e4324e-db45-4a33-ac6b-7452eb583aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_20dede1e-b29e-46fa-88d6-4b9f207c10a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward_31e4324e-db45-4a33-ac6b-7452eb583aa7" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_20dede1e-b29e-46fa-88d6-4b9f207c10a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractWithCustomerAssetAdditions_90620541-0948-470e-9a28-72531c94ad04" xlink:href="akba-20210930.xsd#akba_ContractWithCustomerAssetAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward_31e4324e-db45-4a33-ac6b-7452eb583aa7" xlink:to="loc_akba_ContractWithCustomerAssetAdditions_90620541-0948-470e-9a28-72531c94ad04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractWithCustomerAssetDeductions_9cfcbb0f-fe2e-4868-91f1-93ba30792a0c" xlink:href="akba-20210930.xsd#akba_ContractWithCustomerAssetDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward_31e4324e-db45-4a33-ac6b-7452eb583aa7" xlink:to="loc_akba_ContractWithCustomerAssetDeductions_9cfcbb0f-fe2e-4868-91f1-93ba30792a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_0a367f95-8618-4207-b039-5efcd1b8dc22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward_31e4324e-db45-4a33-ac6b-7452eb583aa7" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_0a367f95-8618-4207-b039-5efcd1b8dc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractWithCustomerLiabilityRollForward_c7ee6123-0ea0-4755-b53a-813e309f24a5" xlink:href="akba-20210930.xsd#akba_ContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e52ffe0e-4037-4ff8-bea1-f771417b8476" xlink:to="loc_akba_ContractWithCustomerLiabilityRollForward_c7ee6123-0ea0-4755-b53a-813e309f24a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_cddffc4b-5c57-458c-ab6d-2b6dbca0fbde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_ContractWithCustomerLiabilityRollForward_c7ee6123-0ea0-4755-b53a-813e309f24a5" xlink:to="loc_us-gaap_ContractWithCustomerLiability_cddffc4b-5c57-458c-ab6d-2b6dbca0fbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractWithCustomerLiabilityAdditions_eca9f22d-1d59-447f-b140-e8103bfac127" xlink:href="akba-20210930.xsd#akba_ContractWithCustomerLiabilityAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_ContractWithCustomerLiabilityRollForward_c7ee6123-0ea0-4755-b53a-813e309f24a5" xlink:to="loc_akba_ContractWithCustomerLiabilityAdditions_eca9f22d-1d59-447f-b140-e8103bfac127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractWithCustomerLiabilityDeductions_fba21e48-04d2-451a-80c4-ba81081809d4" xlink:href="akba-20210930.xsd#akba_ContractWithCustomerLiabilityDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_ContractWithCustomerLiabilityRollForward_c7ee6123-0ea0-4755-b53a-813e309f24a5" xlink:to="loc_akba_ContractWithCustomerLiabilityDeductions_fba21e48-04d2-451a-80c4-ba81081809d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_78288fd1-c10f-4e60-9c4d-740899f135ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_ContractWithCustomerLiabilityRollForward_c7ee6123-0ea0-4755-b53a-813e309f24a5" xlink:to="loc_us-gaap_ContractWithCustomerLiability_78288fd1-c10f-4e60-9c4d-740899f135ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenueRecognizedResultingfromChangesinContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreementsRevenueRecognizedResultingfromChangesinContractAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenueRecognizedResultingfromChangesinContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e858501f-b325-4d04-b5e6-670484ca1e57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_c45c5044-8e69-4d75-b64f-99fa3ace59d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInContractWithCustomerLiabilityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e858501f-b325-4d04-b5e6-670484ca1e57" xlink:to="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_c45c5044-8e69-4d75-b64f-99fa3ace59d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fec1cbb8-f8ad-4c1c-a05f-7594fb9417a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_c45c5044-8e69-4d75-b64f-99fa3ace59d8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fec1cbb8-f8ad-4c1c-a05f-7594fb9417a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_49f16aab-546d-4b83-a1e4-65b58e73164b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerLiabilityAbstract_c45c5044-8e69-4d75-b64f-99fa3ace59d8" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_49f16aab-546d-4b83-a1e4-65b58e73164b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bd5e6084-4243-4959-b9e8-10430653f0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_769bf9bc-9b4c-492d-be9f-39ffdbbd6dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bd5e6084-4243-4959-b9e8-10430653f0a9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_769bf9bc-9b4c-492d-be9f-39ffdbbd6dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_32b649be-6727-47a6-871f-3925c083a4bc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_769bf9bc-9b4c-492d-be9f-39ffdbbd6dd8" xlink:to="loc_srt_CounterpartyNameAxis_32b649be-6727-47a6-871f-3925c083a4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5843784-0e6c-4cbb-9686-d5b5626eb491" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_32b649be-6727-47a6-871f-3925c083a4bc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5843784-0e6c-4cbb-9686-d5b5626eb491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_MitsubishiTanabePharmaCorporationMember_39d7c079-4cb1-4211-ae4a-603f9a2c8d5c" xlink:href="akba-20210930.xsd#akba_MitsubishiTanabePharmaCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5843784-0e6c-4cbb-9686-d5b5626eb491" xlink:to="loc_akba_MitsubishiTanabePharmaCorporationMember_39d7c079-4cb1-4211-ae4a-603f9a2c8d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_22495fc4-c8b1-49c0-b904-115f64d8d46e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_769bf9bc-9b4c-492d-be9f-39ffdbbd6dd8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_22495fc4-c8b1-49c0-b904-115f64d8d46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0ef77f29-ad49-4870-b222-84196c7945d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_22495fc4-c8b1-49c0-b904-115f64d8d46e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0ef77f29-ad49-4870-b222-84196c7945d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndCommercializeCollaborationAgreementMember_14d94e23-d130-4903-a12b-442f81f88fdf" xlink:href="akba-20210930.xsd#akba_DevelopmentAndCommercializeCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0ef77f29-ad49-4870-b222-84196c7945d1" xlink:to="loc_akba_DevelopmentAndCommercializeCollaborationAgreementMember_14d94e23-d130-4903-a12b-442f81f88fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember_51db736c-ed30-4632-b263-f4448cbea158" xlink:href="akba-20210930.xsd#akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0ef77f29-ad49-4870-b222-84196c7945d1" xlink:to="loc_akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember_51db736c-ed30-4632-b263-f4448cbea158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember_ea18b7fb-1ad0-4773-a761-fb66c35cc97d" xlink:href="akba-20210930.xsd#akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0ef77f29-ad49-4870-b222-84196c7945d1" xlink:to="loc_akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember_ea18b7fb-1ad0-4773-a761-fb66c35cc97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_MitsubishiTanabePharmaCorporationSupplyAgreementMember_8d015bc6-42be-44ea-888d-67cc109d4f44" xlink:href="akba-20210930.xsd#akba_MitsubishiTanabePharmaCorporationSupplyAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0ef77f29-ad49-4870-b222-84196c7945d1" xlink:to="loc_akba_MitsubishiTanabePharmaCorporationSupplyAgreementMember_8d015bc6-42be-44ea-888d-67cc109d4f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_361c734b-1efa-4501-9aeb-0c177795c119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_769bf9bc-9b4c-492d-be9f-39ffdbbd6dd8" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_361c734b-1efa-4501-9aeb-0c177795c119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_9e0aee38-a9cb-4b8c-b6ac-1da17d45d3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_361c734b-1efa-4501-9aeb-0c177795c119" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_9e0aee38-a9cb-4b8c-b6ac-1da17d45d3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_RegulatoryMilestonePaymentsMember_2b00de2b-90fd-4fea-a0ff-57d7d191128b" xlink:href="akba-20210930.xsd#akba_RegulatoryMilestonePaymentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_9e0aee38-a9cb-4b8c-b6ac-1da17d45d3ae" xlink:to="loc_akba_RegulatoryMilestonePaymentsMember_2b00de2b-90fd-4fea-a0ff-57d7d191128b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b23203b6-5003-4c46-929d-7d6118952874" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_769bf9bc-9b4c-492d-be9f-39ffdbbd6dd8" xlink:to="loc_srt_ProductOrServiceAxis_b23203b6-5003-4c46-929d-7d6118952874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dad31844-9895-4570-8c78-a4067b256aad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b23203b6-5003-4c46-929d-7d6118952874" xlink:to="loc_srt_ProductsAndServicesDomain_dad31844-9895-4570-8c78-a4067b256aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseCollaborationAndOtherRevenueMember_4351cf99-8942-40e9-8141-ae8dbf314e93" xlink:href="akba-20210930.xsd#akba_LicenseCollaborationAndOtherRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dad31844-9895-4570-8c78-a4067b256aad" xlink:to="loc_akba_LicenseCollaborationAndOtherRevenueMember_4351cf99-8942-40e9-8141-ae8dbf314e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseCollaborationAndOtherRevenueRoyaltiesMember_1d4dbd5b-2372-4865-b93c-4a530fded5da" xlink:href="akba-20210930.xsd#akba_LicenseCollaborationAndOtherRevenueRoyaltiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_LicenseCollaborationAndOtherRevenueMember_4351cf99-8942-40e9-8141-ae8dbf314e93" xlink:to="loc_akba_LicenseCollaborationAndOtherRevenueRoyaltiesMember_1d4dbd5b-2372-4865-b93c-4a530fded5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4167619a-a1f8-4db6-9185-a09e8b43982f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_769bf9bc-9b4c-492d-be9f-39ffdbbd6dd8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4167619a-a1f8-4db6-9185-a09e8b43982f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9286aed7-fc6c-426b-9017-b8c7177284c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4167619a-a1f8-4db6-9185-a09e8b43982f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9286aed7-fc6c-426b-9017-b8c7177284c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_2599bc6e-621c-45dd-8af4-0e25d57acee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9286aed7-fc6c-426b-9017-b8c7177284c4" xlink:to="loc_us-gaap_AccountsReceivableMember_2599bc6e-621c-45dd-8af4-0e25d57acee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_92673123-26ec-4d3e-88d5-c465d2cd334c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9286aed7-fc6c-426b-9017-b8c7177284c4" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_92673123-26ec-4d3e-88d5-c465d2cd334c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_13ddd951-2b7d-4dac-8250-e3951096660e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9286aed7-fc6c-426b-9017-b8c7177284c4" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_13ddd951-2b7d-4dac-8250-e3951096660e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractWithCustomerLiabilityMember_b292c2b4-2a71-4c63-bf61-f2c8722ac13b" xlink:href="akba-20210930.xsd#akba_ContractWithCustomerLiabilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9286aed7-fc6c-426b-9017-b8c7177284c4" xlink:to="loc_akba_ContractWithCustomerLiabilityMember_b292c2b4-2a71-4c63-bf61-f2c8722ac13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_769bf9bc-9b4c-492d-be9f-39ffdbbd6dd8" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_NumberOfPerformanceObligations_481f48ef-f63e-42f4-bb44-9da882f1061d" xlink:href="akba-20210930.xsd#akba_NumberOfPerformanceObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:to="loc_akba_NumberOfPerformanceObligations_481f48ef-f63e-42f4-bb44-9da882f1061d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_UpfrontCashPaymentReceived_1427a609-7af9-4fa2-8567-596ba3c80493" xlink:href="akba-20210930.xsd#akba_UpfrontCashPaymentReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:to="loc_akba_UpfrontCashPaymentReceived_1427a609-7af9-4fa2-8567-596ba3c80493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CostOfResearchServices_d48a26ba-581a-4b80-9471-74d4e3cbe0ab" xlink:href="akba-20210930.xsd#akba_CostOfResearchServices"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:to="loc_akba_CostOfResearchServices_d48a26ba-581a-4b80-9471-74d4e3cbe0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_MilestonePaymentReceived_83472824-5a29-4119-a18c-c29f9a9b9df4" xlink:href="akba-20210930.xsd#akba_MilestonePaymentReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:to="loc_akba_MilestonePaymentReceived_83472824-5a29-4119-a18c-c29f9a9b9df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_84175e09-4710-4a4a-b890-bff555335698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_84175e09-4710-4a4a-b890-bff555335698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_1f5c07ab-21c4-4f61-ac5c-1eca3108a9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:to="loc_us-gaap_ContractWithCustomerLiability_1f5c07ab-21c4-4f61-ac5c-1eca3108a9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5839ab87-5558-435c-828e-ebf761103760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5839ab87-5558-435c-828e-ebf761103760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e747dd19-ac30-4f17-aaa1-37c58f8eab92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e747dd19-ac30-4f17-aaa1-37c58f8eab92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_445a6b26-1e90-4d29-bfde-a51262406ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_445a6b26-1e90-4d29-bfde-a51262406ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b05cdd23-f0ab-4b3f-9735-b0681d0eebaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b05cdd23-f0ab-4b3f-9735-b0681d0eebaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables_8df29572-6eb2-4a09-8f60-91b6aff7b5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BilledContractReceivables"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc03ba2a-08af-496f-a2c0-cd221c0feaf9" xlink:to="loc_us-gaap_BilledContractReceivables_8df29572-6eb2-4a09-8f60-91b6aff7b5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_342d3c38-1954-4a5e-8bf1-bc973a49ad41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_19de97e9-643c-4e3b-9e17-6b897dfd276b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_342d3c38-1954-4a5e-8bf1-bc973a49ad41" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_19de97e9-643c-4e3b-9e17-6b897dfd276b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_044c8cd9-4b1e-4577-89a3-db58f3c5234e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_19de97e9-643c-4e3b-9e17-6b897dfd276b" xlink:to="loc_srt_CounterpartyNameAxis_044c8cd9-4b1e-4577-89a3-db58f3c5234e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7c02d90-486e-4582-8030-787c81101813" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_044c8cd9-4b1e-4577-89a3-db58f3c5234e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7c02d90-486e-4582-8030-787c81101813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OtsukaPharmaceuticalCompanyLimitedMember_d4dfba7c-c45f-42bd-bdd7-8ab35bf2328a" xlink:href="akba-20210930.xsd#akba_OtsukaPharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b7c02d90-486e-4582-8030-787c81101813" xlink:to="loc_akba_OtsukaPharmaceuticalCompanyLimitedMember_d4dfba7c-c45f-42bd-bdd7-8ab35bf2328a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1d66f6e3-c871-4aad-8d9a-a06b91e62f30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_19de97e9-643c-4e3b-9e17-6b897dfd276b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1d66f6e3-c871-4aad-8d9a-a06b91e62f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1ba0048-4f26-47af-af9c-3da5eb5c3c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1d66f6e3-c871-4aad-8d9a-a06b91e62f30" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1ba0048-4f26-47af-af9c-3da5eb5c3c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember_3fd7454d-471a-4692-bdb2-7b228fb9fb45" xlink:href="akba-20210930.xsd#akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1ba0048-4f26-47af-af9c-3da5eb5c3c6b" xlink:to="loc_akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember_3fd7454d-471a-4692-bdb2-7b228fb9fb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_cb6131c4-075f-40cd-976f-39bb471e69d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_19de97e9-643c-4e3b-9e17-6b897dfd276b" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_cb6131c4-075f-40cd-976f-39bb471e69d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_6e5b4d51-e28c-459b-a2e9-e3ac9b0843bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_cb6131c4-075f-40cd-976f-39bb471e69d9" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_6e5b4d51-e28c-459b-a2e9-e3ac9b0843bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_UpFrontNonRefundableAndNonCreditableMember_30a6e9cf-9615-45ff-a2bc-1ca7a2d0d2e1" xlink:href="akba-20210930.xsd#akba_UpFrontNonRefundableAndNonCreditableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_6e5b4d51-e28c-459b-a2e9-e3ac9b0843bd" xlink:to="loc_akba_UpFrontNonRefundableAndNonCreditableMember_30a6e9cf-9615-45ff-a2bc-1ca7a2d0d2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_RegulatoryMilestonePaymentsMember_563e7aa6-4ca3-44f4-b7f4-79c306077155" xlink:href="akba-20210930.xsd#akba_RegulatoryMilestonePaymentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_6e5b4d51-e28c-459b-a2e9-e3ac9b0843bd" xlink:to="loc_akba_RegulatoryMilestonePaymentsMember_563e7aa6-4ca3-44f4-b7f4-79c306077155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndRegulatoryMilestonesMember_235c4b26-dbb3-4354-bf32-26eba5366c8d" xlink:href="akba-20210930.xsd#akba_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_6e5b4d51-e28c-459b-a2e9-e3ac9b0843bd" xlink:to="loc_akba_DevelopmentAndRegulatoryMilestonesMember_235c4b26-dbb3-4354-bf32-26eba5366c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_12116b9f-8d94-4b18-931c-60a62527b412" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_19de97e9-643c-4e3b-9e17-6b897dfd276b" xlink:to="loc_srt_ProductOrServiceAxis_12116b9f-8d94-4b18-931c-60a62527b412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d6523aa4-f190-4836-8074-3ec541e631ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_12116b9f-8d94-4b18-931c-60a62527b412" xlink:to="loc_srt_ProductsAndServicesDomain_d6523aa4-f190-4836-8074-3ec541e631ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseCollaborationAndOtherRevenueMember_aa4f6075-f643-4a00-a91a-8df45f0deb76" xlink:href="akba-20210930.xsd#akba_LicenseCollaborationAndOtherRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d6523aa4-f190-4836-8074-3ec541e631ed" xlink:to="loc_akba_LicenseCollaborationAndOtherRevenueMember_aa4f6075-f643-4a00-a91a-8df45f0deb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_HIFProductMember_e230d38a-2a27-4b0b-be0a-30c51b48246b" xlink:href="akba-20210930.xsd#akba_HIFProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d6523aa4-f190-4836-8074-3ec541e631ed" xlink:to="loc_akba_HIFProductMember_e230d38a-2a27-4b0b-be0a-30c51b48246b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicensedProductsMember_9c889e1b-f41d-402f-9a0c-ca51f8a79927" xlink:href="akba-20210930.xsd#akba_LicensedProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d6523aa4-f190-4836-8074-3ec541e631ed" xlink:to="loc_akba_LicensedProductsMember_9c889e1b-f41d-402f-9a0c-ca51f8a79927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f5460be7-1332-45d8-89ee-8d3ced174fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_19de97e9-643c-4e3b-9e17-6b897dfd276b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f5460be7-1332-45d8-89ee-8d3ced174fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3465d853-d786-488a-bbc8-d0653e89fe95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f5460be7-1332-45d8-89ee-8d3ced174fcc" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3465d853-d786-488a-bbc8-d0653e89fe95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_990f13fd-33ab-40f0-acc6-6a96f3b7eb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3465d853-d786-488a-bbc8-d0653e89fe95" xlink:to="loc_us-gaap_AccountsReceivableMember_990f13fd-33ab-40f0-acc6-6a96f3b7eb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_13c98772-016c-4d37-8a6d-a383a6303430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3465d853-d786-488a-bbc8-d0653e89fe95" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_13c98772-016c-4d37-8a6d-a383a6303430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableMember_bb4888a8-0432-429e-a696-782d9bf6ed77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3465d853-d786-488a-bbc8-d0653e89fe95" xlink:to="loc_us-gaap_AccountsPayableMember_bb4888a8-0432-429e-a696-782d9bf6ed77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ab21e24f-f1d9-4d5a-be38-e2ddb71c5d8e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_19de97e9-643c-4e3b-9e17-6b897dfd276b" xlink:to="loc_srt_RangeAxis_ab21e24f-f1d9-4d5a-be38-e2ddb71c5d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a1e3c79e-5651-4362-bd05-623e7d454837" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ab21e24f-f1d9-4d5a-be38-e2ddb71c5d8e" xlink:to="loc_srt_RangeMember_a1e3c79e-5651-4362-bd05-623e7d454837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c7f34ffb-4f11-4058-9b73-04dd66789f67" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a1e3c79e-5651-4362-bd05-623e7d454837" xlink:to="loc_srt_MinimumMember_c7f34ffb-4f11-4058-9b73-04dd66789f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1897a150-7dfb-4e19-ac24-636067f5a1b1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a1e3c79e-5651-4362-bd05-623e7d454837" xlink:to="loc_srt_MaximumMember_1897a150-7dfb-4e19-ac24-636067f5a1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a6c869c5-abf4-4ad9-9a16-e34ddc49c5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_19de97e9-643c-4e3b-9e17-6b897dfd276b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a6c869c5-abf4-4ad9-9a16-e34ddc49c5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1655105c-ad5c-449d-aef1-1931ec159b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a6c869c5-abf4-4ad9-9a16-e34ddc49c5dc" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1655105c-ad5c-449d-aef1-1931ec159b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_GlobalDevelopmentPlanMember_32169fda-a4e9-4c9f-bfb6-1d87c6b7a83b" xlink:href="akba-20210930.xsd#akba_GlobalDevelopmentPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1655105c-ad5c-449d-aef1-1931ec159b62" xlink:to="loc_akba_GlobalDevelopmentPlanMember_32169fda-a4e9-4c9f-bfb6-1d87c6b7a83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_19de97e9-643c-4e3b-9e17-6b897dfd276b" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_NumberOfPerformanceObligations_6290a7ff-4480-435b-a654-7445a99c96a1" xlink:href="akba-20210930.xsd#akba_NumberOfPerformanceObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_NumberOfPerformanceObligations_6290a7ff-4480-435b-a654-7445a99c96a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_MilestonePaymentReceived_5911fe41-2b45-4d96-ab7f-5fb4b2d34aa4" xlink:href="akba-20210930.xsd#akba_MilestonePaymentReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_MilestonePaymentReceived_5911fe41-2b45-4d96-ab7f-5fb4b2d34aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount_cf0e2188-68a2-4883-85dd-56741bfa51dc" xlink:href="akba-20210930.xsd#akba_CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount_cf0e2188-68a2-4883-85dd-56741bfa51dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable_306a5e48-af1c-4f67-abbd-142c4136b112" xlink:href="akba-20210930.xsd#akba_ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable_306a5e48-af1c-4f67-abbd-142c4136b112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PercentageOfRemainingCreditableAmountAppliedToFuturePayments_67e206d4-d810-4564-8efd-8b560c19ee23" xlink:href="akba-20210930.xsd#akba_PercentageOfRemainingCreditableAmountAppliedToFuturePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_PercentageOfRemainingCreditableAmountAppliedToFuturePayments_67e206d4-d810-4564-8efd-8b560c19ee23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsAmount_ff91bcb6-5b01-4f10-ae61-ae1bc8bf4185" xlink:href="akba-20210930.xsd#akba_CollaborativeArrangementsAdditionalCostSharingPaymentsAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsAmount_ff91bcb6-5b01-4f10-ae61-ae1bc8bf4185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeAndLicenseArrangementTransactionPrice_8ecdea8c-cb97-4af6-8a7f-0d756e1e023f" xlink:href="akba-20210930.xsd#akba_CollaborativeAndLicenseArrangementTransactionPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_CollaborativeAndLicenseArrangementTransactionPrice_8ecdea8c-cb97-4af6-8a7f-0d756e1e023f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_UpfrontCashPaymentReceived_0bff8124-b4d6-4a91-9c38-1b72915b663d" xlink:href="akba-20210930.xsd#akba_UpfrontCashPaymentReceived"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_UpfrontCashPaymentReceived_0bff8124-b4d6-4a91-9c38-1b72915b663d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred_c079e195-5181-4374-99b0-1aebc0e441bf" xlink:href="akba-20210930.xsd#akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred_c079e195-5181-4374-99b0-1aebc0e441bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeArrangementsCostSharingPayments_d050fa54-751a-43c8-be23-439dbe24ff2c" xlink:href="akba-20210930.xsd#akba_CollaborativeArrangementsCostSharingPayments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_CollaborativeArrangementsCostSharingPayments_d050fa54-751a-43c8-be23-439dbe24ff2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount_69374189-5960-402e-b7a2-17e7a4818054" xlink:href="akba-20210930.xsd#akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount_69374189-5960-402e-b7a2-17e7a4818054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_319277f9-5406-4a17-9a39-9163766fe6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_319277f9-5406-4a17-9a39-9163766fe6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_13f893ba-cbf7-44b3-a118-0f129236f3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_13f893ba-cbf7-44b3-a118-0f129236f3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fc0e418f-dadc-4235-b2ab-283754a0cefe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fc0e418f-dadc-4235-b2ab-283754a0cefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3b037d8d-a01b-4018-978e-9fb48520aadf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3b037d8d-a01b-4018-978e-9fb48520aadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_65dac2bf-5bef-4703-8617-4156f2cc0ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_65dac2bf-5bef-4703-8617-4156f2cc0ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CostShareCostsIncurredForLicenseAgreement_7b142246-a424-480a-af2a-5322ba3662f3" xlink:href="akba-20210930.xsd#akba_CostShareCostsIncurredForLicenseAgreement"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_CostShareCostsIncurredForLicenseAgreement_7b142246-a424-480a-af2a-5322ba3662f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred_de0a7ce7-4715-4672-b6e9-4228fb3df204" xlink:href="akba-20210930.xsd#akba_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred_de0a7ce7-4715-4672-b6e9-4228fb3df204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CostShareCostsIncurredByPartnerForLicenseAgreement_28bc96bf-1ff5-4bef-bcc8-3d987303799a" xlink:href="akba-20210930.xsd#akba_CostShareCostsIncurredByPartnerForLicenseAgreement"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_CostShareCostsIncurredByPartnerForLicenseAgreement_28bc96bf-1ff5-4bef-bcc8-3d987303799a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PaymentForLicenseAgreementReimbursementOfCostsIncurred_7731e768-34e0-45b1-aa95-657c375f4d5a" xlink:href="akba-20210930.xsd#akba_PaymentForLicenseAgreementReimbursementOfCostsIncurred"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2b7b503a-e2ad-46b5-a095-09ffbc28018d" xlink:to="loc_akba_PaymentForLicenseAgreementReimbursementOfCostsIncurred_7731e768-34e0-45b1-aa95-657c375f4d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d0f95a16-4fb6-4247-8b3c-3d4b7dc7cff7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c7f68bd8-94d3-49ff-80c9-983bb91557c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d0f95a16-4fb6-4247-8b3c-3d4b7dc7cff7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c7f68bd8-94d3-49ff-80c9-983bb91557c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fe739ff1-8a1e-4158-8d86-b8592ce3a014" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c7f68bd8-94d3-49ff-80c9-983bb91557c9" xlink:to="loc_srt_CounterpartyNameAxis_fe739ff1-8a1e-4158-8d86-b8592ce3a014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5ff0fa9d-dd74-4a49-99dd-0e9787697186" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_fe739ff1-8a1e-4158-8d86-b8592ce3a014" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5ff0fa9d-dd74-4a49-99dd-0e9787697186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OtsukaPharmaceuticalCompanyLimitedMember_9165206a-acd8-40b3-97a9-ccec0a039110" xlink:href="akba-20210930.xsd#akba_OtsukaPharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5ff0fa9d-dd74-4a49-99dd-0e9787697186" xlink:to="loc_akba_OtsukaPharmaceuticalCompanyLimitedMember_9165206a-acd8-40b3-97a9-ccec0a039110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_c84d4e7e-368d-4e50-a014-fba110b8bbee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c7f68bd8-94d3-49ff-80c9-983bb91557c9" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_c84d4e7e-368d-4e50-a014-fba110b8bbee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_fe19d39a-6337-420a-ab41-794e20887902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_c84d4e7e-368d-4e50-a014-fba110b8bbee" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_fe19d39a-6337-420a-ab41-794e20887902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_UpFrontNonRefundableAndNonCreditableMember_c62acaf9-c81c-4318-96e1-fb2c9155feaf" xlink:href="akba-20210930.xsd#akba_UpFrontNonRefundableAndNonCreditableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_fe19d39a-6337-420a-ab41-794e20887902" xlink:to="loc_akba_UpFrontNonRefundableAndNonCreditableMember_c62acaf9-c81c-4318-96e1-fb2c9155feaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4f18fdc0-25da-474b-9906-9a92f886ef50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c7f68bd8-94d3-49ff-80c9-983bb91557c9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4f18fdc0-25da-474b-9906-9a92f886ef50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2912b6ae-834b-4370-9e2c-6e09bd3e4687" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4f18fdc0-25da-474b-9906-9a92f886ef50" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2912b6ae-834b-4370-9e2c-6e09bd3e4687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember_9802f9dc-e2ff-435b-ba96-69c2a6ee5c71" xlink:href="akba-20210930.xsd#akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2912b6ae-834b-4370-9e2c-6e09bd3e4687" xlink:to="loc_akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember_9802f9dc-e2ff-435b-ba96-69c2a6ee5c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1e0e91cd-592c-4249-b68e-be10d6ee116f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c7f68bd8-94d3-49ff-80c9-983bb91557c9" xlink:to="loc_srt_ProductOrServiceAxis_1e0e91cd-592c-4249-b68e-be10d6ee116f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_def7c20f-27a1-46f3-a5b0-1f4bfe1ce734" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1e0e91cd-592c-4249-b68e-be10d6ee116f" xlink:to="loc_srt_ProductsAndServicesDomain_def7c20f-27a1-46f3-a5b0-1f4bfe1ce734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseCollaborationAndOtherRevenueMember_2dfd01dc-a98a-442f-ac5e-ea0a36b1aef9" xlink:href="akba-20210930.xsd#akba_LicenseCollaborationAndOtherRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_def7c20f-27a1-46f3-a5b0-1f4bfe1ce734" xlink:to="loc_akba_LicenseCollaborationAndOtherRevenueMember_2dfd01dc-a98a-442f-ac5e-ea0a36b1aef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicensedHIFProductMember_6045065b-af3e-4f67-afb8-c84a3c6a04a2" xlink:href="akba-20210930.xsd#akba_LicensedHIFProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_def7c20f-27a1-46f3-a5b0-1f4bfe1ce734" xlink:to="loc_akba_LicensedHIFProductMember_6045065b-af3e-4f67-afb8-c84a3c6a04a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicensedProductsMember_61d130c1-99e4-4be2-86f3-3ea9633b41e3" xlink:href="akba-20210930.xsd#akba_LicensedProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_def7c20f-27a1-46f3-a5b0-1f4bfe1ce734" xlink:to="loc_akba_LicensedProductsMember_61d130c1-99e4-4be2-86f3-3ea9633b41e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_399c65bb-08e1-423e-8991-bc8e7727778f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c7f68bd8-94d3-49ff-80c9-983bb91557c9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_399c65bb-08e1-423e-8991-bc8e7727778f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_645360bd-83d4-4ce2-a7c7-ed9c4e8954a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_399c65bb-08e1-423e-8991-bc8e7727778f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_645360bd-83d4-4ce2-a7c7-ed9c4e8954a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_a0b8377a-fde6-448f-99d8-9ecc55ab2ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_645360bd-83d4-4ce2-a7c7-ed9c4e8954a6" xlink:to="loc_us-gaap_AccountsReceivableMember_a0b8377a-fde6-448f-99d8-9ecc55ab2ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_c013d129-ed8b-4192-9505-5c63c7434993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_645360bd-83d4-4ce2-a7c7-ed9c4e8954a6" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_c013d129-ed8b-4192-9505-5c63c7434993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableMember_f89aec8d-b4d4-4d33-8650-a67b815c8356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_645360bd-83d4-4ce2-a7c7-ed9c4e8954a6" xlink:to="loc_us-gaap_AccountsPayableMember_f89aec8d-b4d4-4d33-8650-a67b815c8356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e5a2eccf-0687-4166-87e0-39e3928f6c35" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c7f68bd8-94d3-49ff-80c9-983bb91557c9" xlink:to="loc_srt_RangeAxis_e5a2eccf-0687-4166-87e0-39e3928f6c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_54ee0793-e911-48a4-a889-13b070c2ffc8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e5a2eccf-0687-4166-87e0-39e3928f6c35" xlink:to="loc_srt_RangeMember_54ee0793-e911-48a4-a889-13b070c2ffc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_19f7b702-e4f5-4302-82f6-9b47e589add7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_54ee0793-e911-48a4-a889-13b070c2ffc8" xlink:to="loc_srt_MinimumMember_19f7b702-e4f5-4302-82f6-9b47e589add7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_21d8d953-8512-4ade-b41b-d30b921914e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_54ee0793-e911-48a4-a889-13b070c2ffc8" xlink:to="loc_srt_MaximumMember_21d8d953-8512-4ade-b41b-d30b921914e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c7f68bd8-94d3-49ff-80c9-983bb91557c9" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_NumberOfPerformanceObligations_2b58d00f-d1f2-497f-ba23-0cf64b9c412d" xlink:href="akba-20210930.xsd#akba_NumberOfPerformanceObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:to="loc_akba_NumberOfPerformanceObligations_2b58d00f-d1f2-497f-ba23-0cf64b9c412d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeAndLicenseArrangementTransactionPrice_e9e27b7e-151f-4830-a707-999909e42f70" xlink:href="akba-20210930.xsd#akba_CollaborativeAndLicenseArrangementTransactionPrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:to="loc_akba_CollaborativeAndLicenseArrangementTransactionPrice_e9e27b7e-151f-4830-a707-999909e42f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_UpfrontCashPaymentReceived_18fdb5a1-ac18-4bf6-b449-4ed2afafa6ad" xlink:href="akba-20210930.xsd#akba_UpfrontCashPaymentReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:to="loc_akba_UpfrontCashPaymentReceived_18fdb5a1-ac18-4bf6-b449-4ed2afafa6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred_fa7302b9-0ff8-4bde-beea-cc664028b465" xlink:href="akba-20210930.xsd#akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:to="loc_akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred_fa7302b9-0ff8-4bde-beea-cc664028b465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_EstimateSubsequentCostFundingUnderPlan_144dacf3-d726-47d5-9e48-a724027ffc64" xlink:href="akba-20210930.xsd#akba_EstimateSubsequentCostFundingUnderPlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:to="loc_akba_EstimateSubsequentCostFundingUnderPlan_144dacf3-d726-47d5-9e48-a724027ffc64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount_308c9593-b7c0-41c1-ae7a-51d76e860111" xlink:href="akba-20210930.xsd#akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:to="loc_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount_308c9593-b7c0-41c1-ae7a-51d76e860111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod_662aa5e8-80b3-4708-a0df-9af4fe73aca6" xlink:href="akba-20210930.xsd#akba_RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:to="loc_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod_662aa5e8-80b3-4708-a0df-9af4fe73aca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0aa36882-c8f8-4627-8b61-7e1dd01137d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0aa36882-c8f8-4627-8b61-7e1dd01137d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_0b3c5565-c747-4517-882d-9bc2b27738c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:to="loc_us-gaap_ContractWithCustomerLiability_0b3c5565-c747-4517-882d-9bc2b27738c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_81ae279a-0c2c-409c-ade0-9745c3160f68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_81ae279a-0c2c-409c-ade0-9745c3160f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bf7c051b-67db-4efc-89fb-ca6aaa2c4f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bf7c051b-67db-4efc-89fb-ca6aaa2c4f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_0c417812-2d20-44c7-9e62-28d371f2c611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4554d7d3-a0ea-4704-96c6-708b7ff331c7" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_0c417812-2d20-44c7-9e62-28d371f2c611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_09c5b1cd-d1f7-453c-8f05-8eaf7481d59b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3eb1164-f5c4-43a9-9144-b54b54ddac86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_09c5b1cd-d1f7-453c-8f05-8eaf7481d59b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3eb1164-f5c4-43a9-9144-b54b54ddac86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_186691e1-85b0-47bd-b64a-c6bb0a7dc7cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3eb1164-f5c4-43a9-9144-b54b54ddac86" xlink:to="loc_srt_CounterpartyNameAxis_186691e1-85b0-47bd-b64a-c6bb0a7dc7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_debb79f3-5422-4e18-adaf-4500c67cd750" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_186691e1-85b0-47bd-b64a-c6bb0a7dc7cd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_debb79f3-5422-4e18-adaf-4500c67cd750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_JanssenPharmaceuticaNVMember_8e236cf5-f92a-4988-bcc4-2d9c048bb40e" xlink:href="akba-20210930.xsd#akba_JanssenPharmaceuticaNVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_debb79f3-5422-4e18-adaf-4500c67cd750" xlink:to="loc_akba_JanssenPharmaceuticaNVMember_8e236cf5-f92a-4988-bcc4-2d9c048bb40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_JohnsonAndJohnsonInnovationMember_66273b7e-ffff-401e-a858-6e3ada82babd" xlink:href="akba-20210930.xsd#akba_JohnsonAndJohnsonInnovationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_debb79f3-5422-4e18-adaf-4500c67cd750" xlink:to="loc_akba_JohnsonAndJohnsonInnovationMember_66273b7e-ffff-401e-a858-6e3ada82babd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2a85d721-79c3-4c77-8018-3f75530f37bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3eb1164-f5c4-43a9-9144-b54b54ddac86" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2a85d721-79c3-4c77-8018-3f75530f37bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_de6a5378-6a34-437b-a79d-294b73fabc43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2a85d721-79c3-4c77-8018-3f75530f37bb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_de6a5378-6a34-437b-a79d-294b73fabc43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember_b0a3dd93-aa7b-4529-88b7-7843030023fd" xlink:href="akba-20210930.xsd#akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_de6a5378-6a34-437b-a79d-294b73fabc43" xlink:to="loc_akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember_b0a3dd93-aa7b-4529-88b7-7843030023fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3129c963-7916-46d8-9cde-b8d46704a874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b3eb1164-f5c4-43a9-9144-b54b54ddac86" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3129c963-7916-46d8-9cde-b8d46704a874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeArrangementTerm_15b5b211-60fe-42d9-b161-b5fa3d1e00e9" xlink:href="akba-20210930.xsd#akba_CollaborativeArrangementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3129c963-7916-46d8-9cde-b8d46704a874" xlink:to="loc_akba_CollaborativeArrangementTerm_15b5b211-60fe-42d9-b161-b5fa3d1e00e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_UpfrontPaymentPaidInCash_30fc8d30-1396-4628-8b0d-bae1d89d3d5d" xlink:href="akba-20210930.xsd#akba_UpfrontPaymentPaidInCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3129c963-7916-46d8-9cde-b8d46704a874" xlink:to="loc_akba_UpfrontPaymentPaidInCash_30fc8d30-1396-4628-8b0d-bae1d89d3d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_685756fd-0869-443f-977b-e16586e991b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3129c963-7916-46d8-9cde-b8d46704a874" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_685756fd-0869-443f-977b-e16586e991b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7bfb5c9a-851b-4137-989c-574f2e2dba20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3129c963-7916-46d8-9cde-b8d46704a874" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7bfb5c9a-851b-4137-989c-574f2e2dba20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_c7c2e612-4c32-4e2c-9d30-6c52781d2025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3129c963-7916-46d8-9cde-b8d46704a874" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_c7c2e612-4c32-4e2c-9d30-6c52781d2025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones_d93a1dc9-e283-4bda-b2d4-c02412411129" xlink:href="akba-20210930.xsd#akba_PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3129c963-7916-46d8-9cde-b8d46704a874" xlink:to="loc_akba_PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones_d93a1dc9-e283-4bda-b2d4-c02412411129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PotentialPaymentForAchievementOfSpecifiedCommercialMilestones_26f23ef8-2a99-4240-98f1-54d41cbbb143" xlink:href="akba-20210930.xsd#akba_PotentialPaymentForAchievementOfSpecifiedCommercialMilestones"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3129c963-7916-46d8-9cde-b8d46704a874" xlink:to="loc_akba_PotentialPaymentForAchievementOfSpecifiedCommercialMilestones_26f23ef8-2a99-4240-98f1-54d41cbbb143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsCyclerionTherapeuticsLicenseAgreementDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreementsCyclerionTherapeuticsLicenseAgreementDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsCyclerionTherapeuticsLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9a8cc6fe-e759-4ace-86c5-206b35e6033e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_95343ec0-22d1-4290-827b-cc978b38707a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9a8cc6fe-e759-4ace-86c5-206b35e6033e" xlink:to="loc_us-gaap_AssetAcquisitionTable_95343ec0-22d1-4290-827b-cc978b38707a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_8cb7af8d-c9c8-4c83-a1f3-32df3045512d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_95343ec0-22d1-4290-827b-cc978b38707a" xlink:to="loc_us-gaap_AssetAcquisitionAxis_8cb7af8d-c9c8-4c83-a1f3-32df3045512d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_cdc632a9-e130-40d9-8d88-88245b40d67f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_8cb7af8d-c9c8-4c83-a1f3-32df3045512d" xlink:to="loc_us-gaap_AssetAcquisitionDomain_cdc632a9-e130-40d9-8d88-88245b40d67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CyclerionTherapeuticsLicenseAgreementMember_b12eb8f6-eb27-4c0f-b4c0-7590e6c05c37" xlink:href="akba-20210930.xsd#akba_CyclerionTherapeuticsLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_cdc632a9-e130-40d9-8d88-88245b40d67f" xlink:to="loc_akba_CyclerionTherapeuticsLicenseAgreementMember_b12eb8f6-eb27-4c0f-b4c0-7590e6c05c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_6bef640b-df29-47b4-954b-94e90bf1065c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_95343ec0-22d1-4290-827b-cc978b38707a" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_6bef640b-df29-47b4-954b-94e90bf1065c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_6101cfbe-a381-4e55-a737-da30a8def45b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_6bef640b-df29-47b4-954b-94e90bf1065c" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_6101cfbe-a381-4e55-a737-da30a8def45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_04b983b3-b0ad-4faf-8b5e-c8cd1a397bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_6bef640b-df29-47b4-954b-94e90bf1065c" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_04b983b3-b0ad-4faf-8b5e-c8cd1a397bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_69b5afaa-628f-4851-bc98-a4e6c8a88286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_6bef640b-df29-47b4-954b-94e90bf1065c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_69b5afaa-628f-4851-bc98-a4e6c8a88286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod_7c3549a7-610a-4dee-9183-754c9d128107" xlink:href="akba-20210930.xsd#akba_AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_6bef640b-df29-47b4-954b-94e90bf1065c" xlink:to="loc_akba_AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod_7c3549a7-610a-4dee-9183-754c9d128107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AssetAcquisitionAgreementTerminationNoticePeriod_596febe3-673a-49b6-ae95-eb3540cd531e" xlink:href="akba-20210930.xsd#akba_AssetAcquisitionAgreementTerminationNoticePeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_6bef640b-df29-47b4-954b-94e90bf1065c" xlink:to="loc_akba_AssetAcquisitionAgreementTerminationNoticePeriod_596febe3-673a-49b6-ae95-eb3540cd531e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9e4fe1dc-99ee-4d92-8516-947a527ba14e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_887a636e-d3f6-46bd-a381-684f19d36783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9e4fe1dc-99ee-4d92-8516-947a527ba14e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_887a636e-d3f6-46bd-a381-684f19d36783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_507658ba-d900-45bb-8c94-22e5f2695f0f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_887a636e-d3f6-46bd-a381-684f19d36783" xlink:to="loc_srt_CounterpartyNameAxis_507658ba-d900-45bb-8c94-22e5f2695f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1b32548f-2801-4bec-81a2-67ddef8abc29" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_507658ba-d900-45bb-8c94-22e5f2695f0f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1b32548f-2801-4bec-81a2-67ddef8abc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ViforInternationalLimitedMember_da52b5d6-9323-48e4-845b-4200c90816da" xlink:href="akba-20210930.xsd#akba_ViforInternationalLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1b32548f-2801-4bec-81a2-67ddef8abc29" xlink:to="loc_akba_ViforInternationalLimitedMember_da52b5d6-9323-48e4-845b-4200c90816da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8d85e8be-0831-4f11-9bef-16f40e8beff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_887a636e-d3f6-46bd-a381-684f19d36783" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8d85e8be-0831-4f11-9bef-16f40e8beff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d3c8bfc-22c3-4e8b-b97b-5396c56653ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8d85e8be-0831-4f11-9bef-16f40e8beff9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d3c8bfc-22c3-4e8b-b97b-5396c56653ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseAgreementMember_dfb11aba-2c75-4b93-a3dd-c74e64dfdcea" xlink:href="akba-20210930.xsd#akba_LicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d3c8bfc-22c3-4e8b-b97b-5396c56653ad" xlink:to="loc_akba_LicenseAgreementMember_dfb11aba-2c75-4b93-a3dd-c74e64dfdcea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PriorityReviewVoucherLetterAgreementMember_4e714177-4856-479f-9dd9-35ac90747256" xlink:href="akba-20210930.xsd#akba_PriorityReviewVoucherLetterAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d3c8bfc-22c3-4e8b-b97b-5396c56653ad" xlink:to="loc_akba_PriorityReviewVoucherLetterAgreementMember_4e714177-4856-479f-9dd9-35ac90747256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_97c59ad7-eacd-4a4f-9dc0-7715d96577d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_887a636e-d3f6-46bd-a381-684f19d36783" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_97c59ad7-eacd-4a4f-9dc0-7715d96577d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_da0fc4bc-718b-4b01-a728-302d51eede06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_97c59ad7-eacd-4a4f-9dc0-7715d96577d5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_da0fc4bc-718b-4b01-a728-302d51eede06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0043682f-1204-40c1-ad36-331afe0ad2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_da0fc4bc-718b-4b01-a728-302d51eede06" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0043682f-1204-40c1-ad36-331afe0ad2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e302148e-c8ae-43a6-8eda-291b45732006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_887a636e-d3f6-46bd-a381-684f19d36783" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e302148e-c8ae-43a6-8eda-291b45732006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_6db87af5-066d-48de-b0db-13e7db9aa5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e302148e-c8ae-43a6-8eda-291b45732006" xlink:to="loc_us-gaap_CommonStockSharesIssued_6db87af5-066d-48de-b0db-13e7db9aa5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_8c95a353-a800-48e8-ade2-e37b374b375c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e302148e-c8ae-43a6-8eda-291b45732006" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_8c95a353-a800-48e8-ade2-e37b374b375c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ce9e2a48-2545-45b2-a91d-7cfdbdffb421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e302148e-c8ae-43a6-8eda-291b45732006" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ce9e2a48-2545-45b2-a91d-7cfdbdffb421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ClosingStockPriceOfCommonStock_91582d8e-0fd5-4129-b398-4ad28f1929bd" xlink:href="akba-20210930.xsd#akba_ClosingStockPriceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e302148e-c8ae-43a6-8eda-291b45732006" xlink:to="loc_akba_ClosingStockPriceOfCommonStock_91582d8e-0fd5-4129-b398-4ad28f1929bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock_8b43c8b3-cbb5-4b06-b340-62886e73564c" xlink:href="akba-20210930.xsd#akba_CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e302148e-c8ae-43a6-8eda-291b45732006" xlink:to="loc_akba_CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock_8b43c8b3-cbb5-4b06-b340-62886e73564c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PotentialPaymentForAchievementOfSpecifiedMilestones_8fb4c0b5-e552-47a7-9b15-7afdd9abc15f" xlink:href="akba-20210930.xsd#akba_PotentialPaymentForAchievementOfSpecifiedMilestones"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e302148e-c8ae-43a6-8eda-291b45732006" xlink:to="loc_akba_PotentialPaymentForAchievementOfSpecifiedMilestones_8fb4c0b5-e552-47a7-9b15-7afdd9abc15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f9a228e5-2ea4-4098-ba4e-989b63ed07bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e302148e-c8ae-43a6-8eda-291b45732006" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f9a228e5-2ea4-4098-ba4e-989b63ed07bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AggregateCollaborationAgreementPayments_ad9b2fd3-9f0b-4eb1-9d59-7b61ef73e2dc" xlink:href="akba-20210930.xsd#akba_AggregateCollaborationAgreementPayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e302148e-c8ae-43a6-8eda-291b45732006" xlink:to="loc_akba_AggregateCollaborationAgreementPayments_ad9b2fd3-9f0b-4eb1-9d59-7b61ef73e2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsLicenseAgreementwithPanionBFBiotechIncDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreementsLicenseAgreementwithPanionBFBiotechIncDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsLicenseAgreementwithPanionBFBiotechIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_404d9a05-269c-4f47-993f-0052feab042d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1df47ce8-3c44-466b-a2fe-13735cc111a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_404d9a05-269c-4f47-993f-0052feab042d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1df47ce8-3c44-466b-a2fe-13735cc111a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e275be04-8dad-4a9b-9e20-05b3bb14421c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1df47ce8-3c44-466b-a2fe-13735cc111a4" xlink:to="loc_srt_CounterpartyNameAxis_e275be04-8dad-4a9b-9e20-05b3bb14421c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e2c2d50-f574-43c2-b1e2-32acf3f91416" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e275be04-8dad-4a9b-9e20-05b3bb14421c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e2c2d50-f574-43c2-b1e2-32acf3f91416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember_d81a21a9-d8fe-4c98-aeb7-463cb5f63a77" xlink:href="akba-20210930.xsd#akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e2c2d50-f574-43c2-b1e2-32acf3f91416" xlink:to="loc_akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember_d81a21a9-d8fe-4c98-aeb7-463cb5f63a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1bbb646d-a738-4cf9-9c47-921bc5487346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1df47ce8-3c44-466b-a2fe-13735cc111a4" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1bbb646d-a738-4cf9-9c47-921bc5487346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_42b4b7d4-5a18-4ff1-8aee-27b49d50b736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1bbb646d-a738-4cf9-9c47-921bc5487346" xlink:to="loc_us-gaap_RelatedPartyDomain_42b4b7d4-5a18-4ff1-8aee-27b49d50b736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PanionAndBFBiotechIncorporationMember_f833801d-4121-49ab-9afa-503f155646d0" xlink:href="akba-20210930.xsd#akba_PanionAndBFBiotechIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_42b4b7d4-5a18-4ff1-8aee-27b49d50b736" xlink:to="loc_akba_PanionAndBFBiotechIncorporationMember_f833801d-4121-49ab-9afa-503f155646d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a1e61f5d-98b0-4073-9fee-b9799b91afaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1df47ce8-3c44-466b-a2fe-13735cc111a4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a1e61f5d-98b0-4073-9fee-b9799b91afaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0042c90b-72ac-4cb5-bdee-d32b96e81910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a1e61f5d-98b0-4073-9fee-b9799b91afaa" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0042c90b-72ac-4cb5-bdee-d32b96e81910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LicenseAgreementMember_aa0471fb-8ea6-48f9-ae77-5602bc64f694" xlink:href="akba-20210930.xsd#akba_LicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0042c90b-72ac-4cb5-bdee-d32b96e81910" xlink:to="loc_akba_LicenseAgreementMember_aa0471fb-8ea6-48f9-ae77-5602bc64f694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d1770946-f722-4573-9a12-834edd8237af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1df47ce8-3c44-466b-a2fe-13735cc111a4" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d1770946-f722-4573-9a12-834edd8237af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_RoyaltyPaymentsDue_7a943b64-4361-435f-8fa9-d0af63ee07f1" xlink:href="akba-20210930.xsd#akba_RoyaltyPaymentsDue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d1770946-f722-4573-9a12-834edd8237af" xlink:to="loc_akba_RoyaltyPaymentsDue_7a943b64-4361-435f-8fa9-d0af63ee07f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsSublicenseAgreementwithJapanTobaccoIncanditssubsidiaryToriiPharmaceuticalCoLtdDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LicenseCollaborationandOtherSignificantAgreementsSublicenseAgreementwithJapanTobaccoIncanditssubsidiaryToriiPharmaceuticalCoLtdDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsSublicenseAgreementwithJapanTobaccoIncanditssubsidiaryToriiPharmaceuticalCoLtdDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6572cd8b-fd1c-4036-9d65-1ab414ea1ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_363ba9df-9526-4af0-afef-869998b3fc12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6572cd8b-fd1c-4036-9d65-1ab414ea1ed6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_363ba9df-9526-4af0-afef-869998b3fc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_54f8f5bd-59bd-4d30-89fb-426e540d3bc0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_363ba9df-9526-4af0-afef-869998b3fc12" xlink:to="loc_srt_CounterpartyNameAxis_54f8f5bd-59bd-4d30-89fb-426e540d3bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87a7452a-fed8-489d-ae5d-3da9be4e78ff" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_54f8f5bd-59bd-4d30-89fb-426e540d3bc0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87a7452a-fed8-489d-ae5d-3da9be4e78ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember_4823065d-8ca0-41a3-a50a-2c0ccc8c5bda" xlink:href="akba-20210930.xsd#akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_87a7452a-fed8-489d-ae5d-3da9be4e78ff" xlink:to="loc_akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember_4823065d-8ca0-41a3-a50a-2c0ccc8c5bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b20c772c-b635-4cd6-aece-d010bfdd96ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_363ba9df-9526-4af0-afef-869998b3fc12" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b20c772c-b635-4cd6-aece-d010bfdd96ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_51c2e8d4-7128-492e-a91e-f1fdb417aa71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b20c772c-b635-4cd6-aece-d010bfdd96ae" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_51c2e8d4-7128-492e-a91e-f1fdb417aa71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_SublicenseAgreementMember_9733c1fb-f88b-418e-8d26-fa0c2d86c2fc" xlink:href="akba-20210930.xsd#akba_SublicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_51c2e8d4-7128-492e-a91e-f1fdb417aa71" xlink:to="loc_akba_SublicenseAgreementMember_9733c1fb-f88b-418e-8d26-fa0c2d86c2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_18fbadb8-be59-4443-bfe5-410ccd3c50a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_363ba9df-9526-4af0-afef-869998b3fc12" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_18fbadb8-be59-4443-bfe5-410ccd3c50a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_NumberOfPerformanceObligations_6c434fbf-93b4-4513-a1a1-a67623e28c36" xlink:href="akba-20210930.xsd#akba_NumberOfPerformanceObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_18fbadb8-be59-4443-bfe5-410ccd3c50a6" xlink:to="loc_akba_NumberOfPerformanceObligations_6c434fbf-93b4-4513-a1a1-a67623e28c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aec59665-0bc5-41f2-bc03-2320d484d1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_18fbadb8-be59-4443-bfe5-410ccd3c50a6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aec59665-0bc5-41f2-bc03-2320d484d1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyalties" xlink:type="simple" xlink:href="akba-20210930.xsd#LiabilityRelatedtoSaleofFutureRoyalties"/>
  <link:presentationLink xlink:role="http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyalties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_6ecdba7e-0729-43c7-a259-9d11c7d0f6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_51330ce0-17c6-4f24-88e6-53e4705de872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_6ecdba7e-0729-43c7-a259-9d11c7d0f6fc" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_51330ce0-17c6-4f24-88e6-53e4705de872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables" xlink:type="simple" xlink:href="akba-20210930.xsd#LiabilityRelatedtoSaleofFutureRoyaltiesTables"/>
  <link:presentationLink xlink:role="http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_e8f5a189-10a3-4922-b314-a645fe97df81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_049b49ad-bd8a-4c0d-b3c8-3c97e1743144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_e8f5a189-10a3-4922-b314-a645fe97df81" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_049b49ad-bd8a-4c0d-b3c8-3c97e1743144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ded42455-6304-4f9b-8ef5-ce8eef66ebc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity_a03ef9dd-9a2d-4887-8254-8ae84234427d" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ded42455-6304-4f9b-8ef5-ce8eef66ebc9" xlink:to="loc_akba_ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity_a03ef9dd-9a2d-4887-8254-8ae84234427d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity_00716547-f484-4614-ae64-6932a92231bc" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ded42455-6304-4f9b-8ef5-ce8eef66ebc9" xlink:to="loc_akba_ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity_00716547-f484-4614-ae64-6932a92231bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementPercentageOfRoyaltyPaymentsToBeReceivedContingentOnReachingMaximumAnnualRoyaltyPayoutCapacity_0055c12d-8c46-4532-87f0-59d257f98a20" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementPercentageOfRoyaltyPaymentsToBeReceivedContingentOnReachingMaximumAnnualRoyaltyPayoutCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ded42455-6304-4f9b-8ef5-ce8eef66ebc9" xlink:to="loc_akba_ContractualArrangementRoyaltiesAgreementPercentageOfRoyaltyPaymentsToBeReceivedContingentOnReachingMaximumAnnualRoyaltyPayoutCapacity_0055c12d-8c46-4532-87f0-59d257f98a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties_b3fb72be-a40e-4f8c-8341-5c0b4ba4fa93" xlink:href="akba-20210930.xsd#akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ded42455-6304-4f9b-8ef5-ce8eef66ebc9" xlink:to="loc_akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties_b3fb72be-a40e-4f8c-8341-5c0b4ba4fa93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementProceedsContingentOnAnnualSalesMilestones_f7ca6ec3-9114-412d-b285-a300f0ddca8d" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementProceedsContingentOnAnnualSalesMilestones"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ded42455-6304-4f9b-8ef5-ce8eef66ebc9" xlink:to="loc_akba_ContractualArrangementRoyaltiesAgreementProceedsContingentOnAnnualSalesMilestones_f7ca6ec3-9114-412d-b285-a300f0ddca8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent_3d522896-5d69-45c9-b55a-29d0c68b7ebf" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ded42455-6304-4f9b-8ef5-ce8eef66ebc9" xlink:to="loc_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent_3d522896-5d69-45c9-b55a-29d0c68b7ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage_13f6deee-09b0-47cd-83de-899b1a13f8a7" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ded42455-6304-4f9b-8ef5-ce8eef66ebc9" xlink:to="loc_akba_ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage_13f6deee-09b0-47cd-83de-899b1a13f8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesRollforwardofLiabilityRelatedtoSaleofFutureRoyaltiesDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#LiabilityRelatedtoSaleofFutureRoyaltiesRollforwardofLiabilityRelatedtoSaleofFutureRoyaltiesDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesRollforwardofLiabilityRelatedtoSaleofFutureRoyaltiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_72c8a6d9-6ce5-4ae6-b03e-8c01a3a94dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrentRollForward_2d19889b-a18d-48d0-a194-0f3bb145653e" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrentRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_72c8a6d9-6ce5-4ae6-b03e-8c01a3a94dc5" xlink:to="loc_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrentRollForward_2d19889b-a18d-48d0-a194-0f3bb145653e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent_e2512d7e-d793-464c-add6-a4ab6ca76782" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrentRollForward_2d19889b-a18d-48d0-a194-0f3bb145653e" xlink:to="loc_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent_e2512d7e-d793-464c-add6-a4ab6ca76782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties_513b0011-69d5-47a3-887d-ef059d47422d" xlink:href="akba-20210930.xsd#akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrentRollForward_2d19889b-a18d-48d0-a194-0f3bb145653e" xlink:to="loc_akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties_513b0011-69d5-47a3-887d-ef059d47422d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable_ff96d8c6-75e1-4454-9fb2-5b1cb0678c00" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrentRollForward_2d19889b-a18d-48d0-a194-0f3bb145653e" xlink:to="loc_akba_ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable_ff96d8c6-75e1-4454-9fb2-5b1cb0678c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome_9a91ef5d-583d-4aa7-a48c-b813fce4b534" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrentRollForward_2d19889b-a18d-48d0-a194-0f3bb145653e" xlink:to="loc_akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome_9a91ef5d-583d-4aa7-a48c-b813fce4b534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent_1815dff6-3ff3-400e-ba1f-7b0406f2d462" xlink:href="akba-20210930.xsd#akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrentRollForward_2d19889b-a18d-48d0-a194-0f3bb145653e" xlink:to="loc_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent_1815dff6-3ff3-400e-ba1f-7b0406f2d462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/AvailableforSaleSecurities" xlink:type="simple" xlink:href="akba-20210930.xsd#AvailableforSaleSecurities"/>
  <link:presentationLink xlink:role="http://akebia.com/role/AvailableforSaleSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ffc83d0d-f078-4cb3-84dd-f56632fa7f05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_5657cab7-a63e-4895-a068-41d0baf7897e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ffc83d0d-f078-4cb3-84dd-f56632fa7f05" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_5657cab7-a63e-4895-a068-41d0baf7897e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/AvailableForSaleSecuritiesTables" xlink:type="simple" xlink:href="akba-20210930.xsd#AvailableForSaleSecuritiesTables"/>
  <link:presentationLink xlink:role="http://akebia.com/role/AvailableForSaleSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_23d31f3c-04bc-4745-962a-8b868081b7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_aa914e0f-e86f-4269-b9fc-c271515ac128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_23d31f3c-04bc-4745-962a-8b868081b7d0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_aa914e0f-e86f-4269-b9fc-c271515ac128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b16ef4f1-a99b-45d2-a1ac-c5e3c2d11947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d0ceaeba-89ac-44c9-972d-badf311da210" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b16ef4f1-a99b-45d2-a1ac-c5e3c2d11947" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d0ceaeba-89ac-44c9-972d-badf311da210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3f354bac-cec4-4d78-bc43-ee8fa5d573a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d0ceaeba-89ac-44c9-972d-badf311da210" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3f354bac-cec4-4d78-bc43-ee8fa5d573a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d158d016-c079-4747-ad04-2b4b9ecc9447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3f354bac-cec4-4d78-bc43-ee8fa5d573a0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d158d016-c079-4747-ad04-2b4b9ecc9447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_83ca418e-cbe9-46f8-a2d0-33e3564cbe44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d158d016-c079-4747-ad04-2b4b9ecc9447" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_83ca418e-cbe9-46f8-a2d0-33e3564cbe44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a48883cd-3cdf-4090-93ae-ae7fb98921cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d0ceaeba-89ac-44c9-972d-badf311da210" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a48883cd-3cdf-4090-93ae-ae7fb98921cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4ff7079e-3b83-498f-ba1a-52bb6e3d8735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a48883cd-3cdf-4090-93ae-ae7fb98921cc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4ff7079e-3b83-498f-ba1a-52bb6e3d8735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_555483a0-5fa6-4952-9289-ab59c854d6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a48883cd-3cdf-4090-93ae-ae7fb98921cc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_555483a0-5fa6-4952-9289-ab59c854d6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_e56b05d9-93f7-4175-9798-66b099095b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a48883cd-3cdf-4090-93ae-ae7fb98921cc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_e56b05d9-93f7-4175-9798-66b099095b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8b5a311a-78ba-49e0-acad-a042285be9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_e56b05d9-93f7-4175-9798-66b099095b9b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8b5a311a-78ba-49e0-acad-a042285be9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_19807444-6f38-41af-a3c5-53556302b9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_e56b05d9-93f7-4175-9798-66b099095b9b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_19807444-6f38-41af-a3c5-53556302b9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1d7e05bc-3c0f-4aee-973d-c974aa033717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_e56b05d9-93f7-4175-9798-66b099095b9b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1d7e05bc-3c0f-4aee-973d-c974aa033717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0fa04612-7a33-445e-8acf-248d3e2f4a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_e56b05d9-93f7-4175-9798-66b099095b9b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0fa04612-7a33-445e-8acf-248d3e2f4a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost_4238768e-79e8-4692-ac15-42556910011d" xlink:href="akba-20210930.xsd#akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a48883cd-3cdf-4090-93ae-ae7fb98921cc" xlink:to="loc_akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost_4238768e-79e8-4692-ac15-42556910011d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_01e749d3-9ac0-487f-b7e1-d3b38a6bba7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a48883cd-3cdf-4090-93ae-ae7fb98921cc" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_01e749d3-9ac0-487f-b7e1-d3b38a6bba7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails_1" xlink:type="simple" xlink:href="akba-20210930.xsd#AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails_1"/>
  <link:presentationLink xlink:role="http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://akebia.com/role/AvailableForSaleSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#AvailableForSaleSecuritiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/AvailableForSaleSecuritiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f60bebed-d40f-46e6-8736-b9d7e8a0299f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_affb193d-13ac-4310-b60b-398acb4533a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f60bebed-d40f-46e6-8736-b9d7e8a0299f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_affb193d-13ac-4310-b60b-398acb4533a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease_e0eb3585-2b95-4d7b-8cd5-5aeb5f39cfee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f60bebed-d40f-46e6-8736-b9d7e8a0299f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease_e0eb3585-2b95-4d7b-8cd5-5aeb5f39cfee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_1353fe15-49cc-4d9b-9310-ac3748f480ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f60bebed-d40f-46e6-8736-b9d7e8a0299f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_1353fe15-49cc-4d9b-9310-ac3748f480ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="akba-20210930.xsd#FairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://akebia.com/role/FairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_82e1686e-84a4-4309-93a5-74ed3326941b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_c856666e-07e2-442e-a827-1d29822ac8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_82e1686e-84a4-4309-93a5-74ed3326941b" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_c856666e-07e2-442e-a827-1d29822ac8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="akba-20210930.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://akebia.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_93803fa3-4164-4c4a-b6bd-f9425c087ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_94ebab6a-645d-4840-9439-2d87ecdfa1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_93803fa3-4164-4c4a-b6bd-f9425c087ca8" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_94ebab6a-645d-4840-9439-2d87ecdfa1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_c009c878-c38e-458f-a8b6-c4695c881a24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_93803fa3-4164-4c4a-b6bd-f9425c087ca8" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_c009c878-c38e-458f-a8b6-c4695c881a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7fb41dc0-3b8b-4d3f-8de1-39b64f38e69e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fde1e103-d867-4ad9-bea5-e1fef0c9006f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7fb41dc0-3b8b-4d3f-8de1-39b64f38e69e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fde1e103-d867-4ad9-bea5-e1fef0c9006f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eed663b6-23ce-4a7f-ace4-0902e4d908bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fde1e103-d867-4ad9-bea5-e1fef0c9006f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eed663b6-23ce-4a7f-ace4-0902e4d908bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f3046dbc-93b9-4f82-b32c-cae237910047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eed663b6-23ce-4a7f-ace4-0902e4d908bd" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f3046dbc-93b9-4f82-b32c-cae237910047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_036f0742-b1af-4efb-97c0-0eeabe5de70c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f3046dbc-93b9-4f82-b32c-cae237910047" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_036f0742-b1af-4efb-97c0-0eeabe5de70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de77e96b-88ce-4de9-af9f-52a553d8e0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fde1e103-d867-4ad9-bea5-e1fef0c9006f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de77e96b-88ce-4de9-af9f-52a553d8e0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53a31137-8e95-4f62-adf2-cca694bfa452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_de77e96b-88ce-4de9-af9f-52a553d8e0ef" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53a31137-8e95-4f62-adf2-cca694bfa452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_859c82ca-512c-412d-a43b-c745c990bc88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53a31137-8e95-4f62-adf2-cca694bfa452" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_859c82ca-512c-412d-a43b-c745c990bc88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ba714965-ff92-4bf7-b6d3-0c6e54648e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53a31137-8e95-4f62-adf2-cca694bfa452" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ba714965-ff92-4bf7-b6d3-0c6e54648e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2ca87d6c-be59-4464-8b31-778577bf5ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53a31137-8e95-4f62-adf2-cca694bfa452" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2ca87d6c-be59-4464-8b31-778577bf5ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_00672efb-b1d0-4631-b08b-ca6e9397b5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fde1e103-d867-4ad9-bea5-e1fef0c9006f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_00672efb-b1d0-4631-b08b-ca6e9397b5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d9b39800-2291-423b-9dcd-22df66a86f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_00672efb-b1d0-4631-b08b-ca6e9397b5b5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d9b39800-2291-423b-9dcd-22df66a86f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4f1972a1-7b43-4f6d-97a4-6b8e134c7a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d9b39800-2291-423b-9dcd-22df66a86f8f" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4f1972a1-7b43-4f6d-97a4-6b8e134c7a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5db006fc-e823-4b7f-a655-aa4022609d57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fde1e103-d867-4ad9-bea5-e1fef0c9006f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5db006fc-e823-4b7f-a655-aa4022609d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_4fb78468-cba2-405b-86e4-79da146009da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5db006fc-e823-4b7f-a655-aa4022609d57" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_4fb78468-cba2-405b-86e4-79da146009da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2606e847-ab47-453b-94b8-209ea4a7230d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_4fb78468-cba2-405b-86e4-79da146009da" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2606e847-ab47-453b-94b8-209ea4a7230d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5052f5e5-b8d1-415e-a547-867e6e46466c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_4fb78468-cba2-405b-86e4-79da146009da" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5052f5e5-b8d1-415e-a547-867e6e46466c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_fbbfe6f1-782a-46a9-8efb-1507926237d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_4fb78468-cba2-405b-86e4-79da146009da" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_fbbfe6f1-782a-46a9-8efb-1507926237d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_b4d09b44-7c40-4e7a-a052-9185b77edf62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5db006fc-e823-4b7f-a655-aa4022609d57" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_b4d09b44-7c40-4e7a-a052-9185b77edf62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_3e985962-20c8-4479-ab7c-e78e1901cdad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_b4d09b44-7c40-4e7a-a052-9185b77edf62" xlink:to="loc_us-gaap_DerivativeLiabilities_3e985962-20c8-4479-ab7c-e78e1901cdad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_11504fdb-6c24-4721-bfde-337315a71110" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_b4d09b44-7c40-4e7a-a052-9185b77edf62" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_11504fdb-6c24-4721-bfde-337315a71110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/FairValueofFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#FairValueofFinancialInstrumentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/FairValueofFinancialInstrumentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ec9b0cf5-d9b9-45b3-8efa-3622671b147c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1221e614-86bb-40c1-931c-fbf74f9d5684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ec9b0cf5-d9b9-45b3-8efa-3622671b147c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1221e614-86bb-40c1-931c-fbf74f9d5684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ee8df490-25ab-45e9-bdd6-0990f2a6ea1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1221e614-86bb-40c1-931c-fbf74f9d5684" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ee8df490-25ab-45e9-bdd6-0990f2a6ea1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9154c36a-86f4-4ca5-838a-52ede7909810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ee8df490-25ab-45e9-bdd6-0990f2a6ea1a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9154c36a-86f4-4ca5-838a-52ede7909810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollateralAgentPharmakonMember_4ac06bca-eb31-410f-afca-262a9e7e2dfd" xlink:href="akba-20210930.xsd#akba_CollateralAgentPharmakonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9154c36a-86f4-4ca5-838a-52ede7909810" xlink:to="loc_akba_CollateralAgentPharmakonMember_4ac06bca-eb31-410f-afca-262a9e7e2dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7e9c145b-5672-4873-8865-d3b58f0967f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1221e614-86bb-40c1-931c-fbf74f9d5684" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7e9c145b-5672-4873-8865-d3b58f0967f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0977d406-1704-4979-b741-d31a2139e5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7e9c145b-5672-4873-8865-d3b58f0967f5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0977d406-1704-4979-b741-d31a2139e5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0851a3b4-cc63-43f3-87e3-c654715d2c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0977d406-1704-4979-b741-d31a2139e5d5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0851a3b4-cc63-43f3-87e3-c654715d2c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8199b871-9a91-4719-a27f-b33a1f0567eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1221e614-86bb-40c1-931c-fbf74f9d5684" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8199b871-9a91-4719-a27f-b33a1f0567eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d48d2ec-3a78-44a7-bc8a-6103ad570def" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8199b871-9a91-4719-a27f-b33a1f0567eb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d48d2ec-3a78-44a7-bc8a-6103ad570def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OtherThanDerivativeLiabilitiesMember_c7360cc5-566e-4428-8ea1-c796f56524ac" xlink:href="akba-20210930.xsd#akba_OtherThanDerivativeLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d48d2ec-3a78-44a7-bc8a-6103ad570def" xlink:to="loc_akba_OtherThanDerivativeLiabilitiesMember_c7360cc5-566e-4428-8ea1-c796f56524ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2d865857-8038-4ffc-99e9-3cf32a4c7301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1221e614-86bb-40c1-931c-fbf74f9d5684" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2d865857-8038-4ffc-99e9-3cf32a4c7301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_1fc271a8-464e-470d-afdc-7e7069b1bd96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2d865857-8038-4ffc-99e9-3cf32a4c7301" xlink:to="loc_us-gaap_DerivativeLiabilities_1fc271a8-464e-470d-afdc-7e7069b1bd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_96dcbd72-81b2-461a-87e4-b8855c1f24ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2d865857-8038-4ffc-99e9-3cf32a4c7301" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_96dcbd72-81b2-461a-87e4-b8855c1f24ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_76e43b48-8aa0-4cea-b69f-d1ad8bf192d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2d865857-8038-4ffc-99e9-3cf32a4c7301" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_76e43b48-8aa0-4cea-b69f-d1ad8bf192d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/FairValueofFinancialInstrumentsFairValueDerivativeLiabilityDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#FairValueofFinancialInstrumentsFairValueDerivativeLiabilityDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/FairValueofFinancialInstrumentsFairValueDerivativeLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7b83ac5f-1017-4584-9a91-34f57ee8201b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DerivativeLiabilityFairValueGrossLiabilityRollForward_9358fd5b-8137-4da2-b9b2-d98a488893bf" xlink:href="akba-20210930.xsd#akba_DerivativeLiabilityFairValueGrossLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7b83ac5f-1017-4584-9a91-34f57ee8201b" xlink:to="loc_akba_DerivativeLiabilityFairValueGrossLiabilityRollForward_9358fd5b-8137-4da2-b9b2-d98a488893bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_4ea61a4b-b3bf-4216-afd9-826075ab4172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_DerivativeLiabilityFairValueGrossLiabilityRollForward_9358fd5b-8137-4da2-b9b2-d98a488893bf" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_4ea61a4b-b3bf-4216-afd9-826075ab4172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_15ded012-e8a7-41b6-bd2e-a1879de25ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_DerivativeLiabilityFairValueGrossLiabilityRollForward_9358fd5b-8137-4da2-b9b2-d98a488893bf" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_15ded012-e8a7-41b6-bd2e-a1879de25ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_f7494c72-2a7e-4238-9a3e-92d576d523f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_DerivativeLiabilityFairValueGrossLiabilityRollForward_9358fd5b-8137-4da2-b9b2-d98a488893bf" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_f7494c72-2a7e-4238-9a3e-92d576d523f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/Inventory" xlink:type="simple" xlink:href="akba-20210930.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://akebia.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_2d866726-ce6a-492b-acf5-03b5c87fc114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_0b28520f-4ce6-4340-a214-fae4601d4ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2d866726-ce6a-492b-acf5-03b5c87fc114" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_0b28520f-4ce6-4340-a214-fae4601d4ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/InventoryTables" xlink:type="simple" xlink:href="akba-20210930.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://akebia.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_6bde6970-1368-4b65-b1b5-905888c84d31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_defd605a-f337-42f0-948e-04736b674857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6bde6970-1368-4b65-b1b5-905888c84d31" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_defd605a-f337-42f0-948e-04736b674857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/InventoryComponentsofInventoryDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#InventoryComponentsofInventoryDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/InventoryComponentsofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d7879447-6831-42b5-9198-0a2a9395914f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_92f23b75-9431-466a-80e5-be66fdc4befc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d7879447-6831-42b5-9198-0a2a9395914f" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_92f23b75-9431-466a-80e5-be66fdc4befc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_241cec0d-0633-4fd6-a871-b5335da26521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d7879447-6831-42b5-9198-0a2a9395914f" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_241cec0d-0633-4fd6-a871-b5335da26521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_4108c7ae-da57-4498-a099-08cfbfbc6bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d7879447-6831-42b5-9198-0a2a9395914f" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_4108c7ae-da57-4498-a099-08cfbfbc6bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_InventoryNetCurrentAndNonCurrent_920f7f21-baea-44d8-9964-dfc42e2502ac" xlink:href="akba-20210930.xsd#akba_InventoryNetCurrentAndNonCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d7879447-6831-42b5-9198-0a2a9395914f" xlink:to="loc_akba_InventoryNetCurrentAndNonCurrent_920f7f21-baea-44d8-9964-dfc42e2502ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract_2fb22152-6930-477a-a5e9-9d301c7b84ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d7879447-6831-42b5-9198-0a2a9395914f" xlink:to="loc_us-gaap_InventoryNetAbstract_2fb22152-6930-477a-a5e9-9d301c7b84ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0a98f008-ecef-46ff-ad58-0b159d3a48c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_2fb22152-6930-477a-a5e9-9d301c7b84ba" xlink:to="loc_us-gaap_InventoryNet_0a98f008-ecef-46ff-ad58-0b159d3a48c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_3fea4663-d200-4db6-b94f-5d19bddee3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_2fb22152-6930-477a-a5e9-9d301c7b84ba" xlink:to="loc_us-gaap_InventoryNoncurrent_3fea4663-d200-4db6-b94f-5d19bddee3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/InventoryComponentsofInventoryDetails_1" xlink:type="simple" xlink:href="akba-20210930.xsd#InventoryComponentsofInventoryDetails_1"/>
  <link:presentationLink xlink:role="http://akebia.com/role/InventoryComponentsofInventoryDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://akebia.com/role/InventoryAdditionalInformationDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#InventoryAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/InventoryAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1e0f8058-626c-47c1-bb26-ce7f2404c44c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8d968cc8-e010-4eaa-a880-7107fc5f4648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1e0f8058-626c-47c1-bb26-ce7f2404c44c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8d968cc8-e010-4eaa-a880-7107fc5f4648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_71afd362-7774-4316-b109-089b1632473f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8d968cc8-e010-4eaa-a880-7107fc5f4648" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_71afd362-7774-4316-b109-089b1632473f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_395cd714-a7b7-4da1-9d72-3cb27d44a686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_71afd362-7774-4316-b109-089b1632473f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_395cd714-a7b7-4da1-9d72-3cb27d44a686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_KeryxBiopharmaceuticalsIncMember_aaca6163-1f49-4c93-be5c-c832ef717738" xlink:href="akba-20210930.xsd#akba_KeryxBiopharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_395cd714-a7b7-4da1-9d72-3cb27d44a686" xlink:to="loc_akba_KeryxBiopharmaceuticalsIncMember_aaca6163-1f49-4c93-be5c-c832ef717738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5c27fbc9-7581-4945-bac8-9ef9c9196920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8d968cc8-e010-4eaa-a880-7107fc5f4648" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_5c27fbc9-7581-4945-bac8-9ef9c9196920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_8615ef84-360d-45d6-90c6-e5ee2d44cdf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5c27fbc9-7581-4945-bac8-9ef9c9196920" xlink:to="loc_us-gaap_InventoryWriteDown_8615ef84-360d-45d6-90c6-e5ee2d44cdf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_a6bec215-0df8-412c-bbfb-cd2de51add84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5c27fbc9-7581-4945-bac8-9ef9c9196920" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_a6bec215-0df8-412c-bbfb-cd2de51add84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="akba-20210930.xsd#IntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://akebia.com/role/IntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_67f8ddc5-c957-4b38-b9cd-09142c92d194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_d626fd5d-b5d0-49d9-a4cf-5744b896d785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_67f8ddc5-c957-4b38-b9cd-09142c92d194" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_d626fd5d-b5d0-49d9-a4cf-5744b896d785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="akba-20210930.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://akebia.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7f12e002-e5e3-4248-bf6a-0c4a0f5e582d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_2a305d1b-90a7-4ed4-970e-2bd33daf7f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7f12e002-e5e3-4248-bf6a-0c4a0f5e582d" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_2a305d1b-90a7-4ed4-970e-2bd33daf7f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/IntangibleAssetsandGoodwillIntangibleAssetsDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#IntangibleAssetsandGoodwillIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/IntangibleAssetsandGoodwillIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e8a88a01-3c33-42a3-8106-82a04b7a77cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_566307e2-660a-4e62-b2e3-b4bd9111eeb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e8a88a01-3c33-42a3-8106-82a04b7a77cd" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_566307e2-660a-4e62-b2e3-b4bd9111eeb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b9eca029-ad93-457d-b6f4-ff8782beac3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_566307e2-660a-4e62-b2e3-b4bd9111eeb4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b9eca029-ad93-457d-b6f4-ff8782beac3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_386d4df5-3228-4ec8-9e4c-d75fdcd0aaa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b9eca029-ad93-457d-b6f4-ff8782beac3b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_386d4df5-3228-4ec8-9e4c-d75fdcd0aaa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopedProductRightsForAuryxiaMember_059ec177-0099-4148-bf1b-2d67f504f881" xlink:href="akba-20210930.xsd#akba_DevelopedProductRightsForAuryxiaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_386d4df5-3228-4ec8-9e4c-d75fdcd0aaa1" xlink:to="loc_akba_DevelopedProductRightsForAuryxiaMember_059ec177-0099-4148-bf1b-2d67f504f881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketFavorableLeaseMember_527493f2-2d29-4b04-8dfa-47e5ecf152f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffMarketFavorableLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_386d4df5-3228-4ec8-9e4c-d75fdcd0aaa1" xlink:to="loc_us-gaap_OffMarketFavorableLeaseMember_527493f2-2d29-4b04-8dfa-47e5ecf152f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f7cd59b7-5cac-4563-9329-213480ad242b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_566307e2-660a-4e62-b2e3-b4bd9111eeb4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f7cd59b7-5cac-4563-9329-213480ad242b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d50a9749-b5ed-4fc9-8d57-91378b8deb65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f7cd59b7-5cac-4563-9329-213480ad242b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d50a9749-b5ed-4fc9-8d57-91378b8deb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8e308d51-8482-4ccc-a954-e6aa068f2b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f7cd59b7-5cac-4563-9329-213480ad242b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8e308d51-8482-4ccc-a954-e6aa068f2b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_FiniteLivedIntangibleAssetsAdoptionAdjustment_42a01913-562a-4944-a4a9-d89dc050485a" xlink:href="akba-20210930.xsd#akba_FiniteLivedIntangibleAssetsAdoptionAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f7cd59b7-5cac-4563-9329-213480ad242b" xlink:to="loc_akba_FiniteLivedIntangibleAssetsAdoptionAdjustment_42a01913-562a-4944-a4a9-d89dc050485a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cd1b31b7-9097-466e-9397-b591fe04750c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f7cd59b7-5cac-4563-9329-213480ad242b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cd1b31b7-9097-466e-9397-b591fe04750c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_fabc0e76-e159-4e38-8899-6c471de08f71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f7cd59b7-5cac-4563-9329-213480ad242b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_fabc0e76-e159-4e38-8899-6c471de08f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#IntangibleAssetsandGoodwillAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_24a38c78-5b64-4c75-84d4-8b74f92f9ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1c397be0-59de-4b29-96f8-b6de8e555563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_24a38c78-5b64-4c75-84d4-8b74f92f9ffe" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1c397be0-59de-4b29-96f8-b6de8e555563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e4abbaa9-d8e8-4d79-b312-3ea8f1e4fa73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1c397be0-59de-4b29-96f8-b6de8e555563" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e4abbaa9-d8e8-4d79-b312-3ea8f1e4fa73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b20eace3-70ff-4d57-a148-26bede1d9f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e4abbaa9-d8e8-4d79-b312-3ea8f1e4fa73" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b20eace3-70ff-4d57-a148-26bede1d9f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DevelopedProductRightsForAuryxiaMember_619154c9-2904-4115-bdcf-b6e323fbac96" xlink:href="akba-20210930.xsd#akba_DevelopedProductRightsForAuryxiaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b20eace3-70ff-4d57-a148-26bede1d9f8f" xlink:to="loc_akba_DevelopedProductRightsForAuryxiaMember_619154c9-2904-4115-bdcf-b6e323fbac96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4acb5b2e-a74b-43c3-8de9-903a4a4c32b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1c397be0-59de-4b29-96f8-b6de8e555563" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4acb5b2e-a74b-43c3-8de9-903a4a4c32b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_fad65e35-c53f-4574-aba7-2439bbaefac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4acb5b2e-a74b-43c3-8de9-903a4a4c32b5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_fad65e35-c53f-4574-aba7-2439bbaefac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d561bc82-53cb-4f3a-99d9-c980198f0240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4acb5b2e-a74b-43c3-8de9-903a4a4c32b5" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d561bc82-53cb-4f3a-99d9-c980198f0240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_dbeade6c-f28f-4aaf-bb0c-5912c5aa2521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4acb5b2e-a74b-43c3-8de9-903a4a4c32b5" xlink:to="loc_us-gaap_Goodwill_dbeade6c-f28f-4aaf-bb0c-5912c5aa2521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_83dd35a2-a535-4c67-b6d1-c057e6d58396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4acb5b2e-a74b-43c3-8de9-903a4a4c32b5" xlink:to="loc_us-gaap_NumberOfOperatingSegments_83dd35a2-a535-4c67-b6d1-c057e6d58396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_4e2050b0-4232-4292-87a7-fdd79b4f24ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4acb5b2e-a74b-43c3-8de9-903a4a4c32b5" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_4e2050b0-4232-4292-87a7-fdd79b4f24ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/AccruedExpenses" xlink:type="simple" xlink:href="akba-20210930.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://akebia.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_51f59061-f0ae-4982-92d5-eeb3c130f114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_57564cff-a2fc-482a-9e91-0114c0ce9bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_51f59061-f0ae-4982-92d5-eeb3c130f114" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_57564cff-a2fc-482a-9e91-0114c0ce9bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="akba-20210930.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://akebia.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_73e99f0f-6a6c-439b-af0e-5a5b40d97823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_14995df6-d185-4ad1-a8e9-1ba465c2b4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_73e99f0f-6a6c-439b-af0e-5a5b40d97823" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_14995df6-d185-4ad1-a8e9-1ba465c2b4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_2a2d4488-d524-45fe-bc05-3dae46102015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AccruedProductRevenueAllowancesCurrent_e4b53dd3-7b6c-47bf-8bf9-9bfcd1bff536" xlink:href="akba-20210930.xsd#akba_AccruedProductRevenueAllowancesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2a2d4488-d524-45fe-bc05-3dae46102015" xlink:to="loc_akba_AccruedProductRevenueAllowancesCurrent_e4b53dd3-7b6c-47bf-8bf9-9bfcd1bff536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AccruedClinicalExpensesCurrent_fea6b942-9b36-4626-b177-19426e4c1c01" xlink:href="akba-20210930.xsd#akba_AccruedClinicalExpensesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2a2d4488-d524-45fe-bc05-3dae46102015" xlink:to="loc_akba_AccruedClinicalExpensesCurrent_fea6b942-9b36-4626-b177-19426e4c1c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeArrangementAccruedLiability_9d5b9c80-e71c-4c8e-814e-a4df57228aae" xlink:href="akba-20210930.xsd#akba_CollaborativeArrangementAccruedLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2a2d4488-d524-45fe-bc05-3dae46102015" xlink:to="loc_akba_CollaborativeArrangementAccruedLiability_9d5b9c80-e71c-4c8e-814e-a4df57228aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher_c6f34930-b889-4e07-9683-b44d63a54a3c" xlink:href="akba-20210930.xsd#akba_CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2a2d4488-d524-45fe-bc05-3dae46102015" xlink:to="loc_akba_CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher_c6f34930-b889-4e07-9683-b44d63a54a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4628f8f0-260a-4806-84d3-638c5786c2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2a2d4488-d524-45fe-bc05-3dae46102015" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4628f8f0-260a-4806-84d3-638c5786c2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7605aa5f-54b7-4650-adcd-d3f78f06f431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2a2d4488-d524-45fe-bc05-3dae46102015" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7605aa5f-54b7-4650-adcd-d3f78f06f431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_dcac2b38-5c50-4755-af4a-83a0cea8e4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2a2d4488-d524-45fe-bc05-3dae46102015" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_dcac2b38-5c50-4755-af4a-83a0cea8e4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_a2012f08-c625-4503-882f-997f5bb63e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2a2d4488-d524-45fe-bc05-3dae46102015" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_a2012f08-c625-4503-882f-997f5bb63e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_47138481-50ae-40a5-b4c7-8b3702b64094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2a2d4488-d524-45fe-bc05-3dae46102015" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_47138481-50ae-40a5-b4c7-8b3702b64094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AccruedCommercialManufacturingCurrent_ff4f2c53-aad4-427d-9992-cff3b71420dc" xlink:href="akba-20210930.xsd#akba_AccruedCommercialManufacturingCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2a2d4488-d524-45fe-bc05-3dae46102015" xlink:to="loc_akba_AccruedCommercialManufacturingCurrent_ff4f2c53-aad4-427d-9992-cff3b71420dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_dda9016d-e689-4f98-998b-bac50aa320c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2a2d4488-d524-45fe-bc05-3dae46102015" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_dda9016d-e689-4f98-998b-bac50aa320c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_295fce71-d5f3-46fe-ac15-71baabccbdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2a2d4488-d524-45fe-bc05-3dae46102015" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_295fce71-d5f3-46fe-ac15-71baabccbdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/Debt" xlink:type="simple" xlink:href="akba-20210930.xsd#Debt"/>
  <link:presentationLink xlink:role="http://akebia.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_341f77e4-7485-413a-a174-a74a248a6253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_5289d654-4bb7-4106-a373-ad7d45478cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_341f77e4-7485-413a-a174-a74a248a6253" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_5289d654-4bb7-4106-a373-ad7d45478cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/DebtDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#DebtDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4ffe7e9d-b6d9-456b-8adc-a7a9351b6b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_581c3e52-199d-4950-af61-e511f566f8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4ffe7e9d-b6d9-456b-8adc-a7a9351b6b62" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_581c3e52-199d-4950-af61-e511f566f8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_d9164b34-651e-4300-bc1a-dff88eac9221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_581c3e52-199d-4950-af61-e511f566f8f0" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_d9164b34-651e-4300-bc1a-dff88eac9221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_058bf54a-bd1b-4a35-81cd-b776caa7a339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_d9164b34-651e-4300-bc1a-dff88eac9221" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_058bf54a-bd1b-4a35-81cd-b776caa7a339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember_f314f227-cec4-457f-82c2-51d8b43c334e" xlink:href="akba-20210930.xsd#akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_058bf54a-bd1b-4a35-81cd-b776caa7a339" xlink:to="loc_akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember_f314f227-cec4-457f-82c2-51d8b43c334e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_BPCRLimitedPartnershipMember_545d22cf-6abe-4558-99b0-ec766c8a99be" xlink:href="akba-20210930.xsd#akba_BPCRLimitedPartnershipMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_058bf54a-bd1b-4a35-81cd-b776caa7a339" xlink:to="loc_akba_BPCRLimitedPartnershipMember_545d22cf-6abe-4558-99b0-ec766c8a99be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_3854876e-0503-4e63-ae04-3ad95dfbff5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsByNatureAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_581c3e52-199d-4950-af61-e511f566f8f0" xlink:to="loc_us-gaap_GuaranteeObligationsByNatureAxis_3854876e-0503-4e63-ae04-3ad95dfbff5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_ac6ef5d5-bd18-48fe-8afc-0b0b4297da88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_3854876e-0503-4e63-ae04-3ad95dfbff5b" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_ac6ef5d5-bd18-48fe-8afc-0b0b4297da88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_KeryxMember_30aa19b2-99e3-49ea-b3ac-d0cb19fd10bf" xlink:href="akba-20210930.xsd#akba_KeryxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_ac6ef5d5-bd18-48fe-8afc-0b0b4297da88" xlink:to="loc_akba_KeryxMember_30aa19b2-99e3-49ea-b3ac-d0cb19fd10bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_27983b99-6e8c-4dee-8254-b7e37345f518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_581c3e52-199d-4950-af61-e511f566f8f0" xlink:to="loc_us-gaap_CreditFacilityAxis_27983b99-6e8c-4dee-8254-b7e37345f518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7f5ab425-9271-418d-844d-dba0250faeef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_27983b99-6e8c-4dee-8254-b7e37345f518" xlink:to="loc_us-gaap_CreditFacilityDomain_7f5ab425-9271-418d-844d-dba0250faeef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_TermLoanMember_90754df0-2917-49f6-a7a2-5532a7d4a556" xlink:href="akba-20210930.xsd#akba_TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_7f5ab425-9271-418d-844d-dba0250faeef" xlink:to="loc_akba_TermLoanMember_90754df0-2917-49f6-a7a2-5532a7d4a556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_988a0004-7363-4e41-8326-7bd7ab936f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_581c3e52-199d-4950-af61-e511f566f8f0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_988a0004-7363-4e41-8326-7bd7ab936f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5cc7390c-a554-4490-aad6-05718cddafd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_988a0004-7363-4e41-8326-7bd7ab936f5e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5cc7390c-a554-4490-aad6-05718cddafd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CollateralAgentPharmakonMember_9bca521d-fb60-4ea4-ac41-07850c3fd195" xlink:href="akba-20210930.xsd#akba_CollateralAgentPharmakonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5cc7390c-a554-4490-aad6-05718cddafd3" xlink:to="loc_akba_CollateralAgentPharmakonMember_9bca521d-fb60-4ea4-ac41-07850c3fd195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3f337262-17eb-418c-95b8-4cdd9d228796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_581c3e52-199d-4950-af61-e511f566f8f0" xlink:to="loc_us-gaap_DebtInstrumentAxis_3f337262-17eb-418c-95b8-4cdd9d228796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4b5e15d8-1645-443c-85c2-4b7b2497792f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3f337262-17eb-418c-95b8-4cdd9d228796" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4b5e15d8-1645-443c-85c2-4b7b2497792f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_TrancheAMember_78af4c06-da50-4407-b092-0c3d48d4e44d" xlink:href="akba-20210930.xsd#akba_TrancheAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4b5e15d8-1645-443c-85c2-4b7b2497792f" xlink:to="loc_akba_TrancheAMember_78af4c06-da50-4407-b092-0c3d48d4e44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_TrancheBMember_713c87c5-6b4c-4413-80bb-a602a5789c85" xlink:href="akba-20210930.xsd#akba_TrancheBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4b5e15d8-1645-443c-85c2-4b7b2497792f" xlink:to="loc_akba_TrancheBMember_713c87c5-6b4c-4413-80bb-a602a5789c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_52211f79-4f7e-4f78-80ad-7b7f912389a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_581c3e52-199d-4950-af61-e511f566f8f0" xlink:to="loc_us-gaap_VariableRateAxis_52211f79-4f7e-4f78-80ad-7b7f912389a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_00012e84-8414-4c3f-b2fe-7c52f239940f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_52211f79-4f7e-4f78-80ad-7b7f912389a0" xlink:to="loc_us-gaap_VariableRateDomain_00012e84-8414-4c3f-b2fe-7c52f239940f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ThreeMonthLondonInterbankOfferedRateMember_5f747a41-4d32-4865-be40-11b59a6fda9c" xlink:href="akba-20210930.xsd#akba_ThreeMonthLondonInterbankOfferedRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_00012e84-8414-4c3f-b2fe-7c52f239940f" xlink:to="loc_akba_ThreeMonthLondonInterbankOfferedRateMember_5f747a41-4d32-4865-be40-11b59a6fda9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_15bffa48-a346-4379-8f51-73e883c9ea0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_00012e84-8414-4c3f-b2fe-7c52f239940f" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_15bffa48-a346-4379-8f51-73e883c9ea0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis_2bb5e0b2-c911-4aac-acd9-7cd119dd9627" xlink:href="akba-20210930.xsd#akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_581c3e52-199d-4950-af61-e511f566f8f0" xlink:to="loc_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis_2bb5e0b2-c911-4aac-acd9-7cd119dd9627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain_19559ec4-0c99-46da-99ca-453dd3701ebc" xlink:href="akba-20210930.xsd#akba_DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis_2bb5e0b2-c911-4aac-acd9-7cd119dd9627" xlink:to="loc_akba_DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain_19559ec4-0c99-46da-99ca-453dd3701ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodOneMember_e7258256-2ef6-4031-ab41-397c12444d23" xlink:href="akba-20210930.xsd#akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain_19559ec4-0c99-46da-99ca-453dd3701ebc" xlink:to="loc_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodOneMember_e7258256-2ef6-4031-ab41-397c12444d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodTwoMember_24cd0a55-9f5a-4c9d-a96e-cabbdb653c25" xlink:href="akba-20210930.xsd#akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain_19559ec4-0c99-46da-99ca-453dd3701ebc" xlink:to="loc_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodTwoMember_24cd0a55-9f5a-4c9d-a96e-cabbdb653c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_581c3e52-199d-4950-af61-e511f566f8f0" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1732856d-8a94-4922-8772-b0eae2887478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1732856d-8a94-4922-8772-b0eae2887478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches_77c2313f-35ed-44ee-a8b8-c4a5cc3bb8b0" xlink:href="akba-20210930.xsd#akba_LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_akba_LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches_77c2313f-35ed-44ee-a8b8-c4a5cc3bb8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f0e3046d-47fc-47dd-9950-5b67f1deff41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f0e3046d-47fc-47dd-9950-5b67f1deff41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentFloorRate_0e64ec37-7096-46c6-a8eb-d80169874fe4" xlink:href="akba-20210930.xsd#akba_DebtInstrumentFloorRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_akba_DebtInstrumentFloorRate_0e64ec37-7096-46c6-a8eb-d80169874fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentCapRate_e17a02c8-d9ff-4931-8810-faa608646586" xlink:href="akba-20210930.xsd#akba_DebtInstrumentCapRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_akba_DebtInstrumentCapRate_e17a02c8-d9ff-4931-8810-faa608646586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_aa151d5b-d8fb-4245-ae26-d2f0f39f7939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_us-gaap_DebtInstrumentTerm_aa151d5b-d8fb-4245-ae26-d2f0f39f7939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm_40207454-d8b0-4f78-bd4b-71068ddf2d34" xlink:href="akba-20210930.xsd#akba_LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_akba_LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm_40207454-d8b0-4f78-bd4b-71068ddf2d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentCovenantTermsPotentialMaturityTermReduction_f557ec1d-30ad-4fe0-8699-7ff4cd31aaf9" xlink:href="akba-20210930.xsd#akba_DebtInstrumentCovenantTermsPotentialMaturityTermReduction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_akba_DebtInstrumentCovenantTermsPotentialMaturityTermReduction_f557ec1d-30ad-4fe0-8699-7ff4cd31aaf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction_ae485e45-7dd4-4b31-8767-6c6056594369" xlink:href="akba-20210930.xsd#akba_DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_akba_DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction_ae485e45-7dd4-4b31-8767-6c6056594369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_FacilityFeePercentagePaidOnPrincipalAmount_c4a9f31d-7bfe-40a9-a108-da4a7d5dda82" xlink:href="akba-20210930.xsd#akba_FacilityFeePercentagePaidOnPrincipalAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_akba_FacilityFeePercentagePaidOnPrincipalAmount_c4a9f31d-7bfe-40a9-a108-da4a7d5dda82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_DebtInstrumentFacilityFeePaid_27169481-85d7-4c2a-a357-138fcde48641" xlink:href="akba-20210930.xsd#akba_DebtInstrumentFacilityFeePaid"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_akba_DebtInstrumentFacilityFeePaid_27169481-85d7-4c2a-a357-138fcde48641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_275bb9f2-e656-46e3-b73a-0f32f68a1571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_us-gaap_LongTermDebt_275bb9f2-e656-46e3-b73a-0f32f68a1571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_d1ad20e2-0dff-4767-a73a-a6c9e67eae9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_d1ad20e2-0dff-4767-a73a-a6c9e67eae9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding_96fbb545-eae3-4600-a18c-78b980138d42" xlink:href="akba-20210930.xsd#akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding_96fbb545-eae3-4600-a18c-78b980138d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding_6e191486-adf4-4e40-9c88-29b0479674b4" xlink:href="akba-20210930.xsd#akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding_6e191486-adf4-4e40-9c88-29b0479674b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding_7820c4c4-39b2-472f-b3e7-db0b69fb38bb" xlink:href="akba-20210930.xsd#akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding_7820c4c4-39b2-472f-b3e7-db0b69fb38bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_6eb16b4b-e205-4e10-8b6a-a9a8261fb640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_us-gaap_DerivativeLiabilities_6eb16b4b-e205-4e10-8b6a-a9a8261fb640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_2439c2a3-10be-4080-93ba-c8baa4be57ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7ff49ff7-3d1f-43bc-89b0-3f9e8f5919dc" xlink:to="loc_us-gaap_InterestExpenseDebt_2439c2a3-10be-4080-93ba-c8baa4be57ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/Warrant" xlink:type="simple" xlink:href="akba-20210930.xsd#Warrant"/>
  <link:presentationLink xlink:role="http://akebia.com/role/Warrant" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_d7609b55-792a-4d19-9595-735483f378b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_WarrantDisclosureTextBlock_90886e70-f0e1-4dcd-a319-8042e01338ff" xlink:href="akba-20210930.xsd#akba_WarrantDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_d7609b55-792a-4d19-9595-735483f378b9" xlink:to="loc_akba_WarrantDisclosureTextBlock_90886e70-f0e1-4dcd-a319-8042e01338ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/WarrantDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#WarrantDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/WarrantDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_19d473aa-c3e3-4c42-9595-1922aa5827b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_f32d6fa2-63b5-4180-ac70-717f09334b10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_19d473aa-c3e3-4c42-9595-1922aa5827b0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_f32d6fa2-63b5-4180-ac70-717f09334b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9f2b5888-bde8-487a-a74f-65b246782913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f32d6fa2-63b5-4180-ac70-717f09334b10" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9f2b5888-bde8-487a-a74f-65b246782913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5379ccae-fb2e-40f8-b879-fcd4b9156642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9f2b5888-bde8-487a-a74f-65b246782913" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5379ccae-fb2e-40f8-b879-fcd4b9156642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_JanssenAgreementMember_df772d3d-ea9f-4138-9071-4f991eb8739a" xlink:href="akba-20210930.xsd#akba_JanssenAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5379ccae-fb2e-40f8-b879-fcd4b9156642" xlink:to="loc_akba_JanssenAgreementMember_df772d3d-ea9f-4138-9071-4f991eb8739a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_7ad1a9d0-df5a-4dbc-8b73-2c08f3ab865b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_f32d6fa2-63b5-4180-ac70-717f09334b10" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_7ad1a9d0-df5a-4dbc-8b73-2c08f3ab865b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_54de4581-490e-47c0-8b12-4e4a4db3a4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_7ad1a9d0-df5a-4dbc-8b73-2c08f3ab865b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_54de4581-490e-47c0-8b12-4e4a4db3a4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f6c506df-d182-4e5c-942d-f9690d02510b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_7ad1a9d0-df5a-4dbc-8b73-2c08f3ab865b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f6c506df-d182-4e5c-942d-f9690d02510b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_ede672cd-e52e-42b8-8b34-dfa2277df838" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_7ad1a9d0-df5a-4dbc-8b73-2c08f3ab865b" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_ede672cd-e52e-42b8-8b34-dfa2277df838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/StockholdersEquity" xlink:type="simple" xlink:href="akba-20210930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://akebia.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a0c33b78-4f0a-40b2-88f9-acb2b9ea3769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_92fee1c4-c90b-46ad-ad5c-8c94741e2ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a0c33b78-4f0a-40b2-88f9-acb2b9ea3769" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_92fee1c4-c90b-46ad-ad5c-8c94741e2ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_af686429-be21-464f-9325-22537b8d6192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_8ae6b429-71cb-4a94-9399-8cb4f5ee8876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_af686429-be21-464f-9325-22537b8d6192" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_8ae6b429-71cb-4a94-9399-8cb4f5ee8876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_34ca0a79-e4cc-4f1d-ae55-c454fb5e1501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8ae6b429-71cb-4a94-9399-8cb4f5ee8876" xlink:to="loc_us-gaap_PlanNameAxis_34ca0a79-e4cc-4f1d-ae55-c454fb5e1501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_aafcb1e5-c06f-4598-855d-5ed014773055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_34ca0a79-e4cc-4f1d-ae55-c454fb5e1501" xlink:to="loc_us-gaap_PlanNameDomain_aafcb1e5-c06f-4598-855d-5ed014773055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AtTheMarketEquityOfferingProgramMember_d1a226fb-a324-40e3-b249-c6d1769428d4" xlink:href="akba-20210930.xsd#akba_AtTheMarketEquityOfferingProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_aafcb1e5-c06f-4598-855d-5ed014773055" xlink:to="loc_akba_AtTheMarketEquityOfferingProgramMember_d1a226fb-a324-40e3-b249-c6d1769428d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_TwoThousandAndFourteenPlansMember_dd80e4e3-687d-4326-a6e6-df61b7cd922f" xlink:href="akba-20210930.xsd#akba_TwoThousandAndFourteenPlansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_aafcb1e5-c06f-4598-855d-5ed014773055" xlink:to="loc_akba_TwoThousandAndFourteenPlansMember_dd80e4e3-687d-4326-a6e6-df61b7cd922f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_793f46dd-cc44-4277-bc06-cdc8e1242d88" xlink:href="akba-20210930.xsd#akba_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_aafcb1e5-c06f-4598-855d-5ed014773055" xlink:to="loc_akba_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_793f46dd-cc44-4277-bc06-cdc8e1242d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5ea6a566-e2b5-4476-a302-7fbd08fe0dcb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8ae6b429-71cb-4a94-9399-8cb4f5ee8876" xlink:to="loc_srt_RangeAxis_5ea6a566-e2b5-4476-a302-7fbd08fe0dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3b3262f3-6fb8-4473-91fa-12e9ca2b5116" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5ea6a566-e2b5-4476-a302-7fbd08fe0dcb" xlink:to="loc_srt_RangeMember_3b3262f3-6fb8-4473-91fa-12e9ca2b5116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9cf91ef2-a405-45fe-8c95-01a8b5e15e74" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3b3262f3-6fb8-4473-91fa-12e9ca2b5116" xlink:to="loc_srt_MinimumMember_9cf91ef2-a405-45fe-8c95-01a8b5e15e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_42e1629f-a520-42e4-b56e-7513e2505d9e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3b3262f3-6fb8-4473-91fa-12e9ca2b5116" xlink:to="loc_srt_MaximumMember_42e1629f-a520-42e4-b56e-7513e2505d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_17fe126a-56b8-4490-af00-891d73aa15cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8ae6b429-71cb-4a94-9399-8cb4f5ee8876" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_17fe126a-56b8-4490-af00-891d73aa15cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b8eda34d-f8c9-4c42-95a3-8c87ad3f46da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_17fe126a-56b8-4490-af00-891d73aa15cd" xlink:to="loc_us-gaap_EquityComponentDomain_b8eda34d-f8c9-4c42-95a3-8c87ad3f46da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c027e1d4-a722-491a-9aa0-518aabe926ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8eda34d-f8c9-4c42-95a3-8c87ad3f46da" xlink:to="loc_us-gaap_CommonStockMember_c027e1d4-a722-491a-9aa0-518aabe926ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1787264d-7453-4a7e-9800-381e978c53b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8ae6b429-71cb-4a94-9399-8cb4f5ee8876" xlink:to="loc_us-gaap_AwardTypeAxis_1787264d-7453-4a7e-9800-381e978c53b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d675b3ce-a1ce-425c-9ed2-d448ac2f338d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1787264d-7453-4a7e-9800-381e978c53b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d675b3ce-a1ce-425c-9ed2-d448ac2f338d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_InducementAwardProgramMember_40cf7c52-4da1-45d2-a0cd-c34f30ac6ccf" xlink:href="akba-20210930.xsd#akba_InducementAwardProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d675b3ce-a1ce-425c-9ed2-d448ac2f338d" xlink:to="loc_akba_InducementAwardProgramMember_40cf7c52-4da1-45d2-a0cd-c34f30ac6ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ab27a0e6-b095-4a53-96f4-5acc75bdd132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d675b3ce-a1ce-425c-9ed2-d448ac2f338d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ab27a0e6-b095-4a53-96f4-5acc75bdd132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_68e6d51d-fe75-407c-84de-ad552a7daf34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d675b3ce-a1ce-425c-9ed2-d448ac2f338d" xlink:to="loc_us-gaap_PerformanceSharesMember_68e6d51d-fe75-407c-84de-ad552a7daf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ServiceBasedRestrictedStockUnitsMember_39169fe0-08d5-41d8-b8dd-824c0e99ca4a" xlink:href="akba-20210930.xsd#akba_ServiceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d675b3ce-a1ce-425c-9ed2-d448ac2f338d" xlink:to="loc_akba_ServiceBasedRestrictedStockUnitsMember_39169fe0-08d5-41d8-b8dd-824c0e99ca4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PerformanceBasedRestrictedStockUnitsMember_f8f87132-ad7d-4ed4-ac65-662dc4cc0cdd" xlink:href="akba-20210930.xsd#akba_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d675b3ce-a1ce-425c-9ed2-d448ac2f338d" xlink:to="loc_akba_PerformanceBasedRestrictedStockUnitsMember_f8f87132-ad7d-4ed4-ac65-662dc4cc0cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_01e36c5d-b09a-455e-a50b-69e3d4781c3c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8ae6b429-71cb-4a94-9399-8cb4f5ee8876" xlink:to="loc_srt_TitleOfIndividualAxis_01e36c5d-b09a-455e-a50b-69e3d4781c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cf77b429-5384-4664-888d-8b64da4212a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_01e36c5d-b09a-455e-a50b-69e3d4781c3c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cf77b429-5384-4664-888d-8b64da4212a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_EmployeesMember_b52be249-da83-4f15-8c32-683d5224b04e" xlink:href="akba-20210930.xsd#akba_EmployeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cf77b429-5384-4664-888d-8b64da4212a9" xlink:to="loc_akba_EmployeesMember_b52be249-da83-4f15-8c32-683d5224b04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_74eb1763-7317-4755-a7ba-0d47cee685da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cf77b429-5384-4664-888d-8b64da4212a9" xlink:to="loc_srt_DirectorMember_74eb1763-7317-4755-a7ba-0d47cee685da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_5b375371-1d4e-495a-a855-e9fd8d8c4fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8ae6b429-71cb-4a94-9399-8cb4f5ee8876" xlink:to="loc_us-gaap_VestingAxis_5b375371-1d4e-495a-a855-e9fd8d8c4fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_8c9268d0-8cb8-4cf1-90d5-8157de831e97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_5b375371-1d4e-495a-a855-e9fd8d8c4fb3" xlink:to="loc_us-gaap_VestingDomain_8c9268d0-8cb8-4cf1-90d5-8157de831e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMember_d54c203b-9db1-4ebd-9a1a-d26fede9cf93" xlink:href="akba-20210930.xsd#akba_ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_8c9268d0-8cb8-4cf1-90d5-8157de831e97" xlink:to="loc_akba_ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMember_d54c203b-9db1-4ebd-9a1a-d26fede9cf93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_ca6eb036-587d-4736-8939-84a9a20f109a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_8c9268d0-8cb8-4cf1-90d5-8157de831e97" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_ca6eb036-587d-4736-8939-84a9a20f109a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_7a82ca01-93eb-42c0-9591-b93e002aaea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_8c9268d0-8cb8-4cf1-90d5-8157de831e97" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_7a82ca01-93eb-42c0-9591-b93e002aaea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember_e45f0c9e-9fe2-46e0-85e3-0376a80bf1c7" xlink:href="akba-20210930.xsd#akba_ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_8c9268d0-8cb8-4cf1-90d5-8157de831e97" xlink:to="loc_akba_ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember_e45f0c9e-9fe2-46e0-85e3-0376a80bf1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember_b834fe56-2ad6-43d6-9ca6-c9eb583ceffb" xlink:href="akba-20210930.xsd#akba_ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_8c9268d0-8cb8-4cf1-90d5-8157de831e97" xlink:to="loc_akba_ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember_b834fe56-2ad6-43d6-9ca6-c9eb583ceffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ShareBasedPaymentArrangementTrancheTwoSecondAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember_98e9d71f-f9ee-4821-8fb4-a37fdd2b1e6c" xlink:href="akba-20210930.xsd#akba_ShareBasedPaymentArrangementTrancheTwoSecondAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_8c9268d0-8cb8-4cf1-90d5-8157de831e97" xlink:to="loc_akba_ShareBasedPaymentArrangementTrancheTwoSecondAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember_98e9d71f-f9ee-4821-8fb4-a37fdd2b1e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ShareBasedPaymentArrangementTrancheThreeThirdAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember_2cb6a9dd-b4a0-4bfc-ab70-43014af316b7" xlink:href="akba-20210930.xsd#akba_ShareBasedPaymentArrangementTrancheThreeThirdAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_8c9268d0-8cb8-4cf1-90d5-8157de831e97" xlink:to="loc_akba_ShareBasedPaymentArrangementTrancheThreeThirdAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember_2cb6a9dd-b4a0-4bfc-ab70-43014af316b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8655467e-f4b5-4991-a6a3-dccdb40ceb89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8ae6b429-71cb-4a94-9399-8cb4f5ee8876" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8655467e-f4b5-4991-a6a3-dccdb40ceb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a70c63b1-e48f-4ff9-89e9-a422ecf0d591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8655467e-f4b5-4991-a6a3-dccdb40ceb89" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a70c63b1-e48f-4ff9-89e9-a422ecf0d591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member_aa506806-bdf3-492e-88e3-a0e9c3607afb" xlink:href="akba-20210930.xsd#akba_AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a70c63b1-e48f-4ff9-89e9-a422ecf0d591" xlink:to="loc_akba_AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member_aa506806-bdf3-492e-88e3-a0e9c3607afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8ae6b429-71cb-4a94-9399-8cb4f5ee8876" xlink:to="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f7d5deea-ba4e-4fab-bb3f-3d9aab12e317" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f7d5deea-ba4e-4fab-bb3f-3d9aab12e317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5607ce88-e4d0-410e-8cf5-f9bae99e6f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5607ce88-e4d0-410e-8cf5-f9bae99e6f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_734752ad-f97b-4c01-9d44-c0b14f855e42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_CommonStockSharesIssued_734752ad-f97b-4c01-9d44-c0b14f855e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2be3a260-9a6c-444d-bd83-2c3b68ebbad4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2be3a260-9a6c-444d-bd83-2c3b68ebbad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9a84d183-ad73-4d27-8cd5-b6311d59e540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9a84d183-ad73-4d27-8cd5-b6311d59e540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c0fa019a-be37-48ad-9cb3-4613a7f17223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c0fa019a-be37-48ad-9cb3-4613a7f17223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_ecf7e8ff-438e-4942-9221-5fac94e82587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_PreferredStockSharesIssued_ecf7e8ff-438e-4942-9221-5fac94e82587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f7711fc4-8fda-4f1a-94e9-0f555568bf32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f7711fc4-8fda-4f1a-94e9-0f555568bf32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CommonStockSalesAgreementAmount_fc18fa37-2a6a-4e2a-be23-fb7fb4cfdf3d" xlink:href="akba-20210930.xsd#akba_CommonStockSalesAgreementAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_akba_CommonStockSalesAgreementAmount_fc18fa37-2a6a-4e2a-be23-fb7fb4cfdf3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8f2e0218-14a9-4886-978c-57bee0ea144f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8f2e0218-14a9-4886-978c-57bee0ea144f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_86f29b29-674a-43b6-8427-ba5d680351ec" xlink:href="akba-20210930.xsd#akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_86f29b29-674a-43b6-8427-ba5d680351ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9e4579ed-da8b-4777-9cc1-8df19162586b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9e4579ed-da8b-4777-9cc1-8df19162586b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9620d562-d30c-4d17-bd0f-b764a08956af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9620d562-d30c-4d17-bd0f-b764a08956af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a03660ee-3f81-489f-a76f-e4fa13344ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a03660ee-3f81-489f-a76f-e4fa13344ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding_ed3b2543-85ef-4cee-97c3-a3ff2cfaa0a6" xlink:href="akba-20210930.xsd#akba_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_akba_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding_ed3b2543-85ef-4cee-97c3-a3ff2cfaa0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5d3241a6-e963-482e-b8d9-18d1bf2a9332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5d3241a6-e963-482e-b8d9-18d1bf2a9332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d3f19b77-4d2e-4d60-a292-fc08fa635a77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d3f19b77-4d2e-4d60-a292-fc08fa635a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments_a4d8bb54-f1f4-476f-8ef3-dc090bb729bb" xlink:href="akba-20210930.xsd#akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments_a4d8bb54-f1f4-476f-8ef3-dc090bb729bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f423f007-2ec6-4757-9fd8-bb63af695bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f423f007-2ec6-4757-9fd8-bb63af695bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6c1daf8d-af54-453b-ac26-c10a6ee3a7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6c1daf8d-af54-453b-ac26-c10a6ee3a7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod_f45f44e1-cf54-4fa6-ba59-b908370e86c2" xlink:href="akba-20210930.xsd#akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod_f45f44e1-cf54-4fa6-ba59-b908370e86c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_966a2391-639c-4ab7-b92b-40e5d4d68223" xlink:href="akba-20210930.xsd#akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_966a2391-639c-4ab7-b92b-40e5d4d68223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_8b8f3e9f-a033-4a32-b915-bb561da45feb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_8b8f3e9f-a033-4a32-b915-bb561da45feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_272a56be-cf37-4782-a4ce-ef36daa1980d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71540b34-e06c-448d-9cf1-e89276cc5011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_272a56be-cf37-4782-a4ce-ef36daa1980d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="akba-20210930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://akebia.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4730a547-3ec1-4625-95b4-ab8a594fb317" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4f9a892a-b5dc-461a-bd30-e39498bee220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4730a547-3ec1-4625-95b4-ab8a594fb317" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4f9a892a-b5dc-461a-bd30-e39498bee220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="akba-20210930.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://akebia.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9c926dee-8a80-417c-ac69-2b49f0110b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_121856f9-3ff7-4b8e-8fef-7896f7874750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9c926dee-8a80-417c-ac69-2b49f0110b4f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_121856f9-3ff7-4b8e-8fef-7896f7874750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ScheduleOfDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesAndOperatingLeaseLiabilitiesTableTextBlock_abc6cebb-3cd8-4937-9617-472e01d07f37" xlink:href="akba-20210930.xsd#akba_ScheduleOfDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesAndOperatingLeaseLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9c926dee-8a80-417c-ac69-2b49f0110b4f" xlink:to="loc_akba_ScheduleOfDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesAndOperatingLeaseLiabilitiesTableTextBlock_abc6cebb-3cd8-4937-9617-472e01d07f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1548b913-1565-4752-b0ef-9c971ce7a693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CommitmentsAndContingenciesTable_9b89688e-26e9-4d76-92d7-1a770d087bbb" xlink:href="akba-20210930.xsd#akba_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1548b913-1565-4752-b0ef-9c971ce7a693" xlink:to="loc_akba_CommitmentsAndContingenciesTable_9b89688e-26e9-4d76-92d7-1a770d087bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_831f8bb2-46ce-47aa-825a-e2a823d2c75e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesTable_9b89688e-26e9-4d76-92d7-1a770d087bbb" xlink:to="loc_srt_StatementGeographicalAxis_831f8bb2-46ce-47aa-825a-e2a823d2c75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4fcf4bd2-f9f5-46ed-988f-a41c106a8967" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_831f8bb2-46ce-47aa-825a-e2a823d2c75e" xlink:to="loc_srt_SegmentGeographicalDomain_4fcf4bd2-f9f5-46ed-988f-a41c106a8967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CambridgeMember_a91f0d01-783b-47b9-ad69-b0c2ea2edc0b" xlink:href="akba-20210930.xsd#akba_CambridgeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4fcf4bd2-f9f5-46ed-988f-a41c106a8967" xlink:to="loc_akba_CambridgeMember_a91f0d01-783b-47b9-ad69-b0c2ea2edc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_BostonMember_1e45a5a6-cb20-4908-8df9-742afd0803fb" xlink:href="akba-20210930.xsd#akba_BostonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4fcf4bd2-f9f5-46ed-988f-a41c106a8967" xlink:to="loc_akba_BostonMember_1e45a5a6-cb20-4908-8df9-742afd0803fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ee7a6e53-afce-4476-887c-5d96600563c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesTable_9b89688e-26e9-4d76-92d7-1a770d087bbb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ee7a6e53-afce-4476-887c-5d96600563c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2f0d9e53-c87a-45b3-bcd4-7cb2c36dc75b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ee7a6e53-afce-4476-887c-5d96600563c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2f0d9e53-c87a-45b3-bcd4-7cb2c36dc75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OfficeSpaceMember_a66a82df-e15a-497c-b73b-a185dd9b5893" xlink:href="akba-20210930.xsd#akba_OfficeSpaceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2f0d9e53-c87a-45b3-bcd4-7cb2c36dc75b" xlink:to="loc_akba_OfficeSpaceMember_a66a82df-e15a-497c-b73b-a185dd9b5893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_11c02d0c-ab46-471b-a1a0-0bc5061e0a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesTable_9b89688e-26e9-4d76-92d7-1a770d087bbb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_11c02d0c-ab46-471b-a1a0-0bc5061e0a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a313229d-bd8e-45b4-8179-467d85c0fd24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_11c02d0c-ab46-471b-a1a0-0bc5061e0a6b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a313229d-bd8e-45b4-8179-467d85c0fd24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_KeryxBiopharmaceuticalsIncMember_4a66e4e4-f634-4e34-9305-f2d308ca2f6b" xlink:href="akba-20210930.xsd#akba_KeryxBiopharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a313229d-bd8e-45b4-8179-467d85c0fd24" xlink:to="loc_akba_KeryxBiopharmaceuticalsIncMember_4a66e4e4-f634-4e34-9305-f2d308ca2f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_c8f1b944-1e46-41c4-b7f4-8c98a8af2e34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesTable_9b89688e-26e9-4d76-92d7-1a770d087bbb" xlink:to="loc_us-gaap_CreditFacilityAxis_c8f1b944-1e46-41c4-b7f4-8c98a8af2e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b12c5eec-7c33-4ba4-83f7-9f4170963915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_c8f1b944-1e46-41c4-b7f4-8c98a8af2e34" xlink:to="loc_us-gaap_CreditFacilityDomain_b12c5eec-7c33-4ba4-83f7-9f4170963915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_35209b13-2012-4529-bdca-ec3ea3684719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_b12c5eec-7c33-4ba4-83f7-9f4170963915" xlink:to="loc_us-gaap_LetterOfCreditMember_35209b13-2012-4529-bdca-ec3ea3684719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_09aeb0c9-ea41-495c-9501-4faee8c96518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesTable_9b89688e-26e9-4d76-92d7-1a770d087bbb" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_09aeb0c9-ea41-495c-9501-4faee8c96518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1ff1c5e7-321b-4932-a261-001638717481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_09aeb0c9-ea41-495c-9501-4faee8c96518" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1ff1c5e7-321b-4932-a261-001638717481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_db14bec4-01f9-41a8-a5b0-be1dc3492521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1ff1c5e7-321b-4932-a261-001638717481" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_db14bec4-01f9-41a8-a5b0-be1dc3492521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a48cd2e6-18e4-42d5-ba47-bec7b69c4e53" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesTable_9b89688e-26e9-4d76-92d7-1a770d087bbb" xlink:to="loc_srt_RangeAxis_a48cd2e6-18e4-42d5-ba47-bec7b69c4e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b3f12e5d-9266-4177-8872-006cbd1589b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a48cd2e6-18e4-42d5-ba47-bec7b69c4e53" xlink:to="loc_srt_RangeMember_b3f12e5d-9266-4177-8872-006cbd1589b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a89b55fd-f825-4654-a41e-4f2eababc25d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b3f12e5d-9266-4177-8872-006cbd1589b6" xlink:to="loc_srt_MinimumMember_a89b55fd-f825-4654-a41e-4f2eababc25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5a0f6756-7729-4ae8-9e66-61f017f4337b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b3f12e5d-9266-4177-8872-006cbd1589b6" xlink:to="loc_srt_MaximumMember_5a0f6756-7729-4ae8-9e66-61f017f4337b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_795854dc-c1db-4470-a4a3-4ad984ee8559" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesTable_9b89688e-26e9-4d76-92d7-1a770d087bbb" xlink:to="loc_srt_CounterpartyNameAxis_795854dc-c1db-4470-a4a3-4ad984ee8559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d13e2032-af6d-4bad-b0cf-6f783bd29b46" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_795854dc-c1db-4470-a4a3-4ad984ee8559" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d13e2032-af6d-4bad-b0cf-6f783bd29b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_BioVectraIncMember_686a9d66-41ff-41f5-99db-3b619cf12518" xlink:href="akba-20210930.xsd#akba_BioVectraIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d13e2032-af6d-4bad-b0cf-6f783bd29b46" xlink:to="loc_akba_BioVectraIncMember_686a9d66-41ff-41f5-99db-3b619cf12518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_SiegfriedEvionnazSAMember_fd8476eb-3770-409e-a13a-296fd4379a67" xlink:href="akba-20210930.xsd#akba_SiegfriedEvionnazSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d13e2032-af6d-4bad-b0cf-6f783bd29b46" xlink:to="loc_akba_SiegfriedEvionnazSAMember_fd8476eb-3770-409e-a13a-296fd4379a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_EsteveQuimicaSAMember_4dd23374-e1dd-4df8-84dc-85f695e1e7db" xlink:href="akba-20210930.xsd#akba_EsteveQuimicaSAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d13e2032-af6d-4bad-b0cf-6f783bd29b46" xlink:to="loc_akba_EsteveQuimicaSAMember_4dd23374-e1dd-4df8-84dc-85f695e1e7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_STAPharmaceuticalHongKongLimitedMember_b6c1c51b-ad95-45cc-a8b6-c206ef8c51b7" xlink:href="akba-20210930.xsd#akba_STAPharmaceuticalHongKongLimitedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d13e2032-af6d-4bad-b0cf-6f783bd29b46" xlink:to="loc_akba_STAPharmaceuticalHongKongLimitedMember_b6c1c51b-ad95-45cc-a8b6-c206ef8c51b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_WuXiSTAMember_7d89eeea-64bd-4a34-a7c1-847d55939ce5" xlink:href="akba-20210930.xsd#akba_WuXiSTAMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d13e2032-af6d-4bad-b0cf-6f783bd29b46" xlink:to="loc_akba_WuXiSTAMember_7d89eeea-64bd-4a34-a7c1-847d55939ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_9b95788f-684f-4513-9c0b-0fa9ca3fe38f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesTable_9b89688e-26e9-4d76-92d7-1a770d087bbb" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_9b95788f-684f-4513-9c0b-0fa9ca3fe38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_31d11ad4-d5b1-4480-8630-90dd4ffa49b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_9b95788f-684f-4513-9c0b-0fa9ca3fe38f" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_31d11ad4-d5b1-4480-8630-90dd4ffa49b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_SupplyAgreementPatheonIncMember_bf0f7fe4-ed9b-443b-b16f-2d960eb1936d" xlink:href="akba-20210930.xsd#akba_SupplyAgreementPatheonIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_31d11ad4-d5b1-4480-8630-90dd4ffa49b5" xlink:to="loc_akba_SupplyAgreementPatheonIncMember_bf0f7fe4-ed9b-443b-b16f-2d960eb1936d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_130b8c26-b85d-49f9-bdca-261f2d18d6be" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesTable_9b89688e-26e9-4d76-92d7-1a770d087bbb" xlink:to="loc_srt_StatementScenarioAxis_130b8c26-b85d-49f9-bdca-261f2d18d6be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_c72a691c-6d4a-477b-95fe-0f4136ba4aaf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_130b8c26-b85d-49f9-bdca-261f2d18d6be" xlink:to="loc_srt_ScenarioUnspecifiedDomain_c72a691c-6d4a-477b-95fe-0f4136ba4aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_c8b706cf-8950-4986-887f-9af6cf5f3351" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_c72a691c-6d4a-477b-95fe-0f4136ba4aaf" xlink:to="loc_srt_ScenarioForecastMember_c8b706cf-8950-4986-887f-9af6cf5f3351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:href="akba-20210930.xsd#akba_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesTable_9b89688e-26e9-4d76-92d7-1a770d087bbb" xlink:to="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_9b84ccc5-4f18-4607-b803-ad06ba46306d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_9b84ccc5-4f18-4607-b803-ad06ba46306d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OperatingLeaseAnnualRentExpense_ea926272-2d4d-4805-a90c-045f847cb94b" xlink:href="akba-20210930.xsd#akba_OperatingLeaseAnnualRentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_OperatingLeaseAnnualRentExpense_ea926272-2d4d-4805-a90c-045f847cb94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OperatingLeaseMonthlyRentExpense_a63632eb-09ec-4f66-9702-42bcb2034399" xlink:href="akba-20210930.xsd#akba_OperatingLeaseMonthlyRentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_OperatingLeaseMonthlyRentExpense_a63632eb-09ec-4f66-9702-42bcb2034399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_OperatingLeaseFreeMonthlyRentPeriod_2d52bee4-7c93-4e9b-a514-1c74a9a18cd6" xlink:href="akba-20210930.xsd#akba_OperatingLeaseFreeMonthlyRentPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_OperatingLeaseFreeMonthlyRentPeriod_2d52bee4-7c93-4e9b-a514-1c74a9a18cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions_f1b72f2a-588b-499a-8e0e-9f5ffba0a90f" xlink:href="akba-20210930.xsd#akba_LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions_f1b72f2a-588b-499a-8e0e-9f5ffba0a90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_1453a60b-e144-4c93-903f-10621a739c68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_1453a60b-e144-4c93-903f-10621a739c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_7515dbbf-f36c-43f2-9faf-c5d8f68a3c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_OperatingLeaseCost_7515dbbf-f36c-43f2-9faf-c5d8f68a3c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_0eaedaef-8d0f-4d9d-be78-e0080679e899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_OperatingLeasePayments_0eaedaef-8d0f-4d9d-be78-e0080679e899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_cf3028c7-6bdc-4720-ad4b-c48499c2c73c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_SubleaseIncome_cf3028c7-6bdc-4720-ad4b-c48499c2c73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_fa62ecc0-9743-41b9-aa5c-a219aaed253d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_SecurityDeposit_fa62ecc0-9743-41b9-aa5c-a219aaed253d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ba549b85-effe-418c-9a27-0f087b72df84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ba549b85-effe-418c-9a27-0f087b72df84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_70276153-19d6-404f-b43f-9496f1659042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_70276153-19d6-404f-b43f-9496f1659042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LongTermPurchaseCommitmentRenewalPeriod_dc767b21-f72a-4401-be9f-3efd95d902bc" xlink:href="akba-20210930.xsd#akba_LongTermPurchaseCommitmentRenewalPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_LongTermPurchaseCommitmentRenewalPeriod_dc767b21-f72a-4401-be9f-3efd95d902bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_CostOfPurchasedMinimumQuantityProduct_d444fd92-ce93-4f1e-a3dc-f39a8e75ea37" xlink:href="akba-20210930.xsd#akba_CostOfPurchasedMinimumQuantityProduct"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_CostOfPurchasedMinimumQuantityProduct_d444fd92-ce93-4f1e-a3dc-f39a8e75ea37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod_d658eebc-d6b4-422c-86cc-65c50a1c3108" xlink:href="akba-20210930.xsd#akba_LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod_d658eebc-d6b4-422c-86cc-65c50a1c3108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement_665e8ac3-a94a-4f75-95ef-9667859ecd36" xlink:href="akba-20210930.xsd#akba_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement_665e8ac3-a94a-4f75-95ef-9667859ecd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_ExcessInventoryPurchaseCommitmentsExpenseReversal_52586dcb-6a9f-43a2-af98-612c16e805ea" xlink:href="akba-20210930.xsd#akba_ExcessInventoryPurchaseCommitmentsExpenseReversal"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_ExcessInventoryPurchaseCommitmentsExpenseReversal_52586dcb-6a9f-43a2-af98-612c16e805ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial_e4b115c3-8c5c-490e-91dd-93e2c3cbc2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostDirectMaterial"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_CostDirectMaterial_e4b115c3-8c5c-490e-91dd-93e2c3cbc2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_InitialTermOfSupplyAgreement_3f8546fd-6c3b-49a3-9942-7f300bee7d58" xlink:href="akba-20210930.xsd#akba_InitialTermOfSupplyAgreement"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_InitialTermOfSupplyAgreement_3f8546fd-6c3b-49a3-9942-7f300bee7d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_bc3e92bd-62f6-453c-9974-cd5265d1c1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_bc3e92bd-62f6-453c-9974-cd5265d1c1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_b1356957-31e4-42b9-8166-b21055e1f23f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_b1356957-31e4-42b9-8166-b21055e1f23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_8e77eeec-fbb5-45da-b1f8-90a1fa90a66e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_8e77eeec-fbb5-45da-b1f8-90a1fa90a66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LongTermPurchaseCommitmentFixedPricePeriod_4ee41784-e649-4a26-a581-5798607e4d7e" xlink:href="akba-20210930.xsd#akba_LongTermPurchaseCommitmentFixedPricePeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_LongTermPurchaseCommitmentFixedPricePeriod_4ee41784-e649-4a26-a581-5798607e4d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod_95a7543e-a071-440c-af38-1e0c1e1c80ef" xlink:href="akba-20210930.xsd#akba_LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod_95a7543e-a071-440c-af38-1e0c1e1c80ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_PurchaseCommittedProgramRemainingContractCosts_c2aa444e-e30d-4176-b195-312ae09fd66c" xlink:href="akba-20210930.xsd#akba_PurchaseCommittedProgramRemainingContractCosts"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_akba_PurchaseCommittedProgramRemainingContractCosts_c2aa444e-e30d-4176-b195-312ae09fd66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_2beb0290-5d8f-4e34-b756-0cb6191e9ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_CommitmentsAndContingenciesLineItems_c8791e77-38c0-4218-9094-826ff0e721c7" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_2beb0290-5d8f-4e34-b756-0cb6191e9ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cd4e4795-b1e0-4864-958a-a8daf8f078ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5057eed3-d147-45a9-80fe-fc3c35aa606c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cd4e4795-b1e0-4864-958a-a8daf8f078ed" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5057eed3-d147-45a9-80fe-fc3c35aa606c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4b493531-c5a5-40cf-8f41-7c1ee7ae2903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5057eed3-d147-45a9-80fe-fc3c35aa606c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4b493531-c5a5-40cf-8f41-7c1ee7ae2903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ecadc3e2-a816-4a1f-acdb-ffd7cd5ecaa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5057eed3-d147-45a9-80fe-fc3c35aa606c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ecadc3e2-a816-4a1f-acdb-ffd7cd5ecaa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f3f130fd-8c72-4e9e-9477-3ba76e773810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5057eed3-d147-45a9-80fe-fc3c35aa606c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f3f130fd-8c72-4e9e-9477-3ba76e773810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e24a9b0d-5bcb-44a8-91d0-7b82a4f3cc39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5057eed3-d147-45a9-80fe-fc3c35aa606c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e24a9b0d-5bcb-44a8-91d0-7b82a4f3cc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9d409cd5-a97b-4d51-ac39-304e3f943c89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5057eed3-d147-45a9-80fe-fc3c35aa606c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9d409cd5-a97b-4d51-ac39-304e3f943c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_5a73b76b-77d1-4790-bb9c-07ac648f047d" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5057eed3-d147-45a9-80fe-fc3c35aa606c" xlink:to="loc_akba_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_5a73b76b-77d1-4790-bb9c-07ac648f047d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3c547313-0b13-46fd-9b83-516153cf88be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5057eed3-d147-45a9-80fe-fc3c35aa606c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3c547313-0b13-46fd-9b83-516153cf88be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_d1ec7d25-cf80-46c7-a785-87a0c10a0bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cd4e4795-b1e0-4864-958a-a8daf8f078ed" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_d1ec7d25-cf80-46c7-a785-87a0c10a0bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_8138af12-f089-4527-8147-16939eb07245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_d1ec7d25-cf80-46c7-a785-87a0c10a0bb6" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_8138af12-f089-4527-8147-16939eb07245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_fb8ea3c2-231b-474f-86ad-69bbf3378f40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_d1ec7d25-cf80-46c7-a785-87a0c10a0bb6" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_fb8ea3c2-231b-474f-86ad-69bbf3378f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_152c06ba-947a-41b7-b2d8-d428fb7e03a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_d1ec7d25-cf80-46c7-a785-87a0c10a0bb6" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_152c06ba-947a-41b7-b2d8-d428fb7e03a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_279de256-ec46-4642-b26d-918fda36110a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_d1ec7d25-cf80-46c7-a785-87a0c10a0bb6" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_279de256-ec46-4642-b26d-918fda36110a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_f851c833-85b4-4965-8793-36181cf4c7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_d1ec7d25-cf80-46c7-a785-87a0c10a0bb6" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_f851c833-85b4-4965-8793-36181cf4c7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour_eef40080-5253-4355-9402-02abcb7edf99" xlink:href="akba-20210930.xsd#akba_LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_d1ec7d25-cf80-46c7-a785-87a0c10a0bb6" xlink:to="loc_akba_LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour_eef40080-5253-4355-9402-02abcb7edf99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_cc2ebe65-fd31-4b63-99ae-0483f7003a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_d1ec7d25-cf80-46c7-a785-87a0c10a0bb6" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_cc2ebe65-fd31-4b63-99ae-0483f7003a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_8f65faa1-c9a1-4b3f-a74e-b05070f591be" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cd4e4795-b1e0-4864-958a-a8daf8f078ed" xlink:to="loc_akba_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_8f65faa1-c9a1-4b3f-a74e-b05070f591be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear_a8afb606-400c-4af3-8e0d-8333f9072187" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_8f65faa1-c9a1-4b3f-a74e-b05070f591be" xlink:to="loc_akba_LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear_a8afb606-400c-4af3-8e0d-8333f9072187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne_480bfeca-e410-4e7f-be83-e7b99d611c97" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_8f65faa1-c9a1-4b3f-a74e-b05070f591be" xlink:to="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne_480bfeca-e410-4e7f-be83-e7b99d611c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo_84482c7c-abec-4a79-8f5f-8f612ff3405e" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_8f65faa1-c9a1-4b3f-a74e-b05070f591be" xlink:to="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo_84482c7c-abec-4a79-8f5f-8f612ff3405e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree_443cbed7-77ce-478a-b3d8-e006b1e7eef5" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_8f65faa1-c9a1-4b3f-a74e-b05070f591be" xlink:to="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree_443cbed7-77ce-478a-b3d8-e006b1e7eef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour_930600bf-bf38-4699-aa01-ab0634ed3baa" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_8f65faa1-c9a1-4b3f-a74e-b05070f591be" xlink:to="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour_930600bf-bf38-4699-aa01-ab0634ed3baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour_7aaf68d9-7d38-4c6f-a9ad-e2014ba8f8e3" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_8f65faa1-c9a1-4b3f-a74e-b05070f591be" xlink:to="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour_7aaf68d9-7d38-4c6f-a9ad-e2014ba8f8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNet_586080f9-dace-4973-ae06-d18490bfedce" xlink:href="akba-20210930.xsd#akba_LesseeOperatingLeaseLiabilityPaymentsDueNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_akba_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_8f65faa1-c9a1-4b3f-a74e-b05070f591be" xlink:to="loc_akba_LesseeOperatingLeaseLiabilityPaymentsDueNet_586080f9-dace-4973-ae06-d18490bfedce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1" xlink:type="simple" xlink:href="akba-20210930.xsd#CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1"/>
  <link:presentationLink xlink:role="http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://akebia.com/role/CommitmentsandContingenciesDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesandOperatingLeasesLiabilitiesDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#CommitmentsandContingenciesDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesandOperatingLeasesLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/CommitmentsandContingenciesDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesandOperatingLeasesLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58daf276-ea43-4988-9e8f-ebcdef7f3cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_42f992d6-ff05-49b8-abef-7c023c021d21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58daf276-ea43-4988-9e8f-ebcdef7f3cd9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_42f992d6-ff05-49b8-abef-7c023c021d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7ae6ab27-1ff2-4709-8250-3ae280fdfec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58daf276-ea43-4988-9e8f-ebcdef7f3cd9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7ae6ab27-1ff2-4709-8250-3ae280fdfec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_cfeaad93-1287-4d23-befc-e7bffa851060" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58daf276-ea43-4988-9e8f-ebcdef7f3cd9" xlink:to="loc_us-gaap_OperatingLeaseLiability_cfeaad93-1287-4d23-befc-e7bffa851060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_955458b8-bda4-4e12-b579-da546c25ad9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58daf276-ea43-4988-9e8f-ebcdef7f3cd9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_955458b8-bda4-4e12-b579-da546c25ad9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/NetLossperShare" xlink:type="simple" xlink:href="akba-20210930.xsd#NetLossperShare"/>
  <link:presentationLink xlink:role="http://akebia.com/role/NetLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_bd692c3c-79ef-4741-b9fc-65e648ab33f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_185de838-b41c-48e2-94fb-b590ba53b771" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_bd692c3c-79ef-4741-b9fc-65e648ab33f7" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_185de838-b41c-48e2-94fb-b590ba53b771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="akba-20210930.xsd#NetLossperShareTables"/>
  <link:presentationLink xlink:role="http://akebia.com/role/NetLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8b7626fe-fc16-429b-b3b7-c6fa51442986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2f86a01f-d006-4568-9f1c-01c7c16dea3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8b7626fe-fc16-429b-b3b7-c6fa51442986" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2f86a01f-d006-4568-9f1c-01c7c16dea3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://akebia.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="akba-20210930.xsd#NetLossperShareAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://akebia.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_abd66a78-6a4c-4c67-a3b3-2e6f8636a3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2d1c07a7-f1ad-4686-a5ef-3f22299e7911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_abd66a78-6a4c-4c67-a3b3-2e6f8636a3d2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2d1c07a7-f1ad-4686-a5ef-3f22299e7911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e7c25aec-f1f5-4249-aad7-a77fad480904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2d1c07a7-f1ad-4686-a5ef-3f22299e7911" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e7c25aec-f1f5-4249-aad7-a77fad480904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_619c48d7-a1e7-4d0c-8337-1503dca66a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e7c25aec-f1f5-4249-aad7-a77fad480904" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_619c48d7-a1e7-4d0c-8337-1503dca66a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_389943f2-83eb-4fc8-b77a-de90cb81601a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_619c48d7-a1e7-4d0c-8337-1503dca66a3d" xlink:to="loc_us-gaap_WarrantMember_389943f2-83eb-4fc8-b77a-de90cb81601a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9034fe3d-bc21-475b-993e-5423a1eb7630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_619c48d7-a1e7-4d0c-8337-1503dca66a3d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9034fe3d-bc21-475b-993e-5423a1eb7630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f3c1570e-24b7-4b70-8b8c-74a15c86acf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_619c48d7-a1e7-4d0c-8337-1503dca66a3d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f3c1570e-24b7-4b70-8b8c-74a15c86acf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9bef5288-7a02-405c-8a7e-4ee57f90010d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2d1c07a7-f1ad-4686-a5ef-3f22299e7911" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9bef5288-7a02-405c-8a7e-4ee57f90010d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d559b527-d84d-43fc-a4b1-1755dcf2e13f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9bef5288-7a02-405c-8a7e-4ee57f90010d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d559b527-d84d-43fc-a4b1-1755dcf2e13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>akba-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:akba="http://akebia.com/20210930"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="akba-20210930.xsd" xlink:type="simple"/>
    <context id="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if87a4fc02b5c41baadaddd8ae45a20ef_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i44af4abac88448b5893045bc0002855c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3e2950be526b427487e169a221babd7d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0c63b2719b7a493f89992c1c8a6feb94_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1897c1e5242647279d4844ddf93043fa_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i679a26fb513c4e229079d19e687e23ea_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic6c63a1921cf449cbb7d42a58f2ca535_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if41d416d81e34b9cb6976b49960bf999_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia875941982fa4b738ad20ad8c02ee280_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0d2476903d214660b7d10dfda90d5e62_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic49c106b11074ca28afbe6423ad1783c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9abd651243dc4b3888719db25453a613_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieac2241d842b494ab83cde4c6efacf46_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8cc88afc4d2144b0820d54de176e706b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7aec38034ce44b18a632886540cf60f7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i068e2607df3e46ad958c3aac8d56c8bb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i789136767052440b86082df6969545de_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i35244d2350f3498ebd27593263ce18df_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ife5f777362b84a18b96a34f6b3515a94_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5f2d1adb364d4ff18d2ad533959fe847_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic2d99e2664f844a2acf2c4573bf8df03_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id85007bc927a4536b6b47497569aa944_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i31f726c664944828986c9bc152d3cdbf_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2342b55b98df4c4f97a6deb300c2a324_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i86dc89425ef046d69fcf7b7442f7b3af_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ief1a730691f34e3697272cf628a7de24_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i16965583159a4fb1943935fe0821c8b0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2f18d61adce243dbaa08d8980a32a679_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6909ec0393ec4db2b3cc2706b5126477_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i45ee7fe7e4ea40449ec5093c5cfe4dab_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i97143382c5d94af882a7a099bb719c08_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i847e92f55f2743cc8282356cea6026ae_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib807b33284ab430ca5e62866cfe3994b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i889ed5ea677d43a19e0b2f90cc53dd3f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i18bc18c0ef5546c5baeae2af38f6fac6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i264a47d635da444c86cb87a405c909c4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i82c195ab2c01450cb6639257d18f6117_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i82c5946e60d04544ab9e41f12a391895_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i62615678941c40648470b93e883c6c27_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0c14e7a0bd4c4f3b838b097690f0db73_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5eb0e7b9743b4b5bb8dcad4532a676f4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="icff6bb56ef7f4b71b0ee5439d93c832d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2821e9d04730493782461dc080013c07_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i04f6e21078d54815b0fbcd7ccc3af0dc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iaa53bc3c09164606aeaedf64079be5bc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie7f690b3768a4f10ad9965db748015b2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i575073ad687946c3958e67e8c915001f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i264fd5873c584be39232727f484cadd7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i751bbd3aed3c44479e98241e0fabf680_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia0c080b6e3284262a5a2ac05fc8be6d8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ied2865777ae543ccb7e6733cedf24ead_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibedefb3b11734e53bd359a1087a22569_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i717676096b5a4c5eab55661e5e686861_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5cbbd7587d264a93a0fac886a04d7c90_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i319c95fd8a8d4153a2394567a88f22ab_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idd7f6d1ca07a4a7c81755f54e71d3a96_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9a772f431b4b4e039d186148c8287a6a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8f40f8942af14045ad47dc41f0a655f5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id832960589e2403f88473dd831c88c68_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idc035820389e4d8a96227a92fb46d718_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i00f6c8320acf4b159907d88edddf5125_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i02a8ba6ff0054b678403f9ad5ed7efc4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iba37ce69556348a28b16ed216da9256d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idbc0260c7ae64edbabae5c84ce6356df_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib48d1a5470e1451ea0d90314033b3dfe_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id2fc62f68c514632b6ff5532a6c05123_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic634149430a042a0af7eced0d7b1f3bc_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iba476346b25f4a3b8f5eacda5b591d48_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i952bff9821b4497aa3ea95191dd2fe53_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i362dc8956d2b485d99df3ac257386849_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic9932b64331a4dd3b00728c94fbb38e0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie9bbe8c544974328bc9207e0b78b0928_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6a813010cea049e3b9d06fd62cbe9afe_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic0d58cac5ebc4dde9442518ff67901b4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0c64672624aa423384622e444a575831_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i688f4e0d7a5c4c7e9ee5af402822f7f3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id1bafbc3960143019bb39d791680d09e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:ChargebacksAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie3e27925f7eb4396b50788b1c147f040_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:RebatesFeesAndOtherDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i88110b1102464bb8b4bcc45b892e9014_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic65dcd125e83450aa6300973fab408bb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:ChargebacksAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic138834fb069491a89247c930e50e034_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:RebatesFeesAndOtherDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i73f8120fb3ba417a90e8a529c456c779_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i85f7bb9f4e384e1aa0a5e37af52be036_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:ChargebacksAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4ef44b64c28a444cac3e40fe925ba315_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:RebatesFeesAndOtherDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i34bd677f66094393bebcca2b049effef_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6297767fc6bf43fe877f509f140dada7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:ChargebacksAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia3450ded174e45858afc144e1af9ffac_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:RebatesFeesAndOtherDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i97d48e8612f24efe8996ef27cb3c6569_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i634b8d926257462d9d9e328283bb4259_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:ChargebacksAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i745cf671aea747ba929766351832a180_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:RebatesFeesAndOtherDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9a65cd87641e499c9df380248f663449_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i88b205f60522473db4b1791f35bad380_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:ChargebacksAndDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifbe29fe4d71b45a2807b94520a5f1004_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:RebatesFeesAndOtherDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3e838c8dba8c42b0b61db36cee11b10c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">akba:ReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iba72f4028b53419a9e3df0bc0bb323b5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i68832275b6f74879ad43622f402f836b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iefbe221ac071402e9aa1ff3c33efbea9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1709d1103fa3444fb8a09367a5e7e52e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i31651748afca476c98590cfaeef98a69_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5aabb65b896b4d4693a54ed68c0aa03a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iefd530a7f1a248edbdc9b05c847c8a7e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib09d90891a274c3c818a2cef521eace2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i73b11af5f04a42d9a1071752d045891e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib6fc2047fffc4e2d8558725e0f1d34a0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i945ff9fde11644a58dafd0226b9d6c0f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i738510817c5048b98d2eea09c5a05cf1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7f482f3f6423440ea0d9f6c8bef66818_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8a84c225ba714f219479e22fc09d67e9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0acbf4b49164475f8a36f3979f8e5aff_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib52d8a3a1f814ede864dcab830d03ad3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iae7692c90eb746178a141c1b78cb6a28_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2af3aa2c9e5f4db7bac920c367ee4124_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i95f34cfdea4546b9916e24a997553533_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6d24e1b865b1425f8c6a7c9541a10db2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id1b71df432394860be208c54b443aacb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i06aa1c9bc80b4b6497171fe4199a0347_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4f865ba0db994d3fbe5976932bc384f2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifce4f17d7a3d4682a27f359eb185448b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0455e41ef2d6462b91d81400d4c2e0dd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia6939d08f8a54431bf1d08db5ff563d4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8e10b28a9e47483eab1daecf6b5559db_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i70c28a2a28bc4932a1c94051311c07d4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia4a2508fbe7b4b60998f2800a6721219_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4010db64fe4c4fd08b2112d996676126_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:ViforPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9022775c979849d481205605464f30c6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4d809bfac669408289ffd42f4682ebdf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iac0b3b12cdd94293a710efe9b099ccbf_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if43c4eaad1e5445d9f05ae88eab7739b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i97125a084ecb413d80709a70f9e28986_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i79eda260de9049ddb3c4152a914c8bc8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifd7a9c2a482c488c9e39c164f7f25286_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:DeferredRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3404eb43c0644986a1e29bf11447aefa_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:DeferredRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i196a4d9a61ec429197ab955e5ff2ae4b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:DeferredRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id7a97c0c8d344bda97e123e206e6b3c8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c709aa7d7814c7bab26eccc3b81e798_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia93c22c9b15f4c919a2252df1363cdd4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id60c0fe0efd942ad8b113bef4877c974_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:AccruedExpensesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i76b75bcd1b964770ae1b56eaf8e7a892_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:AccruedExpensesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i253a75db63844161bc3f8de0b86f9a31_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:AccruedExpensesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib6b0e1ca966948bf9b3b29017f33c08b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie67e37ea23d74352995b356f2d5e00a5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i062a629a2436472793e654eaff2d5751_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8991531a317948b9b93df5b26ec241f8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie9224c9eaaef4b0fbb6b3ecd626f0fb5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia0467c81517d465385733a7970a7a414_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifcc593671c2e4622975ac665de36e6c1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:DeferredRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i595577133c66457b807c06fb447cc0ff_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:DeferredRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icd56d876b06146709b43ea24c7d1c59b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:DeferredRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib43b28b4e0ab493fa74148aeaab24813_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iee7892ead75d4547be97c8704445856f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibe962a59b6ea455b88176426838ddf81_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i381ae62687174e09adb9da00b0c38527_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:AccruedExpensesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i13ca6bac21b04356ab2ca6e641f44077_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:AccruedExpensesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id42d54e97e794a2e966b66e8d2cb3aa4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:AccruedExpensesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5ffb0dde1c014cb9abf1b7695c63c0d2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibf4981c415ac4d3faa22e3d1e690bfbf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeResearchAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i59b89b0dc1714bceaf61d6592940372e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">akba:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8bea31568bfb475da7ac289ff0a194bb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">akba:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeResearchAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i049242e1c959495ba03db706d555ef59_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">akba:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8270fb936c044bacb333691798285cad_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8873d2f4f3ab410f8ea8fdc1148178ff_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia2b65de4f50a4ba0aba4c2a04561a742_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicenseCollaborationAndOtherRevenueRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i77a8fd0e1e314ec995a1ea4cb3e26298_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i75a8e981279d4597a75912a5c2d89696_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeResearchAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5ab7efb86c7e4332bb5d1393a1103c7a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i84bfabdde428494b8286364e0b2e04f8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iec08195269f1492b95a796511ae43b19_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic04e3a3ad82e497eab9e0ccc53e84bb7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iddee3a51bc8e41009393c7fffc1d6be2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5008d093e2c14f8e9b0c70b8ad2d6cdf_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i30255726ea164f57b4faf87425b440bf_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2c9c4fa43e814dbbaf59df410140075b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8e8a7ecf26094b9985196caeaf40209b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0713ae0f1c084dc1a951ad2de75526f0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i93d500fdcbc947168636b67aefe164f2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i64af70fdf31a4cfcbd5d1dd0c6e667f3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5c2d9393a8d94a97b1a20c634e92642c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">akba:ContractWithCustomerLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2d43ffd6494e45cea49745bc245eb588_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2182ac591eaa4895935be370490ebd61_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:MitsubishiTanabePharmaCorporationSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i729bdb2febbe40f7a0d7e8b9d41b5707_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i05703e7e166b4e6aa26567e3dd53b0d4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">akba:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib36601c7c6054547b257cbee1cadedd2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">akba:GlobalDevelopmentPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icf1d9f1217594ee99787532eb6416a3e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5df4e367c4894f3baca804f2eba217c6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i044f764231f14772829db57c3b4d1639_D20161201-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">akba:UpFrontNonRefundableAndNonCreditableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="icbdd2b99003a4b868da41de914cb59b4_D20161201-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i500c6fdc5af04a21900cf4f2d9069a5b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:HIFProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if916aba0a4c34bab87b14d995442b804_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicensedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4eff79078bbb43e1882ae7742d0279b6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib0094621113146aebebb1a65434da333_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic6acee9f4bf9402baacb58cb5f057459_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i51de58b6c7be4fb9899538b241b86615_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic5c623ee9ed146eb8cee4622f170592a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i70b7ea01a52041328c8e4e5bcda17a4c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i21debe3a35d84013a5c0a46700b925d1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0fdc68385d154fbd8c01df1bd39dde5d_D20170425-20170425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">akba:UpFrontNonRefundableAndNonCreditableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-25</startDate>
            <endDate>2017-04-25</endDate>
        </period>
    </context>
    <context id="i871f553557614df48044678d328520cb_D20170101-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="id317514fef48482db39eba1dc979e0ad_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicensedHIFProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i587afcb2ee994fd1823e352650f8c16f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicensedHIFProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4f62756447d54a2ea8980a3e5189c028_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicensedHIFProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie73bc5c571f84ec38080d5e084633f19_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">akba:LicensedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9874741da84a44769dea47ee0e59d980_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i02e592c97e6f450ca8dbb9dfbdb2b298_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib0ad25ebad234cb5a72142b53cc43ba6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iac660281115d42f3adbe6635fbbac7b5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:OtsukaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieeebde433f7a49538c99f8eedfadce25_D20170209-20170209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JanssenPharmaceuticaNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeResearchAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-09</startDate>
            <endDate>2017-02-09</endDate>
        </period>
    </context>
    <context id="ifcf133937bdc4353b3c3ba86e059f5cb_I20170209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JanssenPharmaceuticaNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeResearchAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-09</instant>
        </period>
    </context>
    <context id="ifc1340b1d3414996b23a8b1c78d66a9b_I20170209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JohnsonAndJohnsonInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeResearchAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-09</instant>
        </period>
    </context>
    <context id="i8b7b728d6820482185b5f4c1ce9f6131_I20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JohnsonAndJohnsonInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:DevelopmentAndCommercializeResearchAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="ifc1441455f5f427d888f9be3a658edc4_D20210604-20210604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">akba:CyclerionTherapeuticsLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-04</startDate>
            <endDate>2021-06-04</endDate>
        </period>
    </context>
    <context id="i0f7c79b242f844ddad0fc74aecc7c6ca_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">akba:CyclerionTherapeuticsLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9ae72c8b1a6046dc8ea43e24fa8b97b6_I20170512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:ViforInternationalLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-12</instant>
        </period>
    </context>
    <context id="i22c6d8b4a8754f2cabfbd65f0be236dd_D20170512-20170512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:ViforInternationalLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-12</startDate>
            <endDate>2017-05-12</endDate>
        </period>
    </context>
    <context id="i8a3012cc53274e7386ae899217cc4ae0_D20200214-20200214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:ViforInternationalLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:PriorityReviewVoucherLetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-14</startDate>
            <endDate>2020-02-14</endDate>
        </period>
    </context>
    <context id="i7e2acaca8c4648fc8c17812d445090de_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:ViforInternationalLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i41e46089042845efb8effbe91d3866a0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">akba:PanionAndBFBiotechIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i042537cbb7204196925307a6b7f16840_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">akba:PanionAndBFBiotechIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3aadde62784b4aefa36a71ef6d3bb27b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">akba:PanionAndBFBiotechIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib037a9facfea4d249380bdea73ce519b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">akba:PanionAndBFBiotechIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0cc1c74d758f401f8afecb62a3e1d9dd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:SublicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iead0fd037fa94b5eac362dee913b3b35_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:SublicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3917cbc6ebab4fcba1653703ddcaeb89_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:SublicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1bce44b505714f94a8b535b4ea2e5717_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:SublicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i016c3424f40c49faa098233e6b0ce0ef_I20210225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
        </entity>
        <period>
            <instant>2021-02-25</instant>
        </period>
    </context>
    <context id="i8b1ce5c7f57f4300b066a27bf7644888_D20210225-20210225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-02-25</endDate>
        </period>
    </context>
    <context id="i56d517c10b584fe0aaec8d914de26be7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie80f8a6467b14c7cafd2f2e4ce22adf5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4eaaeb5ff6074e36abf2df5bbdcad9c3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4e52064c653743f2a16fd27d8c9a323a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia6cdf790d03c4fed810871ebfea1a32f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i582013b1f37743bc8285c94f50c08ca4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia131987e763f4587a941882e026ee367_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic5b97b6dc8c6458eb7afd794c342c79a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i81fe9de9bf004275abc9aead5654fef0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9965cd10ee2c479390becf868ab08d6b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib35a112c936c43008fd53a2e71e369fe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia5926c8f9dfa40cb830ffa5f3015b27d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i51612bc1340040cb897112531943a394_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9db8d25d5e404f14935648663eb92df6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i469e62d61f624f13a913c992818f42a8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3c2c9bd113fe46629d3834ae5a39ba17_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9b81649bc6244591a493ea134990b511_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0a8144587d5e488cabffbbd0bae0e7a5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">akba:OtherThanDerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i616cde0a70c94c6eb173090f144c4c43_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia9033a88870c408dba279ef74720efd3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">akba:OtherThanDerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3e237cd7f54f4646aa36f63692c06c40_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4e72ecf91b664cca962bacefd5439368_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1cd36c7e7311497ba175179857b7257c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9fdb433b2bca4b748b2b7fa719b097c9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia76ea517ec23406588672981c217b653_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">akba:DevelopedProductRightsForAuryxiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i30e4e068c6214ffabd5a128e3d85c999_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">akba:DevelopedProductRightsForAuryxiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6dcd869a04c44f3ea928848929217e86_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OffMarketFavorableLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i34034b5b7fbe48fe92390732c9576345_D20181212-20181212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">akba:DevelopedProductRightsForAuryxiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-12</startDate>
            <endDate>2018-12-12</endDate>
        </period>
    </context>
    <context id="i4c756e20d9664648aeb18aebeb242523_I20191111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-11</instant>
        </period>
    </context>
    <context id="i3c0d403601654c72b47819a9afbd0792_I20191111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">akba:TrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-11</instant>
        </period>
    </context>
    <context id="ia190616222f745278c0dc5a7620042c1_I20191111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">akba:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-11</instant>
        </period>
    </context>
    <context id="ia00bb356464246a7b22e1821a884688d_D20191111-20191111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">akba:ThreeMonthLondonInterbankOfferedRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-11</startDate>
            <endDate>2019-11-11</endDate>
        </period>
    </context>
    <context id="i8147f4e6a02545de933ea73e8af97025_D20191111-20191111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-11</startDate>
            <endDate>2019-11-11</endDate>
        </period>
    </context>
    <context id="i2c34013e3d5d42798cb44d8508b1ac83_D20191111-20191111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="akba:DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis">akba:DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-11</startDate>
            <endDate>2019-11-11</endDate>
        </period>
    </context>
    <context id="i06ee360513f94ae993a4c6898c417de2_D20191111-20191111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="akba:DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis">akba:DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-11</startDate>
            <endDate>2019-11-11</endDate>
        </period>
    </context>
    <context id="ic6020a0180d34b6a86d7589b54358a92_D20191111-20191111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-11</startDate>
            <endDate>2019-11-11</endDate>
        </period>
    </context>
    <context id="i8cd1fb13915744c284881cee3c9a4457_I20191125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">akba:TrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-25</instant>
        </period>
    </context>
    <context id="iefce2ff8ab894b54be64daf36220401a_D20201210-20201210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">akba:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BPCRLimitedPartnershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-10</startDate>
            <endDate>2020-12-10</endDate>
        </period>
    </context>
    <context id="ied529b6124d840a6ad7b272239c35283_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i43a607fdad03489084b28ba60875d452_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia8d3eda1fa3b436883677e9840266d97_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ida5e89d4588d4e3dbdc420f58130b868_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">akba:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">akba:KeryxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">akba:BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:CollateralAgentPharmakonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i541f7e6319644772b0d0e20228d16057_I20170228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">akba:JanssenAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-28</instant>
        </period>
    </context>
    <context id="i8e4cb62597ae4760a7f0d14dd934eeeb_I20200604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
        </entity>
        <period>
            <instant>2020-06-04</instant>
        </period>
    </context>
    <context id="ia500545ec09246ce9dedea5a7cd9b0d4_D20191112-20191112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-12</startDate>
            <endDate>2019-11-12</endDate>
        </period>
    </context>
    <context id="i81c8895c1f2d4c56b6435144097a2e33_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i66deeb6acb77474a959a2ca2688e2657_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7a4aafef7ebc4f4dbc4da7e3e7952d94_D20200312-20200312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-12</startDate>
            <endDate>2020-03-12</endDate>
        </period>
    </context>
    <context id="ia6fcc0f0e17240bd92fefbacdd946b14_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i48ac3ceb90a14e55a606e7ed5d3716d1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i678d4d68b8d44706b86e94178a818447_D20210225-20210225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">akba:AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-02-25</endDate>
        </period>
    </context>
    <context id="i7c3f11e1bf924040bbe2698d14b92960_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">akba:AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i45bac3731ae447399855606573e4e297_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">akba:AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic405d5f9a6194033b54c67f003fb5108_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:InducementAwardProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id8e692bb054345cb9980a00457fd17f1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:InducementAwardProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1a334797d16148a8bc4de0e3cd01d3a6_I20140228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:TwoThousandAndFourteenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-02-28</instant>
        </period>
    </context>
    <context id="i24f27ec785a94f77bff6f9932edbe262_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:TwoThousandAndFourteenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i928990fc0f0544d7bdc2c92d83eb4503_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">akba:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:TwoThousandAndFourteenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8c0679f11ab54281a697554a5d1b0a16_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:TwoThousandAndFourteenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if883a99477df492ebd6e2365f0c4bb6a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic68dc20e53ac4d9f9315ecf7c3ede580_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i67dd5c6046f64d0e9109b42763967f24_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">akba:ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8f98c7914a2d4498b3182d130d0cb47a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib0f30762d9654703a976783f7172781a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i010b303706c744e2922ea62d41c6df9a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2dd32faea92444fe9357160c0a7b15cc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:TwoThousandAndFourteenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8a366e7c1d9547a89b545b4c5b2edc75_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">akba:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:TwoThousandAndFourteenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id8c33b8456b445388314a4b181f4ad55_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:TwoThousandAndFourteenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id334eb22f65f47a2b8f9ed60a00a7faf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">akba:ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i700b68cc599f4438ba55fcd9dc69cd7a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i73aee313a7a7411d983faf613acc515c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6fe3737b757e4dcb9d9bd2fd3a908513_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:TwoThousandAndFourteenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i02cb18bdb22b463a8143eb77464ade75_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie796bd13e7ae4237ba6a1435f0aa706a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">akba:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia2f38973bd944cfd9a74bfad2e344e99_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">akba:ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3082be42de6d46968f452cdc31f89952_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">akba:ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i82b10f09670f4bceac19cdca7e3acc7f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">akba:ShareBasedPaymentArrangementTrancheThreeThirdAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia03fed5c8b21488386bbe6f120dd55c1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">akba:ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7864c0c76ead4a41b2717cf096dfc1df_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">akba:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">akba:ShareBasedPaymentArrangementTrancheTwoSecondAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8c4a114c87d04f9a86f0cd36147b5c17_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:CambridgeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i2f8032b3bd82471cbcff6a003f19e33b_D20160701-20160731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:CambridgeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-07-31</endDate>
        </period>
    </context>
    <context id="i1ee517b85db6461e9394aeeb76fb30a0_D20170101-20170101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:CambridgeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-01</endDate>
        </period>
    </context>
    <context id="ibe11b29f86744551b0e34d4c7a45321d_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:CambridgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">akba:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="i2085d352fbe244bfae6189887c1b70b1_I20160731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:CambridgeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-07-31</instant>
        </period>
    </context>
    <context id="ifc753862bba346a4b87baf73046febb4_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:CambridgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">akba:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i319033b22a7e40f680e6a60fdad1e84d_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:CambridgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">akba:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7f13ec3e12bf451caafb2291ffc4a2a8_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:CambridgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">akba:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i395d6be571b646d2a729d3d38b72c91b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:BostonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">akba:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i36039c1763334766b650c9db8ccac9a8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:BostonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">akba:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iae8a04efe54e4e2cba598fe2b46d3589_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:CambridgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">akba:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3f8574ce39ac48ada29733a02df6fe06_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:BostonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">akba:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibbf6fa923bcf4b2b92e43786d4da64a2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:BostonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">akba:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9b38f2f3c3db48cdacc6e3dab5c4477a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:BostonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">akba:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib8e6a7b6910d48e294bcb23008415abd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:BostonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">akba:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i99da615448e74f1b956e0da8fde046d6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:BostonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">akba:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2521a8d2d711470090bd6f68bb353f22_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:CambridgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0dca46c47d4447088630d11a10807fbe_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">akba:BostonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0784525677704a0f9da4e0961490be27_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if648f232fd8d44f2853c2848e528087c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if1dd7b6af62e48d89630458d90d092cb_D20200904-20200904">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:BioVectraIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-04</startDate>
            <endDate>2020-09-04</endDate>
        </period>
    </context>
    <context id="i03f1a8e55f924ca6b788d5e2067ae377_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:BioVectraIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib2c7ce4bacf943a6ae4661730894183c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:SiegfriedEvionnazSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i93ce46eca8a74081a9a0a15945f34ee2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:SiegfriedEvionnazSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3ce765a46da74d3ebd33dec7f304c9a8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i85c91980832440e88454196ba38dbd5f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib0bd0fdce45f4f2eb878365dff48b0ae_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">akba:KeryxBiopharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i49ee8d5e6ee44e0aa71f48df84288db0_D20190409-20190409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:EsteveQuimicaSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-09</startDate>
            <endDate>2019-04-09</endDate>
        </period>
    </context>
    <context id="ia777a099e6224fe895fa66b20db9e666_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:EsteveQuimicaSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifc3ad8cedbf646a3badc26d2e706ac87_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">akba:SupplyAgreementPatheonIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifa82e47edba04966993a43c23b18a792_D20200402-20200402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:STAPharmaceuticalHongKongLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-02</startDate>
            <endDate>2020-04-02</endDate>
        </period>
    </context>
    <context id="i6768bc85e77b42ec85b465655fe66cb8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:STAPharmaceuticalHongKongLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1413873e0fc3463794f8307e9bce1a4a_D20210210-20210210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">akba:WuXiSTAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-10</startDate>
            <endDate>2021-02-10</endDate>
        </period>
    </context>
    <context id="ic7117791645b42058a5acb1a3ca00398_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i16a3e0fb50c54a4081eec1b8b2e9d068_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i395ce7f5b8ae45baad50acde1847e4cd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6b7e133601904c7a84c219de00bcfe1b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i85f449f89e6c4ad9b140a31a285c766d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i56668d4d1ae84d8c98f3182984b4d052_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001517022</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>akba:segment</measure>
    </unit>
    <unit id="performance_obligation">
        <measure>akba:performance_obligation</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="security">
        <measure>akba:security</measure>
    </unit>
    <unit id="tranche">
        <measure>akba:tranche</measure>
    </unit>
    <unit id="installment">
        <measure>akba:installment</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="extensionoption">
        <measure>akba:extensionOption</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80L2ZyYWc6YWZmNmM1YWE4MzYxNDc0NDhmMjY3ZDc4M2Q3ZTI4NDYvdGFibGU6ZTc4ZWZkNDViOTA1NDk1ZjkzZTMyYjBiOTJlMmNhMTIvdGFibGVyYW5nZTplNzhlZmQ0NWI5MDU0OTVmOTNlMzJiMGI5MmUyY2ExMl8zLTEtMS0xLTIyMzU3_43f5b333-eac1-4615-9b44-d1bee2ef85a9">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80L2ZyYWc6YWZmNmM1YWE4MzYxNDc0NDhmMjY3ZDc4M2Q3ZTI4NDYvdGFibGU6ZTc4ZWZkNDViOTA1NDk1ZjkzZTMyYjBiOTJlMmNhMTIvdGFibGVyYW5nZTplNzhlZmQ0NWI5MDU0OTVmOTNlMzJiMGI5MmUyY2ExMl80LTEtMS0xLTIyMzU3_ae4e388e-1a7f-4346-a612-d72036ecbf7a">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80L2ZyYWc6YWZmNmM1YWE4MzYxNDc0NDhmMjY3ZDc4M2Q3ZTI4NDYvdGFibGU6ZTc4ZWZkNDViOTA1NDk1ZjkzZTMyYjBiOTJlMmNhMTIvdGFibGVyYW5nZTplNzhlZmQ0NWI5MDU0OTVmOTNlMzJiMGI5MmUyY2ExMl81LTEtMS0xLTIyMzU3_0b5d21a6-1757-43e5-9abc-fa6e922489d8">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80L2ZyYWc6YWZmNmM1YWE4MzYxNDc0NDhmMjY3ZDc4M2Q3ZTI4NDYvdGFibGU6ZTc4ZWZkNDViOTA1NDk1ZjkzZTMyYjBiOTJlMmNhMTIvdGFibGVyYW5nZTplNzhlZmQ0NWI5MDU0OTVmOTNlMzJiMGI5MmUyY2ExMl82LTEtMS0xLTIyMzU3_4fa98e07-6ed6-4dd3-afe4-40675f069790">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80L2ZyYWc6YWZmNmM1YWE4MzYxNDc0NDhmMjY3ZDc4M2Q3ZTI4NDYvdGFibGU6ZTc4ZWZkNDViOTA1NDk1ZjkzZTMyYjBiOTJlMmNhMTIvdGFibGVyYW5nZTplNzhlZmQ0NWI5MDU0OTVmOTNlMzJiMGI5MmUyY2ExMl83LTEtMS0xLTIyMzU3_cbe1ae1e-526c-4221-9117-6ae6428f91d2">0001517022</dei:EntityCentralIndexKey>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNy0wLTEtMS0yMjM1Nw_8a62ce00-dd9c-44ee-980f-eb68f6cf0efd">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNy0wLTEtMS0yMjM1Nw_a0731d02-abdf-4cad-9588-f670833c69ba">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:DebtInstrumentTerm
      contextRef="ic6020a0180d34b6a86d7589b54358a92_D20191111-20191111"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83MC9mcmFnOjJmNDgxYzA3ZjViOTRjMTliZjhiMTE3ZjM5ZGYyY2I0L3RhYmxlOjY2NWRmZmJiMjI4MDQ5YjlhMTE3NDM4MTBhODZmMWExL3RhYmxlcmFuZ2U6NjY1ZGZmYmIyMjgwNDliOWExMTc0MzgxMGE4NmYxYTFfMy0xLTEtMS0yMjM1Nw_bc747731-c308-4c8f-ace4-99c7df61d167">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia2f38973bd944cfd9a74bfad2e344e99_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83OS9mcmFnOmQ4YjFmNjVkOWNlMjRjOGE5ODM4NjM4MjkwMDQ5MTlhL3RhYmxlOmUxNGVhODk0OTRlZjQxYTBhNzEzZjdhN2U4ZTQ3YjkxL3RhYmxlcmFuZ2U6ZTE0ZWE4OTQ5NGVmNDFhMGE3MTNmN2E3ZThlNDdiOTFfMi0xLTEtMS0yMjM1Nw_c757861e-59a7-4bf9-a91f-e80e4cbb2170">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i3082be42de6d46968f452cdc31f89952_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83OS9mcmFnOmQ4YjFmNjVkOWNlMjRjOGE5ODM4NjM4MjkwMDQ5MTlhL3RhYmxlOmUxNGVhODk0OTRlZjQxYTBhNzEzZjdhN2U4ZTQ3YjkxL3RhYmxlcmFuZ2U6ZTE0ZWE4OTQ5NGVmNDFhMGE3MTNmN2E3ZThlNDdiOTFfMy0xLTEtMS0yMjM1Nw_d31484cc-3124-4102-be7f-d00d3f0aa743">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i82b10f09670f4bceac19cdca7e3acc7f_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83OS9mcmFnOmQ4YjFmNjVkOWNlMjRjOGE5ODM4NjM4MjkwMDQ5MTlhL3RhYmxlOmUxNGVhODk0OTRlZjQxYTBhNzEzZjdhN2U4ZTQ3YjkxL3RhYmxlcmFuZ2U6ZTE0ZWE4OTQ5NGVmNDFhMGE3MTNmN2E3ZThlNDdiOTFfNC0xLTEtMS0yMjM1Nw_00db3825-3b88-40ff-8a20-881875209668"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ia03fed5c8b21488386bbe6f120dd55c1_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83OS9mcmFnOmQ4YjFmNjVkOWNlMjRjOGE5ODM4NjM4MjkwMDQ5MTlhL3RhYmxlOmUxNGVhODk0OTRlZjQxYTBhNzEzZjdhN2U4ZTQ3YjkxL3RhYmxlcmFuZ2U6ZTE0ZWE4OTQ5NGVmNDFhMGE3MTNmN2E3ZThlNDdiOTFfNC0xLTEtMS0yMjM1Nw_d3a13164-941b-4c42-9e50-c5809f1fea55"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i7864c0c76ead4a41b2717cf096dfc1df_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83OS9mcmFnOmQ4YjFmNjVkOWNlMjRjOGE5ODM4NjM4MjkwMDQ5MTlhL3RhYmxlOmUxNGVhODk0OTRlZjQxYTBhNzEzZjdhN2U4ZTQ3YjkxL3RhYmxlcmFuZ2U6ZTE0ZWE4OTQ5NGVmNDFhMGE3MTNmN2E3ZThlNDdiOTFfNC0xLTEtMS0yMjM1Nw_de58b467-dd9d-444d-bde2-db6eb3da5d4d"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia03fed5c8b21488386bbe6f120dd55c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83OS9mcmFnOmQ4YjFmNjVkOWNlMjRjOGE5ODM4NjM4MjkwMDQ5MTlhL3RhYmxlOmUxNGVhODk0OTRlZjQxYTBhNzEzZjdhN2U4ZTQ3YjkxL3RhYmxlcmFuZ2U6ZTE0ZWE4OTQ5NGVmNDFhMGE3MTNmN2E3ZThlNDdiOTFfNS0xLTEtMS0yMjM1Nw_4419b77a-0f12-4345-8c3a-5f0347d2d1e2">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7864c0c76ead4a41b2717cf096dfc1df_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83OS9mcmFnOmQ4YjFmNjVkOWNlMjRjOGE5ODM4NjM4MjkwMDQ5MTlhL3RhYmxlOmUxNGVhODk0OTRlZjQxYTBhNzEzZjdhN2U4ZTQ3YjkxL3RhYmxlcmFuZ2U6ZTE0ZWE4OTQ5NGVmNDFhMGE3MTNmN2E3ZThlNDdiOTFfNi0xLTEtMS0yMjM1Nw_b52cdafd-6e15-49a5-bea2-0756f2fc0f82">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i82b10f09670f4bceac19cdca7e3acc7f_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83OS9mcmFnOmQ4YjFmNjVkOWNlMjRjOGE5ODM4NjM4MjkwMDQ5MTlhL3RhYmxlOmUxNGVhODk0OTRlZjQxYTBhNzEzZjdhN2U4ZTQ3YjkxL3RhYmxlcmFuZ2U6ZTE0ZWE4OTQ5NGVmNDFhMGE3MTNmN2E3ZThlNDdiOTFfNy0xLTEtMS0yMjM1Nw_f1d988ac-3107-4d6d-9ef8-0d8db062d672">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i700b68cc599f4438ba55fcd9dc69cd7a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83OS9mcmFnOmQ4YjFmNjVkOWNlMjRjOGE5ODM4NjM4MjkwMDQ5MTlhL3RhYmxlOmUxNGVhODk0OTRlZjQxYTBhNzEzZjdhN2U4ZTQ3YjkxL3RhYmxlcmFuZ2U6ZTE0ZWE4OTQ5NGVmNDFhMGE3MTNmN2E3ZThlNDdiOTFfOC0xLTEtMS0yMjM1Nw_2c6f6187-1ac1-4169-943c-bbc4e67846f8">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOmY2NDc1MWJlODBmNTRjOTY4ZDg5NTUxMjc1NTZjNDVjL3RhYmxlcmFuZ2U6ZjY0NzUxYmU4MGY1NGM5NjhkODk1NTEyNzU1NmM0NWNfNC0wLTEtMS0yMjM1Nw_6f24d764-2b2d-4991-9474-8d0770053a51">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGV4dHJlZ2lvbjpmYTc3MzBkOTA4ZmU0ODY0YWNhOTVkNGMwYTBjYjI3N18yMjE4_2411eb51-21b0-41b8-a749-e9f7c5f2f709">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGV4dHJlZ2lvbjpmYTc3MzBkOTA4ZmU0ODY0YWNhOTVkNGMwYTBjYjI3N18yMjEy_8eabecd0-bf02-4f87-9d53-41e5f12bf653">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGV4dHJlZ2lvbjpmYTc3MzBkOTA4ZmU0ODY0YWNhOTVkNGMwYTBjYjI3N18xNjQ5MjY3NDQxODkwOQ_968e40fa-a265-4511-a933-ab5927bb7126">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGV4dHJlZ2lvbjpmYTc3MzBkOTA4ZmU0ODY0YWNhOTVkNGMwYTBjYjI3N18yMjEw_c7f8f339-e2ea-4c04-b8e8-249b0ac7501e">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGV4dHJlZ2lvbjpmYTc3MzBkOTA4ZmU0ODY0YWNhOTVkNGMwYTBjYjI3N18yMjEz_81cc97eb-1486-49f9-b351-f0d3d35a813e">001-36352</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGV4dHJlZ2lvbjpmYTc3MzBkOTA4ZmU0ODY0YWNhOTVkNGMwYTBjYjI3N18yMjE0_035dc588-1fb4-402b-b8df-7b2f34fc37ea">AKEBIA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6NGRlNWVjN2MyM2I2NDZlOTg4N2RlODhmMmVmZTIwMWQvdGFibGVyYW5nZTo0ZGU1ZWM3YzIzYjY0NmU5ODg3ZGU4OGYyZWZlMjAxZF8wLTAtMS0xLTIyMzU3_9732e761-08d9-4a5b-84de-732032de737f">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6NGRlNWVjN2MyM2I2NDZlOTg4N2RlODhmMmVmZTIwMWQvdGFibGVyYW5nZTo0ZGU1ZWM3YzIzYjY0NmU5ODg3ZGU4OGYyZWZlMjAxZF8wLTQtMS0xLTIyMzU3_9297334a-638f-457a-ace4-20d20c04d3de">20-8756903</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6NGRlNWVjN2MyM2I2NDZlOTg4N2RlODhmMmVmZTIwMWQvdGFibGVyYW5nZTo0ZGU1ZWM3YzIzYjY0NmU5ODg3ZGU4OGYyZWZlMjAxZF8zLTAtMS0xLTIyMzU3L3RleHRyZWdpb246Njk1ZGNhOGQ4OWVhNGRlNjgxYzRhZWNlODI3NDgzNzJfMjc0ODc3OTA2OTUwNA_b6ea468f-b3a0-4211-a5d1-e79d93f57020">245 First Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6NGRlNWVjN2MyM2I2NDZlOTg4N2RlODhmMmVmZTIwMWQvdGFibGVyYW5nZTo0ZGU1ZWM3YzIzYjY0NmU5ODg3ZGU4OGYyZWZlMjAxZF8zLTAtMS0xLTIyMzU3L3RleHRyZWdpb246Njk1ZGNhOGQ4OWVhNGRlNjgxYzRhZWNlODI3NDgzNzJfOA_abb9a84e-ce0a-4125-b00f-dffd21fa3b22">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6NGRlNWVjN2MyM2I2NDZlOTg4N2RlODhmMmVmZTIwMWQvdGFibGVyYW5nZTo0ZGU1ZWM3YzIzYjY0NmU5ODg3ZGU4OGYyZWZlMjAxZF8zLTAtMS0xLTIyMzU3L3RleHRyZWdpb246Njk1ZGNhOGQ4OWVhNGRlNjgxYzRhZWNlODI3NDgzNzJfMTI_9d3d2bab-6668-4f3e-bf0c-1a23d042275f">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6NGRlNWVjN2MyM2I2NDZlOTg4N2RlODhmMmVmZTIwMWQvdGFibGVyYW5nZTo0ZGU1ZWM3YzIzYjY0NmU5ODg3ZGU4OGYyZWZlMjAxZF8zLTQtMS0xLTIyMzU3_2ed02a5a-3655-4566-8cf7-4fb74ce5905f">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGV4dHJlZ2lvbjpmYTc3MzBkOTA4ZmU0ODY0YWNhOTVkNGMwYTBjYjI3N181NTI_a34abf85-5356-4409-90ca-b03f1579de8a">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGV4dHJlZ2lvbjpmYTc3MzBkOTA4ZmU0ODY0YWNhOTVkNGMwYTBjYjI3N18yMjE1_25f1dfb9-9052-4d01-8e53-8b05e1b29dc8">871-2098</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6NjQ4Yjc0YTkyOTE1NDlhYjkwZWUxOGYzZTFmYmJhYmQvdGFibGVyYW5nZTo2NDhiNzRhOTI5MTU0OWFiOTBlZTE4ZjNlMWZiYmFiZF8yLTAtMS0xLTIyMzU3_32b7113d-cfde-4ee7-9f42-b10d7a5f8cca">Common Stock, par value $0.00001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6NjQ4Yjc0YTkyOTE1NDlhYjkwZWUxOGYzZTFmYmJhYmQvdGFibGVyYW5nZTo2NDhiNzRhOTI5MTU0OWFiOTBlZTE4ZjNlMWZiYmFiZF8yLTEtMS0xLTIyMzU3_bfc94008-1103-44f2-99b3-5562e12f4e45">AKBA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6NjQ4Yjc0YTkyOTE1NDlhYjkwZWUxOGYzZTFmYmJhYmQvdGFibGVyYW5nZTo2NDhiNzRhOTI5MTU0OWFiOTBlZTE4ZjNlMWZiYmFiZF8yLTItMS0xLTIyMzU3_e797ff86-3757-4c2b-bc3a-49cb95ca84e8">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGV4dHJlZ2lvbjpmYTc3MzBkOTA4ZmU0ODY0YWNhOTVkNGMwYTBjYjI3N18yMjE2_04511a67-f98b-4bbd-b88f-5523c898e924">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGV4dHJlZ2lvbjpmYTc3MzBkOTA4ZmU0ODY0YWNhOTVkNGMwYTBjYjI3N18yMjEx_c3045fa0-6a3d-454d-a0b2-80ab0bb2acdc">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6N2U5MGQxY2E2ZGMwNDJjMmFiZWUyNDhkMjNiMmQzMDUvdGFibGVyYW5nZTo3ZTkwZDFjYTZkYzA0MmMyYWJlZTI0OGQyM2IyZDMwNV8wLTAtMS0xLTIyMzU3_b6989c42-fa8f-4cf6-b591-ad9181bb8360">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6N2U5MGQxY2E2ZGMwNDJjMmFiZWUyNDhkMjNiMmQzMDUvdGFibGVyYW5nZTo3ZTkwZDFjYTZkYzA0MmMyYWJlZTI0OGQyM2IyZDMwNV8yLTMtMS0xLTIyMzU3_cb488505-9133-48e0-beb9-7028a5cdf0a4">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6N2U5MGQxY2E2ZGMwNDJjMmFiZWUyNDhkMjNiMmQzMDUvdGFibGVyYW5nZTo3ZTkwZDFjYTZkYzA0MmMyYWJlZTI0OGQyM2IyZDMwNV80LTMtMS0xLTIyMzU3_3ba730a4-1526-4768-8329-7c7d33b4314d">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGV4dHJlZ2lvbjpmYTc3MzBkOTA4ZmU0ODY0YWNhOTVkNGMwYTBjYjI3N18yMjE3_4da466fb-d3ad-41a1-b567-0709d91c592a">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="if87a4fc02b5c41baadaddd8ae45a20ef_I20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8xL2ZyYWc6ZmE3NzMwZDkwOGZlNDg2NGFjYTk1ZDRjMGEwY2IyNzcvdGFibGU6Y2FlNzA1NjVmMTAyNGYyMWFkMTU2OTA2MDYzODAyOTMvdGFibGVyYW5nZTpjYWU3MDU2NWYxMDI0ZjIxYWQxNTY5MDYwNjM4MDI5M18xLTEtMS0xLTIyMzU3L3RleHRyZWdpb246MDkzMjExYTgyMGNkNDlmODgyZmU5OTA1Y2FlNjAxN2VfNA_b3c9b191-d984-4c13-afe2-a20d7c1398fd"
      unitRef="shares">174960413</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMy0xLTEtMS0yMjM1Nw_05b1594c-562d-4d2c-a21c-089ab5be5341"
      unitRef="usd">207204000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMy0zLTEtMS0yMjM1Nw_04999223-4008-49a6-9f12-515bcfd7051e"
      unitRef="usd">228698000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfNC0xLTEtMS0yMjM1Nw_5d11599b-6180-424c-8269-8021aa741035"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfNC0zLTEtMS0yMjM1Nw_313050e6-094b-40e7-a76a-bf6694fe3c1f"
      unitRef="usd">39992000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InventoryNet
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfNS0xLTEtMS0yMjM1Nw_9afb3dc9-7a9a-439b-bed2-74b8dd77452c"
      unitRef="usd">33688000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfNS0zLTEtMS0yMjM1Nw_54c40916-ba02-42c7-8242-510057c59669"
      unitRef="usd">61017000</us-gaap:InventoryNet>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfNi0xLTEtMS0yMjM1Nw_521ee917-b41c-4e56-a642-2b6b8919cd55"
      unitRef="usd">49690000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfNi0zLTEtMS0yMjM1Nw_a66fd837-f7d2-4bf2-af7e-97aee2c652de"
      unitRef="usd">26853000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfNy0xLTEtMS0yMjM1Nw_b7e8d7c8-e56e-482d-a9a5-2afeee881027"
      unitRef="usd">39502000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfNy0zLTEtMS0yMjM1Nw_601a3843-3011-4704-8945-46cd8a0dc62a"
      unitRef="usd">14877000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfOC0xLTEtMS0yMjM1Nw_4f8f38fb-d5ab-485b-a927-4b8c586465f0"
      unitRef="usd">330084000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfOC0zLTEtMS0yMjM1Nw_a79b3fa1-920f-4317-aa2d-5c0e0a0b29c8"
      unitRef="usd">371437000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfOS0xLTEtMS0yMjM1Nw_61bdc14f-1d60-4390-bf9b-d02f2b7b12a8"
      unitRef="usd">7196000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfOS0zLTEtMS0yMjM1Nw_a706cfad-64ad-4ade-bbec-47c1f6ab82e7"
      unitRef="usd">8622000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTAtMS0xLTEtMjIzNTc_7402cf7d-ab72-4901-a3e1-7a0f1483b6ec"
      unitRef="usd">23192000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTAtMy0xLTEtMjIzNTc_f6b460cd-4e0b-4038-9037-2897374063f4"
      unitRef="usd">26876000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTEtMS0xLTEtMjIzNTc_262b4849-381d-460c-ad2d-c3e5081b21a7"
      unitRef="usd">55053000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTEtMy0xLTEtMjIzNTc_fd280cab-4fcf-4b95-9e8a-c4ff6f97f285"
      unitRef="usd">55053000</us-gaap:Goodwill>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTItMS0xLTEtMjIzNTc_84a45ebc-4935-4b2a-a2df-8be6acfb1009"
      unitRef="usd">117138000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTItMy0xLTEtMjIzNTc_92b5f11d-70c4-44b0-aa0d-a6fc1a092654"
      unitRef="usd">144170000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTMtMS0xLTEtMjIzNTc_8859be7b-7724-44d3-88bc-2135f8625409"
      unitRef="usd">69604000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTMtMy0xLTEtMjIzNTc_61715161-56b8-4715-bae6-ddf34d922772"
      unitRef="usd">37981000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTQtMS0xLTEtMjIzNTc_a6803592-2ab0-4ecb-a248-ef7cfa6a9462"
      unitRef="usd">602267000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTQtMy0xLTEtMjIzNTc_30973626-fdc5-472e-96cd-69e2ecd13c96"
      unitRef="usd">644139000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTctMS0xLTEtMjIzNTc_52c7c274-fa21-4820-a455-77840ee6b987"
      unitRef="usd">28809000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTctMy0xLTEtMjIzNTc_5ec19c83-64d8-4228-8845-5edc19d608b1"
      unitRef="usd">41308000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTgtMS0xLTEtMjIzNTc_7986a137-ca68-4a23-974c-5405d48f033b"
      unitRef="usd">144704000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTgtMy0xLTEtMjIzNTc_373f0cea-62f6-4482-988e-f0787b29e59b"
      unitRef="usd">130624000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTktMS0xLTEtMjIzNTc_94ba85d2-443e-4bbe-b46f-cb85ed25244b"
      unitRef="usd">15692000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMTktMy0xLTEtMjIzNTc_960d6d68-7d1a-4eb9-b8f4-07eae27dec9c"
      unitRef="usd">15214000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjAtMS0xLTEtMjIzNTc_dfd93a96-e828-4ae0-b6e8-d6532a9e26cf"
      unitRef="usd">189205000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjAtMy0xLTEtMjIzNTc_d50a939b-7a1b-4e06-91fd-f8532407f77f"
      unitRef="usd">187146000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjEtMS0xLTEtMjIzNTc_0e6560a5-897d-4973-945d-ed9c0981a687"
      unitRef="usd">27965000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjEtMy0xLTEtMjIzNTc_ab11753d-b30d-45e8-ab05-1214498c0301"
      unitRef="usd">25345000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjItMS0xLTEtMjIzNTc_ae21ccc9-cda6-4505-8648-4fc48b8fd369"
      unitRef="usd">20257000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjItMy0xLTEtMjIzNTc_5bfbb088-1598-423d-96d1-95fea377bf67"
      unitRef="usd">24621000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilities
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjMtMS0xLTEtMjIzNTc_dd0ed045-43a7-4cc5-b988-50169c54f253"
      unitRef="usd">1930000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjMtMy0xLTEtMjIzNTc_c63a1682-50ee-456d-9d10-9245e56e098b"
      unitRef="usd">2420000</us-gaap:DerivativeLiabilities>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjQtMS0xLTEtMjIzNTc_be7fb2f1-607f-4ab6-9d35-c9bce6fff2bd"
      unitRef="usd">97230000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjQtMy0xLTEtMjIzNTc_b5c0ca84-9750-4248-ac1a-3b6c1f81a3a4"
      unitRef="usd">96378000</us-gaap:LongTermDebtNoncurrent>
    <akba:ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjUtMS0xLTEtMjIzNTc_bf708764-e008-4739-b4f7-cc1c93878ede"
      unitRef="usd">51137000</akba:ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent>
    <akba:ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjUtMy0xLTEtMjIzNTc_c2670a9a-71ce-4f7d-8157-ee7c3b20debf"
      unitRef="usd">0</akba:ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjYtMS0xLTEtMjIzNTc_bfbc88ba-5f61-4aa7-be6c-2472a340037b"
      unitRef="usd">77393000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjYtMy0xLTEtMjIzNTc_f58fc42a-acc2-46ba-9ea2-04efcc8b2429"
      unitRef="usd">60611000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjctMS0xLTEtMjIzNTc_c5f8eb73-8ec0-46b6-b215-ab491a9f4ed6"
      unitRef="usd">465117000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjctMy0xLTEtMjIzNTc_24d2f497-4711-4dd8-a06a-92c4d33e209d"
      unitRef="usd">396521000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjgtMS0xLTEtMjIzNTc_82df45b9-0417-4d8d-b489-55e25829df17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMjgtMy0xLTEtMjIzNTc_66a32945-758e-4fa7-9d82-9c197189e17d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzAtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjoyYzQwMTMyMjkyMmE0YTJlYTIzM2IwYjY4ZjUyN2ExZl8yMA_505dd588-d5e5-4dac-9298-74b97fa817d9"
      unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzAtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjoyYzQwMTMyMjkyMmE0YTJlYTIzM2IwYjY4ZjUyN2ExZl8yMA_be67952d-c919-40c9-b653-f3d4e20c0186"
      unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzAtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjoyYzQwMTMyMjkyMmE0YTJlYTIzM2IwYjY4ZjUyN2ExZl8zNA_21a75bd6-f645-4ae1-adb9-06f2f18bcd7e"
      unitRef="shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzAtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjoyYzQwMTMyMjkyMmE0YTJlYTIzM2IwYjY4ZjUyN2ExZl8zNA_d9da8a9c-33c5-49eb-ba03-a77e75610862"
      unitRef="shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzAtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjoyYzQwMTMyMjkyMmE0YTJlYTIzM2IwYjY4ZjUyN2ExZl81Ng_4740ef7b-3357-45bd-ab30-61ea67f23022"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzAtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjoyYzQwMTMyMjkyMmE0YTJlYTIzM2IwYjY4ZjUyN2ExZl81Ng_5d60582a-8b1a-4183-8333-5191996f1db3"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzAtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjoyYzQwMTMyMjkyMmE0YTJlYTIzM2IwYjY4ZjUyN2ExZl81Ng_7dad568c-c638-4fb4-80ed-59b2839ad442"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzAtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjoyYzQwMTMyMjkyMmE0YTJlYTIzM2IwYjY4ZjUyN2ExZl81Ng_c3003e90-2969-4c4e-9743-49d3e4b35eb9"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzAtMS0xLTEtMjIzNTc_30ef0f10-29c7-4fcb-957a-6f4150f83e0c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzAtMy0xLTEtMjIzNTc_0b3e1f88-ebd8-4cec-9813-564bad483e0d"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzEtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjo4YTlmMDAyYjgxOTE0MjUyOGI3ODlmZGZjNjVmMTEyMV8xOA_73b60055-7193-4ebe-ad9a-12e71e5d96b4"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzEtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjo4YTlmMDAyYjgxOTE0MjUyOGI3ODlmZGZjNjVmMTEyMV8xOA_e769b4d4-d315-4d8e-9664-41f87ae3393a"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzEtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjo4YTlmMDAyYjgxOTE0MjUyOGI3ODlmZGZjNjVmMTEyMV8zMg_0d30c230-f621-450a-a005-bce4ea5cedbb"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzEtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjo4YTlmMDAyYjgxOTE0MjUyOGI3ODlmZGZjNjVmMTEyMV8zMg_ca414d86-2206-4e5d-98b1-ba81409c49af"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzEtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjo4YTlmMDAyYjgxOTE0MjUyOGI3ODlmZGZjNjVmMTEyMV84Mg_0d1b7068-9c3f-49fe-8eaf-97fdc73845c1"
      unitRef="shares">174551989</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzEtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjo4YTlmMDAyYjgxOTE0MjUyOGI3ODlmZGZjNjVmMTEyMV84Mg_c69b48e8-65df-4261-a54c-ce309078edb2"
      unitRef="shares">174551989</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzEtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjo4YTlmMDAyYjgxOTE0MjUyOGI3ODlmZGZjNjVmMTEyMV84OQ_08a8c5cb-774b-40ed-a581-f2f05fdba6f6"
      unitRef="shares">148074085</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzEtMC0xLTEtMjIzNTcvdGV4dHJlZ2lvbjo4YTlmMDAyYjgxOTE0MjUyOGI3ODlmZGZjNjVmMTEyMV84OQ_9c94e722-22dc-4f6f-84fe-f08382a7aa97"
      unitRef="shares">148074085</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzEtMS0xLTEtMjIzNTc_8faa3d81-8a1c-446f-8098-9e16a732ec24"
      unitRef="usd">2000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzEtMy0xLTEtMjIzNTc_302c84ad-81d7-46a8-b5d8-71f34d4bce01"
      unitRef="usd">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzItMS0xLTEtMjIzNTc_62ee4741-2de9-44f7-9757-703fcd37b584"
      unitRef="usd">1526815000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzItMy0xLTEtMjIzNTc_ac064d46-8013-482f-aa9a-544c5e0060a7"
      unitRef="usd">1425115000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzMtMS0xLTEtMjIzNTc_410998c5-88a0-4771-b896-d2c3d5cc793d"
      unitRef="usd">6000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzMtMy0xLTEtMjIzNTc_6288c8bf-7ef6-4da0-b02e-66018fe654c4"
      unitRef="usd">13000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzQtMS0xLTEtMjIzNTc_9a80b854-18b8-471a-9d39-2a9796b60067"
      unitRef="usd">-1389673000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzQtMy0xLTEtMjIzNTc_343e86ca-820f-48e8-bf09-2eddc819b14a"
      unitRef="usd">-1177511000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzUtMS0xLTEtMjIzNTc_8df30f57-5952-4e40-809b-2706b6c3763f"
      unitRef="usd">137150000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzUtMy0xLTEtMjIzNTc_62354a70-755a-4fb1-bf59-3a66af547b7a"
      unitRef="usd">247618000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzYtMS0xLTEtMjIzNTc_7e2cdcc0-541e-4709-b617-a7a4787604a3"
      unitRef="usd">602267000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yMi9mcmFnOmYxYWVjMmQ2YTMwYzQ1YTJhNDFhNTA5MmY4ZTVmYzAwL3RhYmxlOjhkNTk5NGM4Mzg5OTQ2N2RhOGZjMGRmNWFkMTVhNTJmL3RhYmxlcmFuZ2U6OGQ1OTk0YzgzODk5NDY3ZGE4ZmMwZGY1YWQxNWE1MmZfMzYtMy0xLTEtMjIzNTc_a0649dae-f290-437b-b9aa-5a6654e6a0c9"
      unitRef="usd">644139000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c63b2719b7a493f89992c1c8a6feb94_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMy0xLTEtMS0yMjM1Nw_44c25078-0cf0-454b-857a-26fc499cf727"
      unitRef="usd">36753000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1897c1e5242647279d4844ddf93043fa_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMy0zLTEtMS0yMjM1Nw_34a03147-5918-448e-94a4-2435ba4f2626"
      unitRef="usd">34392000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i679a26fb513c4e229079d19e687e23ea_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMy01LTEtMS0yMjM1Nw_a776fc18-352d-4c65-96f1-144a3bc7f567"
      unitRef="usd">100120000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6c63a1921cf449cbb7d42a58f2ca535_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMy03LTEtMS0yMjM1Nw_e4f90322-799c-4293-b487-bf9b35381777"
      unitRef="usd">94297000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if41d416d81e34b9cb6976b49960bf999_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfNC0xLTEtMS0yMjM1Nw_25abf111-100a-4dbe-9b78-60d239a8b59a"
      unitRef="usd">12003000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia875941982fa4b738ad20ad8c02ee280_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfNC0zLTEtMS0yMjM1Nw_f2608666-9f2a-4178-b825-3264deea440e"
      unitRef="usd">25596000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d2476903d214660b7d10dfda90d5e62_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfNC01LTEtMS0yMjM1Nw_61c4ba7d-2e2b-496b-ba31-f99041edac43"
      unitRef="usd">53853000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic49c106b11074ca28afbe6423ad1783c_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfNC03LTEtMS0yMjM1Nw_fecdc811-383d-4137-8a25-dc196d462dc6"
      unitRef="usd">144311000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfNS0xLTEtMS0yMjM1Nw_e79e9791-c02c-4cc1-b398-e60e08476e0d"
      unitRef="usd">48756000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfNS0zLTEtMS0yMjM1Nw_772bae21-177b-4bb7-9994-31c1a5e84cce"
      unitRef="usd">59988000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfNS01LTEtMS0yMjM1Nw_e1fefd4d-1b70-4303-8c9d-cdb94bed9434"
      unitRef="usd">153973000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfNS03LTEtMS0yMjM1Nw_90e87db9-3f8a-45de-b63c-43644aaf9831"
      unitRef="usd">238608000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfNy0xLTEtMS0yMjM1Nw_4bf2be1b-d924-4efa-b63f-8335a9ad446f"
      unitRef="usd">6933000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfNy0zLTEtMS0yMjM1Nw_dfe07700-27e1-4bcd-b835-d8d539c0b81e"
      unitRef="usd">24239000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfNy01LTEtMS0yMjM1Nw_74baea4a-41ae-48af-aea7-c5202f8a9902"
      unitRef="usd">76012000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfNy03LTEtMS0yMjM1Nw_3ee72d4d-cabd-46ca-bc4a-a3bd967999d7"
      unitRef="usd">92840000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfOC0xLTEtMS0yMjM1Nw_a01ea53e-1fb9-43d4-99de-260de1488385"
      unitRef="usd">9011000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfOC0zLTEtMS0yMjM1Nw_1e3a46dc-4dc9-4ca2-a699-3dbd57acdd88"
      unitRef="usd">6106000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfOC01LTEtMS0yMjM1Nw_a7bccc0d-c3a9-4279-a96e-a966183e19d9"
      unitRef="usd">27032000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfOC03LTEtMS0yMjM1Nw_bb0f8c6f-12e9-4f95-b8e3-adeee4d14206"
      unitRef="usd">24307000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <akba:ProductionRelatedImpairmentsOrChargesIntangibles
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfOS0xLTEtMS0yMjM1Nw_01e0a69d-79ae-410a-850d-47a84fcc3a13"
      unitRef="usd">0</akba:ProductionRelatedImpairmentsOrChargesIntangibles>
    <akba:ProductionRelatedImpairmentsOrChargesIntangibles
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfOS0zLTEtMS0yMjM1Nw_ea8477e2-571f-436d-9415-1e581ba6c2fc"
      unitRef="usd">0</akba:ProductionRelatedImpairmentsOrChargesIntangibles>
    <akba:ProductionRelatedImpairmentsOrChargesIntangibles
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfOS01LTEtMS0yMjM1Nw_a81cad87-e087-4419-a2bf-03cd1697a02e"
      unitRef="usd">0</akba:ProductionRelatedImpairmentsOrChargesIntangibles>
    <akba:ProductionRelatedImpairmentsOrChargesIntangibles
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfOS03LTEtMS0yMjM1Nw_f88e51a6-25e3-4236-a124-03d7d1ea2673"
      unitRef="usd">115527000</akba:ProductionRelatedImpairmentsOrChargesIntangibles>
    <us-gaap:CostOfRevenue
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTAtMS0xLTEtMjIzNTc_30e63280-45d1-4f69-8c7c-c060bed74f06"
      unitRef="usd">15944000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTAtMy0xLTEtMjIzNTc_d80941ef-acac-4159-9eec-a065911fb2cc"
      unitRef="usd">30345000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTAtNS0xLTEtMjIzNTc_7aff8aa6-f3c0-47c5-8a9c-bf20e4b36e1c"
      unitRef="usd">103044000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTAtNy0xLTEtMjIzNTc_14caee38-6e89-481d-b3cb-025c5a3698f9"
      unitRef="usd">232674000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTItMS0xLTEtMjIzNTc_946c5c60-23d9-4072-86d6-52278a054fc5"
      unitRef="usd">40471000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTItMy0xLTEtMjIzNTc_ee4b7d3f-68d3-4065-a928-704e469bb146"
      unitRef="usd">46857000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTItNS0xLTEtMjIzNTc_42b13497-3d77-4261-885b-59b4d6d8c01d"
      unitRef="usd">118296000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTItNy0xLTEtMjIzNTc_1ff3e81b-afc0-4981-9b17-da547b1e99e7"
      unitRef="usd">180907000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTMtMS0xLTEtMjIzNTc_d1d3d60f-61c1-4512-9a05-f12e075e2012"
      unitRef="usd">46357000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTMtMy0xLTEtMjIzNTc_c3623ec1-5b29-4def-9f00-75e08ade43c1"
      unitRef="usd">40171000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTMtNS0xLTEtMjIzNTc_b863b1ad-2d48-4c54-babc-5fe869c9ae43"
      unitRef="usd">129336000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTMtNy0xLTEtMjIzNTc_fc96e6e3-9977-4810-bdcd-51e38b04c717"
      unitRef="usd">113636000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <akba:LicenseExpense
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTQtMS0xLTEtMjIzNTc_0cb3dbe5-6272-4f8f-b03f-7972b8377734"
      unitRef="usd">870000</akba:LicenseExpense>
    <akba:LicenseExpense
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTQtMy0xLTEtMjIzNTc_b82752a5-6fd5-4e61-9813-f1195d49ed3c"
      unitRef="usd">710000</akba:LicenseExpense>
    <akba:LicenseExpense
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTQtNS0xLTEtMjIzNTc_d6ecce70-8e31-4f93-8b00-e3001f9c6e7b"
      unitRef="usd">2460000</akba:LicenseExpense>
    <akba:LicenseExpense
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTQtNy0xLTEtMjIzNTc_de77343e-ad19-4957-a92b-2dde3ff94035"
      unitRef="usd">2430000</akba:LicenseExpense>
    <us-gaap:OperatingExpenses
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTUtMS0xLTEtMjIzNTc_1e80d041-2d42-4eb8-8cde-0b99a9e38351"
      unitRef="usd">87698000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTUtMy0xLTEtMjIzNTc_dbe65565-4222-40e5-b081-8d0bfff0defa"
      unitRef="usd">87738000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTUtNS0xLTEtMjIzNTc_36934ca4-b504-494a-b438-0a3c3d4dd88a"
      unitRef="usd">250092000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTUtNy0xLTEtMjIzNTc_58139d1f-6bfb-4c18-bbe6-f043da0f4f9a"
      unitRef="usd">296973000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTYtMS0xLTEtMjIzNTc_9070ac93-b429-4ef9-9f2d-d38f4efcc529"
      unitRef="usd">-54886000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTYtMy0xLTEtMjIzNTc_db05c486-f6b0-4160-afcc-3ae83e718cc2"
      unitRef="usd">-58095000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTYtNS0xLTEtMjIzNTc_632d072e-21e4-4134-8f83-63f28d426d1f"
      unitRef="usd">-199163000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTYtNy0xLTEtMjIzNTc_0549ecdd-53b9-4619-95b3-b3324cd6c810"
      unitRef="usd">-291039000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTgtMS0xLTEtMjIzNTc_c7be4cf5-758e-495a-8fc0-fa599bcea941"
      unitRef="usd">-5085000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTgtMy0xLTEtMjIzNTc_c3053759-8e2f-42ee-864b-cce14540ac77"
      unitRef="usd">-2274000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTgtNS0xLTEtMjIzNTc_98e1daea-3836-48fb-9165-50b563fca060"
      unitRef="usd">-14853000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTgtNy0xLTEtMjIzNTc_1d301af0-ec20-4765-b566-8079f12098c4"
      unitRef="usd">-6554000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTktMS0xLTEtMjIzNTc_b4590276-98a1-4799-81d4-a8395e2103c3"
      unitRef="usd">427000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTktMy0xLTEtMjIzNTc_681257ac-f005-4e22-b6ea-6109d0d74109"
      unitRef="usd">410000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTktNS0xLTEtMjIzNTc_04fcfecb-0e80-4e31-981b-eb35a26e20d1"
      unitRef="usd">1854000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMTktNy0xLTEtMjIzNTc_576a6006-b9fe-4c9d-87c6-45e83d70c95d"
      unitRef="usd">1136000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjAtMS0xLTEtMjIzNTc_a0213a69-67ea-4e44-a1d2-1ae287e0e842"
      unitRef="usd">-59544000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjAtMy0xLTEtMjIzNTc_e3c3c714-1e32-40b1-8058-34a8318f6ac7"
      unitRef="usd">-59959000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjAtNS0xLTEtMjIzNTc_34624dc4-55a1-4c32-b57a-32f4a2dd445f"
      unitRef="usd">-212162000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjAtNy0xLTEtMjIzNTc_1205d296-b3d0-447a-807f-ca38d23ee8b6"
      unitRef="usd">-296457000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjEtMS0xLTEtMjIzNTc_65a82cb2-69d7-492b-9f3b-ba26d8a47a4b"
      unitRef="usdPerShare">-0.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjEtMS0xLTEtMjIzNTc_da6c7e6a-8976-4ae7-909c-1879a7dac6cf"
      unitRef="usdPerShare">-0.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjEtMy0xLTEtMjIzNTc_881482a8-3532-481b-be74-5bba91005c90"
      unitRef="usdPerShare">-0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjEtMy0xLTEtMjIzNTc_c747173c-3146-4456-9b5f-468e5ed32acb"
      unitRef="usdPerShare">-0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjEtNS0xLTEtMjIzNTc_8fd89876-41dd-41d3-ad29-bbff517decbc"
      unitRef="usdPerShare">-1.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjEtNS0xLTEtMjIzNTc_b75c4cc5-d3f5-468c-9192-2b1561743429"
      unitRef="usdPerShare">-1.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjEtNy0xLTEtMjIzNTc_e87a2e76-a121-49db-a3d3-aed965f6956c"
      unitRef="usdPerShare">-2.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjEtNy0xLTEtMjIzNTc_e918d623-2889-4552-b232-21f7a01ee60c"
      unitRef="usdPerShare">-2.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjItMS0xLTEtMjIzNTc_8ee19cc6-d233-4994-9c1e-6bd6303da7f4"
      unitRef="shares">173782151</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjItMS0xLTEtMjIzNTc_ce1da341-e2ad-440a-a7d5-139ced613673"
      unitRef="shares">173782151</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjItMy0xLTEtMjIzNTc_500540fc-8280-4a2d-8eb3-e55c4a3afef2"
      unitRef="shares">143314729</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjItMy0xLTEtMjIzNTc_9b4951cf-4919-4ec7-8963-ab4c6b70bb6d"
      unitRef="shares">143314729</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjItNS0xLTEtMjIzNTc_40fe2027-f749-4d4a-bd61-a6e908aedbf8"
      unitRef="shares">163050769</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjItNS0xLTEtMjIzNTc_f3d550ab-56c2-4fa1-8992-98fa0ddeaf28"
      unitRef="shares">163050769</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjItNy0xLTEtMjIzNTc_bc0f2731-2d75-4b94-9bb6-8bd94cd2d998"
      unitRef="shares">136230889</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjItNy0xLTEtMjIzNTc_ea51b116-b017-4962-98cf-6da18cbaf782"
      unitRef="shares">136230889</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjQtMS0xLTEtMjIzNTc_db9c9a54-7b23-4586-97d0-f7fb79d5818b"
      unitRef="usd">-59544000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjQtMy0xLTEtMjIzNTc_788d914f-ebec-4b44-bfde-fc6c1cad9096"
      unitRef="usd">-59959000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjQtNS0xLTEtMjIzNTc_9f57be9d-132c-447f-a813-4906f564d38d"
      unitRef="usd">-212162000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjQtNy0xLTEtMjIzNTc_2e8153ed-99e4-4d41-a7cf-e5b1ac1e215a"
      unitRef="usd">-296457000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjUtMS0xLTEtMjIzNTc_8120024a-6d1c-4675-9c94-4ad2fa93854c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjUtMy0xLTEtMjIzNTc_3bbf9129-4865-4ca7-9f5f-b922b8a5d3da"
      unitRef="usd">15000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjUtNS0xLTEtMjIzNTc_5cf6d5ef-bc0b-476e-9499-91706cc51b40"
      unitRef="usd">-7000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjUtNy0xLTEtMjIzNTc_aa50f34c-1f44-49fc-8f40-9a0efef2800c"
      unitRef="usd">6000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjYtMS0xLTEtMjIzNTc_26874859-49f7-40f4-a16b-905028fbcff7"
      unitRef="usd">-59544000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjYtMy0xLTEtMjIzNTc_b36fa1f0-2c02-47bd-8a73-753e128928f2"
      unitRef="usd">-59944000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjYtNS0xLTEtMjIzNTc_bdb9016c-db23-4d39-a1db-9f3b14ce81d3"
      unitRef="usd">-212169000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yNS9mcmFnOjVmNzc3MGUzOTBlMDQ3MjFiMGY2NTBiMmUxZWNjYjBiL3RhYmxlOmJhZTRmZmJkMzQwODRlMDViYzMyN2Y0NjNkNDBlNmVlL3RhYmxlcmFuZ2U6YmFlNGZmYmQzNDA4NGUwNWJjMzI3ZjQ2M2Q0MGU2ZWVfMjYtNy0xLTEtMjIzNTc_7978abee-ec0b-480c-a28f-2b5cba80a619"
      unitRef="usd">-296451000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMS0zLTEtMS0yMjM1Ny90ZXh0cmVnaW9uOmU2YmIyZTFkZGVmZTQ0YTE5ZTY3YzIwZDViMGFiN2IyXzQ_2313b99e-5bae-4ca9-bdcb-b4e24fdedfc8"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ieac2241d842b494ab83cde4c6efacf46_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMi0xLTEtMS0yMjM1Nw_ce59793d-710f-4d45-a483-98c331fad351"
      unitRef="shares">121674568</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ieac2241d842b494ab83cde4c6efacf46_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMi0zLTEtMS0yMjM1Nw_8e42ba3a-935f-49a0-b2f3-9e4b71ed609a"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8cc88afc4d2144b0820d54de176e706b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMi01LTEtMS0yMjM1Nw_129923f6-60bf-429d-b58b-220562998680"
      unitRef="usd">1188810000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7aec38034ce44b18a632886540cf60f7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMi03LTEtMS0yMjM1Nw_7a9758e6-31f9-4523-b329-a652050db885"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i068e2607df3e46ad958c3aac8d56c8bb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMi05LTEtMS0yMjM1Nw_c5ccb6d5-422f-4113-a738-2b3209642b26"
      unitRef="usd">-794054000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i789136767052440b86082df6969545de_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMi0xMS0xLTEtMjIzNTc_d6340d93-2f93-4d51-a88c-d9c21e99f4f2"
      unitRef="usd">394757000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i35244d2350f3498ebd27593263ce18df_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMy0xLTEtMS0yMjM1Nw_f015ba4c-58fe-4a7e-bbd7-eab4662b38bc"
      unitRef="shares">7973967</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ife5f777362b84a18b96a34f6b3515a94_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMy01LTEtMS0yMjM1Nw_1685ec7e-5983-4241-a065-b6b57f415103"
      unitRef="usd">56575000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5f2d1adb364d4ff18d2ad533959fe847_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMy0xMS0xLTEtMjIzNTc_269b6a24-3fcc-4e36-8400-576fee18efa8"
      unitRef="usd">56575000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i35244d2350f3498ebd27593263ce18df_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNC0xLTEtMS0yMjM1Nw_f6ba4805-ecc6-4a6b-85b5-7500829a5cd0"
      unitRef="shares">115024</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <akba:StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan
      contextRef="ife5f777362b84a18b96a34f6b3515a94_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNC01LTEtMS0yMjM1Nw_28baad10-30c0-43c3-9b42-401b2b6d58a7"
      unitRef="usd">451000</akba:StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan>
    <akba:StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan
      contextRef="i5f2d1adb364d4ff18d2ad533959fe847_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNC0xMS0xLTEtMjIzNTc_41c62f2e-dd2d-4d3d-8475-7ad825eb29b5"
      unitRef="usd">451000</akba:StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ife5f777362b84a18b96a34f6b3515a94_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNS01LTEtMS0yMjM1Nw_d49fd727-1640-41c2-90a3-2895c7aad5b4"
      unitRef="usd">4916000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5f2d1adb364d4ff18d2ad533959fe847_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNS0xMS0xLTEtMjIzNTc_4777d9f4-ce83-4d03-9299-da90215897d2"
      unitRef="usd">4916000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i35244d2350f3498ebd27593263ce18df_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNi0xLTEtMS0yMjM1Nw_8a121e67-a5fb-46d3-91b1-ce2107d128e8"
      unitRef="shares">64126</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ife5f777362b84a18b96a34f6b3515a94_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNi01LTEtMS0yMjM1Nw_2dfc8c4d-5c4c-4bc3-877a-64a0f08e24d8"
      unitRef="usd">412000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5f2d1adb364d4ff18d2ad533959fe847_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNi0xMS0xLTEtMjIzNTc_0765cfb6-a5bc-431f-a453-4c7b4428e00e"
      unitRef="usd">412000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i35244d2350f3498ebd27593263ce18df_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNy0xLTEtMS0yMjM1Nw_446bd146-54e8-426d-a819-d3e94c10112f"
      unitRef="shares">423755</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="ic2d99e2664f844a2acf2c4573bf8df03_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfOC05LTEtMS0yMjM1Nw_50e7fe32-7ff5-4e68-a55d-7d06c3159bfd"
      unitRef="usd">-60747000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5f2d1adb364d4ff18d2ad533959fe847_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfOC0xMS0xLTEtMjIzNTc_28ecea8d-4ac6-445d-af93-5fcd1f3eeba0"
      unitRef="usd">-60747000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id85007bc927a4536b6b47497569aa944_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfOS0xLTEtMS0yMjM1Nw_0f2f36b0-dcd8-4ece-95f4-fd32ce783143"
      unitRef="shares">130251440</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id85007bc927a4536b6b47497569aa944_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfOS0zLTEtMS0yMjM1Nw_0651cb5b-0bb6-4255-8a9a-447a4fc7523f"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i31f726c664944828986c9bc152d3cdbf_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfOS01LTEtMS0yMjM1Nw_e95a7d8d-8fa8-4256-ad1a-98a30ec41bf0"
      unitRef="usd">1251164000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2342b55b98df4c4f97a6deb300c2a324_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfOS03LTEtMS0yMjM1Nw_b7152991-0a5f-4cd8-a066-b3bfc4a005cd"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i86dc89425ef046d69fcf7b7442f7b3af_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfOS05LTEtMS0yMjM1Nw_a1eccc25-a763-40fc-a4ff-12fe615eaa19"
      unitRef="usd">-854801000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ief1a730691f34e3697272cf628a7de24_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfOS0xMS0xLTEtMjIzNTc_ae1c2db6-2b4c-4e0e-9c00-f4e575f070fc"
      unitRef="usd">396364000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i16965583159a4fb1943935fe0821c8b0_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTAtMS0xLTEtMjIzNTc_2b016a21-d99e-4d28-84f0-5c55628455a5"
      unitRef="shares">12650000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2f18d61adce243dbaa08d8980a32a679_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTAtNS0xLTEtMjIzNTc_55c0d82f-d570-4ddc-bd51-01d6342f0ad1"
      unitRef="usd">142383000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6909ec0393ec4db2b3cc2706b5126477_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTAtMTEtMS0xLTIyMzU3_a359d242-17f3-4a7b-a5a8-bf1df7dcfb0a"
      unitRef="usd">142383000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2f18d61adce243dbaa08d8980a32a679_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTEtNS0xLTEtMjIzNTc_94d3c5b5-c867-446c-afb5-2dcdbd725ba0"
      unitRef="usd">6864000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6909ec0393ec4db2b3cc2706b5126477_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTEtMTEtMS0xLTIyMzU3_3a2110ad-5bec-445a-a0ce-0afe1f876e59"
      unitRef="usd">6864000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i16965583159a4fb1943935fe0821c8b0_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTItMS0xLTEtMjIzNTc_2ba26d26-024f-406e-acca-fde6be4c3514"
      unitRef="shares">48103</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2f18d61adce243dbaa08d8980a32a679_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTItNS0xLTEtMjIzNTc_c138f28e-794c-41a5-a9da-6aa6179e9750"
      unitRef="usd">409000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6909ec0393ec4db2b3cc2706b5126477_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTItMTEtMS0xLTIyMzU3_63c8aab3-0ec0-47ef-a062-e637ce047eb5"
      unitRef="usd">409000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i16965583159a4fb1943935fe0821c8b0_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTMtMS0xLTEtMjIzNTc_42371c12-73bf-400c-a301-f0d8db6b1a9f"
      unitRef="shares">179866</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i45ee7fe7e4ea40449ec5093c5cfe4dab_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTQtNy0xLTEtMjIzNTc_33b41c3e-d465-4358-9719-d6417bb11728"
      unitRef="usd">-9000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i6909ec0393ec4db2b3cc2706b5126477_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTQtMTEtMS0xLTIyMzU3_c7139429-a4aa-45f3-8227-2ceeb3fe52ed"
      unitRef="usd">-9000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i97143382c5d94af882a7a099bb719c08_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTUtOS0xLTEtMjIzNTc_c494c9ad-74ad-4f7d-8206-a86a0e89c754"
      unitRef="usd">-175751000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6909ec0393ec4db2b3cc2706b5126477_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTUtMTEtMS0xLTIyMzU3_f6fb059a-f6a3-4403-8f52-5da6e8ea9676"
      unitRef="usd">-175751000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i847e92f55f2743cc8282356cea6026ae_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTYtMS0xLTEtMjIzNTc_899f991e-e5aa-4a2a-b497-0fd375cfb1f9"
      unitRef="shares">143129409</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i847e92f55f2743cc8282356cea6026ae_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTYtMy0xLTEtMjIzNTc_df61e776-5dd4-40a4-9f8a-e04bb1216791"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib807b33284ab430ca5e62866cfe3994b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTYtNS0xLTEtMjIzNTc_357b7e3d-fd42-407c-9707-fb469ea0387d"
      unitRef="usd">1400820000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i889ed5ea677d43a19e0b2f90cc53dd3f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTYtNy0xLTEtMjIzNTc_ccafed8d-89af-40dc-80ca-6db75cdf02dc"
      unitRef="usd">-9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i18bc18c0ef5546c5baeae2af38f6fac6_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTYtOS0xLTEtMjIzNTc_b2085594-761f-422f-8151-796511523633"
      unitRef="usd">-1030552000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i264a47d635da444c86cb87a405c909c4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTYtMTEtMS0xLTIyMzU3_ed15f7a0-07b1-49ca-a2d1-b5bcdb94cd6f"
      unitRef="usd">370260000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i82c195ab2c01450cb6639257d18f6117_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTctMS0xLTEtMjI4NTE_fa1f2aeb-86a9-4f9c-81f5-88f035e71ddf"
      unitRef="shares">120634</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <akba:StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan
      contextRef="i82c5946e60d04544ab9e41f12a391895_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTctNS0xLTEtMjI5NTU_27c78912-1330-4736-bdf1-ec20deeed34c"
      unitRef="usd">649000</akba:StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan>
    <akba:StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTctMTEtMS0xLTIzMTAy_a3c764fc-cced-4584-b689-35d5033c60c4"
      unitRef="usd">649000</akba:StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i82c5946e60d04544ab9e41f12a391895_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTgtNS0xLTEtMjI5NjI_23258fce-2d36-4d88-adc4-7cec1bf4741c"
      unitRef="usd">6592000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTgtMTEtMS0xLTIzMTA5_540c8a07-c904-496a-8e1d-bf9232be8146"
      unitRef="usd">6592000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i82c195ab2c01450cb6639257d18f6117_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTktMS0xLTEtMjI4NjY_8a31c160-722b-4965-9b02-808a35ee893d"
      unitRef="shares">54404</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i82c5946e60d04544ab9e41f12a391895_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTktNS0xLTEtMjI5Njk_4133bb5a-bd97-45c3-ae2a-acb6ce6cfab2"
      unitRef="usd">405000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTktMTEtMS0xLTIzMTE2_8a49c4a6-d64b-4373-8f0f-f724f3c3f290"
      unitRef="usd">405000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i82c195ab2c01450cb6639257d18f6117_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjAtMS0xLTEtMjI4NzM_88b963c9-763e-4223-a257-ec04bc65e893"
      unitRef="shares">24205</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i62615678941c40648470b93e883c6c27_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjEtNy0xLTEtMjMwMzI_036f57b7-b6fa-4340-a926-d779a21f1c5c"
      unitRef="usd">15000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjEtMTEtMS0xLTIzMTMw_75222538-12d3-463b-acf6-82a65fa16555"
      unitRef="usd">15000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i0c14e7a0bd4c4f3b838b097690f0db73_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjItOS0xLTEtMjMwODg_48a1e74b-f117-4a59-9d9b-965af866f0eb"
      unitRef="usd">-59959000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjItMTEtMS0xLTIzMTM3_a2f0ac71-55a3-48d6-a3b4-74d139f4bda8"
      unitRef="usd">-59959000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5eb0e7b9743b4b5bb8dcad4532a676f4_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjMtMS0xLTEtMjI4OTQ_f20b1991-6ac1-41f5-9b7a-da28c170bd64"
      unitRef="shares">143328652</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5eb0e7b9743b4b5bb8dcad4532a676f4_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjMtMy0xLTEtMjI5NDg_f51f844e-11e9-47aa-9ac7-01027be1b769"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icff6bb56ef7f4b71b0ee5439d93c832d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjMtNS0xLTEtMjI5OTc_d5f36c65-03b3-47e2-bfee-9eab703ff999"
      unitRef="usd">1408466000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2821e9d04730493782461dc080013c07_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjMtNy0xLTEtMjMwNDY_b87ba005-4469-464a-ac30-3c77edddcc15"
      unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i04f6e21078d54815b0fbcd7ccc3af0dc_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjMtOS0xLTEtMjMwOTU_357c6448-634f-40ff-9437-40cb0cb2b677"
      unitRef="usd">-1090511000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaa53bc3c09164606aeaedf64079be5bc_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjMtMTEtMS0xLTIzMTQ0_7685d109-63c0-4706-a9d4-54ea56bc4675"
      unitRef="usd">317962000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie7f690b3768a4f10ad9965db748015b2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTgtMS0xLTEtMjIzNTc_2189f5df-f9a0-4caf-a67e-c64c86aa6f53"
      unitRef="shares">148074085</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie7f690b3768a4f10ad9965db748015b2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTgtMy0xLTEtMjIzNTc_093d9adb-9d58-4ddb-aeb0-61ed8cbcc6e1"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i575073ad687946c3958e67e8c915001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTgtNS0xLTEtMjIzNTc_4a5f5f12-8b91-4e0a-832d-3e3dedb9b1e0"
      unitRef="usd">1425115000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i264fd5873c584be39232727f484cadd7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTgtNy0xLTEtMjIzNTc_08775dd2-2291-43ba-9abd-b00c8154410c"
      unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i751bbd3aed3c44479e98241e0fabf680_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTgtOS0xLTEtMjIzNTc_1cdb71a5-01a9-43f6-96d9-be23de07400f"
      unitRef="usd">-1177511000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTgtMTEtMS0xLTIyMzU3_85d09e3d-dce9-44a6-8e36-48611fdf3b1e"
      unitRef="usd">247618000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia0c080b6e3284262a5a2ac05fc8be6d8_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTktMS0xLTEtMjIzNTc_3da3015e-f6a4-4095-9c67-d68742e8dec4"
      unitRef="shares">9228017</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia0c080b6e3284262a5a2ac05fc8be6d8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTktMy0xLTEtMjIzNTc_246483f9-35c8-4791-a9bb-31703350e7ec"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ied2865777ae543ccb7e6733cedf24ead_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTktNS0xLTEtMjIzNTc_b2953ef6-d7e1-4ff7-8a69-6de43dccd560"
      unitRef="usd">29497000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibedefb3b11734e53bd359a1087a22569_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMTktMTEtMS0xLTIyMzU3_21bc7ab5-61d5-44cf-b582-5acc808f0267"
      unitRef="usd">29498000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ia0c080b6e3284262a5a2ac05fc8be6d8_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjAtMS0xLTEtMjIzNTc_0bc20de6-31d3-430a-931a-9c3968c8fc0d"
      unitRef="shares">154276</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <akba:StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan
      contextRef="ied2865777ae543ccb7e6733cedf24ead_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjAtNS0xLTEtMjIzNTc_c716f90f-1b31-4b20-a653-03f69a2580a1"
      unitRef="usd">367000</akba:StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan>
    <akba:StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan
      contextRef="ibedefb3b11734e53bd359a1087a22569_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjAtMTEtMS0xLTIyMzU3_def14ce3-7c8e-420d-83be-0e778d8d5a5f"
      unitRef="usd">367000</akba:StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ied2865777ae543ccb7e6733cedf24ead_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjEtNS0xLTEtMjIzNTc_a16b3232-35ba-4195-9683-8a9f8838f6fa"
      unitRef="usd">5992000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibedefb3b11734e53bd359a1087a22569_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjEtMTEtMS0xLTIyMzU3_1ce0e808-8c38-4604-8cff-c772abc5f4db"
      unitRef="usd">5992000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ia0c080b6e3284262a5a2ac05fc8be6d8_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjItMS0xLTEtMjIzNTc_19dbb31d-31ee-4652-bea4-b6fdcce23b9f"
      unitRef="shares">1063711</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i717676096b5a4c5eab55661e5e686861_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjMtNy0xLTEtMjIzNTc_14d90125-7405-4bb9-b2f1-8c096b3390eb"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ibedefb3b11734e53bd359a1087a22569_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjMtMTEtMS0xLTIyMzU3_19b8ea85-1c4b-4aa0-b580-b15e80239597"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i5cbbd7587d264a93a0fac886a04d7c90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjQtOS0xLTEtMjIzNTc_9ec9b30c-4785-44f9-8918-838d27938a17"
      unitRef="usd">-69580000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibedefb3b11734e53bd359a1087a22569_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjQtMTEtMS0xLTIyMzU3_6faa81c5-f9a1-4ef3-922b-1db0b6e87eaa"
      unitRef="usd">-69580000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i319c95fd8a8d4153a2394567a88f22ab_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjUtMS0xLTEtMjIzNTc_b3a981e5-dabc-4ec5-9880-6f07e0636e89"
      unitRef="shares">158520089</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i319c95fd8a8d4153a2394567a88f22ab_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjUtMy0xLTEtMjIzNTc_f74b5739-44cb-472a-b202-723d7e029ede"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idd7f6d1ca07a4a7c81755f54e71d3a96_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjUtNS0xLTEtMjIzNTc_5bbac3dd-ce09-4341-bbcc-62639faf4355"
      unitRef="usd">1460971000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9a772f431b4b4e039d186148c8287a6a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjUtNy0xLTEtMjIzNTc_b02a2e65-c9ae-4c79-9f05-fc9577982e43"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8f40f8942af14045ad47dc41f0a655f5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjUtOS0xLTEtMjIzNTc_6b2be9c2-619e-4568-8b8d-7f42830b55e9"
      unitRef="usd">-1247091000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id832960589e2403f88473dd831c88c68_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjUtMTEtMS0xLTIyMzU3_dcfed127-e746-4f7e-bae9-61ded945874e"
      unitRef="usd">213891000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="idc035820389e4d8a96227a92fb46d718_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjYtMS0xLTEtMjIzNTc_a17045ff-0cd3-4cdb-82cd-5e3f712822c6"
      unitRef="shares">10446160</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i00f6c8320acf4b159907d88edddf5125_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjYtNS0xLTEtMjIzNTc_315818d6-4ea2-4f56-b42f-19214e57c536"
      unitRef="usd">37266000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i02a8ba6ff0054b678403f9ad5ed7efc4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjYtMTEtMS0xLTIyMzU3_b722d334-9022-4098-99f6-8b0609373bed"
      unitRef="usd">37266000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i00f6c8320acf4b159907d88edddf5125_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjctNS0xLTEtMjIzNTc_77d9d4e9-3227-4913-8438-52eeab3890a7"
      unitRef="usd">6515000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i02a8ba6ff0054b678403f9ad5ed7efc4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjctMTEtMS0xLTIyMzU3_a74947fc-116a-4330-b79f-379c604e6801"
      unitRef="usd">6515000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="idc035820389e4d8a96227a92fb46d718_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMjktMS0xLTEtMjIzNTc_06d9861a-c730-449b-8b32-38b5eaaa9587"
      unitRef="shares">685174</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="iba37ce69556348a28b16ed216da9256d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMzAtNy0xLTEtMjIzNTc_120d565b-87d4-4dd3-968f-8eb48d4e3352"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i02a8ba6ff0054b678403f9ad5ed7efc4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMzAtMTEtMS0xLTIyMzU3_8d9cdc21-b29c-42b2-8c22-ef843179c013"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="idbc0260c7ae64edbabae5c84ce6356df_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMzEtOS0xLTEtMjIzNTc_5d05455b-59c4-4c05-b9bc-baf9811dcab3"
      unitRef="usd">-83038000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i02a8ba6ff0054b678403f9ad5ed7efc4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMzEtMTEtMS0xLTIyMzU3_8a2b3632-121d-4988-b878-5e705419f712"
      unitRef="usd">-83038000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib48d1a5470e1451ea0d90314033b3dfe_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMzItMS0xLTEtMjIzNTc_057fce88-b275-4d59-8c19-0f9e7bef2801"
      unitRef="shares">169651423</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib48d1a5470e1451ea0d90314033b3dfe_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMzItMy0xLTEtMjIzNTc_1c44b164-5cda-44f5-bd9f-e3a5b345272e"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id2fc62f68c514632b6ff5532a6c05123_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMzItNS0xLTEtMjIzNTc_28d2ff7b-485c-4ffa-85da-15ffccf78e81"
      unitRef="usd">1504752000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic634149430a042a0af7eced0d7b1f3bc_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMzItNy0xLTEtMjIzNTc_54e1be2b-d4c3-4dc4-b59b-725cf85c3eb6"
      unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iba476346b25f4a3b8f5eacda5b591d48_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMzItOS0xLTEtMjIzNTc_59895b46-d040-4912-99ff-255b6391ff18"
      unitRef="usd">-1330129000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i952bff9821b4497aa3ea95191dd2fe53_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfMzItMTEtMS0xLTIyMzU3_daa03561-a148-42a7-bc32-04101c3bb896"
      unitRef="usd">174631000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i362dc8956d2b485d99df3ac257386849_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDAtMS0xLTEtMjMyMDU_8c9182b5-8e13-482f-b706-b9c4ccc2101f"
      unitRef="shares">4730466</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic9932b64331a4dd3b00728c94fbb38e0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDAtNS0xLTEtMjMyOTY_ba001e31-0237-43fd-8a78-ddfed6e30da5"
      unitRef="usd">16092000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDAtMTEtMS0xLTIzNDQ1_413e714e-e60f-4d97-a6b1-dddd9f5cf2ff"
      unitRef="usd">16092000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i362dc8956d2b485d99df3ac257386849_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDEtMS0xLTEtMjQ5ODg_bf2e4f1d-0882-40bc-b775-7f64d248d360"
      unitRef="shares">152917</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <akba:StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan
      contextRef="ic9932b64331a4dd3b00728c94fbb38e0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDEtNS0xLTEtMjUwMDU_1b16f53a-317a-48ee-9f30-e18f05c4311d"
      unitRef="usd">379000</akba:StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan>
    <akba:StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDEtMTEtMS0xLTI1MDY2_08eae059-0a23-4e56-a4e6-d38482f64a43"
      unitRef="usd">379000</akba:StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic9932b64331a4dd3b00728c94fbb38e0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDEtNS0xLTEtMjMzMDM_06fa3df8-30d1-49c4-99f0-3095299c6398"
      unitRef="usd">5592000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDEtMTEtMS0xLTIzNDUy_ff7b37ca-1494-4180-a991-f59f722b5ded"
      unitRef="usd">5592000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i362dc8956d2b485d99df3ac257386849_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDMtMS0xLTEtMjMyMTU_905bed48-8098-44d7-bb00-7010fa0802aa"
      unitRef="shares">17183</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="ie9bbe8c544974328bc9207e0b78b0928_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDUtOS0xLTEtMjM0MzE_debbd729-ba1d-49e3-8865-d1a19e25aa9c"
      unitRef="usd">-59544000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDUtMTEtMS0xLTIzNDgw_fc77ac4c-5c2a-4d12-9851-c0d774066884"
      unitRef="usd">-59544000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6a813010cea049e3b9d06fd62cbe9afe_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDYtMS0xLTEtMjMyMzY_8ab98d37-b23f-486c-80f2-04af02633ca6"
      unitRef="shares">174551989</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6a813010cea049e3b9d06fd62cbe9afe_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDYtMy0xLTEtMjMyODk_9954fb61-e2f6-4fd4-96bd-bcb83ae8e4a0"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic0d58cac5ebc4dde9442518ff67901b4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDYtNS0xLTEtMjMzNDA_d0c5296b-617b-4712-a022-b29fd9749443"
      unitRef="usd">1526815000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0c64672624aa423384622e444a575831_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDYtNy0xLTEtMjMzODk_740ba228-52db-4ca8-975f-7b997809f597"
      unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i688f4e0d7a5c4c7e9ee5af402822f7f3_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDYtOS0xLTEtMjM0Mzg_85527458-853b-4c2b-bbe8-fd763c4d931d"
      unitRef="usd">-1389673000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8yOC9mcmFnOjE0Zjc2YTBiZGYyMjQwZjBhMWI4Y2QyMDYwODMwODQ4L3RhYmxlOjQzMDdmMjFjNWRmMjRlYWZiZGJlNjMyMWYyY2YyYzU3L3RhYmxlcmFuZ2U6NDMwN2YyMWM1ZGYyNGVhZmJkYmU2MzIxZjJjZjJjNTdfNDYtMTEtMS0xLTIzNDg3_838d9650-1286-486b-a0d2-b68db68e64bc"
      unitRef="usd">137150000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMy0xLTEtMS0yMjM1Nw_f1db319e-1e6f-401f-94e3-5a0b2cabd40c"
      unitRef="usd">-212162000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMy0zLTEtMS0yMjM1Nw_75fa879c-2647-4614-b06b-48fa638716cd"
      unitRef="usd">-296457000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfNS0xLTEtMS0yMjM1Nw_32e1306d-2cc0-4e8b-a4fc-e85e326f2880"
      unitRef="usd">1485000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfNS0zLTEtMS0yMjM1Nw_c7f4c8d8-3747-447b-96cc-b296386c9499"
      unitRef="usd">1559000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfNi0xLTEtMS0yMjM1Nw_beed3701-7c94-4b9b-8db9-06efffc8b696"
      unitRef="usd">27032000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfNi0zLTEtMS0yMjM1Nw_1e2cd45a-38ff-4a5c-a830-a502d3accafe"
      unitRef="usd">24307000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfNy0xLTEtMS0yMjM1Nw_509e455d-46ba-450c-a4f0-11cb6254e4c5"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfNy0zLTEtMS0yMjM1Nw_ed91cc37-d600-41b6-beae-facde2fbff5b"
      unitRef="usd">115527000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfOC0xLTEtMS0yMjM1Nw_1adda107-219a-4d48-beb2-c0b5c7ef9da1"
      unitRef="usd">15000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfOC0zLTEtMS0yMjM1Nw_5cf78a4d-b361-4cd9-b2e0-3212c211f225"
      unitRef="usd">31000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <akba:ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfOS0xLTEtMS0yMjM1Nw_4d39b833-9dfd-4358-8afa-30318dd55924"
      unitRef="usd">6779000</akba:ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome>
    <akba:ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfOS0zLTEtMS0yMjM1Nw_89aec5c9-b843-4d4c-ba27-d7709270132f"
      unitRef="usd">0</akba:ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome>
    <akba:ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTAtMS0xLTEtMjIzNTc_754603f1-a212-4da1-a716-9ced398a5205"
      unitRef="usd">425000</akba:ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue>
    <akba:ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTAtMy0xLTEtMjIzNTc_7aa8e466-c8a5-4783-a8fe-630b6bd325e0"
      unitRef="usd">0</akba:ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue>
    <akba:NoncashInterestExpense
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTEtMS0xLTEtMjIzNTc_33cb41e0-ab75-4ed4-85f4-702d8abbd1cf"
      unitRef="usd">852000</akba:NoncashInterestExpense>
    <akba:NoncashInterestExpense
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTEtMy0xLTEtMjIzNTc_5604fff2-99c3-429f-8872-db6f5dae80ef"
      unitRef="usd">1255000</akba:NoncashInterestExpense>
    <us-gaap:StraightLineRent
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTItMS0xLTEtMjIzNTc_4e695068-e267-4262-8ab5-3da517f4f8eb"
      unitRef="usd">1415000</us-gaap:StraightLineRent>
    <us-gaap:StraightLineRent
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTItMy0xLTEtMjIzNTc_d083bac6-df87-49dc-93f6-8640ba032927"
      unitRef="usd">1660000</us-gaap:StraightLineRent>
    <akba:FairValueAdjustmentToInventory
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTMtMS0xLTEtMjIzNTc_a1148cb2-98b6-4df4-9bee-65485b712df3"
      unitRef="usd">21575000</akba:FairValueAdjustmentToInventory>
    <akba:FairValueAdjustmentToInventory
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTMtMy0xLTEtMjIzNTc_3e6c61b4-4da1-4547-bf10-e045e09fc373"
      unitRef="usd">39522000</akba:FairValueAdjustmentToInventory>
    <us-gaap:InventoryWriteDown
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTQtMS0xLTEtMjIzNTc_f25dfd5f-e76b-40cf-8cda-a3ae3d1b9214"
      unitRef="usd">7126000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTQtMy0xLTEtMjIzNTc_fa0a0f38-0c62-4e14-9c51-07490d4d977b"
      unitRef="usd">18608000</us-gaap:InventoryWriteDown>
    <akba:ExcessInventoryPurchaseCommitmentsExpenseReversal
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTUtMS0xLTEtMjIzNTc_4995f24e-45fb-4171-95ac-4c6b22ef75a6"
      unitRef="usd">15376000</akba:ExcessInventoryPurchaseCommitmentsExpenseReversal>
    <akba:ExcessInventoryPurchaseCommitmentsExpenseReversal
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTUtMy0xLTEtMjIzNTc_92e5c8a5-1204-4142-8818-2f6ce426e9e1"
      unitRef="usd">10304000</akba:ExcessInventoryPurchaseCommitmentsExpenseReversal>
    <us-gaap:ShareBasedCompensation
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTYtMS0xLTEtMjIzNTc_dafbdd8c-7014-4a86-b8e4-ede51b91531a"
      unitRef="usd">18099000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTYtMy0xLTEtMjIzNTc_ef4cdb95-2cc8-433c-a095-7025482c77e1"
      unitRef="usd">18372000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTctMS0xLTEtMjIzNTc_b7be2470-f916-4362-b2af-8220f6125b88"
      unitRef="usd">-490000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTctMy0xLTEtMjIzNTc_07605618-e318-4a18-ae79-84770fe87440"
      unitRef="usd">340000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTktMS0xLTEtMjIzNTc_32b4b216-03c6-4405-bcbb-a3564ac6a817"
      unitRef="usd">22837000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMTktMy0xLTEtMjIzNTc_2aea5724-d337-4e7c-8d96-922603edad4a"
      unitRef="usd">-14398000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjAtMS0xLTEtMjIzNTc_0f981a66-ea47-4d8e-8d1b-a66971417432"
      unitRef="usd">35282000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjAtMy0xLTEtMjIzNTc_d22df0d6-7556-4496-a171-f452a5ca19e1"
      unitRef="usd">-6415000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjEtMS0xLTEtMjIzNTc_bf44f4eb-8b79-498b-bf2b-7c13f4fe840d"
      unitRef="usd">25020000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjEtMy0xLTEtMjIzNTc_9c96cd96-5e07-4352-906f-d9f1723a7b12"
      unitRef="usd">2279000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjItMS0xLTEtMjIzNTc_255e64a0-cdd4-4f2b-b2e5-cc37e150addf"
      unitRef="usd">-4728000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjItMy0xLTEtMjIzNTc_aad48ef2-c891-42a5-bfbf-5ec10f17922e"
      unitRef="usd">6518000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjMtMS0xLTEtMjIzNTc_b38744c4-8138-4b2e-861f-dd3ee1d4f5d3"
      unitRef="usd">-14933000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjMtMy0xLTEtMjIzNTc_275444ac-7a0f-4f6e-a70f-b8480752c922"
      unitRef="usd">3028000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjQtMS0xLTEtMjIzNTc_69aa829b-de08-443d-94c7-111d186316c7"
      unitRef="usd">15099000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjQtMy0xLTEtMjIzNTc_2fb3b03a-0025-4df2-a372-aa21cd087ea9"
      unitRef="usd">-6072000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjUtMS0xLTEtMjIzNTc_a751a693-2117-4f0c-99d4-230349a5ca48"
      unitRef="usd">1173000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjUtMy0xLTEtMjIzNTc_4272c994-39b1-458c-ab7c-a7c23750c25a"
      unitRef="usd">1032000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjYtMS0xLTEtMjIzNTc_e93cabbb-021a-4129-9653-78cbe0e5b223"
      unitRef="usd">3098000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjYtMy0xLTEtMjIzNTc_f36cb99c-3f67-4c5d-9e22-77bbd1e1dcf7"
      unitRef="usd">-21256000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjctMS0xLTEtMjIzNTc_024bebbb-c95b-4364-9f67-69b4da56238e"
      unitRef="usd">-190157000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjctMy0xLTEtMjIzNTc_cbbfbba9-e12b-494f-a8ed-e2c361b559bf"
      unitRef="usd">-79606000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjktMS0xLTEtMjIzNTc_d1d69438-ba16-4505-8309-599ee03671e4"
      unitRef="usd">59000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMjktMy0xLTEtMjIzNTc_d3498494-bc5b-43f6-a595-bed507f5536f"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzAtMS0xLTEtMjIzNTc_730a71c5-1b4f-4fd7-9925-0b6732218a57"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzAtMy0xLTEtMjIzNTc_4df5fc38-29e6-4e26-a14c-8487bcfb2c05"
      unitRef="usd">99932000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzEtMS0xLTEtMjIzNTc_be743b1c-2c8f-41b9-bad3-56fafbabbacb"
      unitRef="usd">40000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzEtMy0xLTEtMjIzNTc_37cf64f1-7e23-49aa-9add-4f24a377dce1"
      unitRef="usd">245000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzItMS0xLTEtMjIzNTc_191fa284-e9f1-45d5-a3fb-2b8a9f45815f"
      unitRef="usd">39941000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzItMy0xLTEtMjIzNTc_a14e96a2-ef71-4287-ae04-faf5a3dc5676"
      unitRef="usd">-99687000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <akba:ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzQtMS0xLTEtMjIzNTc_efd552e9-d3cb-45f5-87bf-47b9e2ad9ce6"
      unitRef="usd">44783000</akba:ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties>
    <akba:ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzQtMy0xLTEtMjIzNTc_eccfd2ac-9390-4cd9-95f8-47f0ffb21d09"
      unitRef="usd">0</akba:ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties>
    <akba:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzUtMS0xLTEtMjIzNTc_56801f67-0c80-485a-abc6-a8a3982c91ae"
      unitRef="usd">82799000</akba:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <akba:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzUtMy0xLTEtMjIzNTc_16dcdb05-d83b-4ed8-8240-742ea6cea61f"
      unitRef="usd">198883000</akba:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzYtMS0xLTEtMjIzNTc_2a673c3d-c10a-437f-b10e-a18a8c158af3"
      unitRef="usd">746000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzYtMy0xLTEtMjIzNTc_8d5e1bab-770e-44a4-8aaf-26d73342975b"
      unitRef="usd">1100000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzctMS0xLTEtMjIzNTc_189bc58e-af1c-4b96-83e5-5559b485868d"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzctMy0xLTEtMjIzNTc_39a225d4-4794-4daf-9888-8aaa2a306eba"
      unitRef="usd">1226000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzgtMS0xLTEtMjIzNTc_01a730e1-6675-4ccc-881e-7d35e798719f"
      unitRef="usd">128328000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzgtMy0xLTEtMjIzNTc_cedd5033-0113-4a67-b1a3-c853b3ac57b4"
      unitRef="usd">201209000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzktMS0xLTEtMjIzNTc_2df72b0a-798c-438f-abde-e29d887d5c67"
      unitRef="usd">-21888000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfMzktMy0xLTEtMjIzNTc_5b45e969-6b38-4a4d-85f9-48d27544230d"
      unitRef="usd">21916000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfNDAtMS0xLTEtMjIzNTc_51fc8bb0-8df6-4734-bb73-45f535db53f3"
      unitRef="usd">231132000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i789136767052440b86082df6969545de_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfNDAtMy0xLTEtMjIzNTc_b3bed82f-a5e5-4619-9625-d3ae5f2afa31"
      unitRef="usd">149804000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfNDEtMS0xLTEtMjIzNTc_9b434d4f-76cd-43a8-9993-37ff8a351031"
      unitRef="usd">209244000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaa53bc3c09164606aeaedf64079be5bc_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfNDEtMy0xLTEtMjIzNTc_0d6fcf93-0e38-4c1a-946a-c4501e0b9ac0"
      unitRef="usd">171720000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <akba:DeferredUnpaidOfferingCosts
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfNDMtMS0xLTEtMjIzNTc_4a6f8209-d473-4c15-827b-93d7d5256da5"
      unitRef="usd">57000</akba:DeferredUnpaidOfferingCosts>
    <akba:DeferredUnpaidOfferingCosts
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zMS9mcmFnOjI5MDZkMGE5ZDU0MzRjMDZhYzdlNzljOTEyY2Q4YjQ1L3RhYmxlOjgzNzczYzYwM2Q1NTQ4OWViMjNlYjFlYTQ0MTUxODRkL3RhYmxlcmFuZ2U6ODM3NzNjNjAzZDU1NDg5ZWIyM2ViMWVhNDQxNTE4NGRfNDMtMy0xLTEtMjIzNTc_a9a4422b-c859-41c5-abd8-e9f5c721d7e2"
      unitRef="usd">75000</akba:DeferredUnpaidOfferingCosts>
    <us-gaap:NatureOfOperations
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zNy9mcmFnOjExOTI1ZjA5NDA2ZjQ4M2Y5YWNiMjJmZDQyZTJlYzUyL3RleHRyZWdpb246MTE5MjVmMDk0MDZmNDgzZjlhY2IyMmZkNDJlMmVjNTJfNTUzOQ_7cb06414-86d0-4a99-81e7-7b19fabac0f2">Nature of Organization and Operations&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Akebia Therapeutics, Inc., referred to as Akebia or the Company, was incorporated in the State of Delaware in 2007. Akebia is a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease. Akebia&#x2019;s lead investigational product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease, or CKD. Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, or HIF-PHI, designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, or HIF, which stimulates erythropoietin, or EPO, production, and can lead to red blood cell, or RBC, production and improved oxygen delivery to tissues. Vadadustat is approved and marketed in Japan as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients under the trade name Vafseo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. The Company submitted a New Drug Application, or NDA, to the U.S. Food and Drug Administration, or FDA, for vadadustat in March of 2021 for the treatment of anemia due to CKD in adult patients with CKD on dialysis, or DD-CKD, and adult patients with CKD not on dialysis, or NDD-CKD. The Company's NDA submission was accepted for filing by the FDA in May 2021 and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#373737;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;at the time of filing the NDA, the FDA indicated that they were not currently planning to hold an Advisory Committee meeting to discuss the application&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; for vadadustat. The FDA also assigned the application standard review and a Prescription Drug User Fee Act (PDUFA) target action date of March 29, 2022. The Company&#x2019;s collaboration partner, Otsuka Pharmaceutical Co. Ltd., submitted a Marketing Authorization Application, or MAA, for vadadustat for the treatment of anemia due to CKD in adult patients to the European Medicines Agency, or EMA, in October 2021&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; In addition, the Company has a commercial product, Auryxia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (ferric citrate), which is currently approved by the FDA and marketed for two indications in the United States: the control of serum phosphorus levels in DD-CKD adult patients and the treatment of iron deficiency anemia, or IDA, in NDD-CKD adult patients. Ferric citrate is also approved and marketed in Japan as an oral treatment for IDA in adult patients for the improvement of hyperphosphatemia in adult patients with DD-CKD and NDD-CKD under the trade name Riona (ferric citrate hydrate).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since inception, the Company has devoted most of its resources to research and development, including its preclinical and clinical development activities, and providing general and administrative support for these operations. The Company began recording revenue from the U.S. sales of Auryxia and revenue from sublicensing rights to Auryxia in Japan from the Company&#x2019;s Japanese partners, Japan Tobacco, Inc. and its subsidiary Torii Pharmaceutical Co., Ltd., collectively JT and Torii, on December 12, 2018 following the consummation of a merger with Keryx Biopharmaceuticals, Inc., or Keryx, or the Merger. Additionally, following regulatory approval of vadadustat in Japan, the Company began recognizing royalty revenues from Mitsubishi Tanabe Pharma Corporation, or MTPC, from the sale of Vafseo in August 2020. In February 2021, the Company entered into a royalty interest acquisition agreement with HealthCare Royalty Partners IV, L.P., or the Royalty Agreement, whereby the Company sold its right to receive royalties and sales milestones under its Collaboration Agreement with MTPC, or the MTPC Agreement, subject to certain caps and other terms and conditions (see Note 5 for additional information). The Company has not generated a profit to date and may never generate profits from product sales. Vadadustat and the Company&#x2019;s other potential product candidates are subject to long development cycles, and the Company may be unsuccessful in its efforts to develop, obtain marketing approval for or market vadadustat and its other potential product candidates. If the Company does not successfully commercialize Auryxia, vadadustat or any other potential product candidate, if approved, it may be unable to achieve profitability.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company&#x2019;s management completed its going concern assessment in accordance with Accounting Standards Codification, or ASC, 205-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, or ASC 205-40. The Company believes that its cash resources will be sufficient to allow the Company to fund its current operating plan through at least the next twelve months from the filing of this Quarterly Report on Form 10-Q. If the Company receives regulatory approval of vadadustat in the U.S., the Company expects to incur significant incremental costs to its current operating plan to commercialize vadadustat, including costs of marketing, manufacturing and distribution. The potential timely regulatory approval of vadadustat and the receipt of associated regulatory milestones is an important source of funding of the Company's cash runway. However, the Company will require additional funding to fund its operating plan beyond the next twelve months. There are numerous risks and uncertainties associated with research, development and commercialization activities, and actual results could vary materially as a result of a number of factors, many of which are outside of the Company's control. There can be no assurance, however, that the current operating plan will be achieved in the time frame anticipated by the Company, or that its cash resources will fund the Company&#x2019;s operating plan for the period anticipated by the Company or that additional funding will be available on terms acceptable to the Company, or at all. The Company will require additional capital to pursue development and commercial activities related to Auryxia and vadadustat or any additional products and product candidates, including those that may be in-licensed or acquired. The Company expects to finance future cash needs through product &lt;/span&gt;&lt;/div&gt;revenue, public or private equity or debt transactions, payments from its collaborators, strategic transactions, or a combination of these approaches. However, additional financing may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise capital in sufficient amounts when needed or on attractive terms, it may not be able to pursue development and commercial activities related to Auryxia and vadadustat or any additional products and product candidates, including those that may be in-licensed or acquired.</us-gaap:NatureOfOperations>
    <akba:OperatingPlanSufficientlyFundedByCashResourcesPeriod
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl8zNy9mcmFnOjExOTI1ZjA5NDA2ZjQ4M2Y5YWNiMjJmZDQyZTJlYzUyL3RleHRyZWdpb246MTE5MjVmMDk0MDZmNDgzZjlhY2IyMmZkNDJlMmVjNTJfNDI5Mw_6a408bfb-5730-4228-a978-b101062123ed">P12M</akba:OperatingPlanSufficientlyFundedByCashResourcesPeriod>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80MC9mcmFnOjM0MjMzYjg1NTNmZjRjMTViZDRjYTBlZWRhZTEyMGJiL3RleHRyZWdpb246MzQyMzNiODU1M2ZmNGMxNWJkNGNhMGVlZGFlMTIwYmJfNjMwNg_7635cd15-61d5-47d3-9a83-05868e173547">Summary of Significant Accounting Policies&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S., or GAAP, for interim financial reporting and as required by Regulation&#160;S-X, Rule&#160;10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the ASC and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board, or FASB.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the unaudited condensed consolidated financial statements have been included. Interim results for the three and nine months ended September&#160;30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending December&#160;31, 2021 or any other future period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Management has determined that the Company operates in&#160;one&#160;segment, which is the business of developing and commercializing novel therapeutics for people with kidney disease. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company&#x2019;s consolidated financial statements and the accompanying notes included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2020 filed with the U.S. Securities and Exchange Commission on February 25, 2021, or the 2020 Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant accounting policies used in preparation of these unaudited condensed consolidated financial statements for the three and nine months ended September&#160;30, 2021 are consistent with those discussed in Note 2 to the consolidated financial statements in the Company&#x2019;s 2020 Annual Report on Form 10-K and are updated below as necessary.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements &#x2013; Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This standard became effective for the Company on January 1, 2021. ASU 2019-12 requires certain amendments to be applied using a modified retrospective approach, which requires a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption, while other amendments should be applied on a prospective basis. The adoption of this standard did not have a material impact on the Company&#x2019;s unaudited condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: prepaid and accrued research and development expense, operating lease assets and liabilities, derivative liabilities, other non-current liabilities, including the excess purchase commitment liability, stock-based compensation expense, product and collaboration revenues including various rebates and reserves related to product sales, non-cash interest expense on the liability related to sale of future royalties, inventories, income taxes, intangible assets and goodwill. The Company has made estimates of the impact of COVID-19 within the unaudited condensed consolidated financial statements and there may be changes to those estimates in future periods including changes to sales, payor mix, reserves and allowances, intangible assets and goodwill. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liability Related to Sale of Future Royalties&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company treats the liability related to sale of future royalties, see Note 5, as a debt financing, amortized under the effective interest rate method over the estimated life of the related expected royalty stream. The liability related to sale of future royalties and the debt amortization are based on the Company&#x2019;s current estimates of future royalties expected to be paid over the life of the arrangement. The Company will periodically assess the expected royalty payments. To the extent the Company&#x2019;s estimates of future royalty payments are greater or less than previous estimates or the estimated timing of such payments is materially different than previous estimates, the Company will adjust the effective interest rate and recognize related non-cash interest expense on a prospective basis. Non-cash royalty revenue is reflected as royalty revenue within license, collaboration and other revenue, and non-cash amortization of debt is reflected as interest expense in the unaudited condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80MC9mcmFnOjM0MjMzYjg1NTNmZjRjMTViZDRjYTBlZWRhZTEyMGJiL3RleHRyZWdpb246MzQyMzNiODU1M2ZmNGMxNWJkNGNhMGVlZGFlMTIwYmJfNjMwNw_36182b39-fb58-43e7-b1ad-752d00143c98">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S., or GAAP, for interim financial reporting and as required by Regulation&#160;S-X, Rule&#160;10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the ASC and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board, or FASB.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80MC9mcmFnOjM0MjMzYjg1NTNmZjRjMTViZDRjYTBlZWRhZTEyMGJiL3RleHRyZWdpb246MzQyMzNiODU1M2ZmNGMxNWJkNGNhMGVlZGFlMTIwYmJfNjMxMA_b5b5d5de-0e8b-4a74-81da-2f4e13b9e9c2">In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the unaudited condensed consolidated financial statements have been included. Interim results for the three and nine months ended September&#160;30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending December&#160;31, 2021 or any other future period.The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80MC9mcmFnOjM0MjMzYjg1NTNmZjRjMTViZDRjYTBlZWRhZTEyMGJiL3RleHRyZWdpb246MzQyMzNiODU1M2ZmNGMxNWJkNGNhMGVlZGFlMTIwYmJfMTM5Ng_0ec5b73b-a0a5-4cc0-8a91-d0affcf08ca4"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80MC9mcmFnOjM0MjMzYjg1NTNmZjRjMTViZDRjYTBlZWRhZTEyMGJiL3RleHRyZWdpb246MzQyMzNiODU1M2ZmNGMxNWJkNGNhMGVlZGFlMTIwYmJfNjMxMQ_824ed544-b9db-4e6d-8bf8-f3ee062a33c9">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements &#x2013; Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This standard became effective for the Company on January 1, 2021. ASU 2019-12 requires certain amendments to be applied using a modified retrospective approach, which requires a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption, while other amendments should be applied on a prospective basis. The adoption of this standard did not have a material impact on the Company&#x2019;s unaudited condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80MC9mcmFnOjM0MjMzYjg1NTNmZjRjMTViZDRjYTBlZWRhZTEyMGJiL3RleHRyZWdpb246MzQyMzNiODU1M2ZmNGMxNWJkNGNhMGVlZGFlMTIwYmJfNjMxMg_224ac1d4-4457-4fac-9c25-6fa446e80926">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: prepaid and accrued research and development expense, operating lease assets and liabilities, derivative liabilities, other non-current liabilities, including the excess purchase commitment liability, stock-based compensation expense, product and collaboration revenues including various rebates and reserves related to product sales, non-cash interest expense on the liability related to sale of future royalties, inventories, income taxes, intangible assets and goodwill. The Company has made estimates of the impact of COVID-19 within the unaudited condensed consolidated financial statements and there may be changes to those estimates in future periods including changes to sales, payor mix, reserves and allowances, intangible assets and goodwill. &lt;/span&gt;&lt;/div&gt;Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</us-gaap:UseOfEstimates>
    <akba:ContractualArrangementRoyaltiesAgreementLiabilityPolicyPolicyTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80MC9mcmFnOjM0MjMzYjg1NTNmZjRjMTViZDRjYTBlZWRhZTEyMGJiL3RleHRyZWdpb246MzQyMzNiODU1M2ZmNGMxNWJkNGNhMGVlZGFlMTIwYmJfNjMxMw_6a73dbb8-274c-48c2-ba52-d3180984b673">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liability Related to Sale of Future Royalties&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company treats the liability related to sale of future royalties, see Note 5, as a debt financing, amortized under the effective interest rate method over the estimated life of the related expected royalty stream. The liability related to sale of future royalties and the debt amortization are based on the Company&#x2019;s current estimates of future royalties expected to be paid over the life of the arrangement. The Company will periodically assess the expected royalty payments. To the extent the Company&#x2019;s estimates of future royalty payments are greater or less than previous estimates or the estimated timing of such payments is materially different than previous estimates, the Company will adjust the effective interest rate and recognize related non-cash interest expense on a prospective basis. Non-cash royalty revenue is reflected as royalty revenue within license, collaboration and other revenue, and non-cash amortization of debt is reflected as interest expense in the unaudited condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</akba:ContractualArrangementRoyaltiesAgreementLiabilityPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RleHRyZWdpb246N2M1YjYwNGM1ZGNkNGM2NmI3NWY2MjhmY2Q5MDQ3NDlfMTE0MA_931e5232-4da1-4df3-ac3b-e89eb2d91446">Product Revenue and Reserves for Variable Consideration&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company&#x2019;s only source of product revenue has been from the U.S. sales of Auryxia. Total net product revenue was $36.8 million and $34.4 million for the three months ended September&#160;30, 2021 and 2020, respectively, and $100.1 million and $94.3 million for the nine months ended September&#160;30, 2021 and 2020, respectively. The following table summarizes activity in each of the product revenue allowance and reserve categories for the nine months ended September&#160;30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;br/&gt;and Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates, Fees&lt;br/&gt;and other&lt;br/&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current provisions related to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments related to prior year sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits/payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,979)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current provisions related to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments related to prior year sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits/payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks, discounts and returns are recorded as a direct reduction of revenue on the unaudited condensed consolidated statement of operations with a corresponding reduction to accounts receivable on the unaudited condensed consolidated balance sheets. Rebates, distribution-related fees, and other sales-related deductions are recorded as a reduction in revenue on the unaudited condensed consolidated statement of operations with a corresponding increase to accrued liabilities or accounts payable on the unaudited condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net related to product sales was approximately $22.2 million and $21.9 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c63b2719b7a493f89992c1c8a6feb94_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RleHRyZWdpb246N2M1YjYwNGM1ZGNkNGM2NmI3NWY2MjhmY2Q5MDQ3NDlfMTg3_16bea064-4eec-49af-8915-9159d65d02d9"
      unitRef="usd">36800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1897c1e5242647279d4844ddf93043fa_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RleHRyZWdpb246N2M1YjYwNGM1ZGNkNGM2NmI3NWY2MjhmY2Q5MDQ3NDlfMTk0_d1c81325-9d23-426e-8700-1bf595d54157"
      unitRef="usd">34400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i679a26fb513c4e229079d19e687e23ea_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RleHRyZWdpb246N2M1YjYwNGM1ZGNkNGM2NmI3NWY2MjhmY2Q5MDQ3NDlfMjUz_9743feb0-fa3b-412d-a922-02bf67ceb9a9"
      unitRef="usd">100100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6c63a1921cf449cbb7d42a58f2ca535_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RleHRyZWdpb246N2M1YjYwNGM1ZGNkNGM2NmI3NWY2MjhmY2Q5MDQ3NDlfMjYw_a84d9042-9445-4be8-8776-46460163552f"
      unitRef="usd">94300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <akba:ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RleHRyZWdpb246N2M1YjYwNGM1ZGNkNGM2NmI3NWY2MjhmY2Q5MDQ3NDlfMTE0MQ_74173fd4-bfd1-4783-a66e-6faf6c383038">The following table summarizes activity in each of the product revenue allowance and reserve categories for the nine months ended September&#160;30, 2021 and 2020 (in thousands):&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;br/&gt;and Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates, Fees&lt;br/&gt;and other&lt;br/&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current provisions related to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments related to prior year sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits/payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,979)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current provisions related to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments related to prior year sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits/payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</akba:ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id1bafbc3960143019bb39d791680d09e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMS0xLTEtMS0yMjM1Nw_bc04d067-dc1d-41ab-8701-c94bcb11597c"
      unitRef="usd">802000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ie3e27925f7eb4396b50788b1c147f040_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMS0zLTEtMS0yMjM1Nw_c9218a95-2246-4434-9b8f-6f5954b8e065"
      unitRef="usd">39912000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i88110b1102464bb8b4bcc45b892e9014_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMS01LTEtMS0yMjM1Nw_72d91eef-a83b-4fcc-90a8-0d7904327c27"
      unitRef="usd">649000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMS03LTEtMS0yMjM1Nw_5b934a5c-2414-4a9b-9ee2-527d31d21253"
      unitRef="usd">41363000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="ic65dcd125e83450aa6300973fab408bb_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMi0xLTEtMS0yMjM1Nw_354667cc-f146-46f0-a5af-73e8f7c4f262"
      unitRef="usd">8911000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="ic138834fb069491a89247c930e50e034_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMi0zLTEtMS0yMjM1Nw_c76689ec-4a91-49bb-8fdb-53ba88fea34b"
      unitRef="usd">105432000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i73f8120fb3ba417a90e8a529c456c779_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMi01LTEtMS0yMjM1Nw_ae3759dd-24b8-494e-a800-3fc041948d19"
      unitRef="usd">4866000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMi03LTEtMS0yMjM1Nw_2c236c93-ec57-4aeb-a3e3-4fe13e51d651"
      unitRef="usd">119209000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <akba:ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales
      contextRef="ic65dcd125e83450aa6300973fab408bb_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMy0xLTEtMS0yMjM1Nw_cbd08ffd-eeec-440a-bb44-c797e6518cda"
      unitRef="usd">-1000</akba:ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales>
    <akba:ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales
      contextRef="ic138834fb069491a89247c930e50e034_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMy0zLTEtMS0yMjM1Nw_1d2eee87-7c44-41e5-a11b-3c18d996d277"
      unitRef="usd">-1590000</akba:ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales>
    <akba:ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales
      contextRef="i73f8120fb3ba417a90e8a529c456c779_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMy01LTEtMS0yMjM1Nw_904d561d-66d3-4365-8ac9-56b787d1b263"
      unitRef="usd">0</akba:ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales>
    <akba:ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMy03LTEtMS0yMjM1Nw_d0b5b3b6-3670-448f-9eb6-cc7a7ed58c53"
      unitRef="usd">-1591000</akba:ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ic65dcd125e83450aa6300973fab408bb_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfNC0xLTEtMS0yMjM1Nw_0a44d332-d550-4fc3-8094-a164f9fd3e2c"
      unitRef="usd">8593000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ic138834fb069491a89247c930e50e034_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfNC0zLTEtMS0yMjM1Nw_1fed2e9b-5885-47d9-ad0a-fde388f6e939"
      unitRef="usd">99518000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i73f8120fb3ba417a90e8a529c456c779_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfNC01LTEtMS0yMjM1Nw_8a160a73-de98-4f4b-8f16-210b88e11960"
      unitRef="usd">4979000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfNC03LTEtMS0yMjM1Nw_55d09429-f20b-4ba9-ad31-50d02ce35511"
      unitRef="usd">113090000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i85f7bb9f4e384e1aa0a5e37af52be036_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfNS0xLTEtMS0yMjM1Nw_96ab608e-2ce1-4fe2-8b97-a46451b253ab"
      unitRef="usd">1119000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4ef44b64c28a444cac3e40fe925ba315_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfNS0zLTEtMS0yMjM1Nw_7b1719b0-03c7-4a6e-aaf8-7659a609d5f1"
      unitRef="usd">44236000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i34bd677f66094393bebcca2b049effef_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfNS01LTEtMS0yMjM1Nw_43d97dc8-6d4c-4ee9-a36c-7db18be18cdd"
      unitRef="usd">536000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfNS03LTEtMS0yMjM1Nw_36d4e515-3ed6-45a7-b5c7-a74470cc52dd"
      unitRef="usd">45891000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i6297767fc6bf43fe877f509f140dada7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfNy0xLTEtMS0yMjM1Nw_1b5ceee6-6993-4421-9737-e902c32a1a88"
      unitRef="usd">738000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia3450ded174e45858afc144e1af9ffac_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfNy0zLTEtMS0yMjM1Nw_81d18acf-fc61-4a49-9611-95c417cd1ec0"
      unitRef="usd">30552000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i97d48e8612f24efe8996ef27cb3c6569_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfNy01LTEtMS0yMjM1Nw_67e55253-39c6-4eab-b554-5fbcda32a01e"
      unitRef="usd">253000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i789136767052440b86082df6969545de_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfNy03LTEtMS0yMjM1Nw_c18e3bf9-22b6-4ef8-8fa6-48b2c32d552e"
      unitRef="usd">31543000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i634b8d926257462d9d9e328283bb4259_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfOC0xLTEtMS0yMjM1Nw_b188b900-6542-4e29-a6c6-7fa2d44df5f4"
      unitRef="usd">7833000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i745cf671aea747ba929766351832a180_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfOC0zLTEtMS0yMjM1Nw_abafbced-6c7b-494c-9d56-14517be8a570"
      unitRef="usd">107421000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i9a65cd87641e499c9df380248f663449_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfOC01LTEtMS0yMjM1Nw_ea9a97bc-c57d-4493-9df1-d3b41677dc11"
      unitRef="usd">4184000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfOC03LTEtMS0yMjM1Nw_07f47ea9-7b92-4b1f-b304-b76ff59e6ca3"
      unitRef="usd">119438000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <akba:ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales
      contextRef="i634b8d926257462d9d9e328283bb4259_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfOS0xLTEtMS0yMjM1Nw_4adc4ee5-5a64-4f5b-9e8b-a633d2eb63af"
      unitRef="usd">-85000</akba:ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales>
    <akba:ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales
      contextRef="i745cf671aea747ba929766351832a180_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfOS0zLTEtMS0yMjM1Nw_1de04737-a9e7-47d6-89d2-f43e73150364"
      unitRef="usd">703000</akba:ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales>
    <akba:ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales
      contextRef="i9a65cd87641e499c9df380248f663449_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfOS01LTEtMS0yMjM1Nw_ab3872ef-3700-480a-85da-8b7a49173162"
      unitRef="usd">2328000</akba:ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales>
    <akba:ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfOS03LTEtMS0yMjM1Nw_1a2eba44-9b52-4593-bf3c-9af1f8335568"
      unitRef="usd">2946000</akba:ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i634b8d926257462d9d9e328283bb4259_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMTAtMS0xLTEtMjIzNTc_b8546fbf-b3e0-4f76-951f-f4beb16ac78f"
      unitRef="usd">7701000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i745cf671aea747ba929766351832a180_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMTAtMy0xLTEtMjIzNTc_3394540e-6c0e-4466-b33f-6f83bc958ae8"
      unitRef="usd">96807000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i9a65cd87641e499c9df380248f663449_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMTAtNS0xLTEtMjIzNTc_1b89b2c2-0453-423e-adea-a25eea609afb"
      unitRef="usd">5991000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMTAtNy0xLTEtMjIzNTc_f4037ad8-730b-4bc8-a6ee-1c7ff8af39d3"
      unitRef="usd">110499000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i88b205f60522473db4b1791f35bad380_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMTEtMS0xLTEtMjIzNTc_5b47a9c9-dfce-46ff-94b3-8ab1c94e7c68"
      unitRef="usd">785000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ifbe29fe4d71b45a2807b94520a5f1004_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMTEtMy0xLTEtMjIzNTc_5241c527-464c-4bef-8a28-700f09cb68f4"
      unitRef="usd">41869000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i3e838c8dba8c42b0b61db36cee11b10c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMTEtNS0xLTEtMjIzNTc_066d056e-d4fb-4a92-860b-90d66a7f6db4"
      unitRef="usd">774000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iaa53bc3c09164606aeaedf64079be5bc_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RhYmxlOjI4YzU5OWMxOGM5YjQyNTI4ZjlkZmFiNTRkYzA5MmM0L3RhYmxlcmFuZ2U6MjhjNTk5YzE4YzliNDI1MjhmOWRmYWI1NGRjMDkyYzRfMTEtNy0xLTEtMjIzNTc_40cb8fa5-fd37-4609-85f4-af55ab88c0ad"
      unitRef="usd">43428000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:AccountsReceivableNet
      contextRef="iba72f4028b53419a9e3df0bc0bb323b5_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RleHRyZWdpb246N2M1YjYwNGM1ZGNkNGM2NmI3NWY2MjhmY2Q5MDQ3NDlfMTEwMA_ae89c95e-0ba2-406f-9e46-402153d4494a"
      unitRef="usd">22200000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="i68832275b6f74879ad43622f402f836b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80My9mcmFnOjdjNWI2MDRjNWRjZDRjNjZiNzVmNjI4ZmNkOTA0NzQ5L3RleHRyZWdpb246N2M1YjYwNGM1ZGNkNGM2NmI3NWY2MjhmY2Q5MDQ3NDlfMTEwNw_b11803db-2470-48d7-9496-2f03ed48b1c0"
      unitRef="usd">21900000</us-gaap:AccountsReceivableNet>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDU5MzM_7f463d5e-2ebb-4af1-904d-56fde984eb3e">License, Collaboration and Other Significant Agreements&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2021 and 2020, the Company recognized the following revenues from its license, collaboration and other significant agreements and had the following deferred revenue balances as of September&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;License, Collaboration and Other Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MTPC Agreement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Otsuka U.S. Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Otsuka International Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Proportional Performance Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;JT and Torii&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MTPC Other Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total License, Collaboration and Other Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deferred Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MTPC Agreement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Otsuka U.S. Agreement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Otsuka International Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vifor Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in the Company&#x2019;s contract assets and liabilities during the nine months ended September&#160;30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at&lt;br/&gt;Beginning of&lt;br/&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at End&lt;br/&gt;of Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(156,209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;Excludes accounts receivable from other services related to clinical and regulatory activities performed by the Company on behalf of MTPC that are not included in the performance obligations identified under the MTPC Agreement as of September&#160;30, 2021 and 2020 and December&#160;31, 2020 and 2019. Also excludes accounts receivable related to amounts due to the Company from product sales which are included in the accompanying unaudited condensed consolidated balance sheet as of September&#160;30, 2021 and December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2021 and 2020, the Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the respective periods (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenue Recognized in the Period from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts included in deferred revenue at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance obligations satisfied in previous periods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mitsubishi Tanabe Pharma Corporation Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;On December 11, 2015, the Company and MTPC entered into a collaboration agreement, or the MTPC Agreement, providing MTPC with exclusive development and commercialization rights to vadadustat in Japan and certain other Asian countries, collectively, the MTPC Territory. In addition, the Company will supply vadadustat for both clinical and commercial use in the MTPC Territory, subject to MTPC&#x2019;s option to manufacture commercial drug product in the MTPC Territory. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;A more detailed description of this collaboration agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In February 2021, the Company entered into a royalty interest acquisition agreement with HealthCare Royalty Partners IV, L.P., or the Royalty Agreement, whereby the Company sold its right to receive royalties and sales milestones under the MTPC Agreement, subject to certain caps and other terms and conditions (see Note 5 for additional information). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the elements of the MTPC Agreement in accordance with the provisions of ASC 606 and concluded that the contract counterparty, MTPC, is a customer. The Company&#x2019;s arrangement with MTPC contains the following material promises under the contract at inception: (i) license under certain of the Company&#x2019;s intellectual property to develop and commercialize vadadustat in the MTPC Territory, (ii) clinical supply of vadadustat, (iii) knowledge transfer, (iv) Phase 2 dosing study research services, and (v) rights to future know-how.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identified two performance obligations in connection with its material promises under the MTPC Agreement as follows: (i) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License, Research and Clinical Supply Performance Obligation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and (ii) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rights to Future Know-How Performance Obligation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Factors considered in making the assessment of which material promises will be accounted for as separate performance obligations included, among other things, the capabilities of the collaboration partner, whether any other vendor sells the item separately, whether the good or service is highly interdependent or highly interrelated to the other elements in the arrangement, and whether there are other vendors that can provide the items. Additionally, the MTPC Agreement does not include a general right of return.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocates the transaction price to each performance obligation based on the Company&#x2019;s best estimate of the relative standalone selling price. The Company developed a best estimate of the standalone selling price for the Rights to Future Know-How Performance Obligation primarily based on the likelihood that additional intellectual property covered by the license conveyed will be developed during the term of the arrangement and determined it is immaterial. As such, the Company did not develop a best estimate of standalone selling price for the License, Research and Clinical Supply Performance Obligation and allocated the entire transaction price to this performance obligation. The deliverables associated with the License, Research and Clinical Supply Performance Obligation were satisfied as of June 30, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price at inception was comprised of: (i) the up-front payment, (ii) the estimated cost for the Phase 2 studies, (iii) a non-substantive milestone associated with the first patient enrolled in the NDD-CKD Phase 3 study, and (iv) the cost of all clinical supply provided to MTPC for the Phase 3 studies. No other development and no regulatory milestones were included in the transaction price at inception, as all other milestone amounts were fully constrained. Subsequent to inception, the transaction price also included certain development and regulatory milestones, as described below. As part of its evaluation of the constraint, the Company considers numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee&#x2019;s efforts.&#160;Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to MTPC and therefore have also been excluded from the transaction price.&#160;The Company re-evaluates the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. The Company determined that the remaining consideration that may be payable to the Company subsequent to MTPC's commercial launch of Vafseo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the third quarter of 2020 is quarterly royalties on net sales, sales milestones, and certain regulatory milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, the transaction price was comprised of: (i) the up-front payment of $20.0 million, (ii) the cost for the Phase 2 studies of $20.5 million, (iii) the cost of all clinical supply provided to MTPC for the Phase 3 studies, (iv) $10.0&#160;million in development milestones received, (v) $25.0&#160;million in regulatory milestones received, comprised of $10.0 million relating to the NDA filing in Japan and $15.0 million relating to regulatory approval of vadadustat in Japan, and (vi) $0.9 million in royalties from net sales of Vafseo. As of September&#160;30, 2021, all development milestones and $25.0&#160;million in regulatory milestones have been achieved. No other regulatory milestones have been assessed as probable of being achieved and as a result have been fully constrained. Revenue for the License, Research and Clinical Supply Performance Obligation for the MTPC Agreement is being recognized using a proportional performance method, for which all deliverables have been completed. The Company recognized $0.3 million and $0.4 million of revenue from MTPC royalties for the three and nine months ended September&#160;30, 2021, respectively. The Company recognized a $15.0 million regulatory milestone relating to regulatory approval of vadadustat in Japan as revenue during the nine months ended September&#160;30, 2020. As noted above, in February 2021, the Company entered into the Royalty Agreement, whereby the Company sold its right to receive these royalties and sales milestones under the MTPC Agreement, subject to certain caps and other terms and conditions (see Note 5 for additional information). The revenue is classified as collaboration revenue in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss. As of September&#160;30, 2021, the Company recorded $0.2&#160;million in accounts receivable, no deferred revenue, and no contract assets. There were no asset or liability balances classified as long-term in the unaudited condensed consolidated balance sheet as of September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Supply of Drug Product to MTPC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, in connection with the MTPC Agreement, the Company and MTPC entered into a letter agreement, pursuant to which the Company agreed to supply MTPC with certain vadadustat process validation drug product for commercial use and MTPC agreed to reimburse the Company for certain manufacturing-related expenses. In connection with this arrangement, the Company invoiced the upfront payment of $10.4 million, which it received during the three months ended June 30, 2020. The Company does not recognize revenue under this arrangement until delivery has occurred and risk of loss passes to MTPC. No revenues were recognized during the three and nine months ended September&#160;30, 2021 and approximately $0.5 million and $4.5 million of revenue was recognized during the three and nine months ended September&#160;30, 2020, respectively, for drug product that was delivered during the applicable period. As of September&#160;30, 2021, the Company recorded no accounts receivable, no deferred revenue, $3.0 million in other current liabilities and $0.4&#160;million in other non-current liabilities for drug product that was subject to return by MTPC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 15, 2020, the Company and its collaboration partner MTPC entered into a supply agreement, or the MTPC Supply Agreement. The MTPC Supply Agreement includes the terms and conditions under which the Company will supply vadadustat drug product to MTPC for commercial use in Japan and certain other Asian countries, as contemplated by the MTPC Agreement. A more detailed description of this supply agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized $2.2 million and $6.7 million of revenue under the MTPC Supply Agreement during the three and nine months ended September&#160;30, 2021, respectively. During the nine months ended September&#160;30, 2021, the Company invoiced MTPC for $13.4 million in payments for vadadustat drug product ordered by MTPC. As of September&#160;30, 2021, the Company recorded $4.5 million in accounts receivable, $4.9 million in deferred revenue, $16.3 million in other current liabilities and $5.8 million in other non-current liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;U.S. Collaboration and License Agreement with Otsuka Pharmaceutical Co. Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 18, 2016, the Company entered into a collaboration and license agreement with Otsuka, or the Otsuka U.S. Agreement. The collaboration is focused on the development and commercialization of vadadustat in the United States. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Otsuka U.S. Agreement, the Company granted to Otsuka a co-exclusive, non-sublicensable license under certain intellectual property controlled by the Company solely to perform medical affairs activities and to conduct non-promotional and commercialization activities related to vadadustat in the United States in accordance with the associated plans. The co-exclusive license relates to activities that will be jointly conducted by the Company and Otsuka pursuant to the terms of the Otsuka U.S. Agreement. Additionally, the parties agreed not to promote, market or sell any competing product in the territory covered by the Otsuka U.S. Agreement. A more detailed description of this collaboration agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the elements of the Otsuka U.S. Agreement in accordance with the provisions of ASC 606 and concluded that the contract counterparty, Otsuka, is a customer. The Company&#x2019;s arrangement with Otsuka contains the following material promises under the contract at inception: (i) license under certain of the Company&#x2019;s intellectual property to develop, perform medical affairs activities with respect to and conduct non-promotional and commercialization activities related to vadadustat and products containing or comprising vadadustat, (ii) development services to be performed pursuant to the current global development plan, (iii) rights to future intellectual property, and (iv) joint committee services.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company has identified three performance obligations in connection with its obligations under the Otsuka U.S. Agreement as follows: i) License and Development Services Combined (License Performance Obligation); (ii) Rights to Future Intellectual Property (Future IP Performance Obligation) and (iii) Joint Committee Services (Committee Performance Obligation). Factors considered in making the assessment of which material promises will be accounted for as separate performance obligations included, among other things, the capabilities of the collaboration partner, whether any other vendor sells the item separately, whether the good or service is highly interdependent or highly interrelated to the other elements in the arrangement, and whether there are other vendors that can provide the items. Additionally, the Otsuka U.S. Agreement does not include a general right of return. A more detailed description of the performance obligations under this agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocates the transaction price to each performance obligation based on the Company&#x2019;s best estimate of the relative standalone selling price. The Company developed a best estimate of standalone selling price for the Committee Performance Obligation after considering the nature of the services to be performed and estimates of the associated effort and rates applicable to such services that would be expected to be realized under similar contracts. The Company developed a best estimate of standalone selling price for the Future IP Performance Obligation primarily based on the likelihood that additional intellectual property covered by the license conveyed will be developed during the term of the arrangement. The Company did not develop a best estimate of standalone selling price for the License Performance Obligation due to the following: (i) the best estimates of standalone selling price associated with the Future IP Performance Obligation was determined to be immaterial and (ii) the period of performance and pattern of recognition for the License Performance Obligation and the Committee Performance Obligation was determined to be similar. The Company has concluded that a change in the key assumptions used to determine the best estimate of standalone selling price for each performance obligation would not have a significant impact on the allocation of arrangement consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price at inception was comprised of: (i) the up-front payment, (ii) the cost share payment with respect to amounts incurred by the Company through December 31, 2016, and (iii) an estimate of the cost share payments to be received with respect to amounts incurred by the Company subsequent to December 31, 2016. No development or regulatory milestones were included in the transaction price at inception, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee&#x2019;s efforts. Any consideration related to sales-based milestones will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Otsuka and therefore have also been excluded from the transaction price.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company re-evaluates the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. The Company determined that under ASC 606, the contract was modified in the second quarter of 2019 when the Otsuka Funding Option became effective and the Company became eligible to receive the Additional Funding (defined below) amount. In connection with the modification, the Company adjusted the transaction price to include the Additional Funding amount as additional variable consideration. The Company constrains the variable consideration to an amount for which a significant revenue reversal is not probable. In the event that there is consideration received by Otsuka in the form of activities performed by Otsuka under the global development plan, such consideration is reflected as a reduction to the transaction price as contra revenue rather than as an expense because the associated services are not distinct from the License Performance Obligation. The Company estimates the additional funding as a result of exercising the Otsuka Funding Option, or the Additional Funding, to total approximately $139.8 million or more, depending on the actual costs incurred toward the current global development plan. The Additional Funding is fully creditable against future payments due to the Company under the arrangement, provided that future payments due to the Company may not be reduced by more than 50% in any calendar year and any remaining creditable amount above 50% in any calendar year will be applied to subsequent future payments until fully credited. As of September&#160;30, 2021, the Additional Funding was $106.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No amounts were allocated to the Future IP Performance Obligation because the associated best estimate of standalone selling price was determined to be immaterial. Due to the similar performance period and recognition pattern between the License Performance Obligation and the Committee Performance Obligation, the transaction price has been allocated to the License Performance Obligation and the Committee Performance Obligation on a combined basis. Accordingly, the Company will &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognize revenue related to the allocable arrangement consideration on a proportional performance basis as the underlying development services are performed pursuant to the current global development plan which is commensurate with the period and consistent with the pattern over which the Company&#x2019;s obligations are satisfied for both the License Performance Obligation and the Committee Performance Obligation. Effectively, the Company has treated the arrangement as if the License Performance Obligation and the Committee Performance Obligation are a single performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, the transaction price totaling $504.2 million was comprised of: (i) the up-front payment of $125.0 million, (ii) the cost share payment with respect to amounts incurred by the Company through December 31, 2016 of $33.8 million, and (iii) the estimate of the net cost share consideration to be received of approximately $345.4 million with respect to amounts incurred by the Company subsequent to December 31, 2016. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, the Company is eligible to receive up to $65.0 million in regulatory milestone payments for the first HIF product to achieve the associated event and up to $575 million in commercial milestone payments associated with aggregate sales of licensed products. These future milestones are subject to reduction as a result of the Company's exercise of the Otsuka Funding Option, as described above. As of September&#160;30, 2021, no development or regulatory milestones have been assessed as probable of being reached and thus have been fully constrained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September&#160;30, 2021 and 2020, the Company recognized revenue totaling approximately $6.1 million and $16.3 million, respectively, and approximately $29.0 million and $80.7 million, during the nine months ended September&#160;30, 2021 and 2020, respectively, with respect to the Otsuka U.S. Agreement. The revenue is classified as collaboration revenue in the accompanying unaudited condensed consolidated statements of operations. As of September&#160;30, 2021, there was approximately $23.0 million of deferred revenue related to the Otsuka U.S. Agreement of which $6.3 million is classified as current and $16.7 million is classified as long-term in the accompanying unaudited condensed consolidated balance sheet based on the performance period of the underlying obligations. Additionally, as of September&#160;30, 2021, there was $2.4 million in accounts receivable and $2.4 million in prepaid expenses and other current assets in the accompanying unaudited condensed consolidated balance sheet. As of December&#160;31, 2020, there was approximately $5.0 million in contract liabilities (included in accounts payable) and $1.2 million in prepaid expenses and other current assets in the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the medical affairs, commercialization and non-promotional activities elements of the Otsuka U.S. Agreement represent joint operating activities in which both parties are active participants and of which both parties are exposed to significant risks and rewards that are dependent on the success of the activities. Accordingly, the Company is accounting for the joint medical affairs, commercialization and non-promotional activities in accordance with ASC No. 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Additionally, the Company has determined that in the context of the medical affairs, commercialization and non-promotional activities, Otsuka does not represent a customer as contemplated by ASC 606-10-15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &#x2013; Scope and Scope Exceptions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As a result, the activities conducted pursuant to the medical affairs, commercialization and non-promotional activities plans will be accounted for as a component of the related expense in the period incurred. During the three months ended September&#160;30, 2021 and 2020, the Company incurred approximately $3.6 million and $1.2 million, respectively, of costs related to the cost-sharing provisions of the Otsuka U.S. Agreement, of which approximately $1.8 million and $0.5 million are reimbursable by Otsuka and recorded as a reduction to research and development expense during the three months ended September&#160;30, 2021 and 2020, respectively. During the three months ended September&#160;30, 2021, Otsuka incurred no costs related to the cost-sharing provisions of the Otsuka U.S. Agreement. During the three months ended September&#160;30, 2020, Otsuka incurred $0.5 million of costs related to the cost-sharing provisions of the Otsuka U.S. Agreement, of which approximately $0.3 million were reimbursable by the Company and recorded as an increase to research and development expense during the three months ended September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;International Collaboration and License Agreement with Otsuka Pharmaceutical Co. Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 25, 2017, the Company entered into a collaboration and license agreement with Otsuka, or the Otsuka International Agreement. The collaboration is focused on the development and commercialization of vadadustat in Europe, Russia, China, Canada, Australia, the Middle East and certain other territories, collectively, the Otsuka International Territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Otsuka International Agreement, the Company granted to Otsuka an exclusive, sublicensable license under certain intellectual property controlled by the Company to develop and commercialize vadadustat and products containing or comprising vadadustat in the Otsuka International Territory. Additionally, under the terms of this agreement, the Company is responsible for leading the development of vadadustat. Otsuka has the sole responsibility, at its own cost, for the commercialization of vadadustat in the Otsuka International Territory, subject to the approval by the relevant regulatory authorities. A more detailed description of this collaboration agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has accounted for the Otsuka International Agreement separately from the collaboration arrangement with Otsuka with respect to the U.S. due to the lack of interrelationship and interdependence of the elements and payment terms within each of the contracts as they relate to the respective territories. Accordingly, the Company has applied the guidance in ASC 606 solely in reference to the terms and conditions of the Otsuka International Agreement, while the Otsuka U.S. Agreement has continued to be accounted for as a discrete agreement in its own right. The Company evaluated the Otsuka International Agreement in accordance with the provisions of ASC 606 and concluded that the contract counterparty, Otsuka, is a customer. The Company&#x2019;s arrangement with Otsuka related to the Otsuka International Territory contains the following material promises under the contract at inception: (i) license under certain of the Company&#x2019;s intellectual property to develop and commercialize (including the associated packaging) vadadustat and products containing or comprising vadadustat and development services to be performed pursuant to the current global development plan, (ii) rights to future intellectual property and (iii) joint committee services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company has identified three performance obligations in connection with its obligations under the Otsuka International Agreement as follows: i) License and Development Services Combined (License Performance Obligation); (ii) Rights to Future Intellectual Property (Future IP Performance Obligation) and (iii) Joint Committee Services (Committee Performance Obligation). Factors considered in making this assessment of which material promises will be accounted for as a separate performance obligation included, among other things, the capabilities of the collaboration partner, whether any other vendor sells the item separately, whether the good or service is highly interdependent or highly interrelated to the other elements in the arrangement, and whether there are other vendors that can provide the items.&#160;Additionally, the Otsuka International Agreement does not include a general right of return. A more detailed description of the performance obligations under this agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocates the transaction price to each performance obligation based on the Company&#x2019;s best estimate of the relative standalone selling price. The Company developed a best estimate of standalone selling price for the Committee Performance Obligation after considering the nature of the services to be performed and estimates of the associated effort and rates applicable to such services that would be expected to be realized under similar contracts. The Company developed a best estimate of standalone selling price for the Future IP Performance Obligation primarily based on the likelihood that additional intellectual property covered by the license conveyed will be developed during the term of the arrangement. The Company did not develop a best estimate of standalone selling price for the License Performance Obligation due to the following: (i) the best estimates of standalone selling price associated with the Future IP Performance Obligation was determined to be immaterial and (ii) the period of performance and pattern of recognition for the License Performance Obligation and the Committee Performance Obligation was determined to be similar. The Company has concluded that a change in the key assumptions used to determine the best estimate of standalone selling price for each performance obligation would not have a significant impact on the allocation of arrangement consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price at inception was comprised of: (i) the up-front payment, (ii) the cost share payment with respect to amounts incurred by the Company during the quarter ended March 31, 2017, and (iii) an estimate of the cost share payments to be received with respect to amounts incurred by the Company subsequent to March 31, 2017. No development or regulatory milestones were included in the transaction price at inception, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including whether the receipt of the milestone payment is outside the control of the Company and contingent upon success in future clinical trials and the licensee&#x2019;s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Otsuka and therefore have also been excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company re-evaluates the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. In the event that there is consideration received by a customer in the form of activities performed by such customer under the global development plan, such consideration is reflected as a reduction to the transaction price as contra revenue rather than as an expense because the associated services are not distinct from the License Performance Obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, the transaction price totaling $310.4 million was comprised of: (i) the up-front payment of $73.0 million, (ii) the cost share payment with respect to amounts incurred by the Company during the quarter ended March 31, 2017 of $0.2 million, and (iii) an estimate of the net cost share consideration to be received with respect to amounts incurred by the Company subsequent to March 31, 2017 of $237.3 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2021, the Company is eligible to receive up to $17.0 million in regulatory milestone payments for the licensed HIF product if the Company achieves the associated event within 12 to 24 months of the first HIF product approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company is eligible for up to $525.0 million in commercial milestone payments associated with the aggregate sales of all licensed products. As of September&#160;30, 2021, no development or regulatory milestones have been assessed as probable of being reached and thus have been fully constrained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September&#160;30, 2021 and 2020, the Company recognized revenue totaling approximately $1.9 million and $7.2 million, respectively, and approximately $13.5 million and $39.4&#160;million, respectively, during the nine months ended September&#160;30, 2021 and 2020, with respect to the Otsuka International Agreement. The revenue is classified as collaboration revenue in the accompanying unaudited condensed consolidated statements of operations. As of September&#160;30, 2021, there was approximately $11.1 million of deferred revenue related to the Otsuka International Agreement of which $4.5 million is classified as current and $6.6 million is classified as long-term in the accompanying unaudited condensed consolidated balance sheet based on the performance period of the underlying obligations. Additionally, as of September&#160;30, 2021, there was $1.1 million in accounts receivable and $1.1 million in prepaid expenses and other current assets in the accompanying unaudited condensed consolidated balance sheet. As of December&#160;31, 2020, there was approximately $2.3 million in contract liabilities (included in accounts payable) and $0.5 million in prepaid expenses and other current assets in the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Janssen Pharmaceutica NV Research and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 9, 2017, the Company entered into a Research and License Agreement, or the Janssen Agreement, with Janssen Pharmaceutica NV, or Janssen, a subsidiary of Johnson &amp;amp; Johnson, pursuant to which Janssen granted the Company an exclusive license under certain intellectual property rights to develop and commercialize worldwide certain HIF prolyl hydroxylase targeted compounds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Janssen Agreement, Janssen granted to the Company a license for a three-year research term to conduct research on the HIF compound portfolio, which research term is now expired. During the research term, the Company could designate one or more compounds as candidates for development and commercialization. Once a compound was designated for development and commercialization, the Company was to be solely responsible for the development and commercialization of the compound worldwide at its own cost and expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Under the terms of the Janssen Agreement, the Company made an upfront payment of $1.0 million in cash to Janssen and issued a warrant, or the Warrant, to purchase 509,611 shares of the Company&#x2019;s common stock with an exercise price of $9.81 per share to Johnson &amp;amp; Johnson Innovation &#x2013; JJDC, Inc., or JJDC, an affiliate of Janssen. The Warrant is exercisable by JJDC, in whole or in part, at any time prior to February 9, 2022. The Warrant and the shares issuable upon exercise of the Warrant will be sold and issued without registration under the Securities Act of 1933, as amended, or the Securities Act. The Company recorded the fair value of the Warrant in the amount of $3.4 million to additional paid-in capital and research and development expense in March 2017.&#160;In addition, Janssen is eligible to receive up to an aggregate of $16.5 million from the Company in specified development milestone payments on a product-by-product basis. Janssen is also eligible to receive up to $215.0 million from the Company in specified commercial milestones as well as tiered, escalating royalties ranging from a low- to mid-single digit percentage of net sales, on a product-by-product basis, and subject to reduction upon expiration of patent rights or the launch of a generic product in the territory. A more detailed description of this collaboration agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Cyclerion Therapeutics License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Summary of Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On June 4, 2021, the Company entered into a License Agreement, the Cyclerion Agreement, with Cyclerion Therapeutics Inc., or Cyclerion, pursuant to which Cyclerion granted the Company an exclusive global license under certain intellectual property rights to research, develop and commercialize praliciguat, an investigational oral sGC stimulator.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Under the terms of the Cyclerion Agreement, the Company made an upfront payment of $3.0 million in cash to Cyclerion, which was paid during the second quarter of 2021. Substantially all of the fair value of the assets acquired in conjunction with the Cyclerion Agreement was concentrated in the acquired license. As a result, the Company accounted for this transaction as an asset acquisition under ASU No. 2017-01, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Business Combinations (Topic 805): Clarifying the Definition of a Business&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. The upfront payment was charged to expense at acquisition, as it relates to a development stage compound with no alternative future use. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In addition, Cyclerion is eligible to receive up to an aggregate of $222.0 million from the Company in specified development and regulatory milestone payments on a product-by-product basis. Cyclerion will also be eligible to receive specified &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;commercial milestones as well as tiered royalties ranging from a low-single-digit- to mid-double-digit percentage of net sales, on a product-by-product basis, and subject to reduction upon expiration of patent rights or the launch of a generic product in the territory. The Company recorded the upfront payment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;in the amount of $3.0 million to research and development expense in June 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Unless earlier terminated, the Cyclerion Agreement will expire on a product-by-product and country-by-country basis upon the expiration of the last royalty term, which ends upon the longer of the expiration of the patents licensed under the Cyclerion Agreement, the expiration of regulatory exclusivity for such product, or 10 years from first commercial sale of such product. The Company may terminate the Cyclerion Agreement in its entirety or only with respect to a particular licensed compound or product upon 180 days&#x2019; prior written notice to Cyclerion. The parties also have customary termination rights, subject to a cure period, in the event of the other party&#x2019;s material breach of the Cyclerion Agreement or in the event of certain additional circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Vifor Pharma License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 12, 2017, the Company entered into a License Agreement, or the Vifor Agreement, with Vifor (International) Ltd., or Vifor Pharma, pursuant to which the Company granted Vifor Pharma an exclusive license to sell vadadustat solely to Fresenius Kidney Care Group LLC, or FKC, an affiliate of Fresenius Medical Care North America, or FMCNA, in the United States. On April 8, 2019, the Company and Vifor Pharma entered into an Amended and Restated License Agreement, or the Vifor Amended Agreement, which amended and restated in full the Vifor Agreement. Pursuant to the Vifor Amended Agreement, the Company granted Vifor Pharma an exclusive license to sell vadadustat to FKC and to certain third party dialysis organizations approved by the Company, or Third Party Dialysis Organizations, in the United States. A more detailed description of this collaboration agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investment Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In connection with the Vifor Agreement, in May 2017, the Company and Vifor Pharma entered into an investment agreement, or the Investment Agreement, pursuant to which the Company sold an aggregate of 3,571,429 shares of the Company&#x2019;s common stock, or the Shares, to Vifor Pharma at a price per share of $14.00 for a total of $50.0 million. The amount representing the premium over the closing stock price of $12.69 on the date of the transaction, totaling $4.7 million, was determined by the Company to represent consideration related to the Vifor Agreement.&#160;As the parties&#x2019; rights under the Vifor Agreement are conditioned upon (a) the approval of vadadustat for DD-CKD adult patients by the FDA; (b) the earlier of a determination by the Centers for Medicare &amp;amp; Medicaid Services, or CMS, that vadadustat will be reimbursed using Medicare&#x2019;s bundled reimbursement model or that vadadustat will be reimbursed using the Transitional Drug Add-On Payment Adjustment; and (c) payment by Vifor Pharma of a $25.0&#160;million milestone upon the occurrence of (a) and (b), in accordance with ASC 606, the Company has determined that the full transaction price is fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including clinical and regulatory risks that must be overcome in order for the parties&#x2019; rights to become effective and the probability of the $25.0 million milestone being achieved. Accordingly, the $4.7 million continues to be recorded as deferred revenue in the accompanying unaudited condensed consolidated balance sheets. Upon the satisfaction of the aforementioned conditions, revenue will be recognized as the Company supplies vadadustat to Vifor Pharma using a proportional performance method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vifor Pharma agreed to a&#160;lock-up&#160;restriction such that it agreed not to sell the Shares for a period of time following the effective date of the Investment Agreement as well as a customary standstill agreement. In addition, the Investment Agreement contains voting agreements made by Vifor Pharma with respect to the Shares. The Shares have not been registered pursuant to the Securities Act, and were issued and sold in reliance upon the exemption from registration contained in Section 4(a)(2) of the Securities Act and Rule 506 promulgated thereunder.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Priority Review Voucher Letter Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 14, 2020, the Company entered into a letter agreement, or the Letter Agreement, with Vifor Pharma relating to Vifor Pharma&#x2019;s agreement with a third party to purchase a Priority Review Voucher, or the PRV, issued by the FDA, subject to satisfaction of customary closing conditions, or the PRV Purchase. A PRV entitles the holder to priority review of a New Drug Application, or NDA, or a Biologics License Application for a new drug, which reduces the target FDA review time to six months after official acceptance of the submission, and could lead to expedited approval. Pursuant to the Letter Agreement, Akebia paid Vifor Pharma $10.0 million in connection with the closing of the PRV Purchase. Vifor Pharma is obligated to retain all rights to, and maintain the validity of, the PRV until Akebia and Vifor Pharma (a) enter into a definitive agreement setting forth the financial and other terms by which Vifor Pharma will assign the PRV to Akebia for use with Akebia&#x2019;s NDA for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;vadadustat for the treatment of anemia due to CKD in both dialysis-dependent and non-dialysis dependent patients, or (b) make a mutual decision to sell the PRV and share the proceeds based on certain terms. In March of 2021, the Company submitted an NDA for the treatment of anemia due to CKD in both DD-CKD and NDD-CKD adult patients. The Company's NDA submission did not include a PRV. In August 2021, the Company and Vifor Pharma entered into an amendment to the Letter Agreement whereby the parties agreed that Vifor Pharma would sell the PRV to a third party, and the Company and Vifor Pharma will share the proceeds from the sale based on certain terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the quarter ended March 31, 2020, the $10.0 million payment to Vifor Pharma was recorded to research and development expense in the unaudited condensed consolidated statement of operations and as an operating cash outflow in the unaudited condensed consolidated statement of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreement with Panion&#160;&amp;amp; BF Biotech, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Merger, Keryx entered into a license agreement, or the Panion License Agreement, which was amended from time to time, with Panion&#160;&amp;amp; BF Biotech, Inc., or Panion, under which Keryx in-licensed the exclusive worldwide rights, excluding certain Asian-Pacific countries, or the Licensor Territory, for the development and commercialization of ferric citrate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;On April&#160;17, 2019,&#160;the Company and Panion&#160;entered into a second amended and restated license agreement, or the Panion Amended License Agreement, which amends and restates in full the Panion License Agreement, effective as of April 17, 2019. The Panion Amended License Agreement provides Keryx with an exclusive license under Panion-owned&#160;know-how&#160;and patents with the right to sublicense, develop, make, use, sell, offer for sale, import and export ferric citrate worldwide, excluding the Licensor Territory. The Panion Amended License Agreement also provides Panion with an exclusive license under the Keryx-owned patents, with the right to sublicense (with the Company&#x2019;s written consent), develop, make, use, sell, offer for sale, import and export ferric citrate in certain countries in the Licensor Territory. Under the Panion Amended License Agreement, Panion is eligible to receive from the Company or any sublicensee royalty payments based on a&#160;mid-single&#160;digit percentage of sales of ferric citrate in the Company&#x2019;s licensed territories. The Company is eligible to receive from Panion or any sublicensee royalty payments based on a&#160;mid-single&#160;digit percentage of net sales of ferric citrate in Panion&#x2019;s licensed territories. A more detailed description of this license agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized royalty payments due to Panion of approximately $3.0 million and $2.9 million during the three months ended September&#160;30, 2021 and 2020, respectively, and $8.3 million and $8.2 million during the nine months ended September&#160;30, 2021 and 2020, respectively, relating to the Company&#x2019;s sales of Auryxia in the United States and JT and Torii&#x2019;s sales of Riona in Japan, as the Company is required to pay a mid-single digit percentage of net sales of ferric citrate in the Company&#x2019;s licensed territories to Panion under the terms of the Panion Amended License Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sublicense Agreement with Japan Tobacco, Inc. and its subsidiary, Torii Pharmaceutical Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the Merger, the Company has an Amended and Restated Sublicense Agreement, which was amended in June 2013, with JT and Torii, or the JT and Torii Sublicense Agreement, under which Keryx, the Company&#x2019;s wholly owned subsidiary, remains the contracting party. Under the JT and Torii Sublicense Agreement, JT and Torii obtained the exclusive sublicense rights for the development and commercialization of ferric citrate hydrate in Japan. JT and Torii are responsible for the future development and commercialization costs in Japan. A more detailed description of this sublicense agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the elements of the JT and Torii Sublicense Agreement in accordance with the provisions of ASC 606 and concluded that the contract counterparty, JT and Torii, is a customer. The Company&#x2019;s arrangement with JT and Torii contains the following material promises under the contract at inception: (i) exclusive license to develop and commercialize ferric citrate hydrate in Japan, (ii) supply of ferric citrate hydrate until JT and Torii could secure their own source, (iii) knowledge transfer, and (iv) rights to future know-how. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identified two performance obligations in connection with its obligations under the JT and Torii Sublicense Agreement: (i) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License and Supply Performance Obligation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and (ii) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rights to Future Know-How Performance Obligation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company allocated the transaction price to each performance obligation based on the Company&#x2019;s best estimate of the relative standalone selling price. The Company developed a best estimate of the standalone selling price for the Rights to Future Know-How Performance Obligation primarily based on the likelihood that additional intellectual property covered by the license &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;conveyed will be developed during the term of the arrangement and determined it immaterial. As such, the Company did not develop a best estimate of standalone selling price for the License and Supply Performance Obligation and allocated the entire transaction price to this performance obligation. Additionally, as of the consummation of the Merger, the services associated with the License and Supply Performance Obligation were completed and JT and Torii had secured their own source to manufacture ferric citrate hydrate. As such, any initial license fees as well as any development-based milestones and manufacturing fee revenue were received and recognized prior to the Merger. The Company determined that the remaining consideration that may be payable to the Company under the terms of the sublicense agreement are either quarterly royalties on net sales or payments due upon the achievement of sales-based milestones. In accordance with ASC 606, the Company recognizes sales-based royalties, including milestone payments based on the level of sales, when the related sales occur as these amounts have been determined to relate predominantly to the license granted to JT and Torii and therefore are recognized at the later of when the performance obligation is satisfied, or the related sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized license revenue of $1.4 million and $1.2 million during the three months ended September&#160;30, 2021 and 2020, respectively, and $4.1 million and $4.0 million, respectively, during the nine months ended September&#160;30, 2021 and 2020, respectively, related to royalties earned on net sales of Riona in Japan. The Company records the associated mid-single digit percentage of net sales royalty expense due to Panion, the licensor of Riona, in the same period as the royalty revenue from JT and Torii is recorded.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <akba:CollaborativeArrangementRevenueRecognitionTableTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDU5Mzc_641d2846-0863-4f58-9c16-ff895ea89eac">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2021 and 2020, the Company recognized the following revenues from its license, collaboration and other significant agreements and had the following deferred revenue balances as of September&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;License, Collaboration and Other Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MTPC Agreement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Otsuka U.S. Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Otsuka International Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Proportional Performance Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;JT and Torii&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MTPC Other Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total License, Collaboration and Other Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</akba:CollaborativeArrangementRevenueRecognitionTableTextBlock>
    <akba:DeferredRevenueRecognitionTableTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDU5MzY_762e413f-2b83-404c-90a4-ef2f0bee1f5d">During the three and nine months ended September&#160;30, 2021 and 2020, the Company recognized the following revenues from its license, collaboration and other significant agreements and had the following deferred revenue balances as of September&#160;30, 2021:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deferred Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MTPC Agreement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Otsuka U.S. Agreement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Otsuka International Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vifor Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</akba:DeferredRevenueRecognitionTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefbe221ac071402e9aa1ff3c33efbea9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfMy0xLTEtMS0yMjM1Nw_deab0fc3-e74e-4832-966f-8d355c02c80f"
      unitRef="usd">2555000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1709d1103fa3444fb8a09367a5e7e52e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfMy0zLTEtMS0yMjM1Nw_5622727b-631c-4523-9c65-d7755439645b"
      unitRef="usd">373000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31651748afca476c98590cfaeef98a69_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfMy01LTEtMS0yMjM1Nw_8ed1d7dd-9515-40c2-87b2-97c8eeb7f046"
      unitRef="usd">7167000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5aabb65b896b4d4693a54ed68c0aa03a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfMy03LTEtMS0yMjM1Nw_e717cf79-3f40-439c-a08a-bc3d0a7eb4c2"
      unitRef="usd">15373000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefd530a7f1a248edbdc9b05c847c8a7e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNC0xLTEtMS0yMjM1Nw_adaa7f34-2a59-4d1d-a9df-b9e613543586"
      unitRef="usd">6144000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib09d90891a274c3c818a2cef521eace2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNC0zLTEtMS0yMjM1Nw_2c002284-16ff-4e01-9f09-d636224e054d"
      unitRef="usd">16256000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73b11af5f04a42d9a1071752d045891e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNC01LTEtMS0yMjM1Nw_22b16297-55f7-48f2-a718-01c712eab274"
      unitRef="usd">28988000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6fc2047fffc4e2d8558725e0f1d34a0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNC03LTEtMS0yMjM1Nw_884dc9af-9d3d-400f-bdca-17bf405d42f1"
      unitRef="usd">80721000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i945ff9fde11644a58dafd0226b9d6c0f_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNS0xLTEtMS0yMjM1Nw_133dc8f0-8048-4227-92fa-d1a5bf1c155c"
      unitRef="usd">1860000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i738510817c5048b98d2eea09c5a05cf1_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNS0zLTEtMS0yMjM1Nw_5c9a9979-df3e-4cc0-b883-f364fb0e753d"
      unitRef="usd">7243000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f482f3f6423440ea0d9f6c8bef66818_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNS01LTEtMS0yMjM1Nw_1528b88f-857f-4aa8-8aae-64a0757205d8"
      unitRef="usd">13532000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a84c225ba714f219479e22fc09d67e9_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNS03LTEtMS0yMjM1Nw_b535a7a9-6a0a-4872-b7b3-b6a466c8ddc2"
      unitRef="usd">39445000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0acbf4b49164475f8a36f3979f8e5aff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNi0xLTEtMS0yMjM1Nw_2de9b062-271a-4a73-999a-30dffeadbd97"
      unitRef="usd">10559000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib52d8a3a1f814ede864dcab830d03ad3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNi0zLTEtMS0yMjM1Nw_c3f7b7dd-dfb1-449c-b371-0574fc77df06"
      unitRef="usd">23872000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae7692c90eb746178a141c1b78cb6a28_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNi01LTEtMS0yMjM1Nw_854db31c-90e4-4c62-a0d9-a94ea459eb20"
      unitRef="usd">49687000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2af3aa2c9e5f4db7bac920c367ee4124_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNi03LTEtMS0yMjM1Nw_7406ca17-180f-4742-8241-e8d0bca5168d"
      unitRef="usd">135539000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i95f34cfdea4546b9916e24a997553533_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNy0xLTEtMS0yMjM1Nw_df553ac8-565a-47ae-8633-d8944fbbb5d1"
      unitRef="usd">1444000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d24e1b865b1425f8c6a7c9541a10db2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNy0zLTEtMS0yMjM1Nw_43420c38-c52c-4411-8501-8957eea1cc3d"
      unitRef="usd">1183000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1b71df432394860be208c54b443aacb_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNy01LTEtMS0yMjM1Nw_c04447c5-9ba2-4e72-b1cf-a84d2583076a"
      unitRef="usd">4093000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06aa1c9bc80b4b6497171fe4199a0347_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfNy03LTEtMS0yMjM1Nw_1ff300e9-d109-445e-8e0c-c33165bcd924"
      unitRef="usd">4049000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f865ba0db994d3fbe5976932bc384f2_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfOC0xLTEtMS0yMjM1Nw_e88cdeea-68d9-43c2-9ca0-8fce16dd85d6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifce4f17d7a3d4682a27f359eb185448b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfOC0zLTEtMS0yMjM1Nw_1651a5ae-a17b-48b5-8e70-cb91ebfa61ac"
      unitRef="usd">541000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0455e41ef2d6462b91d81400d4c2e0dd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfOC01LTEtMS0yMjM1Nw_a793ecab-6a7c-4a39-b884-8c29b908f4ee"
      unitRef="usd">73000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia6939d08f8a54431bf1d08db5ff563d4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfOC03LTEtMS0yMjM1Nw_628291d8-7a7b-4485-ab06-49b7717a9747"
      unitRef="usd">4723000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if41d416d81e34b9cb6976b49960bf999_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfOS0xLTEtMS0yMjM1Nw_e4014c29-548d-481b-90a1-b0cb0fe4ad20"
      unitRef="usd">12003000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia875941982fa4b738ad20ad8c02ee280_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfOS0zLTEtMS0yMjM1Nw_248e7458-1a69-4ec9-b03c-b337ebc403b8"
      unitRef="usd">25596000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d2476903d214660b7d10dfda90d5e62_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfOS01LTEtMS0yMjM1Nw_cce9626d-11da-4a12-9b36-168215218cdc"
      unitRef="usd">53853000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic49c106b11074ca28afbe6423ad1783c_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmZkMzJjM2M1NTBiNDQ3OWE4ZWViZDBjNTE2YTgxYzQ5L3RhYmxlcmFuZ2U6ZmQzMmMzYzU1MGI0NDc5YThlZWJkMGM1MTZhODFjNDlfOS03LTEtMS0yMjM1Nw_bcd8a34c-58e0-4ac7-b827-a73324bcdff9"
      unitRef="usd">144311000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8e10b28a9e47483eab1daecf6b5559db_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfMy0xLTEtMS0yMjM1Nw_4dcdaec6-fcee-485b-8eab-1c8cb7d58a03"
      unitRef="usd">4883000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i8e10b28a9e47483eab1daecf6b5559db_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfMy0zLTEtMS0yMjM1Nw_ec7d6f45-084c-405e-8ca6-dc2bb6832259"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i8e10b28a9e47483eab1daecf6b5559db_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfMy01LTEtMS0yMjM1Nw_aa1ea9a3-2d5e-4be5-baff-b54199e4346c"
      unitRef="usd">4883000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i70c28a2a28bc4932a1c94051311c07d4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfNC0xLTEtMS0yMjM1Nw_8f22e554-7ae6-4fa9-b9cc-5ed17c59f7d7"
      unitRef="usd">6308000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i70c28a2a28bc4932a1c94051311c07d4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfNC0zLTEtMS0yMjM1Nw_d2b87f51-f81a-49f4-9c9e-036bbea57cf4"
      unitRef="usd">16664000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i70c28a2a28bc4932a1c94051311c07d4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfNC01LTEtMS0yMjM1Nw_3748a76f-3471-47e9-9313-488ae11050cf"
      unitRef="usd">22972000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia4a2508fbe7b4b60998f2800a6721219_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfNS0xLTEtMS0yMjM1Nw_5c646180-cc40-4b60-bedc-922ce1dd4c4d"
      unitRef="usd">4501000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ia4a2508fbe7b4b60998f2800a6721219_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfNS0zLTEtMS0yMjM1Nw_5603621d-7e18-41df-a7ac-d1362bc686df"
      unitRef="usd">6623000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ia4a2508fbe7b4b60998f2800a6721219_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfNS01LTEtMS0yMjM1Nw_8034047d-f26a-4485-885a-87e821fcbe02"
      unitRef="usd">11124000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i4010db64fe4c4fd08b2112d996676126_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfNi0xLTEtMS0yMjM1Nw_01275c0e-37c1-4da3-a466-35de96a04481"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i4010db64fe4c4fd08b2112d996676126_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfNi0zLTEtMS0yMjM1Nw_7ce03fc4-13ac-49bf-a24d-6c71565af69a"
      unitRef="usd">4678000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i4010db64fe4c4fd08b2112d996676126_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfNi01LTEtMS0yMjM1Nw_12d2bbce-49d7-4fab-96c4-402761e15f99"
      unitRef="usd">4678000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfNy0xLTEtMS0yMjM1Nw_559781be-2741-489c-b240-1e4557d90af7"
      unitRef="usd">15692000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfNy0zLTEtMS0yMjM1Nw_6f8f266f-d24f-4869-b160-eb882c62559f"
      unitRef="usd">27965000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOmE3MjA3ZjBiMWE4OTQ2YjA5ZDc4YTI5MjkxNWM2ZmVlL3RhYmxlcmFuZ2U6YTcyMDdmMGIxYTg5NDZiMDlkNzhhMjkyOTE1YzZmZWVfNy01LTEtMS0yMjM1Nw_c63a7579-41af-4f42-8978-ff77d33e7b9b"
      unitRef="usd">43657000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDU5MzE_8ac98eba-5b70-4fbf-b126-f7bb92f0f922">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in the Company&#x2019;s contract assets and liabilities during the nine months ended September&#160;30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at&lt;br/&gt;Beginning of&lt;br/&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at End&lt;br/&gt;of Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(156,209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;Excludes accounts receivable from other services related to clinical and regulatory activities performed by the Company on behalf of MTPC that are not included in the performance obligations identified under the MTPC Agreement as of September&#160;30, 2021 and 2020 and December&#160;31, 2020 and 2019. Also excludes accounts receivable related to amounts due to the Company from product sales which are included in the accompanying unaudited condensed consolidated balance sheet as of September&#160;30, 2021 and December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i9022775c979849d481205605464f30c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMi0xLTEtMS0yMjM1Nw_5903214a-16fd-4ae4-a62c-8b96eae10add"
      unitRef="usd">3045000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <akba:ContractWithCustomerAssetAdditions
      contextRef="i4d809bfac669408289ffd42f4682ebdf_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMi0zLTEtMS0yMjM1Nw_2db38d32-5888-42c6-8f15-3239c901aecb"
      unitRef="usd">38795000</akba:ContractWithCustomerAssetAdditions>
    <akba:ContractWithCustomerAssetDeductions
      contextRef="i4d809bfac669408289ffd42f4682ebdf_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMi01LTEtMS0yMjM1Nw_c739f25a-2dc2-45c2-962a-0483b0e8b4d3"
      unitRef="usd">20427000</akba:ContractWithCustomerAssetDeductions>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="iac0b3b12cdd94293a710efe9b099ccbf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMi03LTEtMS0yMjM1Nw_2eb30c14-5009-46ee-942d-ba05b3f089f9"
      unitRef="usd">21413000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="if43c4eaad1e5445d9f05ae88eab7739b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMy0xLTEtMS0yMjM1Nw_ded3ccb0-ece7-4375-b842-7d439a9df5d8"
      unitRef="usd">1722000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <akba:ContractWithCustomerAssetAdditions
      contextRef="i97125a084ecb413d80709a70f9e28986_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMy0zLTEtMS0yMjM1Nw_3da18160-ca2e-452e-b4c2-ee83b7731aa9"
      unitRef="usd">1725000</akba:ContractWithCustomerAssetAdditions>
    <akba:ContractWithCustomerAssetDeductions
      contextRef="i97125a084ecb413d80709a70f9e28986_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMy01LTEtMS0yMjM1Nw_3bcea715-543f-4826-82a7-eaf5b8178e79"
      unitRef="usd">5000</akba:ContractWithCustomerAssetDeductions>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i79eda260de9049ddb3c4152a914c8bc8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMy03LTEtMS0yMjM1Nw_8e4230df-8e93-493d-b42c-5efc8c18d3f1"
      unitRef="usd">3442000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ifd7a9c2a482c488c9e39c164f7f25286_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfNS0xLTEtMS0yMjM1Nw_fa68218e-93eb-433b-85cc-61b5a08b171d"
      unitRef="usd">40559000</us-gaap:ContractWithCustomerLiability>
    <akba:ContractWithCustomerLiabilityAdditions
      contextRef="i3404eb43c0644986a1e29bf11447aefa_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfNS0zLTEtMS0yMjM1Nw_70192772-ab33-4c18-af77-4c6cededd977"
      unitRef="usd">65890000</akba:ContractWithCustomerLiabilityAdditions>
    <akba:ContractWithCustomerLiabilityDeductions
      contextRef="i3404eb43c0644986a1e29bf11447aefa_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfNS01LTEtMS0yMjM1Nw_7658a572-5266-4ada-b1bc-5f980a20e71c"
      unitRef="usd">62792000</akba:ContractWithCustomerLiabilityDeductions>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i196a4d9a61ec429197ab955e5ff2ae4b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfNS03LTEtMS0yMjM1Nw_90764af3-3ab8-4098-a0ac-165db8b90b7a"
      unitRef="usd">43657000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="id7a97c0c8d344bda97e123e206e6b3c8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfNi0xLTEtMS0yMjM1Nw_975dbf49-b1dd-47d2-ba2f-afc485e99b95"
      unitRef="usd">7227000</us-gaap:ContractWithCustomerLiability>
    <akba:ContractWithCustomerLiabilityAdditions
      contextRef="i3c709aa7d7814c7bab26eccc3b81e798_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfNi0zLTEtMS0yMjM1Nw_a4a5804f-6b64-4804-977d-1a6e7fd19ae9"
      unitRef="usd">0</akba:ContractWithCustomerLiabilityAdditions>
    <akba:ContractWithCustomerLiabilityDeductions
      contextRef="i3c709aa7d7814c7bab26eccc3b81e798_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfNi01LTEtMS0yMjM1Nw_f78811cd-4f84-4831-911a-d4f718e16910"
      unitRef="usd">7227000</akba:ContractWithCustomerLiabilityDeductions>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ia93c22c9b15f4c919a2252df1363cdd4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfNi03LTEtMS0yMjM1Nw_63c03918-12c5-4240-8be6-5c6a81709583"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="id60c0fe0efd942ad8b113bef4877c974_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfNy0xLTEtMS0yMjM1Nw_7d6b0897-d0e4-4919-8f3a-5463b21d28ef"
      unitRef="usd">10000000</us-gaap:ContractWithCustomerLiability>
    <akba:ContractWithCustomerLiabilityAdditions
      contextRef="i76b75bcd1b964770ae1b56eaf8e7a892_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfNy0zLTEtMS0yMjM1Nw_4eb92ff9-1f6f-4292-b238-e8a2b2316911"
      unitRef="usd">0</akba:ContractWithCustomerLiabilityAdditions>
    <akba:ContractWithCustomerLiabilityDeductions
      contextRef="i76b75bcd1b964770ae1b56eaf8e7a892_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfNy01LTEtMS0yMjM1Nw_6483ac3d-53ad-4b4c-95f5-84db91725f21"
      unitRef="usd">0</akba:ContractWithCustomerLiabilityDeductions>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i253a75db63844161bc3f8de0b86f9a31_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfNy03LTEtMS0yMjM1Nw_c3524073-a842-4715-8773-09a15935e5c0"
      unitRef="usd">10000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="ib6b0e1ca966948bf9b3b29017f33c08b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTEtMS0xLTEtMjIzNTc_5019ad1f-101f-455b-8baa-60130288932e"
      unitRef="usd">15822000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <akba:ContractWithCustomerAssetAdditions
      contextRef="ie67e37ea23d74352995b356f2d5e00a5_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTEtMy0xLTEtMjIzNTc_0d33cd1d-75be-471d-aa8f-10704e280f85"
      unitRef="usd">143148000</akba:ContractWithCustomerAssetAdditions>
    <akba:ContractWithCustomerAssetDeductions
      contextRef="ie67e37ea23d74352995b356f2d5e00a5_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTEtNS0xLTEtMjIzNTc_19b46174-f64e-4111-9e1e-3f2ad9ce52ac"
      unitRef="usd">156209000</akba:ContractWithCustomerAssetDeductions>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i062a629a2436472793e654eaff2d5751_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTEtNy0xLTEtMjIzNTc_1adb1e67-f5b9-446b-89f3-55eb43c14459"
      unitRef="usd">2761000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i8991531a317948b9b93df5b26ec241f8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTItMS0xLTEtMjIzNTc_b5ece30c-e2bd-407b-9fc9-81a73b46bbe5"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <akba:ContractWithCustomerAssetAdditions
      contextRef="ie9224c9eaaef4b0fbb6b3ecd626f0fb5_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTItMy0xLTEtMjIzNTc_aefd5d7d-c691-40bd-8a93-b22a704cd25c"
      unitRef="usd">1248000</akba:ContractWithCustomerAssetAdditions>
    <akba:ContractWithCustomerAssetDeductions
      contextRef="ie9224c9eaaef4b0fbb6b3ecd626f0fb5_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTItNS0xLTEtMjIzNTc_8b19da1d-adde-4ae6-9e34-1afbd977f381"
      unitRef="usd">0</akba:ContractWithCustomerAssetDeductions>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="ia0467c81517d465385733a7970a7a414_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTItNy0xLTEtMjIzNTc_a82b6d92-396c-47c4-bd2d-8eee471a3170"
      unitRef="usd">1248000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ifcc593671c2e4622975ac665de36e6c1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTQtMS0xLTEtMjIzNTc_96a1880c-1be3-4b8c-af6a-cca2a10bee72"
      unitRef="usd">72950000</us-gaap:ContractWithCustomerLiability>
    <akba:ContractWithCustomerLiabilityAdditions
      contextRef="i595577133c66457b807c06fb447cc0ff_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTQtMy0xLTEtMjIzNTc_e26b4015-bfd1-4f9c-9a58-a21d9a8ee898"
      unitRef="usd">110295000</akba:ContractWithCustomerLiabilityAdditions>
    <akba:ContractWithCustomerLiabilityDeductions
      contextRef="i595577133c66457b807c06fb447cc0ff_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTQtNS0xLTEtMjIzNTc_d09b776a-43fe-4e13-97f4-3a9e62d14b77"
      unitRef="usd">131551000</akba:ContractWithCustomerLiabilityDeductions>
    <us-gaap:ContractWithCustomerLiability
      contextRef="icd56d876b06146709b43ea24c7d1c59b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTQtNy0xLTEtMjIzNTc_ca72fe86-2a01-4f68-8dd0-32ea11348b5d"
      unitRef="usd">51694000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ib43b28b4e0ab493fa74148aeaab24813_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTUtMS0xLTEtMjIzNTc_8aea9ad9-33c6-437b-ae7d-b381dfe76d68"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <akba:ContractWithCustomerLiabilityAdditions
      contextRef="iee7892ead75d4547be97c8704445856f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTUtMy0xLTEtMjIzNTc_b8603285-b90c-4c19-aa8a-88b8dc77009c"
      unitRef="usd">10097000</akba:ContractWithCustomerLiabilityAdditions>
    <akba:ContractWithCustomerLiabilityDeductions
      contextRef="iee7892ead75d4547be97c8704445856f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTUtNS0xLTEtMjIzNTc_6d6f7390-428f-45ba-9945-32e274bfe213"
      unitRef="usd">5651000</akba:ContractWithCustomerLiabilityDeductions>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ibe962a59b6ea455b88176426838ddf81_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTUtNy0xLTEtMjIzNTc_c3c35a5d-9e7e-412c-9251-dbdde099805a"
      unitRef="usd">4446000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i381ae62687174e09adb9da00b0c38527_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTYtMS0xLTEtMjIzNTc_c1745b8a-1deb-4317-b8df-8b4cb64ae5cb"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <akba:ContractWithCustomerLiabilityAdditions
      contextRef="i13ca6bac21b04356ab2ca6e641f44077_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTYtMy0xLTEtMjIzNTc_c5dbd1c6-9b96-492a-b836-b5329c0e6e61"
      unitRef="usd">615000</akba:ContractWithCustomerLiabilityAdditions>
    <akba:ContractWithCustomerLiabilityDeductions
      contextRef="i13ca6bac21b04356ab2ca6e641f44077_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTYtNS0xLTEtMjIzNTc_6866efc8-061f-4334-862c-4fbf37e36cbe"
      unitRef="usd">615000</akba:ContractWithCustomerLiabilityDeductions>
    <us-gaap:ContractWithCustomerLiability
      contextRef="id42d54e97e794a2e966b66e8d2cb3aa4_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjgwOGEyOTY2YmRjYzRhN2E4MjMzZjk0ZGI0MjRlYjU2L3RhYmxlcmFuZ2U6ODA4YTI5NjZiZGNjNGE3YTgyMzNmOTRkYjQyNGViNTZfMTYtNy0xLTEtMjIzNTc_01cadeb0-59ca-4cf7-937f-59652535a6e7"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <akba:ScheduleOfRevenueRecognizedResultingFromChangesInContractAssetAndContractLiabilityTableTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDU5MzI_7c3ff6a3-1363-47b9-b633-8e93f556d032">&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2021 and 2020, the Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the respective periods (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenue Recognized in the Period from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts included in deferred revenue at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance obligations satisfied in previous periods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</akba:ScheduleOfRevenueRecognizedResultingFromChangesInContractAssetAndContractLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjY4NzE5ZmUwNGM3MTRiOGFhYTcyMmU3YmEwMzIxNWJiL3RhYmxlcmFuZ2U6Njg3MTlmZTA0YzcxNGI4YWFhNzIyZTdiYTAzMjE1YmJfMi0xLTEtMS0yMjM1Nw_4b642edc-a018-4eb2-9c19-7c3d7e38f9b8"
      unitRef="usd">9159000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjY4NzE5ZmUwNGM3MTRiOGFhYTcyMmU3YmEwMzIxNWJiL3RhYmxlcmFuZ2U6Njg3MTlmZTA0YzcxNGI4YWFhNzIyZTdiYTAzMjE1YmJfMi0zLTEtMS0yMjM1Nw_b2dd033e-6b8e-49fd-b622-0b224c887ea3"
      unitRef="usd">6537000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjY4NzE5ZmUwNGM3MTRiOGFhYTcyMmU3YmEwMzIxNWJiL3RhYmxlcmFuZ2U6Njg3MTlmZTA0YzcxNGI4YWFhNzIyZTdiYTAzMjE1YmJfMi01LTEtMS0yMjM1Nw_d5d4e197-4d27-4a02-8ee8-0d366d354f9f"
      unitRef="usd">20363000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjY4NzE5ZmUwNGM3MTRiOGFhYTcyMmU3YmEwMzIxNWJiL3RhYmxlcmFuZ2U6Njg3MTlmZTA0YzcxNGI4YWFhNzIyZTdiYTAzMjE1YmJfMi03LTEtMS0yMjM1Nw_d0e7a952-bb1d-4b18-91f4-5f197e0bdfda"
      unitRef="usd">29203000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjY4NzE5ZmUwNGM3MTRiOGFhYTcyMmU3YmEwMzIxNWJiL3RhYmxlcmFuZ2U6Njg3MTlmZTA0YzcxNGI4YWFhNzIyZTdiYTAzMjE1YmJfMy0xLTEtMS0yMjM1Nw_109248e6-ef5b-4bd5-bc4e-a69aff76112b"
      unitRef="usd">0</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjY4NzE5ZmUwNGM3MTRiOGFhYTcyMmU3YmEwMzIxNWJiL3RhYmxlcmFuZ2U6Njg3MTlmZTA0YzcxNGI4YWFhNzIyZTdiYTAzMjE1YmJfMy0zLTEtMS0yMjM1Nw_5d5202eb-97e9-485e-a4d3-5acc9b3778b5"
      unitRef="usd">20648000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjY4NzE5ZmUwNGM3MTRiOGFhYTcyMmU3YmEwMzIxNWJiL3RhYmxlcmFuZ2U6Njg3MTlmZTA0YzcxNGI4YWFhNzIyZTdiYTAzMjE1YmJfMy01LTEtMS0yMjM1Nw_cf186fa4-d048-4737-bbbc-3f8fc33831ba"
      unitRef="usd">0</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RhYmxlOjY4NzE5ZmUwNGM3MTRiOGFhYTcyMmU3YmEwMzIxNWJiL3RhYmxlcmFuZ2U6Njg3MTlmZTA0YzcxNGI4YWFhNzIyZTdiYTAzMjE1YmJfMy03LTEtMS0yMjM1Nw_b8a758a7-97fe-4e2a-a9a5-7ec4e31f22a3"
      unitRef="usd">21346000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <akba:NumberOfPerformanceObligations
      contextRef="i5ffb0dde1c014cb9abf1b7695c63c0d2_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjkwMw_8ab6c49b-f99b-486c-ac5a-7582e8b50934"
      unitRef="performance_obligation">2</akba:NumberOfPerformanceObligations>
    <akba:UpfrontCashPaymentReceived
      contextRef="ibf4981c415ac4d3faa22e3d1e690bfbf_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNjA4NQ_350275b8-1905-4f64-a623-a9156b9d64bc"
      unitRef="usd">20000000</akba:UpfrontCashPaymentReceived>
    <akba:CostOfResearchServices
      contextRef="ibf4981c415ac4d3faa22e3d1e690bfbf_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNjEzMA_0ffb9d35-c579-42ad-a1f8-d5f3cae9324f"
      unitRef="usd">20500000</akba:CostOfResearchServices>
    <akba:MilestonePaymentReceived
      contextRef="ibf4981c415ac4d3faa22e3d1e690bfbf_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNjIxOQ_e51ced0b-dcad-49ba-922a-546b1e95e687"
      unitRef="usd">10000000</akba:MilestonePaymentReceived>
    <akba:MilestonePaymentReceived
      contextRef="i59b89b0dc1714bceaf61d6592940372e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNjI2Mg_c2b8fd4b-6178-4d8d-a01d-cc6bc9e828bf"
      unitRef="usd">25000000</akba:MilestonePaymentReceived>
    <akba:MilestonePaymentReceived
      contextRef="i8bea31568bfb475da7ac289ff0a194bb_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNjMxMw_c6325a8f-797b-4b47-9f73-1b99da17505b"
      unitRef="usd">10000000</akba:MilestonePaymentReceived>
    <akba:MilestonePaymentReceived
      contextRef="i049242e1c959495ba03db706d555ef59_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNjM0OA_2d26665b-d56a-4602-928f-016d1676eded"
      unitRef="usd">15000000</akba:MilestonePaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8270fb936c044bacb333691798285cad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNjQxNg_09d95025-1c9a-4c7f-bb21-f55d3d284532"
      unitRef="usd">900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <akba:MilestonePaymentReceived
      contextRef="i59b89b0dc1714bceaf61d6592940372e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNjQ5OQ_08233a63-0ab8-4145-ab27-836eab63a0f6"
      unitRef="usd">25000000</akba:MilestonePaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8873d2f4f3ab410f8ea8fdc1148178ff_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNjkwNA_ac89215c-40e3-4040-a726-e44d06968349"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2b65de4f50a4ba0aba4c2a04561a742_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ5MTA2NA_a43a8f34-655e-4abd-a64c-88285c94d217"
      unitRef="usd">400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <akba:MilestonePaymentReceived
      contextRef="i049242e1c959495ba03db706d555ef59_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNzAxMA_2d26665b-d56a-4602-928f-016d1676eded"
      unitRef="usd">15000000</akba:MilestonePaymentReceived>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i77a8fd0e1e314ec995a1ea4cb3e26298_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTA5OTUxMTY4MDYyMQ_51fcfed6-8480-4bed-8cab-8bb44e988f75"
      unitRef="usd">200000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i75a8e981279d4597a75912a5c2d89696_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNzY0Nw_398a0ff2-666e-4930-833e-e44c5b302ee1"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i75a8e981279d4597a75912a5c2d89696_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNzY3Mg_e5b18d70-87ce-4c5a-be58-40ec994451c9"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <akba:UpfrontCashPaymentReceived
      contextRef="i5ab7efb86c7e4332bb5d1393a1103c7a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfODIxOA_089382e1-da96-42fb-8edb-dc0b32233187"
      unitRef="usd">10400000</akba:UpfrontCashPaymentReceived>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i84bfabdde428494b8286364e0b2e04f8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ5NjAwMA_6834e442-f662-4a01-a76f-d19557c0ec6a"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="iec08195269f1492b95a796511ae43b19_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ5NjAwMA_e344e9ba-e6d5-4997-9770-7e0fcff84362"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ic04e3a3ad82e497eab9e0ccc53e84bb7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTA5OTUxMTY4MDI5OA_b0492925-e858-4961-b099-470020ae6131"
      unitRef="usd">500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="iddee3a51bc8e41009393c7fffc1d6be2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTA5OTUxMTY4MDMyNw_0ec0b227-d4e6-44d5-bb30-82f41ec87192"
      unitRef="usd">4500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i5008d093e2c14f8e9b0c70b8ad2d6cdf_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ5NjAzMg_b0c67fb2-0946-409d-ba9c-a4c0bfc1794d"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i5008d093e2c14f8e9b0c70b8ad2d6cdf_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfODYwNw_b0cf8eb1-cfad-40db-9254-f86a8643bec1"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i30255726ea164f57b4faf87425b440bf_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfODYzMg_d58113fc-1357-4d28-baec-7d399c28fe60"
      unitRef="usd">3000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i2c9c4fa43e814dbbaf59df410140075b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfODY2OA_cd1c5928-e608-47fb-aa17-4f5a0af6cd6f"
      unitRef="usd">400000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i8e8a7ecf26094b9985196caeaf40209b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ5MTQyOQ_f92332fb-a0fb-4411-8b0f-d1a300cb00cb"
      unitRef="usd">2200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i0713ae0f1c084dc1a951ad2de75526f0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfOTM1MQ_98f1485b-7f0c-4d4c-a698-dff04ee663ac"
      unitRef="usd">6700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:BilledContractReceivables
      contextRef="i93d500fdcbc947168636b67aefe164f2_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfOTUwMQ_78f93a08-40d5-4080-a9f8-edb5942b86f9"
      unitRef="usd">13400000</us-gaap:BilledContractReceivables>
    <us-gaap:BilledContractReceivables
      contextRef="i64af70fdf31a4cfcbd5d1dd0c6e667f3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfOTU5Mg_8e27bc66-e5bb-41c1-9cb6-a1d497004a31"
      unitRef="usd">4500000</us-gaap:BilledContractReceivables>
    <us-gaap:BilledContractReceivables
      contextRef="i5c2d9393a8d94a97b1a20c634e92642c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfOTYxOQ_6eaeb336-04c5-4c07-8c9c-75fd7e4911f9"
      unitRef="usd">4900000</us-gaap:BilledContractReceivables>
    <us-gaap:BilledContractReceivables
      contextRef="i2d43ffd6494e45cea49745bc245eb588_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfOTY0Mw_a47259ef-a729-402e-aa77-eea82a2a8857"
      unitRef="usd">16300000</us-gaap:BilledContractReceivables>
    <us-gaap:BilledContractReceivables
      contextRef="i2182ac591eaa4895935be370490ebd61_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfOTY3OQ_9983a1d5-37da-4649-ad9f-4fbb25db3042"
      unitRef="usd">5800000</us-gaap:BilledContractReceivables>
    <akba:NumberOfPerformanceObligations
      contextRef="i729bdb2febbe40f7a0d7e8b9d41b5707_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTE4MDk_61c6ceb7-55ca-44f8-9654-f15c713f4c68"
      unitRef="performance_obligation">3</akba:NumberOfPerformanceObligations>
    <akba:MilestonePaymentReceived
      contextRef="i05703e7e166b4e6aa26567e3dd53b0d4_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTQ2NDU_80df0d1e-8d12-492e-a157-419c88a7bdf0"
      unitRef="usd">0</akba:MilestonePaymentReceived>
    <akba:CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount
      contextRef="ib36601c7c6054547b257cbee1cadedd2_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0Mzk_7ad5e4bc-1c87-40f2-b06d-19ee11a905f2"
      unitRef="usd">139800000</akba:CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount>
    <akba:ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable
      contextRef="icf1d9f1217594ee99787532eb6416a3e_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY3MjQ_4e8e18ec-ea95-4fcc-9936-abebf4e9ad44"
      unitRef="number">0.50</akba:ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable>
    <akba:PercentageOfRemainingCreditableAmountAppliedToFuturePayments
      contextRef="i5df4e367c4894f3baca804f2eba217c6_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY3OTA_cbf36339-998c-4cfb-bd85-182caca9755e"
      unitRef="number">0.50</akba:PercentageOfRemainingCreditableAmountAppliedToFuturePayments>
    <akba:CollaborativeArrangementsAdditionalCostSharingPaymentsAmount
      contextRef="i729bdb2febbe40f7a0d7e8b9d41b5707_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY5MTk_81d5dcb9-fc4a-4a15-9811-df9e303fae4d"
      unitRef="usd">106700000</akba:CollaborativeArrangementsAdditionalCostSharingPaymentsAmount>
    <akba:CollaborativeAndLicenseArrangementTransactionPrice
      contextRef="i729bdb2febbe40f7a0d7e8b9d41b5707_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTgwMzE_a36352ef-2757-4742-b7bd-bbefb6e7a82a"
      unitRef="usd">504200000</akba:CollaborativeAndLicenseArrangementTransactionPrice>
    <akba:UpfrontCashPaymentReceived
      contextRef="i044f764231f14772829db57c3b4d1639_D20161201-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTgwODA_18af043e-fd11-4ddd-93a4-d0031b639718"
      unitRef="usd">125000000</akba:UpfrontCashPaymentReceived>
    <akba:PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred
      contextRef="icbdd2b99003a4b868da41de914cb59b4_D20161201-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTgxODk_94c2b287-6885-40f4-8b79-923cfa959282"
      unitRef="usd">33800000</akba:PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred>
    <akba:CollaborativeArrangementsCostSharingPayments
      contextRef="icbdd2b99003a4b868da41de914cb59b4_D20161201-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTgyODQ_ca00ed0c-9ff8-42be-b206-539e0b43efe6"
      unitRef="usd">345400000</akba:CollaborativeArrangementsCostSharingPayments>
    <akba:RevenueRemainingPerformanceObligationVariableConsiderationAmount
      contextRef="i500c6fdc5af04a21900cf4f2d9069a5b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ4ODE5MQ_d6905de7-a59b-4e5c-ba19-65bac581b7a2"
      unitRef="usd">65000000</akba:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <akba:RevenueRemainingPerformanceObligationVariableConsiderationAmount
      contextRef="if916aba0a4c34bab87b14d995442b804_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ4ODI5OA_fc89c038-b628-4ec6-9f79-ceee5c5fc673"
      unitRef="usd">575000000</akba:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <akba:MilestonePaymentReceived
      contextRef="i05703e7e166b4e6aa26567e3dd53b0d4_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTgzNzg_0060f9f3-e3f9-4c03-9391-ba36556effa7"
      unitRef="usd">0</akba:MilestonePaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefd530a7f1a248edbdc9b05c847c8a7e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTg1OTg_3c673c77-c380-45d3-b465-42107c07a1dc"
      unitRef="usd">6100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib09d90891a274c3c818a2cef521eace2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTg2MDU_eaacef14-3dae-472f-bb20-cfa00a8b99a5"
      unitRef="usd">16300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73b11af5f04a42d9a1071752d045891e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTg2NDE_104f92a4-8b74-4ee9-8f10-ee9b09c2d465"
      unitRef="usd">29000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6fc2047fffc4e2d8558725e0f1d34a0_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTg2NDg_dd40ecb0-5c48-4bc2-af86-302678223ad1"
      unitRef="usd">80700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i70c28a2a28bc4932a1c94051311c07d4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTg5MTI_2c81ef54-1b92-4f60-b7ab-14fa644252c9"
      unitRef="usd">23000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i70c28a2a28bc4932a1c94051311c07d4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTg5ODE_4e34a4b5-edb2-4e54-a35f-1f5437cd5e11"
      unitRef="usd">6300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i70c28a2a28bc4932a1c94051311c07d4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTkwMTM_3eb4c57f-0aa4-4a7d-8fd0-b6599697434e"
      unitRef="usd">16700000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i4eff79078bbb43e1882ae7742d0279b6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTA5OTUxMTY4MDY0MQ_de785720-0a7a-426a-9ff6-cf1760d71572"
      unitRef="usd">2400000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="ib0094621113146aebebb1a65434da333_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTkyNTU_49efc963-e772-490a-91d5-e0fa2f3e0bd1"
      unitRef="usd">2400000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ic6acee9f4bf9402baacb58cb5f057459_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTk0MDU_12954688-9f7e-4f49-a742-1a847c03ad14"
      unitRef="usd">5000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i51de58b6c7be4fb9899538b241b86615_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTk0Njc_b8b5fbb0-da3c-4d4c-a43c-d0157e4d8cba"
      unitRef="usd">1200000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <akba:CostShareCostsIncurredForLicenseAgreement
      contextRef="ic5c623ee9ed146eb8cee4622f170592a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjA2NDI_426c2347-7863-4131-b399-5bc212c4a1a3"
      unitRef="usd">3600000</akba:CostShareCostsIncurredForLicenseAgreement>
    <akba:CostShareCostsIncurredForLicenseAgreement
      contextRef="i70b7ea01a52041328c8e4e5bcda17a4c_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjA2NDk_fd3eb0d4-373b-47d4-a3ad-5c1337f03987"
      unitRef="usd">1200000</akba:CostShareCostsIncurredForLicenseAgreement>
    <akba:PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred
      contextRef="ic5c623ee9ed146eb8cee4622f170592a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjA3Njg_1e9d70d2-e058-4e0a-8ec4-4e9fdd986dfe"
      unitRef="usd">1800000</akba:PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred>
    <akba:PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred
      contextRef="i70b7ea01a52041328c8e4e5bcda17a4c_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjA3NzU_b9461e5d-4f48-4a25-b7f1-fc8d8ba4f9f0"
      unitRef="usd">500000</akba:PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred>
    <akba:CostShareCostsIncurredByPartnerForLicenseAgreement
      contextRef="ic5c623ee9ed146eb8cee4622f170592a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjA5OTU_ece954f8-4c61-4c82-a8ed-575e06682fab"
      unitRef="usd">0</akba:CostShareCostsIncurredByPartnerForLicenseAgreement>
    <akba:CostShareCostsIncurredByPartnerForLicenseAgreement
      contextRef="i70b7ea01a52041328c8e4e5bcda17a4c_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjEwMDI_fdd3066a-414e-4e4f-9e1b-dd77b7d825b4"
      unitRef="usd">500000</akba:CostShareCostsIncurredByPartnerForLicenseAgreement>
    <akba:PaymentForLicenseAgreementReimbursementOfCostsIncurred
      contextRef="i70b7ea01a52041328c8e4e5bcda17a4c_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjExMjg_aad51662-92ae-44db-abaf-be28f9005138"
      unitRef="usd">300000</akba:PaymentForLicenseAgreementReimbursementOfCostsIncurred>
    <akba:NumberOfPerformanceObligations
      contextRef="i21debe3a35d84013a5c0a46700b925d1_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjQwNjI_61cf3965-ffe8-4bde-b126-c91c7b1d9f2c"
      unitRef="performance_obligation">3</akba:NumberOfPerformanceObligations>
    <akba:CollaborativeAndLicenseArrangementTransactionPrice
      contextRef="i21debe3a35d84013a5c0a46700b925d1_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjgxNTE_a833f467-6aa8-41b1-9754-350b03724dee"
      unitRef="usd">310400000</akba:CollaborativeAndLicenseArrangementTransactionPrice>
    <akba:UpfrontCashPaymentReceived
      contextRef="i0fdc68385d154fbd8c01df1bd39dde5d_D20170425-20170425"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjgyMDA_cb085b14-6401-45f8-bb61-66d8a0ed7003"
      unitRef="usd">73000000</akba:UpfrontCashPaymentReceived>
    <akba:PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred
      contextRef="i871f553557614df48044678d328520cb_D20170101-20170331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjgzMjM_f60cbd97-91f8-474b-ae1d-92c5ecb77b38"
      unitRef="usd">200000</akba:PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred>
    <akba:EstimateSubsequentCostFundingUnderPlan
      contextRef="i871f553557614df48044678d328520cb_D20170101-20170331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjg0ODA_359c39b4-8ff6-4129-914c-d54339ded8b1"
      unitRef="usd">237300000</akba:EstimateSubsequentCostFundingUnderPlan>
    <akba:RevenueRemainingPerformanceObligationVariableConsiderationAmount
      contextRef="id317514fef48482db39eba1dc979e0ad_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ5MDAxNA_da1de08d-8884-458e-833b-92d39b7120b5"
      unitRef="usd">17000000</akba:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <akba:RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod
      contextRef="i587afcb2ee994fd1823e352650f8c16f_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ5NjAzOQ_71919e09-6a48-4c8b-ac7e-b498bcb87173">P12M</akba:RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod>
    <akba:RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod
      contextRef="i4f62756447d54a2ea8980a3e5189c028_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ5NjA0OA_237e6155-301a-46e0-91d3-e7fbb0aa8910">P24M</akba:RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod>
    <akba:RevenueRemainingPerformanceObligationVariableConsiderationAmount
      contextRef="ie73bc5c571f84ec38080d5e084633f19_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ5MDAwNA_0b2c91c1-244e-44aa-bec2-753239a78f5a"
      unitRef="usd">525000000</akba:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i945ff9fde11644a58dafd0226b9d6c0f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjg3MTU_41c8b3bf-ec18-41a6-b342-34a7c22b4cac"
      unitRef="usd">1900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i738510817c5048b98d2eea09c5a05cf1_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjg3MjI_eb5e25fa-a960-46ac-aa87-c90e45c03657"
      unitRef="usd">7200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f482f3f6423440ea0d9f6c8bef66818_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjg3NTg_f4e8c1cf-18e5-44e5-af7e-97d7eaab1c1a"
      unitRef="usd">13500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a84c225ba714f219479e22fc09d67e9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjg3NjU_44221040-d6cc-45f4-a66a-ec234cb3293b"
      unitRef="usd">39400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ia4a2508fbe7b4b60998f2800a6721219_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjkwMzg_2fe76e44-573f-4059-aea5-0b5bf4a4ed4a"
      unitRef="usd">11100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia4a2508fbe7b4b60998f2800a6721219_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjkxMTY_8ed179e9-224c-43c9-9e8c-602e3a1741bb"
      unitRef="usd">4500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ia4a2508fbe7b4b60998f2800a6721219_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjkxNDg_008896b2-ff79-4829-b0aa-47f86b223c68"
      unitRef="usd">6600000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i9874741da84a44769dea47ee0e59d980_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTA5OTUxMTY4MDY5MA_379a5b87-9582-4beb-8373-11c68e2a3d1e"
      unitRef="usd">1100000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i02e592c97e6f450ca8dbb9dfbdb2b298_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjkzOTA_16c6ce1a-06ac-4c35-88e9-30be71995989"
      unitRef="usd">1100000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ib0ad25ebad234cb5a72142b53cc43ba6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjk1NDA_4dc4d6de-f756-4abb-83a0-0238836ffce1"
      unitRef="usd">2300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="iac660281115d42f3adbe6635fbbac7b5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMjk2MDI_f43d60e0-73c9-4bb9-ba98-c99bd175937e"
      unitRef="usd">500000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <akba:CollaborativeArrangementTerm
      contextRef="ieeebde433f7a49538c99f8eedfadce25_D20170209-20170209"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDU5Mzg_6b872c39-58d2-4ff8-a42d-03f148705de5">P3Y</akba:CollaborativeArrangementTerm>
    <akba:UpfrontPaymentPaidInCash
      contextRef="ifcf133937bdc4353b3c3ba86e059f5cb_I20170209"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzA3NTk_780a1b1b-598c-4836-b9d8-a91ed3f81a7b"
      unitRef="usd">1000000</akba:UpfrontPaymentPaidInCash>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ifc1340b1d3414996b23a8b1c78d66a9b_I20170209"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzA4MzM_ca647c25-8c93-4cef-9354-b5ebf97756f2"
      unitRef="shares">509611</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ifc1340b1d3414996b23a8b1c78d66a9b_I20170209"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzA4OTk_6868358b-68e6-4a54-b9fc-0053b77a2496"
      unitRef="usdPerShare">9.81</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="i8b7b728d6820482185b5f4c1ce9f6131_I20170331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzEzMzU_7c4174bb-76ef-46b8-b9ab-56109965145f"
      unitRef="usd">3400000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <akba:PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones
      contextRef="ieeebde433f7a49538c99f8eedfadce25_D20170209-20170209"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzE0OTI_13e6c490-04b5-4534-bd9c-27aa0c07bc1b"
      unitRef="usd">16500000</akba:PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones>
    <akba:PotentialPaymentForAchievementOfSpecifiedCommercialMilestones
      contextRef="ieeebde433f7a49538c99f8eedfadce25_D20170209-20170209"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzE2MzQ_4faafd06-95e9-4fd8-9493-1f25e308483a"
      unitRef="usd">215000000</akba:PotentialPaymentForAchievementOfSpecifiedCommercialMilestones>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ifc1441455f5f427d888f9be3a658edc4_D20210604-20210604"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzI2NTA_8c539fd5-77a5-46a2-bdbb-3c3951c8ee2d"
      unitRef="usd">3000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="ifc1441455f5f427d888f9be3a658edc4_D20210604-20210604"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzMyNzg_7eaadf63-c616-447d-bc9c-85d5ea7e96a7"
      unitRef="usd">222000000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0f7c79b242f844ddad0fc74aecc7c6ca_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzM3Njk_99dc6719-6915-4a47-8f0c-3931bdde8686"
      unitRef="usd">3000000</us-gaap:ResearchAndDevelopmentExpense>
    <akba:AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod
      contextRef="ifc1441455f5f427d888f9be3a658edc4_D20210604-20210604"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzQxNDc_e99a0a8e-6c7d-4afb-912d-0bd96042bb10">P10Y</akba:AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod>
    <akba:AssetAcquisitionAgreementTerminationNoticePeriod
      contextRef="ifc1441455f5f427d888f9be3a658edc4_D20210604-20210604"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzQzMzE_86d03782-8c42-463a-8dc3-4b5fef3a6d96">P180D</akba:AssetAcquisitionAgreementTerminationNoticePeriod>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9ae72c8b1a6046dc8ea43e24fa8b97b6_I20170512"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzU4ODU_7a10b57d-428b-43c1-8ba7-49e7cc4116fd"
      unitRef="shares">3571429</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i9ae72c8b1a6046dc8ea43e24fa8b97b6_I20170512"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzU5ODE_3f7901a6-8a35-45a9-b75c-d1a48402713b"
      unitRef="usdPerShare">14.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i22c6d8b4a8754f2cabfbd65f0be236dd_D20170512-20170512"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzU5OTk_45684a82-ae94-4321-bd8e-bdfbccd8d6dd"
      unitRef="usd">50000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <akba:ClosingStockPriceOfCommonStock
      contextRef="i9ae72c8b1a6046dc8ea43e24fa8b97b6_I20170512"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzYwNzE_00ba6cfe-c4c4-45d1-9feb-a064950ccced"
      unitRef="usdPerShare">12.69</akba:ClosingStockPriceOfCommonStock>
    <akba:CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock
      contextRef="i9ae72c8b1a6046dc8ea43e24fa8b97b6_I20170512"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzYxMTU_dd61c79f-a6ca-4521-96ea-537b793c0fbd"
      unitRef="usd">4700000</akba:CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock>
    <akba:PotentialPaymentForAchievementOfSpecifiedMilestones
      contextRef="i22c6d8b4a8754f2cabfbd65f0be236dd_D20170512-20170512"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzY1OTk_99def8e4-3b6c-40b3-b5ec-610619258aff"
      unitRef="usd">25000000</akba:PotentialPaymentForAchievementOfSpecifiedMilestones>
    <akba:PotentialPaymentForAchievementOfSpecifiedMilestones
      contextRef="i22c6d8b4a8754f2cabfbd65f0be236dd_D20170512-20170512"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzY5ODU_6f586ef1-2fe6-496a-9deb-fa107df2a9ff"
      unitRef="usd">25000000</akba:PotentialPaymentForAchievementOfSpecifiedMilestones>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i9ae72c8b1a6046dc8ea43e24fa8b97b6_I20170512"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzcwMzE_cb3f92d6-0bf0-4383-bbf9-c6e2f06095a1"
      unitRef="usd">4700000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <akba:AggregateCollaborationAgreementPayments
      contextRef="i8a3012cc53274e7386ae899217cc4ae0_D20200214-20200214"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzg1NjE_82973862-69d5-4c22-8573-8bdae7119a4a"
      unitRef="usd">10000000</akba:AggregateCollaborationAgreementPayments>
    <akba:AggregateCollaborationAgreementPayments
      contextRef="i7e2acaca8c4648fc8c17812d445090de_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMzkzMzI_189a7a60-1901-4eab-9d52-b934770f0fe3"
      unitRef="usd">10000000.0</akba:AggregateCollaborationAgreementPayments>
    <akba:RoyaltyPaymentsDue
      contextRef="i41e46089042845efb8effbe91d3866a0_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDE2NTA_7d51bfc7-c67a-40d6-935b-68f6805ef4bb"
      unitRef="usd">3000000</akba:RoyaltyPaymentsDue>
    <akba:RoyaltyPaymentsDue
      contextRef="i042537cbb7204196925307a6b7f16840_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ4Nzg4MQ_2b8385b3-7777-49dd-a462-2a72427fae5f"
      unitRef="usd">2900000</akba:RoyaltyPaymentsDue>
    <akba:RoyaltyPaymentsDue
      contextRef="i3aadde62784b4aefa36a71ef6d3bb27b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDE3MDU_bf02985e-6fa9-4d38-9eb7-20cc57caea60"
      unitRef="usd">8300000</akba:RoyaltyPaymentsDue>
    <akba:RoyaltyPaymentsDue
      contextRef="ib037a9facfea4d249380bdea73ce519b_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfMTY0OTI2NzQ4NzkyOA_458efc1c-b239-4f4d-85a8-b6ec4dcb1b89"
      unitRef="usd">8200000</akba:RoyaltyPaymentsDue>
    <akba:NumberOfPerformanceObligations
      contextRef="i0cc1c74d758f401f8afecb62a3e1d9dd_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDM1ODU_92b852e5-2168-464d-bb7f-2cf144b232ea"
      unitRef="performance_obligation">2</akba:NumberOfPerformanceObligations>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iead0fd037fa94b5eac362dee913b3b35_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDU1MjI_527c617a-1949-423a-95e5-836f6f835fe0"
      unitRef="usd">1400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3917cbc6ebab4fcba1653703ddcaeb89_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDU1Mjk_a129b9e5-8bf3-4384-89b1-0ea133a2d64e"
      unitRef="usd">1200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0cc1c74d758f401f8afecb62a3e1d9dd_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDU1OTE_1c3c8d41-9fd9-42d9-aa07-a068e859c853"
      unitRef="usd">4100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1bce44b505714f94a8b535b4ea2e5717_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80Ni9mcmFnOjE4MmNiMzk4NzdlMTQ3Y2M4ZWY3MDYwZDc1YTc0MTcxL3RleHRyZWdpb246MTgyY2IzOTg3N2UxNDdjYzhlZjcwNjBkNzVhNzQxNzFfNDU1OTg_ac168fa8-fd34-4a2f-99f3-a007e438e3ab"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RleHRyZWdpb246MTdiYTE0MmM3OTkyNGNiNTkxODk5NGZjMWYzMTgxNjJfNDIxMw_c64a31ac-77fe-4924-8282-7290514dc0c5">Liability Related to Sale of Future Royalties&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 25, 2021, the Company entered into the Royalty Agreement with HealthCare Royalty Partners IV, L.P., or HCR, pursuant to which the Company sold to HCR its right to receive royalties and sales milestones for vadadustat in Japan and certain other Asian countries, such countries, collectively, the MTPC Territory, and such payments collectively the Royalty Interest Payments, in each case, payable to the Company under the MTPC Agreement, subject to an annual maximum &#x201c;cap&#x201d; of $13.0&#160;million, or the Annual Cap, and an aggregate maximum &#x201c;cap&#x201d; of $150.0&#160;million, or the Aggregate Cap. After HCR receives Royalty Interest Payments equal to the Annual Cap in a given calendar year, the Company will receive 85% of the Royalty Interest Payments for the remainder of that year. After HCR receives Royalty Interest Payments equal to the Aggregate Cap, or the Company pays the Aggregate Cap to HCR (net of the Royalty Interest Payments already received by HCR), the Royalty Interest Payments will revert back to the Company, and HCR would have no further right to any Royalty Interest Payments. The Company received $44.8&#160;million from HCR (net of certain transaction expenses) under the Royalty Agreement, and the Company is eligible to receive an additional $5.0&#160;million in each year from 2021 through 2023 under the Royalty Agreement if specified annual sales milestones are achieved for vadadustat in the MTPC Territory, subject to the satisfaction of certain customary conditions. The Company retains the right to receive all potential future regulatory milestones for vadadustat under the MTPC Agreement. The Royalty Agreement will terminate on the earlier of the date on which HCR has received (i) the last Royalty Interest Payment or (ii) payment by the Company of an amount equal to the Aggregate Cap minus the aggregate amount of all Royalty Interest Payments actually received by HCR.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although the Company sold its right to receive royalties and sales milestones for vadadustat in the MTPC Territory as described above, as a result of its ongoing involvement in the cash flows related to these royalties, the Company will continue to account for these royalties as revenue. The Company recognized the proceeds received from HCR as a liability that is being amortized using the effective interest method over the life of the arrangement. At the transaction date, the Company recorded the net proceeds of $44.8&#160;million as a liability. In order to determine the amortization of the liability, the Company is required to estimate the total amount of future net royalty payments to be made to HCR over the term of the Royalty Agreement. The total threshold of net royalties to be paid, less the net proceeds received, will be recorded as interest expense over the life of the liability. The Company imputes interest on the unamortized portion of the liability using the effective interest method. The annual effective interest rate as of September&#160;30, 2021 was 19.2% which is reflected as interest expense in the unaudited condensed consolidated statements of operations and comprehensive loss. Over the course of the Royalty Agreement, the actual interest rate will be affected by the amount and timing of royalty revenue recognized and changes in forecasted royalty revenue. There are a number of factors that could materially affect the amount and timing of royalty payments from MTPC, none of which are within the Company's control. On a quarterly basis, the Company reassesses the effective interest rate and adjusts the rate prospectively as needed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the activity within the liability account for the nine months ended September&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to sale of future royalties, net &#x2014; beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sale of future royalties, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,783&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MTPC royalties payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(425)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,779&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to sale of future royalties, net &#x2014; ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Royalty Agreement requires the Company to take certain actions, including actions with respect to the Royalty Interest Payments, the MTPC Agreement, the MTPC Supply Agreement, and the Company's intellectual property. The Royalty Agreement also contains certain representations and warranties, covenants, indemnification obligations, events of default and other provisions that are customary for a royalty monetization transaction of this nature. In addition, the Company granted HCR a precautionary security interest in connection with the Royalty Interest Payments.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <akba:ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity
      contextRef="i016c3424f40c49faa098233e6b0ce0ef_I20210225"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RleHRyZWdpb246MTdiYTE0MmM3OTkyNGNiNTkxODk5NGZjMWYzMTgxNjJfNTM3_2442b8f9-bdb9-4b59-8df8-c69dd9883060"
      unitRef="usd">13000000</akba:ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity>
    <akba:ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity
      contextRef="i016c3424f40c49faa098233e6b0ce0ef_I20210225"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RleHRyZWdpb246MTdiYTE0MmM3OTkyNGNiNTkxODk5NGZjMWYzMTgxNjJfNTk0_68f4f666-c52b-4a35-94ba-92ef2316b79a"
      unitRef="usd">150000000</akba:ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity>
    <akba:ContractualArrangementRoyaltiesAgreementPercentageOfRoyaltyPaymentsToBeReceivedContingentOnReachingMaximumAnnualRoyaltyPayoutCapacity
      contextRef="i8b1ce5c7f57f4300b066a27bf7644888_D20210225-20210225"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RleHRyZWdpb246MTdiYTE0MmM3OTkyNGNiNTkxODk5NGZjMWYzMTgxNjJfNzQw_718ea4cf-00e9-4728-b9fd-3271d17aba8d"
      unitRef="number">0.85</akba:ContractualArrangementRoyaltiesAgreementPercentageOfRoyaltyPaymentsToBeReceivedContingentOnReachingMaximumAnnualRoyaltyPayoutCapacity>
    <akba:ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties
      contextRef="i8b1ce5c7f57f4300b066a27bf7644888_D20210225-20210225"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RleHRyZWdpb246MTdiYTE0MmM3OTkyNGNiNTkxODk5NGZjMWYzMTgxNjJfMTE0NA_7595dab7-3ea4-4c0e-9a69-272adedff605"
      unitRef="usd">44800000</akba:ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties>
    <akba:ContractualArrangementRoyaltiesAgreementProceedsContingentOnAnnualSalesMilestones
      contextRef="i8b1ce5c7f57f4300b066a27bf7644888_D20210225-20210225"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RleHRyZWdpb246MTdiYTE0MmM3OTkyNGNiNTkxODk5NGZjMWYzMTgxNjJfMTI3Ng_c8445579-4b78-494b-a5f7-550e5c445dd1"
      unitRef="usd">5000000</akba:ContractualArrangementRoyaltiesAgreementProceedsContingentOnAnnualSalesMilestones>
    <akba:ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent
      contextRef="i016c3424f40c49faa098233e6b0ce0ef_I20210225"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RleHRyZWdpb246MTdiYTE0MmM3OTkyNGNiNTkxODk5NGZjMWYzMTgxNjJfMjQyMQ_3fb24d60-e91f-4161-b55d-c28f41853890"
      unitRef="usd">44800000</akba:ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent>
    <akba:ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RleHRyZWdpb246MTdiYTE0MmM3OTkyNGNiNTkxODk5NGZjMWYzMTgxNjJfMjk0Nw_c1480bb6-615a-4b2c-b6a3-a10e30aac14c"
      unitRef="number">0.192</akba:ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RleHRyZWdpb246MTdiYTE0MmM3OTkyNGNiNTkxODk5NGZjMWYzMTgxNjJfNDIxMg_2178d2ae-bf75-4ceb-84d1-77b4166da6a9">The following table shows the activity within the liability account for the nine months ended September&#160;30, 2021:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to sale of future royalties, net &#x2014; beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sale of future royalties, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,783&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MTPC royalties payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(425)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,779&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to sale of future royalties, net &#x2014; ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <akba:ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RhYmxlOmIwZTJkYTVhOGRlNTQ0NzM4ODFiMzg2ZTdmYTAyNWNkL3RhYmxlcmFuZ2U6YjBlMmRhNWE4ZGU1NDQ3Mzg4MWIzODZlN2ZhMDI1Y2RfMi0xLTEtMS0yMjM1Nw_f3d8aca3-a17c-41f2-a1b7-ab77e3dd01cc"
      unitRef="usd">0</akba:ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent>
    <akba:ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RhYmxlOmIwZTJkYTVhOGRlNTQ0NzM4ODFiMzg2ZTdmYTAyNWNkL3RhYmxlcmFuZ2U6YjBlMmRhNWE4ZGU1NDQ3Mzg4MWIzODZlN2ZhMDI1Y2RfMy0xLTEtMS0yMjM1Nw_9f1e0c64-a375-456f-8a14-6a76675b8654"
      unitRef="usd">44783000</akba:ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties>
    <akba:ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RhYmxlOmIwZTJkYTVhOGRlNTQ0NzM4ODFiMzg2ZTdmYTAyNWNkL3RhYmxlcmFuZ2U6YjBlMmRhNWE4ZGU1NDQ3Mzg4MWIzODZlN2ZhMDI1Y2RfNC0xLTEtMS0yMjM1Nw_c5f4b2d8-c9d7-4a50-84a6-53eece412d12"
      unitRef="usd">425000</akba:ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable>
    <akba:ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RhYmxlOmIwZTJkYTVhOGRlNTQ0NzM4ODFiMzg2ZTdmYTAyNWNkL3RhYmxlcmFuZ2U6YjBlMmRhNWE4ZGU1NDQ3Mzg4MWIzODZlN2ZhMDI1Y2RfNS0xLTEtMS0yMjM1Nw_bfc18b56-d2b5-4a08-a84f-5effe5ad03d7"
      unitRef="usd">6779000</akba:ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome>
    <akba:ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl80OS9mcmFnOjE3YmExNDJjNzk5MjRjYjU5MTg5OTRmYzFmMzE4MTYyL3RhYmxlOmIwZTJkYTVhOGRlNTQ0NzM4ODFiMzg2ZTdmYTAyNWNkL3RhYmxlcmFuZ2U6YjBlMmRhNWE4ZGU1NDQ3Mzg4MWIzODZlN2ZhMDI1Y2RfNi0xLTEtMS0yMjM1Nw_5dd828ba-73bb-4a50-928a-e56ae061a893"
      unitRef="usd">51137000</akba:ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RleHRyZWdpb246NzVhMzkxYzVlYjE1NDIyZGE4MDVhNjgzMmFhYzcwYzlfNDk2_119b26d9-ea3e-4116-beb8-1107aae7868a">Available For Sale Securities&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and available for sale securities at September&#160;30, 2021 and December&#160;31, 2020 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available for sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available for sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and available for sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available for sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available for sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and available for sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no realized gains or losses on available for sale securities for the three and nine months ended September&#160;30, 2021 and 2020 and the Company did not recognize any credit losses during the three and nine months ended September&#160;30, 2021 and 2020. Additionally, the Company did not have any available for sale securities that were in an unrealized loss position as of September&#160;30, 2021 and December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RleHRyZWdpb246NzVhMzkxYzVlYjE1NDIyZGE4MDVhNjgzMmFhYzcwYzlfNDk3_2d087986-330c-4798-95f1-64a5434dcd54">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and available for sale securities at September&#160;30, 2021 and December&#160;31, 2020 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available for sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available for sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and available for sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available for sale securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available for sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and available for sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfMy0xLTEtMS0yMjM1Nw_a7fb527e-535c-4552-abe4-c712c972b4ab"
      unitRef="usd">207204000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfMy03LTEtMS0yMjM1Nw_d0fe45bd-77b9-4c47-a241-0afad83818d3"
      unitRef="usd">207204000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i56d517c10b584fe0aaec8d914de26be7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfNS0xLTEtMS0yMjM1Nw_39b50ac9-dd37-4ad0-a9ed-98596dea1cbf"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i56d517c10b584fe0aaec8d914de26be7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfNS0zLTEtMS0yMjM1Nw_494dd71d-0033-47f5-afd4-2fadd90a1e95"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i56d517c10b584fe0aaec8d914de26be7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfNS01LTEtMS0yMjM1Nw_90a30147-688d-4066-9542-ac5f2009cee6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i56d517c10b584fe0aaec8d914de26be7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfNS03LTEtMS0yMjM1Nw_0a3c60b8-abc6-4b0a-a37d-860b55978c72"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfNi0xLTEtMS0yMjM1Nw_d436b1b0-52a0-4b15-b18d-66f0257c98af"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfNi0zLTEtMS0yMjM1Nw_964dcb55-368e-4fd3-b433-cb3d5205086f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfNi01LTEtMS0yMjM1Nw_bee893b9-02c5-4c91-bf33-d877061207df"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfNi03LTEtMS0yMjM1Nw_2fd410f2-d6ef-4428-ada2-92edefe83ccb"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <akba:CashCashEquivalentsAndShortTermInvestmentsAmortizedCost
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfNy0xLTEtMS0yMjM1Nw_55326865-8bdc-4d7b-9e5c-d81609142a46"
      unitRef="usd">207204000</akba:CashCashEquivalentsAndShortTermInvestmentsAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfNy0zLTEtMS0yMjM1Nw_9d3eeed5-984a-4794-827a-689965e16a89"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfNy01LTEtMS0yMjM1Nw_ef393ae6-b4f6-4cc3-a45c-52ec295239d8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOjMxZWM2ZjI2NWE4ZDRiZjM5OTBmNmY4MTBjODBjY2YwL3RhYmxlcmFuZ2U6MzFlYzZmMjY1YThkNGJmMzk5MGY2ZjgxMGM4MGNjZjBfNy03LTEtMS0yMjM1Nw_438baaf4-1366-4930-b44d-3497a2f7d13d"
      unitRef="usd">207204000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfMy0xLTEtMS0yMjM1Nw_321cbfe6-3984-4386-947a-0915cb17ac4d"
      unitRef="usd">228698000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfMy03LTEtMS0yMjM1Nw_8384e63a-ad7a-4971-9763-32dec234ceb4"
      unitRef="usd">228698000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie80f8a6467b14c7cafd2f2e4ce22adf5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfNS0xLTEtMS0yMjM1Nw_e647610b-12ed-49c4-af3d-1a00a58be0c3"
      unitRef="usd">39979000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie80f8a6467b14c7cafd2f2e4ce22adf5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfNS0zLTEtMS0yMjM1Nw_259ac122-2ce7-49fb-adf2-b7fba357b799"
      unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie80f8a6467b14c7cafd2f2e4ce22adf5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfNS01LTEtMS0yMjM1Nw_a6de48a1-f192-41c9-be9e-09eafd976396"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie80f8a6467b14c7cafd2f2e4ce22adf5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfNS03LTEtMS0yMjM1Nw_8fc305f6-2db4-492f-afcc-4a7642711e87"
      unitRef="usd">39992000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfNi0xLTEtMS0yMjM1Nw_665e2b58-1de3-478c-95c4-ac5dfb8bdf7d"
      unitRef="usd">39979000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfNi0zLTEtMS0yMjM1Nw_26bc2977-a77a-49f9-8802-08f0522e3578"
      unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfNi01LTEtMS0yMjM1Nw_e766f0e6-0c75-412f-803f-1a62bef53a51"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfNi03LTEtMS0yMjM1Nw_da8e6cb3-8d04-4c0c-8f57-a637ee156cd1"
      unitRef="usd">39992000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <akba:CashCashEquivalentsAndShortTermInvestmentsAmortizedCost
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfNy0xLTEtMS0yMjM1Nw_4fa0682b-9b1e-4aec-b18b-ddad388fa3b1"
      unitRef="usd">268677000</akba:CashCashEquivalentsAndShortTermInvestmentsAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfNy0zLTEtMS0yMjM1Nw_f3a5a242-dd2b-4b8d-b4d0-adbcd1259e10"
      unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfNy01LTEtMS0yMjM1Nw_c73e745e-4b4b-46bb-bece-b25248e1e51d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RhYmxlOmY3YzdkZjNlYzIwMTRhNmViMGQyMzUzZGZjNzg1ZjQ4L3RhYmxlcmFuZ2U6ZjdjN2RmM2VjMjAxNGE2ZWIwZDIzNTNkZmM3ODVmNDhfNy03LTEtMS0yMjM1Nw_9b4757bf-25dc-4a79-b55f-77c8d6a6efe3"
      unitRef="usd">268690000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RleHRyZWdpb246NzVhMzkxYzVlYjE1NDIyZGE4MDVhNjgzMmFhYzcwYzlfMTU3_38398184-f68f-44c9-b40e-9fcda898b728"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RleHRyZWdpb246NzVhMzkxYzVlYjE1NDIyZGE4MDVhNjgzMmFhYzcwYzlfMTU3_79dd0387-8cc0-4e6c-b0ce-66cc1b6b68aa"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RleHRyZWdpb246NzVhMzkxYzVlYjE1NDIyZGE4MDVhNjgzMmFhYzcwYzlfMTU3_bfeb1f9a-50ad-4ffd-831a-63aaf212b17b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RleHRyZWdpb246NzVhMzkxYzVlYjE1NDIyZGE4MDVhNjgzMmFhYzcwYzlfMTU3_c2b446dc-e8bf-4ee8-826b-2c07be2c8aae"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RleHRyZWdpb246NzVhMzkxYzVlYjE1NDIyZGE4MDVhNjgzMmFhYzcwYzlfMjgz_10b25e30-762a-4728-91cb-cf020731f0e3"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RleHRyZWdpb246NzVhMzkxYzVlYjE1NDIyZGE4MDVhNjgzMmFhYzcwYzlfMjgz_bcbed93d-72b6-486c-8859-aae545071546"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RleHRyZWdpb246NzVhMzkxYzVlYjE1NDIyZGE4MDVhNjgzMmFhYzcwYzlfMjgz_c0a0b671-b6f8-4959-b7e4-17c3478933ef"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RleHRyZWdpb246NzVhMzkxYzVlYjE1NDIyZGE4MDVhNjgzMmFhYzcwYzlfMjgz_ea497839-875f-466f-85d5-f96c0db231ea"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RleHRyZWdpb246NzVhMzkxYzVlYjE1NDIyZGE4MDVhNjgzMmFhYzcwYzlfMzk0_2f940232-09e6-4364-a7b8-93906cc06dfb"
      unitRef="security">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81Mi9mcmFnOjc1YTM5MWM1ZWIxNTQyMmRhODA1YTY4MzJhYWM3MGM5L3RleHRyZWdpb246NzVhMzkxYzVlYjE1NDIyZGE4MDVhNjgzMmFhYzcwYzlfMzk0_a1965191-2239-4c52-b1fc-7556abe80f70"
      unitRef="security">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RleHRyZWdpb246YzJjODU5ZmMyNTIwNDk1MWFkMzkwMWQ2MWZmODQyZjRfMzgyMg_5d58620a-f834-4362-aa1d-2bc1ee325aaa">Fair Value of Financial InstrumentsThe Company utilizes a portfolio management company for the valuation of the majority of its investments. This company is an independent, third-party vendor recognized to be an industry leader with access to market information that obtains or computes fair market values from quoted market prices, pricing for similar securities, recently executed transactions, cash flow models with yield curves and other pricing models. For valuations obtained from the pricing service, the Company performs due &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;diligence to understand how the valuation was calculated or derived, focusing on the valuation technique used and the nature of the inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the fair value hierarchy, the Company classifies its cash equivalents and available for sale securities within Level&#160;1 or Level&#160;2. This is because the Company values its cash equivalents and available for sale securities using quoted market prices or alternative pricing sources and models utilizing market observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets measured or disclosed at fair value on a recurring basis as of September&#160;30, 2021 and December&#160;31, 2020 are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Loan Agreement with Pharmakon (see Note 11) contains certain provisions that change the underlying cash flows of the debt instrument, including a potential extension to the interest-only period dependent on both (a) no event of default having occurred and continuing and (b) the Company achieving certain regulatory and revenue conditions. The Company also assessed the acceleration of the obligations under the Loan Agreement under an event of default. In addition, under certain circumstances, a default interest rate will apply on all outstanding obligations during the occurrence and continuance of an event of default. In accordance with ASC 815, the Company concluded that these features are not clearly and closely related to the host instrument, and represent a single compound derivative that is required to be re-measured at fair value on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The events of default include maintaining, on an annual basis, a minimum liquidity threshold which started in 2021, and on a quarterly basis, a minimum net sales threshold for Auryxia which started in the fourth quarter of 2020. The Company recorded a derivative liability related to the Company&#x2019;s Loan Agreement with Pharmakon of $1.9 million and $2.4 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively. The Company classified the derivative liability as a non-current liability on the unaudited condensed consolidated balance sheet as of September&#160;30, 2021 and December&#160;31, 2020. The estimated fair value of the derivative liability on both September&#160;30, 2021 and December&#160;31, 2020 was determined using a scenario-based approach and discounted cash flow model that includes principal and interest payments under various scenarios involving clinical development success for vadadustat and various cash flow assumptions. Probabilities surrounding clinical development success were derived using industry benchmarks. Should the Company&#x2019;s assessment of the probabilities around these scenarios change, including for changes in market conditions, there could be a change to the fair value of the derivative liability.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll-forward of the fair value of the derivative liability (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.132%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative liability, recorded as other expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative liability, recorded as other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(570)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative liability, recorded as other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had no other assets or liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level&#160;3) at September&#160;30, 2021 and December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investment securities are exposed to various risks such as interest rate, market and credit risks. When the Company holds investment securities, due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the value of investment securities, the Company considers if changes in risks in the near term would result in material changes in the fair value of investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RleHRyZWdpb246YzJjODU5ZmMyNTIwNDk1MWFkMzkwMWQ2MWZmODQyZjRfMzgyMw_d0492cf9-9f93-48c4-bf79-cf15ff307de2">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets measured or disclosed at fair value on a recurring basis as of September&#160;30, 2021 and December&#160;31, 2020 are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4eaaeb5ff6074e36abf2df5bbdcad9c3_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfNS0xLTEtMS0yMjM1Nw_8331e825-d98d-416e-a341-0a7d9c40ec30"
      unitRef="usd">207204000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4e52064c653743f2a16fd27d8c9a323a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfNS0zLTEtMS0yMjM1Nw_dc11b480-b785-41e2-854e-90625ff45659"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia6cdf790d03c4fed810871ebfea1a32f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfNS01LTEtMS0yMjM1Nw_cceb39a8-3ee1-4459-b6b8-aa090054c18c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i582013b1f37743bc8285c94f50c08ca4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfNS03LTEtMS0yMjM1Nw_6c23bbee-6199-41e5-b3fc-a0d8e63e5344"
      unitRef="usd">207204000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4eaaeb5ff6074e36abf2df5bbdcad9c3_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfNy0xLTEtMS0yMjM1Nw_98b503f5-37a2-47db-a792-9fb39b7e8b19"
      unitRef="usd">207204000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4e52064c653743f2a16fd27d8c9a323a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfNy0zLTEtMS0yMjM1Nw_78fbd334-6cfa-4885-a7d7-ef1a3afe81a3"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia6cdf790d03c4fed810871ebfea1a32f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfNy01LTEtMS0yMjM1Nw_5db44e0e-74c6-4b00-8f8b-593639e5340b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i582013b1f37743bc8285c94f50c08ca4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfNy03LTEtMS0yMjM1Nw_c43ec7a4-1904-490a-9783-d3d3e1765680"
      unitRef="usd">207204000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i4eaaeb5ff6074e36abf2df5bbdcad9c3_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfOS0xLTEtMS0yMjM1Nw_9b33dd35-8d13-40d3-be5c-9e129e82da85"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i4e52064c653743f2a16fd27d8c9a323a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfOS0zLTEtMS0yMjM1Nw_d1871dfc-53be-4101-b03a-1ac1e7d8ed5a"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ia6cdf790d03c4fed810871ebfea1a32f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfOS01LTEtMS0yMjM1Nw_c5f07bbe-7cd8-464b-b18f-87dd8e4f58c4"
      unitRef="usd">1930000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i582013b1f37743bc8285c94f50c08ca4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfOS03LTEtMS0yMjM1Nw_094154c0-f961-44d4-b8be-74512ca5b259"
      unitRef="usd">1930000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i4eaaeb5ff6074e36abf2df5bbdcad9c3_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfMTAtMS0xLTEtMjIzNTc_7bf38ac9-9f8d-4b21-9773-bdd63ceed6da"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i4e52064c653743f2a16fd27d8c9a323a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfMTAtMy0xLTEtMjIzNTc_d9a4feaa-b814-466b-977d-1f3029b70b20"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia6cdf790d03c4fed810871ebfea1a32f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfMTAtNS0xLTEtMjIzNTc_32e38e58-05c7-422d-a256-0be3e67dceec"
      unitRef="usd">1930000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i582013b1f37743bc8285c94f50c08ca4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjg5OTBjMDNjYzBlMTRkNDQ5ZTAzNTU0ZTJiNjVmODhkL3RhYmxlcmFuZ2U6ODk5MGMwM2NjMGUxNGQ0NDllMDM1NTRlMmI2NWY4OGRfMTAtNy0xLTEtMjIzNTc_e498e973-7959-492f-94cf-a697558326aa"
      unitRef="usd">1930000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia131987e763f4587a941882e026ee367_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfNS0xLTEtMS0yMjM1Nw_be4eea8e-de83-4102-927b-7ce262a2cf22"
      unitRef="usd">228698000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic5b97b6dc8c6458eb7afd794c342c79a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfNS0zLTEtMS0yMjM1Nw_ae0b0662-dd28-478e-9e0e-fac8aa7e97c4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i81fe9de9bf004275abc9aead5654fef0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfNS01LTEtMS0yMjM1Nw_7c5d7b84-2aad-492c-8136-b7ec8231f406"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9965cd10ee2c479390becf868ab08d6b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfNS03LTEtMS0yMjM1Nw_eb7f9316-6535-406e-aa69-4903b71b8879"
      unitRef="usd">228698000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib35a112c936c43008fd53a2e71e369fe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfNi0xLTEtMS0yMjM1Nw_8206514d-aa03-4f8b-8622-e4257b01fae2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia5926c8f9dfa40cb830ffa5f3015b27d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfNi0zLTEtMS0yMjM1Nw_2f872d71-fd8e-43b8-927e-66cdd097f68e"
      unitRef="usd">39992000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i51612bc1340040cb897112531943a394_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfNi01LTEtMS0yMjM1Nw_4c57de27-b68c-47b2-8217-99b9e6129299"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9db8d25d5e404f14935648663eb92df6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfNi03LTEtMS0yMjM1Nw_1aed2c82-ff23-4b20-ba68-ef5df03e8de5"
      unitRef="usd">39992000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia131987e763f4587a941882e026ee367_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfNy0xLTEtMS0yMjM1Nw_a657f201-8d7a-4529-83ef-21684d85b8fd"
      unitRef="usd">228698000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic5b97b6dc8c6458eb7afd794c342c79a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfNy0zLTEtMS0yMjM1Nw_760e7dd6-288d-4645-a1f4-3853f25728be"
      unitRef="usd">39992000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i81fe9de9bf004275abc9aead5654fef0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfNy01LTEtMS0yMjM1Nw_67965131-9340-4f15-b362-a19f6cc2b80f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9965cd10ee2c479390becf868ab08d6b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfNy03LTEtMS0yMjM1Nw_f71e6325-118d-485d-94da-ca91a3d4dc72"
      unitRef="usd">268690000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="ia131987e763f4587a941882e026ee367_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfOS0xLTEtMS0yMjM1Nw_129f9085-5563-4813-aec3-4d68da27b90c"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ic5b97b6dc8c6458eb7afd794c342c79a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfOS0zLTEtMS0yMjM1Nw_6af962cf-4f1c-48e9-b400-e51159c40fd2"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i81fe9de9bf004275abc9aead5654fef0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfOS01LTEtMS0yMjM1Nw_143891e8-7e60-404f-beda-9e7ff79d6370"
      unitRef="usd">2420000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i9965cd10ee2c479390becf868ab08d6b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfOS03LTEtMS0yMjM1Nw_14569a9e-b252-4d7a-b4fa-cc2c2681b2e9"
      unitRef="usd">2420000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia131987e763f4587a941882e026ee367_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfMTAtMS0xLTEtMjIzNTc_8a51005c-3913-404f-a2f5-0b89d81453ea"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ic5b97b6dc8c6458eb7afd794c342c79a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfMTAtMy0xLTEtMjIzNTc_7e6b1334-0e52-4426-a0da-bd85d69624aa"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i81fe9de9bf004275abc9aead5654fef0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfMTAtNS0xLTEtMjIzNTc_628bd7b1-261b-4902-b72f-76eaa26edbf8"
      unitRef="usd">2420000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9965cd10ee2c479390becf868ab08d6b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOmU0NGIwN2ZhMWY3YjRkZDk5ODgxZWUxMzc2Nzg4YjdhL3RhYmxlcmFuZ2U6ZTQ0YjA3ZmExZjdiNGRkOTk4ODFlZTEzNzY3ODhiN2FfMTAtNy0xLTEtMjIzNTc_163bffed-c256-4ed9-855a-1f7646579990"
      unitRef="usd">2420000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i469e62d61f624f13a913c992818f42a8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RleHRyZWdpb246YzJjODU5ZmMyNTIwNDk1MWFkMzkwMWQ2MWZmODQyZjRfMjMzNw_8cf5de2d-f6ad-4003-a19b-6c4341342836"
      unitRef="usd">1900000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i3c2c9bd113fe46629d3834ae5a39ba17_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RleHRyZWdpb246YzJjODU5ZmMyNTIwNDk1MWFkMzkwMWQ2MWZmODQyZjRfMjM0NA_29fdce09-ef58-475f-a0e6-c9c2919b6307"
      unitRef="usd">2400000</us-gaap:DerivativeLiabilities>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RleHRyZWdpb246YzJjODU5ZmMyNTIwNDk1MWFkMzkwMWQ2MWZmODQyZjRfMzgyNA_422a9dc0-d9cc-4aa2-b79d-5b1dbd461fbc">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll-forward of the fair value of the derivative liability (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.132%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative liability, recorded as other expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative liability, recorded as other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(570)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative liability, recorded as other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjJiNGViNzNlNmM2YjQ3NWFiZmFiMmQ0ZTBmNGE4YzA1L3RhYmxlcmFuZ2U6MmI0ZWI3M2U2YzZiNDc1YWJmYWIyZDRlMGY0YThjMDVfMC0xLTEtMS0yMjM1Nw_08576cd2-1a23-46cc-a95d-b43c846e4ff3"
      unitRef="usd">2420000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="ibedefb3b11734e53bd359a1087a22569_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjJiNGViNzNlNmM2YjQ3NWFiZmFiMmQ0ZTBmNGE4YzA1L3RhYmxlcmFuZ2U6MmI0ZWI3M2U2YzZiNDc1YWJmYWIyZDRlMGY0YThjMDVfMS0xLTEtMS0yMjM1Nw_3cf2884c-b91b-4604-82ff-493efa8ea84a"
      unitRef="usd">80000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="id832960589e2403f88473dd831c88c68_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjJiNGViNzNlNmM2YjQ3NWFiZmFiMmQ0ZTBmNGE4YzA1L3RhYmxlcmFuZ2U6MmI0ZWI3M2U2YzZiNDc1YWJmYWIyZDRlMGY0YThjMDVfMi0xLTEtMS0yMjM1Nw_d0d078a7-bd34-4026-b148-06b0c26f2223"
      unitRef="usd">2500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="i02a8ba6ff0054b678403f9ad5ed7efc4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjJiNGViNzNlNmM2YjQ3NWFiZmFiMmQ0ZTBmNGE4YzA1L3RhYmxlcmFuZ2U6MmI0ZWI3M2U2YzZiNDc1YWJmYWIyZDRlMGY0YThjMDVfMy0xLTEtMS0yMjM1Nw_ee90bd73-57ef-400a-a72f-9a8971505848"
      unitRef="usd">-570000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i952bff9821b4497aa3ea95191dd2fe53_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjJiNGViNzNlNmM2YjQ3NWFiZmFiMmQ0ZTBmNGE4YzA1L3RhYmxlcmFuZ2U6MmI0ZWI3M2U2YzZiNDc1YWJmYWIyZDRlMGY0YThjMDVfNC0xLTEtMS0yMjM1Nw_ba3c2570-54d5-46f1-8792-cee0b416eee5"
      unitRef="usd">1930000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjJiNGViNzNlNmM2YjQ3NWFiZmFiMmQ0ZTBmNGE4YzA1L3RhYmxlcmFuZ2U6MmI0ZWI3M2U2YzZiNDc1YWJmYWIyZDRlMGY0YThjMDVfNS0xLTEtMS0yMjYyMw_719369e0-a6e3-4a22-af7d-656af84c3a6f"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RhYmxlOjJiNGViNzNlNmM2YjQ3NWFiZmFiMmQ0ZTBmNGE4YzA1L3RhYmxlcmFuZ2U6MmI0ZWI3M2U2YzZiNDc1YWJmYWIyZDRlMGY0YThjMDVfNi0xLTEtMS0yMjYzMA_f02bcea2-0f19-4dd1-85ca-d0e83c42a449"
      unitRef="usd">1930000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9b81649bc6244591a493ea134990b511_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RleHRyZWdpb246YzJjODU5ZmMyNTIwNDk1MWFkMzkwMWQ2MWZmODQyZjRfMzI1Ng_1e1e950d-e38c-4523-80a5-f0cfc4d71957"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0a8144587d5e488cabffbbd0bae0e7a5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RleHRyZWdpb246YzJjODU5ZmMyNTIwNDk1MWFkMzkwMWQ2MWZmODQyZjRfMzI1Ng_4f9c3c37-8534-4b9d-be6e-d7a1ca1cc13d"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i616cde0a70c94c6eb173090f144c4c43_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RleHRyZWdpb246YzJjODU5ZmMyNTIwNDk1MWFkMzkwMWQ2MWZmODQyZjRfMzI1Ng_79277f01-ac94-4242-8819-0f20bec7bd27"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia9033a88870c408dba279ef74720efd3_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81NS9mcmFnOmMyYzg1OWZjMjUyMDQ5NTFhZDM5MDFkNjFmZjg0MmY0L3RleHRyZWdpb246YzJjODU5ZmMyNTIwNDk1MWFkMzkwMWQ2MWZmODQyZjRfMzI1Ng_a203a0d1-77dc-4658-a338-341718859adc"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RleHRyZWdpb246Yjg1YmFhMWU0YzdlNGNhZGJiOWE0ZGUzMmM1MzkyMDFfMTE5NA_2f1bff46-2322-4619-b539-217bfc4915ef">Inventory&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term inventory, which primarily consists of raw materials and work in process, is included in other assets in the Company&#x2019;s unaudited condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory amounts written down as a result of excess, obsolescence, scrap or other reasons and charged to cost of goods sold totaled $1.7 million and $7.1 million during the three and nine months ended September&#160;30, 2021, respectively, and totaled $8.5 million and $18.6 million during the three and nine months ended September&#160;30, 2020, respectively. The decrease in inventory amounts written down for the three and nine months ended September&#160;30, 2021 as compared to the three and nine months ended September&#160;30, 2020 was primarily due to lower write-downs to inventory reserves related to a previously disclosed manufacturing quality issue related to Auryxia during 2020. In addition, there were no related step-up charges during the three months ended September&#160;30, 2021 and $1.4 million related step-up charges during the three months ended September&#160;30, 2020. Related step-up charges were $8.7 million during the nine months ended September&#160;30, 2021 and $7.4 million during the nine months ended September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If future sales of Auryxia are lower than expected, the Company may be required to write-down the value of such inventories. Inventory write-downs and losses on purchase commitments are recorded as a component of cost of sales in the unaudited condensed consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RleHRyZWdpb246Yjg1YmFhMWU0YzdlNGNhZGJiOWE0ZGUzMmM1MzkyMDFfMTE5NQ_d761d21b-ef68-453d-a1b1-ea4e0e98bfcb">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term inventory, which primarily consists of raw materials and work in process, is included in other assets in the Company&#x2019;s unaudited condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjRiNWFiMjQwZTdlYjQzMjFhODFhZmZmYTc5NzhkYjAzL3RhYmxlcmFuZ2U6NGI1YWIyNDBlN2ViNDMyMWE4MWFmZmZhNzk3OGRiMDNfMi0xLTEtMS0yMjM1Nw_227e4e4f-a0e1-4b9f-be40-d7e41d34009d"
      unitRef="usd">2376000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjRiNWFiMjQwZTdlYjQzMjFhODFhZmZmYTc5NzhkYjAzL3RhYmxlcmFuZ2U6NGI1YWIyNDBlN2ViNDMyMWE4MWFmZmZhNzk3OGRiMDNfMi0zLTEtMS0yMjM1Nw_469d0702-a561-4a31-9fdf-ee115810e03c"
      unitRef="usd">2542000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjRiNWFiMjQwZTdlYjQzMjFhODFhZmZmYTc5NzhkYjAzL3RhYmxlcmFuZ2U6NGI1YWIyNDBlN2ViNDMyMWE4MWFmZmZhNzk3OGRiMDNfMy0xLTEtMS0yMjM1Nw_5e354252-ffd4-4a5d-84c7-390036b0d360"
      unitRef="usd">76856000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjRiNWFiMjQwZTdlYjQzMjFhODFhZmZmYTc5NzhkYjAzL3RhYmxlcmFuZ2U6NGI1YWIyNDBlN2ViNDMyMWE4MWFmZmZhNzk3OGRiMDNfMy0zLTEtMS0yMjM1Nw_19f4992b-6047-4228-9c85-c1378cb2eb12"
      unitRef="usd">64076000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjRiNWFiMjQwZTdlYjQzMjFhODFhZmZmYTc5NzhkYjAzL3RhYmxlcmFuZ2U6NGI1YWIyNDBlN2ViNDMyMWE4MWFmZmZhNzk3OGRiMDNfNC0xLTEtMS0yMjM1Nw_2621c0f9-9cd6-4453-8fb6-72fce7745af4"
      unitRef="usd">16177000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjRiNWFiMjQwZTdlYjQzMjFhODFhZmZmYTc5NzhkYjAzL3RhYmxlcmFuZ2U6NGI1YWIyNDBlN2ViNDMyMWE4MWFmZmZhNzk3OGRiMDNfNC0zLTEtMS0yMjM1Nw_2739e9fd-c22f-4cc9-9d6e-8502658b2e27"
      unitRef="usd">19691000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <akba:InventoryNetCurrentAndNonCurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjRiNWFiMjQwZTdlYjQzMjFhODFhZmZmYTc5NzhkYjAzL3RhYmxlcmFuZ2U6NGI1YWIyNDBlN2ViNDMyMWE4MWFmZmZhNzk3OGRiMDNfNS0xLTEtMS0yMjM1Nw_ad5a3c81-1e97-49ad-8e32-58d5cc4bb989"
      unitRef="usd">95409000</akba:InventoryNetCurrentAndNonCurrent>
    <akba:InventoryNetCurrentAndNonCurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjRiNWFiMjQwZTdlYjQzMjFhODFhZmZmYTc5NzhkYjAzL3RhYmxlcmFuZ2U6NGI1YWIyNDBlN2ViNDMyMWE4MWFmZmZhNzk3OGRiMDNfNS0zLTEtMS0yMjM1Nw_934cefe0-e2b1-4791-a5bc-6104735f6f2a"
      unitRef="usd">86309000</akba:InventoryNetCurrentAndNonCurrent>
    <us-gaap:InventoryNet
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjNjMmI3YmU0Y2QwNzRlNjQ4NDQ2OWExNTJlOTEyMzA5L3RhYmxlcmFuZ2U6M2MyYjdiZTRjZDA3NGU2NDg0NDY5YTE1MmU5MTIzMDlfMy0xLTEtMS0yMjM1Nw_b5595d3a-a8de-492d-875e-6dae7d10c572"
      unitRef="usd">33688000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjNjMmI3YmU0Y2QwNzRlNjQ4NDQ2OWExNTJlOTEyMzA5L3RhYmxlcmFuZ2U6M2MyYjdiZTRjZDA3NGU2NDg0NDY5YTE1MmU5MTIzMDlfMy0zLTEtMS0yMjM1Nw_136ae577-06f7-41c0-82c9-584af1a51b60"
      unitRef="usd">61017000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjNjMmI3YmU0Y2QwNzRlNjQ4NDQ2OWExNTJlOTEyMzA5L3RhYmxlcmFuZ2U6M2MyYjdiZTRjZDA3NGU2NDg0NDY5YTE1MmU5MTIzMDlfNC0xLTEtMS0yMjM1Nw_048553f3-40e1-48cc-a55b-38a3ffd8ce3b"
      unitRef="usd">61721000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjNjMmI3YmU0Y2QwNzRlNjQ4NDQ2OWExNTJlOTEyMzA5L3RhYmxlcmFuZ2U6M2MyYjdiZTRjZDA3NGU2NDg0NDY5YTE1MmU5MTIzMDlfNC0zLTEtMS0yMjM1Nw_ff762e4a-3181-48d9-aba7-d190c2ef2496"
      unitRef="usd">25292000</us-gaap:InventoryNoncurrent>
    <akba:InventoryNetCurrentAndNonCurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjNjMmI3YmU0Y2QwNzRlNjQ4NDQ2OWExNTJlOTEyMzA5L3RhYmxlcmFuZ2U6M2MyYjdiZTRjZDA3NGU2NDg0NDY5YTE1MmU5MTIzMDlfNS0xLTEtMS0yMjM1Nw_a45904c5-dccb-4d1f-af28-6ee03fecfed9"
      unitRef="usd">95409000</akba:InventoryNetCurrentAndNonCurrent>
    <akba:InventoryNetCurrentAndNonCurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RhYmxlOjNjMmI3YmU0Y2QwNzRlNjQ4NDQ2OWExNTJlOTEyMzA5L3RhYmxlcmFuZ2U6M2MyYjdiZTRjZDA3NGU2NDg0NDY5YTE1MmU5MTIzMDlfNS0zLTEtMS0yMjM1Nw_f85b5996-2a1d-46a1-890c-b102cce557f9"
      unitRef="usd">86309000</akba:InventoryNetCurrentAndNonCurrent>
    <us-gaap:InventoryWriteDown
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RleHRyZWdpb246Yjg1YmFhMWU0YzdlNGNhZGJiOWE0ZGUzMmM1MzkyMDFfMzk0_38766fa0-aaae-4f91-812c-be6b5b1a7104"
      unitRef="usd">1700000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RleHRyZWdpb246Yjg1YmFhMWU0YzdlNGNhZGJiOWE0ZGUzMmM1MzkyMDFfNDAx_ca82695a-6095-4862-a2b4-339566b03f86"
      unitRef="usd">7100000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RleHRyZWdpb246Yjg1YmFhMWU0YzdlNGNhZGJiOWE0ZGUzMmM1MzkyMDFfNjU5NzA2OTc2ODI4Nw_7858e659-e383-411f-af48-88ddcc12ae02"
      unitRef="usd">8500000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RleHRyZWdpb246Yjg1YmFhMWU0YzdlNGNhZGJiOWE0ZGUzMmM1MzkyMDFfNjU5NzA2OTc2ODI5NQ_8de23bb6-36d6-40c1-8fe6-435e284b0086"
      unitRef="usd">18600000</us-gaap:InventoryWriteDown>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory
      contextRef="i3e237cd7f54f4646aa36f63692c06c40_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RleHRyZWdpb246Yjg1YmFhMWU0YzdlNGNhZGJiOWE0ZGUzMmM1MzkyMDFfMTY0OTI2NzQ0NDIzOQ_b008e216-f47f-4dba-8eee-bca83ccbe1ea"
      unitRef="usd">0</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory
      contextRef="i4e72ecf91b664cca962bacefd5439368_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RleHRyZWdpb246Yjg1YmFhMWU0YzdlNGNhZGJiOWE0ZGUzMmM1MzkyMDFfMTY0OTI2NzQ0NDI4Mw_6fa60f5e-c8f7-4e69-b684-98b1815820b3"
      unitRef="usd">1400000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory
      contextRef="i1cd36c7e7311497ba175179857b7257c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RleHRyZWdpb246Yjg1YmFhMWU0YzdlNGNhZGJiOWE0ZGUzMmM1MzkyMDFfNDg4_9a7a029f-8611-4ef3-b9e4-a4912a4f4959"
      unitRef="usd">8700000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory
      contextRef="i9fdb433b2bca4b748b2b7fa719b097c9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl81OC9mcmFnOmI4NWJhYTFlNGM3ZTRjYWRiYjlhNGRlMzJjNTM5MjAxL3RleHRyZWdpb246Yjg1YmFhMWU0YzdlNGNhZGJiOWE0ZGUzMmM1MzkyMDFfNjU5NzA2OTc2ODQyNQ_577daf22-1c69-4707-b523-272501b25e09"
      unitRef="usd">7400000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfMTIzMg_5bccc1fa-2660-40f0-a6ea-2abde0b1988e">Intangible Assets and Goodwill&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s intangible assets at September&#160;30, 2021 and December&#160;31, 2020 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.964%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed product rights for Auryxia&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96,465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ASC 842&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed product rights for Auryxia&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Favorable lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 12, 2018, the Company completed the Merger, whereby it acquired certain definite-lived intangible assets, including the developed product rights for Auryxia and a favorable lease. The Company amortizes its definite-lived intangible assets acquired as part of the Merger using the straight-line method, which is considered the best estimate of economic benefit, over its estimated useful life of six years. The Company recorded $9.0 million and $6.1 million in amortization expense related to the developed product rights for Auryxia during the three months ended September&#160;30, 2021 and 2020, respectively, and $27.0 million and $24.3 million during the nine months ended September&#160;30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill was $55.1 million as of September&#160;30, 2021 and December&#160;31, 2020. The Company operates in one operating segment which the Company considers to be the only reporting unit. Goodwill is evaluated for impairment at the reporting unit level on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstances suggest that an impairment may exist. There were no impairments of goodwill during the three and nine months ended September&#160;30, 2021 or 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfMTIzMw_a4e9645d-e7ab-4a26-93a0-26c1a8863ab5">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s intangible assets at September&#160;30, 2021 and December&#160;31, 2020 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.964%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed product rights for Auryxia&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96,465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ASC 842&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed product rights for Auryxia&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Favorable lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia76ea517ec23406588672981c217b653_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOjUzNDMzMGNhNThjYjQ3NjM5MGFmYjdhNjJjZDA3ZDA2L3RhYmxlcmFuZ2U6NTM0MzMwY2E1OGNiNDc2MzkwYWZiN2E2MmNkMDdkMDZfMy0xLTEtMS0yMjM1Nw_73e442fb-c551-4e1f-a64f-2b0e742fc877"
      unitRef="usd">213603000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia76ea517ec23406588672981c217b653_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOjUzNDMzMGNhNThjYjQ3NjM5MGFmYjdhNjJjZDA3ZDA2L3RhYmxlcmFuZ2U6NTM0MzMwY2E1OGNiNDc2MzkwYWZiN2E2MmNkMDdkMDZfMy0zLTEtMS0yMjM1Nw_23c9ec93-e7c0-422c-8418-53ca9d31a144"
      unitRef="usd">96465000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia76ea517ec23406588672981c217b653_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOjUzNDMzMGNhNThjYjQ3NjM5MGFmYjdhNjJjZDA3ZDA2L3RhYmxlcmFuZ2U6NTM0MzMwY2E1OGNiNDc2MzkwYWZiN2E2MmNkMDdkMDZfMy01LTEtMS0yMjM1Nw_79f49e09-3d9d-4bc3-9f7a-63b92ed219fb"
      unitRef="usd">117138000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i30e4e068c6214ffabd5a128e3d85c999_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOmRmNWY4ZDUzNmU2NDQwMDA4MWI4YWM4NDYzNTIyN2M2L3RhYmxlcmFuZ2U6ZGY1ZjhkNTM2ZTY0NDAwMDgxYjhhYzg0NjM1MjI3YzZfMy0xLTEtMS0yMjM1Nw_098f81ca-a230-4a58-9350-970af7cf8de1"
      unitRef="usd">213603000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i30e4e068c6214ffabd5a128e3d85c999_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOmRmNWY4ZDUzNmU2NDQwMDA4MWI4YWM4NDYzNTIyN2M2L3RhYmxlcmFuZ2U6ZGY1ZjhkNTM2ZTY0NDAwMDgxYjhhYzg0NjM1MjI3YzZfMy0zLTEtMS0yMjM1Nw_b975024d-d3fd-44af-be6b-776a567ded60"
      unitRef="usd">69433000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i30e4e068c6214ffabd5a128e3d85c999_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOmRmNWY4ZDUzNmU2NDQwMDA4MWI4YWM4NDYzNTIyN2M2L3RhYmxlcmFuZ2U6ZGY1ZjhkNTM2ZTY0NDAwMDgxYjhhYzg0NjM1MjI3YzZfMy03LTEtMS0yMjM1Nw_ccf317c6-d5a3-4ce1-9df5-2e655045975b"
      unitRef="usd">144170000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6dcd869a04c44f3ea928848929217e86_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOmRmNWY4ZDUzNmU2NDQwMDA4MWI4YWM4NDYzNTIyN2M2L3RhYmxlcmFuZ2U6ZGY1ZjhkNTM2ZTY0NDAwMDgxYjhhYzg0NjM1MjI3YzZfNC0xLTEtMS0yMjM1Nw_845f8538-c67a-40cb-85ae-adbf05107ba3"
      unitRef="usd">545000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6dcd869a04c44f3ea928848929217e86_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOmRmNWY4ZDUzNmU2NDQwMDA4MWI4YWM4NDYzNTIyN2M2L3RhYmxlcmFuZ2U6ZGY1ZjhkNTM2ZTY0NDAwMDgxYjhhYzg0NjM1MjI3YzZfNC0zLTEtMS0yMjM1Nw_87b5fe40-102d-4dc1-9b8e-23950431bfc2"
      unitRef="usd">5000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <akba:FiniteLivedIntangibleAssetsAdoptionAdjustment
      contextRef="i6dcd869a04c44f3ea928848929217e86_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOmRmNWY4ZDUzNmU2NDQwMDA4MWI4YWM4NDYzNTIyN2M2L3RhYmxlcmFuZ2U6ZGY1ZjhkNTM2ZTY0NDAwMDgxYjhhYzg0NjM1MjI3YzZfNC01LTEtMS0yMjM1Nw_b0565d07-3fdf-452c-9844-3ac4cfa24e2a"
      unitRef="usd">-540000</akba:FiniteLivedIntangibleAssetsAdoptionAdjustment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6dcd869a04c44f3ea928848929217e86_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOmRmNWY4ZDUzNmU2NDQwMDA4MWI4YWM4NDYzNTIyN2M2L3RhYmxlcmFuZ2U6ZGY1ZjhkNTM2ZTY0NDAwMDgxYjhhYzg0NjM1MjI3YzZfNC03LTEtMS0yMjM1Nw_a66ed007-ca6c-4cae-81f2-28c76b83e729"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOmRmNWY4ZDUzNmU2NDQwMDA4MWI4YWM4NDYzNTIyN2M2L3RhYmxlcmFuZ2U6ZGY1ZjhkNTM2ZTY0NDAwMDgxYjhhYzg0NjM1MjI3YzZfNS0xLTEtMS0yMjM1Nw_1e1cae3b-3ad2-4604-961e-e28085dacdf3"
      unitRef="usd">214148000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOmRmNWY4ZDUzNmU2NDQwMDA4MWI4YWM4NDYzNTIyN2M2L3RhYmxlcmFuZ2U6ZGY1ZjhkNTM2ZTY0NDAwMDgxYjhhYzg0NjM1MjI3YzZfNS0zLTEtMS0yMjM1Nw_f5b4dd86-736b-4253-b876-c70c57e1b6aa"
      unitRef="usd">69438000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <akba:FiniteLivedIntangibleAssetsAdoptionAdjustment
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOmRmNWY4ZDUzNmU2NDQwMDA4MWI4YWM4NDYzNTIyN2M2L3RhYmxlcmFuZ2U6ZGY1ZjhkNTM2ZTY0NDAwMDgxYjhhYzg0NjM1MjI3YzZfNS01LTEtMS0yMjM1Nw_bc84b626-7d27-4484-8f31-d13581568935"
      unitRef="usd">-540000</akba:FiniteLivedIntangibleAssetsAdoptionAdjustment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RhYmxlOmRmNWY4ZDUzNmU2NDQwMDA4MWI4YWM4NDYzNTIyN2M2L3RhYmxlcmFuZ2U6ZGY1ZjhkNTM2ZTY0NDAwMDgxYjhhYzg0NjM1MjI3YzZfNS03LTEtMS0yMjM1Nw_8ee1d88c-dc47-46e4-bb8f-644fc9083e7c"
      unitRef="usd">144170000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i34034b5b7fbe48fe92390732c9576345_D20181212-20181212"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfMjc0ODc3OTA3MDcxMA_9dd1eebd-685b-443a-95ec-3a667077c444">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfNTc5_f0c88edd-421c-4aba-8895-55b69b112d4c"
      unitRef="usd">9000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfNTg2_f2b06c11-abf2-4870-873e-a943853a523f"
      unitRef="usd">6100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfNzI0_16972fcc-8595-40d2-9f9c-00c794262825"
      unitRef="usd">27000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfNzMx_42eb26d1-cb02-48b2-b2a1-3ab54a285c99"
      unitRef="usd">24300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:Goodwill
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfODEw_c2372a12-8c21-40a6-b699-afd02afd8fcb"
      unitRef="usd">55100000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfODEw_f2c951c5-bb53-4627-8b0d-2fcc6cb727d9"
      unitRef="usd">55100000</us-gaap:Goodwill>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfODU0_0ec5b73b-a0a5-4cc0-8a91-d0affcf08ca4"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfMTE1OA_2699deee-c5a5-41b8-a5ee-b2fa713a0ed8"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfMTE1OA_9d184092-fc85-4088-b316-44f9c4ac8753"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfMTE1OA_d391e83e-4d8d-4f63-9834-8edeeccb6fc5"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82MS9mcmFnOmU2Mzc3NzdkZDQzOTQ0MjA4OGRkYjFlOGM5ZWY2Y2I0L3RleHRyZWdpb246ZTYzNzc3N2RkNDM5NDQyMDg4ZGRiMWU4YzllZjZjYjRfMTE1OA_f2393f3c-634b-4aea-b36f-ca0b22d2fbea"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RleHRyZWdpb246YzMwZjgxYTkzZWM3NDZkMmIyMTA0MTY5YWMwZDEwOTRfNzY_9096f7d7-8dd2-4686-b145-d738af311ef3">Accrued Expenses&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses as of September&#160;30, 2021 and December&#160;31, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue allowances&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts due to collaboration partners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Otsuka PRV contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNy0wLTEtMS0yMjM1Nw_8a62ce00-dd9c-44ee-980f-eb68f6cf0efd"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNy0wLTEtMS0yMjM1Nw_a0731d02-abdf-4cad-9588-f670833c69ba"&gt;Lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued commercial manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RleHRyZWdpb246YzMwZjgxYTkzZWM3NDZkMmIyMTA0MTY5YWMwZDEwOTRfNzc_1400faba-4b9c-442d-99f9-1000cef4ece8">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses as of September&#160;30, 2021 and December&#160;31, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue allowances&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts due to collaboration partners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Otsuka PRV contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNy0wLTEtMS0yMjM1Nw_8a62ce00-dd9c-44ee-980f-eb68f6cf0efd"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNy0wLTEtMS0yMjM1Nw_a0731d02-abdf-4cad-9588-f670833c69ba"&gt;Lease liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued commercial manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <akba:AccruedProductRevenueAllowancesCurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfMi0xLTEtMS0yMjM1Nw_f016259a-ce3d-4098-ac5e-b1f91af9f5a3"
      unitRef="usd">44235000</akba:AccruedProductRevenueAllowancesCurrent>
    <akba:AccruedProductRevenueAllowancesCurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfMi0zLTEtMS0yMjM1Nw_70989a53-b412-4eb2-b65c-17d3f69ae190"
      unitRef="usd">38049000</akba:AccruedProductRevenueAllowancesCurrent>
    <akba:AccruedClinicalExpensesCurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfMy0xLTEtMS0yMjM1Nw_875495d0-6609-4201-9575-320eed72ba57"
      unitRef="usd">19249000</akba:AccruedClinicalExpensesCurrent>
    <akba:AccruedClinicalExpensesCurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfMy0zLTEtMS0yMjM1Nw_99ad66ea-9fb7-44d7-bb15-5b1f783db3f8"
      unitRef="usd">28986000</akba:AccruedClinicalExpensesCurrent>
    <akba:CollaborativeArrangementAccruedLiability
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNC0xLTEtMS0yMjM1Nw_6a970d1b-9b46-4c6d-a344-d595a7cd1659"
      unitRef="usd">27375000</akba:CollaborativeArrangementAccruedLiability>
    <akba:CollaborativeArrangementAccruedLiability
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNC0zLTEtMS0yMjM1Nw_c100e9cb-9322-43e5-9d16-8b2a0cba4db9"
      unitRef="usd">17977000</akba:CollaborativeArrangementAccruedLiability>
    <akba:CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNS0xLTEtMS0yMjM1Nw_95882df2-0dcd-466e-a61a-7e95a621cb09"
      unitRef="usd">10000000</akba:CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher>
    <akba:CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNS0zLTEtMS0yMjM1Nw_cac1a703-e155-4b01-abff-ad080d5dadb6"
      unitRef="usd">10000000</akba:CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNi0xLTEtMS0yMjM1Nw_62545827-86f1-473c-869c-a1100eceb4e0"
      unitRef="usd">12834000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNi0zLTEtMS0yMjM1Nw_b1ad97f4-2cac-40e2-9e39-acf249cab3a4"
      unitRef="usd">14899000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNy0xLTEtMS0yMjM1Nw_5db3ca47-2d26-4873-b903-9320ba5fc8d7"
      unitRef="usd">5723000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNy0zLTEtMS0yMjM1Nw_d0cb8872-b2ae-4d51-8b98-c096fcabd977"
      unitRef="usd">5286000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfOS0xLTEtMS0yMjM1Nw_c920389b-ce52-4cf2-8a2f-975f520c318d"
      unitRef="usd">3022000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfOS0zLTEtMS0yMjM1Nw_ab7d26c0-8c2a-4247-94d9-aea2c31e27d0"
      unitRef="usd">2998000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfMTAtMS0xLTEtMjIzNTc_435ab9cd-6c4f-4679-bad4-2c40ccd21316"
      unitRef="usd">9126000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfMTAtMy0xLTEtMjIzNTc_a3727fa7-3800-4367-a22e-8b5b9d9e2d55"
      unitRef="usd">3271000</us-gaap:AccruedProfessionalFeesCurrent>
    <akba:AccruedCommercialManufacturingCurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfMTEtMS0xLTEtMjIzNTc_e90ca1c9-3a3a-4508-862f-a6f616f4b829"
      unitRef="usd">1682000</akba:AccruedCommercialManufacturingCurrent>
    <akba:AccruedCommercialManufacturingCurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfMTEtMy0xLTEtMjIzNTc_c871965c-b292-49be-adab-e75223773676"
      unitRef="usd">514000</akba:AccruedCommercialManufacturingCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfMTMtMS0xLTEtMjIzNTc_322ff401-4ce7-467d-9a74-761b4804e139"
      unitRef="usd">11458000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfMTMtMy0xLTEtMjIzNTc_9b9b4d64-2d48-43f0-a6e2-4f4865f1ef7d"
      unitRef="usd">8644000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfMTQtMS0xLTEtMjIzNTc_a6d4772d-57f0-411d-ba34-7a3819b78162"
      unitRef="usd">144704000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfMTQtMy0xLTEtMjIzNTc_26a4e871-0a21-4214-8acb-660444ff6ae1"
      unitRef="usd">130624000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfNTk2MQ_64079cdd-a861-417f-b368-53716a7ffa3b">Debt&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Term Loans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 11, 2019, the Company, with Keryx as guarantor, entered into a loan agreement, or the Loan Agreement, with BioPharma Credit PLC as collateral agent and a lender, or the Collateral Agent, and BioPharma Credit Investments V (Master) LP as a lender, pursuant to which term loans in an aggregate principal amount of $100.0 million were made available to the Company in two tranches, subject to certain terms and conditions, or the Term Loans. BioPharma Credit PLC subsequently transferred its interest in the Term Loans, solely in its capacity as a lender, to its affiliate, BPCR Limited Partnership. The Collateral Agent and the lenders are collectively referred to as Pharmakon. The first tranche of $80.0 million, or Tranche A, was drawn on November&#160;25, 2019, or the Tranche A Funding Date, and the second&#160;tranche of $20.0 million, or Tranche B, was drawn on December 10, 2020, or the Tranche B Funding Date. Each of the Tranche A Funding Date and the Tranche B Funding Date, a Funding Date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Proceeds from the Term Loans may be used for general corporate purposes. The Company and Keryx entered into a Guaranty and Security Agreement with the Collateral Agent, or the Guaranty and Security Agreement, on the Tranche A Funding Date. Pursuant to the Guaranty and Security Agreement, the Company&#x2019;s obligations under the Term Loans are unconditionally guaranteed by Keryx, or the Guarantee. Additionally, the obligations of the Company and Keryx under the Term Loans and the Guarantee are secured by a first priority lien on certain assets of the Company and Keryx, including Auryxia and certain related assets, cash, and certain equity interests held by the Company and Keryx, collectively the Collateral.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Term Loans bear interest at a floating rate per annum equal to the three-month LIBOR rate plus 7.50%, subject to a 2.00% LIBOR floor and a 3.35% LIBOR cap, payable quarterly in arrears. The Term Loans will mature on the fifth anniversary of the Tranche A Funding Date, or the Maturity Date. The Company will repay the principal under the Term Loans in equal quarterly payments starting on the 33rd-month anniversary of the applicable Funding Date or, if certain conditions are met, it will have the option to repay the principal in equal quarterly payments starting on the 48th-month anniversary of the applicable Funding Date, or collectively the Amortization Schedule. Under certain circumstances, unless certain liquidity conditions are met, the Maturity Date may decrease by up to one year, and the Amortization Schedule may correspondingly commence up to one year earlier.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On the Tranche A Funding Date,&#160;the Company paid to Pharmakon a facility fee equal to 2.00% of the aggregate principal amount of the Term Loans, or $2.0 million, in addition to other expenses incurred by Pharmakon and reimbursed by the Company, or Lender Expenses. The Tranche A draw was $77.3 million, net of facility fee, Lender Expenses and issuance costs. The Tranche B draw was $20.0&#160;million, net of immaterial Lender Expenses and issuance costs. The Loan Agreement permits voluntary prepayment at any time in whole or in part, subject to a prepayment premium. The prepayment premium would be 2.00% of the principal amount being prepaid prior to the third anniversary of the applicable Funding Date, 1.00% on or after the third anniversary, but prior to the fourth anniversary, of the applicable Funding Date, and 0.50% on or after the fourth anniversary of the applicable Funding Date but prior to the Maturity Date, and a make-whole premium on or prior to the second anniversary of the applicable Funding Date in an amount equal to foregone interest through the second anniversary of the applicable Funding Date. A change of control triggers a mandatory prepayment of the Term Loans.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Loan Agreement contains customary representations, warranties, events of default and covenants of the Company and its subsidiaries, including maintaining, on an annual basis, a minimum liquidity threshold which started in 2021, and on a quarterly basis, a minimum net sales threshold for Auryxia which started in the fourth quarter of 2020.&#160;If an event of default occurs and is continuing under the Loan Agreement, the Collateral Agent is entitled to take enforcement action, including acceleration of amounts due under the Loan Agreement. Under certain circumstances, a default interest rate will apply on all outstanding obligations during the occurrence and continuance of an event of default. As of September&#160;30, 2021 and December&#160;31, 2020, the Company determined that no events of default had occurred.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the terms and features of the Loan Agreement in order to identify any potential embedded features that would require bifurcation or any beneficial conversion feature. As part of this analysis, the Company assessed the economic characteristics and risks of the Loan Agreement, including put and call features. The terms and features assessed include a potential extension to the interest-only period dependent on both no event of default having occurred and continuing and the Company achieving certain regulatory and revenue conditions. The Company also assessed the acceleration of the obligations under the Loan Agreement under an event of default. In addition, under certain circumstances, a default interest rate will apply on all outstanding obligations during the occurrence and continuance of an event of default. In accordance with ASC 815, the Company concluded that these features are not clearly and closely related to the host instrument, and represent a single compound derivative that is required to be re-measured at fair value on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the derivative liability related to the Company&#x2019;s Loan Agreement with Pharmakon was $1.9 million and $2.4 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively. The Company classified the derivative liability as a non-current liability on the unaudited condensed consolidated balance sheet as of September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized interest expense related to the Loan Agreement of $2.7 million and $2.2 million, respectively, during the three months ended September&#160;30, 2021 and 2020, and $8.1 million and $6.6 million for the first nine months ended September&#160;30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i4c756e20d9664648aeb18aebeb242523_I20191111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMzQ3_dd48da69-55d9-4df1-9803-31c4cf9ab4c6"
      unitRef="usd">100000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <akba:LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches
      contextRef="i4c756e20d9664648aeb18aebeb242523_I20191111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMzg4_2e2ebf31-1d62-4d5c-9b85-e53447fd3929"
      unitRef="tranche">2</akba:LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i3c0d403601654c72b47819a9afbd0792_I20191111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfNzIw_7126f276-3345-46b6-acec-426f815d7164"
      unitRef="usd">80000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia190616222f745278c0dc5a7620042c1_I20191111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfODEy_b35894b8-8261-400c-906a-98f7a0dc7dbb"
      unitRef="usd">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia00bb356464246a7b22e1821a884688d_D20191111-20191111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMTc4OA_87c133f6-0592-4bbe-9684-5dd5b7c8caef"
      unitRef="number">0.0750</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <akba:DebtInstrumentFloorRate
      contextRef="i8147f4e6a02545de933ea73e8af97025_D20191111-20191111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMTgwNQ_e5b9f0db-7a08-4487-b82b-5f639b277f2f"
      unitRef="number">0.0200</akba:DebtInstrumentFloorRate>
    <akba:DebtInstrumentCapRate
      contextRef="i8147f4e6a02545de933ea73e8af97025_D20191111-20191111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMTgyNg_607a0dae-7d02-425f-9887-160510796e0d"
      unitRef="number">0.0335</akba:DebtInstrumentCapRate>
    <akba:LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm
      contextRef="i2c34013e3d5d42798cb44d8508b1ac83_D20191111-20191111"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMTk3NQ_78374598-6fb8-4d84-8509-b4a0ee364b78">P33M</akba:LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm>
    <akba:LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm
      contextRef="i06ee360513f94ae993a4c6898c417de2_D20191111-20191111"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMjE1NQ_05c0761f-0f2b-44f1-b8eb-98f07699aea2">P48M</akba:LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm>
    <akba:DebtInstrumentCovenantTermsPotentialMaturityTermReduction
      contextRef="ic6020a0180d34b6a86d7589b54358a92_D20191111-20191111"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMjM2Nw_18923edb-8afd-4ae3-ac34-f9a0726fb984">P1Y</akba:DebtInstrumentCovenantTermsPotentialMaturityTermReduction>
    <akba:DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction
      contextRef="ic6020a0180d34b6a86d7589b54358a92_D20191111-20191111"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMjQzNg_23c354af-f04c-4b9a-873b-536e6e0650f3">P1Y</akba:DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction>
    <akba:FacilityFeePercentagePaidOnPrincipalAmount
      contextRef="ic6020a0180d34b6a86d7589b54358a92_D20191111-20191111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMjUzNg_49e74135-18cc-4c88-b04e-2cde5e9855cf"
      unitRef="number">0.0200</akba:FacilityFeePercentagePaidOnPrincipalAmount>
    <akba:DebtInstrumentFacilityFeePaid
      contextRef="ic6020a0180d34b6a86d7589b54358a92_D20191111-20191111"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMjU5NQ_180051f3-f829-4e97-aebb-ef6d5bb3ed1f"
      unitRef="usd">2000000</akba:DebtInstrumentFacilityFeePaid>
    <us-gaap:LongTermDebt
      contextRef="i8cd1fb13915744c284881cee3c9a4457_I20191125"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMjcyNQ_28e4a08c-5877-40c7-ad76-d2485e2a383d"
      unitRef="usd">77300000</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="iefce2ff8ab894b54be64daf36220401a_D20201210-20201210"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMjgwOQ_1cec80b4-6a3a-4e1e-9133-7a6fa1ed6773"
      unitRef="usd">20000000</us-gaap:ProceedsFromLinesOfCredit>
    <akba:PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding
      contextRef="ic6020a0180d34b6a86d7589b54358a92_D20191111-20191111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMzAxMw_d3562936-e9bb-49ac-b38a-3c6f31c52ad0"
      unitRef="number">0.0200</akba:PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding>
    <akba:PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding
      contextRef="ic6020a0180d34b6a86d7589b54358a92_D20191111-20191111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMzExNw_97ebad9e-a560-4d77-a886-baa56ff44418"
      unitRef="number">0.0100</akba:PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding>
    <akba:PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding
      contextRef="ic6020a0180d34b6a86d7589b54358a92_D20191111-20191111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfMzIyOA_23f01c23-7aeb-4dc6-a73e-81d81776a8c3"
      unitRef="number">0.0050</akba:PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding>
    <us-gaap:DerivativeLiabilities
      contextRef="i469e62d61f624f13a913c992818f42a8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfNTU3Mg_5468e543-d2dc-4c33-a655-5085fdc21c36"
      unitRef="usd">1900000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i3c2c9bd113fe46629d3834ae5a39ba17_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfNTU3OQ_feb5606e-e963-4d42-963b-1fcdd72ed1d2"
      unitRef="usd">2400000</us-gaap:DerivativeLiabilities>
    <us-gaap:InterestExpenseDebt
      contextRef="ied529b6124d840a6ad7b272239c35283_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfNTgyNg_9cf4e5a0-9668-457f-a757-c6e44074a063"
      unitRef="usd">2700000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i43a607fdad03489084b28ba60875d452_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfNTgzMw_4c38da69-6fb9-4753-abe5-9dbe5077f9e4"
      unitRef="usd">2200000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ia8d3eda1fa3b436883677e9840266d97_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfNTg5Ng_d56b41b9-9c0a-4bad-89ed-4128c8790d25"
      unitRef="usd">8100000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ida5e89d4588d4e3dbdc420f58130b868_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82Ny9mcmFnOjQ5M2U5MTVhM2M4OTRhODM4OWY2MDYyYTNhZDY5NDljL3RleHRyZWdpb246NDkzZTkxNWEzYzg5NGE4Mzg5ZjYwNjJhM2FkNjk0OWNfNTkwMw_3b05415c-1c77-412b-9c4f-507ec2b4d2b5"
      unitRef="usd">6600000</us-gaap:InterestExpenseDebt>
    <akba:WarrantDisclosureTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83My9mcmFnOjc3ZjZiNzE2M2NjODRlM2FhZGRlMzdlZTgxYThkNDY1L3RleHRyZWdpb246NzdmNmI3MTYzY2M4NGUzYWFkZGUzN2VlODFhOGQ0NjVfNzc5_826727a0-4807-44cb-9c14-94eee1167914">WarrantIn connection with the Janssen Agreement, in February 2017, the Company issued a warrant to purchase 509,611 shares of the Company&#x2019;s common stock at an exercise price of $9.81 per share. The warrant was fully vested upon issuance and exercisable in whole or in part, at any time prior to February 9, 2022. The warrant satisfied the equity classification criteria of ASC 815, and is therefore classified as an equity instrument. The fair value at issuance of $3.4 million was calculated using the Black Scholes option pricing model and was charged to research and development expense as it represented consideration for a license for which the underlying intellectual property was deemed to have no alternative future use. As of September&#160;30, 2021, the warrant remains outstanding and expires on February&#160;9, 2022.</akba:WarrantDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i541f7e6319644772b0d0e20228d16057_I20170228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83My9mcmFnOjc3ZjZiNzE2M2NjODRlM2FhZGRlMzdlZTgxYThkNDY1L3RleHRyZWdpb246NzdmNmI3MTYzY2M4NGUzYWFkZGUzN2VlODFhOGQ0NjVfMTE2_b8910977-b006-4b4c-9bb2-44f55eafc529"
      unitRef="shares">509611</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i541f7e6319644772b0d0e20228d16057_I20170228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83My9mcmFnOjc3ZjZiNzE2M2NjODRlM2FhZGRlMzdlZTgxYThkNDY1L3RleHRyZWdpb246NzdmNmI3MTYzY2M4NGUzYWFkZGUzN2VlODFhOGQ0NjVfMTgw_ca2980f2-3793-4c6e-af15-8bd12423524b"
      unitRef="usdPerShare">9.81</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="i541f7e6319644772b0d0e20228d16057_I20170228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83My9mcmFnOjc3ZjZiNzE2M2NjODRlM2FhZGRlMzdlZTgxYThkNDY1L3RleHRyZWdpb246NzdmNmI3MTYzY2M4NGUzYWFkZGUzN2VlODFhOGQ0NjVfNDY1_61e5677e-da43-4aa6-a861-451d75253029"
      unitRef="usd">3400000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfOTU0MA_181e1abb-c3d5-4d52-8490-c72b3ae16576">Stockholders&#x2019; Equity&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Authorized and Outstanding Capital Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On June 5, 2020, the Company filed a Certificate of Amendment to its Ninth Amended and Restated Certificate of Incorporation, or its Charter, to increase the number of authorized shares of common stock from 175,000,000 to 350,000,000. As of September&#160;30, 2021, the authorized capital stock of the Company included 350,000,000 shares of common stock, par value $0.00001 per share, of which 174,551,989 and 148,074,085 shares were issued and outstanding as of September&#160;30, 2021 and December&#160;31, 2020, respectively; and 25,000,000 shares of undesignated preferred stock, par value $0.00001 per share, of which no shares were issued and outstanding as of September&#160;30, 2021 and December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;At-the-Market Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 12, 2019, the Company entered into an Amended and Restated Controlled Equity Offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Sales Agreement with Cantor Fitzgerald &amp;amp; Co. for the offer and sale of common stock at the then current market prices in amounts to be determined from time to time. Also, on November 12, 2019, the Company filed a prospectus supplement pursuant to which it was able to offer and sell under the sales agreement up to $75.0 million of its common stock at the then current market prices from time to time. Through December 31, 2019, the Company sold 2,684,392 shares of common stock under this program with net proceeds (after deducting commissions and other offering expenses) of $16.8 million. During the three months ended March 31, 2020, the Company sold 7,973,967 shares of common stock under this program with net proceeds (after deducting commissions and other offering expenses) of $56.7 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 12, 2020, the Company filed a prospectus supplement relating to the sales agreement, pursuant to which it was able to offer and sell up to $65.0 million of its common stock at current market prices from time to time. Through December&#160;31, 2020, the Company sold 3,509,381 shares of common stock under this program with net proceeds (after deducting commissions and other offering expenses) of $10.6&#160;million. During the three months ended March 31, 2021, the Company sold 5,224,278 shares of common stock under this program with net proceeds (after deducting commissions and other offering expenses) of $15.9&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 25, 2021, the Company filed a prospectus relating to the sales agreement with its new shelf registration statement (which replaced the prior shelf registration statement and the sales agreement prospectus supplement), pursuant to which it is able to offer and sell up to $100.0&#160;million of its common stock at current market prices from time to time. During the three and nine months ended September&#160;30, 2021 and through the date of this Quarterly Report on Form 10-Q, the Company sold 4,730,466 and 19,180,365 shares of common stock under this program with net proceeds (after deducting commissions and other offering expenses) of $16.1 million and $67.2 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains one stock incentive plan, the 2014 Incentive Plan, or the 2014 Plan, as well as the 2014 Employee Stock Purchase Plan, or the 2014 ESPP. The 2014 Plan replaced the Company&#x2019;s Amended and Restated 2008 Equity Incentive Plan, or the 2008 Plan, however, options or other awards granted under the 2008 Plan prior to the adoption of the 2014 Plan that have not been settled or forfeited remain outstanding and effective. On June 6, 2019, the Company&#x2019;s shareholders approved the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amended and Restated 2014 Employee Stock Purchase Plan, or the ESPP. The Company also maintains an inducement award program that is separate from the Company's equity plans under which inducement awards may be granted consistent with Nasdaq Listing Rule 5635(c)(4). During the nine months ended September&#160;30, 2021, the Company granted 1,228,200 options to purchase shares of the Company&#x2019;s common stock to new hires as inducements material to such employees' entering into employment with the Company, of which 1,154,200 options remained outstanding as of September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2014 Plan allows for the granting of stock options, stock appreciation rights, or SARs, restricted stock, unrestricted stock, RSUs, performance awards and other awards convertible into or otherwise based on shares of the Company&#x2019;s common stock. Dividend equivalents may also be provided in connection with an award under the 2014 Plan. The Company&#x2019;s employees, officers, directors and consultants and advisors are eligible to receive awards under the 2014 Plan. The Company initially reserved 1,785,000 shares of its common stock for the issuance of awards under the 2014 Plan. The 2014 Plan provides that the number of shares reserved and available for issuance under the 2014 Plan will automatically increase annually on January&#160;1 of each calendar year, by an amount equal to three percent (3%)&#160;of the number of Akebia Shares (as defined in Note 1 of the 2020 Annual Report on Form 10-K) outstanding on a fully diluted basis as of the close of business on the immediately preceding December&#160;31, or the 2014 Plan Evergreen Provision. The Company&#x2019;s Board of Directors may act prior to January&#160;1 of any year to provide that there will be no automatic increase in the number of Akebia Shares available for grant under the 2014 Plan for that year (or that the increase will be less than the amount that would otherwise have automatically been made). On December 12, 2018, in connection with the consummation of the Merger, the Company assumed outstanding and unexercised options to purchase Keryx Shares (as defined in Note 1 of the 2020 Annual Report on Form 10-K), as adjusted by the Exchange Multiplier pursuant to the terms of the Merger Agreement, under the following Keryx equity plans, or the Keryx Equity Plans: the Keryx 1999 Share Option Plan, the Keryx 2004 Long-Term Incentive Plan, the Keryx 2007 Incentive Plan, the Keryx Amended and Restated 2013 Incentive Plan, and the Keryx 2018 Equity Incentive Plan, or the Keryx 2018 Plan. In addition, the number of Keryx Shares available for issuance under the Keryx 2018 Plan, as adjusted by the Exchange Multiplier pursuant to the terms of the Merger Agreement, may be used for awards granted by the Company under its 2014 Plan, or the Assumed Shares, provided that the Company uses the Assumed Shares for individuals who were not employees or directors of the Company prior to the consummation of the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company grants annual service-based stock options to employees under the 2014 Plan. During the nine months ended September&#160;30, 2021, the Company issued 1,997,200 options to employees. In addition, the Company issues stock options &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to directors, new hires and occasionally to other employees not in connection with the annual grant process. During the nine months ended September&#160;30, 2021, the Company issued 200,800 options to directors under the 2014 Plan. Options granted by the Company vest over periods of between 12 and 48 months, subject, in each case, to the individual&#x2019;s continued service through the applicable vesting date. Options vest either 100% on the first anniversary of the grant date or in installments of (i) 25% at the one year anniversary and (ii) 12 equal quarterly installments beginning after the one year anniversary of the grant date, subject to the individual&#x2019;s continuous service with the Company. Options generally expire 10 years after the date of grant.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also grants performance-based stock options to employees under the 2014 Plan.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The performance-based stock options granted by the Company vest in connection with the achievement of specified commercial and regulatory milestones. The performance-based stock options also feature a time-based vesting component. The expense recognized for these awards is based on the grant date fair value of the Company&#x2019;s common stock multiplied by the number of options granted and recognized over time based on the probability of meeting such commercial and regulatory milestones.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company issued 99,558 performance-based stock options during the nine months ended September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company also grants annual service-based restricted stock units, or RSUs to employees under the 2014 Plan. During the nine months ended September&#160;30, 2021, the Com&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;pany issued 3,396,012 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;RSUs to employees. In addition, the Company issued 82,200 RSUs to directors under the 2014 Plan during the nine months ended September&#160;30, 2021. The Company also occasionally issues RSUs not in connection with the annual grant process to employees. Generally, RSUs granted by the Company vest in one of the following ways: (i) 100% of each RSU grant vests on either the first anniversary of the grant date, (ii) one third of each RSU grant vests on the first, second and third anniversaries of the grant date, or (iii) 50% of each RSU grant vests on the first anniversary and 25% of each RSU grant vests every six months after the one year anniversary of the grant date, subject, in each case, to the individual&#x2019;s continued service through the applicable vesting date. The expense recognized for these awards is based on the grant date fair value of the Company&#x2019;s common stock multiplied by the number of units granted and recognized on a straight-line basis over the vesting period. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company also grants performance-based restricted stock units, or PSUs to employees under the 2014 Plan. The PSUs granted by the Company vest in connection with the achievement of specified commercial and regulatory milestones. The PSUs also feature a time-based vesting component. The expense recognized for these awards is based on the grant date fair value of the Company&#x2019;s common stock multiplied by the number of units granted and recognized over time based on the probability of meeting such commercial and regulatory milestones.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; The Company issued 37,150 PSUs during the nine months ended September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;The ESPP provides for the issuance of options to purchase shares of the Company&#x2019;s common stock to participating employees at a discount to their fair market value. As noted above, the Company&#x2019;s stockholders approved the ESPP, which amended and restated the Company&#x2019;s 2014 ESPP, on June 6, 2019. As of September&#160;30, 2021, the maximum aggregate number of shares of the Company&#x2019;s common stock available for future issuance under the ESPP is 5,173,141. Under the ESPP, each offering period is six months, at the end of which employees who elect to purchase shares of the Company&#x2019;s common stock through payroll deductions made over the term of the offering. The per-share purchase price at the end of each offering period is equal to the lesser of eighty-five percent (85%) of the closing price of the Company&#x2019;s common stock at the beginning or end of the offering period. The Company issued 307,193 shares under the ESPP during the nine months ended September&#160;30, 2021.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8e4cb62597ae4760a7f0d14dd934eeeb_I20200604"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMjc1_a600d785-7311-4351-9a03-c0f1293cb090"
      unitRef="shares">175000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMjgx_25251880-276a-48fa-a78e-6e6ca6bf3b68"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMzQ4_25251880-276a-48fa-a78e-6e6ca6bf3b68"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMzg1_1c936585-a0fb-4207-9100-43dc77a0fd20"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNDA4_0d88bbfb-4491-4419-ae54-f2afff7d5bc6"
      unitRef="shares">174551989</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNDA4_77871782-3dfd-42d4-8219-c925368e042d"
      unitRef="shares">174551989</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNDE1_bb4e2c9f-808f-4d20-b592-c6e276d742c3"
      unitRef="shares">148074085</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNDE1_f9bbb3f1-593f-4630-8f12-644388d0a5a9"
      unitRef="shares">148074085</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNDg4_e4a53937-0291-40b8-8098-b160777ce7ee"
      unitRef="shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNTQx_6069ddff-5b1f-41a8-b4bc-365421c3e50e"
      unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNTY0_2969ba1c-db2f-4be0-9922-be22002860e7"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNTY0_6ec3b9f6-d173-49c0-a71c-3a3d9e9c6d06"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i3e2950be526b427487e169a221babd7d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNTY0_7bc63cda-cd53-4b18-aed9-1581e161d59d"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNTY0_a0d73625-1e85-49d1-99e0-53c2a0c7902b"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <akba:CommonStockSalesAgreementAmount
      contextRef="ia500545ec09246ce9dedea5a7cd9b0d4_D20191112-20191112"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMTA1Nw_01060b93-4a65-4dd0-b3bd-0c5c2c6cea0f"
      unitRef="usd">75000000</akba:CommonStockSalesAgreementAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i81c8895c1f2d4c56b6435144097a2e33_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMTE3Nw_28549177-c7de-4865-86ac-2db1a0de4cfb"
      unitRef="shares">2684392</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <akba:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="i81c8895c1f2d4c56b6435144097a2e33_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMTMwMQ_d13e65cd-130f-4427-89d4-59da65b14593"
      unitRef="usd">16800000</akba:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i66deeb6acb77474a959a2ca2688e2657_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMTM2OA_0b7f30a6-b1d6-4b7c-bd18-dba450b268d1"
      unitRef="shares">7973967</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <akba:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="i66deeb6acb77474a959a2ca2688e2657_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMTQ5Mg_493b034d-e11e-4492-a306-dd5a72b7ab47"
      unitRef="usd">56700000</akba:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <akba:CommonStockSalesAgreementAmount
      contextRef="i7a4aafef7ebc4f4dbc4da7e3e7952d94_D20200312-20200312"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMTY0NA_d601a59a-263f-4b38-8d0e-0ca3b3b9fb79"
      unitRef="usd">65000000</akba:CommonStockSalesAgreementAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia6fcc0f0e17240bd92fefbacdd946b14_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMTc0MA_1746ab7e-4a71-453f-bbfc-bedd4082a529"
      unitRef="shares">3509381</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <akba:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="ia6fcc0f0e17240bd92fefbacdd946b14_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMTg2NA_96a11b56-ad64-49f8-a2de-0046c2a79f0f"
      unitRef="usd">10600000</akba:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i48ac3ceb90a14e55a606e7ed5d3716d1_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMTkzMQ_ff408765-5398-4369-9eea-381f89fa4c74"
      unitRef="shares">5224278</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <akba:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="i48ac3ceb90a14e55a606e7ed5d3716d1_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMjA1NQ_95a43a63-3ebf-4fe2-8346-ab5bff67f29b"
      unitRef="usd">15900000</akba:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <akba:CommonStockSalesAgreementAmount
      contextRef="i678d4d68b8d44706b86e94178a818447_D20210225-20210225"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMjM0Mw_e01c4dbc-763c-42f8-a905-f15f42f4900e"
      unitRef="usd">100000000</akba:CommonStockSalesAgreementAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7c3f11e1bf924040bbe2698d14b92960_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMjUyOA_ead8076d-77f2-4449-9f89-b983a0ffb052"
      unitRef="shares">4730466</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i45bac3731ae447399855606573e4e297_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMjUzNQ_d9764576-2822-42db-a607-f90025d6671d"
      unitRef="shares">19180365</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <akba:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="i7c3f11e1bf924040bbe2698d14b92960_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMjY1OQ_7ac4729e-1095-46a8-90dc-b08baac6a2c3"
      unitRef="usd">16100000</akba:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <akba:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="i45bac3731ae447399855606573e4e297_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMjY2Ng_c78505a5-2c75-4874-8f6f-99698e69e837"
      unitRef="usd">67200000</akba:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ic405d5f9a6194033b54c67f003fb5108_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMzUwNw_199a2eb1-ad51-4a32-8ddd-26ce3f28f3d1"
      unitRef="shares">1228200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id8e692bb054345cb9980a00457fd17f1_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMzY3NQ_6402089c-a073-4871-a518-1f94bc9299fa"
      unitRef="shares">1154200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i1a334797d16148a8bc4de0e3cd01d3a6_I20140228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNDI0MA_024dc522-d538-49dd-b810-5faa329427d9"
      unitRef="shares">1785000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <akba:AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding
      contextRef="i24f27ec785a94f77bff6f9932edbe262_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNDUzMw_2d512bbc-4182-4551-9c9b-85e495c8f766"
      unitRef="number">0.03</akba:AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i928990fc0f0544d7bdc2c92d83eb4503_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNjExMw_4397c920-4caf-4e6f-9f00-7fcbf5f11906"
      unitRef="shares">1997200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i8c0679f11ab54281a697554a5d1b0a16_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNjM1MA_4f48ba63-52e4-4d02-a932-47ff7263babe"
      unitRef="shares">200800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="if883a99477df492ebd6e2365f0c4bb6a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNjQ1NQ_60603d25-115e-412f-9d12-1e5d9f7c7f2b">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic68dc20e53ac4d9f9315ecf7c3ede580_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNjQ2Mg_b15e168e-f31b-420a-9ea2-6cf8bf0c90e4">P48M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i67dd5c6046f64d0e9109b42763967f24_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNjU4NA_d2c2ee25-764c-4448-a5c8-816620a5621c"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i8f98c7914a2d4498b3182d130d0cb47a_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNjY1Ng_16e3fa01-3b00-4e1b-b840-11d9ffb28caf"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8f98c7914a2d4498b3182d130d0cb47a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNjY2Ng_73e67ff8-a235-4b72-83a5-91a4baf6c36c">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <akba:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments
      contextRef="ib0f30762d9654703a976783f7172781a_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNjY5MA_37240d88-bb79-4fec-a852-d3eb3ab003f0"
      unitRef="installment">12</akba:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ib0f30762d9654703a976783f7172781a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNjc0Mg_15b7e905-942e-471c-bbb3-47cfb54f1e5f">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i010b303706c744e2922ea62d41c6df9a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNjg2Ng_84174d76-d64f-4a5f-97fb-dfaa12c3e897">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i2dd32faea92444fe9357160c0a7b15cc_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMTY0OTI2NzQ1NTI1MQ_c7f6650b-af54-4ea2-ad1c-b55d84539c38"
      unitRef="shares">99558</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i8a366e7c1d9547a89b545b4c5b2edc75_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNzA2Mg_0b52dfdd-0dfd-4691-b542-7b390d51652d"
      unitRef="shares">3396012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="id8c33b8456b445388314a4b181f4ad55_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNzExNg_096be165-6ec9-473e-a5ba-5a665637c10b"
      unitRef="shares">82200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="id334eb22f65f47a2b8f9ed60a00a7faf_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNzM3MQ_5dba28b7-ed7f-42c8-b7be-0325bceb9ab7"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i700b68cc599f4438ba55fcd9dc69cd7a_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNzY3Mg_b17a0e17-d3ab-48a1-adb7-6830b48df9da"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i73aee313a7a7411d983faf613acc515c_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNzcyOA_98b8b8f7-2d4a-4696-869a-c84237cf662d"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i73aee313a7a7411d983faf613acc515c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNzc2MQ_0c42b08f-0192-4cb2-ac60-ac5a8d9cc2cd">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <akba:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod
      contextRef="i73aee313a7a7411d983faf613acc515c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfNzc3NA_a81dcbe8-050d-42ec-b153-98d293b616f8">P1Y</akba:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i6fe3737b757e4dcb9d9bd2fd3a908513_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfMTY0OTI2NzQ1NTI0NA_44524b26-904f-471d-a4d1-6af2e7d26e0b"
      unitRef="shares">37150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i02cb18bdb22b463a8143eb77464ade75_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfOTA2MA_92575872-6a9f-40a0-8c65-7b7821a89c7d"
      unitRef="shares">5173141</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <akba:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="ie796bd13e7ae4237ba6a1435f0aa706a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfOTEwNA_b206c1b2-3aba-4110-835e-4a1a7e57ad69">P6M</akba:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="ie796bd13e7ae4237ba6a1435f0aa706a_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfOTM2Mg_ba43533c-0e21-4b8b-964e-e1d1f0648431"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ie796bd13e7ae4237ba6a1435f0aa706a_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl83Ni9mcmFnOmQ5NTc1YTM4NzFlODRlOTE5NTJmZGM2NDNkMjIyOGIyL3RleHRyZWdpb246ZDk1NzVhMzg3MWU4NGU5MTk1MmZkYzY0M2QyMjI4YjJfOTQ4NA_7b595627-1614-4c68-9376-e806b6b4c77c"
      unitRef="shares">307193</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTcwNTA_ca1dc4e6-f0c6-48f3-a8ef-8559f0711dbc">Commitments and Contingencies&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases approximately 65,167 square feet of office and lab space in Cambridge, Massachusetts under a lease which was most recently amended in November 2020, collectively the Cambridge Lease. Under the Third Amendment to the Cambridge Lease, or the Third Amendment, executed in July 2016, total monthly lease payments under the initial base rent were approximately $242,000 and are subject to annual rent escalations.&#160;In addition to such annual rent escalations, base rent payments for a portion of said premises commenced on January 1, 2017 in the monthly amount of approximately $22,000. The Fourth Amendment to the Cambridge Lease, executed in May 2017, provided additional storage space to the Company and did not impact rent payments. In April 2018, the Company entered into a Fifth Amendment to the Cambridge Lease, or the Fifth Amendment, for an additional 19,805 square feet of office space on the 12t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;h&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; floor. Monthly lease payments for the existing 45,362 square feet of office and lab space, under the Third Amendment, remain unchanged. The new space leased by the Company was delivered in September 2018 and additional monthly lease payments of approximately $135,000 commenced in February 2019 and are subject to annual rent escalations, which commenced in September 2019. In November 2020, the Company entered into a Sixth Amendment to the Cambridge Lease, or the Sixth Amendment, to extend the term of the Cambridge Lease with respect to the lab space from November 30, 2021 to January 31, 2025. The Sixth Amendment includes two months of free rent starting in December 2020 and additional monthly lease payments of approximately $48,000 commencing in December 2021, and is subject to annual rent escalations, which commence in December 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, as a result of the Merger, the Company has a lease for 27,300 square feet of office space in Boston, Massachusetts, or the Boston Lease, which expires in February 2023. The total monthly lease payments under the base rent are approximately $136,000 and are subject to annual rent escalations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The term of the Cambridge Lease with respect to the office space expires on September&#160;11, 2026, with one five-year extension option available. The term of the Boston Lease office space expires on February&#160;28, 2023, with an extension option for one additional five-year term available. The renewal options in these real estate leases were not included in the calculation of the operating lease assets and operating lease liabilities as the renewal is not reasonably certain. The term of the Cambridge Lease with respect to the lab space expires on January&#160;31, 2025, with an extension option for one additional period through September&#160;11, 2026. The renewal option in this real estate lease was included in the calculation of the operating lease assets and operating lease liabilities as the renewal is reasonably certain. The lease agreements do not contain residual value guarantees. Operating lease costs were $1.7 million for each of the three months ended September&#160;30, 2021 and 2020 and $5.0 million for each of the nine months ended September&#160;30, 2021 and 2020. Cash paid for amounts included in the measurement of operating lease liabilities was $1.8 million for each of the three months ended September&#160;30, 2021 and 2020 and $5.3 million for each of the nine months ended September&#160;30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, Keryx entered into an agreement to sublease the Boston office space to Foundation Medicine, Inc., or Foundation. The sublease is subject and subordinate to the Boston Lease between Keryx and the landlord. The term of the sublease commenced on October&#160;16, 2019, upon receipt of the required consent from the landlord for the sublease agreement, and expires on February&#160;27, 2023. Foundation is obligated to pay Keryx rent that approximates the rent due from Keryx to its landlord with respect to the Boston Lease. Sublease rental income is recorded to other income. Keryx continues to be obligated for all payment terms pursuant to the Boston Lease, and the Company will guaranty Keryx&#x2019;s obligations under the sublease. Keryx recorded $0.4 million in sublease rental income from Foundation during each of the three months ended September&#160;30, 2021 and 2020 and $1.3 million during each of the nine months ended September&#160;30, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not entered into any material short-term leases or financing leases as of September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total security deposit in connection with the Cambridge Lease is $1.6 million as of September&#160;30, 2021. Additionally, the Company recorded $0.4 million for the security deposit under the Boston Lease. Both the Cambridge Lease and the Boston Lease have their security deposits in the form of a letter of credit, all of which are included as restricted cash in other assets in the Company&#x2019;s unaudited condensed consolidated balance sheets as of September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, undiscounted minimum rental commitments under non-cancelable leases, for each of the next five years and total thereafter are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Payments&lt;br/&gt;to be Received&lt;br/&gt;from Sublease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Operating&lt;br/&gt;Lease Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In arriving at the operating lease liabilities, the Company applied incremental borrowing rates ranging from 6.22% to 6.94%, which were based on the remaining lease term at either the date of adoption of ASC 842 or the effective date of any subsequent lease term extensions. As of September&#160;30, 2021, the remaining lease terms ranged from 1.41 years to 4.95 years. As of September&#160;30, 2021, the following represents the difference between the remaining undiscounted minimum rental commitments under non-cancelable leases and the operating lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.330%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Undiscounted minimum rental commitments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value adjustment using incremental borrowing rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOmY2NDc1MWJlODBmNTRjOTY4ZDg5NTUxMjc1NTZjNDVjL3RhYmxlcmFuZ2U6ZjY0NzUxYmU4MGY1NGM5NjhkODk1NTEyNzU1NmM0NWNfNC0wLTEtMS0yMjM1Nw_6f24d764-2b2d-4991-9474-8d0770053a51"&gt;Operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Manufacturing Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the Merger, the Company's contractual obligations include Keryx&#x2019;s commercial supply agreements with BioVectra Inc., or BioVectra, and Siegfried Evionnaz SA, or Siegfried, to supply commercial drug substance for Auryxia.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Pursuant to the Manufacture and Supply Agreement with BioVectra and the Product Manufacture and Supply and Facility Construction Agreement with BioVectra, collectively the BioVectra Agreement, the Company agreed to purchase minimum quantities of Auryxia drug substance annually at predetermined prices. On September 4, 2020, the Company and BioVectra entered into an Amended and Restated Product Manufacture and Supply and Facility Construction Agreement, which provided for reduced minimum quantity commitments and revised the predetermined prices. The price per kilogram decreases with an increase in quantity above the predetermined purchase quantity tiers. In addition, the Manufacture and Supply Agreement with BioVectra and the Amended and Restated Product Manufacture and Supply and Facility Construction Agreement with BioVectra, collectively the Amended BioVectra Agreement, requires the Company to reimburse BioVectra for certain costs in connection with construction of a new facility for the manufacture and supply of Auryxia drug substance. These construction costs are recorded in other assets and amortized into drug substance as inventory is released to the Company from BioVectra. The term of the Manufacture and Supply Agreement with BioVectra expires on December 31, 2022. The term of the Amended and Restated Product Manufacture and Supply and Facility Construction Agreement expires on December 31, 2026, after which it automatically renews for successive one-year terms unless either party gives notice of its intention to terminate within a specified time prior to the end of the then-current term. In addition, the Company and BioVectra each have the ability to terminate these agreements upon the occurrence of certain conditions. As of September&#160;30, 2021, the Company is required to reimburse BioVectra for certain costs in connection with the construction of the new facility and to purchase minimum quantities of Auryxia drug substance annually for a total cost of approximately $82.9 million through the end of the contract term.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Pursuant to the Siegfried Master Manufacturing Services and Supply Agreement, as amended (the most recent amendment having been executed on February 11, 2021), or the Siegfried Agreement, the Company has agreed to purchase a minimum quantity of drug substance of Auryxia at predetermined prices. The term of the Siegfried Agreement expires on December&#160;31, 2022, subject to our option to extend the term through December 31, 2023 by providing 12 months&#x2019; prior written notice to Siegfried. The Siegfried Agreement provides the Company and Siegfried with certain early termination rights. As of &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;September&#160;30, 2021, the Company is required to purchase a minimum quantity of drug substance for Auryxia annually at a total cost of approximately $27.7 million through the year ending December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As part of purchase accounting, the Company identified executory contracts in the commercial supply agreements between Keryx and its contract manufacturers for Auryxia, which include future firm purchase commitments. These executory contracts were deemed to have an off-market element related to the amount of purchase commitments that exceed the current forecast. The Company regularly reviews its estimate of the excess purchase commitment liability including a review of assumptions of expected future demand, estimates of anticipated expiry of inventory under firm purchase commitments that are estimated to expire before they could be sold as well as any modifications to supply agreements during each reporting period. The excess purchase commitment liability relating to these executory contracts was $71.2 million and $55.8 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively. During the quarter ended September 30, 2021, the Company reviewed the detailed assumptions above and recorded a $6.0 million reduction to the excess purchase commitments liability within cost of goods sold. The reduction to the excess purchase commitments liability was primarily due to the settlement of all patent litigation proceedings related to Abbreviated New Drug Applications filed with respect to Auryxia, which allows for generic versions of Auryxia beginning in March 2025. The Company recognized this non-cash gain in accordance with ASC 270 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Interim Reporting, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;specifically ASC 270-10-45-6(c) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Other Presentation Matters, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;which allows for recovery of losses on the same inventory in later interim periods of the same fiscal year as long as the as long as the recovery of losses does not exceed the previously recognized loss. During the quarter ended June 30, 2021, the Company completed a routine update of its long-range plan and related estimates of expiry. This routine update included the impact of recent activity with regards to our long-term payor contract strategy which continues to focus on contract economics and net revenue growth and resulted in a $30.3 million charge to cost of goods sold during the quarter ended June&#160;30, 2021. In addition, as of June&#160;30, 2021, the Company also considered whether this increase was a potential indicator of impairment of the Auryxia asset group as of June&#160;30, 2021. As part of its assessment, the Company reviewed the Auryxia net sales and estimated future cash flows included in its long-range plan and concluded that the increase in excess purchase commitment liability was not an indicator of impairment of the Auryxia asset group as of June&#160;30, 2021. In addition, during the first quarter ended March 31, 2021, the Company recorded a non-cash gain to cost of goods sold of $9.0 million driven largely by a reduction in purchase commitments due to the amendment to the Siegfried Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 9, 2019, the Company entered into a Supply Agreement with Esteve Qu&#xed;mica, S.A., or Esteve, or the Esteve Agreement. The Esteve Agreement includes the terms and conditions under which Esteve will manufacture vadadustat drug substance for commercial use. Pursuant to the Esteve Agreement, the Company provides rolling forecasts to Esteve on a quarterly basis, or the Esteve Forecast. The Esteve Forecast reflects the Company&#x2019;s needs for vadadustat drug substance produced by Esteve over a certain number of months, represented as a quantity of vadadustat drug substance per calendar quarter. The parties have agreed to a volume-based pricing structure under the Esteve Agreement. The Esteve Agreement has an initial term of four years, beginning April 9, 2019 and ending April 9, 2023. Pursuant to the Esteve Agreement, the Company has agreed to purchase a certain percentage of the global demand for vadadustat drug substance from Esteve. As of September&#160;30, 2021, the Company has committed to purchase $34.4 million of vadadustat drug substance from Esteve through the fourth quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;On March 11, 2020, the Company entered into a Supply Agreement with Patheon Inc., or Patheon, or the Patheon Agreement. The Patheon Agreement includes the terms and conditions under which Patheon will manufacture vadadustat drug product for commercial use. Pursuant to the Patheon Agreement, the Company provides Patheon a long-term forecast on an annual basis, as well as short-term forecasts on a quarterly basis, or the Patheon Forecast. The Patheon Forecast reflects the Company&#x2019;s needs for commercial supply of vadadustat drug product produced by Patheon, represented as a quantity of drug product per calendar quarter. The parties have agreed to a volume-based pricing structure under the Patheon Agreement. The Patheon Agreement has an initial term beginning March 11, 2020 and ending June 30, 2023. Pursuant to the Patheon Agreement, the Company has agreed to purchase a certain percentage of the global demand for vadadustat drug product from Patheon. As of September&#160;30, 2021, the Company had a minimum commitment with Patheon for $4.2 million through the third quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;On April 2, 2020, the Company entered into a Supply Agreement with STA Pharmaceutical Hong Kong Limited, a subsidiary of WuXi AppTec, or WuXi STA, as amended on April 15, 2021, or the WuXi STA DS Agreement. The WuXi STA DS Agreement includes the terms and conditions under which WuXi STA will manufacture vadadustat drug substance for commercial use. Pursuant to the WuXi STA DS Agreement, the Company provides rolling forecasts to WuXi STA on a quarterly basis, or the WuXi STA DS Forecast. The WuXi STA DS Forecast reflects the Company&#x2019;s needs for vadadustat drug substance produced by WuXi STA over a certain number of quarters. The parties have agreed to a volume-based pricing structure under the WuXi STA DS Agreement. The WuXi STA DS Agreement has an initial term of four years, beginning April 2, 2020 and ending April 2, 2024.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Pursuant to the WuXi STA DS Agreement, the Company has agreed to purchase a certain percentage of the global demand for vadadustat drug substance from WuXi STA. As of September&#160;30, 2021, the Company has committed to purchase $44.8 million of vadadustat drug substance from WuXi STA through the end of 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;On February 10, 2021, the Company entered into a Supply Agreement with WuXi STA, or the WuXi STA DP Agreement. The WuXi STA DP Agreement includes the terms and conditions under which WuXi STA will manufacture and supply vadadustat &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;drug product for commercial purposes. Pursuant to the WuXi STA DP Agreement, the Company will provide rolling forecasts to WuXi STA on a quarterly basis, or the WuXi STA DP Forecast. Each WuXi STA DP Forecast will reflect the quantities of vadadustat drug product that the Company expects to order from WuXi STA over a certain number of months, represented as a quantity of vadadustat drug product per calendar quarter. Pursuant to the WuXi STA DP Agreement, the Company has agreed to purchase a certain percentage of global demand for vadadustat drug product from WuXi STA. The parties have agreed to a volume-based pricing structure under the WuXi STA DP Agreement. The vadadustat drug product price will remain fixed for the first 12 months and thereafter shall be annually reviewed by the Company and WuXi STA. The Company will also reimburse WuXi STA for certain reasonable expenses. The WuXi STA DP Agreement has an initial term of four years, beginning February 10, 2021 and ending February 10, 2025. The WuXi STA DP Agreement may be renewed or extended by mutual agreement of the Company and WuXi STA with at least 18 months&#x2019; prior written notice. The WuXi STA DP Agreement allows the Company to terminate the agreement on 180 calendar days&#x2019; prior written notice to WuXi STA for any reason. In addition, each party has the ability to terminate the WuXi STA DP Agreement upon the occurrence of certain conditions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Third Party Contracts&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Company&#x2019;s agreement with IQVIA to provide contract research organization services for the PRO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;TECT and INNO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;VATE programs, the total remaining contract costs as of September&#160;30, 2021 were approximately $7.6 million, of which Otsuka reimburses a significant portion back to the Company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantive performance for the committed work with IQVIA was completed in 2020 and close out activities will be performed throughout 2021. The Company also contracts with various other organizations to conduct research and development activities with remaining contract costs to the Company of approximately $244.4 million at September&#160;30, 2021. The scope of the services under these research and development contracts can be modified and the contracts cancelled by the Company upon written notice. In some instances, the contracts may be cancelled by the third party upon written notice.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation and Related Matters&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may become subject to legal proceedings and claims which arise in the ordinary course of its business. Consistent with ASC 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company&#x2019;s policy is to record a liability if a loss in a significant legal dispute is considered probable and an amount can be reasonably estimated. The Company provides disclosure when a loss in excess of any reserve is reasonably possible, and if estimable, the Company discloses the potential loss or range of possible loss. Significant judgment is required to assess the likelihood of various potential outcomes and the quantification of loss in those scenarios. The Company&#x2019;s estimates change as litigation progresses and new information comes to light. Changes in Company estimates could have a material impact on the Company&#x2019;s results and financial position. As of September&#160;30, 2021, the Company does not have any significant legal disputes that require a loss liability to be recorded. The Company continually monitors the need for a loss liability for litigation and related matters.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i8c4a114c87d04f9a86f0cd36147b5c17_I20201130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNzY_a84e7900-61d4-41a0-bb48-42aba064759b"
      unitRef="sqft">65167</us-gaap:AreaOfRealEstateProperty>
    <akba:OperatingLeaseAnnualRentExpense
      contextRef="i2f8032b3bd82471cbcff6a003f19e33b_D20160701-20160731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNDE0_38bc9b5d-96fd-4abe-bb8b-59da9834b431"
      unitRef="usd">242000</akba:OperatingLeaseAnnualRentExpense>
    <akba:OperatingLeaseMonthlyRentExpense
      contextRef="i1ee517b85db6461e9394aeeb76fb30a0_D20170101-20170101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNjEx_52f532f9-cb7e-474e-84c0-babf7ae71796"
      unitRef="usd">22000</akba:OperatingLeaseMonthlyRentExpense>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="ibe11b29f86744551b0e34d4c7a45321d_I20180430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfODg5_5ce5a26c-3893-45d4-a1ea-2d2593889d5d"
      unitRef="sqft">19805</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i2085d352fbe244bfae6189887c1b70b1_I20160731"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfOTc5_71ee5dc0-6985-42a0-8ead-9fa76e7eecfa"
      unitRef="sqft">45362</us-gaap:AreaOfRealEstateProperty>
    <akba:OperatingLeaseMonthlyRentExpense
      contextRef="ifc753862bba346a4b87baf73046febb4_D20190201-20190228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTE4Nw_d04d4012-61fd-4760-9149-989e776abaa5"
      unitRef="usd">135000</akba:OperatingLeaseMonthlyRentExpense>
    <akba:OperatingLeaseFreeMonthlyRentPeriod
      contextRef="i319033b22a7e40f680e6a60fdad1e84d_D20201201-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTU1MA_afbd8895-57f4-4b48-a268-971eed9bbb79">P2M</akba:OperatingLeaseFreeMonthlyRentPeriod>
    <akba:OperatingLeaseMonthlyRentExpense
      contextRef="i7f13ec3e12bf451caafb2291ffc4a2a8_D20211201-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTY0Nw_77e706b8-45fb-4e96-9f48-321c9950a999"
      unitRef="usd">48000</akba:OperatingLeaseMonthlyRentExpense>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i395d6be571b646d2a729d3d38b72c91b_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTgyNQ_6d532524-5ca4-4fa4-bc73-1fa0a9ecb893"
      unitRef="sqft">27300</us-gaap:AreaOfRealEstateProperty>
    <akba:OperatingLeaseMonthlyRentExpense
      contextRef="i36039c1763334766b650c9db8ccac9a8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTk5NQ_dd748911-ff2b-4a1a-adc5-a04da10c128a"
      unitRef="usd">136000</akba:OperatingLeaseMonthlyRentExpense>
    <akba:LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions
      contextRef="iae8a04efe54e4e2cba598fe2b46d3589_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMjEyOA_3336642f-3421-4149-b5d5-4bad1f17361c"
      unitRef="extensionoption">1</akba:LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="iae8a04efe54e4e2cba598fe2b46d3589_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTcwNTE_ce44fa73-4c3c-43ee-96eb-f82476d50bcf">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <akba:LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions
      contextRef="i3f8574ce39ac48ada29733a02df6fe06_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMjI1Mw_188899e0-97eb-4869-8e50-77e4617366b2"
      unitRef="extensionoption">1</akba:LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i3f8574ce39ac48ada29733a02df6fe06_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTcwNTI_acc19e1b-cc0d-4743-b939-6bf75e0037e9">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseCost
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMjgyNw_20e83c03-edfe-492a-85d2-f9daddbf4df2"
      unitRef="usd">1700000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMjgyNw_cf3bbcbb-437b-4360-833f-181f90a2bb9c"
      unitRef="usd">1700000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMjg3OQ_0cd96eee-d1c6-488c-b5cc-8bd175a118bd"
      unitRef="usd">5000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMjg3OQ_6d974785-8259-4030-bc90-41919012257c"
      unitRef="usd">5000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="ib6e8a5c2e5c64385869e95063e9128c9_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMzAxMQ_2241e56d-5f2f-41d7-a289-84f918a6f890"
      unitRef="usd">1800000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMzAxMQ_4d93dea0-18af-4f0b-bea0-333ce8907e60"
      unitRef="usd">1800000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMzA2Mw_9b7ba49a-1421-4e09-a297-1c96ab6a01d7"
      unitRef="usd">5300000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMzA2Mw_a9a182f0-fb8b-4c2b-93a2-46255ffbdd6a"
      unitRef="usd">5300000</us-gaap:OperatingLeasePayments>
    <us-gaap:SubleaseIncome
      contextRef="ibbf6fa923bcf4b2b92e43786d4da64a2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMzg0OA_13c4e309-5959-4450-8483-c40e2bf0c922"
      unitRef="usd">400000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i9b38f2f3c3db48cdacc6e3dab5c4477a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMzg0OA_c909ebec-eeb5-44a5-8183-a856407d0998"
      unitRef="usd">400000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="ib8e6a7b6910d48e294bcb23008415abd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMzk0NQ_16183bd0-849c-449a-a396-d340bb889abc"
      unitRef="usd">1300000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i99da615448e74f1b956e0da8fde046d6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMzk0NQ_4b540079-2f1c-4630-9919-e808069a8e17"
      unitRef="usd">1300000</us-gaap:SubleaseIncome>
    <us-gaap:SecurityDeposit
      contextRef="i2521a8d2d711470090bd6f68bb353f22_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNDE2MA_7a0c9751-9aa8-414d-9547-6a0e082b0989"
      unitRef="usd">1600000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="i0dca46c47d4447088630d11a10807fbe_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNDIwOA_31f297e4-ddd7-4e0d-8bfb-2d4b843e2d5c"
      unitRef="usd">400000</us-gaap:SecurityDeposit>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTcwNTM_8563c7ef-c6d7-4916-80e3-5eab19ff7b0b">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, undiscounted minimum rental commitments under non-cancelable leases, for each of the next five years and total thereafter are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Payments&lt;br/&gt;to be Received&lt;br/&gt;from Sublease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Operating&lt;br/&gt;Lease Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfMi0xLTEtMS0yMjM1Nw_a7b204ce-82aa-437f-8683-7b9082dc6cbd"
      unitRef="usd">1803000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfMi0zLTEtMS0yMjM1Nw_73131cc0-e14a-4fb3-b02f-99b40e3f6067"
      unitRef="usd">454000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear>
    <akba:LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfMi01LTEtMS0yMjM1Nw_6d2b2ffa-ac75-4795-add5-5f6883a18965"
      unitRef="usd">1349000</akba:LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfMy0xLTEtMS0yMjM1Nw_9bfdd798-0cca-4e65-9071-757c89cf336c"
      unitRef="usd">7328000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfMy0zLTEtMS0yMjM1Nw_610558f5-3bfa-4068-b50a-c2e14fa5a3ff"
      unitRef="usd">1824000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths>
    <akba:LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfMy01LTEtMS0yMjM1Nw_6375fe97-d454-4697-b11c-156b1523857d"
      unitRef="usd">5504000</akba:LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfNC0xLTEtMS0yMjM1Nw_2a4fb828-dc08-40b0-abe3-b4bad71326b2"
      unitRef="usd">5954000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfNC0zLTEtMS0yMjM1Nw_394760e1-5734-469f-a160-ec4d6ac2ca4f"
      unitRef="usd">307000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears>
    <akba:LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfNC01LTEtMS0yMjM1Nw_c3d404d9-f736-418e-b823-994ddeb69406"
      unitRef="usd">5647000</akba:LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfNS0xLTEtMS0yMjM1Nw_b2fdff4e-adbc-43e9-8c2e-95ccde3a6d47"
      unitRef="usd">5746000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfNS0zLTEtMS0yMjM1Nw_3902a79a-5a79-418d-97a9-46259224563a"
      unitRef="usd">0</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears>
    <akba:LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfNS01LTEtMS0yMjM1Nw_9f790c75-fa4f-4e79-bf0a-450eeab43f8b"
      unitRef="usd">5746000</akba:LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfNi0xLTEtMS0yMjM1Nw_1931e0b9-d4f5-4dea-b049-66eea36af948"
      unitRef="usd">5823000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfNi0zLTEtMS0yMjM1Nw_33a41dd1-1a0e-430b-992d-bf1932caa54e"
      unitRef="usd">0</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears>
    <akba:LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfNi01LTEtMS0yMjM1Nw_df89903c-0a45-4201-9355-27e7d973f476"
      unitRef="usd">5823000</akba:LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour>
    <akba:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfNy0xLTEtMS0yMjM1Nw_ea696d7a-fe4f-4713-b0c1-3a98092a497f"
      unitRef="usd">4052000</akba:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour>
    <akba:LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfNy0zLTEtMS0yMjM1Nw_748f8052-4954-4818-873a-0ed1fffdae93"
      unitRef="usd">0</akba:LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour>
    <akba:LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfNy01LTEtMS0yMjM1Nw_6c7984bf-41a2-415a-940c-05a3bbdb717a"
      unitRef="usd">4052000</akba:LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfOC0xLTEtMS0yMjM1Nw_918770c7-08a4-422f-b5b4-835582f96e65"
      unitRef="usd">30706000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfOC0zLTEtMS0yMjM1Nw_6a8648ec-101b-4fc3-90b5-533faa5af737"
      unitRef="usd">2585000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <akba:LesseeOperatingLeaseLiabilityPaymentsDueNet
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOjcwM2JmNTRlMWE1MTQ3NmM5ZWU2NDA3Yzk3ZmIwOWQwL3RhYmxlcmFuZ2U6NzAzYmY1NGUxYTUxNDc2YzllZTY0MDdjOTdmYjA5ZDBfOC01LTEtMS0yMjM1Nw_2f62de59-9da6-4ec0-97ce-fcc21a0be26d"
      unitRef="usd">28121000</akba:LesseeOperatingLeaseLiabilityPaymentsDueNet>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i0784525677704a0f9da4e0961490be27_I20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNDc2OA_5e220e61-6e24-4b22-9e5f-064b8097443f"
      unitRef="number">0.0622</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="if648f232fd8d44f2853c2848e528087c_I20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNDc3NA_0a7b7ce7-4a02-4dfc-a4a0-a4f385e1ec4e"
      unitRef="number">0.0694</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i0784525677704a0f9da4e0961490be27_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNDk3Ng_a58e4464-fd92-4d6f-9cd2-d9bc1c4f9c5d">P1Y4M28D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="if648f232fd8d44f2853c2848e528087c_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNDk4Mg_3896d8b0-4f18-4865-a7d5-9f2b2f4ba8e3">P4Y11M12D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <akba:ScheduleOfDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesAndOperatingLeaseLiabilitiesTableTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTcwNTQ_3dfe1b7d-7d5d-4cfe-9e15-4735b41f840d">As of September&#160;30, 2021, the following represents the difference between the remaining undiscounted minimum rental commitments under non-cancelable leases and the operating lease liabilities:&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.330%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Undiscounted minimum rental commitments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value adjustment using incremental borrowing rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOmY2NDc1MWJlODBmNTRjOTY4ZDg5NTUxMjc1NTZjNDVjL3RhYmxlcmFuZ2U6ZjY0NzUxYmU4MGY1NGM5NjhkODk1NTEyNzU1NmM0NWNfNC0wLTEtMS0yMjM1Nw_6f24d764-2b2d-4991-9474-8d0770053a51"&gt;Operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</akba:ScheduleOfDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesAndOperatingLeaseLiabilitiesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOmY2NDc1MWJlODBmNTRjOTY4ZDg5NTUxMjc1NTZjNDVjL3RhYmxlcmFuZ2U6ZjY0NzUxYmU4MGY1NGM5NjhkODk1NTEyNzU1NmM0NWNfMi0xLTEtMS0yMjM1Nw_3a060581-9892-449a-95b4-f65681945d9c"
      unitRef="usd">30706000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOmY2NDc1MWJlODBmNTRjOTY4ZDg5NTUxMjc1NTZjNDVjL3RhYmxlcmFuZ2U6ZjY0NzUxYmU4MGY1NGM5NjhkODk1NTEyNzU1NmM0NWNfMy0xLTEtMS0yMjM1Nw_2e6e8334-5fc3-4b3c-995c-60ef7e0ece87"
      unitRef="usd">4380000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOmY2NDc1MWJlODBmNTRjOTY4ZDg5NTUxMjc1NTZjNDVjL3RhYmxlcmFuZ2U6ZjY0NzUxYmU4MGY1NGM5NjhkODk1NTEyNzU1NmM0NWNfNC0xLTEtMS0yMjM1Nw_1d00f0e0-5005-4460-9f84-b4395c50cffe"
      unitRef="usd">26326000</us-gaap:OperatingLeaseLiability>
    <akba:LongTermPurchaseCommitmentRenewalPeriod
      contextRef="if1dd7b6af62e48d89630458d90d092cb_D20200904-20200904"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTcwNDk_7d0e1426-167d-4dd3-a531-489bf15c9702">P1Y</akba:LongTermPurchaseCommitmentRenewalPeriod>
    <akba:CostOfPurchasedMinimumQuantityProduct
      contextRef="i03f1a8e55f924ca6b788d5e2067ae377_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNzQxNw_1272ece4-7f26-40d8-8616-511101d14224"
      unitRef="usd">82900000</akba:CostOfPurchasedMinimumQuantityProduct>
    <akba:LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod
      contextRef="ib2c7ce4bacf943a6ae4661730894183c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNzg4Ng_734e4487-ddd7-4806-8aee-4d2178cab6d4">P12M</akba:LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod>
    <akba:CostOfPurchasedMinimumQuantityProduct
      contextRef="i93ce46eca8a74081a9a0a15945f34ee2_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfODE2MA_29f22caf-1130-41aa-9f24-10e74f9e8fc6"
      unitRef="usd">27700000</akba:CostOfPurchasedMinimumQuantityProduct>
    <akba:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement
      contextRef="i3ce765a46da74d3ebd33dec7f304c9a8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNzY5NjU4MTQxMjkzNQ_8c2daca8-dedc-4535-ba11-2e9fa85632d7"
      unitRef="usd">71200000</akba:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement>
    <akba:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement
      contextRef="i85c91980832440e88454196ba38dbd5f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfNzY5NjU4MTQxMjk0Mw_21642b99-8b9a-486f-841d-e619fa413864"
      unitRef="usd">55800000</akba:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement>
    <akba:ExcessInventoryPurchaseCommitmentsExpenseReversal
      contextRef="ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTY0OTI2NzQ2MDgwMA_2eddafa1-19c4-4885-aefa-801e96463691"
      unitRef="usd">-6000000.0</akba:ExcessInventoryPurchaseCommitmentsExpenseReversal>
    <us-gaap:CostDirectMaterial
      contextRef="i02a8ba6ff0054b678403f9ad5ed7efc4_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTY0OTI2NzQ2MzExNQ_44fe6b3c-3be0-4805-8daa-37a09d7d2ed2"
      unitRef="usd">30300000</us-gaap:CostDirectMaterial>
    <akba:ExcessInventoryPurchaseCommitmentsExpenseReversal
      contextRef="ib0bd0fdce45f4f2eb878365dff48b0ae_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTAxMTM_128d4e8e-97a0-41f4-9a2b-2404a95a663b"
      unitRef="usd">-9000000</akba:ExcessInventoryPurchaseCommitmentsExpenseReversal>
    <akba:InitialTermOfSupplyAgreement
      contextRef="i49ee8d5e6ee44e0aa71f48df84288db0_D20190409-20190409"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTA5ODQ_bea0b8ac-9452-4a07-9236-2965bcc54912">P4Y</akba:InitialTermOfSupplyAgreement>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="ia777a099e6224fe895fa66b20db9e666_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTEyNDA_7de03ebf-ffaf-46cf-8282-4492d6055361"
      unitRef="usd">34400000</us-gaap:LongTermPurchaseCommitmentAmount>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="ifc3ad8cedbf646a3badc26d2e706ac87_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTIzNDY_5cd4181e-9d8f-4dcd-b3e4-c9216b39eeb6"
      unitRef="usd">4200000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:LongtermPurchaseCommitmentPeriod
      contextRef="ifa82e47edba04966993a43c23b18a792_D20200402-20200402"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTMxMjk_04140c53-8c49-490b-ace2-dc670d4f2093">P4Y</us-gaap:LongtermPurchaseCommitmentPeriod>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="i6768bc85e77b42ec85b465655fe66cb8_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTMzOTI_3e1bea0d-a9ad-4845-a297-5993a61e5b64"
      unitRef="usd">44800000</us-gaap:LongTermPurchaseCommitmentAmount>
    <akba:LongTermPurchaseCommitmentFixedPricePeriod
      contextRef="i1413873e0fc3463794f8307e9bce1a4a_D20210210-20210210"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTQ0Mzk_d4ac4f1c-1456-4d57-bc65-afb601597f1d">P12M</akba:LongTermPurchaseCommitmentFixedPricePeriod>
    <us-gaap:LongtermPurchaseCommitmentPeriod
      contextRef="i1413873e0fc3463794f8307e9bce1a4a_D20210210-20210210"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTQ2MzY_7956a8df-8e8c-4372-9c6b-51fa28a257f0">P4Y</us-gaap:LongtermPurchaseCommitmentPeriod>
    <akba:LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod
      contextRef="i1413873e0fc3463794f8307e9bce1a4a_D20210210-20210210"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTQ4MTM_81122226-f267-48ef-ba22-0fbec57000c2">P18M</akba:LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod>
    <akba:LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod
      contextRef="i1413873e0fc3463794f8307e9bce1a4a_D20210210-20210210"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTQ5MTQ_c6192017-cfe1-41fa-a791-9013f7c1e5e4">P180D</akba:LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod>
    <akba:PurchaseCommittedProgramRemainingContractCosts
      contextRef="i44af4abac88448b5893045bc0002855c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTUzMjg_646b33a6-2e15-4b0b-9e57-367702d28fde"
      unitRef="usd">7600000</akba:PurchaseCommittedProgramRemainingContractCosts>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RleHRyZWdpb246ZTcwMzM1Zjc5YzRhNDE1NGI5Zjc1ZjkxMTA0M2EyMmZfMTU3MDk_d8c91153-8ad6-46bb-917e-3d344af15e62"
      unitRef="usd">244400000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84NS9mcmFnOmFkNzhiNmM2ZmE1YzQ3NzRiYzJlMDdhZjkzNzUwNWIyL3RleHRyZWdpb246YWQ3OGI2YzZmYTVjNDc3NGJjMmUwN2FmOTM3NTA1YjJfNjky_36531871-0585-4f65-a9a2-aeb916ffbb77">Net Loss per Share&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For purposes of the diluted net loss per share calculation, preferred stock, stock options, warrants, restricted stock and RSUs are considered to be common stock equivalents and have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for periods presented. Therefore, basic and diluted net loss per share were the same for all periods presented in the unaudited Condensed Consolidated Statement of Operations and Comprehensive Loss. The shares in the table below were excluded from the calculation of diluted net loss per share, prior to the use of the treasury stock method, due to their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,593,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,681,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,378,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,971,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,482,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,163,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84NS9mcmFnOmFkNzhiNmM2ZmE1YzQ3NzRiYzJlMDdhZjkzNzUwNWIyL3RleHRyZWdpb246YWQ3OGI2YzZmYTVjNDc3NGJjMmUwN2FmOTM3NTA1YjJfNjkz_fc9e9af9-9052-46f8-92d6-91929d29f09b">The shares in the table below were excluded from the calculation of diluted net loss per share, prior to the use of the treasury stock method, due to their anti-dilutive effect:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,593,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,681,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,378,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,971,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,482,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,163,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic7117791645b42058a5acb1a3ca00398_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84NS9mcmFnOmFkNzhiNmM2ZmE1YzQ3NzRiYzJlMDdhZjkzNzUwNWIyL3RhYmxlOmMzM2U4NDhiYjVhZTQwMDliMjZlZGU0N2JiZjIwNDU1L3RhYmxlcmFuZ2U6YzMzZTg0OGJiNWFlNDAwOWIyNmVkZTQ3YmJmMjA0NTVfMi0xLTEtMS0yMjM1Nw_6373da03-596f-4c08-a79a-299aa7463a71"
      unitRef="shares">509611</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i16a3e0fb50c54a4081eec1b8b2e9d068_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84NS9mcmFnOmFkNzhiNmM2ZmE1YzQ3NzRiYzJlMDdhZjkzNzUwNWIyL3RhYmxlOmMzM2U4NDhiYjVhZTQwMDliMjZlZGU0N2JiZjIwNDU1L3RhYmxlcmFuZ2U6YzMzZTg0OGJiNWFlNDAwOWIyNmVkZTQ3YmJmMjA0NTVfMi0zLTEtMS0yMjM1Nw_fc7746a1-a16c-4946-93d0-60a331773c1f"
      unitRef="shares">509611</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i395ce7f5b8ae45baad50acde1847e4cd_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84NS9mcmFnOmFkNzhiNmM2ZmE1YzQ3NzRiYzJlMDdhZjkzNzUwNWIyL3RhYmxlOmMzM2U4NDhiYjVhZTQwMDliMjZlZGU0N2JiZjIwNDU1L3RhYmxlcmFuZ2U6YzMzZTg0OGJiNWFlNDAwOWIyNmVkZTQ3YmJmMjA0NTVfMy0xLTEtMS0yMjM1Nw_fa940169-c907-43a7-882b-d0e702cf91b8"
      unitRef="shares">11593539</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6b7e133601904c7a84c219de00bcfe1b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84NS9mcmFnOmFkNzhiNmM2ZmE1YzQ3NzRiYzJlMDdhZjkzNzUwNWIyL3RhYmxlOmMzM2U4NDhiYjVhZTQwMDliMjZlZGU0N2JiZjIwNDU1L3RhYmxlcmFuZ2U6YzMzZTg0OGJiNWFlNDAwOWIyNmVkZTQ3YmJmMjA0NTVfMy0zLTEtMS0yMjM1Nw_33b807ef-58d9-46c4-a629-46f4eda57247"
      unitRef="shares">10681764</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i85f449f89e6c4ad9b140a31a285c766d_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84NS9mcmFnOmFkNzhiNmM2ZmE1YzQ3NzRiYzJlMDdhZjkzNzUwNWIyL3RhYmxlOmMzM2U4NDhiYjVhZTQwMDliMjZlZGU0N2JiZjIwNDU1L3RhYmxlcmFuZ2U6YzMzZTg0OGJiNWFlNDAwOWIyNmVkZTQ3YmJmMjA0NTVfNC0xLTEtMS0yMjM1Nw_f8cfb01c-2300-4093-9993-a56efe2fcc82"
      unitRef="shares">5378916</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i56668d4d1ae84d8c98f3182984b4d052_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84NS9mcmFnOmFkNzhiNmM2ZmE1YzQ3NzRiYzJlMDdhZjkzNzUwNWIyL3RhYmxlOmMzM2U4NDhiYjVhZTQwMDliMjZlZGU0N2JiZjIwNDU1L3RhYmxlcmFuZ2U6YzMzZTg0OGJiNWFlNDAwOWIyNmVkZTQ3YmJmMjA0NTVfNC0zLTEtMS0yMjM1Nw_61b1e61b-26b2-4ce3-bd6e-22efa41c6f25"
      unitRef="shares">4971679</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84NS9mcmFnOmFkNzhiNmM2ZmE1YzQ3NzRiYzJlMDdhZjkzNzUwNWIyL3RhYmxlOmMzM2U4NDhiYjVhZTQwMDliMjZlZGU0N2JiZjIwNDU1L3RhYmxlcmFuZ2U6YzMzZTg0OGJiNWFlNDAwOWIyNmVkZTQ3YmJmMjA0NTVfNS0xLTEtMS0yMjM1Nw_3fc79471-7d77-4ff7-9bb1-86ccc7c5bd3a"
      unitRef="shares">17482066</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9abd651243dc4b3888719db25453a613_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84NS9mcmFnOmFkNzhiNmM2ZmE1YzQ3NzRiYzJlMDdhZjkzNzUwNWIyL3RhYmxlOmMzM2U4NDhiYjVhZTQwMDliMjZlZGU0N2JiZjIwNDU1L3RhYmxlcmFuZ2U6YzMzZTg0OGJiNWFlNDAwOWIyNmVkZTQ3YmJmMjA0NTVfNS0zLTEtMS0yMjM1Nw_fa986263-1f50-4a12-a45d-d46b9e8b0656"
      unitRef="shares">16163054</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933753864616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AKEBIA THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-8756903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">245 First Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">871-2098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.00001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AKBA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,960,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001517022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933753022712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 207,204<span></span>
</td>
<td class="nump">$ 228,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39,992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">33,688<span></span>
</td>
<td class="nump">61,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">49,690<span></span>
</td>
<td class="nump">26,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">39,502<span></span>
</td>
<td class="nump">14,877<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">330,084<span></span>
</td>
<td class="nump">371,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7,196<span></span>
</td>
<td class="nump">8,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">23,192<span></span>
</td>
<td class="nump">26,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">55,053<span></span>
</td>
<td class="nump">55,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">117,138<span></span>
</td>
<td class="nump">144,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">69,604<span></span>
</td>
<td class="nump">37,981<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">602,267<span></span>
</td>
<td class="nump">644,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">28,809<span></span>
</td>
<td class="nump">41,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">144,704<span></span>
</td>
<td class="nump">130,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term deferred revenue</a></td>
<td class="nump">15,692<span></span>
</td>
<td class="nump">15,214<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">189,205<span></span>
</td>
<td class="nump">187,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">27,965<span></span>
</td>
<td class="nump">25,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">20,257<span></span>
</td>
<td class="nump">24,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">1,930<span></span>
</td>
<td class="nump">2,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">97,230<span></span>
</td>
<td class="nump">96,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent', window );">Liability related to sale of future royalties, net</a></td>
<td class="nump">51,137<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">77,393<span></span>
</td>
<td class="nump">60,611<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">465,117<span></span>
</td>
<td class="nump">396,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock $0.00001 par value, 25,000,000 shares authorized; 0 shares issued and &#160;&#160; outstanding at September&#160;30, 2021 and December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock $0.00001 par value; 350,000,000 shares authorized at September&#160;30, 2021 and December 31, 2020; 174,551,989 and 148,074,085 shares issued and outstanding at September&#160;30, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,526,815<span></span>
</td>
<td class="nump">1,425,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,389,673)<span></span>
</td>
<td class="num">(1,177,511)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">137,150<span></span>
</td>
<td class="nump">247,618<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 602,267<span></span>
</td>
<td class="nump">$ 644,139<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Arrangement, Royalties Agreement, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933746866904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 04, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">175,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">174,551,989<span></span>
</td>
<td class="nump">148,074,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">174,551,989<span></span>
</td>
<td class="nump">148,074,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933748920168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 48,756<span></span>
</td>
<td class="nump">$ 59,988<span></span>
</td>
<td class="nump">$ 153,973<span></span>
</td>
<td class="nump">$ 238,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of goods sold:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Product</a></td>
<td class="nump">6,933<span></span>
</td>
<td class="nump">24,239<span></span>
</td>
<td class="nump">76,012<span></span>
</td>
<td class="nump">92,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization of intangibles</a></td>
<td class="nump">9,011<span></span>
</td>
<td class="nump">6,106<span></span>
</td>
<td class="nump">27,032<span></span>
</td>
<td class="nump">24,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ProductionRelatedImpairmentsOrChargesIntangibles', window );">Impairment of intangible asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">115,527<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total cost of goods sold</a></td>
<td class="nump">15,944<span></span>
</td>
<td class="nump">30,345<span></span>
</td>
<td class="nump">103,044<span></span>
</td>
<td class="nump">232,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">40,471<span></span>
</td>
<td class="nump">46,857<span></span>
</td>
<td class="nump">118,296<span></span>
</td>
<td class="nump">180,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">46,357<span></span>
</td>
<td class="nump">40,171<span></span>
</td>
<td class="nump">129,336<span></span>
</td>
<td class="nump">113,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LicenseExpense', window );">License expense</a></td>
<td class="nump">870<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="nump">2,460<span></span>
</td>
<td class="nump">2,430<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">87,698<span></span>
</td>
<td class="nump">87,738<span></span>
</td>
<td class="nump">250,092<span></span>
</td>
<td class="nump">296,973<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(54,886)<span></span>
</td>
<td class="num">(58,095)<span></span>
</td>
<td class="num">(199,163)<span></span>
</td>
<td class="num">(291,039)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense</a></td>
<td class="num">(5,085)<span></span>
</td>
<td class="num">(2,274)<span></span>
</td>
<td class="num">(14,853)<span></span>
</td>
<td class="num">(6,554)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">427<span></span>
</td>
<td class="nump">410<span></span>
</td>
<td class="nump">1,854<span></span>
</td>
<td class="nump">1,136<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (59,544)<span></span>
</td>
<td class="num">$ (59,959)<span></span>
</td>
<td class="num">$ (212,162)<span></span>
</td>
<td class="num">$ (296,457)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic (in dollars per share)</a></td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (1.30)<span></span>
</td>
<td class="num">$ (2.18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (1.30)<span></span>
</td>
<td class="num">$ (2.18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares - basic (in shares)</a></td>
<td class="nump">173,782,151<span></span>
</td>
<td class="nump">143,314,729<span></span>
</td>
<td class="nump">163,050,769<span></span>
</td>
<td class="nump">136,230,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of common shares - diluted (in shares)</a></td>
<td class="nump">173,782,151<span></span>
</td>
<td class="nump">143,314,729<span></span>
</td>
<td class="nump">163,050,769<span></span>
</td>
<td class="nump">136,230,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (59,544)<span></span>
</td>
<td class="num">$ (59,959)<span></span>
</td>
<td class="num">$ (212,162)<span></span>
</td>
<td class="num">$ (296,457)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Other comprehensive gain (loss) - unrealized gain (loss) on debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">(59,544)<span></span>
</td>
<td class="num">(59,944)<span></span>
</td>
<td class="num">(212,169)<span></span>
</td>
<td class="num">(296,451)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">36,753<span></span>
</td>
<td class="nump">34,392<span></span>
</td>
<td class="nump">100,120<span></span>
</td>
<td class="nump">94,297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=akba_LicenseCollaborationAndOtherRevenueMember', window );">License, collaboration and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 12,003<span></span>
</td>
<td class="nump">$ 25,596<span></span>
</td>
<td class="nump">$ 53,853<span></span>
</td>
<td class="nump">$ 144,311<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_LicenseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_LicenseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ProductionRelatedImpairmentsOrChargesIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Production Related Impairments Or Charges, Intangibles</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ProductionRelatedImpairmentsOrChargesIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=akba_LicenseCollaborationAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=akba_LicenseCollaborationAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933834591656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Unrealized Gain/(Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,674,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 394,757<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1,188,810<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (794,054)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,973,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of &#160;&#160; issuance costs</a></td>
<td class="nump">56,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Proceeds from sale of stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan', window );">Proceeds from sale of stock under &#160;&#160; employee stock purchase plan</a></td>
<td class="nump">451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">4,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock unit vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">423,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(60,747)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,747)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,251,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">396,364<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,251,164<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(854,801)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,674,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">394,757<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,188,810<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(794,054)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss)</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(296,457)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,328,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">317,962<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,408,466<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(1,090,511)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,674,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 394,757<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,188,810<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(794,054)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">148,074,085<span></span>
</td>
<td class="nump">148,074,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 247,618<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,425,115<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="num">(1,177,511)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,251,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">396,364<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,251,164<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(854,801)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of &#160;&#160; issuance costs</a></td>
<td class="nump">142,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">6,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock unit vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss)</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(175,751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(175,751)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,129,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">370,260<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,400,820<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(1,030,552)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Proceeds from sale of stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan', window );">Proceeds from sale of stock under &#160;&#160; employee stock purchase plan</a></td>
<td class="nump">649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">6,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock unit vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss)</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(59,959)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59,959)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,328,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">$ 317,962<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,408,466<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(1,090,511)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">148,074,085<span></span>
</td>
<td class="nump">148,074,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 247,618<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,425,115<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="num">(1,177,511)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,228,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of &#160;&#160; issuance costs</a></td>
<td class="nump">29,498<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">29,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Proceeds from sale of stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan', window );">Proceeds from sale of stock under &#160;&#160; employee stock purchase plan</a></td>
<td class="nump">367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">5,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock unit vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,063,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss)</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(69,580)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,580)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,520,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 213,891<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,460,971<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="num">(1,247,091)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">148,074,085<span></span>
</td>
<td class="nump">148,074,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 247,618<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,425,115<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="num">(1,177,511)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss)</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (212,162)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="nump">174,551,989<span></span>
</td>
<td class="nump">174,551,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 137,150<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,526,815<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(1,389,673)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,520,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">213,891<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,460,971<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="num">(1,247,091)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,446,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of &#160;&#160; issuance costs</a></td>
<td class="nump">37,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">6,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock unit vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">685,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss)</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(83,038)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83,038)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,651,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">174,631<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,504,752<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(1,330,129)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,730,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of &#160;&#160; issuance costs</a></td>
<td class="nump">16,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Proceeds from sale of stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan', window );">Proceeds from sale of stock under &#160;&#160; employee stock purchase plan</a></td>
<td class="nump">379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">5,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock unit vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (59,544)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59,544)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="nump">174,551,989<span></span>
</td>
<td class="nump">174,551,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 137,150<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1,526,815<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">$ (1,389,673)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value including offering costs employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933746220408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933752542792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (59,544)<span></span>
</td>
<td class="num">$ (69,580)<span></span>
</td>
<td class="num">$ (59,959)<span></span>
</td>
<td class="num">$ (60,747)<span></span>
</td>
<td class="num">$ (212,162)<span></span>
</td>
<td class="num">$ (296,457)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,485<span></span>
</td>
<td class="nump">1,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangibles</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,032<span></span>
</td>
<td class="nump">24,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">115,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium/discount on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome', window );">Non-cash interest expense related to sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,779<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue', window );">Non-cash royalty revenue related to sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(425)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_NoncashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852<span></span>
</td>
<td class="nump">1,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StraightLineRent', window );">Non-cash operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,415)<span></span>
</td>
<td class="num">(1,660)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_FairValueAdjustmentToInventory', window );">Fair value step-up of inventory sold or written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,575<span></span>
</td>
<td class="nump">39,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Write-down of inventory</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,126<span></span>
</td>
<td class="nump">18,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ExcessInventoryPurchaseCommitmentsExpenseReversal', window );">Change in excess inventory purchase commitments</a></td>
<td class="num">(6,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,376<span></span>
</td>
<td class="nump">10,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,099<span></span>
</td>
<td class="nump">18,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(490)<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,837)<span></span>
</td>
<td class="nump">14,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,282)<span></span>
</td>
<td class="nump">6,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,020)<span></span>
</td>
<td class="num">(2,279)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,728<span></span>
</td>
<td class="num">(6,518)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,933)<span></span>
</td>
<td class="nump">3,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,099<span></span>
</td>
<td class="num">(6,072)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,173<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,098<span></span>
</td>
<td class="num">(21,256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(190,157)<span></span>
</td>
<td class="num">(79,606)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of available for sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(99,932)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from the maturities of available for sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,941<span></span>
</td>
<td class="num">(99,687)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties', window );">Proceeds from sale of future royalties, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,783<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts', window );">Proceeds from the issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,799<span></span>
</td>
<td class="nump">198,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from the sale of stock under employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">746<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,328<span></span>
</td>
<td class="nump">201,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,888)<span></span>
</td>
<td class="nump">21,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 231,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,804<span></span>
</td>
<td class="nump">231,132<span></span>
</td>
<td class="nump">149,804<span></span>
</td>
<td class="nump">$ 149,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of the period</a></td>
<td class="nump">$ 209,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,244<span></span>
</td>
<td class="nump">171,720<span></span>
</td>
<td class="nump">$ 231,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_DeferredUnpaidOfferingCosts', window );">Unpaid offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Arrangement, Royalties Agreement, Noncash Interest Expense (Income)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Arrangement, Royalties Agreement, Noncash Royalty Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_DeferredUnpaidOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred unpaid offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_DeferredUnpaidOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ExcessInventoryPurchaseCommitmentsExpenseReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess Inventory Purchase Commitments Expense (Reversal)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ExcessInventoryPurchaseCommitmentsExpenseReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_FairValueAdjustmentToInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Adjustment To Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_FairValueAdjustmentToInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_NoncashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_NoncashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Contractual Arrangement, Royalties Agreement, Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StraightLineRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between actual rental income due and rental income recognized on a straight-line basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StraightLineRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933747293704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Organization and Operations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Organization and Operations</a></td>
<td class="text">Nature of Organization and Operations<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Akebia Therapeutics, Inc., referred to as Akebia or the Company, was incorporated in the State of Delaware in 2007. Akebia is a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease. Akebia&#8217;s lead investigational product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease, or CKD. Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, or HIF-PHI, designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, or HIF, which stimulates erythropoietin, or EPO, production, and can lead to red blood cell, or RBC, production and improved oxygen delivery to tissues. Vadadustat is approved and marketed in Japan as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients under the trade name Vafseo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The Company submitted a New Drug Application, or NDA, to the U.S. Food and Drug Administration, or FDA, for vadadustat in March of 2021 for the treatment of anemia due to CKD in adult patients with CKD on dialysis, or DD-CKD, and adult patients with CKD not on dialysis, or NDD-CKD. The Company's NDA submission was accepted for filing by the FDA in May 2021 and </span><span style="background-color:#ffffff;color:#373737;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">at the time of filing the NDA, the FDA indicated that they were not currently planning to hold an Advisory Committee meeting to discuss the application</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for vadadustat. The FDA also assigned the application standard review and a Prescription Drug User Fee Act (PDUFA) target action date of March 29, 2022. The Company&#8217;s collaboration partner, Otsuka Pharmaceutical Co. Ltd., submitted a Marketing Authorization Application, or MAA, for vadadustat for the treatment of anemia due to CKD in adult patients to the European Medicines Agency, or EMA, in October 2021</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In addition, the Company has a commercial product, Auryxia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (ferric citrate), which is currently approved by the FDA and marketed for two indications in the United States: the control of serum phosphorus levels in DD-CKD adult patients and the treatment of iron deficiency anemia, or IDA, in NDD-CKD adult patients. Ferric citrate is also approved and marketed in Japan as an oral treatment for IDA in adult patients for the improvement of hyperphosphatemia in adult patients with DD-CKD and NDD-CKD under the trade name Riona (ferric citrate hydrate).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has devoted most of its resources to research and development, including its preclinical and clinical development activities, and providing general and administrative support for these operations. The Company began recording revenue from the U.S. sales of Auryxia and revenue from sublicensing rights to Auryxia in Japan from the Company&#8217;s Japanese partners, Japan Tobacco, Inc. and its subsidiary Torii Pharmaceutical Co., Ltd., collectively JT and Torii, on December 12, 2018 following the consummation of a merger with Keryx Biopharmaceuticals, Inc., or Keryx, or the Merger. Additionally, following regulatory approval of vadadustat in Japan, the Company began recognizing royalty revenues from Mitsubishi Tanabe Pharma Corporation, or MTPC, from the sale of Vafseo in August 2020. In February 2021, the Company entered into a royalty interest acquisition agreement with HealthCare Royalty Partners IV, L.P., or the Royalty Agreement, whereby the Company sold its right to receive royalties and sales milestones under its Collaboration Agreement with MTPC, or the MTPC Agreement, subject to certain caps and other terms and conditions (see Note 5 for additional information). The Company has not generated a profit to date and may never generate profits from product sales. Vadadustat and the Company&#8217;s other potential product candidates are subject to long development cycles, and the Company may be unsuccessful in its efforts to develop, obtain marketing approval for or market vadadustat and its other potential product candidates. If the Company does not successfully commercialize Auryxia, vadadustat or any other potential product candidate, if approved, it may be unable to achieve profitability.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s management completed its going concern assessment in accordance with Accounting Standards Codification, or ASC, 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, or ASC 205-40. The Company believes that its cash resources will be sufficient to allow the Company to fund its current operating plan through at least the next twelve months from the filing of this Quarterly Report on Form 10-Q. If the Company receives regulatory approval of vadadustat in the U.S., the Company expects to incur significant incremental costs to its current operating plan to commercialize vadadustat, including costs of marketing, manufacturing and distribution. The potential timely regulatory approval of vadadustat and the receipt of associated regulatory milestones is an important source of funding of the Company's cash runway. However, the Company will require additional funding to fund its operating plan beyond the next twelve months. There are numerous risks and uncertainties associated with research, development and commercialization activities, and actual results could vary materially as a result of a number of factors, many of which are outside of the Company's control. There can be no assurance, however, that the current operating plan will be achieved in the time frame anticipated by the Company, or that its cash resources will fund the Company&#8217;s operating plan for the period anticipated by the Company or that additional funding will be available on terms acceptable to the Company, or at all. The Company will require additional capital to pursue development and commercial activities related to Auryxia and vadadustat or any additional products and product candidates, including those that may be in-licensed or acquired. The Company expects to finance future cash needs through product </span></div>revenue, public or private equity or debt transactions, payments from its collaborators, strategic transactions, or a combination of these approaches. However, additional financing may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise capital in sufficient amounts when needed or on attractive terms, it may not be able to pursue development and commercial activities related to Auryxia and vadadustat or any additional products and product candidates, including those that may be in-licensed or acquired.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933747408840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S., or GAAP, for interim financial reporting and as required by Regulation&#160;S-X, Rule&#160;10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the ASC and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board, or FASB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the unaudited condensed consolidated financial statements have been included. Interim results for the three and nine months ended September&#160;30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending December&#160;31, 2021 or any other future period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Management has determined that the Company operates in&#160;one&#160;segment, which is the business of developing and commercializing novel therapeutics for people with kidney disease. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company&#8217;s consolidated financial statements and the accompanying notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020 filed with the U.S. Securities and Exchange Commission on February 25, 2021, or the 2020 Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies used in preparation of these unaudited condensed consolidated financial statements for the three and nine months ended September&#160;30, 2021 are consistent with those discussed in Note 2 to the consolidated financial statements in the Company&#8217;s 2020 Annual Report on Form 10-K and are updated below as necessary.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Pronouncements &#8211; Recently Adopted</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard became effective for the Company on January 1, 2021. ASU 2019-12 requires certain amendments to be applied using a modified retrospective approach, which requires a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption, while other amendments should be applied on a prospective basis. The adoption of this standard did not have a material impact on the Company&#8217;s unaudited condensed consolidated financial statements and related disclosures.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: prepaid and accrued research and development expense, operating lease assets and liabilities, derivative liabilities, other non-current liabilities, including the excess purchase commitment liability, stock-based compensation expense, product and collaboration revenues including various rebates and reserves related to product sales, non-cash interest expense on the liability related to sale of future royalties, inventories, income taxes, intangible assets and goodwill. The Company has made estimates of the impact of COVID-19 within the unaudited condensed consolidated financial statements and there may be changes to those estimates in future periods including changes to sales, payor mix, reserves and allowances, intangible assets and goodwill. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liability Related to Sale of Future Royalties</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company treats the liability related to sale of future royalties, see Note 5, as a debt financing, amortized under the effective interest rate method over the estimated life of the related expected royalty stream. The liability related to sale of future royalties and the debt amortization are based on the Company&#8217;s current estimates of future royalties expected to be paid over the life of the arrangement. The Company will periodically assess the expected royalty payments. To the extent the Company&#8217;s estimates of future royalty payments are greater or less than previous estimates or the estimated timing of such payments is materially different than previous estimates, the Company will adjust the effective interest rate and recognize related non-cash interest expense on a prospective basis. Non-cash royalty revenue is reflected as royalty revenue within license, collaboration and other revenue, and non-cash amortization of debt is reflected as interest expense in the unaudited condensed consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933752198200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue and Reserves for Variable Consideration<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Product Revenue and Reserves for Variable Consideration</a></td>
<td class="text">Product Revenue and Reserves for Variable Consideration<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company&#8217;s only source of product revenue has been from the U.S. sales of Auryxia. Total net product revenue was $36.8 million and $34.4 million for the three months ended September&#160;30, 2021 and 2020, respectively, and $100.1 million and $94.3 million for the nine months ended September&#160;30, 2021 and 2020, respectively. The following table summarizes activity in each of the product revenue allowance and reserve categories for the nine months ended September&#160;30, 2021 and 2020 (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.047%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks<br/>and Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates, Fees<br/>and other<br/>Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,912&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provisions related to sales in current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments related to prior year sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,590)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,591)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments made</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,593)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,518)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,979)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113,090)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provisions related to sales in current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments related to prior year sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments made</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,701)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,807)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,991)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,869&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,428&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks, discounts and returns are recorded as a direct reduction of revenue on the unaudited condensed consolidated statement of operations with a corresponding reduction to accounts receivable on the unaudited condensed consolidated balance sheets. Rebates, distribution-related fees, and other sales-related deductions are recorded as a reduction in revenue on the unaudited condensed consolidated statement of operations with a corresponding increase to accrued liabilities or accounts payable on the unaudited condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net related to product sales was approximately $22.2 million and $21.9 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933753205464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration and Other Significant Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License, Collaboration and Other Significant Agreements</a></td>
<td class="text">License, Collaboration and Other Significant Agreements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021 and 2020, the Company recognized the following revenues from its license, collaboration and other significant agreements and had the following deferred revenue balances as of September&#160;30, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">License, Collaboration and Other Revenue:</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MTPC Agreement</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otsuka U.S. Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otsuka International Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Proportional Performance Revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,559&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,872&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,687&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,539&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JT and Torii</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MTPC Other Revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total License, Collaboration and Other Revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,003&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,596&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,853&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,311&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-Term</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-Term</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred Revenue:</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MTPC Agreement</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otsuka U.S. Agreement</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otsuka International Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vifor Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,692&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,965&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,657&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the Company&#8217;s contract assets and liabilities during the nine months ended September&#160;30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.047%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>Beginning of<br/>Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at End<br/>of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable(1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,792)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,227)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable(1)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156,209)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(615)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Excludes accounts receivable from other services related to clinical and regulatory activities performed by the Company on behalf of MTPC that are not included in the performance obligations identified under the MTPC Agreement as of September&#160;30, 2021 and 2020 and December&#160;31, 2020 and 2019. Also excludes accounts receivable related to amounts due to the Company from product sales which are included in the accompanying unaudited condensed consolidated balance sheet as of September&#160;30, 2021 and December&#160;31, 2020.</span></div><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021 and 2020, the Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the respective periods (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue Recognized in the Period from:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts included in deferred revenue at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance obligations satisfied in previous periods</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mitsubishi Tanabe Pharma Corporation Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On December 11, 2015, the Company and MTPC entered into a collaboration agreement, or the MTPC Agreement, providing MTPC with exclusive development and commercialization rights to vadadustat in Japan and certain other Asian countries, collectively, the MTPC Territory. In addition, the Company will supply vadadustat for both clinical and commercial use in the MTPC Territory, subject to MTPC&#8217;s option to manufacture commercial drug product in the MTPC Territory. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">A more detailed description of this collaboration agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In February 2021, the Company entered into a royalty interest acquisition agreement with HealthCare Royalty Partners IV, L.P., or the Royalty Agreement, whereby the Company sold its right to receive royalties and sales milestones under the MTPC Agreement, subject to certain caps and other terms and conditions (see Note 5 for additional information). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the elements of the MTPC Agreement in accordance with the provisions of ASC 606 and concluded that the contract counterparty, MTPC, is a customer. The Company&#8217;s arrangement with MTPC contains the following material promises under the contract at inception: (i) license under certain of the Company&#8217;s intellectual property to develop and commercialize vadadustat in the MTPC Territory, (ii) clinical supply of vadadustat, (iii) knowledge transfer, (iv) Phase 2 dosing study research services, and (v) rights to future know-how.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified two performance obligations in connection with its material promises under the MTPC Agreement as follows: (i) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License, Research and Clinical Supply Performance Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and (ii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rights to Future Know-How Performance Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Factors considered in making the assessment of which material promises will be accounted for as separate performance obligations included, among other things, the capabilities of the collaboration partner, whether any other vendor sells the item separately, whether the good or service is highly interdependent or highly interrelated to the other elements in the arrangement, and whether there are other vendors that can provide the items. Additionally, the MTPC Agreement does not include a general right of return.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price to each performance obligation based on the Company&#8217;s best estimate of the relative standalone selling price. The Company developed a best estimate of the standalone selling price for the Rights to Future Know-How Performance Obligation primarily based on the likelihood that additional intellectual property covered by the license conveyed will be developed during the term of the arrangement and determined it is immaterial. As such, the Company did not develop a best estimate of standalone selling price for the License, Research and Clinical Supply Performance Obligation and allocated the entire transaction price to this performance obligation. The deliverables associated with the License, Research and Clinical Supply Performance Obligation were satisfied as of June 30, 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price at inception was comprised of: (i) the up-front payment, (ii) the estimated cost for the Phase 2 studies, (iii) a non-substantive milestone associated with the first patient enrolled in the NDD-CKD Phase 3 study, and (iv) the cost of all clinical supply provided to MTPC for the Phase 3 studies. No other development and no regulatory milestones were included in the transaction price at inception, as all other milestone amounts were fully constrained. Subsequent to inception, the transaction price also included certain development and regulatory milestones, as described below. As part of its evaluation of the constraint, the Company considers numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee&#8217;s efforts.&#160;Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to MTPC and therefore have also been excluded from the transaction price.&#160;The Company re-evaluates the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. The Company determined that the remaining consideration that may be payable to the Company subsequent to MTPC's commercial launch of Vafseo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the third quarter of 2020 is quarterly royalties on net sales, sales milestones, and certain regulatory milestones.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the transaction price was comprised of: (i) the up-front payment of $20.0 million, (ii) the cost for the Phase 2 studies of $20.5 million, (iii) the cost of all clinical supply provided to MTPC for the Phase 3 studies, (iv) $10.0&#160;million in development milestones received, (v) $25.0&#160;million in regulatory milestones received, comprised of $10.0 million relating to the NDA filing in Japan and $15.0 million relating to regulatory approval of vadadustat in Japan, and (vi) $0.9 million in royalties from net sales of Vafseo. As of September&#160;30, 2021, all development milestones and $25.0&#160;million in regulatory milestones have been achieved. No other regulatory milestones have been assessed as probable of being achieved and as a result have been fully constrained. Revenue for the License, Research and Clinical Supply Performance Obligation for the MTPC Agreement is being recognized using a proportional performance method, for which all deliverables have been completed. The Company recognized $0.3 million and $0.4 million of revenue from MTPC royalties for the three and nine months ended September&#160;30, 2021, respectively. The Company recognized a $15.0 million regulatory milestone relating to regulatory approval of vadadustat in Japan as revenue during the nine months ended September&#160;30, 2020. As noted above, in February 2021, the Company entered into the Royalty Agreement, whereby the Company sold its right to receive these royalties and sales milestones under the MTPC Agreement, subject to certain caps and other terms and conditions (see Note 5 for additional information). The revenue is classified as collaboration revenue in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss. As of September&#160;30, 2021, the Company recorded $0.2&#160;million in accounts receivable, no deferred revenue, and no contract assets. There were no asset or liability balances classified as long-term in the unaudited condensed consolidated balance sheet as of September&#160;30, 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supply of Drug Product to MTPC</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, in connection with the MTPC Agreement, the Company and MTPC entered into a letter agreement, pursuant to which the Company agreed to supply MTPC with certain vadadustat process validation drug product for commercial use and MTPC agreed to reimburse the Company for certain manufacturing-related expenses. In connection with this arrangement, the Company invoiced the upfront payment of $10.4 million, which it received during the three months ended June 30, 2020. The Company does not recognize revenue under this arrangement until delivery has occurred and risk of loss passes to MTPC. No revenues were recognized during the three and nine months ended September&#160;30, 2021 and approximately $0.5 million and $4.5 million of revenue was recognized during the three and nine months ended September&#160;30, 2020, respectively, for drug product that was delivered during the applicable period. As of September&#160;30, 2021, the Company recorded no accounts receivable, no deferred revenue, $3.0 million in other current liabilities and $0.4&#160;million in other non-current liabilities for drug product that was subject to return by MTPC.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2020, the Company and its collaboration partner MTPC entered into a supply agreement, or the MTPC Supply Agreement. The MTPC Supply Agreement includes the terms and conditions under which the Company will supply vadadustat drug product to MTPC for commercial use in Japan and certain other Asian countries, as contemplated by the MTPC Agreement. A more detailed description of this supply agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $2.2 million and $6.7 million of revenue under the MTPC Supply Agreement during the three and nine months ended September&#160;30, 2021, respectively. During the nine months ended September&#160;30, 2021, the Company invoiced MTPC for $13.4 million in payments for vadadustat drug product ordered by MTPC. As of September&#160;30, 2021, the Company recorded $4.5 million in accounts receivable, $4.9 million in deferred revenue, $16.3 million in other current liabilities and $5.8 million in other non-current liabilities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Collaboration and License Agreement with Otsuka Pharmaceutical Co. Ltd.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 18, 2016, the Company entered into a collaboration and license agreement with Otsuka, or the Otsuka U.S. Agreement. The collaboration is focused on the development and commercialization of vadadustat in the United States. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Otsuka U.S. Agreement, the Company granted to Otsuka a co-exclusive, non-sublicensable license under certain intellectual property controlled by the Company solely to perform medical affairs activities and to conduct non-promotional and commercialization activities related to vadadustat in the United States in accordance with the associated plans. The co-exclusive license relates to activities that will be jointly conducted by the Company and Otsuka pursuant to the terms of the Otsuka U.S. Agreement. Additionally, the parties agreed not to promote, market or sell any competing product in the territory covered by the Otsuka U.S. Agreement. A more detailed description of this collaboration agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the elements of the Otsuka U.S. Agreement in accordance with the provisions of ASC 606 and concluded that the contract counterparty, Otsuka, is a customer. The Company&#8217;s arrangement with Otsuka contains the following material promises under the contract at inception: (i) license under certain of the Company&#8217;s intellectual property to develop, perform medical affairs activities with respect to and conduct non-promotional and commercialization activities related to vadadustat and products containing or comprising vadadustat, (ii) development services to be performed pursuant to the current global development plan, (iii) rights to future intellectual property, and (iv) joint committee services.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company has identified three performance obligations in connection with its obligations under the Otsuka U.S. Agreement as follows: i) License and Development Services Combined (License Performance Obligation); (ii) Rights to Future Intellectual Property (Future IP Performance Obligation) and (iii) Joint Committee Services (Committee Performance Obligation). Factors considered in making the assessment of which material promises will be accounted for as separate performance obligations included, among other things, the capabilities of the collaboration partner, whether any other vendor sells the item separately, whether the good or service is highly interdependent or highly interrelated to the other elements in the arrangement, and whether there are other vendors that can provide the items. Additionally, the Otsuka U.S. Agreement does not include a general right of return. A more detailed description of the performance obligations under this agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price to each performance obligation based on the Company&#8217;s best estimate of the relative standalone selling price. The Company developed a best estimate of standalone selling price for the Committee Performance Obligation after considering the nature of the services to be performed and estimates of the associated effort and rates applicable to such services that would be expected to be realized under similar contracts. The Company developed a best estimate of standalone selling price for the Future IP Performance Obligation primarily based on the likelihood that additional intellectual property covered by the license conveyed will be developed during the term of the arrangement. The Company did not develop a best estimate of standalone selling price for the License Performance Obligation due to the following: (i) the best estimates of standalone selling price associated with the Future IP Performance Obligation was determined to be immaterial and (ii) the period of performance and pattern of recognition for the License Performance Obligation and the Committee Performance Obligation was determined to be similar. The Company has concluded that a change in the key assumptions used to determine the best estimate of standalone selling price for each performance obligation would not have a significant impact on the allocation of arrangement consideration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price at inception was comprised of: (i) the up-front payment, (ii) the cost share payment with respect to amounts incurred by the Company through December 31, 2016, and (iii) an estimate of the cost share payments to be received with respect to amounts incurred by the Company subsequent to December 31, 2016. No development or regulatory milestones were included in the transaction price at inception, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon success in future clinical trials and the licensee&#8217;s efforts. Any consideration related to sales-based milestones will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Otsuka and therefore have also been excluded from the transaction price.&#160;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company re-evaluates the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. The Company determined that under ASC 606, the contract was modified in the second quarter of 2019 when the Otsuka Funding Option became effective and the Company became eligible to receive the Additional Funding (defined below) amount. In connection with the modification, the Company adjusted the transaction price to include the Additional Funding amount as additional variable consideration. The Company constrains the variable consideration to an amount for which a significant revenue reversal is not probable. In the event that there is consideration received by Otsuka in the form of activities performed by Otsuka under the global development plan, such consideration is reflected as a reduction to the transaction price as contra revenue rather than as an expense because the associated services are not distinct from the License Performance Obligation. The Company estimates the additional funding as a result of exercising the Otsuka Funding Option, or the Additional Funding, to total approximately $139.8 million or more, depending on the actual costs incurred toward the current global development plan. The Additional Funding is fully creditable against future payments due to the Company under the arrangement, provided that future payments due to the Company may not be reduced by more than 50% in any calendar year and any remaining creditable amount above 50% in any calendar year will be applied to subsequent future payments until fully credited. As of September&#160;30, 2021, the Additional Funding was $106.7 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No amounts were allocated to the Future IP Performance Obligation because the associated best estimate of standalone selling price was determined to be immaterial. Due to the similar performance period and recognition pattern between the License Performance Obligation and the Committee Performance Obligation, the transaction price has been allocated to the License Performance Obligation and the Committee Performance Obligation on a combined basis. Accordingly, the Company will </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognize revenue related to the allocable arrangement consideration on a proportional performance basis as the underlying development services are performed pursuant to the current global development plan which is commensurate with the period and consistent with the pattern over which the Company&#8217;s obligations are satisfied for both the License Performance Obligation and the Committee Performance Obligation. Effectively, the Company has treated the arrangement as if the License Performance Obligation and the Committee Performance Obligation are a single performance obligation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the transaction price totaling $504.2 million was comprised of: (i) the up-front payment of $125.0 million, (ii) the cost share payment with respect to amounts incurred by the Company through December 31, 2016 of $33.8 million, and (iii) the estimate of the net cost share consideration to be received of approximately $345.4 million with respect to amounts incurred by the Company subsequent to December 31, 2016. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company is eligible to receive up to $65.0 million in regulatory milestone payments for the first HIF product to achieve the associated event and up to $575 million in commercial milestone payments associated with aggregate sales of licensed products. These future milestones are subject to reduction as a result of the Company's exercise of the Otsuka Funding Option, as described above. As of September&#160;30, 2021, no development or regulatory milestones have been assessed as probable of being reached and thus have been fully constrained.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021 and 2020, the Company recognized revenue totaling approximately $6.1 million and $16.3 million, respectively, and approximately $29.0 million and $80.7 million, during the nine months ended September&#160;30, 2021 and 2020, respectively, with respect to the Otsuka U.S. Agreement. The revenue is classified as collaboration revenue in the accompanying unaudited condensed consolidated statements of operations. As of September&#160;30, 2021, there was approximately $23.0 million of deferred revenue related to the Otsuka U.S. Agreement of which $6.3 million is classified as current and $16.7 million is classified as long-term in the accompanying unaudited condensed consolidated balance sheet based on the performance period of the underlying obligations. Additionally, as of September&#160;30, 2021, there was $2.4 million in accounts receivable and $2.4 million in prepaid expenses and other current assets in the accompanying unaudited condensed consolidated balance sheet. As of December&#160;31, 2020, there was approximately $5.0 million in contract liabilities (included in accounts payable) and $1.2 million in prepaid expenses and other current assets in the consolidated balance sheet.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the medical affairs, commercialization and non-promotional activities elements of the Otsuka U.S. Agreement represent joint operating activities in which both parties are active participants and of which both parties are exposed to significant risks and rewards that are dependent on the success of the activities. Accordingly, the Company is accounting for the joint medical affairs, commercialization and non-promotional activities in accordance with ASC No. 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Additionally, the Company has determined that in the context of the medical affairs, commercialization and non-promotional activities, Otsuka does not represent a customer as contemplated by ASC 606-10-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers &#8211; Scope and Scope Exceptions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As a result, the activities conducted pursuant to the medical affairs, commercialization and non-promotional activities plans will be accounted for as a component of the related expense in the period incurred. During the three months ended September&#160;30, 2021 and 2020, the Company incurred approximately $3.6 million and $1.2 million, respectively, of costs related to the cost-sharing provisions of the Otsuka U.S. Agreement, of which approximately $1.8 million and $0.5 million are reimbursable by Otsuka and recorded as a reduction to research and development expense during the three months ended September&#160;30, 2021 and 2020, respectively. During the three months ended September&#160;30, 2021, Otsuka incurred no costs related to the cost-sharing provisions of the Otsuka U.S. Agreement. During the three months ended September&#160;30, 2020, Otsuka incurred $0.5 million of costs related to the cost-sharing provisions of the Otsuka U.S. Agreement, of which approximately $0.3 million were reimbursable by the Company and recorded as an increase to research and development expense during the three months ended September&#160;30, 2020.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Collaboration and License Agreement with Otsuka Pharmaceutical Co. Ltd.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2017, the Company entered into a collaboration and license agreement with Otsuka, or the Otsuka International Agreement. The collaboration is focused on the development and commercialization of vadadustat in Europe, Russia, China, Canada, Australia, the Middle East and certain other territories, collectively, the Otsuka International Territory. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Otsuka International Agreement, the Company granted to Otsuka an exclusive, sublicensable license under certain intellectual property controlled by the Company to develop and commercialize vadadustat and products containing or comprising vadadustat in the Otsuka International Territory. Additionally, under the terms of this agreement, the Company is responsible for leading the development of vadadustat. Otsuka has the sole responsibility, at its own cost, for the commercialization of vadadustat in the Otsuka International Territory, subject to the approval by the relevant regulatory authorities. A more detailed description of this collaboration agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounted for the Otsuka International Agreement separately from the collaboration arrangement with Otsuka with respect to the U.S. due to the lack of interrelationship and interdependence of the elements and payment terms within each of the contracts as they relate to the respective territories. Accordingly, the Company has applied the guidance in ASC 606 solely in reference to the terms and conditions of the Otsuka International Agreement, while the Otsuka U.S. Agreement has continued to be accounted for as a discrete agreement in its own right. The Company evaluated the Otsuka International Agreement in accordance with the provisions of ASC 606 and concluded that the contract counterparty, Otsuka, is a customer. The Company&#8217;s arrangement with Otsuka related to the Otsuka International Territory contains the following material promises under the contract at inception: (i) license under certain of the Company&#8217;s intellectual property to develop and commercialize (including the associated packaging) vadadustat and products containing or comprising vadadustat and development services to be performed pursuant to the current global development plan, (ii) rights to future intellectual property and (iii) joint committee services.</span></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company has identified three performance obligations in connection with its obligations under the Otsuka International Agreement as follows: i) License and Development Services Combined (License Performance Obligation); (ii) Rights to Future Intellectual Property (Future IP Performance Obligation) and (iii) Joint Committee Services (Committee Performance Obligation). Factors considered in making this assessment of which material promises will be accounted for as a separate performance obligation included, among other things, the capabilities of the collaboration partner, whether any other vendor sells the item separately, whether the good or service is highly interdependent or highly interrelated to the other elements in the arrangement, and whether there are other vendors that can provide the items.&#160;Additionally, the Otsuka International Agreement does not include a general right of return. A more detailed description of the performance obligations under this agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price to each performance obligation based on the Company&#8217;s best estimate of the relative standalone selling price. The Company developed a best estimate of standalone selling price for the Committee Performance Obligation after considering the nature of the services to be performed and estimates of the associated effort and rates applicable to such services that would be expected to be realized under similar contracts. The Company developed a best estimate of standalone selling price for the Future IP Performance Obligation primarily based on the likelihood that additional intellectual property covered by the license conveyed will be developed during the term of the arrangement. The Company did not develop a best estimate of standalone selling price for the License Performance Obligation due to the following: (i) the best estimates of standalone selling price associated with the Future IP Performance Obligation was determined to be immaterial and (ii) the period of performance and pattern of recognition for the License Performance Obligation and the Committee Performance Obligation was determined to be similar. The Company has concluded that a change in the key assumptions used to determine the best estimate of standalone selling price for each performance obligation would not have a significant impact on the allocation of arrangement consideration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price at inception was comprised of: (i) the up-front payment, (ii) the cost share payment with respect to amounts incurred by the Company during the quarter ended March 31, 2017, and (iii) an estimate of the cost share payments to be received with respect to amounts incurred by the Company subsequent to March 31, 2017. No development or regulatory milestones were included in the transaction price at inception, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including whether the receipt of the milestone payment is outside the control of the Company and contingent upon success in future clinical trials and the licensee&#8217;s efforts. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Otsuka and therefore have also been excluded from the transaction price.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company re-evaluates the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. In the event that there is consideration received by a customer in the form of activities performed by such customer under the global development plan, such consideration is reflected as a reduction to the transaction price as contra revenue rather than as an expense because the associated services are not distinct from the License Performance Obligation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the transaction price totaling $310.4 million was comprised of: (i) the up-front payment of $73.0 million, (ii) the cost share payment with respect to amounts incurred by the Company during the quarter ended March 31, 2017 of $0.2 million, and (iii) an estimate of the net cost share consideration to be received with respect to amounts incurred by the Company subsequent to March 31, 2017 of $237.3 million. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, the Company is eligible to receive up to $17.0 million in regulatory milestone payments for the licensed HIF product if the Company achieves the associated event within 12 to 24 months of the first HIF product approval. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company is eligible for up to $525.0 million in commercial milestone payments associated with the aggregate sales of all licensed products. As of September&#160;30, 2021, no development or regulatory milestones have been assessed as probable of being reached and thus have been fully constrained.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021 and 2020, the Company recognized revenue totaling approximately $1.9 million and $7.2 million, respectively, and approximately $13.5 million and $39.4&#160;million, respectively, during the nine months ended September&#160;30, 2021 and 2020, with respect to the Otsuka International Agreement. The revenue is classified as collaboration revenue in the accompanying unaudited condensed consolidated statements of operations. As of September&#160;30, 2021, there was approximately $11.1 million of deferred revenue related to the Otsuka International Agreement of which $4.5 million is classified as current and $6.6 million is classified as long-term in the accompanying unaudited condensed consolidated balance sheet based on the performance period of the underlying obligations. Additionally, as of September&#160;30, 2021, there was $1.1 million in accounts receivable and $1.1 million in prepaid expenses and other current assets in the accompanying unaudited condensed consolidated balance sheet. As of December&#160;31, 2020, there was approximately $2.3 million in contract liabilities (included in accounts payable) and $0.5 million in prepaid expenses and other current assets in the consolidated balance sheet.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Pharmaceutica NV Research and License Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2017, the Company entered into a Research and License Agreement, or the Janssen Agreement, with Janssen Pharmaceutica NV, or Janssen, a subsidiary of Johnson &amp; Johnson, pursuant to which Janssen granted the Company an exclusive license under certain intellectual property rights to develop and commercialize worldwide certain HIF prolyl hydroxylase targeted compounds.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Janssen Agreement, Janssen granted to the Company a license for a three-year research term to conduct research on the HIF compound portfolio, which research term is now expired. During the research term, the Company could designate one or more compounds as candidates for development and commercialization. Once a compound was designated for development and commercialization, the Company was to be solely responsible for the development and commercialization of the compound worldwide at its own cost and expense.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Under the terms of the Janssen Agreement, the Company made an upfront payment of $1.0 million in cash to Janssen and issued a warrant, or the Warrant, to purchase 509,611 shares of the Company&#8217;s common stock with an exercise price of $9.81 per share to Johnson &amp; Johnson Innovation &#8211; JJDC, Inc., or JJDC, an affiliate of Janssen. The Warrant is exercisable by JJDC, in whole or in part, at any time prior to February 9, 2022. The Warrant and the shares issuable upon exercise of the Warrant will be sold and issued without registration under the Securities Act of 1933, as amended, or the Securities Act. The Company recorded the fair value of the Warrant in the amount of $3.4 million to additional paid-in capital and research and development expense in March 2017.&#160;In addition, Janssen is eligible to receive up to an aggregate of $16.5 million from the Company in specified development milestone payments on a product-by-product basis. Janssen is also eligible to receive up to $215.0 million from the Company in specified commercial milestones as well as tiered, escalating royalties ranging from a low- to mid-single digit percentage of net sales, on a product-by-product basis, and subject to reduction upon expiration of patent rights or the launch of a generic product in the territory. A more detailed description of this collaboration agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cyclerion Therapeutics License Agreement</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Summary of Agreement</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 4, 2021, the Company entered into a License Agreement, the Cyclerion Agreement, with Cyclerion Therapeutics Inc., or Cyclerion, pursuant to which Cyclerion granted the Company an exclusive global license under certain intellectual property rights to research, develop and commercialize praliciguat, an investigational oral sGC stimulator.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the Cyclerion Agreement, the Company made an upfront payment of $3.0 million in cash to Cyclerion, which was paid during the second quarter of 2021. Substantially all of the fair value of the assets acquired in conjunction with the Cyclerion Agreement was concentrated in the acquired license. As a result, the Company accounted for this transaction as an asset acquisition under ASU No. 2017-01, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Business Combinations (Topic 805): Clarifying the Definition of a Business</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The upfront payment was charged to expense at acquisition, as it relates to a development stage compound with no alternative future use. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, Cyclerion is eligible to receive up to an aggregate of $222.0 million from the Company in specified development and regulatory milestone payments on a product-by-product basis. Cyclerion will also be eligible to receive specified </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">commercial milestones as well as tiered royalties ranging from a low-single-digit- to mid-double-digit percentage of net sales, on a product-by-product basis, and subject to reduction upon expiration of patent rights or the launch of a generic product in the territory. The Company recorded the upfront payment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">in the amount of $3.0 million to research and development expense in June 2021.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Unless earlier terminated, the Cyclerion Agreement will expire on a product-by-product and country-by-country basis upon the expiration of the last royalty term, which ends upon the longer of the expiration of the patents licensed under the Cyclerion Agreement, the expiration of regulatory exclusivity for such product, or 10 years from first commercial sale of such product. The Company may terminate the Cyclerion Agreement in its entirety or only with respect to a particular licensed compound or product upon 180 days&#8217; prior written notice to Cyclerion. The parties also have customary termination rights, subject to a cure period, in the event of the other party&#8217;s material breach of the Cyclerion Agreement or in the event of certain additional circumstances. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vifor Pharma License Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2017, the Company entered into a License Agreement, or the Vifor Agreement, with Vifor (International) Ltd., or Vifor Pharma, pursuant to which the Company granted Vifor Pharma an exclusive license to sell vadadustat solely to Fresenius Kidney Care Group LLC, or FKC, an affiliate of Fresenius Medical Care North America, or FMCNA, in the United States. On April 8, 2019, the Company and Vifor Pharma entered into an Amended and Restated License Agreement, or the Vifor Amended Agreement, which amended and restated in full the Vifor Agreement. Pursuant to the Vifor Amended Agreement, the Company granted Vifor Pharma an exclusive license to sell vadadustat to FKC and to certain third party dialysis organizations approved by the Company, or Third Party Dialysis Organizations, in the United States. A more detailed description of this collaboration agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the Vifor Agreement, in May 2017, the Company and Vifor Pharma entered into an investment agreement, or the Investment Agreement, pursuant to which the Company sold an aggregate of 3,571,429 shares of the Company&#8217;s common stock, or the Shares, to Vifor Pharma at a price per share of $14.00 for a total of $50.0 million. The amount representing the premium over the closing stock price of $12.69 on the date of the transaction, totaling $4.7 million, was determined by the Company to represent consideration related to the Vifor Agreement.&#160;As the parties&#8217; rights under the Vifor Agreement are conditioned upon (a) the approval of vadadustat for DD-CKD adult patients by the FDA; (b) the earlier of a determination by the Centers for Medicare &amp; Medicaid Services, or CMS, that vadadustat will be reimbursed using Medicare&#8217;s bundled reimbursement model or that vadadustat will be reimbursed using the Transitional Drug Add-On Payment Adjustment; and (c) payment by Vifor Pharma of a $25.0&#160;million milestone upon the occurrence of (a) and (b), in accordance with ASC 606, the Company has determined that the full transaction price is fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including clinical and regulatory risks that must be overcome in order for the parties&#8217; rights to become effective and the probability of the $25.0 million milestone being achieved. Accordingly, the $4.7 million continues to be recorded as deferred revenue in the accompanying unaudited condensed consolidated balance sheets. Upon the satisfaction of the aforementioned conditions, revenue will be recognized as the Company supplies vadadustat to Vifor Pharma using a proportional performance method.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vifor Pharma agreed to a&#160;lock-up&#160;restriction such that it agreed not to sell the Shares for a period of time following the effective date of the Investment Agreement as well as a customary standstill agreement. In addition, the Investment Agreement contains voting agreements made by Vifor Pharma with respect to the Shares. The Shares have not been registered pursuant to the Securities Act, and were issued and sold in reliance upon the exemption from registration contained in Section 4(a)(2) of the Securities Act and Rule 506 promulgated thereunder.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Priority Review Voucher Letter Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 14, 2020, the Company entered into a letter agreement, or the Letter Agreement, with Vifor Pharma relating to Vifor Pharma&#8217;s agreement with a third party to purchase a Priority Review Voucher, or the PRV, issued by the FDA, subject to satisfaction of customary closing conditions, or the PRV Purchase. A PRV entitles the holder to priority review of a New Drug Application, or NDA, or a Biologics License Application for a new drug, which reduces the target FDA review time to six months after official acceptance of the submission, and could lead to expedited approval. Pursuant to the Letter Agreement, Akebia paid Vifor Pharma $10.0 million in connection with the closing of the PRV Purchase. Vifor Pharma is obligated to retain all rights to, and maintain the validity of, the PRV until Akebia and Vifor Pharma (a) enter into a definitive agreement setting forth the financial and other terms by which Vifor Pharma will assign the PRV to Akebia for use with Akebia&#8217;s NDA for </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vadadustat for the treatment of anemia due to CKD in both dialysis-dependent and non-dialysis dependent patients, or (b) make a mutual decision to sell the PRV and share the proceeds based on certain terms. In March of 2021, the Company submitted an NDA for the treatment of anemia due to CKD in both DD-CKD and NDD-CKD adult patients. The Company's NDA submission did not include a PRV. In August 2021, the Company and Vifor Pharma entered into an amendment to the Letter Agreement whereby the parties agreed that Vifor Pharma would sell the PRV to a third party, and the Company and Vifor Pharma will share the proceeds from the sale based on certain terms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended March 31, 2020, the $10.0 million payment to Vifor Pharma was recorded to research and development expense in the unaudited condensed consolidated statement of operations and as an operating cash outflow in the unaudited condensed consolidated statement of cash flows.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Panion&#160;&amp; BF Biotech, Inc.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger, Keryx entered into a license agreement, or the Panion License Agreement, which was amended from time to time, with Panion&#160;&amp; BF Biotech, Inc., or Panion, under which Keryx in-licensed the exclusive worldwide rights, excluding certain Asian-Pacific countries, or the Licensor Territory, for the development and commercialization of ferric citrate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On April&#160;17, 2019,&#160;the Company and Panion&#160;entered into a second amended and restated license agreement, or the Panion Amended License Agreement, which amends and restates in full the Panion License Agreement, effective as of April 17, 2019. The Panion Amended License Agreement provides Keryx with an exclusive license under Panion-owned&#160;know-how&#160;and patents with the right to sublicense, develop, make, use, sell, offer for sale, import and export ferric citrate worldwide, excluding the Licensor Territory. The Panion Amended License Agreement also provides Panion with an exclusive license under the Keryx-owned patents, with the right to sublicense (with the Company&#8217;s written consent), develop, make, use, sell, offer for sale, import and export ferric citrate in certain countries in the Licensor Territory. Under the Panion Amended License Agreement, Panion is eligible to receive from the Company or any sublicensee royalty payments based on a&#160;mid-single&#160;digit percentage of sales of ferric citrate in the Company&#8217;s licensed territories. The Company is eligible to receive from Panion or any sublicensee royalty payments based on a&#160;mid-single&#160;digit percentage of net sales of ferric citrate in Panion&#8217;s licensed territories. A more detailed description of this license agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized royalty payments due to Panion of approximately $3.0 million and $2.9 million during the three months ended September&#160;30, 2021 and 2020, respectively, and $8.3 million and $8.2 million during the nine months ended September&#160;30, 2021 and 2020, respectively, relating to the Company&#8217;s sales of Auryxia in the United States and JT and Torii&#8217;s sales of Riona in Japan, as the Company is required to pay a mid-single digit percentage of net sales of ferric citrate in the Company&#8217;s licensed territories to Panion under the terms of the Panion Amended License Agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sublicense Agreement with Japan Tobacco, Inc. and its subsidiary, Torii Pharmaceutical Co., Ltd.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Merger, the Company has an Amended and Restated Sublicense Agreement, which was amended in June 2013, with JT and Torii, or the JT and Torii Sublicense Agreement, under which Keryx, the Company&#8217;s wholly owned subsidiary, remains the contracting party. Under the JT and Torii Sublicense Agreement, JT and Torii obtained the exclusive sublicense rights for the development and commercialization of ferric citrate hydrate in Japan. JT and Torii are responsible for the future development and commercialization costs in Japan. A more detailed description of this sublicense agreement can be found in Note 4 of the Notes to the Consolidated Financial Statements in the 2020 Annual Report on Form 10-K. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the elements of the JT and Torii Sublicense Agreement in accordance with the provisions of ASC 606 and concluded that the contract counterparty, JT and Torii, is a customer. The Company&#8217;s arrangement with JT and Torii contains the following material promises under the contract at inception: (i) exclusive license to develop and commercialize ferric citrate hydrate in Japan, (ii) supply of ferric citrate hydrate until JT and Torii could secure their own source, (iii) knowledge transfer, and (iv) rights to future know-how. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified two performance obligations in connection with its obligations under the JT and Torii Sublicense Agreement: (i) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Supply Performance Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and (ii) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rights to Future Know-How Performance Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company allocated the transaction price to each performance obligation based on the Company&#8217;s best estimate of the relative standalone selling price. The Company developed a best estimate of the standalone selling price for the Rights to Future Know-How Performance Obligation primarily based on the likelihood that additional intellectual property covered by the license </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conveyed will be developed during the term of the arrangement and determined it immaterial. As such, the Company did not develop a best estimate of standalone selling price for the License and Supply Performance Obligation and allocated the entire transaction price to this performance obligation. Additionally, as of the consummation of the Merger, the services associated with the License and Supply Performance Obligation were completed and JT and Torii had secured their own source to manufacture ferric citrate hydrate. As such, any initial license fees as well as any development-based milestones and manufacturing fee revenue were received and recognized prior to the Merger. The Company determined that the remaining consideration that may be payable to the Company under the terms of the sublicense agreement are either quarterly royalties on net sales or payments due upon the achievement of sales-based milestones. In accordance with ASC 606, the Company recognizes sales-based royalties, including milestone payments based on the level of sales, when the related sales occur as these amounts have been determined to relate predominantly to the license granted to JT and Torii and therefore are recognized at the later of when the performance obligation is satisfied, or the related sales occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized license revenue of $1.4 million and $1.2 million during the three months ended September&#160;30, 2021 and 2020, respectively, and $4.1 million and $4.0 million, respectively, during the nine months ended September&#160;30, 2021 and 2020, respectively, related to royalties earned on net sales of Riona in Japan. The Company records the associated mid-single digit percentage of net sales royalty expense due to Panion, the licensor of Riona, in the same period as the royalty revenue from JT and Torii is recorded.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933842994664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to Sale of Future Royalties<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Liability Related to Sale of Future Royalties</a></td>
<td class="text">Liability Related to Sale of Future Royalties<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2021, the Company entered into the Royalty Agreement with HealthCare Royalty Partners IV, L.P., or HCR, pursuant to which the Company sold to HCR its right to receive royalties and sales milestones for vadadustat in Japan and certain other Asian countries, such countries, collectively, the MTPC Territory, and such payments collectively the Royalty Interest Payments, in each case, payable to the Company under the MTPC Agreement, subject to an annual maximum &#8220;cap&#8221; of $13.0&#160;million, or the Annual Cap, and an aggregate maximum &#8220;cap&#8221; of $150.0&#160;million, or the Aggregate Cap. After HCR receives Royalty Interest Payments equal to the Annual Cap in a given calendar year, the Company will receive 85% of the Royalty Interest Payments for the remainder of that year. After HCR receives Royalty Interest Payments equal to the Aggregate Cap, or the Company pays the Aggregate Cap to HCR (net of the Royalty Interest Payments already received by HCR), the Royalty Interest Payments will revert back to the Company, and HCR would have no further right to any Royalty Interest Payments. The Company received $44.8&#160;million from HCR (net of certain transaction expenses) under the Royalty Agreement, and the Company is eligible to receive an additional $5.0&#160;million in each year from 2021 through 2023 under the Royalty Agreement if specified annual sales milestones are achieved for vadadustat in the MTPC Territory, subject to the satisfaction of certain customary conditions. The Company retains the right to receive all potential future regulatory milestones for vadadustat under the MTPC Agreement. The Royalty Agreement will terminate on the earlier of the date on which HCR has received (i) the last Royalty Interest Payment or (ii) payment by the Company of an amount equal to the Aggregate Cap minus the aggregate amount of all Royalty Interest Payments actually received by HCR.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company sold its right to receive royalties and sales milestones for vadadustat in the MTPC Territory as described above, as a result of its ongoing involvement in the cash flows related to these royalties, the Company will continue to account for these royalties as revenue. The Company recognized the proceeds received from HCR as a liability that is being amortized using the effective interest method over the life of the arrangement. At the transaction date, the Company recorded the net proceeds of $44.8&#160;million as a liability. In order to determine the amortization of the liability, the Company is required to estimate the total amount of future net royalty payments to be made to HCR over the term of the Royalty Agreement. The total threshold of net royalties to be paid, less the net proceeds received, will be recorded as interest expense over the life of the liability. The Company imputes interest on the unamortized portion of the liability using the effective interest method. The annual effective interest rate as of September&#160;30, 2021 was 19.2% which is reflected as interest expense in the unaudited condensed consolidated statements of operations and comprehensive loss. Over the course of the Royalty Agreement, the actual interest rate will be affected by the amount and timing of royalty revenue recognized and changes in forecasted royalty revenue. There are a number of factors that could materially affect the amount and timing of royalty payments from MTPC, none of which are within the Company's control. On a quarterly basis, the Company reassesses the effective interest rate and adjusts the rate prospectively as needed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity within the liability account for the nine months ended September&#160;30, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to sale of future royalties, net &#8212; beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of future royalties, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,783</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MTPC royalties payable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,779</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to sale of future royalties, net &#8212; ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,137&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Royalty Agreement requires the Company to take certain actions, including actions with respect to the Royalty Interest Payments, the MTPC Agreement, the MTPC Supply Agreement, and the Company's intellectual property. The Royalty Agreement also contains certain representations and warranties, covenants, indemnification obligations, events of default and other provisions that are customary for a royalty monetization transaction of this nature. In addition, the Company granted HCR a precautionary security interest in connection with the Royalty Interest Payments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933744830872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available for Sale Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Available for Sale Securities</a></td>
<td class="text">Available For Sale Securities<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and available for sale securities at September&#160;30, 2021 and December&#160;31, 2020 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and available for sale securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,204&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,204&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,992&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and available for sale securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,677&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,690&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no realized gains or losses on available for sale securities for the three and nine months ended September&#160;30, 2021 and 2020 and the Company did not recognize any credit losses during the three and nine months ended September&#160;30, 2021 and 2020. Additionally, the Company did not have any available for sale securities that were in an unrealized loss position as of September&#160;30, 2021 and December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933834570824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value of Financial InstrumentsThe Company utilizes a portfolio management company for the valuation of the majority of its investments. This company is an independent, third-party vendor recognized to be an industry leader with access to market information that obtains or computes fair market values from quoted market prices, pricing for similar securities, recently executed transactions, cash flow models with yield curves and other pricing models. For valuations obtained from the pricing service, the Company performs due <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">diligence to understand how the valuation was calculated or derived, focusing on the valuation technique used and the nature of the inputs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the fair value hierarchy, the Company classifies its cash equivalents and available for sale securities within Level&#160;1 or Level&#160;2. This is because the Company values its cash equivalents and available for sale securities using quoted market prices or alternative pricing sources and models utilizing market observable inputs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets measured or disclosed at fair value on a recurring basis as of September&#160;30, 2021 and December&#160;31, 2020 are summarized below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.047%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.047%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,992&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Loan Agreement with Pharmakon (see Note 11) contains certain provisions that change the underlying cash flows of the debt instrument, including a potential extension to the interest-only period dependent on both (a) no event of default having occurred and continuing and (b) the Company achieving certain regulatory and revenue conditions. The Company also assessed the acceleration of the obligations under the Loan Agreement under an event of default. In addition, under certain circumstances, a default interest rate will apply on all outstanding obligations during the occurrence and continuance of an event of default. In accordance with ASC 815, the Company concluded that these features are not clearly and closely related to the host instrument, and represent a single compound derivative that is required to be re-measured at fair value on a quarterly basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The events of default include maintaining, on an annual basis, a minimum liquidity threshold which started in 2021, and on a quarterly basis, a minimum net sales threshold for Auryxia which started in the fourth quarter of 2020. The Company recorded a derivative liability related to the Company&#8217;s Loan Agreement with Pharmakon of $1.9 million and $2.4 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively. The Company classified the derivative liability as a non-current liability on the unaudited condensed consolidated balance sheet as of September&#160;30, 2021 and December&#160;31, 2020. The estimated fair value of the derivative liability on both September&#160;30, 2021 and December&#160;31, 2020 was determined using a scenario-based approach and discounted cash flow model that includes principal and interest payments under various scenarios involving clinical development success for vadadustat and various cash flow assumptions. Probabilities surrounding clinical development success were derived using industry benchmarks. Should the Company&#8217;s assessment of the probabilities around these scenarios change, including for changes in market conditions, there could be a change to the fair value of the derivative liability.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll-forward of the fair value of the derivative liability (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:81.132%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.668%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability, recorded as other expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability, recorded as other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(570)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability, recorded as other income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no other assets or liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level&#160;3) at September&#160;30, 2021 and December&#160;31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities are exposed to various risks such as interest rate, market and credit risks. When the Company holds investment securities, due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the value of investment securities, the Company considers if changes in risks in the near term would result in material changes in the fair value of investments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933746306904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,409&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,309&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term inventory, which primarily consists of raw materials and work in process, is included in other assets in the Company&#8217;s unaudited condensed consolidated balance sheets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,409&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,309&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory amounts written down as a result of excess, obsolescence, scrap or other reasons and charged to cost of goods sold totaled $1.7 million and $7.1 million during the three and nine months ended September&#160;30, 2021, respectively, and totaled $8.5 million and $18.6 million during the three and nine months ended September&#160;30, 2020, respectively. The decrease in inventory amounts written down for the three and nine months ended September&#160;30, 2021 as compared to the three and nine months ended September&#160;30, 2020 was primarily due to lower write-downs to inventory reserves related to a previously disclosed manufacturing quality issue related to Auryxia during 2020. In addition, there were no related step-up charges during the three months ended September&#160;30, 2021 and $1.4 million related step-up charges during the three months ended September&#160;30, 2020. Related step-up charges were $8.7 million during the nine months ended September&#160;30, 2021 and $7.4 million during the nine months ended September&#160;30, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If future sales of Auryxia are lower than expected, the Company may be required to write-down the value of such inventories. Inventory write-downs and losses on purchase commitments are recorded as a component of cost of sales in the unaudited condensed consolidated statement of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933744799992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text">Intangible Assets and Goodwill<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s intangible assets at September&#160;30, 2021 and December&#160;31, 2020 (in thousands): </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.964%"><tr><td style="width:1.0%"/><td style="width:50.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.376%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.376%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed product rights for Auryxia</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,465)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:45.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ASC 842<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed product rights for Auryxia</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,433)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Favorable lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,148&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,438)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,170&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 12, 2018, the Company completed the Merger, whereby it acquired certain definite-lived intangible assets, including the developed product rights for Auryxia and a favorable lease. The Company amortizes its definite-lived intangible assets acquired as part of the Merger using the straight-line method, which is considered the best estimate of economic benefit, over its estimated useful life of six years. The Company recorded $9.0 million and $6.1 million in amortization expense related to the developed product rights for Auryxia during the three months ended September&#160;30, 2021 and 2020, respectively, and $27.0 million and $24.3 million during the nine months ended September&#160;30, 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill was $55.1 million as of September&#160;30, 2021 and December&#160;31, 2020. The Company operates in one operating segment which the Company considers to be the only reporting unit. Goodwill is evaluated for impairment at the reporting unit level on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstances suggest that an impairment may exist. There were no impairments of goodwill during the three and nine months ended September&#160;30, 2021 or 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933744824088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses as of September&#160;30, 2021 and December&#160;31, 2020 are as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:59.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.401%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue allowances</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts due to collaboration partners</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otsuka PRV contribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNy0wLTEtMS0yMjM1Nw_8a62ce00-dd9c-44ee-980f-eb68f6cf0efd"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNy0wLTEtMS0yMjM1Nw_a0731d02-abdf-4cad-9588-f670833c69ba">Lease liability</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commercial manufacturing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,704&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933746291880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term Loans</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 11, 2019, the Company, with Keryx as guarantor, entered into a loan agreement, or the Loan Agreement, with BioPharma Credit PLC as collateral agent and a lender, or the Collateral Agent, and BioPharma Credit Investments V (Master) LP as a lender, pursuant to which term loans in an aggregate principal amount of $100.0 million were made available to the Company in two tranches, subject to certain terms and conditions, or the Term Loans. BioPharma Credit PLC subsequently transferred its interest in the Term Loans, solely in its capacity as a lender, to its affiliate, BPCR Limited Partnership. The Collateral Agent and the lenders are collectively referred to as Pharmakon. The first tranche of $80.0 million, or Tranche A, was drawn on November&#160;25, 2019, or the Tranche A Funding Date, and the second&#160;tranche of $20.0 million, or Tranche B, was drawn on December 10, 2020, or the Tranche B Funding Date. Each of the Tranche A Funding Date and the Tranche B Funding Date, a Funding Date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from the Term Loans may be used for general corporate purposes. The Company and Keryx entered into a Guaranty and Security Agreement with the Collateral Agent, or the Guaranty and Security Agreement, on the Tranche A Funding Date. Pursuant to the Guaranty and Security Agreement, the Company&#8217;s obligations under the Term Loans are unconditionally guaranteed by Keryx, or the Guarantee. Additionally, the obligations of the Company and Keryx under the Term Loans and the Guarantee are secured by a first priority lien on certain assets of the Company and Keryx, including Auryxia and certain related assets, cash, and certain equity interests held by the Company and Keryx, collectively the Collateral.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loans bear interest at a floating rate per annum equal to the three-month LIBOR rate plus 7.50%, subject to a 2.00% LIBOR floor and a 3.35% LIBOR cap, payable quarterly in arrears. The Term Loans will mature on the fifth anniversary of the Tranche A Funding Date, or the Maturity Date. The Company will repay the principal under the Term Loans in equal quarterly payments starting on the 33rd-month anniversary of the applicable Funding Date or, if certain conditions are met, it will have the option to repay the principal in equal quarterly payments starting on the 48th-month anniversary of the applicable Funding Date, or collectively the Amortization Schedule. Under certain circumstances, unless certain liquidity conditions are met, the Maturity Date may decrease by up to one year, and the Amortization Schedule may correspondingly commence up to one year earlier.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the Tranche A Funding Date,&#160;the Company paid to Pharmakon a facility fee equal to 2.00% of the aggregate principal amount of the Term Loans, or $2.0 million, in addition to other expenses incurred by Pharmakon and reimbursed by the Company, or Lender Expenses. The Tranche A draw was $77.3 million, net of facility fee, Lender Expenses and issuance costs. The Tranche B draw was $20.0&#160;million, net of immaterial Lender Expenses and issuance costs. The Loan Agreement permits voluntary prepayment at any time in whole or in part, subject to a prepayment premium. The prepayment premium would be 2.00% of the principal amount being prepaid prior to the third anniversary of the applicable Funding Date, 1.00% on or after the third anniversary, but prior to the fourth anniversary, of the applicable Funding Date, and 0.50% on or after the fourth anniversary of the applicable Funding Date but prior to the Maturity Date, and a make-whole premium on or prior to the second anniversary of the applicable Funding Date in an amount equal to foregone interest through the second anniversary of the applicable Funding Date. A change of control triggers a mandatory prepayment of the Term Loans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement contains customary representations, warranties, events of default and covenants of the Company and its subsidiaries, including maintaining, on an annual basis, a minimum liquidity threshold which started in 2021, and on a quarterly basis, a minimum net sales threshold for Auryxia which started in the fourth quarter of 2020.&#160;If an event of default occurs and is continuing under the Loan Agreement, the Collateral Agent is entitled to take enforcement action, including acceleration of amounts due under the Loan Agreement. Under certain circumstances, a default interest rate will apply on all outstanding obligations during the occurrence and continuance of an event of default. As of September&#160;30, 2021 and December&#160;31, 2020, the Company determined that no events of default had occurred.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the terms and features of the Loan Agreement in order to identify any potential embedded features that would require bifurcation or any beneficial conversion feature. As part of this analysis, the Company assessed the economic characteristics and risks of the Loan Agreement, including put and call features. The terms and features assessed include a potential extension to the interest-only period dependent on both no event of default having occurred and continuing and the Company achieving certain regulatory and revenue conditions. The Company also assessed the acceleration of the obligations under the Loan Agreement under an event of default. In addition, under certain circumstances, a default interest rate will apply on all outstanding obligations during the occurrence and continuance of an event of default. In accordance with ASC 815, the Company concluded that these features are not clearly and closely related to the host instrument, and represent a single compound derivative that is required to be re-measured at fair value on a quarterly basis.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the derivative liability related to the Company&#8217;s Loan Agreement with Pharmakon was $1.9 million and $2.4 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively. The Company classified the derivative liability as a non-current liability on the unaudited condensed consolidated balance sheet as of September&#160;30, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized interest expense related to the Loan Agreement of $2.7 million and $2.2 million, respectively, during the three months ended September&#160;30, 2021 and 2020, and $8.1 million and $6.6 million for the first nine months ended September&#160;30, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933744808056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_WarrantDisclosureTextBlock', window );">Warrant</a></td>
<td class="text">WarrantIn connection with the Janssen Agreement, in February 2017, the Company issued a warrant to purchase 509,611 shares of the Company&#8217;s common stock at an exercise price of $9.81 per share. The warrant was fully vested upon issuance and exercisable in whole or in part, at any time prior to February 9, 2022. The warrant satisfied the equity classification criteria of ASC 815, and is therefore classified as an equity instrument. The fair value at issuance of $3.4 million was calculated using the Black Scholes option pricing model and was charged to research and development expense as it represented consideration for a license for which the underlying intellectual property was deemed to have no alternative future use. As of September&#160;30, 2021, the warrant remains outstanding and expires on February&#160;9, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_WarrantDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_WarrantDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933744796424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Authorized and Outstanding Capital Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 5, 2020, the Company filed a Certificate of Amendment to its Ninth Amended and Restated Certificate of Incorporation, or its Charter, to increase the number of authorized shares of common stock from 175,000,000 to 350,000,000. As of September&#160;30, 2021, the authorized capital stock of the Company included 350,000,000 shares of common stock, par value $0.00001 per share, of which 174,551,989 and 148,074,085 shares were issued and outstanding as of September&#160;30, 2021 and December&#160;31, 2020, respectively; and 25,000,000 shares of undesignated preferred stock, par value $0.00001 per share, of which no shares were issued and outstanding as of September&#160;30, 2021 and December&#160;31, 2020.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market Facility</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 12, 2019, the Company entered into an Amended and Restated Controlled Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement with Cantor Fitzgerald &amp; Co. for the offer and sale of common stock at the then current market prices in amounts to be determined from time to time. Also, on November 12, 2019, the Company filed a prospectus supplement pursuant to which it was able to offer and sell under the sales agreement up to $75.0 million of its common stock at the then current market prices from time to time. Through December 31, 2019, the Company sold 2,684,392 shares of common stock under this program with net proceeds (after deducting commissions and other offering expenses) of $16.8 million. During the three months ended March 31, 2020, the Company sold 7,973,967 shares of common stock under this program with net proceeds (after deducting commissions and other offering expenses) of $56.7 million. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2020, the Company filed a prospectus supplement relating to the sales agreement, pursuant to which it was able to offer and sell up to $65.0 million of its common stock at current market prices from time to time. Through December&#160;31, 2020, the Company sold 3,509,381 shares of common stock under this program with net proceeds (after deducting commissions and other offering expenses) of $10.6&#160;million. During the three months ended March 31, 2021, the Company sold 5,224,278 shares of common stock under this program with net proceeds (after deducting commissions and other offering expenses) of $15.9&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2021, the Company filed a prospectus relating to the sales agreement with its new shelf registration statement (which replaced the prior shelf registration statement and the sales agreement prospectus supplement), pursuant to which it is able to offer and sell up to $100.0&#160;million of its common stock at current market prices from time to time. During the three and nine months ended September&#160;30, 2021 and through the date of this Quarterly Report on Form 10-Q, the Company sold 4,730,466 and 19,180,365 shares of common stock under this program with net proceeds (after deducting commissions and other offering expenses) of $16.1 million and $67.2 million, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Plans</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains one stock incentive plan, the 2014 Incentive Plan, or the 2014 Plan, as well as the 2014 Employee Stock Purchase Plan, or the 2014 ESPP. The 2014 Plan replaced the Company&#8217;s Amended and Restated 2008 Equity Incentive Plan, or the 2008 Plan, however, options or other awards granted under the 2008 Plan prior to the adoption of the 2014 Plan that have not been settled or forfeited remain outstanding and effective. On June 6, 2019, the Company&#8217;s shareholders approved the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amended and Restated 2014 Employee Stock Purchase Plan, or the ESPP. The Company also maintains an inducement award program that is separate from the Company's equity plans under which inducement awards may be granted consistent with Nasdaq Listing Rule 5635(c)(4). During the nine months ended September&#160;30, 2021, the Company granted 1,228,200 options to purchase shares of the Company&#8217;s common stock to new hires as inducements material to such employees' entering into employment with the Company, of which 1,154,200 options remained outstanding as of September&#160;30, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2014 Plan allows for the granting of stock options, stock appreciation rights, or SARs, restricted stock, unrestricted stock, RSUs, performance awards and other awards convertible into or otherwise based on shares of the Company&#8217;s common stock. Dividend equivalents may also be provided in connection with an award under the 2014 Plan. The Company&#8217;s employees, officers, directors and consultants and advisors are eligible to receive awards under the 2014 Plan. The Company initially reserved 1,785,000 shares of its common stock for the issuance of awards under the 2014 Plan. The 2014 Plan provides that the number of shares reserved and available for issuance under the 2014 Plan will automatically increase annually on January&#160;1 of each calendar year, by an amount equal to three percent (3%)&#160;of the number of Akebia Shares (as defined in Note 1 of the 2020 Annual Report on Form 10-K) outstanding on a fully diluted basis as of the close of business on the immediately preceding December&#160;31, or the 2014 Plan Evergreen Provision. The Company&#8217;s Board of Directors may act prior to January&#160;1 of any year to provide that there will be no automatic increase in the number of Akebia Shares available for grant under the 2014 Plan for that year (or that the increase will be less than the amount that would otherwise have automatically been made). On December 12, 2018, in connection with the consummation of the Merger, the Company assumed outstanding and unexercised options to purchase Keryx Shares (as defined in Note 1 of the 2020 Annual Report on Form 10-K), as adjusted by the Exchange Multiplier pursuant to the terms of the Merger Agreement, under the following Keryx equity plans, or the Keryx Equity Plans: the Keryx 1999 Share Option Plan, the Keryx 2004 Long-Term Incentive Plan, the Keryx 2007 Incentive Plan, the Keryx Amended and Restated 2013 Incentive Plan, and the Keryx 2018 Equity Incentive Plan, or the Keryx 2018 Plan. In addition, the number of Keryx Shares available for issuance under the Keryx 2018 Plan, as adjusted by the Exchange Multiplier pursuant to the terms of the Merger Agreement, may be used for awards granted by the Company under its 2014 Plan, or the Assumed Shares, provided that the Company uses the Assumed Shares for individuals who were not employees or directors of the Company prior to the consummation of the Merger.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants annual service-based stock options to employees under the 2014 Plan. During the nine months ended September&#160;30, 2021, the Company issued 1,997,200 options to employees. In addition, the Company issues stock options </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to directors, new hires and occasionally to other employees not in connection with the annual grant process. During the nine months ended September&#160;30, 2021, the Company issued 200,800 options to directors under the 2014 Plan. Options granted by the Company vest over periods of between 12 and 48 months, subject, in each case, to the individual&#8217;s continued service through the applicable vesting date. Options vest either 100% on the first anniversary of the grant date or in installments of (i) 25% at the one year anniversary and (ii) 12 equal quarterly installments beginning after the one year anniversary of the grant date, subject to the individual&#8217;s continuous service with the Company. Options generally expire 10 years after the date of grant.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also grants performance-based stock options to employees under the 2014 Plan.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The performance-based stock options granted by the Company vest in connection with the achievement of specified commercial and regulatory milestones. The performance-based stock options also feature a time-based vesting component. The expense recognized for these awards is based on the grant date fair value of the Company&#8217;s common stock multiplied by the number of options granted and recognized over time based on the probability of meeting such commercial and regulatory milestones.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company issued 99,558 performance-based stock options during the nine months ended September&#160;30, 2021.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company also grants annual service-based restricted stock units, or RSUs to employees under the 2014 Plan. During the nine months ended September&#160;30, 2021, the Com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">pany issued 3,396,012 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">RSUs to employees. In addition, the Company issued 82,200 RSUs to directors under the 2014 Plan during the nine months ended September&#160;30, 2021. The Company also occasionally issues RSUs not in connection with the annual grant process to employees. Generally, RSUs granted by the Company vest in one of the following ways: (i) 100% of each RSU grant vests on either the first anniversary of the grant date, (ii) one third of each RSU grant vests on the first, second and third anniversaries of the grant date, or (iii) 50% of each RSU grant vests on the first anniversary and 25% of each RSU grant vests every six months after the one year anniversary of the grant date, subject, in each case, to the individual&#8217;s continued service through the applicable vesting date. The expense recognized for these awards is based on the grant date fair value of the Company&#8217;s common stock multiplied by the number of units granted and recognized on a straight-line basis over the vesting period. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company also grants performance-based restricted stock units, or PSUs to employees under the 2014 Plan. The PSUs granted by the Company vest in connection with the achievement of specified commercial and regulatory milestones. The PSUs also feature a time-based vesting component. The expense recognized for these awards is based on the grant date fair value of the Company&#8217;s common stock multiplied by the number of units granted and recognized over time based on the probability of meeting such commercial and regulatory milestones.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> The Company issued 37,150 PSUs during the nine months ended September&#160;30, 2021.</span></div>The ESPP provides for the issuance of options to purchase shares of the Company&#8217;s common stock to participating employees at a discount to their fair market value. As noted above, the Company&#8217;s stockholders approved the ESPP, which amended and restated the Company&#8217;s 2014 ESPP, on June 6, 2019. As of September&#160;30, 2021, the maximum aggregate number of shares of the Company&#8217;s common stock available for future issuance under the ESPP is 5,173,141. Under the ESPP, each offering period is six months, at the end of which employees who elect to purchase shares of the Company&#8217;s common stock through payroll deductions made over the term of the offering. The per-share purchase price at the end of each offering period is equal to the lesser of eighty-five percent (85%) of the closing price of the Company&#8217;s common stock at the beginning or end of the offering period. The Company issued 307,193 shares under the ESPP during the nine months ended September&#160;30, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933746321544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately 65,167 square feet of office and lab space in Cambridge, Massachusetts under a lease which was most recently amended in November 2020, collectively the Cambridge Lease. Under the Third Amendment to the Cambridge Lease, or the Third Amendment, executed in July 2016, total monthly lease payments under the initial base rent were approximately $242,000 and are subject to annual rent escalations.&#160;In addition to such annual rent escalations, base rent payments for a portion of said premises commenced on January 1, 2017 in the monthly amount of approximately $22,000. The Fourth Amendment to the Cambridge Lease, executed in May 2017, provided additional storage space to the Company and did not impact rent payments. In April 2018, the Company entered into a Fifth Amendment to the Cambridge Lease, or the Fifth Amendment, for an additional 19,805 square feet of office space on the 12t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">h</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> floor. Monthly lease payments for the existing 45,362 square feet of office and lab space, under the Third Amendment, remain unchanged. The new space leased by the Company was delivered in September 2018 and additional monthly lease payments of approximately $135,000 commenced in February 2019 and are subject to annual rent escalations, which commenced in September 2019. In November 2020, the Company entered into a Sixth Amendment to the Cambridge Lease, or the Sixth Amendment, to extend the term of the Cambridge Lease with respect to the lab space from November 30, 2021 to January 31, 2025. The Sixth Amendment includes two months of free rent starting in December 2020 and additional monthly lease payments of approximately $48,000 commencing in December 2021, and is subject to annual rent escalations, which commence in December 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, as a result of the Merger, the Company has a lease for 27,300 square feet of office space in Boston, Massachusetts, or the Boston Lease, which expires in February 2023. The total monthly lease payments under the base rent are approximately $136,000 and are subject to annual rent escalations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Cambridge Lease with respect to the office space expires on September&#160;11, 2026, with one five-year extension option available. The term of the Boston Lease office space expires on February&#160;28, 2023, with an extension option for one additional five-year term available. The renewal options in these real estate leases were not included in the calculation of the operating lease assets and operating lease liabilities as the renewal is not reasonably certain. The term of the Cambridge Lease with respect to the lab space expires on January&#160;31, 2025, with an extension option for one additional period through September&#160;11, 2026. The renewal option in this real estate lease was included in the calculation of the operating lease assets and operating lease liabilities as the renewal is reasonably certain. The lease agreements do not contain residual value guarantees. Operating lease costs were $1.7 million for each of the three months ended September&#160;30, 2021 and 2020 and $5.0 million for each of the nine months ended September&#160;30, 2021 and 2020. Cash paid for amounts included in the measurement of operating lease liabilities was $1.8 million for each of the three months ended September&#160;30, 2021 and 2020 and $5.3 million for each of the nine months ended September&#160;30, 2021 and 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, Keryx entered into an agreement to sublease the Boston office space to Foundation Medicine, Inc., or Foundation. The sublease is subject and subordinate to the Boston Lease between Keryx and the landlord. The term of the sublease commenced on October&#160;16, 2019, upon receipt of the required consent from the landlord for the sublease agreement, and expires on February&#160;27, 2023. Foundation is obligated to pay Keryx rent that approximates the rent due from Keryx to its landlord with respect to the Boston Lease. Sublease rental income is recorded to other income. Keryx continues to be obligated for all payment terms pursuant to the Boston Lease, and the Company will guaranty Keryx&#8217;s obligations under the sublease. Keryx recorded $0.4 million in sublease rental income from Foundation during each of the three months ended September&#160;30, 2021 and 2020 and $1.3 million during each of the nine months ended September&#160;30, 2021 and 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not entered into any material short-term leases or financing leases as of September&#160;30, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total security deposit in connection with the Cambridge Lease is $1.6 million as of September&#160;30, 2021. Additionally, the Company recorded $0.4 million for the security deposit under the Boston Lease. Both the Cambridge Lease and the Boston Lease have their security deposits in the form of a letter of credit, all of which are included as restricted cash in other assets in the Company&#8217;s unaudited condensed consolidated balance sheets as of September&#160;30, 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, undiscounted minimum rental commitments under non-cancelable leases, for each of the next five years and total thereafter are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Payments<br/>to be Received<br/>from Sublease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Operating<br/>Lease Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,706&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,585&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,121&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arriving at the operating lease liabilities, the Company applied incremental borrowing rates ranging from 6.22% to 6.94%, which were based on the remaining lease term at either the date of adoption of ASC 842 or the effective date of any subsequent lease term extensions. As of September&#160;30, 2021, the remaining lease terms ranged from 1.41 years to 4.95 years. As of September&#160;30, 2021, the following represents the difference between the remaining undiscounted minimum rental commitments under non-cancelable leases and the operating lease liabilities:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:81.330%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating <br/>Leases</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undiscounted minimum rental commitments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value adjustment using incremental borrowing rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,380)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOmY2NDc1MWJlODBmNTRjOTY4ZDg5NTUxMjc1NTZjNDVjL3RhYmxlcmFuZ2U6ZjY0NzUxYmU4MGY1NGM5NjhkODk1NTEyNzU1NmM0NWNfNC0wLTEtMS0yMjM1Nw_6f24d764-2b2d-4991-9474-8d0770053a51">Operating lease liabilities</span></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,326&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing Agreements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Merger, the Company's contractual obligations include Keryx&#8217;s commercial supply agreements with BioVectra Inc., or BioVectra, and Siegfried Evionnaz SA, or Siegfried, to supply commercial drug substance for Auryxia.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the Manufacture and Supply Agreement with BioVectra and the Product Manufacture and Supply and Facility Construction Agreement with BioVectra, collectively the BioVectra Agreement, the Company agreed to purchase minimum quantities of Auryxia drug substance annually at predetermined prices. On September 4, 2020, the Company and BioVectra entered into an Amended and Restated Product Manufacture and Supply and Facility Construction Agreement, which provided for reduced minimum quantity commitments and revised the predetermined prices. The price per kilogram decreases with an increase in quantity above the predetermined purchase quantity tiers. In addition, the Manufacture and Supply Agreement with BioVectra and the Amended and Restated Product Manufacture and Supply and Facility Construction Agreement with BioVectra, collectively the Amended BioVectra Agreement, requires the Company to reimburse BioVectra for certain costs in connection with construction of a new facility for the manufacture and supply of Auryxia drug substance. These construction costs are recorded in other assets and amortized into drug substance as inventory is released to the Company from BioVectra. The term of the Manufacture and Supply Agreement with BioVectra expires on December 31, 2022. The term of the Amended and Restated Product Manufacture and Supply and Facility Construction Agreement expires on December 31, 2026, after which it automatically renews for successive one-year terms unless either party gives notice of its intention to terminate within a specified time prior to the end of the then-current term. In addition, the Company and BioVectra each have the ability to terminate these agreements upon the occurrence of certain conditions. As of September&#160;30, 2021, the Company is required to reimburse BioVectra for certain costs in connection with the construction of the new facility and to purchase minimum quantities of Auryxia drug substance annually for a total cost of approximately $82.9 million through the end of the contract term.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the Siegfried Master Manufacturing Services and Supply Agreement, as amended (the most recent amendment having been executed on February 11, 2021), or the Siegfried Agreement, the Company has agreed to purchase a minimum quantity of drug substance of Auryxia at predetermined prices. The term of the Siegfried Agreement expires on December&#160;31, 2022, subject to our option to extend the term through December 31, 2023 by providing 12 months&#8217; prior written notice to Siegfried. The Siegfried Agreement provides the Company and Siegfried with certain early termination rights. As of </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September&#160;30, 2021, the Company is required to purchase a minimum quantity of drug substance for Auryxia annually at a total cost of approximately $27.7 million through the year ending December 31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of purchase accounting, the Company identified executory contracts in the commercial supply agreements between Keryx and its contract manufacturers for Auryxia, which include future firm purchase commitments. These executory contracts were deemed to have an off-market element related to the amount of purchase commitments that exceed the current forecast. The Company regularly reviews its estimate of the excess purchase commitment liability including a review of assumptions of expected future demand, estimates of anticipated expiry of inventory under firm purchase commitments that are estimated to expire before they could be sold as well as any modifications to supply agreements during each reporting period. The excess purchase commitment liability relating to these executory contracts was $71.2 million and $55.8 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively. During the quarter ended September 30, 2021, the Company reviewed the detailed assumptions above and recorded a $6.0 million reduction to the excess purchase commitments liability within cost of goods sold. The reduction to the excess purchase commitments liability was primarily due to the settlement of all patent litigation proceedings related to Abbreviated New Drug Applications filed with respect to Auryxia, which allows for generic versions of Auryxia beginning in March 2025. The Company recognized this non-cash gain in accordance with ASC 270 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interim Reporting, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">specifically ASC 270-10-45-6(c) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other Presentation Matters, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">which allows for recovery of losses on the same inventory in later interim periods of the same fiscal year as long as the as long as the recovery of losses does not exceed the previously recognized loss. During the quarter ended June 30, 2021, the Company completed a routine update of its long-range plan and related estimates of expiry. This routine update included the impact of recent activity with regards to our long-term payor contract strategy which continues to focus on contract economics and net revenue growth and resulted in a $30.3 million charge to cost of goods sold during the quarter ended June&#160;30, 2021. In addition, as of June&#160;30, 2021, the Company also considered whether this increase was a potential indicator of impairment of the Auryxia asset group as of June&#160;30, 2021. As part of its assessment, the Company reviewed the Auryxia net sales and estimated future cash flows included in its long-range plan and concluded that the increase in excess purchase commitment liability was not an indicator of impairment of the Auryxia asset group as of June&#160;30, 2021. In addition, during the first quarter ended March 31, 2021, the Company recorded a non-cash gain to cost of goods sold of $9.0 million driven largely by a reduction in purchase commitments due to the amendment to the Siegfried Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 9, 2019, the Company entered into a Supply Agreement with Esteve Qu&#237;mica, S.A., or Esteve, or the Esteve Agreement. The Esteve Agreement includes the terms and conditions under which Esteve will manufacture vadadustat drug substance for commercial use. Pursuant to the Esteve Agreement, the Company provides rolling forecasts to Esteve on a quarterly basis, or the Esteve Forecast. The Esteve Forecast reflects the Company&#8217;s needs for vadadustat drug substance produced by Esteve over a certain number of months, represented as a quantity of vadadustat drug substance per calendar quarter. The parties have agreed to a volume-based pricing structure under the Esteve Agreement. The Esteve Agreement has an initial term of four years, beginning April 9, 2019 and ending April 9, 2023. Pursuant to the Esteve Agreement, the Company has agreed to purchase a certain percentage of the global demand for vadadustat drug substance from Esteve. As of September&#160;30, 2021, the Company has committed to purchase $34.4 million of vadadustat drug substance from Esteve through the fourth quarter of 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On March 11, 2020, the Company entered into a Supply Agreement with Patheon Inc., or Patheon, or the Patheon Agreement. The Patheon Agreement includes the terms and conditions under which Patheon will manufacture vadadustat drug product for commercial use. Pursuant to the Patheon Agreement, the Company provides Patheon a long-term forecast on an annual basis, as well as short-term forecasts on a quarterly basis, or the Patheon Forecast. The Patheon Forecast reflects the Company&#8217;s needs for commercial supply of vadadustat drug product produced by Patheon, represented as a quantity of drug product per calendar quarter. The parties have agreed to a volume-based pricing structure under the Patheon Agreement. The Patheon Agreement has an initial term beginning March 11, 2020 and ending June 30, 2023. Pursuant to the Patheon Agreement, the Company has agreed to purchase a certain percentage of the global demand for vadadustat drug product from Patheon. As of September&#160;30, 2021, the Company had a minimum commitment with Patheon for $4.2 million through the third quarter of 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On April 2, 2020, the Company entered into a Supply Agreement with STA Pharmaceutical Hong Kong Limited, a subsidiary of WuXi AppTec, or WuXi STA, as amended on April 15, 2021, or the WuXi STA DS Agreement. The WuXi STA DS Agreement includes the terms and conditions under which WuXi STA will manufacture vadadustat drug substance for commercial use. Pursuant to the WuXi STA DS Agreement, the Company provides rolling forecasts to WuXi STA on a quarterly basis, or the WuXi STA DS Forecast. The WuXi STA DS Forecast reflects the Company&#8217;s needs for vadadustat drug substance produced by WuXi STA over a certain number of quarters. The parties have agreed to a volume-based pricing structure under the WuXi STA DS Agreement. The WuXi STA DS Agreement has an initial term of four years, beginning April 2, 2020 and ending April 2, 2024.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Pursuant to the WuXi STA DS Agreement, the Company has agreed to purchase a certain percentage of the global demand for vadadustat drug substance from WuXi STA. As of September&#160;30, 2021, the Company has committed to purchase $44.8 million of vadadustat drug substance from WuXi STA through the end of 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On February 10, 2021, the Company entered into a Supply Agreement with WuXi STA, or the WuXi STA DP Agreement. The WuXi STA DP Agreement includes the terms and conditions under which WuXi STA will manufacture and supply vadadustat </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">drug product for commercial purposes. Pursuant to the WuXi STA DP Agreement, the Company will provide rolling forecasts to WuXi STA on a quarterly basis, or the WuXi STA DP Forecast. Each WuXi STA DP Forecast will reflect the quantities of vadadustat drug product that the Company expects to order from WuXi STA over a certain number of months, represented as a quantity of vadadustat drug product per calendar quarter. Pursuant to the WuXi STA DP Agreement, the Company has agreed to purchase a certain percentage of global demand for vadadustat drug product from WuXi STA. The parties have agreed to a volume-based pricing structure under the WuXi STA DP Agreement. The vadadustat drug product price will remain fixed for the first 12 months and thereafter shall be annually reviewed by the Company and WuXi STA. The Company will also reimburse WuXi STA for certain reasonable expenses. The WuXi STA DP Agreement has an initial term of four years, beginning February 10, 2021 and ending February 10, 2025. The WuXi STA DP Agreement may be renewed or extended by mutual agreement of the Company and WuXi STA with at least 18 months&#8217; prior written notice. The WuXi STA DP Agreement allows the Company to terminate the agreement on 180 calendar days&#8217; prior written notice to WuXi STA for any reason. In addition, each party has the ability to terminate the WuXi STA DP Agreement upon the occurrence of certain conditions.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Third Party Contracts</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s agreement with IQVIA to provide contract research organization services for the PRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TECT and INNO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VATE programs, the total remaining contract costs as of September&#160;30, 2021 were approximately $7.6 million, of which Otsuka reimburses a significant portion back to the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantive performance for the committed work with IQVIA was completed in 2020 and close out activities will be performed throughout 2021. The Company also contracts with various other organizations to conduct research and development activities with remaining contract costs to the Company of approximately $244.4 million at September&#160;30, 2021. The scope of the services under these research and development contracts can be modified and the contracts cancelled by the Company upon written notice. In some instances, the contracts may be cancelled by the third party upon written notice.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation and Related Matters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become subject to legal proceedings and claims which arise in the ordinary course of its business. Consistent with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company&#8217;s policy is to record a liability if a loss in a significant legal dispute is considered probable and an amount can be reasonably estimated. The Company provides disclosure when a loss in excess of any reserve is reasonably possible, and if estimable, the Company discloses the potential loss or range of possible loss. Significant judgment is required to assess the likelihood of various potential outcomes and the quantification of loss in those scenarios. The Company&#8217;s estimates change as litigation progresses and new information comes to light. Changes in Company estimates could have a material impact on the Company&#8217;s results and financial position. As of September&#160;30, 2021, the Company does not have any significant legal disputes that require a loss liability to be recorded. The Company continually monitors the need for a loss liability for litigation and related matters.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933744966936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">Net Loss per Share<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the diluted net loss per share calculation, preferred stock, stock options, warrants, restricted stock and RSUs are considered to be common stock equivalents and have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for periods presented. Therefore, basic and diluted net loss per share were the same for all periods presented in the unaudited Condensed Consolidated Statement of Operations and Comprehensive Loss. The shares in the table below were excluded from the calculation of diluted net loss per share, prior to the use of the treasury stock method, due to their anti-dilutive effect:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,593,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,681,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,378,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,971,679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,482,066&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,163,054&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933746107688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S., or GAAP, for interim financial reporting and as required by Regulation&#160;S-X, Rule&#160;10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the ASC and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board, or FASB.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text">In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the unaudited condensed consolidated financial statements have been included. Interim results for the three and nine months ended September&#160;30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending December&#160;31, 2021 or any other future period.The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements - Recently Adopted</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Pronouncements &#8211; Recently Adopted</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard became effective for the Company on January 1, 2021. ASU 2019-12 requires certain amendments to be applied using a modified retrospective approach, which requires a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption, while other amendments should be applied on a prospective basis. The adoption of this standard did not have a material impact on the Company&#8217;s unaudited condensed consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: prepaid and accrued research and development expense, operating lease assets and liabilities, derivative liabilities, other non-current liabilities, including the excess purchase commitment liability, stock-based compensation expense, product and collaboration revenues including various rebates and reserves related to product sales, non-cash interest expense on the liability related to sale of future royalties, inventories, income taxes, intangible assets and goodwill. The Company has made estimates of the impact of COVID-19 within the unaudited condensed consolidated financial statements and there may be changes to those estimates in future periods including changes to sales, payor mix, reserves and allowances, intangible assets and goodwill. </span></div>Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractualArrangementRoyaltiesAgreementLiabilityPolicyPolicyTextBlock', window );">Liability Related to Sale of Future Royalties</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liability Related to Sale of Future Royalties</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company treats the liability related to sale of future royalties, see Note 5, as a debt financing, amortized under the effective interest rate method over the estimated life of the related expected royalty stream. The liability related to sale of future royalties and the debt amortization are based on the Company&#8217;s current estimates of future royalties expected to be paid over the life of the arrangement. The Company will periodically assess the expected royalty payments. To the extent the Company&#8217;s estimates of future royalty payments are greater or less than previous estimates or the estimated timing of such payments is materially different than previous estimates, the Company will adjust the effective interest rate and recognize related non-cash interest expense on a prospective basis. Non-cash royalty revenue is reflected as royalty revenue within license, collaboration and other revenue, and non-cash amortization of debt is reflected as interest expense in the unaudited condensed consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ContractualArrangementRoyaltiesAgreementLiabilityPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Arrangement, Royalties Agreement, Liability, Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ContractualArrangementRoyaltiesAgreementLiabilityPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933843007192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue and Reserves for Variable Consideration (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock', window );">Product Revenue Allowance and Reserve Categories</a></td>
<td class="text">The following table summarizes activity in each of the product revenue allowance and reserve categories for the nine months ended September&#160;30, 2021 and 2020 (in thousands):<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.047%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks<br/>and Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates, Fees<br/>and other<br/>Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,912&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provisions related to sales in current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments related to prior year sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,590)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,591)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments made</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,593)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,518)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,979)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113,090)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provisions related to sales in current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments related to prior year sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments made</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,701)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,807)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,991)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,869&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,428&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Product Revenue Allowance And Reserve Categories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933752193048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration and Other Significant Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CollaborativeArrangementRevenueRecognitionTableTextBlock', window );">Revenues Recognized from License, Collaboration and Other Significant Agreements</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021 and 2020, the Company recognized the following revenues from its license, collaboration and other significant agreements and had the following deferred revenue balances as of September&#160;30, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">License, Collaboration and Other Revenue:</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MTPC Agreement</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otsuka U.S. Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otsuka International Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Proportional Performance Revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,559&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,872&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,687&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,539&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JT and Torii</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MTPC Other Revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total License, Collaboration and Other Revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,003&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,596&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,853&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,311&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_DeferredRevenueRecognitionTableTextBlock', window );">Deferred Revenues</a></td>
<td class="text">During the three and nine months ended September&#160;30, 2021 and 2020, the Company recognized the following revenues from its license, collaboration and other significant agreements and had the following deferred revenue balances as of September&#160;30, 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-Term</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-Term</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred Revenue:</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MTPC Agreement</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otsuka U.S. Agreement</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otsuka International Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vifor Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,692&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,965&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,657&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Changes in Contract Assets and Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the Company&#8217;s contract assets and liabilities during the nine months ended September&#160;30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.047%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>Beginning of<br/>Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at End<br/>of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable(1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,792)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,227)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable(1)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156,209)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(615)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Excludes accounts receivable from other services related to clinical and regulatory activities performed by the Company on behalf of MTPC that are not included in the performance obligations identified under the MTPC Agreement as of September&#160;30, 2021 and 2020 and December&#160;31, 2020 and 2019. Also excludes accounts receivable related to amounts due to the Company from product sales which are included in the accompanying unaudited condensed consolidated balance sheet as of September&#160;30, 2021 and December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ScheduleOfRevenueRecognizedResultingFromChangesInContractAssetAndContractLiabilityTableTextBlock', window );">Revenue Recognized Resulting from Changes in Contract Assets and Contract Liabilities</a></td>
<td class="text"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021 and 2020, the Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the respective periods (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue Recognized in the Period from:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts included in deferred revenue at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance obligations satisfied in previous periods</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_CollaborativeArrangementRevenueRecognitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenue recognition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_CollaborativeArrangementRevenueRecognitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_DeferredRevenueRecognitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred revenue recognition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_DeferredRevenueRecognitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ScheduleOfRevenueRecognizedResultingFromChangesInContractAssetAndContractLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of revenue recognized resulting from changes in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ScheduleOfRevenueRecognizedResultingFromChangesInContractAssetAndContractLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933744842552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to Sale of Future Royalties (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Activity within Liability Related to Sale of Future Royalties, net</a></td>
<td class="text">The following table shows the activity within the liability account for the nine months ended September&#160;30, 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to sale of future royalties, net &#8212; beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of future royalties, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,783</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MTPC royalties payable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,779</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to sale of future royalties, net &#8212; ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,137&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933746203144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available For Sale Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Cash, Cash Equivalents, and Available for Sale Securities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and available for sale securities at September&#160;30, 2021 and December&#160;31, 2020 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and available for sale securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,204&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,204&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,992&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and available for sale securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,677&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,690&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933747408840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Assets Measured or Disclosed at Fair Value on Recurring Basis</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets measured or disclosed at fair value on a recurring basis as of September&#160;30, 2021 and December&#160;31, 2020 are summarized below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.047%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.047%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,992&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Fair Value Derivative Liability</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll-forward of the fair value of the derivative liability (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:81.132%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.668%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability, recorded as other expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability, recorded as other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(570)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability, recorded as other income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933744830024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory Components</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,409&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,309&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term inventory, which primarily consists of raw materials and work in process, is included in other assets in the Company&#8217;s unaudited condensed consolidated balance sheets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,409&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,309&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933746334424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Intangible Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s intangible assets at September&#160;30, 2021 and December&#160;31, 2020 (in thousands): </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.964%"><tr><td style="width:1.0%"/><td style="width:50.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.376%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.376%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed product rights for Auryxia</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,465)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:45.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ASC 842<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed product rights for Auryxia</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,433)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Favorable lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,148&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,438)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,170&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933854819128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses as of September&#160;30, 2021 and December&#160;31, 2020 are as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:59.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.401%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue allowances</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts due to collaboration partners</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otsuka PRV contribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNy0wLTEtMS0yMjM1Nw_8a62ce00-dd9c-44ee-980f-eb68f6cf0efd"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl82NC9mcmFnOmMzMGY4MWE5M2VjNzQ2ZDJiMjEwNDE2OWFjMGQxMDk0L3RhYmxlOjA3OWUyMmJhYWU0MzQ0YTg4ZjM2MjdhMGU0OGFiNzU4L3RhYmxlcmFuZ2U6MDc5ZTIyYmFhZTQzNDRhODhmMzYyN2EwZTQ4YWI3NThfNy0wLTEtMS0yMjM1Nw_a0731d02-abdf-4cad-9588-f670833c69ba">Lease liability</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commercial manufacturing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,704&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933746430296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, undiscounted minimum rental commitments under non-cancelable leases, for each of the next five years and total thereafter are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Payments<br/>to be Received<br/>from Sublease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Operating<br/>Lease Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,706&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,585&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,121&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ScheduleOfDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesAndOperatingLeaseLiabilitiesTableTextBlock', window );">Difference Between Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases and Operating Leases Liabilities</a></td>
<td class="text">As of September&#160;30, 2021, the following represents the difference between the remaining undiscounted minimum rental commitments under non-cancelable leases and the operating lease liabilities:<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:81.330%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating <br/>Leases</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undiscounted minimum rental commitments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value adjustment using incremental borrowing rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,380)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyYmFjODI4YzY5NzQxMTU4YmUxNGJkZWYwMWJmZThiL3NlYzozMmJhYzgyOGM2OTc0MTE1OGJlMTRiZGVmMDFiZmU4Yl84Mi9mcmFnOmU3MDMzNWY3OWM0YTQxNTRiOWY3NWY5MTEwNDNhMjJmL3RhYmxlOmY2NDc1MWJlODBmNTRjOTY4ZDg5NTUxMjc1NTZjNDVjL3RhYmxlcmFuZ2U6ZjY0NzUxYmU4MGY1NGM5NjhkODk1NTEyNzU1NmM0NWNfNC0wLTEtMS0yMjM1Nw_6f24d764-2b2d-4991-9474-8d0770053a51">Operating lease liabilities</span></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,326&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ScheduleOfDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesAndOperatingLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of difference between undiscounted minimum rental commitments under non-cancelable leases and the operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ScheduleOfDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesAndOperatingLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933744814072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share</a></td>
<td class="text">The shares in the table below were excluded from the calculation of diluted net loss per share, prior to the use of the treasury stock method, due to their anti-dilutive effect:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,593,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,681,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,378,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,971,679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,482,066&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,163,054&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933746175736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Organization and Operations - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_OperatingPlanSufficientlyFundedByCashResourcesPeriod', window );">Period where operating plan is sufficiently funded by cash resources</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_OperatingPlanSufficientlyFundedByCashResourcesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating plan sufficiently funded by cash resources, period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_OperatingPlanSufficientlyFundedByCashResourcesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933744846648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933834676440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue and Reserves for Variable Consideration - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 48,756<span></span>
</td>
<td class="nump">$ 59,988<span></span>
</td>
<td class="nump">$ 153,973<span></span>
</td>
<td class="nump">$ 238,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">36,753<span></span>
</td>
<td class="nump">$ 34,392<span></span>
</td>
<td class="nump">100,120<span></span>
</td>
<td class="nump">$ 94,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable, net</a></td>
<td class="nump">$ 22,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123366838&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933753202936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue and Reserves for Variable Consideration - Product Revenue Allowance and Reserve Categories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">$ 41,363<span></span>
</td>
<td class="nump">$ 31,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Current provisions related to sales in current year</a></td>
<td class="nump">119,209<span></span>
</td>
<td class="nump">119,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales', window );">Adjustments related to prior year sales</a></td>
<td class="num">(1,591)<span></span>
</td>
<td class="nump">2,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits/payments made</a></td>
<td class="num">(113,090)<span></span>
</td>
<td class="num">(110,499)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">45,891<span></span>
</td>
<td class="nump">43,428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=akba_ChargebacksAndDiscountsMember', window );">Chargebacks and Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">802<span></span>
</td>
<td class="nump">738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Current provisions related to sales in current year</a></td>
<td class="nump">8,911<span></span>
</td>
<td class="nump">7,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales', window );">Adjustments related to prior year sales</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits/payments made</a></td>
<td class="num">(8,593)<span></span>
</td>
<td class="num">(7,701)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">1,119<span></span>
</td>
<td class="nump">785<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=akba_RebatesFeesAndOtherDeductionsMember', window );">Rebates, Fees and other Deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">39,912<span></span>
</td>
<td class="nump">30,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Current provisions related to sales in current year</a></td>
<td class="nump">105,432<span></span>
</td>
<td class="nump">107,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales', window );">Adjustments related to prior year sales</a></td>
<td class="num">(1,590)<span></span>
</td>
<td class="nump">703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits/payments made</a></td>
<td class="num">(99,518)<span></span>
</td>
<td class="num">(96,807)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">44,236<span></span>
</td>
<td class="nump">41,869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=akba_ReturnsMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">649<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Current provisions related to sales in current year</a></td>
<td class="nump">4,866<span></span>
</td>
<td class="nump">4,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales', window );">Adjustments related to prior year sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits/payments made</a></td>
<td class="num">(4,979)<span></span>
</td>
<td class="num">(5,991)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">$ 536<span></span>
</td>
<td class="nump">$ 774<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation allowances and reserves adjustments related to prior period sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=akba_ChargebacksAndDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=akba_ChargebacksAndDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=akba_RebatesFeesAndOtherDeductionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=akba_RebatesFeesAndOtherDeductionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=akba_ReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=akba_ReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933748127640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration and Other Significant Agreements - Revenues Recognized From License, Collaboration and Other Significant Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LicenseCollaborationAndOtherRevenueAbstract', window );"><strong>License, Collaboration and Other Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 48,756<span></span>
</td>
<td class="nump">$ 59,988<span></span>
</td>
<td class="nump">$ 153,973<span></span>
</td>
<td class="nump">$ 238,608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LicenseCollaborationAndOtherRevenueAbstract', window );"><strong>License, Collaboration and Other Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=akba_LicenseCollaborationAndOtherRevenueMember', window );">License, collaboration and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LicenseCollaborationAndOtherRevenueAbstract', window );"><strong>License, Collaboration and Other Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">12,003<span></span>
</td>
<td class="nump">25,596<span></span>
</td>
<td class="nump">53,853<span></span>
</td>
<td class="nump">144,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=akba_LicenseCollaborationAndOtherRevenueMember', window );">License, collaboration and other revenue | Mitsubishi Tanabe Pharma Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LicenseCollaborationAndOtherRevenueAbstract', window );"><strong>License, Collaboration and Other Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,555<span></span>
</td>
<td class="nump">373<span></span>
</td>
<td class="nump">7,167<span></span>
</td>
<td class="nump">15,373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=akba_LicenseCollaborationAndOtherRevenueMember', window );">License, collaboration and other revenue | Otsuka Pharmaceutical Company. Ltd. | Otsuka U.S. Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LicenseCollaborationAndOtherRevenueAbstract', window );"><strong>License, Collaboration and Other Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6,144<span></span>
</td>
<td class="nump">16,256<span></span>
</td>
<td class="nump">28,988<span></span>
</td>
<td class="nump">80,721<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=akba_LicenseCollaborationAndOtherRevenueMember', window );">License, collaboration and other revenue | Otsuka Pharmaceutical Company. Ltd. | Otsuka International Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LicenseCollaborationAndOtherRevenueAbstract', window );"><strong>License, Collaboration and Other Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,860<span></span>
</td>
<td class="nump">7,243<span></span>
</td>
<td class="nump">13,532<span></span>
</td>
<td class="nump">39,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=akba_LicenseCollaborationAndOtherRevenueMember', window );">License, collaboration and other revenue | Total Proportional Performance Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LicenseCollaborationAndOtherRevenueAbstract', window );"><strong>License, Collaboration and Other Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">10,559<span></span>
</td>
<td class="nump">23,872<span></span>
</td>
<td class="nump">49,687<span></span>
</td>
<td class="nump">135,539<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=akba_LicenseCollaborationAndOtherRevenueMember', window );">License, collaboration and other revenue | JT and Torii</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LicenseCollaborationAndOtherRevenueAbstract', window );"><strong>License, Collaboration and Other Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,444<span></span>
</td>
<td class="nump">1,183<span></span>
</td>
<td class="nump">4,093<span></span>
</td>
<td class="nump">4,049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=akba_LicenseCollaborationAndOtherRevenueMember', window );">License, collaboration and other revenue | MTPC Other Revenue | Mitsubishi Tanabe Pharma Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LicenseCollaborationAndOtherRevenueAbstract', window );"><strong>License, Collaboration and Other Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 541<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 4,723<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_LicenseCollaborationAndOtherRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License, collaboration and other revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_LicenseCollaborationAndOtherRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=akba_LicenseCollaborationAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=akba_LicenseCollaborationAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933752990632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License, Collaboration and Other Significant Agreements - Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Deferred Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-Term</a></td>
<td class="nump">$ 15,692<span></span>
</td>
<td class="nump">$ 15,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-Term</a></td>
<td class="nump">27,965<span></span>
</td>
<td class="nump">$ 25,345<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total</a></td>
<td class="nump">43,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation | MTPC Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Deferred Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-Term</a></td>
<td class="nump">4,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-Term</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total</a></td>
<td class="nump">4,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember', window );">Otsuka Pharmaceutical Company. Ltd. | Otsuka U.S. Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Deferred Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-Term</a></td>
<td class="nump">6,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-Term</a></td>
<td class="nump">16,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total</a></td>
<td class="nump">22,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember', window );">Otsuka Pharmaceutical Company. Ltd. | Otsuka International Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Deferred Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-Term</a></td>
<td class="nump">4,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-Term</a></td>
<td class="nump">6,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total</a></td>
<td class="nump">11,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_ViforPharmaMember', window );">Vifor Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Deferred Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-Term</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-Term</a></td>
<td class="nump">4,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total</a></td>
<td class="nump">$ 4,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=akba_DevelopmentAndCommercializeCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=akba_DevelopmentAndCommercializeCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=akba_ViforPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=akba_ViforPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933754662968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration and Other Significant Agreements - Changes in Contract Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractWithCustomerLiabilityRollForward', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at End of Period</a></td>
<td class="nump">$ 43,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward', window );"><strong>Contract assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Balance at Beginning of Period</a></td>
<td class="nump">3,045<span></span>
</td>
<td class="nump">$ 15,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractWithCustomerAssetAdditions', window );">Additions</a></td>
<td class="nump">38,795<span></span>
</td>
<td class="nump">143,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractWithCustomerAssetDeductions', window );">Deductions</a></td>
<td class="num">(20,427)<span></span>
</td>
<td class="num">(156,209)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Balance at End of Period</a></td>
<td class="nump">21,413<span></span>
</td>
<td class="nump">2,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward', window );"><strong>Contract assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Balance at Beginning of Period</a></td>
<td class="nump">1,722<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractWithCustomerAssetAdditions', window );">Additions</a></td>
<td class="nump">1,725<span></span>
</td>
<td class="nump">1,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractWithCustomerAssetDeductions', window );">Deductions</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Balance at End of Period</a></td>
<td class="nump">3,442<span></span>
</td>
<td class="nump">1,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=akba_DeferredRevenueMember', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractWithCustomerLiabilityRollForward', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at Beginning of Period</a></td>
<td class="nump">40,559<span></span>
</td>
<td class="nump">72,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="nump">65,890<span></span>
</td>
<td class="nump">110,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractWithCustomerLiabilityDeductions', window );">Deductions</a></td>
<td class="num">(62,792)<span></span>
</td>
<td class="num">(131,551)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at End of Period</a></td>
<td class="nump">43,657<span></span>
</td>
<td class="nump">51,694<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractWithCustomerLiabilityRollForward', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at Beginning of Period</a></td>
<td class="nump">7,227<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractWithCustomerLiabilityDeductions', window );">Deductions</a></td>
<td class="num">(7,227)<span></span>
</td>
<td class="num">(5,651)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at End of Period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,446<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=akba_AccruedExpensesAndOtherCurrentLiabilitiesMember', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractWithCustomerLiabilityRollForward', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at Beginning of Period</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractWithCustomerLiabilityDeductions', window );">Deductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(615)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at End of Period</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ContractWithCustomerAssetAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer asset additions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ContractWithCustomerAssetAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset, After Allowance For Credit Loss, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ContractWithCustomerAssetDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer asset deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ContractWithCustomerAssetDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability additions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ContractWithCustomerLiabilityDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ContractWithCustomerLiabilityDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=akba_DeferredRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=akba_DeferredRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=akba_AccruedExpensesAndOtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=akba_AccruedExpensesAndOtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933752392936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration and Other Significant Agreements - Revenue Recognized Resulting from Changes in Contract Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInContractWithCustomerLiabilityAbstract', window );"><strong>Revenue Recognized in the Period from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amounts included in deferred revenue at the beginning of the period</a></td>
<td class="nump">$ 9,159<span></span>
</td>
<td class="nump">$ 6,537<span></span>
</td>
<td class="nump">$ 20,363<span></span>
</td>
<td class="nump">$ 29,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Performance obligations satisfied in previous periods</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20,648<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 21,346<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933748394952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration and Other Significant Agreements - Mitsubishi Tanabe Pharma Corporation Collaboration Agreement (Details)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>performance_obligation</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Recognized revenue</a></td>
<td class="nump">$ 48,756,000<span></span>
</td>
<td class="nump">$ 59,988,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153,973,000<span></span>
</td>
<td class="nump">$ 238,608,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">43,657,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,657,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">9,159,000<span></span>
</td>
<td class="nump">6,537,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,363,000<span></span>
</td>
<td class="nump">29,203,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">27,965,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,965,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term deferred revenue</a></td>
<td class="nump">15,692,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,692,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,214,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">21,413,000<span></span>
</td>
<td class="nump">2,761,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,413,000<span></span>
</td>
<td class="nump">2,761,000<span></span>
</td>
<td class="nump">$ 3,045,000<span></span>
</td>
<td class="nump">$ 15,822,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=akba_LicenseCollaborationAndOtherRevenueMember', window );">License, collaboration and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Recognized revenue</a></td>
<td class="nump">12,003,000<span></span>
</td>
<td class="nump">25,596,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,853,000<span></span>
</td>
<td class="nump">144,311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Recognized revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation | License, collaboration and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Recognized revenue</a></td>
<td class="nump">2,555,000<span></span>
</td>
<td class="nump">373,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,167,000<span></span>
</td>
<td class="nump">15,373,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation | License Collaboration And Other Revenue, Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Recognized revenue</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation | Regulatory Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_MilestonePaymentReceived', window );">Milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation | MTPC Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_NumberOfPerformanceObligations', window );">Number of performance obligations | performance_obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">4,883,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,883,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term deferred revenue</a></td>
<td class="nump">4,883,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,883,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation | MTPC Agreement | Regulatory Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_MilestonePaymentReceived', window );">Milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation | Development And Commercialize Research And License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_UpfrontCashPaymentReceived', window );">Upfront cash payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CostOfResearchServices', window );">Cost of research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_MilestonePaymentReceived', window );">Milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation | Development And Commercialize Research And License Agreement | Regulatory Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_MilestonePaymentReceived', window );">Milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_UpfrontCashPaymentReceived', window );">Upfront cash payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited | Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited | Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term deferred revenue</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited | Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BilledContractReceivables', window );">Up-front payments invoiced</a></td>
<td class="nump">13,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation Supply Agreement | Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BilledContractReceivables', window );">Up-front payments invoiced</a></td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation Supply Agreement | Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BilledContractReceivables', window );">Up-front payments invoiced</a></td>
<td class="nump">16,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation Supply Agreement | Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BilledContractReceivables', window );">Up-front payments invoiced</a></td>
<td class="nump">5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation Supply Agreement | Contract With Customer, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BilledContractReceivables', window );">Up-front payments invoiced</a></td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_CostOfResearchServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of research services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_CostOfResearchServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of performance obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_UpfrontCashPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront cash payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_UpfrontCashPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BilledContractReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55302-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BilledContractReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=akba_LicenseCollaborationAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=akba_LicenseCollaborationAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=akba_MitsubishiTanabePharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=akba_LicenseCollaborationAndOtherRevenueRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=akba_LicenseCollaborationAndOtherRevenueRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerBasisOfPricingAxis=akba_RegulatoryMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerBasisOfPricingAxis=akba_RegulatoryMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=akba_DevelopmentAndCommercializeCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=akba_DevelopmentAndCommercializeCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=akba_MitsubishiTanabePharmaCorporationSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=akba_MitsubishiTanabePharmaCorporationSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=akba_ContractWithCustomerLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=akba_ContractWithCustomerLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933837191000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration and Other Significant Agreements - U.S. Collaboration and License Agreement with Otsuka Pharmaceutical Co. Ltd. (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>performance_obligation</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Recognized revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,756,000<span></span>
</td>
<td class="nump">$ 59,988,000<span></span>
</td>
<td class="nump">$ 153,973,000<span></span>
</td>
<td class="nump">$ 238,608,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,657,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,657,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,692,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,692,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,214,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,965,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,965,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,413,000<span></span>
</td>
<td class="nump">2,761,000<span></span>
</td>
<td class="nump">21,413,000<span></span>
</td>
<td class="nump">2,761,000<span></span>
</td>
<td class="nump">3,045,000<span></span>
</td>
<td class="nump">$ 15,822,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,442,000<span></span>
</td>
<td class="nump">1,248,000<span></span>
</td>
<td class="nump">3,442,000<span></span>
</td>
<td class="nump">1,248,000<span></span>
</td>
<td class="nump">1,722,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,446,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,446,000<span></span>
</td>
<td class="nump">7,227,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=akba_LicenseCollaborationAndOtherRevenueMember', window );">License, collaboration and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Recognized revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,003,000<span></span>
</td>
<td class="nump">25,596,000<span></span>
</td>
<td class="nump">$ 53,853,000<span></span>
</td>
<td class="nump">144,311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember', window );">Otsuka Pharmaceutical Company. Ltd. | Otsuka U.S. Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_NumberOfPerformanceObligations', window );">Number of performance obligations | performance_obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsAmount', window );">Collaborative arrangements additional cost sharing payments amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CollaborativeAndLicenseArrangementTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred', window );">Reimbursement of costs</a></td>
<td class="nump">$ 33,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CollaborativeArrangementsCostSharingPayments', window );">Collaborative arrangements cost sharing payments</a></td>
<td class="nump">345,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,972,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,972,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,308,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,308,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,664,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,664,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CostShareCostsIncurredForLicenseAgreement', window );">Cost share costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred', window );">Reimbursable costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CostShareCostsIncurredByPartnerForLicenseAgreement', window );">Cost share costs by partner for license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_PaymentForLicenseAgreementReimbursementOfCostsIncurred', window );">Costs reimbursed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember', window );">Otsuka Pharmaceutical Company. Ltd. | Otsuka U.S. Agreement | Global Development Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount', window );">Collaborative arrangements additional cost sharing payments expected amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember', window );">Otsuka Pharmaceutical Company. Ltd. | Otsuka U.S. Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable', window );">Reduction in percentage of future payments due upon current global development costs creditable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember', window );">Otsuka Pharmaceutical Company. Ltd. | Otsuka U.S. Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_PercentageOfRemainingCreditableAmountAppliedToFuturePayments', window );">Percentage of remaining creditable amount applied to future payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember', window );">Otsuka Pharmaceutical Company. Ltd. | Otsuka U.S. Agreement | Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember', window );">Otsuka Pharmaceutical Company. Ltd. | Otsuka U.S. Agreement | Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember', window );">Otsuka Pharmaceutical Company. Ltd. | Otsuka U.S. Agreement | Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember', window );">Otsuka Pharmaceutical Company. Ltd. | Otsuka U.S. Agreement | License, collaboration and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Recognized revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,144,000<span></span>
</td>
<td class="nump">$ 16,256,000<span></span>
</td>
<td class="nump">28,988,000<span></span>
</td>
<td class="nump">$ 80,721,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember', window );">Otsuka Pharmaceutical Company. Ltd. | Otsuka U.S. Agreement | HIF Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Eligible milestone payments (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember', window );">Otsuka Pharmaceutical Company. Ltd. | Otsuka U.S. Agreement | Licensed Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Eligible milestone payments (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">575,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember', window );">Otsuka Pharmaceutical Company. Ltd. | Otsuka U.S. Agreement | Up Front Non Refundable And Non Creditable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_UpfrontCashPaymentReceived', window );">Upfront cash payment received</a></td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember', window );">Otsuka Pharmaceutical Company. Ltd. | Otsuka U.S. Agreement | Development And Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_MilestonePaymentReceived', window );">Milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_CollaborativeAndLicenseArrangementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative and license arrangement, transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_CollaborativeAndLicenseArrangementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangements additional cost sharing payments amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_CollaborativeArrangementsAdditionalCostSharingPaymentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangements additional cost sharing payments expected amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_CollaborativeArrangementsCostSharingPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangements cost sharing payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_CollaborativeArrangementsCostSharingPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_CostShareCostsIncurredByPartnerForLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost share costs incurred by partner for license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_CostShareCostsIncurredByPartnerForLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_CostShareCostsIncurredForLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost share costs incurred for license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_CostShareCostsIncurredForLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of performance obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_PaymentForLicenseAgreementReimbursementOfCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment for license agreement reimbursement of costs incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_PaymentForLicenseAgreementReimbursementOfCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment receivable for license agreement reimbursement of previously costs incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment received for license agreement reimbursement of costs incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_PercentageOfRemainingCreditableAmountAppliedToFuturePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining creditable amount applied to future payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_PercentageOfRemainingCreditableAmountAppliedToFuturePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in percentage of future payments due upon current global development costs creditable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_UpfrontCashPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront cash payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_UpfrontCashPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=akba_LicenseCollaborationAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=akba_LicenseCollaborationAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=akba_GlobalDevelopmentPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=akba_GlobalDevelopmentPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=akba_HIFProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=akba_HIFProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=akba_LicensedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=akba_LicensedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerBasisOfPricingAxis=akba_UpFrontNonRefundableAndNonCreditableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerBasisOfPricingAxis=akba_UpFrontNonRefundableAndNonCreditableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerBasisOfPricingAxis=akba_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerBasisOfPricingAxis=akba_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933752920760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration and Other Significant Agreements - International Collaboration and License Agreement with Otsuka Pharmaceutical Co. Ltd. (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 25, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>performance_obligation</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Recognized revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,756<span></span>
</td>
<td class="nump">$ 59,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153,973<span></span>
</td>
<td class="nump">$ 238,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,413<span></span>
</td>
<td class="nump">2,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,413<span></span>
</td>
<td class="nump">2,761<span></span>
</td>
<td class="nump">3,045<span></span>
</td>
<td class="nump">$ 15,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,442<span></span>
</td>
<td class="nump">1,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,442<span></span>
</td>
<td class="nump">1,248<span></span>
</td>
<td class="nump">1,722<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,446<span></span>
</td>
<td class="nump">7,227<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=akba_LicenseCollaborationAndOtherRevenueMember', window );">License, collaboration and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Recognized revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,003<span></span>
</td>
<td class="nump">25,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,853<span></span>
</td>
<td class="nump">144,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember', window );">Otsuka Pharmaceutical Company. Ltd. | Otsuka International Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_NumberOfPerformanceObligations', window );">Number of performance obligations | performance_obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CollaborativeAndLicenseArrangementTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred', window );">Reimbursement of costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_EstimateSubsequentCostFundingUnderPlan', window );">Estimated current global development costs subsequent to March 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 237,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember', window );">Otsuka Pharmaceutical Company. Ltd. | Otsuka International Agreement | Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember', window );">Otsuka Pharmaceutical Company. Ltd. | Otsuka International Agreement | Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember', window );">Otsuka Pharmaceutical Company. Ltd. | Otsuka International Agreement | Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember', window );">Otsuka Pharmaceutical Company. Ltd. | Otsuka International Agreement | License, collaboration and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Recognized revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,860<span></span>
</td>
<td class="nump">$ 7,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,532<span></span>
</td>
<td class="nump">$ 39,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember', window );">Otsuka Pharmaceutical Company. Ltd. | Otsuka International Agreement | Licensed HIF Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Eligible milestone payments (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember', window );">Otsuka Pharmaceutical Company. Ltd. | Otsuka International Agreement | Licensed HIF Product | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod', window );">Eligible milestone payments, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember', window );">Otsuka Pharmaceutical Company. Ltd. | Otsuka International Agreement | Licensed HIF Product | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod', window );">Eligible milestone payments, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember', window );">Otsuka Pharmaceutical Company. Ltd. | Otsuka International Agreement | Licensed Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Eligible milestone payments (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember', window );">Otsuka Pharmaceutical Company. Ltd. | Up Front Non Refundable And Non Creditable | Otsuka International Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_UpfrontCashPaymentReceived', window );">Upfront cash payment received</a></td>
<td class="nump">$ 73,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_CollaborativeAndLicenseArrangementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative and license arrangement, transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_CollaborativeAndLicenseArrangementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_EstimateSubsequentCostFundingUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimate subsequent cost funding under plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_EstimateSubsequentCostFundingUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of performance obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment receivable for license agreement reimbursement of previously costs incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_UpfrontCashPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront cash payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_UpfrontCashPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=akba_LicenseCollaborationAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=akba_LicenseCollaborationAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=akba_OtsukaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=akba_LicensedHIFProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=akba_LicensedHIFProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=akba_LicensedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=akba_LicensedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerBasisOfPricingAxis=akba_UpFrontNonRefundableAndNonCreditableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerBasisOfPricingAxis=akba_UpFrontNonRefundableAndNonCreditableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933753080520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License, Collaboration and Other Significant Agreements - Janssen Pharmaceutica NV Research and License Agreement (Details) - Development And Commercialize Research And License Agreement - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Feb. 09, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_JanssenPharmaceuticaNVMember', window );">Janssen Pharmaceutica NV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CollaborativeArrangementTerm', window );">Collaborative arrangement, term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_UpfrontPaymentPaidInCash', window );">Upfront payment made in cash</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones', window );">Potential milestone revenue from developmental milestones (up to)</a></td>
<td class="nump">16.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_PotentialPaymentForAchievementOfSpecifiedCommercialMilestones', window );">Potential milestone revenue from commercial milestones (up to)</a></td>
<td class="nump">$ 215.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_JohnsonAndJohnsonInnovationMember', window );">Johnson &amp; Johnson Innovation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase common stock (in shares)</a></td>
<td class="nump">509,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 9.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value of warrant at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_PotentialPaymentForAchievementOfSpecifiedCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential payment for achievement of specified commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_PotentialPaymentForAchievementOfSpecifiedCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential payment for achievement of specified development milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_UpfrontPaymentPaidInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment paid in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_UpfrontPaymentPaidInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=akba_JanssenPharmaceuticaNVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=akba_JanssenPharmaceuticaNVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=akba_JohnsonAndJohnsonInnovationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=akba_JohnsonAndJohnsonInnovationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933752395848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration and Other Significant Agreements - Cyclerion Therapeutics License Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 04, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,471<span></span>
</td>
<td class="nump">$ 46,857<span></span>
</td>
<td class="nump">$ 118,296<span></span>
</td>
<td class="nump">$ 180,907<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=akba_CyclerionTherapeuticsLicenseAgreementMember', window );">Cyclerion Therapeutics License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Upfront payment for asset acquisition</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent consideration from developmental and regulatory milestones</a></td>
<td class="nump">$ 222,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod', window );">Agreement expiration, after first commercial sale, period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_AssetAcquisitionAgreementTerminationNoticePeriod', window );">Agreement termination notice period</a></td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Agreement Expiration, After First Commercial Sale, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_AssetAcquisitionAgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Agreement Termination Notice Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_AssetAcquisitionAgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=akba_CyclerionTherapeuticsLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=akba_CyclerionTherapeuticsLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933748961880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration and Other Significant Agreements - Vifor Pharma License Agreement (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 14, 2020</div></th>
<th class="th"><div>May 12, 2017</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,551,989<span></span>
</td>
<td class="nump">148,074,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,965<span></span>
</td>
<td class="nump">$ 25,345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_ViforInternationalLimitedMember', window );">Vifor (International) Ltd. | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_AggregateCollaborationAgreementPayments', window );">Payments for closing Priority Review Voucher purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_ViforInternationalLimitedMember', window );">Vifor (International) Ltd. | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,571,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ClosingStockPriceOfCommonStock', window );">Premium over the closing stock price of common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock', window );">Premium amount over the closing stock price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_PotentialPaymentForAchievementOfSpecifiedMilestones', window );">Potential milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_ViforInternationalLimitedMember', window );">Vifor (International) Ltd. | Priority Review Voucher Letter Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_AggregateCollaborationAgreementPayments', window );">Payments for closing Priority Review Voucher purchase</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_AggregateCollaborationAgreementPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate collaboration agreement payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_AggregateCollaborationAgreementPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ClosingStockPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Closing stock price of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ClosingStockPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement of premium amount over closing stock price of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_PotentialPaymentForAchievementOfSpecifiedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential payment for achievement of specified milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_PotentialPaymentForAchievementOfSpecifiedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=akba_ViforInternationalLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=akba_ViforInternationalLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=akba_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=akba_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=akba_PriorityReviewVoucherLetterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=akba_PriorityReviewVoucherLetterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933746335832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration and Other Significant Agreements - License Agreement with Panion&#160;&amp; BF Biotech, Inc. (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember', window );">JT and Torii | Panion &amp; BF Biotech, Incorporation | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_RoyaltyPaymentsDue', window );">Royalty payments</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="nump">$ 8.3<span></span>
</td>
<td class="nump">$ 8.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_RoyaltyPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty payments due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_RoyaltyPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=akba_PanionAndBFBiotechIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=akba_PanionAndBFBiotechIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=akba_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=akba_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933752270888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration and Other Significant Agreements - Sublicense Agreement with Japan Tobacco, Inc. and its subsidiary, Torii Pharmaceutical Co., Ltd. (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>performance_obligation</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Collaboration and Other Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Recognized revenue</a></td>
<td class="nump">$ 48,756<span></span>
</td>
<td class="nump">$ 59,988<span></span>
</td>
<td class="nump">$ 153,973<span></span>
</td>
<td class="nump">$ 238,608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember', window );">JT and Torii | Sublicense Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Collaboration and Other Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_NumberOfPerformanceObligations', window );">Number of performance obligations | performance_obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Recognized revenue</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of performance obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=akba_SublicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=akba_SublicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933753684632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to Sale of Future Royalties - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 25, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity', window );">Maximum annual royalty payout capacity</a></td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity', window );">Maximum aggregate royalty payout capacity</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractualArrangementRoyaltiesAgreementPercentageOfRoyaltyPaymentsToBeReceivedContingentOnReachingMaximumAnnualRoyaltyPayoutCapacity', window );">Percentage of royalty payment to be received once maximum annual royalty payout has been paid</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties', window );">Proceeds from sale of future royalties, net</a></td>
<td class="nump">$ 44,800<span></span>
</td>
<td class="nump">$ 44,783<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractualArrangementRoyaltiesAgreementProceedsContingentOnAnnualSalesMilestones', window );">Eligible proceeds to be received, contingent on annual sales milestones</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent', window );">Liability related to sale of future royalties, net</a></td>
<td class="nump">$ 44,800<span></span>
</td>
<td class="nump">$ 51,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage', window );">Annual effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Arrangement, Royalties Agreement, Interest Rate, Effective Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Arrangement, Royalties Agreement, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Arrangement, Royalties Agreement, Maximum Aggregate Royalty Payout Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Arrangement, Royalties Agreement, Maximum Annual Royalty Payout Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ContractualArrangementRoyaltiesAgreementPercentageOfRoyaltyPaymentsToBeReceivedContingentOnReachingMaximumAnnualRoyaltyPayoutCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Arrangement, Royalties Agreement, Percentage Of Royalty Payments To Be Received, Contingent On Reaching Maximum Annual Royalty Payout Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ContractualArrangementRoyaltiesAgreementPercentageOfRoyaltyPaymentsToBeReceivedContingentOnReachingMaximumAnnualRoyaltyPayoutCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ContractualArrangementRoyaltiesAgreementProceedsContingentOnAnnualSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Arrangement, Royalties Agreement, Proceeds, Contingent On Annual Sales Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ContractualArrangementRoyaltiesAgreementProceedsContingentOnAnnualSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Contractual Arrangement, Royalties Agreement, Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933842138936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to Sale of Future Royalties - Rollforward of Liability Related to Sale of Future Royalties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 25, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrentRollForward', window );"><strong>Contractual Arrangement, Royalties Agreement, Liability, Noncurrent [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent', window );">Liability related to sale of future royalties, net &#8212; beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties', window );">Proceeds from sale of future royalties, net</a></td>
<td class="nump">$ 44,800<span></span>
</td>
<td class="nump">44,783<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable', window );">MTPC royalties payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(425)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome', window );">Non-cash interest expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,779<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent', window );">Liability related to sale of future royalties, net &#8212; ending balance</a></td>
<td class="nump">$ 44,800<span></span>
</td>
<td class="nump">$ 51,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Arrangement, Royalties Agreement, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Arrangement, Royalties Agreement, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Arrangement, Royalties Agreement, Noncash Interest Expense (Income)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Arrangement, Royalties Agreement, Royalties, Earned And Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Contractual Arrangement, Royalties Agreement, Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933753380568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available For Sale Securities - Cash Cash Equivalents and Available for Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, amortized cost</a></td>
<td class="nump">$ 207,204<span></span>
</td>
<td class="nump">$ 228,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="nump">207,204<span></span>
</td>
<td class="nump">228,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Available for sale securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available for sale securities, amortized cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available for sale securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available for sale securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale securities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39,992<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost', window );">Total cash, cash equivalents, and available for sale securities, amortized cost</a></td>
<td class="nump">207,204<span></span>
</td>
<td class="nump">268,677<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total cash, cash equivalents, and available for sale securities, fair value</a></td>
<td class="nump">207,204<span></span>
</td>
<td class="nump">268,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Available for sale securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available for sale securities, amortized cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available for sale securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available for sale securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale securities, fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 39,992<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash cash equivalents and short term investments amortized cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933842944824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available For Sale Securities - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>security</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized gains (losses) on available for sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease', window );">Available-for-sale securities, recognized credit losses during period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of available-for-sale securities in a unrealized loss position | security</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in allowance for credit loss of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933748108712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Assets Measured or Disclosed at Fair Value on Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 207,204,000<span></span>
</td>
<td class="nump">$ 228,698,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39,992,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">1,930,000<span></span>
</td>
<td class="nump">2,420,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39,992,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value measurements recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">207,204,000<span></span>
</td>
<td class="nump">228,698,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets fair value disclosure</a></td>
<td class="nump">207,204,000<span></span>
</td>
<td class="nump">268,690,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">1,930,000<span></span>
</td>
<td class="nump">2,420,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities fair value disclosure</a></td>
<td class="nump">1,930,000<span></span>
</td>
<td class="nump">2,420,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value measurements recurring | U.S. government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,992,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value measurements recurring | Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">207,204,000<span></span>
</td>
<td class="nump">228,698,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets fair value disclosure</a></td>
<td class="nump">207,204,000<span></span>
</td>
<td class="nump">228,698,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value measurements recurring | Level&#160;1 | U.S. government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value measurements recurring | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39,992,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value measurements recurring | Level&#160;2 | U.S. government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,992,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value measurements recurring | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">1,930,000<span></span>
</td>
<td class="nump">2,420,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities fair value disclosure</a></td>
<td class="nump">$ 1,930,000<span></span>
</td>
<td class="nump">2,420,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value measurements recurring | Level&#160;3 | U.S. government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933753450984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">$ 1,930,000<span></span>
</td>
<td class="nump">$ 2,420,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value on recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Other than Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value on recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=akba_CollateralAgentPharmakonMember', window );">Collateral Agent, Pharmakon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=akba_OtherThanDerivativeLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=akba_OtherThanDerivativeLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=akba_CollateralAgentPharmakonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=akba_CollateralAgentPharmakonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933753879608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Fair Value Derivative Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_DerivativeLiabilityFairValueGrossLiabilityRollForward', window );"><strong>Derivative Liability, Fair Value, Gross Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Balance at beginning of period</a></td>
<td class="nump">$ 1,930<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 2,420<span></span>
</td>
<td class="nump">$ 2,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value of derivative liability, recorded as other expense (income)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(570)<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="num">(490)<span></span>
</td>
<td class="nump">$ 340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Balance at end of period</a></td>
<td class="nump">$ 1,930<span></span>
</td>
<td class="nump">$ 1,930<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 1,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_DerivativeLiabilityFairValueGrossLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative Liability, Fair Value, Gross Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_DerivativeLiabilityFairValueGrossLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933752825496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Components of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 2,376<span></span>
</td>
<td class="nump">$ 2,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">76,856<span></span>
</td>
<td class="nump">64,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">16,177<span></span>
</td>
<td class="nump">19,691<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_InventoryNetCurrentAndNonCurrent', window );">Total inventory</a></td>
<td class="nump">95,409<span></span>
</td>
<td class="nump">86,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Balance Sheet Classification:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">33,688<span></span>
</td>
<td class="nump">61,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 61,721<span></span>
</td>
<td class="nump">$ 25,292<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_InventoryNetCurrentAndNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory net current and non current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_InventoryNetCurrentAndNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933752404792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory amounts written down</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="nump">$ 7,126<span></span>
</td>
<td class="nump">$ 18,608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=akba_KeryxBiopharmaceuticalsIncMember', window );">Keryx Biopharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory', window );">Inventory step-up charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 8,700<span></span>
</td>
<td class="nump">$ 7,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to inventory acquired in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=akba_KeryxBiopharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=akba_KeryxBiopharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933748086040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 12, 2018</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 214,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,438)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_FiniteLivedIntangibleAssetsAdoptionAdjustment', window );">ASC 842 Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(540)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=akba_DevelopedProductRightsForAuryxiaMember', window );">Developed product rights for Auryxia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213,603<span></span>
</td>
<td class="nump">213,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96,465)<span></span>
</td>
<td class="num">(69,433)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,138<span></span>
</td>
<td class="nump">144,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OffMarketFavorableLeaseMember', window );">Favorable lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_FiniteLivedIntangibleAssetsAdoptionAdjustment', window );">ASC 842 Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(540)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_FiniteLivedIntangibleAssetsAdoptionAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite lived intangible assets adoption adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_FiniteLivedIntangibleAssetsAdoptionAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=akba_DevelopedProductRightsForAuryxiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=akba_DevelopedProductRightsForAuryxiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OffMarketFavorableLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OffMarketFavorableLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933751908744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 12, 2018</div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="nump">$ 27,032,000<span></span>
</td>
<td class="nump">$ 24,307,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,053,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,053,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,053,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=akba_DevelopedProductRightsForAuryxiaMember', window );">Developed product rights for Auryxia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful life</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=akba_DevelopedProductRightsForAuryxiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=akba_DevelopedProductRightsForAuryxiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933751935096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_AccruedProductRevenueAllowancesCurrent', window );">Product revenue allowances</a></td>
<td class="nump">$ 44,235<span></span>
</td>
<td class="nump">$ 38,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_AccruedClinicalExpensesCurrent', window );">Accrued clinical</a></td>
<td class="nump">19,249<span></span>
</td>
<td class="nump">28,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CollaborativeArrangementAccruedLiability', window );">Collaborative arrangement accrued liability</a></td>
<td class="nump">27,375<span></span>
</td>
<td class="nump">17,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher', window );">Otsuka PRV contribution</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related</a></td>
<td class="nump">12,834<span></span>
</td>
<td class="nump">14,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability</a></td>
<td class="nump">$ 5,723<span></span>
</td>
<td class="nump">$ 5,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Total accrued expenses<span></span>
</td>
<td class="text">Total accrued expenses<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties</a></td>
<td class="nump">$ 3,022<span></span>
</td>
<td class="nump">$ 2,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">9,126<span></span>
</td>
<td class="nump">3,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_AccruedCommercialManufacturingCurrent', window );">Accrued commercial manufacturing</a></td>
<td class="nump">1,682<span></span>
</td>
<td class="nump">514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">11,458<span></span>
</td>
<td class="nump">8,644<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 144,704<span></span>
</td>
<td class="nump">$ 130,624<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_AccruedClinicalExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_AccruedClinicalExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_AccruedCommercialManufacturingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Commercial Manufacturing Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_AccruedCommercialManufacturingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_AccruedProductRevenueAllowancesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued product revenue allowances current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_AccruedProductRevenueAllowancesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_CollaborativeArrangementAccruedLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement Accrued Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_CollaborativeArrangementAccruedLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement Accrued Liability, Priority Review Voucher</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933747067272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 10, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 11, 2019 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 25, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,930,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,930,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=akba_CollateralAgentPharmakonMember', window );">Collateral Agent, Pharmakon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember', window );">Biopharma Credit Investments V (Master) LP | Keryx | Term Loan | Collateral Agent, Pharmakon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches', window );">Line of credit, maximum borrowing capacity, number of available tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term loan, maturity term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_DebtInstrumentCovenantTermsPotentialMaturityTermReduction', window );">Term loan, maturity term, potential reduction (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction', window );">Term loan, amortization period, potential reduction (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_FacilityFeePercentagePaidOnPrincipalAmount', window );">Facility fee percentage on principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_DebtInstrumentFacilityFeePaid', window );">Facility fee paid, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding', window );">Prepayment premium percentage on principal if prepaid prior to third anniversary of funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding', window );">Prepayment premium percentage on principal if prepaid prior to fourth anniversary and after third anniversary of funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding', window );">Prepayment premium percentage on principal if prepaid after fourth anniversary of funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="nump">$ 6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember', window );">Biopharma Credit Investments V (Master) LP | Keryx | Term Loan | Collateral Agent, Pharmakon | Debt Instrument, Quarterly Periodic Payment, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm', window );">Term loan, first quarterly principal payment due in</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">33 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember', window );">Biopharma Credit Investments V (Master) LP | Keryx | Term Loan | Collateral Agent, Pharmakon | Debt Instrument, Quarterly Periodic Payment, Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm', window );">Term loan, first quarterly principal payment due in</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember', window );">Biopharma Credit Investments V (Master) LP | Keryx | Term Loan | Collateral Agent, Pharmakon | Three-month LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on floating interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember', window );">Biopharma Credit Investments V (Master) LP | Keryx | Term Loan | Collateral Agent, Pharmakon | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_DebtInstrumentFloorRate', window );">Debt instrument, floor rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_DebtInstrumentCapRate', window );">Debt instrument, cap rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember', window );">Biopharma Credit Investments V (Master) LP | Keryx | Term Loan | Collateral Agent, Pharmakon | Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Term loan, net of facility fees, lender expenses and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember', window );">Biopharma Credit Investments V (Master) LP | Keryx | Term Loan | Collateral Agent, Pharmakon | Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=akba_BPCRLimitedPartnershipMember', window );">BPCR Limited Partnership | Keryx | Term Loan | Collateral Agent, Pharmakon | Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from line of credit</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_DebtInstrumentCapRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument cap rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_DebtInstrumentCapRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Potential Amortization Period Reduction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_DebtInstrumentCovenantTermsPotentialMaturityTermReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Potential Maturity Term Reduction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_DebtInstrumentCovenantTermsPotentialMaturityTermReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_DebtInstrumentFacilityFeePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument facility fee paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_DebtInstrumentFacilityFeePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_DebtInstrumentFloorRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument floor rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_DebtInstrumentFloorRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_FacilityFeePercentagePaidOnPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Facility fee percentage paid on principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_FacilityFeePercentagePaidOnPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, First Quarter Periodic Payment, Principal, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Maximum Borrowing Capacity, Number Of Available Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayment premium percentage on principal if prepaid on or after fourth anniversary of funding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayment premium percentage on principal if prepaid prior to fourth anniversary and after third anniversary of funding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayment premium percentage on principal if prepaid prior to third anniversary of funding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=akba_CollateralAgentPharmakonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=akba_CollateralAgentPharmakonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsByNatureAxis=akba_KeryxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsByNatureAxis=akba_KeryxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=akba_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=akba_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis=akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis=akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis=akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis=akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=akba_ThreeMonthLondonInterbankOfferedRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=akba_ThreeMonthLondonInterbankOfferedRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=akba_TrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=akba_TrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=akba_TrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=akba_TrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=akba_BPCRLimitedPartnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=akba_BPCRLimitedPartnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933752351832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrant (Details) - Janssen Agreement<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase common stock (in shares) | shares</a></td>
<td class="nump">509,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value of warrant at issuance | $</a></td>
<td class="nump">$ 3.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=akba_JanssenAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=akba_JanssenAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933735834312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 25, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 12, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 12, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 04, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2014 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,551,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,551,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,074,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,551,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,551,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,074,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts', window );">Proceeds from the issuance of common stock, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,799<span></span>
</td>
<td class="nump">$ 198,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=akba_InducementAwardProgramMember', window );">Inducement Award Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,228,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,154,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,154,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option | Share-based Compensation Award, Tranche, First Anniversary of Grant Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option | Share Based Compensation Award Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option | Share Based Compensation Award Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments', window );">Number of equal quarterly installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=akba_ServiceBasedRestrictedStockUnitsMember', window );">Service-Based Restricted Stock Units | Share Based Compensation Award Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=akba_ServiceBasedRestrictedStockUnitsMember', window );">Service-Based Restricted Stock Units | Share Based Compensation Award Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod', window );">Award vesting grace period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=akba_ServiceBasedRestrictedStockUnitsMember', window );">Service-Based Restricted Stock Units | Share-based Compensation Award, Tranche, First Or Third Anniversary of Grant Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=akba_ServiceBasedRestrictedStockUnitsMember', window );">Service-Based Restricted Stock Units | Share-Based Payment Arrangement, Tranche One, First Anniversary After Grant Date, Subjected To Individual Continued Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=akba_ServiceBasedRestrictedStockUnitsMember', window );">Service-Based Restricted Stock Units | Share-Based Payment Arrangement, Tranche Two, Second Anniversary After Grant Date, Subjected To Individual Continued Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=akba_ServiceBasedRestrictedStockUnitsMember', window );">Service-Based Restricted Stock Units | Share-Based Payment Arrangement, Tranche Three, Third Anniversary After Grant Date, Subjected To Individual Continued Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,551,989<span></span>
</td>
<td class="nump">169,651,423<span></span>
</td>
<td class="nump">158,520,089<span></span>
</td>
<td class="nump">143,129,409<span></span>
</td>
<td class="nump">130,251,440<span></span>
</td>
<td class="nump">174,551,989<span></span>
</td>
<td class="nump">143,328,652<span></span>
</td>
<td class="nump">148,074,085<span></span>
</td>
<td class="nump">121,674,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,730,466<span></span>
</td>
<td class="nump">10,446,160<span></span>
</td>
<td class="nump">9,228,017<span></span>
</td>
<td class="nump">12,650,000<span></span>
</td>
<td class="nump">7,973,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | At The Market Equity Offering Program Authorized February 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,730,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,180,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts', window );">Proceeds from the issuance of common stock, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Service-Based Restricted Stock Units | Share-based Compensation Award, Tranche, First Or Third Anniversary of Grant Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | At The Market Equity Offering Program Authorized February 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CommonStockSalesAgreementAmount', window );">Common stock sales agreement amount | $</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Service-Based Restricted Stock Units | Share-based Compensation Award, Tranche, First Or Third Anniversary of Grant Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=akba_AtTheMarketEquityOfferingProgramMember', window );">At The Market Equity Offering Program | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,224,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,973,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,509,381<span></span>
</td>
<td class="nump">2,684,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts', window );">Proceeds from the issuance of common stock, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,600<span></span>
</td>
<td class="nump">$ 16,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=akba_AtTheMarketEquityOfferingProgramMember', window );">At The Market Equity Offering Program | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CommonStockSalesAgreementAmount', window );">Common stock sales agreement amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=akba_TwoThousandAndFourteenPlansMember', window );">2014 Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,785,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding', window );">Incremental rate at which the shares reserved for issuance increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=akba_TwoThousandAndFourteenPlansMember', window );">2014 Plans | Share-based Payment Arrangement, Option | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,997,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=akba_TwoThousandAndFourteenPlansMember', window );">2014 Plans | Share-based Payment Arrangement, Option | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=akba_TwoThousandAndFourteenPlansMember', window );">2014 Plans | Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=akba_TwoThousandAndFourteenPlansMember', window );">2014 Plans | Service-Based Restricted Stock Units | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,396,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=akba_TwoThousandAndFourteenPlansMember', window );">2014 Plans | Service-Based Restricted Stock Units | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=akba_TwoThousandAndFourteenPlansMember', window );">2014 Plans | Performance-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=akba_TwoThousandAndFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,173,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,173,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price at the end of offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">307,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual increase in aggregate number of shares reserved for future issuance as percentage shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_CommonStockSalesAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock sales agreement amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_CommonStockSalesAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Grace Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, offering period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, periodic vesting, number of installments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=akba_InducementAwardProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=akba_InducementAwardProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=akba_ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=akba_ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=akba_ServiceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=akba_ServiceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=akba_ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=akba_ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=akba_ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=akba_ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=akba_ShareBasedPaymentArrangementTrancheTwoSecondAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=akba_ShareBasedPaymentArrangementTrancheTwoSecondAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=akba_ShareBasedPaymentArrangementTrancheThreeThirdAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=akba_ShareBasedPaymentArrangementTrancheThreeThirdAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=akba_AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=akba_AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=akba_AtTheMarketEquityOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=akba_AtTheMarketEquityOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=akba_TwoThousandAndFourteenPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=akba_TwoThousandAndFourteenPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=akba_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=akba_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=akba_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=akba_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=akba_TwoThousandAndFourteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=akba_TwoThousandAndFourteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933737400728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 10, 2021</div></th>
<th class="th"><div>Sep. 04, 2020</div></th>
<th class="th"><div>Apr. 02, 2020</div></th>
<th class="th"><div>Apr. 09, 2019</div></th>
<th class="th">
<div>Jan. 01, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2016 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>extensionOption</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>extensionOption</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease, cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ExcessInventoryPurchaseCommitmentsExpenseReversal', window );">Increase (decrease) in purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,000,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,376,000<span></span>
</td>
<td class="nump">10,304,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostDirectMaterial', window );">Charge to cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_PurchaseCommittedProgramRemainingContractCosts', window );">Total remaining contract costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Contract cost incurred in research and development activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=akba_SupplyAgreementPatheonIncMember', window );">Supply Agreement, Patheon Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Minimum purchase commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_BioVectraIncMember', window );">BioVectra Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LongTermPurchaseCommitmentRenewalPeriod', window );">Long-term minimum purchase commitment renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CostOfPurchasedMinimumQuantityProduct', window );">Cost of purchased minimum quantity product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_SiegfriedEvionnazSAMember', window );">Siegfried Evionnaz SA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CostOfPurchasedMinimumQuantityProduct', window );">Cost of purchased minimum quantity product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod', window );">Purchase commitment, option to extend, prior notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_EsteveQuimicaSAMember', window );">Esteve Qu&#237;mica, S.A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_InitialTermOfSupplyAgreement', window );">Initial term of supply agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Long-term minimum purchase commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_STAPharmaceuticalHongKongLimitedMember', window );">STA Pharmaceutical Hong Kong Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Long-term minimum purchase commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Minimum purchase commitment, initial term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=akba_WuXiSTAMember', window );">WuXi STA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod', window );">Purchase commitment, option to extend, prior notice period</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Minimum purchase commitment, initial term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LongTermPurchaseCommitmentFixedPricePeriod', window );">Long-term purchase commitment, fixed price, period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod', window );">Long-term purchase commitment, option to terminate, prior notice period (at least)</a></td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, incremental borrowing rates based on remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.22%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.22%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 4 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 4 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, incremental borrowing rates based on remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.94%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.94%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=akba_KeryxBiopharmaceuticalsIncMember', window );">Keryx Biopharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement', window );">Preliminary fair value of the off-market element</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_ExcessInventoryPurchaseCommitmentsExpenseReversal', window );">Increase (decrease) in purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=akba_CambridgeMember', window );">Cambridge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of property leased (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_OperatingLeaseAnnualRentExpense', window );">Annual lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 242,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_OperatingLeaseMonthlyRentExpense', window );">Monthly lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=akba_CambridgeMember', window );">Cambridge | Letter of Credit | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Total security deposit in connection with lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=akba_CambridgeMember', window );">Cambridge | Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of property leased (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_OperatingLeaseMonthlyRentExpense', window );">Monthly lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_OperatingLeaseFreeMonthlyRentPeriod', window );">Operating lease, free monthly rent, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions', window );">Lease period, number of extension options | extensionOption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=akba_CambridgeMember', window );">Cambridge | Office Space | Scenario Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_OperatingLeaseMonthlyRentExpense', window );">Monthly lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=akba_BostonMember', window );">Boston | Keryx Biopharmaceuticals, Inc. | Letter of Credit | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Total security deposit in connection with lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=akba_BostonMember', window );">Boston | Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of property leased (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_OperatingLeaseMonthlyRentExpense', window );">Monthly lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=akba_BostonMember', window );">Boston | Office Space | Keryx Biopharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions', window );">Lease period, number of extension options | extensionOption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease rental income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed noncurrent liabilities fair value of off-market element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_CostOfPurchasedMinimumQuantityProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of purchased minimum quantity product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_CostOfPurchasedMinimumQuantityProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_ExcessInventoryPurchaseCommitmentsExpenseReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess Inventory Purchase Commitments Expense (Reversal)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_ExcessInventoryPurchaseCommitmentsExpenseReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_InitialTermOfSupplyAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial term of supply agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_InitialTermOfSupplyAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee leasing arrangements, operating leases, number of lease period extension options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_LongTermPurchaseCommitmentFixedPricePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Purchase Commitment, Fixed Price, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_LongTermPurchaseCommitmentFixedPricePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Purchase Commitment, Option To Extend, Prior Notice Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Purchase Commitment, Option To Terminate, Prior Notice Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_LongTermPurchaseCommitmentRenewalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Purchase Commitment, Renewal Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_LongTermPurchaseCommitmentRenewalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_OperatingLeaseAnnualRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Annual Rent Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_OperatingLeaseAnnualRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_OperatingLeaseFreeMonthlyRentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Free Monthly Rent, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_OperatingLeaseFreeMonthlyRentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_OperatingLeaseMonthlyRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Monthly Rent Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_OperatingLeaseMonthlyRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_PurchaseCommittedProgramRemainingContractCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase committed program remaining contract costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_PurchaseCommittedProgramRemainingContractCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostDirectMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of material used for good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostDirectMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=akba_SupplyAgreementPatheonIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=akba_SupplyAgreementPatheonIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=akba_BioVectraIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=akba_BioVectraIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=akba_SiegfriedEvionnazSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=akba_SiegfriedEvionnazSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=akba_EsteveQuimicaSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=akba_EsteveQuimicaSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=akba_STAPharmaceuticalHongKongLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=akba_STAPharmaceuticalHongKongLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=akba_WuXiSTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=akba_WuXiSTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=akba_KeryxBiopharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=akba_KeryxBiopharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=akba_CambridgeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=akba_CambridgeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=akba_OfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=akba_OfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=akba_BostonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=akba_BostonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933746527960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remaining 2021</a></td>
<td class="nump">$ 1,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">7,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">5,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">5,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">5,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">4,052<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">30,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract', window );"><strong>Lease Payments to be Received from Sublease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear', window );">Remaining 2021</a></td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths', window );">2022</a></td>
<td class="nump">1,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears', window );">2023</a></td>
<td class="nump">307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Total</a></td>
<td class="nump">2,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract', window );"><strong>Net Operating Lease Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear', window );">Remaining 2021</a></td>
<td class="nump">1,349<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne', window );">2022</a></td>
<td class="nump">5,504<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo', window );">2023</a></td>
<td class="nump">5,647<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree', window );">2024</a></td>
<td class="nump">5,746<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour', window );">2025</a></td>
<td class="nump">5,823<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour', window );">Thereafter</a></td>
<td class="nump">4,052<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_akba_LesseeOperatingLeaseLiabilityPaymentsDueNet', window );">Total</a></td>
<td class="nump">$ 28,121<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_LesseeOperatingLeaseLiabilityPaymentsDueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_LesseeOperatingLeaseLiabilityPaymentsDueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Liability Payments Due Net After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due net year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Liability Payments Due Net Year One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due net year three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due net year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments net reminder of fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Net Sublease Income, Fiscal Year Maturity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee&#8203;, Operating &#8203;Lease&#8203;, Liability, &#8203;To Be Paid, &#8203;Due &#8203;After&#8203; Year&#8203; Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_akba_LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessor, Operating Lease, Payment to be Received, Due After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">akba_LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>akba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933746351752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Difference Between Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases and Operating Leases Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">$ 30,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Present value adjustment using incremental borrowing rate</a></td>
<td class="num">(4,380)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 26,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued expenses and other current liabilities<span></span>
</td>
<td class="text">Accrued expenses and other current liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139933752071656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">17,482,066<span></span>
</td>
<td class="nump">16,163,054<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">509,611<span></span>
</td>
<td class="nump">509,611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">11,593,539<span></span>
</td>
<td class="nump">10,681,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">5,378,916<span></span>
</td>
<td class="nump">4,971,679<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>82
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M\;HHF2Y0G6FL _U&;H-0D(<L6@I5QX)K6!;MVD-[P!">RY+GL@W/LU@'9K)
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MXVW<D0_F?APJ; G<(-?M4M:UT8!5)F^W,GD7\!2@S6)?O))OHG;V-4B9TF%
M1Q:K+05[1[M9QH'R3;Z4>&915FQLE5?+C40GWS[K58\7NY#WW!A82D*Q@J;6
M^0CFFBHV]HH3+9-\;VPIM991?K@1W!?*/ #W5U+JPXEY0;F].OX/4$L#!!0
M   ( "*!9%-R'(/(L 8  /T:   8    >&PO=V]R:W-H965T<R]S:&5E=#(N
M>&ULK5EM;]PV#/XKPJW85B#)69)?TR1 FV!;@6X+FG;[K-A*SJAMN9)\:?;K
M1]D7^\Z2E718@"1^(:F'E,2'E,\>A/RB-IQK]*VN&G6^VFC=GJ[7*M_PFJD3
MT?(&WMP)63,-M_)^K5K)6=$KU=6:!$&\KEG9K"[.^F?7\N),=+HJ&WXMD>KJ
MFLG'=[P2#^<KO'IZ\+&\WVCS8'UQUK)[?L/UY_9:PMUZM%*4-6]4*1HD^=WY
MZBT^O:214>@E_BKY@]J[1L:56R&^F)OWQ?DJ,(AXQ7-M3##XM^67O*J,)<#Q
M=6=T-8YI%/>OGZS_TCL/SMPRQ2]%]7=9Z,WY*EVA@M^QKM(?Q<-O?.=0#S 7
ME>K_HH>=;+!">:>TJ'?*@* NF^$_^[8+Q)X"#A<4R$Z!O%2![A1H[^B K'?K
MBFEV<2;% Y)&&JR9BSXVO39X4S9F&F^TA+<EZ.F+2]$4,"F\0'"E1%463,/-
M.U:Q)N?HQAA6Z!A]OKE"/[]ZC5ZALD&?-J)3K"G4V5H#!F-IG>_&>S>,1Q;&
MN^'M":+!$2(!P0[U2[_Z%<]!'??JP:'Z&CP?W2>C^Z2W1Y?<[Z3DC49,*?#S
MU&.1CA9I;S%<LLC4!D%L4&XN^->NW+(*AG#&:C 5]Z;,AMM>D" A07BVWN['
MQ"%&TCA+1[$#I.&(-/0B?;ME9<5N*XX@&R %*)'B>2=+77(GVL%<M <CF &U
M)6B69<2-,QIQ1EZ<[YLMQ$_(1Q>FR!Z1QFDZPV5+Q3C B1M7/.**_?'+<]'!
MQ$(VRSG,,D3R"#5<NV#&%H PB[-Y^&PI$J<1=<-,1IB)%^:UY"TK"\2_M6:C
MJWYQ"KWA$O++_NIWX4X<$QH%9(;;EL)AFBR$-QUQIU[<GX1FU0L@IHX5$ 3I
M? \YQ!(<T@60V0@R>R:X0*A2/_9!-9N]!8K3B\L@LT D.(MG2&VA-"8+>P@'
M4YX/O$C_!)Q,E\T]JCC0GB>@.T,'RY#B;#[I+K$X3>(%H'N$A+U ?Q6B>"BK
MR@D-6V-&4;"W0W;0GA,[A#:1!2;^&/:[IFPT:^Y+DSB'("Y.]\[<P<; ":;S
M].22"T.<! N )R["?C(: 'NFFMJ),8LM_G&(T21+\0*\B8"PGX&&+>Z!9_-)
M'! 2)W-\#CF('\T6 $[,@Z,7E0=5R6[+JB=&7XV )^K +^2.ECT:XG!Z[Z"#
M- VRN?,.;L$T6"@.\$0;V,\; %%VW,L;>V%Q.N#BA3"QEY=#C@8Q"1=<F!@$
M^RGD9B.D/M9<UJ:RYP"Z +*&:J)S!]SF"!S%=N)SB1&\A':B$NSGDD/">RZV
M-DO@-"-!- ?KD@/B6TC39.(3XN>3JUE ^R2(Q-WH0 NQAT;-!9XXJ"/)XCEV
MEUA$PV@!^L0PQ,\P<RK<"_5W>6&S#'0ET3PYN<3"F"PD3[+7N?C)Z(I+*#I-
M$SPZX*R0B8-<,CHO/1U2)"0+!$0F B)^ OH@FONG#7B[7!<1FV"RA-@@'6(Q
M3192'9EXB/AYZ,-3_& Q5WW_J\70$,%*N.MT)SF2XI%5XQ)Q.F&S4(0QM=:#
MKXTZ=&#B*>)OD0:>;T1S_,+T0>R.*$EH-B^D'&)Q$..EM3O1'_'3WY#JGL/H
M(+88(FH%U):CD$P6=]C$@,3/@)>BKDMM"OJ!_'+1F*S!FQP0HY__$)HC'+YV
M8O=:-F=SIZIE.3]?M9(K+K=\=8%<QR'_@Z%#[R?R)*FW]KG1(O^R$57!I?JI
M[VWTHZ_X(1/1D>>:IB?N4&8,]"HX"> '0S$DT995ADQ(= 2/S"]2&R9-^=%I
MH//R'UZ\0>/#4BE3HYC9^?$'' =OAK](=%I!E5Z8),\TNN&MYO4ME\/KI_.G
M7N\*NG?S:N%8:3>?-HU:R<DG<GB4-)$L]9.L68&B60S3&T2C8#E.W^WY&X23
M\"B*\%&69KT(]/%' 3P+TL@1\O\0Y=VKW8!'D'!5R_NCW,K)7M11 \Q/QVR1
MA:U/IQ*!^DN$MT51&MZ'+&4.3X[+!N6L+2%K.4':% \589SB>47C$@P)Y+2%
MFH9.U0#U5P-0K7=U-Y#7KD@7-:2$C3EQ-R6"4.X32)OWY^<1#A&\T$K3O5-2
M?V&PCQ=J\S(OG9Q*;<8_AOXYBY,Y53DE<9)$2VQ%I_* OJ1-58Y\Z(1L\SL4
M 3B:YPN'' F3&"]4,W0J!JB_&+#(M=^ +X8?68?-SI[;)>?JN==[WR;,AZ'?
MF;PO&P6E]QTH!B<)V)'#MY;A1HNV_UQQ*[06=7^YX0Q@&P%X?R> =W<WY@O(
M^,7KXE]02P,$%     @ (H%D4P>3OO3U @  .PH  !@   !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6REEM]OVC 0Q_\5*]I#*[7D!PF!"I!:4+5-FH2*MCU,
M>S")(58=.[.=TNVOW]E),Z !@L8#L9W[WGWN?$D\W@KYK#)"-'K-&5<3)].Z
MN'-=E60DQZHG"L+ASEK('&N8RHVK"DEP:D4Y<P//&[@YIMR9CNW:0D['HM2,
M<K*02)5YCN7O!\+$=N+XSMO"$]UDVBRXTW&!-V1)]-=B(6'F-EY2FA.NJ.!(
MDO7$N??OYKYG!-;B&R5;M3-&)I65$,]F\BF=.)XA(HPDVKC <'DA,\*8\00<
MOVJG3A/3"'?';]X?;?*0S HK,A/L.TUU-G&&#DK)&I=,/XGM1U(G%!E_B6#*
M_J-M93N('9242HN\%@-!3GEUQ:]U(78$?GA$$-2"H*N@7POZ705A+0AM9:I4
M;!WF6./I6(HMDL8:O)F!+:950_J4FWU?:@EW*>CT="9X"KM(4@0C)1A-L8;)
M V:8)P0MC6.%KA98$JXSHFF"V36Z11^0BU0&JVKL:N PWMRDCOE0Q0R.Q%R2
MHH?ZW@T*O,!OD<].R^<D ;EOY5Z+?'Y:_KGD/>2%;7(7BM=4,&@J&%A__6/9
M:*@8/ D:B35ZI!SJ1C%#"Z&H[>P?]RNE)?3WSQ/!^DVPO@T6'@FV@*>"2 D[
M!)V1/-^@ DOT@EE)T!7E*!6,8:E0062U.]=MNU.%B&T(\UYXF?KDUHO&[LON
M)IRSVN,/&_[P,GY<ZDQ(^@=63 )52[525XZC'9X@\NSO +R#X1Y[U+!'E[%3
MI<KSW-$[G$/@4Q9[I(.&=' 9*;SPE<8\I7QS#G=P%O>4Q1YNW.#&)W%G(L_A
M0?F/CHX[=?0YJSWX80,_O "^>SL/WU6Q7W?I8;T[6\[?6_KQR=8?-4F.+DBR
M6]^/6F#"*/)'P]%!@BV6X="+0V]X9&]\[]_7S;L _(+'H/;;!;_-] B_N_.A
M-L>J+UAN*%>(D35HO5X,3F1U4JDF6A3VV[T2&DX"=IC!Z8Y(8P#WUT+HMXDY
M#C3GQ>E?4$L#!!0    ( "*!9%-!FM2?Q08  "L>   8    >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&ULI5E=;]LV%/TKA+&'!&AB?HCZ")( C>UA!=HM2-KU
M6;886Z@D>B*==/WUHV3%DLDKQEU?$EL^O.0YNKSWB+I^D?4WM1%"H^]E4:F;
MR4;K[=5TJE8;4:;J4FY%97YYDG69:O.U7D_5MA9IU@XJBRG%.)R6:5Y-;J_;
M:_?U[;7<Z2*OQ'V-U*XLT_K?.U'(EYL)F;Q>>,C7&]U<F-Y>;].U>!3ZR_:^
M-M^FARA97HI*Y;)"M7BZF;PG5PO&F@$MXN]<O*C!9]1064KYK?GR(;N9X&9%
MHA KW81(S;]G,1-%T40RZ_BG"SHYS-D,''Y^C?Y[2]Z06:9*S&3Q-<_TYF82
M3U FGM)=H1_DRQ^B(\2;>"M9J/8O>NFP>()6.Z5EV0TV*RCS:O\__=X),1A@
MXL #:#> V@."D0&L&\!.G2'H!@2GSL"[ 2WUZ9Y[*]P\U>GM=2U?4-V@3;3F
M0ZM^.]KHE5=-HCSJVOR:FW'Z=B:KS-QVD2'S2<DBSU)MOCQJ\\_D@U9(/J&_
MMJ).F_NJ4%HUR-(DY:;)EF>!/DJET 7Z\CA'9[^=H]]07J'/&[E3!JJNI]HL
MLIEJNNH6=+=?$!U9$$.?9*4W"BW,PC)@_-P_/O&,GQIQ#@K15X7NJ#?@H]A>
M(H;?(8HI =8S.WTXANC\VNR+_SW[D1CLD"ZLC<=&XCV(9U'MA+KRQ H.L8(V
M5C 2Z[/4:6&*S3XBE"G[\6$[OJEXS[=!'/'P>OH\U-]%\22)XV/4W$41SI*(
M'<,6+HRR.,1]M".J_$"5>V6;2:6;C;26,E/(;+/,)V!XB!IZ!;RO9;9;:4BY
M_4 ^H!$FS.(Z<T$TH"RQA'-148@)M71S40F- PS+%AT(1EZ"[TM9Z_Q'6WH:
M^?)*I]4Z7Q9PND3N&C A%FD7%!)LI=3<!=$(,YLS@ H8CF#.\8%S[.7\H=RF
M>=V4WF/&*%5*@/<Z=I:!+<YO(N9O(A8N@A#.Z0C;Y, V.:$&K)SM ?%,W!7P
M) @LKBZ*819PBR\0"S-L!UNX,,IH& 4P:8+[IHN]]:!KJ-4:B>_;IOUZ"RH9
M-'/BE?-!*)'6JTW;IC-360NY;5();,/$(1?@(++W"P0+8QY9@@(P0F*:6#MK
M >%BG(SM&D)[ZM1+_=%X32/H.[06E1&W:"5(,V.9<J4;L9\%J (%Z#&;W@R"
M86*+-0=@A)K"ZZ@ X @+![AC%?KV3)A7A8_YJDFGU[0"&3-G[CBR*P8 BHA=
M-  0#4*[<( H-M(92&\>R"GN03H;":0< )3#)+9)0["(V4X"@%&.<6*W!PB7
MA$/+<4R]-Q.$>ZGWU:,PWALDS)VI+W@0Q[9U G%F.]KE$L*1)"&A;9\@($U,
M;4U&2/=>AX3^DJDWHC;]<"5+@<ZZNWWN+9N]S2!^G_&ATJ(6I@?YMHW;[2\X
MCKFM* "C- IL00$8"6+NZ G@0L['&E!O,HC?90S5!-FZ[3Z@3E$$0&Z1 (Q#
MS.U&"Z'(:#GLW07QVXL_A1[?(XEC]2]XPAU# >,2;OMD"$<)):%3%R!@$@9\
MI ?2WE90?!)=9 H$4INT%N;!?)FJ?(7.S%-Y)HLBK0>_GD.Z='/$P^7A2V;+
M L,"B^P<@I%+.\TA%+TD(T]=M/=#U.^'0$&RO-@U9QP_(0DY31(0YDH"P !)
M )1'DMXG4;]/^MH>G8GL(GTV760M4+4KEX:]L=^F&)3F0:O501UESOX2K U@
M92(6Q91PVTI"T( Q$D34WDP0-&288].V;:$ * LIPW$\TG1H;Z>HWT[]A%C#
MK/+)Y;JA4;D Z)A< '1,+@#ZAER])Z/!&\<<PX/!9N/Y^C/M#0_U&QY?&>^&
MOEG&89Q;QB$<6,9!H*^,]U:'^L]U]LUY=23F.C5Y==:(<&Z2;5?5(BWR'R;?
MAC^8?,S$4B,E5KLZUSGLAJE[5F/;?P!";$\(8"XB6R/@'&I$G=ZL4;]9>STR
ML%,-I J9-B@Y0)QSN#"'<&UR.+L, C;)04;H]\Z-^IU;=^CW>F[Z#E7VJ=!Q
MX-XKT>27CW99;T68WXJ\?;C;!3@ZJ0DCVP'/(%C [(>M.0 C&!-J/XT"N"2@
MR<B>9;W38'ZGT3UXOS.):1S%4N[?E[2'$++=SIT4/G'['L[HK]^JP9&^O\F=
M<*N8>WA.,79NE0NCG-M'0', QIG[Z --&@2,V#MH.GCY58IZW;YU5.8^["J]
M?[%QN'IXL_F^?9]G7;\C5S,"7)^3J\7^O64??O\:]5-:K_-*H4(\F:GP9632
MJMZ_F=Q_T7+;OGI;2JUEV7[<B#03=0,POS])J5^_-!,<W@_?_@=02P,$%
M  @ (H%D4P-K3.#E"@  4T<  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6S%G%MSV[@5Q[\*Q]UIDYE51-S!K>.9]6V;G;:3B3?M0Z</C$3;G%"BEJ3B
MI)]^09H61.#@4!?']8,MR7] !]??.0>03A_*ZG-]GV5-]'51+.NW)_=-L_II
M.JUG]]DBK=^4JVQI_G-;5HNT,4^KNVF]JK)TWA5:%%,:QW*Z2//ER=EI]]K[
MZNRT7#=%OLS>5U&]7BS2ZMMY5I0/;T_(R=,+'_*[^Z9]87IVNDKOLINL^;AZ
M7YEGTTTM\WR1+>N\7$95=OOVY&?RTW5"VP*=XE]Y]E!O/8[:IGPJR\_MDW?S
MMR=Q:U%69+.FK2(U?[YD%UE1M#49.W[O*SW9O&=;</OQ4^W77>--8SZE=791
M%O_.Y\W]VQ-]$LVSVW1=-!_*A[]E?8-$6]^L+.KN=_30:^.3:+:NFW+1%S86
M+/+EX]_T:]\16P4("Q2@?0&Z:P'6%V!. :H"!7A?@+L%0N\@^@+"+1!JM.P+
MR*[O'SNKZ^G+M$G/3JOR(:I:M:FM?= -5U?:='"^;&?635.9_^:F7'-V42[G
M9IYD\\@\JLLBGZ>->7+3F#]F C5U5-Z:9^7L\WU9S+.J_DMT]?LZ;[Y%D^CC
MS67TZH?7T0]1OHQ^NR_7=;J<UZ?3QMC5UCZ=]3:</]I  S;\5C9I 12[P(M=
ME(N%F9N=<4#I2[STS_-YWL[MM(C>I_E\\FX97:2K'+;D"J_KX](LZB+_G^FX
M7\QBGK[Z>UG7KX%ZKD=LFLW6BW71C<!E=IO/\F98R=2,[F:(Z6:(:5<K#]1Z
MGMWERV6^O#-+L$B7LRQZ9<:KOD^KK'X=I8UYJ]F;B)$?(QJ3!!J'Q_I%5W^[
M57TY(Y1(Q874I],O@&EL8QK;T[0=S#E_K%-NF<,2KH3:V/)HM2\C0\4EH"!:
M:Q(/=5>^SE%<^XJ)2G@L.-P_?-,_O"O( OWS;CDS,ZLV(V8ZI7OTNEUKX'K\
MSX>R*"*SW3ZDU?R_R+P1FS<7Z."\J^MU-R9F!Y@]KK6Z?>,?HZ4AGGDQ?Q+,
MRMIL%%NS"II$PIM$*E$LD0KN(KFQ4AYGY9__1&3\U\??CLG0Y)*>F4(*)9R9
M,Z8:-$5MFJ+0IKROREF6S>OHMBH749T67:.ZUD1KLTU74;98%>6W+.M?7*VK
MV7T[/59F\8SUO_(7,1$Q#<Q0O;%9'VGSH/^Q!D"CH3VCN7!7,:X9M"K9M"I!
M6W73=N.D]5CF[:0R;ER==HY0]K5]G$&F)KX9"9&.K2.B@;$DM@R/47.OOF;5
M+*^[KB]7K:&CJ[&O<=L2R0D-F;+E3I!]30$= N)W!*%.9XV(AA9:&A(<AQ^R
MNJGR6<O8IVF:-]$7\VK+H;%N\U'(*5,BL/*)!2'!2?A/LUD5QFL .XMY;SJ1
ML>(.\*['=4/C+(4(QP=U.4?<AW^DU1.O:0QV&O>W'A9303B/ Z991A$<4HYI
M.YAS3GP2&0PQR1W_H==A#@10%3'M(FY=5X#0=2$ R40+KN/ 7D8L(0F.R.,=
M0.+S;L0#)!9Z!*?>83X@\7$&.H&]#AU$B(R0&P@(O4'T):@C2"QGB7YY5Y!8
M(!*<B%LASIT)<:)712#$.2<^XP)4H19P% <<MCM2GV03FD@N ML>M2RC(RQ#
MM[V;;&6F:!S>]JB/+\(9HUJ* ,3H5DB'0\S?]L;,.:<^NAA1B72H>]'KL!4#
M5$5XK+ETW)TK0.A(K@')A,1);';10"=9IM)]H\N] U^?J"/['K50I3A4#]OW
M^DI'@U] YXTB@&5PWP.$[KX'2-!]CUK T[T 'Q[!P*P'"&V8JLQT%6Z7[2(=
MML(BF.((]M?KN.72&T'*E23:-=O7>2,-X)NW?HIP1QH0,G>H?<V$$*7""]:Z
M G1?5V!?5Y,"+,==36H)3/%0%URPH]XF]<-3T-OL=>@P^E7!WB8@]!:L+T&]
M36H]!9J\O*/"K*O <%?AF;-6S/<N3)0L8O,32'U:]X+A[L5S9ZX8Y&]0IIT%
M?#FN&S;(.B4,=TH.R9HPP$/0[H2^'%,-#=[*/N,.P@%Y$^9[!-P0,]1WUAM@
M(R'V;GD3YG.6QXG;6[AH:*$%,<-!?%3>A %L58F6@<B 6; R'*R[QR4,X);3
M<U>X9FBBI1K#J88%+PR(%XGQYMPDY_4.PJ%Y%FL,QQKN8/VZ7N)1#@.@Q!FA
M27C*690P/.CTO:8Q<\Z9'WTR%5/I\.^BUZ&G0WY5)LJ)-?6.AWRA.[.N(8W9
M-F(1B@6Y)1Z/7QZXW&*,XQC[OJ<6'( 5C24+':Q96'$<5M_YX((#Q.+N1CTB
M&K;,4HWC5#L$P]S'FA2)FY ?4PT-WCKDW)M]H]/"1YPP+GYH5EC(\9%H<S<,
M<Q]G)M9U>PL7#2VTP.,X\([",/?Y1CD-&F41QW'$[4YA#@1H;A2*:X8F6LQQ
M'',8A3D0#(DD$>XF/JX;&F=!Q_<"W;Z91@Z1"LTT"DL7,7*VN'^FL:]QD*."
M,HV SF6P ,(O,-,("-U,(R#!,XW",E#@#-PGTQCH,R@H@_-4.TF'#;%4%/O>
M%=K)>#]E#*:J )TWX%!J&4I504(W505H\%25L) 5[.6=+F&1*7!D/O?='!^G
M":4Z)H$S%+%UA^C(2T1[)CF$#U43:B3>3!L_NPW4%&JQ!;3  ?U]_6$!9&@%
MIRH02 N+<''LY:.C_&$!G-=*Y0X)+AJVS))?X.0_Q!\6/ND-Z%U_>$PU--AZ
M P+W!HYR\03@"YAX286V/&D] 8E[ KL[>1(@K9NCQC5#$RV')<YAS,F3/C8G
M,A':S8R/ZX;&6;;*O<YLD:,- @VL!( GM*!QK /^I[0TDR.)4/06#63.N?2O
MO%+"=.)LLQ>0SKU,"9RR<ADGBKASQA>Z+CH@F1#CC,1):/Y;YLI]#VSW=?(D
M<.(:</)VD@X;8IDL<28?YN1)'ZF@DP?H7/1*Z*05<O(@H>OD 1K<R9-;5XOE
MRSMYTB)9/E=4+:%K1X'66V[*PR-FZ9]63FA[-2( /VGA)Y\K%(:W)0!_B@M!
M$IVX$W47Z? BMV6E.B9J!BU70#1LL"W<S#6@<S=4!43-@DKMK2] Z$;-@&32
M[O-2!<Z\E*6U.C)J'F6B D)AG(G*XEH=$ J/8E'YE :QJ("0V1U%*!2&L @(
M72P"$AR+ROH.ZO\0"2M+9?6BD; "N!MS+HD,^'_*8E>];"BL@'O,BKJ9L<M1
MV; Y%HX*CW,/":N4'[U*X>Y*EV.JH<%;GZ[!<7I46*5\PDHM#"\"5EG**IRR
MNT-> =EGYFX%J&9HHD6RPI&,.0(*.-?4+&;:W8!&=<./'UG2ZKU(BQQ?@P31
M "IE8J8;IX%^TY9O>J_[PSN8<ZX!H"DNF8N/7H?A ZI*Q%P)1W@%"%TG ) 8
M)X#%A 8PJRUF-7UY?&A++XU'OL^,#PU<#U(LYJ'M5EO.Z2,YMR<]-  ZXUQX
MLVA,-FR.A:'&8?A]LZ0:B!L%34+I;&VAIX]-[A[W<4>??$RYMP9&1,.663IJ
MG(Z'X%S[4!3^K8$QU=#@K0^>XN \"N<:N+6D2.@*I+:HU,_U,1GM S'@82:6
MA<GA'Y-)_+!Q(A+!G;SL=0+$>T/=T#A+P^2Y/DT#DC$!R0@&]CM)AZVPN$J.
M^> -;#EPZ@D%]H#.74I056!@#PA=I@.20& _W?IZD?;K9DP0;$+C.BJR6U,T
M?M-&&-7C-[@\/FG*5?>-(Y_*IBD7W</[+#6[8RLP_[\MR^;I2?LE)IOOT3G[
M U!+ P04    "  B@6135$^H7R,"  "O!   &    'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;(U436_;, S]*X0Q8"W05OYHUJ%P#+3IANTP(&BP[3#LH-AT
M+$2R7$E.VG\_2G:,#&BZ72Q2XGM\I"CG>VVVMD%T\*QD:^=1XUQWRY@M&U3<
M7ND.6SJIM5'<D6LVS'8&>15 2K(TCC\PQ44;%7G86YHBU[V3HL6E =LKQ<W+
M/4J]GT=)=-AX%)O&^0U6Y!W?X K=]VYIR&,32R44ME;H%@S6\^@NN5UD/CX$
M_!"XMT<V^$K66F^]\[6:1[$7A!)+YQDX+3M<H)2>B&0\C9S1E-(#C^T#^^=0
M.]6RYA876OX4E6OFT<<(*JQY+]VCWG_!L9Z9YRNUM.$+^S$VCJ#LK=-J!),"
M)=IAY<]C'XX R?4)0#H"TO\%9",@=(X-RD)9#]SQ(C=Z#\9'$YLW0F\"FJH1
MK;_%E3-T*@CGBH5N*[H3K( LJZ6HN"-GY6BARW(6=$V>+K>-EA4:^QX^/?7"
MO<#9DAL*:-")DLMSN(1WP, VM&MSYDB;S\#*4<?]H",]H6.%W15D\06D<9J\
M E^\#7_ DN!)@,=_PQEU9&I+.K4E#7S9*3F'^D^6_^MN;9VA*?S]1KIL2I>%
M=-<G;T$IFFGK$UU QPWLN.P1SD0+E9:2&PL=FJ&[YZ]U=^"_"?S^Y>Z*!"_C
M6<YVQTW\5]0@GAV-DW_*W[C9B-:"Q)IP\=7-+ (S/(_!<;H+$[;6CN8UF W]
M4=#X #JOM78'QP_M](\J_@!02P,$%     @ (H%D4QC7R3>6"   IR4  !@
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M(8MU(BL=/"1=)=6SP%P4&5!&)MV:$A0<Q"QHXQW:^*<\!)%5R$TQRV2=J@U
MAL>R?!%]]&/08P/8E(Z#"Y'A%$=.O:%R\-S)3)73=L-!6(D*(!+QMM:U!&S0
MO*TB8%?6"3@"#%MNFDT%OZCW)-<;$>5[SXRM,!REK%M$RK.8LE<$T>-,Z?"]
M@P4OHMS\NB747'"?C;V"2-DL88,E[-><@L)D!H H&.]21(BR(+  '1B6\N.
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M(@&&U +P^U*I9GNC)]A]FW7^?U!+ P04    "  B@613G[L,EWP+  #)'
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ML":47KPUA2JF^_>AXJ#G4:_GFZ-O"KQ2S4(\.9B+HX.CPV_(>S+8_83E/7E
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MUWA6JQ5HE%6N@@YM 9?C_-MNK0";&ZDKF>E*AP[>#*($%2HW+ 5J2%YFBP[
M\8TUA:>C4!"PZAXA,;XPE!Z_#CGXD*6],0!<J7/:J.NV0HR\4*X+\&ICM0K:
M\,*WEQ_F?3@Y^0GU"&N,.]0B6&>5M7B+8L%[/KXY&>_A+4"4LS=8FPPH%&'.
M=20B:.];Y>^$K$E;:#]JX+5*2?&[!*PID>0('X28*4"  EJ=67BG !<A/GZO
M4"C0!6T@J<::O?Z3&'TJ4*5$ U<R<;5XV\-1(I9&U@JZKKRRXM.%6%#.]VF,
M>IW5.I"F4KQ'F3UU[5HLFZ9"2D8/0M'WI\LY6XZ-GQ=7"W%&#B2-XO("M4L3
M60X[SF@'V7@S\I$1%](AA(@V$?V/9$URRHZ%C"#ZA&CU_N!C3T_W\#I&_:$]
MQH8[^]['C1/7_,V3W=%!GML48CR9YZHA=Y'R*R 8E 36(3-@<[2QB^:Q$B%:
MB%:'C$L;Z%7TZ;"M(']3DI9Q"])$@3I)V;P%&9M0=:*II#$LP(K25A0"./]&
M>PMD0FV.I!*UHGS@5: 9]!F>#Y+;J.Z$)MI-BLC*$^?WC+&S"VM-(5V!++JA
MGHPMY&J:.]WP$@;$9U0B<09-EJ"51Y>GG\^6CT60;HT^5,8D*U*1B(@X^H5K
M_]$D  -GHPT">=@(+T34!:/ "Q^";Z]Q_+2*G-B%^$<H4,;&T+[@?"2G+-M0
M6M<3SR[2+Y9W<?L_PS1ES-L6'*40J@N%**."HZ2"4_(N,M8%3L3>#R"[#&YC
MZ"Q0B2&MT%&Q4=T5)1,):F6M'+<LB;GFL,QU8%#Q\T^'SXY_%8^HB(/=<TV)
MJ1[W! KJV")J(*T1AB?\Q<9O;(]0;AU2H?]L-*W@>N]?\*L<?2$*$SD($&AK
ME!GK\:]KJ?*B7O+FF&R[WJ)C[[A9.\**6L%OY+'D=G;<^6ETW/M[Q8&C)N8S
M0S.XOT_3?:V?D/5YS.X=I7MLI'K1JXUBIERTG?I)ZGGN)[%>=^C2VW$O?7^D
M1F4WI%S]*;0+<85.C#H (J=[(8-NQ9*AM?71L=  >6M;ERL?"R,:$LI%TF74
MVY"/\ZHM*'=H$_K,'"3&N<;%M7\8]T,\C@&\U!W0(G*.9A$ OG)IJQS5C1N%
M?&W02@[Y1HW?T*Y.BU:FT-="8S2?+!1TI PR<>5LO2U27E:Q2^P3@\Z<+ 5#
M(/MI""4A-.*Q*_KU R@&N;O,Q)])TT1*,#?N^&0S5 H;.^K844 VSO-P ^9C
M+'!:W\-=\T1>Q'F*AUIDZ>^?6 3OF5/Q.E6YJHDM#H^(. ^?PVD5.JZ^N" /
M>1#OFRN)F@#V=1%T?Z"1N15O=AOPH?^'_WG)O._Y+W@SNK_$2+*JNOGH2*?6
MU))1%8KI)9D"IK6?'3,%YC:.:XPI+,EV:"R[/DP^NOX"SFLS[4LM/DDC,Y4<
M!T%Q^ACH^],E>KDA7(0 4B0U/U!BV:ZA$)'L 7/LF<I<2_$@VITJ!QPKQ]1
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M]3+EE"E4<M8K$04&*V33(&ER#EN7+<+.J[RH%>46SWDO_2#39!M6UFG*)W+
M)B ("P0ZQW$ZNV:K>["8!=R0KO3B8T-YY3!/9Q\'G<=OLN5'=UU9_.%-;Z:S
MJZ%X&S791AN*$834TJ"AD\<#CJ0L/Z&3<00&C"CM62:6&HHM9;)HG>-,%H5K
M9>79:J?6FMH_@U=A$_*@.AFEHM@;52COJ1 H^E(LI':$Q!W.DU>_%MT)&B4Y
M'($()>C]GA63AK!R2K'=!K4JZMC\%#4_,2-TUW/DKNM? J7"F.L\T"@#;4ID
MG].9S.Z4A)4,".P6Q@AUWV"HD<E)\T+[ G9OE72DC^+X&E*COG'21^$!^BPV
M.+%H0PO]#1RQ<.DWZ@5=^80DKJ6;R9'K*)SCHW%[L[(H_%.[,9#FVSD2JA$$
M144"S'"U)X,P=RNJA @*=&?C)0_U?GY4I3$?9<C])]F*94/Q+B,2.SS&-H1C
M-=9R7/OV@>\X0AE)L4BC5\N(Y,U*%RLJ1EH];SVV>_:N5&N0FZ;K0S"ZAND(
MC?Y,]XS%8]KD9*/:H(N(F$99-(K8'>]T::@)::_ ,&(Z^GVGPUZL:ICP4RL=
M7*BHS5$/A*6"6 HUN)^$7]FV*@DIQ--2.#ZU)A(AUMCS^/>_>SX9/_O!?T-^
M.?R'4(F]:]_$+X5/C4%9'S'W;QG%'7PAY!"](]A3X7ZVG>8#B@I=0P>=@/'C
M?;&29LFZ:^V9-Y(B-4='08.8/(V5P+V+A+#@APV+>?"]X=J?8MUP;7UT.DZ_
M?LOQW]MT?D5#2=V5@)YB96$&@ 4NF0Q]CWR)23=#OJ6HCR;T*\&+(QD6M4V4
M/:<# ,VGW+&'XCU8>Y^P.&OPNTB*6=7X!T@O< VL3TO+' $3)P-D,AJ_&,2Q
MA6F$\O0M5F"<\9/3\62 Y4"K$A_D/=+UAP^HU$(\.Q_]\26($X:U7C",>5KN
M;*$<]#<2&%!X/HU!N%-(/%.+A>*#14Y:[B-&_%4:!E[JP,.^61U[0-DI%W!Z
M$A!GRN@Y<H/B92X 9ZC5H+4@_R6 J&@L!F=]DQ1CF;.R6'4=*@N6.$#4S('6
MZC0:VAO%D4V09DA$Y0%B2T_Y2?UZKI;:F#2F#X<,;DE*!L#.:M'(XESI.;'K
M0ITCQ*!0)SO3YT1,T_1)XJ*V?J1+7?*<Y%:/*$B:OC $N<,4(*''X/E]E1=)
M1\4+J&@JZS$F8>)'SQ/YQXZ#L,T')?]0]1QR829J.4L[LD09J>6=VC&=Q&MQ
M8F[BN.-I)6,J(SN@PH.QLL[#%NM5<J72<JZK78?<N40+81=!G30_M"=JH8#M
M4/#(7#AF#CB<,FTR@)@+4H$)W+JNZ'8LOF,CTR*T3 HC]2'6 ^03\5TX6Z>>
MEH.T-]T[9LAQ!2<$0JSC+*0W 51)5# XA<@]EGZLM\=Q;E!M%5BGC+2Z-^[)
M_*\EBUJ@W\W%HV/B^%FAYU:-HN4RVN[-HT]MR>0D\P(X1LV52;DL@7\NT$3Y
M4BPHG E"/4H=YS<YE=EEYCCD6*1%$ <CXYC%)D]O9U#)!&U:M+;4;2J^]-X6
MF@LI#^U^<+J8]*+9LX:$;5:*[89?L%M3[PDX-N$$0C'-5L9>B:AFSA_)<V*X
M<4OL,4D!A3X%"@LQ*SDD6ZW0K:1P3"$@H+$T1C4?3\&C/%RG8]DNW]W!HHHW
M.HVV#30VDA?U01(C#/$HU4A$R0):/ >*,XD[V8QCJH>]1G0(L 5HM=TPSFGK
M@/10$Z=8^I<1?^BH#%8Z:_$\ >]T&!W<(V)"V.)4KH,N^Y!3$4-]H%\,L-GI
M=4S!WOV(0&/-*9WS2/3>XQWXN*+N.35-"Y-(&1%J'6=6MPO'=H"BN#NE-W),
MN<G0F-IL-')<MAQK6E%5<FY3X>6>M%.\QMG#MG2HG^=BIKBX-9_TXT@ UCJA
M7E9D.;LD_2J>5Y"@3GTWE[+%?2&TN8=19[>RZB(!RPCN*2S$/P+Q#[K"1%QJ
M D(O_$MKRXVNJHCPCGS0(:>6Y1&T=E-S(:[_\?/;UZ?C%SO8?2]?3>T?GJ0#
M:FH0D6/N-6M"Z=[9LY^#WK84WD9N0:MJ?3_8)8.12QCG(^'7XS*M8$.[W#OS
M0!J]':(#%.VA?ZD5]YO0_A@JF,ZD0=2Q$ A(,TGMSZ3KY O\57NUZA2]>^H-
M! Y#? L%4DD)OS,X%>\GE'#N^=S<RZCI]T;"'6!#+XRX%2<\)UIV.)9T($*N
MU5KYW$%SGVF1^DAF"^W (8F*%>34WS.8;W=@GB4POXEIO>W O&<_VK ,_GLJ
MPN,(Q$<6G-XDD=I2S4.'0[/D_@;Z\)F(<K9[1\MS7=*A7M08*0@V3N1N;WA3
M&UOTWKE$N_*,B>9@]I(;=<S,_^1&9DAL?+(XO5-TS(,C/3YZ+$\=<Z^4OU!P
M, ^YQV<W^\Y)QZ.%*G<?8E0M"8T$J%P:J2<?A *5F6C*!YM6\*GSF </6[Z3
MPW%8$DI@,VJ^BIHE'ZS7#.6>F,/L!7KWPR<5WV*.9:'TZG17J;%VHY5'!0_V
M>@0')!Z8'@55'!6%!2_[O //HY/AZ#'H?;>CBTT:4^2%4XLJ)H!><Q\\3PT<
MI#4.OOUAQ^R-NT!:'XE)MF\/C?PZ"Q ]5/F%$]\Z,'IC K(SB^RX=8TDK(A%
M$F.P8*['OKJ<];YOU<HM^2L>-V03XJ>N?#=_*)S&[V.[Y?$KXSOI<*SU@-<"
M6T?#9T]/A(M?[N)%L U_+9O;$&S-/U<*D]31 CRGU__=!2G(GT\O_PM02P,$
M%     @ (H%D4TI?)__@!   4 P  !D   !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&ULM5?;;MPV$/V5P=8H8H#5ZKHK);8!VVG0/@0PXB9]*/K E697;"12
M)2FOMU_?(:E=V_$%:8H\6,O;G!F>N7!\LE7ZLVD1+=SVG32GL];:X?5\;NH6
M>VXB-:"DG;72/;<TU9NY&33RQ@OUW3R-X\6\YT+.SD[\VI4^.U&C[83$*PUF
M['NN=Q?8J>WI+)GM%SZ(36O=POSL9. ;O$;[<;C2-)L?4!K1HS1"2="X/IV=
M)Z\O<G?>'_@D<&ONC<'=9*749S?YM3F=Q<X@[+"V#H'3SPU>8M<Y(#+C[PES
M=E#I!.^/]^CO_-WI+BMN\%)UOXO&MJ>S<@8-KOG8V0]J^PM.]RD<7JTZX[^P
M#6>+Q0SJT5C53\)D02]D^.6W$P_W!,KX&8%T$DB]W4&1M_(MM_SL1*LM:'>:
MT-S 7]5+DW%".J=<6TV[@N3LV956S5A;^( W*$<$+AL:&]0W:(!\#I^X%GS5
M(5PJ\D2#FCLV3^:6E#N(>3TIN@B*TF<45?!>2=L:^%DVV#R4GY/1!\O3O>47
MZ8N USA$D,4,TCA-7L#+#DQD'B][!F_/P%JKWEW6:HH8\H9MX=+[ 37\<;XR
M?OW/%Q3F!X6Y5YA_?^J_BR+X34'#+3*PK=OJ!RYW/_Y0ILGRC0$ENQT8->H:
M0:UAF'3H24?+#:P09:#3 7R,KB,PO".==/Y\U+M;P2-28GD'DLK/EQ!;@CC*
M%E%)<=]U/H7)\*,LC_+#BK/>@=M6(T(?(@Q=A '%A\5^15[;!XF7IP%--9H!
M?4'H=BS@)G$<)0]557F4/5(EB=UOU$2W)8"UZJ@4"KD!ZTD/]5#\0\3X&B7L
M#H0$Y'7KF'(ZOZ2&.P0NZ^!+'7P)-3EKH[28O/J?C857I-:V:C2T8HY?PV7+
M]097O/YL*&!6!&\8O$-T,SMJ:2;O7? N&&/A+=83>L("Z!&4<4K?K&)5X@:+
MO*)OGK!LD5%J:8W2._]&N$IOZ#H=:6K JBE<R*IZ.K9#KJ$DH 22N&!YED+.
MRL4"DJ1B:5S!>?,7)2N]&O8!T* %,>*E ^:KY)C^6%'%Q^!C.GT3YK1^J;$1
MULP'O@M /6\07I6TFY%45;$B*6F0LVI9.9@D8[$#NL?#$S0?0<+(3'?WG*79
M@@:%_^8%*ZOD!1:]T#(K'8LQ*PK'8EID;DHFY]_&XI*5648L+EE.QN4L*7//
M8DYZOIK%LCB&99Q!RK*TI&^5+YZC;\F6L2.]6K R7M*@8%7EO9#$+*^JE^ES
M<;0LBQ XY<(3LLS=-"/[R_NARJ 1IE:C4QW2(\0JUTCC6FF7!E1;.)VCN<LJ
MEUPNQRG=]BFFI$^@4?*1;D,2M:+\D2:,C.I$XVDQEG[</9TP]4JA=IKP<' Z
MJUT%(%F7\'>:B$U>3T:2$2AN?"WX6JVKB2K_\)OH+COIZE:+U>B4_+1WW1K=
MEN-"$?KDO,-NLS?J*8KN+!;R^W(C9$U=I<&)&CT20$?/DNB$=26-(N_ &(76
M_Z+K_#'US+]!#X(]U-P0Z>XQX@.MW0IJ!:F6PU&:1NG#]R)-HNINQ;]SSY3;
M1V7RBX?BJ?9B?J_+HV9DXWM9 _XFH>$[K![:Y?/0)=X=#[WV>TH608[H<$VB
M<;0L9J!#_QHF5@V^9UPI2YV/'[;4\J-V!VA_K93=3YR"PS\19_\"4$L#!!0
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M!:8 B1LA/4E4GHZ"'DY&@HGGJ2FPZ)LMNBQ;TS%41L*74LT#P Z:!/+4R-9
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M*,/0BH<$UN^-[ ^4:VE&H&[0 AQ]T>NZWR9)Z.Q,)+>=E+&&WC>UX#.- =7
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;*U9;6_;.!+^*X2O."2
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MFBA5E)*!' 3XC*J<(@H;#&4YWB.^T^J85T="PJ&I/'.*3JEFGXD.Z'Q.@C
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MCT+9K9Z%"FCW*FCKTH0N).K4,JP1/$>$R) NTPS>7.F:QFTGG?:6H:51V?K
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M$Z1'C+S"T,,590[K=2YG\?BQRV063_ZSS\%CGW$HU!PSY@0YO^3+?-.-^8Y
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M]ZDO?^+F()0%B1U!TYMR$8&9>MVT<'H(_66O'76K,#W2[P&-=Z#]3FMW7?@
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M8)$6+%CO*(BU?">#O+IT=BT<O0TTNF!3>364TS4%Y2$X/-58%Z[>J66X/ Y
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M+S7*Z?.>>+%5)#@" @D>H] K9D>(!RE&=2FSO(CV?;%UQ"NT@_+)>QR!BT$
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MVN+&P4)<5KJMHL3=^]@CMT3]:AS_G:@O%>47KT="<>?JB5N[_$65.X^B:C)
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M/SM"D^"/:_%'L U_T (I8ZKDRU))I R]@.>%!=6G'R2@^\)Y]5]02P,$%
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M<]LV%OTK&&_:M6<864]+:I/,.*_=/M*X<;O[86<_0"(DH2$)A@ MN[]^S[T
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MA)(,(P(:Y62%+6M-?2#/!5PO>.6QAV&A\D0NP8:H 3NFN'L;*;F/\=ZX.#D
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M2J%!.5J ]_0K;'-#"MH/4E?_ U!+ P04    "  B@613=\;S7ZX#   -"
M&0   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6R=5FUOXS8,_BN$=QA:0*C?
MW[HD0)+;8?MP0-'V;A^&?5!L)M9J6YZD--?]^E&RDTN!-CCL0V12$A^2#R4J
MLX-43[I!-/"M:WL]]QICAEO?UU6#'=<W<L">5K92==R0JG:^'A3RVAEUK1\%
M0>9W7/3>8N;F[M1B)O>F%3W>*=#[KN/J986M/,R]T#M.W(M=8^R$OY@-?(</
M:+X,=XHT_X12BPY[+60/"K=S;QG>KA*[WVWX*O"@SV2PF6RD?++*[_7<"VQ
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MO3>C>2&4&J*9G-3^H]P[RZ>2X]SF1C^B=L8^P>L'L5-(;U:)8UQ_FE0GC.V
MD7\#8P'OC78-P2^ZQOK+^(3YC*3R9U+;_$7 >^PNH$ACR-,\>P&O&(LL E[Q
MW2*O)57*4&\1_KS<D;-\*_YZ(<-DS# )&2;?S7!EVLYH5NAKC7P1Q0_@DCI1
MX3KB"2.TCQAM'AJ$:@0%LP<Y)A-<QS!.\A^L01#LC>(YHR5P#QVV.[1C(^$:
MJY,E"Y847DL-KC$]"5W3&[@31[Y;#JT4BN 5Y'$Q*\-[.LGA X\7YX;.F@J)
M8%;&\VD)Y21.V>NMU)*O80T'8VJ"K(RSV0RR15PN,G@P3J@SWJ]@,8TGZ8*%
M>1D7+/QJ].$GSMQ^]HKAV,BJX7S2%ZB>N V\#&AH@OV"*_,/XW_&+P9)K%:J
MYTOI[<8U7+L@0N</N' ,7TOHIQ]_F.?9[&>"7HN^EHX#.%?-NV>0R"A9"V_>
M"25TQ5WW$T<7_ZO-VQ/&?=BZ5XHIR;VLA%]32[@YZU)1Q.5\SD*9Q6DV@]_.
M2V#;C-/ETSA?Y/^AQ5^[YLG9YFC1'L)^)"ZYUVY8(J-U7,&7P^;Y[#[L[_?"
M'J0F4+CGT/1B-HW #CMQ4)SIPA[:&<=;+8@-_T;0>@<^WQOCGA6?8/PQ;?X%
M4$L#!!0    ( "*!9%.%8Q9_Z0(  )@&   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;+556T_;,!3^*T?9-!6I(M=>*&VE4C;& Q*B;'N8]N FIZV%
M8P?;H;!?OV.G#4Q M9>])/:Y?.?[CN.3\5;I.[-!M/!8"FDFP<;::A2&)M]@
MR<RQJE"29Z5TR2QM]3HTE496^*12A$D4]<.2<1E,Q]YVK:=C55O!)5YK,'59
M,OUTAD)M)T$<[ TW?+VQSA!.QQ5;XP+MM^I:TRYL40I>HC1<2="XF@2S>'26
MN7@?\)WCUKQ8@U.R5.K.;2Z+21 Y0B@PMPZ!T>L!YRB$ R(:]SO,H"WI$E^N
M]^A?O';2LF0&YTK\X(7=3()A  6N6"WLC=I^Q9V>GL/+E3#^"=LFMI<&D-?&
MJG*73 Q*+ILW>]SUX47",'HG(=DE))YW4\BS/&>63<=:;4&[:$)S"R_59Q,Y
M+MVA+*PF+Z<\.[V4ELDU7PJ$F3%H#3!9P(52Q98+ 9U;1BYS- XM%7,I8;X#
M/FN DW> 3^!*2;LQ\%D66/R='Q+)EFFR9WJ6' 1<8'4,:=2%)$KB WAIJSSU
M>.D[>*U&)_AU&\ZYR84RM4;X.5L:J^G[^76@;-:6S7S9[%\;_E9K#T*X>SHR
M%<MQ$M!%-*@?,)C>;A!62M EXW(-UAT;>*\D,9:<<U563#Y]^C!,XL&I ?Y,
MA.U.W@(UV6*Y1-UVVK?G'/.=-?;6"#I<$JJJ#;G-T>BMQ NMC($YT_K)49KE
M>5W6@EDL8%8J;?EOYB_FK;),D/N^YII\KWB-J/P#38^*G)5619U;T.ZR&1*L
M85;KIT?.X",D<=KM1RFM.B?];M;O'=$RC@?=.!V^(>$0O\4<AEGR7ZCU3[I9
MFAZ!/XCDU%',LFX\B. +>U#:'YQ &C30RWK0(1&=7A8]QS><'"1E9<,6<NC4
M-J'/D&]]L.&+:5&B7ON9:"!7M;3-X&BM[=B=-=/F.;R9V5=,K[DTQ'=%J='Q
MH!<T^O<;JRH_>Y;*TB3SRPW].E"[ /*OE++[C2O0_HRF?P!02P,$%     @
M(H%D4WXYC-<C P  = 8  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
MC551;]LV$/XK!Z$/+2!$$B7;4F ;<-H.*]"B1M)U#\,>:.ED$Z%(C:3B^-_W
M2-EJNB7!7D3R>-]WWQW)T_*HS;T](#IX[*2RJ^C@7'^=)+8^8,?ME>Y1T4ZK
M3<<=+<T^L;U!W@10)Q.6IO.DXT)%ZV6P;<UZJ0<GA<*M 3MT'3>G&Y3ZN(JR
MZ&*X%?N#\X9DO>SY'N_0_=%O#:V2B:41'2HKM *#[2K:9-<WA?</#M\%'NV3
M.?A,=EK?^\6G9A6E7A!*K)UGX#0\X'N4TA.1C'_.G-$4T@.?SB_LOX7<*9<=
MM_A>RS]%XPZKJ(R@P98/TMWJX^]XSF?F^6HM;?C"<?3-\PCJP3K=G<&DH!-J
M'/GCN0Y/ &7Z H"= 2SH'@,%E1^XX^NET4<PWIO8_"2D&M D3BA_*'?.T*X@
MG%MOZMH,V,#'1SIFBQ;>?N,[B?;=,G%$[YV2^DQU,U*Q%Z@J^**5.UCXJ!IL
M?L4G)&O2QB[:;MBKA'?87T&>QL!2EKW"ET^YYH$O?X%ORT\A-^"J@9 XEQ;^
MVNRL,W0[_GXE1#&%*$*(XG^6\[DJOLK@'^&U[7F-JXA>F47S@-%$BY=3XA9T
M"U0@A]T.S52ED-H'K,_6+%A3X 8]I-62'J&]?@[X7]!;H< =]&")T[Z#K='-
M4#MZB0^H!N+S7%S5I.8-%$7,\AE-\C).BPHN@FM*3]1<0E;%C.RLC*MR#IM.
M#\I9:(C'::!++/E.&QX>:L^-4V@LL$6<+V:0+>)JL8"OS@[W'+:WW\E?.2-V
M0W#/TCA-T\MP"=SSDR'64 ^#DCNR92PN\P*R(BZK"CXC/6:0@N^$%.X$LWC!
M<OHRTG>K3UPZ0:GE<<H8L+BJ2E^!%JUO1Y10B[1;Q1F;DP];9#]3UEV'IA;D
MTW$UM'2S!B/4'K)X7C*89<7DJMV!"IYE<3$KH8SG10'?M",@__=YOR'51;Q(
M"S^C,YNS IZ[KLF33D J]J'?6=)$Y1Z;PF2=6NIF["0_W<=^_(6;O5 6)+8$
M3:\6LPC,V./&A=-]Z"L[[:A+A>F!?@MHO /MMUJ[R\('F'XTZQ]02P,$%
M  @ (H%D4[NN)U&% P  P0@  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N
M>&ULK59M;^,V#/XKA'<86L!7.WY)TBP)T+0;-N!Z%_1E^S#L@V+3B7:RE)/D
MIOWWHV3'R;8VN WW)19%\N%#BA(SW2G]V6P0+3S70II9L+%V.XDB4VRP9N9"
M;5&2IE*Z9I9$O8[,5B,KO5,MHB2.AU'-N SF4[^WU/.I:JS@$I<:3%/73+\L
M4*C=+!@$^XT[OMY8MQ'-IUNVQGNTC]NE)BGJ44I>HS1<2=!8S8*KP621.WMO
M\"O'G3E:@\MDI=1G)_Q2SH+8$4*!A74(C#Y/>(U".""B\:7##/J0SO%XO4?_
MR>=.N:R8P6LE?N.EW<R"<0 E5JP1]D[M?L8N'T^P4,+X7]AUMG$ 16.LJCMG
M8E!SV7[9<U>'KW%(.H?$\VX#>98WS++Y5*L=:&=-:&[A4_7>1(Y+=RCW5I.6
MDY^=7ZNZYI:J; TP6<*UDI;+-<J"HX&S![82:,ZGD:58SB,J.MQ%BYN\@7L)
MMX2T,?"C++'\NW]$''NBR9[H(CD)>(_;"TCC$)(X&9S 2_O$4X^7_J_$;[@I
MA#*-1OC]:F6LIN[YXT34K(^:^:C9&U$?94G(JI$62[CEDM=-#7=$@@DX9D1V
MJ.&CDN^OF2Q0N&. #TCM9UX[BY-!W;V>F"TK<!;0Q36HGS"87QE0%5!5+=8K
MBK4O;0C-,<>ZXZA;CL41Q\9SE,2Q.' 4GF,(]%P LF+C@M@-@L1G"Q5=0'A!
MIMN26^4@24NO264)BU&YF2%?06^%F<"G+6KF3J5-'9;LI0W]D5ZK@_*,2T)1
MC2%0<T[E=(^14[A\X!T,PG&<TC?+,R^EV:53)3 *TV3LU$D&>9C'F=M.:7E)
MEFD\HM4P&[E-IQ]E0_C^NW$R2'[H)%+DM!R3ST'AI(=#3ED8YTFO;J4'G_@[
M5_-1/*1%$N;CW'W'X8 HGVBTO&^T_&2CW?"J(@YT+K! NT.4\ UZSQ_;/T[%
MP ?.5EQPRU]OSI-$_VMSNEYJ^\,1T.A]'&NG* ])K[JDW;;N&^(;M';;N82J
M^C)X!8A#%29O-^?C5S+HFV/9)@A/3#1T.\H_:28X$VB,@^>RH/1:_Y72NJL+
MLPAG69B.X_,C+O\BZEIN2)=@^&K+14=CI4:]]L/3@&??3IA^MY_/5^U8.IBW
MP_V6Z367AAA4Y!I?C*@I=#LP6\&JK1]2*V5IY/GEAOYCH'8&I*^4LGO!!>C_
MM<S_ E!+ P04    "  B@613F<X11.@"   &!@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6R-5-MNVS@0_96!GG8!-;K8EN/ -N"D7>P"VS:HT^W#
MH@^T-+*(4*26',7IWW=(R6J"-L&^2+S,.7-FAC/KD['WKD$D>&R5=INH(>JN
MDL25#;;"79@.-=_4QK:">&N/B>LLBBJ 6I7D:5HDK9 ZVJ[#V:W=KDU/2FJ\
MM>#ZMA7VVS4J<]I$670^^"2/#?F#9+ONQ!'W2)^[6\N[9&*I9(O:2:/!8KV)
M=MG5]=S;!X-_))[<DS7X2 [&W/O-7]4F2KT@5%B29Q#\>\ ;5,H3L8S_1LYH
M<NF!3]=G]C]"[!S+03B\,>J+K*C91)<15%B+7M$G<_H3QW@6GJ\TRH4OG$;;
M-(*R=V3:$<P*6JF'OW@<\_!_ /D(R(/NP5%0^5:0V*ZM.8'UULSF%R'4@&9Q
M4ONB[,GRK60<;3]PW?\VSD&'%O:-L B_W8F#0O?[.B%VX,V2<B2['LCR%\A6
M\-YH:AR\TQ56S_$)"YO4Y6=UU_FKA'OL+F"6QI"G>?8*WVR*=A;X9B_PO1-6
M2WUT<#M%^^_NX,CRX_CZ"O]\XI\'_OD+_#M-\LU;J7K_U&"/96\E2>2$/):J
MYYQ ;4T+-T*5O1+A69H: H#O?J[%KTKPJ@+?PU>N$R5N(FY2A_8!H^U=@^ \
MGP.I@7A'OL1P\#T))^0TX#.!WJ1\+K(:16H6J<XB VD,G97& IF ZQUZ^^"%
MQX3K[3?@9US>0XO4F"J&JL?16%H0/F75.658U]RN5[!SGH/+3]@>V-'Y#?A/
M"E^$M8R#1;J*BRR;_A][<B1TQ24>79K.ZW>09?%B-8L7LQ5D:5Q<9O&RF,-G
M_8#.!\69(2M+OQQPO9;D8!'/EI?Q*BM@'J^665PL5W!G2"C(EO'\,H_3HH"L
MB+-B%J>+.?SJ!25/>K-%>PP3R$%I>DU#FTZGTY#;#;W]PWR8D.^%/4H.1F'-
MT/1BN8C #E-GV)#I0J<?#/'<",N&!S5:;\#WM3%TWG@'T^C??@=02P,$%
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M\X%>\W&+K Y7='<%//<"(!=! Y_%^>:NA8[73H]7^?/&_'U>@)5:NDF9T0L
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M40^"/ZXHC8_C=,<NZDV) 12-K46(.G[H_U"49I23"##L5Y4!%<7>B";"KI%
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M+553PS5 O7]B3+[>Z ':(]3Y?U!+ P04    "  B@613A[B&-)T$  #E%0
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MX G,DK=!H?/OD<<>]Z\$$&0&D-/\^[Y).VJ]'T/GXFN)*<C<Q P<C"+UI11
MFJ)FB=16YRUA5U.)-,B,-*?Y]"-&X$A""YJ<BZ<ER* 3WQ_5GE;[E1Y/#R1<
M:PB-!3F2&(7,B/!!:7Y\EHTELF#[3#R/)<9@<]\RH =?UR*(4LOWO1F7:(+-
MV_II3OJ <3*6L('/Y4P%EJ"!/^)4!5;G7,1!:CN_P)K3$@1HSE\L-2+!5'<
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M)5'Y<4]=GV:"@'^_31)VN! /:'Z0<?U_4$L#!!0    ( "*!9%,B.["A*@<
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M'U><S7F2"ZCO%T+(S47^'MKV[<SS_P%02P,$%     @ (H%D4W.K]5B! P
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MX]3[S8J<?3@G'XA%% ) $9Z0^X1K=8$O\?GW4&0*%U5S2^.N##?++W=P5>S
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MG-)>-AL6@6GTDDXJL0HDQ53D;')>@<F'5/7;=HKT5#%N![O:WZG3+V<I?(
MY2Q%3/Q&YH@24=#*PSGAX74KE];&3ON=?2TAYEE,Q"'7"53=5= I$F<<LTGR
M)])7K#YMIL\9CKOJ6QL[[7?V%]HL%AG*_&?8M](\]7%WTIG<VL=IOY&OA<8F
MY"S"GXP1X.K8<N51U,K".VD'Q^NN<6WG=/Q?'8/+,O0;,U/[.>TW]%[+[#+V
M6] X_4U.2FOOIM/WXJ6UO=/9_W+<797K_.B\LQH7%W.1Q9_3>YXH$L$.<?9P
M@I*4Q=VP&&B1YG>9K=!X,\H?0[Q/@S03\/N=0.67 W,]JF[HB[\!4$L#!!0
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MIIL^"&.@]Q/.U69BVD3[-V+\!U!+ P04    "  B@613$!UYP6X#  !3#@
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M>(%2*N_8YALN%N3I> &C(OL%FV*N98 @%9)%!5@IB$B</]%SD8@* +H- +L
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M.X%QNR:3K+6D;:E1&/?POH["<'@6'GFEV5#5"1>UX<)XE%W2M<6R).[#>QV
MX? $?'.UW-:&DK/&%J?!9?_KDHN"!%^B^B?'-GMF_D+4F@F-.%V!8G"=0JCJ
M< P]W!BY=2>YA31P+G27&SBZ4V4%X/U*2G.\L8?#YL_ ]']02P,$%     @
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M .]G4IKUC?WPN/D</_@74$L#!!0    ( "*!9%.K26.(;@(  $L%   9
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M.]3.@/972MGMQ'5@_W[F?P!02P,$%     @ (H%D4Y'LS8!0"P  ADD  !D
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M( @/(/R;2:!:YV6&OAW]!-[W^&GM)G"=&#VA81,/ 9M8PR8VPV;-$SW3Q<(
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MJ66;KF;BW51EUYJS]L'M\N[?HGS2UQ1<J%;V(9H4F?A8S=@H*5:G*M%,:FI
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M#')^L7VC5.+6A#/Q;23X^.DY39*("R#B&?+3$)W3E$?IC*1!1#)TB$9A&$F
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MO?EN FDGF/M;(?3KP&[EVR^QY4]02P,$%     @ (H%D4]:^7;+N @  40<
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MCO:AAB]*GJ:,\(*-!<(=DN=5JJ]SU,PEVRS><3;F@EN7^7B EG%A3HC#TV@
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MW0;Z/E'*;B:NK=:O:/\74$L#!!0    ( "*!9%.<@_6%*@,  (8+   9
M>&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;,U6VT[C,!#]%2M/BP3DUB8-:BM!
M8;5(RVY%Q?*PV@>33%L+Q\[:#H6_7]M)W0LE[&-?6E]FCL^9F=@S7''Q+)<
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ML)'S&V96UC56>#P4?(6$L=9H9F!C8[VU&L),&F=*Z%VB_=3XAZZ4[UQ*5(%
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M<' N>&UL4$L! A0#%     @ (H%D4_:=5+KN    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ (H%D4YE<G",0
M!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    "  B@613VMC*9$ %  !J%0  &               @($-"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ (H%D4W(<@\BP
M!@  _1H  !@              ("!@PT  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( "*!9%,'D[[T]0(  #L*   8              "
M@6D4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  B@613
M09K4G\4&   K'@  &               @(&4%P  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ (H%D4P-K3.#E"@  4T<  !@
M     ("!CQX  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M "*!9%-43ZA?(P(  *\$   8              " @:HI  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    "  B@613&-?)-Y8(  "G)0  &
M            @($#+   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ (H%D4Y^[#)=\"P  R1P  !@              ("!SS0  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( "*!9%-<H(#QK@H  $H=
M   8              " @8%   !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    "  B@6132E\G_^ $  !0#   &0              @(%E2P
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( "*!9%,Y=1!$
ME1L  '&%   9              " @7Q0  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ (H%D4YT PEX\"   I18  !D
M ("!2&P  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  B
M@613A3F^WU\#  #D"0  &0              @(&[=   >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( "*!9%,.724<UP@  "48   9
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M970Q."YX;6Q02P$"% ,4    "  B@613#I!YI*$#  " !P  &0
M    @(&ZF   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M "*!9%/#6-9O:PP  $,K   9              " @9*<  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ (H%D4_F"<"9X%@  5D\  !D
M             ("!-*D  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    "  B@613DJ!4F7@#  "Y!P  &0              @('COP  >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( "*!9%,OF,+XF@D
M )P:   9              " @9+#  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ (H%D4W?&\U^N P  #0@  !D              ("!
M8\T  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  B@613
MKU;'B]<&  !X%   &0              @(%(T0  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( "*!9%,"!N%#UP(  &X&   9
M      " @5;8  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ (H%D4_6#_R;U @  7P@  !D              ("!9-L  'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  B@613EK\H/ZD#  !="@
M&0              @(&0W@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( "*!9%/%GG+)& ,  *0&   9              " @7#B  !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ (H%D4X5C%G_I
M @  F 8  !D              ("!O^4  'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    "  B@613?CF,UR,#  !T!@  &0
M@('?Z   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( "*!
M9%.[KB=1A0,  ,$(   9              " @3GL  !X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ (H%D4YG.$43H @  !@8  !D
M         ("!]>\  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
M    "  B@613SNKQXDH"  #E!   &0              @($4\P  >&PO=V]R
M:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( "*!9%/YA-#-"@(  &8$
M   9              " @97U  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL
M4$L! A0#%     @ (H%D4U&<LI<2 P  MPD  !D              ("!UO<
M 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  B@613R?*@
M=-H$  !.%0  &0              @($?^P  >&PO=V]R:W-H965T<R]S:&5E
M=#,W+GAM;%!+ 0(4 Q0    ( "*!9%.'N(8TG00  .45   9
M  " @3   0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
M(H%D4W@C5=R) P  $0X  !D              ("!! 4! 'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    "  B@613A"#[!,$$  ![%0  &0
M            @('$" $ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( "*!9%,SKS'S!@,  #\(   9              " @;P- 0!X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ (H%D4V$NO^)&"
MM#<  !D              ("!^1 ! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    "  B@6139CY *74(  "<,0  &0              @(%V
M&0$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( "*!9%,B
M.["A*@<  *DI   9              " @2(B 0!X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @ (H%D4W.K]5B! P  %@H  !D
M     ("!@RD! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "*!9%,)67BN30,  .$)   9              "
M@9T[ 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ (H%D
M4V_G*TGP @  4@@  !D              ("!(3\! 'AL+W=O<FMS:&5E=',O
M<VAE970U,2YX;6Q02P$"% ,4    "  B@613$!UYP6X#  !3#@  &0
M        @(%(0@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0
M   ( "*!9%/&8 \I# ,  &X)   9              " @>U% 0!X;"]W;W)K
M<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ (H%D4^<S:I3/!   N!T
M !D              ("!,$D! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q0
M2P$"% ,4    "  B@613L7KD(?("  #C"0  &0              @($V3@$
M>&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( "*!9%.>JB9@
M%P,  (X)   9              " @5]1 0!X;"]W;W)K<VAE971S+W-H965T
M-38N>&UL4$L! A0#%     @ (H%D4_ 4Z8#, @  VP<  !D
M ("!K50! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    "  B
M@613>Z$P<,\"  !:"   &0              @(&P5P$ >&PO=V]R:W-H965T
M<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( "*!9%/OS]+6; ,  &$,   9
M          " @;9: 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#
M%     @ (H%D4\:B,R(@ P  9PH  !D              ("!65X! 'AL+W=O
M<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    "  B@613%%HY1<8#   8
M#   &0              @(&P80$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM
M;%!+ 0(4 Q0    ( "*!9%-YFD-="08  )H?   9              " @:UE
M 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ (H%D4ZM)
M8XAN @  2P4  !D              ("![6L! 'AL+W=O<FMS:&5E=',O<VAE
M970V,RYX;6Q02P$"% ,4    "  B@613D>S-@% +  "&20  &0
M    @(&2;@$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    (
M "*!9%-$J[2+HPD  %PV   9              " @1EZ 0!X;"]W;W)K<VAE
M971S+W-H965T-C4N>&UL4$L! A0#%     @ (H%D4[>'/X>. P  E0T  !D
M             ("!\X,! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"
M% ,4    "  B@613UKY=LNX"  !1!P  &0              @(&XAP$ >&PO
M=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( "*!9%.<@_6%*@,
M (8+   9              " @=V* 0!X;"]W;W)K<VAE971S+W-H965T-C@N
M>&UL4$L! A0#%     @ (H%D4]2GV? E P  ;!(   T              ( !
M/HX! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  B@613EXJ[',     3 @
M"P              @ &.D0$ 7W)E;',O+G)E;'-02P$"% ,4    "  B@613
M*%<D.@,%   ;+0  #P              @ %WD@$ >&PO=V]R:V)O;VLN>&UL
M4$L! A0#%     @ (H%D4Q;=:Q0F @  8R@  !H              ( !IY<!
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ (H%D4^'L
M7A'T 0  HB<  !,              ( !!9H! %M#;VYT96YT7U1Y<&5S72YX
8;6Q02P4&     $P 3 #+%   *IP!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>346</ContextCount>
  <ElementCount>404</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>102</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of Organization and Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/NatureofOrganizationandOperations</Role>
      <ShortName>Nature of Organization and Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Product Revenue and Reserves for Variable Consideration</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/ProductRevenueandReservesforVariableConsideration</Role>
      <ShortName>Product Revenue and Reserves for Variable Consideration</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - License, Collaboration and Other Significant Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreements</Role>
      <ShortName>License, Collaboration and Other Significant Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2124105 - Disclosure - Liability Related to Sale of Future Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyalties</Role>
      <ShortName>Liability Related to Sale of Future Royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2128106 - Disclosure - Available for Sale Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/AvailableforSaleSecurities</Role>
      <ShortName>Available for Sale Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2132107 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/FairValueofFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2137108 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2141109 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/IntangibleAssetsandGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2145110 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2148111 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2150112 - Disclosure - Warrant</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/Warrant</Role>
      <ShortName>Warrant</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2152113 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2154114 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2159115 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/NetLossperShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://akebia.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Product Revenue and Reserves for Variable Consideration (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationTables</Role>
      <ShortName>Product Revenue and Reserves for Variable Consideration (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://akebia.com/role/ProductRevenueandReservesforVariableConsideration</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - License, Collaboration and Other Significant Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsTables</Role>
      <ShortName>License, Collaboration and Other Significant Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2325303 - Disclosure - Liability Related to Sale of Future Royalties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables</Role>
      <ShortName>Liability Related to Sale of Future Royalties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyalties</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2329304 - Disclosure - Available For Sale Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/AvailableForSaleSecuritiesTables</Role>
      <ShortName>Available For Sale Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2333305 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/FairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://akebia.com/role/FairValueofFinancialInstruments</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2338306 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://akebia.com/role/Inventory</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2342307 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/IntangibleAssetsandGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://akebia.com/role/IntangibleAssetsandGoodwill</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2346308 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://akebia.com/role/AccruedExpenses</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2355309 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://akebia.com/role/CommitmentsandContingencies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2360310 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/NetLossperShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://akebia.com/role/NetLossperShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Nature of Organization and Operations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/NatureofOrganizationandOperationsAdditionalInformationDetails</Role>
      <ShortName>Nature of Organization and Operations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://akebia.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Product Revenue and Reserves for Variable Consideration - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationAdditionalInformationDetails</Role>
      <ShortName>Product Revenue and Reserves for Variable Consideration - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Product Revenue and Reserves for Variable Consideration - Product Revenue Allowance and Reserve Categories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationProductRevenueAllowanceandReserveCategoriesDetails</Role>
      <ShortName>Product Revenue and Reserves for Variable Consideration - Product Revenue Allowance and Reserve Categories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - License, Collaboration and Other Significant Agreements - Revenues Recognized From License, Collaboration and Other Significant Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails</Role>
      <ShortName>License, Collaboration and Other Significant Agreements - Revenues Recognized From License, Collaboration and Other Significant Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - License, Collaboration and Other Significant Agreements - Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails</Role>
      <ShortName>License, Collaboration and Other Significant Agreements - Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - License, Collaboration and Other Significant Agreements - Changes in Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails</Role>
      <ShortName>License, Collaboration and Other Significant Agreements - Changes in Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - License, Collaboration and Other Significant Agreements - Revenue Recognized Resulting from Changes in Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenueRecognizedResultingfromChangesinContractAssetsandLiabilitiesDetails</Role>
      <ShortName>License, Collaboration and Other Significant Agreements - Revenue Recognized Resulting from Changes in Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - License, Collaboration and Other Significant Agreements - Mitsubishi Tanabe Pharma Corporation Collaboration Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails</Role>
      <ShortName>License, Collaboration and Other Significant Agreements - Mitsubishi Tanabe Pharma Corporation Collaboration Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2417410 - Disclosure - License, Collaboration and Other Significant Agreements - U.S. Collaboration and License Agreement with Otsuka Pharmaceutical Co. Ltd. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails</Role>
      <ShortName>License, Collaboration and Other Significant Agreements - U.S. Collaboration and License Agreement with Otsuka Pharmaceutical Co. Ltd. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2418411 - Disclosure - License, Collaboration and Other Significant Agreements - International Collaboration and License Agreement with Otsuka Pharmaceutical Co. Ltd. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails</Role>
      <ShortName>License, Collaboration and Other Significant Agreements - International Collaboration and License Agreement with Otsuka Pharmaceutical Co. Ltd. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2419412 - Disclosure - License, Collaboration and Other Significant Agreements - Janssen Pharmaceutica NV Research and License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails</Role>
      <ShortName>License, Collaboration and Other Significant Agreements - Janssen Pharmaceutica NV Research and License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2420413 - Disclosure - License, Collaboration and Other Significant Agreements - Cyclerion Therapeutics License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsCyclerionTherapeuticsLicenseAgreementDetails</Role>
      <ShortName>License, Collaboration and Other Significant Agreements - Cyclerion Therapeutics License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2421414 - Disclosure - License, Collaboration and Other Significant Agreements - Vifor Pharma License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails</Role>
      <ShortName>License, Collaboration and Other Significant Agreements - Vifor Pharma License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2422415 - Disclosure - License, Collaboration and Other Significant Agreements - License Agreement with Panion??&amp; BF Biotech, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsLicenseAgreementwithPanionBFBiotechIncDetails</Role>
      <ShortName>License, Collaboration and Other Significant Agreements - License Agreement with Panion??&amp; BF Biotech, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2423416 - Disclosure - License, Collaboration and Other Significant Agreements - Sublicense Agreement with Japan Tobacco, Inc. and its subsidiary, Torii Pharmaceutical Co., Ltd. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsSublicenseAgreementwithJapanTobaccoIncanditssubsidiaryToriiPharmaceuticalCoLtdDetails</Role>
      <ShortName>License, Collaboration and Other Significant Agreements - Sublicense Agreement with Japan Tobacco, Inc. and its subsidiary, Torii Pharmaceutical Co., Ltd. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2426417 - Disclosure - Liability Related to Sale of Future Royalties - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetails</Role>
      <ShortName>Liability Related to Sale of Future Royalties - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2427418 - Disclosure - Liability Related to Sale of Future Royalties - Rollforward of Liability Related to Sale of Future Royalties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesRollforwardofLiabilityRelatedtoSaleofFutureRoyaltiesDetails</Role>
      <ShortName>Liability Related to Sale of Future Royalties - Rollforward of Liability Related to Sale of Future Royalties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2430419 - Disclosure - Available For Sale Securities - Cash Cash Equivalents and Available for Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails</Role>
      <ShortName>Available For Sale Securities - Cash Cash Equivalents and Available for Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2431420 - Disclosure - Available For Sale Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/AvailableForSaleSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Available For Sale Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2434421 - Disclosure - Fair Value of Financial Instruments - Assets Measured or Disclosed at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Assets Measured or Disclosed at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2435422 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/FairValueofFinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2436423 - Disclosure - Fair Value of Financial Instruments - Fair Value Derivative Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/FairValueofFinancialInstrumentsFairValueDerivativeLiabilityDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Fair Value Derivative Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2439424 - Disclosure - Inventory - Components of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/InventoryComponentsofInventoryDetails</Role>
      <ShortName>Inventory - Components of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2440425 - Disclosure - Inventory - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/InventoryAdditionalInformationDetails</Role>
      <ShortName>Inventory - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2443426 - Disclosure - Intangible Assets and Goodwill - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/IntangibleAssetsandGoodwillIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2444427 - Disclosure - Intangible Assets and Goodwill - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2447428 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://akebia.com/role/AccruedExpensesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2449429 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/DebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://akebia.com/role/Debt</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2451430 - Disclosure - Warrant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/WarrantDetails</Role>
      <ShortName>Warrant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://akebia.com/role/Warrant</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2453431 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://akebia.com/role/StockholdersEquity</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2456432 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2457433 - Disclosure - Commitments and Contingencies - Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2458434 - Disclosure - Commitments and Contingencies - Difference Between Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases and Operating Leases Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/CommitmentsandContingenciesDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesandOperatingLeasesLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Difference Between Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases and Operating Leases Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="akba-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2461435 - Disclosure - Net Loss per Share - Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://akebia.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossperShareDetails</Role>
      <ShortName>Net Loss per Share - Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="akba-20210930.htm">akba-20210930.htm</File>
    <File>akba-20210930.xsd</File>
    <File>akba-20210930_cal.xml</File>
    <File>akba-20210930_def.xml</File>
    <File>akba-20210930_lab.xml</File>
    <File>akba-20210930_pre.xml</File>
    <File>exhibit101-formofperforman.htm</File>
    <File>exhibit102-formofpsuagreem.htm</File>
    <File>exhibit103-akebiaxformofca.htm</File>
    <File>exhibit311-q320211.htm</File>
    <File>exhibit312-q320211.htm</File>
    <File>exhibit321-q320211.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>88
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "akba-20210930.htm": {
   "axisCustom": 1,
   "axisStandard": 32,
   "contextCount": 346,
   "dts": {
    "calculationLink": {
     "local": [
      "akba-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "akba-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "akba-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "akba-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "akba-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "akba-20210930.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 582,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 13,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 18
   },
   "keyCustom": 105,
   "keyStandard": 299,
   "memberCustom": 69,
   "memberStandard": 31,
   "nsprefix": "akba",
   "nsuri": "http://akebia.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://akebia.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Product Revenue and Reserves for Variable Consideration",
     "role": "http://akebia.com/role/ProductRevenueandReservesforVariableConsideration",
     "shortName": "Product Revenue and Reserves for Variable Consideration",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - License, Collaboration and Other Significant Agreements",
     "role": "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreements",
     "shortName": "License, Collaboration and Other Significant Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124105 - Disclosure - Liability Related to Sale of Future Royalties",
     "role": "http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyalties",
     "shortName": "Liability Related to Sale of Future Royalties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128106 - Disclosure - Available for Sale Securities",
     "role": "http://akebia.com/role/AvailableforSaleSecurities",
     "shortName": "Available for Sale Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132107 - Disclosure - Fair Value of Financial Instruments",
     "role": "http://akebia.com/role/FairValueofFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137108 - Disclosure - Inventory",
     "role": "http://akebia.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141109 - Disclosure - Intangible Assets and Goodwill",
     "role": "http://akebia.com/role/IntangibleAssetsandGoodwill",
     "shortName": "Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145110 - Disclosure - Accrued Expenses",
     "role": "http://akebia.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148111 - Disclosure - Debt",
     "role": "http://akebia.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "akba:WarrantDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150112 - Disclosure - Warrant",
     "role": "http://akebia.com/role/Warrant",
     "shortName": "Warrant",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "akba:WarrantDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i44af4abac88448b5893045bc0002855c_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://akebia.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i44af4abac88448b5893045bc0002855c_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152113 - Disclosure - Stockholders' Equity",
     "role": "http://akebia.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2154114 - Disclosure - Commitments and Contingencies",
     "role": "http://akebia.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2159115 - Disclosure - Net Loss per Share",
     "role": "http://akebia.com/role/NetLossperShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://akebia.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "akba:ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Product Revenue and Reserves for Variable Consideration (Tables)",
     "role": "http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationTables",
     "shortName": "Product Revenue and Reserves for Variable Consideration (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "akba:ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "akba:CollaborativeArrangementRevenueRecognitionTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - License, Collaboration and Other Significant Agreements (Tables)",
     "role": "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsTables",
     "shortName": "License, Collaboration and Other Significant Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "akba:CollaborativeArrangementRevenueRecognitionTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325303 - Disclosure - Liability Related to Sale of Future Royalties (Tables)",
     "role": "http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables",
     "shortName": "Liability Related to Sale of Future Royalties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329304 - Disclosure - Available For Sale Securities (Tables)",
     "role": "http://akebia.com/role/AvailableForSaleSecuritiesTables",
     "shortName": "Available For Sale Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333305 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "role": "http://akebia.com/role/FairValueofFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338306 - Disclosure - Inventory (Tables)",
     "role": "http://akebia.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i44af4abac88448b5893045bc0002855c_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://akebia.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2342307 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "role": "http://akebia.com/role/IntangibleAssetsandGoodwillTables",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2346308 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://akebia.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2355309 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://akebia.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2360310 - Disclosure - Net Loss per Share (Tables)",
     "role": "http://akebia.com/role/NetLossperShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "akba:OperatingPlanSufficientlyFundedByCashResourcesPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Nature of Organization and Operations - Additional Information (Details)",
     "role": "http://akebia.com/role/NatureofOrganizationandOperationsAdditionalInformationDetails",
     "shortName": "Nature of Organization and Operations - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "akba:OperatingPlanSufficientlyFundedByCashResourcesPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://akebia.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Product Revenue and Reserves for Variable Consideration - Additional Information (Details)",
     "role": "http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationAdditionalInformationDetails",
     "shortName": "Product Revenue and Reserves for Variable Consideration - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i68832275b6f74879ad43622f402f836b_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i3e2950be526b427487e169a221babd7d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Product Revenue and Reserves for Variable Consideration - Product Revenue Allowance and Reserve Categories (Details)",
     "role": "http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationProductRevenueAllowanceandReserveCategoriesDetails",
     "shortName": "Product Revenue and Reserves for Variable Consideration - Product Revenue Allowance and Reserve Categories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i3e2950be526b427487e169a221babd7d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - License, Collaboration and Other Significant Agreements - Revenues Recognized From License, Collaboration and Other Significant Agreements (Details)",
     "role": "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails",
     "shortName": "License, Collaboration and Other Significant Agreements - Revenues Recognized From License, Collaboration and Other Significant Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i0acbf4b49164475f8a36f3979f8e5aff_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i44af4abac88448b5893045bc0002855c_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - License, Collaboration and Other Significant Agreements - Deferred Revenue (Details)",
     "role": "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails",
     "shortName": "License, Collaboration and Other Significant Agreements - Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i4010db64fe4c4fd08b2112d996676126_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i44af4abac88448b5893045bc0002855c_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - License, Collaboration and Other Significant Agreements - Changes in Contract Assets and Liabilities (Details)",
     "role": "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails",
     "shortName": "License, Collaboration and Other Significant Agreements - Changes in Contract Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i4d809bfac669408289ffd42f4682ebdf_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "akba:ContractWithCustomerAssetAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - License, Collaboration and Other Significant Agreements - Revenue Recognized Resulting from Changes in Contract Assets and Liabilities (Details)",
     "role": "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenueRecognizedResultingfromChangesinContractAssetsandLiabilitiesDetails",
     "shortName": "License, Collaboration and Other Significant Agreements - Revenue Recognized Resulting from Changes in Contract Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - License, Collaboration and Other Significant Agreements - Mitsubishi Tanabe Pharma Corporation Collaboration Agreement (Details)",
     "role": "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
     "shortName": "License, Collaboration and Other Significant Agreements - Mitsubishi Tanabe Pharma Corporation Collaboration Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i8873d2f4f3ab410f8ea8fdc1148178ff_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417410 - Disclosure - License, Collaboration and Other Significant Agreements - U.S. Collaboration and License Agreement with Otsuka Pharmaceutical Co. Ltd. (Details)",
     "role": "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
     "shortName": "License, Collaboration and Other Significant Agreements - U.S. Collaboration and License Agreement with Otsuka Pharmaceutical Co. Ltd. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i729bdb2febbe40f7a0d7e8b9d41b5707_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "akba:NumberOfPerformanceObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "performance_obligation",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418411 - Disclosure - License, Collaboration and Other Significant Agreements - International Collaboration and License Agreement with Otsuka Pharmaceutical Co. Ltd. (Details)",
     "role": "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
     "shortName": "License, Collaboration and Other Significant Agreements - International Collaboration and License Agreement with Otsuka Pharmaceutical Co. Ltd. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i21debe3a35d84013a5c0a46700b925d1_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "akba:NumberOfPerformanceObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "performance_obligation",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ieeebde433f7a49538c99f8eedfadce25_D20170209-20170209",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "akba:CollaborativeArrangementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419412 - Disclosure - License, Collaboration and Other Significant Agreements - Janssen Pharmaceutica NV Research and License Agreement (Details)",
     "role": "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails",
     "shortName": "License, Collaboration and Other Significant Agreements - Janssen Pharmaceutica NV Research and License Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ieeebde433f7a49538c99f8eedfadce25_D20170209-20170209",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "akba:CollaborativeArrangementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420413 - Disclosure - License, Collaboration and Other Significant Agreements - Cyclerion Therapeutics License Agreement (Details)",
     "role": "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsCyclerionTherapeuticsLicenseAgreementDetails",
     "shortName": "License, Collaboration and Other Significant Agreements - Cyclerion Therapeutics License Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifc1441455f5f427d888f9be3a658edc4_D20210604-20210604",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireProductiveAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i44af4abac88448b5893045bc0002855c_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421414 - Disclosure - License, Collaboration and Other Significant Agreements - Vifor Pharma License Agreement (Details)",
     "role": "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails",
     "shortName": "License, Collaboration and Other Significant Agreements - Vifor Pharma License Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i7e2acaca8c4648fc8c17812d445090de_D20200101-20200331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "akba:AggregateCollaborationAgreementPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i41e46089042845efb8effbe91d3866a0_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "akba:RoyaltyPaymentsDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422415 - Disclosure - License, Collaboration and Other Significant Agreements - License Agreement with Panion\u00a0& BF Biotech, Inc. (Details)",
     "role": "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsLicenseAgreementwithPanionBFBiotechIncDetails",
     "shortName": "License, Collaboration and Other Significant Agreements - License Agreement with Panion\u00a0& BF Biotech, Inc. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i41e46089042845efb8effbe91d3866a0_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "akba:RoyaltyPaymentsDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423416 - Disclosure - License, Collaboration and Other Significant Agreements - Sublicense Agreement with Japan Tobacco, Inc. and its subsidiary, Torii Pharmaceutical Co., Ltd. (Details)",
     "role": "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsSublicenseAgreementwithJapanTobaccoIncanditssubsidiaryToriiPharmaceuticalCoLtdDetails",
     "shortName": "License, Collaboration and Other Significant Agreements - Sublicense Agreement with Japan Tobacco, Inc. and its subsidiary, Torii Pharmaceutical Co., Ltd. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i0cc1c74d758f401f8afecb62a3e1d9dd_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "akba:NumberOfPerformanceObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "performance_obligation",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ieac2241d842b494ab83cde4c6efacf46_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i5f2d1adb364d4ff18d2ad533959fe847_D20200101-20200331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i016c3424f40c49faa098233e6b0ce0ef_I20210225",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "akba:ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426417 - Disclosure - Liability Related to Sale of Future Royalties - Additional Information (Details)",
     "role": "http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetails",
     "shortName": "Liability Related to Sale of Future Royalties - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i016c3424f40c49faa098233e6b0ce0ef_I20210225",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "akba:ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i3e2950be526b427487e169a221babd7d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "akba:ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427418 - Disclosure - Liability Related to Sale of Future Royalties - Rollforward of Liability Related to Sale of Future Royalties (Details)",
     "role": "http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesRollforwardofLiabilityRelatedtoSaleofFutureRoyaltiesDetails",
     "shortName": "Liability Related to Sale of Future Royalties - Rollforward of Liability Related to Sale of Future Royalties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "akba:ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i44af4abac88448b5893045bc0002855c_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430419 - Disclosure - Available For Sale Securities - Cash Cash Equivalents and Available for Sale Securities (Details)",
     "role": "http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails",
     "shortName": "Available For Sale Securities - Cash Cash Equivalents and Available for Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i44af4abac88448b5893045bc0002855c_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431420 - Disclosure - Available For Sale Securities - Additional Information (Details)",
     "role": "http://akebia.com/role/AvailableForSaleSecuritiesAdditionalInformationDetails",
     "shortName": "Available For Sale Securities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i44af4abac88448b5893045bc0002855c_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434421 - Disclosure - Fair Value of Financial Instruments - Assets Measured or Disclosed at Fair Value on Recurring Basis (Details)",
     "role": "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails",
     "shortName": "Fair Value of Financial Instruments - Assets Measured or Disclosed at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i582013b1f37743bc8285c94f50c08ca4_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i44af4abac88448b5893045bc0002855c_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435422 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details)",
     "role": "http://akebia.com/role/FairValueofFinancialInstrumentsAdditionalInformationDetails",
     "shortName": "Fair Value of Financial Instruments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AssetsFairValueDisclosure",
       "us-gaap:LiabilitiesFairValueDisclosure",
       "us-gaap:AssetsFairValueDisclosure",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ia9033a88870c408dba279ef74720efd3_I20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i952bff9821b4497aa3ea95191dd2fe53_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436423 - Disclosure - Fair Value of Financial Instruments - Fair Value Derivative Liability (Details)",
     "role": "http://akebia.com/role/FairValueofFinancialInstrumentsFairValueDerivativeLiabilityDetails",
     "shortName": "Fair Value of Financial Instruments - Fair Value Derivative Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i02a8ba6ff0054b678403f9ad5ed7efc4_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IncreaseDecreaseInDerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i44af4abac88448b5893045bc0002855c_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439424 - Disclosure - Inventory - Components of Inventory (Details)",
     "role": "http://akebia.com/role/InventoryComponentsofInventoryDetails",
     "shortName": "Inventory - Components of Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i44af4abac88448b5893045bc0002855c_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440425 - Disclosure - Inventory - Additional Information (Details)",
     "role": "http://akebia.com/role/InventoryAdditionalInformationDetails",
     "shortName": "Inventory - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i3e237cd7f54f4646aa36f63692c06c40_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i3e2950be526b427487e169a221babd7d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443426 - Disclosure - Intangible Assets and Goodwill - Intangible Assets (Details)",
     "role": "http://akebia.com/role/IntangibleAssetsandGoodwillIntangibleAssetsDetails",
     "shortName": "Intangible Assets and Goodwill - Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i3e2950be526b427487e169a221babd7d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i44af4abac88448b5893045bc0002855c_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444427 - Disclosure - Intangible Assets and Goodwill - Additional Information (Details)",
     "role": "http://akebia.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails",
     "shortName": "Intangible Assets and Goodwill - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i44af4abac88448b5893045bc0002855c_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "akba:AccruedProductRevenueAllowancesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447428 - Disclosure - Accrued Expenses (Details)",
     "role": "http://akebia.com/role/AccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i44af4abac88448b5893045bc0002855c_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "akba:AccruedProductRevenueAllowancesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i44af4abac88448b5893045bc0002855c_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449429 - Disclosure - Debt (Details)",
     "role": "http://akebia.com/role/DebtDetails",
     "shortName": "Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i4c756e20d9664648aeb18aebeb242523_I20191111",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i541f7e6319644772b0d0e20228d16057_I20170228",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451430 - Disclosure - Warrant (Details)",
     "role": "http://akebia.com/role/WarrantDetails",
     "shortName": "Warrant (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i541f7e6319644772b0d0e20228d16057_I20170228",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i44af4abac88448b5893045bc0002855c_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453431 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://akebia.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ic405d5f9a6194033b54c67f003fb5108_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456432 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i44af4abac88448b5893045bc0002855c_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457433 - Disclosure - Commitments and Contingencies - Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases (Details)",
     "role": "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails",
     "shortName": "Commitments and Contingencies - Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i44af4abac88448b5893045bc0002855c_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i44af4abac88448b5893045bc0002855c_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458434 - Disclosure - Commitments and Contingencies - Difference Between Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases and Operating Leases Liabilities (Details)",
     "role": "http://akebia.com/role/CommitmentsandContingenciesDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesandOperatingLeasesLiabilitiesDetails",
     "shortName": "Commitments and Contingencies - Difference Between Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases and Operating Leases Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "i44af4abac88448b5893045bc0002855c_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461435 - Disclosure - Net Loss per Share - Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)",
     "role": "http://akebia.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossperShareDetails",
     "shortName": "Net Loss per Share - Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ic37e5fac8a9c4aefae3a034715660bff_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of Organization and Operations",
     "role": "http://akebia.com/role/NatureofOrganizationandOperations",
     "shortName": "Nature of Organization and Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://akebia.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "akba-20210930.htm",
      "contextRef": "ifeaddfb02a984ee28270a9ad4e1079ee_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 102,
   "tag": {
    "akba_AccruedClinicalExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/AccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical expenses current.",
        "label": "Accrued Clinical Expenses Current",
        "terseLabel": "Accrued clinical"
       }
      }
     },
     "localname": "AccruedClinicalExpensesCurrent",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_AccruedCommercialManufacturingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/AccruedExpensesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Commercial Manufacturing Current",
        "label": "Accrued Commercial Manufacturing Current",
        "terseLabel": "Accrued commercial manufacturing"
       }
      }
     },
     "localname": "AccruedCommercialManufacturingCurrent",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_AccruedExpensesAndOtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities [Member]",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_AccruedProductRevenueAllowancesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/AccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued product revenue allowances current.",
        "label": "Accrued Product Revenue Allowances Current",
        "terseLabel": "Product revenue allowances"
       }
      }
     },
     "localname": "AccruedProductRevenueAllowancesCurrent",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_AggregateCollaborationAgreementPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate collaboration agreement payments.",
        "label": "Aggregate Collaboration Agreement Payments",
        "terseLabel": "Payments for closing Priority Review Voucher purchase"
       }
      }
     },
     "localname": "AggregateCollaborationAgreementPayments",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual increase in aggregate number of shares reserved for future issuance as percentage shares outstanding.",
        "label": "Annual Increase In Aggregate Number Of Shares Reserved For Future Issuance As Percentage Shares Outstanding",
        "terseLabel": "Incremental rate at which the shares reserved for issuance increase"
       }
      }
     },
     "localname": "AnnualIncreaseInAggregateNumberOfSharesReservedForFutureIssuanceAsPercentageSharesOutstanding",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "akba_AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Agreement Expiration, After First Commercial Sale, Period",
        "label": "Asset Acquisition, Agreement Expiration, After First Commercial Sale, Period",
        "terseLabel": "Agreement expiration, after first commercial sale, period"
       }
      }
     },
     "localname": "AssetAcquisitionAgreementExpirationAfterFirstCommercialSalePeriod",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsCyclerionTherapeuticsLicenseAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "akba_AssetAcquisitionAgreementTerminationNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Agreement Termination Notice Period",
        "label": "Asset Acquisition, Agreement Termination Notice Period",
        "terseLabel": "Agreement termination notice period"
       }
      }
     },
     "localname": "AssetAcquisitionAgreementTerminationNoticePeriod",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsCyclerionTherapeuticsLicenseAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "akba_AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Equity Offering Program Authorized February 2021",
        "label": "At The Market Equity Offering Program Authorized February 2021 [Member]",
        "terseLabel": "At The Market Equity Offering Program Authorized February 2021"
       }
      }
     },
     "localname": "AtTheMarketEquityOfferingProgramAuthorizedFebruary2021Member",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_AtTheMarketEquityOfferingProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market equity offering program.",
        "label": "At The Market Equity Offering Program [Member]",
        "terseLabel": "At The Market Equity Offering Program"
       }
      }
     },
     "localname": "AtTheMarketEquityOfferingProgramMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_BPCRLimitedPartnershipMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BPCR Limited Partnership",
        "label": "BPCR Limited Partnership [Member]",
        "terseLabel": "BPCR Limited Partnership"
       }
      }
     },
     "localname": "BPCRLimitedPartnershipMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_BioVectraIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BioVectra Inc.",
        "label": "Bio Vectra Inc [Member]",
        "terseLabel": "BioVectra Inc"
       }
      }
     },
     "localname": "BioVectraIncMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_BiopharmaCreditInvestmentsVMasterLimitedPartnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biopharma Credit Investments V (Master) Limited Partner",
        "label": "Biopharma Credit Investments V Master Limited Partner [Member]",
        "terseLabel": "Biopharma Credit Investments V (Master) LP"
       }
      }
     },
     "localname": "BiopharmaCreditInvestmentsVMasterLimitedPartnerMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_BostonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boston.",
        "label": "Boston [Member]",
        "terseLabel": "Boston"
       }
      }
     },
     "localname": "BostonMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed noncurrent liabilities fair value of off-market element.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Fair Value Of Off Market Element",
        "terseLabel": "Preliminary fair value of the off-market element"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesFairValueOfOffMarketElement",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_CambridgeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cambridge.",
        "label": "Cambridge [Member]",
        "terseLabel": "Cambridge"
       }
      }
     },
     "localname": "CambridgeMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash cash equivalents and short term investments amortized cost.",
        "label": "Cash Cash Equivalents And Short Term Investments Amortized Cost",
        "totalLabel": "Total cash, cash equivalents, and available for sale securities, amortized cost"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAmortizedCost",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_ChargebacksAndDiscountsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chargebacks and Discounts.",
        "label": "Chargebacks And Discounts [Member]",
        "terseLabel": "Chargebacks and Discounts"
       }
      }
     },
     "localname": "ChargebacksAndDiscountsMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationProductRevenueAllowanceandReserveCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_ClosingStockPriceOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing stock price of common stock.",
        "label": "Closing Stock Price Of Common Stock",
        "terseLabel": "Premium over the closing stock price of common stock (in dollars per share)"
       }
      }
     },
     "localname": "ClosingStockPriceOfCommonStock",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "akba_CollaborativeAndLicenseArrangementTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative and license arrangement, transaction price.",
        "label": "Collaborative And License Arrangement Transaction Price",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "CollaborativeAndLicenseArrangementTransactionPrice",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_CollaborativeArrangementAccruedLiability": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/AccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement Accrued Liability",
        "label": "Collaborative Arrangement Accrued Liability",
        "terseLabel": "Collaborative arrangement accrued liability"
       }
      }
     },
     "localname": "CollaborativeArrangementAccruedLiability",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/AccruedExpensesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement Accrued Liability, Priority Review Voucher",
        "label": "Collaborative Arrangement Accrued Liability, Priority Review Voucher",
        "terseLabel": "Otsuka PRV contribution"
       }
      }
     },
     "localname": "CollaborativeArrangementAccruedLiabilityPriorityReviewVoucher",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement of premium amount over closing stock price of common stock.",
        "label": "Collaborative Arrangement Of Premium Amount Over Closing Stock Price Of Common Stock",
        "terseLabel": "Premium amount over the closing stock price of common stock"
       }
      }
     },
     "localname": "CollaborativeArrangementOfPremiumAmountOverClosingStockPriceOfCommonStock",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_CollaborativeArrangementRevenueRecognitionTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement revenue recognition.",
        "label": "Collaborative Arrangement Revenue Recognition [Table Text Block]",
        "terseLabel": "Revenues Recognized from License, Collaboration and Other Significant Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueRecognitionTableTextBlock",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "akba_CollaborativeArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Term",
        "label": "Collaborative Arrangement, Term",
        "terseLabel": "Collaborative arrangement, term"
       }
      }
     },
     "localname": "CollaborativeArrangementTerm",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "akba_CollaborativeArrangementsAdditionalCostSharingPaymentsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangements additional cost sharing payments amount.",
        "label": "Collaborative Arrangements Additional Cost Sharing Payments Amount",
        "terseLabel": "Collaborative arrangements additional cost sharing payments amount"
       }
      }
     },
     "localname": "CollaborativeArrangementsAdditionalCostSharingPaymentsAmount",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangements additional cost sharing payments expected amount.",
        "label": "Collaborative Arrangements Additional Cost Sharing Payments Expected Amount",
        "terseLabel": "Collaborative arrangements additional cost sharing payments expected amount"
       }
      }
     },
     "localname": "CollaborativeArrangementsAdditionalCostSharingPaymentsExpectedAmount",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_CollaborativeArrangementsCostSharingPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangements cost sharing payments.",
        "label": "Collaborative Arrangements Cost Sharing Payments",
        "terseLabel": "Collaborative arrangements cost sharing payments"
       }
      }
     },
     "localname": "CollaborativeArrangementsCostSharingPayments",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_CollateralAgentPharmakonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateral Agent, Pharmakon.",
        "label": "Collateral Agent Pharmakon [Member]",
        "terseLabel": "Collateral Agent, Pharmakon"
       }
      }
     },
     "localname": "CollateralAgentPharmakonMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/DebtDetails",
      "http://akebia.com/role/FairValueofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "akba_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "akba_CommonStockSalesAgreementAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock sales agreement amount.",
        "label": "Common Stock Sales Agreement Amount",
        "terseLabel": "Common stock sales agreement amount"
       }
      }
     },
     "localname": "CommonStockSalesAgreementAmount",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_ContractWithCustomerAssetAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer asset additions.",
        "label": "Contract With Customer Asset Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAdditions",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Asset, After Allowance For Credit Loss, Current",
        "label": "Contract With Customer, Asset, After Allowance For Credit Loss, Current [Roll Forward]",
        "terseLabel": "Contract assets:"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAfterAllowanceForCreditLossCurrentRollForward",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "akba_ContractWithCustomerAssetDeductions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer asset deductions.",
        "label": "Contract With Customer Asset Deductions",
        "negatedLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetDeductions",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_ContractWithCustomerLiabilityAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability additions.",
        "label": "Contract With Customer Liability Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAdditions",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_ContractWithCustomerLiabilityDeductions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability deductions.",
        "label": "Contract With Customer Liability Deductions",
        "negatedLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDeductions",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_ContractWithCustomerLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability",
        "label": "Contract With Customer, Liability [Member]",
        "terseLabel": "Contract With Customer, Liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_ContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability",
        "label": "Contract With Customer, Liability [Roll Forward]",
        "terseLabel": "Contract liabilities:"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRollForward",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "akba_ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Arrangement, Royalties Agreement, Interest Rate, Effective Percentage",
        "label": "Contractual Arrangement, Royalties Agreement, Interest Rate, Effective Percentage",
        "terseLabel": "Annual effective interest rate"
       }
      }
     },
     "localname": "ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Arrangement, Royalties Agreement, Liability, Noncurrent",
        "label": "Contractual Arrangement, Royalties Agreement, Liability, Noncurrent",
        "periodEndLabel": "Liability related to sale of future royalties, net \u2014 ending balance",
        "periodStartLabel": "Liability related to sale of future royalties, net \u2014 beginning balance",
        "terseLabel": "Liability related to sale of future royalties, net"
       }
      }
     },
     "localname": "ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets",
      "http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetails",
      "http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesRollforwardofLiabilityRelatedtoSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_ContractualArrangementRoyaltiesAgreementLiabilityNoncurrentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Arrangement, Royalties Agreement, Liability, Noncurrent",
        "label": "Contractual Arrangement, Royalties Agreement, Liability, Noncurrent [Roll Forward]",
        "terseLabel": "Contractual Arrangement, Royalties Agreement, Liability, Noncurrent [Roll Forward]"
       }
      }
     },
     "localname": "ContractualArrangementRoyaltiesAgreementLiabilityNoncurrentRollForward",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesRollforwardofLiabilityRelatedtoSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "akba_ContractualArrangementRoyaltiesAgreementLiabilityPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Arrangement, Royalties Agreement, Liability, Policy",
        "label": "Contractual Arrangement, Royalties Agreement, Liability, Policy [Policy Text Block]",
        "terseLabel": "Liability Related to Sale of Future Royalties"
       }
      }
     },
     "localname": "ContractualArrangementRoyaltiesAgreementLiabilityPolicyPolicyTextBlock",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "akba_ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Arrangement, Royalties Agreement, Maximum Aggregate Royalty Payout Capacity",
        "label": "Contractual Arrangement, Royalties Agreement, Maximum Aggregate Royalty Payout Capacity",
        "terseLabel": "Maximum aggregate royalty payout capacity"
       }
      }
     },
     "localname": "ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Arrangement, Royalties Agreement, Maximum Annual Royalty Payout Capacity",
        "label": "Contractual Arrangement, Royalties Agreement, Maximum Annual Royalty Payout Capacity",
        "terseLabel": "Maximum annual royalty payout capacity"
       }
      }
     },
     "localname": "ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Arrangement, Royalties Agreement, Noncash Interest Expense (Income)",
        "label": "Contractual Arrangement, Royalties Agreement, Noncash Interest Expense (Income)",
        "terseLabel": "Non-cash interest expense related to sale of future royalties",
        "verboseLabel": "Non-cash interest expense recognized"
       }
      }
     },
     "localname": "ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesRollforwardofLiabilityRelatedtoSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Arrangement, Royalties Agreement, Noncash Royalty Revenue",
        "label": "Contractual Arrangement, Royalties Agreement, Noncash Royalty Revenue",
        "negatedTerseLabel": "Non-cash royalty revenue related to sale of future royalties"
       }
      }
     },
     "localname": "ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_ContractualArrangementRoyaltiesAgreementPercentageOfRoyaltyPaymentsToBeReceivedContingentOnReachingMaximumAnnualRoyaltyPayoutCapacity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Arrangement, Royalties Agreement, Percentage Of Royalty Payments To Be Received, Contingent On Reaching Maximum Annual Royalty Payout Capacity",
        "label": "Contractual Arrangement, Royalties Agreement, Percentage Of Royalty Payments To Be Received, Contingent On Reaching Maximum Annual Royalty Payout Capacity",
        "terseLabel": "Percentage of royalty payment to be received once maximum annual royalty payout has been paid"
       }
      }
     },
     "localname": "ContractualArrangementRoyaltiesAgreementPercentageOfRoyaltyPaymentsToBeReceivedContingentOnReachingMaximumAnnualRoyaltyPayoutCapacity",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "akba_ContractualArrangementRoyaltiesAgreementProceedsContingentOnAnnualSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Arrangement, Royalties Agreement, Proceeds, Contingent On Annual Sales Milestones",
        "label": "Contractual Arrangement, Royalties Agreement, Proceeds, Contingent On Annual Sales Milestones",
        "terseLabel": "Eligible proceeds to be received, contingent on annual sales milestones"
       }
      }
     },
     "localname": "ContractualArrangementRoyaltiesAgreementProceedsContingentOnAnnualSalesMilestones",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Arrangement, Royalties Agreement, Royalties, Earned And Payable",
        "label": "Contractual Arrangement, Royalties Agreement, Royalties, Earned And Payable",
        "negatedTerseLabel": "MTPC royalties payable"
       }
      }
     },
     "localname": "ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesRollforwardofLiabilityRelatedtoSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_CostOfPurchasedMinimumQuantityProduct": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of purchased minimum quantity product.",
        "label": "Cost Of Purchased Minimum Quantity Product",
        "terseLabel": "Cost of purchased minimum quantity product"
       }
      }
     },
     "localname": "CostOfPurchasedMinimumQuantityProduct",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_CostOfResearchServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of research services.",
        "label": "Cost Of Research Services",
        "terseLabel": "Cost of research services"
       }
      }
     },
     "localname": "CostOfResearchServices",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_CostShareCostsIncurredByPartnerForLicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost share costs incurred by partner for license agreement.",
        "label": "Cost Share Costs Incurred By Partner For License Agreement",
        "terseLabel": "Cost share costs by partner for license agreement"
       }
      }
     },
     "localname": "CostShareCostsIncurredByPartnerForLicenseAgreement",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_CostShareCostsIncurredForLicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost share costs incurred for license agreement.",
        "label": "Cost Share Costs Incurred For License Agreement",
        "terseLabel": "Cost share costs incurred"
       }
      }
     },
     "localname": "CostShareCostsIncurredForLicenseAgreement",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_CyclerionTherapeuticsLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cyclerion Therapeutics License Agreement",
        "label": "Cyclerion Therapeutics License Agreement [Member]",
        "terseLabel": "Cyclerion Therapeutics License Agreement"
       }
      }
     },
     "localname": "CyclerionTherapeuticsLicenseAgreementMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsCyclerionTherapeuticsLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_DebtInstrumentCapRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument cap rate.",
        "label": "Debt Instrument Cap Rate",
        "terseLabel": "Debt instrument, cap rate"
       }
      }
     },
     "localname": "DebtInstrumentCapRate",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "akba_DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Potential Amortization Period Reduction",
        "label": "Debt Instrument, Covenant Terms, Potential Amortization Period Reduction",
        "terseLabel": "Term loan, amortization period, potential reduction (up to)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsPotentialAmortizationPeriodReduction",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "akba_DebtInstrumentCovenantTermsPotentialMaturityTermReduction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Potential Maturity Term Reduction",
        "label": "Debt Instrument, Covenant Terms, Potential Maturity Term Reduction",
        "terseLabel": "Term loan, maturity term, potential reduction (up to)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsPotentialMaturityTermReduction",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "akba_DebtInstrumentFacilityFeePaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument facility fee paid.",
        "label": "Debt Instrument Facility Fee Paid",
        "terseLabel": "Facility fee paid, amount"
       }
      }
     },
     "localname": "DebtInstrumentFacilityFeePaid",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, First Quarterly Periodic Payment, Period",
        "label": "Debt Instrument, First Quarterly Periodic Payment, Period [Axis]",
        "terseLabel": "Debt Instrument, Quarterly Periodic Payment, Period"
       }
      }
     },
     "localname": "DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodAxis",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, First Quarterly Periodic Payment, Period One",
        "label": "Debt Instrument, First Quarterly Periodic Payment, Period One [Member]",
        "terseLabel": "Debt Instrument, Quarterly Periodic Payment, Period One"
       }
      }
     },
     "localname": "DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodOneMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, First Quarterly Periodic Payment, Period Two",
        "label": "Debt Instrument, First Quarterly Periodic Payment, Period Two [Member]",
        "terseLabel": "Debt Instrument, Quarterly Periodic Payment, Period Two"
       }
      }
     },
     "localname": "DebtInstrumentFirstQuarterlyPeriodicPaymentPeriodTwoMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_DebtInstrumentFloorRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument floor rate.",
        "label": "Debt Instrument Floor Rate",
        "terseLabel": "Debt instrument, floor rate"
       }
      }
     },
     "localname": "DebtInstrumentFloorRate",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "akba_DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Quarterly Periodic Payment, Period",
        "label": "Debt Instrument, Quarterly Periodic Payment, Period [Domain]",
        "terseLabel": "Debt Instrument, Quarterly Periodic Payment, Period"
       }
      }
     },
     "localname": "DebtInstrumentQuarterlyPeriodicPaymentPeriodDomain",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_DeferredRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred revenue.",
        "label": "Deferred Revenue [Member]",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_DeferredRevenueRecognitionTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred revenue recognition.",
        "label": "Deferred Revenue Recognition [Table Text Block]",
        "terseLabel": "Deferred Revenues"
       }
      }
     },
     "localname": "DeferredRevenueRecognitionTableTextBlock",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "akba_DeferredUnpaidOfferingCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred unpaid offering costs.",
        "label": "Deferred Unpaid Offering Costs",
        "terseLabel": "Unpaid offering costs"
       }
      }
     },
     "localname": "DeferredUnpaidOfferingCosts",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_DerivativeLiabilityFairValueGrossLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Liability, Fair Value, Gross Liability",
        "label": "Derivative Liability, Fair Value, Gross Liability [Roll Forward]",
        "terseLabel": "Derivative Liability, Fair Value, Gross Liability [Roll Forward]"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueGrossLiabilityRollForward",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/FairValueofFinancialInstrumentsFairValueDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "akba_DevelopedProductRightsForAuryxiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Developed product rights for Auryxia.",
        "label": "Developed Product Rights For Auryxia [Member]",
        "terseLabel": "Developed product rights for Auryxia"
       }
      }
     },
     "localname": "DevelopedProductRightsForAuryxiaMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails",
      "http://akebia.com/role/IntangibleAssetsandGoodwillIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_DevelopmentAndCommercializeCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and commercialize collaboration agreement",
        "label": "Development And Commercialize Collaboration Agreement [Member]",
        "terseLabel": "MTPC Agreement"
       }
      }
     },
     "localname": "DevelopmentAndCommercializeCollaborationAgreementMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and commercialize international collaboration and license agreement.",
        "label": "Development And Commercialize International Collaboration And License Agreement [Member]",
        "terseLabel": "Otsuka International Agreement"
       }
      }
     },
     "localname": "DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and commercialize research and license agreement.",
        "label": "Development And Commercialize Research And License Agreement [Member]",
        "terseLabel": "Development And Commercialize Research And License Agreement"
       }
      }
     },
     "localname": "DevelopmentAndCommercializeResearchAndLicenseAgreementMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and commercialize united states collaboration and license agreement.",
        "label": "Development And Commercialize United States Collaboration And License Agreement [Member]",
        "terseLabel": "Otsuka U.S. Agreement"
       }
      }
     },
     "localname": "DevelopmentAndCommercializeUnitedStatesCollaborationAndLicenseAgreementMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_DevelopmentAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and regulatory milestones.",
        "label": "Development And Regulatory Milestones [Member]",
        "terseLabel": "Development And Regulatory Milestones"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestonesMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_EmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees.",
        "label": "Employees [Member]",
        "terseLabel": "Employees"
       }
      }
     },
     "localname": "EmployeesMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_EsteveQuimicaSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Esteve Quimica, S.A",
        "label": "Esteve Quimica S A [Member]",
        "terseLabel": "Esteve Qu\u00edmica, S.A"
       }
      }
     },
     "localname": "EsteveQuimicaSAMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_EstimateSubsequentCostFundingUnderPlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimate subsequent cost funding under plan.",
        "label": "Estimate Subsequent Cost Funding Under Plan",
        "terseLabel": "Estimated current global development costs subsequent to March 31, 2017"
       }
      }
     },
     "localname": "EstimateSubsequentCostFundingUnderPlan",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_ExcessInventoryPurchaseCommitmentsExpenseReversal": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess Inventory Purchase Commitments Expense (Reversal)",
        "label": "Excess Inventory Purchase Commitments Expense (Reversal)",
        "terseLabel": "Change in excess inventory purchase commitments",
        "verboseLabel": "Increase (decrease) in purchase commitments"
       }
      }
     },
     "localname": "ExcessInventoryPurchaseCommitmentsExpenseReversal",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_FacilityFeePercentagePaidOnPrincipalAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility fee percentage paid on principal amount.",
        "label": "Facility Fee Percentage Paid On Principal Amount",
        "terseLabel": "Facility fee percentage on principal amount"
       }
      }
     },
     "localname": "FacilityFeePercentagePaidOnPrincipalAmount",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "akba_FairValueAdjustmentToInventory": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Adjustment To Inventory",
        "label": "Fair Value Adjustment To Inventory",
        "terseLabel": "Fair value step-up of inventory sold or written off"
       }
      }
     },
     "localname": "FairValueAdjustmentToInventory",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_FiniteLivedIntangibleAssetsAdoptionAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/IntangibleAssetsandGoodwillIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite lived intangible assets adoption adjustment.",
        "label": "Finite Lived Intangible Assets Adoption Adjustment",
        "terseLabel": "ASC 842 Adjustment"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAdoptionAdjustment",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/IntangibleAssetsandGoodwillIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_GlobalDevelopmentPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global development plan.",
        "label": "Global Development Plan [Member]",
        "terseLabel": "Global Development Plan"
       }
      }
     },
     "localname": "GlobalDevelopmentPlanMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_HIFProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIF Product",
        "label": "HIF Product [Member]",
        "terseLabel": "HIF Product"
       }
      }
     },
     "localname": "HIFProductMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_InducementAwardProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement award program.",
        "label": "Inducement Award Program [Member]",
        "terseLabel": "Inducement Award Program"
       }
      }
     },
     "localname": "InducementAwardProgramMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_InitialTermOfSupplyAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial term of supply agreement.",
        "label": "Initial Term Of Supply Agreement",
        "terseLabel": "Initial term of supply agreement"
       }
      }
     },
     "localname": "InitialTermOfSupplyAgreement",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "akba_InventoryNetCurrentAndNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/InventoryComponentsofInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://akebia.com/role/InventoryComponentsofInventoryDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory net current and non current.",
        "label": "Inventory Net Current And Non Current",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNetCurrentAndNonCurrent",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_JanssenAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen agreement.",
        "label": "Janssen Agreement [Member]",
        "terseLabel": "Janssen Agreement"
       }
      }
     },
     "localname": "JanssenAgreementMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/WarrantDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_JanssenPharmaceuticaNVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Pharmaceutica NV.",
        "label": "Janssen Pharmaceutica N V [Member]",
        "terseLabel": "Janssen Pharmaceutica NV"
       }
      }
     },
     "localname": "JanssenPharmaceuticaNVMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Japan tobacco incorporation and torii pharmaceutical company limited.",
        "label": "Japan Tobacco Incorporation And Torii Pharmaceutical Company Limited [Member]",
        "terseLabel": "JT and Torii"
       }
      }
     },
     "localname": "JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsLicenseAgreementwithPanionBFBiotechIncDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsSublicenseAgreementwithJapanTobaccoIncanditssubsidiaryToriiPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_JohnsonAndJohnsonInnovationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Johnson and Johnson Innovation.",
        "label": "Johnson And Johnson Innovation [Member]",
        "terseLabel": "Johnson &amp; Johnson Innovation"
       }
      }
     },
     "localname": "JohnsonAndJohnsonInnovationMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_KeryxBiopharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Keryx Biopharmaceuticals, Inc.",
        "label": "Keryx Biopharmaceuticals Inc [Member]",
        "terseLabel": "Keryx Biopharmaceuticals, Inc."
       }
      }
     },
     "localname": "KeryxBiopharmaceuticalsIncMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://akebia.com/role/InventoryAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_KeryxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Keryx.",
        "label": "Keryx [Member]",
        "terseLabel": "Keryx"
       }
      }
     },
     "localname": "KeryxMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee leasing arrangements, operating leases, number of lease period extension options.",
        "label": "Lessee Leasing Arrangements Operating Leases Number Of Lease Period Extension Options",
        "terseLabel": "Lease period, number of extension options"
       }
      }
     },
     "localname": "LesseeLeasingArrangementsOperatingLeasesNumberOfLeasePeriodExtensionOptions",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "akba_LesseeOperatingLeaseLiabilityPaymentsDueNet": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due net.",
        "label": "Lessee Operating Lease Liability Payments Due Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNet",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "akba_LesseeOperatingLeaseLiabilityPaymentsDueNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Liability Payments Due Net After Year Four",
        "label": "Lessee Operating Lease Liability Payments Due Net After Year Four",
        "totalLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "akba_LesseeOperatingLeaseLiabilityPaymentsDueNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due net year four.",
        "label": "Lessee Operating Lease Liability Payments Due Net Year Four",
        "totalLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1": {
       "order": 4.0,
       "parentTag": "akba_LesseeOperatingLeaseLiabilityPaymentsDueNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Liability Payments Due Net Year One",
        "label": "Lessee Operating Lease Liability Payments Due Net Year One",
        "totalLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1": {
       "order": 6.0,
       "parentTag": "akba_LesseeOperatingLeaseLiabilityPaymentsDueNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due net year three.",
        "label": "Lessee Operating Lease Liability Payments Due Net Year Three",
        "totalLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1": {
       "order": 3.0,
       "parentTag": "akba_LesseeOperatingLeaseLiabilityPaymentsDueNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due net year two.",
        "label": "Lessee Operating Lease Liability Payments Due Net Year Two",
        "totalLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails_1": {
       "order": 5.0,
       "parentTag": "akba_LesseeOperatingLeaseLiabilityPaymentsDueNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments net reminder of fiscal year.",
        "label": "Lessee Operating Lease Liability Payments Net Reminder Of Fiscal Year",
        "totalLabel": "Remaining 2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Net Sublease Income, Fiscal Year Maturity",
        "label": "Lessee, Operating Lease, Liability, Payments, Net Sublease Income, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Net Operating Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "akba_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee\u200b, Operating \u200bLease\u200b, Liability, \u200bTo Be Paid, \u200bDue \u200bAfter\u200b Year\u200b Four",
        "label": "Lessee\u200b, Operating \u200bLease\u200b, Liability, \u200bTo Be Paid, \u200bDue \u200bAfter\u200b Year\u200b Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessor, Operating Lease, Payment to be Received, Due After Year Four",
        "label": "Lessor, Operating Lease, Payment to be Received, Due After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsLicenseAgreementwithPanionBFBiotechIncDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_LicenseCollaborationAndOtherRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License, collaboration and other revenue.",
        "label": "License Collaboration And Other Revenue [Abstract]",
        "terseLabel": "License, Collaboration and Other Revenue:"
       }
      }
     },
     "localname": "LicenseCollaborationAndOtherRevenueAbstract",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "akba_LicenseCollaborationAndOtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License, collaboration and other revenue.",
        "label": "License Collaboration And Other Revenue [Member]",
        "terseLabel": "License, collaboration and other revenue"
       }
      }
     },
     "localname": "LicenseCollaborationAndOtherRevenueMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_LicenseCollaborationAndOtherRevenueRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Collaboration And Other Revenue, Royalties",
        "label": "License Collaboration And Other Revenue, Royalties [Member]",
        "terseLabel": "License Collaboration And Other Revenue, Royalties"
       }
      }
     },
     "localname": "LicenseCollaborationAndOtherRevenueRoyaltiesMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_LicenseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License expense.",
        "label": "License Expense",
        "terseLabel": "License expense"
       }
      }
     },
     "localname": "LicenseExpense",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_LicensedHIFProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensed HIF Product",
        "label": "Licensed HIF Product [Member]",
        "terseLabel": "Licensed HIF Product"
       }
      }
     },
     "localname": "LicensedHIFProductMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_LicensedProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensed Products",
        "label": "Licensed Products [Member]",
        "terseLabel": "Licensed Products"
       }
      }
     },
     "localname": "LicensedProductsMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, First Quarter Periodic Payment, Principal, Term",
        "label": "Line Of Credit Facility, First Quarter Periodic Payment, Principal, Term",
        "terseLabel": "Term loan, first quarterly principal payment due in"
       }
      }
     },
     "localname": "LineOfCreditFacilityFirstQuarterPeriodicPaymentPrincipalTerm",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "akba_LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Maximum Borrowing Capacity, Number Of Available Tranches",
        "label": "Line Of Credit Facility, Maximum Borrowing Capacity, Number Of Available Tranches",
        "terseLabel": "Line of credit, maximum borrowing capacity, number of available tranches"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityNumberOfAvailableTranches",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "akba_LongTermPurchaseCommitmentFixedPricePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Purchase Commitment, Fixed Price, Period",
        "label": "Long-Term Purchase Commitment, Fixed Price, Period",
        "terseLabel": "Long-term purchase commitment, fixed price, period"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentFixedPricePeriod",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "akba_LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Purchase Commitment, Option To Extend, Prior Notice Period",
        "label": "Long-Term Purchase Commitment, Option To Extend, Prior Notice Period",
        "terseLabel": "Purchase commitment, option to extend, prior notice period"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "akba_LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Purchase Commitment, Option To Terminate, Prior Notice Period",
        "label": "Long-Term Purchase Commitment, Option To Terminate, Prior Notice Period",
        "terseLabel": "Long-term purchase commitment, option to terminate, prior notice period (at least)"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "akba_LongTermPurchaseCommitmentRenewalPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Purchase Commitment, Renewal Period",
        "label": "Long-Term Purchase Commitment, Renewal Period",
        "terseLabel": "Long-term minimum purchase commitment renewal term"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentRenewalPeriod",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "akba_MilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment received.",
        "label": "Milestone Payment Received",
        "terseLabel": "Milestone revenue"
       }
      }
     },
     "localname": "MilestonePaymentReceived",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mitsubishi Tanabe Pharma Corporation and Otsuka Pharmaceutical Company Limited.",
        "label": "Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited [Member]",
        "terseLabel": "Total Proportional Performance Revenue",
        "verboseLabel": "Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited"
       }
      }
     },
     "localname": "MitsubishiTanabePharmaCorporationAndOtsukaPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_MitsubishiTanabePharmaCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mitsubishi Tanabe Pharma Corporation.",
        "label": "Mitsubishi Tanabe Pharma Corporation [Member]",
        "terseLabel": "Mitsubishi Tanabe Pharma Corporation"
       }
      }
     },
     "localname": "MitsubishiTanabePharmaCorporationMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_MitsubishiTanabePharmaCorporationSupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mitsubishi Tanabe Pharma Corporation Supply Agreement",
        "label": "Mitsubishi Tanabe Pharma Corporation Supply Agreement [Member]",
        "terseLabel": "Mitsubishi Tanabe Pharma Corporation Supply Agreement"
       }
      }
     },
     "localname": "MitsubishiTanabePharmaCorporationSupplyAgreementMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_NoncashInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash interest expense.",
        "label": "Noncash Interest Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NoncashInterestExpense",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_NumberOfPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of performance obligations.",
        "label": "Number Of Performance Obligations",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "localname": "NumberOfPerformanceObligations",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsSublicenseAgreementwithJapanTobaccoIncanditssubsidiaryToriiPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "akba_OfficeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office space .",
        "label": "Office Space [Member]",
        "terseLabel": "Office Space"
       }
      }
     },
     "localname": "OfficeSpaceMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_OperatingLeaseAnnualRentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Annual Rent Expense",
        "label": "Operating Lease, Annual Rent Expense",
        "terseLabel": "Annual lease expense"
       }
      }
     },
     "localname": "OperatingLeaseAnnualRentExpense",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_OperatingLeaseFreeMonthlyRentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Free Monthly Rent, Period",
        "label": "Operating Lease, Free Monthly Rent, Period",
        "terseLabel": "Operating lease, free monthly rent, period"
       }
      }
     },
     "localname": "OperatingLeaseFreeMonthlyRentPeriod",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "akba_OperatingLeaseMonthlyRentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Monthly Rent Expense",
        "label": "Operating Lease, Monthly Rent Expense",
        "terseLabel": "Monthly lease expense"
       }
      }
     },
     "localname": "OperatingLeaseMonthlyRentExpense",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_OperatingPlanSufficientlyFundedByCashResourcesPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating plan sufficiently funded by cash resources, period.",
        "label": "Operating Plan Sufficiently Funded By Cash Resources Period",
        "terseLabel": "Period where operating plan is sufficiently funded by cash resources"
       }
      }
     },
     "localname": "OperatingPlanSufficientlyFundedByCashResourcesPeriod",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/NatureofOrganizationandOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "akba_OtherThanDerivativeLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other than derivative liabilities.",
        "label": "Other Than Derivative Liabilities [Member]",
        "terseLabel": "Other than Derivative Liabilities"
       }
      }
     },
     "localname": "OtherThanDerivativeLiabilitiesMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/FairValueofFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_OtsukaPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Otsuka Pharmaceutical Company Limited.",
        "label": "Otsuka Pharmaceutical Company Limited [Member]",
        "terseLabel": "Otsuka Pharmaceutical Company. Ltd."
       }
      }
     },
     "localname": "OtsukaPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_PanionAndBFBiotechIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Panion and BF Biotech, Incorporation.",
        "label": "Panion And B F Biotech Incorporation [Member]",
        "terseLabel": "Panion &amp; BF Biotech, Incorporation"
       }
      }
     },
     "localname": "PanionAndBFBiotechIncorporationMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsLicenseAgreementwithPanionBFBiotechIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_PaymentForLicenseAgreementReimbursementOfCostsIncurred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for license agreement reimbursement of costs incurred.",
        "label": "Payment For License Agreement Reimbursement Of Costs Incurred",
        "terseLabel": "Costs reimbursed"
       }
      }
     },
     "localname": "PaymentForLicenseAgreementReimbursementOfCostsIncurred",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment receivable for license agreement reimbursement of previously costs incurred.",
        "label": "Payment Receivable For License Agreement Reimbursement Of Previously Costs Incurred",
        "terseLabel": "Reimbursement of costs"
       }
      }
     },
     "localname": "PaymentReceivableForLicenseAgreementReimbursementOfPreviouslyCostsIncurred",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment received for license agreement reimbursement of costs incurred.",
        "label": "Payment Received For License Agreement Reimbursement Of Costs Incurred",
        "terseLabel": "Reimbursable costs"
       }
      }
     },
     "localname": "PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_PercentageOfRemainingCreditableAmountAppliedToFuturePayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of remaining creditable amount applied to future payments.",
        "label": "Percentage Of Remaining Creditable Amount Applied To Future Payments",
        "terseLabel": "Percentage of remaining creditable amount applied to future payments"
       }
      }
     },
     "localname": "PercentageOfRemainingCreditableAmountAppliedToFuturePayments",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "akba_PerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance-Based Restricted Stock Units",
        "label": "Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "Performance-Based Restricted Stock Units"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_PotentialPaymentForAchievementOfSpecifiedCommercialMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential payment for achievement of specified commercial milestones.",
        "label": "Potential Payment For Achievement Of Specified Commercial Milestones",
        "terseLabel": "Potential milestone revenue from commercial milestones (up to)"
       }
      }
     },
     "localname": "PotentialPaymentForAchievementOfSpecifiedCommercialMilestones",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential payment for achievement of specified development milestones.",
        "label": "Potential Payment For Achievement Of Specified Development Milestones",
        "terseLabel": "Potential milestone revenue from developmental milestones (up to)"
       }
      }
     },
     "localname": "PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_PotentialPaymentForAchievementOfSpecifiedMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential payment for achievement of specified milestones.",
        "label": "Potential Payment For Achievement Of Specified Milestones",
        "terseLabel": "Potential milestone revenue"
       }
      }
     },
     "localname": "PotentialPaymentForAchievementOfSpecifiedMilestones",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment premium percentage on principal if prepaid on or after fourth anniversary of funding.",
        "label": "Prepayment Premium Percentage On Principal If Prepaid On Or After Fourth Anniversary Of Funding",
        "terseLabel": "Prepayment premium percentage on principal if prepaid after fourth anniversary of funding"
       }
      }
     },
     "localname": "PrepaymentPremiumPercentageOnPrincipalIfPrepaidOnOrAfterFourthAnniversaryOfFunding",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment premium percentage on principal if prepaid prior to fourth anniversary and after third anniversary of funding.",
        "label": "Prepayment Premium Percentage On Principal If Prepaid Prior To Fourth Anniversary And After Third Anniversary Of Funding",
        "terseLabel": "Prepayment premium percentage on principal if prepaid prior to fourth anniversary and after third anniversary of funding"
       }
      }
     },
     "localname": "PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToFourthAnniversaryAndAfterThirdAnniversaryOfFunding",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "akba_PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment premium percentage on principal if prepaid prior to third anniversary of funding",
        "label": "Prepayment Premium Percentage On Principal If Prepaid Prior To Third Anniversary Of Funding",
        "terseLabel": "Prepayment premium percentage on principal if prepaid prior to third anniversary of funding"
       }
      }
     },
     "localname": "PrepaymentPremiumPercentageOnPrincipalIfPrepaidPriorToThirdAnniversaryOfFunding",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "akba_PriorityReviewVoucherLetterAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Priority review voucher letter agreement.",
        "label": "Priority Review Voucher Letter Agreement [Member]",
        "terseLabel": "Priority Review Voucher Letter Agreement"
       }
      }
     },
     "localname": "PriorityReviewVoucherLetterAgreementMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Contractual Arrangement, Royalties Agreement, Sale Of Future Royalties",
        "label": "Proceeds From Contractual Arrangement, Royalties Agreement, Sale Of Future Royalties",
        "terseLabel": "Proceeds from sale of future royalties, net"
       }
      }
     },
     "localname": "ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetails",
      "http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesRollforwardofLiabilityRelatedtoSaleofFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock net of issuance costs.",
        "label": "Proceeds From Issuance Of Common Stock Net Of Issuance Costs",
        "terseLabel": "Proceeds from the issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_ProductionRelatedImpairmentsOrChargesIntangibles": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Production Related Impairments Or Charges, Intangibles",
        "label": "Production Related Impairments Or Charges, Intangibles",
        "terseLabel": "Impairment of intangible asset"
       }
      }
     },
     "localname": "ProductionRelatedImpairmentsOrChargesIntangibles",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_PurchaseCommittedProgramRemainingContractCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase committed program remaining contract costs.",
        "label": "Purchase Committed Program Remaining Contract Costs",
        "terseLabel": "Total remaining contract costs"
       }
      }
     },
     "localname": "PurchaseCommittedProgramRemainingContractCosts",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_RebatesFeesAndOtherDeductionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rebates, Fees and other Deductions.",
        "label": "Rebates Fees And Other Deductions [Member]",
        "terseLabel": "Rebates, Fees and other Deductions"
       }
      }
     },
     "localname": "RebatesFeesAndOtherDeductionsMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationProductRevenueAllowanceandReserveCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in percentage of future payments due upon current global development costs creditable.",
        "label": "Reduction In Percentage Of Future Payments Due Upon Current Global Development Costs Creditable",
        "terseLabel": "Reduction in percentage of future payments due upon current global development costs creditable"
       }
      }
     },
     "localname": "ReductionInPercentageOfFuturePaymentsDueUponCurrentGlobalDevelopmentCostsCreditable",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "akba_RegulatoryMilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestone payments.",
        "label": "Regulatory Milestone Payments [Member]",
        "terseLabel": "Regulatory Milestone Payments"
       }
      }
     },
     "localname": "RegulatoryMilestonePaymentsMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_ReturnsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Returns.",
        "label": "Returns [Member]",
        "terseLabel": "Returns"
       }
      }
     },
     "localname": "ReturnsMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationProductRevenueAllowanceandReserveCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_RevenueRemainingPerformanceObligationVariableConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "terseLabel": "Eligible milestone payments (up to)"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount, Period",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount, Period",
        "terseLabel": "Eligible milestone payments, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmountPeriod",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "akba_RoyaltyPaymentsDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty payments due.",
        "label": "Royalty Payments Due",
        "terseLabel": "Royalty payments"
       }
      }
     },
     "localname": "RoyaltyPaymentsDue",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsLicenseAgreementwithPanionBFBiotechIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_STAPharmaceuticalHongKongLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "STA Pharmaceutical Hong Kong Limited",
        "label": "STA Pharmaceutical Hong Kong Limited [Member]",
        "terseLabel": "STA Pharmaceutical Hong Kong Limited"
       }
      }
     },
     "localname": "STAPharmaceuticalHongKongLimitedMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_ScheduleOfDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesAndOperatingLeaseLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of difference between undiscounted minimum rental commitments under non-cancelable leases and the operating lease liabilities.",
        "label": "Schedule Of Difference Between Undiscounted Minimum Rental Commitments Under Non Cancelable Leases And Operating Lease Liabilities [Table Text Block]",
        "terseLabel": "Difference Between Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases and Operating Leases Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesAndOperatingLeaseLiabilitiesTableTextBlock",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "akba_ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Product Revenue Allowance And Reserve Categories.",
        "label": "Schedule Of Product Revenue Allowance And Reserve Categories [Table Text Block]",
        "terseLabel": "Product Revenue Allowance and Reserve Categories"
       }
      }
     },
     "localname": "ScheduleOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "akba_ScheduleOfRevenueRecognizedResultingFromChangesInContractAssetAndContractLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of revenue recognized resulting from changes in contract asset and contract liability.",
        "label": "Schedule Of Revenue Recognized Resulting From Changes In Contract Asset And Contract Liability [Table Text Block]",
        "terseLabel": "Revenue Recognized Resulting from Changes in Contract Assets and Contract Liabilities"
       }
      }
     },
     "localname": "ScheduleOfRevenueRecognizedResultingFromChangesInContractAssetAndContractLiabilityTableTextBlock",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "akba_ServiceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service-Based Restricted Stock Units",
        "label": "Service-Based Restricted Stock Units [Member]",
        "terseLabel": "Service-Based Restricted Stock Units"
       }
      }
     },
     "localname": "ServiceBasedRestrictedStockUnitsMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Grace Period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Grace Period",
        "terseLabel": "Award vesting grace period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingGracePeriod",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, offering period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "akba_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, periodic vesting, number of installments.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Periodic Vesting Number Of Installments",
        "terseLabel": "Number of equal quarterly installments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodicVestingNumberOfInstallments",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "akba_ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation award, tranche, first anniversary of grant date.",
        "label": "Share Based Compensation Award Tranche First Anniversary Of Grant Date [Member]",
        "terseLabel": "Share-based Compensation Award, Tranche, First Anniversary of Grant Date"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheFirstAnniversaryOfGrantDateMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation award tranche first or third anniversary of grant date.",
        "label": "Share Based Compensation Award Tranche First Or Third Anniversary Of Grant Date [Member]",
        "terseLabel": "Share-based Compensation Award, Tranche, First Or Third Anniversary of Grant Date"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheFirstOrThirdAnniversaryOfGrantDateMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement, Tranche One, First Anniversary After Grant Date, Subjected To Individual Continued Service",
        "label": "Share-Based Payment Arrangement, Tranche One, First Anniversary After Grant Date, Subjected To Individual Continued Service [Member]",
        "terseLabel": "Share-Based Payment Arrangement, Tranche One, First Anniversary After Grant Date, Subjected To Individual Continued Service"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementTrancheOneFirstAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_ShareBasedPaymentArrangementTrancheThreeThirdAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement, Tranche Three, Third Anniversary After Grant Date, Subjected To Individual Continued Service",
        "label": "Share-Based Payment Arrangement, Tranche Three, Third Anniversary After Grant Date, Subjected To Individual Continued Service [Member]",
        "terseLabel": "Share-Based Payment Arrangement, Tranche Three, Third Anniversary After Grant Date, Subjected To Individual Continued Service"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementTrancheThreeThirdAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_ShareBasedPaymentArrangementTrancheTwoSecondAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement, Tranche Two, Second Anniversary After Grant Date, Subjected To Individual Continued Service",
        "label": "Share-Based Payment Arrangement, Tranche Two, Second Anniversary After Grant Date, Subjected To Individual Continued Service [Member]",
        "terseLabel": "Share-Based Payment Arrangement, Tranche Two, Second Anniversary After Grant Date, Subjected To Individual Continued Service"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementTrancheTwoSecondAnniversaryAfterGrantDateSubjectedToIndividualContinuedServiceMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_SiegfriedEvionnazSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Siegfried Evionnaz SA.",
        "label": "Siegfried Evionnaz S A [Member]",
        "terseLabel": "Siegfried Evionnaz SA"
       }
      }
     },
     "localname": "SiegfriedEvionnazSAMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value including offering costs employee stock purchase plan.",
        "label": "Stock Issued During Period Value Including Offering Costs Employee Stock Purchase Plan",
        "terseLabel": "Proceeds from sale of stock under \u00a0\u00a0 employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_SublicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublicense agreement.",
        "label": "Sublicense Agreement [Member]",
        "terseLabel": "Sublicense Agreement"
       }
      }
     },
     "localname": "SublicenseAgreementMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsSublicenseAgreementwithJapanTobaccoIncanditssubsidiaryToriiPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_SupplyAgreementPatheonIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Agreement, Patheon Inc.",
        "label": "Supply Agreement, Patheon Inc. [Member]",
        "terseLabel": "Supply Agreement, Patheon Inc."
       }
      }
     },
     "localname": "SupplyAgreementPatheonIncMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan.",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_ThreeMonthLondonInterbankOfferedRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three-month London interbank offered rate.",
        "label": "Three Month London Interbank Offered Rate [Member]",
        "terseLabel": "Three-month LIBOR"
       }
      }
     },
     "localname": "ThreeMonthLondonInterbankOfferedRateMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_TrancheAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche A",
        "label": "Tranche A [Member]",
        "terseLabel": "Tranche A"
       }
      }
     },
     "localname": "TrancheAMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_TrancheBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche B.",
        "label": "Tranche B [Member]",
        "terseLabel": "Tranche B"
       }
      }
     },
     "localname": "TrancheBMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_TwoThousandAndFourteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and fourteen employee stock purchase plan.",
        "label": "Two Thousand And Fourteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2014 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandAndFourteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_TwoThousandAndFourteenPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and fourteen plans.",
        "label": "Two Thousand And Fourteen Plans [Member]",
        "terseLabel": "2014 Plans"
       }
      }
     },
     "localname": "TwoThousandAndFourteenPlansMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_UpFrontNonRefundableAndNonCreditableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Up front, non refundable and non creditable,",
        "label": "Up Front Non Refundable And Non Creditable [Member]",
        "terseLabel": "Up Front Non Refundable And Non Creditable"
       }
      }
     },
     "localname": "UpFrontNonRefundableAndNonCreditableMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_UpfrontCashPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront cash payment received.",
        "label": "Upfront Cash Payment Received",
        "terseLabel": "Upfront cash payment received"
       }
      }
     },
     "localname": "UpfrontCashPaymentReceived",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_UpfrontPaymentPaidInCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment paid in cash.",
        "label": "Upfront Payment Paid In Cash",
        "terseLabel": "Upfront payment made in cash"
       }
      }
     },
     "localname": "UpfrontPaymentPaidInCash",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowances and reserves adjustments related to prior period sales.",
        "label": "Valuation Allowances And Reserves Adjustments Related To Prior Period Sales",
        "terseLabel": "Adjustments related to prior year sales"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationProductRevenueAllowanceandReserveCategoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "akba_ViforInternationalLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vifor International Limited.",
        "label": "Vifor International Limited [Member]",
        "terseLabel": "Vifor (International) Ltd."
       }
      }
     },
     "localname": "ViforInternationalLimitedMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_ViforPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vifor Pharma.",
        "label": "Vifor Pharma [Member]",
        "terseLabel": "Vifor Pharma"
       }
      }
     },
     "localname": "ViforPharmaMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "akba_WarrantDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant disclosure.",
        "label": "Warrant Disclosure [Text Block]",
        "terseLabel": "Warrant"
       }
      }
     },
     "localname": "WarrantDisclosureTextBlock",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/Warrant"
     ],
     "xbrltype": "textBlockItemType"
    },
    "akba_WuXiSTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WuXi STA",
        "label": "WuXi STA [Member]",
        "terseLabel": "WuXi STA"
       }
      }
     },
     "localname": "WuXiSTAMember",
     "nsuri": "http://akebia.com/20210930",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "verboseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "verboseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://akebia.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r60",
      "r62",
      "r110",
      "r111",
      "r253",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsLicenseAgreementwithPanionBFBiotechIncDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsSublicenseAgreementwithJapanTobaccoIncanditssubsidiaryToriiPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r252",
      "r289",
      "r349",
      "r352",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r473",
      "r521",
      "r524",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r252",
      "r289",
      "r349",
      "r352",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r473",
      "r521",
      "r524",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r173",
      "r326",
      "r330",
      "r477",
      "r520",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r173",
      "r326",
      "r330",
      "r477",
      "r520",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r252",
      "r289",
      "r338",
      "r349",
      "r352",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r473",
      "r521",
      "r524",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r252",
      "r289",
      "r338",
      "r349",
      "r352",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r473",
      "r521",
      "r524",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r61",
      "r62",
      "r110",
      "r111",
      "r253",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsLicenseAgreementwithPanionBFBiotechIncDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsSublicenseAgreementwithJapanTobaccoIncanditssubsidiaryToriiPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r128",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Scenario Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r128",
      "r133",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r174",
      "r175",
      "r326",
      "r331",
      "r523",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r174",
      "r175",
      "r326",
      "r331",
      "r523",
      "r532",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r128",
      "r133",
      "r234",
      "r350",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r177",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationProductRevenueAllowanceandReserveCategoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r117",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationProductRevenueAllowanceandReserveCategoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r39",
      "r440"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableMember": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations incurred and payable to vendors for goods and services received.",
        "label": "Accounts Payable [Member]",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r20",
      "r508",
      "r533"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r20",
      "r178",
      "r179"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premium/discount on investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://akebia.com/role/AccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AccruedExpensesDetails",
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r43"
     ],
     "calculation": {
      "http://akebia.com/role/AccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r43"
     ],
     "calculation": {
      "http://akebia.com/role/AccruedExpensesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r64",
      "r65",
      "r66",
      "r69",
      "r75",
      "r76",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized Gain/(Loss)"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r67",
      "r68",
      "r69",
      "r512",
      "r529",
      "r530"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r366",
      "r367",
      "r368",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r353",
      "r355",
      "r370",
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r98",
      "r216",
      "r221"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangibles",
        "verboseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://akebia.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from calculation of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of property leased (in square feet)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/DebtDetails",
      "http://akebia.com/role/FairValueofFinancialInstrumentsAdditionalInformationDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsLicenseAgreementwithPanionBFBiotechIncDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsSublicenseAgreementwithJapanTobaccoIncanditssubsidiaryToriiPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails",
      "http://akebia.com/role/WarrantDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsCyclerionTherapeuticsLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": {
     "auth_ref": [
      "r382",
      "r383",
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration",
        "terseLabel": "Contingent consideration from developmental and regulatory milestones"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsCyclerionTherapeuticsLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsCyclerionTherapeuticsLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Asset Acquisition [Line Items]",
        "terseLabel": "Asset Acquisition [Line Items]"
       }
      }
     },
     "localname": "AssetAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsCyclerionTherapeuticsLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTable": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset acquisition.",
        "label": "Asset Acquisition [Table]",
        "terseLabel": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsCyclerionTherapeuticsLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r108",
      "r162",
      "r165",
      "r171",
      "r195",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r389",
      "r392",
      "r412",
      "r438",
      "r440",
      "r494",
      "r509"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r56",
      "r108",
      "r195",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r389",
      "r392",
      "r412",
      "r438",
      "r440"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets measured at fair value on recurring basis",
        "totalLabel": "Total assets fair value disclosure"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/FairValueofFinancialInstrumentsAdditionalInformationDetails",
      "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Available for sale securities, gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r186"
     ],
     "calculation": {
      "http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Available for sale securities, gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r183",
      "r202"
     ],
     "calculation": {
      "http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails_1": {
       "order": 2.0,
       "parentTag": "akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Available for sale securities, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r181",
      "r184",
      "r202",
      "r499"
     ],
     "calculation": {
      "http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Available for sale securities",
        "verboseLabel": "Available for sale securities, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets",
      "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]",
        "terseLabel": "Available for sale securities:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r356",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r394",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BilledContractReceivables": {
     "auth_ref": [
      "r52",
      "r475"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.",
        "label": "Billed Contracts Receivable",
        "terseLabel": "Up-front payments invoiced"
       }
      }
     },
     "localname": "BilledContractReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r348",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://akebia.com/role/InventoryAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r348",
      "r351",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://akebia.com/role/InventoryAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/InventoryAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to inventory acquired in connection with a business combination for which the initial accounting was incomplete.",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory",
        "terseLabel": "Inventory step-up charges"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/InventoryAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r35",
      "r100"
     ],
     "calculation": {
      "http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails_1": {
       "order": 1.0,
       "parentTag": "akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost",
       "weight": 1.0
      },
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents, amortized cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      },
      "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents, fair value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "akba_CashCashEquivalentsAndShortTermInvestmentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "totalLabel": "Total cash, cash equivalents, and available for sale securities, fair value"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r95",
      "r100",
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of the period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r95",
      "r413"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Contract with Customer, Liability [Abstract]",
        "terseLabel": "Revenue Recognized in the Period from:"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenueRecognizedResultingfromChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails",
      "http://akebia.com/role/WarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/WarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrant to purchase common stock (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails",
      "http://akebia.com/role/WarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r311",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/WarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r385",
      "r386",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License, Collaboration and Other Significant Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "License, Collaboration and Other Revenue:",
        "verboseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsLicenseAgreementwithPanionBFBiotechIncDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsSublicenseAgreementwithJapanTobaccoIncanditssubsidiaryToriiPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r48",
      "r233",
      "r500",
      "r516"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 14)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r235",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock, reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r120",
      "r121",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails",
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "verboseLabel": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19",
      "r440"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock $0.00001 par value; 350,000,000 shares authorized at September\u00a030, 2021 and December 31, 2020; 174,551,989 and 148,074,085 shares issued and outstanding at September\u00a030, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r71",
      "r73",
      "r74",
      "r81",
      "r502",
      "r518"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r103",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Changes in Contract Assets and Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r313",
      "r315",
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "periodEndLabel": "Balance at End of Period",
        "periodStartLabel": "Balance at Beginning of Period",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerBasisOfPricingAxis": {
     "auth_ref": [
      "r326",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by basis of pricing for contract representing right to consideration in exchange for good or service transferred to customer.",
        "label": "Contract with Customer, Basis of Pricing [Axis]",
        "terseLabel": "Contract with Customer, Basis of Pricing"
       }
      }
     },
     "localname": "ContractWithCustomerBasisOfPricingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerBasisOfPricingDomain": {
     "auth_ref": [
      "r326",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of pricing for contract with customer. Includes, but is not limited to, fixed-price and time-and-materials contracts.",
        "label": "Contract with Customer, Basis of Pricing [Domain]",
        "terseLabel": "Contract with Customer, Basis of Pricing"
       }
      }
     },
     "localname": "ContractWithCustomerBasisOfPricingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r313",
      "r314",
      "r327"
     ],
     "calculation": {
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Balance at End of Period",
        "periodStartLabel": "Balance at Beginning of Period",
        "terseLabel": "Deferred revenue",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability [Abstract]",
        "terseLabel": "Deferred Revenue:"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r313",
      "r314",
      "r327"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Short-term deferred revenue",
        "verboseLabel": "Short-Term"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r313",
      "r314",
      "r327"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion",
        "verboseLabel": "Long-Term"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized",
        "verboseLabel": "Amounts included in deferred revenue at the beginning of the period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenueRecognizedResultingfromChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Performance obligations satisfied in previous periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenueRecognizedResultingfromChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostDirectMaterial": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of material used for good produced and service rendered.",
        "label": "Cost, Direct Material",
        "terseLabel": "Charge to cost of goods sold"
       }
      }
     },
     "localname": "CostDirectMaterial",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r78",
      "r79"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.",
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "terseLabel": "Product"
       }
      }
     },
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldAmortization": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.",
        "label": "Cost, Amortization",
        "terseLabel": "Amortization of intangibles"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r84",
      "r108",
      "r195",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r412"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "totalLabel": "Total cost of goods sold"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenue [Abstract]",
        "terseLabel": "Cost of goods sold:"
       }
      }
     },
     "localname": "CostOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r104",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r266",
      "r273",
      "r274",
      "r276",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r107",
      "r112",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r279",
      "r280",
      "r281",
      "r282",
      "r420",
      "r495",
      "r496",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on floating interest rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r46",
      "r107",
      "r112",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r279",
      "r280",
      "r281",
      "r282",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term loan, maturity term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in allowance for credit loss of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Period Increase (Decrease)",
        "terseLabel": "Available-for-sale securities, recognized credit losses during period"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AvailableForSaleSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain (Loss)",
        "terseLabel": "Realized gains (losses) on available for sale securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AvailableForSaleSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Cash, Cash Equivalents, and Available for Sale Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AvailableForSaleSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r189",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of available-for-sale securities in a unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AvailableForSaleSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r57",
      "r62",
      "r63",
      "r395",
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/FairValueofFinancialInstrumentsFairValueDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r58",
      "r59",
      "r62",
      "r411"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets",
      "http://akebia.com/role/DebtDetails",
      "http://akebia.com/role/FairValueofFinancialInstrumentsAdditionalInformationDetails",
      "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r326",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r82",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r134",
      "r136",
      "r138",
      "r139",
      "r140",
      "r144",
      "r145",
      "r401",
      "r402",
      "r503",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r82",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r136",
      "r138",
      "r139",
      "r140",
      "r144",
      "r145",
      "r401",
      "r402",
      "r503",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/NetLossperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://akebia.com/role/AccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll and related"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossperShareDetails",
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r75",
      "r76",
      "r77",
      "r120",
      "r121",
      "r122",
      "r124",
      "r130",
      "r132",
      "r147",
      "r196",
      "r303",
      "r310",
      "r366",
      "r367",
      "r368",
      "r376",
      "r377",
      "r400",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r525",
      "r526",
      "r527",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/FairValueofFinancialInstrumentsAdditionalInformationDetails",
      "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/FairValueofFinancialInstrumentsAdditionalInformationDetails",
      "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Assets Measured or Disclosed at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r264",
      "r279",
      "r280",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r404",
      "r445",
      "r446",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/FairValueofFinancialInstrumentsAdditionalInformationDetails",
      "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r403",
      "r404",
      "r406",
      "r407",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/FairValueofFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r264",
      "r339",
      "r340",
      "r345",
      "r347",
      "r404",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r264",
      "r279",
      "r280",
      "r339",
      "r340",
      "r345",
      "r347",
      "r404",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r264",
      "r279",
      "r280",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r404",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/FairValueofFinancialInstrumentsAdditionalInformationDetails",
      "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r264",
      "r279",
      "r280",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r445",
      "r446",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/FairValueofFinancialInstrumentsAdditionalInformationDetails",
      "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r408",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair value measurements recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r187",
      "r188",
      "r192",
      "r193",
      "r194",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r204",
      "r205",
      "r206",
      "r207",
      "r275",
      "r301",
      "r399",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://akebia.com/role/FairValueofFinancialInstrumentsAdditionalInformationDetails",
      "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Intangible assets, estimated useful life",
        "verboseLabel": "Finite-Lived Intangible Asset, Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails",
      "http://akebia.com/role/IntangibleAssetsandGoodwillIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r220"
     ],
     "calculation": {
      "http://akebia.com/role/IntangibleAssetsandGoodwillIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/IntangibleAssetsandGoodwillIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r217",
      "r218",
      "r220",
      "r222",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails",
      "http://akebia.com/role/IntangibleAssetsandGoodwillIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r220",
      "r479"
     ],
     "calculation": {
      "http://akebia.com/role/IntangibleAssetsandGoodwillIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/IntangibleAssetsandGoodwillIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails",
      "http://akebia.com/role/IntangibleAssetsandGoodwillIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r217",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails",
      "http://akebia.com/role/IntangibleAssetsandGoodwillIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r220",
      "r478"
     ],
     "calculation": {
      "http://akebia.com/role/IntangibleAssetsandGoodwillIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/IntangibleAssetsandGoodwillIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r211",
      "r213",
      "r440",
      "r493"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets",
      "http://akebia.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/IntangibleAssetsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r98",
      "r212",
      "r214",
      "r215"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GuaranteeObligationsByNatureAxis": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nature of guarantee.",
        "label": "Guarantor Obligations, Nature [Axis]",
        "terseLabel": "Guarantor Obligations, Nature"
       }
      }
     },
     "localname": "GuaranteeObligationsByNatureAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GuaranteeObligationsNatureDomain": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees.",
        "label": "Guarantor Obligations, Nature [Domain]",
        "terseLabel": "Guarantor Obligations, Nature"
       }
      }
     },
     "localname": "GuaranteeObligationsNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r98",
      "r223"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Intangible asset impairment charge"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r228",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expense"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r97",
      "r474"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "Increase (Decrease) in Derivative Liabilities",
        "terseLabel": "Change in fair value of derivative liability",
        "verboseLabel": "Change in fair value of derivative liability, recorded as other expense (income)"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://akebia.com/role/FairValueofFinancialInstrumentsFairValueDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r97",
      "r429"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other long-term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r87",
      "r270",
      "r278",
      "r281",
      "r282"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r27",
      "r209"
     ],
     "calculation": {
      "http://akebia.com/role/InventoryComponentsofInventoryDetails_1": {
       "order": 3.0,
       "parentTag": "akba_InventoryNetCurrentAndNonCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r53",
      "r440"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://akebia.com/role/InventoryComponentsofInventoryDetails": {
       "order": 2.0,
       "parentTag": "akba_InventoryNetCurrentAndNonCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets",
      "http://akebia.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "terseLabel": "Balance Sheet Classification:"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://akebia.com/role/InventoryComponentsofInventoryDetails": {
       "order": 1.0,
       "parentTag": "akba_InventoryNetCurrentAndNonCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r29",
      "r209"
     ],
     "calculation": {
      "http://akebia.com/role/InventoryComponentsofInventoryDetails_1": {
       "order": 1.0,
       "parentTag": "akba_InventoryNetCurrentAndNonCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r28",
      "r209"
     ],
     "calculation": {
      "http://akebia.com/role/InventoryComponentsofInventoryDetails_1": {
       "order": 2.0,
       "parentTag": "akba_InventoryNetCurrentAndNonCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r208"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Write-down of inventory",
        "verboseLabel": "Inventory amounts written down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://akebia.com/role/InventoryAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r191",
      "r492",
      "r505",
      "r531",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Available for Sale Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AvailableforSaleSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Undiscounted Minimum Rental Commitments Under Non-Cancelable Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://akebia.com/role/CommitmentsandContingenciesDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesandOperatingLeasesLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "akba_LesseeOperatingLeaseLiabilityPaymentsDueNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesandOperatingLeasesLiabilitiesDetails",
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remaining 2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://akebia.com/role/CommitmentsandContingenciesDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesandOperatingLeasesLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Present value adjustment using incremental borrowing rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesandOperatingLeasesLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating lease, remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease extension period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Lease Payments to be Received from Sublease"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "akba_LesseeOperatingLeaseLiabilityPaymentsDueNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year",
        "terseLabel": "Remaining 2021"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "akba_LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r42",
      "r108",
      "r166",
      "r195",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r390",
      "r392",
      "r393",
      "r412",
      "r438",
      "r439"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r108",
      "r195",
      "r412",
      "r440",
      "r498",
      "r514"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r45",
      "r108",
      "r195",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r390",
      "r392",
      "r393",
      "r412",
      "r438",
      "r439",
      "r440"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "terseLabel": "Liabilities measured at fair value on recurring basis",
        "totalLabel": "Total liabilities fair value disclosure"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/FairValueofFinancialInstrumentsAdditionalInformationDetails",
      "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r41",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r41",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r41",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r16",
      "r263",
      "r277",
      "r279",
      "r280",
      "r496",
      "r510"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Term loan, net of facility fees, lender expenses and issuance costs"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.",
        "label": "Long-term Purchase Commitment, Amount",
        "terseLabel": "Long-term minimum purchase commitment"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermPurchaseCommitmentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Long-term Purchase Commitment, Period",
        "terseLabel": "Minimum purchase commitment, initial term"
       }
      }
     },
     "localname": "LongtermPurchaseCommitmentPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationProductRevenueAllowanceandReserveCategoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r150",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Organization and Operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/NatureofOrganizationandOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r95",
      "r96",
      "r99"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r70",
      "r72",
      "r77",
      "r80",
      "r99",
      "r108",
      "r123",
      "r125",
      "r126",
      "r127",
      "r128",
      "r131",
      "r132",
      "r137",
      "r162",
      "r164",
      "r167",
      "r170",
      "r172",
      "r195",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r402",
      "r412",
      "r501",
      "r517"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements - Recently Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash financing activities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails",
      "http://akebia.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OffMarketFavorableLeaseMember": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifiable intangible asset established upon acquisition based on a favorable difference between the terms of an acquired lease and the current market terms for that lease.",
        "label": "Off-Market Favorable Lease [Member]",
        "terseLabel": "Favorable lease"
       }
      }
     },
     "localname": "OffMarketFavorableLeaseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/IntangibleAssetsandGoodwillIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r162",
      "r164",
      "r167",
      "r170",
      "r172"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r427",
      "r432"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease, cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r422"
     ],
     "calculation": {
      "http://akebia.com/role/CommitmentsandContingenciesDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesandOperatingLeasesLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesandOperatingLeasesLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r422"
     ],
     "calculation": {
      "http://akebia.com/role/AccruedExpensesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AccruedExpensesDetails",
      "http://akebia.com/role/CommitmentsandContingenciesDifferenceBetweenUndiscountedMinimumRentalCommitmentsUnderNonCancelableLeasesandOperatingLeasesLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r422"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r424",
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease, payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r421"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r430",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease, incremental borrowing rates based on remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r43"
     ],
     "calculation": {
      "http://akebia.com/role/AccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r64",
      "r65",
      "r67"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Other comprehensive gain (loss) - unrealized gain (loss) on debt securities",
        "verboseLabel": "Unrealized gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r394",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherDepreciationAndAmortization": {
     "auth_ref": [
      "r85",
      "r98",
      "r225"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.",
        "label": "Other Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "OtherDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeMember": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other revenue.",
        "label": "Other Income [Member]",
        "terseLabel": "MTPC Other Revenue"
       }
      }
     },
     "localname": "OtherIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIntangibleAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.",
        "label": "Other Intangible Assets, Net",
        "terseLabel": "Other intangible assets, net"
       }
      }
     },
     "localname": "OtherIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other liabilities.",
        "label": "Other Liabilities Disclosure [Text Block]",
        "terseLabel": "Liability Related to Sale of Future Royalties"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyalties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Table Text Block]",
        "terseLabel": "Activity within Liability Related to Sale of Future Royalties, net"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r89",
      "r91",
      "r182"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchase of available for sale securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r92",
      "r382",
      "r383",
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Upfront payment for asset acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsCyclerionTherapeuticsLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r356",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (in shares)",
        "verboseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r18",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued (in shares)",
        "verboseLabel": "Preferred stock, issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Preferred stock, outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r18",
      "r440"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock $0.00001 par value, 25,000,000 shares authorized; 0 shares issued and \u00a0\u00a0 outstanding at September\u00a030, 2021 and December 31, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r33",
      "r34"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from common stock sold"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r94",
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from line of credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r89",
      "r90",
      "r182"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from the maturities of available for sale securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r93",
      "r365"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from the sale of stock under employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenue, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r36",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r227",
      "r440",
      "r506",
      "r515"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r12",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": {
     "auth_ref": [
      "r17",
      "r497",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Axis]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Axis]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": {
     "auth_ref": [
      "r17",
      "r497",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Domain]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Domain]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r17",
      "r497",
      "r511"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Minimum purchase commitment"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r346",
      "r434",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsLicenseAgreementwithPanionBFBiotechIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r346",
      "r434",
      "r437",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsLicenseAgreementwithPanionBFBiotechIncDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": {
     "auth_ref": [
      "r373",
      "r375"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross",
        "terseLabel": "Contract cost incurred in research and development activities"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r372",
      "r476",
      "r547"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsCyclerionTherapeuticsLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r310",
      "r369",
      "r440",
      "r513",
      "r528",
      "r530"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r120",
      "r121",
      "r122",
      "r124",
      "r130",
      "r132",
      "r196",
      "r366",
      "r367",
      "r368",
      "r376",
      "r377",
      "r400",
      "r525",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r160",
      "r161",
      "r163",
      "r168",
      "r169",
      "r173",
      "r174",
      "r176",
      "r325",
      "r326",
      "r477"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues",
        "verboseLabel": "Recognized revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsSublicenseAgreementwithJapanTobaccoIncanditssubsidiaryToriiPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r324",
      "r329",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Product Revenue and Reserves for Variable Consideration"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/ProductRevenueandReservesforVariableConsideration"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/NetLossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/InventoryAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsChangesinContractAssetsandLiabilitiesDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsLicenseAgreementwithPanionBFBiotechIncDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsSublicenseAgreementwithJapanTobaccoIncanditssubsidiaryToriiPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "terseLabel": "Fair Value Derivative Liability"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r217",
      "r219",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails",
      "http://akebia.com/role/IntangibleAssetsandGoodwillIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r217",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r10",
      "r30",
      "r31",
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventory Components"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r49",
      "r105",
      "r148",
      "r149",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r296",
      "r301",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Total security deposit in connection with lease"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of shares granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Number of shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r360",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Number of shares outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r354",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share Based Compensation Award Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Share Based Compensation Award Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price at the end of offering period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r102",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r51",
      "r75",
      "r76",
      "r77",
      "r120",
      "r121",
      "r122",
      "r124",
      "r130",
      "r132",
      "r147",
      "r196",
      "r303",
      "r310",
      "r366",
      "r367",
      "r368",
      "r376",
      "r377",
      "r400",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r525",
      "r526",
      "r527",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r147",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r18",
      "r19",
      "r303",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Proceeds from sale of stock under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r303",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs (in shares)",
        "verboseLabel": "Issuance of common stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r18",
      "r19",
      "r303",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock unit vesting (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r19",
      "r303",
      "r310",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r303",
      "r310"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of \u00a0\u00a0 issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r51",
      "r303",
      "r310"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r24",
      "r25",
      "r108",
      "r180",
      "r195",
      "r412",
      "r440"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets",
      "http://akebia.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r106",
      "r288",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r310",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StraightLineRent": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between actual rental income due and rental income recognized on a straight-line basis.",
        "label": "Straight Line Rent",
        "negatedTerseLabel": "Non-cash operating lease expense"
       }
      }
     },
     "localname": "StraightLineRent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r428",
      "r432"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease rental income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r187",
      "r188",
      "r192",
      "r193",
      "r194",
      "r275",
      "r301",
      "r399",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://akebia.com/role/FairValueofFinancialInstrumentsAdditionalInformationDetails",
      "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/DebtDetails",
      "http://akebia.com/role/FairValueofFinancialInstrumentsAdditionalInformationDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsDeferredRevenueDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsInternationalCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsLicenseAgreementwithPanionBFBiotechIncDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsMitsubishiTanabePharmaCorporationCollaborationAgreementDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsRevenuesRecognizedFromLicenseCollaborationandOtherSignificantAgreementsDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsSublicenseAgreementwithJapanTobaccoIncanditssubsidiaryToriiPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsUSCollaborationandLicenseAgreementwithOtsukaPharmaceuticalCoLtdDetails",
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsViforPharmaLicenseAgreementDetails",
      "http://akebia.com/role/WarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r109",
      "r339",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government debt securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/AvailableForSaleSecuritiesCashCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://akebia.com/role/FairValueofFinancialInstrumentsAssetsMeasuredorDisclosedatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r113",
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationProductRevenueAllowanceandReserveCategoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "terseLabel": "Current provisions related to sales in current year"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationProductRevenueAllowanceandReserveCategoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedLabel": "Credits/payments made"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationProductRevenueAllowanceandReserveCategoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r117",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationProductRevenueAllowanceandReserveCategoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r117",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/ProductRevenueandReservesforVariableConsiderationProductRevenueAllowanceandReserveCategoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Note Disclosure [Abstract]",
        "terseLabel": "Warrants and Rights Note Disclosure [Abstract]"
       }
      }
     },
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "auth_ref": [
      "r403"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity.",
        "label": "Warrants Not Settleable in Cash, Fair Value Disclosure",
        "terseLabel": "Fair value of warrant at issuance"
       }
      }
     },
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/LicenseCollaborationandOtherSignificantAgreementsJanssenPharmaceuticaNVResearchandLicenseAgreementDetails",
      "http://akebia.com/role/WarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r135",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average number of common shares - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r134",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of common shares - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://akebia.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL108322424-203045"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=SL65897772-128472"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55302-109406"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123366838&loc=d3e3073-115593"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r548": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r549": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r551": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r552": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r553": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r554": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r555": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r556": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r557": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r558": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r559": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r561": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>89
<FILENAME>0001628280-21-021760-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-021760-xbrl.zip
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M$5B$PFF9.5ID66??+V%N!>-]JU@GO-;)AHBS8U&RK&I02"^RAFC1V^R82M&
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MHQ7KR;MVKN]+F_IKHQNBKR9//GG^KZMKK]=__'#RT=6SGXRTXN3=8(C]84V
M>#A!2<C)[SY_=W&;^=*AH56S\*Y^,WD_N<C]*P,U.4\-84>#-J@Z?' Q#,<L
MVZ=]>GA^^=&7DU-,OIN\K^?X.@[>(;!/HZ))[*\B9L8E>R0PJ 25L8Z10LL%
M&/YQ_NEP/*)2C/(DKG[SG2-Z.F+SU2$[S^U\\/K5^G>/YG=H[ 4;S2O\_+[1
MO#("WY&HL% C("9Y-[?E$[M1(U_KXO%R^SW?UN5#1UH;A[W^#U+OB]_7#]>I
MVSMF:_Z5T]Y405PYQ?VK=_\MYHMD=8UV.:9&"+HN_ 259/)H"\4 Y_K<S5"?
MGS\V'5179_PV\\4^GG3:J3W<I#H?N);;Q]7?J1LF!OWA@Y?]7CY-P^W^*^J_
M;R=Z]+'-"G?B5IU_._[IK_>_>L:+H;JX\ _8%3<+NW(%/^F#2Y+%%I0%IUS(
MP"J,37358+J,HQ QP4^L\/MS_,3-\1-3P\\Z5K*V1",U1QQ*!?:BL@QD60$K
M35^-(E?XS=6ONX)?LJQ 408E4P$(*4:70:'Q124TVIS+GUS)WTWD[Z;X34_^
M"LC,87_VDC1$QL\&QQY0"%;$$BZR8YII_VH(^. %O^T.Z$FOT\'8ZX^GF+IY
M>WA(_1UZ3]U36D;#B-Z9 #)X51"BTQZS$I@]ATPU;!6--HP+ NQ<+*;("IP-
M0F<EP;*8NBQ%+AF#R(;L5[.65L VP92R^93"1LGJ%A(JCR76#'R-63JO4Z--
MZ8( .Q<;F[0C4Y!CRI  J2!IK(NUTE3Q+64.-K81)BQ:\FB2(I,L:&^\#12,
ML)J"5#Z%.9BP1EB(@#%;(Q7HG"!J[[V3(4=EP&BT4L]!D31"3@F34NP/>U#L
M 0-&5KJ9(%D668YN;)T#E&$6<X#?JW<O%E0G*V0;_SZMZV:]XY->E]\.KL8S
M_/EQK_MJV$OOIJ]O/T].RG";R<DKT/B4/-O#!-7I@2B\8F<',DEGR;'-7!IH
M'N4\6L_$SDMLY^?=)WC2'F*G(3 YI*0]V[9$C)+T:+7RWAH0J5A1W/+ E-+I
M\6FGUJ/9HN'K;I^PT_Y$#-A[&@SK[Y]AN_NB-Q@T!#EA/2DK7"Z:P&(.IF:5
ML<^2C4T^+H^ [="0D:&\@?UNNWO0%'R<#U);9YTP"D!$;UD'YF*##6S6,\T.
MGWF-@*X/GI4VHF@(GF)6S@2MK$XD_7F.XB6O1C>>JG=JIF_A;NE+@-YFZI&#
M(N><MBIZ0.ECL*BAV*B--'B^]+94@,[,N,\?7%-4EIBCMI"A%!90A=EH'4PH
MY,'- =Q&C%M2.02VQ!:*!T#%@8=*8)R.A76<^")V:[Y0W+U!GC^JV1LA7$Q!
M.>0@W$8;P4%PQ@9D30?C[)(E '-&D>5U:&[C5LCBE$TL<(R#5SYXFT),TJC,
MT7\L2P/-'"++*<*D-*AH3 RL!2%!"0YMIJB%2 JU6AX)6HS(<HK(>9N3#Z ,
M%0$VVU!2<=$!*/Z?QN41L%E&EE/$AXI$IX4-DN,JTC8XY50J5GETF68I6?,:
M <E1M#%>2Q,02I0!=-"F$$?8,ODX62J'B<]E%V_A;9',]'5W"V[N;MGI3.2K
M&F]8#C\2U460B"A\9LLNV%*@=6'Y )U;9#E[<&T0@9)@$:4$.:JH4U)U#<#(
MF@+JY@!N(\8-#)$KY @(00#P(!H1=#*I$&2,2R@4<W2EYH]W<!*T]BJ9' "+
M]PH=BA!B=#(DX9</[]G/),P>50^.@BK&%.6 -1]'K$H;FPBM4!;IW%MK/I@S
MG$FPT]E"%+W@@$8K#QA!BX0U&\];R_I5AP!Q::"9TTS"E&#R/E V+"_.9:BI
MZR2B*D&D9'3.NBP/3 LSDS EY*2/2?HDB-4?V&0B$I+"HGVQ!9-=&N1F/9,P
M)7S8_49PV6J3$0"2MRG6;;K")/;9$\P.G[GI%I5D,!A5$A*,2-%:'91Q63)%
MI70-2+I?)#,]_U3*ZCX'L&1%%F" +7L@D$4JU$'Z8)8/T+G-),QA[Z&RTECG
M \@$P@+[UB(&3=[K9)-:0FE=I(AX#CMGD@3B&#CFNH*DH]<^BE#WTA21H]/+
MA_?L(^+9HVHH"G(Q<#@<(9H8?4Z8P8RF>FV9>!W-!W.&$?&4BFJD4FR,QE)Q
M!:*3#!09T"$'G;Q6>6F@F5-$/"68E%>2 CLX3@L(VGD%5N8D/ ^I3L(M#TP+
M$Q%/"3D!Q5+=.N:S 2]-%"6F[%)*&MFFI:5!;M81\93P030Z)I:A("U88>N$
M12X6A N13)PA/O,: 7*%_:NHG?4(10K,(5C#WA9XOMVH9E=7:6FL\[02ZHTS
MPFG,UCL.<9,.QI-UY%.0AD>R+ TT\['.TX))62C9>*>3\1!)!Z654^Q0^=I0
M*;OE@6E1K//4]NP8&6/6K/)U @ 7*+!K)4D4C,5ZL33(S=@Z3PL?%-7'C9;J
MFIVR"DW-MQ>F)!_)9G^]DD;S4Q1G-UO[?14TII1F3UEY:YQS6,/,E*)C@Z9U
M8I]+ 6%>/D#G,UL[%W C92I11RF=!F*_.FL34 KO4"ECO^CCMA@)J_,?-R>=
M=58$&PU",H31&&LE&;*>_WS1]6,)A&)19KGG@K=)['0X=AAS78\-&D4M/>,M
M"L@N!;%\>,]XEGLNJ&H94C E>_09I-&H= !C'7I?E,)X7J&Y^6#.*HZ64]L^
MP#%8L5DF% X!7?+2&5,,D)/L_ >[--#,(XZ>'DP!G5,%M(P0@80.6;+U U]3
M*!U:7!Z8%B..GAYROH H=0L9%@D"#&9P.8$L FV5M*5!;J9Q]!05H-<J6&%\
M( 5"%^_!Z<R?2O8[DO6SPV=N(Y"$-EX)S4, ;*.#5<IA4"6"S4Y.9A)@XG,U
M/T5QIC,)-TVSEU-+LQ>BV+I$+6KAMRA-",)E[RGG7(Q49OD G=M,PAS 5>@C
MVE*$,!!KERM66@&SH>RH))@#N(T8MXC:);+!&*O!H_)16LI*VLRJSMB\A$*Q
M0#,)L\<[QR24%<DA6: <,2*9Y($YH!GNLGQXSWXF80Y2##Y+-. $23"24.0@
M-#O66D>="YU[:\T'<X8S"5/:/I!52585ZY.18+6*;*/,*)$Q"?8Z]-) ,Z>9
MA"G!E-C\20B@!0H.2@461XFRR"[*HF-:'I@69B9A6ELT$1R#9Z,R!5!'7PQA
MRFBB"3*#7QKD9CV3,"5\@E&QE."5C #!(6K"8"1CPZJ1S P5X+Q&0%M5RR6Q
M>Z784)L<0BX:DS).>^NA"?UX%LE,7W>W9M_$((50#3EH+1%RUE$(5YL70(E1
M>Q++!^C<9A)F#RZ%&(F]M:JL0'- G((2CD1T=6>1\LL'[NPCI-FC:M%++:1(
M'!M!(!U#%K9DJU*D@!<14O/!G&&$-*T=12(;GS 9BHFU*04 9:0OQ;H@V&E8
M&FCF%"%-:U]*LF"=L@H006GMP2I% (#&U4)[RP/3PD1(4T+.>E^ .)1%DR Y
M"D0&"PCEE2JNZ*5!;M81TH_C<]&E^_SB7W1^'_56._]R<HX;MW[/,F*)20<K
M)+#58X]&A^R"M%YD$6CQD]3?8.=TW$JNT^E]P&ZBP:-NWJ$!]5D(=\].+K>@
M>W*(_0.*F-[5@];;@]0[96XT)&.=-"D7E"F.(NB:TBF<]U$F":X(:,".@N\"
M:X>!&M+@*8T.&K4)7*?:7)!_WQ3(O)=2U)Z."BS$Z"/$E,!$'Q2QRP)+!]GP
MM-\8<)(U.66I#'D-1B!:+41PNF $4;L>+7XOU<76@K=(G)W6_(O4GL$M4=@
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M/BIABA5&J;K7+T*4KC:0XU OZTEEHZ5!<CZ+1M,*)$HD%6J/)R<C&%2U34D
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M51/\X!7[&NM_*BP:D>E'ID".+F*M"9HT^YX$4D$#_,\5^QKK]P53-*22"<&
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MDFFI\M$6A4T@ZM**A4*0H+!S%I64*H=@K;-2+7!I_&\@]*9=>OTQ0 V!(O#
M.&=2<,%#R%"[4!@K## Z6B2[N%6H)H+]&#NU0MNK0Z(_<9 ?I7')PQU*U'Z/
ML7,',ZUW4I@*LA<A%DS6LNGVRH=2,JA2YYTHYM*@T'PQ4%J X#2)J*-4*><
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M,9LL<Q;)DK6NZ,4G36/S#E:$_:$9FJ1RG19$GP-@<%&B8K9JH* LJ-1DPHZ
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MG >*Y16CF>F-LD8+&Q-@#Z &H^2M!VM=='Q5V97N6=+J=K]4OHE!57#FBRL
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M]HZ,,JEX5M6Z\4;H$IK$RIG5U-Y&])(/R/@N4Z,[ID&]##<&DED?R73<>7>
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M(=S.&O&#BZ[OC5VUAL+4HV&_[P/CK>Y5Y5?U-7E.^P_LO8.;-EZ6]7COAVV
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M_>ZX8=VXJF?L-Y],ZH$+@<8[HQ3:JF)P+CG?]^\OF:'N.C,%=#XQ:)Q(ZY.
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MC8D^"9,8%8[N@:&E;!L)X&'<SVIV&U^]8QN'UDZJ?>-:G,G"G:I]'OI>+H<
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M<A:=@>Z<%]CHHG0WA J2C:L+_F0.1P=3AEJ#U_.N2'0XISZD4LO(989()2)
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M&N4VTW$>[XC6%\3E-A"4,DJZA'/0^*PA,H]SDDJ0F3E-1<IUHK5* -ADVJ0
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MRR0&+=5R)F,0W8EEU.96*VHC%_/@,]DQ%I_UF<3,R$PGEG#',R)5G)%,"T9
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MWW0.0^#[^_']\8R\3W2>IQHLDUP8$/J)B0BJ;23+.75@A<:.&9R.(YHT"/S
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MLBPG<99G1!J6D@QT 9)3.%%-<YDK9'X5-U4B=H+Y5Y0OL+T^BW$7C5:WO]0
MT4<%6K^MUU71AZ>%W^X'7X<=TVV[UW!\ <#N!&!G\RT'X)2T40)T%DQ!=KDB
M*N>66)'F\)<Q$5=[3R/93-/YE*;?MZL!4.C\M3X(6(''(D# AB!@SGE!(R-3
M4%KBC!()*@D611HBM$N%2UAJ# <(2,%^F6_]&2#@EX6 %3@N @1L!@)F?1BQ
MX)8FW!'.G 0($)*D>2I(+'*>6LEC,''VGC*EFBR>-V,"!ORR&+ "_T7 @ UA
MP(P:0".IG+&61"(#2R!F8 E$&1@&0G!I;&Q21M&5P9I4J&W'@,??"W1PX7J-
MPI-_X[<J[^+WT _T5[G'KU/6<PCBIN?Z@U^QKF<'G'+U\922N HL''<[HZ2P
M8S<(LOE.LOE\SDMGDLQ)DT<DB5*'>9 :]'-#@>@BI3+CM)(,3/0F35=@H>^B
M OZ8&7M#KK; V _!V',=0&@DDDB1U/&<2.X<26.9$2!K)B-)M4D23'#F"WKP
M!\;><<;>D ,M,/8#,/:L1TVECEGM-!&IB(E,\XPH%D<DHED4B]QH&H,US60S
MC5;@4 N<O5V<O2&W6.#LA^#LV<ZA5E"F<TJ<X3@Q"Y@:6#HF*6!VSCA5J9%[
M3^-F%&V#R/YU6H9.>L1";]"'[?TQ\L/CGD\"S!3R!*BY$]1\F3/[,QDIRI.8
MJ%0S@!H%=@*SDNA4J,C! 0DC]I[*[1D9'IJ(;5E54&#7AV37&<T@3AF/$FU(
M3BEV".&<P!%J$@.26FH3"?\"NR[?(22PZS:RZYH+>0(OKY*79^UW*G.3.YR'
MZ5+0\K%SB,)Q 2X3D>:QX]0RL-_!?%]Z.&;@YFWDYC57Y@1N7BDWSY;I)+&.
M*8U)IG)'I%&6I(F)B8Q<*FQ"C8IP>$^3/;J^G=MKKQ^[P<(*G'LG#OT<C;9K
M _[[@9Y\B_%W!_(9@"Q#4N']@/?SP9P'0\/)@+A4)$[ $)).2J*9Y81IT(\3
M!\J5Q-H"U8SD"KREMV.0309( K@%<-M@3D< MZ7 ;7; JS#")$P2Y@1V?<D8
M26F4$B%U*EB:Q]HD'MQ4]) )TP'< KAM%;AM**\E@-LRX#;7UD;&7%HC211A
M[,D PF51HHG@N=3<6BFC?.\I9[S)XOFV-@'= KH]4G3;4&Y/0+>ET&TVB8?3
MR'(5DTQ82J0$8$MIDA.C16JY<"[-XK)OCUPP47.;T.W15[K5?L+&I>LU^A>Z
MYQJDD>E^8?Q08%NTA@-GEVBB)&#;;7>8M=PCA^L[/OJNXO4;UWN/9+):?R*?
M@.UI9'ZA>QW8M'[]O7\B;8X0F@:$O@5"OYCS',:13KG).(F538C$KN\J%QG)
M-(]MJ@&Q9?;C@-ZFZ>!YB4R!$I:D!*MCD[@8)+1*8@)'EA!%E2$L391.K#:Q
M 4N$[HMY#_(2DOMN8+G)@'T0=4'4K=2['"#NP2%NQAQ)4R93KE,B(O0D8Z)1
MYA))HBS3"N@@,HK>2]BMC1*"TK,*.C )Z"&),$0P":).1C%16903&:<N<E9P
M;3(4=7+>XQ9$71!UOZ"H6S+6$$3=0T/<;%PAS6VJ4E3DF;7X0Q!MN2(9F%X1
M2^!H,G,O4;<V2@BB;A5TD"61D<9$Q(H\0@%GB&**$YZ!(<X2*20V'F;["R:[
M!5$71-TO*.J6##P%4??@$#>;'Y0FFCL0=9IQ1B2<%=$"Y9VS*H[R6$7Q_43=
MVB@AB+J5T(%BJ8VY(#Q-%9%1Q$G&P<[G+$\T9<[%%.B [[/YV6#;+>H>?8W"
M1_^'LT3#DO2Y:W2&[<SU&MT<GK?=!F[U <G^;2*2=^F-<O.AW4J^+SRWK#L8
M=-O;5GA5[M]J0S3T3HD5]1D?E$=\[$_X)*^$H(?!_LEPT!_ V<*N!S2\$QH>
MSH5S4N>8,B8FE@L!4E%)H@QS) :9)JBP.LGE+A+,'*4$X;D*<C'81TM(1AS7
MEDA)-=&)C0@3RC@+RDZ<"+ 3$]%,4MYD$?NY#+W?9/#;8_+M9>D(D[>@<?VO
M*&B6#(\$W-@BW)@M^:4TDC0W).58P*^Y):G+!'%1!")"Z-SE?!?))>@E#T0P
M*I,J8B8'E83A)#23D%3%8*UGTL190K,LQAIQ*9J"R6;"YTMZ@J )@N8&Y%@R
M.!$$S?;@QFP@ X2,@S-+2)Y(P V+\Y]!+R4Z=HJFVMDL3W>17(*@>2""R86-
M(JHS$L6&$YEK!H)&<:+27%-KG<XY$ R+19-&M)G$0= $07-KY%@R-! $S1;A
MQHR"FAF:\__'WK<VM94D:?\5!;NQ[TR$REWW2_<$$0S8,\P.X ON7O<7HJY&
MMI 82=C&O_[-.I*X2& C)*0C5#%C&B2=HSJ5E4\^F965J1@(+BB!N,N!,R"E
M2+M@N \T&#.SH:G#<BF&YHD63+2".$(D<ICD(Q0RVQAP<&2P1'MGD]+@ A,F
MFY3AIM9K;&B>_2FXW>[9>2^>QDZ_]256Y^'FZO7V@%W!5;<]*T-<Q1 WIZ_<
M8^O//=OLJKN>;UU3J$HMN76G,V^FSP$ZXXT5'"E'&>)"2V14P"BIY)0)0A/M
M%E=+;EW*CA0XJL>#E>IOSQV.)KPKI74PA"<47?3@CG..7 H1)2\]\388;.3B
MJK\5."IP5.JU%3BZ@J.IAH-)*!=-0(11GRL:)60UR0EV6"8A>6 Z++!>6\&C
M@D>EPEK!HVL\FJ!'-&HB6 S(F,CSMCA!5GE@2\(1ZTFD1-@%5EA;ESIJ*]U*
M'+9(]+="R1]MJ]/X2PZ$_;6!0"M[$0;Z/89;;X"^AN@&C7[T%[W6H!6GHF8/
MVJ*=JVM,/3=AGR36=!.T4NL;*-'WV.O>V3/FUK[ -7SM?+&MMG7M^*K;>P<X
M]NY*<#OATT5_<!8[ \"[HW1LOQ6HFPGJWD^?:"!@A"BW2 8"U$LJ@8PW 'HV
MT&0-./C<;VW_SW]I8%^_K;2_S..R,U;>,&I=5/]I&C86%5^!BD^P&>9< AD:
MQ+44B'NK$#A<"3E#J0.9!Q: S1!1M'O-M'M5<9*BY[70\\DHBO!)!A%!L3UV
MN;E[1(8;@PQ16'HOB.-X:WL>?Z5H>'WM]P("#T6OZZ'7$_;;6H$3XQZ1Q(&8
MFWPN+'&,C,4QGP33.)=@6&WSQSDSVGX0"&'X!15U#GL>=P>V/1&86&AOR ?E
M?M=K3A;7AF/JX9])G'A%63UWX'G!Z4?A](>I4 J56G$M3(9HA3A.N5^D=,A@
M@:E.SJ>DEM O\O%IR37J.U0P[QEBWHI2APKF+1#S)L_U,)DL21A1CRGXG"X@
M;15#2K (,C6 >\,>N:9@7L&\#<2\%>4G%<Q;'.9-5?\-SF B/0I5+G=@)O<%
M'[;X(=Q'30(;9RL]9>_< GH%].H)>BM*@BJ@MT#0F\P8-TI;%R.*U>:"QAY9
M('>(.N&=U1C$:L8I4=-E[&H&>J/XY'@4XW4N*DB[&Q%G.<_XH!/##[A1^<Y%
M?.?3"KM\M$QZ73Y:3?HO@[PO!_\-K2_;?ZM^+)DNT$P7)C:?QH,9#^,&6/L(
MS*&W?%93#?-=C WK\^:-[5S"A#8ZW0'<?= %>F,O0FL0\_1W G"*X6^5);+Y
MY=3JV(YOV3:,&5[(6Y[]%U,//'RL[;^YWB_;L[TYH3N<OE!Y'^R\VV]EF_IK
M+[;M (C.;U];87 ZWC"^<>%P3^Y7?'V)=3#\B\']E]1%+.;V;-S\F4=;,3A&
M@3UHJKTTBA,BM(N$NQ 3)BY%[4YR):K11:>]:\7Y&)'K1?L9V00/^*MM?[67
M_:U?;LW#6:LS'A C+_*T3\[8_:*KP5I7=T[JSO^^_/O^3N/XGR_?[KQ^^?YX
M?_==L[%_N#N]:'\V\I^LV+H\\.Z5XN[>5-QW5^J::^&_&W3]Y]-N&VA%OTIS
M5;\U7O[GHC6XK/WS_>7]&*/^6O^QMCJ-P6GW NX1^LU&_.9CYO552W00BYWM
M"2H;-\$)X4G:]KP??QW_\EMH]<_;]O+75J<:3W71;V>V]Q&T>P2.6;4G_83\
M?<.W1UIOS LM6%;\44[#Z(M'F/"BPH0)SV;X'I,OF";WOHU?W/_>CVZK7RAL
M'G77'[\G&"UC+6/=]+$2_J"[_B3+:9T.5]V=*G;U4.8A#S4$Y^4\EOJ9S1G7
M'<MM;BH+_X""8[5QZM9B<G^R9,H$+#J64FN<F9RR1\',G6&^GX9_Z[U*#L=-
MMRJ7:5@G=%$3,%N\=*:)_.'*6:9[\;!9_N]'-"+DW"9N<PQ!<ZZ=T(9A+IR'
M@5(MA#_9OVM#?O_PU1W;3F!F*BOSVO:.>I5_&7ZW[8MX_=4U*0=[M#O>?GJ)
M__SDZ8?CO\-G/EP>?'KS]<]/?S\]^ .^E[ZY/-C[\/5H[P#^O>%7VT^?WGP_
MV MG!Y]>?3K\XRW\]VW[PQ]_PO7_:A_"N _^^'#Y@<*_[^_9Y/;3(=SK$-X[
M^.. Y.\[_,?OIWD;"YZ+'GS?__;GIW]]RO\.CT,Z>(>_5UM/[S",ZX <7AK\
MY_^=8G_V>\?^82Z.X)H/9_N7?QZ_^IR?[\_C-_C#\4OQY_$']N'[_M<_]WYO
M'?SC5>N0[E_^W_<W)Y01YHR)2#@;\_DW@USP#CD>*4\AAN1U;DR?E^A='9A6
MY5D_;.G#DFM4:VTB"K5Y!GD'QII%9MN-U[85T'ZGPMQ=>]X:V/8&,Y7W5X41
MJ@GYAVUU?OE+/L8SM2V[09.RX_W%V44[0W4U*WLQM7QKL,$S,CS(<C,>^O^J
MF9F(AB[P@,]JN*I^$%?]NVW;CH\-.VCL11\K%L=(LT$Q,?<NDMEZ/#PB$VJ)
M1Q0?-DVSE>R/UE/*2="<.FZ ?6GF0^1>QF1]XC)S+F((6.PISC5;'M"8D-6W
M,/]:,+'6* EHS,2^GO@HC#(L($5PRJ61!+)<LUR<GS&2;&"";&T32II2\::0
MTVVAYR[#OZB$H"=I]_*TZE\WD%QE*F0M46\Z%_)QD#=]'/NF71Y:Y-KD-*X)
ME'V?@#(=02266628R)T3+4:.)H"RR)TB,4AL<EV4 F %P#89P+3W6MOD>:"$
M<X<UQ4'P$(F246'I[@>P&2A;0;=YT8U,H!NAQE"6),K'R1&G)B GM$.48B'A
M/2TU!G1K$JV;FN""<@7E-AGEE(V>:<RXCP!R1%O)J-92<.R3Q$D]#.7N+WA9
M &Y>@&,3 *>L44)'B<#M-(@+RI!CU" K!4 <#DYKL;#*E07>"KS5#MYF.9*'
MI8Y48A42BUS:8(3VS%JO@Y!>NQ^PN,><Q"MH-R_:B<FXF_#>R2" R5&@<X0P
M9!73B +F82/!DZ5R:UL9WL2BGI46"M 5H%L"C].&,*FDPH)RCIV6X+"&)(TT
M@HL0B[=:"WC[-M4@3S*.@V&()I.+*@B"K-8>!>,IB<8DG@O),, W=4?+A9JR
MN;7NR_ PU=SO]R^J?=)NRC40<[YM/VM'L]&)@W':VU \PY^-UO@*W^T/YNK%
M\/#6S,]Q+Y5E@ N45<5!C8XN4"4,HY+Y2'1(DT46V'R;JA7F96G'L'?1@XE]
M#<_8'74^A^>OWNJ7[=59</!R:GLU82*<Y1X)G2+B5D7D7% H6L>E!+*GG0>:
MUS2*-8V<&PAG5J0U*O?\W-!A%,DH$GZV$IZIK)A(2BD&D*"Y)=H9:1E/TC%!
MA#7\)^#_&+X[C?U5VNDT]!<*_"#HG]JPD5I$#X OC 8&3'/3,2P%<M()E3@1
M!+.M;2&;0BVJ54=!A35 A8+[1<)%PNLMX1DLNT@T$!L<DSSPE,"3HS8(QHPP
M*6JNBF6OO66?"FY1:9RTE".6O$<\,HDT+!0DE$P1G/68K%X[T[X!9P!>][HP
MYM!OI%[WK-$''<AAKBJ^!2H,\SL=W8IGY^WN98RC3YU?]/RI[<?&>=MVYCDV
M\(PPK_;1K)<C&0Z/=(XD^!H$6,);LR#AX>YT>$LZRS46*'HO$;?2(2V<0$I@
MK*FQPH><E$9$$]/I7<S'1?EKM%OYO!7^<32V2*DFL/PD0:8AZMK/SOZ0:NYW
M?/LB3^112C&_MYOWAN[%X4)(9X/AR5 3U<[:0#!BV&/$F6?(.$X1Q\31G&6B
MK=K:OJN0<U'N6BMW@> BI2*E=8S9%$-9!T,Y%;GAQ$N::$0AT(!X8 &!/,%A
ML4%3$1TU3M3-4FY UE'EIR-GAT6YS\YCIV\K)8W?\N]QGJRB]4.JN?8/UG2'
MH$BI2&G]W>,9(I;7C=7[Q]WK4E>YTM5^9U3CJH+%"A5W;X#BV_B?BU:_-8CO
M8N]+R\<AG7@;??=CI[I+Q2P*59B%*KR;\JD#-RDHJA"1''QJXBDRV#)$M1%>
M@;LM' >FT#2D3IW:"R84Y"Y2*E*JHWU=;B9$L:_ULJ_3KCAPK6 21S[F_,B
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M0\:'=Z*:[=G7$^WNZ%'U**@K33J? L(F=G*3XDXHEAM0>0=^$[7(@3"0HBP
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M*E(J4EJUE&9AR\%Y3"7VRD;)8W#6V2B\YCY*)F1(L[#ETE1F*7SXY53).1'
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MR0*2D]XT#D)[ZT5TGH<0#>=4$)V25 83Q^\'R5)*?YD(>O,0RN'>SDG 7E#
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M[-P04K%1,]BHJV,#US:*T4@8E@%1[S'B43MD>?(H:A$9E8EJG9OS-KF>^]1
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MKB%_&0=E*M("ZAMBKQ'/SMO=RQA'+YZ/4\C/V[93JF<O[U#:#12K4"N?7RE
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M5GFIDM.*&OK@HOJ+'7:&;]."F)Y7/Y^UJ)Y]9))HZIA!R0F-.(NE('Y 2M"
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M_BB&<3>^3;4Q6\O*[N1\:;<7:I/V92[+40[F#K)-^ZS]BS\^@ANM6 H<N13
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M)(;R1 WIG;98.,6E2U#=]PO(79]-OUT,SF8!,+_Z6A=<[]02<FB^/N'CZ)C
M]XY8.F2<E,BQ1*TN/$.65^#+IF5Q6!KB,_8RN3\H;HLUF,1*@TQ(L%.<(LI0
M%Z*@!#9G2SQV3YQT&Z%822CHWN[[HV!@'2+AB'D3$)<T(@L^9V+IP=@HJ\&=
MN0%T<I(:[&XTAI)90DP4R;'BX% 9$$XB!?68"Q"DF\K>-B+S745F?_?5$<$\
M:FIR_(NC5)J(5"08A<2MI1WUH%2>O:!ZD3NULB*IHJ.89\Y"'JA70BA)14+Y
M]XP;?+\,AANI6%4JCH^\YS@XBY%P'#P<ZR@R456(85I)12DSGCQ[H?""LJ'M
M;H_R:K2ILR@*)P-A<R$62EUQ8PNE_/4I6):E.\5,(L^U7VMJFETQJ]*XK_KF
M*A?594"CXFFY+B["<(2& &9J:N4NF>QEBO N2M'0'30K=A2.7T.5=5PS:HC3
M' O""('3W]\M8K 4'<93WB1B[_#U$04+"*P?CHC5%/%8862EL8CP:"K.J:!.
M@^I<2((&8C*)\CU9-3(;2*0%?WE<0O/4Z?.2[!S L<L#''3<BL0X05,4DR/#
M1$0$Y(E)YT4@))GOB]#!IU1;7=&SZG'\\%*QX<X#P?CT9>]P[X@%RYV0$6$#
M1ADWTH,]YD&S5$+K2DO.>,@F_ )2G2G).!WTCU'&";G506?-::Y.&IZ$<#D.
M=3*CBK4.%G:JTSI57I-(26;9DW(5@>8A1JFQ5-:F/!M1BIH@)3@@F$IMJ^\F
MT/,X@Y^>,'?9L#_@E+8)4@D)OB@VTB!.*Y/RHA6XID16V$L"'R;JL,6$.S-H
M46X1QDBTQ9004'"\,L$&:XFI0.]R;QB['WJ<C70L5'77^X?OC[@.T>F*(=B;
M"6,"@T@DB@3P PV-+&";G(R;1.+\(IR;GF\:> LTPCAM1HHL=W#?;J_[&LN^
MR:O7ZHITN#KO;-B[RCAPOB.W$4YA:HUQ5BCX)V(AN=!9//$MJS@VAOT-@HE3
M&(U0+7BE5,KJ!3#L$UE'*FPD)L6_<7)^4RO@#1GF%B"AR]KR4Q?TI-5FY^8Z
MJ;*?5]9E@O@@E*V<M(%'JY76@BEX;V)551'QW81EH\M&(K/_T1U9!1O46HS@
M"&FH$#G\Y#$<;(%[V, &S+9%1;"WT64+5-6:Y\ 6H8UD)(YQS.GM6<C1B?]Q
M$F-Z!#JQ'#PXS/A%&*:?"D9S'<9)V;/1K7I-.T3N2&BY%2Y"^5)-M^!Z\#:7
M]:+%>5? V@YJ@+8Q:([>\-.P[@!++?0U#*+)P#HMS&F-KE+# S6@?^U %S12
MI;:1HF[2NS7U+>6=[S[7,T#6$UC,_N#YEL)JNZTZ6P\,_+$RQJUN'>-W'N?"
M4<T"D>VVITSNDI$*2.=!BS]UU[5L8.U'4+6C+3)"N9_%M%W# R&"4:(O7Z\U
M;W@/,EQ+<Z+5^/7-H3;<RHU)Y)>M=P[T0)ZH\M.KKS4*V4-+R*A<9WMB[W?(
M929;O>Z^OS,'SGQ4Z=S0>3[HUX')+EQ8@ZO3:^,%*4;0E*^.\?#>N1:B+8J]
M@_4M7$49V-\!;+PJ6 6V.#B+%+Q4+#0U]U/X4!=3EYKI,%::/Z.F_^D:5Q]W
MZ/[NZR-.*T<9ET@J\!8Y^.W(,JU1(K,DU'%##'OV@CVO[B]%*;&5P6!B!,7P
M0*J<"CS  [TATG!W/[4.&SE800X^'47/0BKY0TPRB[CT*6AN/!*.,"8C9EK)
MQ4;V9%81E%4!,)K(N:0_HF%I:)B@BIEK2FZ/C+Y'H7\F"AUO;B;:M!#5PLCV
M/QX?D:"]Q)ZB@$4J L8&J>!2"86.WFM5^9@"]8O M=98*6V$X_;"\>W]D=6\
M(D'X%#P"X3!4("LC0=$IKZSA42?X7+R(!+R >)8YSG'N$71B@Q.2F>&G01"3
ML6XNDAKJ^[$BW,86\W>TN;HZ])86W/8(-+*VV1Y.2<ZI")]]+O]Z_::PFRPZ
MH)]<K?C'G.\Y FVA12(/XJXB\"]%D5$PMT**@*M*T6CL[%KQ>SN%;R>/>%H>
MUU0QWT$JGYXR?O5E#]P'.(X92)\!SX$'.)]Y1#H0B[R7TDJOJ+#\!F6\=G;B
MCS<%-B; TE+W=0_L0V.\(%5%$1Q(('7<6V2LB<@&JJ+&J;Y&):E;4.&3X<PF
M;8!)[/@Q0R!E$=Q%,,/PW0P!_/AXYA.IVT7?U&&M#>'\2H3S#\?\>M#?VCF_
MZ)UN49&[U^7W))L?EY'OSSK_ZBJ1/VUOO;T:#GLPFI<GO7[ZC^G#U[:W=JY2
M,]MI^B0]8*_G/6S_5V98/Z"A=BTPYC5#=X[>I[&.8US-?,/#AM5[.4B AY."
MQ63W<Y;M1M;[FDVB<-Y_#[[[$8_NE$2$N[#;-H'TFQ9U/)=T-6L2N^2 4\G"
MY..E+O T(RG*?QJ,;\Z*L<;.KF _;X9U4D/4#0>G872K7%VRG5E=4EKV2S_;
M3]MM-G*);7/SJV]W&YUSBB0969_A*_4*@0D7/A<VA+8AU5Q=GL#^J7.H?U\"
M^R<)CZG7'Q[S1KC+"7A,C<%M"0J^+27W.F@J(C8V.+ KM25B/CSFP]AE?T,N
M^J3BQA.A-Q]+':+;$6_(A"J90Q0_J_\I^Y4=ZH)3XSYELJN6 S<YHR>]<@2-
M4>:Z%M2A+9,I](<%3JV<$NF9#?G0B#&KSIPWW$\UT5,]A%%HL&N5+*A+.3'#
M$=YY(H.YZI4B$GAP75"03Y%,[9NX7\#FZ[OV>66@#>M\[W*&]SW71  ?_#0L
M* VJJ1?+MJLANV:DOGT/CH=PV;4SD[U0GW"9U7>"_*7F>_++2,R,RIJ<1Q^+
M-3035<]#ERRRNVA;9>P7J1SI>KLUA'O#3F''V%!;G-9Y4CF[56G.R=R8-\4T
M:#E"9]!7C\R5=NA=*K@"#SG;3AL',6E?8+;YMM!(^ZE+]#:&]',.^\R -CK^
M^4Z6W*17/I===T7HWAHI\:+E-J_Q8&;/P0C%KA2#N1:\MAG/BJ[NK*.O/1=_
MH,;&<H;&[J4ZNM(7,S?:UNEI.1JUKDP$X"CQP09FF/"*8\*,<-CP2F)LX3#V
M9$58&G@_EZ)P7V"G#T-_+ "WGVE #N),R*;A$TXZ_ %_>WU4$;"=="50C"'U
M*GNPXPBMD-/$29MH=ZA[]B+'MZ9#;?,(U'O3_'!9H\_@6+]1A9MAK>R&_]B"
M;=9$F]+&ZQ#R;+UKMO_+!AS_I\5XTS__4C;ZVW:C-TP'W8W^IMGH/]W$@_!S
M1Q?\,^N"$9!U.[B?;@*W_OGYUF^%*K-+HPGS>68^%5V:$<Q3K_UX(^OT,;"@
MWJPQI.9Q%#=E]ML),3$IX1(H 7/F>%CS%YKS45E^:]UT3;'SDE))AD+(ER<E
M4FX$=JN'H206B'*:]<!GZUAWHVNR39.8P//7\R2F _<$UBR;-!V;+*,D=3^8
M.%W+HUM[K6EGZ;)<I07L/#D5*%^$L3'7=<7)3ZTIL=KQ#VOVS.DRU!L$O*T4
M;2@0S=9Q@)F#+^5#J+!I@_#UEW"NYRWI:,-UXQ9KX'"O=6E]0^,QCUL4IF81
MU?=8K^>D337%C]+6?2;S?QY9RB31:,-H?QM&^IN!]I,KW^JA%HW"9$58CWBN
MV94VTQAC_23@8Z;:+4F8_)7LQQ2"ATS=!/,ZNGG:=84YW>8F@$)AV0 !9Y/3
MUR+>4,2TSM9]SMF-;#CP=9!C$,OQU3_M?0JGO9.DRDIGPHA%:EYL]'/H(-0V
MYCJ\U.=PG6$-BW8?O4XW'14*B>B$AIN8B%ZAH6]M^%M,QPV4#AWONG581NCT
M8X\;+GS>))[C4DMQ Z]0<U[_W"VMAD%T-W/QZFLRCCA&+[3D%"S-:C%SM+4L
MCR]<[5EW_513\Q,W.OA3N$YS=G5V7BO_NF>F?<#T MRXWHLT7=F:29H*Z_18
M<TX/ANW:]IM:I]8GUEPJE\=P3"RF7%^!E^%^T?D[BJ"AD"XIZ;V<SJ[1K&47
M@CUE=":.HNF!#%M]6P.OWPU>>WPTS\':6 [S,N?UNXV@L\_F[E)DI 00O Y4
M[!CIV30&9NH5219L#@C"U^JH4\?.:K\]D?WIF.W@D8:+P14X,,6DW]X:!46Z
M%FZ>T/-1$](DGFTR>0=7E\/&W*SS9A/1FB9^E5K4TD57YS#8IMFMUV_B& YD
M.:?B+Y,2'+8*JCYA0FN@E ,Z11\[;]4 /[6F=<;31>6LZRQ2)_QS,;@VI\E/
M^+D]M#JPFRVI>7//&J WL:JW4=*\2./*L0Z<GL,\@[\#UNCEZ74;R:U5\JS,
MI2^6?4QF=-%5I\-!04+-.<TD4VUP>4JJ'H-6&F&;HB96.L]^;<+3%]E,S^I^
M1$QEDL_0! 8S//>P+JL%/R#S+EPTW;7Y["EN?^_"79VE<\0UJWA+6O1.M]R2
MU.B%\+RYZ*DQI*^Y9/XXQJL[QA8WC%??*=YX_'7_\-6148Q%6 U4&:,0)Y8@
M+05'3&"+,[UA",]>,((7\GI\/\:KZ%VEF (Y$3Q:KQPF/A+KF?8^")_I8"3F
M5*#FAPWCU7T*R?7>;J*&QDI8PE$%&QAQ$16RMB*HJKPR.'C8R^S9"[D(&_!!
M3.I5I4U)$H5@0LB*<!^YPARVAO*,*D&QL[6T%54%/[ -_=7#2N>WO8][1[&"
MI?%:(DU2LX;D%IE /-+4B>"LE+;4)B]JI%SH>JU"?G6?/M@:B^^K>HK>M<-/
M,EES:>0BQS=@TCUET<2)*I )[9BV'*F$#L<)U2@QF2$O.(,3+'AE$R@8DPL*
MYQ\;R]76=R:X\HQ(07@,(.!<46^9#C81!&BI S9^PRZT#NQ" NR&K_L[1QY6
M)F#ED5**@^F@ @*+TX)R!A/.2I @FT#\Y;T07+4<0EV.J]Y$5*;P70VG\A^?
M&T,$'E>+XWX*&/7<!$J9DB8Z2T/0FD=/%&6!"5H)')4C59SISTP61X !D[M3
M[E7NWN1@P1.6N?V/.]\._CB21!-0!1I\FM2O[!08!$X&9+E6UEDX)A.C%6GM
M@7J97R1-M&CE>:RH%!7G$O2WH<$HK;!A09#$H$759N4?<N7QP<X1G*2A(D(@
MAHE!O HX@7 F3,X$9P<>KB88SEL^M?)UJUAM\$T3Y35E]Y.'\:8^?<(8H'C]
MZ]-OK#>?J$\/M K4I6/,A(1S;HEETAN&!?,.=O_\^O0'-,KFHJ]U#;%T<*YN
M@07)K!-.@+NA>$B430I[ =/#*\8BT1L+;"UT(EA@7\ "PY:FXD$XDWAJ&.?&
M(!!UBJ1@E&DC512)TWXA7?GJ#(_9NIIF>4Q)OQE,CS=$H_M+IB(W]'OK2+^G
MN8A11Q\( =O)".5-])C2RFI?.1PW]'L/&*9@>PF[G("-S&Q$P9&4!# 5LHQ3
MQ+B1CE++G7$)_4G?(_H34X)@1:03F"NKE0>'RF#MA,'"1;*AWWM0H?CX^BA8
M$< P,LCH"H,M;1P" UHBIW'@PF%6"?GLA5P!G^Z.['N1*QI9K#AEG&,0%J]C
M!8(;8E4I,MO[VDC,#Y*8_</CH\B#<L1%1%008&G OTS"G-?2RV",!2,DP8:S
MA4!A*^H1910'%26LD81'2C27.E :'8;#10:]8=][4*GX"(<+I[ ;.49PV+N4
M/.3()/RBD%!0G654,_OL!=,S$LS%:)FC3>Y(R+> @F\A>L;?GHO/)( _K*(-
MTG);8:U5I IC4TE*Z!V]NPUEQ^(M\^G+WK?C(QJ#K +G2$@6$<="(Q.,0-@*
M&[GAP?.D2,DB/N3EN?CF-<+<BI3OX:7GR9-X?/R4J*J.5/ $SD*-*.6@=YG3
M2,/YC"I, S-$<F)![_)%A_&]D?(]O%1L2/FR8"0Z7(R5TI6E*/'*(3"J-4JQ
M<<1E5/!GRERE$EOC @#RI\[)IY7DL($\&)^&<UEI'PR7(> @M-<*;UC7?BPG
MG]C;.6)2&V'!0=5"4<1ML$@QR1 A(,^!&N9)AK!><&;>$R<?*%BAJ=,R5)$+
M[(SRUFH?K;?44JTVTO']-1U\;^>(5*YR@1B$4_2".R:04G B,@P'$=%::*5O
M%HF_&R<?*'M/1;#P[^2 "0-G,*=6,.<XLZ;:</)]3\$D^[L[1]P[[BL?4)2B
M0MS8I*L,1I@RI5@5(TAM(HM<1)C\8SCYC*O 8%2$$.$YC<QX&ZJ*)7HXXZ3=
M</+] )&A&?>9,U_A@)%,ECR' P59HQ5R6ELP](5F,MR ^_P0G'SKA)S[3[C;
M,/3',7"W]O_<>MN%%I["SWUP%+>G@(W[6[ 75VG4>@ETW,7KU8+A-NO=14E+
M4;]Y<I OK#_<3DW35W;8\[UZ+O\Y.(&MT-_Z_\S9^2_-;]MC<%8E7-+<OFUW
M'.L)'4&UKH3-.L*_FH_Q]65P<>J_I*[4YEYU"=/I]>G6R;4'>^'Z-*-IPZ*'
M8I*<G2>LD>50L1XPRST'-W?&"D_-_F!\ =I9S^@["^O]0@C6!\Y8E(8G*EK0
MM5&%X*/Q+E!1U]-3K%'SP\QZOUDP6..M:IT&-7B])W;"[>^^%RGJ68'S1AW3
M2"@/#ER,"AE./<(L$JXD%CZ(&OH*7</^GRKB:Q'B<R "%KXF$1Q]4,<4TK9H
M1'\KM=I&..(&V_7^';]-+X$!?4D'9F^2XF_LBY-=YPF P8>$NY [2?HA*9>,
M%M1NNAQ1@VV<3]=2Q7PC]O;SK8,,A#$:?P&JJ!_DE[O+^&#3'6I\BX)-.0F7
MG+Z\%"IXL1B:@;7J: (CN6#1% MDC15/AMQ;7O%T9_3,I+<&P_K\3MV/T47"
M&%AV%OP%)IAE#APT504L=!3.)N.[T3MW:GJLN]'>@&GXNI\Z()^NN?UMA^T?
M?CJ2"AMBB45"*X<X.&7(:@\:29/@653$2)M"!S?4S,%4IJW5B$M&KAT.KS+:
MT9<,MC(R5_[3_ X7@%7A3M)1/5=:<B_:<$I@"./8$L\XX3H%>9E1ECBI?%49
M/4=@\&K.6@K\'L1ZM <7&;"O075\%\"-R([H2Y. Y'^]KK\WK+_XA!$>O^WP
MO6][1\Y47#HJ$)@3#'$7(M),<&1%L%%+*:I(G[T06&]79$9@JJS[/&38I)43
MS,CEP'TJQFZV.).B'H:ZB_\F)?0F7&1.IGN1+;J4^+RJ1YA[\ML/6YDA3UIH
M#D =5:I23"B+*A52P"C)BXX.80RG@I2&<ET]>Z&?JQD2<YY V'+G:M)$L[R8
MK=?]_N!S.<4;TNA__G/WY39\X)X7MRC_FN S8NR=]NKNV%JOE<J(>M5R@7E9
MSX;EIUR<>><3A<(@0X@D.)],GY ))N#,3N*95.%@PAFD=/S^#4).O1.2/LT/
MR@ [K:S7&Z2YJ(&Z 0O'=]5PVB.#JTR?T$LEO_5N: []D3[;VG'Y_"::L8)?
M=)9+35KU/?[5<8BPEM8H=Y>8WL560H*9&F03/\XU["MW_UII)87-J"CFL(9*
M6!&Y(R[H6!%&ZOUYNZ;?9O<V.W-_</DN7%Z>AC3SQ63X#5[KS_16N[VA.QT,
MKRZ>,+K&MU??]KZ]/Y*.$\FM1;("-<_!PX%M:\"HJ @&%2H(%S%Q/2_ UD@!
MCQ$X80K>H6Q8G*=X4,V9=0,Q%GR_-)9G8*^24GC=;V\[\ID7]NBFO=\6]*\H
MF[?RI&\)K#"X3*#8YG3$]+936CX+BL*[<[@HI:T[:,5[;0O!4Y;8U#AR1%BH
M'-<886X%XH+!0>.U0U0:@QV6UI%D]U:+XLPM1-*(RGYKV$S[F(3.:"1)-:!-
M9PBRUZCIP+-FV!L^[XIJ1@J[GY[R=93/EZV#O1'/))YT[]L?1SR:U#Q2(2V"
M1CR"1Z8YF-$D4A$85N"HF6<O*%G8S+18/F?U.>50S9< )D0*E?12+'I[*Z2U
M,)=CF'I;*9"7_I*?8;9.!U]0$L8S4-N),0$$U8/ 7B:C+/5IFN.L2Q/"2.Z1
MVEXL_Z6&OD,)-4)#JZV?\]Y%&XTY-TG4FM!QTR-OKOJ% :7&M>ZY4:M\OXET
MM,1;CYH]:NEHDC7NT_%%&BBJ TLQ_^^7!TE6$?I?SUZ\O':GJ=RIGPS)"W.>
MLQ3#);)3*_!6/.AK3\7;\FLOE;Q:LU=<^$('_:U_7L$!QV>!HDSDM6:DLO*W
M6U&8S&3-$9+6:VL_GY6G&EU\8Z:JAFR\7<*JL4^W%Z2NSA,]I.L=7YF,^P_W
M_)Q0F(Z;JN1!@M\?_OYR*^$.E<[/Z;W^F,1B3EQYYE)_E\@RX1R\#Q'!1Z32
M*Z6B3BB-E5#!.UXW4U68H^:'.WB-M:DS/!SLN/]WU;L(;\J!DU)?N=K@"=LU
MK^G^X<Z1<H+IZ 62THC4;$?![ :_D3FF!7%@BE*?',7EPLV=;5^V>LKPY+J/
M3M/,,*3T6(N?!P*45OKY5H+TNC391#W-E LM*L94W*(N%3%E47U=D_01#(P1
MT<P<J:XQ(_O)"+K(QWY;/%??K%8VN2(N(;D.KTXG]L(D81W8(EW,T@+TFL=8
M[EJP-&KMM?/N/=@@S[-/C##HY49CK/D!^2MHY'Z"D"[$.C6;R$^'@W,PY!06
M/_]CZ^6I@8==-PN]&V*O!LG/5E]SAX=ZX86O5^)FD]HM"\M)JEK("?TFL&'&
M%C9'Y7J7=9=+/GK,."59-K='^<DDGGWXTFG=__(Y-*#<5TGN'O7Y,A;?&>V_
M[Q;A^;$'2CXU=D9+/P8!DC%^2^?3RQ9^?>P;3_BXV;O>_W9\E-IQ?:P8<A6I
M4 *T0M9IAY3P(A@9=&4DN-&4WMZ-GJP76(S@=D/49R3 .8Y?8\3/%.71"#9(
M38N1FLCZ(S7=B+PT@=1D&8^><JL,\5QQJC1WD5A,M2,2Y/W9.JKJ)0-.BX-,
M);B$<G"IC3CYP95M_OA8(DYSTV83-L$LZ^7N*T:76K$'LQ47CNI.V4,<I9,:
MSA,:%>?>&X^CD]P$YZ2KG&G/[QI=H[HCCD()">STNVF85\6L>\JG,]O_^.E(
M:^\J232J- %GT'")5,0.,<V(]3ZH2E4W.(.=L,NBM&".3&6W[U$;N^_[I\DC
M@M<][:6H2N:E24[EW/A9L2-*4>=<!5C"5+"9+J[3G^L?BUXLVB_3J(QIP*+P
MAI>UMKZN:T.+&QY2T6=[8>J9+8[W[-L493H<X:6-RA+FAHG&[]*QN9I87@^&
ME+SES+52OV@.%2XJA+Z5<3^C$#I5[8XEPR;M^/9M7K7OL9.LCM\2(.<H(?8.
MU,/3A#Q-_]UU1T%K@XT*J')@NG,3+=(DE4I;KV'R*1A*^-D+@J=*I-,*#(O=
M4$!..\9',@<RZUQ'-,;/XS-S/=I<<[=6S1>?LIP7 <0M\1+U3Z^GH?%S"5#/
M725VR%;(6_<<+FLV8MXR/T) O;E>3CX/ZUF O^T/X!V>K#A^V_OVZDA5'C.I
M*%*.4\0K9I#RCB%N10P15L&GZC2BIN41)GQ8%R_6Y5]?+A(M8S^1+M64KJV,
M%6',0A/J]'\&;BP<4REK=#E:EMH(W>[:KHG#ZJ*!$=ANC,^"_%TKW=(+EYXQ
M*JIL&2IM!HY<$*NO2]O&[MJD23I5/&.L7$OB^Z]3(]V?O72$E/:II]LO]X#M
M4 >IHNMZB] EFN7F]\>599S,*9:__C2&"O3SUK\O?4DI=M=^5E:Q.Y(FKS@F
M+S-;X!)S8?)V/QOP/*X2_E73BY+*09,IV^]=#;?^U?/]<+WU,A6S_@X6Y_G6
MO__],@_KMW_-*$\=7;@7?"99S%?N#R[@/7>R"C+EZKV7^SNM0GC?S_WZN?I@
MF!INMG9 -YUNJ3S;>B()T9]XO_'I[Z?G9$BR]$7P>RYSLN/&1:DOZBY.GE[3
MN=M%<[=>P:V=M:C/M]YTEFCA ^YMY=*2_>MEJ=,=M/KO\J1WX8MFW?*@3:^3
M%3VX.#;]NH&HQC3X/$62D^?F,%_^)E^^VUQ^T+U\WOH]MAJ6=3X/9JNCUSE;
MGR?LIJ*-'Z@IFSP(6(K],)&1G%)]O:)1I[7IC?N[-WIY,[6;9\W,35JS+E$?
MS\6LU@>D39#4*4L,6+J5=RH8S@+ET2BKI:WJ6G!!:#>(\WK_MQ5A&U*SR;O4
M:Y(;1H:O<TW]$V[6>,\/=M\?24.P%<DQH\HFY#6"E#42<1VD<YR0*J9D_K:0
M9)O3&:#*R_?XC+H/\B6Y=VQ<9U_FV$:OH&?5?2"W[ "ZG51-=0 E[_T@9K')
M_3ZCISU=N1$'NZ^.6)0:)_!M95BJO38:62D<\L1PQ3&5)"&E$OX<SXC\E7;V
M#->^:NR74E=Y9;E14O!(G;'1^DI$; -EE6](-F%=T:P%7K48Z&+@0O##!**;
M%$8F=8@=7?*$X[\@!X>?CKBH%"P&129H#OJ#$F2]"O"O:)WSRL.:I [!!0'@
MXBK7J8"+<)X-X<NF(@1^/>M=G6V!K56T1^K721^6OL$[M0G>44D4<(0RG)&*
MF"T?3T]/?/BR_^W5$<;65"X&Y+A+G&J>(!V#10977 OLG(-#^ 6ASZL99TL=
M?/8=?LM.T=3V[3B>;[?HMZ=V'N%E9%K4),R%^.4 )'I)Z7EZVN5#&O^1]Q5Q
M4D<$,F1 >D"[Z"H8))BT4C.'0?DG7%BY ->_8$Z4:-LTIVE./M4J9XI1?@R!
M>-)9+;UI.\,Z_Y$#?4UXL$XJCY(@$Q=OU=RL)<J6TB4I:OR3*:3##8%7DOF.
MJYKNL+N+7OYK=PO^=)JRR_#,Y*S5[_3;[LXO6S_9<I,FP913V<W[EQ=KIB![
M!P7+H\0<8%"EU[;\VDO8Y(5;OE1H[[U+_@8,I3.JIEGUHB$ AI?)^KFY96L+
M6IB.TXSPW*$*!G_7A]-B&2YYXS3V7#?5A"AW+ZZ.$Y(J.NAOU>6[\.O'J^+,
M_%((<]W/;84>O/^8W9FG:/V,D-5:L#:-5TEKD&23:.U#5($C9BN'.+8L 18X
M5!%<$4V%,C$^>S&31&H,Q;]3_-4F0@>N8,\5HR/MV"Q=]N?M!L/PPF?<N>R^
M[[Q[N57A:MQ+/QE72%GN<\UR#HMUBH*+;=,;SB!Z2H7&2>>D0>0$5JIUGH"V
MJ;]].8GV4W0</+F?,AN#*[@_/'!PD8-2-2D$6%F]?HY"3M3#7?2&GX9ES&>P
MP=(&3989^'DY29]*8"Y:')[96C'#]^0+0HR%(Z'MDR_\5QEXLWF1S<;\.VQ,
MD8(-512J"I$@&A,RA*X,@JUJ430$2Q^IT7,WYM;TGBS\:#5';MH2>?.EVK*:
M17!MK,(-ZONR<N*^I!RMLRQJZBN$;<3@5"I0X#9JY*I (ZZP%H8L-OO:6LL&
M+:PMS\O*=X)KXNY8R,/G6^^;(V((>G@8:Y%KND] 2K)B*.9>:_H-M]M!C.R=
MEMC.#,>#K5?GYZ<IG3R>OQBS98J)E$N$4K2^1F+HX-*?A<N3P=HS!8['!9/9
MG.UP4\[G4_"-T-5Y^25EEN"@S+.=RT'RX=2[;"[K#R[;Q,\H^EC'H#HH_0G5
M)8+G-OC2&)FCXZGK@<X*DW<K8$TGQY_2YGYXF>O 1UFNL7Z'N;=,$@S'-ZSV
M( =#VAL,2V/=I!4[BR2HO&L)L-3OG:L0TIQD"LD")9.M@?.)W-LX1DRIK?V2
M$+T;4+!4:YO"_YGR_+27I:M3:1;.2MHJ%_",0=;4;U:2@>_J= <'6^HG^G,S
MRQ-@-CDA>74:M@2NDFR?79T>F[H-]")D/VN=,7YG"_F;5$22+)VWX7,/'O+G
M ,07S*=_A\O4Y;8^10I+ ^(2OCV#JG,BR7]:7F\Z 37YWF-)_EK*2Y=#VJ#C
MBJ_U,DVG;#)!BHWE<KMH=69KSORWXWGS]L_M1MI'+O98E<ZDKA]M_29,V57U
MH_NF3'<>1DKYIM_3T7"9B&?3%TY@6X6,+G7>#/&B##&[JFGABL^;S@-7HV3"
MS??3Z+)>^[4'JW\\UH0_^FZM^_IP&P^W&6&)^BM7CZ"@[J;7;9Z<]6-ZX][7
MAKXL-UG D&(O9X_A^ SGN4ZHV<0P46<P?Z7?K12H@KXX#:;MC"LG[(BQ?+(
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M*T;C*$XYSLE[;S@=9GC1L]S?C@=:@JH3F,P-0,D(F[G%9)[4X:.R_RF'/X'
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MFG-W^G9=QYR;6\9EN]FQ)LO&J-6E5CW9#^V=U6P+D[4,W=+>-,23)(<%IW(
MGX&IVL$_Z]H0=6FPV2K[(VNXPEE8C(/2V=IT)X Q689W\\A:I9AMCV1J;2?D
M]U"JC3.PYD4ISAZ'!_GO8>GX'9S"K*9P[ZA<W)IA;SAI/9A26#2<IUV*WDA)
MCLQ;6KL@I:IZ,"I[2>+2!QTZ5?FQGN;QCRAQ&%DOG6*'PY3"?-)U#L='E$CE
MJ0G(1ID(58)%BGN"I+1@V53>5$9/$3\P'+VOHL&^XHY@0[1/(6GA1(HAD,DZ
MA\.Q_OC+G#@&L^#+L%$@O<_I8.WLG]%I.^%"+%\2]H_%!1.W*()ZRKUW?/U[
M[Y:M7IG=N'>32+_XO[7<-FN9#'64"BC,^3#\H_GA%]\;GI^:ZW_T^GD6\T6_
MC)? I3=..8>$;%0O;E[G\O%H,I[C,B&7%_"/;YY<?_P\?_0_EW[Z,R6>,\SF
M?HR?D[F?+;HMH<^YEDO=]G_RD,NP86;2 F9+LY637.CV#[Q%<HE;<[\%7Z7G
M7].7?YG:$),S62;QOK>)NJE^+Z]4JXFV&B74"N\3GI6?LDX?7 T3R>7/J\Q(
MRLD=7R2L(%2/U8%K&.,O"]X_%4_^F+=? AB^P"<T1UDGC#:LB_R:^/ HGI9<
MX-PG3W\! QJT1FYGK%EDQR9OM &7FB>\]1AFZ__<Z16[KY;#JFOU;JOT6P6J
M!;9!T,IR*KF2@53:4$JLL5[Z[,MC0B<X<=AX_"_VO@:/OH6+P;V'_MCCM)9/
M/IQ]/3TX>_WEK\-_?OIP^.?)P>]O3_</_\#[W_;X =Q_[]LQ_>O0GWTXW+G>
M_\_^I^8:>-;57_1]]>'CKZ=[9V]/]O_SBO_U^WNRO_L'VTO8O?]Y_>U@]Z_3
M??K7R=[N:_*!OHU[/?SUWX>O+O?>X>N]CWMD_\M19%X9EP,!TB%.(H6?K$3&
M2AF8]Y@XE_A>\OZ?$SV\RPZ![;^UXDY9Y>CJ/H*P-5<U;\9HNA9JY,DI7^U(
M?M2:Z%8.^'R5]&-K3S9::@DM=3VEI70D ;N*(\-23$!4$2E#.*J,K"HIK*H$
M3PF.;:FFD:2_AX'W.!1*3L&.,AQUB?P2NN,V=N[Z*96??JQ6N85!T_[E56X
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M!&+*4L15<,@J0Y%)H)@[%;4C9F%G6]TIM :[EPYVC^L:K7%N03@WZPI5.KG
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M>J[Q: %X-!</RH4TUD3DJ*!@I"D+&E*RR'OJJ=3$T6B6#X_>@E_YN9OVO#8
MKON#/9NC[2VT!GLB"+^J*[BV D@N/&*&L$JGM#0)A)TV00/"LUAW!:\;+M:
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M$,Z7C^Q7A'!R83#W @7O'>*!)&03U4C&B%F*/L50AW#6(9PUI+X*%;F&U$>
MU#EE60LGC)&(6A(0EY8@#6HR<@134&Z%4,F\A1#.:YLF+5V!_W'YWR/8V>&@
M..FWA\/8A2T\Z>8BP'92E+Z7BOBK"J+L.=C"./"QZ^,JR$O?'N>F"U4P96Y&
MV>M6X9>^9?O[XU+ZO4$Y1IG&G4F07P6='=[]7T_87E/<L^X"[$K<@"V9PH-\
MF?!P_WK79X=XCVDE9;(866LCXLF <!/J<\\=)QRQBN"<G+PV[T<O@'D[F;:9
M+>Y"\'M5,*\)_G""-S?6?^UYJZDTPB*)C4!<2XHL=1PQ9D#@'"C)6JZ\5VOS
M?LLIP<.H[*^2(ZN'K7Z,)0=T 8F*(Z!S:U#$;@[&OJ:#2FY./#B./C<U[)RN
M5IT[[H$;3D9MA:=1>,F9%EJ:W A,LF@(U=Z4;(0GN(%K-EH8&QU\AS6LYWG1
MO"90$11L?Y3"Y"9L#'%26EU<(ZT#V&&$VHAI;MPA%H<B!K1'*0CE+'CN6&X*
M14QP5'#!K"1L3'Y2D_]QR9];)N@0*7-.(B9SA0OLX1!)$7YB N"=.XPSIA"]
M-E]G9S&@@B^#REJ1VR*$<1OM8MPTZ :M"#CAOG"6-:K<@,'V*ZWHG@LH3F"<
M\QR8<5>D3N\$]*\\U8CR1 ?YQ?.U],<5'2XV.+(P2OR9VS?E8:J&,? .Z)4C
M4+*&U2[_=V1S*]FB/1C @RY\>WW4/_W5MA-JE&VMBDV03M"H,[W*CDC]6)SD
MO^YF!3+E@TJ")R[!AK!,)LFDH1Y+S_$=E;SK.[C]D?M]@4K[H7?DVMTRZ/9+
MO_>S/8 ?;&>S6XT"OVS"9-NVL^Y]Y@=8[&8WD[$3AW$]'(RJ'DQ3L7_I-N0#
MFJ+LX*WM30KK 'MQ\VSKZUX6YTB)1(FKA'AP%ND8(W*@6C#O72317MD&;LIH
M@V$\1J/CL3$QF)?]VPG>'4\,'A6-'C1<)R7WWAJ9.V/%% 1GADF]6(7AL1GQ
MK1T[,XS(&R=[8+=(G$1$7N<PH"@-<E)S9+0CF@A-L6/9=N'7GSJ+Y$A RF_7
M#%?"Y5UXE?C I%=1,4*X4<X2)8@R6BBGJ%!^L392S:N+-K3V^9ZQRF)J$M*2
M$.#.Q) SD2/+P3ZQ< P:D=UF-UG6%[CP#OK(717I%!QGS%' ;^X4U_"32F#X
M&X>-FMI1"U*D:U9[3&W\ZREHXT*I8!.EB'A 1*ZP0BZWQ:: ')B A12QR1;^
M#;!X#\9[(>U/4Y%&H 3'8@#L4J:83U3>W"VMTK>'+9A8_)7-B1@N]P ]LJ>%
MRQKS?T?ML<)_KIU?[BA:MDV=Z.KM.,AZ]$1QOZC19WD%'7V09],MCD=].#0&
M95.WHW;5"+2<6C_Z[/,.E0=WVO(M/VGBB*V6-,YY_VV.^V (_QR-A^@=QWXI
M=K?J.CJAVGAK.:V"48][@])(>%>>JF")C3/#QW=&%[XX=NSC\Z_8[( >#:__
MRER^X]-??94<1-7,!EWXN]4_STW=!X48S,]#9!-,]IWMG-C3P<K_7,[8;W?1
MS![.+O]Z&;J=F-VR!ZPD5_6 O5P%0&82+VU76//6NL+FPHXG@-?KW;#9'=KN
M?MMU8M6+?NGZQ-+&M&/Y=]HX\ZQY%@YW-[Z>;6U_Q7 $\JW/WPYW#CYU8"P!
MSZ([='.N8_GN]LY9,W^7?CML;C1$$XZ[!FA:N[GZS ]XSEFGLWNP>["3.Y;G
MZ\S]/>&\]R191*7$B..$D941?K7 _-@1HW6<[1-+/-712NMM"IS89 +-'XR2
M!J\,8_-]8B>;7U2[7R+ZA#HW-X^]LC_L;R=PLXP^GOR5([YK#P&%_:UN(F<V
M9F[M3]+C-A="'<:_X#B:DY-E:G?[/"*2 Z:BD5P$%)5UB%LJD6$6@\1X8K66
MS#JQ7.UNJR:VI7Y:%K@YSF[0K"9=5>JG?<Z$XYI =GBCZ30I23%^:UR7HKA<
MT>!=L23Z['*7!-)BS51%;>Y:$DC@-:6N?_O>57;X&E/R$4H"25%/EBE=M_N]
MM"@B7F4-HY= P(64YIFKNO0*2O-\[O<&@^*#[?=/8<ZET?A/=EDL:A-N7\+J
M%6SFNO>CHU'E\U\_ZL&\SDI%OM[,>VQFF?#SMFI%K?NQ'W%.37U0I:C[\L3R
M!9HO1QFI>C^7>#^730%\^II=S[H#&_%G[/2. <..^[TP\L.BI-*@C*D:WZT\
M246O9]V%1ZZD\ZQKN\-=LE4R6D%4])1Q+(764E&CB:=$.2G80NI9W.#0*Y7;
M98G5NJ]';YSO\_VLN=$X:WQNMIK;K8.=@Z^L>= 0C<^?CG8.0JMY\&>9RP/_
MT;F2[=L-#-\\V:%Y;LUV<\/#\P]/=G[LMIOT(VT<-0\;&P'^V[VJRI=BD7.:
M'/)"Y,"%',PK>4+4X:C@#:^56GE/"5N5F#UK>9VI6"Q]F:\:G!YI;?]Z0>AT
MP5J\:"S6>'4WO)KKQ\:\B=XP%)7'N<^K1YH3C03SU@1&+.%\Y;V1JUS.YQ_\
MNT:J)9+FUXQ4+PBHEJA$X4L!)3*K1.7FTQ$;Q(()B#O/D$G*(LF<H3%08I);
M>4^(6B7L>6NE7H:FZUK7//'%(1B^Q-SGXI"+-?48[3G(FI"/<A=73_:%3?:6
MU])WNR1[*=Z>W_@/*7F9%YY/V8?DD?R_I+[PK"\\G_+"L]S)^M+SH1OZ]X="
M<UIMYC2OI=[*EW1__*PG\DNX0EYFE67)KSR7CM]>WW;6%_*O6]KK"_GGN9!_
M6;4[7VGU31QYQ%)[20E/R;H@+*$ZLJ"%-\8LI$#]V[B0/_IVU/RQPW<WOI\U
MCW(!S:\GC8UUWO@!<_W1X,V-G;/F]N9IDS;F?,F[GW?([D'KL+G=H+O;.[BY
ML0[?W?^U<]#*<\?-@P9I'&RRG;,K+^2QT4D3;Y&E#"-NA4:&"8R,PC8IGW2(
M9#DNY.N^6V\>G.YR(?_<Z/2J+^2?#J]F+^2=40)3'E!@*:!<4[\L)XJ4DE9(
M%6(HVW.95<[FX>J)+N0?!:D>H%TN-5Z5V93T?E9*#>ZO"-Q?$+:_FAB&I\-Q
M-H/CWB=&E)<(2,<0]Y$@$Y) -$HA,!< \SF&@?-5HO 2Z9U/WV?Q60W^3_9G
MKU^&9W1RN=.ZV^)UD"2##UH:B[GG/+%H#=6::T,-)2IJ>3TDU?;NH^'.%=T5
M-1=)"Z:1E\KF<L(.:6$CLL$E+ A6SK*5]X+/1W/6K1676UCO8AP^@;36]M]"
MY'?6_M/*B10Y1@13L/^"![W!Z8@H,Z V,.*2IR"_#S#]:L%]E8([@'7"3Y>Z
M.]TDOJ%WG"=S'C=12^[=)'<V:MEA(47 "K$4$N*">F0TYXA9SWVRE$=J\\D[
MK^W7LKNTLOLDHGN[ZORUO;Y(Z9VUUZV4,6"07F^E!WL=5&9-$D54>R6=9E%1
M<\&9MS2Z\T+;&ILEM];GH]1NWP_OK3?6K/MF+KBU?.W)6"0BSW<C)I$ "C,'
M"E2@B$O,D9$DHD@UUB)8'Q++-_=\E?!%98&]LF[#"\2\EY7:ND#,>S$9^L\-
M>K5#:"$P.-=!6#@>P+! BDF'.!4,.:TD\@I[ 21VTMIQ0, \"MXY(. 1 /!9
MTO=K *P!\/8 6/O.GACDYGQG7G,G*8!<H IQKCG2B1$4"!.:"*D-$P_UG=4(
M5YNUM5E;AP4]*=#-NAEUC"1H[5'P'(!.1HZ<TPE)SI,W./L9_:+#@A[=J+VB
M[LELYY;E[&BVU9VVK"@(S=4+B+[<LVS2-B^4KS9B?S_V5XN3W,?7G1;M86$G
M*:0>=LBVNR!XJ90@U,DB-)]9N@HO^<XH3'K$A5ND')7--6R1+@<K59V:)S.U
ME<V5FYC!EW\WB_-YY];)ME\V,CM?8I$[#5;S&PS[-D\(=<IF=G'8ZH6\ ^W<
MH6U0MD5K WN-=\C%P;" _P!9AF4GMP@?Z!VU/;S3A3D-5XL>\%(YQ\G' CPM
MIE&GZ+13^9V;VMLPCAEWPJGD(M<I&LH,5HQZ(Y1D7.3V-D032BB:_' )_H!5
M_+LPZI^ 4 QB]_;H][V<XU\PQ9>)?/?O=7/@\=:&9UO;ZZRQX7\UUO=,""1&
M%Y#4 FQ2SBPR(GK$K)0**^5YKAHW:/\J3J/M#V;1X#+C3IOSW:7QIF<JBF2]
MML9S&Y.-S )C*- 5)78IW;$G]F_.Q(O^C*TT>RPN2__,)^>,YK87>PE[K6,(
MB%/B$;>YH[4V @GAI'&$T,!][C W?YI-.V;>M>NJDU%;X6D47G*FA98F@F(D
M632$ZFG7U04UHZZ)?PWQ]^E>H@Y+3PBR+E$$"BE&6K&(K,ET8590EE;>RS5R
M/?'AR+07=KCL'=H=Q&EWZ6'O]L?D_7NA9SY9A6<.<N-20/_.Z>J=V?)>G==J
MMEPP6YYMXCVPBA1-WB,M (DX#A299#S"V"O#J032B-R-=)&@9, $DX)0SD"U
M=TQKK8@)C@H.<B )6VPKZ)KZUU"_\6N/T^BH# 1YD$64>W(C1RU!N1L?M[1,
MH0'J\[7Y!+J'=P^?!Y([]G:>V$#+VYORO#WG4AAQD^D4)V#*W$5B<W)EUE=
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MC):\S'$-J#6@+J?67 /JP@!U1F&FTO*H%4'8YN;PE'"DK7>YQBGG/"5I(P%
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M*:^]C6GEO5H3\V?@_[YDKM@[TEP3,(IXE!;GHJXA&L:B52QJFXR"UVY/\]*
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M50;ZWE&^7FK9?.;!I@V&;5\M%'X^O&:5%R7D>#3&K\RQDQ55-N85FS9]?#5
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MO5D^9 >[QTYF5(/Z(DSB";WA)2E=YL'OT=Q@B-T4ZMES>1N_Y];NSE4LS[<
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M9\=3JH;)8/EOO[][#]>>^U'<(9'N/MF_:4BH_D/J;3[N)0I\/'NIX?8%]E/
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MFG^WV:9MTW4+0X2I^&9IU+,QE59^TT>S@?5?9OX.+JY*;]M)3E,=!II> 7Z
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M!Q [#2T,?9U<S_"?);*CI'BCT;PD(5*[WXX3[5:[XB$"X0WW\QN<EKGF#'5
M_,>-AA\>[<>J6@WKPKDEF6>4"%,:HJ3PQ%-'0R9%*3A]]KQ<$0W_>9:(+$I6
ME+T;&>PDG],:$S#;M;#.2GD;\+FS6WI'@?QF;FFR^:F]T0_O>QX>O<4RV\+D
M*I>L(,A&2H25)5&\D,27F332"%L4%EGYP>%4R\Q]C4I>0(&W]$"7G,Z-(I%I
M^3@SVI8,P(K"(X"\-)X*XWS(J F^-,<E>[;>BZH]5(EN+69"#4Y(WP=P<DKX
M2_1%>_ .@_$O!/_RX+[6ZBXG5'RC,-:JQ\_/2[Z3QVFXBN_#PQ>"R9A6I?">
ME:S(M *'T-.L4-ZO5 [+Z+TWCH&DW0%L^DBF[ >VYZL]<-U 00)R/X(G_MH'
M_?>X^UCLM_OX/=_?V_]Z\.<'?OCG?O;AZ.V7 [C^$'Z'O\&^!"2U=W"Z__%?
M9TO[^,A>['_=IW]]M/F'K[^?'NR]I ?_?)W#[_"W3S#>7=C++R]A7V,#\HN#
MH]UCJZFSPDL2,BN)* ,GNO2!E'FN0E90ZHQ=;$RA##+HV2 R7H@@J':9T,&5
MHH3O&%4^ZWC0CN<8AQE-_+/G,PL1O=>YI5C$>/,;=&5\X/KGSX]7:Y79S'DI
M*1<LYX:*7#AE,U,*21%R7KFG'Z%/T>IHR6_(A+G<H>CQJYGZ<6 I=/&E=Y98
M3M>#@?^$Q=+FTH(+0(4M"UC*H'0I01P=!]L"AL;2(KKS&:7S""#;R/[OCKP^
M#+][W7\9@R=O1D. ,N/+IV+*O[D*./CZX5B#<BU4EA%)'=AQ"@Z[,:(D@H&'
M!DBSR+%9L@2/718KS#C6*?M.\#X>1R52];C%^]IT0"IMY(A]H<_,J.=.?+>S
MKZL*/)\)-E%J[+].\E-[<Q<:?*UA-8X,ZX,Q"%(3^(I<J)\38RN*0Q=DJ-]O
MNHXE@-L\J1/WRFPXX2AFJD4^T'A\5KM8"]]H*2T7+N]V_!=O(^5O#V-J\#R0
M1XF'Q+![$U+IUQL!O<>D[*;XIJ9_C\=2G=B%-K);SN^837KJL5!F %JX<27#
MNF%C0Y :"\NI\IP;M(^ DU*71?QAH0<YOWE/O4/8)C$ &F<H<<_^#J_P,IT)
M_KC[9^]E=LQ+8Y7)'3AHF.2OC8<-!/Y:KAP@%RY,=-688*O9WR/Q.@C"3*EV
MG5X<A03M:#]:OFHGX=Z97/NV"<N:;W1GI*T5R4CTVD'>X)H9M=(][*'DSWJH
MPN-IZ,"FH].:+;I#8_2X:.B>&V&OR9>11/K68DR]SVEARMP9";;8*ZZ$]MX4
M,F!OK$CO18L:YJ4?[D>,]]-+;.7XKTCQ>9RSD',6%+&F0"8"X4DI+%@#;0+X
MYP4%9QWD>+48IV# J^%D-#Z]@8J=5:7[.FK28H8TN)%O+"X;#T<:OIA,27._
M)E$#]HX#X8VI^O G.YZ7]5B8LGL^ZO5K<N_9+\=3P3@$W'*=5[UPHZ'7UF'A
M\F[:5H/9H6\"?\#9I(:I4,I"(/^]R3P7#IQH+6!1J(N]/<I,;.'//8K]X=Y)
M?IQ;GVLF+>&EXD3D ((T]9HPQW+%RU*Y//5D+K-5_9A7XI\DK'7J"67C!_&Z
MU8U ^NFC%F:'_G XVNGLKP9'S8FM_U+WT-MDQ[ ,3 8'I64\$\($[24M55D6
MEIHB,[$5V#+JV>Z8N^V8(YL?%VBR'5@&J<H<_82,E%X#_@FZD+[PWF(W+Y%W
MN5Q1TG@#CV&VU\ 2"J_[K$X&B?V^#D,CZW+:=5'&EE+J+F)'A3[F@":KTP83
M$\M^ZO34JNXU:/Y.0"?8(N>E9,9H+J06IBR,#@5'.DD/+E<$.@J=7))^F._C
MM 4Z]Q+S>BD.+HY=!K8UHPQ\7H3LA<R(HD(152I?%!(<7YV#SN=K&C9-(3((
MTBMO1A$CXZ)M@.:;I(ZYF\U)I8KP9<'AO0+!O .QV #!+%P>LYU!6'W=!6/V
M?'/A%BD;M6[XW9Y4MOY^[+K:#KL)T\\TG^GPZ$^P/.W=Q7'W!K8_P8R>JZ+#
M''8(.+F,Z<*++,@R\U+++#CMJ"^%B]%A6.(4'88?T [<\(1_?ON\&OG9+?04
M3N\?8=^\1PYQ'8P#1)23O B"" P3 70JB4*3X)1!KKMGS\<7PW75&"!/ 9MZ
MQ<T )G4T3NU"IXUX8G>;;Z"-BT"YM]Q39H+(J=7P;HPI&H(5FNFZ2VXC/S3)
MSZ8X8JN,KQ:J#QDHXZ+P129-"=@[&"*\DH D0++ [;%*Y9E62B&!])6Z>(48
MT=31!_M!;ZR,%^_%OHN>,;OMEL&R<VP9A$IZTA]?U;#J-%Z7MA8"\DTP.%>Y
MD\;G!<78C0-=S)3CCI>F8%91LSH';XO![[AM3BZ1;]_EG.5,D-QJT,4!_C&V
MX(0&#5O&6P/N[+/GK.CRE3TGK_!;0?9_'6+9PT*POD4.Z=,&3M0I6)$0LEI
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M?ME_>\R8H#Z7CN2!!1!)5Q#-2O!H15"TU#*4*MM(VSPFKMPN:EI4X11W7F>
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MF-)+71BI:.9$Z9D2QAK&LZP4- =(>;^P<2MPM<!]R@[>'E,)XF4<Z@QE0>#
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MO=CRT8YB:W+=[\#*CH87^.51;"0^TH,3_"VV9EBK@D!5&#]:[%Q7E")GN2S
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MR+&<.-R*;CQ);P]7KC3IU8Q-KP]?&I_M9#AT5809"1?<]JZPD<Y'(#$CP.
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M^CH=(IR/?/#HV<&@04"[Z7_JIA6 [B\T^HCCF(]3C6$FQ\VE"=>^>Y\:DLU
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M?TOMQE5N?8&]2K4'8*2URS-MG:>E*+RP;HN*OF_M=KF$BH)6(J-2$:NR@@@
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M49X8ST&'LK&86Q5S.Q73@(H(,*O3X<6\+".P'@P'X"Y@1"/1Q@#&,_Y\B,X
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M)H MDF,@ T^9ZW9:Z11U]Y,W/1T[KD7SU](-;Q?D[D!Q!(A!]QLT$4\!T0*
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MGP(3DH\*6G7!-W$\J*<Z*'44% BQO4,SZKV"!5U4PV,\;3-OD:39\80>\81
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M#K/ ?L'G["'0OH2B\5SC4/B(CX,YY"<\*J%?ZFNLC"#+/<A9WL090?(&!:4
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MO/7^!);NPH4:L;FF/L =KD>08,P(]97RFL'$R-JE4DR@TVQ>8 Y%" ?-7I>
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M>2>VS$$<\C?K!)6'A7PRX932+,;5PRI?W>6'9_4I80P"C&L'G%\]YFBTL2#
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M-J&(/=%JG-ITA; F8J*XQE$/TB]'AGS<#OWRM34Z9*Z#(K/R*-T;.%'&C<N
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M[Q![K2:J3SJAS^*<T>6+KS&6O0(P,+<U2X ,D.T1[IRB=5@@7Y6&\Y[!;[!
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M=7RM] P8&JWW5 ]Y:9ZZN-8F>F7,*XV&F3E_.B<?07L*TM?.[Y]9\U"#DJV
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M3T)J(P'*0D:IX4O6VW!^ML/4@18#9?K" <3=C7OHW@5@N"9-Z.8+)G);],/
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M7/[.NTS28/%G604H38X-V;!OSF5A.+[9XKIH+??S65%\SGE&>]0J7Y$-T/P
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M<6>*ZIIECGAV9H'W@\G@DW,AH05Y,,Y?]R.5QY)B?;[)K)ZE0G'*48F@U:
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MIB!)UR]S.FFD>8ELSF1[DY-W9ZJ% ?RG\0&W.17MY']+_PRMTI>YG#C5Y$?
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M*X%M1V#<\4H)<%OW"B[NNFIKA+.!:H=6F"R>'V-374#:FM#T/ _6LG7TD''
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MHSGU! ?63F6%T,M=@V@T[5O/W[JNJL2P:"%L[SI)-[MF4[='70\+58>0>55
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M_IMT5K&Z\L@['WI"\M6BIZYK'&=]+FY]W,1DZQH1$/OCQ<77YU\'#V,1)>5
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M263F_M1#^(S,EKG:@QR("5@Y*_6;(<I ($"^E2"-M)#03[@;JPI83&-:DT(
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MJ <C'1K;"+'3HI2P0T0VZ<Y+T%D=>BILK=LELP%[W)6)(4.*U&*V<@Z25WU
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M%;A\XC3Z:7![!&@P,]D8-SE5&DX,C&VL<%A>4U;M3D!B WUGC!J4S&$L>)0
M.F>06>9O<14E8K,'7B)0X-9-7%4(A]":5G ,-?B4AQ+-O$<J>Y).$C,BLF?Y
MQRG9<X#FM3&'J4P=UST"12E<XO$VNX9LLTKSA#G#$ZL#TNT&'93M8&+5GAQ0
MRTH"$NKB16I6KT>;%H>\L<3*=7">^LCS'AV:N!.;F/M/9R%0 (<J3E>9*(69
M.WWW3I>2R&P4(J;3L03CY9^!M6:+..;P1YY=9(K:5(T09[J>=4&K?D"W:KW9
M:E* ?19&@_%/,2$89/-$0F_(TVX0;"VD8>0D -;BV%@?:$J3'J2H.S*(GX*E
M5/$S[#%?,YW<9&VBVLF:D6$\(SD6%Z10Y O\6KQGLXK]/4-?_>V)H.VAT()Y
M"1J?757*!Q#]_/I.*;\QS4_\^O@D/WEJV0>:6WHM7?9!BYRS<1 -9X^WTBD]
M03<\=./;WSUT0UQPVJC_V8Z)$[!MD(T:=C/;VP/>@_@L(LXS%4/0-[93\\.U
M>HQ/61/:0M;^ ]$*[C[))P?@&$*/Z8G,XZ$XLH[KBIV<$(E$$3OO/B3D,GV/
MSI]BT[21?DAM#GG7HV\<"6V3>)TP1.PA_LCZ105Y$L\T1_H8X_[R+:W)^=_H
MK6D<']?-1C$K4WQ,'BY]3U+?4W)"YZ)G?4DKL9".C\F?H;U32?MH\G.X=2&W
MD:U6:#V%9F0VYQ@B7VBM9;S/%N^P:M -J[]IM><QD]0!OA-RA/_QORZ^^>)[
MC?8ONH(7@\C$7D"$9I!D;7$\X8,$WLM3R>.S7*$F\7G=<;NXM-POM7B"@P?.
MI":9Q APM.3X((*ZD[^OL>@X+0R(%LTE$AMH3N,;FR9?[S*YT"G$/Q@AIW J
MN4N'TA+MC6U-"[?E7*;D6+OR&Y[KHN9*U:ZRU'P J7F?5I-3B?*=H-E99/'(
MFVZ"B&ZQ]&YDT?:UWWTI39LP6;PM?&-9O,U[%9EZD5L-<D9.8IF+T(6JTD"6
MK6 E-NO5Y^\(>-!,UJW1/S=(L^:X>P7\T0KFX7X:/@MJI]U"ZHC7:L-L':EY
M"6+,EE8.-M2:1+F@])J)_O7ZUON/#$_Q3R6501:^9D20<MW<U/%!_GOR)/N5
M3A?^9K!H07!,S(0.X& Z.[Y;9+$=FC(.N9_1>?SHBXMOIR*FZOK'LW[+>!@"
MQ!1KR4 J(<O6="HN*60K<<D_31&4M[O,ZZ[=(,V<L6G\M< [?/:T4MI51-"?
M3W[>+LYY[N7C%UP*1,5IDK^EQ<6) WLN0QJF<QP/@;\5BXI,'9\!/]&$;B8_
M__R8+_[CWQY+%2O)I6G@&\:OHTFD"_(U?_4%?_6)??5Y^E4O!K!KIR/#CX5B
M[Q+6=D32<)8H[5*;,"N!Y\QP[RYA?3=<X_ZI?EQG+WD6*\3T;:DPY%E#ZYO3
M\X^?O0J$'0,X-A]G:NHB[/:%ZGGSF-&<MY8E$1J&Q>+L>47#N&>K<+GXC2XC
M:\S&^<GEB\MIM"NM6\=F%*0!.X@@(V=A%7&_?LYIY"4:+>+"[:UN&9ATW>FS
MR!\OXSZ@!10*'[<OB'!&U[-21$P9$LVXQCRQLI662O]^_NK<%+HZJ;%<$SOO
M^ CSJ[J6/7/HOGK+P04[%8RGO8LEU.#E $,BERV"TGMDRQY<F++\.P,;+HJ:
MGUQ6:$_(DHM!Q_4[^YW&P;)B?.-LN:0G8>]X.>82_D+'^)4X>?/L'89Q^*E#
M)=4>/SQ]VHVA9U*W=5P>NR_,QIX.F5HY#[Z?7%GAV%RI] <BBBO3++%5.!&#
M;CN>VPV?+.^]_^78K[* ,]>W2(P/.Z,C[H(*QH[ZJ0,;# _FV^Y[(R>/)@/3
M"6PT2_U^8<T#.EZ!(NS&4X"9JR$RSF7Q!HYIQ_9V^B(.6V)853U13*S&NV>&
M!1(+.^B\#;B&55[P&O:W#/D_N665^',C%Z8O#*\'US<R!]8DG)+35!- 77AI
M+/5V0ATZ%P^!IG]5;]E0C%6+EKTJ8[+J4U(.3O;/?LNC7&V4L@WBL%RQ6*A0
MP +4K]>@64S*7)D9.C&<"TT72!#A'Z8[QC03PHJH+$9HX&"^8*B=2]DX^!+!
MBTA?0KH)G)+A;L.7\03?KOKNQSA4JC.A6]&SV^)$SH!L%APLZ/C(4S<[8_TQ
MVD99*!QT#LP F08Z10TA!8I+;/2D4![<#83;1;V( :L;*=BS2A3%>=WU-1NM
MX!4B0NNU^#C9X+O!9L\?,A6=HCH2\$QTY:Z+%M)7P! 6;6MQ.WWQQ26[W6#!
M"%YGF:^*5DN&8 ##D6=7F-6+O2CU5JN&.7DK84%L)TW4\>U >+A6/F5D#$ <
M:W7W>(&9*5(%9HZX^!I5?E.Z@ABSPCGRI@H,VQIP+B$I?B-X1H8PTWC3]K82
M(++Q-2 ,_-G%]TY03-MDL1=*B.KN.XFBQ+D=L9#F$SB?RE&6,/;@?#SK?QPG
M7>+.QKIR3(]R5.>(M4:/.G0?]B)Y25V%1C.S) 5',YW6+"DS<O=25'/MYU%[
MZ0FSAWI'YUPCHO!*(L$+ALI;7;^1U68'CWK=:98.\('G@\:(H2V^YZLPK?-6
M")XVD?>/@B8QILNL%6+ +/ZQ%?63H9:IRSNTI76AUN1&..B*2I0R:J< HH_;
MYQ0G"T0JJSPP$X0A:/QP#JC<AAO%S703R $'!"D^O2K!ZZND(7:P%#*H]^OU
MJ95ZR!!^7='[@Z"*,=C[[85_A;2;,"UG6Q6+=03S< O#4!\@Q#2TO$OH37 H
M)$2WV*H(6AP\2S;?3/FP\;U9#=K..S4!0"I*K78"0?0E@^@\:H<GZ!5D6H6Y
MG D@ZYO)>L>Z*TEEKO^&O&).A6%?&/[NV K#Q[5-#&.F"[;K*;5B7R3-N6LJ
M#4'!\+*H;ZJ;#"L0_MN. ?$*Y!%+8;A/M.JV6SD):Q "%#@@BVMM/ B10;*K
M+-WG]A-L)'MO]+E[(+MEG_4Z(($$V:OX0,:*T^)=ARH=PZ7I*0<2QKJOK+MI
M".J^!.$N7&<D[YI\N1-O00=V.N!RA-)20+SI2##;@A58!/75I0P9X$Z(; GR
M.@EI0JM PI1 H4V<K4X6<BAQWAD';@KAAG-V3 8'12JGB;X0OOW#J\MV!*/4
M2W"K*XYO5G5U%OW!GI:?Y8M;LM-EU@P^4^2+0*N*K@W&P#_]\>S%7YZ"C;G]
M",]VH-S&NV[@U^HE=M0)TM17/W153& W&V>^5-(E>#<N G:W9TV=P2&7@C'*
MM/20K73$:P'Y>]RZ!]IS*1-L;:2\<"G!1BMD\WIX4^E"$YT^#?$'08&6:D3"
M99L^F7F]_^A"-,A@+0JA1]>:=DA;>"#GH8XI,35F9["BM+]-?>,Z 7S+:'X2
M6,/$$J"#JUX[>6,/'5Y+<U,K-6(M4/ZP Z<O/?;?*TL._/#W:?=82$#U::]D
MVUDXB>^J1XAU?+;)D]GU+0*31A^8SU'_E^RA9-)2'(? 7?F5@ MFC^"P2E[:
M>-L#/"-'AGM9AP)%0KP6P\F9!%D>"=WB\80'GW>CHIC'_,Y$A[S5B&');JRY
MM[J8C2;D15V*CLQT@@:>>EW,]>I!YUQ[6>318$2-&IRIXM 4E \._C2)&Y)I
MX:*$8<-L?/WK(,4SRY&Y4[GL\\G+G#L9'7)XITVEZ"NI=RVMM,ZB%$>B00&_
M3"!7@K1J9L66-_LLW][@9F5]<\8C+)6-*]H7]N_DPE.>31L&AV?.6ZMJAE,4
MT /$NS@\.:?;C_]Z=#X(X9>(4A3L[%'XM=6?,@>C 0W?1KO:L?BZN_8F[S/[
M& *\ [H (H?AVQ%*LV4B:M?21PLL#]W?ZTW6Y&H\>YW<:3;!7##_I^B3\#DA
M04] >A]JT? 0NUX>V=9(2!M,7K H6_!#8C<(MY,--6+XO(>S&ABT$F@29 QU
M#0SYP'G;/T7L3.IAW+MI%T:5)(AWJ]'!*,_)R/(29DMEH"U[9TYF;7$>[JJ!
M$W%JW7.Z#$W5<WBN!N8I8&,6%#CND:Q3AG]!3@$ML[W::WZ^-3MZ>!7B+-?G
M$"2:J$E$NF5=SOLQN#\2PKL-7UW8H\5+2+%J0XYP:.2,[W4K_;HY9I_$D?XR
MG^?",R^O&6QK>A;Q]NCDBVBE-60P*;88!(8-<5='-#M(3>H61[JP%39"&9$+
M3I*E/V!AY73J74KJ\8TB0C4[FE>AZ-7P6XE!3BH-*LOG;\I1(^=RK"(F(F%2
M06; Z5P;D5V"2&I-L&[5?&^*1_%284_BJUI5L$TO\6C(R"+S*D4WO"?R0N&!
MX6$+#G&9+_C%ZB:\%)+6<U^[BZTV4V_DZN6TT]1T:\RG&"E1)2@X2+OJ-D[%
M]."-1M:A9(U\UC(K[$W[@&2GP6&7-WY07V-,;=XRPE ^75:_?R M/T\9Z9VR
M2-I$A8P@&RG) O"A=,VPDJGY74*=VB-1C EZ[D"?!AN72%R@,L 6<U$?.?;[
M=>R:#I6&P51Y2*MB%<* E/ND99&Y_&( @1+-HJ<%L,WG5Q4'<[!:$@1*S*UY
M%QW%0/O7;RNDO4CVDWMTM!M9?9&T@S*V3W93.=N[OO'!G(]/]@SN^[3=DVM9
MCCV3YEW1<AR79W/Q!&4L:A[%0C9\1Z(A;:_S H+Z3KWWR7GJPKK5-ECV$AI8
M;9J*^7[JI:I1!2QQ/LF@JT<"6K+MGOU<;FN=BQKD,&VCY033!U$^!<Q2;F(-
M0J]HBJ]G\/#\/CO>[2/D)9ZKQ.3R]-"^ZG$\&'1YZ%!WN+4?GUR>Q2&U"TQF
M*/(W;2A8O\Q1I2X_"GCAZ_/O;FW^HP$8;_Z[.-C]]Q__Z^+;KQZ*IXPG;O(9
M/)HRH]5)$[5HZOD5W9C<LL]Y ]'8XM/3V/ZK8SNG<+\&)NCSJ13Q?'_KJZRJ
ME\5T\H+6^,\?IXGUWW^PF4.6!K#<-Z?U^I[KE9YK7NS6= [G6UFK?IG>!?$\
MG?Q8MQ2RU"=[_)YS4)*_1@XAS8*W&8FYN$(1[$4G<2U]*)MR+K'5KWE)1V9S
MLB;O:[IW\Z96A<WZ[9[/QK<X%]]G3SC&:L179^3>G D^#R>#[+DPV]%[- _G
M]=^?O3K-XWN?"FLR9N49'@M=DU("L*'-2M"+[M:0$;5])^'4JLI;FI?SR3--
M$''NJ.>%JLHCPZVU]GFCQ)*>,-^D'%&U[O;=:-9YE4>Q:A^9^0CJ^8N_/=>6
M8NXH#BU4ER7R5WGU40;[3W<::WJ6K[Y[]+#3_=HD<FGGTA0R$%+^]/DT!I[]
M]EN'BSCZ;HX#H1:8\FX/KKH6B#DGH2(\94EAE'C:7;GDX+T.]850,0U?-VXJ
M+;?%56I7696[.9NT>.'E;HVV9>NNJ,M]F\V!D $*B"\:-%BEDK5M,HK'\=.#
MM_R1KGJ5K_,',Y,'*6".V$P*^![[9;>F<V[+$"G.N]05[9E?:>SIL].POM^P
M\IIE5P(LF6Y<:;TV0+)N3R/[?B/;U@MX3>JA!4MCYH/KE /C_I3_.SLMZ7_%
M4K!:.=S5M_LUN2+=,8;A?DU7A\-S&N5_:90W^Z:./N>\X'S_Y^?"US+@1"+%
MG;9']["$XB/<X@3%=B *-O-R<4)U)ZCN/WT*J.Z'E5?.-IR9:)&1^,^6_;/Y
MO-F=[,&_9 _8W):?6Q47A7 ?90K^<7S?,_\4IN%T_GW@F0!QC0"(QFB,1B>%
M/,2_[LK]Y$+9MXX\_DSH0/6X"&D(!^N*C%:&6ILY+O;&=4G'7D.I6P.4Y:NX
M>CRE157D24J4R$48EAOVA08X-O"C5,OZ:LS'/%EAY!'-*D;>E7JEA]$R )/G
M 6 J),.,TAF HM%$&_JS19%=.R4IM#;PHN<$\]5V%.#Q.,!<2-NDUJN#D$4
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M<_?X(1<Y+%GDPM#3PKO'8UYT*C%I%"-B_3$1LP29*35T=^V=INGHZ( <T<\
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M&<<% \@E^(6(;@#ZTT3A\:((._![]YM?;@N31<+4/[9=C9#O>N:-B/S.9F\
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M=QW:+@&4Z2#K4(2[)"E(N.@5W(]L0I(__PG=#1*1W/ ,_>E33'*4F(6>+O9
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M]-]E:U,J4(80'SS-SFC=>Z)!$_U8/3BB*XB_$$@&;WQ7?](UZ)^VW%J?=@C
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M2"H>F2>*W]  CK '!4IKC&-,=V)H*Q2-L5R+!3P-0:-#$&LW'BY*<JI,D'H
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M6M%AE:2FB7W2G+ 0TEB25\K<9:4^;6T]!F=UHBP*SJW)UAFN&TC*0H<.[?G
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M")H.=6UH72/%7&+2H?Y/B0\P20?R#@&\J=W/V@BAP(W(J7SQZAV"&U-?+_1
M7"/@Z1(1\@1D95&]V6KC?JN454WA07._X=?P<E0W$U8 .=O-B",B=@N"%L#!
MM>,10:FAL8XVKFR&AZZ0^><WJ0M",Q3A3'CI*#Q*5&]-'A.B.<2J;6#2_#FX
MU)@#@U[[$&?3I_%Q[/GO29NO /]# ZWS+XFHS;MC"03Y9<6 W!?>"/?8":;%
M]7\T>*DZ?,D/\WL?'G0H[;I4UR^W9R A%:\S<'1Q^\C44#1%X19!-DH1#)&?
ME$@D&^!C<VYZ@\]U=Y;&3L'"+=O#=DYV_9:UE/-H)>3.J*^\R[,4)Q;:!/VH
M7/&@/I;H=8SL?C? #G<\JGX-MDLRA] &A9<A)K>O\1+G=(GX1\L*68><^2&3
MP*TJ$0_FX:>&M&JUZJ!=!H(Z[FHO:S&$H?V-\(F<2D*;R%VN <=EQ75@+TI;
M3Q@G7B$P3A!'3JP!L'_#?F2]>>CA(K1]I6=MJ!<;/U2S=7/-G?RQP!L=Y2XT
MD++EIA"3!,DT/0,VVW@DO)H^0B_FX?;R^[6T BJ.E!,2!IH4UULXUL?C 0-^
M3%)PTQ.2%I%>$VXX*.H,1&PUH=W6S)9,MA)W(DB.A'D5XL6_B [<JD9^CK0?
M@7 5U+N2DQ\+^-JE8^QCW^2S.7/T8C&6BPAU!!K+):A"VD%I]P>Y#>6UE%H5
MX0,->B@H6$@?'660>#-U)/Q'(#$Z5Z( E./<L0\Z":T6B(E5*#C^L^<=LTM0
MD_\?OV9LF_6!A71:/-G%<Y%14C.NOFG])-FTV.'$>402 S#T"Q8*\P=0U6L3
ML7?VB-D,!8W3#!^G-I(>RY#\:8BTK]G0@U-C/CG81[[N1RPQ,&-NY+.C8MJ2
MTKG!:T<2^XX(69:L^XWDT-'R&*%1S<2^XXVE?4I\24ZQ!87<5IH&0=UDV%SB
M),8DBW!"*A5"YV+ZA,Y2'!N9L5F-W[B&4J)_T WVU;80 OPZU$S!\?[0TL+H
M^E]^$TE=6CT.O^E0WSCZA;*@V,7#^T0W+?8[.*Y?L6 U[^&?>G9!)$3K8 .#
MUW%@ ^ B]V$2;A9TR7 ^P?\ITGT+B+392UH+L V22T$$@UL$.# Z:&.KNC6H
M>[AJ(^4VS "6?OC6YN '9XSQR84BD;G4QR.'@GK5@NW)?$^B"D!IP*&1M.I0
M8E(GFKX/0X\CQ;*_;AE4ZM6"=!!Y@]HTO>"!E\.22#HL9+X).])$"YID53CT
M*F>]=]X)<;F?X84CZ1T,)%FC1-P7E1@>P;7]?\T;CADO67FUJE=\2D"?2E):
M>NOWFY_=-SXF#+D1\-2AEMJZ-:MLOWC]SY]>/CI_#F<"5*#LV=.F/;HAY,RO
M,4&W(GPY=#:%S/4C$8,,KKCA(1QVB * O3 $JO99JI%F"EA^@($+I5K*D3%R
MU:53+(3$X3/W&PM1QU%ZP)1 O;2F;BIA3R/>%VQ1&^.^Z"PG\V&#1_TBKA,&
M]"W*79K^>?+EL7OTLH/83\$3V 1.1EB59XGU6R)MX%W9(2F^76L82T]PYUHG
M2,_8!*9E]TIH+PS>3\3M2)(NXM?$;HB*WP%!BJ+&0N<OA=G!TFOA8[% ?>W0
M8XR;&:ZP:;"@,B+,%.M?4)I *9G (A312_NO^[@/)8*I[0C'C$37T=RID:.!
M&#8?9.7[)QEQR5V2EVHJ2I92A=(:.J<*EQI/*\DRS*LE#VRS\(XA'V<JT#J[
M)DG?;/NGX=6$[>]-4-MI^R,;$ZFA56W&B\C6QY2D@G$->LP*EXVZK\.&<J'^
M<;=,KQ5G\V&=#'U4%;,]5KR^/@TWCY(4F^H#%#O0]\UH"?.>Q.&"$D>6Q, R
MD5EIPY$C+>&Z%L31>OH#(R%YC227D]JLJ5*. ^T#U5A91A.5V(CIC!8&'??H
M$VP)+#HQ2J-WALZ<</[((@Q+7+AK8TW@4+P10(=9AFES[4T*I%*HRI$<M'80
M Z*5UC2I._O+,FL;\#=PF(@#:IN*;ZQPS_"17$\\<>&'IQJPK0%_?:H!'QH?
M7&6&-H07FFQH398C<>H2VQXY0"/3@S1'G&5E%\P*Z00/4"DLD?FP!#(#+KM>
MEL)_$'722]]Y1#PBO-3LG6#\U\HIHQ%PI.:P%SHTI=PX==W>+]7^S9:V^PA3
M>X*4W]\L)GWTJ%F5P)7F$-1"T.$GL*S:D7MWFJX'FRY&*5*VN:J9SMS0CL1A
MF?HR":QQFG;D-+</-K>4H$+0]Y7SD0"C#1=KW(PH!<$S+CQ8U-EX:MRX]V-0
M(4I]^9OX]]>.4^^,-"&!PMNEIHZ)8_"G%;R*-_R;E*'<U5=5VS!):B%90^'_
M]XLXKYAR[933?X$,X*&&@'2GLTCZCA*\0VO9<.GGD N)"OD/J81WO,2# M1.
M2)'K8>L0[_R1LV@9&)I.0@/2\YLW+0'X33)+"HMK_X\-)A,'$&_N_/?\656
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MJIZF;Y^06.&KR*62?M'_?BL-PM1/!7)M$2..;5Q0#WCN"%N_3*T+F18A_VF
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MWZ(?&K4:3>2)X46I<=W92F$D-#NA$DOJU%0)R\U1?#S[%3,YE]DPG\RYS3
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M-S83QX- QEXUXO*^0SB=3<MS$KF69ML^DD 1AXI- =- L'/(_:@2:(ZC9/Z
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M< :F5ESV2MV-5P1V.1I?P@]2:#YQ6TEYW.6&3*GG;SAB&QVW,#,25OIM;*,
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MI+A9POV&&-CPRZE*A-*^4DIEVCD<+Q9*G\#2MFXTP:GAKX$1*RFB4)<B2B'
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M;A-23IVGYT0Y-30 A]#X<DEI9BAHV;'PER3Z_9IOUX1#:"*H7#*$.*XE'0R
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M3BF$FBD1LP>$&B1KR+P01UK<BPM-5Y=%UD%;^-5%1>@<TVZ@A* PTWC=D#@
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MX0LC()'/9<JZAT:@*GL$]$9=">$LC8>I(AQN"6&^6[5Y#5@C%QR-E>U(P54
M'?[HCQON8-#/\PHU?HL96,MB6]G4^X4:(WF$WWEVE(19T<T)!W1^S*G7KB2,
MJ]I,Y6@P6ET#U591"HWT)WV)#.,LE1GR)KS!101.^21@\O;?]7*CG;2:$"$)
M'XQL+3F-.JK[-'S$^1/IK=%_V?CT%L.KU>.IS75(D1/K5P9?C#D0>(:BM;J>
M!&8O6QITI?]1!4U@**(>(;4 72"[XO>:I2]B5]CN9W"UU)$P2S^R+V!-Z-AS
M3]_EPV>X2MWRB;$#$=#MREG4T<^\4W3X>4@W,1C"(*3&0'BF\GXZD"KZ B02
M, ].3KK"9_MO[-KP"9MA019_$;,F0+>CHM:7.?-=5:04IY+F@O<]1Z<&WNE3
MOB@N*CKRQ0/?[3C#2!#CGI%Y\0<X;2GTB>"?.F%HC.;5K&O",5:SL!*)N<%D
M+A\.Q!DYLW,P7%ERWSZOE,Z$EDI!?K<J &*QPV_TX=F>FZQQ-.]$@H<4:DH%
M*Y-KR?,%1T.F3$8$B75X,4++-H$7,<V-0TQ>]O 2O2QPA?49^H6&1]8@^T/!
M.]-C-$+T!V<#=W#AGB"_Y7HEP!M.DZ:>U@4T2',.VF>@^)7D/<2*<E;7^1P=
M6#<HO")"0<6$^\.,O6!NL^2MO#XUE_2MA']N73= 4E<ZA[BY\$@(6_%,VP'+
M(LJ!@8BCJ 5QG9$S<\B$ AQC=<J)74JF(M)4,9_*2.292M&Z:#X,/"F?,.9#
M!$0DMCA9_>L$7&OZ.@_OO/A ?05KEFYD!ZFO12S5>*.1X?/T-JH,VG'8,[OF
M9U5X82%.KR V;4P"OB_];9!7!THU2=D#RNRJ:WU>&_796&\ET> 7C8QF$.:(
ME,!+2K]([%9<"Q1)!-IJI,-LDF)FK&(OX6]2NW/P5(Q(15X2+]">(-LN9_=D
M^S+SQE JZ6^E)(!HCH!1*1H*2<R0875X<].RQVB><EF)UB]F:^[JK[N5$) T
M8H8,#!^T-LSU?'B%!^ :,CGZ,_<A@D1U^P]E\TCJ,'+];7J!:.=[O:'L2-]V
MS$;':%+F[555?^),)%G#.!6(7!9ECIJ:DK+#S$/90"B%OVPKY,ZU>E$H%)TH
M+65@E4VW,5BKNBK1WXB^P0D9+-^C#^3\ .AZRLF.Z@":-*)_<E:5Q"P+ND;J
MY.*3B]6C, YJ9A R8.P&*%]B)UE3Q3&@#UK7U6+!(MA(&5)_HJI:X\ZNK%M$
M/\'DC7-@9Q?0!F][!$=F!/,%E\Z]PRF&OL4+;G^5PXI267AAGQ^P&H/*?*$3
MVE3S%GBQ80HKSB(NW:!#\I0KX21RXM>SY#1X<+%(RG-.1Z+,.T[1G.-TSGEW
M[H-E'KSCKJ=XF)Z/4MWU&AO"O=OAZ]1F.XX).6M"4]>3:7D"IQ)1*;B$) M)
MR>VB%KX6^(+LS6!5CY9NXXZ F 5+=XM==[%4_=26+JE-(_)7:&OSIJ;O^7WH
M1J+,N;G=.^Q!)NOL_=MQ8T7P"1;2Y=W?ZVSH/PY7OJAQC6[3NRY?;< :X4H7
M:32L6K$PO&WPDZ9J/WV!O]BOR04C6>>KKGT0N^!,LVW&1$L.C9QK7[8P2@RD
M&(>P ]LDD+H0/<NMT1X\+^$D/4C;-IU]LC=F0A"</T!;A$%!2OJCL&:&G7]!
MH9'6)K4"8GH1EU%PE&B: P([;JMKJA64ER3EA#_R;^]>?O8IKWG-NC/] "MC
M%2K)T)L<3L[019#[<Z9I6E<IR'90E OX#N&N5CI_L)X'LQH<PRQ@LK"+SL0N
M!&SBK<IG!_W=&R@NOXJA)WGY)HR]PJGH\07RB,<F@0R9A 7XKQL$0")?>5W\
M@VD5&XY0YWT5F><_/4ZRUMC3 O_EU;OW^/.SLW>GHASBABQ?-#E!<E5M,Z"$
MD*JF,]N7SBT-'%%L,.5[,%])0FLM,;P5U8R9.C<CN0S^+S@6JMIX/=;3,>%@
M0.IH^F84,G7#>)'VA6[X6:J=H6X++,A/@7GL(!=W6=0=NG:PX8)TS.#:E \C
M3)*N"4])"E?'^RR[TL/#T%H3G(<W&(AU@#K?.=(@8=W7_7UE3Q4,-$#PV$QQ
M(R5);#[(W2:D*JWI:^4!8!5/%N5FWDQ2F08DF.E[-0 PTW0#7R\Y'[1T5KBK
MN>]9V^\UFV&T/!&206\H#6K%DK;"9,Y*X3S<7)NGS_Q &\X*:MP:7%6&ZX\[
MDXP)X_ZF(J)&#@X$U(@-,T2>_5N2=ZN+=8/FI I""@JPB[(96E#@S%9+6FZ
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M%K&B1)2D<X,. 2\1X'QY*TW#!\,UN:"1!Z?A"*.@12'CX0UF: ]DKP_VWXS
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MZ)'-;9O44>HO +_IRLCRRGJ@?G2AYN0?,?M2;%[\!G/K$,YM:@GSJ2V47L"
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M*]:5A[:123V0L-BP4>ZNNX*QS&TD9;?1AB57&0HW!$Y4IYE3!'>B&2M:)IC
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M);:Y4N1N)'U$!%F;WB!NE(/><*.\(\5LY;2T*NE63VCL!M0?@J](]^(B4[]
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M^2JOL0I5DE'!7>Y<FK?4TS!Y)Q_/\H,?L6><Q&[?4G/L*;18)]QU$_HO8!+
M"0)$YV4^>;=(244N);.U-Q9?K;$XV1N+K\Q8G(BQ:#J"S'EC@=OXZW@=L'M?
MT>N,F_#W#"55:PYD GM;OK?E?5O^1&SY_]@;\Z_$F#\Y2#%?]9FLQBP=]OS.
M /3\8U5VS>3G'!NU%6Z]W^]?YWY_<NP"O7W2_.%O\B?'QP?_? *PZ5[BFU/6
M[^JBA":FQ>2U*FK+SG\O*J1$7?&^6^23XR?IP?'31^EC)7GPZ'E+A@ ?'[]\
M\G3O'OQ;F(N3O;GX*LS%R=;FPK.P[<W%WES<R%R<[+V+K\-<G/PKW@64JVYI
M3J:W,2?$&7'\8O+;X8?#LT-WK6='7\[$W&,H_! @DC?:F _AA;Y>\WQ\='SX
MYM</-['0][IBMWRM![1DMWRC-]BF,OFO']__/'G#3'F35RQX/GE$=(3\9]%!
M]PQ\Z6H%ZJ3,D8 ,\$!KXPSTJ[1-G3U>Y"H-C;=H4R8?@J;<+&/:+_V]?Q:Y
MU^,_>3M]>9.Z1YT_1&/UX>RO>V/UD(S5Q_1S55;+M7/9VKQ$'J@/LXM\F:KU
MVEN.O>6X \MQ=OKSWG(\<,MQEBYFS+$[^;DH/TU!F&%O1_9VY [MR*O7/^WM
MR .W(Z_R.8HN[,W(WHS<DQGY^?3'O1EYX&;DYW2:+YJ]"=F;D'LQ(>_>O]Z;
MD =N0MX!LV?9[D.:O2&Y+T/R=&]$=MV(G(%ZP>0=:-0,%V\>$:D@@/O3)BC0
M"*-T6I0D!B%]H.X$^5>+-E\+U"9ZC^.G7\F+["?D?E_D6V05_(_M^4FO(=N\
MX<_NAQWS_Z!%RE"QJNFFRP*M4K[(9VU=E6!.01<+]-&@I+PC#_T_G,W,D.NC
MF4#ONTARD=(>&<Q'!7^%%!2!=AJD=AX3,36*J%;\ME;8$.6&GA\=/YH^?G1\
M]/A1<8F IO>J%C?Y</#W'>(='QX@;@@RP^2E7":B6("B,]5RY7S;%.4,5HMT
M@S+%77+'#E&<]CVS>QK<X^/C<)!N2RC[\IO_V E"V=ZJ'1WJ:RS>W<_0".W^
MF[_\>OKQM_>O/]SX46]IT^]Z#;XS)@MEQ(QPR=8 3/HA4/+7<"D0E\ZZ!>CD
MD 8\Z)#51"X""I Y*F<3K0@*<Z+2K<AM(A*5O\!ZFNY'>+VT:R^JVKW=]2KL
M9@T:5O1G]\ 4_/+EX7='W]V&*-CMR!<O7GQQ\MWGAT<OGG[QJS[][O"[D^T>
M]LM2H]Y?>'9-P/E\E]]HF*+X].^O?WQS.OGXU]?O3]^]_NWCF[,/R>3-KV>'
MP4ON_OR=?'4)@_T;_:G+[SXB$'R_5\ZI_MYR:/]:71I%G*<DB'/C]H4=LC3#
M[_WC^ON'L4RW>YUOFV\G?ZLNRLF[P\F/7;O(ZP=F,?]=4ZQ;OQ'[B:A9N6HG
MJ,TZD>=[,*^[7Z/[-[J;-\(K#DFO#K\C%$1!<I%T(L\NBGP^T$_X:$.SX>,'
MMIKW'MU7_$;[Y;=_H_WRVT_6O^<;[9??_HV^LN5WOPFBR62?%GJ(KP-IH5?I
M99%-3@\G'U;Y8N$N^<!,Y5<<H^XS0];.[)?I_HUV,SG$0O;_*&;Y1!-%"6>)
M^JQ2D$'Z6.<IJ*4'.:/>5P=S1C$*\=ENH!#W3_>5/]W>7]U)6_7OYJ_^HZ@6
M>=NFD[.J=4:TNXT?\&4WS=?A8.W>N.[2T'U)C^!T-JNZLG6O-E0XZG^ZC1=P
M\F2'SHHOW6!PEXCLW0%?GT3'D?V_TRI;N_^Y:)>+__C_4$L#!!0    ( "*!
M9%.J\ZM_*AT  -51 0 1    86MB82TR,#(Q,#DS,"YX<V3M/6MSXS:2W_,K
M>+ZJO5Q5--;+'GLVDRWYE776,_;:FDGNTQ9$0A+6%*$ I&WEUU\#?$H409"B
M1LA*6YO$DM"-!KK1Z&XT&C_^[6WF6B^8<4*]CT>==^TC"WLV=8@W^7CT97C3
M.COZVT_????C?[5:OUT\WEE7U YFV/.M2X:1CQWKE?A3ZU<'\V=KS.C,^I6R
M9_*"6JV?)- EG2\8F4Q]J]ON=E9_91_.SL]/QEULM\Y/SM^W^N/12>NL<X9;
M)^W.&7+>CWJG)_T?)A_&_>ZXVT;C%FZ?V:V^@T>M$>HYK2XZ.ST[0]U1N^-(
MI&_\ [>G>(8L&)C'/[SQCT=3WY]_.#Y^?7U]]]I[1]GDN-MN=XY_^W3W))L>
M16U=XCTOM7X;,3=NWSL6/X\0QW%S!)^2YN@9CPAZ9]/9L1AH^[S7CML)+$2!
MEWC<1YZ=X'5\UO(7<\S7P\#/Q^)GT4^[U>ZTNIUL3XZ?@&6[.3D.?SRRD.\S
M,@I\?$/9[ J/4> "2.#]'B"7C EV0 )<+'B\U"#SLX_8!/N?T0SS.;*Q<@Y^
M^LZR!%/(;$Z9;WDYH#'B(TDD9[X$$T/JP9!"-MY1&_E2-D5['H\J!W6,79^+
M3ZT4Q[LW[AP=ZU,0\-8$H7D-*K*0(271-]6IR4AIY_S\_/A-B-UZ.M9*DVS?
M$G^V.MUJW1:)I7[?\*D5PS5!0[KDJM$0PVU(P]JE5B0199#R,]<D8_W2U9R$
M&$",_J1*AQS;[R;TY=C!1(IRB?BO-A=_2(%?[A-Y'O4EO/@F^FX^)]Z8AE_
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MT28U=*U>3)BY!X;G\:Z+9R28I8*:$=+;L6PG!/>>#<:^4%,!\Z=+QRDW@>>
MC5RX&K;1E1&KILCJRZ0\QTI?^!#A'/ 2W;$94E,WC#BX_BOQIY<!]RDLH<0J
MCD=6?"JJ"VYL!'/= ,(05*VQKX*:RO8U#ZB5G.H6 YB@-:_P& NK[8LG-544
M'9 &G2+JJH Q5F#OJ#<1;MA#()XN%H_FQ;D9]W/1TY!>O_G8<T!_4Z85<=T
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MJ[,S;&&9KI'H]F(Z?\?3U>G)R>8S8;K&DXO?K[JMC?S7B];S?B9APK\O!:X
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MK50^\)BY=CSVR6M<13$FI[X="W:>YY:.V.*4E-9;3$@*C A)4"Z&YI%)+K&
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MYK)I:-7NP/;3YS0[K6V87B MQS3=X*-_SW CB_EUW!B\0F<TR"0TX4Y(D&4
M8WR.)>14?)\@<7_L8_*>.O.MGTS;',A]LUSDTU0?_A8WFU _GU @O-Q8B=?+
MY^_#\AVNOE;2KR;<:BE8/1I3= 1EDX3H(\V0=887&V)"_RW;N-.3Q^1&[4^:
M_I/?_LC:U]W(B5'.9U'W'K,D-"()\NE8@<A%TLQRYE2?B.P.,/M766S$^)*D
M?)<_>[F":S:(_N2Z"RL<9EMHH>9DZ^83K=&@(P=!(DC"\>1MG\.;.X =DW7?
METNW"S'ZRJZQP;_0&#%RE%$7()5(D73@2$$T09"A:G_K2E)]COD]X/Q^TPS#
MHV+&[A/>7G&>IY57$Y0)I<D&O"ZJGD*GL82DP246K62>:]&Y <H%E"VMZ>.2
M_7X3W[+4]V8ISV493U),<R<\%)6K);<,/#<<K&99.J%<['30]P%0^XZ7/N>J
M )U1*9SE"&G)<>G!!1,A66\Y"O2N]&DD=PW&F(Q?*S[<I/ON\][VB.L]I6OW
MUV0\R_^7#/5Y/X:S>5 A&X*<P&DO2%%K :%NLHE2&_XRXVSN>"JVP0C&%=OV
M(=Q1I-V,J]>72^):"5:;&#G&:+G0P@FT0H"QDIFW@JO0Y_C% VIJE\JB-2YQ
M=?Z)YV;OGXOYXL(2UDH8-$[:1"+'0(A4-!Z\T!Q"5(6;')6V?6S.$'1C4M2[
M,^1V)5)CN72-ZA//A"!8>KPIH$JHS7"$!<%EILC(:LOZF.QO1O7'U:/M^+#O
MK+<UV%>)>(VA$V>$-8%E\KF+!U6SD3%S S&A%J&(Y#MIQ8=QC2D'V) 4[631
M,7;E3DOO SD,@525TB2[4$("BI\X4XF)7N<4OQ&[[I+P6R%-4:TQ?X$?<;;8
MM 2[F&ZNO&=.)V"RYEB35D BI=FW7&M,QFC>YW3#@[#&9![WX\;M%%XK:;0[
MA8XS^M&[?^"<!CJKFS3Y9#J?KM;+3=/^"VPV6^\0!9"-=C1JI2 JYH I9IAE
MR16KNC!E&+XQ6="VE.D@GS:[::^FJ3[Y H @U<UK<T$*8R21-\NJM#.@8\8D
M9]"I&^F^>_;*KG_NF*Q@&\'N.WG'*ANJ1Y1>SA:?^E0(??WTSL5 ]PRC4=U/
MK;BG![Q9+CY.Z=-^_/([0?EY_G(Z#_-4]V82+=JS4SG.E*A0D(X/M>>(I<7J
MC10078E66.W)R>H5C _$N.]N>T+,J[I?]?-J=5KO*WI=KIPSWV1&+GY2MS!H
M3K1/A=7>!*4(4%G5E'C*D# :K8)+*LI!2F2'AX_)Z^A$HYL;\EWETZQFXQ+E
MT/[=-17WNKP\79\N\?*G$RVRCBG0<E"&O"M)CI5#%R#$9*13R/+-?<@!W-H+
MTIB<ED,S[G"R;-GA^A+^9H'43LNKB47F(T\<-/.U=Y2KU74V0:IMZ@,J)V*O
M TQWX1F3P]295 T%TX\DKS]L*H]_^HS+-*7A3T)DVO.$P&W,H(0BGU$5"<ER
M%T.0Q8@^1YJ^"6U,QR*/19V]Q-5RV^:NT=>SOJOU]=%[G1R/M8;7!AH]9P@^
M24\6.FMIG= .NVT]#\2X]YH*7S;.^V^+9^F_3J=+O+?5_227XG)6!4HA!B@N
M"\3:-R&B,;%$9#;WV?89CG%+/[-O-4HGHMU:9GTDV$5K_Q+6YYNXFX.R7RX;
MB(;9;/6ZW+_G.Y&6>V9X@>#K##GZ$NOQ6:.8Q*!J\_4^6>,F\!^!-]J<E@<7
M>SO&WEQ1#W<#F;B0> I! >>9EI5QEN#&""Q[1;"-*:9/-=Z60$=5JW<L[=A0
MENT*_&@B;G0I>DNSL)RF->;S+D;77[CRSC>XG"YHYM*R7D/R L_^IN_/*I9_
M^IS>UQ#P;5CC3Z5@6D]$/62 A5PY8>NI;.?!<:7 T/0F)UGH=3'S8<?9R5&\
MS%1?86C@1B7!"B17KQBPAAB*GKS90/R4249N^KA&PS&.*04W8K[?41/9@P3'
MB&8,L\$;[Z#88$%%I\$QE0BIM*1%/><W[ST\<C1SY*+'1T_2?4G0FZ1W)1S0
M!\R">< 8/:B<JNLG%"A5-_ %JF0/&G)_<^?FR <('SU)]R5!;Y+>I>DE\LT=
M;E ;I1(JBD^<Y@YT84$(89SO= G-KN9^W^+F(%&SH#C$E.H]T+59BQ81$D.+
M&)POG1J)C?8,1B>V/'PD8QLQM*WPO'KJ_.9A<^]*%IN2PEC[LA@"Y#)Z LEK
MIQ83!>]4[?L-9&/R)@[$EZ;":M>1ZPJ"U^7F?7H3##D:07!X<G4S26N(01BP
M45K/5"10G=IR/8AK3';^0/1I**BF[=S.FEQ< _=BNCIK.4<,?[/$D^GIR>K,
MX=WD>R:2:,XDZ4J+E>A!"8CU$L#@4D@V$MM=GY/UN^'=<G_P*+FYYFSK+]DV
MA3+UZD>:CXM#.!>5A4:Q4-!E*&1Z*8+RF6(I5Z^&325K88K+-RAV3]7+W9\_
MI@ZIG1G1:I8;WA^V#'5:7TWG^+9NG5EF2&8J@ FAYH5E;3Y'WW(N"Y>&VY)Z
M729W'<F6%ZQ^%XIB+VFT40$OPW2YN2_@Z^G3WQ:7_<$G*6K&3 X0 J^CJUL4
MZ!"P\!"]2RS?/.=TCRIX^#E#A&^_(Y70<-;;-]__UY(FZ,7BTWR2Z5W*&0<V
M\YI*,Q&"2(R(B8B9BRQB'U_C-I8A#''?!T,:":2=S7@?EOACV-3'GU3;=19Q
MZ:*U="Z!KX?M5"F)@JT2H' *UYT-7.D^X?'=>(80Q']?!&D@F(;:XV:V]04N
MIQ\WYXVN7K<<9-32,P<BB1JGZT3^+?W+&U>2MUIR[.-O# 0X*!?'OB\>]9!=
M1V+=OK."D(D0N=!@;=VB-#8#!?0U&20**NVU"'W.Q0Q!-XA2QZ[>Z\^I/<76
MD5 7AK:..6GM><DTTLPE ;$2G,T:A$BR".Z3P#[U> _"&D2A@[6B.QJ%=A54
M1^Z<7XSRXOSVY#LO2)G$C(Q;+P"Q^O,F.P@Q2JBO^Y 9U_Y01F\(WD%L.W9!
M77^V-1=M1QI>M,A(9W<*G(/CPF67LR0+[2TH84B_>F9!>&5%M$DJT6=[<R#
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M(Z,=CE^,9J]E:TKMO<JV$>DQ*]!,XMI1[*:S<N16JP#>L4WW++31%.G*(ZI
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M V@,^9:#<JB%8 9Z"N>OUR^1GO7W/_T_4$L#!!0    ( "*!9%,KP$?:!X
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M/>W)/CP 9HRV*/)MT8X]*3\\)0W%0(-SB2_KT-NJYK- BXQ)N0!+C.(8PVB
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M\>&H:G#S_*8QPO;QK^7>!6[3$X&>@(]S1C  U9MEI4?@J45KF9ZPO8XR,^F
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M)."RUO@MY.=&9CRD3%Z0< *S/L*L\^CDTHN'!B<.#7;5D_$97>+ "V>U_[6
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MA16R3I6;V6&[NMUL?O2#8_@PXS78HMF1 V**#YYBM\)B/0H-#((C9#;$(F+
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M';=*=@O[;E3+%BJ0P\*%UDDJEDQDK,2BDU8JDB19_VK9 X$^H:K9-"%'S60
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M./Z^>?3(5]?V-?YL",L-Z)JO@(0_KP'AM ($KAG0.D!HD'N*$80"(PTSMNC
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M"I*9\YY#3 ZM%=9:U\F)[[W_\ @Z8AVR=SH(8>-VQ.J"[*DC5F\.>_0]VH.
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MLR2 9M9H1_-@]G6;IC9T<\DK$ )U$<;KPCJ=ECX5:.DIB+L*M/0AYFC%-KJ
M?/0%6GHQN5?5C7UH.%Y1GRB%KLW\A"->5<0$C@<!QF:"Z"ALV2SV>'^UTK=
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M;ZSZC^EHCC]-?J/5W@J#Q6M&KT9FVF3+ D^6H4&46>N42YO<P8=8#C]W#::
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MY_EY^9^;AG$RDCT*KQM4VOMJPX?T&?/U):Y,].+;PF#+.A<>T-:[J,R)1(L
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M.M5J,084O0?>05YLY^!'%\030=!#ZV$7D[>M!+E:TA*7#D76#)R43(=:%@:
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MJG0!1)*Y-:)-=<EMB$[/%QC$]@TJ2F["M9)_%V1MHPM;L1TIK# (AQV$T8.
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MA8))%!//AO&.#3(U5FMD!(4$C91V?'841C/.NA:<@7EI'Y<!V.4< DX9Y.A
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M9+#_S%'>\!.*=*_MJ5_WS9"YX5Q-=-7^]2G+A3^/620#KJR6,& 4(H$1I#Q
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M0JUXNFM"+;]^DY</ E!QG^6U-:Q>>OW!DT7B9\\9$U3OQ\,$^E%*($J)#TE
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M<8BE48:J>]&FQG.WRVKU=P)^^_'KC[T,3;?S9F#[O]IL#,QEVW4/=>?C'<U
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M&E)4U[M G+ X0%:VG<W@4]OT[7'5596,+\!N9@0.!>9TG)ZSFOV'.&SJ@]V
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M-2.JJBB/=VJ]*]Z(9BQ% Y[DE%'&H4AUUGU$(TBI)V'D"^YC+V$$"2L7C>'
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MO_2GGS[*&WY1N>YUOGQAGWS-C.G"UET/Y3CV$T%#JHS+D*O]@>]#[(4,DB#
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M#-6!J7S3EE,GM/Q:Y/)XG\ZM2*QWE[_8UU0B.(/74/4'C@WY6E4'SJA_IM;
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MT,H.&N%[^<LL)L' 138,M /SC2FJ?1QA%O!:^+Z&@7DD=]<:[K*!^[F%>]'
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MHXGAKVY*3&:&$?(&-/J8?]MJ!!J5 'L!??.N[@Z//CA/^/I-DKU2IFG39_T
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M8,)J<1YPV"\;Y^.!PUP')[H;FS/")CQJD:0T19(S&"1Z,4.*I9!QL\HA(<(
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M)+,P,K>]2FSMU*B[/VDC==LJN5.EZ0O5*S/); S..QYI5MXJ[=C?[%R3>SP
M5(?48Y>GOU7F\0 $SB0>#WF:V^(E9+YX;Q(+2DG?%T(N)!,XCE$ J4JHV9EG
MD$HL(0Z)B"1)0QE:M9T^?/#<%ICW==*+%@X8Z>RXZA58Y]>":R 8F=TMM;?F
M@E.J'C%'*\G_[:'X^>_ZEL82U3_4GW[]V;]ZT"0?\BGQNT_SY+\/+0ZYUN:F
M%!]I:9QRU2W7B\9F:8(+/TB5\WR]B#D2 A$"E>#:*B19#*D@VDC,!,L$C8(P
M86Z5'R\-.;</=$="(!H17>LS7D39;E/J%[N1O^Q.6-!)"W[91;(5^+2I/*!>
MHBTZGHLA7AQVXDJ'MC"\+F-H?>? ;&%31X_1RG2/?'J6JZH)!=K627SWLKVD
M/0*HC\ __OF<E_7%7>H,5@AS1"'-H@@BB02DA"@8Q3C!/&0(A6[)Q;XDFQMY
M;>5KTV,<\Y"]S9@=P[W)/(Q,A+7 L)88[&JU5X*;O8#=ZUK5FMBD&[ SB[Z3
M9KPC[C=EVIMTTV98^P;U54*V]P$&5Q=?ESE?M\TG?UOEZ^K[C]^ZFH9*<AZC
M%&;4I#6JD$$6$FR:=>$H%0G1'.Y8-?ST:'-CWM_J#%3]+9>]U&UMSXV1V[G$
M]QF<;:U'3^B-;CCV>#5%96M)P2]:UNHOE^,SA]39OHR+[_K99T:<NB[V9>6/
MU+NVN&EH11EM;QJZNE/GBLL@IF0<(BAIK"#*D@22D(0P33!.2(QP&CGM2JU&
MG1O#]$*;&(VCM52&]MFRFP1+D\XWM&.;:SY0'5"*Q@$ESU5I;$:>N$"- QBO
M:]6XW#S@A/7KQM#<G3J:N5PM4(9YE"4!Y$$J(0J#"-(T2"!6-$@#+*2>!^MC
MU/-CS8V0&FG-=_-\O'"#PTG<!90M#C_]83<RX[2PW:D3Y1,\PN9P2ND/OHF.
M(B^^?;XBA>V0.7N>>.$1TQT:VNFR=S)H><L5!05-"VDI/FS*?/70;%/KS6SU
M\>EY6;Q(V53N;_N_?M,O0;6(A,@D8@',1,HA2J6$A$?Z/R((.:,JRT)'@W"0
M''-CY/VFZQ5=UH'VW3943PN0K2Y=WXFN^_&S?D[="*5N?E)9AK1<.XVV)N7H
MDS.ZD6G ;E0 C0ZM9^^F\0-6-Z!3I&NMTLU,K8OG(HC#P?1?(7& +-.73QP.
MV-':BE<\;F!1A7RY-,[#IH##=\EE_M-D8U2++$U3C&BF#=8@@RBFYL"7*4@8
MI::N0J285=S%Q9'FQI6_/4,]V2;-H:O$G*]^%CF7CF<FIZ&U8S<O@(W,7XV,
M?5^\"FS%]%A:X1(0?FLKG!QMVN(*EY1^55WAX@W#&.*+K"HI]W,C^O2M^F\F
M[&N1IAQE$:&0IXA"1%0&:<8PQ+'"$4V%H,2I"(O=L'/CCH,LJIN=7,8FK<J$
M#+O1B"7^=ISB']61":81^ :\RJ3:IO+6OZB#2?U1CAM.7OG'<NA)R<@-CD-F
M<KQ[H"&SJ?*5'NB6_W.35[G9@W[1OZA+O2[""%&:!3&,TE23$X\U+R6,0*DX
M#BD32<*<=H7G!IL;)76R@AUAP>]&W*:FL>.1P%F<+0T;3^B-;=L,!L[=PK%
MQ*^1<V[ :>T<"]5?F3HV]UP1FO;N54"%"9FX+^F*/\K[/XKVN)T8*X<H 6,6
M(%,EE$&6ZI_2*$V20$0L"IS"&AS&GAO)U**#=T=BF^J*0*WX0,L_(.[,<CHL
M?4;C@#RVG^A83-AN9_(=A$<(C1@ FO_P+\OQIP_P<@/F: B7XR.&<=OG%2^>
M9'\NVI_?(QHA1"6'(HACB-)4OVE1*&"&$AXK&M,X4RX\=F*<N7%6(R;8GO,/
MC9(XA:L=(7E :V3R&0*4,\5<@,$KG9P::U+JN*#P(4U<NMP]R^Y6/T?46>=+
M^K! $9)9EL60R"PTD?084B$C*(E^/914,LV2Q4]9LL(FT6[OV2ZO\NX(X[W1
MO7C R&>?:[</V?GO^RH81OZB+?5WRK8[JNN@=+O])TV6;W=4@=V$N^,7#%V+
M?^H'%>7+A[SBR\(4@.C7C50AQ+,@@"P(4KVOB!&D<1I!'B4XS6C"!+.*'+(8
M:WYK<BLJV,IZQ;I\&F/;M=D+<J.OS\- &[!&7X3#\SI]>KR)U^J+BK]>KR_?
M,B#H<+M;Z+(YMKO [7;AA]2*B=O5*M?K:47+EUNEO]Z_ZG]??] &Q(\-^R]I
MPK;OB\\KD?_,Q88NS<E1OMI(\4.6/W/>=@]?,)2J,!,)9*')W4@R#)D,)50B
M"$(4Q!E!5LVIWD3ZN=%;LXU_9[6-OP$-#F '"% C 6HH@,%"7]2A80J7;O$
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M6(:SVH!MM^L] 3BR"#ALH5T3"O:4^FS==1$.S^VZSL\W<8NNBXP?M^6Z_,J
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MW6R=9/>"M==]8TJC[02EKVRO4T\,4VX^T;SX.UUNY8>\Y,MUN=5KN&\N$_&
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M_W8_F&7Z77Z*R9.;^^2# R-VU^7F0UY(OOF-Z@V4T^6"$J0PIQ%,TX!"1$@
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M)&$OY0=2K_])+\:K%J+Z7XJM%)U+\'WLS'?Y<_-.4_[/11I&-!94P# D%**
M*(AEBF&<DC2AG*@P=7)^#Z1C;K*R(?IRY+[7Q1AD(H\!\=1&M%' 6L@[7!Q$
M[!E&0,7)>+:V*Y9C6N/6M+REO>X*V 6+WGFX0>47=\KF#WEK0@P?JHSW1M]L
M:D^9\[/*,]WOSB3D.(Z#&+(D-9>%60@)"D-(XR@*54PC)J1#-<9A5,Q-4#;T
MEMV:757KH)VI]?[(U*KMVF^Y?ESI$] TR&YKKUD*VNL6TD)?G6)Y1A:R!RR
M#@_@59FUN@1'Q0>P$;(>5\*I(N3X*S)9@<CNRM#.RC3N!_W?'3?^RD->A]^%
M:I$#!Y^R>.1U_+^J)7GE8&[GEI#YXD/S;?['EA9:L"]?OLKG=;%9I$01')G*
M_8GIS"T)@S0**"2!3*-41FD28+M:!3VSN&RB:4H4M(2"':6@)M5.;/4AVG\\
M>$)I9.'O#H^U-+$ X(1:7$K^;P_K'_^NWZXU8OU#)4@J(=(WYB0BPH*I5@#8
M/#HP#G5)R_).-7DO=T65]?+QIRQX7LK[0BM4NU^6S6_+<(%2BJ54$62"8VW!
M,ZV14A7 (":9(H2$+'+*4AE$Q=S4TI9>\&P(!K_D*R",S"Y*\*QUSZHZLV,C
MAV&K8V?2CX[YV+JFH=_$##=$ZL^^SKPS39^;E:C8Z#Q3[A[R6!?A*B#]1MH.
MHF3:8-QKP#J*U[UJL&O:']5Y/1V'01NY(S,9)SB"6BXJB%# (<YH -,D5"A0
MB&?$*:JO=[:Y"<#:QFZH[?K4AG2O.8>PG7#SAMO(0NPL9&,E]%S"9(1^,.=F
M?(,F+Q>8/]VYY=)+_E(#ZJJ(E(9AAH2"L2E(B4*M7&&,!8P3DL:8I11QI^B_
MLS/-37Y\.=UE<%C]R?/XVDD0+ZB-+#V& N8E?V"\JI+G9WOS#(+>"I*77QAP
M=?"/[?^;?_O>WNL3D49!0D)(A.00)4+K%ZG$,$QHG"4R35!H?Q]P,/3<A($A
M#FCJ'%S"AU!9>-P' S#ROFYY'Q(/<@B"@[-[,!@3>; O?A!NONF3[/8ZG _?
MF,Z+?)+2 ]?PZ2>N*JK4?C^!""A) A@$(89(!H&6/(I +BDA7$@FW/(4#T:?
MG<BIB1M4^<C).AF,PMARI_&D^+<]3G(\1C6BM[ M3C)WIK+057O4N($_KC9:
MK7B_?GI:K[YMUOR?53I2>;?=E!NZ$OGJ88$HBSA*(YB0*-$&1!I AE(.922R
ME(LPC9%5?R^[Z>:VBVN*04TRJ&B^J7/G2M AV_[.Q@+QR]<W?G$<60Y<"Z'3
MO8X],H.N>"R&G^RVQY[5[L6/PUL#[(MOV^?GY<LN&.:>;A[E>O5YQ9L3+29I
M2)FBD" 40J1D"FF:<$AQIC(6LB *K'IDV$PV-U%2D[N/%+H!#<6FZL[Y( EW
MD"UL%8_0C2P]^E$;8M-<@L_!RO$(XT1VS\"/T,T:LH2EUSZZ-,9T%I,E-P<V
ME.T[ T3L_Y;%R\]W^?I9R^TGO<C;3<[ILMQ_OQ$7(E0\@B(+B):QD2D#(8C6
MVD(197'($;7WZER:;6Y"MJ(7'!-\XRID+\)L(65]@C>RF#V'FX%MB)"]")^#
ME/4)XT1B=N!GZ"9F;7'IE;,7!YE.T-KR<R!IK5\:H_';'ZM"TJ4)&?^R+LO[
M=5E%3/Z^-1/?J?;OY8*&/$U"DL(L0MJ&QE$(*8\QY GAA)$$,>%4C,\+57,3
MW36!Y@:*'C<Y*W?<FN;/%&QW/(*E9A(\-USY;"MGN[IV;KK)UVSD$\.B-=T-
MV+,%#%^@9>0&[%=[Q]Q4'>P<L9ZPQYTM93/J@N<(IEN?/-?!!P9/K%</IM>P
MH:53W#M."0W2.($9DQ(B3C&D2<"AS 31<IR&&<).D1,GIYF;%#940M/_&PA-
MYX".>6?0M!.2UV,TLM3;P_.A@N?C3[[<&J_9+NSJM[J)>E^@FGO$1"\L?L,E
M3D\U;:Q$+[M'@1+]3P\PL7=),*9SL%[;>UGH(^V):N+OV#)_J(R'O],B-Z+J
MO19 N9!-Z8\GDPRZH%'$0R(RJ'#"(:)*02I5"DF&,Y:E.$Y3JZ K+]3,3<)\
MU#3G)E7O*5_*<K->25.DK<J=!+]LG\%F;1G7[F>M+.SX*5=@9/G5L'(#=LR
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M4825/D<QH2Q.>8;M;UN/AI^;CE\3""H*'>[FCF&SN/J\"HR19507AR&7E<>
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M0)=H_;>>"N/.0LL%)*]RRFKB2463"Q2OI9'3NX/;CDH3!+/\O!+RY_^6+XN
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MI0PA34+UE40I3J0,,#>OJ'YPNG.S!2V9X%=Z__ ;Z+YMJ+:('!V&VB#"YA1
MSTJW0TN?.7V)W)ASIX<AM C$.85RHJ!<!R-]%5)7H3EC9 ;#=(='F2YD9\S1
M5OC._*X1FG>MT*^5A+\_2CG/Y^H!6CQ_?BQJO:^MP+?VV:FNZ\V1LP"GDD8R
MA2C4#=]8D$(B,(.<(B0%X2),S<^;C*'@W/1S0Q7X]TXL^XVR'M1%8%Z!JL<5
MD#5;>CU7+]P[,FRVTHP2FH%:]RT*SYI^LRK6](,^ Z#A 'QX;I;5:R; M445
MUO'@6Q@$WT*8R$9<;;\%1J_ 15L3UY4%.0;*0:,R:N#I[,PQ?&^9GJ,&\M]]
M]*H0LQAC(@/&8(HBJ@\5($BDH)#*E*"4QB01S%?S436_E26:IO<H\M< 4P-N
M8$?\PNC9BHSL/*J8\(N[O[ZCEOA/VW;4I1R\-AWMH>BRYZ@>]FQ;CO9X/J;C
M:'^8<5F+[:ET"^T9XBBGF,00L210AD$JFR!0#K,P2WF8T""0V";G\'**<_-"
M-J_*HMG8F"LB[6+_K^!H%KD_#IW)'(-VQ^?'(6"L@^3[>7<:XGYEFDD#U/O9
MW TO#UPYJDK&0GTNEW5'@-X6]NH]YW-M@^A"3_']CB[U2K75+K__]R#RE>!M
ML\,XH$&:1 SF3&]?("&'C(L<XC0A3($1!\Q(&SBCZ-R4QQ9/@/:8 G3-5:U1
M0-7PM>G[+5K.QK3W="!;@Q7IU!+SK-"VA=7G!VP8JK4<:%G:K)8ZIL8T%'4@
M+*OJ&=,*;;+2&<[>-'<M3-TA?:!DAH.)IJR7X0Z7G6(9#@<>DW"EA5JA%]=J
M_'OUE#[JCIM??[;9JT#9R"B.0YCF@5"V$N>08AS"6*!,1BQ-PL"H/<7!F<[-
M!K:T@BUBP=>?-KG!(6!-,JN.X/*=5'T=*?!S5#YU"#.;5*HC[*;*HNYYVISE
M3PW@&$Z=#@TP8=;4@(_MA*G)#2.4YA^+DM'%)_$D%N6#?D!T5+PKI,Y#QBF/
M()51 &.*&"293*' .1(ASF3(S"M##$QT;BJS(17T:*V3;Q9O_Q"J!@K3$5:>
M]>4>F,9HRR&\+)2E(]PFTI4M?KR'GTXKNE*5!F ,:LJA^Z=3E 9<;.E)D^O'
MA6.[ DU7<J!B\8TN>SX+LR1(0HX@1WIC'Z$(TDA(2 .1BXAR0F*C#DOV4Y^;
M*NTHUP<IADMQ@]N: 4.M,4(H9C%?/U![UL0.4;8.%-L#YC2 ;#']I(%E>UAV
M \XC1ABGV/;[[74[AWS/GV_4ITH?R"B+ZLN\$)<K<5_-,*:<$99"F4NU9L1I
M!#.=L&)9QC'-*8\#/GL22U::*C^7Y-F\LWTB3Q#UK#>B]K]?K>[$$JSNU IK
M^Z9;S1ZH^;/4GDXEST1"2, PQ#(3,,YX &E"$A@J%R)0/P4HCFR,WJGD/H59
M_#+/1=$D[=9<=,<P:S%_:[H.6IYR<BI/,WMY*BF=*AGA^+6T-K<^\'9JD)T2
M.*G)]@'MKE'W,L<^L]]_ZM1=_[S[I?M%_<=H)=[]\C]02P,$%     @ (H%D
M4QM!S?.&M0  '& ( !4   !A:V)A+3(P,C$P.3,P7W!R92YX;6SLO5EW6TF2
M)OA>OR(F^W4LP_>E3E7U46C)T4QD2"TI*GOF!<=\D] ) FH 5$CUZ\<<!+B3
MN@#NQ74Q\U060R(IN"V?FYNYV_)O__WKV>RG+WFYFB[F__XG_F?VIY_R/"[2
M=/[QW__T^X=7X/[TW__C7_[EW_X/@/_YR[M??WJQB.=G>;[^Z?DRXSJGG_Z8
MKC_]]+>45W__J2P79S_];;'\^_0+ OS'YA\]7WS^MIQ^_+3^23#!;_]T^:_.
M>UU$CN"UMZ!*T."XRZ 9=YALD$:K__/COQ8EBF!8(#,70:4<(*!,(- 9YU $
MQM/F0V?3^=__M7X)N,H_$7/SU>:O__ZG3^OUYW_]^><__OCCSU_#<O;GQ?+C
MSX(Q^?/NM_^T_?6O=W[_#[GY;>Z]_WGST\M?74WO^T7Z6/[S__SKK^_CIWR&
M,)VOUCB/=8'5]%]7FV_^NHBXWLC\NW3]].!OU+_![M>@?@NX ,G__'65_O0?
M__+33Q?B6"YF^5TN/]7__O[N]>62^/<<IOCGN#C[N?[HY^<+ L);_%@)W?S#
M];?/^=__M)J>?9Y=?N_3,I=__Q/2DE URKQD=;G_=O6/?[Y:^?,RKP@L&TY_
MI6]L/Z.NMB\5^>LZSU.^X&OW^;-%O/%+LRK5Q7+W+V<8\FSSW4G*T\GFDY^%
MU7J)<3W1":-/6H%"$IK*U@*:&,%R+WTH(27/;C)="5X1Q1LEK'+\\\?%EY_I
M@W^N@JA_V$AD(XT[RUU(Y3"Z=WON _WNA 6IK(\!K.-$N]<:@HX*?"[%&J-3
M$,>1?7VUFU1?U^:S9?QIL4QY249CMQPNXPW-W@7L]C=^_HQ+^B"(GZ:SM/O7
MU7KTH:OUH@?)7:B%R/W33\1UR<ME3K]>:.5!YC:<K<F4YLUO]J'Q_W&.2_K$
MV;=W^?-BN9X$;7EQQA +DEC09 &]0 &9FY2""C'PV(OR;RW<"0>B?1P<(\^#
M(4$,A$6/H'B;E]-%>CE/+^@ GMCBB?LH@!-\086"X)%IB$&SC,9ZRU0OD+BQ
M;"= R/8!<;@L&[$0'Y8X7TVKX+>0UA:%E0*AR.!!,=3$@Y40C$W6*Z:1^7[.
MAULK=X*$:A\21TET9%2\G*^GZV^OIK/\V_E9R,N)5JKPR#E8*S.HJ!VYU]I
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M7_UM$M"3+Z=8[=T0:ZT=@O-,0XGD^OG"6,R/I0D>8:TZ4CA.#XWAX#:(9AI
MW.OY%Q+18OGMM[R><"9R5%D"ANH3V!0!&=$>;$Z\)".Y&<9[ND[%.,TVAD/.
MP1)N !W/8JRUO:MW.68RL01_8F*7(&,STSQ* Y+I ,H% S73$IP(]3O2:?]8
MO<H1-N@1JL;IRS&@W>E+ PV@Z>TR?\9I>OGU<PV5Z?!^L_Z4ES=D-HE%^=IX
M 'BJ%: \>@BY%@D'%AES2ADVC!O>@;AQNGT,AZV^]=$ Q&X27Z0// :$X'7M
M2!#(^_-T-#.?4C921?2/U?#W%-.-TQYD0)-TL(P/!\ABC;.>;-#B<UZNO[V=
M(8ECGFKL\+G>E=336619&/(,R<4,=$QK\"R0%Z=\"C);J0?R?QZCJ@5/NI>K
M@-Y$/^J[YXZ;-\0+UHSR7S.N\KO:]/5-^9W,:!78A/RXC(I),$G2KHBU_,B6
M!")E%<F>>CG0,?8H62VXUKU J3_A-W!F_66Q2'],9[-)D#P3Z"U)1&E0PG-
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M,Z1O*S2)S6!6?)C\OGO):00YQZO[]@O T;)O $#7FGQNN]$XS@*Y=P%T2,0
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M2[Z(M2 "\X%"'LO9,'+8G]9F#-MQ:+HG"!U2:0U$JK?"[(0&D20D32'B;8B
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MP375//ZV%PTN1XE%ZSKIAM6:( &8,@.6=,I66Z;Y,#GG7:@;U_@-@8J]@'>
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M=G&XW;=<FQ*(<$@L.*!]Y(@/'<!&8M/4[#(WS%WNHV2-ZW/UIOQNH#I $PW
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M4$R(+$)$S8M#Z[VP^]B'6Y\_CJ,[K#$X1H0-7!(^V"FU:&58R!:X) ]<Z>2
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M,4"%9;3%N) <>/7_L_=NW7'<R+K@7YDU[S$;]\M:\R*[K1Z=8UL:2=W[D2L
M!*3:355I5Y&RM7_]"12OHD@JJRK!S&);MF5>,P,1'P(1B%O18%@30A Y0@PZ
MI2@MJZH^X^+&7\NT]89/C^^[]QT3HV/BID+WCA2OY#43+2%@&RDN;8!0@H,4
M;%29- IIAJ![4&^A^RB8%I-3(V(UHGBF[E0W>/2XK554C 5*\:T9B&'FQ%)
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M6V1,I1#IU"<]YQYB9F(TCP^5_=A]I'=$)W?,^Q%OB?C13W%/='<%US=%_W$
MR\;N>C?LP6.QZ\D[V3UVR$L2-0C6LTZYS)LRLV67MM$CMO*,,-F8SO=+/:,
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M780V;SS>+.QW_'0=50JNF%(M:*4"LW%[Q64R%&]KR44@8J=&O[L1.GE/]#Z
M&0[,@Z4W=:3W;VTLQNHSE3?K53G/9V\7'SZ>;5ZNUB_.UU__7.#5P S+_)/>
M@VBE(49N+7 VD%5I<U^$J2'('UF,.[QOMK@Z7-ZKOLR?@;)[7>MON/X7G;W$
M+ZMU.Q9^;7V2+A=CE3=15\74\VXT21@(I?)9X=FYRU5:5?NHMD?)FGR.=G?
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M;"P$)O%&CJX&2*Y0(,M_G.["D.<9P=T%7P=$<'>1VKQ-O^]B.V0P)=R:L13
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MZ<7IZ>H/7&;:7(U2(I-L\R3!IVW+]%0AI,KN1*HM@;)6JX=%XX:];[[*9!<
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M[?D8+;X8:WS(G7K?/T#0M&'A$;!P5Q>,P?CYY9)L5[5_ LGM7Q]!+_1,%7D
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MU"[V+$L,P]96)V]&$_PWKYY8]/L(;C4&%Z<6_T6[Z$O"C2+I5*R 5@D^M<A
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M )/$((VC[7R8RZ>/43,FR!RBXP=%3D<*? 2@>1YFM:3D_ OBZFW]Z6NOC_F
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M8>H0+<\'$GGK"_S7U]3/$UZ&Q72^*:>7++K:Y#\Z33Z$+]L",6%X$9F[;.(
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M#20#.3FR>&8%=]U:$QY#1<-Q=FV1<PB&CU;C2=C>==GBJO+VX1(GRK%8, 5
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MIR^8KV;XH3RC33E/9U>KZ3<\QU33Z[0]4U@QNR*!OJ:%1;OXUZN-RCZ4W4M
M%&<"XP4RJ\5IVM#V76@Q,)XL22UCD,.TJ^V?EY&:KGU0>-]T-5;XZ&U>E<K+
MG5*I2GH19NEJMG[CO*Q_M-X?OO.0(_+@0Y+3K_T=3E)#6_% >[\)UH$)*M5#
M9 M!1@D"#4%9&L+K,*FN\5OQNJ=.1.:)V6"A\)!!&5>GX9"3)(L0PGNTG@_C
M0_;+QTBM]S[H&\YZ[ZWH$:1SCN3Y^??''_#LS^ER@K8&]76@&"^:]E15BY]R
MO3-E2\C*,<^&&:P[(%-M%T!+K,['"9S1KJ'WX0)?SFLOGXGA/BE7&>!84[PL
MU1LE%KAF,J=@S%#N^Z\H:XOFT4"H$[0/U.<(\/F/4(?^K-[A1<3%1#KO%:UP
M(ADCJ)(<1&L#9/0L1<<-X\-T_KA#QAB1=ZB&YWV)>P18>44!U?P[XOF*PM#-
M@+TM(YY)55!FB$G4AJ0Z@O<202LA24H4/\MAS@UWDM3VP'I0#/6CAA'@Z0S)
M19\FBE+7K/QV.5TMS\Y_VS)39.+:,@2A(HDH6@8NN@16!:Z3,R&58>:Y_)2L
MMB?2@^*J/W6, %M'^@]O;\;L^8A%"^? !B9 ,4T2#19!(6I;/&.</:5_MC\'
M;2WAOTY4<A@D3G\I;&N<LM8^UM:BV2F2O"P)@HH<N-4ZIR*0RV%*,GHA?XPN
MY=#(ZQ?^!\!@^,.'[0?U2PQ+_*]_^W]02P,$%     @ (X%D4]::=.1,&@
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MZN@44F'R)(5',G(=*OP='H+58F0C\)2E34NR^$X3Z$.-3Q=;K.LDFI$>@5:
M'GGT>K"%K<<9P?T"B=F%55NQ5%),AM(]/&RU\6'EA*.;^NY^]>3L&SP(W( +
M0:R5E:V8= + ,C5WB U#KX[-@8--UBZ31*5(XUU'*6JPZPN'EEB-(_BK@^::
MD[X,R-'38BM!#(!FX8I:!(5$(@\/R")"YY4E"]&?H@[Q3=3]: I>-%#+@HX.
M"T95D-Z*AU/" $U#\V)E8S&11=JT ITV>>BRR!S? >8*;^5(9<3- 2ZAH#-1
M8%^K@V1),X8*Y6HB8BY4&(.KD,;),.T))U<409Q'K<L80AUW@]A-T&Q#"V-7
M ^.6')O<.SXKTLD=BKDT+Y,!*DX2U!OBM>$4C'T6L/[A5>,,]!;AA[%^:.\*
M:O]E866O35BY_>Q-0Z1M#UC.00$:IXE$FV=;A!'RDZM1(4.^#OF7<[Y5!7 G
M,R3@^B!A)"H"3)G/@(@Z-I]DR./@-D+)>$HT 08:#B[@?P(ED[0!UN0QLT'0
M>"/%-<T(@-R(;4&A;40Y#;,T]]7@/H/,5XSVP52UGT%D!"$E:MD#=-*40B 6
M\5*\F;  ^5CTH. G/RT(%"@BL-!Y,#0@DLB]8E08AO)TTU;W6_$H?IL\R@O(
MOLW,Z\\$@]OC3,H%.TR-YJX"5%S=T;PY&F-:G49&Q#]#@$7Q6(KS*F]:./ H
MUJDEDW-[+V9R[G_!(<'%C!E_4>DD\G$,[8(Q/HZSO^FT0/V7!O,WY)4O "(Y
M1'Z93Z$3BJICL[7._:V;Q_YB'3ZZK[_T8IRN[YW6?ZYI#*A-V[O;M5%X^21_
M>X)LVR9='^""UEP.<%:>UR<X9PN[#!0K>3WB0A?"I+^6"NVX\D!+@=X5JFI,
MY(P,56JKU6C"!1UET[W*+]3DR-DLT"9H5KBH4N-LB#:(N'1.&R*S\/*.JWXK
ME<0UE<^;>@;Q6TCTHY(PB$C#P36,^SL(_$>07."OX#MU^&>FDPE.0D(^\&D&
M^-;O-%7I%XF G+FWE5$E^226Z+^DZ57,'F[4G8HI"2_1U4P2VDGG?(G04*5S
M9!Q+*,:^PE&,-=E1QH"CPI.I&/&2D73@W? ?=@$-]])4C]VQEF,2X&MF3/*"
M1!![.\'GC0<CA^S\V3K-$S*[5&)+A"-8[B'EJB/G$E#H*JG&:A8W:N3L,&?$
M=)',AVV3IDZS(.@8LDEF$!TD+? -3(E@B=\BL\<;%O8!>$W1#[!B8>I:;T"Y
M#[GZP!WY0'U+[%/K9FI7V8K;9*$!)*\YN%U'+E U(?BI1-UTQ=.XXC?5 6NA
MO0_5%=GP2UED54 C7<DU.F2CU*M>9KGEQD5:: T%#UDLM"9GFC.ZY-2IU@Z/
M\[JY4LV/R9C%)DT<<F<X''"M0T(%R_=4'-D.T]TVC+@>.S%,LP1C"E?7W-5F
M$)&90AX>O$OHZ1G20[1TW,SV%)HVDW'*Y;NU@B8<))R=H:)<ZC7^YS%OK_F=
M,\E9E_%*^""W2*%>D%@IEC=:,,.Y5YR6@.<!#)C0[,Q$P0#>(ZR.F?A,:Z16
M,<IV&DN/W,R G8X82EXA8?;1&<71E&>C*SP"33A),9(:)11_!)]X)X,,WH\E
MU+G'+/441&$E95I7N<!.?9=#B)DM+3GA&0*?M#!?5A%).HFC;#R!)@[CZ".,
ML$P233:"LF4,E;\[&L?RWC*<#D^+E17'UND1+J()8S.<]SR,>%Q^&BHJ:-/0
M4IRNBL)$5>XK-!^?A39$]FD$R7,T>8W@4NR9.QE\I9DN*D[FEI6E/(_,QL\U
M F$DHF&@Q](Z(A_ YIU=\)$05. K,\:J:#+LV#0M5F#TIKEJSL@&XO>DQ#B7
M?4G1W=4ZQ[YK"@B=P!\3P@C8/=[#+I_S"N0\,3882**$>7XS+)3L/R#9J/MM
M5PX(#^CWB) .429)88U :7G:"UAE]!;T,7"$%#6_!2PH1H:KANAFZFQ*6HX7
M-?1BZ3#GLQS5 :?QI3\()A:QI<O 5BTK>EGHKVUSCZNT].D4Z9JAX=62.N0"
MA^LIF:CD_J2*"LP"$(3O@*!U2.7DWO$#=H[] ;#1+"&K%V$UE$ S?7#/*HKO
M9.^SD;U[WQK9V^\=K<\MZO:XQ4'WX!@%<9/G<EX@,USOR+E Z!O4/%1@D?2W
MJ[BI%Y@V,&YE#V-)ER;&ADK#BB[V/K=&CH-C;9F!(8Q(;S7L)CP,RR1<#43N
MBZ#A8G,/"^["=)(4EW@5BM8(IGO-WM\54BP!"1U#$-%:M4KJ$:L['64)""&'
M&YCQE5,23&.,R/<@I&)F]R 8\600L5[C:)%U]+N,GFK6\7DV40V[-G@^V1#\
M3''^1&M%GF06(QUCP4X]VUBRTNK9E?ZA6O]T[+QFM6^/WO>/NKT]%,4#H"4Z
M43=U5&/-S K[XK+ZY557J%,CJ8,L)FW&(ZX&%SWR!5M>$[=&ZQM=H:RO$R]6
M;&F88?N*FZBV.J[8V3::+ P+^+EA.O:R*2)33YGI-\.ZV6>4;+),Q' U.BT*
MI@)J7-MXKS30.*S\[A4V5N21%#H-5-KF?**(A*$Z-^M5C-4TVHKE(!V>+\Q=
M%'K[>:O&UF10]TTOE7Q2:1*1=L%@&I=F:9\^1^FJ)"^*I=F&STUH-)O@DG'=
MQ13)L.JX(H%L@V8P_8RW)A$XQZV)!^/E)J2>6+951C,US5J":,0FSQN8I2NM
MYY?R47E'36X#N=0 A'GJ8\G@\LG:$.-B(@_Z[.>$9&5"O[2\RV@$O;HB%)HN
M*;MS<%6^:0^H#N^: K^8AY1TH+BW#I',^01/Z%KMNRGRG+S&<U*[-0CPR"=;
M$TWN+Y\_;:ENMF+ZG1:C+\KL3#5\D&^B.<*2!M3TZ'F2K@)9) ))_/K"96+5
M-CU["O90&O>M\?#R+C(+3+! /,J&::<T';"4+D,XE%0=?J-YUZ)\*:Z;7<]J
MDF3[7D4X?R?9GHUD&WQK)%N[)B/\K9:-^CVAXQ(]5&+1F?O^Q]HA3K=6N@6N
M#-<]CPOKWL%-#K?0+9.[M)P&/#NF%0)ZU"FL-6B:6C.>TW@L.%!P?@;EYK"W
M]%YBR#JNV-+C^L@JQ <43A\T,]/8^2QO(.?X<HL_+'2?17!!Z4+H5*)!OA#M
M%O!;FE$&;&"4K7A0X5B.C6BHX'.FPFU3YH!+7O/=)#NK1%%PUH_KMIU;*9>U
M4?#S[19[,JW&7(W)S^9>;PN#Q9+X7!9G&(D@"G$I<$&P-0EPN4-5!"]Q?<C@
MQ:P/><L@((O-4I#W<!5@!\( J-S@8^3Z"]R^D0GOME7M\P:@]3(T#Z%C@.7=
MB0=RZU!JB95;+@&CW?0"\&^4D^'.DK'V&@J"9$I^C>B&:GYI2BF(\*M4U6!I
M6^Y*B1))\H+!4E)KB[IY1UZL!:R\!@$/I%D)-60%^X*W5NFWZBH!W/T4&ZM2
MS?PA;8>*OE^GDH_H$.NCJ.\)EBT6-J@8X=ZJN,1>IQCD:%$JT4VV\)@$2GZ7
M$X#"5J6RE /C'C4B4"ENM-#4D<*?^9I\C,>X.O?2Q*""$#<OJJW#CXW<E#J&
M1R[ROI/@WT">$42S*>V^XQZW]7TCJ:^VE/5\82K^7*I7GCDJ:K[ZA/6DF+Q*
M[V,8S0/ECQ77R9$Z&0I[PMO[(*U"G[!*.L:HHL3MN)0GO+1O ZB?:JR#[N0?
M$ZH<=^IN62(^+;T_,UPRLN0^;!B8OZ>4[XI$56D7D-0NS)%QJ>;80I\#\+J;
M^VY3%/[J0]Z8\@X0SM-L$8RUJ)5096TSW[Q:F>8AXHRY 3)B.SIC%4(B[KR9
M3>=MXX[J#NTEPIW]%P-W;HWVMNN;";=-!?L8$*CLB5N,-J+<EK:Y:>>66=X^
MF_1^KZ3W+U&U#EZ,:GTP&&G]2QU+M?]+EVB,D62/-:\#-#,X<SG&3<YX/6+!
MF<[SOIGG/S;(-,XP<;C)*[E+46*B^#ROIP2TF*"#-<7?Q*O:/M9\?RD*@D^?
MSG"#N9E<%#;EL&@)X2>N@MBLK=4PV[ _N-+>S#'GT\M;O/>4_ 0-CI6)<]P;
M$J@*?%Z[8SJ55SKF)E_\0$%:&]<J2U^KA#=\2))+BV5;7VB!3;0AOKH1OI#3
M*$-5SG!9BU;<'*ZOYW4%(^5CG.O0'DJ*<'@0>;C)2JXY* DK!T*,=-F$!.PK
M(_3"MFY)OOX2OS50:545FO.T-,JZJJ&FYO\OLW7A??/M+M>A)YJ>$_2@N^CO
MXI[BT;S^,0('Z7,$@0L25@,'7$RK[JK3L1:!07XTU(C-:6+8R!XO+L"WPGJ)
M'$[EP*4ACS+1XON6"2T@^/>_ 8*_):CA\,6@ADO: AQGX%JS8N#:[!Q&^8O]
MP%@]H0L-SX"!V4Y>-D7GYKMS"%)R=K0\IA#U(9"Z^@ *?R2DXE=;ZKM5FLT@
MT;>?V:UL,:=E2>>XXH%W4NDDQ'3HVMCN0>GI&8J.0T3>^)SLHM!FWICWR<ZK
MNCM*Y5T%1U[<8"=_Z$O$[T<OQA+?5:)C^7O!:X/RU4\P%7;R0#U%R@Z,Q,&C
M:HRWQ"@O/$2<G.\EFN^&0MO5(JD#=HS5( !,9HL29<)?/%'.6Z6UE89NE]]1
M%H>\(T@%%<&3SQ=%'&KV:R6"2<9+_$S9/YB4@IS#$*"8*RJM[6)B2*P2MU)9
MQ&J@%5*S =+7Q5U#EA51E?GFYC?GY5IQ%#QRO5Y+[/;XA=KMROJQ-1NSN%U>
M5HK60]_EMKM!WUM96N7].YP8\$RKL!O/KWX&%VH53+NBT0]X!-=;+WC32Y<9
M-Y0V&G.H?6JF9('WUC VEFE]K_3[[*WQVNN)^KWVN*+^:E=TEC-@1&"L'3P4
M(^<J=FZ3OA)0,K1\[P$P?@/ YY'[T(*'-(B*,6P#MJ8]Q=R'"QR]@5^#!.1+
M12OT2HSW]JHT&O."!.<>['[JT%X79FD;\OS#-F8/$FJK7-I64\])^ROY(B.L
M,9(>U>, -,>Z2J+Q_,C+[,J)*8KAW9NW5)9$FYO$4:@]P=]BRF)E,%3YLZ*=
M>NN+G78WDV_&"]WW(O/M*_)%E+S/OKNGLES&TH-#;>JJQNB[TQJI1=>Y_=\#
M-::BGOPN%T F*JR..OQA1K9IRQVEOK8ITA-/Z'M\W@.4_/'("AX\#D\\"K5?
MSZ$]LAL_O#KNG]ZX<4<:QZYQ[\*YO>^+W%M SQT\D9Y#N6O_QPV]ORN/#_H]
M>7@X] ;>X&BX._3D\3'\?C0XZ/L'OP\VUD[I?6,?4;VZ%A^N;J\O;V[$AY\O
MWU_^^K:\XQ"B;D_2OJ 51\@9IHLHX 9I;B?#>2X[G^";;;[BIA1OE> >(M0*
M\#CH'E0K8\S!%GFQ5EDMM>GLWY?G5V?B%@;_[-WE;[=7%S<=<75]L:*DL 6"
M_RPQ?[8&/E4[UR2/\P7M [-,++^O_+>D\^TUIG7]7*<17T,.P%]3(J $/PX.
MCT^;@5&[;')=/V]Q>?GC1/94/_'<HD;2V>>N/27H/GL RM-NSDL)8OC-6U>]
MK)$X7ZS=J:Y.#N$?:7^M[H@="MC"<A3PC,GB$S/<KY[Z/9\H>D]-_RN)\SM,
MG &Y4_$Z?<P-"X?>Y3NV;Y]+Q/J&E\[1_K;XE9%\\@5=Y-.2P,,OD 0>[7>/
M#SX_#WQ6]3]L'.$Z;=[:IA;43)A/7KA=VQ_=^-7H^VEW/8(2>WIB8$1RW.\>
M'GU=3NHSK'%G&/D+^&^23H.?_A]02P,$%     @ (X%D4Q,R=9O@%   N7P
M !X   !E>&AI8FET,3 R+69O<FUO9G!S=6%G<F5E;2YH=&WM75M3VTJV?C^_
MHH?4[($J&3 F@9!,J@@X$^KL35+@3.8\3;6EEMT36:U12QB?7S]KK;[H8IE
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MM:Z 7/.9*E%D7!S7#H@HL M#O,FGI+3(N&V>I%VL0.$[2;TMO-%T!J\5.9H
M%&"1ZJH=QK0]4LT]5O9UV'<I-28=4<#=?&Q&5\M[MOL"NPI3(']]AT"],Z^B
MG878$N8"P-L,*'VQ+P4)9V,\( 8S=A%?M :D^JGG@5ES?0*V*991KC9VU=F@
M,XW03-::[)#%]]AIT8P5T#98AA Q([7<R&>HBAT%<9.P/OE=;;V 6S#FTB6(
MY$W5D>2,0W\?S4.OC];1MF^8@JZ;1&6<=!5&XXQ:QOE!Z[.-MB?<)-M#OOJA
M33.F[0W$PA['H)Q9:%D3X:V)-PY4S\X=0&;9-,=PU@>H)'EY:1),ELLUJ]-M
M"%:TV"])W=3W 7<(J;9-NG9'HBVVN)P2=DR# Z3[T.AR>DEA]B'M!8UNAM4V
MLMD-U6SVB80AWE(OODD;(LQ8&L]:ST>IG/P]6^W6J1K1)JF&<<N(8[E1!5?B
MPT;L[L(<#TF*S:8UP[ 9>( )BG^.0+52GSG$+MH)2<WDH:6U/;$=:<L5*)H\
M+L(Z:TJG9LL*FEN;VO03"FP#FO-'?KOM6-1REW8]Y'3LL@,RT*N[9@B,9[B5
M!?RK&]W)-78N<#W%$B2*/+D]XPZL?F@B%,I^B/ZK7L)JU)IP)/08D=1A+JB.
M:%K<^3W,UUH1FWXWM!1)1%WN[8I;M=C'%MW:"ZYRR.">L$LI:O71^66;58=3
M$7ZAMCUR@4 %/,E+6B1NRFP+0E"Q $[Q)*">7T+ZB0JQ2[ 2#EQQRS?F=,V"
M?TUPOIKBC$?">>!J[XBNJGLJ7W13O#.O3O2V MJ\'?@8."Y1XW?%JH"ZO=D8
M9-=Q@VP[DL25"S*TC,42K7%F@A0*%.!.JA)UP+2'MW=H(Z1KERR!+G7:-4G5
M)",A1].H26!*^Q)_K;J*"YZ5,]N3C:2K#P^$$'O;F#8\W9JTX3N3T8:@U\#>
M&[C+&>2+&G)=;RYQ&WWP9J:2EFP,&%8 I DVJ.H0R!9X#?2]H[33G(Z"P$ON
MG+!:\PHWA5B*F^52W.RR0-+U15 ?A2E:8G1;60,?7G8<%^3AHCE@ CW8\ILP
MAPG>09OPV3_J6]=K96 RJ^58RTCR7'8T Z4J[5'L5DAC<_$";CX+[9$8:)TQ
M^40!L\:SO&J["&,LQ.(V&UDL:E A8,XJ$CW)TYE@O\+]M8DC!W C,4L$9O0[
M%]*Y+P>3'\B9H4.]/Y/QZT_&#[8C&;\F@UEI^NY%6W^N0?5N&ZJ'5RXJ[23K
M<"GN1*(R S_\<-\.('XF5AL1W-N%#2I<4%([#N1[Q%8N(X#](2X!3R"6S*3M
MN1,^,VO?[@^U]7G<*BPSG:$&S2[WDXBJMP8<3RA$9&$TY2MK.X0+5]%H!6Y^
MJP;X^MWG/E%BCA&LIM'<?5BE4,V>84I-VY1@A@T^D=E'G1;"N,EVD@="//(=
MC@L3D6*,X_RH@^H^F=%?]J7;"*E?;@VD'M7:0]=^:I@++4G2$>[9'CNG3Z@0
M52M+I;J5YAEU:<CZH"'KVRA-_</-$:?^P^(T-%E5H/W&=%U=VVVHOF&QG>Q.
M+2Z-EK8M+!6O;!6(4GM=W9WUO%HN;!+9-=\30>BL!EO>6CYTPI[I@'#?=WVB
MJ[&Y:I^Y>^235!.7.H3%3-Q1$C!;))-)Z#3F7\5%%+'8EU;+<I6KI0R-W4)8
M=Y*U?K;:N%NI?!MTBN=7E.]C*R)M'BZ_-H/>"(RE]J#$I@L1.8.N+*I23-<J
M MOGC*BF.GBB.BF.>I-MP0K>>@X8)%LT0(XY-4YX X4?5&?F5@?VQ&6>FHVO
MG7W3+6#9/&BNH4\6/I(Q&"O@DZO[- Y\]F>3ME /M8PT-NV@%F&PGF ^H[X?
MMC;> TF([C>3/:,N Y5LY0;P_@8=U?@5_3RO(@P*^]:NF2V!?2@ VJ4SM1KB
M96LW@K9T6S\W5_Y8,FKQ$'D&;P 7AJFNZI@O%RAP//1 @F1A2& ;2/Q-A9H(
MLQO<RJAK65"I\+)-)\)("C=,4\NN=#/E*V>*#PM[Q)S[7I^8AQHBE02<'^ZF
MHQ1?Y+X"B+9M Q$^7KZCQ@;J_,I5*D.&J31N&LQHVE0&H=6&7(M@:?+U)?MG
MJ6D%%^\+\E4M$2=KSC2S?2/NF585V=%T+&TKT80C71KW4*L,3<B=Q$/[R? 4
M'/^4ST-.Q=+1N5([MMIO [!SJ)O(/UBJ:<0S.C,T?,J6H<>8M(8V]T]K5W(S
MY*E3\!_SG2Q/7"N=8WSKY0-S<[8/2>_3N<8_\ZKKSZL>/Y!7??R7@1WOK#T7
M^U]V6/_5-?M\-;H>WMZRS^^'-\,/[YK[P1$?4L-R&ZE9A.>="YA$ZE4H,:=8
M%E.P]GBXL3)?X-75H_,0X1Y#U!8(>;'_HD76GKVX099JHS3SX2_M6NU"-H#P
MOXO,OUL"OU4ZUT2/MPLZH/*?#_Y;L<C-59IU_5RGLEX#[#>'C2Y]><./X]]6
M<6N$V[J?1K)OM0<_FM28OXG,TK[%N?YP1U/%V284)2@1=7_SP'9QXNUB[4;U
MX6@0_I'T=^VG,#;E>ZK#?_69QXTXX ^-A_N/XNW%A^MW5Y?#Z]'5^:^/Y](&
M?.5JUUE%#];8_O'^ZNW5J-H?_SV_1'7M*]]Y\W%X\^[#S6_GUQ=#]O?A[>CJ
M^F_L]N+]\/+3K\,-5[$#\Z7>]/7B;_X#4$L#!!0    ( ".!9%.=79210 \
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M56&?UV"7.$$7TAR3Z?CC%1 )YVFZVX;<KP3HXR"'$[P0V+%]@EW)G=ZCF\C
M6KQ,Y%S+5OA] F-B;%=15&CT_TH@W3)JJHR%YQ$64C'H!P/]X<]XR,$S76(
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MVYY_(3F%C8].5^'(U1#-51<^QIA4V,TNG_A.M?SU7\VZ[W=/_@102P,$%
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M,#(Q,#DS,"YX<V102P$"% ,4    "  B@613V^+WQ HE  !'?P$ %0
M        @ '(- 0 86MB82TR,#(Q,#DS,%]C86PN>&UL4$L! A0#%     @
M(H%D4RO 1]H'@   K\8% !4              ( !!5H$ &%K8F$M,C R,3 Y
M,S!?9&5F+GAM;%!+ 0(4 Q0    ( "*!9%,S(Z8W8B ! +S/"P 5
M      "  3_:! !A:V)A+3(P,C$P.3,P7VQA8BYX;6Q02P$"% ,4    "  B
M@613&T'-\X:U   <8 @ %0              @ '4^@4 86MB82TR,#(Q,#DS
M,%]P<F4N>&UL4$L! A0#%     @ (X%D4]::=.1,&@  U*@  !X
M     ( !C; & &5X:&EB:70Q,#$M9F]R;6]F<&5R9F]R;6%N+FAT;5!+ 0(4
M Q0    ( ".!9%,3,G6;X!0  +E\   >              "  17+!@!E>&AI
M8FET,3 R+69O<FUO9G!S=6%G<F5E;2YH=&U02P$"% ,4    "  C@613G5V4
MD4 /  !?1P  '@              @ $QX 8 97AH:6)I=#$P,RUA:V5B:6%X
M9F]R;6]F8V$N:'1M4$L! A0#%     @ (X%D4ZJ-H)LF"   \BL  !8
M         ( !K>\& &5X:&EB:70S,3$M<3,R,#(Q,2YH=&U02P$"% ,4
M"  C@6133MRU""\(   :+   %@              @ $'^ 8 97AH:6)I=#,Q
M,BUQ,S(P,C$Q+FAT;5!+ 0(4 Q0    ( ".!9%,YAHBV+04  ,HC   6
M          "  6H !P!E>&AI8FET,S(Q+7$S,C R,3$N:'1M4$L%!@     ,
-  P .@,  ,L%!P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
